PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Enokizono, Y; Konishi, Y; Nagata, K; Ouhashi, K; Uesugi, S; Ishikawa, F; Katahira, M				Enokizono, Y; Konishi, Y; Nagata, K; Ouhashi, K; Uesugi, S; Ishikawa, F; Katahira, M			Structure of hnRNP D complexed with single-stranded telomere DNA and unfolding of the quadruplex by heterogeneous nuclear ribonucleoprotein D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING DOMAIN; TRIPLET REPEAT DNA; G-RICH STRAND; CRYSTAL-STRUCTURE; INTRAMOLECULAR QUADRUPLEX; 3-DIMENSIONAL STRUCTURES; PARALLEL QUADRUPLEXES; BACKBONE DYNAMICS; IN-VITRO; G-TETRAD	Heterogeneous nuclear ribonucleoprotein D, also known as AUF1, has two DNA/RNA-binding domains, each of which can specifically bind to single-stranded d(TTAGGG)(n), the human telomeric repeat. Here, the structure of the C-terminal-binding domain (BD2) complexed with single-stranded d(TTAGGG) determined by NMR is presented. The structure has revealed that each residue of the d(TAG) segment is recognized by BD2 in a base-specific manner. The interactions deduced from the structure have been confirmed by gel retardation experiments with mutant BD2 and DNA. It is known that single-stranded DNA with the telomeric repeat tends to form a quadruplex and that the quadruplex has an inhibitory effect on telomere elongation by telomerase. This time it is revealed that BD2 unfolds the quadruplex of such DNA upon binding. Moreover, the effect of BD2 on the elongation by telomerase was examined in vitro. These results suggest the possible involvement of heterogeneous nuclear ribonucleoprotein D in maintenance of the telomere 3'-overhang either through protection of a single-stranded DNA or destabilization of the potentially deleterious quadruplex structure for the elongation by telomerase.	Yokohama Natl Univ, Grad Sch Environm & Informat Sci, Dept Environm & Nat Sci, Hodogaya Ku, Yokohama, Kanagawa 2408501, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Sakyo Ku, Kyoto 6068502, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Yokohama National University; Kyoto University; Yokohama City University	Katahira, M (corresponding author), Yokohama Natl Univ, Grad Sch Environm & Informat Sci, Dept Environm & Nat Sci, Hodogaya Ku, 79-7 Tokiwadai, Yokohama, Kanagawa 2408501, Japan.	katahira@tsurumi.yokohama-cu.ac.jp	Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305				BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BRUNGER AT, 1993, SYSTEM XRAY CRYSTALL; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Catasti P, 1996, J MOL BIOL, V264, P534, DOI 10.1006/jmbi.1996.0659; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dallaire F, 2000, J BIOL CHEM, V275, P14509, DOI 10.1074/jbc.275.19.14509; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Eversole A, 2000, MOL CELL BIOL, V20, P5425, DOI 10.1128/MCB.20.15.5425-5432.2000; Fletcher TM, 1998, BIOCHEMISTRY-US, V37, P5536, DOI 10.1021/bi972681p; Fukuda H, 2002, P NATL ACAD SCI USA, V99, P12685, DOI 10.1073/pnas.152456899; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gomez D, 2002, CANCER RES, V62, P3365; HODGKIN J, 1995, SCIENCE, V270, P410, DOI 10.1126/science.270.5235.410; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; Izbicka E, 1999, CANCER RES, V59, P639; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; Katahira M, 1999, BIOCHEM BIOPH RES CO, V264, P327, DOI 10.1006/bbrc.1999.1521; Katahira M, 2001, J MOL BIOL, V311, P973, DOI 10.1006/jmbi.2001.4862; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; Kettani A, 2000, J MOL BIOL, V297, P627, DOI 10.1006/jmbi.2000.3524; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lei M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092; Matsugami A, 2003, J BIOL CHEM, V278, P28147, DOI 10.1074/jbc.M303694200; Matsugami A, 2003, STRUCTURE, V11, P533, DOI 10.1016/S0969-2126(03)00069-8; Matsugami A, 2001, J MOL BIOL, V313, P255, DOI 10.1006/jmbi.2001.5047; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; Miyanoiri Y, 2003, J BIOL CHEM, V278, P41309, DOI 10.1074/jbc.M306210200; Myers JC, 2003, J BIOL CHEM, V278, P42300, DOI 10.1074/jbc.M306147200; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Nagata T, 1999, J MOL BIOL, V287, P221, DOI 10.1006/jmbi.1999.2616; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755; Phan AT, 2004, J AM CHEM SOC, V126, P8710, DOI 10.1021/ja048805k; Phan AT, 2003, J AM CHEM SOC, V125, P15021, DOI 10.1021/ja037616j; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZIMMER DP, 1995, P NATL ACAD SCI USA, V92, P3091, DOI 10.1073/pnas.92.8.3091	43	74	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18862	18870		10.1074/jbc.M411822200	http://dx.doi.org/10.1074/jbc.M411822200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15734733	hybrid			2022-12-25	WOS:000228932300038
J	Musiani, F; Dikiy, A; Semenov, AY; Ciurli, S				Musiani, F; Dikiy, A; Semenov, AY; Ciurli, S			Structure of the intermolecular complex between plastocyanin and cytochrome f from spinach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM PHORMIDIUM-LAMINOSUM; ELECTRON-TUNNELING PATHWAYS; PHOTOSYSTEM-I; BC(1) COMPLEX; CRYSTAL-STRUCTURE; B(6)F COMPLEX; COMPUTATIONAL SIMULATION; ANGSTROM RESOLUTION; BROWNIAN DYNAMICS; NMR-SPECTROSCOPY	In oxygenic photosynthesis, plastocyanin shuttles electrons between the membrane-bound complexes cytochrome b(6)f and photosystem I. The homologous complex between cytochrome f and plastocyanin, both from spinach, is the object of this study. The solution structure of the reduced spinach plastocyanin was determined using high field NMR spectroscopy, whereas the model structure of oxidized cytochrome f was obtained by homology modeling calculations and molecular dynamics. The model structure of the intermolecular complex was calculated using the program AUTODOCK, taking into account biological information obtained from mutagenesis experiments. The best electron transfer pathway from the heme group of cytochrome f to the copper ion of plastocyanin was calculated using the program HARLEM, obtaining a coupling decay value of 1.8 x 10(-4). Possible mechanisms of interaction and electron transfer between plastocyanin and cytochrome f were discussed considering the possible formation of a supercomplex that associates one cytochrome b(6)f, one photosystem I, and one plastocyanin.	Univ Bologna, Dept Agroenvironm Sci & Technol, Lab Bioinorgan Chem, I-40127 Bologna, Italy; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia	University of Bologna; Lomonosov Moscow State University	Ciurli, S (corresponding author), Univ Bologna, Dept Agroenvironm Sci & Technol, Lab Bioinorgan Chem, Viale Giuseppe Fanin 40, I-40127 Bologna, Italy.	stefano.ciurli@unibo.it	Musiani, Francesco/A-7410-2016; Musiani, Francesco/AAA-2385-2021; Semenov, Alexey Yu/G-2759-2014; Ciurli, Stefano/K-4355-2014	Musiani, Francesco/0000-0003-0200-1712; Musiani, Francesco/0000-0003-0200-1712; Semenov, Alexey Yu/0000-0003-1035-0381; Ciurli, Stefano/0000-0001-9557-926X				Allen JF, 2004, TRENDS PLANT SCI, V9, P130, DOI 10.1016/j.tplants.2004.01.009; ALT J, 1984, CURR GENET, V8, P551, DOI 10.1007/BF00410443; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Banci L, 2002, CHEMBIOCHEM, V3, P299, DOI 10.1002/1439-7633(20020402)3:4<299::AID-CBIC299>3.0.CO;2-0; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; Beratan DN, 1998, CURR OPIN CHEM BIOL, V2, P235, DOI 10.1016/S1367-5931(98)80065-3; Bergkvist A, 2001, PROTEIN SCI, V10, P2623, DOI 10.1110/ps.ps.27101; Bertini I, 2001, J BIOL CHEM, V276, P47217, DOI 10.1074/jbc.M100304200; Bertini I, 2001, J AM CHEM SOC, V123, P2405, DOI 10.1021/ja0033685; BETTS JN, 1992, J AM CHEM SOC, V114, P4043, DOI 10.1021/ja00037a004; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Carrell CJ, 1999, BIOCHEMISTRY-US, V38, P9590, DOI 10.1021/bi9903190; Case DAPD, 1999, AMBER 6; Chi YI, 2000, BIOCHEMISTRY-US, V39, P7689, DOI 10.1021/bi000090k; Cramer WA, 2004, BIOCHEMISTRY-US, V43, P5921, DOI 10.1021/bi049444o; Crofts AR, 2004, ANNU REV PHYSIOL, V66, P689, DOI 10.1146/annurev.physiol.66.032102.150251; Crowley PB, 2002, BIOCHEMISTRY-US, V41, P15698, DOI 10.1021/bi026349b; Crowley PB, 2001, J AM CHEM SOC, V123, P10444, DOI 10.1021/ja0112700; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; De Rienzo F, 2001, BIOPHYS J, V81, P3090, DOI 10.1016/S0006-3495(01)75947-4; Donaire A, 1998, INORG CHIM ACTA, V276, P73; DRACHEV LA, 1989, FEBS LETT, V245, P43, DOI 10.1016/0014-5793(89)80188-7; Drepper F, 1996, BIOCHEMISTRY-US, V35, P1282, DOI 10.1021/bi951471e; Ejdeback M, 2000, BIOCHEMISTRY-US, V39, P5022, DOI 10.1021/bi992757c; FREEMAN HC, 2001, HDB METALLOPROTEINS, P1153; Gong XS, 2000, EUR J BIOCHEM, V267, P1732, DOI 10.1046/j.1432-1327.2000.01168.x; Gong XS, 2000, EUR J BIOCHEM, V267, P3461, DOI 10.1046/j.1432-1327.2000.01366.x; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; Hart SE, 2003, BIOCHEMISTRY-US, V42, P4829, DOI 10.1021/bi020674h; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; Hope AB, 2000, BBA-BIOENERGETICS, V1456, P5, DOI 10.1016/S0005-2728(99)00101-2; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Illerhaus J, 2000, J BIOL CHEM, V275, P17590, DOI 10.1074/jbc.275.23.17590; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Joliot P, 2002, P NATL ACAD SCI USA, V99, P10209, DOI 10.1073/pnas.102306999; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kannt A, 1996, BBA-BIOENERGETICS, V1277, P115, DOI 10.1016/S0005-2728(96)00090-4; KATOH S, 1962, J BIOCHEM-TOKYO, V51, P32, DOI 10.1093/oxfordjournals.jbchem.a127497; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; Kurnikov I. V., 2000, HARLEM 1 0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE BH, 1995, J BIOCHEM, V117, P1209; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; Mamedov MD, 2003, BIOFIZIKA+, V48, P1044; Mamedov MD, 2001, FEBS LETT, V500, P172, DOI 10.1016/S0014-5793(01)02615-1; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; Matias PM, 1999, J BIOL INORG CHEM, V4, P478, DOI 10.1007/s007750050334; MODI S, 1992, BIOCHIM BIOPHYS ACTA, V1101, P64, DOI 10.1016/0167-4838(92)90467-R; MORAND LZ, 1993, BIOCHIM BIOPHYS ACTA, V1141, P105, DOI 10.1016/0005-2728(93)90195-L; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Myshkin E, 2002, BIOPHYS J, V82, P3305, DOI 10.1016/S0006-3495(02)75671-3; OVERFIELD RE, 1980, BIOCHEMISTRY-US, V19, P3322, DOI 10.1021/bi00555a034; Pearson DC, 1998, BIOPHYS J, V75, P2698, DOI 10.1016/S0006-3495(98)77714-8; Pearson DC, 1996, BIOPHYS J, V71, P64, DOI 10.1016/S0006-3495(96)79236-6; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Sainz G, 2000, BIOCHEMISTRY-US, V39, P9164, DOI 10.1021/bi0004596; Schlarb-Ridley BG, 2002, BIOCHEMISTRY-US, V41, P3279, DOI 10.1021/bi0116588; Schmitz-Linneweber C, 2001, PLANT MOL BIOL, V45, P307, DOI 10.1023/A:1006478403810; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Soriano GM, 1997, BIOPHYS J, V73, P3265, DOI 10.1016/S0006-3495(97)78351-6; Soriano GM, 2001, HDB METALLOPROTEINS, P172; Stroebel D, 2003, NATURE, V426, P413, DOI 10.1038/nature02155; SYKES AG, 1991, STRUCT BOND, V75, P175; Ubbink M, 1998, STRUCTURE, V6, P323, DOI 10.1016/S0969-2126(98)00035-5; Ubbink M, 2004, PHOTOSYNTH RES, V81, P277, DOI 10.1023/B:PRES.0000036880.67124.e7; Ullmann GM, 1997, J AM CHEM SOC, V119, P42, DOI 10.1021/ja962237u; VANGUNSTEREN WF, 1995, COMPUT PHYS COMMUN, V91, P305, DOI 10.1016/0010-4655(95)00055-K; WIDER G, 1984, J MAGN RESON, V56, P207, DOI 10.1016/0022-2364(84)90099-4; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xue YF, 1998, PROTEIN SCI, V7, P2099, DOI 10.1002/pro.5560071006; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	80	17	18	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18833	18841		10.1074/jbc.M412760200	http://dx.doi.org/10.1074/jbc.M412760200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15691836	hybrid			2022-12-25	WOS:000228932300035
J	Wang, DA; Sebti, SM				Wang, DA; Sebti, SM			Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptotic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; EXPRESSION; GTPASES; RAS; TRANSFORMATION; TRANSCRIPTION; PRENYLATION; PROGRESSION; METASTASIS; RECEPTORS	RhoA and RhoB share 86% amino acid sequence identity, yet RhoA promotes whereas RhoB suppresses malignant transformation. Amino acids 29, 100, 116, 123, 129, 140-143, 141, 146, 152, 154, 155, 173, 181, 183-187, 189, 190, 191, 192, and 193 in RhoB were mutated to the corresponding RhoA residues to determine those critical for RhoB tumor-suppressive activity. Of all the mutants made, only the cysteine 192 (one of two palmitoylation sites) and cysteine 193 (the prenylation site) point mutations abolish RhoB functions. In contrast, mutation of the other palmitoylation site, cysteine 189, did not affect RhoB functions. Moving cysteine 192 to position 190 did not affect RhoB function either. Mutation of cysteine 192 to glycine, alanine, or serine blocks the ability of RhoB to suppress transforming growth factor beta type II receptor, p2lwaf, and AP-1 promoter transcriptional activities. Furthermore, mutations of cysteines 192 and 193, but not 189, mislocalize RhoB and prevent RhoB from inhibiting anchorage-dependent and anchorage-independent tumor growth and colony formation as well as prevent it from inducing apoptosis. The cysteine 192 RhoB mutant is farnesylated and geranylgeranylated as efficiently as wild type RhoB. A RhoA-(1-180)/RhoB-(181-196) chimera inhibited tumor cell proliferation and induced apoptosis as efficiently as RhoB. These results demonstrate that the presence of neither cysteine 193 nor cysteine 192 alone is sufficient and that both palmitoylated cysteine 192 and prenylated cysteine 193, but not palmitoylated cysteine 189, are required for RhoB tumor-suppressive and proapoptotic activities.	H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Sebti, SM (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Dept Interdisciplinary Oncol, 12902 Magnolia Dr,SRB3-DRDIS, Tampa, FL 33612 USA.	Sebti@moffitt.usf.edu						ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Adnane J, 2002, CLIN CANCER RES, V8, P2225; Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Adnane J, 2002, J BIOL CHEM, V277, P8500, DOI 10.1074/jbc.M104367200; ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; Baron R, 2000, P NATL ACAD SCI USA, V97, P11626, DOI 10.1073/pnas.97.21.11626; BIERMANN BJ, 1994, J BIOL CHEM, V269, P25251; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Forget MA, 2002, CLIN EXP METASTAS, V19, P9, DOI 10.1023/A:1013884426692; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Jiang K, 2004, ONCOGENE, V23, P1136, DOI 10.1038/sj.onc.1207236; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Symons M, 2003, CURR BIOL, V13, pR409, DOI 10.1016/S0960-9822(03)00324-5; Wang DA, 2001, J BIOL CHEM, V276, P49213, DOI 10.1074/jbc.M107301200; Welsh CF, 2004, BREAST CANCER RES TR, V84, P33, DOI 10.1023/B:BREA.0000018425.31633.07	26	40	46	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19243	19249		10.1074/jbc.M411472200	http://dx.doi.org/10.1074/jbc.M411472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15713677	hybrid			2022-12-25	WOS:000228932300081
J	Angeletti, B; Waldron, KJ; Freeman, KB; Bawagan, H; Hussain, I; Miller, CCJ; Lau, KF; Tennant, ME; Dennison, C; Robinson, NJ; Dingwall, C				Angeletti, B; Waldron, KJ; Freeman, KB; Bawagan, H; Hussain, I; Miller, CCJ; Lau, KF; Tennant, ME; Dennison, C; Robinson, NJ; Dingwall, C			BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; SECRETASE CYTOSOLIC DOMAIN; C-TERMINAL DOMAIN; ALZHEIMERS-DISEASE; BETA-SECRETASE; CLEAVING ENZYME; A-BETA; AXONAL-TRANSPORT; TRANSGENIC MICE; HYDROGEN-PEROXIDE	The amyloidogenic pathway leading to the production and deposition of A beta peptides, major constituents of Alzheimer disease senile plaques, is linked to neuronal metal homeostasis. The amyloid precursor protein binds copper and zinc in its extracellular domain, and the A beta peptides also bind copper, zinc, and iron. The first step in the generation of A beta is cleavage of amyloid precursor protein by the aspartic protease BACE1. Here we show that BACE1 interacts with CCS ( the copper chaperone for superoxide dismutase-1 (SOD1)) through domain I and the proteins co-immunoprecipitate from rat brain extracts. We have also been able to visualize the cotransport of membranous BACE1 and soluble CCS through axons. BACE1 expression reduces the activity of SOD1 in cells consistent with direct competition for available CCS as overexpression of CCS restores SOD1 activity. Finally, we demonstrate that the twenty-four residue C-terminal domain of BACE1 binds a single Cu(I) atom with high affinity through cysteine residues.	GlaxoSmithKline, Neurol & Gastrointestinal Ctr Excellence Drug Dis, Harlow CM19 5AW, Essex, England; Univ Newcastle Upon Tyne, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; GlaxoSmithKline, Comparat Genom, Collegeville, PA 19426 USA; Inst Psychiat, Dept Neurosci, London SE5 8AF, England; Inst Psychiat, Dept Neurol, London SE5 8AF, England	GlaxoSmithKline; Newcastle University - UK; GlaxoSmithKline; University of London; King's College London; University of London; King's College London	Dingwall, C (corresponding author), GlaxoSmithKline, Neurol & Gastrointestinal Ctr Excellence Drug Dis, New Frontiers Sci Pk,3rd Ave, Harlow CM19 5AW, Essex, England.	Colin_Dingwall@gsk.com	Waldron, Kevin John/HHM-8983-2022; Waldron, Kevin/J-2368-2016; Robinson, Nigel J/J-6363-2012; Miller, Christopher/H-5733-2012	Waldron, Kevin John/0000-0002-5577-7357; Waldron, Kevin/0000-0002-5577-7357; Robinson, Nigel J/0000-0001-5586-1092; Lau, Kwok-Fai/0000-0002-0193-1152; Miller, Christopher/0000-0002-5130-1845; Dennison, Christopher/0000-0001-8665-052X	Medical Research Council [G0000749] Funding Source: Medline; MRC [G0000749] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ackerley S, 2003, J CELL BIOL, V161, P489, DOI 10.1083/jcb.200303138; Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Bayer TA, 2003, P NATL ACAD SCI USA, V100, P14187, DOI 10.1073/pnas.2332818100; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Bellingham SA, 2004, J BIOL CHEM, V279, P20378, DOI 10.1074/jbc.M400805200; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bodendorf U, 2001, J BIOL CHEM, V276, P12019, DOI 10.1074/jbc.M008861200; Borchelt DR, 1998, NEUROBIOL DIS, V5, P27, DOI 10.1006/nbdi.1998.0178; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Brown NM, 2004, P NATL ACAD SCI USA, V101, P5518, DOI 10.1073/pnas.0401175101; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; Bush AI, 2003, ALZ DIS ASSOC DIS, V17, P147, DOI 10.1097/00002093-200307000-00005; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Ehehalt R, 2002, BIOCHEM BIOPH RES CO, V293, P30, DOI 10.1016/S0006-291X(02)00169-9; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hasler DW, 1998, BIOCHEMISTRY-US, V37, P14966, DOI 10.1021/bi9813734; He XY, 2003, BIOCHEMISTRY-US, V42, P12174, DOI 10.1021/bi035199h; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Huang XD, 2004, ANN NY ACAD SCI, V1012, P153, DOI 10.1196/annals.1306.012; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Hussain I, 2003, J BIOL CHEM, V278, P36264, DOI 10.1074/jbc.M304186200; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Khvotchev M, 2004, J BIOL CHEM, V279, P47101, DOI 10.1074/jbc.M408474200; Kihlken MA, 2002, BIOCHEM J, V368, P729, DOI 10.1042/BJ20021036; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; McLoughlin DM, 2001, J BIOL CHEM, V276, P9303, DOI 10.1074/jbc.M010023200; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Pastorino L, 2002, MOL CELL NEUROSCI, V19, P175, DOI 10.1006/mcne.2001.1065; Phinney AL, 2003, P NATL ACAD SCI USA, V100, P14193, DOI 10.1073/pnas.2332851100; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Rae TD, 2001, J BIOL CHEM, V276, P5166, DOI 10.1074/jbc.M008005200; Rothstein JD, 1999, J NEUROCHEM, V72, P422, DOI 10.1046/j.1471-4159.1999.0720422.x; Schmechel A, 2004, J BIOL CHEM, V279, P39710, DOI 10.1074/jbc.M402785200; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Sheng JG, 2003, EXP NEUROL, V184, P1053, DOI 10.1016/j.expneurol.2003.08.018; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; Sparks DL, 2003, P NATL ACAD SCI USA, V100, P11065, DOI 10.1073/pnas.1832769100; Strausak D, 2001, BRAIN RES BULL, V55, P175, DOI 10.1016/S0361-9230(01)00454-3; Tanahashi H, 2001, NEUROSCI LETT, V307, P9, DOI 10.1016/S0304-3940(01)01912-7; Treiber C, 2004, J BIOL CHEM, V279, P51958, DOI 10.1074/jbc.M407410200; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Westmeyer GG, 2004, J BIOL CHEM, V279, P53205, DOI 10.1074/jbc.M410378200; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200	60	100	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17930	17937		10.1074/jbc.M412034200	http://dx.doi.org/10.1074/jbc.M412034200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15722349	hybrid			2022-12-25	WOS:000228807200046
J	Lefebvre-Legendre, L; Salin, B; Schaeffer, J; Brethes, D; Dautant, A; Ackerman, SH; di Rago, JP				Lefebvre-Legendre, L; Salin, B; Schaeffer, J; Brethes, D; Dautant, A; Ackerman, SH; di Rago, JP			Failure to assemble the alpha(3)beta(3) subcomplex of the ATP synthase leads to accumulation of the alpha and beta subunits within inclusion bodies and the loss of mitochondrial cristae in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; YEAST MITOCHONDRIA; DELTA-SUBUNIT; GENES; COMPLEXES; F1-ATPASE; MEMBRANE; IDENTIFICATION; PROTEIN; FAMILY	The F-1 component of mitochondrial ATP synthase is an oligomeric assembly of five different subunits, alpha, beta, gamma, delta, and epsilon. In terms of mass, the bulk of the structure (similar to 90%) is provided by the alpha and beta subunits, which form an (alpha beta)(3) hexamer with adenine nucleotide binding sites at the alpha/beta interfaces. We report here ultrastructural and immunocytochemical analyses of yeast mutants that are unable to form the alpha(3)beta(3) oligomer, either because the alpha or the beta subunit is missing or because the cells are deficient for proteins that mediate F-1 assembly (e.g. Atp11p, Atp12p, or Fmc1p). The F-1 alpha and beta subunits of such mutant strains are detected within large electron-dense particles in the mitochondrial matrix. The composition of the aggregated species is principally full-length F-1 alpha and/or beta subunit protein that has been processed to remove the amino-terminal targeting peptide. To our knowledge this is the first demonstration of mitochondrial inclusion bodies that are formed largely of one particular protein species. We also show that yeast mutants lacking the alpha(3)beta(3) oligomer are devoid of mitochondrial cristae and are severely deficient for respiratory complexes III and IV. These observations are in accord with other studies in the literature that have pointed to a central role for the ATP synthase in biogenesis of the mitochondrial inner membrane.	Univ Victor Segalen, CNRS, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Wayne State University	di Rago, JP (corresponding author), Univ Victor Segalen, CNRS, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	jp.dirago@ibgc.u-bordeaux2.fr			NIGMS NIH HHS [GM48157] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; Ackerman SH, 2002, BBA-BIOENERGETICS, V1555, P101, DOI 10.1016/S0005-2728(02)00262-1; ALLEN RD, 1995, PROTOPLASMA, V189, P1, DOI 10.1007/BF01280286; ALLEN RD, 1989, J CELL BIOL, V108, P2233, DOI 10.1083/jcb.108.6.2233; Amutha B, 2004, BIOCHEM J, V381, P19, DOI 10.1042/BJ20040566; ANSORGE W, 1983, ELECTROPHORESIS 82, P235; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arselin G, 2004, J BIOL CHEM, V279, P40392, DOI 10.1074/jbc.M404316200; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BURNS DJ, 1986, J BIOL CHEM, V261, P2066; Church C, 1998, J EXP BIOL, V201, P1729; CLAISSE ML, 1974, EUR J BIOCHEM, V49, P49, DOI 10.1111/j.1432-1033.1974.tb03810.x; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; CRIVELLONE MD, 1994, J BIOL CHEM, V269, P21284; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; Duvezin-Caubet S, 2003, P NATL ACAD SCI USA, V100, P13235, DOI 10.1073/pnas.2135169100; Frey TG, 2002, BBA-BIOENERGETICS, V1555, P196, DOI 10.1016/S0005-2728(02)00278-5; Gavin PD, 2004, J CELL SCI, V117, P2333, DOI 10.1242/jcs.01074; Gilkerson RW, 2003, FEBS LETT, V546, P355, DOI 10.1016/S0014-5793(03)00633-1; GIRAUD MF, 1994, EUR J BIOCHEM, V222, P851, DOI 10.1111/j.1432-1033.1994.tb18932.x; Guelin E, 1996, FEBS LETT, V381, P42, DOI 10.1016/0014-5793(96)00074-9; GUELIN E, 1993, J BIOL CHEM, V268, P161; Guerin B, 1979, Methods Enzymol, V55, P149; Hell K, 2000, J BIOL CHEM, V275, P4571, DOI 10.1074/jbc.275.7.4571; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefebvre-Legendre L, 2001, J BIOL CHEM, V276, P6789, DOI 10.1074/jbc.M009557200; NAKAI T, 1995, MOL CELL BIOL, V15, P4441; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; PAUL MF, 1994, J BIOL CHEM, V269, P26158; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Rep M, 1996, CURR GENET, V30, P367, DOI 10.1007/s002940050145; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SLONIMSKI PP, 1949, ANN I PASTEUR PARIS, V77, P47; Stevens B., 1981, MOL BIOL YEAST SACCH, V11, P471; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; TAKEDA M, 1985, J BIOL CHEM, V260, P5458; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; Tokatlidis K, 1999, J BIOL CHEM, V274, P35285, DOI 10.1074/jbc.274.50.35285; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; Van Dyck L, 1999, CELL MOL LIFE SCI, V56, P825, DOI 10.1007/s000180050029; VANDYCK L, 1994, J BIOL CHEM, V269, P238; Wang ZG, 2000, EMBO J, V19, P1486, DOI 10.1093/emboj/19.7.1486; Wang ZG, 2000, J BIOL CHEM, V275, P5767, DOI 10.1074/jbc.275.8.5767; WHITE M, 1995, ARCH BIOCHEM BIOPHYS, V319, P299, DOI 10.1006/abbi.1995.1296; Xiao Y, 2000, J BIOL CHEM, V275, P6963, DOI 10.1074/jbc.275.10.6963; YOTSUYANAGI Y, 1962, J ULTRA MOL STRUCT R, V7, P141, DOI 10.1016/S0022-5320(62)80032-X; YOTSUYANAGI Y, 1988, J ULTRA MOL STRUCT R, V98, P254, DOI 10.1016/S0889-1605(88)80918-2	54	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18386	18392		10.1074/jbc.M410789200	http://dx.doi.org/10.1074/jbc.M410789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15716275	hybrid			2022-12-25	WOS:000228807200100
J	Mehta, D; Konstantoulaki, M; Ahmmed, GU; Malik, AB				Mehta, D; Konstantoulaki, M; Ahmmed, GU; Malik, AB			Sphingosine 1-phosphate-induced mobilization of intracellular Ca2+ mediates Rac activation and adherens junction assembly in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; BARRIER FUNCTION; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; SHAPE CHANGE; PHOSPHORYLATION; PROTEIN; ENTRY; PERMEABILITY; RECEPTOR	Sphingosine 1-phosphate (S1P) ligation of endothelial differentiation gene-1 receptor coupled to the heterotrimeric G protein, G(i), promotes endothelial barrier strengthening via Rac-dependent assembly of adherens junctions (AJs). However, the mechanism of Rac activation induced by S1P stimulation remains unclear. In live endothelial cells expressing GFP-Rac, we observed that S1P induced the translocation of Rac to intercellular junctions, resulting in junctional sealing. We investigated the role of intracellular Ca2+ in signaling Rac activation and the enhancement of endothelial barrier function. We observed that S1P activated the release of Ca2+ from endoplasmic reticulum stores, and subsequent Ca2+ entry via lanthanum-sensitive store-operated Ca2+ channels (SOC) after store depletion. Inhibition of Gi, phospholipase C, or inositol trisphosphate receptor prevented the S1P-activated increase in intracellular Ca2+ as well as Rac activation, AJ assembly, and enhancement of endothelial barrier. Chelation of intracellular Ca2+ with BAPTA blocked S1P-induced Rac activation, indicating the requirement for Ca2+ in the response. Inhibition of SOC by lanthanum or transient receptor potential channel 1 (TRPC1), a SOC constituent, by TRPC1 antibody, failed to prevent S1P-induced Rac translocation to junctions and AJ assembly. Thus, our results demonstrate that S1P promotes endothelial junctional integrity by activating the release of endoplasmic reticulum-Ca2+, which induces Rac activation and promotes AJ annealing.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mehta, D (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.	dmehta@uic.edu		Malik, Asrar/0000-0002-8205-7128	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007829, R01HL045638, R01HL071794] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL71794, HL45638, R01 HL071794, T32 HL07829] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmmed GU, 2004, J BIOL CHEM, V279, P20941, DOI 10.1074/jbc.M313975200; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003; Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200; Kouklis P, 2004, CIRC RES, V94, P159, DOI 10.1161/01.RES.0000110418.38500.31; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; LUM H, 1994, AM J PHYSIOL, V267, P223; McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc; McVerry BJ, 2004, J CELL BIOCHEM, V92, P1075, DOI 10.1002/jcb.20088; Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL574, DOI 10.1152/ajplung.1998.275.3.L574; Muraki K, 2001, J PHYSIOL-LONDON, V537, P431, DOI 10.1111/j.1469-7793.2001.00431.x; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Ong HL, 2002, BIOCHEM J, V364, P641, DOI 10.1042/BJ20020061; Paria BC, 2003, J BIOL CHEM, V278, P37195, DOI 10.1074/jbc.M304287200; Price LS, 2003, J BIOL CHEM, V278, P39413, DOI 10.1074/jbc.M302083200; Rosado JA, 2002, J BIOL CHEM, V277, P42157, DOI 10.1074/jbc.M207320200; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; Sandoval R, 2001, J PHYSIOL-LONDON, V533, P433, DOI 10.1111/j.1469-7793.2001.0433a.x; Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002; Shikata Y, 2003, FASEB J, V17, P2240, DOI 10.1096/fj.03-0198com; Shikata Y, 2003, J APPL PHYSIOL, V94, P1193, DOI 10.1152/japplphysiol.00690.2002; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537-1891(03)00007-7; Vouret-Craviari V, 2002, J CELL SCI, V115, P2475; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; Young KW, 2002, CELL CALCIUM, V32, P335, DOI 10.1016/S0143416002001835	40	119	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17320	17328		10.1074/jbc.M411674200	http://dx.doi.org/10.1074/jbc.M411674200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728185	hybrid			2022-12-25	WOS:000228615500096
J	Tian, B; Nowak, DE; Jamaluddin, M; Wang, SF; Brasier, AR				Tian, B; Nowak, DE; Jamaluddin, M; Wang, SF; Brasier, AR			Identification of direct genomic targets downstream of the nuclear factor-kappa B transcription factor mediating tumor necrosis factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-8 GENE-EXPRESSION; UBIQUITIN-PROTEASOME PATHWAY; PULMONARY EPITHELIAL-CELLS; DNA-BINDING SITES; FACTOR-ALPHA; TNF-ALPHA; DEPENDENT INDUCTION; INDUCED APOPTOSIS; RESPONSE ELEMENT; ACTIVATION	Tumor necrosis factor (TNF) is a pro-inflammatory cytokine that controls expression of inflammatory genetic networks. Although the nuclear factor-kappa B (NF-kappa B) pathway is crucial for mediating cellular TNF responses, the complete spectrum of NF-kappa B-dependent genes is unknown. In this study, we used a tetracycline-regulated cell line expressing an NF-kappa B inhibitor to systematically identify NF-kappa B-dependent genes. A microarray data set generated from a time course of TNF stimulation in the presence or absence of NF-kappa B signaling was analyzed. We identified 50 unique genes that were regulated by TNF (Pr( F) < 0.001) and demonstrated a change in signal intensity of +/- 3-fold relative to control. Of these, 28 were NF-kappa B-dependent, encoding proteins involved in diverse cellular activities. Quantitative real-time PCR assays of eight characterized NF-kappa B-dependent genes and five genes not previously known to be NF-kappa B-dependent (Gro-beta and-gamma, I kappa B epsilon, interleukin (IL)-7R, and Naf-1) were used to determine whether they were directly or indirectly NF-kappa B regulated. Expression of constitutively active enhanced green fluorescent center dot NF-kappa B/Rel A fusion protein transactivated all but IL-6 and IL-7R in the absence of TNF stimulation. Moreover, TNF strongly induced all 12 genes in the absence of new protein synthesis. High probability NF-kappa B sites in novel genes were predicted by binding site analysis and confirmed by electrophoretic mobility shift assay. Chromatin immunoprecipitation assays show the endogenous I kappa B alpha/epsilon, Gro-beta/gamma, and Naf-1 promoters directly bound NF-kappa B/Rel A in TNF-stimulated cells. Together, these studies systematically identify the direct NF-kappa B-dependent gene network downstream of TNF signaling, extending our knowledge of biological processes regulated by this pathway.	Univ Texas, Med Branch, Div Endocrinol, Dept Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Brasier, AR (corresponding author), Univ Texas, Med Branch, Div Endocrinol, Dept Med, MRB 8-138,301 Univ Blvd, Galveston, TX 77555 USA.	arbrasie@utmb.edu		Brasier, Allan/0000-0002-5012-4090	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI40218] Funding Source: Medline; NIEHS NIH HHS [P30 ES06676] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; BEUTLER B, 1995, J INVEST MED, V43, P227; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Brasier AR, 2004, J VIROL, V78, P11461, DOI 10.1128/JVI.78.21.11461-11476.2004; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; BRASIER AR, 1996, J HYPERTENS, V27, P465; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Garofalo R, 1996, J VIROL, V70, P8773, DOI 10.1128/JVI.70.12.8773-8781.1996; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAN Y, 1997, J BIOL CHEM, V272, P9823; Han YQ, 1999, CIRC RES, V84, P695, DOI 10.1161/01.RES.84.6.695; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Han YQ, 1999, J BIOL CHEM, V274, P939, DOI 10.1074/jbc.274.2.939; HANNINK M, 1990, ONCOGENE, V5, P1843; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Harant H, 2001, FEBS LETT, V509, P439, DOI 10.1016/S0014-5793(01)03138-6; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hromas R, 1997, BLOOD, V89, P3315; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Jamaluddin M, 1998, J VIROL, V72, P4849, DOI 10.1128/JVI.72.6.4849-4857.1998; Jamaluddin M, 2000, MOL ENDOCRINOL, V14, P99, DOI 10.1210/me.14.1.99; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Lai WS, 1998, J BIOL CHEM, V273, P506, DOI 10.1074/jbc.273.1.506; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Lipniacki T, 2004, J THEOR BIOL, V228, P195, DOI 10.1016/j.jtbi.2004.01.001; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu Y, 2001, ONCOGENE, V20, P4777, DOI 10.1038/sj.onc.1204607; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; McKinsey TA, 2000, MOL IMMUNOL, V37, P783, DOI 10.1016/S0161-5890(00)00099-7; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Newton R, 1996, BIOCHEM BIOPH RES CO, V218, P518, DOI 10.1006/bbrc.1996.0093; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Phillips K, 2004, P NATL ACAD SCI USA, V101, P2011, DOI 10.1073/pnas.0400148101; Pickert L, 1998, BIOINFORMATICS, V14, P244, DOI 10.1093/bioinformatics/14.3.244; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ray S, 2004, J BIOL CHEM, V279, P35604, DOI 10.1074/jbc.M401851200; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; Stormo GD, 2000, BIOINFORMATICS, V16, P16, DOI 10.1093/bioinformatics/16.1.16; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; Thomas LH, 1998, J IMMUNOL, V161, P1007; Tian B, 2002, J VIROL, V76, P6800, DOI 10.1128/JVI.76.13.6800-6814.2002; Vlahopoulos S, 1999, BLOOD, V94, P1878, DOI 10.1182/blood.V94.6.1878; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wood LD, 1995, J BIOL CHEM, V270, P30619, DOI 10.1074/jbc.270.51.30619; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Zhang YF, 1999, J BIOL CHEM, V274, P14786, DOI 10.1074/jbc.274.21.14786; Zhang YH, 2001, J VIROL, V75, P9044, DOI 10.1128/JVI.75.19.9044-9058.2001; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262; [No title captured]	75	191	200	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17435	17448		10.1074/jbc.M500437200	http://dx.doi.org/10.1074/jbc.M500437200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722553	hybrid			2022-12-25	WOS:000228615500110
J	Creagh, AL; Tiong, JWC; Tian, MM; Haynes, CA; Jefferies, WA				Creagh, AL; Tiong, JWC; Tian, MM; Haynes, CA; Jefferies, WA			Calorimetric studies of melanotransferrin (p97) and its interaction with iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; TERMINAL HALF-MOLECULE; HUMAN TRANSFERRIN; HYPOTRANSFERRINEMIC MICE; SCANNING CALORIMETRY; SERUM TRANSFERRIN; HUMAN MELANOMAS; FERRIC IONS; BOUND IRON; BINDING	The mammalian molecule melanotransferrin ( mTf), also called p97, is a member of the transferrin family of molecules. It exists in both secreted and glycosylphosphatidylinositol-anchored forms and is thought to play a role in angiogenesis and in transporting iron across the blood brain barrier. The binding affinity of iron to this molecule has not been formally established. Here, the binding of ferric ion ( chelated with a 2- fold molar ratio of nitrilotriacetate) to mTf has been studied using isothermal titration calorimetry and differential scanning calorimetry. One iron- binding site was determined for mTf with similar binding characteristics to other transferrins. In the absence of bicarbonate, binding occurs quickly with an apparent association constant of 2.6 x 10(7) M (-1) at 25 degrees C. The presence of bicarbonate introduces kinetic effects that prevent direct determination of the apparent binding constant by isothermal titration calorimetry. Differential scanning calorimetry thermograms of mTf unfolding in the presence and absence of iron were therefore used to determine the apparent binding constant in the bicarbonate- containing system; at pH 7.5 and 25 degrees C, iron binding occurs in a 1: 1 ratio with a K-app of 4.4 x 10(17) M-1. This affinity is intermediate between the high and low affinity lobes of transferrin and suggests that mTf is likely to play a significant role in iron transport where the high affinity lobe of transferrin is occupied or where transferrin is in proportionally low concentrations.	Univ British Columbia, Dept Microbiol & Immunol, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Microbiol & Immunol, Biomed Res Ctr, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Biol & Chem Engn, Vancouver, BC V6T 1Z4, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Jefferies, WA (corresponding author), Univ British Columbia, Michael Smith Labs, 2185 East Mall, Vancouver, BC V6T 1Z3, Canada.	wilf@brc.ubc.ca						AISEN P, 1978, J BIOL CHEM, V253, P1930; ALEMANY R, 1993, J CELL SCI, V104, P1155; Andrews NC, 2000, ANNU REV GENOM HUM G, V1, P75, DOI 10.1146/annurev.genom.1.1.75; BAKER EN, 1992, FEBS LETT, V298, P215, DOI 10.1016/0014-5793(92)80060-T; BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; Baker HM, 2003, P NATL ACAD SCI USA, V100, P3579, DOI 10.1073/pnas.0637295100; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; BRANDTS JF, 1990, BIOCHEMISTRY-US, V29, P6927, DOI 10.1021/bi00481a024; BUYS SS, 1991, BLOOD, V78, P3288; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; Creagh AL, 1998, BIOCHEMISTRY-US, V37, P3529, DOI 10.1021/bi971983o; DANIELSEN EM, 1995, J CELL BIOL, V131, P939, DOI 10.1083/jcb.131.4.939; DEWAN JC, 1993, BIOCHEMISTRY-US, V32, P11963, DOI 10.1021/bi00096a004; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; FOOD MR, 1994, J BIOL CHEM, V269, P3034; GOMEZ J, 1995, PROTEINS, V22, P404, DOI 10.1002/prot.340220410; GROSSMANN JG, 1993, J MOL BIOL, V231, P554, DOI 10.1006/jmbi.1993.1308; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Gutierrez JA, 1998, J CELL PHYSIOL, V177, P585, DOI 10.1002/(SICI)1097-4652(199812)177:4<585::AID-JCP9>3.3.CO;2-P; KENNARD ML, 1995, EMBO J, V14, P4178, DOI 10.1002/j.1460-2075.1995.tb00091.x; Kuser P, 2002, ACTA CRYSTALLOGR D, V58, P777, DOI 10.1107/S0907444902003724; LIN LN, 1993, BIOCHEMISTRY-US, V32, P9398, DOI 10.1021/bi00087a019; LIN LN, 1991, BIOCHEMISTRY-US, V30, P11660, DOI 10.1021/bi00114a008; LIN LN, 1994, BIOCHEMISTRY-US, V33, P1881, DOI 10.1021/bi00173a035; LIN LN, 1993, BIOCHEM J, V293, P517, DOI 10.1042/bj2930517; Martell A. E., 1974, CRITICAL STABILITY C; McNagny KM, 1996, BLOOD, V87, P1343, DOI 10.1182/blood.V87.4.1343.bloodjournal8741343; Mcnamara L, 1999, J GASTROEN HEPATOL, V14, P126, DOI 10.1046/j.1440-1746.1999.01830.x; Moroo I, 2003, MICROCIRCULATION, V10, P457, DOI 10.1038/sj.mn.7800213; MOTEKAITIS RJ, 1994, J COORD CHEM, V31, P67, DOI 10.1080/00958979408022546; ROSE TM, 1986, P NATL ACAD SCI USA, V83, P1261, DOI 10.1073/pnas.83.5.1261; Rothenberger S, 1996, BRAIN RES, V712, P117, DOI 10.1016/0006-8993(96)88505-2; Takeda A, 1998, J NEUROSCI RES, V51, P454, DOI 10.1002/(SICI)1097-4547(19980215)51:4<454::AID-JNR5>3.0.CO;2-B; TIONG JWC, 2001, THESIS U BRIT COLUMB; Wessling-Resnick M, 2000, ANNU REV NUTR, V20, P129, DOI 10.1146/annurev.nutr.20.1.129; WOODBURY RG, 1980, P NATL ACAD SCI-BIOL, V77, P2183, DOI 10.1073/pnas.77.4.2183	37	19	20	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15735	15741		10.1074/jbc.M414650200	http://dx.doi.org/10.1074/jbc.M414650200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705575	hybrid			2022-12-25	WOS:000228444800035
J	Karaveg, K; Siriwardena, A; Tempel, W; Liu, ZJ; Glushka, J; Wang, BC; Moremen, KW				Karaveg, K; Siriwardena, A; Tempel, W; Liu, ZJ; Glushka, J; Wang, BC; Moremen, KW			Mechanism of class 1 (Glycosylhydrolase family 47) alpha-mannosidases involved in N-glycan processing and endoplasmic reticulum quality control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I ALPHA-1,2-MANNOSIDASE; CRYSTAL-STRUCTURE; MISFOLDED GLYCOPROTEINS; STRUCTURAL BASIS; PROTEIN; SUBSTRATE; CRYSTALLIZATION; GLYCOSIDASES; SPECIFICITY; CATALYSIS	Quality control in the endoplasmic reticulum ( ER) determines the fate of newly synthesized glycoproteins toward either correct folding or disposal by ER-associated degradation. Initiation of the disposal process involves selective trimming of N-glycans attached to misfolded glycoproteins by ER alpha-mannosidase I and subsequent recognition by the ER degradation-enhancing alpha-mannosidase-like protein family of lectins, both members of glycosylhydrolase family 47. The unusual inverting hydrolytic mechanism catalyzed by members of this family is investigated here by a combination of kinetic and binding analyses of wild type and mutant forms of human ER alpha-mannosidase I as well as by structural analysis of a co-complex with an uncleaved thiodisaccharide substrate analog. These data reveal the roles of potential catalytic acid and base residues and the identification of a novel S-3(1) sugar conformation for the bound substrate analog. The co-crystal structure described here, in combination with the C-1(4) conformation of a previously identified co-complex with the glycone mimic, 1-deoxymannojirimycin, indicates that glycoside bond cleavage proceeds through a least motion conformational twist of a properly predisposed substrate in the -1 subsite. A novel H-3(4) conformation is proposed as the exploded transition state.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Mississippi, Dept Chem & Biochem, University, MS 38677 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Mississippi	Moremen, KW (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 220 Riverbend Rd, Athens, GA 30602 USA.	moremen@uga.edu	Liu, Zhi-Jie/A-3946-2012; Moremen, Kelley/AAD-4661-2019	Liu, Zhi-Jie/0000-0001-7279-2893; 	NCRR NIH HHS [RR05351] Funding Source: Medline; NIGMS NIH HHS [GM47533] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cabral CM, 2001, TRENDS BIOCHEM SCI, V26, P619, DOI 10.1016/S0968-0004(01)01942-9; CHAYEN NE, 1990, J APPL CRYSTALLOGR, V23, P297, DOI 10.1107/S0021889890003260; Cleland W W, 1979, Methods Enzymol, V63, P103; DArcy A, 1996, J CRYST GROWTH, V168, P175, DOI 10.1016/0022-0248(96)00351-X; Davies GJ, 2003, BIOCHEM SOC T, V31, P523, DOI 10.1042/BST0310523; Davis IW, 2004, NUCLEIC ACIDS RES, V32, pW615, DOI 10.1093/nar/gkh398; Deras IL, 1998, CARBOHYD RES, V306, P469; Deras IL, 2000, ANAL BIOCHEM, V278, P213, DOI 10.1006/abio.1999.4458; Evers DL, 1998, ANAL BIOCHEM, V265, P313, DOI 10.1006/abio.1998.2895; Golan G, 2004, J BIOL CHEM, V279, P3014, DOI 10.1074/jbc.M310098200; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; Guerin DMA, 2002, J MOL BIOL, V316, P1061, DOI 10.1006/jmbi.2001.5404; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guimaraes BG, 2002, J MOL BIOL, V320, P587, DOI 10.1016/S0022-2836(02)00497-7; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Herscovics A, 1999, BBA-GEN SUBJECTS, V1426, P275, DOI 10.1016/S0304-4165(98)00129-9; HERSCOVICS A, 1999, COMPREHENSIVE NATURA, V3, P13; Hosokawa N, 2003, J BIOL CHEM, V278, P26287, DOI 10.1074/jbc.M303395200; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Johnston BD, 1998, CARBOHYD RES, V310, P17, DOI 10.1016/S0008-6215(98)00162-1; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Lal A, 1998, GLYCOBIOLOGY, V8, P981, DOI 10.1093/glycob/8.10.981; Lipari F, 1999, BIOCHEMISTRY-US, V38, P1111, DOI 10.1021/bi981643i; Lobsanov YD, 2002, J BIOL CHEM, V277, P5620, DOI 10.1074/jbc.M110243200; MAST SW, 2005, IN PRESS GLYCOBIOLOG; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Miyake H, 2003, BIOCHEMISTRY-US, V42, P5574, DOI 10.1021/bi020712x; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Moremen K., 2000, OLIGOSACCHARIDES CHE, VII, P81; Mulakala C, 2002, PROTEINS, V49, P125, DOI 10.1002/prot.10206; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; RICE KG, 1990, ANAL BIOCHEM, V184, P249, DOI 10.1016/0003-2697(90)90676-Z; Rings S-M, 1980, EUR J BIOCHEM, V100, P295, DOI DOI 10.1111/J1432-1033.1980.TB04941.X; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; Schlippe YVG, 2005, ARCH BIOCHEM BIOPHYS, V433, P266, DOI 10.1016/j.abb.2004.09.018; Stoddard J. F., 1971, STEREOCHEMISTRY CARB; Sutton C W, 1997, Methods Mol Biol, V64, P73; TAYLOR R, 1984, ACCOUNTS CHEM RES, V17, P320, DOI 10.1021/ar00105a004; Tempel W, 2004, J BIOL CHEM, V279, P29774, DOI 10.1074/jbc.M403065200; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; Vallee F, 2000, J BIOL CHEM, V275, P41287, DOI 10.1074/jbc.M006927200; Van Petegem F, 2001, J MOL BIOL, V312, P157, DOI 10.1006/jmbi.2001.4946; Winn MD, 2003, J SYNCHROTRON RADIAT, V10, P23, DOI 10.1107/S0909049502017235; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Zechel DL, 2001, CURR OPIN CHEM BIOL, V5, P643, DOI 10.1016/S1367-5931(01)00260-5	56	93	95	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16197	16207		10.1074/jbc.M500119200	http://dx.doi.org/10.1074/jbc.M500119200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713668	hybrid			2022-12-25	WOS:000228444800089
J	Schnizler, K; Saeger, B; Pfeffer, C; Gerbaulet, A; Ebbinghaus-Kintscher, U; Methfessel, C; Franken, EM; Raming, K; Wetzel, CH; Saras, A; Pusch, H; Hatt, H; Gisselmann, G				Schnizler, K; Saeger, B; Pfeffer, C; Gerbaulet, A; Ebbinghaus-Kintscher, U; Methfessel, C; Franken, EM; Raming, K; Wetzel, CH; Saras, A; Pusch, H; Hatt, H; Gisselmann, G			A novel chloride channel in Drosophila melanogaster is inhibited by protons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; RAT HIPPOCAMPAL SLICES; GATED ION CHANNELS; SENSORY NEURONS; GABA(A) RECEPTORS; XENOPUS-OOCYTES; EXTRACELLULAR PH; PHARMACOLOGICAL CHARACTERIZATION; CAENORHABDITIS-ELEGANS; FUNCTIONAL EXPRESSION	A systematic analysis of the Drosophila genome data reveals the existence of pHCl, a novel member of ligand-gated ion channel subunits. pHCl shows nearly identical similarity to glutamate-, glycine-, and histamine-gated ion channels, does however not belong to any of these ion channel types. We identified three different sites, where splicing generates multiple transcripts of the pHCl mRNA. The pHCl is expressed in Drosophila embryo, larvae, pupae, and the adult fly. In embryos, in situ hybridization detected pHCl in the neural cord and the hindgut. Functional expression of the three different splice variants of pHCl in oocytes of Xenopus laevis and Sf9 cells induces a chloride current with a linear current-voltage relationship that is inhibited by extracellular protons and activated by avermectins in a pH-dependent manner. Further, currents through pHCl channels were induced by a raise in temperature. Our data give genetic and electrophysiological evidence that pHCl is a member of a new branch of ligand-gated ion channels in invertebrates with, however, a hitherto unique combination of pharmacological and biophysical properties.	Bayer AG, Bayer Technol Serv GmbH, D-51368 Leverkusen, Germany; Bayer AG, Bayer CropSci, D-40789 Mannheim, Germany; Ruhr Univ Bochum, Lehrstuhl Zellphysiol ND4, Fak Biol, D-44780 Bochum, Germany	Bayer AG; Bayer AG; Bayer CropScience; Ruhr University Bochum	Gisselmann, G (corresponding author), Bayer AG, Bayer Technol Serv GmbH, D-51368 Leverkusen, Germany.	guenter.gisselmann@rub.de	Wetzel, Christian/F-1366-2018; Wetzel, Christian/C-2501-2009; Wetzel, Christian H/N-9880-2017	Wetzel, Christian/0000-0002-5762-0003; Wetzel, Christian H/0000-0002-5762-0003				Ai T, 2004, MOL PHARMACOL, V65, P1415, DOI 10.1124/mol.65.6.1415; AKINS PT, 1993, NEUROSCIENCE, V56, P759, DOI 10.1016/0306-4522(93)90372-M; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; ARENA JP, 1992, MOL BRAIN RES, V15, P339, DOI 10.1016/0169-328X(92)90127-W; BAKER MD, 1994, P ROY SOC B-BIOL SCI, V255, P259, DOI 10.1098/rspb.1994.0037; BALLIVET M, 1988, NEURON, V1, P847, DOI 10.1016/0896-6273(88)90132-8; Beg AA, 2003, NAT NEUROSCI, V6, P1145, DOI 10.1038/nn1136; Bielefeldt K, 2000, NEUROSCIENCE, V101, P727, DOI 10.1016/S0306-4522(00)00375-4; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; CASTLE NA, 1992, CARDIOVASC RES, V26, P1137, DOI 10.1093/cvr/26.11.1137; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; Cully DF, 1996, J BIOL CHEM, V271, P20187, DOI 10.1074/jbc.271.33.20187; DILGER JP, 1991, BIOCHIM BIOPHYS ACTA, V1063, P253, DOI 10.1016/0005-2736(91)90379-M; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Etter A, 1999, J NEUROCHEM, V72, P318, DOI 10.1111/jnc.1999.72.1.318; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; FFRENCHMULLEN JMH, 1988, BRIT J PHARMACOL, V95, P753, DOI 10.1111/j.1476-5381.1988.tb11701.x; Fischer BS, 2001, J PHARMACOL EXP THER, V299, P238; Flemming R, 2003, BRIT J PHARMACOL, V139, P955, DOI 10.1038/sj.bjp.0705327; Gisselmann G, 2004, BRIT J PHARMACOL, V142, P409, DOI 10.1038/sj.bjp.0705818; Gisselmann G, 2002, NAT NEUROSCI, V5, P11, DOI 10.1038/nn787; Gisselmann G, 2002, EUR J NEUROSCI, V16, P69, DOI 10.1046/j.1460-9568.2002.02070.x; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harrison JF, 2001, ANNU REV ENTOMOL, V46, P221, DOI 10.1146/annurev.ento.46.1.221; Hille B., 1992, ION CHANNELS EXCITAB, P51; KAILA K, 1994, PROG NEUROBIOL, V42, P489, DOI 10.1016/0301-0082(94)90049-3; KAILA K, 1992, NEUROREPORT, V3, P105, DOI 10.1097/00001756-199201000-00028; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KEHL SJ, 1994, BRIT J PHARMACOL, V112, P616, DOI 10.1111/j.1476-5381.1994.tb13119.x; Kehoe J, 1998, J NEUROSCI, V18, P8198; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831, DOI 10.1152/jn.1983.49.3.831; Krause RM, 1998, MOL PHARMACOL, V53, P283, DOI 10.1124/mol.53.2.283; Krishek BJ, 1996, J PHYSIOL-LONDON, V492, P431, DOI 10.1113/jphysiol.1996.sp021319; Krishek BJ, 2001, J PHYSIOL-LONDON, V530, P219, DOI 10.1111/j.1469-7793.2001.0219l.x; KRISHTAL OA, 1987, BRAIN RES, V436, P352, DOI 10.1016/0006-8993(87)91678-7; Kuenzi FM, 1996, BRIT J PHARMACOL, V119, P81, DOI 10.1111/j.1476-5381.1996.tb15680.x; Lankiewicz S, 1998, MOL PHARMACOL, V53, P202, DOI 10.1124/mol.53.2.202; Maksay G, 2003, NEUROPHARMACOLOGY, V44, P994, DOI 10.1016/S0028-3908(03)00116-3; Mozrzymas JW, 2003, J NEUROSCI, V23, P7981; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pasternack M, 1996, NEUROPHARMACOLOGY, V35, P1279, DOI 10.1016/S0028-3908(96)00075-5; PASTERNACK M, 1992, NEUROSCIENCE, V47, P921, DOI 10.1016/0306-4522(92)90040-9; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSEN M, 1987, PFLUG ARCH EUR J PHY, V409, P403, DOI 10.1007/BF00583794; Ranganathan R, 2000, NATURE, V408, P470, DOI 10.1038/35044083; Rivera C, 2000, NEUROPHARMACOLOGY, V39, P977, DOI 10.1016/S0028-3908(99)00208-7; ROBELLO M, 1994, NEUROSCIENCE, V61, P833, DOI 10.1016/0306-4522(94)90406-5; Saeger B, 2001, FASEB J, V15, P1332, DOI 10.1096/fj.00-0664fje; Schnizler K, 2003, RECEPTOR CHANNEL, V9, P41, DOI 10.1080/10606820308253; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vassilatis DK, 1997, J MOL EVOL, V44, P501, DOI 10.1007/PL00006174; Vyklicky L, 1999, J PHYSIOL-LONDON, V517, P181, DOI 10.1111/j.1469-7793.1999.0181z.x; Wegelius K, 1996, NEUROREPORT, V7, P2005, DOI 10.1097/00001756-199608120-00030; Wellerdieck C, 1997, CHEM SENSES, V22, P467, DOI 10.1093/chemse/22.4.467; Wilkins ME, 2002, J NEUROSCI, V22, P5328; Witte I, 2002, J NEUROCHEM, V83, P504, DOI 10.1046/j.1471-4159.2002.01076.x; Xue H, 1998, J MOL EVOL, V47, P323, DOI 10.1007/PL00006390; Zhai J, 1998, PFLUG ARCH EUR J PHY, V435, P539, DOI 10.1007/s004240050550; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756; Zheng YC, 2002, J BIOL CHEM, V277, P2000, DOI 10.1074/jbc.M107635200	71	43	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16254	16262		10.1074/jbc.M411759200	http://dx.doi.org/10.1074/jbc.M411759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713676	hybrid			2022-12-25	WOS:000228444800095
J	Cam, JA; Zerbinatti, CV; Li, YH; Bu, GJ				Cam, JA; Zerbinatti, CV; Li, YH; Bu, GJ			Rapid endocytosis of the low density lipoprotein receptor-related protein modulates cell surface distribution and processing of the beta-amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CYTOPLASMIC DOMAIN; LIPID RAFTS; PEPTIDE; LRP; GENERATION; SIGNALS; FORMS; MODEL	The low density lipoprotein receptor-related protein (LRP) is a similar to 600-kDa multifunctional endocytic receptor that is highly expressed in the brain. LRP and its ligands apolipoprotein E, alpha 2-macroglobulin, and beta-amyloid precursor protein (APP), are genetically linked to Alzheimer disease and are found in characteristic plaque deposits in brains of patients with Alzheimer disease. To identify which extracellular domains of LRP interact with APP, we used minireceptors of each of the individual LRP ligand binding domains and assessed their ability to bind and degrade a soluble APP fragment. LRP minireceptors containing ligand binding domains II and IV, but not I or III, interacted with APP. To test whether APP trafficking is directly related to the rapid endocytosis of LRP, we generated stable Chinese hamster ovary cell lines expressing either a wild-type LRP minireceptor or its endocytosis mutants. Chinese hamster ovary cells stably expressing wild-type LRP minireceptor had less cell surface APP than pcDNA3 vector-transfected cells, whereas those stably expressing endocytosis-defective LRP minireceptors accumulated APP at the cell surface. We also found that the steady-state levels of the amyloid beta-peptides (A beta) is dictated by the relative expression levels of APP and LRP, probably reflecting the dual roles of LRP in both A beta production and clearance. Together, these data establish a relationship between LRP rapid endocytosis and APP trafficking and proteolytic processing to generate A beta.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Bu, GJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, CB 8208,660 S Euclid Ave, St Louis, MO 63110 USA.	bu@wustl.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS041872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005681] Funding Source: NIH RePORTER; NIA NIH HHS [P50-AG05681] Funding Source: Medline; NINDS NIH HHS [NS41872] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; Cam JA, 2004, J BIOL CHEM, V279, P29639, DOI 10.1074/jbc.M313893200; Cescato R, 2000, J NEUROCHEM, V74, P1131; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gylys KH, 2003, J NEUROCHEM, V84, P1442, DOI 10.1046/j.1471-4159.2003.01643.x; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Moir RD, 1998, J BIOL CHEM, V273, P5013, DOI 10.1074/jbc.273.9.5013; Neels JG, 1999, J BIOL CHEM, V274, P31305, DOI 10.1074/jbc.274.44.31305; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Qiu ZH, 1999, J NEUROCHEM, V73, P1393, DOI 10.1046/j.1471-4159.1999.0731393.x; Rebeck GW, 2001, MOL BRAIN RES, V87, P238, DOI 10.1016/S0169-328X(01)00006-7; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Zerbinatti CV, 2004, P NATL ACAD SCI USA, V101, P1075, DOI 10.1073/pnas.0305803101	34	77	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15464	15470		10.1074/jbc.M500613200	http://dx.doi.org/10.1074/jbc.M500613200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705569	hybrid			2022-12-25	WOS:000228236800134
J	Fernandes, N; Sun, YL; Chen, SJ; Paul, P; Shaw, RJ; Cantley, LC; Price, BD				Fernandes, N; Sun, YL; Chen, SJ; Paul, P; Shaw, RJ; Cantley, LC; Price, BD			DNA damage-induced association of ATM with its target proteins requires a protein interaction domain in the N terminus of ATM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAKAGE SYNDROME GENE; S-PHASE CHECKPOINT; ATAXIA-TELANGIECTASIA; DEPENDENT PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY; IONIZING-RADIATION; FUNCTIONAL-LINK; KINASE; P53; ACTIVATION	The ATM protein kinase regulates the response of the cell to DNA damage by associating with and then phosphorylating proteins involved in cell cycle checkpoints and DNA repair. Here, we report on deletion studies designed to identify protein domains required for ATM to phosphorylate target proteins and to control cell survival following exposure to ionizing radiation. Deletion studies demonstrated that amino acids 1 - 150 of ATM were required for the ATM protein to regulate cellular radiosensitivity. Additional deletions and point mutations indicated that this domain extended from amino acids 81 - 106 of ATM, with amino acid substitutions located between amino acids 91 and 97 inactivating the functional activity of ATM. When ATM with mutations in this region ( termed ATM90) was expressed in AT cells, it was unable to restore normal radiosensitivity to the cells. However, ATM90 retained normal kinase activity and was autophosphorylated on serine 1981 following exposure to DNA damage. Furthermore, wild-type ATM displayed DNA-damage induced association with p53, brca1, and LKB1 in vivo, whereas ATM90 failed to form productive complexes with these target proteins either in vivo or in vitro. Furthermore, ATM90 did not phosphorylate p53 in vivo and did not form nuclear foci in response to ionizing radiation. We propose that amino acids 91 - 97 of ATM contain a protein interaction domain required for the DNA damage-induced association between ATM and its target proteins, including the brca1, p53, and LKB1 proteins. Furthermore, this domain of ATM is required for ATM to form nuclear foci following exposure to ionizing radiation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Price, BD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, JF513,44 Binney St, Boston, MA 02115 USA.	brendan_price@dfci.harvard.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NCI NIH HHS [CA93602, CA64585] Funding Source: Medline; NIGMS NIH HHS [R01 GM056203] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064585, R01CA093602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beamish H, 2002, J BIOL CHEM, V277, P30515, DOI 10.1074/jbc.M203801200; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bradbury JM, 2003, CURR BIOL, V13, pR468, DOI 10.1016/S0960-9822(03)00403-2; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen SJ, 2003, ONCOGENE, V22, P6332, DOI 10.1038/sj.onc.1206760; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kishi S, 2001, J BIOL CHEM, V276, P29282, DOI 10.1074/jbc.M011534200; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Luo CM, 1996, J BIOL CHEM, V271, P4497; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; Mochan TA, 2003, CANCER RES, V63, P8586; Price BD, 1996, CANCER RES, V56, P246; Sapkota GP, 2002, BIOCHEM J, V368, P507, DOI 10.1042/BJ20021284; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Tauchi H, 2002, ONCOGENE, V21, P8967, DOI 10.1038/sj.onc.1206136; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Turenne GA, 2001, ONCOGENE, V20, P5100, DOI 10.1038/sj.onc.1204665; Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	37	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15158	15164		10.1074/jbc.M412065200	http://dx.doi.org/10.1074/jbc.M412065200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15713674	hybrid			2022-12-25	WOS:000228236800099
J	Iwakura, H; Hosoda, K; Son, C; Fujikura, J; Tomita, T; Noguchi, M; Ariyasu, H; Takaya, K; Masuzaki, H; Ogawa, Y; Hayashi, T; Inoue, G; Akamizu, T; Hosoda, H; Kojima, M; Itoh, H; Toytokuni, S; Kangawa, K; Nakao, K				Iwakura, H; Hosoda, K; Son, C; Fujikura, J; Tomita, T; Noguchi, M; Ariyasu, H; Takaya, K; Masuzaki, H; Ogawa, Y; Hayashi, T; Inoue, G; Akamizu, T; Hosoda, H; Kojima, M; Itoh, H; Toytokuni, S; Kangawa, K; Nakao, K			Analysis of rat insulin II promoter-ghrelin transgenic mice and rat glucagon promoter-ghrelin transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DES-ACYL GHRELIN; GROWTH-HORMONE SECRETAGOGUE; PANCREATIC-ISLET CELLS; GASTRIC-ACID-SECRETION; FOOD-INTAKE; BETA-CELLS; NONACYLATED GHRELIN; GH SECRETION; PEPTIDE; ENDOCRINE	We developed and analyzed two types of transgenic mice: rat insulin II promoter-ghrelin transgenic (RIP-G Tg) and rat glucagon promoter-ghrelin transgenic mice (RGP-G Tg). The pancreatic tissue ghrelin concentration measured by C-terminal radioimmuno-assay (RIA) and plasma desacyl ghrelin concentration ofRIP-G Tg were about 1000 and 3.4 times higher than those of nontransgenic littermates, respectively. The pancreatic tissue n-octanoylated ghrelin concentration measured by N-terminal RIA and plasma n-octanoylated ghrelin concentration of RIP-G Tg were not distinguishable from those of nontransgenic littermates. RIP-G Tg showed suppression of glucose-stimulated insulin secretion. Arginine-stimulated insulin secretion, pancreatic insulin mRNA and peptide levels, beta cell mass, islet architecture, and GLUT2 and PDX-1 immunoreactivity in RIP-G Tg pancreas were not significantly different from those of nontransgenic littermates. Islet batch incubation study did not show suppression of insulin secretion of RIP-G Tg in vitro. The insulin tolerance test showed lower tendency of blood glucose levels in RIP-G Tg. Taking lower tendency of triglyceride level of RIP-G Tg into consideration, these results may indicate that the suppression of insulin secretion is likely due to the effect of desacyl ghrelin on insulin sensitivity. RGP-G Tg, in which the pancreatic tissue ghrelin concentration measured by C-RIA was about 50 times higher than that of nontransgenic littermates, showed no significant changes in insulin secretion, glucose metabolism, islet mass, and islet architecture. The present study raises the possibility that desacyl ghrelin may have influence on glucose metabolism.	Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ Hosp, Translat Res Ctr, Kyoto 6068507, Japan; Kurume Univ, Inst Life Sci, Dept Mol Genet, Fukuoka 8390861, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Biochem, Osaka 5658565, Japan	Kyoto University; Kyoto University; Kyoto University; Kurume University; National Cerebral & Cardiovascular Center - Japan	Hosoda, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	kh@kuhp.kyoto-u.ac.jp	Toyokuni, Shinya/C-1358-2010; Fujikura, Junji/AAR-2684-2020; Toyokuni, Shinya/ABE-7714-2021	Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109; Akamizu, Takashi/0000-0003-4960-8271; Iwakura, Hiroshi/0000-0001-8033-0736; Ogawa, Yoshihiro/0000-0002-0834-2836; hayashi, Tatsuya/0000-0001-7600-4735				Adeghate E, 2002, J NEUROENDOCRINOL, V14, P555, DOI 10.1046/j.1365-2826.2002.00811.x; Ariyasu H, 2005, ENDOCRINOLOGY, V146, P355, DOI 10.1210/en.2004-0629; Arvat E, 2000, J ENDOCRINOL INVEST, V23, P493, DOI 10.1007/BF03343763; Asakawa A, 2005, GUT, V54, P18, DOI 10.1136/gut.2004.038737; Asakawa A, 2001, NEUROENDOCRINOLOGY, V74, P143, DOI 10.1159/000054680; Baldanzi G, 2002, J CELL BIOL, V159, P1029, DOI 10.1083/jcb.200207165; Broglio F, 2003, J CLIN ENDOCR METAB, V88, P4268, DOI 10.1210/jc.2002-021940; Broglio F, 2003, J ENDOCRINOL INVEST, V26, P192, DOI 10.1007/BF03345156; Broglio F, 2004, J CLIN ENDOCR METAB, V89, P3062, DOI 10.1210/jc.2003-031964; Broglio F, 2001, J CLIN ENDOCR METAB, V86, P5083, DOI 10.1210/jc.86.10.5083; Date Y, 2000, BIOCHEM BIOPH RES CO, V275, P477, DOI 10.1006/bbrc.2000.3342; Date Y, 2000, ENDOCRINOLOGY, V141, P4255, DOI 10.1210/en.141.11.4255; Date Y, 2002, DIABETES, V51, P124, DOI 10.2337/diabetes.51.1.124; Date Y, 2001, BIOCHEM BIOPH RES CO, V280, P904, DOI 10.1006/bbrc.2000.4212; Dheen ST, 1997, J ENDOCRINOL, V155, P551, DOI 10.1677/joe.0.1550551; Egido EM, 2002, EUR J ENDOCRINOL, V146, P241, DOI 10.1530/eje.0.1460241; Garcia-Ocana A, 2000, J BIOL CHEM, V275, P1226, DOI 10.1074/jbc.275.2.1226; Gauna C, 2004, J CLIN ENDOCR METAB, V89, P5035, DOI 10.1210/jc.2004-0363; Gauna C, 2005, J CLIN ENDOCR METAB, V90, P1055, DOI 10.1210/jc.2004-1069; GILON P, 1992, J BIOL CHEM, V267, P20713; Gualillo O, 2001, ENDOCRINOLOGY, V142, P788, DOI 10.1210/en.142.2.788; GUZ Y, 1995, DEVELOPMENT, V121, P11; Herrera PL, 2002, ENDOCRINE, V19, P267, DOI 10.1385/ENDO:19:3:267; Hosoda H, 2000, BIOCHEM BIOPH RES CO, V279, P909, DOI 10.1006/bbrc.2000.4039; Inui A, 2001, NAT REV NEUROSCI, V2, P551, DOI 10.1038/35086018; Iwakura H, 2002, J CLIN ENDOCR METAB, V87, P4885, DOI 10.1210/jc.2002-020882; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Korbonits M, 2001, ENDOCRINE, V14, P101, DOI 10.1385/ENDO:14:1:101; Lee HM, 2002, ENDOCRINOLOGY, V143, P185, DOI 10.1210/en.143.1.185; Masuda Y, 2000, BIOCHEM BIOPH RES CO, V276, P905, DOI 10.1006/bbrc.2000.3568; Mori K, 2000, FEBS LETT, V486, P213, DOI 10.1016/S0014-5793(00)02308-5; Murakami N, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740283; Nagaya N, 2001, CIRCULATION, V104, P1430, DOI 10.1161/hc3601.095575; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Petrik J, 1999, ENDOCRINOLOGY, V140, P2353, DOI 10.1210/en.140.5.2353; Porter SE, 1998, ENDOCRINOLOGY, V139, P3743, DOI 10.1210/en.139.9.3743; Prado CL, 2004, P NATL ACAD SCI USA, V101, P2924, DOI 10.1073/pnas.0308604100; Reimer MK, 2003, ENDOCRINOLOGY, V144, P916, DOI 10.1210/en.2002-220819; Salehi A, 2004, REGUL PEPTIDES, V118, P143, DOI 10.1016/j.regpep.2003.12.001; SCHMIDT HHHW, 1992, SCIENCE, V255, P721, DOI 10.1126/science.1371193; Seoane LM, 2000, EUR J ENDOCRINOL, V143, pR7, DOI 10.1530/eje.0.143R007; Shintani M, 2001, DIABETES, V50, P227, DOI 10.2337/diabetes.50.2.227; Smith PA, 1997, J PHYSIOL-LONDON, V499, P625, DOI 10.1113/jphysiol.1997.sp021955; Sun YX, 2003, MOL CELL BIOL, V23, P7973, DOI 10.1128/MCB.23.22.7973-7981.2003; Takaya K, 2000, J CLIN ENDOCR METAB, V85, P4908, DOI 10.1210/jc.85.12.4908; Tena-Sempere M, 2002, ENDOCRINOLOGY, V143, P717, DOI 10.1210/en.143.2.717; Thompson NM, 2004, ENDOCRINOLOGY, V145, P234, DOI 10.1210/en.2003-0899; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Volante M, 2002, J CLIN ENDOCR METAB, V87, P1300, DOI 10.1210/jc.87.3.1300; WEINHAUS AJ, 1995, DIABETES, V44, P118, DOI 10.2337/diabetes.44.1.118; Wierup N, 2004, J HISTOCHEM CYTOCHEM, V52, P301, DOI 10.1177/002215540405200301; Wierup N, 2002, REGUL PEPTIDES, V107, P63, DOI 10.1016/S0167-0115(02)00067-8; Wortley KE, 2004, P NATL ACAD SCI USA, V101, P8227, DOI 10.1073/pnas.0402763101; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325	55	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15247	15256		10.1074/jbc.M411358200	http://dx.doi.org/10.1074/jbc.M411358200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701644	hybrid			2022-12-25	WOS:000228236800110
J	Loverix, S; Geerlings, P; McNaughton, M; Augustyns, K; Vandemeulebroucke, A; Steyaert, J; Versees, W				Loverix, S; Geerlings, P; McNaughton, M; Augustyns, K; Vandemeulebroucke, A; Steyaert, J; Versees, W			Substrate-assisted leaving group activation in enzyme-catalyzed N-glycosidic bond cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALYSIS; NUCLEOSIDE HYDROLASE; PURIFICATION; SPECIFICITY; STACKING; DENSITY	In enzymatic depurination of nucleosides, the 5'-OH group of the ribose moiety of the substrate is often shown to contribute substantially to catalysis. The purine-specific nucleoside hydrolase from Trypanosoma vivax (TvNH) fixes the 5'-OH group in a gauche, trans orientation about the C4'-C5' bond, enabling the 5'-oxygen to accept an intramolecular hydrogen bond from the C8-atom of the purine leaving group. High level ab initio quantum chemical calculations indicate that this interaction promotes protonation of the purine at N7. Steady state kinetics comprising engineered substrates confirm that a considerable fraction of the catalytic 5'-OH effect can be attributed to leaving group activation.	Free Univ Brussels VIB, Dept Cellular & Mol Interact, Eenheid Algemene Chem, B-1050 Brussels, Belgium; Free Univ Brussels, Dept Gen Chem, B-1050 Brussels, Belgium; Univ Antwerp, Dept Med Chem, B-2610 Antwerp, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Antwerp	Loverix, S (corresponding author), Free Univ Brussels VIB, Dept Cellular & Mol Interact, Eenheid Algemene Chem, Lokaal 10G703,Pleinlaan 2, B-1050 Brussels, Belgium.	sloverix@vub.ac.be	steyaert, jan/GQP-7811-2022; Versées, Wim/H-5518-2015; Steyaert, Jan/H-4662-2011; Augustyns, Koen/ABG-2306-2020; Augustyns, Koen/C-1102-2008	Steyaert, Jan/0000-0002-3825-874X; Augustyns, Koen/0000-0002-5203-4339; Augustyns, Koen/0000-0002-5203-4339; Versees, Wim/0000-0002-4695-696X				BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; Berti PJ, 2002, ADV PHYS ORG CHEM, V37, P239, DOI 10.1016/S0065-3160(02)37004-7; Birck MR, 2004, J AM CHEM SOC, V126, P6882, DOI 10.1021/ja0492642; BRENEMAN CM, 1990, J COMPUT CHEM, V11, P361, DOI 10.1002/jcc.540110311; Degano M, 1998, BIOCHEMISTRY-US, V37, P6277, DOI 10.1021/bi973012e; ESTUPINAN B, 1994, J BIOL CHEM, V269, P23068; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; FERSHT A, 1985, ENZYME STRUCTURE MEC, P121; Frisch M.J., 2016, GAUSSIAN 16 REVISION; Hehre W.J., 1986, AB INITIO MOL ORBITA, P65; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10788, DOI 10.1021/bi00108a026; Kampf G, 2002, J CHEM SOC PERK T 2, P1320, DOI 10.1039/b202023h; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; Lide D. R., 2007, CRC HDB CHEM PHYS, V129, P724, DOI 10.1021/ja069813z; MCGEE DPC, 1986, CAN J CHEM, V64, P1885, DOI 10.1139/v86-310; Mignon P, 2004, J PHYS CHEM A, V108, P6038, DOI 10.1021/jp049240h; PARKIN DW, 1991, J BIOL CHEM, V266, P20658; Parkin DW, 1996, J BIOL CHEM, V271, P21713, DOI 10.1074/jbc.271.36.21713; Saenger W., 1984, PRINCIPLES NUCLEIC A, P62; Scheiner S, 2002, J AM CHEM SOC, V124, P13257, DOI 10.1021/ja027200q; Vandemeulebroucke A, 2003, BIOCHEMISTRY-US, V42, P12902, DOI 10.1021/bi0347914; Versees W, 2004, J MOL BIOL, V338, P1, DOI 10.1016/j.jmb.2004.02.049; Versees W, 2002, J BIOL CHEM, V277, P15938, DOI 10.1074/jbc.M111735200; Versees W, 2001, J MOL BIOL, V307, P1363, DOI 10.1006/jmbi.2001.4548	24	28	28	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14799	14802		10.1074/jbc.M413231200	http://dx.doi.org/10.1074/jbc.M413231200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15695817	hybrid			2022-12-25	WOS:000228236800057
J	Lu, GM; Chhum, S; Krishnaswamy, S				Lu, GM; Chhum, S; Krishnaswamy, S			The affinity of protein C for the thrombin center dot thrombomodulin complex is determined in a primary way by active site-dependent interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR SUBSTRATE RECOGNITION; EXTRINSIC XASE COMPLEX; FACTOR-X; PROTHROMBINASE COMPLEX; BLOOD-COAGULATION; SERINE PROTEASES; STRUCTURAL BASIS; ACTIVATION; BINDING; SPECIFICITY	The interaction of thrombin (IIa) with thrombomodulin (TM) is essential for the efficient activation of protein C (PC). Interactions between PC and extended surfaces, likely contributed by TM within the IIa.TM complex, have been proposed to play a key role in PC activation. Initial velocities of PC activation at different concentrations of PC and TM could be accounted for by a model that did not require consideration of direct binding interactions between PC and TM. Reversible inhibitors directed toward the active site of IIa within the IIa.TM complex behaved as classic competitive inhibitors of both peptidyl substrate cleavage as well as PC activation. The ability of these small molecule inhibitors to block PC binding to the enzyme points to a principal role for active site-dependent substrate recognition in determining the affinity of IIa.TM for its protein substrate. Selective abrogation of active site docking by mutation of the P1 Arg in PC to Gln yielded an uncleavable derivative (PCR15Q). PCR15Q was a poor inhibitor (K-i >= 30 mu M) of PC activation as well as peptidyl substrate cleavage by IIa.TM. Thus, inhibition by PCR15Q most likely results from its ability to weakly interfere with active site function rather than by blocking extended interactions with the enzyme complex. The data suggest a primary role for active site-dependent substrate recognition in driving the affinity of the IIa.TM complex for its protein substrate. Interactions between PC and extended surfaces contributed by IIa and/or TM within the IIa.TM complex likely contribute in a secondary or minor way to protein substrate affinity.	Childrens Hosp Philadelphia, Joseph Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Krishnaswamy, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Res Inst, 310A Abramson,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	skrishna@mail.med.upenn.edu	Krishnaswamy, Sriram/Z-4380-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL074124, R01HL047465] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-74124, HL-47465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington P. R., 1992, DATA REDUCTION ERROR, P141; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; Camire RM, 2000, BIOCHEMISTRY-US, V39, P14322, DOI 10.1021/bi001074q; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1993, ANNU REV CELL BIOL, V9, P1; EVANS SA, 1982, J BIOL CHEM, V257, P3014; FERSHT A, 1977, ENZYME STRUCTURE MEC, P84; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KLEIN JD, 1986, BIOCHEMISTRY-US, V25, P4175, DOI 10.1021/bi00363a001; Knobe KE, 1999, PROTEINS, V35, P218, DOI 10.1002/(SICI)1097-0134(19990501)35:2<218::AID-PROT8>3.0.CO;2-2; Krishnaswamy S, 2005, J THROMB HAEMOST, V3, P54, DOI 10.1111/j.1538-7836.2004.01021.x; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LEATHERBARROW RJ, 1990, TRENDS BIOCHEM SCI, V15, P455, DOI 10.1016/0968-0004(90)90295-M; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; MUSCI G, 1988, BIOCHEMISTRY-US, V27, P769, DOI 10.1021/bi00402a042; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; OLSEN PH, 1992, BIOCHEMISTRY-US, V31, P746, DOI 10.1021/bi00118a016; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; Orcutt SJ, 2004, J BIOL CHEM, V279, P54927, DOI 10.1074/jbc.M410866200; Orcutt SJ, 2002, J BIOL CHEM, V277, P46191, DOI 10.1074/jbc.M208677200; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Rezaie AR, 2003, P NATL ACAD SCI USA, V100, P12051, DOI 10.1073/pnas.2135346100; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; Wang W, 2000, J BIOL CHEM, V275, P22942, DOI 10.1074/jbc.M001760200; Wilkens M, 2002, J BIOL CHEM, V277, P9366, DOI 10.1074/jbc.M110848200; Xu H, 2005, J BIOL CHEM, V280, P7956, DOI 10.1074/jbc.M412869200; Xu J, 1999, J BIOL CHEM, V274, P6704, DOI 10.1074/jbc.274.10.6704; Yang LK, 2003, J BIOL CHEM, V278, P10484, DOI 10.1074/jbc.M211797200; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1992, J BIOL CHEM, V267, P11023	56	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15471	15478		10.1074/jbc.M500881200	http://dx.doi.org/10.1074/jbc.M500881200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705565	hybrid			2022-12-25	WOS:000228236800135
J	Sadagurski, M; Weingarten, G; Rhodes, CJ; White, MF; Wertheimer, E				Sadagurski, M; Weingarten, G; Rhodes, CJ; White, MF; Wertheimer, E			Insulin receptor substrate 2 plays diverse cell-specific roles in the regulation of glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; GLUT4 TRANSLOCATION; SKIN COMPLICATIONS; SKELETAL-MUSCLE; RESISTANCE; BETA; DIFFERENTIATION; TRANSDUCTION; ACTIVATION	The insulin receptor substrate 2 (IRS-2) protein is one of the major insulin-signaling substrates. In the present study, we investigated the role of IRS-2 in skin epidermal keratinocytes and dermal fibroblasts. Although skin is not a classical insulin target tissue, we have previously demonstrated that insulin, via the insulin receptor, is essential for normal skin cell physiology. To identify the role of IRS-2 in skin cells, we studied cells isolated from IRS-2 knock-out ( KO) mice. Whereas proliferation and differentiation were not affected in the IRS-2 KO cells, a striking effect was observed on glucose transport. In IRS-2 KO keratinocytes, the lack of IRS-2 resulted in a dramatic increase in basal and insulin-stimulated glucose transport. The increase in glucose transport was associated with an increase in total phosphatidylinositol ( PI) 3-kinase and Akt activation. In contrast, fibroblasts lacking IRS-2 exhibited a significant decrease in basal and insulin- induced glucose transport. We identified the point of divergence, leading to these differences between keratinocytes and fibroblasts, at the IRS-PI3- kinase association step. In epidermal keratinocytes, PI 3-kinase is associated with and activated by only the IRS-1 protein. On the other hand, in dermal fibroblasts, PI 3-kinase is exclusively associated with and activated by the IRS-2 protein. These observations suggest that IRS-2 functions as a negative or positive regulator of glucose transport in a cell-specific manner. Our results also show that IRS-2 function depends on its cell-specific association with PI 3-kinase.	Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL-69978 Tel Aviv, Israel; Pacific NW Res Inst, Seattle, WA USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Div Endocrinol, Boston, MA 02115 USA	Tel Aviv University; Sackler Faculty of Medicine; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Wertheimer, E (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL-69978 Tel Aviv, Israel.	effy@patholog.tau.ac.il						Barbour LA, 2004, ENDOCRINOLOGY, V145, P1144, DOI 10.1210/en.2003-1297; Belke DD, 2002, J CLIN INVEST, V109, P629, DOI 10.1172/JCI200213946; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Buren J, 2002, EUR J ENDOCRINOL, V146, P419, DOI 10.1530/eje.0.1460419; Buren J, 2003, EUR J ENDOCRINOL, V148, P157, DOI 10.1530/eje.0.1480157; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; Cushman SW, 1998, ADV EXP MED BIOL, V441, P63; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Fasshauer M, 2000, J BIOL CHEM, V275, P25494, DOI 10.1074/jbc.M004046200; Friedman JE, 1999, DIABETES, V48, P1807, DOI 10.2337/diabetes.48.9.1807; Furtado LM, 2002, BIOCHEM CELL BIOL, V80, P569, DOI 10.1139/O02-156; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; Higaki Y, 1999, J BIOL CHEM, V274, P20791, DOI 10.1074/jbc.274.30.20791; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kitamura T, 2003, ANNU REV PHYSIOL, V65, P313, DOI 10.1146/annurev.physiol.65.092101.142540; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Laviola L, 2001, DIABETES, V50, P2709, DOI 10.2337/diabetes.50.12.2709; Lemieux K, 2003, FASEB J, V17, P1658, DOI 10.1096/fj.02-1125com; Li L, 2004, J BIOL CHEM, V279, P34107, DOI 10.1074/jbc.M312672200; Lingohr MK, 2002, DIABETES, V51, P966, DOI 10.2337/diabetes.51.4.966; Nandi A, 2004, PHYSIOL REV, V84, P623, DOI 10.1152/physrev.00032.2003; Sesti G, 2001, FASEB J, V15, P2099, DOI 10.1096/fj.01-0009rev; Shao JH, 2002, DIABETES, V51, P19, DOI 10.2337/diabetes.51.1.19; Spravchikov N, 2001, DIABETES, V50, P1627, DOI 10.2337/diabetes.50.7.1627; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; WERTHEIMER E, 1994, J BIOL CHEM, V269, P7587; Wertheimer E, 2000, J INVEST DERMATOL, V115, P24, DOI 10.1046/j.1523-1747.2000.00008.x; Wertheimer E, 2004, ISR MED ASSOC J, V6, P287; WERTHEIMER E, 1990, J CELL PHYSIOL, V143, P330, DOI 10.1002/jcp.1041430217; Wertheimer E, 2001, ENDOCRINOLOGY, V142, P1234, DOI 10.1210/en.142.3.1234; Wertheimer E., 2004, DIABETES MELLITUS, P1411; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Zhou LX, 1997, J BIOL CHEM, V272, P29829, DOI 10.1074/jbc.272.47.29829	36	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14536	14544		10.1074/jbc.M410227200	http://dx.doi.org/10.1074/jbc.M410227200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705592	hybrid			2022-12-25	WOS:000228236800025
J	Hay, E; Faucheu, C; Suc-Royer, I; Touitou, R; Stiot, V; Vayssiere, B; Baron, R; Roman-Roman, S; Rawadi, G				Hay, E; Faucheu, C; Suc-Royer, I; Touitou, R; Stiot, V; Vayssiere, B; Baron, R; Roman-Roman, S; Rawadi, G			Interaction between LRP5 and Frat1 mediates the activation of the Wnt canonical pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; SIGNALING PATHWAY; BETA-CATENIN; XENOPUS DEVELOPMENT; RECEPTOR; AXIN; PROTEIN; DICKKOPF-1; MECHANISM; GBP	Low density lipoprotein receptor-related protein 5 (LRP5) has been identified as a Wnt co-receptor involved in the activation of the beta-catenin signaling pathway. To improve our understanding of the molecular mechanisms by which LRP5 triggers the canonical Wnt signaling cascade, we have screened for potential partners of LRP5 using the yeast two-hybrid system and identified Frat1 as a protein interacting with the cytoplasmic domain of LRP5. We demonstrate here that LRP5/Frat1 interaction is involved in beta-catenin nuclear translocation and TCF-1 transcriptional activation. The addition of Wnt3a or overexpression of constitutively active truncated LRP5 (LRP5C) induces Frat1 recruitment to the cell membrane. Overexpression of a dominant negative form of disheveled (Dvl) shows that this protein positively affects LRP5/Frat1 interaction. Furthermore, the fact that dominant negative Dvl does not interfere with LRP5C/Frat1 interaction can explain how LRP5C is capable of acting independently of this major Wnt signaling player. Axin, which has been shown to interact with LRP5 and to be recruited to the membrane through this interaction, was found to co-immunoprecipitate with Frat1 and LRP5. We propose that recruitment of Axin and Frat1 to the membrane by LRP5 leads to both Axin degradation and Frat1-mediated inhibition of glycogen synthase kinase-3. As a consequence, beta-catenin is no longer bound to Axin or phosphorylated by glycogen synthase kinase-3, resulting in TCF-1 activation.	Proskelia Pharmaceut, F-93230 Romainville, France		Rawadi, G (corresponding author), Proskelia Pharmaceut, 102 Route Noisy, F-93230 Romainville, France.	georges.rawadi@prostrakan.com	Roman-Roman, Sergio/K-9993-2014	Roman-Roman, Sergio/0000-0001-6459-2613; Rawadi, Georges/0000-0003-4735-2188; Hay, Eric/0000-0002-0131-9983				Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Ferkey DM, 2002, J BIOL CHEM, V277, P16147, DOI 10.1074/jbc.M112363200; Franca-Koh J, 2002, J BIOL CHEM, V277, P43844, DOI 10.1074/jbc.M207265200; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Freemantle SJ, 2002, GENE, V291, P17, DOI 10.1016/S0378-1119(02)00594-2; Garcia T, 2002, BONE, V31, P205, DOI 10.1016/S8756-3282(02)00781-0; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Jonkers J, 1999, MECH DEVELOP, V88, P183, DOI 10.1016/S0925-4773(99)00187-2; Jossin Y, 2003, CEREB CORTEX, V13, P627, DOI 10.1093/cercor/13.6.627; Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liu GZ, 2003, MOL CELL BIOL, V23, P5825, DOI 10.1128/MCB.23.16.5825-5835.2003; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nusse R, 2001, NATURE, V411, P254, DOI 10.1038/35077199; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Saitoh T, 2001, BIOCHEM BIOPH RES CO, V281, P815, DOI 10.1006/bbrc.2001.4421; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shibamoto S, 1998, GENES CELLS, V3, P659; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; van Amerongen R, 2004, J BIOL CHEM, V279, P26967, DOI 10.1074/jbc.M400439200; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8	36	58	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13616	13623		10.1074/jbc.M411999200	http://dx.doi.org/10.1074/jbc.M411999200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15699046	hybrid			2022-12-25	WOS:000228095500055
J	Schulz, JM; Ross, KL; Malmstrom, K; Krieger, M; Fridovich-Keil, JL				Schulz, JM; Ross, KL; Malmstrom, K; Krieger, M; Fridovich-Keil, JL			Mediators of galactose sensitivity in UDP-galactose 4 '-epimerase-impaired mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIMERASE-DEFICIENCY GALACTOSEMIA; LOW-DENSITY-LIPOPROTEIN; DIPHOSPHATE GALACTOSE-4-EPIMERASE DEFICIENCY; HUMAN UDP-GALACTOSE-4-EPIMERASE; SACCHAROMYCES-CEREVISIAE; N-ACETYLGLUCOSAMINE; LELOIR PATHWAY; EXPRESSION; 4-EPIMERASE; PATIENT	UDP-galactose 4'-epimerase (GALE) catalyzes the final step in the Leloir pathway of galactose metabolism, interconverting UDP-galactose and UDP-glucose. Unlike its Escherichia coli counterpart, mammalian GALE also interconverts UDP-N-acetylgalactosamine and UDP-N-acetylglucosamine. Considering the key roles played by all four of these UDP-sugars in glycosylation, human GALE therefore not only contributes to the Leloir pathway, but also functions as a gatekeeper overseeing the ratios of important substrate pools required for the synthesis of glycosylated macromolecules. Defects in human GALE result in the disorder epimerase-deficiency galactosemia. To explore the relationship among GALE activity, substrate specificity, metabolic balance, and galactose sensitivity in mammalian cells, we employed a previously described GALE-null line of Chinese hamster ovary cells, ldlD. Using a transfection protocol, we generated ldlD derivative cell lines that expressed different levels of wild-type human GALE or E. coli GALE and compared the phenotypes and metabolic profiles of these lines cultured in the presence versus absence of galactose. We found that GALE-null cells accumulated abnormally high levels of Gal-1-P and UDP-Gal and abnormally low levels of UDP-Glc and UDP-GlcNAc in the presence of galactose and that human GALE expression corrected each of these defects. Comparing the human GALE- and E. coli GALE- expressing cells, we found that although GALE activity toward both substrates was required to restore metabolic balance, UDPGalNAc activity was not required for cell proliferation in the presence of otherwise cytostatic concentrations of galactose. Finally, we found that uridine supplementation, which essentially corrected UDP-Glc and, to a lesser extent UDP-GlcNAc depletion, enabled ldlD cells to proliferate in the presence of galactose despite the continued accumulation of Gal-1-P and UDP-Gal. These data offer important insights into the mechanism of galactose sensitivity in epimerase-impaired cells and suggest a potential novel therapy for patients with epimerase-deficiency galactosemia.	Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA; Emory Univ, Grad Program Nutr & Hlth Sci, Atlanta, GA 30322 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Emory University; Emory University; Massachusetts Institute of Technology (MIT)	Fridovich-Keil, JL (corresponding author), Emory Univ, Sch Med, Dept Human Genet, 325-2 Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	jfridov@emory.edu						Alano A, 1998, J INHERIT METAB DIS, V21, P341, DOI 10.1023/A:1005342306080; Berry GT, 2000, PEDIATR RES, V48, P323, DOI 10.1203/00006450-200009000-00010; Berry GT, 2001, MOL GENET METAB, V72, P316, DOI 10.1006/mgme.2001.3151; DOUGLAS HC, 1964, GENETICS, V49, P837; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Hanisch FA, 2001, BIOL CHEM, V382, P143, DOI 10.1515/BC.2001.022; Henderson JM, 2001, CLIN GENET, V60, P350, DOI 10.1034/j.1399-0004.2001.600505.x; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; Holton J. B., 2000, METABOLIC MOL BASES, P1553; HOLTON JB, 1981, ARCH DIS CHILD, V56, P885, DOI 10.1136/adc.56.11.885; ISSELBACHER KJ, 1957, SCIENCE, V126, P652, DOI 10.1126/science.126.3275.652-a; Kabir MA, 2000, MOL GEN GENET, V262, P1113, DOI 10.1007/PL00008654; KEPPLER DOR, 1974, J BIOL CHEM, V249, P211; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KINGSLEY DM, 1986, NEW ENGL J MED, V314, P1257; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1981, J MOL BIOL, V150, P167, DOI 10.1016/0022-2836(81)90447-2; Krieger M, 1986, Methods Enzymol, V129, P227; KRIEGER M, 1989, METHOD CELL BIOL, V32, P57; Lai K, 2000, BIOCHEM BIOPH RES CO, V271, P392, DOI 10.1006/bbrc.2000.2629; Lai K, 2003, GLYCOBIOLOGY, V13, P285, DOI 10.1093/glycob/cwg033; Leslie ND, 2001, MOL GENET METAB, V72, P31, DOI 10.1006/mgme.2000.3116; Mehta DV, 1999, BBA-MOL BASIS DIS, V1454, P217, DOI 10.1016/S0925-4439(99)00037-X; PILLER F, 1983, J BIOL CHEM, V258, P774; Quimby BB, 1997, AM J HUM GENET, V61, P590, DOI 10.1086/515517; Riehman K, 2001, J BIOL CHEM, V276, P10634, DOI 10.1074/jbc.M009583200; Ross KL, 2004, MOL GENET METAB, V83, P103, DOI 10.1016/j.ymgme.2004.07.005; SARDHARWALLA IB, 1988, J INHERIT METAB DIS, V11, P249, DOI 10.1007/BF01804249; Schulz JM, 2004, J BIOL CHEM, V279, P32796, DOI 10.1074/jbc.M405005200; SEGAL S, 1995, EUR J PEDIATR, V154, pS65, DOI 10.1007/BF02143806; SEGAL S, 1995, METABOLIC MOL BASIS, V7, P967; Shin YS, 2000, J INHERIT METAB DIS, V23, P383, DOI 10.1023/A:1005699719068; Smits HP, 1998, ANAL BIOCHEM, V261, P36, DOI 10.1006/abio.1998.2714; Thoden JB, 2002, J BIOL CHEM, V277, P27528, DOI 10.1074/jbc.M204413200; Thoden JB, 2001, J BIOL CHEM, V276, P15131, DOI 10.1074/jbc.M100220200; Walter JH, 1999, ARCH DIS CHILD, V80, P374, DOI 10.1136/adc.80.4.374; Wasilenko J, 2005, MOL GENET METAB, V84, P32, DOI 10.1016/j.ymgme.2004.09.003; Wohlers TM, 2000, J INHERIT METAB DIS, V23, P713, DOI 10.1023/A:1005682913784; Wohlers TM, 1999, AM J HUM GENET, V64, P462, DOI 10.1086/302263	39	26	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13493	13502		10.1074/jbc.M414045200	http://dx.doi.org/10.1074/jbc.M414045200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15701638	hybrid			2022-12-25	WOS:000228095500040
J	Tsuji, T; Kunieda, T				Tsuji, T; Kunieda, T			A loss-of-function mutation in natriuretic peptide receptor 2 (Npr2) gene is responsible for disproportionate dwarfism in cn/cn mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-II; CN-CN MICE; ENDOCHONDRAL OSSIFICATION; GROWTH-PLATE; ACROMESOMELIC DYSPLASIA; GUANYLATE-CYCLASE; SKELETAL GROWTH; MESSENGER-RNA; CARTILAGE; CHONDROCYTES	The achondroplastic mouse is a spontaneous mutant characterized by disproportionate dwarfism with short limbs and tail due to disturbed chondrogenesis during endochondral ossification. These abnormal phenotypes are controlled by an autosomal recessive gene (cn). In this study, linkage analysis using 115 affected mice of F-2 progeny mapped the cn locus on an similar to 0.8-cM region of chromosome 4, and natriuretic peptide receptor 2 (Npr2) gene was identified as the most potent candidate for the cn mutant in this region. This gene encodes a receptor for C-type natriuretic peptide (CNP) that positively regulates longitudinal bone growth by producing cGMP in response to CNP binding to the extracellular domain. Sequence analyses of the Npr2 gene in cn/cn mice revealed a T to G transversion leading to the amino acid substitution of highly conserved Leu with Arg in the guanylyl cyclase domain. In cultured chondrocytes of cn/cn mice, stimulus with CNP did not significantly increase intracellular cGMP concentration, whereas it increased in +/+ mice. Transfection of the mutant Npr2 gene into COS-7 cells also showed similar results, indicating that the missense mutation of the Npr2 gene in cn/cn mice resulted in disruption of the guanylyl cyclase activity of the receptor. We therefore concluded that the dwarf phenotype of cn/cn mouse is caused by a loss-of-function mutation of the Npr2 gene, and cn/cn mouse will be a useful model to further study the molecular mechanism regulating endochondral ossification by CNP/natriuretic peptide receptor B signal.	Okayama Univ, Grad Sch Nat Sci & Technol, Okayama 7008530, Japan	Okayama University	Tsuji, T (corresponding author), Okayama Univ, Grad Sch Nat Sci & Technol, 1-1-1 Tsushima Naka, Okayama 7008530, Japan.	takehito@cc.okayama-u.ac.jp						Bartels CF, 2004, AM J HUM GENET, V75, P27, DOI 10.1086/422013; Cameron VA, 2003, ENDOCRINOLOGY, V144, P2191, DOI 10.1210/en.2003-0127; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098; Cohen MM, 2002, AM J MED GENET, V112, P304, DOI 10.1002/ajmg.10780; DELMARCO A, 1981, REPROD NUTR DEV, V21, P1025, DOI 10.1051/rnd:19810715; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; JEWETT JRS, 1993, EMBO J, V12, P769, DOI 10.1002/j.1460-2075.1993.tb05711.x; JOHNSON DR, 1978, J ANAT, V125, P267; LANE PW, 1968, J HERED, V59, P300, DOI 10.1093/oxfordjournals.jhered.a107725; LANGER LO, 1980, RADIOLOGY, V137, P349, DOI 10.1148/radiology.137.2.7433666; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; Levin ER, 1998, NEW ENGL J MED, V339, P321; LOPEZ MJ, 1995, NATURE, V378, P65, DOI 10.1038/378065a0; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MAROTEAUX P, 1971, PRESSE MED, V79, P1839; Mericq V, 2000, PEDIATR RES, V47, P189, DOI 10.1203/00006450-200002000-00007; Miyazawa T, 2002, ENDOCRINOLOGY, V143, P3604, DOI 10.1210/en.2002-220307; Naski MC, 1998, DEVELOPMENT, V125, P4977; Newman B, 2003, CLIN GENET, V63, P241, DOI 10.1034/j.1399-0004.2003.00046.x; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; SANNASGALA SSMMK, 1990, J ANAT, V172, P245; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SILBERBERG R, 1975, GROWTH, V39, P17; Stepan H, 2000, REGUL PEPTIDES, V95, P81, DOI 10.1016/S0167-0115(00)00141-5; Suda M, 2002, J BONE MINER METAB, V20, P136, DOI 10.1007/s007740200019; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; THURSTON MN, 1985, J ANAT, V140, P425; Tokudome T, 2004, ENDOCRINOLOGY, V145, P2131, DOI 10.1210/en.2003-1260; WIKSTROM B, 1986, COLLAGEN REL RES, V6, P279; Yamashita Y, 2000, J BIOCHEM-TOKYO, V127, P177, DOI 10.1093/oxfordjournals.jbchem.a022591; Yasoda A, 2004, NAT MED, V10, P80, DOI 10.1038/nm971; Yasoda A, 1998, J BIOL CHEM, V273, P11695, DOI 10.1074/jbc.273.19.11695	34	102	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14288	14292		10.1074/jbc.C500024200	http://dx.doi.org/10.1074/jbc.C500024200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15722353	hybrid			2022-12-25	WOS:000228095500132
J	Wang, YZ; Wang, JN; Gao, L; Lafyatis, R; Stamm, S; Andreadis, A				Wang, YZ; Wang, JN; Gao, L; Lafyatis, R; Stamm, S; Andreadis, A			Tau exons 2 and 10, which are misregulated in neurodegenerative diseases, are partly regulated by silencers which bind a SRp30c center dot SRp55 complex that either recruits or antagonizes htra2 beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; EXONIC SPLICING ENHANCER; CAUSES FRONTOTEMPORAL DEMENTIA; TAU-PROTEIN; MYOTONIC-DYSTROPHY; ALZHEIMERS-DISEASE; PROJECTION DOMAIN; HUMAN-BRAIN; EXPRESSION; GENE	Tau is a microtubule- associated protein whose transcript undergoes complex regulated splicing in the mammalian nervous system. Exon 2 modulates the tau N- terminal domain, which interacts with the axonal membrane. Exon 10 codes for a microtubule binding domain, increasing the affinity of tau for microtubules. Both exons are excluded from fetal brain, but their default behavior is inclusion, suggesting that silencers are involved in their regulation. Exon 2 is significantly reduced in myotonic dystrophy type 1, whose symptoms include dementia. Mutations that affect exon 10 splicing cause frontotemporal dementia ( FTDP). In this study, we investigated three regulators of exon 2 and 10 splicing: serine/ arginine- rich ( SR) proteins SRp55, SRp30c, and htra2 beta 1. The first two inhibit both exons; htra2 beta 1 inhibits exon 2 but activates exon 10. By deletion analysis, we identified splicing silencers located at the 5' end of each exon. Furthermore, we demonstrated that SRp30c and SRp55 bind to both silencers and to each other. In exon 2, htra2 beta 1 binds to the inhibitory heterodimer through its RS1 domain but not to exon 2, whereas in exon 10 the heterodimer may sterically interfere with htra2 beta 1 binding to a purine- rich enhancer ( defined by FTDP mutation E10- Delta 5 = Delta 280K) directly downstream of the silencer. Increased exon 10 inclusion in FTDP mutant ENH ( N279K) may arise from abolishing SRp30c binding. Also, htra2 beta 3, a naturally occurring variant of htra2 beta 1, no longer inhibits exon 2 splicing but can partially rescue splicing of exon 10 in FTDP mutation E10- Delta 5. This work provides interesting insights into the splicing regulation of the tau gene.	Univ Massachusetts, Sch Med, Shriver Ctr, Waltham, MA 02452 USA; Boston Univ, Sch Med, Ctr Arthritis, Boston, MA 02118 USA; Univ Erlangen Nurnberg, Dept Biochem, D-91054 Erlangen, Germany; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	University of Massachusetts System; Boston University; University of Erlangen Nuremberg; University of Massachusetts System; University of Massachusetts Worcester	Andreadis, A (corresponding author), Univ Massachusetts, Sch Med, Shriver Ctr, 200 Trapelo Rd, Waltham, MA 02452 USA.	athena.andreadis@umassmed.edu	Wang, Jenny Y./ABD-2091-2020	Lafyatis, Robert/0000-0002-9398-5034; Wang, Jenny Y./0000-0002-1325-7943	NIA NIH HHS [R01 AG18486] Funding Source: Medline; NINDS NIH HHS [R01 NS38051] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018486] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREADIS A, 1995, NUCLEIC ACIDS RES, V23, P3585, DOI 10.1093/nar/23.17.3585; Andreadis A, 2005, BBA-MOL BASIS DIS, V1739, P91, DOI 10.1016/j.bbadis.2004.08.010; Arikan MC, 2002, MOL BRAIN RES, V101, P109, DOI 10.1016/S0169-328X(02)00178-X; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BRANDT R, 1995, J CELL BIOL, V131, P1327, DOI 10.1083/jcb.131.5.1327; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; D'Souza I, 2000, J BIOL CHEM, V275, P17700, DOI 10.1074/jbc.M909470199; D'Souza I, 2002, J BIOL CHEM, V277, P26587, DOI 10.1074/jbc.M203794200; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; FRAPPIER TF, 1994, J NEUROCHEM, V63, P2288; Gao QS, 2000, J NEUROCHEM, V74, P490, DOI 10.1046/j.1471-4159.2000.740490.x; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Grabowski PJ, 1998, CELL, V92, P709, DOI 10.1016/S0092-8674(00)81399-9; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Hanamura A, 1998, RNA, V4, P430; Hartmann AM, 2001, MOL CELL NEUROSCI, V18, P80, DOI 10.1006/mcne.2001.1000; Hofmann Y, 2000, P NATL ACAD SCI USA, V97, P9618, DOI 10.1073/pnas.160181697; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; Jiang H, 2004, HUM MOL GENET, V13, P3079, DOI 10.1093/hmg/ddh327; Jiang ZH, 2003, J BIOL CHEM, V278, P18997, DOI 10.1074/jbc.M301800200; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; KANAI Y, 1992, EMBO J, V11, P3953, DOI 10.1002/j.1460-2075.1992.tb05489.x; Kempf M, 1996, J NEUROSCI, V16, P5583; Kondo S, 2004, GENES CELLS, V9, P121, DOI 10.1111/j.1356-9597.2004.00709.x; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; Lee G, 2004, J NEUROSCI, V24, P2304, DOI 10.1523/JNEUROSCI.4162-03.2004; Lemaire R, 1999, EUR J IMMUNOL, V29, P823, DOI 10.1002/(SICI)1521-4141(199903)29:03<823::AID-IMMU823>3.0.CO;2-C; Li K, 2003, MOL BRAIN RES, V116, P94, DOI 10.1016/S0169-328X(03)00259-6; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; Nayler O, 1998, GENOMICS, V53, P191, DOI 10.1006/geno.1998.5471; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Ranum LPW, 2002, CURR OPIN GENET DEV, V12, P266, DOI 10.1016/S0959-437X(02)00297-6; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Sergeant N, 2001, HUM MOL GENET, V10, P2143, DOI 10.1093/hmg/10.19.2143; Simard MJ, 2002, MOL CELL BIOL, V22, P4001, DOI 10.1128/MCB.22.12.4001-4010.2002; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stamm S, 1999, MOL BRAIN RES, V64, P108, DOI 10.1016/S0169-328X(98)00313-1; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; Stanford PM, 2003, BRAIN, V126, P814, DOI 10.1093/brain/awg090; Stoilov P, 2002, DNA CELL BIOL, V21, P803, DOI 10.1089/104454902320908450; Stoilov P, 2004, HUM MOL GENET, V13, P509, DOI 10.1093/hmg/ddh051; Thanaraj T A, 2003, Prog Mol Subcell Biol, V31, P1; Tran Q, 2003, BBA-GENE STRUCT EXPR, V1625, P141, DOI 10.1016/S0167-4781(02)00600-0; Tran Q, 2003, BIOCHEMISTRY-US, V42, P951, DOI 10.1021/bi026753a; Wang JN, 2004, J NEUROCHEM, V88, P1078, DOI 10.1046/j.1471-4159.2003.02232.x; Young PJ, 2002, HUM MOL GENET, V11, P577, DOI 10.1093/hmg/11.5.577; Zheng ZM, 2004, J BIOMED SCI, V11, P278, DOI 10.1159/000077096	58	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14230	14239		10.1074/jbc.M413846200	http://dx.doi.org/10.1074/jbc.M413846200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695522	hybrid			2022-12-25	WOS:000228095500126
J	Izeradjene, K; Douglas, L; Delaney, A; Houghton, JA				Izeradjene, K; Douglas, L; Delaney, A; Houghton, JA			Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines	ONCOGENE			English	Article						TRAIL; apoptosis; DISC; CK2	KAPPA-B-ALPHA; MEDIATED APOPTOSIS; CANCER-CELLS; ACTIVATION; CD95; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION; CLEAVAGE; LIGAND	Protein kinase casein kinase II (CK2) is increased in response to diverse growth stimuli, as well as being elevated in many human cancers examined. We have demonstrated that CK2 is a key survival factor that protects human colon carcinoma cells from TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. We determined that inhibition of CK2 phosphorylation events by DRB (5,6- dichlorobenzimidazole) resulted in dramatic sensitization of tumor cells to TRAIL-induced apoptosis, in the absence of effects in normal cells. Sensitization was caspase dependent, and independent of regulation via NF-kappa B. Further, inhibition of phosphorylation by CK2 did not modify the expression level of antiapoptotic proteins. Analysis of TRAIL-induced death-inducing signaling complex ( DISC) formation demonstrated enhanced formation of the DISC, enhanced cleavage of caspase-8 and cleavage of Bid in the presence of DRB, thereby facilitating the release of proapoptotic factors from the mitochondria with subsequent down-regulation of the expression of XIAP and c-IAP1. Further, silencing of CK2 alpha in HT29 cells following transfection of CK2 alpha shRNA abrogated CK2 kinase activity while simultaneously increasing TRAIL sensitivity. These findings demonstrate that CK2 plays a critical antiapoptotic role by conferring resistance to TRAIL at the level of the DISC.	St Jude Childrens Res Hosp, Div Mol Therapeut, Dept Hematol Oncol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Izeradjene, K (corresponding author), St Jude Childrens Res Hosp, Div Mol Therapeut, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	izeradjene@stjude.org			NCI NIH HHS [CA 32613, CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032613, R37CA032613, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Faust RA, 1999, INT J BIOCHEM CELL B, V31, P941, DOI 10.1016/S1357-2725(99)00050-3; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Guo CH, 2001, J BIOL CHEM, V276, P5992, DOI 10.1074/jbc.M004862200; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Holmstrom TH, 2000, CRIT REV IMMUNOL, V20, P121; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Jeremias I, 1998, EUR CYTOKINE NETW, V9, P687; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; Krippner-Heidenreich A, 2001, BIOCHEM J, V358, P705, DOI 10.1042/0264-6021:3580705; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Petak I, 2003, CELL DEATH DIFFER, V10, P729, DOI 10.1038/sj.cdd.4401232; Ravi R, 2002, CANCER RES, V62, P4180; Romieu-Mourez R, 2002, CANCER RES, V62, P6770; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Sarker M, 2002, ONCOGENE, V21, P4323, DOI 10.1038/sj.onc.1205523; Sarker M, 2001, CELL DEATH DIFFER, V8, P172, DOI 10.1038/sj.cdd.4400791; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Tillman DM, 1998, CELL DEATH DIFFER, V5, P450, DOI 10.1038/sj.cdd.4400369; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; Varadhachary AS, 2001, J IMMUNOL, V166, P6564, DOI 10.4049/jimmunol.166.11.6564; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang HM, 2001, MOL CELL BIOCHEM, V227, P167, DOI 10.1023/A:1013112908734; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729	43	70	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2050	2058		10.1038/sj.onc.1208397	http://dx.doi.org/10.1038/sj.onc.1208397			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688023				2022-12-25	WOS:000227681900009
J	Robb, VA; Gerber, MA; Hart-Mahon, EK; Gutmann, DH				Robb, VA; Gerber, MA; Hart-Mahon, EK; Gutmann, DH			Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression	ONCOGENE			English	Article						meningioma; brain tumor; Protein 4.1B; DAL-1; tumor suppressor	TUMOR-SUPPRESSOR; NF2 GENE; FUNCTIONAL-CHARACTERIZATION; MERLIN EXPRESSION; CELL-SURVIVAL; DAL-1; IDENTIFICATION; ASSOCIATION; ACTIVATION; EZRIN	Meningiomas are common central nervous system tumors; however, the molecular mechanisms underlying their pathogenesis are largely undefined. Previous work has implicated Protein 4.1B as an important tumor suppressor involved in the development of these neoplasms. In this report, we demonstrate that the U2 domain is necessary and sufficient for the ability of Protein 4.1B to function as a meningioma growth suppressor. Using a series of truncation and deletion constructs of DAL-1 (a fragment of Protein 4.1B that retains all the growth suppressive properties), we narrowed the domain required for 4.1B growth suppression to a fragment containing a portion of the FERM domain and the U2 domain using clonogenic assays on meningioma cells. Deletion of the U2 domain in the context of the full-length DAL-1 molecule eliminated growth suppressor function, as measured by thymidine incorporation and caspase-3 activation. Moreover, targeting the U2 domain to the plasma membrane using a membrane localization signal (MLS) reduced cell proliferation, similar to wild-type DAL-1. Collectively, the data suggest that the U2 domain, when properly targeted to the plasma membrane, contains all the residues necessary for mediating Protein 4.1B growth suppression.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu		Gutmann, David/0000-0002-3127-5045	NCI NIH HHS [1-F32-CA-097816-01] Funding Source: Medline; NINDS NIH HHS [NS41520] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA097816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bostrom J, 2001, AM J PATHOL, V159, P661, DOI 10.1016/S0002-9440(10)61737-3; Brault E, 2001, J CELL SCI, V114, P1901; Cai DX, 2001, AM J CLIN PATHOL, V115, P213; Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; Dard N, 2004, DEV BIOL, V271, P87, DOI 10.1016/j.ydbio.2004.03.024; Deguen B, 1998, HUM MOL GENET, V7, P217, DOI 10.1093/hmg/7.2.217; Denisenko-Nehrbass N, 2003, EUR J NEUROSCI, V17, P411, DOI 10.1046/j.1460-9568.2003.02441.x; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Gutmann DH, 2001, NEUROBIOL DIS, V8, P266, DOI 10.1006/nbdi.2000.0376; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; Holgado-Madruga M, 2003, MOL CELL BIOL, V23, P4471, DOI 10.1128/MCB.23.13.4471-4484.2003; Huang S, 2001, EUR J CLIN INVEST, V31, P907, DOI 10.1046/j.1365-2362.2001.00892.x; Huynh DP, 1997, J NEUROPATH EXP NEUR, V56, P382, DOI 10.1097/00005072-199704000-00007; Ikeda K, 1999, J NEUROSURG, V91, P85, DOI 10.3171/jns.1999.91.1.0085; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; Kanda H, 2004, J BIOCHEM, V136, P1, DOI 10.1093/jb/mvh098; Kim H, 2004, J BIOL CHEM, V279, P7812, DOI 10.1074/jbc.M305526200; LEE WH, 1990, NEUROSURGERY, V27, P389, DOI 10.1227/00006123-199009000-00008; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Leone PE, 1999, ONCOGENE, V18, P2231, DOI 10.1038/sj.onc.1202531; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; Lozupone F, 2004, J BIOL CHEM, V279, P9199, DOI 10.1074/jbc.M305561200; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Matsuguchi T, 2003, EMBO J, V22, P4455, DOI 10.1093/emboj/cdg438; Menon AG, 1997, ONCOGENE, V14, P611, DOI 10.1038/sj.onc.1200853; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; Perry A, 1996, CANCER, V77, P2567, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2567::AID-CNCR21>3.0.CO;2-P; Perry A, 2001, J NEUROPATH EXP NEUR, V60, P994, DOI 10.1093/jnen/60.10.994; Perry A, 2000, J NEUROPATH EXP NEUR, V59, P872, DOI 10.1093/jnen/59.10.872; Peters LL, 1998, GENOMICS, V54, P348, DOI 10.1006/geno.1998.5537; Robb VA, 2003, NEUROBIOL DIS, V13, P191, DOI 10.1016/S0969-9961(03)00071-8; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; SIMON M, 1995, CANCER RES, V55, P4696; Singh V, 2004, ONCOGENE, V23, P7761, DOI 10.1038/sj.onc.1208057; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Sun YQ, 2004, MOL CELL BIOL, V24, P1531, DOI 10.1128/MCB.24.4.1531-1539.2004; Surace EI, 2004, ANN NEUROL, V56, P295, DOI 10.1002/ana.20201; TCHERNIA G, 1981, J CLIN INVEST, V68, P454, DOI 10.1172/JCI110275; Toby G, 1998, BIOTECHNIQUES, V24, P637, DOI 10.2144/98244st05; Tran YK, 1999, CANCER RES, V59, P35; Tse JYM, 1998, HUM PATHOL, V29, P1200, DOI 10.1016/S0046-8177(98)90246-5; Ueki K, 1999, CANCER RES, V59, P5995; Weber RG, 1997, P NATL ACAD SCI USA, V94, P14719, DOI 10.1073/pnas.94.26.14719; Yageta M, 2002, CANCER RES, V62, P5129; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yu TX, 2002, BIOCHEM J, V365, P783, DOI 10.1042/BJ20020060; Zhang SP, 2003, J BIOL CHEM, V278, P52810, DOI 10.1074/jbc.M308244200	53	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1946	1957		10.1038/sj.onc.1208335	http://dx.doi.org/10.1038/sj.onc.1208335			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688033				2022-12-25	WOS:000227542000013
J	Hitomi, K; Oyama, T; Han, SG; Arvai, AS; Getzoff, ED				Hitomi, K; Oyama, T; Han, SG; Arvai, AS; Getzoff, ED			Tetrameric architecture of the circadian clock protein KaiB - A novel interface for intermolecular interactions and its impact on the circadian rhythm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCOCCUS-ELONGATUS; CRYSTAL-STRUCTURE; HISTIDINE KINASE; CYANOBACTERIA; SASA; SYSTEM; OSCILLATION; MECHANISM; EVOLUTION; BACTERIA	Cyanobacteria are among the simplest organisms that show daily rhythmicity. Their circadian rhythms consist of the localization, interaction, and accumulation of various proteins, including KaiA, KaiB, KaiC, and SasA. We have determined the 1.9-angstrom resolution crystallographic structure of the cyanobacterial KaiB clock protein from Synechocystis sp. PCC6803. This homotetrameric structure reveals a novel KaiB interface for protein-protein interaction; the protruding hydrophobic helix-turn-helix motif of one subunit fits into a groove between two beta-strands of the adjacent subunit. A cyanobacterial mutant, in which the Asp-Lys salt bridge mediating this tetramer-forming interaction is disrupted by mutation of Asp to Gly, exhibits severely impaired rhythmicity (a short free-running period; similar to 19 h). The KaiB tetramer forms an open square, with positively charged residues around the perimeter. KaiB is localized on the phospholipid-rich membrane and translocates to the cytosol to interact with the other Kai components, KaiA and KaiC. KaiB antagonizes the action of KaiA on KaiC, and shares a sequence-homologous domain with the SasA kinase. Based on our structure, we discuss functional roles for KaiB in the circadian clock.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Japan Sci & Technol Agcy, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Scripps Research Institute; Scripps Research Institute; Japan Science & Technology Agency (JST)	Oyama, T (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Furu Cho, Nagoya, Aichi 4648602, Japan.	oyama@bio.nagoya-u.ac.jp; edg@scripps.edu			NIGMS NIH HHS [R01 GM37684] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037684] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ditty JL, 2003, ANNU REV GENET, V37, P513, DOI 10.1146/annurev.genet.37.110801.142716; Dvornyk V, 2004, MOL BIOL EVOL, V21, P1468, DOI 10.1093/molbev/msh106; Dvornyk V, 2003, P NATL ACAD SCI USA, V100, P2495, DOI 10.1073/pnas.0130099100; Garces RG, 2004, EMBO J, V23, P1688, DOI 10.1038/sj.emboj.7600190; Golden SS, 2003, NAT REV MICROBIOL, V1, P191, DOI 10.1038/nrmicro774; Golden SS, 1997, ANNU REV PLANT PHYS, V48, P327, DOI 10.1146/annurev.arplant.48.1.327; Golden SS, 2003, CURR OPIN MICROBIOL, V6, P535, DOI 10.1016/j.mib.2003.10.012; Hayashi F, 2003, GENES CELLS, V8, P287, DOI 10.1046/j.1365-2443.2003.00633.x; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Iwasaki H, 2000, CELL, V101, P223, DOI 10.1016/S0092-8674(00)80832-6; Iwasaki H, 1999, EMBO J, V18, P1137, DOI 10.1093/emboj/18.5.1137; Iwase R, 2004, ACTA CRYSTALLOGR D, V60, P727, DOI 10.1107/S0907444904002112; Johnson CH, 2004, NATURE, V430, P23, DOI 10.1038/430023a; Kageyama H, 2003, J BIOL CHEM, V278, P2388, DOI 10.1074/jbc.M208899200; Kitayama Y, 2003, EMBO J, V22, P2127, DOI 10.1093/emboj/cdg212; Klewer DA, 2002, J BIOMOL NMR, V24, P77, DOI 10.1023/A:1020649703380; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nishimura H, 2002, MICROBIOL-SGM, V148, P2903, DOI 10.1099/00221287-148-9-2903; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pattanayek R, 2004, MOL CELL, V15, P375, DOI 10.1016/j.molcel.2004.07.013; Uzumaki T, 2004, NAT STRUCT MOL BIOL, V11, P623, DOI 10.1038/nsmb781; Vakonakis I, 2004, J MOL BIOL, V342, P9, DOI 10.1016/j.jmb.2004.07.010; Vakonakis L, 2004, P NATL ACAD SCI USA, V101, P1479, DOI 10.1073/pnas.0305516101; Williams SB, 2002, P NATL ACAD SCI USA, V99, P15357, DOI 10.1073/pnas.232517099; Xu Y, 2003, EMBO J, V22, P2117, DOI 10.1093/emboj/cdg168; Ye S, 2004, J BIOL CHEM, V279, P20511, DOI 10.1074/jbc.M400077200	29	72	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19127	19135		10.1074/jbc.M411284200	http://dx.doi.org/10.1074/jbc.M411284200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15716274	hybrid			2022-12-25	WOS:000228932300069
J	Coustou, V; Besteiro, S; Riviere, L; Biran, M; Biteau, N; Franconi, JM; Boshart, M; Baltz, T; Bringaud, F				Coustou, V; Besteiro, S; Riviere, L; Biran, M; Biteau, N; Franconi, JM; Boshart, M; Baltz, T; Bringaud, F			A mitochondrial NADH-dependent fumarate reductase involved in the production of succinate excreted by procyclic Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; SUBSTRATE LEVEL PHOSPHORYLATION; MOLECULAR CHARACTERIZATION; ENERGY-METABOLISM; CARBOHYDRATE-METABOLISM; INTERFERENCE RNAI; COA-TRANSFERASE; GLYCEROL KINASE; DEHYDROGENASE; CRUZI	Trypanosoma brucei is a parasitic protist responsible for sleeping sickness in humans. The procyclic stage of T. brucei expresses a soluble NADH-dependent fumarate reductase (FRDg) in the peroxisome-like organelles called glycosomes. This enzyme is responsible for the production of about 70% of the excreted succinate, the major end product of glucose metabolism in this form of the parasite. Here we functionally characterize a new gene encoding FRD (FRDm1) expressed in the procyclic stage. FRDm1 is a mitochondrial protein, as evidenced by immunolocalization, fractionation of digitonin-permeabilized cells, and expression of EGFP-tagged FRDm1 in the parasite. RNA interference was used to deplete FRDm1, FRDg, or both together. The analysis of the resulting mutant cell lines showed that FRDm1 is responsible for 30% of the cellular NADH-FRD activity, which solves a long standing debate regarding the existence of a mitochondrial FRD in trypanosomatids. FRDg and FRDm1 together account for the total NADH-FRD activity in procyclics, because no activity was measured in the double mutant lacking expression of both proteins. Analysis of the end products of C-13-enriched glucose excreted by these mutant cell lines showed that FRDm1 contributes to the production of between 14 and 44% of the succinate excreted by the wild type cells. In addition, depletion of one or both FRD enzymes results in up to 2-fold reduction of the rate of glucose consumption. We propose that FRDm1 is involved in the maintenance of the redox balance in the mitochondrion, as proposed for the ancestral soluble FRD presumably present in primitive anaerobic cells.	Univ Bordeaux 2, CNRS, UMR 5162, Lab Genom Fonct Trypanosomatides, F-33076 Bordeaux, France; Univ Bordeaux 2, CNRS, UMR 5536, F-33076 Bordeaux, France; Univ Munich, Dept Biol 1, D-80638 Munich, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; University of Munich	Bringaud, F (corresponding author), Univ Bordeaux 2, CNRS, UMR 5162, Lab Genom Fonct Trypanosomatides, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	bringaud@u-bordeaux2.fr	Besteiro, Sébastien/F-3622-2014; Boshart, Michael/A-2700-2011	Besteiro, Sébastien/0000-0003-1853-1494; Boshart, Michael/0000-0002-5070-2663; Biteau, Nicolas/0000-0003-1301-0665				Arikawa Y, 1998, FEMS MICROBIOL LETT, V165, P111, DOI 10.1111/j.1574-6968.1998.tb13134.x; Bastin P, 2000, J CELL SCI, V113, P3321; Besteiro S, 2002, J BIOL CHEM, V277, P38001, DOI 10.1074/jbc.M201759200; BESTEIRO S, 2005, IN PRESS TRENDS PARA; Bochud-Allemann N, 2002, J BIOL CHEM, V277, P32849, DOI 10.1074/jbc.M205776200; BOVERIS A, 1986, MOL BIOCHEM PARASIT, V19, P163, DOI 10.1016/0166-6851(86)90121-0; Bringaud F, 1995, MOL BIOCHEM PARASIT, V74, P119, DOI 10.1016/0166-6851(95)02486-7; Bringaud F, 1998, MOL BIOCHEM PARASIT, V94, P249, DOI 10.1016/S0166-6851(98)00080-2; Bringaud F, 2000, MOL BIOCHEM PARASIT, V111, P283, DOI 10.1016/S0166-6851(00)00319-4; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; BRUN R, 1979, ACTA TROP, V36, P289; CAZZULO JJ, 1992, FASEB J, V6, P3153, DOI 10.1096/fasebj.6.13.1397837; Chen M, 2001, APMIS, V109, P801, DOI 10.1034/j.1600-0463.2001.091201.x; Chen M, 2001, ANTIMICROB AGENTS CH, V45, P2023, DOI 10.1128/AAC.45.7.2023-2029.2001; Christmas PB, 2000, FEMS MICROBIOL LETT, V183, P225, DOI 10.1111/j.1574-6968.2000.tb08962.x; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Coustou V, 2003, J BIOL CHEM, V278, P49625, DOI 10.1074/jbc.M307872200; CROSS GAM, 1975, PARASITOLOGY, V71, P311, DOI 10.1017/S0031182000046758; DaRocha WD, 2004, MOL BIOCHEM PARASIT, V133, P175, DOI 10.1016/j.molbiopara.2003.10.005; Denicola A, 2002, COMP BIOCHEM PHYS B, V133, P23, DOI 10.1016/S1096-4959(02)00094-5; DENICOLASEOANE A, 1992, MOL BIOCHEM PARASIT, V54, P43, DOI 10.1016/0166-6851(92)90093-Y; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; Fang J, 2002, BIOCHEMISTRY-US, V41, P3065, DOI 10.1021/bi015989w; Fang J, 2001, EUR J BIOCHEM, V268, P3075, DOI 10.1046/j.1432-1327.2001.02205.x; FREEMAN R, 1981, J MAGN RESON, V42, P341, DOI 10.1016/0022-2364(81)90227-4; GEST H, 1980, FEMS MICROBIOL LETT, V7, P73, DOI 10.1111/j.1574-6941.1980.tb01579.x; HAMMOND DJ, 1980, MOL BIOCHEM PARASIT, V2, P77, DOI 10.1016/0166-6851(80)90033-X; HAMMOND DJ, 1985, J BIOL CHEM, V260, P5646; Hannaert Veronique, 2003, Kinetoplastid Biology and Disease, V2, pUnpaginated; Harlow E., 1988, ANTIBODIES LAB MANUA; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Lamour N, 2005, J BIOL CHEM, V280, P11902, DOI 10.1074/jbc.M414274200; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Marche S, 2000, MOL BIOCHEM PARASIT, V106, P83, DOI 10.1016/S0166-6851(99)00204-2; Michels PAM, 2000, PARASITOL TODAY, V16, P482, DOI 10.1016/S0169-4758(00)01810-X; MRACEK J, 1991, J PROTOZOOL, V38, P554, DOI 10.1111/j.1550-7408.1991.tb06079.x; MURATSUBAKI H, 1994, PREP BIOCHEM, V24, P289, DOI 10.1080/10826069408010100; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Obungu VH, 1999, INDIAN J BIOCHEM BIO, V36, P305; OPPERDOES FR, 1981, MOL BIOCHEM PARASIT, V4, P291, DOI 10.1016/0166-6851(81)90062-1; PEALING SL, 1992, BIOCHEMISTRY-US, V31, P12132, DOI 10.1021/bi00163a023; Riviere L, 2004, J BIOL CHEM, V279, P45337, DOI 10.1074/jbc.M407513200; Robinson KA, 2003, MOL BIOCHEM PARASIT, V128, P217, DOI 10.1016/S0166-6851(03)00079-3; ROTHMAN DL, 1985, P NATL ACAD SCI USA, V82, P1633, DOI 10.1073/pnas.82.6.1633; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCHEZMORENO M, 1992, MOL BIOCHEM PARASIT, V54, P185, DOI 10.1016/0166-6851(92)90111-V; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; SIMPSON L, 1972, INT REV CYTOL, V32, P139, DOI 10.1016/S0074-7696(08)60340-X; Takashima E, 2002, MOL BIOCHEM PARASIT, V122, P189, DOI 10.1016/S0166-6851(02)00100-7; Tetaud E, 2001, MOL BIOCHEM PARASIT, V116, P171, DOI 10.1016/S0166-6851(01)00320-6; Tielens AGM, 1999, PARASITOL TODAY, V15, P347, DOI 10.1016/S0169-4758(99)01480-5; Tielens AGM, 1998, BBA-BIOENERGETICS, V1365, P71, DOI 10.1016/S0005-2728(98)00045-0; Tielens AGM, 1998, PARASITOL TODAY, V14, P265, DOI 10.1016/S0169-4758(98)01263-0; Turrens J, 1999, PARASITOL TODAY, V15, P346, DOI 10.1016/S0169-4758(99)01479-9; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; van Weelden SWH, 2003, J BIOL CHEM, V278, P12854, DOI 10.1074/jbc.M213190200; VANHELLEMOND JJ, 1994, BIOCHEM J, V304, P321, DOI 10.1042/bj3040321; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	59	70	80	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16559	16570		10.1074/jbc.M500343200	http://dx.doi.org/10.1074/jbc.M500343200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15718239	hybrid			2022-12-25	WOS:000228615500005
J	Geisbrecht, BV; Hamaoka, BY; Perman, B; Zemla, A; Leahy, DJ				Geisbrecht, BV; Hamaoka, BY; Perman, B; Zemla, A; Leahy, DJ			The crystal structures of EAP domains from Staphylococcus aureus reveal an unexpected homology to bacterial superantigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ADHERENCE PROTEIN; SECONDARY STRUCTURE; HUMAN FIBRONECTIN; BINDING PROTEINS; ZINC; RECOGNITION; PREDICTION; AFFINITY; PROGRAM; SITE	The Eap (extracellular adherence protein) of Staphylococcus aureus functions as a secreted virulence factor by mediating interactions between the bacterial cell surface and several extracellular host proteins. Eap proteins from different Staphylococcal strains consist of four to six tandem repeats of a structurally uncharacterized domain (EAP domain). We have determined the three-dimensional structures of three different EAP domains to 1.8, 2.2, and 1.35 angstrom resolution, respectively. These structures reveal a core fold that is comprised of an alpha-helix lying diagonally across a five-stranded, mixed beta-sheet. Comparison of EAP domains with known structures reveals an unexpected homology with the C-terminal domain of bacterial superantigens. Examination of the structure of the superantigen SEC2 bound to the beta-chain of a T-cell receptor suggests a possible ligand-binding site within the EAP domain (Fields, B. A., Malchiodi, E. L., Li, H., Ysern, X., Stauffacher, C. V., Schlievert, P. M., Karjalainen, K., and Mariuzza, R. (1996) Nature 384, 188-192). These results provide the first structural characterization of EAP domains, relate EAP domains to a large class of bacterial toxins, and will guide the design of future experiments to analyze EAP domain structure/function relationships.	Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Lawrence Livermore Natl Lab, Livermore, CA 94550 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Leahy, DJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	dleahy@jhmi.edu						ACHARYA KR, 1994, NATURE, V367, P94, DOI 10.1038/367094a0; Al-Daccak R, 1998, J IMMUNOL, V160, P225; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beneken J, 2000, NEURON, V26, P143, DOI 10.1016/S0896-6273(00)81145-9; BODEN MK, 1992, MICROB PATHOGENESIS, V12, P289, DOI 10.1016/0882-4010(92)90047-R; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chavakis T, 2002, NAT MED, V8, P687, DOI 10.1038/nm728; Earhart CA, 1998, BIOCHEMISTRY-US, V37, P7194, DOI 10.1021/bi9721896; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; Flock JI, 1999, MOL MED TODAY, V5, P532, DOI 10.1016/S1357-4310(99)01597-X; Flock M, 2001, J BACTERIOL, V183, P3999, DOI 10.1128/JB.183.13.3999-4003.2001; Geisbrecht BV, 2003, J BIOL CHEM, V278, P32561, DOI 10.1074/jbc.M302943200; Geisbrecht BV, 1999, J BIOL CHEM, V274, P21797, DOI 10.1074/jbc.274.31.21797; Haggar A, 2003, INFECT IMMUN, V71, P2310, DOI 10.1128/IAI.71.5.2310-2317.2003; Harraghy N, 2003, MICROBIOL-SGM, V149, P2701, DOI 10.1099/mic.0.26465-0; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hussain M, 2001, CLIN DIAGN LAB IMMUN, V8, P1271, DOI 10.1128/CDLI.8.6.1271-1276.2001; Hussain M, 2002, INFECT IMMUN, V70, P2933, DOI 10.1128/IAI.70.6.2933-2940.2002; IRWIN MJ, 1992, NATURE, V359, P841, DOI 10.1038/359841a0; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONSSON K, 1995, J BIOL CHEM, V270, P21457, DOI 10.1074/jbc.270.37.21457; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kreikemeyer B, 2002, INT J MED MICROBIOL, V292, P283, DOI 10.1078/1438-4221-00212; Kronvall G, 1999, J MOL RECOGNIT, V12, P38, DOI 10.1002/(SICI)1099-1352(199901/02)12:1<38::AID-JMR378>3.0.CO;2-Q; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; Li YL, 2001, IMMUNITY, V14, P93, DOI 10.1016/S1074-7613(01)00092-9; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MARRACK P, 1990, SCIENCE, V248, P1066; MCGAVIN MH, 1993, INFECT IMMUN, V61, P2479, DOI 10.1128/IAI.61.6.2479-2485.1993; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Palma M, 1999, J BACTERIOL, V181, P2840, DOI 10.1128/JB.181.9.2840-2845.1999; PAPAGEORGIOU AC, 1995, STRUCTURE, V3, P769, DOI 10.1016/S0969-2126(01)00212-X; Papageorgiou AC, 1997, STRUCTURE, V5, P991, DOI 10.1016/S0969-2126(97)00252-9; Papageorgiou AC, 1998, J MOL BIOL, V277, P61, DOI 10.1006/jmbi.1997.1577; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; Petersson K, 2001, EMBO J, V20, P3306, DOI 10.1093/emboj/20.13.3306; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Roussel A, 1997, NAT STRUCT BIOL, V4, P635, DOI 10.1038/nsb0897-635; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; YOUSIF Y, 1991, ZBL BAKT S, V21, P168; Zemla A, 2003, NUCLEIC ACIDS RES, V31, P3370, DOI 10.1093/nar/gkg571	52	54	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17243	17250		10.1074/jbc.M412311200	http://dx.doi.org/10.1074/jbc.M412311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15691839	Green Submitted, hybrid			2022-12-25	WOS:000228615500087
J	Hee Ryu, OK; Choi, SJ; Firatli, E; Choi, SW; Hart, PS; Shen, RF; Wang, GH; Wu, WW; Hart, TC				Hee Ryu, OK; Choi, SJ; Firatli, E; Choi, SW; Hart, PS; Shen, RF; Wang, GH; Wu, WW; Hart, TC			Proteolysis of macrophage inflammatory protein-1 alpha isoforms LD78 beta and LD78 alpha by neutrophil-derived serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CC CHEMOKINES; ALPHA; MIP-1-ALPHA; MIP-1-BETA; EXPRESSION; IDENTIFICATION; INACTIVATION; CYTOKINE; RESIDUES	Macrophage inflammatory protein-1 alpha (MIP-1 alpha) is a chemokine that leads to leukocyte recruitment and activation at sites of infection. Controlling chemokine activity at sites of infection is important, since excess accumulation of leukocytes may contribute to localized tissue damage. Neutrophil-derived serine proteases modulate the bioactivity of chemokine and cytokine networks through proteolytic cleavage. Because MIP-1 alpha is temporally expressed with neutrophils at sites of infection, we examined proteolysis of MIP-1 alpha in vitro by the neutrophil-derived serine proteases: cathepsin G, elastase, and proteinase 3. Recombinant human MIP-1 alpha isoforms LD78 beta and LD78 alpha were expressed and purified, and the protease cleavage sites were analyzed by mass spectrometry and peptide sequencing. Chemotactic activities of parent and cleavage molecules were also compared. Both LD78 beta and LD78 alpha were cleaved by neutrophil lysates at Thr(16)- Ser(17), Phe(24)- Ile(25), Tyr(28)- Phe(29), and Thr(31)-Ser(32). This degradation was inhibited by serine protease inhibitors phenylmethylsulfonyl fluoride and 4-(2-aminoethyl)-benzenesulfonyl fluoride. Incubation of the substrates with individual proteases revealed that cathepsin G preferentially cleaved at Phe24- Ile25 and Tyr28- Phe29, whereas elastase and proteinase 3 cleaved at Thr(16)- Ser(17) and Thr(31)- Ser(32). Proteolysis of LD78 beta resulted in loss of chemotactic activity. The role of these proteases in LD78 beta and LD78 alpha degradation was confirmed by incubation with neutrophil lysates from Papillon-Lefevre syndrome patients, demonstrating that the cell lysates containing inactivated serine proteases could not degrade LD78 beta and LD78 alpha. These findings suggest that severe periodontal tissue destruction in Papillon-Lefevre syndrome may be related to excess accumulation of LD78 beta and LD78 alpha and dysregulation of the microbial-induced inflammatory response in the periodontium.	NIDCR, Human Craniofacial Genet Sect, NIH, Bethesda, MD 20892 USA; Istanbul Univ, Sch Dent, Dept Periodontol, TR-34390 Istanbul, Turkey; NHGRI, Off Clin Director, NIH, Bethesda, MD 20892 USA; NHLBI, Proteom Core Facil, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Istanbul University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hart, TC (corresponding author), 10 Ctr Dr,Bldg 10,Rm 5-2531, Bethesda, MD 20892 USA.	thart@mail.nih.gov	FIRATLI, Erhan/AAS-6413-2020; FIRATLI, Erhan/E-4241-2013; Fıratlı, Sönmez/AAC-4795-2020	FIRATLI, Erhan/0000-0002-4154-6929; 	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000711, Z01DE000711] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bank U, 1999, FEBS LETT, V461, P235, DOI 10.1016/S0014-5793(99)01466-0; Bank U, 2001, J LEUKOCYTE BIOL, V69, P197; BLACK RA, 1988, J BIOL CHEM, V263, P9437; Choi SJ, 2000, BLOOD, V96, P671; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; de Haar Susanne F, 2004, Hum Mutat, V23, P524, DOI 10.1002/humu.9243; GANZ T, 1998, J CLIN INVEST, V85, P552; Gemmell E, 2001, CLIN EXP IMMUNOL, V125, P134, DOI 10.1046/j.1365-2249.2001.01511.x; Haringman JJ, 2004, ANN RHEUM DIS, V63, P1186, DOI 10.1136/ard.2004.020529; Hart PS, 2000, J MED GENET, V37, P927, DOI 10.1136/jmg.37.12.927; Hirashima M, 1992, DNA Seq, V3, P203, DOI 10.3109/10425179209034019; HIROAKI K, 2002, CYTOKINE, V20, P70; HYUN J, 2002, J ENDODONT, V28, P754; John AE, 2003, SARCOIDOSIS VASC DIF, V20, P180; KASAMA T, 1993, J EXP MED, V178, P63, DOI 10.1084/jem.178.1.63; Kim S, 2001, BIOCHEMISTRY-US, V40, P10782, DOI 10.1021/bi011065x; KOCH AE, 1994, J CLIN INVEST, V93, P921, DOI 10.1172/JCI117097; Leavell KJ, 1997, J LEUKOCYTE BIOL, V61, P361, DOI 10.1002/jlb.61.3.361; Li TW, 2004, P NATL ACAD SCI USA, V101, P8551, DOI 10.1073/pnas.0402889101; Mahalingam S, 1999, IMMUNOL CELL BIOL, V77, P469, DOI 10.1046/j.1440-1711.1999.00858.x; Menten P, 1999, J CLIN INVEST, V104, pR1, DOI 10.1172/JCI7318; Menten P, 2002, CYTOKINE GROWTH F R, V13, P455, DOI 10.1016/S1359-6101(02)00045-X; *MIAM VALL LAB PRO, 1994, EXP LUNG RES, V20, P473; Nibbs RJB, 1999, J BIOL CHEM, V274, P17478, DOI 10.1074/jbc.274.25.17478; Nufer O, 1999, BIOCHEMISTRY-US, V38, P636, DOI 10.1021/bi981294s; Patel DD, 2001, CLIN IMMUNOL, V98, P39, DOI 10.1006/clim.2000.4957; Proost P, 2000, BLOOD, V96, P1674, DOI 10.1182/blood.V96.5.1674.h8001674a_1674_1680; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SCUDERI P, 1991, CELL IMMUNOL, V135, P299, DOI 10.1016/0008-8749(91)90275-G; STANDIFORD TJ, 1993, J IMMUNOL, V151, P2852; VANKESSEL KPM, 1991, J IMMUNOL, V147, P3862; Weber C, 1996, J CELL BIOL, V134, P1063, DOI 10.1083/jcb.134.4.1063; Wolf M, 2003, AM J PATHOL, V162, P1183, DOI 10.1016/S0002-9440(10)63914-4; Yang SK, 1997, GASTROENTEROLOGY, V113, P1214, DOI 10.1053/gast.1997.v113.pm9322516; YANLING J, 1999, J PERIODONTOL, V70, P1472	37	40	43	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17415	17421		10.1074/jbc.M500340200	http://dx.doi.org/10.1074/jbc.M500340200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728180	hybrid			2022-12-25	WOS:000228615500107
J	Voisin, S; Houliston, RS; Kelly, J; Brisson, JR; Watson, D; Bardy, SL; Jarrell, KF; Logan, SM				Voisin, S; Houliston, RS; Kelly, J; Brisson, JR; Watson, D; Bardy, SL; Jarrell, KF; Logan, SM			Identification and characterization of the unique N-linked glycan common to the flagellins and S-layer glycoprotein of Methanococcus voltae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMPYLOBACTER-JEJUNI; PLASMA-MEMBRANE; CAPSULAR POLYSACCHARIDE; PROTEIN GLYCOSYLATION; ARCHAEAL FLAGELLUM; ESCHERICHIA-COLI; TRANSLOCATION; BIOSYNTHESIS; BACTERIA; ACID	The flagellum of Methanococcus voltae is composed of four structural flagellin proteins FlaA, FlaB1, FlaB2, and FlaB3. These proteins possess a total of 15 potential N-linked sequons (NX(S/T)) and show a mass shift on an SDS-polyacrylamide gel indicating significant posttranslational modification. We describe here the structural characterization of the flagellin glycan from M. voltae using mass spectrometry to examine the proteolytic digests of the flagellin proteins in combination with NMR analysis of the purified glycan using a sensitive, cryogenically cooled probe. Nano-liquid chromatography-tandem mass spectrometry analysis of the proteolytic digests of the flagellin proteins revealed that they are post-translationally modified with a novel N-linked trisaccharide of mass 779 Da that is composed of three sugar residues with masses of 318, 258, and 203 Da, respectively. In every instance the glycan is attached to the peptide through the asparagine residue of a typical N-linked sequon. The glycan modification has been observed on 14 of the 15 sequon sites present on the four flagellin structural proteins. The novel glycan structure elucidated by NMR analysis was shown to be a trisaccharide composed of beta-ManpNAcA6Thr-(1 - 4)-beta-Glc-pNAc3NAcA( 1 - 3)-beta-GlcpNAc linked to Asn. In addition, the same trisaccharide was identified on a tryptic peptide of the S-layer protein from this organism implicating a common N-linked glycosylation pathway.	CNR, Inst Biol Sci, Ottawa, ON K1A OR6, Canada; Queens Univ, Dept Microbiol & Immunol, Kingston, ON K7L 3N6, Canada	National Research Council Canada; Queens University - Canada	Logan, SM (corresponding author), CNR, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A OR6, Canada.	susan.logan@nrc-cnrc.gc.ca		Voisin, Sebastien/0000-0001-5897-333X				Bardy S, 2004, J MOL MICROB BIOTECH, V7, P41, DOI 10.1159/000077868; Bardy SL, 2003, MOL MICROBIOL, V50, P1339, DOI 10.1046/j.1365-2958.2003.03758.x; Bardy SL, 2002, J BACTERIOL, V184, P5223, DOI 10.1128/JB.184.19.5223-5233.2002; BASU S, 1987, EUR J BIOCHEM, V162, P75, DOI 10.1111/j.1432-1033.1987.tb10544.x; Benz I, 2002, MOL MICROBIOL, V45, P267, DOI 10.1046/j.1365-2958.2002.03030.x; BEYNON LM, 1990, CARBOHYD RES, V205, P347, DOI 10.1016/0008-6215(90)80152-S; BRANEFORSHELANDER P, 1981, CARBOHYD RES, V97, P285, DOI 10.1016/S0008-6215(00)80674-6; Brisson JR, 2002, CAN J CHEM, V80, P949, DOI 10.1139/V02-114; BRISSON JR, 2002, NMR SPECTROSCOPY GLY, P59; Correia JD, 2000, J BACTERIOL, V182, P855, DOI 10.1128/JB.182.3.855-858.2000; DILL K, 1979, FEBS LETT, V107, P26, DOI 10.1016/0014-5793(79)80454-8; Eichler J, 2003, MICROBIOL-SGM, V149, P3347, DOI 10.1099/mic.0.26591-0; Eichler J, 2001, EUR J BIOCHEM, V268, P4366, DOI 10.1046/j.1432-1327.2001.02361.x; ERICKSON PR, 1993, J BIOL CHEM, V268, P23780; FAGUY DM, 1994, CAN J MICROBIOL, V40, P67, DOI 10.1139/m94-011; Faguy DM, 1996, J BACTERIOL, V178, P902, DOI 10.1128/jb.178.3.902-905.1996; Hashimoto M, 2003, EUR J BIOCHEM, V270, P2671, DOI 10.1046/j.1432-1033.2003.03644.x; KALMOKOFF ML, 1988, J BACTERIOL, V170, P1752, DOI 10.1128/jb.170.4.1752-1758.1988; KOVAL SF, 1987, J BACTERIOL, V169, P1298, DOI 10.1128/jb.169.3.1298-1306.1987; LECHNER J, 1985, J BIOL CHEM, V260, P860; Macnab RM, 2003, ANNU REV MICROBIOL, V57, P77, DOI 10.1146/annurev.micro.57.030502.090832; MESSNER P, 2002, PROGR CHEM ORGANIC N, P51; Perepelov AV, 2000, J CHEM SOC PERK T 1, P363, DOI 10.1039/a908141k; Pohlschroder M, 2004, FEMS MICROBIOL REV, V28, P3, DOI 10.1016/j.femsre.2003.07.004; Rademaker G J, 1996, Methods Mol Biol, V61, P231; Ring G, 2004, J BIOENERG BIOMEMBR, V36, P35, DOI 10.1023/B:JOBB.0000019596.76554.7a; Schaffer C, 2004, GLYCOBIOLOGY, V14, p31R, DOI 10.1093/glycob/cwh064; Schirm M, 2004, J BACTERIOL, V186, P6721, DOI 10.1128/JB.186.20.6721-6727.2004; Schirm M, 2004, J BACTERIOL, V186, P2523, DOI 10.1128/JB.186.9.2523-2531.2004; Schirm M, 2003, MOL MICROBIOL, V48, P1579, DOI 10.1046/j.1365-2958.2003.03527.x; SHASHKOV AS, 1995, CARBOHYD RES, V269, P157, DOI 10.1016/0008-6215(94)00351-F; Spiro R G, 1973, Adv Protein Chem, V27, P349, DOI 10.1016/S0065-3233(08)60451-9; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; SUMPER M, 1987, BIOCHIM BIOPHYS ACTA, V906, P69, DOI 10.1016/0304-4157(87)90005-0; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Thomas NA, 2001, FEMS MICROBIOL REV, V25, P147, DOI 10.1016/S0168-6445(00)00061-9; Uhrin D, 2000, NMR IN MICROBIOLOGY: THEORY AND APPLICATIONS, P165; Upreti RK, 2003, PROTEOMICS, V3, P363, DOI 10.1002/pmic.200390052; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Ventosa A, 1996, INT J SYST BACTERIOL, V46, P347, DOI 10.1099/00207713-46-1-347; Vinogradov E, 2005, CARBOHYD RES, V340, P85, DOI 10.1016/j.carres.2004.10.015; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; WIELAND F, 1985, J BIOL CHEM, V260, P5180; WIELAND F, 1980, FEBS LETT, V120, P110, DOI 10.1016/0014-5793(80)81058-1; YANG LL, 1979, BIOCHIM BIOPHYS ACTA, V556, P265, DOI 10.1016/0005-2736(79)90047-6; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200	46	117	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16586	16593		10.1074/jbc.M500329200	http://dx.doi.org/10.1074/jbc.M500329200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15723834	hybrid			2022-12-25	WOS:000228615500008
J	Brady, KL; Setzer, DR				Brady, KL; Setzer, DR			Is there a dynamic DNA-protein interface in the transcription factor IIIA-5 S rRNA gene complex?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL ZINC FINGERS; INTERNAL CONTROL REGION; 5S RNA; CRYSTAL-STRUCTURE; RECOGNITION; BINDING; TFIIIA; OOCYTES	Others ( Foster, M. P., Wuttke, D. S., Radhakrishnan, I., Case, D. A., Gottesfeld, J. M., and Wright, P. E. ( 1997) Nat. Struct. Biol. 4, 605 - 608; Wuttke, D. S., Foster, M. P., Case, D. A., Gottesfeld, J. M., and Wright, P. E. ( 1997) J. Mol. Biol. 273, 183 - 206) have proposed that several amino acid side chains exhibit considerable conformational mobility at the DNA-protein interface in the transcription factor IIIA center dot 5 S rRNA gene complex and that the rapid movements of these side chains permit them to make fluctuating contacts with adjacent bp in the DNA target site. This "dynamic interface" model makes biochemical predictions concerning the consequences of truncating specific amino acid side chains and the effects of these truncations on sequence selectivity in DNA binding. The model also makes predictions concerning the effects of DNA sequence context on the apparent energetic contributions to binding made by individual bp. We have tested these predictions, and our results are inconsistent with any significant energetic role being played by the contact of multiple bp by conformationally mobile amino acid side chains. They do, however, show that some individual amino acids affect the recognition of multiple bp through mechanisms other than direct interaction.	Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA; Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA	University of Missouri System; University of Missouri Columbia; Case Western Reserve University	Setzer, DR (corresponding author), Univ Missouri, Div Biol Sci, 410 Tucker Hall, Columbia, MO 65211 USA.	setzerd@missouri.edu			NIGMS NIH HHS [GM48035] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; DELRIO S, 1993, J MOL BIOL, V233, P567, DOI 10.1006/jmbi.1993.1536; DELRIO S, 1991, NUCLEIC ACIDS RES, V19, P6197; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; Foster MP, 1997, NAT STRUCT BIOL, V4, P605, DOI 10.1038/nsb0897-605; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; HAYES JJ, 1992, BIOCHEMISTRY-US, V31, P11600, DOI 10.1021/bi00161a045; Kehres DG, 1997, J BIOL CHEM, V272, P20152, DOI 10.1074/jbc.272.32.20152; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Nolte RT, 1998, P NATL ACAD SCI USA, V95, P2938, DOI 10.1073/pnas.95.6.2938; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; RAWLINGS SL, 1996, J BIOL CHEM, V271, P868; ROMANIUK PJ, 1985, NUCLEIC ACIDS RES, V13, P5369, DOI 10.1093/nar/13.14.5369; ROMANIUK PJ, 1990, J BIOL CHEM, V265, P17593; Setzer DR, 1996, RNA, V2, P1254; SETZER DR, 1990, NUCLEIC ACIDS RES, V18, P4175, DOI 10.1093/nar/18.14.4175; Tsui V, 2000, J MOL BIOL, V302, P1101, DOI 10.1006/jmbi.2000.4108; VELDHOEN N, 1994, BIOCHEMISTRY-US, V33, P7568, DOI 10.1021/bi00190a009; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028	25	2	2	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16115	16124		10.1074/jbc.M414660200	http://dx.doi.org/10.1074/jbc.M414660200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713659	hybrid			2022-12-25	WOS:000228444800079
J	Joerger, AC; Ang, HC; Veprintsev, DB; Blair, CM; Fersht, AR				Joerger, AC; Ang, HC; Veprintsev, DB; Blair, CM; Fersht, AR			Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; CRYSTAL-STRUCTURE; CORE DOMAIN; 53BP1; MOLSCRIPT; PEPTIDE; SITE	We have solved the crystal structures of three oncogenic mutants of the core domain of the human tumor suppressor p53. The mutations were introduced into a stabilized variant. The cancer hot spot mutation R273H simply removes an arginine involved in DNA binding without causing structural distortions in neighboring residues. In contrast, the "structural" oncogenic mutations H168R and R249S induce substantial structural perturbation around the mutation site in the L2 and L3 loops, respectively. H168R is a specific intragenic suppressor mutation for R249S. When both cancer mutations are combined in the same molecule, Arg(168) mimics the role of Arg(249) in wild type, and the wild type conformation is largely restored in both loops. Our structural and biophysical data provide compelling evidence for the mechanism of rescue of mutant p53 by intragenic suppressor mutations and reveal features by which proteins can adapt to deleterious mutations.	MRC, Ctr Prot Engn, Cambridge CB2 2QH, England	University of Cambridge	Fersht, AR (corresponding author), MRC, Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.	arf25@cam.ac.uk	Fersht, Alan R/B-2189-2008; Veprintsev, Dmitry B/H-2228-2012	Veprintsev, Dmitry B/0000-0002-3583-5409; Joerger, Andreas/0000-0002-1232-0138				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baroni TE, 2004, P NATL ACAD SCI USA, V101, P4930, DOI 10.1073/pnas.0401162101; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Friedler A, 2005, J BIOL CHEM, V280, P8051, DOI 10.1074/jbc.M411176200; Friedler A, 2004, J MOL BIOL, V336, P187, DOI 10.1016/j.jmb.2003.12.005; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hainaut P, 2000, ADV CANCER RES, V77, P81; Joerger AC, 2004, J BIOL CHEM, V279, P1291, DOI 10.1074/jbc.M309732200; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Turk D., 1992, THESIS TU MUNCHEN GE; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Zhao KH, 2001, J BIOL CHEM, V276, P12120, DOI 10.1074/jbc.M011644200	34	130	133	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16030	16037		10.1074/jbc.M500179200	http://dx.doi.org/10.1074/jbc.M500179200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15703170	hybrid			2022-12-25	WOS:000228444800070
J	Komar, AA; Gross, SR; Barth-Baus, D; Strachan, R; Hensold, JO; Kinzy, TG; Merrick, WC				Komar, AA; Gross, SR; Barth-Baus, D; Strachan, R; Hensold, JO; Kinzy, TG; Merrick, WC			Novel characteristics of the biological properties of the yeast Saccharomyces cerevisiae eukaryotic initiation factor 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION; PROTEIN-SYNTHESIS; MESSENGER-RNA; PURIFICATION; COMPLEX; OVEREXPRESSION; IDENTIFICATION; EXPRESSION; PREFOLDIN; SEQUENCES	Eukaryotic initiation factor 2A (eIF2A) has been shown to direct binding of the initiator methionyl-tRNA (Met-tRNA(i)) to 40 S ribosomal subunits in a codon-dependent manner, in contrast to eIF2, which requires GTP but not the AUG codon to bind initiator tRNA to 40 S subunits. We show here that yeast eIF2A genetically interacts with initiation factor eIF4E, suggesting that both proteins function in the same pathway. The double eIF2A/eIF4E-ts mutant strain displays a severe slow growth phenotype, which correlated with the accumulation of 85% of the double mutant cells arrested at the G(2)/M border. These cells also exhibited a disorganized actin cytoskeleton and elevated actin levels, suggesting that eIF2A might be involved in controlling the expression of genes involved in morphogenic processes. Further insights into eIF2A function were gained from the studies of eIF2A distribution in ribosomal fractions obtained from either an eIF5B Delta (fun12 Delta) strain or a eIF3b-ts (prt1-1) strain. It was found that the binding of eIF2A to 40 and 80 S ribosomes was not impaired in either strain. We also found that eIF2A functions as a suppressor of Ure2p internal ribosome entry site-mediated translation in yeast cells. The regulation of expression from the URE2 internal ribosome entry site appears to be through the levels of eIF2A protein, which has been found to be inherently unstable with a half-life of similar to 17 min. It was hypothesized that this instability allows for translational control through the level of eIF2A protein in yeast cells.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, Piscataway, NJ 08854 USA; Vet Affairs Med Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA	Case Western Reserve University; Rutgers State University New Brunswick; Rutgers State University Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University	Merrick, WC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	wcm2@cwru.edu		Komar, Anton/0000-0003-4188-0633; gross, stephane/0000-0002-0867-8866; Kinzy, Terri/0000-0003-1394-9226	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068079, R01GM026796, R01GM062789] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43414] Funding Source: Medline; NIGMS NIH HHS [GM62789, GM26796, GM68079] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SL, 1975, J BIOL CHEM, V250, P9083; ALTMANN M, 1993, EMBO J, V12, P3997, DOI 10.1002/j.1460-2075.1993.tb06077.x; ALTMANN M, 1989, MOL CELL BIOL, V9, P4467, DOI 10.1128/MCB.9.10.4467; Altmann M, 1997, METHODS, V11, P343, DOI 10.1006/meth.1996.0432; ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; Benne R, 1979, Methods Enzymol, V60, P15; Bonnal S, 2003, NUCLEIC ACIDS RES, V31, P427, DOI 10.1093/nar/gkg003; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; Clemens MJ, 2001, PROG MOLEC, V27, P57; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; *CLONT, 2001, YEAST PROT HDB; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; Danaie P, 1999, BIOCHEM J, V340, P135, DOI 10.1042/0264-6021:3400135; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DRUBIN DG, 2000, CELL POLARITY; Entian KD, 1999, MOL GEN GENET, V262, P683, DOI 10.1007/PL00013817; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; GUPTA NK, 1973, J BIOL CHEM, V248, P4500; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; HINCK AP, 1993, PROTEIN ENG, V6, P221, DOI 10.1093/protein/6.2.221; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; JOHNSTON M, 1994, MOL CELL BIOL, V14, P3834, DOI 10.1128/MCB.14.6.3834; Karpova TS, 1998, J CELL BIOL, V142, P1501, DOI 10.1083/jcb.142.6.1501; Kimball SR, 1999, INT J BIOCHEM CELL B, V31, P25, DOI 10.1016/S1357-2725(98)00128-9; Komar AA, 2003, EMBO J, V22, P1199, DOI 10.1093/emboj/cdg103; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN DH, 1973, P NATL ACAD SCI USA, V70, P41, DOI 10.1073/pnas.70.1.41; LIU HP, 1992, GENETICS, V132, P665; Madden K, 1998, ANNU REV MICROBIOL, V52, P687, DOI 10.1146/annurev.micro.52.1.687; Majumdar A, 1979, Methods Enzymol, V60, P35; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; MERRICK WC, 1975, J BIOL CHEM, V250, P5556; MERRICK WC, 1975, J BIOL CHEM, V250, P1197; MUELLER PP, 1987, P NATL ACAD SCI USA, V84, P2863, DOI 10.1073/pnas.84.9.2863; Nielsen KH, 2004, EMBO J, V23, P1166, DOI 10.1038/sj.emboj.7600116; Norden C, 2004, MOL MICROBIOL, V53, P469, DOI 10.1111/j.1365-2958.2004.04148.x; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Prevot D, 2003, BIOL CELL, V95, P141, DOI 10.1016/S0248-4900(03)00031-5; Proud C G, 2001, Prog Mol Subcell Biol, V26, P95; Pyronnet S, 2001, CURR OPIN GENET DEV, V11, P13, DOI 10.1016/S0959-437X(00)00150-7; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rose MD., 1990, METHODS YEAST GENETI; Saito TL, 2004, NUCLEIC ACIDS RES, V32, pD319, DOI 10.1093/nar/gkh113; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schneider BL, 1998, NATURE, V395, P86, DOI 10.1038/25774; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; Staehelin T, 1979, Methods Enzymol, V60, P136; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ukiyama E, 2001, MOL ENDOCRINOL, V15, P363, DOI 10.1210/me.15.3.363; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zoll WL, 2002, J BIOL CHEM, V277, P37079, DOI 10.1074/jbc.M207109200	59	39	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15601	15611		10.1074/jbc.M413728200	http://dx.doi.org/10.1074/jbc.M413728200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15718232	hybrid, Green Accepted			2022-12-25	WOS:000228444800019
J	Martic, G; Karetsou, Z; Kefala, K; Politou, AS; Clapier, CR; Straub, T; Papamarcaki, T				Martic, G; Karetsou, Z; Kefala, K; Politou, AS; Clapier, CR; Straub, T; Papamarcaki, T			Parathymosin affects the binding of linker histone H1 to nucleosomes and remodels chromatin structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZN2+-BINDING PROTEIN PARATHYMOSIN; PROTHYMOSIN-ALPHA; IN-VIVO; CRYSTAL-STRUCTURE; GLOBULAR DOMAIN; GENE-EXPRESSION; CORE PARTICLE; DNA; TRANSCRIPTION; SEQUENCE	Linker histone H1 is the major factor that stabilizes higher order chromatin structure and modulates the action of chromatin-remodeling enzymes. We have previously shown that parathymosin, an acidic, nuclear protein binds to histone H1 in vitro and in vivo. Confocal laser scanning microscopy reveals a nuclear punctuate staining of the endogenous protein in interphase cells, which is excluded from dense heterochromatic regions. Using an in vitro chromatin reconstitution system under physiological conditions, we show here that parathymosin (ParaT) inhibits the binding of H1 to chromatin in a dose-dependent manner. Consistent with these findings, H1-containing chromatin assembled in the presence of ParaT has reduced nucleosome spacing. These observations suggest that interaction of the two proteins might result in a conformational change of H1. Fluorescence spectroscopy and circular dichroism-based measurements on mixtures of H1 and ParaT confirm this hypothesis. Human sperm nuclei challenged with ParaT become highly decondensed, whereas overexpression of green fluorescent protein- or FLAG-tagged protein in HeLa cells induces global chromatin decondensation and increases the accessibility of chromatin to micrococcal nuclease digestion. Our data suggest a role of parathymosin in the remodeling of higher order chromatin structure through modulation of H1 interaction with nucleosomes and point to its involvement in chromatin-dependent functions.	Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece; EMBL, Grenoble Outstn, F-38042 Grenoble, France; Adolf Butenandt Inst, D-80336 Munich, Germany; Fdn Res & Technol Hellas, Biomed Res Inst, Ioannina 45110, Greece	University of Ioannina; European Molecular Biology Laboratory (EMBL); University of Munich; Foundation for Research & Technology - Hellas (FORTH)	Papamarcaki, T (corresponding author), Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece.	thpapama@cc.uoi.gr	Straub, Tobias/B-2023-2009	Straub, Tobias/0000-0002-0547-0453				Alami R, 2003, P NATL ACAD SCI USA, V100, P5920, DOI 10.1073/pnas.0736105100; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; An WJ, 1998, P NATL ACAD SCI USA, V95, P3396, DOI 10.1073/pnas.95.7.3396; BECKER PB, 1994, METHOD CELL BIOL, V44, P207, DOI 10.1016/S0091-679X(08)60915-2; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; Bharath MMS, 2003, NUCLEIC ACIDS RES, V31, P4264, DOI 10.1093/nar/gkg481; BLANK TA, 1995, J MOL BIOL, V252, P305, DOI 10.1006/jmbi.1995.0498; Bonaldi T, 2002, EMBO J, V21, P6865, DOI 10.1093/emboj/cdf692; BRAND IA, 1991, J BIOL CHEM, V266, P20984; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; Catez F, 2004, MOL CELL BIOL, V24, P4321, DOI 10.1128/MCB.24.10.4321-4328.2004; CLINTON M, 1989, ARCH BIOCHEM BIOPHYS, V269, P256, DOI 10.1016/0003-9861(89)90107-0; CLINTON M, 1989, BIOCHEM BIOPH RES CO, V158, P855, DOI 10.1016/0006-291X(89)92801-5; Cotter MA, 2000, MOL CELL BIOL, V20, P5722, DOI 10.1128/MCB.20.15.5722-5735.2000; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; Doenecke D, 1997, HISTOCHEM CELL BIOL, V107, P1, DOI 10.1007/s004180050083; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Fan YH, 2003, MOL CELL BIOL, V23, P4559, DOI 10.1128/MCB.23.13.4559-4572.2003; FEDOR M J, 1992, Current Opinion in Cell Biology, V4, P436, DOI 10.1016/0955-0674(92)90009-2; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Flavin M, 2004, MOL CELL BIOL, V24, P7891, DOI 10.1128/MCB.24.18.7891-7901.2004; FRANGOULAZARIDIS M, 1988, ARCH BIOCHEM BIOPHYS, V263, P305, DOI 10.1016/0003-9861(88)90640-6; GIANCOTTI V, 1980, BIOCHIM BIOPHYS ACTA, V624, P60, DOI 10.1016/0005-2795(80)90225-1; Goytisolo FA, 1996, EMBO J, V15, P3421, DOI 10.1002/j.1460-2075.1996.tb00708.x; Greenfield Norma J, 2004, Methods Mol Biol, V261, P55; Gunjan A, 2001, J BIOL CHEM, V276, P3635, DOI 10.1074/jbc.M007590200; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P1050, DOI 10.1073/pnas.82.4.1050; Hendzel MJ, 2004, J BIOL CHEM, V279, P20028, DOI 10.1074/jbc.M400070200; Hill DA, 2000, BIOCHEMISTRY-US, V39, P11649, DOI 10.1021/bi001330z; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Juan LJ, 1997, J BIOL CHEM, V272, P3635, DOI 10.1074/jbc.272.6.3635; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; Karetsou Z, 2002, EMBO REP, V3, P361, DOI 10.1093/embo-reports/kvf071; Knapp S, 2004, BIOCHEMISTRY-US, V43, P11992, DOI 10.1021/bi049364k; Kondili K, 1996, EUR J BIOCHEM, V242, P67, DOI 10.1111/j.1432-1033.1996.0067r.x; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lee H, 2004, SCIENCE, V304, P1675, DOI 10.1126/science.1098096; Lu X, 2004, J BIOL CHEM, V279, P8701, DOI 10.1074/jbc.M311348200; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Martini PGV, 2000, MOL CELL BIOL, V20, P6224, DOI 10.1128/MCB.20.17.6224-6232.2000; Matsumoto K, 1999, MOL CELL BIOL, V19, P6940; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Mizzen CA, 2000, SCIENCE, V289, P2290, DOI 10.1126/science.289.5488.2290; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Okamoto K, 2000, EUR J BIOCHEM, V267, P155, DOI 10.1046/j.1432-1327.2000.00987.x; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; ROSE SM, 1984, J BIOL CHEM, V259, P8534; Sambrook J., 2002, MOL CLONING LAB MANU; SANDALTZOPOULOS R, 1994, EMBO J, V13, P373, DOI 10.1002/j.1460-2075.1994.tb06271.x; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; Travers AA, 2003, EMBO REP, V4, P131, DOI 10.1038/sj.embor.embor741; Trompeter HI, 1996, J BIOL CHEM, V271, P1187, DOI 10.1074/jbc.271.2.1187; TROMPETER HI, 1989, FEBS LETT, V253, P63, DOI 10.1016/0014-5793(89)80930-5; van Holde K.E., 1988, CHROMATIN; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; Vareli K, 2000, EXP CELL RES, V257, P152, DOI 10.1006/excr.2000.4857; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; Zlatanova J, 2000, FASEB J, V14, P1697, DOI 10.1096/fj.99-0869rev	65	23	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16143	16150		10.1074/jbc.M410175200	http://dx.doi.org/10.1074/jbc.M410175200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15716277	hybrid			2022-12-25	WOS:000228444800082
J	Elkabetz, Y; Argon, Y; Bar-Nun, S				Elkabetz, Y; Argon, Y; Bar-Nun, S			Cysteines in CH1 underlie retention of unassembled ig heavy chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN LIGHT-CHAINS; ENDOPLASMIC-RETICULUM; BINDING-PROTEIN; VARIABLE DOMAIN; QUALITY-CONTROL; DISULFIDE BOND; THIOREDOXIN FAMILY; IN-VIVO; BIP; SECRETION	Conformation, structure, and oligomeric state of immunoglobulins not only control quality and functional properties of antibodies but are also critical for immunoglobulins secretion. Unassembled immunoglobulin heavy chains are retained intracellularly by delayed folding of the C(H)1 domain and irreversible interaction of BiP with this domain. Here we show that the three C(H)1 cysteines play a central role in immunoglobulin folding, assembly, and secretion. Remarkably, ablating all three C(H)1 cysteines negates retention and enables BiP cycling and non-canonical folding and assembly. This phenomenon is explained by interdependent formation of intradomain and interchain disulfides, although both bonds are dispensable for secretion. Substituting Cys-195 prevents formation not only of the intradomain disulfide, but also of the interchain disulfide bond with light chain, BiP displacement, and secretion. Mutating the light chain-interacting Cys-128 hinders disulfide bonding of intradomain cysteines, allowing their opportunistic bonding with light chain, without hampering secretion. We propose that the role of C(H)1 cysteines in immunoglobulin assembly and secretion is not simply to engage in disulfide bridges, but to direct proper folding and interact with the retention machinery.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA	Tel Aviv University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Bar-Nun, S (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.	shoshbn@tauex.tau.ac.il			FOGARTY INTERNATIONAL CENTER [F06TW002378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030178] Funding Source: NIH RePORTER; FIC NIH HHS [TW-002378] Funding Source: Medline; NIAID NIH HHS [AI-30178] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Anelli T, 2003, EMBO J, V22, P5015, DOI 10.1093/emboj/cdg491; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; Bottomley MJ, 2001, CURR BIOL, V11, P1114, DOI 10.1016/S0960-9822(01)00317-7; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Brewer JW, 1996, J CELL SCI, V109, P2383; Brumlik MJ, 1997, J BACTERIOL, V179, P3116, DOI 10.1128/jb.179.10.3116-3121.1997; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; DAVIS AC, 1989, EMBO J, V8, P2519, DOI 10.1002/j.1460-2075.1989.tb08389.x; Davis DP, 1999, J IMMUNOL, V163, P3842; Davis DP, 2000, IMMUNITY, V13, P433, DOI 10.1016/S1074-7613(00)00043-1; DUL JL, 1990, P NATL ACAD SCI USA, V87, P8135, DOI 10.1073/pnas.87.20.8135; DUL JL, 1992, J IMMUNOL, V149, P1927; Elkabetz Y, 2003, J BIOL CHEM, V278, P18922, DOI 10.1074/jbc.M208730200; Frisch C, 1996, FOLD DES, V1, P431, DOI 10.1016/S1359-0278(96)00059-4; Gething M J, 1990, Semin Cell Biol, V1, P65; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; Hellman R, 1999, J CELL BIOL, V144, P21, DOI 10.1083/jcb.144.1.21; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; Hu YK, 2000, J BIOL CHEM, V275, P30734, DOI 10.1074/jbc.M003737200; KALOFF CR, 1995, IMMUNITY, V2, P629, DOI 10.1016/1074-7613(95)90007-1; KATAOKA T, 1979, P NATL ACAD SCI USA, V76, P4240, DOI 10.1073/pnas.76.9.4240; KEREM A, 1993, J BIOL CHEM, V268, P180; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; Knoblach B, 2003, MOL CELL PROTEOMICS, V2, P1104, DOI 10.1074/mcp.M300053-MCP200; Lee YK, 1999, MOL BIOL CELL, V10, P2209, DOI 10.1091/mbc.10.7.2209; Leitzgen K, 1997, J BIOL CHEM, V272, P3117, DOI 10.1074/jbc.272.5.3117; Liebeton K, 2001, J BACTERIOL, V183, P597, DOI 10.1128/JB.183.2.597-603.2001; MA J, 1990, MOL IMMUNOL, V27, P623, DOI 10.1016/0161-5890(90)90004-J; Mayer M, 2000, J BIOL CHEM, V275, P29421, DOI 10.1074/jbc.M002655200; NAKAKI T, 1989, MOL CELL BIOL, V9, P2233, DOI 10.1128/MCB.9.5.2233; Noiva R, 1999, SEMIN CELL DEV BIOL, V10, P481, DOI 10.1006/scdb.1999.0319; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; Reddy PS, 1998, BIOESSAYS, V20, P546, DOI 10.1002/(SICI)1521-1878(199807)20:7<546::AID-BIES5>3.0.CO;2-I; ROSE DR, 1993, PROTEIN SCI, V2, P1106, DOI 10.1002/pro.5560020705; Sargsyan E, 2002, J BIOL CHEM, V277, P17009, DOI 10.1074/jbc.M200539200; SECHER DS, 1977, IMMUNOL REV, V36, P51, DOI 10.1111/j.1600-065X.1977.tb00382.x; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; Skowronek MH, 1998, P NATL ACAD SCI USA, V95, P1574, DOI 10.1073/pnas.95.4.1574; Uson I, 1997, FOLD DES, V2, P357, DOI 10.1016/S1359-0278(97)00049-7; Vanhove M, 2001, IMMUNITY, V15, P105, DOI 10.1016/S1074-7613(01)00163-7	50	17	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14402	14412		10.1074/jbc.M500161200	http://dx.doi.org/10.1074/jbc.M500161200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705573	hybrid			2022-12-25	WOS:000228236800008
J	Hollenbach, E; Vieth, M; Roessner, A; Neumann, M; Malfertheiner, P; Naumann, M				Hollenbach, E; Vieth, M; Roessner, A; Neumann, M; Malfertheiner, P; Naumann, M			Inhibition of RICK/nuclear factor-kappa B and p38 signaling attenuates the inflammatory response in a murine model of Crohn Disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INTESTINAL EPITHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; ESTABLISHED EXPERIMENTAL COLITIS; BOWEL-DISEASE; IMMUNE-RESPONSES; TNF-ALPHA; T-CELLS; MICE; NOD2	Nuclear factor-kappa B (NF-kappa B) is the main target of anti-inflammatory therapies in human chronic inflammatory bowel diseases (IBD), Crohn disease, and ulcerative colitis. This study investigates the molecular anti-inflammatory mechanisms of SB203580, an inhibitor of the mitogen-activated protein kinase p38. The murine trinitrobenzene sulfonic acid (TNBS)-induced colitis was used as an established model of human Crohn disease. Here we show that SB203580 improved the clinical condition, reduced intestinal inflammation, and suppressed mRNA levels of pro-inflammatory cytokines elevated upon induction of colitis. Besides p38 kinase activity, the "classical" I kappa B-dependent NF-kappa B pathway was strongly up-regulated during colitis induction, whereas the "alternative" was not. SB203580 treatment resulted in a drastic down-regulation of p38 and NF-kappa B activity. The molecular analysis of NF-kappa B activation revealed that Rip-like interacting caspase-like apoptosis-regulatory protein kinase (RICK), a key component of a pathway leading to NF-kappa B induction, is also strongly inhibited by SB203580. In contrast, SB203580 had no effect on the colitis-induced activation of other potential NF-kappa B-activating kinases such as protein kinase C theta (PKC theta), mixed lineage kinase 3, and the oncogene product Cot/TPL2. Thus, the inhibitory effect of SB203580 on NF-kappa B activation is to a large extent mediated by RICK inhibition. RICK is the effector kinase of the intracellular receptor of bacterial peptidoglycan NOD. Because bacterial products are suggested to be the key pathogenic agents triggering IBD, inhibition of the NOD/RICK pathway may serve as a novel target of future therapies in human IBD.	Otto Von Guericke Univ, Inst Expt Internal Med, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Dept Gastroenterol Hepatol & Infectiol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Inst Pathol, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University; Otto von Guericke University	Naumann, M (corresponding author), Otto Von Guericke Univ, Inst Expt Internal Med, Leipziger Str 44, D-39120 Magdeburg, Germany.	Naumann@medizin.uni-magdeburg.de	Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313				Athman R, 2004, CURR OPIN MICROBIOL, V7, P25, DOI 10.1016/j.mib.2003.12.013; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; BEAGLEY KW, 1991, GASTROENTEROLOGY, V100, P560; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bonen DK, 2003, GASTROENTEROLOGY, V124, P140, DOI 10.1053/gast.2003.50019; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; D'Haens GR, 1998, GASTROENTEROLOGY, V114, P262, DOI 10.1016/S0016-5085(98)70476-7; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; Elson CO, 1996, J IMMUNOL, V157, P2174; Fuss IJ, 1999, GASTROENTEROLOGY, V117, P1078, DOI 10.1016/S0016-5085(99)70392-6; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2003, TRENDS IMMUNOL, V24, P652, DOI 10.1016/j.it.2003.10.007; Godl K, 2003, P NATL ACAD SCI USA, V100, P15434, DOI 10.1073/pnas.2535024100; Hampe J, 1999, AM J HUM GENET, V65, P1647, DOI 10.1086/302677; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Hogaboam CM, 1997, J CLIN INVEST, V100, P2766, DOI 10.1172/JCI119823; Hommes D, 2002, GASTROENTEROLOGY, V122, P7, DOI 10.1053/gast.2002.30770; Hu MCT, 1999, J BIOL CHEM, V274, P7095, DOI 10.1074/jbc.274.11.7095; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2002, CURR OPIN MICROBIOL, V5, P76, DOI 10.1016/S1369-5274(02)00289-8; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; MUNKHOLM P, 1994, GUT, V35, P360, DOI 10.1136/gut.35.3.360; Neurath M, 2000, Int Rev Immunol, V19, P51, DOI 10.3109/08830180009048389; NEURATH MF, 1995, J EXP MED, V182, P1281, DOI 10.1084/jem.182.5.1281; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Neurath MF, 1998, ANN NY ACAD SCI, V859, P149, DOI 10.1111/j.1749-6632.1998.tb11119.x; Nick JA, 2000, J IMMUNOL, V164, P2151, DOI 10.4049/jimmunol.164.4.2151; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Parhar K, 2003, IMMUNOLOGY, V108, P502, DOI 10.1046/j.1365-2567.2003.01603.x; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Rosenstiel P, 2003, GASTROENTEROLOGY, V124, P1001, DOI 10.1053/gast.2003.50157; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; Schreiber S, 1999, LANCET, V353, P459, DOI 10.1016/S0140-6736(98)03339-X; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Stoll M, 2004, NAT GENET, V36, P476, DOI 10.1038/ng1345; Swidsinski A, 2002, GASTROENTEROLOGY, V122, P44, DOI 10.1053/gast.2002.30294; TAUROG JD, 1994, J EXP MED, V180, P2359, DOI 10.1084/jem.180.6.2359; ten Hove T, 2002, GUT, V50, P507, DOI 10.1136/gut.50.4.507; Van den Blink B, 2004, J CLIN IMMUNOL, V24, P37, DOI 10.1023/B:JOCI.0000018061.58504.75; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Waetzig GH, 2003, ALIMENT PHARM THER, V18, P17, DOI 10.1046/j.1365-2036.2003.01642.x; Wallace JL, 1990, AM J PHYSIOL, V258, P527; Weih F, 1997, J IMMUNOL, V158, P5211; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wex T, 2003, CLIN CHEM LAB MED, V41, P1033, DOI 10.1515/CCLM.2003.159; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Zhao M, 1999, MOL CELL BIOL, V19, P21	64	126	137	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14981	14988		10.1074/jbc.M500966200	http://dx.doi.org/10.1074/jbc.M500966200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15691843	hybrid			2022-12-25	WOS:000228236800079
J	Michael, IP; Sotiropoulou, G; Pampalakis, G; Magklara, A; Ghosh, M; Wasney, G; Diamandis, EP				Michael, IP; Sotiropoulou, G; Pampalakis, G; Magklara, A; Ghosh, M; Wasney, G; Diamandis, EP			Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; MOLECULAR-WEIGHT KININOGEN; HUMAN TISSUE KALLIKREINS; SOMATOMEDIN-B DOMAIN; PLASMINOGEN-ACTIVATOR INHIBITOR; HUMAN-PLASMA KALLIKREIN; HEPARIN-BINDING DOMAIN; FIBRIN BETA-CHAIN; GENE FAMILY; OVARIAN-CANCER	Human kallikrein 5 (KLK5) is a member of the human kallikrein gene family of serine proteases. Preliminary results indicate that the protein, hK5, may be a potential serological marker for breast and ovarian cancer. Other studies implicate hK5 with skin desquamation and skin diseases. To gain further insights on hK5 physiological functions, we studied its substrate specificity, the regulation of its activity by various inhibitors, and identified candidate physiological substrates. After producing and purifying recombinant hK5 in yeast, we determined the k(cat)/K-m ratio of the fluorogenic substrates Gly-Pro-Arg-AMC and Gly-Pro-Lys-AMC, and showed that it has trypsin-like activity with strong preference for Arg over Lys in the P1 position. The serpins alpha(2)-antiplasmin and antithrombin were able to inhibit hK5 with an inhibition constant (k(+2)/K-i) of 1.0 x 10(-2) and 4.2 x 10(-4) M-1 min(-1), respectively. No inhibition was observed with the serpins alpha(1)-antitrypsin and alpha(1)-antichymotrypsin, although alpha(2)-macroglobulin partially inhibited hK5 at high concentrations. We also demonstrated that hK5 can efficiently digest the extracellular matrix components, collagens type I, II, III, and IV, fibronectin, and laminin. Furthermore, our results suggest that hK5 can potentially release (a) angiostatin 4.5 from plasminogen, (b) "cystatin-like domain 3" from low molecular weight kininogen, and ( c) fibrinopeptide B and peptide beta 15-42 from the B beta chain of fibrinogen. hK5 could also play a role in the regulation of the binding of plasminogen activator inhibitor 1 to vitronectin. Our findings suggest that hK5 may be implicated in tumor progression, particularly in invasion and angiogenesis, and may represent a novel therapeutic target.	Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Univ Patras, Dept Pharm, Sch Hlth Sci, Patras 26500, Greece	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Patras	Diamandis, EP (corresponding author), Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	ediamandis@mtsinai.on.ca	Michael, Iacovos P/C-8695-2016; Magklara, Angeliki/AAK-8347-2020	Michael, Iacovos P/0000-0001-7674-1233; Magklara, Angeliki/0000-0003-3408-6722; Diamandis, Eleftherios/0000-0002-1589-820X				Bach TL, 1998, J BIOL CHEM, V273, P30719, DOI 10.1074/jbc.273.46.30719; Bayes A, 2004, BIOL CHEM, V385, P517, DOI 10.1515/BC.2004.061; Bernett MJ, 2002, J BIOL CHEM, V277, P24562, DOI 10.1074/jbc.M202392200; Borgono CA, 2004, MOL CANCER RES, V2, P257; Borgono CA, 2003, CANCER RES, V63, P9032; Brattsand M, 1999, J BIOL CHEM, V274, P30033, DOI 10.1074/jbc.274.42.30033; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; CHALUPOWICZ DG, 1995, J CELL BIOL, V130, P207, DOI 10.1083/jcb.130.1.207; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; Denmeade SR, 2001, PROSTATE, V48, P122, DOI 10.1002/pros.1088; Deperthes D, 1996, J ANDROL, V17, P659; Diamandis EP, 2000, CLIN CHEM, V46, P1855; Diamandis EP, 2003, TUMOR BIOL, V24, P299, DOI 10.1159/000076462; Diamandis EP, 1998, TRENDS ENDOCRIN MET, V9, P310, DOI 10.1016/S1043-2760(98)00082-4; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; Diamandis EP, 2002, CLIN CHEM, V48, P1198; Ekholm IE, 2000, J INVEST DERMATOL, V114, P56, DOI 10.1046/j.1523-1747.2000.00820.x; Fortier AH, 2003, PROSTATE, V56, P212, DOI 10.1002/pros.10256; Foussias G, 2000, GENOMICS, V67, P171, DOI 10.1006/geno.2000.6208; Gately S, 1996, CANCER RES, V56, P4887; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; Gechtman Z, 1997, BIOCHEM J, V325, P339, DOI 10.1042/bj3250339; Gettins PGW, 2000, GENOME RES, V10, P1833, DOI 10.1101/gr.168900; Ghosh MC, 2004, TUMOR BIOL, V25, P193, DOI 10.1159/000081102; HAMAGUCHI M, 1993, BLOOD, V81, P2348; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; Heidtmann HH, 1999, BRIT J CANCER, V81, P1269, DOI 10.1038/sj.bjc.6692167; Hsieh MC, 2002, BIOCHEMISTRY-US, V41, P2990, DOI 10.1021/bi0117450; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; JORNVALL H, 1979, FEBS LETT, V106, P358, DOI 10.1016/0014-5793(79)80532-3; Kapadia C, 2004, BIOCHEM BIOPH RES CO, V323, P1084, DOI 10.1016/j.bbrc.2004.08.206; Khan AR, 1998, PROTEIN SCI, V7, P815; Kim H, 2001, BRIT J CANCER, V84, P643, DOI 10.1054/bjoc.2000.1649; KITZ R, 1962, J BIOL CHEM, V237, P3245; Komatsu N, 2003, J INVEST DERMATOL, V121, P542, DOI 10.1046/j.1523-1747.2003.12363.x; Lannutti BJ, 1997, CANCER RES, V57, P5277; LILJA H, 1985, J CLIN INVEST, V76, P1899, DOI 10.1172/JCI112185; Lovgren J, 1999, EUR J BIOCHEM, V266, P1050, DOI 10.1046/j.1432-1327.1999.00946.x; Luo LY, 2001, CLIN CHEM, V47, P237; Magklara A, 2003, BIOCHEM BIOPH RES CO, V307, P948, DOI 10.1016/S0006-291X(03)01271-3; MORII M, 1983, J BIOL CHEM, V258, P2749; MORTENSEN SB, 1981, FEBS LETT, V135, P295, DOI 10.1016/0014-5793(81)80804-6; Mosesson MW, 2001, ANN NY ACAD SCI, V936, P11; Odrljin TM, 1996, ARTERIOSCL THROM VAS, V16, P1544, DOI 10.1161/01.ATV.16.12.1544; Odrljin TM, 1996, BLOOD, V88, P2050, DOI 10.1182/blood.V88.6.2050.bloodjournal8862050; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; RIBES JA, 1989, J CLIN INVEST, V84, P435, DOI 10.1172/JCI114184; SCHAPIRA M, 1981, BIOCHEMISTRY-US, V20, P2738, DOI 10.1021/bi00513a006; SCHAPIRA M, 1982, BIOCHEMISTRY-US, V21, P567, DOI 10.1021/bi00532a024; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schvartz I, 1999, INT J BIOCHEM CELL B, V31, P539, DOI 10.1016/S1357-2725(99)00005-9; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Soff GA, 2000, CANCER METAST REV, V19, P97, DOI 10.1023/A:1026525121027; Sotiropoulou G, 2003, ONCOL RES, V13, P381; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SPORN LA, 1995, BLOOD, V86, P1802, DOI 10.1182/blood.V86.5.1802.bloodjournal8651802; Stathakis P, 1999, J BIOL CHEM, V274, P8910, DOI 10.1074/jbc.274.13.8910; STENMAN UH, 1991, CANCER RES, V51, P222; VOGEL R, 1988, J BIOL CHEM, V263, P12661; Wang H, 2004, CANCER RES, V64, P162, DOI 10.1158/0008-5472.CAN-03-1862; WIMAN B, 1979, J BIOL CHEM, V254, P9291; WU HL, 1987, P NATL ACAD SCI USA, V84, P8292, DOI 10.1073/pnas.84.23.8292; WU HL, 1987, P NATL ACAD SCI USA, V84, P8793, DOI 10.1073/pnas.84.24.8793; Yousef GM, 2004, TUMOR BIOL, V25, P122, DOI 10.1159/000079144; Yousef GM, 2002, BIOL CHEM, V383, P1045, DOI 10.1515/BC.2002.113; Yousef GM, 1999, J BIOL CHEM, V274, P37511, DOI 10.1074/jbc.274.53.37511; Yousef GM, 2003, CANCER RES, V63, P3958; Yousef GM, 2002, UROLOGY, V60, P714, DOI 10.1016/S0090-4295(02)01811-3; Yousef GM, 2002, PROSTATE, V51, P126, DOI 10.1002/pros.10067; Yousef GM, 2002, CLIN CHEM, V48, P1241; Yousef GM, 2001, GENOMICS, V74, P385, DOI 10.1006/geno.2001.6556; Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184	75	131	132	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14628	14635		10.1074/jbc.M408132200	http://dx.doi.org/10.1074/jbc.M408132200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15713679	hybrid			2022-12-25	WOS:000228236800037
J	Schmitt, S; Ahting, U; Eichacker, L; Granvogl, B; Go, NE; Nargang, FE; Neupert, W; Nussberger, S				Schmitt, S; Ahting, U; Eichacker, L; Granvogl, B; Go, NE; Nargang, FE; Neupert, W; Nussberger, S			Role of TOM5 in maintaining the structural stability of the TOM complex of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; PROTEIN-IMPORT; NEUROSPORA-CRASSA; BIOCHEMICAL-CHARACTERIZATION; PREPROTEIN TRANSLOCASE; CORE COMPLEX; PORE; BIOGENESIS; CHANNEL; RECEPTORS	Transport of nuclear encoded proteins into mitochondria is mediated by multisubunit translocation machineries in the outer and inner membranes of mitochondria. The TOM complex contains receptor and pore components that facilitate the recognition of preproteins and their transfer through the outer membrane. In addition, the complex contains a set of small proteins. Tom7 and Tom6 have been found in Neurospora and yeast, Tom5 has been found so far only in the latter organism. In the present study, we identified Neurospora Tom5 and analyzed its function in comparison to yeast Tom5, which has been proposed to play a role as a receptor-like component. Neurospora Tom5 crosses the outer membrane with its carboxyl terminus facing the intermembrane space like the other small Tom components. The temperature-sensitive growth phenotype of the yeast TOM5 deletion was rescued by overexpression of Neurospora Tom5. On the other hand, Neurospora cells deficient in tom5 did not exhibit any defect in growth. The structural stability of TOM complexes from cells devoid of Tom5 was significantly altered in yeast but not in Neurospora. The efficiency of protein import in Neurospora mitochondria was not affected by deletion of tom5, whereas in yeast it was reduced as compared with wild type. We conclude that the main role of Tom5, rather than being a receptor, is maintaining the structural integrity of the TOM complex.	Univ Stuttgart, Biophys Abt, Inst Biol, D-70550 Stuttgart, Germany; Univ Munich, Adolf Butenandt Inst Physiol Chem, D-81377 Munich, Germany; GSF Forschungszentrum Umwelt & Gesundheit, Inst Humangenet, D-85764 Neuherberg, Germany; Univ Munich, Inst Bot, D-80638 Munich, Germany; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	University of Stuttgart; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Alberta	Nussberger, S (corresponding author), Univ Stuttgart, Biophys Abt, Inst Biol, Pfaffenwaldring 57, D-70550 Stuttgart, Germany.	nussberger@bio.uni-stuttgart.de	Nargang, Frank/A-2669-2014	Nargang, Frank/0000-0002-1383-4720; Nussberger, Stephan/0000-0003-3619-4452				Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Ahting U, 2001, J CELL BIOL, V153, P1151, DOI 10.1083/jcb.153.6.1151; ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Allen R, 2002, FEBS LETT, V514, P347, DOI 10.1016/S0014-5793(02)02433-X; Braun HP, 1999, PLANTA, V209, P267, DOI 10.1007/s004250050632; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; Dembowski M, 2001, J BIOL CHEM, V276, P17679, DOI 10.1074/jbc.M009653200; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Habib SJ, 2003, FEBS LETT, V555, P511, DOI 10.1016/S0014-5793(03)01325-5; Hammen PK, 2000, FEBS LETT, V468, P101, DOI 10.1016/S0014-5793(00)01160-1; HARKNESS TAA, 1994, GENETICS, V136, P107; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; Horie C, 2003, J BIOL CHEM, V278, P41462, DOI 10.1074/jbc.M307047200; Jansch L, 1998, J BIOL CHEM, V273, P17251, DOI 10.1074/jbc.273.27.17251; JENO P, 1995, ANAL BIOCHEM, V224, P75, DOI 10.1006/abio.1995.1010; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Kurz M, 1999, MOL BIOL CELL, V10, P2461, DOI 10.1091/mbc.10.7.2461; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; Model K, 2002, J MOL BIOL, V316, P657, DOI 10.1006/jmbi.2001.5365; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Muller A, 2002, EMBO J, V21, P1916, DOI 10.1093/emboj/21.8.1916; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Paschen SA, 2001, IUBMB LIFE, V52, P101, DOI 10.1080/15216540152845894; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Prokisch H, 2002, FUNGAL GENET BIOL, V36, P85, DOI 10.1016/S1087-1845(02)00018-X; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rapaport D, 1998, MOL CELL BIOL, V18, P5256, DOI 10.1128/MCB.18.9.5256; Rapaport D, 2002, TRENDS BIOCHEM SCI, V27, P191, DOI 10.1016/S0968-0004(02)02065-0; Rapaport D, 2001, MOL BIOL CELL, V12, P1189, DOI 10.1091/mbc.12.5.1189; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; Shevchenko A, 1996, BIOCHEM SOC T, V24, P893, DOI 10.1042/bst0240893; Suzuki H, 2000, J BIOL CHEM, V275, P37930, DOI 10.1074/jbc.M006558200; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	38	48	49	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14499	14506		10.1074/jbc.M413667200	http://dx.doi.org/10.1074/jbc.M413667200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701639	hybrid			2022-12-25	WOS:000228236800020
J	Sineshchevkov, OA; Trivedi, VD; Sasaki, J; Spudich, JL				Sineshchevkov, OA; Trivedi, VD; Sasaki, J; Spudich, JL			Photochromicity of Anabaena sensory rhodopsin, an atypical microbial receptor with a cis-retinal light-adapted form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON RELEASE; BACTERIORHODOPSIN; ISOMERIZATION; PHOTOTROPHY; ARGININE-82; ADAPTATION; PROTEINS; PK(A)	We characterize changes in isomeric states of the retinylidene chromophore during light-dark adaptation and photochemical reactions of Anabaena (Nostoc) sp. PCC7120 sensory rhodopsin (ASR). The results show that ASR represents a new type of microbial rhodopsin with a number of unusual characteristics. The three most striking are: (i) a primarily all-trans configuration of retinal in the dark-adapted state and (ii) a primarily 13-cis light-adapted state with a blue-shifted and lower extinction absorption spectrum, opposite of the case of bacteriorhodopsin; and (iii) efficient reversible light-induced interconversion between the 13-cis and all-trans unphotolyzed states of the pigment. The relative amount of ASR with cis and trans chromophore forms depends on the wavelength of illumination, providing a mechanism for single-pigment color sensing analogous to that of phytochrome pigments. In addition ASR exhibits unusually slow formation of L-like and M-like intermediates, with a dominant accumulation of M during the photocycle. Co-expression of ASR with its putative cytoplasmic transducer protein shifts the absorption maximum and strongly decreases the rate of dark adaptation of ASR, confirming interaction between the two proteins. Thus ASR, the first non-haloarchaeal sensory rhodopsin character-ized, demonstrates the diversity of photochemistry of microbial rhodopsins. Its photochromic properties and the position of its two ground state absorption maxima suggest it as a candidate for controlling differential photosynthetic light-harvesting pigment synthesis (chromatic adaptation) or other color-sensitive physiological responses in Anabaena cells.	Univ Texas, Sch Med, Ctr Membrane Biol, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Moscow MV Lomonosov State Univ, Dept Biol, Moscow 119899, Russia	University of Texas System; Lomonosov Moscow State University	Spudich, JL (corresponding author), Univ Texas, Sch Med, Ctr Membrane Biol, Dept Biochem & Mol Biol, MSB 6-130,6431 Fannin St, Houston, TX 77030 USA.	John.L.Spudich@uth.tmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027750] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balashov SP, 2000, BBA-BIOENERGETICS, V1460, P75, DOI 10.1016/S0005-2728(00)00131-6; BALASHOV SP, 1995, BIOCHEMISTRY-US, V34, P8820, DOI 10.1021/bi00027a034; BALASHOV SP, 1988, PHYSICOCHEMICAL BIOL, V8, P1; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Beja O, 2001, NATURE, V411, P786, DOI 10.1038/35081051; Brown LS, 2004, PHOTOCH PHOTOBIO SCI, V3, P555, DOI 10.1039/b315527g; CASADIO R, 1980, BIOCHIM BIOPHYS ACTA, V590, P13, DOI 10.1016/0005-2728(80)90142-5; Govindjee R, 1996, BIOPHYS J, V71, P1011, DOI 10.1016/S0006-3495(96)79302-5; Grossman AR, 2001, J BIOL CHEM, V276, P11449, DOI 10.1074/jbc.R100003200; Gyula N, 2003, CURR OPIN PLANT BIOL, V6, P446, DOI 10.1016/S1369-5266(03)00082-7; Jung KH, 2003, MOL MICROBIOL, V47, P1513, DOI 10.1046/j.1365-2958.2003.03395.x; JUNG KH, 2004, CRC HDB ORGANIC PHOT, P1; Kateriya S, 2004, NEWS PHYSIOL SCI, V19, P133, DOI 10.1152/nips.01517.2004; KORENSTEIN R, 1977, FEBS LETT, V82, P7, DOI 10.1016/0014-5793(77)80874-0; KOUYAMA T, 1985, BIOPHYS J, V48, P201, DOI 10.1016/S0006-3495(85)83773-5; OHNO K, 1977, BIOCHIM BIOPHYS ACTA, V462, P575, DOI 10.1016/0005-2728(77)90102-5; PETTEI MJ, 1977, BIOCHEMISTRY-US, V16, P1955, DOI 10.1021/bi00628a031; SCHERRER P, 1989, BIOCHEMISTRY-US, V28, P829, DOI 10.1021/bi00428a063; Sineshchekov OA, 2002, P NATL ACAD SCI USA, V99, P8689, DOI 10.1073/pnas.122243399; SPUDICH E N, 1986, Proteins Structure Function and Genetics, V1, P239, DOI 10.1002/prot.340010306; Spudich JL, 2000, ANNU REV CELL DEV BI, V16, P365, DOI 10.1146/annurev.cellbio.16.1.365; Vogeley L, 2004, SCIENCE, V306, P1390, DOI 10.1126/science.1103943; WAGNER G, 2001, COMPREHENSIVE SERIES, V1, P421; Wang H.S.., 2002, ARABIDOPSIS BOOK, P1; Wang WW, 2003, J BIOL CHEM, V278, P33985, DOI 10.1074/jbc.M305716200	25	69	71	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14663	14668		10.1074/jbc.m501416200	http://dx.doi.org/10.1074/jbc.m501416200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15710603	hybrid			2022-12-25	WOS:000228236800041
J	Wharton, J; Meshulam, T; Vallega, G; Pilch, P				Wharton, J; Meshulam, T; Vallega, G; Pilch, P			Dissociation of insulin receptor expression and signaling from caveolin-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; TYROSINE PHOSPHORYLATION; ENDOCYTIC TRAFFICKING; GLUCOSE-TRANSPORT; LIPID RAFTS; PROTEINS; VESICLES; DOMAIN; CELLS; ENDOTHELIUM	The presence of cell surface caveolin/caveolae has been postulated to influence the localization, expression levels, and kinase activity of numerous receptors, including the insulin receptor. However, there are conflicting data concerning the effects of caveolin on insulin receptor expression and function. To help clarify this issue, we created a gain of function situation by expressing caveolin-1 at various levels in HEK-293 cells where the endogenous level of caveolin-1 is very low. We generated four permanent lines of this cell expressing amounts of caveolin-1 ranging from 10 to 40 times that of parental cells. The amount of caveolin-1 in the human embryonic kidney cells expressing the highest caveolin levels is comparable with that of adipocytes, cells that naturally express one of the highest levels of caveolin-1. We measured insulin receptor amount and insulin-dependent receptor autophosphorylation as well as insulin receptor substrate 1 (IRS1) tyrosine phosphorylation as an index of insulin signaling. We found that the insulin receptor level was essentially the same in the parental and all four derived cell lines. Likewise, we determined that insulin-dependent insulin receptor and IRS1 tyrosine phosphorylation was not significantly different in the four cell lines representing parental, low, medium, and high levels of caveolin-1 expression. We conclude that insulin receptor expression and ligand-dependent signaling is independent of caveolin-1 expression.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Pilch, P (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	ppilch@bu.edu		Meshulam, Tova/0000-0002-7635-0328; Pilch, Paul/0000-0003-1997-0499	NIDDK NIH HHS [DK-56935] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056935] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V285, pC222, DOI 10.1152/ajpcell.00006.2003; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; FAN JY, 1983, J CELL SCI, V61, P219; Fastenberg ME, 2003, BIOCHEMISTRY-US, V42, P12376, DOI 10.1021/bi034718d; Fielding CJ, 2000, BBA-MOL CELL BIOL L, V1529, P210, DOI 10.1016/S1388-1981(00)00150-5; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; Gross DN, 2004, MOL CELL BIOL, V24, P7151, DOI 10.1128/MCB.24.16.7151-7162.2004; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Kimura A, 2002, J BIOL CHEM, V277, P30153, DOI 10.1074/jbc.M203375200; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipardi C, 1998, J CELL BIOL, V140, P617, DOI 10.1083/jcb.140.3.617; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Maxfield FR, 1997, ADV EXP MED BIOL, V419, P355; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Pichler H, 2004, BBA-BIOMEMBRANES, V1666, P51, DOI 10.1016/j.bbamem.2004.05.011; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; PILCH PF, 1983, J CELL BIOL, V96, P133, DOI 10.1083/jcb.96.1.133; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Schlegel A, 1999, J BIOL CHEM, V274, P22660, DOI 10.1074/jbc.274.32.22660; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Souto RP, 2003, J BIOL CHEM, V278, P18321, DOI 10.1074/jbc.M211541200; TERCYAK A, 1991, J NUTR BIOCH, V2, P282; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; Vainio S, 2002, EMBO REP, V3, P95, DOI 10.1093/embo-reports/kvf010; Wang LB, 2003, J LIPID RES, V44, P807, DOI 10.1194/jlr.M200449-JLR200; Whiteman Eileen L, 2003, Methods Mol Med, V83, P119; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962	40	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13483	13486		10.1074/jbc.M413891200	http://dx.doi.org/10.1074/jbc.M413891200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15699039	hybrid			2022-12-25	WOS:000228095500038
J	Heidenblad, M; Lindgren, D; Veltman, JA; Jonson, T; Mahlamaki, EH; Gorunova, L; van Kessel, AG; Schoenmakers, EFPM; Hoglund, M				Heidenblad, M; Lindgren, D; Veltman, JA; Jonson, T; Mahlamaki, EH; Gorunova, L; van Kessel, AG; Schoenmakers, EFPM; Hoglund, M			Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic implications	ONCOGENE			English	Article						expression profiling; genomic profiling; microarray; pancreatic cancer	AMPLIFICATION; EXPRESSION; GENES; CARCINOMAS; TUMORS; 18Q; 12P; 15Q	DNA copy number alterations are believed to play a major role in the development and progression of human neoplasms. Although most of these genomic imbalances have been associated with dysregulation of individual genes, their large-scale transcriptional consequences remain unclear. Pancreatic carcinomas frequently display gene copy number variation of entire chromosomes as well as of chromosomal subregions. These changes range from homozygous deletions to high-level amplifications and are believed to constitute key genetic alterations in the cellular transformation of this tumor type. To investigate the transcriptional consequences of the most drastic genomic changes, that is, genomic amplifications, and to analyse the genome-wide transcriptional effects of DNA copy number changes, we performed expression pro. ling of 29 pancreatic carcinoma cell lines and compared the results with matching genomic pro. ling data. We show that a strong association between DNA copy numbers and mRNA expression levels is present in pancreatic cancer, and demonstrate that as much as 60% of the genes within highly amplified genomic regions display associated overexpression. Consequently, we identified 67 recurrently overexpressed genes located in seven precisely mapped commonly amplified regions. The presented findings indicate that more than one putative target gene may be of importance in most pancreatic cancer amplicons.	Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden; Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Univ Tampere, Canc Genet Lab, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland	Lund University; Skane University Hospital; Radboud University Nijmegen; Tampere University; Tampere University; Tampere University Hospital	Heidenblad, M (corresponding author), Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden.	markus.heidenblad@klingen.lu.se	Veltman, Joris A/F-5128-2010; van Kessel, Ad Geurts/A-2810-2010	Veltman, Joris A/0000-0002-3218-8250; Hoglund, Mattias/0000-0001-9283-4421				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Gorunova L, 1998, GENE CHROMOSOME CANC, V23, P81, DOI 10.1002/(SICI)1098-2264(199810)23:2<81::AID-GCC1>3.0.CO;2-0; HAHN SA, 1995, CANCER RES, V55, P4670; Heidenblad M, 2004, CANCER RES, V64, P3052, DOI 10.1158/0008-5472.CAN-03-3159; Heidenblad M, 2002, GENE CHROMOSOME CANC, V34, P211, DOI 10.1002/gcc.10063; Hyman E, 2002, CANCER RES, V62, P6240; Jonson T, 1999, GENE CHROMOSOME CANC, V24, P62, DOI 10.1002/(SICI)1098-2264(199901)24:1<62::AID-GCC9>3.0.CO;2-4; Mahlamaki EH, 2004, NEOPLASIA, V6, P432, DOI 10.1593/neo.04130; Mahlamaki EH, 1997, GENE CHROMOSOME CANC, V20, P383, DOI 10.1002/(SICI)1098-2264(199712)20:4<383::AID-GCC10>3.0.CO;2-O; Mertens F, 1997, CANCER RES, V57, P2765; Platzer P, 2002, CANCER RES, V62, P1134; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Rodriguez S, 2003, ONCOGENE, V22, P1880, DOI 10.1038/sj.onc.1206302; Saal LH, 2002, GENOME BIOL, V3; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01	17	79	83	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1794	1801		10.1038/sj.onc.1208383	http://dx.doi.org/10.1038/sj.onc.1208383			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15688027				2022-12-25	WOS:000227345100015
J	da Silva, GFZ; Tay, WM; Ming, LJ				da Silva, GFZ; Tay, WM; Ming, LJ			Catechol oxidase-like oxidation chemistry of the 1-20 and 1-16 fragments of Alzheimer's disease-related beta-amyloid peptide - Their structure-activity correlation and the fate of hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; SUPEROXIDE-DISMUTASE; COPPER(II) COMPLEX; PRECURSOR PROTEIN; STRAND SCISSION; ALPHA-SYNUCLEIN; BINDING; SITE; ANTIOXIDANT; REACTIVITY	The Cu2+ complexes of the 1 - 16 and the 1 - 20 fragments of the Alzheimer's disease-related beta-amyloid peptide (CuA beta) show significant oxidative activities toward a catechol-like substrate trihydroxylbenzene and plasmid DNA cleavage. The latter reflects possible oxidative stress to biological macromolecules, yielding supporting data to the pathological role of these soluble A beta fragments. The former exhibits enzyme-like kinetics and is dependent on [H2O2], exhibiting k(cat) of 0.066 s(-1) (6000-fold higher than the reaction without CuA beta) and k(cat)/K-m of 37.2 M-1 s(-1) under saturating [H2O2] of similar to 0.24%. This kinetic profile is consistent with metal-centered redox chemistry for the action of CuA beta. A mechanism is proposed by the use of the catalytic cycle of dinuclear catechol oxidase as a working model. Trihydroxylbenzene is also oxidized by CuA beta aerobically without H2O2, affording rate constants of 6.50 x 10(-3) s(-1) and 3.25 M-1 s(-1). This activity is also consistent with catechol oxidase action in the absence of H2O2, wherein the substrate binds and reduces the Cu2+ center first, followed by O-2 binding to afford the mu-eta(2): eta(2)-peroxo intermediate, which oxidizes a second substrate to complete the catalytic cycle. A tetragonally distorted octahedral metal coordination sphere with three coordinated His side chains and some specific H-bonding interactions is concluded from the electronic spectrum of CuA beta, hyperfine-shifted H-1 NMR spectrum of CoA beta, and molecular mechanics calculations. The results presented here are expected to add further insight into the chemistry of metallo-A beta, which may assist better understanding of the neuropathology of Alzheimer's disease.	Univ S Florida, Dept Chem, Tampa, FL 33620 USA; Univ S Florida, Inst Biomol Sci, Tampa, FL 33620 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Ming, LJ (corresponding author), Univ S Florida, Dept Chem, 4202 E Fowler Ave,SCA400, Tampa, FL 33620 USA.	ming@shell.cas.usf.edu						ARUOMA OI, 1991, BIOCHEM J, V273, P601, DOI 10.1042/bj2730601; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Bagchi D, 1997, RES COMMUN MOL PATH, V95, P179; Bertini I, 1984, Adv Inorg Biochem, V6, P71; BERTINI I, 1994, BIOINORGANIC, pCH4; Blackburn NJ, 2000, J BIOL INORG CHEM, V5, P341, DOI 10.1007/PL00010663; BURGER AR, 1980, BIOCHEMISTRY-US, V19, P4140; BURROWS CJ, 1999, INORG CHEM, V38, P3500; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Chen P, 2004, J AM CHEM SOC, V126, P4991, DOI 10.1021/ja031564g; CHIU SM, 1995, BIOCHEMISTRY-US, V34, P2653, DOI 10.1021/bi00008a032; COTTON FA, 1988, ADV INORG CHEM, P865; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; EHRENFELD GM, 1985, BIOCHEMISTRY-US, V24, P81, DOI 10.1021/bi00322a013; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Evin G, 2003, J NEUROSCI RES, V74, P386, DOI 10.1002/jnr.10745; Evin G, 2002, PEPTIDES, V23, P1285, DOI 10.1016/S0196-9781(02)00063-3; FLORINI JR, 1957, BIOCHIM BIOPHYS ACTA, V25, P575, DOI 10.1016/0006-3002(57)90529-2; Garzon-Rodriguez W, 1999, BIOORG MED CHEM LETT, V9, P2243, DOI 10.1016/S0960-894X(99)00357-1; Hegg EL, 1999, INORG CHEM, V38, P2961, DOI 10.1021/ic981087g; Huang XD, 2004, J BIOL INORG CHEM, V9, P954, DOI 10.1007/s00775-004-0602-8; Humphreys KJ, 2002, J BIOL INORG CHEM, V7, P835, DOI 10.1007/s00775-002-0369-8; Jang JH, 2002, ANN NY ACAD SCI, V973, P228, DOI 10.1111/j.1749-6632.2002.tb04639.x; KITAJIMA N, 1990, J AM CHEM SOC, V112, P8833, DOI 10.1021/ja00180a026; Kontush A, 2001, FREE RADICAL BIO MED, V30, P119, DOI 10.1016/S0891-5849(00)00458-5; Kontush A, 2001, FREE RADICAL BIO MED, V31, P1120, DOI 10.1016/S0891-5849(01)00688-8; Kowalik-Jankowska T, 2003, J INORG BIOCHEM, V95, P270, DOI 10.1016/S0162-0134(03)00128-4; LESKOVAC V, 2002, COMPREHENSIVE ENZYME; LEVER ABP, 1986, INORGANIC ELECT SPEC, P554; Lewis EA, 2004, CHEM REV, V104, P1047, DOI 10.1021/cr020633r; Ling Y, 2003, INT J BIOCHEM CELL B, V35, P1505, DOI 10.1016/S1357-2725(03)00133-X; Lonnrot K, 1996, FREE RADICAL BIO MED, V21, P211, DOI 10.1016/0891-5849(95)02207-4; Mahadevan V, 2000, J AM CHEM SOC, V122, P10249, DOI 10.1021/ja002527h; McKenzie D, 1998, J BIOL CHEM, V273, P25545, DOI 10.1074/jbc.273.40.25545; MING LJ, 2000, PHYSICAL METHODS BIO, pCH8; Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479; Miura T, 2001, J MOL STRUCT, V598, P79, DOI 10.1016/S0022-2860(01)00807-9; NUNOMURA A, 1999, J ANTI-AGING MED, V2, P227; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Paik SR, 2000, ARCH BIOCHEM BIOPHYS, V378, P269, DOI 10.1006/abbi.2000.1822; Paik SR, 1999, BIOCHEM J, V340, P821, DOI 10.1042/0264-6021:3400821; Park HI, 1998, J INORG BIOCHEM, V72, P57, DOI 10.1016/S0162-0134(98)10063-6; Que L, 2002, ANGEW CHEM INT EDIT, V41, P1114; RAO PS, 1988, BIOCHEM BIOPH RES CO, V150, P39, DOI 10.1016/0006-291X(88)90483-4; ROCHE E, 1993, MED HYPOTHESES, V40, P342, DOI 10.1016/0306-9877(93)90215-C; SAGRIPANTI JL, 1989, J BIOL CHEM, V264, P1729; Seo SY, 2003, J AGR FOOD CHEM, V51, P2837, DOI 10.1021/jf020826f; SHINOBU LA, 1997, METALS OXIDATIVE DAM; SIGMAN DS, 1993, CHEM REV, V93, P2295, DOI 10.1021/cr00022a011; Srivatsan SG, 2001, APPL CATAL A-GEN, V209, P327, DOI 10.1016/S0926-860X(00)00765-1; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Syme CD, 2004, J BIOL CHEM, V279, P18169, DOI 10.1074/jbc.M313572200; Tolman WB, 1997, ACCOUNTS CHEM RES, V30, P227, DOI 10.1021/ar960052m; Waiter MF, 1997, BIOCHEM BIOPH RES CO, V233, P760, DOI 10.1006/bbrc.1997.6547; YAMAMOTO K, 1989, J BIOL CHEM, V264, P15435; YAMAMOTO K, 1991, J BIOL CHEM, V266, P1509; Yamazaki S, 2003, J AM CHEM SOC, V125, P13034, DOI 10.1021/ja036425d; Zou K, 2002, J NEUROSCI, V22, P4833, DOI 10.1523/JNEUROSCI.22-12-04833.2002	61	39	39	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16601	16609		10.1074/jbc.M411533200	http://dx.doi.org/10.1074/jbc.M411533200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15699049	hybrid			2022-12-25	WOS:000228615500010
J	Freedman, BD; Lee, EJ; Park, Y; Jameson, JL				Freedman, BD; Lee, EJ; Park, Y; Jameson, JL			A dominant negative peroxisome proliferator-activated receptor-gamma knock-in mouse exhibits features of the metabolic syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; INSULIN-RESISTANCE; MICE; GENE; OBESITY; FAT; DISRUPTION; EXPRESSION; MUTATIONS; MUTANT	Peroxisome proliferator-activated receptor-gamma (PPAR gamma), a member of the nuclear hormone receptor family, is a master regulator of adipogenesis. Humans with dominant negative PPAR gamma mutations have features of the metabolic syndrome ( severe insulin resistance, dyslipidemia, and hypertension). We created a knock-in mouse model containing a potent dominant negative PPAR gamma L466A mutation, shown previously to inhibit wild-type PPAR gamma action in vitro. Homozygous PPAR gamma L466A knock-in mice die in utero. Heterozygous PPAR gamma L466A knock-in (PPARKI) mice exhibit hypoplastic adipocytes, hypoadiponectinemia, increased serum-free fatty acids, and hepatic steatosis. When subjected to high fat diet feeding, PPARKI mice gain significantly less weight than controls. Hyperinsulinemic-euglycemic clamp studies in PPARKI mice revealed insulin resistance and reduced glucose uptake into skeletal muscle. Female PPARKI mice exhibit hypertension independent of diet. The PPARKI mouse provides a novel model for studying the relationship between impaired PPAR gamma function and the metabolic syndrome.	Northwestern Univ, Feinberg Sch Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Jameson, JL (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Endocrinol Metab & Mol Med, Galter Pavil,Suite 3-150,251 E Huron St, Chicago, IL 60611 USA.	ljameson@northwestern.edu		Jameson, James/0000-0001-9538-4059	NIDDK NIH HHS [U24 DK59637] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK059637] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal AK, 2002, J CLIN ENDOCR METAB, V87, P408, DOI 10.1210/jc.87.1.408; Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; FRAYN KN, 1980, J LIPID RES, V21, P139; Halseth AE, 1999, AM J PHYSIOL-ENDOC M, V276, pE70, DOI 10.1152/ajpendo.1999.276.1.E70; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Hegele RA, 2002, DIABETES, V51, P3586, DOI 10.2337/diabetes.51.12.3586; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Leiter EH, 2002, DIABETOLOGIA, V45, P296, DOI 10.1007/s00125-001-0743-z; LEITER EH, 1989, FASEB J, V3, P2231, DOI 10.1096/fasebj.3.11.2673897; Ma LJ, 2004, DIABETES, V53, P336, DOI 10.2337/diabetes.53.2.336; Martin G, 1998, ATHEROSCLEROSIS, V137, pS75, DOI 10.1016/S0021-9150(97)00315-8; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Norris AW, 2003, J CLIN INVEST, V112, P608, DOI 10.1172/JCI200317305; Park Y, 2003, DIABETOLOGIA, V46, P365, DOI 10.1007/s00125-003-1037-4; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2003, MOL CELL BIOL, V23, P7222, DOI 10.1128/MCB.23.20.7222-7229.2003; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Savage DB, 2003, DIABETES, V52, P910, DOI 10.2337/diabetes.52.4.910; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Tsai YS, 2004, J CLIN INVEST, V114, P240, DOI 10.1172/JCI200420964; VidalPuig AJ, 1997, J CLIN INVEST, V99, P2416, DOI 10.1172/JCI119424	34	61	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17118	17125		10.1074/jbc.M407539200	http://dx.doi.org/10.1074/jbc.M407539200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15716267	hybrid			2022-12-25	WOS:000228615500071
J	Li, HT; Cui, HM; Liu, XP; Zweier, JL				Li, HT; Cui, HM; Liu, XP; Zweier, JL			Xanthine oxidase catalyzes anaerobic transformation of organic nitrates to nitric oxide and nitrosothiols - Characterization of this mechanism and the link between organic nitrate and guanylyl cyclase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CORONARY DILATATION; GLUTATHIONE S-TRANSFERASES; GLYCERYL TRINITRATE; FLAVOPROTEIN INHIBITOR; REDUCTASE-ACTIVITY; ISCHEMIC-HEART; NITROGLYCERIN; GENERATION; BIOTRANSFORMATION; HEME	Organic nitrates have been used clinically in the treatment of ischemic heart disease for more than a century. Recently, xanthine oxidase (XO) has been reported to catalyze organic nitrate reduction under anaerobic conditions, but questions remain regarding the initial precursor of nitric oxide ( NO) and the link of organic nitrate to the activation of soluble guanylyl cyclase (sGC). To characterize the mechanism of XO-mediated biotransformation of organic nitrate, studies using electron paramagnetic resonance spectroscopy, chemiluminescence NO analyzer, NO electrode, and immunoassay were performed. The XO reducing substrates xanthine, NADH, and 2,3-dihydroxybenz-aldehyde triggered the reduction of organic nitrate to nitrite anion (NO2-). Studies of the pH dependence of nitrite formation indicated that XO-mediated organic nitrate reduction occurred via an acid-catalyzed mechanism. In the absence of thiols or ascorbate, no NO generation was detected from XO-mediated organic nitrate reduction; however, addition of L-cysteine or ascorbate triggered prominent NO generation. Studies suggested that organic nitrite (R-ONO) is produced from XO-mediated organic nitrate reduction. Further reaction of organic nitrite with thiols or ascorbate leads to the generation of NO or nitrosothiols and thus stimulates the activation of sGC. Only flavin site XO inhibitors such as diphenyleneiodonium inhibited XO-mediated organic nitrate reduction and sGC activation, indicating that organic nitrate reduction occurs at the flavin site. Thus, organic nitrite is the initial product in the process of XO-mediated organic nitrate biotransformation and is the precursor of NO and nitrosothiols, serving as the link between organic nitrate and sGC activation.	Ohio State Univ, Coll Med, Davis Heart & Lung Res Inst, Ctr Biomed Electron Paramagnet Resonance Spect &, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Internal Med, Div Cardiovasc Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Li, HT (corresponding author), 110G Davis Heart & Ling Res Inst, 473 W 12th Ave, Columbus, OH 43210 USA.	li-13@medctr.osu.edu; zweier-1@medctr.osu.edu	Liu, Xiaoping/A-4516-2008		NHLBI NIH HHS [HL38324, HL65608, HL63744] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038324, R01HL063744, R01HL038324, P01HL065608] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BENNETT BM, 1994, TRENDS PHARMACOL SCI, V15, P245, DOI 10.1016/0165-6147(94)90319-0; BOYNE AF, 1972, ANAL BIOCHEM, V46, P639, DOI 10.1016/0003-2697(72)90335-1; BURGER IH, 1971, BIOCHEM J, V123, pP9; Chen ZQ, 2002, P NATL ACAD SCI USA, V99, P8306, DOI 10.1073/pnas.122225199; CHUNG SJ, 1990, J PHARMACOL EXP THER, V253, P614; Doel JJ, 2001, BBA-GEN SUBJECTS, V1527, P81, DOI 10.1016/S0304-4165(01)00148-9; FEELISCH M, 1992, BIOCHEM PHARMACOL, V44, P1149, DOI 10.1016/0006-2952(92)90379-W; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; GRUETTER CA, 1986, CAN J PHYSIOL PHARM, V64, P1395, DOI 10.1139/y86-236; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HUTTER J, 1988, EUR J PHARMACOL, V156, P215, DOI 10.1016/0014-2999(88)90324-X; Ignarro LJ, 2002, P NATL ACAD SCI USA, V99, P7816, DOI 10.1073/pnas.132271799; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; Ji YB, 1996, BIOCHEM J, V313, P377, DOI 10.1042/bj3130377; Khramtsov VV, 2004, ANTIOXID REDOX SIGN, V6, P667, DOI 10.1089/152308604773934431; Kleschyov AL, 2003, CIRC RES, V93, pE104, DOI 10.1161/01.RES.0000100067.62876.50; KOWALUK EA, 1993, DRUG METAB DISPOS, V21, P967; Kozlov AV, 1999, FEBS LETT, V454, P127, DOI 10.1016/S0014-5793(99)00788-7; LANCASTER JR, 1992, J BIOL CHEM, V267, P10994; Lee WI, 2003, NITRIC OXIDE-BIOL CH, V8, P103, DOI 10.1016/S1089-8603(02)00183-0; Li HT, 2004, J BIOL CHEM, V279, P16939, DOI 10.1074/jbc.M314336200; Li HT, 2003, BIOCHEMISTRY-US, V42, P1150, DOI 10.1021/bi026385a; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; Maia L, 2002, ARCH BIOCHEM BIOPHYS, V400, P48, DOI 10.1006/abbi.2002.2781; Mayer B, 2003, ANGEW CHEM INT EDIT, V42, P388, DOI 10.1002/anie.200390124; MCDONALD BJ, 1990, CAN J PHYSIOL PHARM, V68, P1552, DOI 10.1139/y90-236; MCGUIRE JJ, 1994, J PHARMACOL EXP THER, V271, P708; McGuire JJ, 1998, BIOCHEM PHARMACOL, V56, P881, DOI 10.1016/S0006-2952(98)00216-0; Meah Y, 2001, P NATL ACAD SCI USA, V98, P8560, DOI 10.1073/pnas.151249098; MELLION BT, 1983, MOL PHARMACOL, V23, P653; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; MEYER DJ, 1994, FEBS LETT, V351, P427, DOI 10.1016/0014-5793(94)00904-X; MohazzabH KM, 1999, CIRC RES, V84, P220; MUKERJEE N, 1994, J BIOL CHEM, V269, P21664; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; NEEDLEMAN P, 1973, J PHARMACOL EXP THER, V184, P709; NEEDLEMAN P, 1973, J PHARMACOL EXP THER, V187, P324; Nigam R, 1996, J PHARMACOL EXP THER, V279, P1527; Nohl H, 2000, ACTA BIOCHIM POL, V47, P913, DOI 10.18388/abp.2000_3946; Ratz JD, 2000, J PHARMACOL EXP THER, V293, P569; ROMANIN C, 1988, J MOL CELL CARDIOL, V20, P389, DOI 10.1016/S0022-2828(88)80130-5; Samouilov A, 1998, ANAL BIOCHEM, V258, P322, DOI 10.1006/abio.1998.2609; Samouilov A, 1998, ARCH BIOCHEM BIOPHYS, V357, P1, DOI 10.1006/abbi.1998.0785; SCHNEEWEISS A, 1990, ADV NITRATE THERAPY; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; SHINOBU LA, 1984, ACTA PHARMACOL TOX, V54, P189; Tiravanti E, 2004, J BIOL CHEM, V279, P11065, DOI 10.1074/jbc.M311908200; TSUCHIDA S, 1990, J BIOL CHEM, V265, P7150; WALTERS CL, 1967, BIOCHIM BIOPHYS ACTA, V143, P310, DOI 10.1016/0005-2728(67)90085-0; WALTERS CL, 1965, BIOCHIM BIOPHYS ACTA, V96, P522, DOI 10.1016/0005-2787(65)90570-8; WINNIFORD MD, 1986, CIRCULATION, V73, P138, DOI 10.1161/01.CIR.73.1.138; Wong PSY, 1999, DRUG METAB DISPOS, V27, P502; XIA Y, 1995, J BIOL CHEM, V270, P18797, DOI 10.1074/jbc.270.32.18797; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; Zweier JL, 1999, BBA-BIOENERGETICS, V1411, P250, DOI 10.1016/S0005-2728(99)00018-3; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304	58	52	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16594	16600		10.1074/jbc.M411905200	http://dx.doi.org/10.1074/jbc.M411905200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15695823	hybrid			2022-12-25	WOS:000228615500009
J	Yu, YD; Li, S; Xu, X; Li, Y; Guan, KL; Arnold, E; Ding, JP				Yu, YD; Li, S; Xu, X; Li, Y; Guan, KL; Arnold, E; Ding, JP			Structural basis for the unique biological function of small GTPase RHEB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBEROUS SCLEROSIS COMPLEX; TUMOR-SUPPRESSOR PROTEINS; RAS-RELATED PROTEIN; TSC2 GAP ACTIVITY; CELL-GROWTH; GENE-PRODUCTS; DIRECT TARGET; ACTIVATION; DROSOPHILA; MUTANTS	The small GTPase Rheb displays unique biological and biochemical properties different from other small GTPases and functions as an important mediator between the tumor suppressor proteins TSC1 and TSC2 and the mammalian target of rapamycin to stimulate cell growth. We report here the three-dimensional structures of human Rheb in complexes with GDP, GTP, and GppNHp (5'-(beta, gamma-imide) triphosphate), which reveal novel structural features of Rheb and provide a molecular basis for its distinct properties. During GTP/GDP cycling, switch I of Rheb undergoes conformational change while switch II maintains a stable, unusually extended conformation, which is substantially different from the alpha-helical conformation seen in other small GTPases. The unique switch II conformation results in a displacement of Gln(64) ( equivalent to the catalytic Gln(61) of Ras), making it incapable of participating in GTP hydrolysis and thus accounting for the low intrinsic GTPase activity of Rheb. This rearrangement also creates space to accommodate the side chain of Arg(15), avoiding its steric hindrance with the catalytic residue and explaining its noninvolvement in GTP hydrolysis. Unlike Ras, the phosphate moiety of GTP in Rheb is shielded by the conserved Tyr(35) of switch I, leading to the closure of the GTP-binding site, which appears to prohibit the insertion of a potential arginine finger from its GTPase-activating protein. Taking the genetic, biochemical, biological, and structural data together, we propose that Rheb forms a new group of the Ras/Rap subfamily and uses a novel GTP hydrolysis mechanism that utilizes Asn(1643) of the tuberous sclerosis complex 2 GTPase-activating protein domain instead of Gln(64) of Rheb as the catalytic residue.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Shanghai 200031, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China; Univ Michigan, Dept Biol Chem, Inst Life Sci, Ann Arbor, MI 48109 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Michigan System; University of Michigan; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Ding, JP (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	jpding@sibs.ac.cn	Xu, Xiang/G-5528-2012	ding, jian ping/0000-0001-7029-7346				Aspuria PJ, 2004, CELL SIGNAL, V16, P1105, DOI 10.1016/j.cellsig.2004.03.019; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Cherfils J, 1997, EMBO J, V16, P5582, DOI 10.1093/emboj/16.18.5582; Clark GJ, 1997, J BIOL CHEM, V272, P10608; Daumke O, 2004, NATURE, V429, P197, DOI 10.1038/nature02505; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; GOMEZ MR, 1999, TUBEROUS SCLEROSIS; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Maheshwar MM, 1996, HUM MOL GENET, V5, P131, DOI 10.1093/hmg/5.1.131; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Mizuki N, 1996, GENOMICS, V34, P114, DOI 10.1006/geno.1996.0248; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Patel PH, 2003, J CELL SCI, V116, P3601, DOI 10.1242/jcs.00661; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Sparagana Steven P., 2000, Current Opinion in Neurology, V13, P115, DOI 10.1097/00019052-200004000-00001; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; WITTINGHOFER A, 1999, GTPASE; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yu YD, 2004, ACTA CRYSTALLOGR D, V60, P1883, DOI 10.1107/S0907444904018232; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	41	57	62	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17093	17100		10.1074/jbc.M501253200	http://dx.doi.org/10.1074/jbc.M501253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728574	hybrid			2022-12-25	WOS:000228615500068
J	Batsche, E; Moschopoulos, P; Desroches, J; Bilodeau, S; Drouin, J				Batsche, E; Moschopoulos, P; Desroches, J; Bilodeau, S; Drouin, J			Retinoblastoma and the related pocket protein p107 act as coactivators of NeuroD1 to enhance gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-BOX FACTOR; NUCLEAR RECEPTORS; CELL-CYCLE; NGFI-B; EXPRESSION; DIFFERENTIATION; MECHANISM; NUR77; TPIT; PTX1	Gene inactivation studies have suggested that the product of the retinoblastoma gene, Rb, is particularly limiting in pituitary pro-opiomelanocortin (POMC)-expressing cell lineages. Indeed, in Rb knock- out mice, these cells develop tumors with high frequency. To understand the implication of limiting Rb expression in these cells, we investigated the action of Rb and its related pocket proteins, p107 and p130, on POMC gene transcription. This led to the identification of the neurogenic basic helix-loop-helix transcription factor, NeuroD1, as a target of Rb action. Rb and to a lesser extent p107, but not p130, enhance NeuroD1-dependent transcription, and this activity appears to depend on direct protein interactions between the Rb pocket and the helix-loop-helix domain of NeuroD1. In vivo, NeuroD is found in a complex that includes Rb and also the orphan nuclear receptor NGFI-B, which mediates corticotropin-releasing hormone activation of POMC transcription. The formation of a similar complex in vitro requires the presence of Rb as a bridge between NeuroD and NGFI-B. In POMC-expressing AtT-20 cells, Rb and p107 are present on the POMC promoter and inhibition of their expression through small interfering RNA decreases POMC mRNA levels. The action of Rb and its related proteins on POMC transcription may contribute to the establishment and/or maintenance of the differentiation phenotype.	Inst Rech Clin Montreal, Genet Mol Lab, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Drouin, J (corresponding author), Inst Rech Clin Montreal, Genet Mol Lab, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada.	jacques.drouin@ircm.qc.ca		Drouin, Jacques/0000-0001-8226-5691; Bilodeau, Steve/0000-0002-9799-3832; Batsche, Eric/0000-0002-5145-5270				Asa SL, 1998, ENDOCR REV, V19, P798, DOI 10.1210/er.19.6.798; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BATSCHE E, 2005, J BIOL CHEM, DOI DOI 10.1074/JBCM41328200; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; COPPOLA JA, 1990, ONCOGENE, V5, P1731; Drouin J, 1998, J STEROID BIOCHEM, V65, P59, DOI 10.1016/S0960-0760(97)00180-5; Frost SJ, 1999, MOL ENDOCRINOL, V13, P1801, DOI 10.1210/me.13.11.1801; HAMEL PA, 1992, ONCOGENE, V7, P693; Hinton DR, 1998, CANCER LETT, V126, P209, DOI 10.1016/S0304-3835(98)00013-5; HU NP, 1994, ONCOGENE, V9, P1021; Iavarone A, 2004, CANCER LETT, V204, P189, DOI 10.1016/S0304-3835(03)00455-5; Jiang Z, 1997, ONCOGENE, V14, P1789, DOI 10.1038/sj.onc.1201014; Lamolet B, 2001, CELL, V104, P849, DOI 10.1016/S0092-8674(01)00282-3; Lamolet B, 2004, MOL ENDOCRINOL, V18, P995, DOI 10.1210/me.2003-0127; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Lanctot C, 1999, DEVELOPMENT, V126, P1805; Lanctot C, 1997, DEVELOPMENT, V124, P2807; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; LUNDBLAD JR, 1988, ENDOCR REV, V9, P135, DOI 10.1210/edrv-9-1-135; Maira M, 2003, J BIOL CHEM, V278, P46523, DOI 10.1074/jbc.M305626200; Maira M, 2003, MOL CELL BIOL, V23, P763, DOI 10.1128/MCB.23.3.763-776.2003; Maira M, 1999, MOL CELL BIOL, V19, P7549; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Phillips A, 1997, MOL CELL BIOL, V17, P5952, DOI 10.1128/MCB.17.10.5952; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Poulin G, 1997, MOL CELL BIOL, V17, P6673, DOI 10.1128/MCB.17.11.6673; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; Pulichino AM, 2003, GENE DEV, V17, P738, DOI 10.1101/gad.1065703; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Ratineau C, 2002, J BIOL CHEM, V277, P8847, DOI 10.1074/jbc.M110747200; Russell RG, 2004, CANCER RES, V64, P7220, DOI 10.1158/0008-5472.CAN-04-2095; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Suh H, 2002, DEVELOPMENT, V129, P329; Suhardja A, 2001, J NEURO-ONCOL, V52, P195, DOI 10.1023/A:1010655419332; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; THERRIEN M, 1991, MOL CELL BIOL, V11, P3492, DOI 10.1128/MCB.11.7.3492; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; THERRIEN M, 1993, MELANOTROPIC PEPTIDE, P663; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; van Gurp MF, 1999, CANCER RES, V59, P5980; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926	50	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16088	16095		10.1074/jbc.M413427200	http://dx.doi.org/10.1074/jbc.M413427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15701640	hybrid			2022-12-25	WOS:000228444800076
J	Chung, MK; Guler, AD; Caterina, MJ				Chung, MK; Guler, AD; Caterina, MJ			Biphasic currents evoked by chemical or thermal activation of the heat-gated ion channel, TRPV3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSAICIN RECEPTOR VR1; OPERATED CA2+ ENTRY; 2-AMINOETHOXYDIPHENYL BORATE; VANILLOID RECEPTOR; CATION CHANNEL; CALCIUM-ENTRY; DIRECT PHOSPHORYLATION; PORE PROPERTIES; BINDING-SITE; PAIN PATHWAY	2-Aminoethyl diphenylborinate was recently identified as a chemical activator of TRPV1, TRPV2, and TRPV3, three heat-gated members of the transient receptor potential vanilloid (TRPV) ion channel subfamily. Here we demonstrated that two structurally related compounds, diphenylboronic anhydride ( DPBA) and diphenyltetrahydrofuran (DPTHF), can also modulate the activity of these channels. DPBA acted as a TRPV3 agonist, whereas DPTHF exhibited prominent antagonistic activity. However, all three diphenyl-containing compounds promoted some degree of channel activation or potentiation, followed by channel block. Strong TRPV3 activation by DPBA often leads to the appearance of a secondary, enhanced, current phase. A similar biphasic response was observed during TRPV3 heat stimulation; an initial, gradually sensitizing phase (I-1) was followed by an abrupt transition to a secondary phase (I-2). I-2 was characterized by larger current amplitude, loss of outward rectification, and alterations in the following properties: permeability among cations; ruthenium red and DPTHF sensitivity; temperature dependence; and voltage-dependent gating. The I-1 to I-2 transition depended strongly on TRPV3 current density. Removal of extracellular divalent cations resulted in heat-evoked currents resembling I-2, whereas mutation of a putative Ca2+-binding residue in the pore loop domain, aspartate 641, facilitated detection of the I-1 to I-2 transition, suggesting that the conversion to I-2 resulted from the agonist- and time-dependent loss of divalent cationic inhibition. Primary keratinocytes overexpressing exogenous TRPV3 also exhibited biphasic agonist- evoked currents. Thus, strong activation by either chemical or thermal stimuli led to biphasic TRPV3 signaling behavior that may be associated with changes in the channel pore.	Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Caterina, MJ (corresponding author), Johns Hopkins Sch Med, Dept Biol Chem, Rm 408,Biophys Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.	caterina@jhmi.edu	Chung, Man-Kyo/S-7433-2019	Chung, Man-Kyo/0000-0001-7637-1148; Guler, Ali Deniz/0000-0001-8218-850X				Benham CD, 2003, CELL CALCIUM, V33, P479, DOI 10.1016/S0143-4160(03)00063-0; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Brauchi S, 2004, P NATL ACAD SCI USA, V101, P15494, DOI 10.1073/pnas.0406773101; Braun FJ, 2003, MOL PHARMACOL, V63, P1304, DOI 10.1124/mol.63.6.1304; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Chung MK, 2004, J BIOL CHEM, V279, P21569, DOI 10.1074/jbc.M401872200; Chung MK, 2004, J NEUROSCI, V24, P5177, DOI 10.1523/JNEUROSCI.0934-04.2004; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Fujiwara Y, 2004, J PHYSIOL-LONDON, V558, P31, DOI 10.1113/jphysiol.2004.064568; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; Guler AD, 2002, J NEUROSCI, V22, P6408; Gunthorpe MJ, 2000, J PHYSIOL-LONDON, V525, P747, DOI 10.1111/j.1469-7793.2000.t01-1-00747.x; Hellwig N, 2004, J BIOL CHEM, V279, P34553, DOI 10.1074/jbc.M402966200; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Khakh BS, 1999, NEURON, V23, P653, DOI 10.1016/S0896-6273(01)80025-8; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Lemonnier L, 2004, FEBS LETT, V556, P121, DOI 10.1016/S0014-5793(03)01387-5; Lyfenko A, 2002, PAIN, V95, P207, DOI 10.1016/S0304-3959(01)00401-8; Ma HT, 2003, BIOCHEM J, V376, P667, DOI 10.1042/BJ20031345; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Meyers JR, 2003, J NEUROSCI, V23, P4054; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003; Numazaki M, 2003, P NATL ACAD SCI USA, V100, P8002, DOI 10.1073/pnas.1337252100; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Strotmann R, 2003, J BIOL CHEM, V278, P26541, DOI 10.1074/jbc.M302590200; Tu CL, 2004, CELL CALCIUM, V35, P265, DOI 10.1016/j.ceca.2003.10.019; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200; Voets T, 2004, NATURE, V430, P748, DOI 10.1038/nature02732; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882	45	111	127	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15928	15941		10.1074/jbc.M500596200	http://dx.doi.org/10.1074/jbc.M500596200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722340	hybrid			2022-12-25	WOS:000228444800059
J	Gongadze, GM; Korepanov, AP; Stolboushkina, EA; Zelinskaya, NV; Korobeinikova, AV; Ruzanov, MV; Eliseev, BD; Nikonov, OS; Nikonov, SV; Garber, MB; Lim, VI				Gongadze, GM; Korepanov, AP; Stolboushkina, EA; Zelinskaya, NV; Korobeinikova, AV; Ruzanov, MV; Eliseev, BD; Nikonov, OS; Nikonov, SV; Garber, MB; Lim, VI			The crucial role of conserved intermolecular H-bonds inaccessible to the solvent in formation and stabilization of the TL5 center dot 5 SrRNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN TL5; GENERAL STRESS-PROTEINS; THERMUS-THERMOPHILUS; RNA; EXPRESSION; INSIGHTS; PROVIDES; SUBUNIT; REGION	Analysis of the structures of two complexes of 5 S rRNA with homologous ribosomal proteins, Escherichia coli L25 and Thermus thermophilus TL5, revealed that amino acid residues interacting with RNA can be divided into two different groups. The first group consists of non-conserved residues, which form intermolecular hydrogen bonds accessible to solvent. The second group, comprised of strongly conserved residues, form intermolecular hydrogen bonds that are shielded from solvent. Site-directed mutagenesis was used to introduce mutations into the RNA-binding site of protein TL5. We found that replacement of residues of the first group does not influence the stability of the TL5 center dot 5 S rRNA complex, whereas replacement of residues of the second group leads to destabilization or disruption of the complex. Stereochemical analysis shows that the replacements of residues of the second group always create complexes with uncompensated losses of intermolecular hydrogen bonds. We suggest that these shielded intermolecular hydrogen bonds are responsible for the recognition between the protein and RNA.	Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow 119991, Russia	Russian Academy of Sciences; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Gongadze, GM (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia.	gongadze@vega.protres.ru	Korobeinikova, Anna/L-8964-2015; Korepanov, Alexey/I-9052-2012; Garber, Maria/I-4262-2013; Gongadze, George/E-6674-2012; Nikonov, Oleg/M-4253-2015; STOLBOUSHKINA, ELENA/J-7732-2015	Garber, Maria/0000-0002-3986-4848; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benson DA, 2004, NUCLEIC ACIDS RES, V32, pD23, DOI 10.1093/nar/gkh045; Brodersen DE, 2002, J MOL BIOL, V316, P725, DOI 10.1006/jmbi.2001.5359; DOUTHWAITE S, 1979, NUCLEIC ACIDS RES, V6, P2453, DOI 10.1093/nar/6.7.2453; Fedorov R, 2001, ACTA CRYSTALLOGR D, V57, P968, DOI 10.1107/S0907444901006291; Frishman D, 2003, NUCLEIC ACIDS RES, V31, P207, DOI 10.1093/nar/gkg005; GONGADZE GM, 1993, FEBS LETT, V330, P46, DOI 10.1016/0014-5793(93)80916-I; Gongadze GM, 1999, FEBS LETT, V451, P51, DOI 10.1016/S0014-5793(99)00538-4; Gryaznova OI, 1996, BIOCHIMIE, V78, P915, DOI 10.1016/S0300-9084(97)86713-2; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klein DJ, 2004, J MOL BIOL, V340, P141, DOI 10.1016/j.jmb.2004.03.076; Korepanov AP, 2004, BIOCHEMISTRY-MOSCOW+, V69, P607, DOI 10.1023/B:BIRY.0000033733.60180.e3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lim VI, 2001, RNA, V7, P942, DOI 10.1017/S135583820100214X; Lu M, 2000, P NATL ACAD SCI USA, V97, P2023, DOI 10.1073/pnas.97.5.2023; Meshcheryakov VA, 1997, BIOCHEMISTRY-MOSCOW+, V62, P537; Nevskaia N A, 2004, Mol Biol (Mosk), V38, P926; NEVSKAYA N, 2003, PROTEIN STRUCTURES K, P87; Nierhaus K H, 1979, Methods Enzymol, V59, P443; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Serganov AA, 1996, RNA, V2, P1124; Stoldt M, 1998, EMBO J, V17, P6377, DOI 10.1093/emboj/17.21.6377; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Szymanski M, 2002, NUCLEIC ACIDS RES, V30, P176, DOI 10.1093/nar/30.1.176; Treger M, 2001, J MOL RECOGNIT, V14, P199, DOI 10.1002/jmr.534; VOLKER U, 1994, MICROBIOL-UK, V140, P741, DOI 10.1099/00221287-140-4-741	29	14	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16151	16156		10.1074/jbc.M413596200	http://dx.doi.org/10.1074/jbc.M413596200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15718233	hybrid			2022-12-25	WOS:000228444800083
J	Jacob, C; Cottrell, GS; Gehringer, D; Schmidlin, F; Grady, EF; Bunnett, NW				Jacob, C; Cottrell, GS; Gehringer, D; Schmidlin, F; Grady, EF; Bunnett, NW			c-Cbl mediates ubiquitination, degradation, and down-regulation of human protease-activated receptor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE-ACTIVATED RECEPTOR-2; GROWTH-FACTOR RECEPTOR; ARRESTIN-DEPENDENT ENDOCYTOSIS; BETA-ARRESTIN; EGF RECEPTOR; COUPLED RECEPTORS; CELL-PROLIFERATION; PLASMA-MEMBRANE; TRAFFICKING; PHOSPHORYLATION	Mechanisms that arrest G-protein- coupled receptor ( GPCR) signaling prevent uncontrolled stimulation that could cause disease. Although uncoupling from heterotrimeric G-proteins, which transiently arrests signaling, is well described, little is known about the mechanisms that permanently arrest signaling. Here we reported on the mechanisms that terminate signaling by protease-activated receptor 2 (PAR(2)), which mediated the proinflammatory and nociceptive actions of proteases. Given its irreversible mechanism of proteolytic activation, PAR(2) is a model to study the permanent arrest of GPCR signaling. By immunoprecipitation and immunoblotting, we observed that activated PAR(2) was mono-ubiquitinated. Immunofluorescence indicated that activated PAR(2) translocated from the plasma membrane to early endosomes and lysosomes where it was degraded, as determined by immunoblotting. Mutant PAR(2) lacking intracellular lysine residues (PAR(2)Delta 14K/R) was expressed at the plasma membrane and signaled normally but was not ubiquitinated. Activated PAR(2)Delta 14K/R internalized but was retained in early endosomes and avoided lysosomal degradation. Activation of wild type PAR(2) stimulated tyrosine phosphorylation of the ubiquitin-protein isopeptide ligase c-Cbl and promoted its interaction with PAR(2) at the plasma membrane and in endosomes in an Src-dependent manner. Dominant negative c-Cbl lacking the ring finger domain inhibited PAR(2) ubiquitination and induced retention in early endosomes, thereby impeding lysosomal degradation. Although wild type PAR(2) was degraded, and recovery of agonist responses required synthesis of new receptors, lysine mutation and dominant negative c-Cbl impeded receptor ubiquitination and degradation and allowed PAR(2) to recycle and continue to signal. Thus, c-Cbl mediated ubiquitination and lysosomal degradation of PAR(2) to irrevocably terminate signaling by this and perhaps other GPCRs.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bunnett, NW (corresponding author), Univ Calif San Francisco, Dept Surg, 521 Parnassus ave,Rm C317, San Francisco, CA 94143 USA.	nigelb@itsa.ucsf.edu	Jacob, Claire/C-1485-2012	Jacob, Claire/0000-0001-9567-3950; Bunnett, Nigel W./0000-0003-3367-0644; Cottrell, Graeme/0000-0001-9098-7627	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057840, R01DK052388, R56DK043207, R37DK039957, R01DK039957, R01DK043207] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43207, DK52388, DK39957, DK57840] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Bohm SK, 1996, BIOCHEM J, V314, P1009; BRASS LF, 1994, J BIOL CHEM, V269, P2943; Compton SJ, 2002, BIOCHEM J, V368, P495, DOI 10.1042/BJ20020706; Darmoul D, 2004, J BIOL CHEM, V279, P20927, DOI 10.1074/jbc.M401430200; de Melker AA, 2001, J CELL SCI, V114, P2167; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Dupre DJ, 2003, J BIOL CHEM, V278, P48228, DOI 10.1074/jbc.M304082200; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Luttrell LM, 2002, J CELL SCI, V115, P455; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Roosterman D, 2003, AM J PHYSIOL-CELL PH, V284, pC1319, DOI 10.1152/ajpcell.00540.2002; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Scaife RM, 2000, J CELL SCI, V113, P215; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Tanowitz M, 2002, J BIOL CHEM, V277, P50219, DOI 10.1074/jbc.C200536200; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; Vergnolle N, 2001, NAT MED, V7, P821, DOI 10.1038/89945; Wang P, 2003, J BIOL CHEM, V278, P6363, DOI 10.1074/jbc.M210350200; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308	42	113	116	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16076	16087		10.1074/jbc.M500109200	http://dx.doi.org/10.1074/jbc.M500109200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15708858	hybrid			2022-12-25	WOS:000228444800075
J	Yi, XP; McChargue, M; Laborde, S; Frankel, LK; Bricker, TM				Yi, XP; McChargue, M; Laborde, S; Frankel, LK; Bricker, TM			The manganese-stabilizing protein is required for photosystem II assembly/stability and photoautotrophy in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN EVOLUTION; COMPLEX; MUTANTS; TRANSFORMATION; COMPONENTS; PARTICLES; PCC6803; GENES; LUMEN; OEE1	Interfering RNA was used to suppress the expression of two genes that encode the manganese-stabilizing protein of photosystem II in Arabidopsis thaliana, MSP-1 ( encoded by psbO-1, At5g66570), and MSP-2 ( encoded by psbO-2, At3g50820). A phenotypic series of transgenic plants was recovered that expressed high, intermediate, and low amounts of these two manganese-stabilizing proteins. Chlorophyll fluorescence induction and decay analyses were performed. Decreasing amounts of expressed protein led to the progressive loss of variable fluorescence and a marked decrease in the fluorescence quantum yield (F-v/F-m) in both the absence and the presence of dichloromethylurea. This result indicated that the amount of functional photosystem II reaction centers was compromised in the plants that exhibited intermediate and low amounts of the manganese-stabilizing proteins. An analysis of the decay of the variable fluorescence in the presence of dichlorophenyldimethylurea indicated that charge recombination between Q(A)(-) and the S-2 state of the oxygen-evolving complex was seriously retarded in the plants that expressed low amounts of the manganese-stabilizing proteins. This may have indicated a stabilization of the S2 state in the absence of the extrinsic component. Immunological analysis of the photosystem II protein complement indicated that significant losses of the CP47, CP43, and D1 proteins occurred upon the loss of the manganese-stabilizing proteins. This indicated that these extrinsic proteins were required for photosystem II core assembly/stability. Additionally, although the quantity of the 24-kDa extrinsic protein was only modestly affected by the loss of the manganese-stabilizing proteins, the 17-kDa extrinsic protein dramatically decreased. The control proteins ribulose bisphosphate carboxylase and cytochrome f were not affected by the loss of the manganese-stabilizing proteins; the photosystem I PsaB protein, however, was significantly reduced in the low expressing transgenic plants. Finally, it was determined that the transgenic plants that expressed low amounts of the manganese-stabilizing proteins could not grow photoautotrophically.	Louisiana State Univ, Dept Biol Sci, Biochem & Mol Biol Sect, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Bricker, TM (corresponding author), Louisiana State Univ, Dept Biol Sci, Biochem & Mol Biol Sect, Baton Rouge, LA 70803 USA.	btbric@lsu.edu						ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BRICKER TM, 1992, BIOCHEMISTRY-US, V31, P4623, DOI 10.1021/bi00134a012; BRICKER TM, 2005, PHOTOSYSTEM, V2; BRICKER TM, 1996, OXYGENIC PHOTOSYNTHE, P113; BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; CHU HA, 1994, BIOCHEMISTRY-US, V33, P6137, DOI 10.1021/bi00186a013; Chuang CF, 2000, P NATL ACAD SCI USA, V97, P4985, DOI 10.1073/pnas.060034297; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; ENGELS DH, 1994, PHOTOSYNTH RES, V42, P227, DOI 10.1007/BF00018265; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Frankel LK, 1999, BIOCHEMISTRY-US, V38, P14271, DOI 10.1021/bi991366v; HAILTON AJ, 1999, SCIENCE, V286, P950; HASHIMOTO A, 1993, BIOCHIM BIOPHYS ACTA, V1183, P397, DOI 10.1016/0005-2728(93)90245-B; Hashimoto A, 1996, FEBS LETT, V391, P29; HOLSTERS M, 1978, MOL GEN GENET, V163, P181, DOI 10.1007/BF00267408; IKEUCHI M, 1989, FEBS LETT, V242, P263, DOI 10.1016/0014-5793(89)80482-X; MAYFIELD SP, 1989, PLANT MOL BIOL, V12, P683, DOI 10.1007/BF00044159; MAYFIELD SP, 1987, EMBO J, V6, P313, DOI 10.1002/j.1460-2075.1987.tb04756.x; Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286; MIYAO M, 1987, BIOCHIM BIOPHYS ACTA, V890, P151, DOI 10.1016/0005-2728(87)90016-8; Murakami R, 2002, FEBS LETT, V523, P138, DOI 10.1016/S0014-5793(02)02963-0; MURATA N, 1984, BIOCHIM BIOPHYS ACTA, V765, P363, DOI 10.1016/0005-2728(84)90177-4; Peltier JB, 2002, PLANT CELL, V14, P211, DOI 10.1105/tpc.010304; PHILBRICK JB, 1991, J BIOL CHEM, V266, P13370; Schubert M, 2002, J BIOL CHEM, V277, P8354, DOI 10.1074/jbc.M108575200; Waterhouse PM, 2003, NAT REV GENET, V4, P29, DOI 10.1038/nrg982; Wesley SV, 2001, PLANT J, V27, P581, DOI 10.1046/j.1365-313X.2001.01105.x; ZHAO D, 2003, PLANT PHYSIOL, V133, P1	29	124	132	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16170	16174		10.1074/jbc.M501550200	http://dx.doi.org/10.1074/jbc.M501550200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722336	Green Published, hybrid			2022-12-25	WOS:000228444800086
J	Drury, J; Narayanaswami, V				Drury, J; Narayanaswami, V			Examination of lipid-bound conformation of apolipoprotein E4 by pyrene excimer fluorescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING DOMAIN; REVERSE CHOLESTEROL TRANSPORT; HUMAN-PLASMA-LIPOPROTEINS; HIGH-DENSITY-LIPOPROTEIN; C-TERMINAL DOMAIN; APOLIPOPHORIN-III; ALZHEIMERS-DISEASE; PROTEIN STABILITY; ESCHERICHIA-COLI; LACTOSE PERMEASE	Apolipoprotein E (apoE) is a 34-kDa resident of lipoproteins that plays a key role in cholesterol homeostasis in plasma and in brain. It is composed of an N-terminal (NT) domain (residues 1-191) and a C-terminal (CT) domain (residues 201-299). Of the three major isoforms (apoE2, -E3, and -E4), apoE4 is considered a risk factor for both cardiovascular and Alzheimer disease. Compared with apoE3, domain interaction between NT and CT domains is believed to direct the lipoprotein distribution preference of apoE4 for very low density lipoprotein-sized particles. We examined the relative disposition of apoE4 NT and CT domains in lipid-free and lipid-bound forms by monitoring pyrene excimer fluorescence emission as a direct indicator of spatial proximity. Site-specific labeling of apoE4 by N-(1-pyrene)maleimide was accomplished after substitution of Cys residues for Arg-61 in NT domain and Glu-255 in CT domain. Pyrene labeling did not alter the lipoprotein distribution pattern of apoE4 in plasma. Pyrene excimer fluorescence was noted in lipid-free pyrene-R61C/E255C/apoE4 in mixtures containing excess wildtype apoE4, which was attributed to intramolecular spatial proximity between these specified sites. Upon disruption of tertiary interaction, a large decrease in excimer fluorescence emission was noted in pyrene-R61C/E255C/apoE4. In dimyristoylphosphatidylcholine/pyrene-R61C/E255C/apoE4 discoidal complexes, pyrene excimer fluorescence emission was retained. Taken together with fluorescence quenching and cross-linking analysis, a looped-back model of apoE4 is proposed in lipid-bound state, including spherical lipoprotein particles, wherein residues Arg-61 and Glu-255 are proximal to one another.	Childrens Hosp Oakland, Res Inst, Lipid Biol Hlth & Dis Res Grp, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Narayanaswami, V (corresponding author), 5700 Martin Luther King Way, Oakland, CA 94609 USA.	vnarayan@chori.org		Narayanaswami, Vasanthy/0000-0001-7088-4057				AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; AKKE M, 1990, PROTEINS, V8, P23, DOI 10.1002/prot.340080106; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BETCHERLANGE SL, 1978, J BIOL CHEM, V253, P3757; BLATT E, 1985, BIOCHIM BIOPHYS ACTA, V822, P43, DOI 10.1016/0304-4157(85)90003-6; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Choy N, 2003, J MOL BIOL, V334, P527, DOI 10.1016/j.jmb.2003.09.059; Clement-Collin V, 1999, EUR J BIOCHEM, V264, P358, DOI 10.1046/j.1432-1327.1999.00608.x; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Davignon J, 1999, CLIN CHIM ACTA, V286, P115, DOI 10.1016/S0009-8981(99)00097-2; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Fagan AM, 2000, MICROSC RES TECHNIQ, V50, P297, DOI 10.1002/1097-0029(20000815)50:4<297::AID-JEMT9>3.0.CO;2-C; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fisher CA, 2000, J BIOL CHEM, V275, P33601, DOI 10.1074/jbc.M002643200; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; Hammarstrom P, 1997, FEBS LETT, V420, P63, DOI 10.1016/S0014-5793(97)01488-9; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; Huang YD, 2004, J MOL NEUROSCI, V23, P189, DOI 10.1385/JMN:23:3:189; JUNG K, 1994, BIOCHEMISTRY-US, V33, P3980, DOI 10.1021/bi00179a026; KALYANASUNDARAM K, 1977, J AM CHEM SOC, V99, P2039, DOI 10.1021/ja00449a004; Kumar S, 1999, J MOL BIOL, V293, P1241, DOI 10.1006/jmbi.1999.3218; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Mahley RW, 1996, ANN NY ACAD SCI, V777, P139, DOI 10.1111/j.1749-6632.1996.tb34412.x; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; NAKAJIMA A, 1971, B CHEM SOC JPN, V44, P3272, DOI 10.1246/bcsj.44.3272; Narayanaswami V, 1996, J BIOL CHEM, V271, P26855, DOI 10.1074/jbc.271.43.26855; Narayanaswami V, 2001, J BIOL CHEM, V276, P37853; Narayanaswami V, 2004, J BIOL CHEM, V279, P14273, DOI 10.1074/jbc.M313318200; Perugini MA, 2000, J BIOL CHEM, V275, P36758, DOI 10.1074/jbc.M005565200; Poirier J, 2000, ANN NY ACAD SCI, V924, P81; Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298; Sahoo D, 2000, BIOCHEMISTRY-US, V39, P6594, DOI 10.1021/bi992609m; Sahoo D, 1998, J BIOL CHEM, V273, P1403, DOI 10.1074/jbc.273.3.1403; Sahoo D, 2002, J MOL BIOL, V321, P201, DOI 10.1016/S0022-2836(02)00618-6; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SEGREST JP, 1992, J LIPID RES, V33, P141; SHIMANO H, 1992, J CLIN INVEST, V90, P2084, DOI 10.1172/JCI116091; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; STEINMETZ A, 1989, ARTERIOSCLEROSIS, V9, P405, DOI 10.1161/01.ATV.9.3.405; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; Waldburger CD, 1996, P NATL ACAD SCI USA, V93, P2629, DOI 10.1073/pnas.93.7.2629; Weers PMM, 2001, EUR J BIOCHEM, V268, P3728, DOI 10.1046/j.1432-1327.2001.02282.x; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WEISGRABER KH, 1992, HIGH DENSITY LIPOPRO, V3, P175; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; Yamana K, 1999, NUCLEIC ACIDS RES, V27, P2387, DOI 10.1093/nar/27.11.2387; YOKOYAMA S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P99, DOI 10.1016/0005-2760(90)90266-Z; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhao M, 1999, BIOCHEMISTRY-US, V38, P7407, DOI 10.1021/bi9906524	60	36	36	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14605	14610		10.1074/jbc.M414019200	http://dx.doi.org/10.1074/jbc.M414019200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708851	hybrid			2022-12-25	WOS:000228236800034
J	Tong, YR; Kanost, MR				Tong, YR; Kanost, MR			Manduca sexta serpin-4 and serpin-5 inhibit the prophenol oxidase activation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-PHENOL-OXIDASE; HOLOTRICHIA-DIOMPHALIA LARVAE; PROTEINASE-INHIBITORS; INSECT IMMUNITY; SERINE-PROTEASE; DROSOPHILA; SUPERFAMILY; HEMOLYMPH; PURIFICATION; EXPRESSION	Infection stimulates the innate immune responses of insects, including activation of prophenol oxidase ( proPO) in plasma as the last step of a serine protease cascade. To investigate the roles of protease inhibitors in regulating this pathway, we cloned cDNAs for two new serpins (serpin-4 and serpin-5) from the tobacco hornworm, Manduca sexta. Serpin-4 and serpin-5 mRNAs are constitutively expressed at a low level in larval hemocytes and fat body and increased dramatically upon bacterial challenge. These serpins are present in larval plasma at similar to 3 (serpin-4) and similar to 1 mu g/ml (serpin-5) and increased 3-8-fold by 24 h after injection of bacteria or fungi. Recombinant serpin-4 and serpin-5 decreased pro-PO activation when added to plasma, but they did not directly inhibit the pro-PO-activating proteases. Instead, they apparently regulate the pathway by inhibiting one or more target proteases upstream of the pro-PO-activating proteases.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Kanost, MR (corresponding author), Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA.	kanost@ksu.edu		Kanost, Michael/0000-0002-6827-0061	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041247, R01GM041247, R37GM041247] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41247, R37 GM041247] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ashida M., 1997, MOL MECH IMMUNE RESP, P135; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; DUNN PE, 1983, J INVERTEBR PATHOL, V41, P77, DOI 10.1016/0022-2011(83)90238-0; Elliott PR, 2000, PROTEIN SCI, V9, P1274, DOI 10.1110/ps.9.7.1274; Gan H, 2001, INSECT BIOCHEM MOLEC, V31, P887, DOI 10.1016/S0965-1748(01)00034-0; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Jiang H, 1996, INSECT MOL BIOL, V5, P31, DOI 10.1111/j.1365-2583.1996.tb00038.x; Jiang H, 1995, INSECT BIOCHEM MOLEC, V25, P1093, DOI 10.1016/0965-1748(95)00042-9; JIANG HB, 1994, J BIOL CHEM, V269, P55; Jiang HB, 2003, INSECT BIOCHEM MOLEC, V33, P1049, DOI 10.1016/S0965-1748(03)00123-1; Jiang HB, 2003, J BIOL CHEM, V278, P3552, DOI 10.1074/jbc.M205743200; Jiang HB, 1996, J BIOL CHEM, V271, P28017, DOI 10.1074/jbc.271.45.28017; Jiang HB, 2000, INSECT BIOCHEM MOLEC, V30, P95, DOI 10.1016/S0965-1748(99)00113-7; Jiang HB, 2001, ADV EXP MED BIOL, V484, P313; Jiang HB, 1997, J BIOL CHEM, V272, P1082, DOI 10.1074/jbc.272.2.1082; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Kanost Michael R., 1996, P155; Kanost MR, 1997, ADV EXP MED BIOL, V425, P155; KANOST MR, 1989, J BIOL CHEM, V264, P965; Kanost MR, 2001, ADV EXP MED BIOL, V484, P319; Kanost MR, 1999, DEV COMP IMMUNOL, V23, P291, DOI 10.1016/S0145-305X(99)00012-9; KANOST MR, 1995, INSECT BIOCHEM MOLEC, V25, P285, DOI 10.1016/0965-1748(94)00067-R; Kawabata Shun-ichiro, 1996, P255; LEE E, 1994, METHOD ENZYMOL, V237, P146; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Li JP, 1999, STRUCTURE, V7, P103, DOI 10.1016/S0969-2126(99)80013-6; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Moore DD, 1995, GLOB MOB SURV; Nappi AJ, 2001, ADV EXP MED BIOL, V484, P329; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Ross J, 2003, GENE, V304, P117, DOI 10.1016/S0378-1119(02)01187-3; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Tong YR, 2005, J BIOL CHEM, V280, P14932, DOI 10.1074/jbc.M500532200; Wang RG, 2001, EUR J BIOCHEM, V268, P895, DOI 10.1046/j.1432-1327.2001.01945.x; Wang Y, 2004, INSECT BIOCHEM MOLEC, V34, P387, DOI 10.1016/j.ibmb.2003.12.005; Wang Y, 2001, PROTEIN EXPRES PURIF, V23, P328, DOI 10.1006/prep.2001.1517; Zhu Y, 2003, INSECT BIOCHEM MOLEC, V33, P541, DOI 10.1016/S0965-1748(03)00028-6; Zhu YF, 2003, J BIOL CHEM, V278, P46556, DOI 10.1074/jbc.M309682200	47	102	112	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14923	14931		10.1074/jbc.M500531200	http://dx.doi.org/10.1074/jbc.M500531200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15695807	hybrid			2022-12-25	WOS:000228236800072
J	Yamanaka, N; Hua, YJ; Mizoguchi, A; Watanabe, K; Niwa, R; Tanaka, Y; Kataoka, H				Yamanaka, N; Hua, YJ; Mizoguchi, A; Watanabe, K; Niwa, R; Tanaka, Y; Kataoka, H			Identification of a novel prothoracicostatic hormone and its receptor in the silkworm Bombyx mori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; ECDYSONE BIOSYNTHESIS; NEUROSECRETORY-CELLS; JUVENILE-HORMONE; BLOWFLY LARVAE; MANDUCA-SEXTA; NEUROPEPTIDE; BRAIN; PEPTIDE; DROSOPHILA	The insect brain regulates the activity of the prothoracic glands to secrete ecdysteroids, which affect growth, molting, and metamorphosis. Here we report the identification of a novel prothoracicostatic factor and its receptor in the silkworm Bombyx mori. The prothoracicostatic factor purified from pupal brains of B. mori is a decapeptide with the conserved structure of an insect myosuppressin and thus named Bommo-myosuppressin. Bommo-myosuppressin dose dependently suppressed the cAMP level and inhibited ecdysteroido-genesis in the larval prothoracic glands at much lower concentrations than the prothoracicostatic peptide, the other prothoracicostatic factor reported previously. In vitro analyses using a prothoracic gland incubation method revealed that Bommo-myosuppressin and prothoracicostatic peptide regulate the prothoracic gland activity via different receptors. In situ hybridization and immunohistochemistry revealed the existence of Bommo-myosuppressin in the brain neurosecretory cells projecting to neurohemal organs in which it is stored. We also identified and functionally characterized a specific receptor for Bommo-myosuppressin and showed its high expression in the prothoracic glands. All these results suggest that Bommo-myosuppressin functions as a prothoracicostatic hormone and plays an important role in controlling insect development.	Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Chiba 2778562, Japan; Zhejiang Univ, Inst Nuclearagr Sci, Zhejiang 310029, Peoples R China; Nagoya Univ, Div Biol Sci, Grad Sch Sci, Nagoya, Aichi 4648602, Japan; Natl Inst Agrobiol Sci, Lab Insect Growth Regulat, Tsukuba 3058634, Japan	University of Tokyo; Zhejiang University; Nagoya University; National Institute of Agrobiological Sciences - Japan	Kataoka, H (corresponding author), Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Chiba 2778562, Japan.	kataoka@k.u-tokyo.ac.jp	Yamanaka, Naoki/F-1358-2010	Yamanaka, Naoki/0000-0002-6244-2686				BUDD E, 1993, ARCH INSECT BIOCHEM, V23, P181, DOI 10.1002/arch.940230405; CARLISLE DB, 1968, NATURE, V220, P706, DOI 10.1038/220706a0; Coast GM, 1998, PEPTIDES, V19, P469, DOI 10.1016/S0196-9781(97)00461-0; Egerod K, 2003, P NATL ACAD SCI USA, V100, P9808, DOI 10.1073/pnas.1632197100; Gilbert LI, 2002, ANNU REV ENTOMOL, V47, P883, DOI 10.1146/annurev.ento.47.091201.145302; Gu SH, 1996, J INSECT PHYSIOL, V42, P625, DOI 10.1016/0022-1910(96)00025-X; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; HOLMAN GM, 1986, COMP BIOCHEM PHYS C, V85, P329, DOI 10.1016/0742-8413(86)90202-1; Hua YJ, 1999, J BIOL CHEM, V274, P31169, DOI 10.1074/jbc.274.44.31169; Hua YJ, 1997, ARCH INSECT BIOCHEM, V35, P125, DOI 10.1002/(SICI)1520-6327(1997)35:1/2<125::AID-ARCH11>3.3.CO;2-A; Ichikawa T, 1995, ZOOL SCI, V12, P703, DOI 10.2108/zsj.12.703; ISHIBASHI J, 1994, BIOCHEMISTRY-US, V33, P5912, DOI 10.1021/bi00185a031; ISHIZAKI H, 1994, INT J DEV BIOL, V38, P301; Katada S, 2003, BIOCHEM BIOPH RES CO, V305, P964, DOI 10.1016/S0006-291X(03)00863-5; KINGAN TG, 1990, PEPTIDES, V11, P849, DOI 10.1016/0196-9781(90)90203-H; KIRIISHI S, 1992, ZOOL SCI, V9, P149; Kopec S, 1922, BIOL BULL-US, V42, P323, DOI 10.2307/1536759; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Labrouche S, 1998, J NEUROENDOCRINOL, V10, P559, DOI 10.1046/j.1365-2826.1998.00241.x; Lange AB, 1998, PEPTIDES, V19, P459, DOI 10.1016/S0196-9781(97)00465-8; Liu X, 2004, ARCH INSECT BIOCHEM, V56, P155, DOI 10.1002/arch.20005; Lu D, 2002, J COMP NEUROL, V446, P377, DOI 10.1002/cne.10205; MACKEY SL, 1987, P NATL ACAD SCI USA, V84, P8730, DOI 10.1073/pnas.84.23.8730; MALA J, 1977, J INSECT PHYSIOL, V23, P309, DOI 10.1016/0022-1910(77)90267-0; Matsuoka T, 2000, DEV GENES EVOL, V210, P120, DOI 10.1007/s004270050018; Mita K, 2003, P NATL ACAD SCI USA, V100, P14121, DOI 10.1073/pnas.2234984100; MIZOGUCHI A, 1990, DEV GROWTH DIFFER, V32, P591; Mizoguchi A, 2001, J INSECT PHYSIOL, V47, P767, DOI 10.1016/S0022-1910(01)00052-X; NAGATA K, 1992, PEPTIDES, V13, P653, DOI 10.1016/0196-9781(92)90169-4; Nelson LS, 1998, SCIENCE, V281, P1686, DOI 10.1126/science.281.5383.1686; NICHOLS R, 1992, J MOL NEUROSCI, V3, P213, DOI 10.1007/BF03380141; Nichols R, 2003, ANNU REV ENTOMOL, V48, P485, DOI 10.1146/annurev.ento.48.091801.112525; Niwa R, 2004, J BIOL CHEM, V279, P35942, DOI 10.1074/jbc.M404514200; Orchard I, 2002, PEPTIDES, V23, P693, DOI 10.1016/S0196-9781(01)00663-5; ROBB S, 1989, BIOCHEM BIOPH RES CO, V160, P850, DOI 10.1016/0006-291X(89)92512-6; Roller L, 2003, CELL TISSUE RES, V312, P393, DOI 10.1007/s00441-003-0722-4; Sakurai S, 1998, J INSECT PHYSIOL, V44, P867, DOI 10.1016/S0022-1910(98)00075-4; WANG Z, 1995, NEUROPEPTIDES, V28, P147, DOI 10.1016/0143-4179(95)90109-4; WILLIAMS CM, 1947, BIOL BULL, V93, P89, DOI 10.2307/1538279; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757	41	71	74	4	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14684	14690		10.1074/jbc.M500308200	http://dx.doi.org/10.1074/jbc.M500308200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701625	hybrid			2022-12-25	WOS:000228236800044
J	Browne, RJ; Barr, EW; Stitt, BL				Browne, RJ; Barr, EW; Stitt, BL			Catalytic cooperativity among subunits of Escherichia coli transcription termination factor Rho - Kinetics and substrate structural requirements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; ATP-BINDING DOMAINS; PROTEIN-RHO; CONFORMATIONAL-CHANGES; TRYPTOPHAN SYNTHASE; NUCLEOTIDE-BINDING; HYDROLYTIC SITES; AMP DEAMINASE; MECHANISM; RNA	Escherichia coli transcription termination factor Rho shows a 30-fold faster rate of ATP hydrolysis when all three catalytic sites are filled with ATP than when only a single site is filled (Stitt, B. L. and Xu, Y. ( 1998) J. Biol. Chem. 273, 26477-26486). To study the structural requirements of the substrate for this catalytic cooperativity, rapid mix/chemical quench experiments using various ATP analogs were performed. The results indicate that it is the configuration of the beta- and gamma-phosphoryl groups of ATP that is of primary importance for the rate enhancement. Our results also show that there are kinetically slow branches of the enzyme mechanism that are not seen when the chemistry step of the catalytic cycle is fast. These branches become prominent, however, when two of the three Rho active sites are empty or bear non-hydrolyzable compounds. A first-order step that is slow compared with V-max catalysis enables a single ATP molecule bound in any one of the three Rho active sites to be hydrolyzed and defines the kinetically slow branches. This first-order step could be a protein conformation change or a rearrangement of bound RNA. The results reinforce the importance of catalytic cooperativity in normal Rho function and suggest that several protein conformations exist along the catalytic pathway.	Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Stitt, BL (corresponding author), Temple Univ, Sch Med, Dept Biochem, 3420 N Broad St, Philadelphia, PA 19140 USA.	stitt@temple.edu			NIGMS NIH HHS [GM60247] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060247] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; CROSS RL, 1982, J BIOL CHEM, V257, P2101; DAWSON RMC, 1986, DATA BIOCH RES, P485; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; Garcia JJ, 1997, EUR J BIOCHEM, V249, P622, DOI 10.1111/j.1432-1033.1997.00622.x; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; GLYNN JM, 1964, BIOCHEM J, V90, P147; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; Jeong YJ, 2004, J BIOL CHEM, V279, P18370, DOI 10.1074/jbc.M309162200; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; KUBO K, 1990, BIOCHIM BIOPHYS ACTA, V1040, P251, DOI 10.1016/0167-4838(90)90084-S; MERKLER DJ, 1990, J BIOL CHEM, V265, P4420; MERKLER DJ, 1989, J BIOL CHEM, V264, P21422; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NEET KE, 1995, METHOD ENZYMOL, V249, P519; NEHRKE KW, 1992, NUCLEIC ACIDS RES, V20, P6107, DOI 10.1093/nar/20.22.6107; OPPERMAN T, 1994, J BACTERIOL, V176, P5033, DOI 10.1128/jb.176.16.5033-5043.1994; Raboni S, 2003, BBA-PROTEINS PROTEOM, V1647, P157, DOI 10.1016/S1570-9639(03)00084-0; Richardson JP, 2002, BBA-GENE STRUCT EXPR, V1577, P251, DOI 10.1016/S0167-4781(02)00456-6; RICHARDSON JP, 1980, BIOCHEMISTRY-US, V19, P4293, DOI 10.1021/bi00559a022; Skordalakes E, 2003, CELL, V114, P135, DOI 10.1016/S0092-8674(03)00512-9; Stitt BL, 1998, J BIOL CHEM, V273, P26477, DOI 10.1074/jbc.273.41.26477; Stitt BL, 2001, BIOCHEMISTRY-US, V40, P2276, DOI 10.1021/bi002253a; STITT BL, 1988, J BIOL CHEM, V263, P11130; STITT BL, 1986, J BIOL CHEM, V261, P5906; STRAMBINI GB, 1992, BIOCHEMISTRY-US, V31, P7535, DOI 10.1021/bi00148a014; WEBB MR, 1982, METHOD ENZYMOL, V87, P301; WEBER J, 1993, J BIOL CHEM, V268, P20126; YOUNT RG, 1975, ADV ENZYMOL RAMB, V43, P1	33	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13292	13299		10.1074/jbc.M500221200	http://dx.doi.org/10.1074/jbc.M500221200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15703178	hybrid			2022-12-25	WOS:000228095500014
J	Shpanchenko, OV; Zvereva, MI; Ivanov, PV; Bugaeva, EY; Rozov, AS; Bogdanov, AA; Kalkum, M; Isaksson, LA; Nierhaus, KH; Dontsova, OA				Shpanchenko, OV; Zvereva, MI; Ivanov, PV; Bugaeva, EY; Rozov, AS; Bogdanov, AA; Kalkum, M; Isaksson, LA; Nierhaus, KH; Dontsova, OA			Stepping transfer messenger RNA through the ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSLATION TERMINATION; STALLED RIBOSOME; TAGGING SYSTEM; 10SA RNA; TMRNA; PROTEINS; BINDING; SMPB; IDENTIFICATION	tmRNA ( transfer messenger RNA) is a unique molecule used by all bacteria to rescue stalled ribosomes and to mark unfinished peptides with a specific degradation signal. tmRNA is recruited by arrested ribosomes in which it facilitates the translational switch from cellular mRNA to the mRNA part of tmRNA. Small protein B (SmpB) is a key partner for the trans-translation activity of tmRNA both in vivo and in vitro. It was shown that SmpB acts at the initiation step of the trans-translation process by facilitating tmRNA aminoacylation and binding to the ribosome. Little is known about the subsequent steps of trans-translation. Here we demonstrated the first example of an investigation of tmRNA.ribosome complexes at different stages of trans-translation. Our results show that the structural element at the position of tmRNA pseudoknot 3 remains intact during the translation of the mRNA module of tmRNA and that it is localized on the surface of the ribosome. At least one SmpB molecule remains bound to a ribosome.tmRNA complex isolated from the cell when translation is blocked at different positions within the mRNA part of tmRNA.	Moscow MV Lomonosov State Univ, Dept Chem, Moscow 119899, Russia; AG Ribosomen, Max Planck Inst Mol Genet, D-14195 Berlin, Germany; City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; Stockholm Univ, Dept Genet Microbiol & Toxicol, S-10691 Stockholm, Sweden	Lomonosov Moscow State University; Max Planck Society; City of Hope; Beckman Research Institute of City of Hope; Stockholm University	Dontsova, OA (corresponding author), Moscow MV Lomonosov State Univ, Dept Chem, Moscow 119899, Russia.	dontsova@genebee.msu.su	Shpanchenko, Olga/C-7813-2015; Dontsova, Olga/T-6072-2019; Rozov, Andrei/C-1997-2015; Zvereva, Maria Imilievna/J-9724-2013; Ivanov, Pavel/AAZ-9197-2021; Bogdanov, Alexey A/L-1407-2013; Ivanov, Pavel/F-3339-2016	Zvereva, Maria Imilievna/0000-0002-7432-1574; Ivanov, Pavel/0000-0002-7986-7760; Ivanov, Pavel/0000-0002-7986-7760; Rozov, Alexey/0000-0003-2545-1978; Kalkum, Markus/0000-0002-9506-671X				Barends S, 2001, J MOL BIOL, V314, P9, DOI 10.1006/jmbi.2001.5114; Bjornsson A, 1996, NUCLEIC ACIDS RES, V24, P1753, DOI 10.1093/nar/24.9.1753; Bjornsson A, 1996, EMBO J, V15, P1696, DOI 10.1002/j.1460-2075.1996.tb00515.x; Flynn JM, 2001, P NATL ACAD SCI USA, V98, P10584, DOI 10.1073/pnas.191375298; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Gutmann S, 2003, NATURE, V424, P699, DOI 10.1038/nature01831; Hallier M, 2004, J BIOL CHEM, V279, P25978, DOI 10.1074/jbc.M314086200; Hanawa-Suetsugu K, 2002, NUCLEIC ACIDS RES, V30, P1620, DOI 10.1093/nar/30.7.1620; Hayes CS, 2002, J BIOL CHEM, V277, P33825, DOI 10.1074/jbc.M205405200; Ivanov PV, 2002, FEBS LETT, V514, P55, DOI 10.1016/S0014-5793(02)02310-4; Kalkum M, 2003, P NATL ACAD SCI USA, V100, P2795, DOI 10.1073/pnas.0436605100; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Keiler KC, 2000, P NATL ACAD SCI USA, V97, P7778, DOI 10.1073/pnas.97.14.7778; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; Krutchinsky AN, 2001, ANAL CHEM, V73, P5066, DOI 10.1021/ac010682o; LEE SY, 1978, J BACTERIOL, V133, P1015, DOI 10.1128/JB.133.2.1015-1023.1978; Leonov AA, 2003, J BIOL CHEM, V278, P25664, DOI 10.1074/jbc.M302873200; Mukherjee S, 2003, BIOTECHNOL APPL BIOC, V37, P183, DOI 10.1042/BA20020044; Nameki N, 2000, FEBS LETT, V470, P345, DOI 10.1016/S0014-5793(00)01349-1; NOWOTNY P, 1988, METHOD ENZYMOL, V164, P131; ODOM OW, 1984, ARCH BIOCHEM BIOPHYS, V230, P178, DOI 10.1016/0003-9861(84)90099-7; PLATT T, 1972, EXPT MOL GENETICS, P352; RHEINBERGER HJ, 1988, METHOD ENZYMOL, V164, P658; Roche ED, 2001, J BIOL CHEM, V276, P28509, DOI 10.1074/jbc.M103864200; ROHL R, 1982, P NATL ACAD SCI-BIOL, V79, P729, DOI 10.1073/pnas.79.3.729; RUDINGERTHIRION J, 1999, RNA, V5, P1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Srisawat C, 2001, RNA, V7, P632, DOI 10.1017/S135583820100245X; TU CL, 1992, P NATL ACAD SCI USA, V89, P8636, DOI 10.1073/pnas.89.18.8636; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392; Valle M, 2003, SCIENCE, V300, P127, DOI 10.1126/science.1081798; Williams KP, 1999, EMBO J, V18, P5423, DOI 10.1093/emboj/18.19.5423; Wower IK, 2000, EMBO J, V19, P6612, DOI 10.1093/emboj/19.23.6612; Zvereva MI, 2001, J BIOL CHEM, V276, P47702, DOI 10.1074/jbc.M106786200; Zwieb C, 1999, NUCLEIC ACIDS RES, V27, P2063, DOI 10.1093/nar/27.10.2063	37	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18368	18374		10.1074/jbc.M409094200	http://dx.doi.org/10.1074/jbc.M409094200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15713678	hybrid			2022-12-25	WOS:000228807200098
J	Nakav, S; Jablonka-Shariff, A; Kaner, S; Chadna-Mohanty, P; Grotjan, HE; Ben-Menahem, D				Nakav, S; Jablonka-Shariff, A; Kaner, S; Chadna-Mohanty, P; Grotjan, HE; Ben-Menahem, D			The LH beta gene of several mammals embeds a carboxyl-terminal peptide-like sequence revealing a critical role for mucin oligosaccharides in the evolution of lutropin to chorionic gonadotropin in the animal phyla	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE-BETA; O-GLYCOSYLATION SITES; SUBUNIT PRECURSOR MOLECULES; AMINO-ACID-SEQUENCES; LINKED GLYCOSYLATION; SECRETORY GRANULES; SUBMAXILLARY MUCIN; TRANSGENIC MICE; HUMAN PLACENTA; MESSENGER-RNA	The expression of a previously untranslated carboxyl-terminal sequence is associated with the ancestral lutropin (LH) beta to the beta-subunit gene evolution of choriogonadotropins (CG). The peptide extension ( denoted as CTP) is rich in mucin-type O-glycans and confers new hormonal properties on CG relative to the LH. Although the LH beta gene is conserved among mammals and only a few frameshift mutations account for the extension, it is merely seen in primates and equids. Bioinformatics identified a CTP-like sequence that is encrypted in the LH beta gene of several mammalian species but not in birds, amphibians, or fish. We then examined whether or not decoding of the cryptic CTP in the bovine LH beta gene (boCTP) would be sufficient to generate the LH beta species of a ruminant with properties typical to the CG beta subunit. The mutated bovine LH beta-boCTP subunit was expressed and N-glycosylated in transfected Chinese hamster ovary cells. However, unlike human ( h) CG beta CTP, the cryptic boCTP was devoid of mucin O-glycans. This deficiency was further confirmed when the boCTP domain was substituted for the natural CTP in the human CG beta subunit. Moreover, when expressed in polarized Madin-Darby canine kidney cells, this hCG beta-boCTP chimera was secreted basolaterally rather than from the apical compartment, which is the route of the wild type hCG beta subunit, a sorting function attributed to the O-glycans attached to the CTP. This result shows that the cryptic peptide does not orientate CG to the apical face of the placenta, to the maternal circulation as seen in primates. The absence of this function, which distinguishes CG from LH, provides an explanation as to why the LH beta to CG beta evolution did not occur in ruminants. We propose that in primates and equids, further natural mutations in the progenitor LH beta gene resulted in the efficient O-glycosylation of the CTP, thus favoring the retention of an elongated reading frame.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Pharmacol, IL-84105 Beer Sheva, Israel; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Nebraska, Dept Anim Sci, Lincoln, NE 68583 USA	Ben Gurion University; Washington University (WUSTL); University of Nebraska System; University of Nebraska Lincoln	Ben-Menahem, D (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Pharmacol, IL-84105 Beer Sheva, Israel.	dbm@bgumail.bgu.ac.il		Ben-Menahem, David/0000-0002-8985-0591				ANDO H, 1994, GEN COMP ENDOCR, V93, P357, DOI 10.1006/gcen.1994.1040; Bousfield GR, 2001, BIOL REPROD, V64, P136, DOI 10.1095/biolreprod64.1.136; BROWN P, 1993, MOL CELL ENDOCRINOL, V93, P157, DOI 10.1016/0303-7207(93)90119-5; Catt KJ, 1986, REPRODUCTIVE ENDOCRI, P75; CHILDS GV, 1980, AM J ANAT, V158, P397, DOI 10.1002/aja.1001580403; CHOPINEAU M, 1995, GENE, V160, P253, DOI 10.1016/0378-1119(95)00150-5; Chopineau M, 1999, J REPROD FERTIL, V115, P159; Christlet THT, 2001, BIOPHYS J, V80, P952, DOI 10.1016/S0006-3495(01)76074-2; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; CRAWFORD RJ, 1986, GENE, V46, P161, DOI 10.1016/0378-1119(86)90400-2; CURRIE RJW, 1995, J ENDOCRINOL, V147, P259, DOI 10.1677/joe.0.1470259; EZASHI T, 1990, J MOL ENDOCRINOL, V5, P137, DOI 10.1677/jme.0.0050137; FARES FA, 1992, P NATL ACAD SCI USA, V89, P4304, DOI 10.1073/pnas.89.10.4304; FIDDES JC, 1980, NATURE, V286, P684, DOI 10.1038/286684a0; Fritz TA, 2004, P NATL ACAD SCI USA, V101, P15307, DOI 10.1073/pnas.0405657101; Gerken TA, 2002, J BIOL CHEM, V277, P49850, DOI 10.1074/jbc.M205851200; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; Harrison GA, 1998, MAMM GENOME, V9, P638; HASSIN S, 1995, J MOL ENDOCRINOL, V15, P23, DOI 10.1677/jme.0.0150023; HILL HD, 1977, J BIOL CHEM, V252, P3799; ILES RK, 1992, J ENDOCRINOL, V135, P563, DOI 10.1677/joe.0.1350563; Jablonka-Shariff A, 2004, BIOL REPROD, V70, P649, DOI 10.1095/biolreprod.103.022699; Jablonka-Shariff A, 2002, J BIOL CHEM, V277, P879, DOI 10.1074/jbc.C100402200; JAMESON L, 1984, J BIOL CHEM, V259, P5474; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; KAETZEL DM, 1989, MOL ENDOCRINOL, V3, P1765, DOI 10.1210/mend-3-11-1765; Komoike Y, 2003, GEN COMP ENDOCR, V132, P333, DOI 10.1016/S0016-6480(03)00095-9; Kumar TR, 1995, GENE, V166, P335, DOI 10.1016/0378-1119(96)81753-7; Li MD, 1998, J ENDOCRINOL, V156, P529, DOI 10.1677/joe.0.1560529; Mamluk R, 1998, BIOL REPROD, V58, P849, DOI 10.1095/biolreprod58.3.849; Maston GA, 2002, MOL BIOL EVOL, V19, P320, DOI 10.1093/oxfordjournals.molbev.a004085; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; MATZUK MM, 1989, J CELL BIOL, V109, P1429, DOI 10.1083/jcb.109.4.1429; MURPHY BD, 1991, ENDOCR REV, V12, P27, DOI 10.1210/edrv-12-1-27; Muyan M, 1998, MOL ENDOCRINOL, V12, P766, DOI 10.1210/me.12.5.766; Muyan M, 1996, MOL ENDOCRINOL, V10, P1678, DOI 10.1210/me.10.12.1678; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; POLICASTRO P, 1983, J BIOL CHEM, V258, P1492; RAO CV, 1981, J BIOL CHEM, V256, P2628; RISMA KA, 1995, P NATL ACAD SCI USA, V92, P1322, DOI 10.1073/pnas.92.5.1322; ROBERTS RM, 1989, BIOL REPROD, V40, P449, DOI 10.1095/biolreprod40.3.449; SEKINE S, 1989, P NATL ACAD SCI USA, V86, P8645, DOI 10.1073/pnas.86.22.8645; SENGER PL, 2003, PATHWAYS PREGNANCY P, P248; SHERMAN GB, 1992, MOL ENDOCRINOL, V6, P951, DOI 10.1210/me.6.6.951; Sherman GB, 2001, J MOL ENDOCRINOL, V26, P267, DOI 10.1677/jme.0.0260267; Sherman GB, 1997, GENE, V195, P131, DOI 10.1016/S0378-1119(97)00080-2; SIMULA AP, 1995, BIOL REPROD, V53, P380, DOI 10.1095/biolreprod53.2.380; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; THIEDE HA, 1963, OBSTET GYNECOL, V22, P433; Thomas SG, 1997, ENDOCRINOLOGY, V138, P1347, DOI 10.1210/en.138.3.1347; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; VIRGIN JB, 1985, J BIOL CHEM, V260, P7072; WOLF DL, 1987, NUCLEIC ACIDS RES, V15, P10602, DOI 10.1093/nar/15.24.10602; WYNN RM, 1972, AM J OBSTET GYNECOL, V114, P339, DOI 10.1016/0002-9378(72)90612-6; Yoshiura Y, 1997, GEN COMP ENDOCR, V105, P379, DOI 10.1006/gcen.1996.6839; YOU S, 1995, J MOL ENDOCRINOL, V14, P117, DOI 10.1677/jme.0.0140117	57	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16676	16684		10.1074/jbc.M500730200	http://dx.doi.org/10.1074/jbc.M500730200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15723833	hybrid			2022-12-25	WOS:000228615500019
J	Snyder, EM; Colledge, M; Crozier, RA; Chen, WS; Scott, JD; Bear, MF				Snyder, EM; Colledge, M; Crozier, RA; Chen, WS; Scott, JD; Bear, MF			Role for A kinase-anchoring proteins (AKAPS) in glutamate receptor trafficking and long term synaptic depression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SILENT SYNAPSES; PHOSPHORYLATION SITES; AMPA RECEPTORS; GLUR1 SUBUNIT; ACTIVATION; LTP; HIPPOCAMPUS; INVOLVEMENT; EXPRESSION; PLASTICITY	Expression of N-methyl D-aspartate ( NMDA) receptor-dependent homosynaptic long term depression at synapses in the hippocampus and neocortex requires the persistent dephosphorylation of postsynaptic protein kinase A substrates. An attractive mechanism for expression of long term depression is the loss of surface AMPA (alpha-amino-3-hydroxy-5-methylisoxazale-4-propionate) receptors at synapses. Here we show that a threshold level of NMDA receptor activation must be exceeded to trigger a stable loss of AMPA receptors from the surface of cultured hippocampal neurons. NMDA also causes displacement of protein kinase A from the synapse, and inhibiting protein kinase A (PKA) activity mimics the NMDA-induced loss of surface AMPA receptors. PKA is targeted to the synapse by an interaction with the A kinase-anchoring protein, AKAP79/150. Disruption of the PKA-AKAP interaction is sufficient to cause a long-lasting reduction in synaptic AMPA receptors in cultured neurons. In addition, we demonstrate in hippocampal slices that displacement of PKA from AKADs occludes synaptically induced long term depression. These data indicate that synaptic anchoring of PKA through association with AKAPs plays an important role in the regulation of AMPA receptor surface expression and synaptic plasticity.	MIT, Howard Hughes Med Inst, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; Oregon Hlth & Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97239 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Oregon Health & Science University	Bear, MF (corresponding author), MIT, Howard Hughes Med Inst, Picower Ctr Learning & Memory, E19-551,77 Massachusetts Ave, Cambridge, MA 02139 USA.	mbear@mit.edu		Crozier, Robert/0000-0003-0134-3972; Bear, Mark/0000-0002-9903-2541	NIGMS NIH HHS [GM48231, R37 GM048231, R01 GM048231] Funding Source: Medline; NINDS NIH HHS [P01 NS039321, NS39321] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048231, R37GM048231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS039321] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Banke TG, 2000, J NEUROSCI, V20, P89, DOI 10.1523/JNEUROSCI.20-01-00089.2000; Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; Beattie EC, 2000, NAT NEUROSCI, V3, P1291, DOI 10.1038/81823; Becker JW, 1999, J MED CHEM, V42, P2798, DOI 10.1021/jm9806042; Bernstein MA, 1998, EUR J PHARMACOL, V341, P173, DOI 10.1016/S0014-2999(97)01502-1; Blanpied TA, 2002, NEURON, V36, P435, DOI 10.1016/S0896-6273(02)00979-0; CARR DW, 1992, J BIOL CHEM, V267, P16816; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Chung HJ, 2000, J NEUROSCI, V20, P7258; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Esteban JA, 2003, NAT NEUROSCI, V6, P136, DOI 10.1038/nn997; Genin A, 2003, EUR J NEUROSCI, V17, P331, DOI 10.1046/j.1460-9568.2003.02462.x; Gomez LL, 2002, J NEUROSCI, V22, P7027; Harrison DA, 2000, BIOL REPROD, V62, P811, DOI 10.1095/biolreprod62.3.811; Heynen AJ, 2000, NEURON, V28, P527, DOI 10.1016/S0896-6273(00)00130-6; Heynen AJ, 2003, NAT NEUROSCI, V6, P854, DOI 10.1038/nn1100; Kameyama K, 1998, NEURON, V21, P1163, DOI 10.1016/S0896-6273(00)80633-9; Kandler K, 1998, NAT NEUROSCI, V1, P119, DOI 10.1038/368; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Kolleker A, 2003, NEURON, V40, P1199, DOI 10.1016/S0896-6273(03)00722-0; Lee HK, 2003, CELL, V112, P631, DOI 10.1016/S0092-8674(03)00122-3; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Lee HW, 1999, J NEUROCHEM, V73, P1769, DOI 10.1046/j.1471-4159.1999.731769.x; Liao DH, 1999, NAT NEUROSCI, V2, P37, DOI 10.1038/4540; Liao DZ, 2001, J NEUROSCI, V21, P6008, DOI 10.1523/JNEUROSCI.21-16-06008.2001; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Liu JM, 2004, J NEUROSCI, V24, P2465, DOI 10.1523/JNEUROSCI.4331-03.2004; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Moita MAP, 2002, NAT NEUROSCI, V5, P837, DOI 10.1038/nn901; Oliveria SF, 2003, J CELL BIOL, V160, P101, DOI 10.1083/jcb.200209127; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; SELIG DK, 1995, NEURON, V15, P417, DOI 10.1016/0896-6273(95)90045-4; Snyder EM, 2001, NAT NEUROSCI, V4, P1079, DOI 10.1038/nn746; Tavalin SJ, 2002, J NEUROSCI, V22, P3044, DOI 10.1523/JNEUROSCI.22-08-03044.2002	44	92	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16962	16968		10.1074/jbc.M409693200	http://dx.doi.org/10.1074/jbc.M409693200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15718245	Green Accepted, hybrid, Green Published			2022-12-25	WOS:000228615500052
J	Denton, CP; Lindahl, GE; Khan, K; Xu, SW; Ong, VH; Gaspar, NJ; Lazaridis, K; Edwards, DR; Leask, A; Eastwood, M; Leoni, P; Renzoni, EA; Gharios, GB; Abraham, DJ; Black, CM				Denton, CP; Lindahl, GE; Khan, K; Xu, SW; Ong, VH; Gaspar, NJ; Lazaridis, K; Edwards, DR; Leask, A; Eastwood, M; Leoni, P; Renzoni, EA; Gharios, GB; Abraham, DJ; Black, CM			Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II transforming growth factor-beta receptor (T beta RII Delta k)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; SCLERODERMA FIBROBLASTS; SYSTEMIC-SCLEROSIS; GENE-EXPRESSION; SIGNALING PATHWAYS; DERMAL FIBROBLASTS; SKIN; FIBROSIS; MATRIX; INHIBITOR	We have generated transgenic mice expressing a kinase-deficient type II transforming growth factor-beta (TGF beta) receptor selectively on fibroblasts (T beta RII Delta k-fib). These mice develop dermal and pulmonary fibrosis. In the present study we explore activation of TGF beta signaling pathways in this strain and examine the profibrotic properties of explanted transgenic fibroblasts including myofibroblast differentiation and abnormal metalloproteinase production. Gene expression profiles of littermate wild type or transgenic fibroblasts were compared using high-density gene arrays and validated by Taqman reverse transcriptase-PCR, Northern and Western blotting. Using a specific inhibitor (SD-208) we demonstrate that the abnormal phenotype of these cells is dependent upon T beta RI kinase (ALK5) activity, and that transgenic fibroblasts show enhanced expression and activation of TGF beta together with increased levels of wild type T beta RII. Moreover, we confirm that transgene expression is itself regulated by TGF beta and that expression at low levels facilitates signaling, whereas high level expression is inhibitory. For a subset of TGF beta responsive genes basal up-regulation is normalized or suppressed by exogenous recombinant TGF beta 1 at time points coincident with increased transgene expression. These findings explain the profound refractoriness of T beta RII Delta k-fib fibroblasts to exogenous TGF beta 1, despite their activated phenotype. Thus, transgenic fibroblasts recapitulate many hallmark biochemical properties of fibrotic cells, including high level CTGF (CCN2) expression and type I collagen overproduction, altered MMP production, and myofibroblast differentiation. These cells also show an enhanced ability to contract collagen gel matrices. Our study demonstrates that altered high affinity TGF beta receptor function may lead to ligand-dependent activation of downstream signaling, and provides further evidence of a pivotal role for sustained TGF beta overactivity in fibrosis.	UCL Royal Free & Univ Coll Med Sch, Ctr Rheumatol, London NW3 2PF, England; Scios Inc, Fremont, CA 94555 USA; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ London Imperial Coll Sci Technol & Med, Interstitial Lung Dis Unit, London SW7 2BU, England; Univ London Imperial Coll Sci Technol & Med, Dept Med, London SW7 2BU, England; Univ Westminster, London W1W 6UW, England	University of London; University College London; UCL Medical School; Scios; University of East Anglia; Imperial College London; Imperial College London; University of Westminster	Denton, CP (corresponding author), UCL Royal Free & Univ Coll Med Sch, Ctr Rheumatol, Rowland Hill St,Hampstead Campus, London NW3 2PF, England.	c.denton@medsch.ucl.ac.uk	Ong, Voon/AAB-9836-2020; Lazaridis, Konstantinos/AAB-2761-2022; Edwards, Dylan R/B-4734-2009; Leask, Andrew/G-5217-2015; Leask, Andy/ABH-9433-2020	Edwards, Dylan R/0000-0002-3292-2064; Lazaridis, Konstantinos/0000-0003-4386-2578; Renzoni, Elisabetta/0000-0002-1118-797X				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Asano Y, 2004, J CLIN INVEST, V113, P253, DOI 10.1172/JCI200416269; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Daniels JT, 2003, AM J PATHOL, V163, P2043, DOI 10.1016/S0002-9440(10)63562-6; Denton CP, 2004, AUTOIMMUN REV, V3, P285, DOI 10.1016/j.autrev.2003.10.003; Denton CP, 2001, ARTHRITIS RHEUM-US, V44, P712; Denton CP, 2001, CURR OPIN RHEUMATOL, V13, P505, DOI 10.1097/00002281-200111000-00010; Denton CP, 2003, J BIOL CHEM, V278, P25109, DOI 10.1074/jbc.M300636200; DENTON CP, 2004, ARTHRITIS RHEUM S34, V50; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dong CM, 2002, P NATL ACAD SCI USA, V99, P3908, DOI 10.1073/pnas.062010399; EASTWOOD M, 1994, BBA-GEN SUBJECTS, V1201, P186, DOI 10.1016/0304-4165(94)90040-X; Feghali CA, 1999, ARTHRITIS RHEUM-US, V42, P1451, DOI 10.1002/1529-0131(199907)42:7<1451::AID-ANR19>3.0.CO;2-6; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Grotendorst GR, 2004, FASEB J, V18, P469, DOI 10.1096/fj.03-0699com; Haverty PM, 2004, BIOINFORMATICS, V20, P3431, DOI 10.1093/bioinformatics/bth421; Holmes A, 2003, J BIOL CHEM, V278, P41728, DOI 10.1074/jbc.M305019200; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Jelaska A, 2000, ARTHRITIS RHEUM-US, V43, P2230, DOI 10.1002/1529-0131(200010)43:10<2230::AID-ANR10>3.0.CO;2-8; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Karsdal MA, 2002, J BIOL CHEM, V277, P44061, DOI 10.1074/jbc.M207205200; Kawakami T, 1998, J INVEST DERMATOL, V110, P47, DOI 10.1046/j.1523-1747.1998.00073.x; KIRK TZ, 1995, J BIOL CHEM, V270, P3423, DOI 10.1074/jbc.270.7.3423; Kissin Eugene, 2002, Curr Rheumatol Rep, V4, P129, DOI 10.1007/s11926-002-0008-y; Kubo M, 2002, J RHEUMATOL, V29, P2558; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Leask A, 2004, J INVEST DERMATOL, V122, P1, DOI 10.1046/j.0022-202X.2003.22133.x; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Leask A, 2002, ARTHRITIS RHEUM-US, V46, P1857, DOI 10.1002/art.10333; Mirastschijski U, 2004, EXP CELL RES, V299, P465, DOI 10.1016/j.yexcr.2004.06.007; Mori Y, 2003, ARTHRITIS RHEUM-US, V48, P1964, DOI 10.1002/art.11157; Pannu J, 2004, ARTHRITIS RHEUM-US, V50, P1566, DOI 10.1002/art.20225; Shi-Wen X, 2000, EXP CELL RES, V259, P213, DOI 10.1006/excr.2000.4972; Strehlow D, 1999, J CLIN INVEST, V103, P1179, DOI 10.1172/JCI1918; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Varga J, 2002, ARTHRITIS RHEUM-US, V46, P1703, DOI 10.1002/art.10413; Whitfield ML, 2003, P NATL ACAD SCI USA, V100, P12319, DOI 10.1073/pnas.1635114100; Xu SW, 2004, MOL BIOL CELL, V15, P2707, DOI 10.1091/mbc.E03-12-0902; Xu SW, 1997, ARTHRITIS RHEUM-US, V40, P1237; Yamane K, 2002, ARTHRITIS RHEUM-US, V46, P2421, DOI 10.1002/art.10477; Zhou XD, 2001, J IMMUNOL, V167, P7126, DOI 10.4049/jimmunol.167.12.7126	47	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16053	16065		10.1074/jbc.M413134200	http://dx.doi.org/10.1074/jbc.M413134200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15708853	Green Accepted, hybrid			2022-12-25	WOS:000228444800073
J	Muralidhar, D; Jobby, MK; Krishnan, K; Annapurna, V; Chary, KVR; Jeromin, A; Sharma, Y				Muralidhar, D; Jobby, MK; Krishnan, K; Annapurna, V; Chary, KVR; Jeromin, A; Sharma, Y			Equilibrium unfolding of neuronal calcium sensor-1 - N-terminal myristoylation influences unfolding and reduces protein stiffening in the presence of calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANIDINE-HYDROCHLORIDE; CONFORMATIONAL-CHANGES; YEAST HOMOLOG; BINDING; FREQUENIN; UREA; STABILIZATION; SPECTROSCOPY; REGULATOR; SWITCH	Neuronal calcium sensor-1 (NCS-1), a Ca2+-binding protein of the calcium sensor family, modulates various functions in intracellular signaling pathways. The N-terminal glycine in this protein is myristoylated, which is presumably necessary for its physiological functions. In order to understand the structural role of myristoylation and calcium on conformational stability, we have investigated the equilibrium unfolding and refolding of myristoylated and non-myristoylated NCS-1. The unfolding of these two forms of NCS-1 in the presence of calcium is best characterized by a five-state equilibrium model, and multiple intermediates accumulate during unfolding. Calcium exerts an extrinsic stabilizing effect on both forms of the protein. In the absence of calcium, the stability of both forms is dramatically decreased, and the unfolding follows a four-state equilibrium model. The equilibrium transitions are fully reversible in the presence of calcium. Myristoylation affects the pattern of equilibrium transitions substantially but not the number of intermediates, suggesting a structural role. Our data suggest that myristoylation reduces the stiffening of the protein during initial unfolding in the presence of calcium. The effects of myristoylation are more pronounced when calcium is present, suggesting a relationship between them. Inactivating the third EF-hand motif (E120Q mutant) drastically affects the equilibrium unfolding transitions, and calcium has no effect on these transitions of the mutants. The unfolding transitions of both forms of the mutant are similar to the transitions followed by the apo forms of myristoylated and non-myristoylated NCS-1. These results suggest that the role of myristoylation in unfolding/ refolding of the protein is largely dependent on the presence of calcium.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; Tata Inst Fundamental Res, Dept Chem Sci, Bombay 400005, Maharashtra, India; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Tata Institute of Fundamental Research (TIFR); Baylor College of Medicine	Jeromin, A (corresponding author), Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA.	jeromin@ltp.neusc.bcm.tmc.edu; yogendra@ccmb.res.in						AKAIKE H, 1973, 2 INT S INF THEOR, P261; Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Bhuyan AK, 2002, BIOCHEMISTRY-US, V41, P13386, DOI 10.1021/bi020371n; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Burgoyne RD, 2004, TRENDS NEUROSCI, V27, P203, DOI 10.1016/j.tins.2004.01.010; Burgoyne RD, 2001, BIOCHEM J, V353, P1; COX JA, 1994, J BIOL CHEM, V269, P32807; Dignam JD, 2001, J BIOL CHEM, V276, P4028, DOI 10.1074/jbc.M006840200; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Fisher JR, 2000, PROTEIN EXPRES PURIF, V20, P66, DOI 10.1006/prep.2000.1298; Guo WN, 2002, J BIOL CHEM, V277, P26436, DOI 10.1074/jbc.M201431200; Hamasaki-Katagiri N, 2004, J BIOL CHEM, V279, P12744, DOI 10.1074/jbc.M311895200; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Hilfiker S, 2003, BIOCHEM SOC T, V31, P828, DOI 10.1042/BST0310828; Hirst JD, 2003, FARADAY DISCUSS, V122, P253, DOI 10.1039/b200714b; Hung HC, 2003, B MATH BIOL, V65, P553, DOI 10.1016/S0092-8240(03)00024-7; Hwang JY, 2002, BBA-PROTEINS PROTEOM, V1600, P111, DOI 10.1016/S1570-9639(02)00451-X; Jeromin A, 2004, J BIOL CHEM, V279, P27158, DOI 10.1074/jbc.M312172200; Kumar R, 2004, BIOPHYS J, V87, P2656, DOI 10.1529/biophysj.104.044701; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; O'Callaghan DW, 2004, J BIOL CHEM, V279, P14347, DOI 10.1074/jbc.M310152200; Park SH, 1997, PROTEIN SCI, V6, P1694, DOI 10.1002/pro.5560060809; Patel S, 2004, BIOCHEMISTRY-US, V43, P1724, DOI 10.1021/bi0347104; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; SAMISTOTONOV GV, 1991, BIOPOLYMERS, V31, P119; Sippy T, 2003, NAT NEUROSCI, V6, P1031, DOI 10.1038/nn1117; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Wilson G, 1996, BIOCHEMISTRY-US, V35, P12518, DOI 10.1021/bi961314v; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	32	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15569	15578		10.1074/jbc.M414243200	http://dx.doi.org/10.1074/jbc.M414243200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15699030	hybrid			2022-12-25	WOS:000228444800015
J	Zaric, B; Chami, M; Remigy, H; Engel, A; Ballmer-Hofer, K; Winkler, FK; Kambach, C				Zaric, B; Chami, M; Remigy, H; Engel, A; Ballmer-Hofer, K; Winkler, FK; Kambach, C			Reconstitution of two recombinant LSm protein complexes reveals aspects of their architecture, assembly, and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SM-LIKE PROTEINS; SNRNP CORE; U7 SNRNPS; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURES; RNA DEGRADATION; YEAST; HFQ; ASSOCIATION; STABILITY	Sm and Sm-like (LSm) proteins form complexes engaging in various RNA-processing events. Composition and architecture of the complexes determine their intracellular distribution, RNA targets, and function. We have reconstituted the human LSm1-7 and LSm2-8 complexes from their constituent components in vitro. Based on the assembly pathway of the canonical Sm core domain, we used heterodimeric and heterotrimeric sub-complexes to assemble LSm1-7 and LSm2-8. Isolated sub-complexes form ring-like higher order structures. LSm1-7 is assembled and stable in the absence of RNA. LSm1-7 forms ring-like structures very similar to LSm2-8 at the EM level. Our in vitro reconstitution results illustrate likely features of the LSm complex assembly pathway. We prove the complexes to be functional both in an RNA bandshift and an in vivo cellular transport assay.	Paul Scherrer Inst, CH-5232 Villigen, Switzerland; Univ Basel, Biozentrum, ME Muller Inst Microscopy, CH-4056 Basel, Switzerland	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; University of Basel	Kambach, C (corresponding author), Paul Scherrer Inst, OFLC 110, CH-5232 Villigen, Switzerland.	christian.kambach@psi.ch	Zaric, Bozidarka/Y-9475-2019	Zaric, Bozidarka/0000-0003-4244-3283; Ballmer-Hofer, Kurt/0000-0002-3800-9129				Achsel T, 1999, EMBO J, V18, P5789, DOI 10.1093/emboj/18.20.5789; Albrecht M, 2004, FEBS LETT, V569, P18, DOI 10.1016/j.febslet.2004.03.126; Anantharaman V, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-45; Antson AA, 1996, CURR OPIN STRUC BIOL, V6, P142, DOI 10.1016/S0959-440X(96)80067-4; BLUMENTHAL T, 1995, TRENDS GENET, V11, P132, DOI 10.1016/S0168-9525(00)89026-5; BOELENS WC, 1995, RNA, V1, P273; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Cougot N, 2004, J CELL BIOL, V165, P31, DOI 10.1083/jcb.200309008; Donahue WF, 2002, MOL CELL, V9, P7, DOI 10.1016/S1097-2765(02)00429-X; Eystathioy T, 2003, RNA, V9, P1171, DOI 10.1261/rna.5810203; Eystathioy T, 2002, ARTHRITIS RHEUM, V46, P726, DOI 10.1002/art.10220; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Fromont-Racine M, 2000, YEAST, V17, P95, DOI 10.1002/1097-0061(20000630)17:2<95::AID-YEA16>3.0.CO;2-H; Ingelfinger D, 2002, RNA, V8, P1489, DOI 10.1017/S1355838202021726; Jeruzalmi D, 2002, CURR OPIN STRUC BIOL, V12, P217, DOI 10.1016/S0959-440X(02)00313-5; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; KASTNER B, 1990, P NATL ACAD SCI USA, V87, P1710, DOI 10.1073/pnas.87.5.1710; Kufel J, 2003, NUCLEIC ACIDS RES, V31, P6788, DOI 10.1093/nar/gkg904; Kufel J, 2003, J BIOL CHEM, V278, P2147, DOI 10.1074/jbc.M208856200; Kufel J, 2002, MOL CELL BIOL, V22, P5248, DOI 10.1128/MCB.22.14.5248-5256.2002; Lange TS, 2000, MOL BIOL CELL, V11, P2419, DOI 10.1091/mbc.11.7.2419; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; Meister G, 2002, TRENDS CELL BIOL, V12, P472, DOI 10.1016/S0962-8924(02)02371-1; Moller T, 2002, MOL CELL, V9, P23, DOI 10.1016/S1097-2765(01)00436-1; Mura C, 2001, P NATL ACAD SCI USA, V98, P5532, DOI 10.1073/pnas.091102298; NILSEN TW, 1995, MOL BIOCHEM PARASIT, V73, P1, DOI 10.1016/0166-6851(94)00107-X; Pannone BK, 2000, CURR BIOL, V10, pR478, DOI 10.1016/S0960-9822(00)00552-2; Pillai RS, 2003, GENE DEV, V17, P2321, DOI 10.1101/gad.274403; Pillai RS, 2001, EMBO J, V20, P5470, DOI 10.1093/emboj/20.19.5470; Plessel G, 1997, J MOL BIOL, V265, P87, DOI 10.1006/jmbi.1996.0713; Raker VA, 1999, MOL CELL BIOL, V19, P6554; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; Schumacher MA, 2002, EMBO J, V21, P3546, DOI 10.1093/emboj/cdf322; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; Stanek D, 2003, J CELL BIOL, V160, P505, DOI 10.1083/jcb.200210087; Stark H, 2001, NATURE, V409, P539, DOI 10.1038/35054102; STEFANOVIC B, 1995, NUCLEIC ACIDS RES, V23, P3141, DOI 10.1093/nar/23.16.3141; SUMPTER V, 1992, MOL BIOL REP, V16, P229, DOI 10.1007/BF00419662; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; Thore S, 2003, J BIOL CHEM, V278, P1239, DOI 10.1074/jbc.M207685200; Tomasevic N, 2002, MOL CELL BIOL, V22, P4101, DOI 10.1128/MCB.22.12.4101-4112.2002; Toro I, 2001, EMBO J, V20, P2293, DOI 10.1093/emboj/20.9.2293; Urlaub H, 2001, EMBO J, V20, P187, DOI 10.1093/emboj/20.1.187; Valentin-Hansen P, 2004, MOL MICROBIOL, V51, P1525, DOI 10.1111/j.1365-2958.2003.03935.x; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; Vivona JB, 2003, FEBS LETT, V546, P167, DOI 10.1016/S0014-5793(03)00622-7; Walke S, 2001, J MOL BIOL, V308, P49, DOI 10.1006/jmbi.2001.4549; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; Zhang AX, 2002, MOL CELL, V9, P11, DOI 10.1016/S1097-2765(01)00437-3	54	56	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16066	16075		10.1074/jbc.M414481200	http://dx.doi.org/10.1074/jbc.M414481200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15711010	hybrid, Green Published			2022-12-25	WOS:000228444800074
J	Zhang, YH; Su, ZL; Zhang, F; Chen, Y; Shin, YK				Zhang, YH; Su, ZL; Zhang, F; Chen, Y; Shin, YK			A partially zipped SNARE complex stabilized by the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-SNARE; CRYSTAL-STRUCTURE; SYNAPTIC EXOCYTOSIS; 4-HELIX BUNDLE; FUSION; PROTEINS; VESICLE; REGION; INHIBITION; RESONANCE	The SNARE complex acts centrally for intracellular membrane fusion, an essential process for vesicular transport in cells. Association between vesicle-associated (v-) SNARE and target membrane (t-) SNARE results in the coiled coil core that bridges two membranes. Here, the structure of the SNARE complex assembled by recombinant t- SNARE Sso1p/Sec9 and v- SNARE Snc2p, which are involved in post-Golgi trafficking in yeast, was investigated using EPR. In detergent solutions, SNAREs formed a fully assembled core. However, when t- SNAREs were reconstituted into the proteoliposome and mixed with the soluble SNARE motif of Snc2p, a partially zipped core in which the N-terminal region is structured, whereas the C-terminal region is frayed, was detected. The partially zipped and fully assembled complexes coexisted with little free energy difference between them. Thus, the core complex formation of yeast SNAREs might not serve as the energy source for the fusion, which is different from what has been known for neuronal SNAREs. On the other hand, the results from the proteoliposome fusion assay, employing cysteine- and nitroxide-scanning mutants of Sso1p, suggested that the formation of the complete core is required for membrane fusion. This implies that core SNARE assembly plays an essential role in setting up the proper geometry of the lipid-protein complex for the successful fusion.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Shin, YK (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	colishin@iastate.edu	Su, Zengliu/E-3156-2010; Zhang, Fan/A-3477-2011					Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Chen Y, 2004, EMBO J, V23, P681, DOI 10.1038/sj.emboj.7600083; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Chernomordik LV, 1999, MOL MEMBR BIOL, V16, P33; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Fasshauer D, 2003, BBA-MOL CELL RES, V1641, P87, DOI 10.1016/S0167-4889(03)00090-9; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Gerst JE, 2003, BBA-MOL CELL RES, V1641, P99, DOI 10.1016/S0167-4889(03)00096-X; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hua SY, 1999, NAT NEUROSCI, V2, P1078, DOI 10.1038/16005; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Katz L, 1998, EMBO J, V17, P6200, DOI 10.1093/emboj/17.21.6200; Kim CS, 2002, BIOCHEMISTRY-US, V41, P10928, DOI 10.1021/bi026266v; Kweon DH, 2003, NAT STRUCT BIOL, V10, P440, DOI 10.1038/nsb928; Kweon DH, 2003, J BIOL CHEM, V278, P12367, DOI 10.1074/jbc.M211123200; Kweon DH, 2002, BIOCHEMISTRY-US, V41, P9264, DOI 10.1021/bi025934+; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Mahal LK, 2002, J CELL BIOL, V158, P273, DOI 10.1083/jcb.200203135; Margittai M, 2003, P NATL ACAD SCI USA, V100, P15516, DOI 10.1073/pnas.2331232100; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Matos MF, 2003, NEUROPHARMACOLOGY, V45, P777, DOI 10.1016/S0028-3908(03)00318-6; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Melia TJ, 2002, J CELL BIOL, V158, P929, DOI 10.1083/jcb.200112081; Misura KMS, 2001, J BIOL CHEM, V276, P41301, DOI 10.1074/jbc.M106853200; Munson M, 2000, NAT STRUCT BIOL, V7, P894; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Rice LM, 1997, FEBS LETT, V415, P49, DOI 10.1016/S0014-5793(97)01091-0; SCHNEIDER DJ, 1989, LASERS MOL METHOD, P385; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Thorgeirsson TE, 1996, BIOCHEMISTRY-US, V35, P1803, DOI 10.1021/bi952300c; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Zhang F, 2004, J BIOL CHEM, V279, P38668, DOI 10.1074/jbc.M404904200; Zhang F, 2002, J BIOL CHEM, V277, P24294, DOI 10.1074/jbc.M201200200	44	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15595	15600		10.1074/jbc.M500736200	http://dx.doi.org/10.1074/jbc.M500736200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713667	hybrid			2022-12-25	WOS:000228444800018
J	Huang, LP; Kirschke, CP; Zhang, YF; Yu, YY				Huang, LP; Kirschke, CP; Zhang, YF; Yu, YY			The ZIP7 gene (Slc39a7) encodes a zinc transporter involved in zinc homeostasis of the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ACRODERMATITIS-ENTEROPATHICA; FUNCTIONAL-CHARACTERIZATION; CONFERS RESISTANCE; PROTEIN; EXPRESSION; CLONING; MOUSE; CELLS; DEFICIENCY	It has been suggested that ZIP7 (Ke4, Slc39a7) belongs to the ZIP family of zinc transporters. Transient expression of the V5-tagged human ZIP7 fusion protein in CHO cells led to elevation of the cytoplasmic zinc level. However, the precise function of ZIP7 in cellular zinc homeostasis is not clear. Here we report that the ZIP7 gene is ubiquitously expressed in human and mouse tissues. The endogenous ZIP7 was associated with the Golgi apparatus and was capable of transporting zinc from the Golgi apparatus into the cytoplasm of the cell. Moreover, by using the yeast mutant strain Delta zrt3 that was defective in release of stored zinc from vacuoles, we found that ZIP7 was able to decrease the level of accumulated zinc and in the meantime to increase the nuclear/cytoplasmic labile zinc level in the ZIP7-expressing zrt3 mutant. We showed that the protein expression of ZIP7 was repressed under zinc-rich condition, whereas there were no effects of zinc on ZIP7 gene expression and intracellular localization. Neither did zinc deficiency affect the intracellular distribution of ZIP7 in mammalian cells. Our study demonstrates that ZIP7 is a functional zinc transporter that acts by transporting zinc from the Golgi apparatus to the cytoplasm of the cell.	Univ Calif Davis, Rowe Program Genet, Davis, CA 95616 USA; Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; Univ Calif Davis, ARS, USDA, Western Human Nutr Res Ctr, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; United States Department of Agriculture (USDA); University of California System; University of California Davis	Huang, LP (corresponding author), Univ Calif Davis, Rowe Program Genet, 1 Shields Ave, Davis, CA 95616 USA.	lhuang@whnrc.usda.gov						Ando A, 1996, GENOMICS, V35, P600, DOI 10.1006/geno.1996.0405; Andree KB, 2004, J NUTR, V134, P1716, DOI 10.1093/jn/134.7.1716; Chen HJ, 2003, BLOOD, V102, P1893, DOI 10.1182/blood-2003-02-0347; Dufner-Beattie J, 2004, J BIOL CHEM, V279, P49082, DOI 10.1074/jbc.M409962200; Eide DJ, 2004, PFLUG ARCH EUR J PHY, V447, P796, DOI 10.1007/s00424-003-1074-3; Ellis CD, 2004, J CELL BIOL, V166, P325, DOI 10.1083/jcb.200401157; Franklin RB, 2003, J INORG BIOCHEM, V96, P435, DOI 10.1016/S0162-0134(03)00249-6; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Huang LP, 2002, J BIOL CHEM, V277, P26389, DOI 10.1074/jbc.M200462200; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kelleher SL, 2003, J NUTR, V133, P3378, DOI 10.1093/jn/133.11.3378; Kim BE, 2004, J BIOL CHEM, V279, P4523, DOI 10.1074/jbc.M310799200; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; LAI F, 1994, GENOMICS, V23, P338, DOI 10.1006/geno.1994.1509; Lasswell J, 2000, PLANT CELL, V12, P2395, DOI 10.1105/tpc.12.12.2395; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MANNING DL, 1988, MOL CELL ENDOCRINOL, V59, P205, DOI 10.1016/0303-7207(88)90105-0; Miyabe S, 2000, BIOCHEM BIOPH RES CO, V276, P879, DOI 10.1006/bbrc.2000.3580; Miyabe S, 2001, BIOCHEM BIOPH RES CO, V282, P79, DOI 10.1006/bbrc.2001.4522; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Palmiter RD, 2004, P NATL ACAD SCI USA, V101, P4918, DOI 10.1073/pnas.0401022101; Palmiter RD, 2004, PFLUG ARCH EUR J PHY, V447, P744, DOI 10.1007/s00424-003-1070-7; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Prasad AS, 2001, NUTRITION, V17, P67, DOI 10.1016/S0899-9007(00)00469-X; Prasad AS, 1998, J AM COLL NUTR, V17, P542, DOI 10.1080/07315724.1998.10718800; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sehgal VN, 2000, CLIN DERMATOL, V18, P745, DOI 10.1016/S0738-081X(00)00150-4; Taylor KM, 2004, BIOCHEM J, V377, P131, DOI 10.1042/BJ20031183; Taylor KM, 2003, BIOCHEM J, V375, P51, DOI 10.1042/BJ20030478; Wang FD, 2004, J BIOL CHEM, V279, P51433, DOI 10.1074/jbc.M408361200; Wang FD, 2004, J BIOL CHEM, V279, P24631, DOI 10.1074/jbc.M400680200; Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	40	154	161	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15456	15463		10.1074/jbc.M412188200	http://dx.doi.org/10.1074/jbc.M412188200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705588	hybrid			2022-12-25	WOS:000228236800133
J	Eschenburg, S; Priestman, MA; Abdul-Latif, FA; Delachaume, C; Fassy, F; Schonbrunn, E				Eschenburg, S; Priestman, MA; Abdul-Latif, FA; Delachaume, C; Fassy, F; Schonbrunn, E			A novel inhibitor that suspends the induced fit mechanism of UDP-N-acetylglucosamine enolpyruvyl transferase (MurA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PEPTIDOGLYCAN; FOSFOMYCIN RESISTANCE; SHIKIMATE PATHWAY; CRYSTAL-STRUCTURE; DIFFRACTION DATA; TARGET; ENZYME; SYNTHASE; BIOSYNTHESIS; GLYPHOSATE	MurA (UDP-N-acetylglucosamine enolpyruvyl transferase, EC 2.5.1.7) catalyzes the first committed step in the synthesis of the bacterial cell wall. It is the target of the naturally occurring, broad-spectrum antibiotic fosfomycin. Fosfomycin, an epoxide, is a relatively poor drug because an ever-increasing number of bacteria have developed resistance to fosfomycin. Thus, there is a critical need for the development of novel drugs that target MurA by a different molecular mode of action. We have identified a new scaffold of potent MurA inhibitors, derivatives of 5-sulfonoxy-anthranilic acid, using high-throughput screening. T6361 and T6362 are competitive inhibitors of MurA with respect to the first substrate, UDP-N-acetylglucosamine (UNAG), with a K-i of 16 mu M. The crystal structure of the MurA.T6361 complex at 2.6 angstrom resolution, together with fluorescence data, revealed that the inhibitor targets a loop, Pro(112) to Pro(121), that is crucial for the structural changes of the enzyme during catalysis. Thus, this new class of MurA inhibitors is not active site-directed but instead obstructs the transition from the open (unliganded) to the closed (UNAG-liganded) enzyme form. The results provide evidence for the existence of a MurA.UNAG collision complex that may be specifically targeted by small molecules different from ground-state analogs of the enzymatic reaction.	Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA; Max Planck Inst Mol Physiol, Dept Biol Struct, D-44227 Dortmund, Germany; Aventis Pharma, F-94403 Vitry Sur Seine, France; Novexel, F-93320 Romainville, France; Aventis Pharma, Combinatorial Technol Ctr, Tucson, AZ 85737 USA	University of Kansas; Max Planck Society; Sanofi-Aventis; Sanofi France; Sanofi-Aventis	Schonbrunn, E (corresponding author), Univ Kansas, Dept Med Chem, 4040A Malott Hall, Lawrence, KS 66045 USA.	eschoenb@ku.edu		Schonbrunn, Ernst/0000-0002-3589-3510; Fassy, Florence/0000-0001-8337-9674				An M, 2001, J ORG CHEM, V66, P1326, DOI 10.1021/jo001121k; ARCA P, 1988, ANTIMICROB AGENTS CH, V32, P1552, DOI 10.1128/AAC.32.10.1552; Baum EZ, 2001, ANTIMICROB AGENTS CH, V45, P3182, DOI 10.1128/AAC.45.11.3182-3188.2001; BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; BROWN ED, 1995, J BACTERIOL, V177, P4194, DOI 10.1128/jb.177.14.4194-4197.1995; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Byczynski B, 2003, J AM CHEM SOC, V125, P12541, DOI 10.1021/ja0349655; Dai HJ, 2002, J CHROMATOGR B, V766, P123, DOI 10.1016/S0378-4347(01)00461-3; De Smet KAL, 1999, MICROBIOL-UK, V145, P3177, DOI 10.1099/00221287-145-11-3177; DeVito JA, 2002, NAT BIOTECHNOL, V20, P478, DOI 10.1038/nbt0502-478; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Du WS, 2000, J BACTERIOL, V182, P4146, DOI 10.1128/JB.182.15.4146-4152.2000; El Zoeiby A, 2003, MOL MICROBIOL, V47, P1, DOI 10.1046/j.1365-2958.2003.03289.x; Eschenburg S, 2003, J BIOL CHEM, V278, P49215, DOI 10.1074/jbc.M309741200; Eschenburg S, 2000, PROTEINS, V40, P290, DOI 10.1002/(SICI)1097-0134(20000801)40:2<290::AID-PROT90>3.0.CO;2-0; Eschenburg S, 2005, J BIOL CHEM, V280, P3757, DOI 10.1074/jbc.M411325200; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Green David W, 2002, Expert Opin Ther Targets, V6, P1, DOI 10.1517/14728222.6.1.1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KAHAN FM, 1974, ANN NY ACAD SCI, V235, P364, DOI 10.1111/j.1749-6632.1974.tb43277.x; Kim DH, 1996, BIOCHEMISTRY-US, V35, P4923, DOI 10.1021/bi952937w; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; McCoy AJ, 2003, J BACTERIOL, V185, P1218, DOI 10.1128/JB.185.4.1218-1228.2003; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Rife CL, 2002, J AM CHEM SOC, V124, P11001, DOI 10.1021/ja026879v; Roberts CW, 2002, J INFECT DIS, V185, pS25, DOI 10.1086/338004; Schonbrunn E, 1998, EUR J BIOCHEM, V253, P406, DOI 10.1046/j.1432-1327.1998.2530406.x; Schonbrunn E, 2001, P NATL ACAD SCI USA, V98, P1376, DOI 10.1073/pnas.98.4.1376; Schonbrunn E, 1996, STRUCTURE, V4, P1065, DOI 10.1016/S0969-2126(96)00113-X; Schonbrunn E, 2000, P NATL ACAD SCI USA, V97, P6345, DOI 10.1073/pnas.120120397; Schonbrunn E, 2000, BIOCHEMISTRY-US, V39, P2164, DOI 10.1021/bi991091j; Skarzynski T, 1996, STRUCTURE, V4, P1465, DOI 10.1016/S0969-2126(96)00153-0; STALLINGS WC, 1991, P NATL ACAD SCI USA, V88, P5046, DOI 10.1073/pnas.88.11.5046; Thomas AM, 2004, EUR J BIOCHEM, V271, P2682, DOI 10.1111/j.1432-1033.2004.04196.x; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; VANHEIJENOORT J, 1994, N COMP BIOC, V27, P39; VENKATESWARAN PS, 1972, J BACTERIOL, V110, P935, DOI 10.1128/JB.110.3.935-944.1972	40	59	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14070	14075		10.1074/jbc.M414412200	http://dx.doi.org/10.1074/jbc.M414412200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15701635	hybrid			2022-12-25	WOS:000228095500109
J	Ishii, R; Minagawa, A; Takaku, H; Takagi, M; Nashimoto, M; Yokoyama, S				Ishii, R; Minagawa, A; Takaku, H; Takagi, M; Nashimoto, M; Yokoyama, S			Crystal structure of the tRNA 3 ' processing endoribonuclease tRNase Z from Thermotoga maritima	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLO-BETA-LACTAMASE; CANCER SUSCEPTIBILITY GENE; PROTEIN FOLD; IN-VIVO; SEQUENCE; PRECURSORS; MATURATION; RESOLUTION; MOLECULES; MECHANISM	The maturation of the tRNA 3 ' end is catalyzed by a tRNA 3 ' processing endoribonuclease named tRNase Z ( RNase Z or 3 '- tRNase) in eukaryotes, Archaea, and some bacteria. The tRNase Z generally cuts the 3 ' extra sequence from the precursor tRNA after the discriminator nucleotide. In contrast, Thermotoga maritima tRNase Z cleaves the precursor tRNA precisely after the CCA sequence. In this study, we determined the crystal structure of T. maritima tRNase Z at 2.6-angstrom resolution. The tRNase Z has a four- layer alpha beta/beta alpha sandwich fold, which is classified as a metallo- beta- lactamase fold, and forms a dimer. The active site is located at one edge of the beta- sandwich and is composed of conserved motifs. Based on the structure, we constructed a docking model with the tRNAs that suggests how tRNase Z may recognize the substrate tRNAs.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; Niigata Univ Pharm & Appl Life Sci, Dept Appl Life Sci, Niigata 9568603, Japan; RIKEN Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; SPring 8, RIKEN Harima Inst, Mikazuki, Hyogo 6795148, Japan	University of Tokyo; Niigata University; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN	Yokoyama, S (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Ishii, Ryohei/0000-0003-2486-1393				Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Aravind L, 1999, In Silico Biol, V1, P69; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; DEUTSCHER MP, 1984, CRC CR REV BIOCH MOL, V17, P45, DOI 10.3109/10409238409110269; Deutscher Murray P., 1995, P51; Dubrovsky EB, 2004, NUCLEIC ACIDS RES, V32, P255, DOI 10.1093/nar/gkh182; Fitzgerald PMD, 1998, BIOCHEMISTRY-US, V37, P6791, DOI 10.1021/bi9730339; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; LEVINGER L, 1995, J BIOL CHEM, V270, P18903, DOI 10.1074/jbc.270.32.18903; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; Minagawa A, 2004, J BIOL CHEM, V279, P15688, DOI 10.1074/jbc.M313951200; Morl M, 2001, EMBO REP, V2, P17, DOI 10.1093/embo-reports/kve006; NASHIMOTO M, 1995, NUCLEIC ACIDS RES, V23, P3642, DOI 10.1093/nar/23.18.3642; Nashimoto M, 1999, J MOL BIOL, V287, P727, DOI 10.1006/jmbi.1999.2639; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papadimitriou A, 1996, EUR J BIOCHEM, V242, P747, DOI 10.1111/j.1432-1033.1996.0747r.x; Pellegrini O, 2003, EMBO J, V22, P4534, DOI 10.1093/emboj/cdg435; Schierling K, 2002, J MOL BIOL, V316, P895, DOI 10.1006/jmbi.2001.5395; Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769; Schurer H, 2001, BIOL CHEM, V382, P1147, DOI 10.1515/BC.2001.144; Takaku H, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh092; Takaku H, 2004, NUCLEIC ACIDS RES, V32, P4429, DOI 10.1093/nar/gkh774; Takaku H, 2003, NUCLEIC ACIDS RES, V31, P2272, DOI 10.1093/nar/gkg337; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vogel A, 2002, J BIOL CHEM, V277, P29078, DOI 10.1074/jbc.M112047200; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2	42	75	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14138	14144		10.1074/jbc.M500355200	http://dx.doi.org/10.1074/jbc.M500355200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15701599	hybrid			2022-12-25	WOS:000228095500117
J	Ishmael, FT; Shier, VK; Ishmael, SS; Bond, JS				Ishmael, FT; Shier, VK; Ishmael, SS; Bond, JS			Intersubunit and domain interactions of the meprin B metalloproteinase - Disulfide bonds and protein-protein interactions in the MAM and TRAF domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; 3-DIMENSIONAL STRUCTURE; MASS-SPECTROMETRY; ASTACIN FAMILY; ALPHA-SUBUNIT; CROSS-LINKING; BINDING-SITE; BETA-SUBUNIT; AMINO-ACIDS; IDENTIFICATION	Meprins, multimeric metalloproteases expressed in kidney and intestinal epithelial cells as well as in certain leukocytes and cancer cells, have the ability to hydrolyze a variety of growth factors, vasoactive peptides, cytokines, and extracellular matrix proteins. The meprin B isoform exists primarily as a cell-surface homo-oligomer composed of disulfide-linked, multidomain beta-subunits. To gain insight into how the tertiary and quaternary structure of meprin B affects function, the disulfide-bonding pattern and sites of domain-domain interactions were investigated using sedimentation equilibrium ultracentrifugation, cross-linking, and mass spectrometry techniques. Three symmetrical intersubunit disulfide bonds were identified in the noncatalytic interaction domains; two in the MAM (meprin, A-5 protein, protein-tyrosine phosphatase mu) domain and one in the TRAF (tumor necrosis factor receptor-associated factor) domain. These disulfide bridges are unique for the known homophilic interactions of these domains. Mutation of any of the intersubunit cysteine residues resulted in the inability of meprin B to form disulfide-linked dimers. The four cysteines of the protease domain formed intradomain disulfide bonds. The MAM domain also had one intradomain disulfide bond and one free cysteine. Cross-linking studies of the meprin B dimer with the amine-reactive cross-linker disuccinimidyl suberate revealed inter- and intradomain contacts within the protein, including prosequence-prosequence, protease-TRAF, protease-epidermal growth factor, and TRAF-TRAF interactions. From these observations, a model of the meprin B dimer structure is proposed that provides insight into the relationship between structure and function of this isoform.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Bond, JS (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, H171, Hershey, PA 17033 USA.	jbond@psu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK019691, R01DK054625, R56DK019691, R01DK019691] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19691, DK54625] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alley SC, 2000, J AM CHEM SOC, V122, P6126, DOI 10.1021/ja000591t; Becker C, 2003, BIOL CHEM, V384, P825, DOI 10.1515/BC.2003.092; Bertenshaw GP, 2003, J BIOL CHEM, V278, P2522, DOI 10.1074/jbc.M208808200; Bertenshaw GP, 2002, BIOL CHEM, V383, P1175, DOI 10.1515/BC.2002.129; Bertenshaw GP, 2001, J BIOL CHEM, V276, P13248, DOI 10.1074/jbc.M011414200; BERTENSHAW GP, 2004, HDB PROTEOLYTIC ENZY, P599; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Chevallier S, 1996, BIOCHEM J, V317, P731, DOI 10.1042/bj3170731; Cismasiu VB, 2004, J BIOL CHEM, V279, P26922, DOI 10.1074/jbc.M313115200; CRAIG SS, 1987, AM J PHYSIOL, V253, P535; Crisman JM, 2004, J IMMUNOL, V172, P4510, DOI 10.4049/jimmunol.172.7.4510; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Edelstein S J, 1973, Methods Enzymol, V27, P82; Eldering JA, 1997, EUR J BIOCHEM, V247, P920, DOI 10.1111/j.1432-1033.1997.00920.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GLOCKER MO, 1993, BIOCHEMISTRY-US, V32, P482, DOI 10.1021/bi00053a012; Hengst JA, 2004, J BIOL CHEM, V279, P34856, DOI 10.1074/jbc.M405774200; Ishmael FT, 2001, J BIOL CHEM, V276, P23207, DOI 10.1074/jbc.M102654200; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; JOHNSON GD, 1994, J BIOL CHEM, V269, P7682; Kadowaki T, 2000, J BIOL CHEM, V275, P25577, DOI 10.1074/jbc.M003521200; Marchand P, 1996, J BIOL CHEM, V271, P24236, DOI 10.1074/jbc.271.39.24236; MARCHAND P, 1995, J BIOL CHEM, V270, P5449, DOI 10.1074/jbc.270.10.5449; Matters GL, 1999, MOL CARCINOGEN, V25, P169, DOI 10.1002/(SICI)1098-2744(199907)25:3<169::AID-MC3>3.0.CO;2-Y; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Stetefeld J, 1996, J MOL BIOL, V257, P644, DOI 10.1006/jmbi.1996.0191; STOCKER W, 1993, EUR J BIOCHEM, V214, P215, DOI 10.1111/j.1432-1033.1993.tb17915.x; STOCKER W, 1995, PROTEIN SCI, V4, P823; Sunnerhagen M, 2002, FEBS LETT, V530, P1, DOI 10.1016/S0014-5793(02)03330-6; Tang J, 1998, ARCH BIOCHEM BIOPHYS, V349, P192, DOI 10.1006/abbi.1997.0453; TARENTINO AL, 1995, ARCH BIOCHEM BIOPHYS, V319, P281, DOI 10.1006/abbi.1995.1293; Tsukuba T, 2002, ARCH BIOCHEM BIOPHYS, V397, P191, DOI 10.1006/abbi.2001.2672; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; Villa JP, 2003, BIOCHEM SOC SYMP, V70, P53, DOI 10.1042/bss0700053; Villa JP, 2003, J BIOL CHEM, V278, P42545, DOI 10.1074/jbc.M303718200; Welker E, 2001, BIOCHEMISTRY-US, V40, P9059, DOI 10.1021/bi010409g; Young MM, 2000, P NATL ACAD SCI USA, V97, P5802, DOI 10.1073/pnas.090099097; Zapata JM, 2001, J BIOL CHEM, V276, P24242, DOI 10.1074/jbc.M100354200	40	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13895	13901		10.1074/jbc.M414218200	http://dx.doi.org/10.1074/jbc.M414218200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695509	hybrid			2022-12-25	WOS:000228095500089
J	Moshynska, O; Moshynskyy, I; Misra, V; Saxena, A				Moshynska, O; Moshynskyy, I; Misra, V; Saxena, A			G125A single-nucleotide polymorphism in the human BAX promoter affects gene expression	ONCOGENE			English	Article						apoptosis; BAX; single-nucleotide polymorphism; Luciferase activity; gene expression; chronic lymphocytic leukemia	CHRONIC LYMPHOCYTIC-LEUKEMIA; MICROSATELLITE MUTATOR PHENOTYPE; IN-VIVO; FRAMESHIFT MUTATIONS; HEMATOPOIETIC MALIGNANCIES; DISEASE PROGRESSION; INDUCED APOPTOSIS; P53 EXPRESSION; OVARIAN-CANCER; CELL-SURVIVAL	Earlier we had reported a guanine to adenosine substitution at position 125 (G125A) in the BAX promoter, and its association with higher stage of the disease and failure to achieve complete response to treatment in chronic lymphocytic leukemia (CLL) patients. The aim of this study was to test the hypothesis that G125A leads to a reduction in the transcription of the BAX gene and that this is a direct cause of altered BAX mRNA and protein expression. In lymphocytes of CLL patients, BAX mRNA expression was determined by RNase protection assay and Bax protein was detected by immunoblotting. The presence of G125A in the BAX promoter was associated with lower BAX mRNA (P = 0.004) and protein (P = 0.024) levels. In transient expression assays using wild-type and mutant BAX promoter sequences linked to Luciferase as a reporter, the G125A polymorphism reduced expression of the BAX promoter by 2.6-fold. These studies suggest a mechanism for the biological effect of the G125A.	Univ Saskatchewan, Dept Pathol, Royal Univ Hosp, Coll Med, Saskatoon, SK S7N 0W8, Canada; Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK S7N 5E3, Canada; Univ Saskatchewan, Dept Microbiol, Western Coll Vet Med, Saskatoon, SK S7N 5B4, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Saxena, A (corresponding author), Univ Saskatchewan, Dept Pathol, Royal Univ Hosp, Coll Med, Room 2870,2nd Floor,G Wing,103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada.	saxena@sask.usask.ca	Moshynska, Oksana/AAC-6994-2019; Misra, Vikram/AAC-4266-2020; Moshynska, Oksana/AAJ-7893-2020	Moshynska, Oksana/0000-0003-4842-7786; Misra, Vikram/0000-0001-6818-7156; 				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Catasus L, 2000, CANCER, V88, P2290, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2290::AID-CNCR13>3.3.CO;2-9; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Cordone I, 1998, BLOOD, V91, P4342, DOI 10.1182/blood.V91.11.4342.411k39_4342_4349; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Kay Neil E, 2002, Hematology Am Soc Hematol Educ Program, P193, DOI 10.1182/asheducation-2002.1.193; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kitada S, 1999, BRIT J HAEMATOL, V106, P995, DOI 10.1046/j.1365-2141.1999.01642.x; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kokawa K, 1999, CANCER, V85, P1799, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1799::AID-CNCR21>3.3.CO;2-D; Kokawa K, 1999, CANCER, V86, P79; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lee HS, 2002, MODERN PATHOL, V15, P632, DOI 10.1038/modpathol.3880578; Levitsky VG, 2001, BIOINFORMATICS, V17, P998, DOI 10.1093/bioinformatics/17.11.998; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moshynska O, 2004, JNCI-J NATL CANCER I, V96, P673, DOI 10.1093/jnci/djh122; Moshynska O, 2003, J CLIN PATHOL-MOL PA, V56, P205, DOI 10.1136/mp.56.4.205; Ouyang H, 1998, CLIN CANCER RES, V4, P1071; Peng HZ, 1998, J PATHOL, V186, P378, DOI 10.1002/(SICI)1096-9896(199812)186:4<378::AID-PATH203>3.0.CO;2-5; Pepper C, 1999, BRIT J HAEMATOL, V104, P581, DOI 10.1046/j.1365-2141.1999.01210.x; Pepper C, 1996, BRIT J HAEMATOL, V95, P513, DOI 10.1046/j.1365-2141.1996.d01-1927.x; Pepper C, 1997, BRIT J CANCER, V76, P935, DOI 10.1038/bjc.1997.487; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Sakuragi N, 2002, GYNECOL ONCOL, V86, P288, DOI 10.1006/gyno.2002.6742; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCHEZ MS, 1986, ANTIMICROB AGENTS CH, V29, P634, DOI 10.1128/AAC.29.4.634; Sanz L, 2004, BIOCHEM BIOPH RES CO, V315, P562, DOI 10.1016/j.bbrc.2004.01.095; Saxena A, 2004, AM J HEMATOL, V75, P22, DOI 10.1002/ajh.10453; Saxena A, 2002, CANCER LETT, V187, P199, DOI 10.1016/S0304-3835(02)00378-6; Tai YT, 1999, CANCER RES, V59, P2121; Tai YT, 1998, J CLIN ONCOL, V16, P2583, DOI 10.1200/JCO.1998.16.8.2583; Thomas A, 1996, ONCOGENE, V12, P1055; Violette S, 2002, INT J CANCER, V98, P498, DOI 10.1002/ijc.10146; Yamamoto H, 1997, CANCER RES, V57, P4420; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	45	20	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2042	2049		10.1038/sj.onc.1208377	http://dx.doi.org/10.1038/sj.onc.1208377			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688029				2022-12-25	WOS:000227681900008
J	Dennler, S; Pendaries, V; Tacheau, C; Costas, MA; Mauviel, A; Verrecchia, F				Dennler, S; Pendaries, V; Tacheau, C; Costas, MA; Mauviel, A; Verrecchia, F			The steroid receptor co-activator-1 (SRC-1) potentiates TGF-beta/Smad signaling: role of p300/CBP	ONCOGENE			English	Article						p300; Smad; SRC-1 TGF-beta	GROWTH-FACTOR-BETA; CREB-BINDING-PROTEIN; BREAST-CANCER; TRANSCRIPTIONAL COACTIVATORS; MEDIATED TRANSACTIVATIONS; PROGESTERONE-RECEPTOR; NUCLEAR RECEPTORS; C-JUN; AIB1; GENE	The three related 160-kDa proteins, SRC-1, TIF-2 and RAC-3, were initially identified as factors interacting with nuclear receptors. They have also been reported to potentiate the activity of other transcription factors such as AP-1 or NF-kappa B. The aim of this work was to identify whether SRC-1 interferes with the TGF-beta/Smad signaling pathway, and if so, to identify its underlying mechanisms of action. Using transient cell transfection experiments performed in human dermal fibroblasts with the Smad3/4-specific (SBE)(4)-lux reporter construct, as well as the human PAI-1 promoter, we determined that SRC-1 enhances TGF-beta-induced, Smad-mediated, transcription. Likewise, SRC-1 overexpression potentiated TGF-beta-induced upregulation of PAI-1 steady-state mRNA levels. Using a mammalian two-hybrid system, we demonstrated that SRC-1 interacts with the transcriptional co-activators p300/CBP, but not with Smad3. Overexpression of the adenovirus E1A oncoprotein, an inhibitor of CBP/p300 activity, prevented the enhancing effect of SRC-1 on Smad3/4-mediated transcription, indicating that p300/CBP may be required for SRC-1 effect. Such hypothesis was validated, as expression of a mutant form of SRC-1 lacking the CBP/p300-binding site failed to upregulate Smad3/4-dependent transcription, while full-length SRC-1 potentiated p300. Smad3 interactions. These results identify SRC-1 as a novel Smad3/4 transcriptional partner, facilitating the functional link between Smad3 and p300/CBP.	Hop St Louis, INSERM, U697, Inst Rech Peau, F-75475 Paris 10, France; Univ Buenos Aires, Dept Cs Biol, Fac Ciencias Exactas & Nat, RA-1053 Buenos Aires, DF, Argentina	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Buenos Aires	Verrecchia, F (corresponding author), Hop St Louis, INSERM, U697, Inst Rech Peau, Pavillon Bazin,1 Ave Claude Vellefaux, F-75475 Paris 10, France.	franck.verrecchia@stlouis.inserm.fr	Verrecchia, Franck/G-5535-2018; MAUVIEL, Alain/F-6251-2013	Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793; Costas, Monica/0000-0002-4773-3389				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Berns EMJJ, 1998, BREAST CANCER RES TR, V48, P87, DOI 10.1023/A:1005903226483; Bouras T, 2001, CANCER RES, V61, P903; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Cottone E, 2001, INT J BIOL MARKER, V16, P151, DOI 10.1177/172460080101600301; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Glass CK, 2000, GENE DEV, V14, P121; Guan XY, 1996, CANCER RES, V56, P3446; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1996, CANCER SURV, V27, P41; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; ONATE SA, 1995, SCIENCE, V270, P1354; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Powell SM, 2004, ENDOCR-RELAT CANCER, V11, P117, DOI 10.1677/erc.0.0110117; Sakakura C, 2000, INT J CANCER, V89, P217; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Snowden AW, 1998, BIOCHEM PHARMACOL, V55, P1947, DOI 10.1016/S0006-2952(98)00020-3; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	46	14	14	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1936	1945		10.1038/sj.onc.1208343	http://dx.doi.org/10.1038/sj.onc.1208343			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688032	Green Published			2022-12-25	WOS:000227542000012
J	Cole, SL; Grudzien, A; Manhart, IO; Kelly, BL; Oakley, H; Vassar, R				Cole, SL; Grudzien, A; Manhart, IO; Kelly, BL; Oakley, H; Vassar, R			Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; INTRANEURONAL A-BETA-42 ACCUMULATION; TOTAL CHOLESTEROL LEVEL; ALZHEIMERS-DISEASE; A-BETA; APOLIPOPROTEIN-E; DOWN-SYNDROME; MEVALONATE PATHWAY; BINDING PROTEIN; LIPID RAFTS	The use of statins, 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors that block the synthesis of mevalonate ( and downstream products such as cholesterol and nonsterol isoprenoids), as a therapy for Alzheimer disease is currently the subject of intense debate. It has been reported that statins reduce the risk of developing the disorder, and a link between cholesterol and Alzheimer disease pathophysiology has been proposed. Moreover, experimental studies focusing on the cholesterol-dependent effects of statins have demonstrated a close association between cellular cholesterol levels and amyloid production. However, evidence suggests that statins are pleiotropic, and the potential cholesterol-independent effects of statins on amyloid precursor protein (APP) metabolism and amyloid beta-peptide (A beta) genesis are unknown. In this study, we developed a novel in vitro system that enabled the discrete analysis of cholesterol-dependent and -independent (i.e. isoprenoid-dependent) statin effects on APP cleavage and A beta formation. Given the recent interest in the role that intracellular A beta may play in Alzheimer disease, we analyzed statin effects on both secreted and cell-associated A beta. As reported previously, low cellular cholesterol levels favored the alpha-secretase pathway and decreased A beta secretion presumably within the endocytic pathway. In contrast, low isoprenoid levels resulted in the accumulation of APP, amyloidogenic fragments, and A beta likely within biosynthetic compartments. Importantly, low cholesterol and low isoprenoid levels appeared to have completely independent effects on APP metabolism and A beta formation. Although the implications of these effects for Alzheimer disease pathophysiology have yet to be investigated, to our knowledge, these results provide the first evidence that isoprenylation is involved in determining levels of intracellular A beta.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Cole, SL (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.	s-cole4@northwestern.edu; r-vassar@northwestern.edu						Bi XN, 2004, J BIOL CHEM, V279, P48238, DOI 10.1074/jbc.M405442200; Blasko I, 2000, NEUROBIOL DIS, V7, P682, DOI 10.1006/nbdi.2000.0321; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; BROWN MS, 1980, J LIPID RES, V21, P505; Burns M, 2003, J NEUROSCI, V23, P5645; Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9; Buxbaum JD, 2001, J ALZHEIMERS DIS, V3, P221; Cataldo AM, 2004, NEUROBIOL AGING, V25, P1263, DOI 10.1016/j.neurobiolaging.2004.02.027; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; DUGAN JM, 1995, J BIOL CHEM, V270, P10982, DOI 10.1074/jbc.270.18.10982; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Frears ER, 1999, NEUROREPORT, V10, P1699, DOI 10.1097/00001756-199906030-00014; Galbete JL, 2000, BIOCHEM J, V348, P307, DOI 10.1042/0264-6021:3480307; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Goslin K., 1991, RAT HIPPOCAMPAL NEUR; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Gyure KA, 2001, ARCH PATHOL LAB MED, V125, P489; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEIDER JG, 1978, J LIPID RES, V19, P514; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; Honig LS, 2003, ARCH NEUROL-CHICAGO, V60, P1707, DOI 10.1001/archneur.60.12.1707; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Jin LW, 2004, AM J PATHOL, V164, P975, DOI 10.1016/S0002-9440(10)63185-9; Kato T, 2004, BBA-MOL BASIS DIS, V1689, P267, DOI 10.1016/j.bbadis.2004.04.006; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kim SH, 2004, J BIOL CHEM, V279, P48615, DOI 10.1074/jbc.C400396200; Kivipelto M, 2002, ANN INTERN MED, V137, P149, DOI 10.7326/0003-4819-137-3-200208060-00006; KNEBL J, 1994, MECH AGEING DEV, V73, P69, DOI 10.1016/0047-6374(94)90039-6; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Kuo YM, 1998, BIOCHEM BIOPH RES CO, V252, P711, DOI 10.1006/bbrc.1998.9652; Luchsinger JA, 2001, AM J EPIDEMIOL, V154, P635, DOI 10.1093/aje/154.7.635; Mason JC, 2003, CLIN SCI, V105, P251, DOI 10.1042/CS20030148; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; McConlogue L, 1996, J BIOL CHEM, V271, P1343, DOI 10.1074/jbc.271.3.1343; McIlroy SP, 2002, STROKE, V33, P2351, DOI 10.1161/01.STR.0000032550.90046.38; Meske V, 2003, EUR J NEUROSCI, V17, P93, DOI 10.1046/j.1460-9568.2003.02433.x; Mori C, 2002, AMYLOID, V9, P88, DOI 10.3109/13506120208995241; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Racchi M, 1997, BIOCHEM J, V322, P893, DOI 10.1042/bj3220893; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Ross SL, 1998, J BIOL CHEM, V273, P15309, DOI 10.1074/jbc.273.25.15309; Runz H, 2002, J NEUROSCI, V22, P1679, DOI 10.1523/JNEUROSCI.22-05-01679.2002; Schmitz C, 2004, AM J PATHOL, V164, P1495, DOI 10.1016/S0002-9440(10)63235-X; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sisodia SS, 1999, AM J HUM GENET, V65, P7, DOI 10.1086/302475; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2004, J MOL NEUROSCI, V23, P105, DOI 10.1385/JMN:23:1-2:105; Vicent D, 2000, MOL CELL BIOL, V20, P2158, DOI 10.1128/MCB.20.6.2158-2166.2000; Werner N, 2002, BASIC RES CARDIOL, V97, P105, DOI 10.1007/s003950200000; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Yamazaki T, 2001, J BIOL CHEM, V276, P4454, DOI 10.1074/jbc.M009598200; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1	71	120	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18755	18770		10.1074/jbc.M413895200	http://dx.doi.org/10.1074/jbc.M413895200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15718241	hybrid			2022-12-25	WOS:000228932300027
J	Flaig, R; Greschik, H; Peluso-Iltis, C; Moras, D				Flaig, R; Greschik, H; Peluso-Iltis, C; Moras, D			Structural basis for the cell-specific activities of the NGFI-B and the Nurr1 ligand-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTORS; RETINOID-X-RECEPTOR; PROTEIN-KINASE-A; COACTIVATOR RECRUITMENT; TRANSCRIPTION FACTOR; HORMONE RECEPTORS; CRYSTAL-STRUCTURE; NUR77; HETERODIMERIZATION; ACTIVATION	NGFI-B is a ligand-independent orphan nuclear receptor of the NR4A subfamily that displays important functional differences with its homolog Nurr1. In particular, the NGFI-B ligand-binding domain (LBD) exhibits only modest activity in cell lines in which the Nurr1 LBD strongly activates transcription. To gain insight into the structural basis for the distinct activation potentials, we determined the crystal structure of the NGFI-B LBD at 2.4-angstrom resolution. Superimposition with the Nurr1 LBD revealed a significant shift of the position of helix 12, potentially caused by conservative amino acids exchanges in helix 3 or helix 12. Replacement of the helix 11-12 region of Nurr1 with that of NGFI-B dramatically reduces the transcriptional activity of the Nurr1 LBD. Similarly, mutation of Met(414) in helix 3 to leucine or of Leu(591) in helix 12 to isoleucine (the corresponding residues found in NGFI-B) significantly affects Nurr1 transactivation. In comparison, swapping the helix 11-12 region of Nurr1 into NGFI-B results in a modest increase of activity. These observations reveal a high sensitivity of LBD activity to changes that influence helix 12 positioning. Furthermore, mutation of hydrophobic surface residues in the helix 11-12 region (outside the canonical co-activator surface constituted by helices 3, 4, and 12) severely affects Nurr1 transactivation. Together, our data suggest that a novel co-regulator surface that includes helix 11 and a specifically positioned helix 12 determine the cell type-dependent activities of the NGFI-B and the Nurr1 LBD.	ULP, CNRS, INSERM, IGBMC,Dept Biol & Genom Struct, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moras, D (corresponding author), ULP, CNRS, INSERM, IGBMC,Dept Biol & Genom Struct, 1 Rue Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	moras@igbmc.u-strasbg.fr						Aarnisalo P, 2002, J BIOL CHEM, V277, P35118, DOI 10.1074/jbc.M201707200; Auwerx J, 1999, CELL, V97, P161; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; Beitz E, 2000, BIOINFORMATICS, V16, P135, DOI 10.1093/bioinformatics/16.2.135; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Castillo SO, 1998, GENE EXPRESSION, V7, P1; Castro DS, 1999, J BIOL CHEM, V274, P37483, DOI 10.1074/jbc.274.52.37483; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; Codina A, 2004, J BIOL CHEM, V279, P53338, DOI 10.1074/jbc.M409096200; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Ethier I, 2004, NEUROPSYCHOPHARMACOL, V29, P335, DOI 10.1038/sj.npp.1300318; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Galleguillos D, 2004, J BIOL CHEM, V279, P2005, DOI 10.1074/jbc.M308113200; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Greschik I, 2003, CURR TOP MED CHEM, V3, P1573, DOI 10.2174/1568026033451736; He YW, 2002, J LEUKOCYTE BIOL, V72, P440; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kovalovsky D, 2002, MOL ENDOCRINOL, V16, P1638, DOI 10.1210/me.16.7.1638; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Le WD, 2003, NAT GENET, V33, P85, DOI 10.1038/ng1066; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Maira M, 2003, MOL CELL BIOL, V23, P763, DOI 10.1128/MCB.23.3.763-776.2003; Maira M, 1999, MOL CELL BIOL, V19, P7549; Maruyama K, 1998, INT J ONCOL, V12, P1237; Murphy EP, 1996, GENE EXPRESSION, V5, P169; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; Paulsen RE, 1995, J MOL NEUROSCI, V6, P249, DOI 10.1007/BF02736784; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Pissios P, 2000, MOL CELL, V6, P245, DOI 10.1016/S1097-2765(00)00026-5; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Slagsvold HH, 2002, BIOCHEM BIOPH RES CO, V291, P1146, DOI 10.1006/bbrc.2002.6579; Sohn YC, 2001, J BIOL CHEM, V276, P43734, DOI 10.1074/jbc.M107208200; Song KH, 2004, MOL ENDOCRINOL, V18, P1929, DOI 10.1210/me.2004-0043; SUTHERLAND JD, 1995, P NATL ACAD SCI USA, V92, P7966, DOI 10.1073/pnas.92.17.7966; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	50	97	100	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19250	19258		10.1074/jbc.M413175200	http://dx.doi.org/10.1074/jbc.M413175200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15716272	Green Published, hybrid			2022-12-25	WOS:000228932300082
J	Blundell, CD; Almond, A; Mahoney, DJ; DeAngelis, PL; Campbell, ID; Day, AJ				Blundell, CD; Almond, A; Mahoney, DJ; DeAngelis, PL; Campbell, ID; Day, AJ			Towards a structure for a TSG-6 center dot hyaluronan complex by modeling and NMR spectroscopy - Insights into other members of the link module superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PNEUMONIAE HYALURONATE LYASE; FACTOR-STIMULATED GENE-6; NECROSIS-FACTOR-ALPHA; MOLECULAR-DYNAMICS SIMULATIONS; BINDING PROTEIN TSG-6; SMOOTH-MUSCLE CELLS; EXTRACELLULAR-MATRIX; INDUCED ARTHRITIS; CRYSTAL-STRUCTURE; AQUEOUS-SOLUTION	The Link module from human TSG-6, a hyaladherin with roles in ovulation and inflammation, has a hyaluronan (HA)-binding groove containing two adjacent tyrosine residues that are likely to form CH-pi stacking interactions with sequential rings in the sugar. We have used this observation to construct a model of a protein center dot HA complex, which was then tested against existing experimental information and by acquisition of new NMR data sets of [C-13, N-15] HA (8-mer) complexed with unlabeled protein. A major finding of this analysis was that acetamido side chains of two GlcNAc rings fit into hydrophobic pockets on either side of the adjacent tyrosines, providing a selectivity mechanism of HA over other polysaccharides. Furthermore, two basic residues have a separation that matches that of glucuronic acids in the sugar, consistent with the formation of salt bridges; NMR experiments at a range of pH values identified protein groups that titrate due to their proximity to a free carboxylate in HA. Sequence alignment and construction of homology models for all human Link modules in their HA-bound states revealed that many of these features are conserved across the superfamily, thus allowing the prediction of functionally important residues. In the case of cartilage link protein, its two Link modules were docked together ( using bound HA as a guide), identifying hydrophobic residues likely to form an intra-Link module interface as well as amino acids that could be involved in supporting intermolecular interactions between link proteins and chondroitin sulfate proteoglycans. Here, we propose a mechanism for ternary complex formation that generates higher order helical structures, as may exist in cartilage aggregates.	Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	University of Oxford; University of Oklahoma System; University of Oklahoma Health Sciences Center	Day, AJ (corresponding author), Univ Oxford, Dept Biochem, MRC, Immunochem Unit, South Pks Rd, Oxford OX1 3QU, England.	tony.day@bioch.ox.ac.uk	Day, Anthony/O-1658-2015	Day, Anthony/0000-0002-1415-3134; Blundell, Charles/0000-0002-1439-9126; Almond, Andrew/0000-0001-7471-6333	MRC [MC_U138274352] Funding Source: UKRI; Medical Research Council [MC_U138274352] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Almond A, 1998, GLYCOBIOLOGY, V8, P973, DOI 10.1093/glycob/8.10.973; Almond A, 1997, GLYCOBIOLOGY, V7, P597, DOI 10.1093/glycob/7.5.597; Almond A, 2004, BIOCHEMISTRY-US, V43, P5853, DOI 10.1021/bi0354886; Almond A, 2000, J PHYS CHEM B, V104, P5634, DOI 10.1021/jp000402t; ATKINS EDT, 1972, BIOCHEM J, V128, P1255, DOI 10.1042/bj1281255; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P42, DOI 10.1053/joca.2000.0348; Beisel HG, 1999, EMBO J, V18, P2313, DOI 10.1093/emboj/18.9.2313; Blundell C. D., 2002, HYALURONAN, P161; Blundell CD, 2004, CHEMISTRY AND BIOLOGY OF HYALURONAN, P189; Blundell CD, 2004, GLYCOBIOLOGY, V14, P999, DOI 10.1093/glycob/cwh117; Blundell CD, 2003, J BIOL CHEM, V278, P49261, DOI 10.1074/jbc.M309623200; BROCCHIERI L, 1994, P NATL ACAD SCI USA, V91, P9297, DOI 10.1073/pnas.91.20.9297; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Bush CA, 1999, ANNU REV BIOPH BIOM, V28, P269, DOI 10.1146/annurev.biophys.28.1.269; Carrette O, 2001, BIOL REPROD, V65, P301, DOI 10.1095/biolreprod65.1.301; CHRISTNER JE, 1979, J BIOL CHEM, V254, P2303; COWMAN MK, 1984, ARCH BIOCHEM BIOPHYS, V230, P203, DOI 10.1016/0003-9861(84)90101-2; Cowman MK, 1996, MACROMOLECULES, V29, P2894, DOI 10.1021/ma951701x; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; Day AJ, 2001, CURR OPIN STRUC BIOL, V11, P617, DOI 10.1016/S0959-440X(00)00256-6; DAY AJ, 2004, HYAL 2003 P OCT 11 1; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022; Fujimoto T, 2002, AM J PATHOL, V160, P1495, DOI 10.1016/S0002-9440(10)62575-8; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Glant TT, 2002, ARTHRITIS RHEUM-US, V46, P2207, DOI 10.1002/art.10555; HOLMBECK SMA, 1994, BIOCHEMISTRY-US, V33, P14246, DOI 10.1021/bi00251a037; Jackson DG, 2003, TRENDS CARDIOVAS MED, V13, P1, DOI 10.1016/S1050-1738(02)00189-5; Jedrzejas MJ, 2002, J BIOL CHEM, V277, P28287, DOI 10.1074/jbc.M112009200; Johnson MA, 2004, CARBOHYD RES, V339, P907, DOI 10.1016/j.carres.2003.12.028; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; Kogelberg H, 2003, CURR OPIN STRUC BIOL, V13, P646, DOI 10.1016/j.sbi.2003.08.001; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; Li SL, 2001, J BIOL CHEM, V276, P41407, DOI 10.1074/jbc.M106634200; Mahoney DJ, 2004, ANAL BIOCHEM, V330, P123, DOI 10.1016/j.ab.2004.03.055; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6; Matsumoto K, 2003, J BIOL CHEM, V278, P41205, DOI 10.1074/jbc.M305060200; Mello LV, 2002, J BIOL CHEM, V277, P36678, DOI 10.1074/jbc.M205140200; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Mindrescu C, 2002, ARTHRITIS RHEUM, V46, P2453, DOI 10.1002/art.10503; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Nukui M, 2003, J BIOL CHEM, V278, P3079, DOI 10.1074/jbc.M204999200; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P4376, DOI 10.1210/en.2003-0487; Parkar AA, 1997, FEBS LETT, V410, P413, DOI 10.1016/S0014-5793(97)00621-2; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; Ponnuraj K, 2000, J MOL BIOL, V299, P885, DOI 10.1006/jmbi.2000.3817; Prevo R, 2004, J BIOL CHEM, V279, P52580, DOI 10.1074/jbc.M406897200; QUIOCHO FA, 1993, BIOCHEM SOC T, V21, P442, DOI 10.1042/bst0210442; Rauch U, 2004, MATRIX BIOL, V22, P629, DOI 10.1016/j.matbio.2003.11.007; Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056; Seyfried NT, 2005, J BIOL CHEM, V280, P5435, DOI 10.1074/jbc.M411297200; Seyfried NT, 2005, GLYCOBIOLOGY, V15, P303, DOI 10.1093/glycob/cwi008; SICINSKA W, 1993, CARBOHYD RES, V242, P29, DOI 10.1016/0008-6215(93)80020-F; Spicer AP, 2003, J BIOL CHEM, V278, P21083, DOI 10.1074/jbc.M213100200; Szanto S, 2004, ARTHRITIS RHEUM-US, V50, P3012, DOI 10.1002/art.20655; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Teriete P, 2004, MOL CELL, V13, P483, DOI 10.1016/S1097-2765(04)00080-2; Thompson SE, 2002, J AM CHEM SOC, V124, P442, DOI 10.1021/ja011973h; TOFFANIN R, 1993, CARBOHYD RES, V245, P113, DOI 10.1016/0008-6215(93)80064-L; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Wight TN, 2004, CIRC RES, V94, P1158, DOI 10.1161/01.RES.0000126921.29919.51; Wisniewski HG, 2004, CYTOKINE GROWTH F R, V15, P129, DOI 10.1016/j.cytogfr.2004.01.005; Ye L, 1997, CIRC RES, V81, P289, DOI 10.1161/01.RES.81.3.289	70	62	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18189	18201		10.1074/jbc.M414343200	http://dx.doi.org/10.1074/jbc.M414343200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15718240	hybrid			2022-12-25	WOS:000228807200077
J	Conti, BJ; Davis, BK; Zhang, JH; O'Connor, W; Williams, KL; Ting, JPY				Conti, BJ; Davis, BK; Zhang, JH; O'Connor, W; Williams, KL; Ting, JPY			CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CLASS-II TRANSACTIVATOR; CONTAINING APAF1-LIKE PROTEIN; INFLAMMATORY-BOWEL-DISEASE; BARE LYMPHOCYTE SYNDROME; RICH REPEAT DOMAINS; CROHNS-DISEASE; NUCLEAR EXPORT; CUTTING EDGE; BACTERIAL PEPTIDOGLYCAN	The newly discovered mammalian CATERPILLER (NOD, NALP, PAN) family of proteins share similarities with the NBD-LRR superfamily of plant disease resistance (R) proteins and are predicted to mediate important immune regulatory function. This report describes the first cloning and characterization of a novel CATERPILLER gene, CLR16.2 that is located on human chromosome 16. The protein encoded by this gene has a typical NBD-LRR configuration. Analysis of CLR16.2 suggests the highest expression among T lymphocytes. Cellular localization studies of CLR16.2 revealed that it is a cytoplasmic protein. Querying microarray studies in the public data base showed that CLR16.2 was significantly (>90%) down-regulated 6 h after anti-CD3 and anti-CD28 stimulation of primary T lymphocytes. Its reduction upon T cell stimulation is consistent with a potential negative regulatory role. Indeed CLR16.2 decreased NF-kappa B, NFAT, and AP-1 induction of reporter gene constructs in response to T cell activation by anti-CD3 and anti-CD28 antibodies or PMA and ionomycin. Following T cell stimulation, the presence of CLR16.2 reduced the levels of the endogenous transcripts for the IL-2 and CD25 proteins that are central in maintaining T cell activation and preventing T cell anergy. This reduction was accompanied by a delay of I kappa B alpha degradation. We propose that CLR16.2 serves to attenuate T cell activation via TCR and co-stimulatory molecules, and its reduction during T cell stimulation allows the ensuing cellular activation.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ting, JPY (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	panyun@med.unc.edu			NIAID NIH HHS [AI54309, AI29564] Funding Source: Medline; NIDDK NIH HHS [DK38108] Funding Source: Medline; NINDS NIH HHS [NS34910] Funding Source: Medline; PHS HHS [41751, 45580] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029564, R56AI029564, R01AI029564, R01AI054309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038108] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Beutler B, 2001, IMMUNITY, V15, P5, DOI 10.1016/S1074-7613(01)00176-5; Boldrick JC, 2002, P NATL ACAD SCI USA, V99, P972, DOI 10.1073/pnas.231625398; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Cressman DE, 2001, J IMMUNOL, V167, P3626, DOI 10.4049/jimmunol.167.7.3626; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; Diehn M, 2002, P NATL ACAD SCI USA, V99, P11796, DOI 10.1073/pnas.092284399; Dode C, 2002, AM J HUM GENET, V70, P1498, DOI 10.1086/340786; Dowds TA, 2003, BIOCHEM BIOPH RES CO, V302, P575, DOI 10.1016/S0006-291X(03)00221-3; DOWDS TA, 2004, J BIOL CHEM; Galfalvy HC, 2003, BMC BIOINFORMATICS, V4, P1, DOI 10.1186/1471-2105-4-37; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Girardin SE, 2003, TRENDS IMMUNOL, V24, P652, DOI 10.1016/j.it.2003.10.007; Gollub J, 2003, NUCLEIC ACIDS RES, V31, P94, DOI 10.1093/nar/gkg078; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Hampe J, 2002, P NATL ACAD SCI USA, V99, P321, DOI 10.1073/pnas.261567999; Harton JA, 2002, J IMMUNOL, V169, P4088, DOI 10.4049/jimmunol.169.8.4088; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; Hillig RC, 1999, MOL CELL, V3, P781, DOI 10.1016/S1097-2765(01)80010-1; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hollander GA, 1999, SEMIN IMMUNOL, V11, P357; Huang SG, 2004, GENOMICS, V84, P767, DOI 10.1016/j.ygeno.2004.06.013; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kim HP, 2002, EMBO J, V21, P3051, DOI 10.1093/emboj/cdf321; Kobayashi KS, 2003, NAT IMMUNOL, V4, P652, DOI 10.1038/ni0703-652; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; LI J, 2005, IN PRESS PHYSL GENOM; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin Jian-Xin, 1997, Cytokine and Growth Factor Reviews, V8, P313; Linhoff MW, 2001, MOL CELL BIOL, V21, P3001, DOI 10.1128/MCB.21.9.3001-3011.2001; Lord GM, 1999, IMMUNOL TODAY, V20, P33, DOI 10.1016/S0167-5699(98)01379-6; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Nel AE, 2002, J ALLERGY CLIN IMMUN, V109, P901, DOI 10.1067/mai.2002.124965; Neven B, 2004, BLOOD, V103, P2809, DOI 10.1182/blood-2003-07-2531; Nurnberger T, 2002, CURR OPIN PLANT BIOL, V5, P318, DOI 10.1016/S1369-5266(02)00265-0; O'Connor W, 2003, J IMMUNOL, V171, P6329, DOI 10.4049/jimmunol.171.12.6329; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; Williams KL, 2003, J IMMUNOL, V170, P5354, DOI 10.4049/jimmunol.170.11.5354; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Wong AW, 2003, NAT IMMUNOL, V4, P891, DOI 10.1038/ni960; Young ND, 2000, CURR OPIN PLANT BIOL, V3, P285, DOI 10.1016/S1369-5266(00)00081-9	68	100	102	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18375	18385		10.1074/jbc.M413169200	http://dx.doi.org/10.1074/jbc.M413169200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15705585	hybrid, Green Published			2022-12-25	WOS:000228807200099
J	Demuro, A; Mina, E; Kayed, R; Milton, SC; Parker, I; Glabe, CG				Demuro, A; Mina, E; Kayed, R; Milton, SC; Parker, I; Glabe, CG			Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN MISFOLDING DISEASES; ALZHEIMERS-DISEASE; BETA-PEPTIDE; COMMON MECHANISM; LIPID-BILAYERS; PRECURSOR PROTEIN; FIBRIL FORMATION; CHANNELS; HYPOTHESIS; APOPTOSIS	Increasing evidence suggests that amyloid peptides associated with a variety of degenerative diseases induce neurotoxicity in their intermediate oligomeric state, rather than as monomers or fibrils. To test this hypothesis and investigate the possible involvement of Ca2+ signaling disruptions in amyloid-induced cytotoxicity, we made homogeneous preparations of disease-related amyloids (A beta, prion, islet amyloid polypeptide, polyglutamine, and lysozyme) in various aggregation states and tested their actions on fluo-3-loaded SH-SY5Y cells. Application of oligomeric forms of all amyloids tested (0.6 -6 mu g ml(-1)) rapidly (similar to 5 s) elevated intracellular Ca2+, whereas equivalent amounts of monomers and fibrils did not. Ca2+ signals evoked by A beta 42 oligomers persisted after depletion of intracellular Ca2+ stores, and small signals remained in Ca2+-free medium, indicating contributions from both extracellular and intracellular Ca2+ sources. The increased membrane permeability to Ca2+ cannot be attributed to activation of endogenous Ca2+ channels, because responses were unaffected by the potent Ca2+-channel blocker cobalt (20 mu m). Instead, observations that A beta 42 and other oligomers caused rapid cellular leakage of anionic fluorescent dyes point to a generalized increase in membrane permeability. The resulting unregulated flux of ions and molecules may provide a common mechanism for oligomer-mediated toxicity in many amyloidogenic diseases, with dysregulation of Ca2+ ions playing a crucial role because of their strong trans-membrane concentration gradient and involvement in cell dysfunction and death.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Glabe, CG (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3238 McGaugh Hall, Irvine, CA 92697 USA.	cglabe@uci.edu			NIA NIH HHS [AG00538] Funding Source: Medline; NIGMS NIH HHS [GM48071] Funding Source: Medline; NINDS NIH HHS [NS31230] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048071, R01GM048071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG000538] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anguiano M, 2002, BIOCHEMISTRY-US, V41, P11338, DOI 10.1021/bi020314u; Arispe N, 2004, J MEMBRANE BIOL, V197, P33, DOI 10.1007/s00232-003-0638-7; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; Avdulov NA, 1997, J NEUROCHEM, V69, P1746; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Blanchard BJ, 2004, P NATL ACAD SCI USA, V101, P14326, DOI 10.1073/pnas.0405941101; Bucciantini M, 2004, J BIOL CHEM, V279, P31374, DOI 10.1074/jbc.M400348200; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BURDICK D, 1992, J BIOL CHEM, V267, P546; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Dobson CM, 2004, SCIENCE, V304, P1259, DOI 10.1126/science.1093078; Glabe CG, 2004, TRENDS BIOCHEM SCI, V29, P542, DOI 10.1016/j.tibs.2004.08.009; Green JD, 2004, J MOL BIOL, V342, P877, DOI 10.1016/j.jmb.2004.07.052; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hirakura Y, 1999, J NEUROSCI RES, V57, P458, DOI 10.1002/(SICI)1097-4547(19990815)57:4<458::AID-JNR5>3.0.CO;2-4; Kagan BL, 2002, PEPTIDES, V23, P1311, DOI 10.1016/S0196-9781(02)00067-0; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Kawahara M, 1997, BIOPHYS J, V73, P67, DOI 10.1016/S0006-3495(97)78048-2; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 2002, J BIOL CHEM, V277, P42881, DOI 10.1074/jbc.M206593200; Li YP, 1996, BRAIN RES, V738, P196, DOI 10.1016/S0006-8993(96)00733-0; Lin MCA, 2002, PEPTIDES, V23, P1215, DOI 10.1016/S0196-9781(02)00057-8; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Mason RP, 1996, ANN NY ACAD SCI, V777, P368, DOI 10.1111/j.1749-6632.1996.tb34447.x; Mattson MP, 2003, NAT CELL BIOL, V5, P1041, DOI 10.1038/ncb1203-1041; MATTSON MP, 1992, NEUROBIOL AGING, V13, P617, DOI 10.1016/0197-4580(92)90068-9; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; MULLER WE, 1995, BRAIN RES, V674, P133, DOI 10.1016/0006-8993(94)01463-R; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Pierrot N, 2004, J NEUROCHEM, V88, P1140, DOI 10.1046/j.1471-4159.2003.02227.x; Relini A, 2004, J MOL BIOL, V338, P943, DOI 10.1016/j.jmb.2004.03.054; SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989; SELKOE DJ, 1991, SCI AM, V265, P40, DOI 10.1038/scientificamerican1191-68; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Stutzmann GE, 2004, J NEUROSCI, V24, P508, DOI 10.1523/JNEUROSCI.4386-03.2004; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Tucker HM, 1998, J NEUROCHEM, V71, P506	47	788	813	5	145	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17294	17300		10.1074/jbc.M500997200	http://dx.doi.org/10.1074/jbc.M500997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722360	hybrid			2022-12-25	WOS:000228615500093
J	Hernick, M; Gennadios, HA; Whittington, DA; Rusche, KM; Christianson, DW; Fierke, CA				Hernick, M; Gennadios, HA; Whittington, DA; Rusche, KM; Christianson, DW; Fierke, CA			UDP-3-O-((R)-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase functions through a general acid-base catalyst pair mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-DEPENDENT DEACETYLASE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI ENCODES; ENDOTOXIN BIOSYNTHESIS; UDP-3-O-(R-3-HYDROXYMYRISTOYL)-N-ACETYLGLUCOSAMINE DEACETYLASE; MOLECULAR REPLACEMENT; ANTIBACTERIAL AGENTS; ENZYME-SYSTEMS; LPXC; INHIBITORS	UDP-3-O-(( R)-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase ( LpxC) is a zinc-dependent enzyme that catalyzes the deacetylation of UDP-3-O-(( R)-3-hydroxymyristoyl)N- acetylglucosamine to form UDP-3-O-(R-hydroxymyristoyl) glucosamine and acetate. The structural similarity of the active site of LpxC to metalloproteases led to the proposal that LpxC functions via a metalloprotease-like mechanism. The pH dependence of k(cat)/K-m catalyzed by Escherichia coli and Aquifex aeolicus LpxC displayed a bell-shaped curve ( EcLpxC yields apparent pK(a) values of 6.4 +/- 0.1 and 9.1 +/- 0.1), demonstrating that at least two ionizations are important for maximal activity. Metal substitution and mutagenesis experiments suggest that the basic limb of the pH profile is because of deprotonation of a zinc-coordinated group such as the zinc-water molecule, whereas the acidic limb of the pH profile is caused by protonation of either Glu(78) or His(265). Furthermore, the magnitude of the activity decreases and synergy observed for the active site mutants suggest that Glu(78) and His(265) act as a general acid-base catalyst pair. Crystal structures of LpxC complexed with cacodylate or palmitate demonstrate that both Glu(78) and His(265) hydrogenbond with the same oxygen atom of the tetrahedral intermediate and the product carboxylate. These structural features suggest that LpxC catalyzes deacetylation by using Glu(78) and His(265) as a general acid-base pair and the zinc-bound water as a nucleophile.	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	University of Michigan System; University of Michigan; University of Pennsylvania	Fierke, CA (corresponding author), Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.	fierke@umich.edu		Hernick, Marcy/0000-0002-2839-5767	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040602, R01GM040602] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40602, GM49758] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; [Anonymous], 2003, COMPREHENSIVE COORDI, DOI DOI 10.1016/B0-08-043748-6/08139-1; Bachovchin WW, 2001, MAGN RESON CHEM, V39, pS199, DOI 10.1002/mrc.951; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cha J, 1997, BIOCHEMISTRY-US, V36, P16019, DOI 10.1021/bi972223g; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; CLELAND WW, 1982, METHOD ENZYMOL, V87, P390; Clements JM, 2002, ANTIMICROB AGENTS CH, V46, P1793, DOI 10.1128/AAC.46.6.1793-1799.2002; Coggins BE, 2003, NAT STRUCT BIOL, V10, P645, DOI 10.1038/nsb948; Coggins BE, 2005, BIOCHEMISTRY-US, V44, P1114, DOI 10.1021/bi047820z; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fersht A., 1999, STRUCTURE MECH PROTE, P169; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; Hernick M, 2005, ARCH BIOCHEM BIOPHYS, V433, P71, DOI 10.1016/j.abb.2004.08.006; Huheey J.E., 1993, INORGANIC CHEM PRINC, P318; Jackman JE, 1999, BIOCHEMISTRY-US, V38, P1902, DOI 10.1021/bi982339s; Jackman JE, 2000, J BIOL CHEM, V275, P11002, DOI 10.1074/jbc.275.15.11002; Jackman JE, 2001, BIOCHEMISTRY-US, V40, P514, DOI 10.1021/bi001872g; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLY TM, 1993, J BIOL CHEM, V268, P19866; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; Manocha S, 2002, EXPERT OPIN INV DRUG, V11, P1795, DOI 10.1517/13543784.11.12.1795; McClerren AL, 2005, BIOCHEMISTRY-US, V44, P1106, DOI 10.1021/bi048001h; McClure CP, 2003, J INORG BIOCHEM, V94, P78, DOI 10.1016/S0162-0134(02)00611-6; MERKLER DJ, 1993, BIOCHEMISTRY-US, V32, P5792, DOI 10.1021/bi00073a011; Mildvan AS, 2004, BIOCHEMISTRY-US, V43, P14517, DOI 10.1021/bi048052e; MILDVAN AS, 1992, ARCH BIOCHEM BIOPHYS, V294, P327, DOI 10.1016/0003-9861(92)90692-P; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Pirrung MC, 2002, J MED CHEM, V45, P4359, DOI 10.1021/jm020183v; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; Sorensen PG, 1996, J BIOL CHEM, V271, P25898, DOI 10.1074/jbc.271.42.25898; SRERE PA, 1961, BIOCHIM BIOPHYS ACTA, V50, P184, DOI 10.1016/0006-3002(61)91081-2; WETTERHOLM A, 1992, P NATL ACAD SCI USA, V89, P9141, DOI 10.1073/pnas.89.19.9141; White RJ, 2003, CURR OPIN PHARMACOL, V3, P502, DOI 10.1016/S1471-4892(03)00115-2; Whittington DA, 2003, P NATL ACAD SCI USA, V100, P8146, DOI 10.1073/pnas.1432990100; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; Young K, 1995, J BIOL CHEM, V270, P30384, DOI 10.1074/jbc.270.51.30384	43	50	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16969	16978		10.1074/jbc.M413560200	http://dx.doi.org/10.1074/jbc.M413560200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15705580	hybrid			2022-12-25	WOS:000228615500053
J	Roldan, A; Warren, OU; Russell, RS; Liang, C; Wainberg, MA				Roldan, A; Warren, OU; Russell, RS; Liang, C; Wainberg, MA			A HIV-1 minimal gag protein is superior to nucleocapsid at in vitro tRNA(3)(Lys) annealing and exhibits multimerization-induced inhibition of reverse transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PRIMER ACTIVATION SIGNAL; TYPE-1 GAG; TRANSFER-RNA; CAPSID PROTEIN; BINDING-SITE; GENOMIC RNA; RECOGNITION ELEMENT; SECONDARY STRUCTURE; VIRAL-RNA	HIV-1 uses tRNA(3)(Lys) to prime reverse transcription of its viral RNA. In this process, the 3'-end of tRNA(3)(Lys) must be annealed to the primer binding site of HIV-1 genomic RNA, and the two molecules together form a complex structure. During annealing, the nucleocapsid (NC) protein enhances the unwinding of tertiary structures within both RNA molecules. Moreover, the packaging of tRNA(3)(Lys) occurs prior to viral budding at a time when NC is still part of the Pr55(Gag) polyprotein. In contrast, Pr55(Gag) is able to produce virus-like particles on its own. We have recently shown that an N-terminal extended form of NC (mGag), containing all of the minimal elements required for virus-like particle formation, possesses greater affinity for HIV-1 genomic RNA than does NC alone. We have now studied the tRNA(3)(Lys)- annealing properties of mGag in comparison to those of NC and report that the former is more efficient in this regard than the latter. We have also tested each of a mutant version of mGag, an extended form of mGag, and an almost full-length form of Gag, and showed that all of these possessed greater tRNA-annealing capacity than did the viral NC protein. Yet, surprisingly, multimerization of Gag-related proteins did not abrogate this annealing process but rather resulted in dramatically reduced levels of reverse transcriptase processivity. These results suggest that the initial stages of reverse transcription may be regulated by the multimerization of Pr55(Gag) polyprotein at times prior to the cleavage of NC.	Jewish Gen Hosp, Lady Davis Inst, McGill AIDS Ctr, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Div Expt Med, Montreal, PQ H3A 2B4, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Wainberg, MA (corresponding author), Jewish Gen Hosp, Lady Davis Inst, McGill AIDS Ctr, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	mark.wainberg@mcgill.ca	Russell, Rod/AAU-3109-2021	Roldan, Ariel/0000-0002-8159-5450				Abbink TEM, 2003, J BIOL CHEM, V278, P11601, DOI 10.1074/jbc.M210291200; Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000; Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979; Andersen ES, 2003, J VIROL, V77, P3020, DOI 10.1128/JVI.77.5.3020-3030.2003; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; Beerens N, 2002, J VIROL, V76, P2329, DOI 10.1128/JVI.76.5.2329-2339.2002; Beerens N, 2001, J BIOL CHEM, V276, P31247, DOI 10.1074/jbc.M102441200; BERKOWITZ RD, 1993, J VIROL, V67, P7190, DOI 10.1128/JVI.67.12.7190-7200.1993; Borsetti A, 1998, J VIROL, V72, P9313, DOI 10.1128/JVI.72.11.9313-9317.1998; Burniston MT, 1999, J VIROL, V73, P8527, DOI 10.1128/JVI.73.10.8527-8540.1999; Callahan EM, 2003, J VIROL, V77, P9388, DOI 10.1128/JVI.77.17.9388-9398.2003; Campbell S, 1999, J VIROL, V73, P2270, DOI 10.1128/JVI.73.3.2270-2279.1999; Cen S, 2000, J VIROL, V74, P10796, DOI 10.1128/JVI.74.22.10796-10800.2000; Cen S, 2001, J VIROL, V75, P5043, DOI 10.1128/JVI.75.11.5043-5048.2001; CHAZAL N, 1994, J VIROL, V68, P111, DOI 10.1128/JVI.68.1.111-122.1994; CLEVER J, 1995, J VIROL, V69, P2101, DOI 10.1128/JVI.69.4.2101-2109.1995; CRAWFORD S, 1985, J VIROL, V53, P899, DOI 10.1128/JVI.53.3.899-907.1985; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; Feng YX, 1999, J VIROL, V73, P4251, DOI 10.1128/JVI.73.5.4251-4256.1999; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; Gao K, 2003, J VIROL, V77, P1598, DOI 10.1128/JVI.77.2.1598-1603.2003; Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000; Huang Y, 1997, J VIROL, V71, P726, DOI 10.1128/JVI.71.1.726-728.1997; Huang Y, 1997, J VIROL, V71, P4378, DOI 10.1128/JVI.71.6.4378-4384.1997; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; ISEL C, 1993, J BIOL CHEM, V268, P25269; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Kaye JF, 1998, J VIROL, V72, P5877, DOI 10.1128/JVI.72.7.5877-5885.1998; Kleiman L, 2002, IUBMB LIFE, V53, P107, DOI 10.1080/15216540211469; KLEIMAN L, 1991, BIOCHEM BIOPH RES CO, V174, P1272, DOI 10.1016/0006-291X(91)91559-U; Liang C, 2002, J VIROL, V76, P11729, DOI 10.1128/JVI.76.22.11729-11737.2002; LITVAK S, 1994, TRENDS BIOCHEM SCI, V19, P114, DOI 10.1016/0968-0004(94)90203-8; Mak J, 1997, J MOL BIOL, V265, P419, DOI 10.1006/jmbi.1996.0742; Maki AH, 2001, BIOCHEMISTRY-US, V40, P1403, DOI 10.1021/bi002010i; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; MELY Y, 1995, J BIOL CHEM, V270, P1650, DOI 10.1074/jbc.270.4.1650; Morikawa Y, 2000, J VIROL, V74, P16, DOI 10.1128/JVI.74.1.16-23.2000; Paillart JC, 2002, J BIOL CHEM, V277, P5995, DOI 10.1074/jbc.M108972200; Provitera P, 2001, BIOCHEMISTRY-US, V40, P5565, DOI 10.1021/bi002040l; Roldan A, 2004, J BIOL CHEM, V279, P39886, DOI 10.1074/jbc.M405632200; Russell RS, 2003, J VIROL, V77, P12986, DOI 10.1128/JVI.77.24.12986-12995.2003; SAKAGUCHI K, 1993, P NATL ACAD SCI USA, V90, P5219, DOI 10.1073/pnas.90.11.5219; Shubsda MF, 2002, BIOCHEMISTRY-US, V41, P5276, DOI 10.1021/bi016045+; STEWART L, 1990, J VIROL, V64, P5076, DOI 10.1128/JVI.64.10.5076-5092.1990; von Schwedler UK, 2003, J VIROL, V77, P5439, DOI 10.1128/JVI.77.9.5439-5450.2003; VONPOBLOTZKI A, 1993, VIROLOGY, V193, P981, DOI 10.1006/viro.1993.1210; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; Zabransky A, 2002, VIROLOGY, V294, P141, DOI 10.1006/viro.2001.1315	53	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17488	17496		10.1074/jbc.M501310200	http://dx.doi.org/10.1074/jbc.M501310200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731102	hybrid			2022-12-25	WOS:000228615500116
J	Handy, DE; Zhang, YF; Loscalzo, J				Handy, DE; Zhang, YF; Loscalzo, J			Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE INSERTION-SEQUENCE; ENDOPLASMIC-RETICULUM STRESS; CYSTATHIONINE BETA-SYNTHASE; VASCULAR ENDOTHELIAL-CELLS; MESSENGER-RNA STABILITY; ACCELERATES ATHEROSCLEROSIS; SELENOPROTEIN SYNTHESIS; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; MEDIATED DECAY	Hyperhomocysteinemia contributes to vascular dysfunction and an increase in the risk of cardiovascular disease. An elevated level of homocysteine in vivo and in cell culture systems results in a decrease in the activity of cellular glutathione peroxidase (GPx1), an intracellular antioxidant enzyme that reduces hydrogen peroxide and lipid peroxides. In this study, we show that homocysteine interferes with GPx1 protein expression without affecting transcript levels. Expression of the selenocysteine (SEC)-containing GPx1 protein requires special translational cofactors to "read-through" a UGA-stop codon that specifies SEC incorporation at the active site of the enzyme. These factors include a selenocysteine incorporation sequence ( SECIS) in the 3'-untranslated region of the GPx1 mRNA and cofactors involved in the biosynthesis and translational insertion of SEC. To monitor SEC incorporation, we used a reporter gene system that has a UGA codon within the protein-coding region of the luciferase mRNA. Addition of either the GPx1 or GPx3 SECIS element in the 3'-untranslated region of the luciferase gene stimulated read-through by 6 - 11-fold in selenium-replete cells; absence of selenium prevented translation. To alter cellular homocysteine production, we used methionine in the presence of aminopterin, a folate antagonist, co-administered with hypoxanthine and thymidine (HAT/Met). This treatment increased homocysteine levels in the media by 30% ( p < 0.01) and decreased GPx1 enzyme activity by 45% ( p = 0.0028). HAT/Met treatment decreased selenium-mediated read-through significantly ( p < 0.001) in luciferase constructs containing the GPx1 or GPx3 SECIS element; most importantly, the suppression of selenium-dependent read-through was similar whether an SV40 promoter or the GPx1 promoter was used to drive transcription of the SECIS-containing constructs. Furthermore, HAT/Met had no effect on steady-state GPx1 mRNA levels but decreased GPx1 protein levels, suggesting that this effect is not transcriptionally mediated. These data support the conclusion that homocysteine decreases GPx1 activity by altering the translational mechanism essential for the synthesis of this selenocysteine-containing protein.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA	Boston University	Loscalzo, J (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W507, Boston, MA 02118 USA.	jloscalz@bu.edu	Loscalzo, Joseph/ABD-8980-2021	Handy, Diane/0000-0002-4310-8527	DIVISION OF HEART AND VASCULAR DISEASES [N01HV028178] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061795, P50HL055993, R37HL061795] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55993, HL58796, N01 HV28178, HL61795] Funding Source: Medline	DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antony AC, 2004, J CLIN INVEST, V113, P285, DOI 10.1172/JCI200411548; BAKER RD, 1993, ARCH BIOCHEM BIOPHYS, V304, P53, DOI 10.1006/abbi.1993.1320; BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BERRY MJ, 1994, NUCLEIC ACIDS RES, V22, P3753, DOI 10.1093/nar/22.18.3753; Chen CY, 2000, J SURG RES, V88, P26, DOI 10.1006/jsre.1999.5756; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cheng WH, 1997, J NUTR, V127, P1445, DOI 10.1093/jn/127.8.1445; CHRISTENSEN B, 1991, J CELL PHYSIOL, V146, P52, DOI 10.1002/jcp.1041460108; Copeland PR, 1999, J BIOL CHEM, V274, P25447, DOI 10.1074/jbc.274.36.25447; de Koning ABL, 2003, CLIN BIOCHEM, V36, P431, DOI 10.1016/S0009-9120(03)00062-6; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; Eberhardt RT, 2000, J CLIN INVEST, V106, P483, DOI 10.1172/JCI8342; Ferraiuolo MA, 2004, P NATL ACAD SCI USA, V101, P4118, DOI 10.1073/pnas.0400933101; FINKELSTEIN JD, 1971, ARCH BIOCHEM BIOPHYS, V146, P84, DOI 10.1016/S0003-9861(71)80044-9; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; Grundner-Culemann E, 1999, RNA, V5, P625, DOI 10.1017/S1355838299981542; Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588; Huang RFS, 2001, J NUTR, V131, P33, DOI 10.1093/jn/131.1.33; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Leonard JL, 1996, J CELL BIOCHEM, V61, P410, DOI 10.1002/(SICI)1097-4644(19960601)61:3<410::AID-JCB8>3.0.CO;2-W; Lescure A, 2002, CURR PROTEIN PEPT SC, V3, P143, DOI 10.2174/1389203023380783; Lesoon A, 1997, MOL CELL BIOL, V17, P1977, DOI 10.1128/MCB.17.4.1977; Martin GW, 1996, RNA, V2, P171; Martin GW, 2001, GENES CELLS, V6, P121, DOI 10.1046/j.1365-2443.2001.00402.x; Mehta A, 2004, J BIOL CHEM, V279, P37852, DOI 10.1074/jbc.M404639200; Merante F, 2002, MOL CELL BIOCHEM, V229, P73, DOI 10.1023/A:1017921110363; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Muller C, 2003, BIOL CHEM, V384, P11, DOI 10.1515/BC.2003.002; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; Refsum H, 2004, CLIN CHEM, V50, P3, DOI 10.1373/clinchem.2003.021634; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; SHEN QC, 1995, RNA, V1, P519; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Tan MJ, 1999, J BIOL CHEM, V274, P12061, DOI 10.1074/jbc.274.17.12061; Title LM, 2000, J AM COLL CARDIOL, V36, P758, DOI 10.1016/S0735-1097(00)00809-3; UELAND PM, 1993, CLIN CHEM, V39, P1764; Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012; Wang H, 2003, BLOOD, V101, P3901, DOI 10.1182/blood-2002-08-2606; Wang H, 1997, J BIOL CHEM, V272, P25380, DOI 10.1074/jbc.272.40.25380; Weiss N, 2002, ARTERIOSCL THROM VAS, V22, P34, DOI 10.1161/hq1201.100456; Weiss N, 2001, P NATL ACAD SCI USA, V98, P12503, DOI 10.1073/pnas.231428998; Wen W, 1998, J BIOL CHEM, V273, P28533, DOI 10.1074/jbc.273.43.28533; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Wingler K, 1999, EUR J BIOCHEM, V259, P149, DOI 10.1046/j.1432-1327.1999.00012.x; Wingler K, 2001, BIOFACTORS, V14, P43, DOI 10.1002/biof.5520140107; Zavacki AM, 2003, MOL CELL, V11, P773, DOI 10.1016/S1097-2765(03)00064-9; Zhou J, 2001, ARTERIOSCL THROM VAS, V21, P1470, DOI 10.1161/hq0901.096582	48	101	107	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15518	15525		10.1074/jbc.M501452200	http://dx.doi.org/10.1074/jbc.M501452200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15734734	hybrid			2022-12-25	WOS:000228444800009
J	Martinez-Ceballos, E; Chambon, P; Gudas, LJ				Martinez-Ceballos, E; Chambon, P; Gudas, LJ			Differences in gene expression between wild type and Hoxa1 knockout embryonic stem cells after retinoic acid treatment or leukemia inhibitory factor (LIF) removal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HOMEOBOX-CONTAINING GENES; REGION-SPECIFIC EXPRESSION; F9 TERATOCARCINOMA CELLS; ZINC-FINGER GENE; TRANSCRIPTION FACTOR; NEURAL CREST; MOUSE EMBRYO; DNA-BINDING; FUNCTIONAL-ANALYSIS; EARLY HINDBRAIN	Homeobox (Hox) genes encode a family of transcription factors that regulate embryonic patterning and organogenesis. In embryos, alterations of the normal pattern of Hox gene expression result in homeotic transformations and malformations. Disruption of the Hoxa1 gene, the most 3' member of the Hoxa cluster and a retinoic acid ( RA) direct target gene, results in abnormal ossification of the skull, hindbrain, and inner ear deficiencies, and neonatal death. We have generated Hoxa1(-/-) embryonic stem (ES) cells ( named Hoxa1-15) from Hoxa1(-/-) mutant blastocysts to study the Hoxa1 signaling pathway. We have characterized in detail these Hoxa1(-/-) ES cells by performing microarray analyses, and by this technique we have identified a number of putative Hoxa-1 target genes, including genes involved in bone development ( e. g. Col1a1, Postn/Osf2, and the bone sialoprotein gene or BSP), genes that are expressed in the developing brain ( e. g. Nnat, Wnt3a, BDNF, RhoB, and Gbx2), and genes involved in various cellular processes ( e. g. M-RAS, Sox17, Cdkn2b, LamA1, Col4a1, Foxa2, Foxq1, Klf5, and Igf2). Cell proliferation assays and Northern blot analyses of a number of ES cell markers ( e. g. Rex1, Oct3/4, Fgf4, and Bmp4) suggest that the Hoxa1 protein plays a role in the inhibition of cell proliferation by RA in ES cells. Additionally, Hoxa1(-/-) ES cells express high levels of various endodermal markers, including Gata4 and Dab2, and express much less Fgf5 after leukemia inhibitory factor (LIF) withdrawal. Finally, we propose a model in which the Hoxa1 protein mediates repression of endodermal differentiation while promoting expression of ectodermal and mesodermal characteristics.	Cornell Univ, Dept Pharmacol, Weill Med Coll, New York, NY 10021 USA; Univ Louis Pasteur Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM,Coll France, F-67404 Illkirch Graffenstaden, France	Cornell University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gudas, LJ (corresponding author), Cornell Univ, Dept Pharmacol, Weill Med Coll, 1300 York Ave,Rm E-409, New York, NY 10021 USA.	ljgudas@med.cornell.edu			NCI NIH HHS [R01CA43796] Funding Source: Medline; NICHD NIH HHS [2U19HDO35466] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U19HD035466] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043796] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIGNER T, 1995, LAB INVEST, V73, P236; Alexandre D, 1996, DEVELOPMENT, V122, P735; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Auerbach W, 2000, BIOTECHNIQUES, V29, P1024, DOI 10.2144/00295st04; AUGUSTINE KA, 1995, TERATOLOGY, V51, P107, DOI 10.1002/tera.1420510209; Avantaggiato V, 1996, DEV BIOL, V175, P347, DOI 10.1006/dbio.1996.0120; Barrow JR, 2000, DEVELOPMENT, V127, P933; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Benson MD, 1999, J BONE MINER RES, V14, P396, DOI 10.1359/jbmr.1999.14.3.396; Borday C, 2004, PROG BIOPHYS MOL BIO, V84, P89, DOI 10.1016/j.pbiomolbio.2003.11.002; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Capecchi MR, 1997, COLD SPRING HARB SYM, V62, P273, DOI 10.1101/SQB.1997.062.01.034; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; Castelo-Branco GA, 2003, P NATL ACAD SCI USA, V100, P12747, DOI 10.1073/pnas.1534900100; CHALEPAKIS G, 1994, DNA CELL BIOL, V13, P891, DOI 10.1089/dna.1994.13.891; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chen AC, 2003, ARCH BIOCHEM BIOPHYS, V411, P159, DOI 10.1016/S0003-9861(02)00732-4; Chen AC, 1996, J BIOL CHEM, V271, P14971, DOI 10.1074/jbc.271.25.14971; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; Chou AH, 2000, MOL BRAIN RES, V77, P232, DOI 10.1016/S0169-328X(00)00058-9; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; Coucouvanis E, 1999, DEVELOPMENT, V126, P535; Dacic S, 2001, J BONE MINER RES, V16, P1228, DOI 10.1359/jbmr.2001.16.7.1228; del Toro ED, 2001, J NEUROSCI, V21, P5637, DOI 10.1523/JNEUROSCI.21-15-05637.2001; DESCHAMPS J, 1992, Critical Reviews in Oncogenesis, V3, P117; Di Rocco G, 2001, J BIOL CHEM, V276, P20506, DOI 10.1074/jbc.M011175200; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; Dodig M, 1996, J BIOL CHEM, V271, P16422, DOI 10.1074/jbc.271.27.16422; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; Dupe V, 1997, DEVELOPMENT, V124, P399; FRASCH M, 1995, DEVELOPMENT, V121, P957; Fujikura J, 2002, GENE DEV, V16, P784, DOI 10.1101/gad.968802; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; Gavalas A, 2003, DEVELOPMENT, V130, P5663, DOI 10.1242/dev.00802; Gavalas A, 1998, DEVELOPMENT, V125, P1123; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521-1878(200002)22:2<138::AID-BIES5>3.3.CO;2-W; Han X, 2002, CONNECT TISSUE RES, V43, P63; HAUB O, 1991, DEVELOPMENT, V112, P397; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; Hempstead BL, 2004, J CLIN INVEST, V113, P811, DOI 10.1172/JCI200421309; Henderson DJ, 2000, MECH DEVELOP, V95, P211, DOI 10.1016/S0925-4773(00)00333-6; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; HOSLER BA, 1993, MOL CELL BIOL, V13, P2919, DOI 10.1128/MCB.13.5.2919; Hudson C, 1997, CELL, V91, P397, DOI 10.1016/S0092-8674(00)80423-7; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JOSEPH R, 1995, BRAIN RES, V690, P92, DOI 10.1016/0006-8993(95)00621-V; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; Kanzler B, 1998, DEVELOPMENT, V125, P2587; KIM RH, 1994, MATRIX BIOL, V14, P31, DOI 10.1016/0945-053X(94)90027-2; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kruzynska-Frejtag A, 2004, DEV DYNAM, V229, P857, DOI 10.1002/dvdy.10453; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; Langston AW, 1997, J BIOL CHEM, V272, P2167, DOI 10.1074/jbc.272.4.2167; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; Litvin J, 2004, J CELL BIOCHEM, V92, P1044, DOI 10.1002/jcb.20115; Liu JP, 1998, DEVELOPMENT, V125, P5055; Loebel DAF, 2003, DEV BIOL, V264, P1, DOI 10.1016/S0012-1606(03)00390-7; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MARK M, 1993, DEVELOPMENT, V119, P319; Martin G, 2001, BIOESSAYS, V23, P865, DOI 10.1002/bies.1126; MAVILIO F, 1993, EUR J BIOCHEM, V212, P273, DOI 10.1111/j.1432-1033.1993.tb17660.x; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; Morrisey EE, 2000, J BIOL CHEM, V275, P19949, DOI 10.1074/jbc.M001331200; Murasawa H, 2000, ANAT RECORD, V259, P383, DOI 10.1002/1097-0185(20000801)259:4<383::AID-AR20>3.0.CO;2-N; MURPHY P, 1991, DEVELOPMENT, V111, P61; Murray P, 2001, DIFFERENTIATION, V68, P227, DOI 10.1046/j.1432-0436.2001.680410.x; Nakamura T, 1996, ONCOGENE, V13, P2235; Nakazawa T, 2004, J ORTHOP RES, V22, P520, DOI 10.1016/j.orthres.2003.10.007; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012-1606(02)00026-X; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2001, CELL STRUCT FUNCT, V26, P137, DOI 10.1247/csf.26.137; Oshima A, 2002, J CELL BIOCHEM, V86, P792, DOI 10.1002/jcb.10272; Otero JJ, 2004, DEVELOPMENT, V131, P3545, DOI 10.1242/dev.01218; Otte AP, 2003, CURR OPIN GENET DEV, V13, P448, DOI 10.1016/S0959-437X(03)00108-4; Papenbrock T, 1998, DEV DYNAM, V212, P540, DOI 10.1002/(SICI)1097-0177(199808)212:4<540::AID-AJA7>3.0.CO;2-H; PARR BA, 1993, DEVELOPMENT, V119, P247; Pelton TA, 2002, J CELL SCI, V115, P329; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perry A, 2004, J NEURO-ONCOL, V70, P183, DOI 10.1007/s11060-004-2749-0; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; Qin P, 2004, J CELL BIOCHEM, V92, P147, DOI 10.1002/jcb.20057; RAPPOLEE DA, 1994, DEVELOPMENT, V120, P2259; Riley BB, 2004, DEV DYNAM, V231, P278, DOI 10.1002/dvdy.20133; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; ROGERS MB, 1991, DEVELOPMENT, V113, P815; Rossel M, 1999, DEVELOPMENT, V126, P5027; SASAKI M, 1988, J BIOL CHEM, V263, P16536; Scott LM, 1996, BLOOD, V88, P2517, DOI 10.1182/blood.V88.7.2517.bloodjournal8872517; Shen J, 2000, CELL GROWTH DIFFER, V11, P11; Shen J, 2000, EXP CELL RES, V259, P274, DOI 10.1006/excr.2000.4963; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Shimozaki K, 2003, DEVELOPMENT, V130, P2505, DOI 10.1242/dev.00476; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; STORNAIUOLO A, 1990, CELL DIFFER DEV, V31, P119, DOI 10.1016/0922-3371(90)90015-O; Studer M, 1998, DEVELOPMENT, V125, P1025; SUEMORI H, 1995, MECH DEVELOP, V51, P265, DOI 10.1016/0925-4773(95)00371-1; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; TAM PPL, 1989, DEVELOPMENT, V107, P55; Thompson JR, 1998, CELL GROWTH DIFFER, V9, P969; Tighe AP, 2004, J CELL PHYSIOL, V198, P223, DOI 10.1002/jcp.10424; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; VOGEL KS, 1993, MOL NEUROBIOL, V7, P363, DOI 10.1007/BF02769183; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; WIJNHOLDS J, 1995, DEV BIOL, V171, P73, DOI 10.1006/dbio.1995.1261; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xu LF, 2000, GENE DEV, V14, P585; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zandstra PW, 2000, BIOTECHNOL BIOENG, V69, P607, DOI 10.1002/1097-0290(20000920)69:6<607::AID-BIT4>3.3.CO;2-6; ZHANG MB, 1994, DEVELOPMENT, V120, P2431; Zhuang Y, 2003, MOL CANCER RES, V1, P619	125	61	65	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16484	16498		10.1074/jbc.M414397200	http://dx.doi.org/10.1074/jbc.M414397200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722554	hybrid			2022-12-25	WOS:000228444800123
J	Murcha, MW; Elhafez, D; Millar, AH; Whelan, J				Murcha, MW; Elhafez, D; Millar, AH; Whelan, J			The C-terminal region of TIM17 links the outer and inner mitochondrial membranes in Arabidopsis and is essential for protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPROTEIN TRANSLOCASE; PLANT-MITOCHONDRIA; INTERMEMBRANE SPACE; ALTERNATIVE OXIDASE; CARRIER PROTEINS; TOM COMPLEX; MACHINERY; EVOLUTION; BIOGENESIS; RECEPTOR	The translocase of the inner membrane 17 (AtTIM17-2) protein from Arabidopsis has been shown to link the outer and inner mitochondrial membranes. This was demonstrated by several approaches: (i) In vitro organelle import assays indicated the imported AtTIM17-2 protein remained protease accessible in the outer membrane when inserted into the inner membrane. (ii) N-terminal and C-terminal tagging indicated that it was the C-terminal region that was located in the outer membrane. (iii) Antibodies raised to the C-terminal 100 amino acids recognize a 31-kDa protein from purified mitochondria, but cross-reactivity was abolished when mitochondria were protease-treated to remove outer membrane-exposed proteins. Antibodies to AtTIM17-2 inhibited import of proteins via the general import pathway into outer membrane-ruptured mitochondria, but did not inhibit protein import via the carrier import pathway. Together these results indicate that the C-terminal region of AtTIM17-2 is exposed on the outer surface of the outer membrane, and the C-terminal region is essential for protein import into mitochondria.	Univ Western Australia, Plant Mol Biol Grp, Sch Biomed & Chem Sci, Crawley, WA 6009, Australia	University of Western Australia	Whelan, J (corresponding author), Univ Western Australia, Plant Mol Biol Grp, Sch Biomed & Chem Sci, 35 Stirling Highway, Crawley, WA 6009, Australia.	seamus@cyllene.uwa.edu.au	Whelan, James/F-6402-2011; Millar, A. Harvey/A-5452-2008; Murcha, Monika W/H-5495-2014; Murcha, Monika W/C-3834-2011	Whelan, James/0000-0001-5754-025X; Millar, A. Harvey/0000-0001-9679-1473; Murcha, Monika W/0000-0002-3689-6158; 				Adams KL, 2003, MOL PHYLOGENET EVOL, V29, P380, DOI 10.1016/S1055-7903(03)00194-5; Ahting U, 2005, J BIOL CHEM, V280, P48, DOI 10.1074/jbc.M410905200; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Bauer MF, 1999, FEBS LETT, V464, P41, DOI 10.1016/S0014-5793(99)01665-8; Chew O, 2004, FEBS LETT, V557, P109, DOI 10.1016/S0014-5793(03)01457-1; Considine MJ, 2001, PLANT PHYSIOL, V126, P1619, DOI 10.1104/pp.126.4.1619; Dessi P, 1996, ARCH BIOCHEM BIOPHYS, V335, P358, DOI 10.1006/abbi.1996.0517; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Dyall SD, 2004, SCIENCE, V304, P253, DOI 10.1126/science.1094884; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Frazier AE, 2003, MOL CELL BIOL, V23, P7818, DOI 10.1128/MCB.23.21.7818-7828.2003; Gentle I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/jcb.200310092; Harlow D., 1988, ANTIBODIES LAB MANUA; Herrmann JM, 2003, TRENDS MICROBIOL, V11, P74, DOI 10.1016/S0966-842X(02)00033-1; Hood DA, 2004, P NUTR SOC, V63, P293, DOI 10.1079/PNS2004342; Hoogenraad NJ, 2002, BBA-MOL CELL RES, V1592, P97, DOI 10.1016/S0167-4889(02)00268-9; Hwa JJ, 2004, FEBS LETT, V572, P141, DOI 10.1016/j.febslet.2004.07.025; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Koehler CM, 2004, ANNU REV CELL DEV BI, V20, P309, DOI 10.1146/annurev.cellbio.20.010403.105057; Komiya T, 1998, EMBO J, V17, P3886, DOI 10.1093/emboj/17.14.3886; Lang BF, 1999, ANNU REV GENET, V33, P351, DOI 10.1146/annurev.genet.33.1.351; Lister R, 2004, PLANT PHYSIOL, V134, P777, DOI 10.1104/pp.103.033910; Lister R, 2003, NUCLEIC ACIDS RES, V31, P325, DOI 10.1093/nar/gkg055; Lister R, 2002, PLANT J, V30, P555, DOI 10.1046/j.1365-313X.2002.01316.x; LISTER R, 2005, IN PRESS MOL MEMBR B; Lucattini R, 2004, MOL BIOL EVOL, V21, P652, DOI 10.1093/molbev/msh058; Macasev D, 2000, PLANT PHYSIOL, V123, P811, DOI 10.1104/pp.123.3.811; Macasev D, 2004, MOL BIOL EVOL, V21, P1557, DOI 10.1093/molbev/msh166; McFadden GI, 2001, PLANT PHYSIOL, V125, P50, DOI 10.1104/pp.125.1.50; Millar AH, 2001, PLANT PHYSIOL, V127, P1711, DOI 10.1104/pp.010387; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Murcha MW, 2004, J MOL BIOL, V344, P443, DOI 10.1016/j.jmb.2004.09.045; Murcha MW, 2003, PLANT PHYSIOL, V131, P1737, DOI 10.1104/pp.102.016808; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Pfanner N, 2002, BBA-MOL CELL RES, V1592, P15, DOI 10.1016/S0167-4889(02)00260-4; Rassow J, 1999, J MOL BIOL, V286, P105, DOI 10.1006/jmbi.1998.2455; Rehling P, 2004, NAT REV MOL CELL BIO, V5, P519, DOI 10.1038/nrm1426; Rehling P, 2001, CRIT REV BIOCHEM MOL, V36, P291, DOI 10.1080/20014091074200; Taylor RD, 2004, BBA-BIOENERGETICS, V1658, P37, DOI 10.1016/j.bbabio.2004.04.017; Vasiljev A, 2004, MOL BIOL CELL, V15, P1445, DOI 10.1091/mbc.E03-05-0272; Waizenegger T, 2004, EMBO REP, V5, P704, DOI 10.1038/sj.embor.7400183; Werhahn W, 2003, PLANT PHYSIOL BIOCH, V41, P407, DOI 10.1016/S0981-9428(03)00047-0; WHELAN J, 1995, PLANT MOL BIOL, V27, P769, DOI 10.1007/BF00020229; Zara V, 2001, J MOL BIOL, V310, P965, DOI 10.1006/jmbi.2001.4833	47	35	37	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16476	16483		10.1074/jbc.M413299200	http://dx.doi.org/10.1074/jbc.M413299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722347	hybrid			2022-12-25	WOS:000228444800122
J	Duzhyy, D; Harvey, M; Sokolowski, B				Duzhyy, D; Harvey, M; Sokolowski, B			A secretory-type protein, containing a pentraxin domain, interacts with an A-type K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; NEURONAL PENTRAXIN; BETA-SUBUNIT; HAIR-CELLS; ENDOPLASMIC-RETICULUM; POTASSIUM CHANNELS; VOLTAGE CLAMP; MEMBRANE; COCHLEA; MODULATION	A-type K+ channels belonging to the Shal subfamily are found in various receptor and neuronal cells. Although their kinetics and cell surface expression are regulated by auxiliary subunits, little is known about the proteins that may interact with Kv4 during development. A yeast two-hybrid screening of a cDNA library made from the sensory epithelium of embryonic chick cochlea revealed a novel association of Kv4.2 with a protein containing a pentraxin domain (PPTX). Sequence analysis shows that PPTX is a member of the long pentraxin family, is 53% identical to mouse PTX3, and has a signal peptide at the N terminus. Studies with chick cochlear tissues reveal that Kv4.2 coprecipitates PPTX and that both proteins are colocalized to the sensory and ganglion cells. A yeast two-hybrid assay demonstrated that the last 22 amino acids of the PPTX C terminus interact with the N terminus of Kv4.2. Chinese hamster ovary cells transfected with recombinant PPTX reveal secretory products in both non-truncated and truncated forms. Among the secreted variants are several blocked by Brefeldin A, suggesting export via a classical pathway. PPTX is soluble in the presence of sodium carbonate, suggesting localization to the cytosolic side of the plasmalemma. Immunohistochemical studies show that Kv4.2 and PPTX colocalize in the region of the plasmalemma of Chinese hamster ovary cells; however, both are locked in the endoplasmic reticulum of COS-7 cells, suggesting that PPTX does not act as a shuttle protein. Reverse transcription-PCR demonstrates that PPTX mRNA is found in tissues that include brain, eye, heart, and blood vessels.	Univ S Florida, Dept Otolaryngol Head & Neck Surg, Otol Lab MDC83, Tampa, FL 33612 USA; Univ S Florida, Dept Physiol & Biophys, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Sokolowski, B (corresponding author), Univ S Florida, Dept Otolaryngol Head & Neck Surg, Otol Lab MDC83, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	bsokolow@hsc.usf.edu		Duzhyy, Dmytro/0000-0001-8082-8913	NIDCD NIH HHS [DC43095] Funding Source: Medline	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; BATTAZII B, 1997, J BIOL CHEM, V272, P32817; Beckmann G, 1998, J MOL BIOL, V275, P725, DOI 10.1006/jmbi.1997.1510; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; Chen B, 2005, J COMP NEUROL, V481, P391, DOI 10.1002/cne.20391; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P21, DOI 10.1113/jphysiol.1971.sp009365; Denny PW, 2000, J BIOL CHEM, V275, P11017, DOI 10.1074/jbc.275.15.11017; Deschenes I, 2002, FEBS LETT, V528, P183, DOI 10.1016/S0014-5793(02)03296-9; Dodds DC, 1997, J BIOL CHEM, V272, P21488, DOI 10.1074/jbc.272.34.21488; FISCHER FP, 1992, HEARING RES, V61, P167, DOI 10.1016/0378-5955(92)90048-R; FUCHS PA, 1990, P ROY SOC B-BIOL SCI, V241, P122, DOI 10.1098/rspb.1990.0075; FUCHS PA, 1992, J NEUROSCI, V12, P800; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEWURZ H, 1995, CURR OPIN IMMUNOL, V7, P54, DOI 10.1016/0952-7915(95)80029-8; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Goodman Adam R., 1996, Cytokine and Growth Factor Reviews, V7, P191, DOI 10.1016/1359-6101(96)00019-6; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; Kaltner H, 2001, ADV EXP MED BIOL, V491, P79; Kros CJ, 1998, NATURE, V394, P281, DOI 10.1038/28401; Kuryshev YA, 2000, AM J PHYSIOL-CELL PH, V278, pC931, DOI 10.1152/ajpcell.2000.278.5.C931; Mehul B, 1997, J CELL SCI, V110, P1169; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; Nakamura TY, 2001, P NATL ACAD SCI USA, V98, P12808, DOI 10.1073/pnas.221168498; NEHER E, 1971, J GEN PHYSIOL, V58, P36, DOI 10.1085/jgp.58.1.36; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; O'Brien RJ, 1999, NEURON, V23, P309, DOI 10.1016/S0896-6273(00)80782-5; OLIVEIRA EB, 1979, J BIOL CHEM, V254, P489; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; ROGAWSKI MA, 1985, ANN NY ACAD SCI, V448, P403, DOI 10.1111/j.1749-6632.1985.tb29934.x; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SCHLIMGEN AK, 1995, NEURON, V14, P519, DOI 10.1016/0896-6273(95)90308-9; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Shrive AK, 1999, J MOL BIOL, V290, P997, DOI 10.1006/jmbi.1999.2956; Sokolowski B, 2005, J NEUROSCI RES, V79, P459, DOI 10.1002/jnr.20376; Sokolowski BHA, 2004, J NEUROSCI, V24, P6265, DOI 10.1523/JNEUROSCI.1291-04.2004; Tsui CC, 1996, J NEUROSCI, V16, P2463; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839	40	11	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15165	15172		10.1074/jbc.M500111200	http://dx.doi.org/10.1074/jbc.M500111200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708850	hybrid			2022-12-25	WOS:000228236800100
J	Golks, A; Brenner, D; Fritsch, C; Krammer, PH; Lavrik, IN				Golks, A; Brenner, D; Fritsch, C; Krammer, PH; Lavrik, IN			c-FLIPR, a new regulator of death receptor-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FLICE-INHIBITORY PROTEINS; CELL-DEATH; CD95-MEDIATED APOPTOSIS; CD95 APO-1/FAS; UP-REGULATION; ACTIVATION; CASPASE-8; FAS; INDUCTION	c-FLIPs (c-FLICE inhibitory proteins) play an essential role in regulation of death receptor-induced apoptosis. Multiple splice variants of c-FLIP have been described on the mRNA level; so far only two of them, c-FLIPL and c-FLIPS, had been found to be expressed at the protein level. In this report, we reveal the endogenous expression of a third isoform of c-FLIP. We demonstrate its presence in a number of T and B cell lines as well as in primary human T cells. We identified this isoform as c-FLIPR, a death effector domain-only splice variant previously identified on the mRNA level. Importantly, c-FLIPR is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex upon CD95 stimulation. Several properties of c-FLIPR are similar to c-FLIPS: both isoforms have a short half-life, a similar pattern of expression during activation of primary human T cells, and are strongly induced in T cells upon CD3/CD28 costimulation. Taken together, our data demonstrate endogenous expression of c-FLIPR and similar roles of c-FLIPR and c-FLIPS isoforms in death receptor-mediated apoptosis.	German Canc Res Ctr, Div Immunogenet, Tumorimmunol Program, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Krammer, PH (corresponding author), German Canc Res Ctr, Div Immunogenet, Tumorimmunol Program, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	p.krammer@dkfz.de	Lavrik, Inna N/C-1700-2009	Lavrik, Inna N/0000-0002-9324-309X; Brenner, Dirk/0000-0001-8979-1045				Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Djerbi M, 2001, SCAND J IMMUNOL, V54, P180, DOI 10.1046/j.1365-3083.2001.00941.x; Fulda S, 2000, CANCER RES, V60, P3947; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavrik I, 2003, CELL DEATH DIFFER, V10, P144, DOI 10.1038/sj.cdd.4401156; Legembre P, 2004, EMBO REP, V5, P1084, DOI 10.1038/sj.embor.7400280; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schmitz I, 2004, J IMMUNOL, V172, P2194, DOI 10.4049/jimmunol.172.4.2194; Schmitz I, 2000, INT J BIOCHEM CELL B, V32, P1123, DOI 10.1016/S1357-2725(00)00048-0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wajant H, 2003, ESSAYS BIOCHEM, V39, P53, DOI 10.1042/bse0390053; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	33	213	225	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14507	14513		10.1074/jbc.M414425200	http://dx.doi.org/10.1074/jbc.M414425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701649	hybrid			2022-12-25	WOS:000228236800021
J	Reinicke, AT; Hutchinson, JL; Magee, AI; Mastroeni, P; Trowsdale, J; Kelly, AP				Reinicke, AT; Hutchinson, JL; Magee, AI; Mastroeni, P; Trowsdale, J; Kelly, AP			A Salmonella typhimurium effector protein SifA is modified by host cell prenylation and S-acylation machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; INTRACELLULAR TRAFFICKING; CONTAINING VACUOLES; III SECRETION; MACROPHAGES; COMPARTMENTS; BIOGENESIS; MATURATION; PHAGOSOMES; INTEGRITY	SifA is a Salmonella effector protein that is required for maintenance of the vacuolar membrane that surrounds replicating bacteria. It associates with the Salmonella-containing vacuole but how it interacts with the membrane is unknown. Here we show by immunofluorescence, S100 fractionation and Triton X-114 partitioning that the membrane association and targeting properties of SifA are influenced by a motif encoded within the C-terminal six amino acids. This sequence shares homology with both CAAX and Rab geranylgeranyl transferase prenylation motifs. We characterized the post-translational processing of SifA and showed that the cysteine residue within the CAAX motif is modified by isoprenoid addition through the action of protein geranylgeranyl transferase I. SifA was additionally modified by S-acylation of an adjacent cysteine residue. Similar modifications to host cell proteins regulate numerous functions including protein targeting, membrane association, protein-protein interaction, and signal transduction. This is the only known example of a bacterial effector protein that is modified both by mammalian cell S-acylation and prenylation machinery.	Univ Cambridge, Dept Pathol, Div Immunol, Cambridge CB2 1QP, England; Univ Cambridge, Bacterial Infect Grp, Dept Vet Clin Med, Ctr Vet Sci, Cambridge CB2 1QP, England; Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, London SW7 2AZ, England	University of Cambridge; University of Cambridge; Imperial College London	Kelly, AP (corresponding author), Univ Cambridge, Dept Pathol, Div Immunol, Tennis Court Rd, Cambridge CB2 1QP, England.	apk23@mole.bio.cam.ac.uk	Magee, Anthony/V-8345-2019	Mastroeni, Pietro/0000-0003-3838-4962	MRC [G9800943] Funding Source: UKRI; Medical Research Council [G9800943] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Beuzon CR, 1999, MOL MICROBIOL, V33, P806, DOI 10.1046/j.1365-2958.1999.01527.x; Beuzon CR, 2002, MICROBIOL-SGM, V148, P2705, DOI 10.1099/00221287-148-9-2705; Beuzon CR, 2000, EMBO J, V19, P3235, DOI 10.1093/emboj/19.13.3235; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Boucrot E, 2003, J BIOL CHEM, V278, P14196, DOI 10.1074/jbc.M207901200; Brumell JH, 1999, CURR BIOL, V9, pR277, DOI 10.1016/S0960-9822(99)80178-X; Brumell JH, 2001, TRAFFIC, V2, P643, DOI 10.1034/j.1600-0854.2001.20907.x; Coligan JE, 1995, CURRENT PROTOCOLS PR; Copier J, 1996, J IMMUNOL, V157, P1017; FINLAY BB, 1991, J CELL SCI, V99, P283; GARCIADELPORTILLO F, 1993, P NATL ACAD SCI USA, V90, P10544, DOI 10.1073/pnas.90.22.10544; GARCIADELPORTILLO F, 1995, J CELL BIOL, V129, P81, DOI 10.1083/jcb.129.1.81; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; Gomes AQ, 2003, MOL BIOL CELL, V14, P1882, DOI 10.1091/mbc.E02-10-0639; Gorvel JP, 2001, MICROBES INFECT, V3, P1299, DOI 10.1016/S1286-4579(01)01490-3; HANCOCK JF, 1995, METHOD ENZYMOL, V255, P237; Harrison RE, 2004, MOL BIOL CELL, V15, P3146, DOI 10.1091/mbc.E04-02-0092; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Knodler LA, 2003, TRAFFIC, V4, P587, DOI 10.1034/j.1600-0854.2003.00118.x; Magee Anthony I, 2003, Biochem J, V376, pe3, DOI 10.1042/BJ20031531; MARSMAN M, 2004, MOL BIOL CELL; Martinez-Lorenzo MJ, 2001, CELL MICROBIOL, V3, P407, DOI 10.1046/j.1462-5822.2001.00123.x; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; Miao EA, 2000, P NATL ACAD SCI USA, V97, P7539, DOI 10.1073/pnas.97.13.7539; Mitchell EK, 2004, EUR J IMMUNOL, V34, P2559, DOI 10.1002/eji.200425314; Philippe N, 2004, PLASMID, V51, P246, DOI 10.1016/j.plasmid.2004.02.003; Rathman M, 1996, INFECT IMMUN, V64, P2765, DOI 10.1128/IAI.64.7.2765-2773.1996; Rathman M, 1997, INFECT IMMUN, V65, P1475, DOI 10.1128/IAI.65.4.1475-1485.1997; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RichterDahlfors A, 1997, J EXP MED, V186, P569, DOI 10.1084/jem.186.4.569; Salcedo SP, 2001, CELL MICROBIOL, V3, P587, DOI 10.1046/j.1462-5822.2001.00137.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Stein MA, 1996, MOL MICROBIOL, V20, P151, DOI 10.1111/j.1365-2958.1996.tb02497.x; Tafazoli F, 2003, INFECT IMMUN, V71, P872, DOI 10.1128/IAI.71.2.872-881.2003; Trueblood CE, 2000, MOL CELL BIOL, V20, P4381, DOI 10.1128/MCB.20.12.4381-4392.2000; Yik JHN, 2002, J BIOL CHEM, V277, P40844, DOI 10.1074/jbc.M204780200; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	40	81	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14620	14627		10.1074/jbc.M500076200	http://dx.doi.org/10.1074/jbc.M500076200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15710609	hybrid			2022-12-25	WOS:000228236800036
J	Unemo, M; Aspholm-Hurtig, M; Ilver, D; Bergstrom, J; Boren, T; Danielsson, D; Teneberg, S				Unemo, M; Aspholm-Hurtig, M; Ilver, D; Bergstrom, J; Boren, T; Danielsson, D; Teneberg, S			The sialic acid binding SabA adhesin of Helicobacter pylori is essential for nonopsonic activation of human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-SELECTIVE CHANNELS; NORMAL HUMAN-LEUKOCYTES; PEPTIC-ULCER DISEASE; LEUKEMIA HL60 CELLS; INFLUENZA-A VIRUS; PROTEIN HP-NAP; HUMAN-GRANULOCYTES; NADPH-OXIDASE; DELAYED PHAGOCYTOSIS; VACUOLATING TOXIN	Infiltration of neutrophils and monocytes into the gastric mucosa is a hallmark of chronic gastritis caused by Helicobacter pylori. Certain H. pylori strains nonopsonized stimulate neutrophils to production of reactive oxygen species causing oxidative damage of the gastric epithelium. Here, the contribution of some H. pylori virulence factors, the blood group antigen-binding adhesin BabA, the sialic acid-binding adhesin SabA, the neutrophil-activating protein HP-NAP, and the vacuolating cytotoxin VacA, to the activation of human neutrophils in terms of adherence, phagocytosis, and oxidative burst was investigated. Neutrophils were challenged with wild type bacteria and isogenic mutants lacking BabA, SabA, HP-NAP, or VacA. Mutant and wild type strains lacking SabA had no neutrophil-activating capacity, demonstrating that binding of H. pylori to sialylated neutrophil receptors plays a pivotal initial role in the adherence and phagocytosis of the bacteria and the induction of the oxidative burst. The link between receptor binding and oxidative burst involves a G-protein-linked signaling pathway and downstream activation of phosphatidylinositol 3-kinase as shown by experiments using signal transduction inhibitors. Collectively our data suggest that the sialic acid-binding SabA adhesin is a prerequisite for the nonopsonic activation of human neutrophils and, thus, is a virulence factor important for the pathogenesis of H. pylori infection.	Univ Gothenburg, Inst Med Biochem, SE-40530 Gothenburg, Sweden; Orebro Univ Hosp, Dept Clin Microbiol, SE-70185 Orebro, Sweden; Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	University of Gothenburg; Orebro University; Umea University	Teneberg, S (corresponding author), Univ Gothenburg, Inst Med Biochem, POB 440, SE-40530 Gothenburg, Sweden.	Susann.Teneberg@medkem.gu.se	Aspholm, Marina/ABB-5298-2020; Unemo, Magnus/ABD-6653-2021	Aspholm, Marina/0000-0003-3175-6022; Ilver, Dag/0000-0002-3618-9496				Allen LAH, 2000, J EXP MED, V191, P115, DOI 10.1084/jem.191.1.115; Allen LAH, 2002, CURR BIOL, V12, P1762, DOI 10.1016/S0960-9822(02)01216-2; Almkvist J, 2002, J IMMUNOL, V168, P4034, DOI 10.4049/jimmunol.168.8.4034; Angstrom J, 1998, GLYCOBIOLOGY, V8, P297, DOI 10.1093/glycob/8.4.297; Balk SC, 1996, CANCER RES, V56, P1279; Blaser MJ, 1996, SCI AM, V274, P104, DOI 10.1038/scientificamerican0296-104; Blom K, 2001, FEMS IMMUNOL MED MIC, V30, P173; BOYUM A, 1974, TISSUE ANTIGENS, V4, P269; Bylund J, 2001, ANTIMICROB AGENTS CH, V45, P1700, DOI 10.1128/AAC.45.6.1700-1704.2001; Chester MA, 1998, EUR J BIOCHEM, V257, P293; COHEN MS, 1980, BLOOD, V55, P1003; CONNOR RJ, 1994, VIROLOGY, V205, P17, DOI 10.1006/viro.1994.1615; Danielsson D, 2000, J CLIN PATHOL, V53, P318, DOI 10.1136/jcp.53.4.318; de Bernard M, 1998, INFECT IMMUN, V66, P6014, DOI 10.1128/IAI.66.12.6014-6016.1998; EVANS DJ, 1995, INFECT IMMUN, V63, P2213, DOI 10.1128/IAI.63.6.2213-2220.1995; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; Hansen PS, 2001, CLIN EXP IMMUNOL, V123, P73, DOI 10.1046/j.1365-2249.2001.01368.x; HARTSHORN KL, 1992, J LEUKOCYTE BIOL, V51, P230, DOI 10.1002/jlb.51.3.230; HARTSHORN KL, 1990, BLOOD, V75, P218; HOLMGREN J, 1973, INFECT IMMUN, V8, P208, DOI 10.1128/IAI.8.2.208-214.1973; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Karlsson A, 1998, BLOOD, V91, P3430, DOI 10.1182/blood.V91.9.3430.3430_3430_3438; Karlsson A, 2000, J LEUKOCYTE BIOL, V67, P396, DOI 10.1002/jlb.67.3.396; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P212; KNIBBS RN, 1993, J BIOL CHEM, V268, P18524; Leakey A, 2001, J MED MICROBIOL, V50, P787, DOI 10.1099/0022-1317-50-9-787; LOCK R, 1988, APMIS, V96, P299, DOI 10.1111/j.1699-0463.1988.tb05306.x; MACHER BA, 1980, J BIOL CHEM, V255, P2092; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; Makristathis A, 1998, J INFECT DIS, V177, P803, DOI 10.1086/517814; Miller-Podraza H, 1999, INFECT IMMUN, V67, P6309; MillerPodraza H, 1997, INFECT IMMUN, V65, P2480, DOI 10.1128/IAI.65.6.2480-2482.1997; Montecucco C, 2003, MICROBES INFECT, V5, P715, DOI 10.1016/S1286-4579(03)00124-2; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; Nishioka H, 2003, EUR J IMMUNOL, V33, P840, DOI 10.1002/eji.200323726; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; OFEK I, 1988, INFECT IMMUN, V56, P539, DOI 10.1128/IAI.56.3.539-547.1988; PACUSZKA T, 1990, J BIOL CHEM, V265, P7673; RAUTELIN H, 1993, GUT, V34, P599, DOI 10.1136/gut.34.5.599; RAUTELIN H, 1994, SCAND J GASTROENTERO, V29, P128, DOI 10.3109/00365529409090450; RAUTELIN H, 1994, J CLIN PATHOL, V47, P667, DOI 10.1136/jcp.47.7.667; REST RF, 1992, INFECT IMMUN, V60, P989, DOI 10.1128/IAI.60.3.989-997.1992; Reyrat JM, 1999, J MOL BIOL, V290, P459, DOI 10.1006/jmbi.1999.2877; Roche N, 2004, INFECT IMMUN, V72, P1519, DOI 10.1128/IAI.72.3.1519-1529.2004; Roche N, 2001, GLYCOBIOLOGY, V11, P935, DOI 10.1093/glycob/11.11.935; Satin B, 2000, J EXP MED, V191, P1467, DOI 10.1084/jem.191.9.1467; SHAFER WM, 1989, ANNU REV MICROBIOL, V43, P121; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; Stein M, 2001, HELICOBACTER PYLORI: MOLECULAR AND CELLULAR BIOLOGY, P227; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P770, DOI 10.1021/bi952461g; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P758, DOI 10.1021/bi951600r; SUERBAUM S, 1993, J BACTERIOL, V175, P3278, DOI 10.1128/jb.175.11.3278-3288.1993; Szabo I, 1999, EMBO J, V18, P5517, DOI 10.1093/emboj/18.20.5517; Teneberg S, 2000, GLYCOBIOLOGY, V10, P1171, DOI 10.1093/glycob/10.11.1171; Teneberg S, 1997, J BIOL CHEM, V272, P19067, DOI 10.1074/jbc.272.30.19067; Tombola F, 1999, BIOPHYS J, V76, P1401, DOI 10.1016/S0006-3495(99)77301-7; Waldi D., 1962, DUNNSCHICHT CHROMATO, P496; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277; Yoshikawa T, 2000, FREE RADICAL RES, V33, P785, DOI 10.1080/10715760000301301	60	81	89	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15390	15397		10.1074/jbc.M412725200	http://dx.doi.org/10.1074/jbc.M412725200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15689619	hybrid			2022-12-25	WOS:000228236800125
J	West, JD; Ji, CA; Marnett, LJ				West, JD; Ji, CA; Marnett, LJ			Modulation of DNA fragmentation factor 40 nuclease activity by poly(ADP-ribose) polymerase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-ACTIVATED DNASE; CHROMATIN CONDENSATION; OXIDATIVE STRESS; CELL-DEATH; APOPTOSIS; CLEAVAGE; ENDONUCLEASE; HISTONE; IDENTIFICATION; INVOLVEMENT	Poly(ADP-ribose) polymerase-1 (PARP-1) influences numerous cellular processes, including DNA repair, transcriptional regulation, and caspase-independent cell death, by utilizing NAD(+) to synthesize long chains of poly( ADP- ribose) ( PAR) on target proteins, including itself. During the apoptotic response, caspases-3 and - 7 cleave PARP-1, thereby inhibiting its activity. Here, we have examined the role of PARP-1 activation and cleavage in the latter stages of apoptosis in response to DNA fragmentation. PARP-1 poly( ADP- ribosyl) ation correlated directly with induction of apoptosis by the lipid peroxidation product, 4-hydroxy-2-nonenal. A significant decrease in PAR accumulation was observed upon caspase or DNA fragmentation factor 40 (DFF40) inhibition. Because DNA fragmentation mediated by DFF40 augmented PARP-1 modification status in apoptotic cells, we hypothesized that PARP-1 alters DFF40 function following PAR accumulation. Indeed, PARP-1, in the presence of NAD(+), significantly decreased DFF40 activity on plasmid substrates. Conversely, PARP-1 enhanced the DNase activity of DFF40 in the absence of NAD(+). The inhibition of DFF40 activity in the presence of NAD(+) was reduced by co-incubation with poly( ADPribose) glycohydrolase and a PARP inhibitor. Additionally, caspase-cleaved PARP-1, in the presence of NAD(+), did not inhibit DFF40 activity significantly. Our results suggest that PARP-1 poly( ADP- ribosyl) ation is a terminal event in the apoptotic response that occurs in response to DNA fragmentation and directly influences DFF40 activity.	Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Vanderbilt Inst Chem Biol,Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Vanderbilt Inst Chem Biol,Dept Biochem, 854 Robinson Res Bldg,23rd Ave & Pierce, Nashville, TN 37232 USA.	larry.marnett@vanderbilt.edu	West, James D./J-1619-2019	West, James D./0000-0003-0892-5254	NATIONAL CANCER INSTITUTE [P30CA068485, R37CA087819, R01CA087819, T32CA078136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, CA78136, CA87819] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Boulares AH, 2002, BIOCHEM BIOPH RES CO, V290, P796, DOI 10.1006/bbrc.2001.6280; Boulares AH, 2001, J BIOL CHEM, V276, P38185; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Durrieu F, 2000, CURR BIOL, V10, P923, DOI 10.1016/S0960-9822(00)00620-5; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Haynes RL, 2001, FREE RADICAL BIO MED, V30, P884, DOI 10.1016/S0891-5849(01)00476-2; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Ji C, 2001, CHEM RES TOXICOL, V14, P1090, DOI 10.1021/tx000186f; Kruman I, 1997, J NEUROSCI, V17, P5089; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leist M, 1997, BIOCHEM BIOPH RES CO, V233, P518, DOI 10.1006/bbrc.1997.6491; Leppard JB, 2003, MOL CELL BIOL, V23, P5919, DOI 10.1128/MCB.23.16.5919-5927.2003; Li BM, 2004, J BIOL CHEM, V279, P13659, DOI 10.1074/jbc.M311606200; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Liu W, 2000, J CELL SCI, V113, P635; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Marnett LJ, 2003, J CLIN INVEST, V111, P583, DOI 10.1172/JCI200318022; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sayre LM, 2001, CURR MED CHEM, V8, P721, DOI 10.2174/0929867013372922; Shiokawa D, 2002, J BIOL CHEM, V277, P31031, DOI 10.1074/jbc.M204038200; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Talasz H, 2002, CELL DEATH DIFFER, V9, P27, DOI 10.1038/sj.cdd.4400925; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Toh SY, 1998, BIOCHEM BIOPH RES CO, V250, P598, DOI 10.1006/bbrc.1998.9369; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; von Kobbe C, 2004, NUCLEIC ACIDS RES, V32, P4003, DOI 10.1093/nar/gkh721; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Widlak P, 2000, J BIOL CHEM, V275, P8226, DOI 10.1074/jbc.275.11.8226; Widlak P, 2003, J BIOL CHEM, V278, P26915, DOI 10.1074/jbc.M303807200; WIELCKENS K, 1982, J BIOL CHEM, V257, P2872; Woo EJ, 2004, MOL CELL, V14, P531, DOI 10.1016/S1097-2765(04)00258-8; Yakovlev AG, 2000, J BIOL CHEM, V275, P21302, DOI 10.1074/jbc.M001087200; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Yoon YS, 1996, J BIOL CHEM, V271, P9129, DOI 10.1074/jbc.271.15.9129; Yoshida A, 2003, J BIOL CHEM, V278, P37768, DOI 10.1074/jbc.M304914200; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	58	25	28	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15141	15147		10.1074/jbc.M413147200	http://dx.doi.org/10.1074/jbc.M413147200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15703174	hybrid			2022-12-25	WOS:000228236800097
J	Bullesbach, EE; Schwabe, C				Bullesbach, EE; Schwabe, C			The trap-like relaxin-binding site of the leucine-rich G-protein-coupled receptor 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE INHIBITOR; HORMONE; REPEATS	The pleated sheet region of the leucine-rich G-protein-coupled receptor 7 supports a relaxin-binding group of amino acids that perfectly matches the binding cassette of relaxin. Arginines B13 and B17 are each chelated by an aspartic acid/glutamic acid pair and by isoleucine B20, which, offset by a one-quarter helix turn from a straight line connecting the arginines, interacts with a cluster of hydrophobic amino acids. The binding cassette of relaxin cuts at an angle of similar to 45 degrees across five parallel leucine-rich repeats. The arginine residues 13 and 17, which evolve parallel from the B-chain alpha-helix of relaxin, neutralize the charge repulsion of the juxtaposed acidic groups on the receptor and thereby trigger closure of a hydrogen bonding network around the guanidinium groups. Thus, relaxin is bound by synchronized chelation of two arginines and stabilized by hydrophobic interaction of isoleucine B20 with tryptophan, isoleucine, and leucine in neighboring leucine-rich repeats of the receptor. Deletion of any one of the three features diminishes interaction to the level of nonspecific binding. This model explains the exquisite sensitivity of relaxin binding avidity to minute changes in the disposition of the guanidinium and the size dependence of the hydrophobic binding residue in position B20.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Schwabe, C (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	schwabec@musc.edu						Bathgate RAD, 2003, TRENDS ENDOCRIN MET, V14, P207, DOI 10.1016/S1043-2760(03)00081-X; BULLESBACH EE, 1992, J BIOL CHEM, V267, P22957; Bullesbach EE, 2000, J BIOL CHEM, V275, P35276, DOI 10.1074/jbc.M005728200; BULLESBACH EE, 1994, J BIOL CHEM, V269, P13124; Dschietzig T, 2003, CELL MOL LIFE SCI, V60, P688, DOI 10.1007/s00018-003-2169-x; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; GODZIK A, 1992, J MOL BIOL, V227, P227, DOI 10.1016/0022-2836(92)90693-E; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hsu SYT, 2003, MOL CELL ENDOCRINOL, V202, P165, DOI 10.1016/S0303-7207(03)00078-9; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kobe B, 1996, J MOL BIOL, V264, P1028, DOI 10.1006/jmbi.1996.0694; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; SCHWABE C, 1994, FASEB J, V8, P1152, DOI 10.1096/fasebj.8.14.7958621; Schwabe C, 1998, RELAXIN FINE STRUCTU; Smits G, 2003, EMBO J, V22, P2692, DOI 10.1093/emboj/cdg260; Sowdhamini R, 1997, PROTEIN ENG, V10, P207, DOI 10.1093/protein/10.3.207; Sudo S, 2003, J BIOL CHEM, V278, P7855, DOI 10.1074/jbc.M212457200; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006	20	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14051	14056		10.1074/jbc.M500030200	http://dx.doi.org/10.1074/jbc.M500030200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695505	hybrid			2022-12-25	WOS:000228095500107
J	Card, GL; Peterson, NA; Smith, CA; Rupp, B; Schick, BM; Baker, EN				Card, GL; Peterson, NA; Smith, CA; Rupp, B; Schick, BM; Baker, EN			The crystal structure of Rv1347c, a putative antibiotic resistance protein from Mycobacterium tuberculosis, reveals a GCN5-related fold and suggests an alternative function in siderophore biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; SEROTONIN N-ACETYLTRANSFERASE; AMINOGLYCOSIDE 2'-N-ACETYLTRANSFERASE; CATALYTIC MECHANISM; ANGSTROM RESOLUTION; IRON ACQUISITION; COENZYME-A; GENES; ACETYLATION; SUPERFAMILY	Mycobacterium tuberculosis, the cause of tuberculosis, is a devastating human pathogen. The emergence of multidrug resistance in recent years has prompted a search for new drug targets and for a better understanding of mechanisms of resistance. Here we focus on the gene product of an open reading frame from M. tuberculosis, Rv1347c, which is annotated as a putative aminoglycoside N-acetyltransferase. The Rv1347c protein does not show this activity, however, and we show from its crystal structure, coupled with functional and bioinformatic data, that its most likely role is in the biosynthesis of mycobactin, the M. tuberculosis siderophore. The crystal structure of Rv1347c was determined by multiwavelength anomalous diffraction phasing from selenomethionine-substituted protein and refined at 2.2 angstrom resolution (r = 0.227, R-free = 0.257). The protein is monomeric, with a fold that places it in the GCN5-related N-acetyltransferase ( GNAT) family of acyltransferases. Features of the structure are an acyl-CoA binding site that is shared with other GNAT family members and an adjacent hydrophobic channel leading to the surface that could accommodate long-chain acyl groups. Modeling the postulated substrate, the N-epsilon-hydroxylysine side chain of mycobactin, into the acceptor substrate binding groove identifies two residues at the active site, His(130) and Asp(168), that have putative roles in substrate binding and catalysis.	Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand; Univ Auckland, Ctr Mol Biodiscovery, Auckland 1, New Zealand; Lawrence Livermore Natl Lab, Macromol Crystallog & Struct Genom Grp, Livermore, CA 94550 USA	University of Auckland; University of Auckland; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Baker, EN (corresponding author), Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand.	ted.baker@auckland.ac.nz		Baker, Edward/0000-0003-2456-7661; Rupp, Bernhard/0000-0002-3300-6965	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062410] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50 GM62410] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Angus-Hill ML, 1999, J MOL BIOL, V294, P1311, DOI 10.1006/jmbi.1999.3338; Babbette B, 2004, J BACTERIOL, V186, P374, DOI 10.1128/JB.186.2.374-382.2004; Barker KF, 1999, BRIT J CLIN PHARMACO, V48, P109, DOI 10.1046/j.1365-2125.1999.00997.x; Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215, DOI 10.1146/annurev.bi.65.070196.001243; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P961; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Daigle DM, 1999, CHEM BIOL, V6, P11, DOI 10.1016/S1074-5521(99)80016-7; De Voss JJ, 1999, J BACTERIOL, V181, P4443, DOI 10.1128/JB.181.15.4443-4451.1999; De Voss JJ, 2000, P NATL ACAD SCI USA, V97, P1252, DOI 10.1073/pnas.97.3.1252; DELORENZO V, 1986, J BACTERIOL, V165, P570, DOI 10.1128/jb.165.2.570-578.1986; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Draker KA, 2003, J ANTIBIOT, V56, P135, DOI 10.7164/antibiotics.56.135; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Farazi TA, 2001, BIOCHEMISTRY-US, V40, P6335, DOI 10.1021/bi0101401; GOBIN J, 1995, P NATL ACAD SCI USA, V92, P5189, DOI 10.1073/pnas.92.11.5189; He HZ, 2003, J MOL BIOL, V325, P1019, DOI 10.1016/S0022-2836(02)01284-6; Hegde SS, 2001, J BIOL CHEM, V276, P45876, DOI 10.1074/jbc.M108810200; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; Hon WC, 1997, CELL, V89, P887, DOI 10.1016/S0092-8674(00)80274-3; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; MAKITA Y, 2002, GENOME INFORMATICS, V13, P297; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; Modis Y, 1998, STRUCTURE, V6, P1345, DOI 10.1016/S0969-2126(98)00134-8; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; O'Regan A, 2001, BRIT MED J, V323, P635, DOI 10.1136/bmj.323.7313.635b; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parrish NM, 1998, TRENDS MICROBIOL, V6, P107, DOI 10.1016/S0966-842X(98)01216-5; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Peneff C, 2001, J BIOL CHEM, V276, P16328, DOI 10.1074/jbc.M009988200; Ratledge C, 2004, TUBERCULOSIS, V84, P110, DOI 10.1016/j.tube.2003.08.012; Rodriguez GM, 2002, INFECT IMMUN, V70, P3371, DOI 10.1128/IAI.70.7.3371-3381.2002; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Segelke BW, 2001, J CRYST GROWTH, V232, P553, DOI 10.1016/S0022-0248(01)01154-X; Smith Clyde A., 2002, Current Drug Targets - Infectious Disorders, V2, P143, DOI 10.2174/1568005023342533; Stokstad E, 2000, SCIENCE, V287, P2391; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Vetting MW, 2004, CHEM BIOL, V11, P565, DOI 10.1016/j.chembiol.2004.03.017; Vetting MW, 2002, NAT STRUCT BIOL, V9, P653, DOI 10.1038/nsb830; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8	52	37	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13978	13986		10.1074/jbc.M413904200	http://dx.doi.org/10.1074/jbc.M413904200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695811	Green Submitted, hybrid			2022-12-25	WOS:000228095500100
J	Dummitt, B; Micka, WS; Chang, YH				Dummitt, B; Micka, WS; Chang, YH			Yeast glutamine-fructose-6-phosphate aminotransferase (Gfa1) requires methionine aminopeptidase activity for proper function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL GROWTH; SACCHAROMYCES-CEREVISIAE; ANGIOGENESIS INHIBITOR; PROTEIN-SYNTHESIS; TNP-470 AGM-1470; GENE; AMIDOTRANSFERASE; PATHWAY; OVEREXPRESSION; IDENTIFICATION	Methionine aminopeptidase (MetAP) catalyzes the co-translational processing of initiator methionine from nascent proteins. A cellular requirement for MetAP activity is likely due to dysfunction of MetAP substrates that require methionine removal for proper protein function. Glutamine-fructose-6-phosphate aminotransferase (Gfa1) is an essential enzyme in yeast that catalyzes the first and rate-limiting step in hexosamine biosynthesis. The alpha-amino group of Gfa1 Cys-1 has been proposed to act as a nucleophile in the catalytic mechanism. We used two mutational strategies to evaluate whether removal of initiator methionine, catalyzed by MetAP, is required for Gfa1 function. Our results demonstrate that exposure of the alpha-amino group of Cys-1 is required for normal Gfa1 function as failure to do so results in decreased enzyme activity and slow growth. Further, either isoform of MetAP in yeast is sufficient for Gfa1 processing in vivo. These results are the first demonstration of an endogenous yeast protein that requires the exposure of the alpha-amino group by MetAP action for normal function. Additionally, Gfa1 will be a relevant target in therapeutic or physiological applications in which MetAP activity is inhibited.	St Louis Univ, Sch Med, EA Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Chang, YH (corresponding author), St Louis Univ, Sch Med, EA Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA.	changyh@slu.edu						ADAMS JM, 1966, P NATL ACAD SCI USA, V55, P147, DOI 10.1073/pnas.55.1.147; ADAMS JM, 1968, J MOL BIOL, V33, P571, DOI 10.1016/0022-2836(68)90307-0; ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BIANCHETTI R, 1977, J BIOL CHEM, V252, P2519; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG SYP, 1989, J BACTERIOL, V171, P4071, DOI 10.1128/jb.171.7.4071-4072.1989; CHANG YH, 1992, J BIOL CHEM, V267, P8007; Chen SP, 2002, ARCH BIOCHEM BIOPHYS, V398, P87, DOI 10.1006/abbi.2001.2675; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Giglione C, 2003, EMBO J, V22, P13, DOI 10.1093/emboj/cdg007; Giglione C, 2000, EMBO J, V19, P5916, DOI 10.1093/emboj/19.21.5916; HARLOW E, 1988, ANTIBODIES LABORATOR, P72; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUSAKA M, 1994, BRIT J CANCER, V69, P212, DOI 10.1038/bjc.1994.41; Lagorce A, 2002, EUR J BIOCHEM, V269, P1697, DOI 10.1046/j.1432-1327.2002.02814.x; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MILLER CG, 1989, J BACTERIOL, V171, P5215, DOI 10.1128/jb.171.9.5215-5217.1989; Miura N, 1999, FEBS LETT, V458, P215, DOI 10.1016/S0014-5793(99)01158-8; Serero A, 2003, J BIOL CHEM, V278, P52953, DOI 10.1074/jbc.M309770200; Towbin H, 2003, J BIOL CHEM, V278, P52964, DOI 10.1074/jbc.M309039200; WATZELE G, 1989, J BIOL CHEM, V264, P8753; YAMAMOTO T, 1994, ANTICANCER RES, V14, P1; Zhang P, 2002, J BIOMED SCI, V9, P34, DOI 10.1007/BF02256576	26	11	12	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14356	14360		10.1074/jbc.M501059200	http://dx.doi.org/10.1074/jbc.M501059200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15699032	hybrid			2022-12-25	WOS:000228095500141
J	Hardy, S; St-Onge, GG; Joly, E; Langelier, Y; Prentki, M				Hardy, S; St-Onge, GG; Joly, E; Langelier, Y; Prentki, M			Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE FATTY-ACIDS; GROWTH-FACTOR RECEPTOR; LYSOPHOSPHATIDIC ACID; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CROSS-TALK; IN-VITRO; ACTIVATION; INHIBITION; APOPTOSIS	Evidence from epidemiological studies and animal models suggests a link between high levels of dietary fat intake and risk of breast cancer. In addition, obesity, in which circulating lipids are elevated, is associated with increased risk of various cancers. Relative to this point, we previously showed that oleate stimulates the proliferation of breast cancer cells and that phosphatidylinositol 3-kinase plays a role in this process. Nonetheless, questions remain regarding the precise mechanism(s) by which oleate promotes breast cancer cell growth. Pharmacological inhibitors of the GTP-binding proteins G(i)/G(o), phospholipase C, Src, and mitogenic-extracellular signal-regulated kinase 1/2 (MEK 1/2) decreased oleate-induced [H-3]thymidine incorporation in the breast cancer cell line MDA-MB-231. In addition, oleate caused a rapid and transient rise in cytosolic Ca2+ and an increase in protein kinase B phosphorylation. Overexpressing in these cells the G protein-coupled receptor GPR40, a fatty acid receptor, amplified oleate-induced proliferation, whereas silencing the GPR40 gene using RNA interference decreased it. Overexpressing GPR40 in T47D and MCF-7 breast cancer cells that are poorly responsive to oleate allowed a robust proliferative action of oleate. The data indicate that the phospholipase C, MEK 1/2, Src, and phosphatidylinositol 3-kinase/protein kinase B signaling pathways are implicated in the proliferative signal induced by oleate and that these effects are mediated at least in part via the G protein-coupled receptor GPR40. The results suggest that GPR40 is implicated in the control of breast cancer cell growth by fatty acids and that GPR40 may provide a link between fat and cancer.	Univ Montreal, Ctr Hosp, Ctr Rech, Mol Nutr Unit, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Nutr, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Montreal Diabet Res Ctr, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Langelier, Y (corresponding author), Univ Montreal, Notre Dame Hosp, Ctr Hosp, Ctr Rech, Y-5603,1560 Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.	yves.langelier@umontreal.ca						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANEL A, 1993, BIOCHEMISTRY-US, V32, P530, DOI 10.1021/bi00053a018; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Boney CM, 2001, CELL GROWTH DIFFER, V12, P379; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Buteau J, 2003, DIABETES, V52, P124, DOI 10.2337/diabetes.52.1.124; Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fay MP, 1997, CANCER RES, V57, P3979; FELBER JP, 2002, INT J OBES RELAT S2, V26, P39; Ferre P, 2004, DIABETES, V53, pS43, DOI 10.2337/diabetes.53.2007.S43; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; Greco S, 2003, J CELL PHYSIOL, V196, P370, DOI 10.1002/jcp.10313; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hardy RW, 1997, ADV EXP MED BIOL, V422, P57; Hardy S, 2000, CANCER RES, V60, P6353; Hardy S, 2003, J BIOL CHEM, V278, P31861, DOI 10.1074/jbc.M300190200; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; Hosoi T, 2002, J BIOL CHEM, V277, P31459, DOI 10.1074/jbc.M203194200; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Kinoshita M, 2001, J BIOL CHEM, V276, P28731, DOI 10.1074/jbc.M104806200; Kotarsky K, 2003, BIOCHEM BIOPH RES CO, V301, P406, DOI 10.1016/S0006-291X(02)03064-4; Lee MM, 2000, ANNU REV NUTR, V20, P221, DOI 10.1146/annurev.nutr.20.1.221; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Louet JF, 2001, BIOCHEM J, V354, P189, DOI 10.1042/0264-6021:3540189; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; McArthur MJ, 1999, J LIPID RES, V40, P1371; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; PRENTKI M, 1984, NATURE, V309, P562, DOI 10.1038/309562a0; Price JT, 1999, CANCER RES, V59, P5475; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; Roche E, 1999, DIABETES, V48, P2007, DOI 10.2337/diabetes.48.10.2007; Rose DP, 1997, AM J CLIN NUTR, V66, P1513; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Sauer LA, 2000, CANCER RES, V60, P5289; Schulte G, 2003, CELL SIGNAL, V15, P813, DOI 10.1016/S0898-6568(03)00058-5; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; Tobin AB, 1997, PHARMACOL THERAPEUT, V75, P135, DOI 10.1016/S0163-7258(97)00053-3; Vacaresse N, 1999, CIRC RES, V85, P892; Yart A, 2002, BBA-MOL CELL BIOL L, V1582, P107, DOI 10.1016/S1388-1981(02)00144-0; Yonezawa T, 2004, BIOCHEM BIOPH RES CO, V314, P805, DOI 10.1016/j.bbrc.2003.12.175; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	55	150	164	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13285	13291		10.1074/jbc.M410922200	http://dx.doi.org/10.1074/jbc.M410922200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695516	hybrid			2022-12-25	WOS:000228095500013
J	Tye, CE; Hunter, GK; Goldberg, HA				Tye, CE; Hunter, GK; Goldberg, HA			Identification of the type I collagen-binding domain of bone sialoprotein and characterization of the mechanism of interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SITE-DIRECTED MUTAGENESIS; HYDROXYAPATITE; OSTEOPONTIN; RECOMBINANT; BSP; EXPRESSION; INTERFACES; RESIDUES; AFFINITY	Bone sialoprotein (BSP) is an anionic phosphorylated glycoprotein that is expressed almost exclusively in mineralized tissues and has been shown to be a potent nucleator of hydroxyapatite formation. The binding of BSP to collagen is thought to be important for the initiation of bone mineralization and in the adhesion of bone cells to the mineralized matrix. Using a solid phase assay, we have investigated the interaction between BSP and collagen. Initial studies showed that raising the ionic strength, decreasing the pH below 7, or introducing divalent cations diminishes but does not abolish the binding of BSP to collagen, indicating that the interaction is only partly electrostatic in nature. Both bone-extracted and recombinant (r) BSP exhibited similar binding affinities, indicating that post-translational modifications are not critical for binding. To identify the collagen-binding domain, recombinant peptides of BSP were studied. Peptide rBSP-(1-100) binds to type I collagen with an affinity similar to that of full-length rBSP, whereas peptides containing the sequences 99 201 or 200-301 do not bind. Further studies showed that rBSP-(1-75) competitively inhibits the binding of rBSP (1-100), whereas rBSP-(21-100) inhibits binding to a lesser extent, and rBSP-(43-100) does not inhibit binding. These results suggest that the collagen-binding site of rat BSP is within the sequence 21-42, with residues N-terminal of this region likely also involved. This site was confirmed by the demonstration of collagen-binding activity of a synthetic peptide corresponding to residues 19-46. The collagen-binding domain, which is highly conserved among species, is enriched in hydrophobic residues and lacks acidic residues. We conclude that residues 19-46 of BSP represent a novel collagen-binding site.	Univ Western Ontario, Sch Dent, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Goldberg, HA (corresponding author), Univ Western Ontario, Sch Dent, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, Dent Sci Bldg, London, ON N6A 5C1, Canada.	hagoldbe@uwo.ca	Goldberg, Harvey/B-5742-2015	Tye, Coralee/0000-0002-3349-1833				BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; CHEN Y, 1992, J BIOL CHEM, V267, P24871; Dahl T, 2003, CONNECT TISSUE RES, V44, P206, DOI 10.1080/03008200390181672; Davis SJ, 1998, P NATL ACAD SCI USA, V95, P5490, DOI 10.1073/pnas.95.10.5490; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; FRATZL P, 1991, CALCIFIED TISSUE INT, V48, P407, DOI 10.1007/BF02556454; Fratzl P, 1996, Connect Tissue Res, V34, P247, DOI 10.3109/03008209609005268; FUJISAWA R, 1995, CALCIFIED TISSUE INT, V56, P140, DOI 10.1007/BF00296346; FUJISAWA R, 1992, CALCIFIED TISSUE INT, V51, P438; Ganss B, 1999, CRIT REV ORAL BIOL M, V10, P79, DOI 10.1177/10454411990100010401; GERSTENFELD LC, 1994, CALCIFIED TISSUE INT, V55, P230, DOI 10.1007/BF00425880; Goldberg Harvey A., 1994, Journal of Tissue Culture Methods, V16, P211, DOI 10.1007/BF01540653; Harris NL, 2000, BONE, V27, P795, DOI 10.1016/S8756-3282(00)00392-6; He G, 2004, J BIOL CHEM, V279, P11649, DOI 10.1074/jbc.M309296200; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; Hunter GK, 2001, J BIOMED MATER RES, V55, P496, DOI 10.1002/1097-4636(20010615)55:4<496::AID-JBM1042>3.0.CO;2-2; KASUGAI S, 1992, J CELL PHYSIOL, V152, P467, DOI 10.1002/jcp.1041520305; Ma BY, 2003, P NATL ACAD SCI USA, V100, P5772, DOI 10.1073/pnas.1030237100; Maurer P, 1997, CELL MOL LIFE SCI, V53, P478, DOI 10.1007/s000180050059; Ofran Y, 2003, J MOL BIOL, V325, P377, DOI 10.1016/S0022-2836(02)01223-8; Pampena DA, 2004, BIOCHEM J, V378, P1083, DOI 10.1042/BJ20031150; POGULIS RJ, 1996, METH MOL B, V57, P167; Romijn RA, 2003, J BIOL CHEM, V278, P15035, DOI 10.1074/jbc.M208977200; Sasaki T, 1998, EMBO J, V17, P1625, DOI 10.1093/emboj/17.6.1625; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; Schreiber G, 2002, CURR OPIN STRUC BIOL, V12, P41, DOI 10.1016/S0959-440X(02)00287-7; STETLERSTEVENSON WG, 1986, CALCIFIED TISSUE INT, V38, P135, DOI 10.1007/BF02556873; Stubbs JT, 1997, J BONE MINER RES, V12, P1210, DOI 10.1359/jbmr.1997.12.8.1210; Tenni R, 2002, EUR J BIOCHEM, V269, P1428, DOI 10.1046/j.1432-1033.2002.02784.x; Tsai CJ, 1997, PROTEIN SCI, V6, P53; Tye CE, 2003, J BIOL CHEM, V278, P7949, DOI 10.1074/jbc.M211915200; VEIS A, 2000, CHEM BIOL MINERALIZE; WEINER S, 1991, FEBS LETT, V285, P49, DOI 10.1016/0014-5793(91)80722-F; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200; Xiao L, 1999, J MOL BIOL, V289, P1435, DOI 10.1006/jmbi.1999.2810; ZHANG R, 1990, J BIOL CHEM, V265, P15375; Zhou HX, 2001, BIOPOLYMERS, V59, P427, DOI 10.1002/1097-0282(200111)59:6<427::AID-BIP1047>3.0.CO;2-7; Zhu XL, 2001, BIOCHEM CELL BIOL, V79, P737, DOI 10.1139/bcb-79-6-737	44	95	98	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13487	13492		10.1074/jbc.M408923200	http://dx.doi.org/10.1074/jbc.M408923200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15703183	hybrid			2022-12-25	WOS:000228095500039
J	Ghosh, S; Wu, YM; Li, R; Hu, YF				Ghosh, S; Wu, YM; Li, R; Hu, YF			Jun proteins modulate the ovary-specific promoter of aromatase gene in ovarian granulosa cells via a cAMP-responsive element	ONCOGENE			English	Article						Jun; aromatase; transcriptional repression; granulosa cells; ovary	MESSENGER-RIBONUCLEIC-ACID; C-JUN; TRANSCRIPTIONAL ACTIVATION; CONSTITUTIVE EXPRESSION; ESTROGEN BIOSYNTHESIS; BINDING PROTEIN; RECEPTOR; AP-1; TRANSFORMATION; MECHANISMS	Estrogen is critical to both normal mammary gland and breast cancer development. Circulating levels of estrogen in premenopausal women are primarily determined by the action of aromatase in ovarian granulosa cells that converts testosterone to estradiol. In the current study, we unraveled an important role of Jun proteins in modulating ovary-specific aromatase expression. Ectopic expression of the Jun proteins in a human granulosa cell line significantly inhibited an ovary-specific promoter (PII) of the aromatase gene, whereas expression of dominant-negative mutants of Jun led to increased promoter activity. The Jun-mediated repression was specific to the aromatase promoter, as Jun proteins stimulated known AP1-responsive promoters in the same cellular context. Both the activation and basic leucine zipper domains of Jun were required for the transcriptional repression. Electrophoretic gel mobility assay showed that endogenous Jun proteins bound to a functionally important cAMP-responsive element (CRE) in the PII promoter-proximal region. Alteration of the CRE-like site impaired both the cAMP-responsive transcriptional activation and Jun-mediated repression. Furthermore, chromatin immunoprecipitation indicated the presence of cJun at the proximal region of the native PII promoter. Taken together, our work suggests that Jun proteins may attenuate estrogen biosynthesis by directly downregulating transcription of the aromatase gene in ovarian granulosa cells.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Hu, YF (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	yh4b@virginia.edu			NCI NIH HHS [CA093506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aiyar SE, 2004, GENE DEV, V18, P2134, DOI 10.1101/gad.1214104; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BROWN PH, 1993, ONCOGENE, V8, P877; Bulun SE, 2003, J STEROID BIOCHEM, V86, P219, DOI 10.1016/S0960-0760(03)00359-5; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; Christenson LK, 2001, ENDOCRINOLOGY, V142, P28, DOI 10.1210/endo.142.1.7867; Chu S, 2004, MOL ENDOCRINOL, V18, P1919, DOI 10.1210/me.2004-0021; DELIDOW BC, 1992, BIOL REPROD, V47, P428, DOI 10.1095/biolreprod47.3.428; FITZPATRICK SL, 1994, MOL ENDOCRINOL, V8, P1309, DOI 10.1210/me.8.10.1309; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; FITZPATRICK SL, 1991, ENDOCRINOLOGY, V129, P1452, DOI 10.1210/endo-129-3-1452; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Gonzalez-Robayna IJ, 1999, MOL ENDOCRINOL, V13, P1318, DOI 10.1210/me.13.8.1318; Guberman AS, 2003, J BIOL CHEM, V278, P2317, DOI 10.1074/jbc.M205057200; HERBER B, 1994, ONCOGENE, V9, P1295; HICKEY GJ, 1988, ENDOCRINOLOGY, V122, P1426, DOI 10.1210/endo-122-4-1426; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Hu YF, 2002, GENE DEV, V16, P1509, DOI 10.1101/gad.995502; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kamat A, 2002, TRENDS ENDOCRIN MET, V13, P122, DOI 10.1016/S1043-2760(02)00567-2; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; Manna PR, 2004, MOL ENDOCRINOL, V18, P558, DOI 10.1210/me.2003-0223; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; MICHAEL MD, 1995, J BIOL CHEM, V270, P13561, DOI 10.1074/jbc.270.22.13561; Morinaga H, 2004, ENDOCRINOLOGY, V145, P1860, DOI 10.1210/en.2003-1182; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; Mukasa C, 2003, ENDOCRINOLOGY, V144, P1603, DOI 10.1210/en.2002-220978; Nishi Y, 2001, ENDOCRINOLOGY, V142, P437, DOI 10.1210/en.142.1.437; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; Richards JS, 1998, MOL CELL ENDOCRINOL, V145, P47, DOI 10.1016/S0303-7207(98)00168-3; RICHARDS JS, 1995, RECENT PROG HORM RES, V50, P223; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Sasano H, 1998, ENDOCR REV, V19, P593, DOI 10.1210/er.19.5.593; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Sharma SC, 2000, J BIOL CHEM, V275, P33718, DOI 10.1074/jbc.M003555200; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Simpson ER, 2001, ENDOCRINOLOGY, V142, P4589, DOI 10.1210/endo.142.11.8547; Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703; Thepot D, 2000, DEVELOPMENT, V127, P143; WOODRUFF TK, 1987, MOL ENDOCRINOL, V1, P561, DOI 10.1210/mend-1-8-561; WU Y, 2004, IN PRESS ENDOCRINOLO; Young M, 1997, J STEROID BIOCHEM, V61, P341	49	35	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2236	2246		10.1038/sj.onc.1208415	http://dx.doi.org/10.1038/sj.onc.1208415			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15688015				2022-12-25	WOS:000227857900011
J	Hirota, T; Irie, K; Okamoto, R; Ikeda, W; Takai, Y				Hirota, T; Irie, K; Okamoto, R; Ikeda, W; Takai, Y			Transcriptional activation of the mouse Necl-5/Tage4/PVR/CD155 gene by broblast growth factor or oncogenic Ras through the Raf-MEK-ERK-AP-1 pathway	ONCOGENE			English	Article						Necl-5; nectin Ras; MAP kinase; AP-1 fibroblast growth factor	ENHANCES CELL-MIGRATION; IMMUNOGLOBULIN SUPERFAMILY; INTERCELLULAR-JUNCTIONS; POLIOVIRUS RECEPTOR; CORE PROMOTER; CD155 GENE; NECTIN; IDENTIFICATION; PROLIFERATION; EXPRESSION	Necl-5/Tage4/poliovirus receptor/CD155 is the poliovirus receptor and upregulated in rodent and human carcinoma. We have recently shown that mouse Necl-5 is upregulated by an oncogenic Ki-Ras (V12Ki-Ras) in NIH3T3 cells and enhances cell movement induced by growth factors, including platelet-derived growth factor and. broblast growth factor (FGF), in an integrin alpha(v)beta(3)-dependent manner in wild type and V12Ki-Ras-transformed NIH3T3 cells. In addition, it enhances the growth factor-induced cell proliferation. We examined here how mouse Necl-5 was upregulated by (V12Ki-Ras in NIH3T3 cells. Expression of the luciferase reporter gene fused to the Necl-5 promoter was induced by (V12Ki-Ras in NIH3T3 cells. This induction was mediated through the Raf-MEK-ERK pathway. The Necl-5 promoter has an AP-1-binding site and this site was required for the V12Ki-Ras-induced activation of the Necl-5 promoter. Expression of the luciferase reporter gene fused to the Necl-5 promoter was also induced by FGF through the Raf-MEK-ERK-AP-1 pathway in NIH3T3 cells. These results indicate that the expression of mouse Necl-5 is induced by FGF or V12Ki-Ras through the Raf-MEK-ERK-AP-1 pathway.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058				Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; Chadeneau C, 1996, INT J CANCER, V68, P817; CHADENEAU C, 1994, J BIOL CHEM, V269, P15601; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Ikeda W, 2004, J BIOL CHEM, V279, P18015, DOI 10.1074/jbc.M312969200; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; Kakunaga S, 2004, J BIOL CHEM, V279, P36419, DOI 10.1074/jbc.M406340200; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Mercer JA, 2000, SEMIN CELL DEV BIOL, V11, P309, DOI 10.1006/scdb.2000.0181; Mueller S, 2003, J BIOL CHEM, V278, P31251, DOI 10.1074/jbc.M304166200; Sato T, 2004, GENES CELLS, V9, P791, DOI 10.1111/j.1365-2443.2004.00763.x; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Shibuya K, 2003, J EXP MED, V198, P1829, DOI 10.1084/jem.20030958; Solecki D, 1999, J BIOL CHEM, V274, P1791, DOI 10.1074/jbc.274.3.1791; Solecki D, 2000, J BIOL CHEM, V275, P12453, DOI 10.1074/jbc.275.17.12453; Solecki DJ, 2002, J BIOL CHEM, V277, P25697, DOI 10.1074/jbc.M201378200; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167	23	56	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2229	2235		10.1038/sj.onc.1208409	http://dx.doi.org/10.1038/sj.onc.1208409			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15688018				2022-12-25	WOS:000227857900010
J	Chan, EH; Nousiainen, M; Chalamalasetty, RB; Schafer, A; Nigg, EA; Sillje, HHW				Chan, EH; Nousiainen, M; Chalamalasetty, RB; Schafer, A; Nigg, EA; Sillje, HHW			The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1	ONCOGENE			English	Article						Lats1; Mst2; Ste20; hWW45; apoptosis; tumor suppressor	CELL-CYCLE EXIT; PROTEIN-KINASE; PROMOTES APOPTOSIS; HUMAN HOMOLOG; PROLIFERATION ARREST; MASS-SPECTROMETRY; DROSOPHILA LATS; FAMILY PROTEIN; GENE; GROWTH	Originally identified in Drosophila melanogaster, the Warts(Wts)/Lats protein kinase has been proposed to function with two other Drosophila proteins, Hippo (Hpo) and Salvador (Sav), in the regulation of cell cycle exit and apoptosis. In mammals, two candidate Warts/Lats homologs, termed Lats1 and Lats2, have been described, and the targeted disruption of LATS1 in mice increases tumor formation. Little, however, is known about the function and regulation of human Lats kinases. Here we report that human Mst2, a STE20-family member and purported Hpo ortholog, phosphorylates and activates both Lats1 and Lats2. Deletion analysis revealed that regulation of Lats1 occurs through the C-terminal, catalytic domain. Within this domain, two regulatory phosphorylation sites were identified by mass spectrometry. These sites, S909 in the activation loop and T1079 within a hydrophobic motif, have been highly conserved during evolution. Moreover, a direct interaction was observed between Mst2 and hWW45, a putative ortholog of Drosophila Sav. These results indicate that Mst2-like kinases regulate Lats kinase activities in an evolutionarily conserved regulatory pathway. Although the function of this pathway remains poorly understood in mammals, it is intriguing that, in Drosophila, it has been linked to development and tissue homeostasis.	Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Sillje, HHW (corresponding author), Max Planck Inst Biochem, Dept Cell Biol, Klopferspitz 18, D-82152 Martinsried, Germany.	sillje@biochem.mpg.de		nigg, erich/0000-0003-4835-5719; Nousiainen, Marjaana/0000-0001-6701-2047; Chan, Eunice Ho-Yee/0000-0003-3162-3609				Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Hisaoka M, 2002, LAB INVEST, V82, P1427, DOI 10.1097/01.LAB.0000032381.68634.CA; Hoffmann R, 1999, J MASS SPECTROM, V34, P1195, DOI 10.1002/(SICI)1096-9888(199911)34:11<1195::AID-JMS881>3.0.CO;2-C; Hori T, 2000, ONCOGENE, V19, P3101, DOI 10.1038/sj.onc.1203659; James P, 1996, GENETICS, V144, P1425; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Li YF, 2003, ONCOGENE, V22, P4398, DOI 10.1038/sj.onc.1206603; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Morisaki T, 2002, FEBS LETT, V529, P319, DOI 10.1016/S0014-5793(02)03360-4; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Preisinger C, 2004, J CELL BIOL, V164, P1009, DOI 10.1083/jcb.200310061; Scheel H, 2003, CURR BIOL, V13, pR899, DOI 10.1016/j.cub.2003.11.007; Seelos C, 1997, ANAL BIOCHEM, V245, P109, DOI 10.1006/abio.1996.9948; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sillje HHW, 1999, EMBO J, V18, P5691, DOI 10.1093/emboj/18.20.5691; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Valverde P, 2000, BIOCHEM BIOPH RES CO, V276, P990, DOI 10.1006/bbrc.2000.3582; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; XU TA, 1995, DEVELOPMENT, V121, P1053; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817	42	422	443	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 17	2005	24	12					2076	2086		10.1038/sj.onc.1208445	http://dx.doi.org/10.1038/sj.onc.1208445			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688006				2022-12-25	WOS:000227681900012
J	Begum, S; Emani, N; Cheung, A; Wilkins, O; Der, S; Hamel, PA				Begum, S; Emani, N; Cheung, A; Wilkins, O; Der, S; Hamel, PA			Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR	ONCOGENE			English	Article						Pax3; Pax3/ FKHR; microarray; gene targets; rhabdomyosarcoma	HORMONE-RELATED PROTEIN; PAX3-FKHR FUSION PROTEIN; NEURAL CREST MIGRATION; DNA-BINDING; WAARDENBURG SYNDROME; PAIRED-DOMAIN; ALVEOLAR RHABDOMYOSARCOMA; TWISTED GASTRULATION; TRANSCRIPTIONAL ACTIVATOR; EMBRYONIC-DEVELOPMENT	The oncogenic fusion protein, Pax3/FKHR, is a more potent transcription factor relative to its normal counterpart, Pax3. Since Pax3 induced a mesenchymal to epithelial transition (MET) in human SaOS-2 osteosarcomas, we hypothesized that Pax3/FKHR would also induce a morphological change in SaOS-2 cells. We demonstrate here that Pax3/FKHR more potently induces a MET in SaOS-2 cells than Pax3. This greater potency was further evident where Pax3/FKHR, but not Pax3, induced a morphological alteration in U2-OS osteosarcoma cells. By microarray analysis, we determined that Pax3/FKHR altered the expression of gene targets in a manner quantitatively and qualitatively distinct from Pax3. Three classes of genes were identified: (i) genes induced or repressed by Pax3 and Pax3/FKHR, (ii) genes induced or repressed by Pax3/FKHR but not Pax3 and (iii) genes induced by Pax3/FKHR but repressed by Pax3. Chromatin immunoprecipitations confirmed the direct binding of Pax3/FKHR to the promoter region of several factors including cannabinoid receptor-1, EPHA2 and EPHA4. Verification of the microarray data also revealed coordinate alteration in the expression of factors involved in BMP4 signalling. Regulation of gene expression by Pax3 and Pax3/FKHR is, however, cell-type specific. BMP4 expression, for example, was repressed by both Pax3 and Pax3/FKHR in SaOS-2 cells, while in the rhabdomyosarcoma, RD, Pax3/FKHR, but not Pax3, induced BMP4 expression. Thus, our data reveal that Pax3/FKHR regulates a distinct but overlapping set of genes relative to Pax3 and that the global set of Pax3 and Pax3/FKHR gene targets is cell-type specific.	Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada	University of Toronto	Hamel, PA (corresponding author), Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, 1 Kings Coll Circle,6318 Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	paul.hamel@utoronto.ca	Wilkins, Olivia/AGG-7629-2022; Xiao, Yang/B-5668-2012	Wilkins, Olivia/0000-0001-9762-7069				Anderson J, 1999, GENE CHROMOSOME CANC, V26, P275, DOI 10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3; Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; Ba-Charvet KTN, 1999, NEURON, V22, P463, DOI 10.1016/S0896-6273(00)80702-3; BALDWIN CT, 1994, HUM MUTAT, V3, P205, DOI 10.1002/humu.1380030306; Barrios A, 2003, CURR BIOL, V13, P1571, DOI 10.1016/j.cub.2003.08.030; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Blake J, 2003, HISTOL HISTOPATHOL, V18, P529, DOI 10.14670/HH-18.529; BOBER E, 1994, DEVELOPMENT, V120, P603; BOUIZAR Z, 1993, CANCER RES, V53, P5076; Buckley NE, 1998, NEUROSCIENCE, V82, P1131; Bundred NJ, 1996, ANN ROY COLL SURG, V78, P354; Cao Y, 2000, J BIOL CHEM, V275, P9854, DOI 10.1074/jbc.275.13.9854; CHALEPAKIS G, 1994, NUCLEIC ACIDS RES, V22, P3131, DOI 10.1093/nar/22.15.3131; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; Chang CB, 2001, NATURE, V410, P483, DOI 10.1038/35068583; Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159; Conway SJ, 1997, CARDIOVASC RES, V36, P163, DOI 10.1016/S0008-6363(97)00172-7; Conway SJ, 1997, DEVELOPMENT, V124, P505; De Bellard ME, 2002, DEV BIOL, V249, P121, DOI 10.1006/dbio.2002.0756; DIETRICH S, 1993, MECH DEVELOP, V44, P189, DOI 10.1016/0925-4773(93)90067-8; Dunbar ME, 1999, J MAMMARY GLAND BIOL, V4, P21, DOI 10.1023/A:1018700502518; Durbin L, 1998, GENE DEV, V12, P3096, DOI 10.1101/gad.12.19.3096; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; Farquharson C, 2001, ENDOCRINOLOGY, V142, P4131, DOI 10.1210/en.142.9.4131; Foley J, 2001, DEVELOPMENT, V128, P513; Fortin AS, 1997, HUM MOL GENET, V6, P1781, DOI 10.1093/hmg/6.11.1781; Fredericks William J., 2001, Cancer Letters, V162, pS23, DOI 10.1016/S0304-3835(00)00649-2; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GERARD M, 1995, CR ACAD SCI III-VIE, V318, P57; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; HOTH CF, 1993, AM J HUM GENET, V52, P455; Hu HY, 1999, NEURON, V23, P703, DOI 10.1016/S0896-6273(01)80029-5; Johnson J, 2001, DEV BIOL, V229, P176, DOI 10.1006/dbio.2000.9969; Kaestner KH, 2000, GENE DEV, V14, P142; Kawasaki H, 1998, J PEDIAT HEMATOL ONC, V20, P327, DOI 10.1097/00043426-199807000-00009; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Khan J, 1998, CANCER RES, V58, P5009; Kissin M W, 1993, Eur J Surg Oncol, V19, P134; Koblar SA, 2000, J NEUROBIOL, V42, P437, DOI 10.1002/(SICI)1097-4695(200003)42:4<437::AID-NEU5>3.3.CO;2-F; Kwang SJ, 2002, DEVELOPMENT, V129, P527; Lagutina I, 2002, MOL CELL BIOL, V22, P7204, DOI 10.1128/MCB.22.20.7204-7216.2002; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Libura J, 2002, BLOOD, V100, P2597, DOI 10.1182/blood-2002-01-0031; Luo T, 2001, INT J DEV BIOL, V45, P681; Mayanil CSK, 2000, J BIOL CHEM, V275, P23259, DOI 10.1074/jbc.M002975200; Mayanil CSK, 2001, J BIOL CHEM, V276, P49299, DOI 10.1074/jbc.M107933200; Park GT, 2002, NUCLEIC ACIDS RES, V30, P515, DOI 10.1093/nar/30.2.515; Popkin DL, 2003, P NATL ACAD SCI USA, V100, P14309, DOI 10.1073/pnas.1835673100; Poser I, 2004, HISTOL HISTOPATHOL, V19, P173, DOI 10.14670/HH-19.173; Relaix F, 2003, GENE DEV, V17, P2950, DOI 10.1101/gad.281203; Ross JJ, 2001, NATURE, V410, P479, DOI 10.1038/35068578; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; Schubert FR, 2001, DEV DYNAM, V222, P506, DOI 10.1002/dvdy.1211; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; SEBAG M, 1994, AM J PHYSIOL, V267, pC723, DOI 10.1152/ajpcell.1994.267.3.C723; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Song ZH, 2000, J PHARMACOL EXP THER, V294, P204; SUBLETT JE, 1995, ONCOGENE, V11, P545; TASSABEHJI M, 1994, HUM MOL GENET, V3, P1069, DOI 10.1093/hmg/3.7.1069; Terzic J, 1999, INT J DEV BIOL, V43, P501; TREMBLAY P, 1995, DEV BIOL, V171, P317, DOI 10.1006/dbio.1995.1284; Tremblay P, 1998, DEV BIOL, V203, P49, DOI 10.1006/dbio.1998.9041; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; Underhill DA, 1997, J BIOL CHEM, V272, P14175, DOI 10.1074/jbc.272.22.14175; Vachtenheim J, 1999, CELL MOL BIOL, V45, P1075; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Wardle FC, 1999, DEV BIOL, V206, P63, DOI 10.1006/dbio.1998.9127; Wardle FC, 1999, MECH DEVELOP, V86, P75, DOI 10.1016/S0925-4773(99)00114-8; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wiggan O, 2002, J CELL SCI, V115, P517; Wiggan O, 2002, J CELL SCI, V115, P531; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; Xia SJJ, 2002, CANCER BIOL THER, V1, P97, DOI 10.4161/cbt.51; Yu K, 2000, DEVELOPMENT, V127, P2143	84	49	53	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1860	1872		10.1038/sj.onc.1208315	http://dx.doi.org/10.1038/sj.onc.1208315			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688035				2022-12-25	WOS:000227542000005
J	Renfrow, MB; Cooper, HJ; Tomana, M; Kulhavy, R; Hiki, Y; Toma, K; Emmett, MR; Mestecky, J; Marshall, AG; Novak, J				Renfrow, MB; Cooper, HJ; Tomana, M; Kulhavy, R; Hiki, Y; Toma, K; Emmett, MR; Mestecky, J; Marshall, AG; Novak, J			Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation Fourier transform-ion cyclotron resonance mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFRARED MULTIPHOTON DISSOCIATION; GALACTOSE-DEFICIENT IGA1; HUMAN SERUM IGA1; LINKED OLIGOSACCHARIDES; CARBOHYDRATE MOIETIES; EXTERNAL ACCUMULATION; RHEUMATOID-ARTHRITIS; NEPHROPATHY PATIENTS; IMMUNE-COMPLEXES; GLYCOPEPTIDES	In a number of human diseases of chronic inflammatory or autoimmune character, immunoglobulin molecules display aberrant glycosylation patterns of N- or O-linked glycans. In IgA nephropathy, IgA1 molecules with incompletely galactosylated O-linked glycans in the hinge region (HR) are present in mesangial immunodeposits and in circulating immune complexes. It is not known whether the Gal deficiency in IgA1 proteins occurs randomly or preferentially at specific sites. To develop experimental approaches to address this question, the synthetic IgA1 hinge region and hinge region from a naturally Gal-deficient IgA1 myeloma protein have been analyzed by 9.4 tesla Fourier transform-ion cyclotron resonance mass spectrometry. Fourier transform-ion cyclotron resonance mass spectrometry offers two complementary fragmentation techniques for analysis of protein glycosylation by tandem mass spectrometry. Infrared multiphoton dissociation of isolated myeloma IgA1 hinge region peptides confirms the amino acid sequence of the de-glycosylated peptide and positively identifies a series of fragments differing in O-glycosylation. To localize sites of O-glycan attachment, synthetic IgA1 HR glycopeptides and HR from a naturally Gal-deficient polymeric IgA1 myeloma protein were analyzed by electron capture dissociation and activated ion-electron capture dissociation. Multiple sites of O-glycan attachment (including sites of Gal deficiency) in myeloma IgA1 HR glycoforms were identified (in all but one case uniquely). These results represent the first direct identification of multiple sites of O-glycan attachment in IgA1 hinge region by mass spectrometry, thereby enabling future characterization at the molecular level of aberrant glycosylation of IgA1 in diseases such as IgA nephropathy.	Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Florida State Univ, Natl High Magnet Field Lab, Tallahassee, FL 32310 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Fujita Hlth Univ, Sch Med, Dept Med, Div Nephrol, Toyoake, Aichi 4701192, Japan; Noguchi Inst, Dept Res, Tokyo 1730003, Japan; Florida State Univ, Dept Chem, Tallahassee, FL 32306 USA	University of Alabama System; University of Alabama Birmingham; State University System of Florida; Florida State University; University of Alabama System; University of Alabama Birmingham; Fujita Health University; State University System of Florida; Florida State University	Novak, J (corresponding author), Univ Alabama, Dept Microbiol, 845 19th St S,BBRB 734 Box 1, Birmingham, AL 35294 USA.	Jan_Novak@microbio.uab.edu	Cooper, Helen/M-4488-2017; Emmett, Mark R/C-3478-2013	Cooper, Helen/0000-0003-4590-9384; Emmett, Mark R/0000-0002-9248-5767; Renfrow, Matthew B./0000-0002-4193-7305	NIDCR NIH HHS [DE13694] Funding Source: Medline; NIDDK NIH HHS [DK61525, DK57750] Funding Source: Medline; NIGMS NIH HHS [R01 GM098539] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK061525, R01DK057750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM098539] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen A, 1998, ADV EXP MED BIOL, V435, P175; Allen AC, 2001, KIDNEY INT, V60, P969, DOI 10.1046/j.1523-1755.2001.060003969.x; ALLEN AC, 1995, CLIN EXP IMMUNOL, V100, P470; Alving K, 1999, J MASS SPECTROM, V34, P395, DOI 10.1002/(SICI)1096-9888(199904)34:4<395::AID-JMS771>3.3.CO;2-T; ANDRE PM, 1990, J CLIN LAB ANAL, V4, P115, DOI 10.1002/jcla.1860040208; BAENZIGER J, 1974, J BIOL CHEM, V249, P7270; Belov ME, 2001, ANAL CHEM, V73, P253, DOI 10.1021/ac000633w; BLAKNEY GT, 2001, 49 ASMS C MASS SPECT; Chalmers MJ, 2004, PROTEOMICS, V4, P970, DOI 10.1002/pmic.200300650; CHOWDHURY SK, 1990, RAPID COMMUN MASS SP, V4, P81, DOI 10.1002/rcm.1290040305; Cooper HJ, 2003, EUR J MASS SPECTROM, V9, P221, DOI 10.1255/ejms.555; Cooper HJ, 2005, MASS SPECTROM REV, V24, P201, DOI 10.1002/mas.20014; Coppo R, 2004, KIDNEY INT, V65, P1544, DOI 10.1111/j.1523-1755.2004.05407.x; DWEK RA, 1995, SCIENCE, V269, P1234, DOI 10.1126/science.7652569; EMMETT MR, 1994, J AM SOC MASS SPECTR, V5, P605, DOI 10.1016/1044-0305(94)85001-1; FIELD MC, 1994, BIOCHEM J, V299, P261, DOI 10.1042/bj2990261; FIELD MC, 1989, BIOCHEM SOC T, V17, P1034, DOI 10.1042/bst0171034; FRANGION.B, 1972, P NATL ACAD SCI USA, V69, P3673, DOI 10.1073/pnas.69.12.3673; Guan SH, 1996, INT J MASS SPECTROM, V157, P5, DOI 10.1016/S0168-1176(96)04461-8; Hakansson K, 2001, ANAL CHEM, V73, P4530, DOI 10.1021/ac0103470; Hakansson K, 2003, ANAL CHEM, V75, P3256, DOI 10.1021/ac030015q; Haselmann KF, 2001, ANAL CHEM, V73, P2998, DOI 10.1021/ac0015523; HENDRICKSON CL, 2004, 52 ASMS C MASS SPECT; HENDRICKSON CL, 2000, 48 ASMS C MASS SPECT; Hiki Y, 2001, KIDNEY INT, V59, P1077, DOI 10.1046/j.1523-1755.2001.00591.x; Hiki Y, 1998, J AM SOC NEPHROL, V9, P577; HIKI Y, 1995, CONTRIB NEPHROL, V111, P73; HIKI Y, 1998, 8 INT IGA NEPHR S NO; Horn DM, 2000, ANAL CHEM, V72, P4778, DOI 10.1021/ac000494i; Iwasaki H, 2003, J BIOL CHEM, V278, P5613, DOI 10.1074/jbc.M211097200; Iwase H, 1996, J BIOCHEM-TOKYO, V120, P393; Julian BA, 2004, CURR OPIN NEPHROL HY, V13, P171, DOI 10.1097/00041552-200403000-00005; Kelleher RL, 1999, ANAL CHEM, V71, P4250, DOI 10.1021/ac990684x; Kobata A, 1998, GLYCOCONJUGATE J, V15, P323, DOI 10.1023/A:1006961532182; Kokubo T, 1999, NEPHROL DIAL TRANSPL, V14, P81, DOI 10.1093/ndt/14.1.81; Kokubo T, 2000, NEPHROL DIAL TRANSPL, V15, P28, DOI 10.1093/ndt/15.1.28; LEDFORD EB, 1984, ANAL CHEM, V56, P2744, DOI 10.1021/ac00278a027; MARSHALL AG, 1985, J AM CHEM SOC, V107, P7893, DOI 10.1021/ja00312a015; Marshall AG, 1998, MASS SPECTROM REV, V17, P1, DOI 10.1002/(SICI)1098-2787(1998)17:1<1::AID-MAS1>3.0.CO;2-K; Marshall AG, 1990, FOURIER TRANSFORMS N; Mattu TS, 1998, J BIOL CHEM, V273, P2260, DOI 10.1074/jbc.273.4.2260; MCFARLAND MA, 2004, 52 ASMS C MASS SPECT; Medzihradszky KF, 1996, J AM SOC MASS SPECTR, V7, P319, DOI 10.1016/1044-0305(95)00682-6; MEDZIHRADSZKY KF, 1990, BIOMED ENVIRON MASS, V19, P777, DOI 10.1002/bms.1200191205; MESTECKY J, 1986, MONOGR ALLERGY, V19, P277; Mestecky J, 2002, NEPHROLOGY, V7, pS92, DOI 10.1046/j.1440-1797.7.s3.3.x; MESTECKY J, 1993, CONTRIB NEPHROL, V104, P172; Mestecky J, 1997, NEPHROLOGY, V3, P85, DOI 10.1111/j.1440-1797.1997.tb00195.x; Mestecky J, 2005, MUCOSAL IMMUNOLOGY, 3RD EDITION, P153, DOI 10.1016/B978-012491543-5/50013-9; MULLINAX F, 1975, ARTHRITIS RHEUM, V18, P417; Nemeth JF, 2001, BIOCHEMISTRY-US, V40, P3109, DOI 10.1021/bi002313c; Novak J, 2002, KIDNEY INT, V62, P465, DOI 10.1046/j.1523-1755.2002.00477.x; Novak J, 2001, J CLIN IMMUNOL, V21, P310, DOI 10.1023/A:1012284402054; Novak J, 2000, MOL IMMUNOL, V37, P1047, DOI 10.1016/S0161-5890(01)00019-0; QUINN JP, 1998, 46 ASMS C MASS SPECT, P1388; Ritchie MA, 2002, J AM SOC MASS SPECTR, V13, P1065, DOI 10.1016/S1044-0305(02)00421-X; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; Senko MW, 1996, RAPID COMMUN MASS SP, V10, P1839, DOI 10.1002/(SICI)1097-0231(199611)10:14<1839::AID-RCM718>3.0.CO;2-V; Senko MW, 1997, J AM SOC MASS SPECTR, V8, P970, DOI 10.1016/S1044-0305(97)00126-8; Senko MW, 1996, RAPID COMMUN MASS SP, V10, P1824; Shi SDH, 2000, INT J MASS SPECTROM, V195, P591, DOI 10.1016/S1387-3806(99)00226-2; Smith AC, 2003, SPRINGER SEMIN IMMUN, V24, P477, DOI 10.1007/s00281-002-0115-x; TOMANA M, 1984, J LAB CLIN MED, V103, P137; Tomana M, 1999, J CLIN INVEST, V104, P73, DOI 10.1172/JCI5535; Tomana M, 1997, KIDNEY INT, V52, P509, DOI 10.1038/ki.1997.361; Tomana M., 1996, GLYCOPROTEINS DIS, P291; Wilcox BE, 2002, J AM SOC MASS SPECTR, V13, P1304, DOI 10.1016/S1044-0305(02)00622-0; WOLFENST.C, 1972, BIOCHEMISTRY-US, V11, P3971, DOI 10.1021/bi00771a021; Zaia J, 2004, MASS SPECTROM REV, V23, P161, DOI 10.1002/mas.10073; Zhu XG, 2000, BIOCHEMISTRY-US, V39, P11194, DOI 10.1021/bi000432m; Zubarev RA, 1998, J AM CHEM SOC, V120, P3265, DOI 10.1021/ja973478k; Zubarev RA, 2003, MASS SPECTROM REV, V22, P57, DOI 10.1002/mas.10042	73	112	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19136	19145		10.1074/jbc.M411368200	http://dx.doi.org/10.1074/jbc.M411368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15728186	hybrid			2022-12-25	WOS:000228932300070
J	Liu, BS; Sutton, A; Sternglanz, R				Liu, BS; Sutton, A; Sternglanz, R			A yeast polyamine acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SPERMIDINE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE; ACETYLATION; CHROMATIN; BIOSYNTHESIS; METABOLISM; COMPLEXES; OXIDASE	An uncharacterized yeast gene has been shown to encode a polyamine acetyltransferase and named PAA1. The recombinant Paa1 protein readily acetylates various polyamines such as putrescine, spermidine, and spermine. paa1 mutants are viable and grow normally under standard conditions. The mutants are sensitive to hydroxyurea, and they are synthetically temperature-sensitive with a rad53-21 mutation. The mutants also show genetic interactions with components of the transcriptional co-activator complex, SAGA, and partially suppress Spt(-) phenotypes of two spt mutants. These phenotypes suggest that acetylation of polyamines removes them from chromatin and makes the chromatin more accessible. It is known that spermine, but not acetyl spermine, is a precursor in the pathway for synthesis of coenzyme A in yeast. When Paa1 is overexpressed, leading to a lower level of spermine, cells show a growth dependence on either of two downstream compounds in the coenzyme A pathway, pantothenate or beta-alanine. This demonstrates that spermine and perhaps other polyamines are the in vivo targets of Paa1.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Sternglanz, R (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Life Sci Bldg, Stony Brook, NY 11794 USA.	rolf@life.bio.sunysb.edu			NIGMS NIH HHS [GM28220] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028220, R56GM028220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babbar N, 2003, BIOCHEM SOC T, V31, P388, DOI 10.1042/BST0310388; CARPER SW, 1991, J BIOL CHEM, V266, P12439; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; Chattopadhyay MK, 2003, P NATL ACAD SCI USA, V100, P13869, DOI 10.1073/pnas.1835918100; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; DESIDERIO MA, 1993, BIOCHEM J, V293, P475, DOI 10.1042/bj2930475; DOD B, 1982, EUR J BIOCHEM, V121, P401, DOI 10.1111/j.1432-1033.1982.tb05801.x; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FUKUCHI J, 1994, J BIOL CHEM, V269, P22581; FUKUCHI JI, 1995, J BIOL CHEM, V270, P18831, DOI 10.1074/jbc.270.32.18831; Ganguly S, 2001, J BIOL CHEM, V276, P47239, DOI 10.1074/jbc.M107222200; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Landry J, 2003, BIOCHEM BIOPH RES CO, V303, P771, DOI 10.1016/S0006-291X(03)00416-9; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Meyskens FL, 1999, CLIN CANCER RES, V5, P945; MORGAN DML, 1998, POLYAMINE PROTOCOLS, P77; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Pollard KJ, 1999, EMBO J, V18, P5622, DOI 10.1093/emboj/18.20.5622; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Raspaud E, 1999, BIOPHYS J, V77, P1547, DOI 10.1016/S0006-3495(99)77002-5; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Tabor H, 1971, METHODS ENZYMOLOGY B, V17, P829; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; White WH, 2001, J BIOL CHEM, V276, P10794, DOI 10.1074/jbc.M009804200; XIAO L, 1991, BIOCHEM BIOPH RES CO, V179, P407, DOI 10.1016/0006-291X(91)91385-P	27	31	33	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16659	16664		10.1074/jbc.M414008200	http://dx.doi.org/10.1074/jbc.M414008200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15723835	hybrid			2022-12-25	WOS:000228615500017
J	O'Connor, CM; Lai, CK; Collins, K				O'Connor, CM; Lai, CK; Collins, K			Two purified domains of telomerase reverse transcriptase reconstitute sequence-specific interactions with RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAHYMENA TELOMERASE; FUNCTIONAL MULTIMERIZATION; CATALYTIC SUBUNIT; TEMPLATE; COMPONENT	Telomerase reverse transcriptase ( TERT) and telomerase RNA (TER) function together to create a uniquely specialized polymerase. Here we have described for the first time domains of bacterially expressed Tetrahymena TERT that interacted directly with TER in the absence of assembly chaperones. We used quantitative binding assays to define TER sequence requirements for recognition by the high affinity RNA binding domain and an independent N-terminal RNA interaction domain. The TERT RNA binding domain and N-terminal RNA interaction domain had distinct, nonoverlapping requirements for TER sequence and structure that together accounted for all of the sites of TER contact inferred for full-length TERT. The TER residues important for TERT binding are only a subset of the residues required for catalytic activity. Our findings demonstrate telomerase functional specialization by an elaborate ribonucleoprotein architecture physically separable from the active site.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Collins, K (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	kcollins@socrates.berkeley.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054198] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054198-09, R01 GM054198, GM54198] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUTEXIER C, 1995, GENE DEV, V9, P2227, DOI 10.1101/gad.9.18.2227; Beattie TL, 2001, MOL CELL BIOL, V21, P6151, DOI 10.1128/MCB.21.18.6151-6160.2001; Cech TR, 2004, CELL, V116, P273, DOI 10.1016/S0092-8674(04)00038-8; Chan SRWL, 2004, PHILOS T R SOC B, V359, P109, DOI 10.1098/rstb.2003.1370; Chen JL, 2004, TRENDS BIOCHEM SCI, V29, P183, DOI 10.1016/j.tibs.2004.02.003; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; Harrington L, 2003, CANCER LETT, V194, P139, DOI 10.1016/S0304-3835(02)00701-2; Kelleher C, 2002, TRENDS BIOCHEM SCI, V27, P572, DOI 10.1016/S0968-0004(02)02206-5; Lai CK, 2003, MOL CELL, V11, P1673, DOI 10.1016/S1097-2765(03)00232-6; Lai CK, 2002, GENE DEV, V16, P415, DOI 10.1101/gad.962602; Lai CK, 2001, MOL CELL BIOL, V21, P990, DOI 10.1128/MCB.21.4.990-1000.2001; Licht JD, 1999, GENE DEV, V13, P1116, DOI 10.1101/gad.13.9.1116; MCCORMICKGRAHAM M, 1995, NUCLEIC ACIDS RES, V23, P1091, DOI 10.1093/nar/23.7.1091; Miller MC, 2002, P NATL ACAD SCI USA, V99, P6585, DOI 10.1073/pnas.102024699; Moriarty TJ, 2002, MOL CELL BIOL, V22, P1253, DOI 10.1128/MCB.22.4.1253-1265.2002; Shay JW, 2002, CANCER CELL, V2, P257, DOI 10.1016/S1535-6108(02)00159-9; Sperger JM, 2001, BIOCHEMISTRY-US, V40, P7005, DOI 10.1021/bi0103359; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Witkin KL, 2004, GENE DEV, V18, P1107, DOI 10.1101/gad.1201704; Wong JMY, 2003, LANCET, V362, P983, DOI 10.1016/S0140-6736(03)14369-3; Xia JQ, 2000, MOL CELL BIOL, V20, P5196, DOI 10.1128/MCB.20.14.5196-5207.2000; ZAUG AJ, 1995, RNA, V1, P363	24	66	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17533	17539		10.1074/jbc.M501211200	http://dx.doi.org/10.1074/jbc.M501211200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731105	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000228615500122
J	Shinoda, T; Arai, K; Shigematsu-Iida, M; Ishikura, Y; Tanaka, S; Yamada, T; Kimber, MS; Pai, EF; Fushinobu, S; Taguchi, H				Shinoda, T; Arai, K; Shigematsu-Iida, M; Ishikura, Y; Tanaka, S; Yamada, T; Kimber, MS; Pai, EF; Fushinobu, S; Taguchi, H			Distinct conformation-mediated functions of an active site loop in the catalytic reactions of NAD-dependent D-lactate dehydrogenase and formate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELBRUECKII SUBSP BULGARICUS; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; D-2-HYDROXYISOCAPROATE DEHYDROGENASE; LACTOBACILLUS-PLANTARUM; NUCLEOTIDE-SEQUENCE; SUBSTRATE-BINDING; LEUCONOSTOC-MESENTEROIDES; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE	The three-dimensional structures of NAD-dependent D-lactate dehydrogenase (D-LDH) and formate dehydrogenase (FDH), which resemble each other, imply that the two enzymes commonly employ certain main chain atoms, which are located on corresponding loop structures in the active sites of the two enzymes, for their respective catalytic functions. These active site loops adopt different conformations in the two enzymes, a difference likely attributable to hydrogen bonds with Asn(97) and Glu(141), which are also located at equivalent positions in D-LDH and FDH, respectively. X-ray crystallography at 2.4-angstrom resolution revealed that replacement of Asn(97) with Asp did not markedly change the overall protein structure but markedly perturbed the conformation of the active site loop in Lactobacillus pentosus D-LDH. The Asn(97) --> Asp mutant D-LDH exhibited virtually the same k(cat), but about 70-fold higher K-M value for pyruvate than the wild-type enzyme. For Paracoccus sp. 12-A FDH, in contrast, replacement of Glu(141) with Gln and Asn induced only 5.5- and 4.3- fold increases in the K-M value, but 110 and 590-fold decreases in the k(cat) values for formate, respectively. Furthermore, these mutant FDHs, particularly the Glu(141) --> Asn enzyme, exhibited markedly enhanced catalytic activity for glyoxylate reduction, indicating that FDH is converted to a 2-hydroxyacid dehydrogenase on the replacement of Glu(141). These results indicate that the active site loops play different roles in the catalytic reactions of D-LDH and FDH, stabilization of substrate binding and promotion of hydrogen transfer, respectively, and that Asn(97) and Glu(141), which stabilize suitable loop conformations, are essential elements for proper loop functioning.	Tokyo Univ Sci, Fac Sci & Technol, Dept Appl Biol Sci, Chiba 2788510, Japan; Affinium Pharmaceut Inc, Toronto, ON M5J 1V6, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	Tokyo University of Science; University of Toronto; University of Toronto; University of Tokyo	Taguchi, H (corresponding author), Tokyo Univ Sci, Fac Sci & Technol, Dept Appl Biol Sci, 2641 Yamazaki, Chiba 2788510, Japan.	htaguchi@rs.noda.tus.ac.jp	Fushinobu, Shinya/E-4987-2011; Pai, Emil/R-8908-2019; Kimber, Matthew/Q-8144-2019; Pai, Emil F/D-2526-2013	Fushinobu, Shinya/0000-0003-1346-6435; Pai, Emil/0000-0002-1162-7242; Taguchi, Hayao/0000-0001-5270-581X; Kimber, Matthew/0000-0001-9454-5586				ALLEN SJ, 1995, GENE, V162, P99, DOI 10.1016/0378-1119(95)00347-9; ARTHUR M, 1991, GENE, V103, P133, DOI 10.1016/0378-1119(91)90405-Z; Baker PJ, 1998, NAT STRUCT BIOL, V5, P561, DOI 10.1038/817; BERNARD N, 1991, FEBS LETT, V290, P61, DOI 10.1016/0014-5793(91)81226-X; BERNARD N, 1994, EUR J BIOCHEM, V224, P439, DOI 10.1111/j.1432-1033.1994.00439.x; Bunch PK, 1997, MICROBIOL-UK, V143, P187, DOI 10.1099/00221287-143-1-187; CHOW CM, 1993, J BACTERIOL, V175, P3703, DOI 10.1128/JB.175.12.3703-3709.1993; CLARKE AR, 1989, TRENDS BIOCHEM SCI, V14, P101, DOI 10.1016/0968-0004(89)90131-X; CLARKE AR, 1986, NATURE, V324, P699, DOI 10.1038/324699a0; COLOWICK SP, 1957, METHOD ENZYMOL, V4, P840, DOI 10.1016/0076-6879(57)04082-3; DARTOIS V, 1995, RES MICROBIOL, V146, P291, DOI 10.1016/0923-2508(96)81052-7; Dengler U, 1997, J MOL BIOL, V267, P640, DOI 10.1006/jmbi.1996.0864; DESFRANCSSMALL CC, 1993, PLANT PHYSIOL, V102, P1171, DOI 10.1104/pp.102.4.1171; EVENTOFF W, 1977, P NATL ACAD SCI USA, V74, P2677, DOI 10.1073/pnas.74.7.2677; FERSHT A, 1977, ENZYME STRUCTURE MEC, P95; FERSHT AR, 1985, NATURE, V314, P35; Flick MJ, 2002, BIOCHEM BIOPH RES CO, V295, P910, DOI 10.1016/S0006-291X(02)00768-4; Galkin A, 1995, APPL MICROBIOL BIOT, V44, P479, DOI 10.1007/BF00169947; GARMYN D, 1995, J BACTERIOL, V177, P3427, DOI 10.1128/jb.177.12.3427-3437.1995; GOLDBERG JD, 1994, J MOL BIOL, V236, P1123, DOI 10.1016/0022-2836(94)90016-7; GRANT GA, 1989, BIOCHEM BIOPH RES CO, V165, P1371, DOI 10.1016/0006-291X(89)92755-1; GREENLER JM, 1989, PLANT MOL BIOL, V13, P139, DOI 10.1007/BF00016133; HART KW, 1987, BIOCHIM BIOPHYS ACTA, V914, P294, DOI 10.1016/0167-4838(87)90289-5; Holbrook JJ., 1975, ENZYMES, P191; KOCHHAR S, 1992, J BIOL CHEM, V267, P8499; KOCHHAR S, 1992, J BIOL CHEM, V267, P20298; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMZIN VS, 1994, J MOL BIOL, V236, P759, DOI 10.1006/jmbi.1994.1188; Lapierre L, 1999, APPL ENVIRON MICROB, V65, P4002; LERCH HP, 1989, GENE, V78, P47, DOI 10.1016/0378-1119(89)90313-2; Liang MP, 2003, NUCLEIC ACIDS RES, V31, P3324, DOI 10.1093/nar/gkg553; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Milewski WM, 1996, ANTIMICROB AGENTS CH, V40, P166, DOI 10.1128/AAC.40.1.166; NIKOLAOS EL, 2001, BIOCHEM J, V354, P455; Ohshima T, 2001, EUR J BIOCHEM, V268, P4740, DOI 10.1046/j.1432-1327.2001.02394.x; POPOV VO, 1994, BIOCHEM J, V301, P625, DOI 10.1042/bj3010625; POPOV VO, 1990, BIOORG KHIM+, V16, P324; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; Razeto A, 2002, J MOL BIOL, V318, P109, DOI 10.1016/S0022-2836(02)00086-4; Rumsby G, 1999, BBA-GENE STRUCT EXPR, V1446, P383, DOI 10.1016/S0167-4781(99)00105-0; SALEEBA JA, 1992, MOL GEN GENET, V235, P349, DOI 10.1007/BF00279380; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P68; Shinoda T, 2002, BIOSCI BIOTECH BIOCH, V66, P271, DOI 10.1271/bbb.66.271; Steiner RA, 2003, ACTA CRYSTALLOGR D, V59, P2114, DOI 10.1107/S0907444903018675; Steller I, 1997, J APPL CRYSTALLOGR, V30, P1036, DOI 10.1107/S0021889897008777; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; Stoll VS, 1995, PROTEIN PEPTIDE LETT, V2, P435; Stoll VS, 1996, STRUCTURE, V4, P437, DOI 10.1016/S0969-2126(96)00049-4; TAGUCHI H, 1993, J BIOL CHEM, V268, P18030; TAGUCHI H, 1991, J BIOL CHEM, V266, P12588; TAGUCHI H, 1994, J BIOCHEM-TOKYO, V115, P930, DOI 10.1093/oxfordjournals.jbchem.a124441; Taguchi H, 1997, J BIOCHEM-TOKYO, V122, P802; Tishkov VI, 1996, FEBS LETT, V390, P104, DOI 10.1016/0014-5793(96)00641-2; TISHKOV VI, 1993, BIOCHEM BIOPH RES CO, V192, P976, DOI 10.1006/bbrc.1993.1511; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; Tokuda C, 2003, J BACTERIOL, V185, P5023, DOI 10.1128/JB.185.16.5023-5026.2003; VINALS C, 1993, BIOCHEM BIOPH RES CO, V192, P182, DOI 10.1006/bbrc.1993.1398	63	20	21	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17068	17075		10.1074/jbc.M500970200	http://dx.doi.org/10.1074/jbc.M500970200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15734738	hybrid			2022-12-25	WOS:000228615500065
J	Novgorodov, SA; Szulc, ZM; Luberto, C; Jones, JA; Bielawski, J; Bielawska, A; Hannun, YA; Obeid, LM				Novgorodov, SA; Szulc, ZM; Luberto, C; Jones, JA; Bielawski, J; Bielawska, A; Hannun, YA; Obeid, LM			Positively charged ceramide is a potent inducer of mitochondrial permeabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION PORE; RESPIRATORY-CHAIN; CELL-DEATH; APOPTOSIS; MEMBRANE; PHOSPHORYLATION; MECHANISM; COMMITMENT; ACTIVATION; INDUCTION	Ceramide-induced cell death is thought to be mediated by change in mitochondrial function, although the precise mechanism is unclear. Proposed models suggest that ceramide induces cell death through interaction with latent binding sites on the outer or inner mitochondrial membranes, followed by an increase in membrane permeability, as an intermediate step in ceramide signal propagation. To investigate these models, we developed a new generation of positively charged ceramides that readily accumulate in isolated and in situ mitochondria. Accumulated, positively charged ceramides increased inner membrane permeability and triggered release of mitochondrial cytochrome c. Furthermore, the positively charged ceramide-induced permeability increase was suppressed by cyclosporin A (60%) and 1,3-dicyclohexylcarbodiimide (90%). These observations suggest that the inner membrane permeability increase is due to activation of specific ion transporters, not the generalized loss of lipid bilayer barrier functions. The difference in sensitivity of ceramide-induced ion fluxes to inhibitors of mitochondrial transporters suggests activation of at least two transport systems: the permeability transition pore and the electrogenic H+ channel. Our results indicate the presence of specific ceramide targets in the mitochondrial matrix, the occupation of which triggers permeability alterations of the inner and outer mitochondrial membranes. These findings also suggest a novel therapeutic role for positively charged ceramides.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA.	obeidl@musc.edu		Jones, Jeffrey/0000-0002-5133-0427; obeid, lina/0000-0002-0734-0847	NATIONAL CANCER INSTITUTE [P01CA097132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016583] Funding Source: NIH RePORTER; NCI NIH HHS [IPO1CA097132] Funding Source: Medline; NIA NIH HHS [AG16583] Funding Source: Medline; NIDDK NIH HHS [DK59340] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; AZZI A, 1984, BIOCHIM BIOPHYS ACTA, V768, P209, DOI 10.1016/0304-4173(84)90017-X; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BIELAWSKI J, 2005, IN PRESS METHODS; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS S, 1985, J BIOL CHEM, V260, P3844; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P23, DOI 10.1016/S0005-2728(03)00108-7; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Gudz T, 1997, ARCH BIOCHEM BIOPHYS, V342, P143, DOI 10.1006/abbi.1997.0113; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; LI XQ, 1990, J BIOL CHEM, V265, P15316; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; MATSUNOYAGI A, 1985, P NATL ACAD SCI USA, V82, P7550, DOI 10.1073/pnas.82.22.7550; Mimeault M, 2002, FEBS LETT, V530, P9, DOI 10.1016/S0014-5793(02)03432-4; Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9; MODICANAPOLITANO JS, 1987, CANCER RES, V47, P4361; NOVGORODOV S A, 1984, Biokhimiya, V49, P185; NOVGORODOV SA, 1989, FEBS LETT, V247, P255, DOI 10.1016/0014-5793(89)81347-X; Novgorodov SA, 1996, J BIOENERG BIOMEMBR, V28, P139, DOI 10.1007/BF02110644; NOVGORODOV SA, 1987, J BIOENERG BIOMEMBR, V19, P191, DOI 10.1007/BF00762412; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; PETRONILLI V, 1986, EUR J BIOCHEM, V155, P423, DOI 10.1111/j.1432-1033.1986.tb09508.x; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Siskind LJ, 2003, BIOPHYS J, V85, P1560, DOI 10.1016/S0006-3495(03)74588-3; Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Walter L, 2002, FREE RADICAL RES, V36, P405, DOI 10.1080/10715760290021252; WOLFF RA, 1994, J BIOL CHEM, V269, P19605	44	93	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16096	16105		10.1074/jbc.M411707200	http://dx.doi.org/10.1074/jbc.M411707200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722351	hybrid			2022-12-25	WOS:000228444800077
J	Kovacs, M; Wang, F; Sellers, JR				Kovacs, M; Wang, F; Sellers, JR			Mechanism of action of myosin X, a membrane-associated molecular motor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; RABBIT SKELETAL-MUSCLE; DICTYOSTELIUM MYOSIN; KINETIC MECHANISM; NUCLEOTIDE-BINDING; SINGLE TRYPTOPHAN; FLUORESCENT-PROBE; HEAVY-MEROMYOSIN; V PROCESSIVITY; SMOOTH-MUSCLE	We have performed a detailed biochemical kinetic and spectroscopic study on a recombinant myosin X head construct to establish a quantitative model of the enzymatic mechanism of this membrane-bound myosin. Our model shows that during steady-state ATP hydrolysis, myosin X exhibits a duty ratio (i.e. the fraction of the cycle time spent strongly bound to actin) of around 16%, but most of the remaining myosin heads are also actin-attached even at moderate actin concentrations in the so-called "weak" actin-binding states. Contrary to the high duty ratio motors myosin V and VI, the ADP release rate constant from actomyosin X is around five times greater than the maximal steady-state ATPase activity, and the kinetic partitioning between different weak actin-binding states is a major contributor to the rate limitation of the enzymatic cycle. Two different ADP states of myosin X are populated in the absence of actin, one of which shows very similar kinetic properties to actomyosin center dot ADP. The nucleotide-free complex of myosin X with actin shows unique spectral and biochemical characteristics, indicating a special mode of actomyosin interaction.	NHLBI, Lab Mol Physiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kovacs, M (corresponding author), NHLBI, Lab Mol Physiol, NIH, Bldg 10, Bethesda, MD 20892 USA.	kovacsm@mail.nih.gov	Kovacs, Mihaly/A-6841-2011	Kovacs, Mihaly/0000-0002-1200-4741	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004231, Z01HL004231] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker JE, 2004, P NATL ACAD SCI USA, V101, P5542, DOI 10.1073/pnas.0307247101; Batra R, 1999, BIOL CHEM, V380, P1017, DOI 10.1515/BC.1999.126; Belyantseva IA, 2003, P NATL ACAD SCI USA, V100, P13958, DOI 10.1073/pnas.2334417100; Berg JS, 2000, J CELL SCI, V113, P3439; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Berg JS, 2002, NAT CELL BIOL, V4, P246, DOI 10.1038/ncb762; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Chen LF, 2002, J STRUCT BIOL, V138, P92, DOI 10.1016/S1047-8477(02)00013-8; Coluccio LR, 1999, J BIOL CHEM, V274, P21575, DOI 10.1074/jbc.274.31.21575; Conibear PB, 2003, NAT STRUCT BIOL, V10, P831, DOI 10.1038/nsb986; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; Cox D, 2002, NAT CELL BIOL, V4, P469, DOI 10.1038/ncb805; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De La Cruz EM, 2004, CURR OPIN CELL BIOL, V16, P61, DOI 10.1016/j.ceb.2003.11.011; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; El Mezgueldi M, 2002, J BIOL CHEM, V277, P21514, DOI 10.1074/jbc.M200713200; Furch M, 1999, J MOL BIOL, V290, P797, DOI 10.1006/jmbi.1999.2921; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; HARRIS DE, 1993, J BIOL CHEM, V268, P14764; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; Homma K, 2001, J BIOL CHEM, V276, P34348, DOI 10.1074/jbc.M104785200; Klopfenstein DR, 2004, MOL BIOL CELL, V15, P3729, DOI 10.1091/mbc.E04-04-0326; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Kovacs M, 2002, J BIOL CHEM, V277, P28459, DOI 10.1074/jbc.M202180200; Lister I, 2004, EMBO J, V23, P1729, DOI 10.1038/sj.emboj.7600180; Malnasi-Csizmadia A, 2001, BIOCHEMISTRY-US, V40, P12727, DOI 10.1021/bi010963q; Malnasi-Csizmadia A, 2001, J BIOL CHEM, V276, P19483, DOI 10.1074/jbc.M010886200; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Mashanov GI, 2004, J BIOL CHEM, V279, P15274, DOI 10.1074/jbc.M312140200; OKAMOTO Y, 1985, J BIOCHEM-TOKYO, V98, P1143, DOI 10.1093/oxfordjournals.jbchem.a135365; Park S, 2000, BIOCHEMISTRY-US, V39, P11732, DOI 10.1021/bi000945t; Reubold TF, 2003, NAT STRUCT BIOL, V10, P826, DOI 10.1038/nsb987; Robblee JP, 2004, J BIOL CHEM, V279, P38608, DOI 10.1074/jbc.M403504200; Rosenfeld SS, 2004, J BIOL CHEM, V279, P40100, DOI 10.1074/jbc.M402583200; Sato O, 2004, J BIOL CHEM, V279, P28844, DOI 10.1074/jbc.M314332200; Sellers J. R., 1999, MYOSINS; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tokuo H, 2004, BIOCHEM BIOPH RES CO, V319, P214, DOI 10.1016/j.bbrc.2004.04.167; TRENTHAM DR, 1972, BIOCHEM J, V126, P635, DOI 10.1042/bj1260635; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wang F, 2000, BIOCHEMISTRY-US, V39, P5555, DOI 10.1021/bi000133x; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Yengo CM, 2000, J BIOL CHEM, V275, P25481, DOI 10.1074/jbc.M002910200; Zhang HQ, 2004, NAT CELL BIOL, V6, P523, DOI 10.1038/ncb1136	50	35	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15071	15083		10.1074/jbc.M500616200	http://dx.doi.org/10.1074/jbc.M500616200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705568	hybrid			2022-12-25	WOS:000228236800090
J	Wingate, H; Zhang, N; McGarhen, MJ; Bedrosian, I; Harper, JW; Keyomarsi, K				Wingate, H; Zhang, N; McGarhen, MJ; Bedrosian, I; Harper, JW; Keyomarsi, K			The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; RETINOBLASTOMA PROTEIN; P27(KIP1) EXPRESSION; DEPENDENT KINASES; PROGNOSTIC FACTOR; REDUNDANT CYCLIN; E OVEREXPRESSION; CDK INHIBITORS; GENE; D1	The low molecular weight (LMW) isoforms of cyclin E are unique to cancer cells. In breast cancer, such alteration of cyclin E is a very strong predictor of poor patient outcome. Here we show that alteration in binding properties of these LMW isoforms to CDK2 and the CDK inhibitors (CKIs), p21 and p27, results in their functional hyperactivity. The LMW forms of cyclin E are severalfold more effective at binding to CDK2. Additionally, compared with the full-length cyclin E-CDK2 complexes, the LMW cyclin E-CDK2 complexes are significantly more resistant to inhibition by p21 and p27, despite equal binding of the CKIs to the LMW complexes. When both the full-length and the LMW cyclin E are co-expressed, p27 preferentially binds to the LMW forms yet is unable to inhibit the CDK2 activity. Thus, the LMW forms of cyclin E may contribute to tumorigenesis through their resistance to the inhibitory activities of p21 and p27 while sequestering these CKIs from the full-length cyclin E.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Canc Biol Program, Houston, TX 77030 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Harvard University; Harvard Medical School	Keyomarsi, K (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd,box 66, Houston, TX 77030 USA.	kkeyomar@mdanderson.org	Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849; Harper, Jeffrey/0000-0002-6944-7236	NCI NIH HHS [P30-CA16672, R01-CA87548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087548, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahamed S, 2002, MOL CARCINOGEN, V34, P45, DOI 10.1002/mc.10048; Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Albrecht JH, 1999, AM J PHYSIOL-GASTR L, V277, pG1207, DOI 10.1152/ajpgi.1999.277.6.G1207; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Ciaparrone M, 1998, CANCER RES, V58, P114; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; GERLOFF DL, 1993, BIOCHEM BIOPH RES CO, V194, P560, DOI 10.1006/bbrc.1993.1856; GRANT AJ, 1990, BIOCH INT, V22; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harwell RM, 2000, CANCER RES, V60, P481; KATO J, 1993, GENE DEV, V7, P331; KEYOMARSI K, 1994, CANCER RES, V54, P380; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Loden M, 2002, ONCOGENE, V21, P4680, DOI 10.1038/sj.onc.1205578; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Musgrove EA, 2001, J BIOL CHEM, V276, P47675, DOI 10.1074/jbc.M106371200; NEVINS JR, 1992, SCIENCE, V258, P424; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1999, BREAST CANCER RES TR, V56, P105; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sgambato A, 1999, MOL CARCINOGEN, V26, P172, DOI 10.1002/(SICI)1098-2744(199911)26:3<172::AID-MC6>3.0.CO;2-8; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; Sgambato A, 1997, CLIN CANCER RES, V3, P1879; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Sgambato A, 2000, CANCER-AM CANCER SOC, V89, P2247, DOI 10.1002/1097-0142(20001201)89:11<2247::AID-CNCR13>3.0.CO;2-5; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tsuchida R, 2002, JPN J CANCER RES, V93, P1000, DOI 10.1111/j.1349-7006.2002.tb02476.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YAMASHITA JI, 1994, BRIT J CANCER, V69, P72, DOI 10.1038/bjc.1994.11; ZEYDEL M, 1986, CANCER RES, V46, P6438	53	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15148	15157		10.1074/jbc.M409789200	http://dx.doi.org/10.1074/jbc.M409789200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708847	hybrid			2022-12-25	WOS:000228236800098
J	Zito, SR; Antony, E; Hunt, JF; Oliver, DB; Hingorani, MM				Zito, SR; Antony, E; Hunt, JF; Oliver, DB; Hingorani, MM			Role of a conserved glutamate residue in the Escherichia coli SecA ATPase mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATION ATPASE; BACILLUS-SUBTILIS; BINDING-SITE; INORGANIC-PHOSPHATE; CATALYTIC CYCLE; ABC TRANSPORTER; PREPROTEIN TRANSLOCATION; NUCLEOTIDE EXCHANGE; MODEL MEMBRANES; INNER MEMBRANE	Escherichia coli SecA uses ATP to drive the transport of proteins across cell membranes. Glutamate 210 in the "DEVD" Walker B motif of the SecA ATP-binding site has been proposed as the catalytic base for ATP hydrolysis (Hunt, J. F., Weinkauf, S., Henry, L., Fak, J. J., McNicholas, P., Oliver, D. B., and Deisenhofer, J. (2002) Science 297, 2018-2026). Consistent with this hypothesis, we find that mutation of glutamate 210 to aspartate results in a 90-fold reduction of the ATP hydrolysis rate compared with wild type SecA, 0.3 s(-1) versus 27 s(-1), respectively. SecA-E210D also releases ADP at a slower rate compared with wild type SecA, suggesting that in addition to serving as the catalytic base, glutamate 210 might aid turnover as well. Our results contradict an earlier report that proposed aspartate 133 as the catalytic base (Sato, K., Mori, H., Yoshida, M., and Mizushima, S. (1996) J. Biol. Chem. 271, 17439-17444). Re-evaluation of the SecA-D133N mutant used in that study confirms its loss of ATPase and membrane translocation activities, but surprisingly, the analogous SecA-D133A mutant retains full activity, revealing that this residue does not play a key role in catalysis.	Wesleyan Univ, Dept Mol Biol & Biochem, Hall Atwater Labs 205, Middletown, CT 06459 USA; Columbia Univ, New York, NY 10027 USA	Wesleyan University; Columbia University	Hingorani, MM (corresponding author), Wesleyan Univ, Dept Mol Biol & Biochem, Hall Atwater Labs 205, Middletown, CT 06459 USA.	mhingorani@wesleyan.edu	Antony, Edwin/AAA-3596-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064514, R01GM042033] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM64514, R01 GM042033, R01 GM064514, GM42033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn T, 1998, J BIOL CHEM, V273, P21692, DOI 10.1074/jbc.273.34.21692; Antony E, 2003, BIOCHEMISTRY-US, V42, P7682, DOI 10.1021/bi034602h; Baird CL, 2001, J BIOL CHEM, V276, P27893, DOI 10.1074/jbc.M102544200; Bertram JG, 2000, J BIOL CHEM, V275, P28413, DOI 10.1074/jbc.M910441199; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; de Keyzer J, 2003, CELL MOL LIFE SCI, V60, P2034, DOI 10.1007/s00018-003-3006-y; de Keyzer J, 2003, J BIOL CHEM, V278, P29581, DOI 10.1074/jbc.M303490200; denBlaauwen T, 1996, BIOCHEMISTRY-US, V35, P11994, DOI 10.1021/bi9605088; Ding HY, 2003, BIOCHEMISTRY-US, V42, P8729, DOI 10.1021/bi0342057; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; Economou A, 2002, MOL MEMBR BIOL, V19, P159, DOI 10.1080/09687680210152609; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; Fak JJ, 2004, BIOCHEMISTRY-US, V43, P7307, DOI 10.1021/BI0357208; Geourjon C, 2001, TRENDS BIOCHEM SCI, V26, P539, DOI 10.1016/S0968-0004(01)01907-7; Gilbert SP, 2000, METHODS, V22, P337, DOI 10.1006/meth.2000.1086; Hopfner KP, 2003, CURR OPIN STRUC BIOL, V13, P249, DOI 10.1016/S0959-440X(03)00037-X; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; Jeong YJ, 2002, J BIOL CHEM, V277, P43778, DOI 10.1074/jbc.M208634200; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Miller A, 2002, BIOCHEMISTRY-US, V41, P5325, DOI 10.1021/bi025639p; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Natale P, 2004, J BIOL CHEM, V279, P13769, DOI 10.1074/jbc.M312892200; Orelle C, 2003, J BIOL CHEM, V278, P47002, DOI 10.1074/jbc.M308268200; Rajapandi T, 1996, MOL MICROBIOL, V20, P43, DOI 10.1111/j.1365-2958.1996.tb02487.x; RHOADS DB, 1984, J BACTERIOL, V159, P63, DOI 10.1128/JB.159.1.63-70.1984; Sato K, 1996, J BIOL CHEM, V271, P17439, DOI 10.1074/jbc.271.29.17439; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Schmidt M, 2000, J BIOL CHEM, V275, P15440, DOI 10.1074/jbc.M000605200; Shilton B, 1998, FEBS LETT, V436, P277, DOI 10.1016/S0014-5793(98)01141-7; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Triplett TL, 2001, J BIOL CHEM, V276, P19648, DOI 10.1074/jbc.M100098200; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; VANDERWOLK J, 1993, MOL MICROBIOL, V8, P31; VANDERWOLK JPW, 1995, J BIOL CHEM, V270, P18975, DOI 10.1074/jbc.270.32.18975; vanderWolk JPW, 1997, BIOCHEMISTRY-US, V36, P14924, DOI 10.1021/bi971766n; Wang LG, 2000, J BIOL CHEM, V275, P10154, DOI 10.1074/jbc.275.14.10154; Weinkauf S, 2001, ACTA CRYSTALLOGR D, V57, P559, DOI 10.1107/S0907444901001202; Zito CR, 2003, J BIOL CHEM, V278, P40640, DOI 10.1074/jbc.M308025200	49	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14611	14619		10.1074/jbc.M414224200	http://dx.doi.org/10.1074/jbc.M414224200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15710614	Green Accepted, hybrid, Green Published			2022-12-25	WOS:000228236800035
J	Breazeale, SD; Ribeiro, AA; McClerren, AL; Raetz, RH				Breazeale, SD; Ribeiro, AA; McClerren, AL; Raetz, RH			A formyltransferase required for polymyxin resistance in Escherichia coli and the modification of lipid a with 4-amino-4-deoxy-L-arabinose - Identification and function of UDP-4-deoxy-4-formamido-L-arabinose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-SPECIFIC POLYSACCHARIDE; SALMONELLA-TYPHIMURIUM; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY; GENOME SEQUENCE; MOLECULAR-BASIS; BACTERIAL; MUTANTS; PHOSPHOETHANOLAMINE; SYSTEM	Modification of the phosphate groups of lipid A with 4- amino- 4- deoxy- L- arabinose ( L- Ara4N) is required for resistance to polymyxin and cationic antimicrobial peptides in Escherichia coli and Salmonella typhimurium. We previously demonstrated that the enzyme ArnA catalyzes the NAD (+)- dependent oxidative decarboxylation of UDP- glucuronic acid to yield the UDP- 4 "- ketopentose, uridine 5 '- diphospho- beta- ( L- threo- pentapyranosyl- 4 "- ulose), which is converted by ArnB to UDP- beta- ( L- Ara4N). E. coli ArnA is a bi- functional enzyme with a molecular mass of similar to 74 kDa. The oxidative decarboxylation of UDP- glucuronic acid is catalyzed by the 345- residue C-terminal domain of ArnA. The latter shows sequence similarity to enzymes that oxidize the C- 4" position of sugar nucleotides, like UDP- galactose epimerase, dTDP-glucose-4,6- dehydratase, and UDP- xylose synthase. We now show that the 304- residue N- terminal domain catalyzes the N- 10- formyltetrahydrofolate- dependent formylation of the 4 "- amine of UDP- L- Ara4N, generating the novel sugar nucleotide, uridine 5 "- diphospho- beta- ( 4-deoxy- 4- formamido- L- arabinose). The N- terminal domain is highly homologous to methionyl- tRNA(f) (Met) formyltransferase. The structure of the formylated sugar nucleotide generated in vitro by ArnA was validated by H-1 and C-13 NMR spectroscopy. The two domains of ArnA were expressed independently as active proteins in E. coli. Both were required for maintenance of polymyxin resistance and L- Ara4N modification of lipid A. We conclude that N- formylation of UDP- L- Ara4N is an obligatory step in the biosynthesis of L- Ara4N-modified lipid A in polymyxin- resistant mutants. We further demonstrate that only the formylated sugar nucleotide is converted in vitro to an undecaprenyl phosphate- linked form by the enzyme ArnC. Because the L- Ara4N unit attached to lipid A is not derivatized with a formyl group, we postulate the existence of a deformylase, acting later in the pathway.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, NMR Spect Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Raetz, RH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL CANCER INSTITUTE [P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-14236] Funding Source: Medline; NIGMS NIH HHS [GM-51310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRAWAL PK, 1992, PHYTOCHEMISTRY, V31, P3307, DOI 10.1016/0031-9422(92)83678-R; Akman L, 2002, NAT GENET, V32, P402, DOI 10.1038/ng986; Allard STM, 2001, J MOL BIOL, V307, P283, DOI 10.1006/jmbi.2000.4470; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLANQUET S, 1984, METHOD ENZYMOL, V106, P141; Brade H., 1999, ENDOTOXIN HLTH DIS; Breazeale SD, 2003, J BIOL CHEM, V278, P24731, DOI 10.1074/jbc.M304043200; Breazeale SD, 2002, J BIOL CHEM, V277, P2886, DOI 10.1074/jbc.M109377200; FISS EH, 1994, MOL MICROBIOL, V14, P557, DOI 10.1111/j.1365-2958.1994.tb02189.x; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; Gatzeva-Topalova PZ, 2004, BIOCHEMISTRY-US, V43, P13370, DOI 10.1021/bi048551f; Gibbons HS, 2000, J BIOL CHEM, V275, P32940, DOI 10.1074/jbc.M005779200; Gibbons HS, 2005, MOL MICROBIOL, V55, P425, DOI 10.1111/j.1365-2958.2004.04409.x; Godfroid F, 2000, RES MICROBIOL, V151, P655, DOI 10.1016/S0923-2508(00)90130-X; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Gunn JS, 2000, INFECT IMMUN, V68, P6139, DOI 10.1128/IAI.68.11.6139-6146.2000; Gunn JS, 2001, J ENDOTOXIN RES, V7, P57, DOI 10.1177/09680519010070011001; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Hegeman AD, 2001, BIOCHEMISTRY-US, V40, P6598, DOI 10.1021/bi010441a; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; INGLESE J, 1990, BIOCHEMISTRY-US, V29, P1436, DOI 10.1021/bi00458a014; KATZENELLENBOGEN E, 1995, CARBOHYD RES, V273, P187, DOI 10.1016/0008-6215(95)00084-7; KENNE L, 1988, J CHEM SOC PERK T 1, P1183, DOI 10.1039/p19880001183; KNIREL YA, 1985, EUR J BIOCHEM, V150, P541, DOI 10.1111/j.1432-1033.1985.tb09055.x; Kocharova NA, 2003, CARBOHYD RES, V338, P1425, DOI 10.1016/S0008-6215(03)00178-2; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee H, 2004, J BACTERIOL, V186, P4124, DOI 10.1128/JB.186.13.4124-4133.2004; Lien E, 2002, CRIT CARE MED, V30, pS1, DOI 10.1097/00003246-200201001-00001; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; Muldoon J, 2001, CARBOHYD RES, V330, P231, DOI 10.1016/S0008-6215(00)00280-9; NALEWAY JJ, 1988, CARBOHYD RES, V179, P199, DOI 10.1016/0008-6215(88)84118-1; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Noland BW, 2002, STRUCTURE, V10, P1569, DOI 10.1016/S0969-2126(02)00879-1; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; ROSENTHAL SN, 1976, ADV PHYS ORG CHEM, V13, P280; Salanoubat M, 2002, NATURE, V415, P497, DOI 10.1038/415497a; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmitt E, 1998, EMBO J, V17, P6819, DOI 10.1093/emboj/17.23.6819; Schmitt E, 1996, EMBO J, V15, P4749, DOI 10.1002/j.1460-2075.1996.tb00852.x; Shim JH, 1999, BIOCHEMISTRY-US, V38, P10024, DOI 10.1021/bi9904609; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Trent M. Stephen, 2002, Journal of Endotoxin Research, V8, P158; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; VINOGRADOV EV, 1991, CARBOHYD RES, V214, P289, DOI 10.1016/0008-6215(91)80036-M; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Warren MS, 1996, BIOCHEMISTRY-US, V35, P8855, DOI 10.1021/bi9528715; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 2000, J BIOL CHEM, V275, P13542, DOI 10.1074/jbc.275.18.13542	65	123	130	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14154	14167		10.1074/jbc.M414265200	http://dx.doi.org/10.1074/jbc.M414265200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695810	hybrid			2022-12-25	WOS:000228095500119
J	Erker, W; Beister, U; Decker, H				Erker, W; Beister, U; Decker, H			Cooperative transition in the conformation of 24-mer tarantula hemocyanin upon oxygen binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; ALLOSTERIC INTERACTIONS; EURYPELMA-CALIFORNICUM; LOBSTER HEMOCYANIN; CRYSTAL-STRUCTURE; NESTED ALLOSTERY; CARBON-MONOXIDE; SPINY LOBSTER; MODEL; PROTEIN	Hemocyanins are large respiratory proteins of arthropods and mollusks, which bind oxygen with very high cooperativity. Here, we investigated the relationship between oxygen binding and structural changes of the 24-mer tarantula hemocyanin. Oxygen binding of the hemocyanin was detected following the fluorescence intensity of the intrinsic tryptophans. Under the same conditions, structural changes were monitored by the non-covalently bound fluorescence probe Prodan (6-propionyl-2-(dimethylamino)-naphthalene), which is very sensitive to its surroundings. Upon oxygen binding of the hemocyanin a red shift of 5 nm in the emission maximum of the label was observed. A comparison of oxygen binding curves recorded with tryptophan and Prodan emission revealed that structural changes in tarantula hemocyanin lag behind oxygen binding at the beginning of oxygenation. Analyses based on the nested two-state model, which describes cooperative oxygen binding of hemocyanins, indicated that the transition monitored by Prodan emission is closely related to one of the four conformations (rR) predicted for the allosteric unit. Earlier, the allosteric unit of tarantula hemocyanin was found to be the 12-mer half-molecule. Here, fluorescence titration revealed that the number of Prodan binding sites/ 24-mer tarantula hemocyanin is similar to 2, matching the number of allosteric units/hemocyanin. Based on the agreement between oxygen binding curves and fluorescence titration we concluded that Prodan monitors a conformational transition of the allosteric unit.	Univ Mainz, Dept Phys Chem, D-55099 Mainz, Germany; Univ Mainz, Dept Mol Biophys, D-55128 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Erker, W (corresponding author), Univ Mainz, Dept Phys Chem, Welderweg 11, D-55099 Mainz, Germany.	erker@mail.uni-mainz.de						CONNELLY PR, 1989, J MOL BIOL, V207, P829, DOI 10.1016/0022-2836(89)90248-9; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; DECKER H, 1990, J MOL BIOL, V211, P281, DOI 10.1016/0022-2836(90)90027-J; Decker H, 1996, FEBS LETT, V393, P226, DOI 10.1016/0014-5793(96)00887-3; Decker H., 1986, P383; DECKER H, 1990, BIOPHYS CHEM, V37, P257, DOI 10.1016/0301-4622(90)88025-N; DECKER H, 1988, BIOCHEMISTRY-US, V27, P6901, DOI 10.1021/bi00418a036; Erker W, 2004, BIOCHEM BIOPH RES CO, V324, P893, DOI 10.1016/j.bbrc.2004.09.138; Erker W, 2004, EUR BIOPHYS J BIOPHY, V33, P386, DOI 10.1007/s00249-003-0371-2; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; Hartmann H, 2002, BBA-PROTEINS PROTEOM, V1601, P132, DOI 10.1016/S1570-9639(02)00459-4; Hartmann H, 2001, J BIOL CHEM, V276, P19954, DOI 10.1074/jbc.M010435200; HAZES B, 1993, PROTEIN SCI, V2, P597; Hellmann N, 2003, J BIOL CHEM, V278, P44355, DOI 10.1074/jbc.M307810200; Hellmann N, 2002, BBA-PROTEINS PROTEOM, V1599, P45, DOI 10.1016/S1570-9639(02)00399-0; Hiratsuka T, 1998, BIOCHEMISTRY-US, V37, P7167, DOI 10.1021/bi973083d; KITAJIMA N, 1989, J AM CHEM SOC, V111, P8975, DOI 10.1021/ja00206a062; KITAJIMA N, 1992, J AM CHEM SOC, V114, P1277, DOI 10.1021/ja00030a025; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P53; LOEWE R, 1978, J COMP PHYSIOL, V128, P161, DOI 10.1007/BF00689480; MAGNUS KA, 1994, PROTEINS, V19, P302, DOI 10.1002/prot.340190405; MAKINO N, 1985, EUR J BIOCHEM, V146, P563, DOI 10.1111/j.1432-1033.1985.tb08688.x; MAKINO N, 1987, EUR J BIOCHEM, V163, P35, DOI 10.1111/j.1432-1033.1987.tb10733.x; MAKINO N, 1993, BIOCHIM BIOPHYS ACTA, V1162, P237, DOI 10.1016/0167-4838(93)90287-2; MARKL J, 1981, H-S Z PHYSIOL CHEM, V362, P1631, DOI 10.1515/bchm2.1981.362.2.1631; Markl J., 1992, Advances in Comparative and Environmental Physiology, V13, P325; MARRIOTT G, 1988, BIOCHEMISTRY-US, V27, P6214, DOI 10.1021/bi00417a004; MAS MT, 1985, BIOCHEMISTRY-US, V24, P1634, DOI 10.1021/bi00328a011; MAZUMDAR M, 1992, EUR J BIOCHEM, V204, P127, DOI 10.1111/j.1432-1033.1992.tb16614.x; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; ROBERT CH, 1987, P NATL ACAD SCI USA, V84, P1891, DOI 10.1073/pnas.84.7.1891; SALVATO B, 1987, LIFE CHEM REPORTS, V5, P249; STERNER R, 1990, INVERTEBRATE DIOXYGEN CARRIERS, P193; STERNER R, 1994, P NATL ACAD SCI USA, V91, P4835, DOI 10.1073/pnas.91.11.4835; TORGERSON PM, 1979, BIOCHEMISTRY-US, V18, P3079, DOI 10.1021/bi00581a026; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; Voit R, 2000, J BIOL CHEM, V275, P39339, DOI 10.1074/jbc.M005442200; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025; WYMAN J, 1990, BINDING LINKAGE FUNC, P298	39	4	4	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12391	12396		10.1074/jbc.M414516200	http://dx.doi.org/10.1074/jbc.M414516200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15695808	hybrid			2022-12-25	WOS:000227922000040
J	Wang, JH; Boxer, LM				Wang, JH; Boxer, LM			Regulatory elements in the immunoglobulin heavy chain gene 3 '-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BURKITTS-LYMPHOMA; EXPRESSION; APOPTOSIS; ENHANCER; OVEREXPRESSION; INACTIVATION; ONCOGENE; DELETION; PATHWAY; MATTER	Burkitt's lymphoma is invariably associated with chromosomal translocations that juxtapose the c-myc proto-oncogene with regulatory elements of the immunoglobulin heavy (IgH) or light chain loci resulting in the deregulation of c-myc expression. However, the enhancer elements mediating c-myc deregulation in vivo remain largely unidentified. To investigate the role of the IgH 3 '-enhancers in c-myc deregulation, we used gene targeting to generate knock-in mice in which four DNase I hypersensitive regions from the murine IgH 3 '-region were integrated into the 5 '-region of the c-myc locus. The IgH 3 '-enhancers induced the up-regulation of c-myc expression specifically in B cells of IgH-3 '-E-myc mice. After similar to 10 months, the mice developed a Burkitt-like B cell lymphoma with the phenotype of B220(+), IgM(+), and IgD(low). Analysis of immunoglobulin gene rearrangements indicated that the lymphoma cells were of clonal origin. The presence of a rapidly expanding population of B cells in the spleen and bone marrow of young knock-in mice at 2-4 months of age was observed. Premalignant splenic B cells of knock-in mice showed higher spontaneous and induced apoptosis; however, malignant B cells were more resistant to apoptosis. The p53-ARF-Mdm2 pathway was disabled in half of the lymphomas examined, in most cases through Mdm2 overexpression. Although c-myc expression was increased in premalignant B cells, the promoter shift from P2 to P1 was observed only in malignant B cells. Our studies demonstrate that the IgH 3 '- enhancers play an important role in c-myc deregulation and B cell lymphomagenesis in vivo.	Stanford Univ, Sch Med, CCSR 1155, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol Med, Stanford, CA 94305 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Boxer, LM (corresponding author), Stanford Univ, Sch Med, CCSR 1155, Dept Med, 269 Campus Dr, Stanford, CA 94305 USA.	lboxer@stanford.edu			NATIONAL CANCER INSTITUTE [R01CA069322] Funding Source: NIH RePORTER; NCI NIH HHS [CA69322] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Butzler C, 1997, ONCOGENE, V14, P1383, DOI 10.1038/sj.onc.1200968; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; GERONDAKIS S, 1984, CELL, V36, P973, DOI 10.1016/0092-8674(84)90047-3; Hecht JL, 2000, J CLIN ONCOL, V18, P3707, DOI 10.1200/JCO.2000.18.21.3707; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hu HM, 2002, J BIOL CHEM, V277, P9819, DOI 10.1074/jbc.M111426200; Kanda K, 2000, J BIOL CHEM, V275, P32338, DOI 10.1074/jbc.M004148200; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Lewandoski M, 1997, COLD SPRING HARB SYM, V62, P159; Lindstrom MS, 2001, ONCOGENE, V20, P2171, DOI 10.1038/sj.onc.1204303; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Mundt CA, 2001, J IMMUNOL, V166, P3315, DOI 10.4049/jimmunol.166.5.3315; Palomo C, 1999, CANCER RES, V59, P5625; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 2003, ARCH BIOCHEM BIOPHYS, V416, P129, DOI 10.1016/S0003-9861(03)00294-7; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Wilda M, 2004, LEUKEMIA, V18, P584, DOI 10.1038/sj.leu.2403254; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	30	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12766	12773		10.1074/jbc.M412446200	http://dx.doi.org/10.1074/jbc.M412446200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15687498	hybrid			2022-12-25	WOS:000227922000084
J	Caldas, H; Jiang, YY; Holloway, MP; Fangusaro, J; Mahotka, C; Conway, EM; Altura, RA				Caldas, H; Jiang, YY; Holloway, MP; Fangusaro, J; Mahotka, C; Conway, EM; Altura, RA			Survivin splice variants regulate the balance between proliferation and cell death	ONCOGENE			English	Article						apoptosis; cell division; drug therapy; mitosis; neoplasms	ANTI-APOPTOSIS GENE; SUBCELLULAR-LOCALIZATION; HUMAN NEUROBLASTOMA; PROTEIN SURVIVIN; EXPRESSION; CYCLE; IDENTIFICATION; CANCER; BRAIN; OVEREXPRESSION	Survivin is an inhibitor of apoptosis protein that also plays critical roles in regulating the cell cycle and mitosis. Its prominent expression in essentially all human malignancies, and low or absent expression in most normal tissues, suggests that it would be an ideal target for cancer-directed therapy. Impeding development of safe and effective survivin antagonists for clinical use is a lack of understanding of the molecular mechanisms by which survivin differentially affects apoptosis and cell division, in normal and malignant cells. We show that the diverse functional roles of survivin can be explained, in part, by its heterodimerization with survivin splice variants in tumor cells. Survivin and survivin-Delta Ex3 interact within the mitochondria where they may inhibit mitochondrial-dependent apoptosis. If the expression of all survivin forms is eliminated by siRNA transfections, cells undergo both apoptosis and defective cell division. Overall, we provide new insights suggesting that targeting specific survivin isoforms, rather than survivin alone, may selectively and effectively destroy tumor cells. These findings are likely to have a significant impact in the design of biologic agents for clinical therapy.	Ohio State Univ, Ctr Childhood Canc, Columbus Childrens Res Inst, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Univ Dusseldorf, Inst Pathol, D-4000 Dusseldorf, Germany; Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Heinrich Heine University Dusseldorf; Flanders Institute for Biotechnology (VIB); KU Leuven	Altura, RA (corresponding author), Ohio State Univ, Ctr Childhood Canc, Columbus Childrens Res Inst, 700 Childrens Dr,Rm WA5021, Columbus, OH 43205 USA.	alturar@pediatrics.ohio-state.edu		Conway, Edward/0000-0003-0081-0305				Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Altura RA, 2003, BRIT J CANCER, V89, P1743, DOI 10.1038/sj.bjc.6601334; Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Armit CJ, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-27; Badran A, 2004, BIOCHEM BIOPH RES CO, V314, P902, DOI 10.1016/j.bbrc.2003.12.178; Bronfman M, 1998, ANAL BIOCHEM, V255, P252, DOI 10.1006/abio.1997.2453; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; Chen J, 2003, J BIOL CHEM, V278, P486, DOI 10.1074/jbc.M211119200; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Conway EM, 2003, AM J PATHOL, V163, P935, DOI 10.1016/S0002-9440(10)63453-0; Conway EM, 2002, GASTROENTEROLOGY, V123, P619, DOI 10.1053/gast.2002.34753; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; HS U, 1998, NEUROSCI LETT, V244, P411; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Islam A, 2000, MED PEDIATR ONCOL, V35, P550, DOI 10.1002/1096-911X(20001201)35:6<550::AID-MPO12>3.0.CO;2-Y; JACOBSEN PF, 1985, J NEUROPATH EXP NEUR, V44, P472, DOI 10.1097/00005072-198509000-00003; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Krieg A, 2002, BRIT J CANCER, V86, P737, DOI 10.1038/sj.bjc.6600153; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lee SH, 2001, CHILD NERV SYST, V17, P134, DOI 10.1007/s003810000341; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Mahotka C, 1999, CANCER RES, V59, P6097; Mahotka C, 2002, CELL DEATH DIFFER, V9, P1334, DOI 10.1038/sj.cdd.4401091; Mahotka C, 2002, INT J CANCER, V100, P30, DOI 10.1002/ijc.10450; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pennartz S, 2004, MOL CELL NEUROSCI, V25, P692, DOI 10.1016/j.mcn.2003.12.011; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2001, GENOME BIOL, V2; Wang HW, 2002, EMBO J, V21, P2602, DOI 10.1093/emboj/21.11.2602; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; Yamada Y, 2003, J NEUROSURG, V99, P738, DOI 10.3171/jns.2003.99.4.0738	49	157	176	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					1994	2007		10.1038/sj.onc.1208350	http://dx.doi.org/10.1038/sj.onc.1208350			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688031				2022-12-25	WOS:000227681900004
J	Perez, GI; Jurisicova, A; Matikainen, T; Moriyama, T; Kim, MR; Takai, Y; Pru, JK; Kolesnick, RN; Tilly, JL				Perez, GI; Jurisicova, A; Matikainen, T; Moriyama, T; Kim, MR; Takai, Y; Pru, JK; Kolesnick, RN; Tilly, JL			A central role for ceramide in the age-related acceleration of apoptosis in the female germline	FASEB JOURNAL			English	Article						aging; ovary; oocyte; Bax	CELL-DEATH; OXIDATIVE STRESS; DEFICIENT MICE; CUMULUS CELLS; BAX; GENE; ACTIVATION; EXPRESSION; MEMBRANE; OOCYTES	An age-dependent acceleration of apoptosis occurs in female germ cells (oocytes), and this requires communication between the oocyte and its surrounding somatic ( cumulus) cells. Here we show in aged mice that ceramide is translocated from cumulus cells into the adjacent oocyte and induces germ cell apoptosis that can be prevented by sphingosine-1-phosphate. Trafficking of ceramide requires gap junction-dependent communication between the cumulus cells and the oocyte as well as intact lipid rafts. Further, the occurrence of the elevated incidence of apoptosis in oocytes of aged females is concomitant with an enhanced sensitivity of the oocyte to a spike in cytosolic ceramide levels, as well as increased bax mRNA and Bax protein levels. Thus, the force driving the age-related increase in female germ cell death is multifactorial, but changes in the intercellular trafficking of ceramide, along with hypersensitivity of oocytes to ceramide, are key factors in this process.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Vincent Obstet & Gynecol Serv,Vincent Ctr Reprod, Boston, MA 02114 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Obstet & Gynecol, Toronto, ON M5G 1X5, Canada; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Memorial Sloan Kettering Cancer Center	Perez, GI (corresponding author), Michigan State Univ, Dept Physiol, 4173 BPS, E Lansing, MI 48824 USA.	perezg@msu.edu	Jurisicova, Andrea/E-4580-2013; Perez, Gloria I/GMX-1286-2022	Kim, Mee-Ran/0000-0003-4492-0768	NATIONAL INSTITUTE ON AGING [R01AG012279] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG12279] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anisimov VN, 2003, EXP GERONTOL, V38, P1041, DOI 10.1016/S0531-5565(03)00169-4; Bezombes C, 2004, BLOOD, V104, P1166, DOI 10.1182/blood-2004-01-0277; Braeckman BP, 2001, MECH AGEING DEV, V122, P673, DOI 10.1016/S0047-6374(01)00222-6; Brandwagt BF, 2000, P NATL ACAD SCI USA, V97, P4961, DOI 10.1073/pnas.97.9.4961; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Chi FL, 2004, ARCH OTOLARYNGOL, V130, P307, DOI 10.1001/archotol.130.3.307; Contreras FX, 2003, J BIOL CHEM, V278, P37169, DOI 10.1074/jbc.M303206200; Cottrell D A, 2000, Curr Opin Clin Nutr Metab Care, V3, P473, DOI 10.1097/00075197-200011000-00009; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Cutler RG, 2001, MECH AGEING DEV, V122, P895, DOI 10.1016/S0047-6374(01)00246-9; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Diatlovitskaia E V, 1995, Biokhimiia, V60, P1302; DMELLO NP, 1994, J BIOL CHEM, V269, P15451; DOWNS SM, 1995, DEV BIOL, V167, P502, DOI 10.1006/dbio.1995.1044; FADDY MJ, 1992, HUM REPROD, V7, P1342, DOI 10.1093/oxfordjournals.humrep.a137570; Fujino Y, 1996, HUM REPROD, V11, P1480; Gems D, 2001, CURR OPIN GENET DEV, V11, P287, DOI 10.1016/S0959-437X(00)00192-1; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Grazide S, 2004, J BIOL CHEM, V279, P18256, DOI 10.1074/jbc.M314105200; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Gulbins Erich, 2002, Subcell Biochem, V36, P229; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Jazwinski SM, 2000, TRENDS GENET, V16, P506, DOI 10.1016/S0168-9525(00)02119-3; Jiang JC, 1998, GENOME RES, V8, P1259, DOI 10.1101/gr.8.12.1259; JIN K, 1994, ACTA DERM-VENEREOL, V74, P337; Jurisicova A, 1998, MOL REPROD DEV, V51, P243, DOI 10.1002/(SICI)1098-2795(199811)51:3&lt;243::AID-MRD3&gt;3.0.CO;2-P; Knight JA, 2001, ADV CLIN CHEM, V35, P1, DOI 10.1016/S0065-2423(01)35014-X; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Krutovskikh VA, 2002, ONCOGENE, V21, P1989, DOI 10.1038/sj.onc.1205187; Lang KS, 2004, AM J PHYSIOL-RENAL, V286, pF1046, DOI 10.1152/ajprenal.00263.2003; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lightle SA, 2000, MECH AGEING DEV, V120, P111, DOI 10.1016/S0047-6374(00)00191-3; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; Matikainen TM, 2002, ENDOCRINOLOGY, V143, P615, DOI 10.1210/en.143.2.615; Meivar-Levy I, 1999, J BIOL CHEM, V274, P4607, DOI 10.1074/jbc.274.8.4607; Merrill AH, 2001, ENVIRON HEALTH PERSP, V109, P283, DOI 10.2307/3435020; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Muradian K, 2001, Z GERONTOL GERIATR, V34, P441, DOI 10.1007/s003910170015; Nagasawa H, 2002, CANCER RES, V62, P2531; Nicolas A S, 1999, J Nutr Health Aging, V3, P77; Obeid Lina M, 2003, Sci Aging Knowledge Environ, V2003, pPE27, DOI 10.1126/sageke.2003.39.pe27; Pan H, 2001, GENOMICS, V77, P58, DOI 10.1006/geno.2001.6614; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Perez GI, 1997, HUM REPROD, V12, P2781, DOI 10.1093/humrep/12.12.2781; Perez GI, 1999, NAT GENET, V21, P200, DOI 10.1038/5985; Perez GI, 1999, MOL HUM REPROD, V5, P414, DOI 10.1093/molehr/5.5.414; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; RAMBHATLA L, 1995, MOL REPROD DEV, V41, P314, DOI 10.1002/mrd.1080410306; RICHARDSON SJ, 1987, J CLIN ENDOCR METAB, V65, P1231, DOI 10.1210/jcem-65-6-1231; Rucker EB, 2000, MOL ENDOCRINOL, V14, P1038, DOI 10.1210/me.14.7.1038; Schondorf T, 2001, CLIN EXP MED, V1, P1, DOI 10.1007/PL00012236; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200; Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Tilly JL, 2001, NAT REV MOL CELL BIO, V2, P838, DOI 10.1038/35099086; Van Remmen H, 2001, EXP GERONTOL, V36, P957; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wilcke M, 2001, BBA-PROTEIN STRUCT M, V1544, P358, DOI 10.1016/S0167-4838(00)00250-8; Wu J, 2000, FERTIL STERIL, V74, P1137, DOI 10.1016/S0015-0282(00)01597-1	67	77	88	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					860	+		10.1096/fj.04-2903fje	http://dx.doi.org/10.1096/fj.04-2903fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15728664				2022-12-25	WOS:000227591900011
J	Williams, JC; Xie, H; Hendrickson, WA				Williams, JC; Xie, H; Hendrickson, WA			Crystal structure of dynein light chain TcTex-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DYNEIN; SUBUNIT HETEROGENEITY; PROTEIN; INTERACTS; COMPLEX; LC8; INHIBITOR; RECEPTOR; FAMILY; IDENTIFICATION	TcTex-1, one of three dynein light chains of the dynein motor complex, has been implicated in targeting and binding cargoes to cytoplasmic dynein for retrograde or apical transport. Interactions between TcTex-1 and a diverse set of proteins such as the dynein intermediate chain, Fyn, DOC2, FIP1, the poliovirus receptor, CD155, and the rhodopsin cytoplasmic tail have been reported; yet, despite the broad range of targets, a consensus binding sequence remains uncertain. Consequently, we have solved the crystal structure of the full-length Drosophila homolog of TcTex-1 to 1.7 angstrom resolution using MAD phasing to gain insight into its function and target specificity. The structure is homodimeric with a domain swapping of beta-strand 2 and has a fold similar to the dynein light chain, LC8. Based on structural alignment, the TcTex-1 1 and LC8 sequences show no identity, although the root mean square deviation between secondary structural elements is less than 1.6 angstrom. Moreover, the N terminus, which is equivalent to beta-strand 1 in LC8, is splayed out and binds to a crystallographic dimer as an anti-parallel beta-strand at the same position as the neuronal nitric-oxide synthase peptide in the LC8 complex. Similarity to LC8 and comparison to the LC8-neuronal nitricoxide synthase complex suggest that TcTex-1 binds its targets in a similar manner as LC8 and provides insight to the lack of strict sequence identity among the targets for TcTex-1.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute	Hendrickson, WA (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA.	wayne@convex.hhmi.columbia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034102, R01GM034102] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34102] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Bauch A, 1998, EUR J IMMUNOL, V28, P2167, DOI 10.1002/(SICI)1521-4141(199807)28:07<2167::AID-IMMU2167>3.0.CO;2-L; BODE W, 1986, EMBO J, V5, P813, DOI 10.1002/j.1460-2075.1986.tb04286.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgess SA, 2003, NATURE, V421, P715, DOI 10.1038/nature01377; Caggese C, 2001, MOL GENET GENOMICS, V265, P436, DOI 10.1007/s004380000431; Campbell KS, 1998, J IMMUNOL, V161, P1728; Chuang JZ, 2001, J NEUROSCI, V21, P5501, DOI 10.1523/JNEUROSCI.21-15-05501.2001; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; Day CL, 2004, BIOCHEM J, V377, P597, DOI 10.1042/BJ20031251; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Holleran EA, 2001, J BIOL CHEM, V276, P36598, DOI 10.1074/jbc.M104838200; Jacob Y, 2000, J VIROL, V74, P10217, DOI 10.1128/JVI.74.21.10217-10222.2000; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kai N, 1997, J NEUROSCI RES, V48, P407, DOI 10.1002/(SICI)1097-4547(19970601)48:5<407::AID-JNR3>3.3.CO;2-F; King SJ, 2002, PROTEIN SCI, V11, P1239, DOI 10.1110/ps.2520102; LADER E, 1989, CELL, V58, P969, DOI 10.1016/0092-8674(89)90948-3; Liang J, 1999, NAT STRUCT BIOL, V6, P735; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Lukashok SA, 2000, J VIROL, V74, P4705, DOI 10.1128/JVI.74.10.4705-4709.2000; Machado RD, 2003, HUM MOL GENET, V12, P3277, DOI 10.1093/hmg/ddg365; Makokha M, 2002, BIOCHEMISTRY-US, V41, P4302, DOI 10.1021/bi011970h; Martinez-Moreno M, 2003, FEBS LETT, V544, P262, DOI 10.1016/S0014-5793(03)00516-7; Miki F, 2002, MOL BIOL CELL, V13, P930, DOI 10.1091/mbc.01-11-0543; Mok YK, 2001, J BIOL CHEM, V276, P14067, DOI 10.1074/jbc.M011358200; Mou T, 1998, FEBS LETT, V435, P275, DOI 10.1016/S0014-5793(98)01069-2; Mueller S, 2002, J BIOL CHEM, V277, P7897, DOI 10.1074/jbc.M111937200; Nadano D, 2002, BIOCHEM J, V364, P669, DOI 10.1042/BJ20011836; Nagano F, 1998, J BIOL CHEM, V273, P30065, DOI 10.1074/jbc.273.46.30065; ONEILL MJ, 1995, DEVELOPMENT, V121, P561; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Purohit A, 1999, J CELL BIOL, V147, P481, DOI 10.1083/jcb.147.3.481; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Raux H, 2000, J VIROL, V74, P10212, DOI 10.1128/JVI.74.21.10212-10216.2000; SAMBROOK J, 1989, MOL CLONING LAB MANU, V1, P436; SAMBROOK J, 1989, MOL CLONING LAB MANU, V2, P436; Schnorrer F, 2000, NAT CELL BIOL, V2, P185, DOI 10.1038/35008601; Schwarzer C, 2002, INT J BIOCHEM CELL B, V34, P1059, DOI 10.1016/S1357-2725(02)00026-2; Sugai M, 2003, BIOCHEM BIOPH RES CO, V311, P24, DOI 10.1016/j.bbrc.2003.09.157; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tai AW, 2001, J CELL BIOL, V153, P1499, DOI 10.1083/jcb.153.7.1499; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314; VAUGHAN KT, 1995, BIOCHEM SOC T, V23, P50, DOI 10.1042/bst0230050; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; Wu HW, 2001, J BIOMOL NMR, V20, P89, DOI 10.1023/A:1011299813395; Yano H, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-03-j0003.2001	53	34	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21981	21986		10.1074/jbc.M414643200	http://dx.doi.org/10.1074/jbc.M414643200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15701632	hybrid			2022-12-25	WOS:000229557900040
J	Mishra, SK; Keyel, PA; Edeling, MA; Dupin, AL; Owen, DJ; Traub, LM				Mishra, SK; Keyel, PA; Edeling, MA; Dupin, AL; Owen, DJ; Traub, LM			Functional dissection of an AP-2 beta 2 appendage-binding sequence within the autosomal recessive hypercholesterolemia protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; DENSITY-LIPOPROTEIN RECEPTOR; COATED PITS; TERMINAL DOMAIN; ACCESSORY PROTEINS; COUPLED RECEPTORS; CRYSTAL-STRUCTURE; SORTING SIGNALS; ALPHA-APPENDAGE; ADAPTER PROTEIN	The autosomal recessive hypercholesterolemia (ARH) protein plays a critical role in regulating plasma low density lipoprotein (LDL) levels. Inherited defects in ARH lead to a hypercholesterolemia that closely phenocopies that caused by a defective LDL receptor. The elevated serum LDL-cholesterol levels typical of ARH patients and the pronounced accumulation of the LDL receptor at the cell surface of hepatocytes in ARH-null mice argue that ARH operates by promoting the internalization of the LDL receptor within clathrin-coated vesicles. ARH contains an amino-terminal phosphotyrosine-binding domain that associates physically with the LDL receptor internalization sequence and with phosphoinositides. The carboxyl-terminal half of ARH contains a clathrin-binding sequence and a separate AP-2 adaptor binding region providing a plausible mechanism for how ARH can act as an endocytic adaptor or CLASP (clathrin-associated sorting protein) to couple LDL receptors with the clathrin machinery. Because the interaction with AP-2 is highly selective for the independently folded appendage domain of the beta 2 subunit, we have characterized the ARH beta 2 appendage-binding sequence in detail. Unlike the known alpha appendage-binding motifs, ARH requires an extensive sequence tract to bind the beta appendage with comparably high affinity. A minimal 16-residue sequence functions autonomously and depends upon ARH residues Asp(253), Phe(259), Leu(262), and Arg(266). We suggested that biased beta subunit engagement by ARH and the only other beta 2 appendage selective adaptor, beta-arrestin, promotes efficient incorporation of this mechanistically distinct subset of CLASPs into clathrin-coated buds.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Cambridge	Traub, LM (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, 3500 Terrace St,S325 BST, Pittsburgh, PA 15261 USA.	traub@pitt.edu	Mishra, Santosh/S-7516-2017	Mishra, Santosh/0000-0001-8616-2606; Traub, Linton/0000-0002-1303-0298	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK061296, R01DK053249] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK53249, 5T32 DK061296-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boll W, 2002, TRAFFIC, V3, P590, DOI 10.1034/j.1600-0854.2002.30808.x; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bonifacino JS, 2003, NAT REV MOL CELL BIO, V4, P409, DOI 10.1038/nrm1099; Brett TJ, 2002, STRUCTURE, V10, P797, DOI 10.1016/S0969-2126(02)00784-0; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Cohen JC, 2003, CURR OPIN LIPIDOL, V14, P121, DOI 10.1097/00041433-200304000-00002; Collins BM, 2003, NAT STRUCT BIOL, V10, P607, DOI 10.1038/nsb955; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Conner SD, 2002, J CELL BIOL, V156, P921, DOI 10.1083/jcb.200108123; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Drake MT, 2001, J BIOL CHEM, V276, P28700, DOI 10.1074/jbc.M104226200; Eden ER, 2002, J CLIN INVEST, V110, P1695, DOI 10.1172/JCI200216445; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Janvier K, 2003, J CELL BIOL, V163, P1281, DOI 10.1083/jcb.200307157; Jha A, 2004, J BIOL CHEM, V279, P2281, DOI 10.1074/jbc.M305644200; Kim YM, 2002, J BIOL CHEM, V277, P30760, DOI 10.1074/jbc.M204528200; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 2002, J BIOL CHEM, V277, P9247, DOI 10.1074/jbc.M108490200; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Mattera R, 2004, J BIOL CHEM, V279, P31409, DOI 10.1074/jbc.M402183200; McMahon HT, 2004, CURR OPIN CELL BIOL, V16, P379, DOI 10.1016/j.ceb.2004.06.009; Miele AE, 2004, NAT STRUCT MOL BIOL, V11, P242, DOI 10.1038/nsmb736; Milano SK, 2002, BIOCHEMISTRY-US, V41, P3321, DOI 10.1021/bi015905j; Mills IG, 2003, J CELL BIOL, V160, P213, DOI 10.1083/jcb.200208023; Mishra SK, 2004, J BIOL CHEM, V279, P46191, DOI 10.1074/jbc.M408095200; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Olusanya O, 2001, CURR BIOL, V11, P896, DOI 10.1016/S0960-9822(01)00240-8; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; Owen DJ, 2004, BIOCHEM SOC T, V32, P1, DOI 10.1042/BST0320001; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Ricotta D, 2002, J CELL BIOL, V156, P791, DOI 10.1083/jcb.200111068; Ritter B, 2003, EMBO REP, V4, P1089, DOI 10.1038/sj.embor.7400004; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Santini F, 2000, J CELL SCI, V113, P2463; Scheele U, 2003, J BIOL CHEM, V278, P25357, DOI 10.1074/jbc.M303738200; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001; Soutar AK, 2003, ARTERIOSCL THROM VAS, V23, P1963, DOI 10.1161/01.ATV.0000094410.66558.9A; Stang E, 2004, MOL BIOL CELL, V15, P3591, DOI 10.1091/mbc.E04-01-0041; Stolt PC, 2003, STRUCTURE, V11, P569, DOI 10.1016/S0969-2126(03)00068-6; Traub LM, 2003, J CELL BIOL, V163, P203, DOI 10.1083/jcb.200309175; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Tulipano G, 2004, J BIOL CHEM, V279, P21374, DOI 10.1074/jbc.M313522200; Walther K, 2004, P NATL ACAD SCI USA, V101, P964, DOI 10.1073/pnas.0307862100; Warren RA, 1998, J BIOL CHEM, V273, P17056, DOI 10.1074/jbc.273.27.17056; Wu JH, 2003, J BIOL CHEM, V278, P44238, DOI 10.1074/jbc.M309450200; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200; Zhou Y, 2003, J BIOL CHEM, V278, P44584, DOI 10.1074/jbc.M308870200	57	48	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19270	19280		10.1074/jbc.M501029200	http://dx.doi.org/10.1074/jbc.M501029200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15728179	hybrid			2022-12-25	WOS:000228932300084
J	Zhan, YG; Tremblay, MR; Melian, N; Carbonetto, S				Zhan, YG; Tremblay, MR; Melian, N; Carbonetto, S			Evidence that dystroglycan is associated with dynamin and regulates endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; GROWTH-FACTOR-RECEPTOR; ALPHA-DYSTROGLYCAN; BETA-DYSTROGLYCAN; DIFFERENTIAL DISTRIBUTION; MEDIATED ENDOCYTOSIS; MUSCULAR-DYSTROPHY; BINDING-PROTEIN; DOMAIN; NERVE	Disruption of the dystroglycan gene in humans and mice leads to muscular dystrophies and nervous system defects including malformation of the brain and defective synaptic transmission. To identify proteins that interact with dystroglycan in the brain we have used immunoaffinity purification followed by mass spectrometry (LC/MS-MS) and found that the GTPase dynamin 1 is a novel dystroglycan-associated protein. The beta-dystroglycandynamin 1 complex also included alpha-dystroglycan and Grb2. Overlay assays indicated that dynamin interacts directly with dystroglycan, and immunodepletion showed that only a pool of dynamin is associated with dystroglycan. Dystroglycan was associated and colocalized immunohistochemically with dynamin 1 in the central nervous system in the outer plexiform layer of retina where photoreceptor terminals are found. Endocytosis in neurons is both constitutive, as in non-neural cells, and regulated by neural activity. To assess the function of dystroglycan in the former, we have assayed transferrin uptake in fibroblastic cells differentiated from embryonic stem cells null for both dystroglycan alleles. In wild-type cells, dystroglycan formed a complex with dynamin and codistributed with cortactin at membrane ruffles, which are organelles implicated in endocytosis. Dystroglycan-null cells had a significantly greater transferrin uptake, a process well known to require dynamin. Expression of dystroglycan in null cells by infection with an adenovirus containing dystroglycan reduced transferrin uptake to levels seen in wildtype embryonic stem cells. These data suggest that dystroglycan regulates endocytosis possibly as a result of its interaction with dynamin.	McGill Univ, Montreal Gen Hosp, Res Inst, Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada; McGill Univ, Montreal Gen Hosp, Res Inst, Dept Neurol & Neurosurg, Montreal, PQ H3G 1A4, Canada; McGill Univ, Montreal Gen Hosp, Res Inst, Dept Biol, Montreal, PQ H3G 1A4, Canada	McGill University; McGill University; McGill University	Carbonetto, S (corresponding author), McGill Univ, Montreal Gen Hosp, Res Inst, Ctr Res Neurosci, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	sal.carbonetto@mcgill.ca						Blake DJ, 2000, TRENDS NEUROSCI, V23, P92, DOI 10.1016/S0166-2236(99)01510-6; Blank M, 2002, NEUROSCIENCE, V111, P259, DOI 10.1016/S0306-4522(02)00032-5; Blank M, 1999, EUR J NEUROSCI, V11, P2121, DOI 10.1046/j.1460-9568.1999.00636.x; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; Bretscher MS, 1998, CURR BIOL, V8, P721, DOI 10.1016/S0960-9822(98)70281-7; Brunig I, 2002, J NEUROSCI, V22, P4805, DOI 10.1523/JNEUROSCI.22-12-04805.2002; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Chen YJ, 2003, BIOCHEM J, V375, P329, DOI 10.1042/BJ20030808; COHEN MW, 1995, J CELL BIOL, V129, P1093, DOI 10.1083/jcb.129.4.1093; Cohn RD, 2002, CELL, V110, P639, DOI 10.1016/S0092-8674(02)00907-8; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; D'Hondt K, 2000, ANNU REV GENET, V34, P255, DOI 10.1146/annurev.genet.34.1.255; Dalloz C, 2001, MOL CELL NEUROSCI, V17, P908, DOI 10.1006/mcne.2001.0978; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Deng WM, 2003, DEVELOPMENT, V130, P173, DOI 10.1242/dev.00199; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Durbeej M, 1998, CURR OPIN CELL BIOL, V10, P594, DOI 10.1016/S0955-0674(98)80034-3; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Estes PS, 1996, J NEUROSCI, V16, P5443; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1993, J BIOL CHEM, V268, P14972; Gingras J, 2001, J NEUROBIOL, V48, P228, DOI 10.1002/neu.1053; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; Grewal PK, 2001, NAT GENET, V28, P151, DOI 10.1038/88865; Holzfeind PJ, 2002, HUM MOL GENET, V11, P2673, DOI 10.1093/hmg/11.21.2673; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; Ido H, 2004, J BIOL CHEM, V279, P10946, DOI 10.1074/jbc.M313626200; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; Jarousse N, 2001, CURR OPIN CELL BIOL, V13, P461, DOI 10.1016/S0955-0674(00)00237-4; Kanagawa M, 2004, CELL, V117, P953, DOI 10.1016/j.cell.2004.06.003; Karoor V, 1998, J BIOL CHEM, V273, P33035, DOI 10.1074/jbc.273.49.33035; Koulen P, 1998, J NEUROSCI RES, V51, P735, DOI 10.1002/(SICI)1097-4547(19980315)51:6<735::AID-JNR7>3.0.CO;2-C; Koulen P, 1999, EUR J NEUROSCI, V11, P4188, DOI 10.1046/j.1460-9568.1999.00848.x; Leschziner A, 2000, J NEUROCHEM, V74, P70, DOI 10.1046/j.1471-4159.2000.0740070.x; Levi S, 2002, J NEUROSCI, V22, P4274, DOI 10.1523/JNEUROSCI.22-11-04274.2002; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; Michele DE, 2003, J BIOL CHEM, V278, P15457, DOI 10.1074/jbc.R200031200; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Montanaro F, 2003, NEURON, V37, P193, DOI 10.1016/S0896-6273(03)00032-1; MONTANARO F, 1995, J NEUROSCI RES, V42, P528, DOI 10.1002/jnr.490420411; Moore SA, 2002, NATURE, V418, P422, DOI 10.1038/nature00838; Moukhles H, 2001, J NEUROCHEM, V78, P824, DOI 10.1046/j.1471-4159.2001.00466.x; Moukhles H, 2000, J COMP NEUROL, V420, P182, DOI 10.1002/(SICI)1096-9861(20000501)420:2<182::AID-CNE3>3.0.CO;2-2; Oak SA, 2001, BIOCHEMISTRY-US, V40, P11270, DOI 10.1021/bi010490n; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Peng HB, 1998, CELL ADHES COMMUN, V5, P475, DOI 10.3109/15419069809005605; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Roos J, 1999, CURR BIOL, V9, P1411, DOI 10.1016/S0960-9822(00)80087-1; Russo K, 2000, BIOCHEM BIOPH RES CO, V274, P93, DOI 10.1006/bbrc.2000.3103; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Sherman DL, 2001, NEURON, V30, P677, DOI 10.1016/S0896-6273(01)00327-0; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; SMALHEISER NR, 1995, J BIOL CHEM, V270, P15425, DOI 10.1074/jbc.270.25.15425; Spence HJ, 2004, HUM MOL GENET, V13, P1657, DOI 10.1093/hmg/ddh170; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; Tian M, 1996, EUR J NEUROSCI, V8, P2739, DOI 10.1111/j.1460-9568.1996.tb01568.x; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Vidal M, 1999, J MOL BIOL, V290, P717, DOI 10.1006/jmbi.1999.2899; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; Winder SJ, 2001, TRENDS BIOCHEM SCI, V26, P118, DOI 10.1016/S0968-0004(00)01731-X; Yamazaki T, 2002, J CELL SCI, V115, P1791; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; Zaccaria ML, 2001, NEUROSCIENCE, V104, P311, DOI 10.1016/S0306-4522(01)00092-6	87	25	25	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18015	18024		10.1074/jbc.M409682200	http://dx.doi.org/10.1074/jbc.M409682200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728588	hybrid			2022-12-25	WOS:000228807200057
J	Torrents, E; Poplawski, A; Sjoberg, BM				Torrents, E; Poplawski, A; Sjoberg, BM			Two proteins mediate class II ribonucleotide reductase activity in pseudomonas aeruginosa - Expression and transcriptional analysis of the aerobic enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; VITAMIN-B-12 METABOLISM; SEQUENCE; STREPTOMYCES; SPECIFICITY; PROKARYOTES; STRATEGIES; EVOLUTION; BACTERIA; GENES	The opportunistic human pathogen Pseudomonas aeruginosa is one of a few microorganisms that code for three different classes ( I, II, and III) of the enzyme ribonucleotide reductase (RNR). Class II RNR of P. aeruginosa differs from all hitherto known class II enzymes by being encoded by two consecutive open reading frames denoted nrdJa and nrdJb and separated by 16 bp. Split nrdJ genes were also found in the few other gamma-proteobacteria that code for a class II RNR. Interestingly, the two genes encoding the split nrdJ in P. aeruginosa were co-transcribed, and both proteins were expressed. Exponentially growing aerobic cultures were predominantly expressing the class I RNR ( encoded by the nrdAB operon) compared with the class II RNR ( encoded by the nrdJab operon). Upon entry to stationary phase, the relative amount of nrdJa transcript increased about 6 - 7-fold concomitant with a 6-fold decrease in the relative amount of nrdA transcript. Hydroxyurea treatment known to knock out the activity of class I RNR caused strict growth inhibition of P. aeruginosa unless 5'-deoxyadenosylcobalamin, a cofactor specifically required for activity of class II RNRs, was added to the rich medium. Rescue of the hydroxyurea-treated cells in the presence of the vitamin B-12 cofactor strongly implies that P. aeruginosa produces a functionally active NrdJ protein. Biochemical studies showed for the first time that presence of both NrdJa and NrdJb subunits were absolutely essential for enzyme activity. Based on combined genetic and biochemical results, we suggest that the two-component class II RNR in P. aeruginosa is primarily used for DNA repair and/or possibly DNA replication at low oxygen tension.	Stockholm Univ, Dept Mol Biol & Funct Genom, Arrhenius Labs Nat Sci, SE-10691 Stockholm, Sweden	Stockholm University	Sjoberg, BM (corresponding author), Stockholm Univ, Dept Mol Biol & Funct Genom, Arrhenius Labs Nat Sci, Svante Arrhenius Vag 16-18 F3, SE-10691 Stockholm, Sweden.	britt-marie.sjoberg@molbio.su.se	Torrents, Eduard/C-7184-2008	Torrents, Eduard/0000-0002-3010-1609; Sjoberg, Britt-Marie/0000-0001-5953-3360				*APPL BIOS, 1997, US B APPL BIOS, V2, P1; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; BAGDASARIAN M, 1981, GENE, V16, P237, DOI 10.1016/0378-1119(81)90080-9; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; Borovok I, 2004, MOL MICROBIOL, V54, P1022, DOI 10.1111/j.1365-2958.2004.04325.x; Borovok I, 2002, MICROBIOL-SGM, V148, P391, DOI 10.1099/00221287-148-2-391; de Lorenzo V, 2000, Environ Microbiol, V2, P349; DELORENZO V, 1993, GENE, V123, P17, DOI 10.1016/0378-1119(93)90533-9; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Eliasson R, 1999, J BIOL CHEM, V274, P7182, DOI 10.1074/jbc.274.11.7182; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; GALE GR, 1964, CANCER RES, V24, P1012; Jacobson BA, 1998, MOL MICROBIOL, V28, P1307, DOI 10.1046/j.1365-2958.1998.00896.x; Jordan A, 1997, P NATL ACAD SCI USA, V94, P13487, DOI 10.1073/pnas.94.25.13487; Jordan A, 1999, J BACTERIOL, V181, P3974, DOI 10.1128/JB.181.13.3974-3980.1999; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kasai S, 2002, EUR J BIOCHEM, V269, P5851, DOI 10.1046/j.1432-1033.2002.03304.x; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Larsson K, 2004, THESIS STOCKHOLM U S; Larsson KM, 2004, NAT STRUCT MOL BIOL, V11, P1142, DOI 10.1038/nsmb838; Lyczak JB, 2000, MICROBES INFECT, V2, P1051, DOI 10.1016/S1286-4579(00)01259-4; Mayhew C N, 2002, Antivir Chem Chemother, V13, P305; Nocentini G, 1996, CRIT REV ONCOL HEMAT, V22, P89, DOI 10.1016/1040-8428(95)00187-5; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Rodionov DA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-11-r90; Rodionov DA, 2003, J BIOL CHEM, V278, P41148, DOI 10.1074/jbc.M305837200; Sabra W, 2002, MICROBIOL-SGM, V148, P3195, DOI 10.1099/00221287-148-10-3195; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Savli H, 2003, J MED MICROBIOL, V52, P403, DOI 10.1099/jmm.0.05132-0; SHINE J, 1975, EUR J BIOCHEM, V57, P221, DOI 10.1111/j.1432-1033.1975.tb02294.x; Sintchak MD, 2002, NAT STRUCT BIOL, V9, P293, DOI 10.1038/nsb774; SITJES J, 1992, MUTAGENESIS, V7, P47, DOI 10.1093/mutage/7.1.47; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291; Thelander L, 1978, Methods Enzymol, V51, P227; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Torrents E, 2003, MICROBIOL-SGM, V149, P1011, DOI 10.1099/mic.0.26133-0; Torrents E, 2002, J MOL EVOL, V55, P138, DOI 10.1007/s00239-002-2311-7; Torrents E, 2001, J BIOL CHEM, V276, P33488, DOI 10.1074/jbc.M103743200; Tsimberidou Apostolia-Maria, 2002, Expert Rev Anticancer Ther, V2, P437, DOI 10.1586/14737140.2.4.437; Vitreschak AG, 2003, RNA, V9, P1084, DOI 10.1261/rna.5710303; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	43	26	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16571	16578		10.1074/jbc.M501322200	http://dx.doi.org/10.1074/jbc.M501322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722359	hybrid			2022-12-25	WOS:000228615500006
J	Yamakoshi, Y; Hu, JCC; Fukae, M; Zhang, HM; Simmer, JP				Yamakoshi, Y; Hu, JCC; Fukae, M; Zhang, HM; Simmer, JP			Dentin glycoprotein - The protein in the middle of the dentin sialophosphoprotein chimera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPERFECTA TYPE-II; DENTINOGENESIS IMPERFECTA; SEQUENCE DETERMINATION; MATRIX PROTEINS; LINKED OLIGOSACCHARIDES; MAPPING TECHNIQUE; DSPP; PHOSPHOPROTEIN; SIALOPROTEIN; MUTATION	Dentin sialophosphoprotein ( DSPP) is a major secretory product of odontoblasts and is critical for proper dentin formation. DSPP is believed to be processed into only two structural/functional domains: dentin sialoprotein (DSP) and dentin phosphoprotein ( DPP). Here we report the isolation and characterization of a third domain of DSPP, designated dentin glycoprotein (DGP). DGP was isolated from a guanidine/EDTA extract of porcine tooth dentin by ion exchange, hydroxyapatite affinity, size exclusion, and RP-HPL chromatography. Endoproteinase lysine C digestion products of DGP were characterized by Edman sequencing and mass spectrometry. The porcine DGP backbone is the 81-amino acid segment of DSPP (Ser(392) to Gly(472)) between the DSP and DPP domains. DGP has four phosphorylated serine residues (Ser(453), Ser(455), Ser(457), and Ser(462)) and one glycosylated asparagine (Asn(397)). There are no other posttranslational modifications. DGP is a stains-all positive protein with an apparent molecular mass on SDS-PAGE of 19 kDa, which is reduced by glycopeptidase A digestion to 16 kDa. A variety of glycans can be linked to Asn(397). All are complex biantennary structures with a common N-linked pentasaccharide core (mannose(3)-N-acetylglucosamine(2)), most with a fucosyl residue on the innermost N-acetylglucosamine. The alpha 1-3 and alpha 1-6 arms are always galactose beta 1-4 N-acetylglucosamine beta 1-2 mannose, and either or both arms can be unsialidated or monosialidated. The calculated monoisotopic molecular masses of the different glycosylated forms of the DGP phosphoprotein are: unsialidated 10,523 and 10,670, monosialidated 10,815 and 10,961, and disialidated 11,106, and 11,252 Da, with the disialidated forms being the most abundant.	Univ Michigan, Dent Res Lab, Ann Arbor, MI 48108 USA; Tsurumi Univ, Sch Dent Med, Dept Biochem, Tsurumi Ku, Yokohama, Kanagawa 230, Japan	University of Michigan System; University of Michigan; Tsurumi University	Simmer, JP (corresponding author), Univ Michigan, Dent Res Lab, 1210 Eisenhower Pl, Ann Arbor, MI 48108 USA.	jsimmer@umich.edu	Hu, Jan C-C./F-5679-2015	Hu, Jan C-C./0000-0002-9294-0248	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011301, R01DE012769, R29DE011301, R56DE011301] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12769, DE15846, DE11301] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Begue-Kirn C, 1998, EUR J ORAL SCI, V106, P963, DOI 10.1046/j.0909-8836.1998.eos106510.x; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; Fukae M, 1996, Adv Dent Res, V10, P111; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; JONSSON M, 1978, J CHROMATOGR, V157, P235, DOI 10.1016/S0021-9673(00)92338-0; Kim JW, 2005, HUM GENET, V116, P186, DOI 10.1007/s00439-004-1223-6; Kim JW, 2004, HUM GENET, V115, P248, DOI 10.1007/s00439-004-1143-5; LINDE A, 1989, ANAT REC, V224, P154, DOI 10.1002/ar.1092240206; MacDougall M, 1997, CYTOGENET CELL GENET, V79, P121, DOI 10.1159/000134697; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; Malmgren B, 2004, HUM GENET, V114, P491, DOI 10.1007/s00439-004-1084-z; Nakagawa H, 1996, EUR J BIOCHEM, V237, P76, DOI 10.1111/j.1432-1033.1996.0076n.x; O'Connell AC, 1999, ORAL SURG ORAL MED O, V87, P189, DOI 10.1016/S1079-2104(99)70272-6; Pallos D, 2001, ARCH ORAL BIOL, V46, P459, DOI 10.1016/S0003-9969(00)00130-8; Patel PI, 2001, NAT GENET, V27, P129, DOI 10.1038/84728; Qin C, 2004, CRIT REV ORAL BIOL M, V15, P126, DOI 10.1177/154411130401500302; Qin CL, 2001, J BIOL CHEM, V276, P904, DOI 10.1074/jbc.M006271200; Rajpar MH, 2002, HUM MOL GENET, V11, P2559, DOI 10.1093/hmg/11.21.2559; RITCHIE HH, 1994, J BIOL CHEM, V269, P3698; Ritchie HH, 1996, J BIOL CHEM, V271, P21695, DOI 10.1074/jbc.271.36.21695; SHIELDS ED, 1973, ARCH ORAL BIOL, V18, P543, DOI 10.1016/0003-9969(73)90075-7; TAKAHASHI N, 1992, HDB ENDOGLYCOSIDASES, P199; TAKEMOTO H, 1985, ANAL BIOCHEM, V145, P245, DOI 10.1016/0003-2697(85)90357-4; TANABE T, 1990, CALCIFIED TISSUE INT, V46, P205, DOI 10.1007/BF02555046; TERMINE JD, 1980, J BIOL CHEM, V255, P9769; TOMIYA N, 1991, ANAL BIOCHEM, V193, P90, DOI 10.1016/0003-2697(91)90047-W; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; VEIS A, 1967, BIOCHEMISTRY-US, V6, P2409, DOI 10.1021/bi00860a017; Wallwork ML, 2002, CALCIFIED TISSUE INT, V71, P249, DOI 10.1007/s00223-001-1011-4; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; Yamakoshi Y, 2005, J BIOL CHEM, V280, P1552, DOI 10.1074/jbc.M409606200; YAMAKOSHI Y, 1995, CALCIFIED TISSUE INT, V56, P323, DOI 10.1007/BF00318054; Yamakoshi Y, 2003, EUR J ORAL SCI, V111, P60, DOI 10.1034/j.1600-0722.2003.00009.x; Yamakoshi Y, 1998, CONNECT TISSUE RES, V39, P39, DOI 10.3109/03008209809023910; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	35	78	84	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17472	17479		10.1074/jbc.M413220200	http://dx.doi.org/10.1074/jbc.M413220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728577	hybrid			2022-12-25	WOS:000228615500114
J	Baba, T; Shimizu, T; Suzuki, Y; Ogawara, M; Isono, K; Koseki, H; Kurosawa, H; Shirasawa, T				Baba, T; Shimizu, T; Suzuki, Y; Ogawara, M; Isono, K; Koseki, H; Kurosawa, H; Shirasawa, T			Estrogen, insulin, and dietary signals cooperatively regulate longevity signals to enhance resistance to oxidative stress in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MN-SUPEROXIDE DISMUTASE; LIFE-SPAN; CAENORHABDITIS-ELEGANS; ADIPOSE-TISSUE; GENE-EXPRESSION; KNOCKOUT MICE; RECEPTOR GENE; DWARF MICE; DROSOPHILA; EXTENSION	To investigate the biological significance of a longevity mutation found in daf-2 of Caenorhabditis elegans, we generated a homologous murine model by replacing Pro-1195 of insulin receptors with Leu using a targeted knock-in strategy. Homozygous mice died in the neonatal stage from diabetic ketoacidosis, whereas heterozygous mice showed the suppressed kinase activity of the insulin receptor but grew normally without spontaneously developing diabetes during adulthood. We examined heterozygous insulin receptor mutant mice for longevity phenotypes. Under 80% oxygen, mutant female mice survived 33.3% longer than wild-type female mice, whereas mutant male mice survived 18.2% longer than wild-type male mice. These results suggested that mutant mice acquired more resistance to oxidative stress, but the benefit of the longevity mutation was more pronounced in females than males. Manganese superoxide dismutase activity in mutant mice was significantly upregulated, suggesting that the suppressed insulin signaling leads to an enhanced antioxidant defense. To analyze the molecular basis of the gender difference, we administered estrogen to mutant mice. It was found that the survival of mice under 80% oxygen was extended when they were administered estradiol. In contrast, mutant and wild-type female mice showed shortened survivals when their ovaries were removed. The influence of estrogen is remarkable in mutant mice compared with wild-type mice, suggesting that estrogen modulates insulin signaling in mutant mice. Furthermore, we showed additional extension of survival under oxidative conditions when their diet was restricted. Collectively, we show that three distinct signals; insulin, estrogen, and dietary signals work in independent and cooperative ways to enhance the resistance to oxidative stress in mice.	Tokyo Metropolitan Inst Gerontol, Dept Mol Gerontol, Itabashi Ku, Tokyo 1730015, Japan; Chiba Univ, Grad Sch Med, Chiba 2608670, Japan; Juntendo Univ, Dept Orthoped, Bunkyo Ku, Tokyo 1138421, Japan	Tokyo Metropolitan Institute of Gerontology; Chiba University; Juntendo University	Shirasawa, T (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Mol Gerontol, Itabashi Ku, 35-2 Sakaecho, Tokyo 1730015, Japan.	sirasawa@tmig.or.jp	Koseki, Haruhiko/I-3825-2014	Koseki, Haruhiko/0000-0001-8424-5854; Isono, Kyoichi/0000-0002-4609-8985				Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; BAILEY CJ, 1980, DIABETOLOGIA, V19, P475, DOI 10.1007/BF00281829; Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646; Bartke A, 2000, RES PRO CEL, V29, P181; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Borras C, 2003, FREE RADICAL BIO MED, V34, P546, DOI 10.1016/S0891-5849(02)01356-4; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729; Ho YS, 1998, AM J RESP CELL MOL, V18, P538, DOI 10.1165/ajrcmb.18.4.2959; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Houthoofd K, 2003, EXP GERONTOL, V38, P947, DOI 10.1016/S0531-5565(03)00161-X; Ikegami T, 2002, BIOCHEM BIOPH RES CO, V296, P729, DOI 10.1016/S0006-291X(02)00933-6; Imanaka T, 1998, J BIOL CHEM, V273, P25347, DOI 10.1074/jbc.273.39.25347; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kitamura T, 2003, ANNU REV PHYSIOL, V65, P313, DOI 10.1146/annurev.physiol.65.092101.142540; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q; Lee SS, 2002, NATURE, V418, P287, DOI 10.1038/418287a; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; NAGY ZP, 1993, HUM REPROD, V8, P2180, DOI 10.1093/oxfordjournals.humrep.a138000; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; PEDERSEN SB, 1992, MOL CELL ENDOCRINOL, V85, P13, DOI 10.1016/0303-7207(92)90120-U; Phillips JP, 2000, EXP GERONTOL, V35, P1157, DOI 10.1016/S0531-5565(00)00117-0; Sakai K, 1997, BIOCHEM BIOPH RES CO, V237, P318, DOI 10.1006/bbrc.1997.7111; SMITH DWE, 1989, BIOL REV, V64, P1, DOI 10.1111/j.1469-185X.1989.tb00635.x; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Strehlow K, 2003, CIRC RES, V93, P170, DOI 10.1161/01.RES.0000082334.17947.11; Taniguchi M, 1998, NUCLEIC ACIDS RES, V26, P679, DOI 10.1093/nar/26.2.679; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Tchernof A, 1998, CORONARY ARTERY DIS, V9, P503, DOI 10.1097/00019501-199809080-00006; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; WISPE JR, 1992, J BIOL CHEM, V267, P23937; Yu XR, 2004, J BIOL CHEM, V279, P13086, DOI 10.1074/jbc.M313283200	48	54	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16417	16426		10.1074/jbc.M500924200	http://dx.doi.org/10.1074/jbc.M500924200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713666	hybrid			2022-12-25	WOS:000228444800115
J	Banno, Y; Ohguchi, K; Matsumoto, N; Koda, M; Ueda, M; Hara, A; Dikic, I; Nozawa, Y				Banno, Y; Ohguchi, K; Matsumoto, N; Koda, M; Ueda, M; Hara, A; Dikic, I; Nozawa, Y			Implication of phospholipase D2 in oxidant-induced phosphoinositide 3-kinase signaling via Pyk2 activation in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; PROTEIN-KINASE-B; GROWTH-FACTOR RECEPTOR; SMOOTH-MUSCLE-CELLS; HYDROGEN-PEROXIDE; MAP KINASE; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MEMBRANE DEPOLARIZATION; POSSIBLE INVOLVEMENT	The role of phospholipase D (PLD) activation in hydrogen peroxide (H2O2)-induced signal transduction and cellular responses is not completely understood. Here we present evidence that Ca2+-dependent tyrosine kinase, Pyk2, requires PLD activation to mediate survival pathways in rat pheochromocytoma PC12 cells under oxidative stress. The H2O2-induced phosphorylation of two Pyk2 sites (Tyr(580), and Tyr(881)) was suppressed by 1-butanol, an inhibitor of transphosphatidylation by PLD, and also by transfection of catalytically negative mouse PLD2K758R (PLD2KR). Furthermore, we found that PLD2 was associated with Pyk2 and Src, and that activation of PLD2 was required for H2O2-enhanced association of Src with Pyk2 leading to full activation of Pyk2. H2O2-induced phosphorylation of Akt and p70S6K was dependent on phosphatidylinositol 3-kinase (PI3K) activity and was abolished by 1-butanol but not t-butanol. Furthermore, the PI3K/Akt activation in response to H2O2 was reduced by transfection of either PLD2KR or the dominant negative Pyk2DN. This study is the first demonstration that PLD2 activation is implicated in Src-dependent phosphorylation of Pyk2 (Tyr(580) and Tyr(881)) by promoting the complex formation between Pyk2 and activated Src in PC12 cells exposed to H2O2, thereby resulting in activation of the survival signaling pathway PI3K/Akt/p70S6K.	Gifu Univ, Grad Sch Med, Dept Cell Signalling, Gifu 5011194, Japan; Gifu Int Inst Biotechnol, Kakamigahara 5040838, Japan; Gifu Pharmaceut Univ, Dept Biochem, Gifu 5028585, Japan; Goethe Univ Frankfurt, Inst Biochem 2, D-60590 Frankfurt, Germany	Gifu University; Gifu Pharmaceutical University; Goethe University Frankfurt	Banno, Y (corresponding author), Gifu Univ, Grad Sch Med, Dept Cell Signalling, Yanagido 1-1, Gifu 5011194, Japan.	banno@cc.gifu-u.ac.jp	Dikic, Ivan/O-4650-2015	Dikic, Ivan/0000-0001-8156-9511				Ahn BH, 2003, MOL CELL BIOL, V23, P3103, DOI 10.1128/MCB.23.9.3103-3115.2003; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Banno Y, 2003, BIOCHEM J, V369, P363, DOI 10.1042/BJ20021368; Banno Y, 2001, J BIOL CHEM, V276, P35622, DOI 10.1074/jbc.M105673200; Banno Y, 2001, NEUROREPORT, V12, P2271, DOI 10.1097/00001756-200107200-00045; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Esposito F, 2003, J BIOL CHEM, V278, P20828, DOI 10.1074/jbc.M211841200; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Finkel T, 2001, IUBMB LIFE, V52, P3, DOI 10.1080/15216540252774694; Foster DA, 2003, MOL CANCER RES, V1, P789; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ito Y, 1998, J NEUROCHEM, V71, P2278; Ito Y, 1997, J NEUROCHEM, V69, P729; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; KISS Z, 1994, ARCH BIOCHEM BIOPHYS, V311, P450; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kumada H, 1999, BIOMED RES-TOKYO, V20, P87, DOI 10.2220/biomedres.20.87; Lee BD, 2000, J LEUKOCYTE BIOL, V67, P630, DOI 10.1002/jlb.67.5.630; Lee SD, 2000, J NEUROCHEM, V75, P1053, DOI 10.1046/j.1471-4159.2000.0751053.x; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Marcil J, 1997, J BIOL CHEM, V272, P20660, DOI 10.1074/jbc.272.33.20660; Mehta S, 2003, BBA-MOL CELL BIOL L, V1631, P246, DOI 10.1016/S1388-1981(03)00023-4; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; NATARAJAN V, 1993, J BIOL CHEM, V268, P930; NATARAJAN V, 1996, AM J PHYSIOL, V271, P400; Nozawa Y, 2002, BBA-MOL CELL BIOL L, V1585, P77, DOI 10.1016/S1388-1981(02)00327-X; Parinandi NL, 2001, ARCH BIOCHEM BIOPHYS, V396, P231, DOI 10.1006/abbi.2001.2609; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Wang XT, 2001, J BIOL CHEM, V276, P28364, DOI 10.1074/jbc.M102693200; Yamada M, 2004, BIOCHEM J, V378, P649, DOI 10.1042/BJ20031398; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	37	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16319	16324		10.1074/jbc.M410903200	http://dx.doi.org/10.1074/jbc.M410903200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705590	hybrid			2022-12-25	WOS:000228444800103
J	Byers, SA; Price, JP; Cooper, JJ; Li, QT; Price, DH				Byers, SA; Price, JP; Cooper, JJ; Li, QT; Price, DH			HEXIM2, a HEXIM1-related protein, regulates positive transcription elongation factor b through association with 7SK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SMOOTH-MUSCLE-CELLS; RECRUITS P-TEFB; GENE-EXPRESSION; HIV-1 TAT; IN-VITRO; IDENTIFICATION; BINDING; KINASE; COMPLEXES	The kinase activity of positive transcription elongation factor b (P-TEFb), composed of cyclin-dependent kinase 9 and cyclin T1 or T2, is required for the transition of RNA polymerase II into productive elongation. P-TEFb activity has been shown to be negatively regulated by association with the small nuclear RNA 7SK and the HEXIM1 protein. Here, we characterize HEXIM2, a previously predicted protein with sequence similarity to HEXIM1. HEXIM2 is expressed in HeLa and Jurkat cells, and glycerol gradient analysis and immunoprecipitations indicate that HEXIM2, like HEXIM1, has a regulated association with P-TEFb. As HEXIM1 is knocked down, HEXIM2 functionally compensates for its association with P-TEFb. Electrophoretic mobility shift assays and in vitro kinase assays demonstrate that HEXIM2 forms complexes containing 7SK and P-TEFb and, in conjunction with 7SK, inhibits P-TEFb kinase activity. Our results provide strong evidence that HEXIM2 is a regulator of P-TEFb function. Furthermore, our results support the idea that the utilization of HEXIM1 or HEXIM2 to bind and inhibit P-TEFb can be differentially regulated in vivo.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Program Mol Biol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Price, DH (corresponding author), Univ Iowa, Dept Biochem, 375 Newton Rd, Iowa City, IA 52242 USA.	david-price@uiowa.edu	Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X; Li, Qintong/0000-0002-8447-9770	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Carson JP, 2004, CANCER RES, V64, P2096, DOI 10.1158/0008-5472.CAN-03-2029; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Fong YW, 2000, MOL CELL BIOL, V20, P5897, DOI 10.1128/MCB.20.16.5897-5907.2000; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Garriga J, 2004, GENE, V337, P15, DOI 10.1016/j.gene.2004.05.007; Ghatpande S, 1999, DEV BIOL, V208, P210, DOI 10.1006/dbio.1998.9180; Huang FC, 2002, GENE, V292, P245, DOI 10.1016/S0378-1119(02)00596-6; Jiang Y, 2004, CELL CYCLE, V3, P1151; Kanazawa S, 2003, ONCOGENE, V22, P5707, DOI 10.1038/sj.onc.1206800; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kulkarni PA, 2004, RECENT PROG HORM RES, V59, P125, DOI 10.1210/rp.59.1.125; Kusuhara M, 1999, BIOMED RES-TOKYO, V20, P273, DOI 10.2220/biomedres.20.273; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Michels AA, 2004, EMBO J, V23, P2608, DOI 10.1038/sj.emboj.7600275; Michels AA, 2003, MOL CELL BIOL, V23, P4859, DOI 10.1128/MCB.23.14.4859-4869.2003; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Ouchida R, 2003, GENES CELLS, V8, P95, DOI 10.1046/j.1365-2443.2003.00618.x; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Petroziello J, 2004, ONCOGENE, V23, P7734, DOI 10.1038/sj.onc.1207921; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; Rome S, 2003, J BIOL CHEM, V278, P18063, DOI 10.1074/jbc.M300293200; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; Sano M, 2003, CELL CYCLE, V2, P99, DOI 10.4161/cc.2.2.332; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Shore SM, 2003, GENE, V307, P175, DOI 10.1016/S0378-1119(03)00466-9; Stone B, 2003, INT J CANCER, V104, P73, DOI 10.1002/ijc.10900; ULLU E, 1982, NUCLEIC ACIDS RES, V10, P2209, DOI 10.1093/nar/10.7.2209; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wittmann BM, 2003, CANCER RES, V63, P5151; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Yik JHN, 2004, MOL CELL BIOL, V24, P5094, DOI 10.1128/MCB.24.12.5094-5105.2004; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	42	95	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16360	16367		10.1074/jbc.M500424200	http://dx.doi.org/10.1074/jbc.M500424200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713662	hybrid			2022-12-25	WOS:000228444800108
J	Fabbro, C; de Gemmis, P; Braghetta, P; Colombatti, A; Volpin, D; Bonaldo, P; Bressan, GM				Fabbro, C; de Gemmis, P; Braghetta, P; Colombatti, A; Volpin, D; Bonaldo, P; Bressan, GM			Analysis of regulatory regions of Emilin1 gene and their combinatorial contribution to tissue-specific transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1(VI) COLLAGEN GENE; FAR-UPSTREAM ENHANCER; REPORTER GENES; DNA ELEMENTS; EXPRESSION; PROMOTER; CELLS; ACTIVATION; COMPONENT; DOMAINS	The location of regions that regulate transcription of the murine Emilin1 gene was investigated in a DNA fragment of 16.8 kb, including the entire gene and about 8.7 and 0.6 kb of 5 '- and 3 '- flanking sequences, respectively. The 8.7- kb segment contains the 5 '- end of the putative 2310015E02Rik gene and the sequence that separates it from Emilin1, whereas the 0.6- kb fragment covers the region between Emilin1 and Ketohexokinase genes. Sequence comparison between species identified several conserved regions in the 5 '- flanking sequence. Most of them contained chromatin DNase I- hypersensitive sites, which were located at about - 950 ( HS1), - 3100 ( HS2), - 4750 ( HS3), and - 5150 ( HS4) in cells expressing Emilin1 mRNA. Emilin1 transcription initiates at multiple sites, the major of which correspond to two Initiator sequences. Promoter assays suggest that core promoter activity was mainly dependent on Initiator1 and on Sp1- binding sites close to the Initiators. Moreover, one important regulatory region was contained between - 1 and - 169 bp and a second one between - 630 bp and - 1.1 kb. The latter harbors a putative binding site for transcription factor AP1 matching the location of HS1. The function of different regions was studied by expressing lacZ constructs in transgenic mice. The results show that the 16.8- kb segment contains regulatory sequences driving high level transcription in all the tissues where Emilin1 is expressed. Moreover, the data suggest that transcription in different tissues is achieved through combinatorial cooperation between various regions, rather than being dependent on a single cis- activating region specific for each tissue.	Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35131 Padua, Italy; Ctr Riferimento Oncol, IRCCS, Div Expt Oncol, I-33081 Aviano, Italy; Univ Udine, Dept Biomed Sci & Technol, I-33100 Udine, Italy	University of Padua; IRCCS Aviano (CRO); University of Udine	Bressan, GM (corresponding author), Univ Padua, Dept Histol Microbiol & Med Biotechnol, Viale G Colombo 3, I-35131 Padua, Italy.	bressan@civ.bio.unipd.it	Braghetta, Paola/K-5478-2016	Braghetta, Paola/0000-0003-2547-8679; Bonaldo, Paolo/0000-0002-9571-8140; colombatti, alfonso/0000-0002-3676-2379				Antoniv TT, 2001, J BIOL CHEM, V276, P21754, DOI 10.1074/jbc.M101397200; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; Braghetta P, 1996, J CELL BIOL, V135, P1163, DOI 10.1083/jcb.135.4.1163; Braghetta P, 2002, MATRIX BIOL, V21, P603, DOI 10.1016/S0945-053X(02)00072-0; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Colombatti A, 2000, MATRIX BIOL, V19, P289, DOI 10.1016/S0945-053X(00)00074-3; de Laat W, 2003, CHROMOSOME RES, V11, P447, DOI 10.1023/A:1024922626726; Doliana R, 2000, J BIOL CHEM, V275, P785, DOI 10.1074/jbc.275.2.785; Doliana R, 2000, FEBS LETT, V484, P164, DOI 10.1016/S0014-5793(00)02140-2; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Fabbro C, 1999, J BIOL CHEM, V274, P1759, DOI 10.1074/jbc.274.3.1759; GHIGO D, 1995, J EXP MED, V181, P9, DOI 10.1084/jem.181.1.9; Girotto D, 2000, J BIOL CHEM, V275, P17381, DOI 10.1074/jbc.M000075200; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Kaufman M.H., 1999, ANATOMICAL BASIS MOU; Labrador M, 2002, CELL, V111, P151, DOI 10.1016/S0092-8674(02)01004-8; Leach KM, 2001, MOL CELL BIOL, V21, P2629, DOI 10.1128/MCB.21.8.2629-2640.2001; Leimeister C, 2002, DEV BIOL, V249, P204, DOI 10.1006/dbio.2002.0764; Leung KKH, 1998, J CELL BIOL, V141, P1291, DOI 10.1083/jcb.141.6.1291; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; MALLEINGERIN F, 1993, P NATL ACAD SCI USA, V90, P3289, DOI 10.1073/pnas.90.8.3289; Nagy A., 2003, MANIPULATING MOUSE E; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; PICCOLO S, 1995, J BIOL CHEM, V270, P19583, DOI 10.1074/jbc.270.33.19583; Reinke H, 2004, BBA-GENE STRUCT EXPR, V1677, P24, DOI 10.1016/j.bbaexp.2003.09.014; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; Sambrook J, 2001, MOL CLONING LAB MANU; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Taniuchi I, 2004, ONCOGENE, V23, P4341, DOI 10.1038/sj.onc.1207671; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLIAMS RL, 1988, CELL, V52, P121; Zanetti M, 2004, MOL CELL BIOL, V24, P638, DOI 10.1128/MCB.24.2.638-650.2004	38	6	6	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15749	15760		10.1074/jbc.M412548200	http://dx.doi.org/10.1074/jbc.M412548200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705587	hybrid			2022-12-25	WOS:000228444800037
J	Hubalek, F; Binda, C; Khalil, A; Li, M; Mattevi, A; Castagnoli, N; Edmondson, DE				Hubalek, F; Binda, C; Khalil, A; Li, M; Mattevi, A; Castagnoli, N; Edmondson, DE			Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; BENZYLAMINE ANALOGS; SUBSTRATE; OXIDATION	Several reversible inhibitors selective for human monoamine oxidase B ( MAO B) that do not inhibit MAO A have been described in the literature. The following compounds: 8-( 3- chlorostyryl) caffeine, 1,4- diphenyl- 2-butene, and trans, trans- farnesol are shown to inhibit competitively human, horse, rat, and mouse MAO B with K-i values in the low micromolar range but are without effect on either bovine or sheep MAO B or human MAO A. In contrast, the reversible competitive inhibitor isatin binds to all known MAO B and MAO A with similar affinities. Sequence alignments and the crystal structures of human MAO B in complex with 1,4- diphenyl- 2-butene or with trans, trans- farnesol provide molecular insights into these specificities. These inhibitors span the substrate and entrance cavities with the side chain of Ile- 199 rotated out of its normal conformation suggesting that Ile- 199 is gating the substrate cavity. Ile- 199 is conserved in all known MAO B sequences except bovine MAO B, which has Phe in this position ( the sequence of sheep MAO B is unknown). Phe is conserved in the analogous position in MAO A sequences. The human MAO B I199F mutant protein of MAO B binds to isatin ( K-i = 3 mu M) but not to the three inhibitors listed above. The crystal structure of this mutant demonstrates that the side chain of Phe- 199 interferes with the binding of those compounds. This suggests that the Ile-199 " gate" is a determinant for the specificity of these MAO B inhibitors and provides a molecular basis for the development of MAO B- specific reversible inhibitors without interference with MAO A function in neurotransmitter metabolism.	Emory Univ, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Dept Chem, Atlanta, GA 30322 USA; Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy; Virginia Tech, Dept Chem, Blacksburg, VA 24061 USA	Emory University; Emory University; University of Pavia; Virginia Polytechnic Institute & State University	Edmondson, DE (corresponding author), Emory Univ, Dept Biochem, 1510 Clifton Rd,Rollins Res Bldg, Atlanta, GA 30322 USA.	deedmon@emory.edu	Mattevi, Andrea/R-4469-2019; mattevi, andrea/K-5464-2012	Mattevi, Andrea/0000-0002-9523-7128; mattevi, andrea/0000-0002-9523-7128; Binda, Claudia/0000-0003-2038-9845; Hubalek, Frantisek/0000-0003-3983-7900	NIGMS NIH HHS [GM-29433] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029433] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Binda C, 2002, NAT STRUCT BIOL, V9, P22, DOI 10.1038/nsb732; Binda C, 2004, J MED CHEM, V47, P1767, DOI 10.1021/jm031087c; Binda C, 2003, P NATL ACAD SCI USA, V100, P9750, DOI 10.1073/pnas.1633804100; Chen JF, 2002, J BIOL CHEM, V277, P36040, DOI 10.1074/jbc.M206830200; Edmondson DE, 2004, CURR MED CHEM, V11, P1983, DOI 10.2174/0929867043364784; Fowler JS, 2003, P NATL ACAD SCI USA, V100, P11600, DOI 10.1073/pnas.1833106100; Geha RM, 2000, J NEUROCHEM, V75, P1304, DOI 10.1046/j.1471-4159.2000.751304.x; Geha RM, 2001, J BIOL CHEM, V276, P9877, DOI 10.1074/jbc.M006972200; GOTTOWIK J, 1995, EUR J BIOCHEM, V230, P934, DOI 10.1111/j.1432-1033.1995.tb20639.x; Grimsby J, 1996, LIFE SCI, V58, P777, DOI 10.1016/0024-3205(95)02356-9; HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4; Hubalek F, 2004, J MED CHEM, V47, P1760, DOI 10.1021/jm0310885; Hubalek F, 2003, ACTA CRYSTALLOGR D, V59, P1874, DOI 10.1107/S0907444903016883; HUSAIN M, 1982, BIOCHEMISTRY-US, V21, P595, DOI 10.1021/bi00532a028; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEARNEY EB, 1971, EUR J BIOCHEM, V24, P321, DOI 10.1111/j.1432-1033.1971.tb19689.x; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumar MJ, 2003, J BIOL CHEM, V278, P46432, DOI 10.1074/jbc.M306378200; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Li M, 2002, PROTEIN EXPRES PURIF, V24, P152, DOI 10.1006/prep.2001.1546; Ma JC, 2004, J MOL BIOL, V338, P103, DOI 10.1016/j.jmb.2004.02.032; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miller JR, 1999, BIOCHEMISTRY-US, V38, P13670, DOI 10.1021/bi990920y; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Newton-Vinson P, 2000, PROTEIN EXPRES PURIF, V20, P334, DOI 10.1006/prep.2000.1309; Sharkey TD, 2001, ANNU REV PLANT PHYS, V52, P407, DOI 10.1146/annurev.arplant.52.1.407; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Tsugeno Y, 1997, J BIOL CHEM, V272, P14033, DOI 10.1074/jbc.272.22.14033; WALKER MC, 1994, BIOCHEMISTRY-US, V33, P7088, DOI 10.1021/bi00189a011; Yu J, 1999, BIOORGAN MED CHEM, V7, P231, DOI 10.1016/S0968-0896(98)00201-6	32	182	190	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15761	15766		10.1074/jbc.M500949200	http://dx.doi.org/10.1074/jbc.M500949200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710600	hybrid			2022-12-25	WOS:000228444800038
J	Klyachko, NL; Shchedrina, VA; Efimov, AV; Kazakov, SV; Gazaryan, IG; Kristal, BS; Brown, AM				Klyachko, NL; Shchedrina, VA; Efimov, AV; Kazakov, SV; Gazaryan, IG; Kristal, BS; Brown, AM			pH-dependent substrate preference of pig heart lipoamide dehydrogenase varies with oligomeric state - Response to mitochondrial matrix acidification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE; REVERSED MICELLES; DIHYDROLIPOAMIDE DEHYDROGENASE; GLUTATHIONE-REDUCTASE; PERMEABILITY TRANSITION; MULTIENZYME COMPLEX; CRYSTAL-STRUCTURE; ORGANIC-SOLVENTS; PROTEIN; ENZYMES	Cycling of intracellular pH has recently been shown to play a critical role in ischemia-reperfusion injury. Ischemia-reperfusion also leads to mitochondrial matrix acidification and dysfunction. However, the mechanism by which matrix acidification contributes to mitochondrial dysfunction, oxidative stress, and the resultant cellular injury has not been elucidated. We observe pH-dependent equilibria between monomeric, dimeric, and a previously undescribed tetrameric form of pig heart lipoamide dehydrogenase (LADH), a mitochondrial matrix enzyme. Dynamic light scattering studies of native LADH in aqueous solution indicate that lowering pH favors a shift in average molecular mass from higher oligomeric states to monomer. Sedimentation velocity of LADH entrapped in reverse micelles reveals dimer and tetramer at both pH 5.8 and 7.5, but monomer was observed only at pH 5.8. Enzyme activity measurements in reverse Aerosol OT micelles in octane indicate that LADH dimer and tetramer possess lipoamide dehydrogenase and diaphorase activities at pH 7.5. Upon acidification to pH 5.8 only the LADH monomer is active and only the diaphorase activity is observed. These results indicate a correlation between pH-dependent changes in the LADH reaction specificity and its oligomeric state. The acidification of mitochondrial matrix that occurs during ischemia-reperfusion injury is sufficient to alter the structure and enzymatic specificity of LADH, thereby reducing mitochondrial defenses, increasing oxidative stress, and slowing the recovery of energy metabolism. Matrix acidification may also disrupt the quaternary structure of other mitochondrial protein complexes critical for cellular homeostasis and survival.	Burke Med Res Inst, Dementia Res Serv, White Plains, NY 10605 USA; Moscow MV Lomonosov State Univ, Dept Chem Enzymol, Moscow 119899, Russia; Russian Acad Sci, Inst Prot Res, Pushchino, Moscow region, Russia; Pace Univ, Dept Chem & Phys Sci, Pleasantville, NY 10570 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA	Lomonosov Moscow State University; Russian Academy of Sciences; Pace University; Cornell University; Cornell University	Brown, AM (corresponding author), Burke Med Res Inst, Dementia Res Serv, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	ambrown@med.cornell.edu	Gazaryan, Irina G/T-8578-2017; Kazakov, Sergey/K-4789-2019; brown, abraham/R-8823-2019; Efimov, Alexander V/L-9720-2015; Klyachko, Natalia L/J-9512-2013; Klyachko, Natalia L./AAU-8856-2021; shchedrina, valentina a/B-8398-2015	Gazaryan, Irina G/0000-0002-9670-5579; Klyachko, Natalia L./0000-0002-9357-8236; shchedrina, valentina a/0000-0003-1627-982X	NINDS NIH HHS [R01 NS038741, NS38741] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038741] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abad MFC, 2004, J BIOL CHEM, V279, P11521, DOI 10.1074/jbc.M306766200; AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; ASSAF HM, 1990, METAB BRAIN DIS, V5, P143, DOI 10.1007/BF00999841; Awaji T, 2001, BIOCHEM BIOPH RES CO, V289, P457, DOI 10.1006/bbrc.2001.6004; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; CARDELL M, 1989, J CEREBR BLOOD F MET, V9, P350, DOI 10.1038/jcbfm.1989.53; Das D K, 1996, EXS, V76, P155; de Gomez-Puyou MT, 1998, CRIT REV BIOCHEM MOL, V33, P53, DOI 10.1080/10409239891204170; de Kok A, 1998, BBA-PROTEIN STRUCT M, V1385, P353, DOI 10.1016/S0167-4838(98)00079-X; Eicke H F, 1980, Top Curr Chem, V87, P85; Faure M, 2000, EUR J BIOCHEM, V267, P2890, DOI 10.1046/j.1432-1033.2000.01330.x; Gazaryan IG, 2002, J BIOL CHEM, V277, P10064, DOI 10.1074/jbc.M108264200; Gazaryan IG, 1997, BIOCHEM J, V328, P643; Ghafourifar P, 1999, BIOL CHEM, V380, P1025, DOI 10.1515/BC.1999.127; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Halle B, 2003, P NATL ACAD SCI USA, V100, P12135, DOI 10.1073/pnas.2033320100; Igamberdiev AU, 2004, FEBS LETT, V568, P146, DOI 10.1016/j.febslet.2004.05.024; KABANOV AV, 1991, PROTEIN ENG, V4, P1009, DOI 10.1093/protein/4.8.1009; KABANOV AV, 1991, FEBS LETT, V278, P143, DOI 10.1016/0014-5793(91)80103-A; Kazakov SV, 2002, INT J THERMOPHYS, V23, P161, DOI 10.1023/A:1013957127723; Klyachko NL, 2003, CURR OPIN COLLOID IN, V8, P179, DOI 10.1016/S1359-0294(03)00016-5; KLYACHKO NL, 1990, BIOL MEMBRANY, V7, P467; KOBAYASHI K, 1983, J MOL CELL CARDIOL, V15, P359, DOI 10.1016/0022-2828(83)90320-6; Kohling R, 2002, LANGMUIR, V18, P8626, DOI 10.1021/la020405s; Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200; KOTLARCHYK M, 1985, J PHYS CHEM-US, V89, P4382, DOI 10.1021/j100266a046; LEICHUS BN, 1992, BIOCHEMISTRY-US, V31, P3065, DOI 10.1021/bi00127a006; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; LEVASHOV AV, 1982, J COLLOID INTERF SCI, V88, P444, DOI 10.1016/0021-9797(82)90273-9; Levashov AV, 2001, RUSS CHEM B+, V50, P1718, DOI 10.1023/A:1014361508512; LEVASHOV AV, 1981, ANAL BIOCHEM, V118, P42, DOI 10.1016/0003-2697(81)90153-6; LUISI PL, 1988, BIOCHIM BIOPHYS ACTA, V947, P209, DOI 10.1016/0304-4157(88)90025-1; Mande SS, 1996, STRUCTURE, V4, P277, DOI 10.1016/S0969-2126(96)00032-9; MARTINEK K, 1986, EUR J BIOCHEM, V155, P453, DOI 10.1111/j.1432-1033.1986.tb09512.x; MARTINEK K, 1989, BIOCHIM BIOPHYS ACTA, V981, P161, DOI 10.1016/0005-2736(89)90024-2; MARTINEK K, 1982, SCIENCE, V218, P889, DOI 10.1126/science.6753152; MASSEY V, 1962, J BIOL CHEM, V237, P3820; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; MATTHEWS RG, 1976, J BIOL CHEM, V251, P3956; MATUDA S, 1982, J BIOCHEM, V91, P553, DOI 10.1093/oxfordjournals.jbchem.a133727; Muiswinkel-Voetberg H.v., 1973, EUR J BIOCHEM, V33, P265; NAKAMURA M, 1972, BIOCHIM BIOPHYS ACTA, V267, P249, DOI 10.1016/0005-2728(72)90113-2; Oldfield C, 1994, Biotechnol Genet Eng Rev, V12, P255; Orlich B, 2002, ADV BIOCHEM ENG BIOT, V75, P185; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; POPOV VO, 1985, BIOCHIM BIOPHYS ACTA, V827, P466, DOI 10.1016/0167-4838(85)90234-1; RACEYBURNS LA, 1989, LIFE SCI, V44, P2015, DOI 10.1016/0024-3205(89)90347-0; Raddatz G, 1997, J MOL MODEL, V3, P423, DOI 10.1007/s008940050060; REED JK, 1973, J BIOL CHEM, V248, P4834; RENDON JL, 1989, ARCH BIOCHEM BIOPHYS, V268, P255, DOI 10.1016/0003-9861(89)90587-0; ROSS J, 1988, J GEN MICROBIOL, V134, P1131; SAHLMAN L, 1989, J BIOL CHEM, V264, P8033; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THORPE C, 1976, J BIOL CHEM, V251, P3553; Toyoda T, 1998, J BIOCHEM-TOKYO, V123, P668; TSAI CS, 1981, ARCH BIOCHEM BIOPHYS, V206, P77, DOI 10.1016/0003-9861(81)90068-0; VANBERKEL WJH, 1991, EUR J BIOCHEM, V202, P1049; VANBERKEL WJH, 1991, EUR J BIOCHEM, V197, P769; Veeger C., 1973, EUR J BIOCHEM, V33, P271; VISSER J, 1968, BIOCHIM BIOPHYS ACTA, V159, P265, DOI 10.1016/0005-2744(68)90075-2; WILKINSON KD, 1979, J BIOL CHEM, V254, P852; ZAIDAN E, 1993, J CEREBR BLOOD F MET, V13, P98, DOI 10.1038/jcbfm.1993.12; Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P14802, DOI 10.1073/pnas.011597698	70	36	38	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16106	16114		10.1074/jbc.M414285200	http://dx.doi.org/10.1074/jbc.M414285200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710613	hybrid			2022-12-25	WOS:000228444800078
J	Sattlegger, E; Hinnebusch, AG				Sattlegger, E; Hinnebusch, AG			Polyribosome binding by GCN1 is required for full activation of eukaryotic translation initiation factor 2 alpha kinase GCN2 during amino acid starvation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; N-TERMINUS; RNA; ASSOCIATION; GENE; PHOSPHORYLATION; REINITIATION; RIBOSOMES; COMPLEX	The protein kinase GCN2 mediates translational control of gene expression in amino acid-starved cells by phosphorylating eukaryotic translation initiation factor 2 alpha. In Saccharomyces cerevisiae, activation of GCN2 by uncharged tRNAs in starved cells requires its direct interaction with both the GCN1 center dot GCN20 regulatory complex and ribosomes. GCN1 also interacts with ribosomes in cell extracts, but it was unknown whether this activity is crucial for its ability to stimulate GCN2 function in starved cells. We describe point mutations in two conserved, noncontiguous segments of GCN1 that lead to reduced polyribosome association by GCN1 center dot GCN20 in living cells without reducing GCN1 expression or its interaction with GCN20. Mutating both segments simultaneously produced a greater reduction in polyribosome binding by GCN1 center dot GCN20 and a stronger decrease in eukaryotic translation initiation factor 2 alpha phosphorylation than did mutating in one segment alone. These findings provide strong evidence that ribosome binding by GCN1 is required for its role as a positive regulator of GCN2. A particular mutation in the GCN1 domain, related in sequence to translation elongation factor 3 (eEF3), decreased GCN2 activation much more than it reduced ribosome binding by GCN1. Hence, the eEF3-like domain appears to have an effector function in GCN2 activation. This conclusion supports the model that an eEF3-related activity of GCN1 influences occupancy of the ribosomal decoding site by uncharged tRNA in starved cells.	NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Hinnebusch, AG (corresponding author), NICHD, Lab Gene Regulat & Dev, NIH, Bldg 6A,Rm B1A-13, Bethesda, MD 20892 USA.	ahinnebusch@nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001004] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; DEALDANA CRV, 1995, EMBO J, V14, P3184, DOI 10.1002/j.1460-2075.1995.tb07321.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Garcia-Barrio M, 2000, EMBO J, V19, P1887, DOI 10.1093/emboj/19.8.1887; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLDMAN E, 1990, MOL MICROBIOL, V4, P2035, DOI 10.1111/j.1365-2958.1990.tb00563.x; Gontarek RR, 1998, J BIOL CHEM, V273, P10249, DOI 10.1074/jbc.273.17.10249; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; Nielsen KH, 2004, EMBO J, V23, P1166, DOI 10.1038/sj.emboj.7600116; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; Sattlegger E, 2000, EMBO J, V19, P6622, DOI 10.1093/emboj/19.23.6622; Schroeder R, 2000, EMBO J, V19, P1, DOI 10.1093/emboj/19.1.1; SIKORSKI RS, 1989, GENETICS, V122, P19; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P20473, DOI 10.1074/jbc.270.35.20473; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808	21	48	50	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16514	16521		10.1074/jbc.M414566200	http://dx.doi.org/10.1074/jbc.M414566200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722345	hybrid			2022-12-25	WOS:000228444800126
J	Schonherr, E; Sunderkotter, C; Iozzo, RV; Schaefer, L				Schonherr, E; Sunderkotter, C; Iozzo, RV; Schaefer, L			Decorin, a novel player in the insulin-like growth factor system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEAT; FACTOR-I RECEPTOR; ENDOTHELIAL-CELLS; EXTRACELLULAR-MATRIX; CRYSTAL-STRUCTURE; CARCINOMA-CELLS; UP-REGULATION; EXPRESSION; COLLAGEN; BINDING	Decorin is a multifunctional proteoglycan that is expressed by sprouting endothelial cells. Its expression supports capillary formation and cell survival. Previously, it was shown that some effects of decorin are mediated by protein kinase B and the cyclin- dependent kinase inhibitor, p21. However, the cell surface receptor responsible for these effects was unknown. We demonstrate that decorin binds to the insulin- like growth factor-I ( IGF- I) receptor on endothelial cells with an affinity in the nanomolar range ( K-D = 18 nM), which is comparable with IGF- I ( K-D = 1.2 nM). Furthermore, decorin can bind IGF- I itself, but with a lower affinity ( K-D = 190 nM) than classical IGF- I- binding proteins. Decorin addition causes IGF- I receptor phosphorylation and activation, which is followed by receptor down- regulation. These effects are caused by the core protein of decorin, and the binding region could be mapped to the N terminus of the molecule. The physiological relevance of the decorin/ IGF- I receptor interaction was corroborated in two animal models ( e. g. inflammatory angiogenesis in the cornea and unilateral ureteral obstruction). In both models the IGF- I receptor was up- regulated in decorin- deficient mice compared with controls and the up- regulation could not compensate the decorin deficiency in the disease models. These data indicate that decorin is an important player in the IGF system and its loss cannot fully be compensated in different types of diseases.	Cardiff Univ Dent Sch, Matrix Biol & Tissue Repair Res Unit, Cardiff CF14 4XY, S Glam, Wales; Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany; Univ Munster, Inst Expt Dermatol, D-48149 Munster, Germany; Univ Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Munster, Dept Internal Med D, D-48149 Munster, Germany; Univ Hosp Munster, D-48149 Munster, Germany; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Ulm, Dept Dermatol, D-8901 Ulm, Germany; Univ Hosp Ulm, D-8901 Ulm, Germany	Cardiff University; University of Munster; University of Munster; University of Munster; University of Munster; University of Munster; Jefferson University; Jefferson University; Ulm University; Ulm University	Schonherr, E (corresponding author), Cardiff Univ Dent Sch, Matrix Biol & Tissue Repair Res Unit, Cardiff CF14 4XY, S Glam, Wales.	schonherreh@cardiff.ac.uk	Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112; Schaefer, Liliana/0000-0002-3318-3005; Sunderkotter, Cord/0000-0002-2929-145X	NCI NIH HHS [R01 CA-39481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chevalier RL, 2000, KIDNEY INT, V57, P882, DOI 10.1046/j.1523-1755.2000.057003882.x; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Diamond JR, 1997, KIDNEY INT, V51, P1133, DOI 10.1038/ki.1997.156; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; Han RNN, 2003, AM J RESP CELL MOL, V28, P159, DOI 10.1165/rcmb.4764; Henger A, 2004, KIDNEY INT, V65, P904, DOI 10.1111/j.1523-1755.2004.00499.x; Jansson M, 1997, FEBS LETT, V416, P259, DOI 10.1016/S0014-5793(97)01149-6; Kinsella MG, 2004, CRIT REV EUKAR GENE, V14, P203, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i3.40; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; Kresse H, 2001, J CELL PHYSIOL, V189, P266, DOI 10.1002/jcp.10030; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019; Mynarcik DC, 1997, J BIOL CHEM, V272, P18650, DOI 10.1074/jbc.272.30.18650; Nelimarkka L, 2001, AM J PATHOL, V158, P345, DOI 10.1016/S0002-9440(10)63975-2; Partovian C, 2004, CELL SIGNAL, V16, P951, DOI 10.1016/j.cellsig.2004.01.008; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Reinmuth N, 2002, LAB INVEST, V82, P1377, DOI 10.1097/01.LAB.0000032411.41603.C2; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Schaefer L, 2002, AM J PATHOL, V160, P1181, DOI 10.1016/S0002-9440(10)64937-1; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; Schonherr E, 2004, J VASC RES, V41, P499, DOI 10.1159/000081806; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Scott PG, 2004, P NATL ACAD SCI USA, V101, P15633, DOI 10.1073/pnas.0402976101; Scott PG, 2003, J BIOL CHEM, V278, P18353, DOI 10.1074/jbc.M211936200; Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963; Strazynski M, 2004, J BIOL CHEM, V279, P21266, DOI 10.1074/jbc.M309782200; Su EJ, 2003, AM J PHYSIOL-HEART C, V284, pH1429, DOI 10.1152/ajpheart.00885.2002; Tralhao JG, 2003, FASEB J, V17, P464, DOI 10.1096/fj.02-0534fje; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124	34	172	174	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15767	15772		10.1074/jbc.M500451200	http://dx.doi.org/10.1074/jbc.M500451200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15701628	hybrid			2022-12-25	WOS:000228444800039
J	Wu, JJ; Bennett, AM				Wu, JJ; Bennett, AM			Essential role for mitogen-activated protein (MAP) kinase phosphatase-1 in stress-responsive MAP kinase and cell survival signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; CONDITIONAL EXPRESSION; MKP-1 EXPRESSION; P38; TRANSDUCTION; APOPTOSIS; TRANSCRIPTION; INHIBITION; ENCODES; 3CH134	Mitogen-activated protein kinase ( MAPK) phosphatases (MKPs) constitute a family of 11 dual-specificity phosphatases that inactivate the MAPKs by dephosphorylation. Although the contribution of MAPKs to cell growth and cell death has been examined extensively, it remains unclear whether MKPs play an essential role in the regulation of these processes. To clarify the role of MKP-1, we determined the effects on the MAPKs and cell growth and death in primary fibroblasts derived from mice lacking MKP-1. Here we have shown that MKP-1 is critical for the inactivation of p38 MAPK and JNK following stimulation with serum, anisomycin, and osmotic stress. In addition, MKP-1 was identified as a critical negative regulator of the cAMP-mediated p38 MAPK pathway. MKP-1-deficient mouse embryonic fibroblasts (MEFs) displayed enhanced p38 MAPK activity and cAMP-response element-dependent transcriptional activation in response to forskolin. Surprisingly, MKP-1-deficient fibroblasts exhibited reduced cell growth compared with wild type MEFs as a result of enhanced cell death. The enhanced level of cell death in MKP-1-deficient MEFs was rescued by SB203580, an inhibitor of p38 MAPK. MKP-1-deficient MEFs were also sensitive to anisomycin-induced apoptosis. Collectively, these data demonstrate that MKP-1 promotes cell survival by attenuating stress-responsive MAPK-mediated apoptosis.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Bennett, AM (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, POB 208066, New Haven, CT 06520 USA.	anton.bennett@yale.edu		Bennett, Anton/0000-0001-5187-7599	NATIONAL CANCER INSTITUTE [T32CA009085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK057751] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09085] Funding Source: Medline; NIDDK NIH HHS [DK57751] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Awad MM, 2000, J BIOL CHEM, V275, P38716, DOI 10.1074/jbc.M008040200; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dorfman K, 1996, ONCOGENE, V13, P925; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Guo YL, 1998, J BIOL CHEM, V273, P10362, DOI 10.1074/jbc.273.17.10362; Kaiser RA, 2004, J BIOL CHEM, V279, P15524, DOI 10.1074/jbc.M313717200; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lornejad-Schafer MR, 2003, BIOCHEM J, V371, P609, DOI 10.1042/BJ20021357; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Nimah M, 2005, SHOCK, V23, P80, DOI 10.1097/01.shk.0000145206.28812.60; Nishina H, 1999, DEVELOPMENT, V126, P505; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; Schliess F, 1998, ARCH BIOCHEM BIOPHYS, V351, P35, DOI 10.1006/abbi.1997.0517; Shifrin VI, 1999, J BIOL CHEM, V274, P13985, DOI 10.1074/jbc.274.20.13985; Srikanth S, 1999, MOL CELL BIOCHEM, V199, P169, DOI 10.1023/A:1006980326855; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Theodosiou A, 2002, GENOME BIOL, V3; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Zhao Q, 2005, J BIOL CHEM, V280, P8101, DOI 10.1074/jbc.M411760200	39	135	139	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16461	16466		10.1074/jbc.M501762200	http://dx.doi.org/10.1074/jbc.M501762200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722358	hybrid			2022-12-25	WOS:000228444800120
J	Murphy, HN; Stewart, GR; Mischenko, VV; Apt, AS; Harris, R; McAlister, MSB; Driscoll, PC; Young, DB; Robertson, BD				Murphy, HN; Stewart, GR; Mischenko, VV; Apt, AS; Harris, R; McAlister, MSB; Driscoll, PC; Young, DB; Robertson, BD			The OtsAB pathway is essential for trehalose biosynthesis in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORYNEBACTERIUM-GLUTAMICUM; PHOSPHATE PHOSPHATASE; PURIFICATION; EXPRESSION; SMEGMATIS; SYNTHASE; CLONING; GROWTH; MICE; TREHALOSE-6-PHOSPHATE	The disaccharide trehalose is the major free sugar in the cytoplasm of mycobacteria; it is a constituent of cell wall glycolipids, and it plays a role in mycolic acid transport during cell wall biogenesis. The pleiotropic role of trehalose in the biology of Mycobacterium tuberculosis and its absence from mammalian cells suggests that its biosynthesis may provide a useful target for novel drugs. However, there are three potential pathways for trehalose biosynthesis in M. tuberculosis, and the aim of the present study was to introduce mutations into each of the pathways to determine whether or not they are functionally redundant. The results show that the OtsAB pathway, which generates trehalose from glucose and glucose-6-phosphate, is the dominant pathway required for M. tuberculosis growth in laboratory culture and for virulence in a mouse model. Of the two otsB homologues annotated in the genome sequence of M. tuberculosis, only OtsB2 (Rv3372) has a functional role in the pathway. OtsB2, trehalose-6-phosphate phosphatase, is strictly essential for growth and provides a tractable target for high throughput screening. Inactivation of the TreYZ pathway, which can generate trehalose from alpha-1,4-linked glucose polymers, had no effect on the growth of M. tuberculosis in vitro or in mice. Deletion of the treS gene altered the late stages of pathogenesis of M. tuberculosis in mice, significantly increasing the time to death in a chronic infection model. Because the TreS enzyme catalyzes the interconversion of trehalose and maltose, the mouse phenotype could reflect either a requirement for synthesis of additional trehalose or, conversely, a requirement for breakdown of stored trehalose to liberate free glucose.	Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, London SW7 2AZ, England; Cent Inst TB, Immunogenet Lab, Moscow 107564, Russia; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Univ London Birkbeck Coll, Sch Crystallog, London WC1E 7HX, England	Imperial College London; University of London; University College London; University of London; Birkbeck University London	Robertson, BD (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, S Kensington Campus, London SW7 2AZ, England.	b.robertson@imperial.ac.uk	Driscoll, Paul C/B-8007-2010	Driscoll, Paul C/0000-0002-4124-6950; mcalister, mark/0000-0003-3986-1767; Apt, Alexander/0000-0002-3683-3085; Stewart, Graham/0000-0002-6867-6248; Harris, Richard/0000-0001-7459-1745; Robertson, Brian D./0000-0001-5785-5307	Medical Research Council [MC_U117533887, MC_U117581288] Funding Source: Medline; MRC [MC_U117581288, MC_U117533887] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alvarez-Peral FJ, 2002, MICROBIOL-SGM, V148, P2599, DOI 10.1099/00221287-148-8-2599; Andersson U, 2001, J BIOL CHEM, V276, P42707, DOI 10.1074/jbc.M108279200; Arguelles JC, 2000, ARCH MICROBIOL, V174, P217, DOI 10.1007/s002030000192; BLAZQUEZ MA, 1993, FEBS LETT, V329, P51, DOI 10.1016/0014-5793(93)80191-V; Chen QF, 2004, J EXP BIOL, V207, P3125, DOI 10.1242/jeb.01133; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; De Smet KAL, 2000, MICROBIOL-UK, V146, P199, DOI 10.1099/00221287-146-1-199; Edavana VK, 2004, ARCH BIOCHEM BIOPHYS, V426, P250, DOI 10.1016/j.abb.2004.02.014; Elbein AD, 2003, GLYCOBIOLOGY, V13, p17R, DOI 10.1093/glycob/cwg047; ELBEIN AD, 1973, J BACTERIOL, V113, P863, DOI 10.1128/JB.113.2.863-873.1973; Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100; Klutts S, 2003, J BIOL CHEM, V278, P2093, DOI 10.1074/jbc.M209937200; LEE MH, 1991, P NATL ACAD SCI USA, V88, P3111, DOI 10.1073/pnas.88.8.3111; Lyadova I, 1998, INFECT IMMUN, V66, P4981, DOI 10.1128/IAI.66.10.4981-4988.1998; MATULA M, 1971, J BACTERIOL, V107, P217, DOI 10.1128/JB.107.1.217-222.1971; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; Mischenko VV, 2004, J INFECT DIS, V190, P2137, DOI 10.1086/425909; Nikonenko BV, 2000, TUBERCLE LUNG DIS, V80, P15, DOI 10.1054/tuld.1999.0225; Pan YT, 2004, EUR J BIOCHEM, V271, P4259, DOI 10.1111/j.1432-1033.2004.04365.x; Pan YT, 2002, EUR J BIOCHEM, V269, P6091, DOI 10.1046/j.1432-1033.2002.03327.x; Ryll R, 2001, MICROBIOL IMMUNOL, V45, P801, DOI 10.1111/j.1348-0421.2001.tb01319.x; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Stewart GR, 2002, MICROBIOL-SGM, V148, P3129, DOI 10.1099/00221287-148-10-3129; Stewart GR, 2001, NAT MED, V7, P732, DOI 10.1038/89113; Timm J, 2003, P NATL ACAD SCI USA, V100, P14321, DOI 10.1073/pnas.2436197100; Tzvetkov M, 2003, MICROBIOL-SGM, V149, P1659, DOI 10.1099/mic.0.26205-0; Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205; Wolf A, 2003, MOL MICROBIOL, V49, P1119, DOI 10.1046/j.1365-2958.2003.03625.x; Woodruff PJ, 2004, J BIOL CHEM, V279, P28835, DOI 10.1074/jbc.M313103200	32	104	112	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14524	14529		10.1074/jbc.M414232200	http://dx.doi.org/10.1074/jbc.M414232200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15703182	hybrid			2022-12-25	WOS:000228236800023
J	Purusharth, RI; Klein, F; Sulthana, S; Jager, S; Jagannadham, MV; Evguenieva-Hackenberg, E; Ray, MK; Klug, G				Purusharth, RI; Klein, F; Sulthana, S; Jager, S; Jagannadham, MV; Evguenieva-Hackenberg, E; Ray, MK; Klug, G			Exoribonuclease R interacts with endoribonuclease e and an RNA helicase in the psychrotrophic Bacterium pseudomonas syringae Lz4W	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) POLYMERASE I; ESCHERICHIA-COLI; MESSENGER-RNA; POLYNUCLEOTIDE PHOSPHORYLASE; RIBOSOMAL-RNA; TRANSCRIPTIONAL ACTIVITY; RHODOBACTER-CAPSULATUS; QUALITY-CONTROL; DEGRADOSOME; PNPASE	Endoribonuclease E, a key enzyme involved in RNA decay and processing in bacteria, organizes a protein complex called degradosome. In Escherichia coli, Rhodobacter capsulatus, and Streptomyces coelicolor, RNase E interacts with the phosphate-dependent exoribonuclease polynucleotide phosphorylase, DEAD-box helicase(s), and additional factors in an RNA-degrading complex. To characterize the degradosome of the psychrotrophic bacterium Pseudomonas syringae Lz4W, RNase E was enriched by cation exchange chromatography and fractionation in a glycerol density gradient. Most surprisingly, the hydrolytic exoribonuclease RNase R was found to co-purify with RNase E. Co-immunoprecipitation and Ni2+-affinity pull-down experiments confirmed the specific interaction between RNase R and RNase E. Additionally, the DEAD-box helicase RhlE was identified as part of this protein complex. Fractions comprising the three proteins showed RNase E and RNase R activity and efficiently degraded a synthetic stem-loop containing RNA in the presence of ATP. The unexpected association of RNase R with RNase E and RhlE in an RNA-degrading complex indicates that the cold-adapted P. syringae has a degradosome of novel structure. The identification of RNase R instead of polynucleotide phosphorylase in this complex underlines the importance of the interaction between endo- and exoribonucleases for the bacterial RNA metabolism. The physical association of RNase E with an exoribonuclease and an RNA helicase apparently is a common theme in the composition of bacterial RNA-degrading complexes.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; Univ Giessen, Inst Mikrobiol & Molekularbiol, D-35392 Giessen, Germany	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Justus Liebig University Giessen	Ray, MK (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	malay@ccmb.res.in	Klug, Gabriele/K-5322-2014; Jagannadham, Medicharla V. V./AAW-6773-2021; Evguenieva-Hackenberg, Elena/ABA-8876-2020	Klug, Gabriele/0000-0002-3527-5093; Evguenieva-Hackenberg, Elena/0000-0001-7270-3168; RAJYAGURU, PURUSHARTH/0000-0003-3794-418X				Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Aloy P, 2002, EMBO REP, V3, P628, DOI 10.1093/embo-reports/kvf135; Baginsky S, 2001, RNA, V7, P1464; Bernstein JA, 2004, P NATL ACAD SCI USA, V101, P2758, DOI 10.1073/pnas.0308747101; Bessarab DA, 1998, P NATL ACAD SCI USA, V95, P3157, DOI 10.1073/pnas.95.6.3157; Bidle KA, 1999, J BACTERIOL, V181, P2330, DOI 10.1128/JB.181.8.2330-2337.1999; Bizebard T, 2004, BIOCHEMISTRY-US, V43, P7857, DOI 10.1021/bi049852s; BLUELL CR, 2003, P NATL ACAD SCI USA, V100, P10181; Blum E, 1997, MOL MICROBIOL, V26, P387, DOI 10.1046/j.1365-2958.1997.5901947.x; Bollenbach TJ, 2004, PROG NUCLEIC ACID RE, V78, P305, DOI 10.1016/S0079-6603(04)78008-3; Cairrao F, 2003, MOL MICROBIOL, V50, P1349, DOI 10.1046/j.1365-2958.2003.03766.x; Callaghan AJ, 2004, J MOL BIOL, V340, P965, DOI 10.1016/j.jmb.2004.05.046; Callaghan AJ, 2003, BIOCHEMISTRY-US, V42, P13848, DOI 10.1021/bi0351099; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Charollais J, 2004, NUCLEIC ACIDS RES, V32, P2751, DOI 10.1093/nar/gkh603; Charollais J, 2003, MOL MICROBIOL, V48, P1253, DOI 10.1046/j.1365-2958.2003.03513.x; Cheng ZF, 2003, P NATL ACAD SCI USA, V100, P6388, DOI 10.1073/pnas.1231041100; Cheng ZF, 2002, J BIOL CHEM, V277, P21624, DOI 10.1074/jbc.M202942200; Cheng ZF, 1998, J BIOL CHEM, V273, P14077, DOI 10.1074/jbc.273.23.14077; Clements MO, 2002, P NATL ACAD SCI USA, V99, P8784, DOI 10.1073/pnas.132047099; Coburn GA, 1999, GENE DEV, V13, P2594, DOI 10.1101/gad.13.19.2594; Coburn GA, 1998, J MOL BIOL, V279, P1061, DOI 10.1006/jmbi.1998.1842; Conrad C, 1998, NUCLEIC ACIDS RES, V26, P4446, DOI 10.1093/nar/26.19.4446; Dziembowski A, 2003, J BIOL CHEM, V278, P1603, DOI 10.1074/jbc.M208287200; Evguenieva-Hackenberg E, 2003, EMBO REP, V4, P889, DOI 10.1038/sj.embor.embor929; Favaro R, 2003, J BACTERIOL, V185, P5279, DOI 10.1128/JB.185.17.5279-5286.2003; FRITSCH J, 1995, MOL MICROBIOL, V15, P1017, DOI 10.1111/j.1365-2958.1995.tb02277.x; Goverde RLJ, 1998, MOL MICROBIOL, V28, P555, DOI 10.1046/j.1365-2958.1998.00816.x; Jager S, 2001, NUCLEIC ACIDS RES, V29, P4581, DOI 10.1093/nar/29.22.4581; Janiyani KL, 2002, APPL ENVIRON MICROB, V68, P1, DOI 10.1128/AEM.68.1.1-10.2002; Jiang XQ, 2000, J BACTERIOL, V182, P2468, DOI 10.1128/JB.182.9.2468-2475.2000; Kaberdin VR, 1998, P NATL ACAD SCI USA, V95, P11637, DOI 10.1073/pnas.95.20.11637; KALMAN M, 1991, NEW BIOL, V3, P886; Karzai AW, 2001, P NATL ACAD SCI USA, V98, P3040, DOI 10.1073/pnas.051628298; Khemici V, 2004, MOL MICROBIOL, V51, P777, DOI 10.1046/j.1365-2958.2003.03862.x; KOBE T, 1992, J BACTERIOL, V174, P6359; Koonin EV, 2001, GENOME RES, V11, P240, DOI 10.1101/gr.162001; Lee K, 2003, MOL MICROBIOL, V48, P349, DOI 10.1046/j.1365-2958.2003.03435.x; Lin-Chao S, 1999, P NATL ACAD SCI USA, V96, P12406, DOI 10.1073/pnas.96.22.12406; Liou GG, 2002, J BIOL CHEM, V277, P41157, DOI 10.1074/jbc.M206618200; Liou GG, 2001, P NATL ACAD SCI USA, V98, P63, DOI 10.1073/pnas.011535498; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Mohanty BK, 1999, MOL MICROBIOL, V34, P1094, DOI 10.1046/j.1365-2958.1999.01673.x; Polissi A, 2003, RES MICROBIOL, V154, P573, DOI 10.1016/S0923-2508(03)00167-0; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Ray MK, 1999, CURR MICROBIOL, V38, P143, DOI 10.1007/PL00006778; Raynal LC, 1999, MOL MICROBIOL, V32, P765, DOI 10.1046/j.1365-2958.1999.01394.x; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; Symmons MF, 2002, TRENDS BIOCHEM SCI, V27, P11, DOI 10.1016/S0968-0004(01)01999-5; Tran H, 2004, MOL CELL, V13, P101, DOI 10.1016/S1097-2765(03)00481-7; Uma S, 1999, FEBS LETT, V453, P313, DOI 10.1016/S0014-5793(99)00660-2; Vanzo NF, 1998, GENE DEV, V12, P2770, DOI 10.1101/gad.12.17.2770; Zangrossi S, 2000, MOL MICROBIOL, V36, P1470, DOI 10.1046/j.1365-2958.2000.01971.x; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	55	98	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14572	14578		10.1074/jbc.M413507200	http://dx.doi.org/10.1074/jbc.M413507200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705581	hybrid			2022-12-25	WOS:000228236800029
J	Siegenthaler, RK; Christen, P				Siegenthaler, RK; Christen, P			The importance of having thermosensor control in the DnaK chaperone system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; HEAT-SHOCK; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; HSP70 CHAPERONES; ATP HYDROLYSIS; FACTOR GRPE; PROTEIN; MECHANISM; BINDING	In addition to the sigma(32)-mediated heat shock response, the DnaK/DnaJ/GrpE molecular chaperone system of Escherichia coli directly adapts to elevated temperatures by sequestering a higher fraction of substrate. This immediate heat shock response is due to the differential temperature dependence of the activity of DnaJ, which stimulates the hydrolysis of DnaK-bound ATP, and the activity of GrpE, which facilitates ADP/ATP exchange and converts DnaK from its high-affinity ADP-liganded state into its low-affinity ATP-liganded state. GrpE acts as thermosensor with its ADP/ATP exchange activity decreasing above 40 degrees C. To assess the importance of this reversible thermal adaptation for the chaperone action of the DnaK/DnaJ/GrpE system during heat shock, we used glucose-6-phosphate dehydrogenase and luciferase as substrates. We compared the performance of wild-type GrpE as a component of the chaperone system with that of GrpE R40C. In this mutant, the thermosensing helices are stabilized with an intersubunit disulfide bond and its nucleotide exchange activity thus increases continuously with increasing temperature. Wild-type GrpE with intact thermosensor proved superior to GrpE R40C with desensitized thermosensor. The chaperone system with wild-type GrpE yielded not only a higher fraction of refolding-competent protein at the end of a heat shock but also protected luciferase more efficiently against inactivation during heat shock. Consistent with their differential thermal behavior, the protective effects of wild-type GrpE and GrpE R40C diverged more and more with increasing temperature. Thus, the direct thermal adaptation of the DnaK chaperone system by thermosensing GrpE is essential for efficient chaperone action during heat shock.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Christen, P (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	christen@bioc.unizh.ch						ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; Ben-Zvi A, 2004, J BIOL CHEM, V279, P37298, DOI 10.1074/jbc.M405627200; Bischofberger P, 2003, J BIOL CHEM, V278, P19044, DOI 10.1074/jbc.M300922200; Brehmer D, 2004, J BIOL CHEM, V279, P27957, DOI 10.1074/jbc.M403558200; Diamant S, 1998, BIOCHEMISTRY-US, V37, P9688, DOI 10.1021/bi980338u; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Feifel B, 1996, EUR J BIOCHEM, V237, P318, DOI 10.1111/j.1432-1033.1996.0318n.x; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; Gelinas AD, 2003, BIOCHEMISTRY-US, V42, P9050, DOI 10.1021/bi034416b; Gelinas AD, 2002, J MOL BIOL, V323, P131, DOI 10.1016/S0022-2836(02)00915-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Grimshaw JPA, 2003, J BIOL CHEM, V278, P19048, DOI 10.1074/jbc.M300924200; Grimshaw JPA, 2001, J BIOL CHEM, V276, P6098, DOI 10.1074/jbc.M009290200; Groemping Y, 2001, J MOL BIOL, V314, P167, DOI 10.1006/jmbi.2001.5116; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HELLEBUST H, 1990, J BACTERIOL, V172, P5030, DOI 10.1128/jb.172.9.5030-5034.1990; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIU X, 2002, THESIS U ZURICH ZURI; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, P1334; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Pierpaoli EV, 1998, J BIOL CHEM, V273, P6643, DOI 10.1074/jbc.273.12.6643; Rizvi SM, 2004, MOL CELL, V15, P913, DOI 10.1016/j.molcel.2004.09.001; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Schonfeld HJ, 1995, PROG COLL POL SCI S, V99, P7; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Siegenthaler RK, 2004, FEBS LETT, V562, P105, DOI 10.1016/S0014-5793(04)00190-5; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Watanabe Y, 2004, J BIOL CHEM, V279, P15723, DOI 10.1074/jbc.M308782200; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	39	16	17	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14395	14401		10.1074/jbc.M413803200	http://dx.doi.org/10.1074/jbc.M413803200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705578	hybrid			2022-12-25	WOS:000228236800007
J	Yao, J; Chen, X; Li, H; Zhou, Y; Yao, LJ; Wu, G; Chen, X; Zhang, NX; Zhou, Z; Xu, T; Wu, HM; Ding, JP				Yao, J; Chen, X; Li, H; Zhou, Y; Yao, LJ; Wu, G; Chen, X; Zhang, NX; Zhou, Z; Xu, T; Wu, HM; Ding, JP			BmP09, a "long chain" scorpion peptide blocker of BK channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUTHUS-MARTENSI KARSCH; ADRENAL CHROMAFFIN CELLS; DEPENDENT POTASSIUM CHANNELS; K+-CHANNELS; MOLECULAR-BASIS; BMK AS-1; CALCIUM; VOLTAGE; TOXINS; INACTIVATION	A novel "long chain" toxin BmP09 has been purified and characterized from the venom of the Chinese scorpion Buthus martensi Karsch. The toxin BmP09 is composed of 66 amino acid residues, including eight cysteines, with a mass of 7721.0 Da. Compared with the B. martensi Karsch AS-1 as a Na+ channel blocker (7704.8 Da), the BmP09 has an exclusive difference in sequence by an oxidative modification at the C terminus. The sulfoxide Met-66 at the C terminus brought the peptide a dramatic switch from a Na+ channel blocker to a K+ channel blocker. Upon probing the targets of the toxin BmP09 on the isolated mouse adrenal medulla chromaffin cells, where a variety of ion channels coexists, we found that the toxin BmP09 specifically blocked large conductance Ca2+- and voltage-dependent K+ channels (BK) but not Na+ channels at a range of 100 nM concentration. This was further confirmed by blocking directly the BK channels encoded with mSlo1 alpha-subunits in Xenopus oocytes. The half-maximum concentration EC50 of BmP09 was 27 nM, and the Hill coefficient was 1.8. In outside-out patches, the 100 nM BmP09 reduced similar to 70% currents of BK channels without affecting the single-channel conductance. In comparison with the "short chain" scorpion peptide toxins such as Charybdotoxin, the toxin BmP09 behaves much better in specificity and reversibility, and thus it will be a more efficient tool for studying BK channels. A three-dimensional simulation between a BmP09 toxin and an mSlo channel shows that the Lys-41 in BmP09 lies at the center of the interface and plugs into the entrance of the channel pore. The stable binding between the toxin BmP09 and the BK channel is favored by aromatic pi-pi interactions around the center.	Chinese Acad Sci, Shanghai Inst Organ Chem, State Key Lab Bioorgan & Nat Prod Chem, Shanghai 200032, Peoples R China; Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Inst Biochem & Biophys, Wuhan 430074, Hubei, Peoples R China; Peking Univ, Inst Mol Med, Beijing 100031, Peoples R China; Chinese Acad Sci, SIBS, Inst Neurosci, Shanghai 200031, Peoples R China; Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Organic Chemistry, CAS; Huazhong University of Science & Technology; Peking University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS	Wu, HM (corresponding author), Chinese Acad Sci, Shanghai Inst Organ Chem, State Key Lab Bioorgan & Nat Prod Chem, 345 Lingling Lu, Shanghai 200032, Peoples R China.	hmwu@mail.sioc.ac.cn; jpding@mail.hust.edu.cn	zhou, zhuan/A-8285-2011; Chen, Xiang/E-2840-2010; chen, xiaoke/E-5385-2011; Xu, Tao/G-5474-2010	Yao, Jing/0000-0003-1844-3988				Cook WJ, 2002, PROTEIN SCI, V11, P479, DOI 10.1110/ps.39202; Corona M, 2001, TOXICON, V39, P1893, DOI 10.1016/S0041-0101(01)00174-X; de la Vega RCR, 2004, TOXICON, V43, P865, DOI 10.1016/j.toxicon.2004.03.022; de la Vega RCR, 2003, TRENDS PHARMACOL SCI, V24, P222, DOI 10.1016/S0165-6147(02)00080-4; Ding JP, 2002, BIOPHYS J, V82, P2448, DOI 10.1016/S0006-3495(02)75588-4; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Elhamdani A, 1998, J NEUROSCI, V18, P6230; Fan CX, 2003, J BIOL CHEM, V278, P12624, DOI 10.1074/jbc.M210200200; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; Gao YD, 2003, PROTEINS, V52, P146, DOI 10.1002/prot.10341; Garcia-Valdes J, 2001, FEBS LETT, V505, P369, DOI 10.1016/S0014-5793(01)02791-0; Goudet C, 2002, TOXICON, V40, P1239, DOI 10.1016/S0041-0101(02)00142-3; Hille B., 2001, ION CHANNELS EXCITAB, P505; Hirschberg B, 1998, J GEN PHYSIOL, V111, P565, DOI 10.1085/jgp.111.4.565; Ji YH, 1999, TOXICON, V37, P519, DOI 10.1016/S0041-0101(98)00190-1; Ji YH, 2003, J NEUROCHEM, V84, P325, DOI 10.1046/j.1471-4159.2003.01516.x; Jin P, 2002, J BIOL CHEM, V277, P43724, DOI 10.1074/jbc.M205795200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaczorowski GJ, 1996, J BIOENERG BIOMEMBR, V28, P255, DOI 10.1007/BF02110699; KREZEL AM, 1995, PROTEIN SCI, V4, P1478, DOI 10.1002/pro.5560040805; Lan ZD, 1999, TOXICON, V37, P815, DOI 10.1016/S0041-0101(98)00221-9; Li HM, 1996, J MOL BIOL, V261, P415, DOI 10.1006/jmbi.1996.0473; MCMANUS OB, 1993, BIOCHEMISTRY-US, V32, P6128, DOI 10.1021/bi00075a002; Meera P, 2000, P NATL ACAD SCI USA, V97, P5562, DOI 10.1073/pnas.100118597; Meyer EA, 2003, ANGEW CHEM INT EDIT, V42, P1210, DOI 10.1002/anie.200390319; Morita T, 1997, AM J PHYSIOL-RENAL, V273, pF615, DOI 10.1152/ajprenal.1997.273.4.F615; Mouhat S, 2004, BIOCHEM J, V378, P717, DOI 10.1042/BJ20031860; NEELY A, 1992, J PHYSIOL-LONDON, V453, P97, DOI 10.1113/jphysiol.1992.sp019220; NEELY A, 1992, J PHYSIOL-LONDON, V453, P133, DOI 10.1113/jphysiol.1992.sp019221; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; Prakriya M, 1999, J NEUROPHYSIOL, V81, P2267, DOI 10.1152/jn.1999.81.5.2267; ROGOWSKI RS, 1994, P NATL ACAD SCI USA, V91, P1475, DOI 10.1073/pnas.91.4.1475; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; Tan ZY, 2001, NEUROSCI LETT, V297, P65, DOI 10.1016/S0304-3940(00)01642-6; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; Wu HM, 1999, PURE APPL CHEM, V71, P1157, DOI 10.1351/pac199971061157; Wu JJ, 2002, BIOCHEMISTRY-US, V41, P2844, DOI 10.1021/bi011367z; Xia XM, 1999, J NEUROSCI, V19, P5255, DOI 10.1523/jneurosci.19-13-05255.1999; Xiong YM, 1997, TOXICON, V35, P1025, DOI 10.1016/S0041-0101(96)00224-3; Xu CQ, 2004, J BIOL CHEM, V279, P34562, DOI 10.1074/jbc.M312798200; Xu CQ, 2003, TRENDS PHARMACOL SCI, V24, P446, DOI 10.1016/S0165-6147(03)00223-2; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Zhang NX, 2004, BIOCHEMISTRY-US, V43, P12469, DOI 10.1021/bi0490643; Zhang NX, 2004, PROTEINS, V55, P835, DOI 10.1002/prot.20117; ZHOU Z, 1995, J BIOL CHEM, V270, P3498, DOI 10.1074/jbc.270.8.3498; ZHOU ZA, 1993, J PHYSIOL-LONDON, V469, P245, DOI 10.1113/jphysiol.1993.sp019813	48	31	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14819	14828		10.1074/jbc.M412735200	http://dx.doi.org/10.1074/jbc.M412735200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15695820	hybrid			2022-12-25	WOS:000228236800060
J	Chiang, MC; Lee, YC; Huang, CL; Chern, YJ				Chiang, MC; Lee, YC; Huang, CL; Chern, YJ			cAMP-response element-binding protein contributes to suppression of the A(2A) adenosine receptor promoter by mutant huntingtin with expanded polyglutamine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION CHANGES; MEDIATED TRANSCRIPTION; CELL-DEATH; REPRESSES TRANSCRIPTION; DISEASE PROTEIN; GRANULOSA-CELLS; STRIATAL CELLS; MOUSE MODELS; PC12 CELLS; RAT-BRAIN	Huntington's disease is a neurodegenerative disease resulting from a CAG (glutamine) trinucleotide expansion in exon 1 of the Huntingtin (Htt) gene. The role of the striatum-enriched A(2A) adenosine receptor (A(2A)-R) in Huntington's disease has attracted much attention lately. In the present study, we found that expression of mutant Htt with expanded poly( Q) significantly reduced the transcript levels of the endogenous A(2A)-R in PC12 cells and primary striatal neurons. Cotransfection of various promoter constructs of the A(2A)-R gene and an expression construct of poly(Q)-expanded Htt revealed that the Htt mutant suppressed the core promoter activity of the A(2A)-R gene. Stimulation of the A(2A)-R using CGS21680, forskolin, and a constitutively active cAMP-response element-binding protein ( CREB) mutant elevated the reduced promoter activity of the A(2A)-R gene by mutant Htt. Moreover, the effect of CGS was blocked by an A(2A)-R- selective antagonist (CSC), two inhibitors of protein kinase A, and two dominant negative mutants of (CREB). The protein kinase A/CREB pathway therefore is involved in regulating A(2A)-R promoter activity. Consistently, an atypical CRE site (TCCAGG) is located in the core promoter region of the A(2A)-R gene. Electrophoretic gel mobility shift assay and mutational inactivation further demonstrated the functional binding of CREB to the core promoter region and showed that expression of poly(Q)-expanded Htt abolished the binding of CREB to this site. Stimulation of the A(2A)-R restored the reduced CREB binding caused by the mutant and concurrently reduced mutant Htt aggregation. Collectively, the poly(Q)-expanded mutant Htt suppressed expression of the A(2A)-R by inhibiting its core promoter at least partially by preventing CREB binding.	Acad Sinica, Inst Biomed Sci, Div Neurosci, Taipei 11529, Taiwan; Natl Yang Ming Univ, Inst Neurosci, Taipei 11529, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Chern, YJ (corresponding author), Acad Sinica, Inst Biomed Sci, Div Neurosci, Taipei 11529, Taiwan.	bmychern@ibms.sinica.edu.tw	chern, yijuang/S-7013-2018	chern, yijuang/0000-0002-5842-5429; Lee, Yi-Chao/0000-0003-3451-183X				Blum D, 2003, J NEUROSCI, V23, P5361; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; Chan EYW, 2002, HUM MOL GENET, V11, P1939, DOI 10.1093/hmg/11.17.1939; Chen WS, 2001, MOL CELL BIOL, V21, P4636, DOI 10.1128/MCB.21.14.4636-4646.2001; Cheng JS, 2001, J RECEPT SIGNAL TR R, V21, P1, DOI 10.1081/RRS-100107138; CHERN YJ, 1993, MOL PHARMACOL, V44, P950; CHERN YJ, 1992, BIOCHEM BIOPH RES CO, V185, P304, DOI 10.1016/S0006-291X(05)90000-4; Chu YY, 1996, DNA CELL BIOL, V15, P329, DOI 10.1089/dna.1996.15.329; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; Day YJ, 2004, AM J PHYSIOL-GASTR L, V286, pG285, DOI 10.1152/ajpgi.00348.2003; Day YJ, 2003, J CLIN INVEST, V112, P883, DOI 10.1172/JCI200315483; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; FERRE S, 1993, J NEUROSCI, V13, P5402, DOI 10.1523/JNEUROSCI.13-12-05402.1993; Fink JS, 2004, J NEUROCHEM, V88, P538, DOI 10.1046/j.1471-4159.2003.02145.x; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; GINTY DD, 1991, J BIOL CHEM, V266, P15325; Glass M, 2000, NEUROSCIENCE, V97, P505, DOI 10.1016/S0306-4522(00)00008-7; Huang NK, 2001, J BIOL CHEM, V276, P13838, DOI 10.1074/jbc.M008589200; Ionescu AM, 2004, J CELL PHYSIOL, V198, P428, DOI 10.1002/jcp.10421; Ionescu AM, 2001, J BIOL CHEM, V276, P11639, DOI 10.1074/jbc.M006564200; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; Kegel KB, 2002, J BIOL CHEM, V277, P7466, DOI 10.1074/jbc.M103946200; Kiang JG, 2002, AM J PHYSIOL-GASTR L, V282, pG415, DOI 10.1152/ajpgi.00138.2001; Kiang JG, 2000, MOL CELL BIOCHEM, V204, P169, DOI 10.1023/A:1007016822939; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai HL, 1997, J BIOL CHEM, V272, P4970, DOI 10.1074/jbc.272.8.4970; Lee YC, 1999, J NEUROCHEM, V73, P1790, DOI 10.1046/j.1471-4159.1999.0731790.x; Lee YC, 2003, EUR J NEUROSCI, V18, P1786, DOI 10.1046/j.1460-9568.2003.02907.x; LEE YC, 2003, BRAIN RES MOL BRAIN, V111, P61; Li SH, 2002, MOL CELL BIOL, V22, P1277, DOI 10.1128/MCB.22.5.1277-1287.2002; Luthi-Carter R, 2002, HUM MOL GENET, V11, P1927, DOI 10.1093/hmg/11.17.1927; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; POPOLI P, 1994, EUR J PHARMACOL, V257, pR5, DOI 10.1016/0014-2999(94)90715-3; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Ravikumar B, 2003, HUM MOL GENET, V12, P985, DOI 10.1093/hmg/ddg109; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Sipione S, 2002, HUM MOL GENET, V11, P1953, DOI 10.1093/hmg/11.17.1953; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Sugars KL, 2004, J BIOL CHEM, V279, P4988, DOI 10.1074/jbc.M310226200; Tanaka M, 2004, NAT MED, V10, P148, DOI 10.1038/nm985; Varani K, 2003, FASEB J, V17, P2148, DOI 10.1096/fj.03-0079fje; Varani K, 2001, FASEB J, V15, P1245, DOI 10.1096/fj.00-0730fje; Walker BAM, 1997, J IMMUNOL, V158, P2926; WEAVER DR, 1993, MOL BRAIN RES, V20, P313, DOI 10.1016/0169-328X(93)90058-W; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; Wyttenbach A, 2001, HUM MOL GENET, V10, P1829, DOI 10.1093/hmg/10.17.1829; Yohrling GJ, 2003, MOL CELL NEUROSCI, V23, P28, DOI 10.1016/S1044-7431(03)00032-0; Zuccato C, 2003, NAT GENET, V35, P76, DOI 10.1038/ng1219	53	68	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14331	14340		10.1074/jbc.M413279200	http://dx.doi.org/10.1074/jbc.M413279200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15689617	hybrid			2022-12-25	WOS:000228095500138
J	Iseli, TJ; Walter, M; van Denderen, BJW; Katsis, F; Witters, LA; Kemp, BE; Michell, BJ; Stapleton, D				Iseli, TJ; Walter, M; van Denderen, BJW; Katsis, F; Witters, LA; Kemp, BE; Michell, BJ; Stapleton, D			AMP-activated protein kinase beta subunit tethers alpha and gamma Subunits via its C-terminal sequence (186-270)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATIONS; YEAST; DOMAIN; COMPLEX; PHOSPHORYLATION; GLYCOGEN; SITE	dAMP-activated protein kinase (AMPK) is an important metabolic stress-sensing protein kinase responsible for regulating metabolism in response to changing energy demand and nutrient supply. Mammalian AMPK is a stable alpha beta gamma heterotrimer comprising a catalytic alpha and two non-catalytic subunits, beta and gamma. The beta subunit targets AMPK to membranes via an N-terminal myristoyl group and to glycogen via a mid-molecule glycogen-binding domain. Here we find that the conserved C-terminal 85-residue sequence of the beta subunit, beta 1-(186-270), is sufficient to form an active AMP-dependent heterotrimer alpha 1 beta 1-(186-270)-gamma 1, whereas the 25-residue beta 1 C-terminal (246 270) sequence is sufficient to bind gamma 1, gamma 2, or gamma 3 but not the alpha subunit. Deletion of the beta C-terminal Ile-270 precludes beta gamma association in the absence of the alpha subunit, but the presence of the alpha subunit or substitution of Ile-270 with Ala or Glu restores beta gamma binding. Truncation of the alpha subunit reveals that beta 1 binding requires the alpha 1-(313-473) sequence. The conserved C-terminal 85-residue sequence of the beta subunit (90% between beta 1 and beta 2) is the primary alpha gamma binding sequence responsible for the formation of the AMPK alpha beta gamma heterotrimer.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia; Dartmouth Coll Sch Med, Dept Med, Endocrine Metab Div, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Biochem, Endocrine Metab Div, Hanover, NH 03755 USA; Commonwealth Sci & Ind Res Org Hlth Sci & Nutr, Parkville, Vic 3052, Australia	St. Vincent's Institute of Medical Research; University of Melbourne; Dartmouth College; Dartmouth College; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Kemp, BE (corresponding author), St Vincents Inst Med Res, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.	bkemp@svi.edu.au	Kemp, Bruce E/L-2633-2014; van Denderen, Bryce/AAW-5454-2021; Iseli, Tristan/A-9537-2012; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082	NIDDK NIH HHS [DK35712] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams J, 2004, PROTEIN SCI, V13, P155, DOI 10.1110/ps.03340004; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; CARLING D, 1994, J BIOL CHEM, V269, P11442; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hudson ER, 2003, CURR BIOL, V13, P861, DOI 10.1016/S0960-9822(03)00249-5; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Jiang R, 1997, MOL CELL BIOL, V17, P2099, DOI 10.1128/MCB.17.4.2099; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Michell BJ, 1996, J BIOL CHEM, V271, P28445, DOI 10.1074/jbc.271.45.28445; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; Mitchelhill KI, 1997, J BIOL CHEM, V272, P24475, DOI 10.1074/jbc.272.39.24475; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Polekhina G, 2003, CURR BIOL, V13, P867, DOI 10.1016/S0960-9822(03)00292-6; Prieto J, 1997, J MOL BIOL, V274, P276, DOI 10.1006/jmbi.1997.1322; Schmidt MC, 2000, EMBO J, V19, P4936, DOI 10.1093/emboj/19.18.4936; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Warden SM, 2001, BIOCHEM J, V354, P275, DOI 10.1042/0264-6021:3540275; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2003, J BIOL CHEM, V278, P28434, DOI 10.1074/jbc.M303946200; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x	26	106	109	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13395	13400		10.1074/jbc.M412993200	http://dx.doi.org/10.1074/jbc.M412993200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695819	hybrid			2022-12-25	WOS:000228095500026
J	Shiraki, T; Kamiya, N; Shiki, S; Kodama, TS; Kakizuka, A; Jingami, H				Shiraki, T; Kamiya, N; Shiki, S; Kodama, TS; Kakizuka, A; Jingami, H			alpha,beta-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA LIGAND; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); ADIPOCYTE DIFFERENTIATION; NUCLEAR RECEPTORS; CRYSTAL-STRUCTURE; GENE-EXPRESSION; MOLECULAR-BASIS; DNA-BINDING; MACROPHAGES; INHIBITION	Peroxisome proliferator- activated receptor gamma( PPAR gamma) functions in various biological processes, including macrophage and adipocyte differentiation. Several natural lipid metabolites have been shown to activate PPAR gamma. Here, we report that some PPAR gamma ligands, including 15- deoxy- Delta(12,14)- prostaglandin J(2), covalently bind to a cysteine residue in the PPAR gamma ligand binding pocket through a Michael addition reaction by an alpha,beta-unsaturated ketone. Using rhodamine- maleimide as well as mass spectroscopy, we showed that the binding of these ligands is covalent and irreversible. Consistently, mutation at the cysteine residue abolished abilities of these ligands to activate PPAR gamma, but not of BRL49653, a non- covalent synthetic agonist, indicating that covalent binding of the alpha, beta- unsaturated ketone in the natural ligands was required for their transcriptional activities. Screening of lipid metabolites containing the alpha,beta- unsaturated ketone revealed that several other oxidized metabolites of hydroxyeicosatetraenoic acid, hydroxyeicosadecaenoic acid, and prostaglandins can also function as novel covalent ligands for PPAR gamma. We propose that PPAR gamma senses oxidation of fatty acids by recognizing such an alpha,beta- unsaturated ketone as a common moiety.	Biomol Engn Res Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Computat Biol, Suita, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Biol Struct, Suita, Osaka 5650874, Japan; Japan Biol Informat Consortium, Japan Biol Informat Res Inst Ctr, Koto Ku, Tokyo 1350064, Japan; Kyoto Univ, Grad Sch Biostudies, Lab Funct Biol, Sakyo Ku, Kyoto 6068501, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Jingami, H (corresponding author), Biomol Engn Res Inst, Dept Mol Biol, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.	jingami@beri.or.jp	Kamiya, Narutoshi/C-4548-2016	Kamiya, Narutoshi/0000-0002-0527-6968				Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; CORNELL WD, 1993, J AM CHEM SOC, V115, P9620, DOI 10.1021/ja00074a030; Cronet P, 2001, STRUCTURE, V9, P699, DOI 10.1016/S0969-2126(01)00634-7; Elbrecht A, 1999, J BIOL CHEM, V274, P7913, DOI 10.1074/jbc.274.12.7913; Erlemann KR, 2004, J BIOL CHEM, V279, P40376, DOI 10.1074/jbc.M401294200; Evans RM, 2004, NAT MED, V10, P1; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Frisch G.W., 2016, GAUSSIAN 16 REVISION; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; HAMBERG M, 1971, J BIOL CHEM, V246, P6713; Hodgkinson CP, 2003, BIOCHEM BIOPH RES CO, V308, P505, DOI 10.1016/S0006-291X(03)01416-5; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Ivanov AI, 2003, AM J PHYSIOL-REG I, V284, pR698, DOI 10.1152/ajpregu.00570.2002; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; Lee G, 2002, J BIOL CHEM, V277, P19649, DOI 10.1074/jbc.M200743200; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Nomura T, 2004, MOL PHARMACOL, V65, P973, DOI 10.1124/mol.65.4.973; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Oliva JL, 2003, P NATL ACAD SCI USA, V100, P4772, DOI 10.1073/pnas.0735842100; Perez-Sala D, 2003, J BIOL CHEM, V278, P51251, DOI 10.1074/jbc.M309409200; Powell WS, 2003, J CLIN INVEST, V112, P828, DOI 10.1172/JCI200319796; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sanchez-Gomez FJ, 2004, MOL PHARMACOL, V66, P1349, DOI 10.1124/mol.104.002824; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; Shiraki T, 2003, J BIOL CHEM, V278, P11344, DOI 10.1074/jbc.M212859200; Shiraki T, 2005, PROTEINS, V58, P418, DOI 10.1002/prot.20266; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Uppenberg J, 1998, J BIOL CHEM, V273, P31108, DOI 10.1074/jbc.273.47.31108; Wang XK, 1999, FEBS LETT, V462, P145, DOI 10.1016/S0014-5793(99)01521-5; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198	38	193	207	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14145	14153		10.1074/jbc.M500901200	http://dx.doi.org/10.1074/jbc.M500901200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695504	hybrid			2022-12-25	WOS:000228095500118
J	West, DC; Rees, CG; Duchesne, L; Patey, SJ; Terry, CJ; Turnbull, JE; Delehedde, M; Heegaard, CW; Allain, F; Vanpouille, C; Ron, D; Fernig, DG				West, DC; Rees, CG; Duchesne, L; Patey, SJ; Terry, CJ; Turnbull, JE; Delehedde, M; Heegaard, CW; Allain, F; Vanpouille, C; Ron, D; Fernig, DG			Interactions of multiple heparin binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; OPTICAL BIOSENSOR; FACTOR RECEPTOR-1; FACTOR FGF; BASIC FGF; SULFATE; PROTEIN; COMPLEXES; FORM; IDENTIFICATION	The hypothesis that neuropilin-1 (Npn-1) may interact with heparin-binding proteins other than vascular endothelial growth factor has been tested using an optical biosensor-based binding assay. The results show that fibroblast growth factor (FGF) 1, 2, 4, and 7, FGF receptor 1, hepatocyte growth factor/scatter factor (HGF/SF), FGF-binding protein, normal protease sensitive form of prion protein, antithrombin III, and Npn-1 itself are all able to interact with Npn-1 immobilized on the sensor surface. FGF-2, FGF-4, and HGF/SF are also shown to interact with Npn-1 in a solution assay. Moreover, these protein-protein interactions are dependent on the ionic strength of the medium and are inhibited by heparin, and the kinetics of binding of FGF-2, FGF-4 and HGF/SF to Npn-1 are characterized by fast association rate constants (270,000 1,600,000 M(-1)s(-1)). These results suggest that Npn-1 possesses a "heparin" mimetic site that is able to interact at least in part through ionic bonding with the heparin binding site on many of the proteins studied. Npn-1 was also found to potentiate the growth stimulatory activity of FGF-2 on human umbilical vein endothelial cells, indicating that Npn-1 may not just bind but also regulate the activity of heparin-binding proteins.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus, Denmark; USTL, CNRS, UMR 8576, F-59655 Villeneuve Dascq, France; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	University of Liverpool; Aarhus University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Technion Israel Institute of Technology	Fernig, DG (corresponding author), Univ Liverpool, Sch Biol Sci, Biosci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	dgfernig@liv.ac.uk	Heegaard, Christian W/A-4814-2019; Patey, Susannah/D-6114-2014; Fernig, David G/A-3590-2008	Fernig, David G/0000-0003-4875-4293; Duchesne, Laurence/0000-0003-1985-6266; Allain, Fabrice/0000-0002-4484-6302; DELEHEDDE, Maryse/0000-0003-2724-143X; Wurtz Heegaard, Christian/0000-0002-7989-2624				Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200; Castellani V, 2000, NEURON, V27, P237, DOI 10.1016/S0896-6273(00)00033-7; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P221, DOI 10.1016/0968-0004(88)90088-6; Cross GH, 2003, BIOSENS BIOELECTRON, V19, P383, DOI 10.1016/S0956-5663(03)00203-3; Delehedde M, 2002, BIOCHEM J, V366, P235, DOI 10.1042/BJ20011718; Delehedde M, 2002, J BIOL CHEM, V277, P12456, DOI 10.1074/jbc.M111345200; Delehedde M, 2001, J MAMMARY GLAND BIOL, V6, P253, DOI 10.1023/A:1011367423085; Edwards PR, 1997, ANAL BIOCHEM, V246, P1, DOI 10.1006/abio.1996.9922; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fernig D G, 2001, Methods Mol Biol, V171, P505; Fernig DG, 2000, BIOCHEM BIOPH RES CO, V267, P770, DOI 10.1006/bbrc.1999.2028; Fuh G, 2000, J BIOL CHEM, V275, P26690; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Gluzman-Poltorak Z, 2001, J BIOL CHEM, V276, P18688, DOI 10.1074/jbc.M006909200; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; KE YQ, 1990, BIOCHEM BIOPH RES CO, V171, P963, DOI 10.1016/0006-291X(90)90778-L; KE YQ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P307, DOI 10.1016/0167-4781(92)90029-Y; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; Lametsch R, 2000, J BIOL CHEM, V275, P19469, DOI 10.1074/jbc.M002550200; Lee CC, 2003, STRUCTURE, V11, P99, DOI 10.1016/S0969-2126(02)00941-3; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; Matthies AM, 2002, AM J PATHOL, V160, P289, DOI 10.1016/S0002-9440(10)64372-6; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Powell AK, 2002, J BIOL CHEM, V277, P28554, DOI 10.1074/jbc.M111754200; Rahmoune H, 1998, BIOCHEMISTRY-US, V37, P6003, DOI 10.1021/bi972468t; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Rohm B, 2000, MECH DEVELOP, V93, P95, DOI 10.1016/S0925-4773(00)00269-0; SANDERSON PN, 1987, BIOCHEM J, V243, P175, DOI 10.1042/bj2430175; Sher I, 1999, J BIOL CHEM, V274, P35016, DOI 10.1074/jbc.274.49.35016; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; SPIK G, 1991, J BIOL CHEM, V266, P10735; Swann MJ, 2004, ANAL BIOCHEM, V329, P190, DOI 10.1016/j.ab.2004.02.019; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Uematsu F, 2000, BIOCHEM BIOPH RES CO, V272, P830, DOI 10.1006/bbrc.2000.2872; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Yamada Y, 2001, BLOOD, V97, P1671, DOI 10.1182/blood.V97.6.1671	56	124	126	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13457	13464		10.1074/jbc.M410924200	http://dx.doi.org/10.1074/jbc.M410924200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695515	hybrid			2022-12-25	WOS:000228095500034
J	Song, JH; Wang, CX; Song, DK; Wang, P; Shuaib, A; Hao, CH				Song, JH; Wang, CX; Song, DK; Wang, P; Shuaib, A; Hao, CH			Interferon gamma induces neurite outgrowth by up-regulation of p35 neuron-specific cyclin-dependent kinase 5 activator via activation of ERK1/2 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING COMPLEX; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; INFLAMMATORY CYTOKINES; INDUCED APOPTOSIS; NERVOUS-SYSTEM; RETINOIC ACID; INDUCED DEATH; PC12 CELLS; DIFFERENTIATION	Interferon gamma (IFN-gamma) is a cytokine predominantly involved in antiproliferative and antiviral responses, immune surveillance, and tumor suppression. However, it has been shown that IFN-gamma is also involved in central nervous system development. Here we studied the underlying mechanism for IFN-gamma-induced neuronal differentiation using the human neuroblastoma Paju cell line. Our results indicate that IFN-gamma treatment led to neurite outgrowth followed by growth arrest in the G(1) phase of the cell cycle. IFN-gamma-induced ERK1/2 phosphorylation and subsequently the transcription factor early gene response 1, which in turn up-regulated p35 expression and increased cyclin-dependent kinase 5 (Cdk5) activity. IFN-gamma-induced neurite outgrowth was abolished by the treatment of MEK1/2 kinase inhibitors, such as U0126 and PD98059, which inhibit the ERK1/2 activation and subsequently prevent the up-regulation of p35 expression and Cdk5 activity. In agreement with the role of p35-Cdk5 in neuronal differentiation, small interfering RNA targeting Cdk5 abrogate the IFN-gamma-induced neurite outgrowth. Together, these results demonstrate for the first time that IFN-gamma-triggered neuronal differentiation mediated through the up-regulation of p35-associated Cdk5 depends on the activation of the ERK1/2 pathway. Therefore, the present study suggests that IFN-gamma is not only involved in tumorigenicity but also involved in neurogenesis by regulating cell proliferation and differentiation.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Winship Canc Inst,Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada	Emory University; University of Alberta	Hao, CH (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Winship Canc Inst,Ctr Neurodegenerat Dis, 1365 C Clifton Rd NE,Rm C5082, Atlanta, GA 30322 USA.	chao@emory.edu		SONG, JIN/0000-0002-0123-2909				Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; BARISH ME, 1991, DEV BIOL, V144, P412, DOI 10.1016/0012-1606(91)90433-4; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; DiProspero NA, 1997, EXP NEUROL, V148, P628, DOI 10.1006/exnr.1997.6700; Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471-4159.2000.0750991.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; IMPROTA T, 1988, EXP CELL RES, V179, P1, DOI 10.1016/0014-4827(88)90342-4; JONAKAIT GM, 1994, NEURON, V12, P1149; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lambert C, 2003, APOPTOSIS, V8, P551, DOI 10.1023/A:1026113222478; LASORELLA A, 1995, CANCER RES, V55, P4711; Li BS, 2003, J BIOL CHEM, V278, P35702, DOI 10.1074/jbc.M302004200; Lombet A, 2001, EUR J BIOCHEM, V268, P1352, DOI 10.1046/j.1432-1327.2001.02002.x; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Plunkett JA, 2001, EXP NEUROL, V168, P144, DOI 10.1006/exnr.2000.7604; Pouly S, 2000, J NEUROPATH EXP NEUR, V59, P280, DOI 10.1093/jnen/59.4.280; Qiu JH, 2002, J NEUROSCI, V22, P3504; Saas P, 1999, J IMMUNOL, V162, P2326; Sharma P, 2002, J BIOL CHEM, V277, P528, DOI 10.1074/jbc.M109324200; Shu CH, 1997, APOPTOSIS, V2, P463, DOI 10.1023/A:1026422111457; Song JH, 2004, NEUROPHARMACOLOGY, V46, P984, DOI 10.1016/j.neuropharm.2004.01.001; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Westberg JA, 1999, FASEB J, V13, P1621, DOI 10.1096/fasebj.13.12.1621; Wong G, 2004, EXP NEUROL, V187, P171, DOI 10.1016/j.expneurol.2004.01.009; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200; Yang XZ, 2003, CANCER RES, V63, P1122; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	38	81	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12896	12901		10.1074/jbc.M412139200	http://dx.doi.org/10.1074/jbc.M412139200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15695523	hybrid			2022-12-25	WOS:000227922000098
J	Yang, HL; Zhao, RY; Yang, HY; Lee, MH				Yang, HL; Zhao, RY; Yang, HY; Lee, MH			Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity	ONCOGENE			English	Article						FOXO; Akt; p27; HER2	FORKHEAD TRANSCRIPTION FACTORS; CELL-CYCLE PROGRESSION; PROTEIN-KINASE-B; GENE-EXPRESSION; CYTOPLASMIC LOCALIZATION; ACUTE LEUKEMIAS; BREAST-CANCER; P27(KIP1); GROWTH; PHOSPHORYLATION	The FOXO family of Forkhead transcription factors, regulated by the phosphoinositide-3-kinase-Akt pathway, is involved in cell cycle regulation and apoptosis. Strong expression of HER2, a receptor tyrosine kinase oncogene, in cancers has been associated with a poor prognosis. Recently, FOXO4 was shown to regulate the transcription of the cyclin-dependent kinase inhibitor p27 Kip1 gene directly. Also, we have shown that HER2 promotes mitogenic growth and transformation of cancer cells by downregulation of p27 Kip1. Given the fact that FOXO4 mediates p27 transcription, we hypothesize that an Akt phosphorylation mutant of FOXO4 ( FOXO4A3), which maintains the activity to transactivate p27 Kip1, may be used as an anticancer agent for HER2-overexpressing cancers. Here, we applied the FOXO4 gene as a novel anticancer agent for HER2-overexpressing cells under the control of a tetracycline (tet)-regulated gene expression system. Overexpression of FOXO4A3 inhibits HER2-activated cell growth. We found that FOXO4A3 inhibited the kinase activity of protein kinase B/Akt and reversed HER2-mediated p27 mislocation in the cytoplasm. FOXO4A3 expression also led to decreased levels of CSN5, a protein involved in p27 degradation. These data suggest that FOXO4A3 also can regulate p27 post-transcriptionally. In addition, we found that FOXO4A3 sensitized cells to apoptosis induced by the chemotherapeutic agent 2-methoxyestradiol. Most significantly for clinical application, FOXO4A3 expression in HER2-overexpressing cells can be regulated in vivo and reduces the tumor volume in a tumor model. These findings indicate the applicability of employing FOXO4 regulation as a therapeutic intervention in HER2-overexpressing cancers.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Programs Genes & Dev, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Programs Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Box 79, Houston, TX 77030 USA.	mhlee@mdanderson.org		Lee, Mong-Hong/0000-0001-8675-8215	NATIONAL CANCER INSTITUTE [R01CA089266, R56CA089266] Funding Source: NIH RePORTER; NCI NIH HHS [R56 CA089266, R01 CA089266, R01CA 089266] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cunningham MA, 2004, MOL ENDOCRINOL, V18, P1756, DOI 10.1210/me.2004-0071; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MILLER SJ, 1995, ONCOL REP, V2, P497; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Rassidakis GZ, 2003, CLIN CANCER RES, V9, P1121; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TANG TT, 2003, J BIOL CHEM, V21, P21; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Yang HY, 2001, ONCOGENE, V20, P3695, DOI 10.1038/sj.onc.1204472; Zhang L, 2003, J BIOL CHEM, V278, P27, DOI 10.1074/jbc.M205424200; Zhang YJ, 2004, ONCOGENE, V23, P7132, DOI 10.1038/sj.onc.1207918; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	44	66	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1924	1935		10.1038/sj.onc.1208352	http://dx.doi.org/10.1038/sj.onc.1208352			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688030				2022-12-25	WOS:000227542000011
J	Yang, WC; Lu, YB; Kalajzic, I; Guo, DY; Harris, MA; Gluhak-Heinrich, J; Kotha, S; Bonewald, LF; Feng, JQ; Rowe, DW; Turner, CH; Robling, AG; Harris, SE				Yang, WC; Lu, YB; Kalajzic, I; Guo, DY; Harris, MA; Gluhak-Heinrich, J; Kotha, S; Bonewald, LF; Feng, JQ; Rowe, DW; Turner, CH; Robling, AG; Harris, SE			Dentin matrix protein 1 gene cis-regulation - Use in osteocytes to characterize local responses to mechanical loading in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-FORMATION; CHROMOSOME 4Q21; GAP-JUNCTIONS; NITRIC-OXIDE; EXPRESSION; CELLS; DMP1; DIFFERENTIATION; OSTEOBLASTS; RECEPTOR	Dentin matrix protein 1 (DMP1) is highly expressed in osteocytes and is mechanically responsive. To study osteocyte-specific and mechanically regulated DMP1 gene expression, the transcriptional activity of three cis-regulatory regions was first examined in an osteoblast differentiation model in vitro using a green fluorescent protein (GFP) reporter. Expression of the -9624 to -1996 bp ( 10 kb) and -7892 to +4439 bp ( 8 kb) DMP1 cis-regulatory regions dramatically increased in areas of mineralized matrix, in dendritic, osteocyte-like cells. Mineralizing cultures expressing the 8-kb construct show dramatic GFP increases in response to loading in cells with a dendritic morphology. Transgenic mice expressing the 8-kb DMP1-GFP and -2433 to +4439 bp (2.5 kb) DMP1-LacZ were generated. Osteocyte-specific expression was found with the 8 kb but not with the 2.5 kb in postnatal animals. However, the 2.5 kb could support expression in rapidly forming osteoblasts and pre-osteocytes in the embryo. Primary calvarial osteoblast cultures demonstrated that the 2.5 kb supports weak expression in a subset of osteoblasts and pre-osteocytes, but not in mature osteocytes. However, the 8 kb supports robust expression in primary bone marrow cultures. Therefore the region -7892 to -2433 bp, termed a 5.5-kb "Osteocyte Enhancer Module," appears to be required for osteocyte specificity. Ulnae of mice with the 8-kb DMP1-GFP were subjected to mechanical loading where GFP expression increased selectively and locally in osteocytes, distal to the mid-shaft and near the surface of the bone. Thus, the 8-kb region of the DMP1 gene is a target for mechanotransduction in osteocytes, and its cis-regulatory activity may be correlated to local strain in bone.	Univ Texas, Hlth Sci Ctr, Dept Periodont & Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Univ Missouri, Dept Oral Biol, Kansas City, MO 64109 USA; Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX 78229 USA; Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA	University of Texas System; University of Texas Health San Antonio; University of Connecticut; University of Missouri System; University of Missouri Kansas City; University of Texas System; University of Texas Health San Antonio; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Harris, SE (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Periodont & Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	harris@uthscsa.edu	Bonewald, Lynda/Q-3638-2019	Lu, Yongbo/0000-0003-3692-1736	NIAMS NIH HHS [AR046530, AR46798, AR44728, AR43457] Funding Source: Medline; NIDDK NIH HHS [DK 63478] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046530, R01AR043457, P01AR046798, R01AR044728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK063478] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APLIN HM, 1995, GENOMICS, V30, P347, DOI 10.1006/geno.1995.9867; Bonewald LF, 2003, CALCIFIED TISSUE INT, V72, P537, DOI 10.1007/s00223-002-1057-y; Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chambers TJ, 1999, OSTEOARTHR CARTILAGE, V7, P422, DOI 10.1053/joca.1998.0231; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Cheng BX, 2001, J BONE MINER RES, V16, P249, DOI 10.1359/jbmr.2001.16.2.249; DOTY SB, 1981, CALCIFIED TISSUE INT, V33, P509, DOI 10.1007/BF02409482; Fedarko NS, 2004, FASEB J, V18, P734, DOI 10.1096/fj.03-0966fje; Feng JQ, 2003, J DENT RES, V82, P776, DOI 10.1177/154405910308201003; Feng JQ, 2002, J BONE MINER RES, V17, P1822, DOI 10.1359/jbmr.2002.17.10.1822; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; GEORGE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1527, DOI 10.1177/42.12.7983353; GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331; Gluhak-Heinrich J, 2003, J BONE MINER RES, V18, P807, DOI 10.1359/jbmr.2003.18.5.807; Gottgens B, 2000, NAT BIOTECHNOL, V18, P181, DOI 10.1038/72635; Han YF, 2004, P NATL ACAD SCI USA, V101, P16689, DOI 10.1073/pnas.0407429101; Hao JJ, 2004, BONE, V34, P921, DOI 10.1016/j.bone.2004.01.020; Harris SE, 2003, FRONT BIOSCI, V8, pS1249, DOI 10.2741/1170; Harris Stephen E., 1995, Molecular and Cellular Differentiation, V3, P137; He G, 2004, J BIOL CHEM, V279, P11649, DOI 10.1074/jbc.M309296200; HUGHES DE, 1994, J BONE MINER RES, V9, P39; Huiskes R, 2000, NATURE, V405, P704, DOI 10.1038/35015116; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; Kalajzic I, 2004, BONE, V35, P74, DOI 10.1016/j.bone.2004.03.006; Li J, 2003, ENDOCRINOLOGY, V144, P1226, DOI 10.1210/en.2002-220821; Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223-001-1025-y; Liu YF, 2004, NEW CARBON MATER, V19, P197; Lobe CG, 1999, DEV BIOL, V208, P281, DOI 10.1006/dbio.1999.9209; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; MacDougall M, 2002, CONNECT TISSUE RES, V43, P320, DOI 10.1080/03008200290000556; MacDougall M, 1998, J BONE MINER RES, V13, P422, DOI 10.1359/jbmr.1998.13.3.422; Marotti G, 1996, Ital J Anat Embryol, V101, P25; MAROTTI G, 1992, BONE, V13, P363, DOI 10.1016/8756-3282(92)90452-3; McAllister TN, 1999, J BONE MINER RES, V14, P930, DOI 10.1359/jbmr.1999.14.6.930; NAKAMURA H, 1995, CELL TISSUE RES, V280, P225, DOI 10.1007/BF00307793; Okabayashi K, 2004, BONE, V34, P124, DOI 10.1016/j.bone.2003.08.010; Robling AG, 2002, BONE, V31, P562, DOI 10.1016/S8756-3282(02)00871-2; Rubin J, 2003, J BIOL CHEM, V278, P34018, DOI 10.1074/jbc.M302822200; Strauss W M, 1996, Methods Mol Biol, V54, P307; Tanaka-Kamioka K, 1998, J BONE MINER RES, V13, P1555, DOI 10.1359/jbmr.1998.13.10.1555; Tartaix PH, 2004, J BIOL CHEM, V279, P18115, DOI 10.1074/jbc.M314114200; Tate MLK, 2004, INT J BIOCHEM CELL B, V36, P1, DOI 10.1016/S1357-2725(03)00241-3; Tate MLK, 2003, J BIOMECH, V36, P1409, DOI 10.1016/S0021-9290(03)00123-4; TORRANCE AG, 1994, CALCIFIED TISSUE INT, V54, P241, DOI 10.1007/BF00301686; Toyosawa S, 2001, J BONE MINER RES, V16, P2017, DOI 10.1359/jbmr.2001.16.11.2017; Yang W., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P386; Ye L, 2004, J BIOL CHEM, V279, P19141, DOI 10.1074/jbc.M400490200; You LD, 2004, ANAT REC PART A, V278A, P505, DOI 10.1002/ar.a.20050	49	85	93	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20680	20690		10.1074/jbc.M500104200	http://dx.doi.org/10.1074/jbc.M500104200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15728181	hybrid			2022-12-25	WOS:000229242000066
J	Neeli, R; Roitel, O; Scrutton, NS; Munro, AW				Neeli, R; Roitel, O; Scrutton, NS; Munro, AW			Switching pyridine nucleotide specificity in P450BM3 - Mechanistic analysis of the W1046H AND W1046A enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HUMAN CYTOCHROME-P450 REDUCTASE; ELECTRON-TRANSFER; CRYSTAL-STRUCTURE; OXIDIZED FLAVODOXIN; REDOX POTENTIALS; BINDING SITE; PROTEIN; DOMAIN; NADPH	Flavocytochrome P450 BM3 is a member of the diflavin reductase enzyme family. Members include cytochrome P450 reductase, nitric-oxide synthase, methionine synthase reductase, and novel oxidoreductase 1. These enzymes show a strong preference for NADPH over NADH as reducing coenzyme. An aromatic residue stacks over the FAD isoalloxazine ring in each enzyme, and in some cases it is important in controlling coenzyme specificity. In P450 BM3, the aromatic residue inferred from sequence alignments to stack over the FAD is Trp-1046. Mutation to Ala-1046 and His-1046 effected a remarkable coenzyme specificity switch. P450 BM3 W1046A/W106H FAD and reductase domains are efficient NADH-dependent ferricyanide reductases with selectivity coefficients (k(cat)/K-m(NADPH)/k(cat)/K-m(NADH)) of 1.5, 67, and 8571 for the W1046A, W1046H, and wild-type reductase domains, respectively. Stopped-flow photodiode array absorption studies indicated a charge-transfer intermediate accumulated in the W1046A FAD domain (and to a lesser extent in the W1046H FAD domain) and was attributed to formation of a reduced FADH(2)-NAD(P)(+) charge-transfer species, suggesting a relatively slow rate of release of NAD(P)(+) from reduced enzymes. Unlike wild-type enzymes, there was no formation of the blue semiquinone species observed during reductive titration of the W0146A/W146H FAD and reductase domains with dithionite or NAD(P) H. This was a consequence of elevation of the semiquinone/hydroquinone couple of the FAD with respect to the oxidized/semiquinone couple, and a concomitant similar to 100-mV elevation in the 2-electron redox couple for the enzyme-bound FAD (-320, -220, and -224 mV in the wild-type, W1046A, and W1046H FAD domains, respectively).	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Scrutton, NS (corresponding author), Univ Leicester, Dept Biochem, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	nss4@le.ac.uk; awm9@le.ac.uk	Munro, Andrew/G-5639-2019	Munro, Andrew/0000-0002-4642-180X				Adak S, 2002, P NATL ACAD SCI USA, V99, P13516, DOI 10.1073/pnas.192283399; Carmichael AB, 2001, EUR J BIOCHEM, V268, P3117, DOI 10.1046/j.1432-1327.2001.02212.x; Daff S, 1996, BIOCHEMISTRY-US, V35, P6351, DOI 10.1021/bi9522561; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Dohr O, 2001, P NATL ACAD SCI USA, V98, P81, DOI 10.1073/pnas.98.1.81; Dunford AJ, 2004, EUR J BIOCHEM, V271, P2548, DOI 10.1111/j.1432-1033.2004.04185.x; Dutton P L, 1978, Methods Enzymol, V54, P411; Elmore CL, 2002, J BIOL CHEM, V277, P48960, DOI 10.1074/jbc.M210173200; Finn RD, 2003, EUR J BIOCHEM, V270, P1164, DOI 10.1046/j.1432-1033.2003.03474.x; Freigang J, 2002, PROTEIN SCI, V11, P253, DOI 10.1110/ps.28602; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; Glieder A, 2002, NAT BIOTECHNOL, V20, P1135, DOI 10.1038/nbt744; Govindaraj S, 1997, J BIOL CHEM, V272, P7915, DOI 10.1074/jbc.272.12.7915; Gutierrez A, 2003, BIOCHEM SOC T, V31, P497, DOI 10.1042/BST0310497; Gutierrez A, 2003, EUR J BIOCHEM, V270, P2612, DOI 10.1046/j.1432-1033.2003.03633.x; Gutierrez A, 2000, BIOCHEMISTRY-US, V39, P15990, DOI 10.1021/bi002135n; Hoover DM, 1997, PROTEIN SCI, V6, P2525; Konas DW, 2004, J BIOL CHEM, V279, P35412, DOI 10.1074/jbc.M400872200; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; MILES JS, 1992, BIOCHEM J, V288, P503, DOI 10.1042/bj2880503; Munro AW, 2002, TRENDS BIOCHEM SCI, V27, P250, DOI 10.1016/S0968-0004(02)02086-8; Munro AW, 1996, EUR J BIOCHEM, V239, P403, DOI 10.1111/j.1432-1033.1996.0403u.x; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; Munro AW, 1996, MOL MICROBIOL, V20, P1115, DOI 10.1111/j.1365-2958.1996.tb02632.x; NARHI LO, 1987, J BIOL CHEM, V262, P6683; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Noble MA, 1999, BIOCHEM J, V339, P371, DOI 10.1042/0264-6021:3390371; Ost TWB, 2000, FEBS LETT, V486, P173, DOI 10.1016/S0014-5793(00)02267-5; Paine MJI, 2000, J BIOL CHEM, V275, P1471, DOI 10.1074/jbc.275.2.1471; Peters MW, 2003, J AM CHEM SOC, V125, P13442, DOI 10.1021/ja0303790; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Roitel O, 2003, BIOCHEMISTRY-US, V42, P10809, DOI 10.1021/bi034562h; Rowland P, 1997, STRUCTURE, V5, P239, DOI 10.1016/S0969-2126(97)00182-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11548, DOI 10.1021/bi00094a011; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; Wolthers KR, 2004, BIOCHEMISTRY-US, V43, P490, DOI 10.1021/bi0356303; Wolthers KR, 2003, BIOCHEMISTRY-US, V42, P3911, DOI 10.1021/bi027290b	43	48	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17634	17644		10.1074/jbc.M413826200	http://dx.doi.org/10.1074/jbc.M413826200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15710617	hybrid			2022-12-25	WOS:000228807200010
J	Morimura, T; Hattori, M; Ogawa, M; Mikoshiba, K				Morimura, T; Hattori, M; Ogawa, M; Mikoshiba, K			Disabled1 regulates the intracellular trafficking of Reelin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTORS; BRAIN-DEVELOPMENT; NEURONAL MIGRATION; STIMULATED NEURONS; MOUSE DISABLED-1; PLASMA-MEMBRANE; PROTEIN; ADAPTER; FAMILY; PHOSPHORYLATION	Reelin is a huge secreted protein that controls proper laminar formation in the developing brain. It is generally believed that tyrosine phosphorylation of Disabled1 (Dab1) by Src family tyrosine kinases is the most critical downstream event in Reelin signaling. The receptors for Reelin belong to the low density lipoprotein receptor family, most of whose members undergo regulated intracellular trafficking. In this study, we propose novel roles for Dab1 in Reelin signaling. We first demonstrated that cell surface expression of Reelin receptors was decreased in Dab1-deficient neurons. In heterologous cells, Dab1 enhanced cell surface expression of Reelin receptors, and this effect was mediated by direct interaction with the receptors. Moreover, Dab1 did not stably associate with the receptors at the plasma membrane in the resting state. When Reelin was added to primary cortical neurons, Dab1 was recruited to the receptors, and its tyrosine residues were phosphorylated. Although Reelin and Dab1 colocalized well shortly after the addition of Reelin, Dab1 was no longer associated with internalized Reelin. When Src family tyrosine kinases were inhibited, internalization of Reelin was severely abrogated, and Reelin colocalized with Dab1 near the plasma membrane for a prolonged period. Taken together, these results indicate that Dab1 regulates both cell surface expression and internalization of Reelin receptors, and these regulations may play a role in correct laminar formation in the developing brain.	RIKEN, Lab Cell Culture Dev, BSI, Wako, Saitama 3510198, Japan; Univ Tokyo, Div Mol Neurobiol, Dept Basic Med Sci, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, Saitama, Japan; Japan Sci & Technol Agcy, Calcium Oscillat Project, ICORP, Chiyoda Ku, Tokyo 1020084, Japan	RIKEN; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Morimura, T (corresponding author), RIKEN, Lab Cell Culture Dev, BSI, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	morimura@brain.riken.jp	Hattori, Mitsuharu/F-3859-2010; Mikoshiba, Katsuhiko/N-7943-2015	Hattori, Mitsuharu/0000-0002-0503-4969; 				Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0; Arnaud L, 2003, MOL CELL BIOL, V23, P9293, DOI 10.1128/MCB.23.24.9293-9302.2003; Ballif BA, 2004, CURR BIOL, V14, P606, DOI 10.1016/j.cub.2004.03.038; Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200; Beglova N, 2004, MOL CELL, V16, P281, DOI 10.1016/j.molcel.2004.09.038; Bock HH, 2003, J BIOL CHEM, V278, P38772, DOI 10.1074/jbc.M306416200; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; de Melker AA, 2001, J CELL SCI, V114, P2167; deBergeyck V, 1997, MOL BRAIN RES, V50, P85, DOI 10.1016/S0169-328X(97)00166-6; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Gleeson JG, 2000, TRENDS NEUROSCI, V23, P352, DOI 10.1016/S0166-2236(00)01607-6; Gonzallez-Gaitan M, 2003, NAT REV MOL CELL BIO, V4, P213, DOI 10.1038/nrm1053; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; Hoppe HC, 2000, CELL MICROBIOL, V2, P569, DOI 10.1046/j.1462-5822.2000.00081.x; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Huang YC, 2004, BIOCHEM BIOPH RES CO, V318, P204, DOI 10.1016/j.bbrc.2004.04.023; Kamikura DM, 2003, GENE DEV, V17, P2798, DOI 10.1101/gad.1136103; Keshvara L, 2001, J BIOL CHEM, V276, P16008, DOI 10.1074/jbc.M101422200; Magrane J, 1999, FEBS LETT, V451, P56, DOI 10.1016/S0014-5793(99)00494-9; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; May P, 2003, J BIOL CHEM, V278, P37386, DOI 10.1074/jbc.M305858200; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Pramatarova A, 2003, MOL CELL BIOL, V23, P7210, DOI 10.1128/MCB.23.20.7210-7221.2003; Riddell DR, 2001, J LIPID RES, V42, P998; Sato M, 2003, NAT CELL BIOL, V5, P1016, DOI 10.1038/ncb1054; Shah BH, 2002, MOL ENDOCRINOL, V16, P610, DOI 10.1210/me.16.3.610; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Suetsugu S, 2004, BIOCHEM J, V384, P1, DOI 10.1042/BJ20041103; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tissir F, 2003, NAT REV NEUROSCI, V4, P496, DOI 10.1038/nrn1113; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Yoneshima H, 1997, NEUROSCI RES, V29, P217, DOI 10.1016/S0168-0102(97)00088-6; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200	43	65	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16901	16908		10.1074/jbc.M409048200	http://dx.doi.org/10.1074/jbc.M409048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15718228	hybrid			2022-12-25	WOS:000228615500044
J	Adegbola, O; Pasternack, GR				Adegbola, O; Pasternack, GR			Phosphorylated retinoblastoma protein complexes with pp32 and inhibits pp32-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; CELL-CYCLE; NUCLEAR PHOSPHOPROTEIN; G(1) CONTROL; RB; GENE; IDENTIFICATION; ACTIVATION; ARREST; DEATH	The retinoblastoma gene product (Rb) is a tumor suppressor that affects apoptosis paradoxically. Most sporadic cancers inactivate Rb by preferentially targeting the pathway that regulates Rb phosphorylation, resulting in resistance to apoptosis; this contrasts with Rb inactivation by mutation, which is associated with high rates of apoptosis. How phosphorylated Rb protects cells from apoptosis is not well understood, but there is evidence that Rb may sequester a pro-apoptotic nuclear factor. pp32 (ANP32A) is a pro-apoptotic nuclear phosphoprotein, the expression of which is commonly increased in cancer. We report that hyperphosphorylated Rb interacts with pp32 but not with the closely related proteins pp32r1 and pp32r2. We further demonstrate that pp32-Rb interaction inhibits the apoptotic activity of pp32 and stimulates proliferation. These results suggest a mechanism whereby cancer cells gain both a proliferative and survival advantage when Rb is inactivated by hyperphosphorylation.	Johns Hopkins Univ, Sch Med, Dept Pathol, Div Mol Pathol, Baltimore, MD 21205 USA	Johns Hopkins University	Pasternack, GR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, 417 N Caroline St,Rm B300, Baltimore, MD 21231 USA.	gpastern@jhmi.edu		Adegbola, Onikepe/0000-0002-7339-3015	NATIONAL CANCER INSTITUTE [T32CA067751] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA67751] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Bai JN, 2001, ONCOGENE, V20, P2153, DOI 10.1038/sj.onc.1204294; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Berry DE, 1996, ONCOGENE, V12, P1809; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brody JR, 1999, J BIOL CHEM, V274, P20053, DOI 10.1074/jbc.274.29.20053; Brody JR, 2004, AM J PATHOL, V164, P273, DOI 10.1016/S0002-9440(10)63117-3; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; JOSEPH LF, 1995, CELL GROWTH DIFFER, V6, P51; Kadkol SS, 1999, NAT MED, V5, P275, DOI 10.1038/6488; Kadkol SS, 1998, PROSTATE, V34, P231, DOI 10.1002/(SICI)1097-0045(19980215)34:3<231::AID-PROS11>3.0.CO;2-F; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MALEK SN, 1990, J BIOL CHEM, V265, P13400; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; OHSUMI T, 1993, BIOCHEM J, V294, P465, DOI 10.1042/bj2940465; Rassidakis GZ, 2004, AM J PATHOL, V164, P2259, DOI 10.1016/S0002-9440(10)63782-0; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shackney SE, 1999, CYTOMETRY, V35, P97, DOI 10.1002/(SICI)1097-0320(19990201)35:2<97::AID-CYTO1>3.3.CO;2-X; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; WALENSKY LD, 1993, CANCER RES, V53, P4720; Wallace M, 2001, ONCOGENE, V20, P3597, DOI 10.1038/sj.onc.1204496; Wang H, 1996, ONCOGENE, V13, P373; Wang J, 1997, CANCER RES, V57, P351; Wang RH, 2001, ONCOGENE, V20, P6111, DOI 10.1038/sj.onc.1204829	44	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15497	15502		10.1074/jbc.M411382200	http://dx.doi.org/10.1074/jbc.M411382200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15716273	hybrid			2022-12-25	WOS:000228444800006
J	He, ZH; Way, KJ; Arikawa, E; Chou, E; Opland, DM; Clermont, A; Isshiki, K; Ma, RCW; Scott, JA; Schoen, FJ; Feener, EP; King, GL				He, ZH; Way, KJ; Arikawa, E; Chou, E; Opland, DM; Clermont, A; Isshiki, K; Ma, RCW; Scott, JA; Schoen, FJ; Feener, EP; King, GL			Differential regulation of angiotensin II-induced expression of connective tissue growth factor by protein kinase C isoforms in the myocardium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE-EXPRESSION; HIGH GLUCOSE; DELTA-PKC; ACTIVATION; HEART; PHOSPHORYLATION; RECEPTOR; INSULIN; OVEREXPRESSION; CARDIOMYOPATHY	Protein kinase C ( PKC) and angiotensin II ( AngII) can regulate cardiac function in pathological conditions such as in diabetes or ischemic heart disease. We have reported that expression of connective tissue growth factor ( CTGF) is increased in the myocardium of diabetic mice. Now we showed that the increase in CTGF expression in cardiac tissues of streptozotocin- induced diabetic rats was reversed by captopril and islet cell transplantation. Infusion of AngII in rats increased CTGF mRNA expression by 15- fold, which was completely inhibited by co- infusion with AT1 receptor antagonist, candesartan. Similarly, incubation of cultured cardiomyocytes with AngII increased CTGF mRNA expression by 2- fold, which was blocked by candesartan and a general PKC inhibitor, GF109203X. The role of PKC isoform- dependent action was further studied using adenoviral vector- mediated gene transfer of dominant negative ( dn) PKC or wild type PKC isoforms. Expression of dnPKC alpha, -epsilon, and - zeta isoforms suppressed AngII- induced CTGF expression in cardiomyocytes. In contrast, expression of dominant negative PKC delta significantly increased AngII- induced CTGF expression, whereas expression of wild type PKC delta inhibited this induction. This inhibitory effect was further confirmed in the myocardium of transgenic mice with cardiomyocyte-specific overexpression of PKC delta ( delta Tg mice). Thus, AngII can regulate CTGF expression in cardiomyocytes through a PKC activation- mediated pathway in an isoform-selective manner both in physiological and diabetic states and may contribute to the development of cardiac fibrosis in diabetic cardiomyopathy.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital	King, GL (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	george.king@joslin.harvard.edu	Ma, Ronald/C-2788-2009	Ma, Ronald/0000-0002-1227-803X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060165, P30DK036836, R01DK059725] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59725, DK36836, DK60165] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Ahmed MS, 2004, J MOL CELL CARDIOL, V36, P393, DOI 10.1016/j.yjmcc.2003.12.004; Allen JT, 1999, AM J RESP CELL MOL, V21, P693, DOI 10.1165/ajrcmb.21.6.3719; BELL DSH, 1995, DIABETES CARE, V18, P708, DOI 10.2337/diacare.18.5.708; Berry C, 2001, AM J PHYSIOL-HEART C, V281, pH2337, DOI 10.1152/ajpheart.2001.281.6.H2337; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Burnier M, 2000, LANCET, V355, P637, DOI 10.1016/S0140-6736(99)10365-9; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Chou E, 2002, CIRCULATION, V105, P373, DOI 10.1161/hc0302.102143; Fan WH, 2000, BIOCHEM BIOPH RES CO, V275, P312, DOI 10.1006/bbrc.2000.3314; Feener EP, 2001, CONTEMP CARDIOL, P103; Finckenberg P, 2003, AM J PATHOL, V163, P355, DOI 10.1016/S0002-9440(10)63659-0; Hahn HS, 2002, CIRC RES, V91, P741, DOI 10.1161/01.RES.0000037091.64492.69; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Inagaki K, 2003, CIRCULATION, V108, P2304, DOI 10.1161/01.CIR.0000101682.24138.36; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; Iwanciw D, 2003, ARTERIOSCL THROM VAS, V23, P1782, DOI 10.1161/01.ATV.0000092913.60428.E6; Kaneto H, 2002, J BIOL CHEM, V277, P3680, DOI 10.1074/jbc.M109647200; Leitges M, 2001, J CLIN INVEST, V108, P1505; Makino Hisashi, 2003, Clin Exp Nephrol, V7, P33, DOI 10.1007/s101570300004; Malhotra A, 2001, DIABETES, V50, P1918, DOI 10.2337/diabetes.50.8.1918; McLennan SV, 2004, ENDOCRINOLOGY, V145, P5646, DOI 10.1210/en.2004-0436; Murriel CL, 2004, J BIOL CHEM, V279, P47985, DOI 10.1074/jbc.M405071200; Napoli R, 1996, J CLIN INVEST, V97, P1389, DOI 10.1172/JCI118559; OLIVER FJ, 1991, J BIOL CHEM, V266, P23251; Pratt RE, 1999, J AM SOC NEPHROL, V10, pS120; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; Ruperez M, 2003, CIRCULATION, V108, P1499, DOI 10.1161/01.CIR.0000089129.51288.BA; Segarini PR, 2001, J BIOL CHEM, V276, P40659, DOI 10.1074/jbc.M105180200; Shimoni Y, 2003, AM J PHYSIOL-HEART C, V284, pH1168, DOI 10.1152/ajpheart.00748.2002; Simonis G, 2003, J MOL CELL CARDIOL, V35, P1349, DOI 10.1016/S0022-2828(03)00250-5; SPIRO MJ, 1993, DIABETOLOGIA, V36, P93, DOI 10.1007/BF00400687; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; Suzuma K, 2000, J BIOL CHEM, V275, P40725, DOI 10.1074/jbc.M006509200; Tikellis C, 2004, ENDOCRINOLOGY, V145, P860, DOI 10.1210/en.2003-0967; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Wang SN, 2001, KIDNEY INT, V60, P96, DOI 10.1046/j.1523-1755.2001.00776.x; Way KJ, 2001, DIABETIC MED, V18, P945, DOI 10.1046/j.0742-3071.2001.00638.x; Way KJ, 2002, DIABETES, V51, P2709, DOI 10.2337/diabetes.51.9.2709; Yang M, 2004, FASEB J, V18, P1920, DOI 10.1096/fj.04-2357fje; Zuanetti G, 1997, CIRCULATION, V96, P4239	42	82	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15719	15726		10.1074/jbc.M413493200	http://dx.doi.org/10.1074/jbc.M413493200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15699040	hybrid			2022-12-25	WOS:000228444800033
J	Kim, MS; Day, CJ; Morrison, NA				Kim, MS; Day, CJ; Morrison, NA			MCP-1 is induced by receptor activator of nuclear factor-kappa B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; DIFFERENTIATION; TRANSCRIPTION; EXPRESSION; FAMILY; GENES; NFAT2; MICE	Human osteoclast formation from monocyte precursors under the action of receptor activator of nuclear factor-kappa B ligand ( RANKL) was suppressed by granulocyte macrophage colony-stimulating factor (GM-CSF), with down-regulation of critical osteoclast-related nuclear factors. GM-CSF in the presence of RANKL and macrophage colony-stimulating factor resulted in mononuclear cells that were negative for tartrate-resistant acid phosphatase ( TRAP) and negative for bone resorption. CD1a, a dendritic cell marker, was expressed in GM-CSF, RANKL, and macrophage colony-stimulating factor-treated cells and absent in osteoclasts. Microarray showed that the CC chemokine, monocyte chemotactic protein 1 (MCP-1), was profoundly repressed by GMCSF. Addition of MCP-1 reversed GM-CSF suppression of osteoclast formation, recovering the bone resorption phenotype. MCP-1 and chemokine RANTES ( regulated on activation normal T cell expressed and secreted) permitted formation of TRAP-positive multinuclear cells in the absence of RANKL. However, these cells were negative for bone resorption. In the presence of RANKL, MCP-1 significantly increased the number of TRAP-positive multinuclear bone-resorbing osteoclasts ( p = 0.008). When RANKL signaling through NFATc1 was blocked with cyclosporin A, both MCP-1 and RANTES expression was down-regulated. Furthermore, addition of MCP-1 and RANTES reversed the effects of cyclosporin A and recovered the TRAP-positive multinuclear cell phenotype. Our model suggests that RANKL-induced chemokines are involved in osteoclast differentiation at the stage of multinucleation of osteoclast precursors and provides a rationale for increased osteoclast activity in inflammatory conditions where chemokines are abundant.	Griffith Univ, Sch Med Sci, Gold Coast, Qld 4215, Australia	Griffith University	Morrison, NA (corresponding author), Griffith Univ, Sch Med Sci, Gold Coast Campus,PMB50, GCMC, Qld 9726, Australia.	N.Morrison@griffith.edu.au	Morrison, Nigel A/F-4082-2012	Morrison, Nigel A/0000-0003-4774-3808; Day, Christopher/0000-0001-7953-4408				Cakouros D, 2001, J IMMUNOL, V167, P302, DOI 10.4049/jimmunol.167.1.302; Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200; Day CJ, 2004, J CELL BIOCHEM, V91, P303, DOI 10.1002/jcb.10780; Fujikawa Y, 2001, BONE, V28, P261, DOI 10.1016/S8756-3282(00)00453-1; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Granfar RMS, 2005, MOL CELL PROBE, V19, P119, DOI 10.1016/j.mcp.2004.10.003; Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200; Hodge JM, 2004, J BONE MINER RES, V19, P190, DOI 10.1359/JBMR.0301232; Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359-6101(01)00014-4; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; KASINRERK W, 1993, J IMMUNOL, V150, P579; Miyamoto T, 2001, BLOOD, V98, P2544, DOI 10.1182/blood.V98.8.2544; Myint YY, 1999, AM J PATHOL, V154, P553, DOI 10.1016/S0002-9440(10)65301-1; Sakiyama H, 2001, J BONE MINER METAB, V19, P220, DOI 10.1007/s007740170024; Sambrook J., 2002, MOL CLONING LAB MANU; SHUTO T, 1994, ENDOCRINOLOGY, V134, P831, DOI 10.1210/en.134.2.831; Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Wise GE, 2002, CRIT REV ORAL BIOL M, V13, P323, DOI 10.1177/154411130201300403; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	21	202	211	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16163	16169		10.1074/jbc.M412713200	http://dx.doi.org/10.1074/jbc.M412713200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722361	hybrid			2022-12-25	WOS:000228444800085
J	Kuznetsov, VY; Blair, E; Farmer, PJ; Poulos, TL; Pifferitti, A; Sevrioukova, IF				Kuznetsov, VY; Blair, E; Farmer, PJ; Poulos, TL; Pifferitti, A; Sevrioukova, IF			The putidaredoxin reductase-putidaredoxin electron transfer complex - Theoretical and experimental studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P450CAM MONOOXYGENASE SYSTEM; CRYSTAL-STRUCTURE; OXIDIZED PUTIDAREDOXIN; PSEUDOMONAS-PUTIDA; REDOX PARTNERS; ADRENODOXIN REDUCTASE; GLUTATHIONE-REDUCTASE; MOLECULAR RECOGNITION; CYTOCHROME P450CAM; CARBOXYLATE GROUPS	Interaction and electron transfer between putidaredoxin reductase (Pdr) and putidaredoxin (Pdx) from Pseudomonas putida was studied by molecular modeling, mutagenesis, and stopped flow techniques. Based on the crystal structures of Pdr and Pdx, a complex between the proteins was generated using computer graphics methods. In the model, Pdx is docked above the isoalloxazine ring of FAD of Pdr with the distance between the flavin and [2Fe-2S] of 14.6 angstrom. This mode of interaction allows Pdx to easily adjust and optimize orientation of its cofactor relative to Pdr. The key residues of Pdx located at the center, Asp(38) and Trp(106), and at the edge of the protein-protein interface, Tyr(33) and Arg(66), were mutated to test the Pdr-Pdx computer model. The Y33F, Y33A, D38N, D38A, R66A, R66E, W106F, W106A, and Delta 106 mutations did not affect assembly of the [2Fe-2S] cluster and resulted in a marginal change in the redox potential of Pdx. The electron-accepting ability of Delta 106 Pdx was similar to that of the wild-type protein, whereas electron transfer rates from Pdr to other mutants were diminished to various degrees with the smallest and largest effects on the kinetic parameters of the Pdr-to-Pdx electron transfer reaction caused by the Trp(106) and Tyr(33)/Arg(66) substitutions, respectively. Compared with wild-type Pdx, the binding affinity of all studied mutants to Pdr was significantly higher. Experimental results were in agreement with theoretical predictions and suggest that: (i) Pdr-Pdx complex formation is mainly driven by steric complementarity, (ii) bulky side chains of Tyr(33), Arg(66), and Trp(106) prevent tight binding of oxidized Pdx and facilitate dissociation of the reduced iron-sulfur protein from Pdr, and (iii) transfer of an electron from FAD to [2Fe-2S] can occur with various orientations between the cofactors through multiple electron transfer pathways that do not involve Trp(106) but are likely to include Asp(38) and Cys(39).	Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92612 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92612 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92612 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92612 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Sevrioukova, IF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3205 McGaugh Hall, Irvine, CA 92697 USA.	sevrioui@uci.edu	Farmer, Patrick J/J-3757-2019	Farmer, Patrick J/0000-0001-9911-999X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033688, R01GM067637] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM67637, GM33688] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki M, 1998, BBA-PROTEIN STRUCT M, V1386, P168, DOI 10.1016/S0167-4838(98)00091-0; Aoki M, 1998, BBA-PROTEIN STRUCT M, V1386, P157, DOI 10.1016/S0167-4838(98)00094-6; Aoki M, 1998, BBA-PROTEIN STRUCT M, V1384, P180, DOI 10.1016/S0167-4838(98)00017-X; Avila L, 1999, J BIOL INORG CHEM, V4, P664, DOI 10.1007/s007750050390; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMBILLAU C, 1988, PROTEINS, V4, P63, DOI 10.1002/prot.340040109; DAVIES MD, 1990, J AM CHEM SOC, V112, P7396, DOI 10.1021/ja00176a050; DUGAD LB, 1990, BIOCHEMISTRY-US, V29, P2263, DOI 10.1021/bi00461a009; GEREN L, 1986, J BIOL CHEM, V261, P5491; GEREN LM, 1984, J BIOL CHEM, V259, P2155; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HINTZ MJ, 1982, J BIOL CHEM, V257, P4324; Holden M, 1997, J BIOL CHEM, V272, P21720, DOI 10.1074/jbc.272.35.21720; Ivanov YD, 2001, ARCH BIOCHEM BIOPHYS, V391, P255, DOI 10.1006/abbi.2001.2405; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jung YS, 1999, J BIOL CHEM, V274, P32402, DOI 10.1074/jbc.274.45.32402; KADKHODAYAN S, 1995, J BIOL CHEM, V270, P28042; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurnikov IV., 2000, HARLEM MOL MODELING; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mo HP, 1999, BIOCHEMISTRY-US, V38, P5666, DOI 10.1021/bi983063r; Morales R, 2000, EMBO REP, V1, P271, DOI 10.1093/embo-reports/kvd057; Muller JJ, 2001, J BIOL CHEM, V276, P2786, DOI 10.1074/jbc.M008501200; MURPHY MM, 1991, ANAL CHEM, V63, P2743, DOI 10.1021/ac00023a015; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Pochapsky TC, 1996, BIOCHIMIE, V78, P723, DOI 10.1016/S0300-9084(97)82530-8; POCHAPSKY TC, 1994, BIOCHEMISTRY-US, V33, P6424, DOI 10.1021/bi00187a006; Pochapsky TC, 1999, BIOCHEMISTRY-US, V38, P4681, DOI 10.1021/bi983030b; POULOS TL, 1985, J BIOL CHEM, V260, P6122; Purdy MM, 2004, BIOCHEMISTRY-US, V43, P271, DOI 10.1021/bi0356045; ROOME PW, 1983, J BIOL CHEM, V258, P2593; ROOME PW, 1988, ARCH BIOCHEM BIOPHYS, V266, P41, DOI 10.1016/0003-9861(88)90234-2; Senda T, 2000, J MOL BIOL, V304, P397, DOI 10.1006/jmbi.2000.4200; Sevrioukova IF, 2004, J MOL BIOL, V336, P889, DOI 10.1016/j.jmb.2003.12.067; Sevrioukova IF, 2003, J MOL BIOL, V333, P377, DOI 10.1016/j.jmb.2003.08.028; Sevrioukova IF, 2002, J BIOL CHEM, V277, P25831, DOI 10.1074/jbc.M201110200; Sevrioukova IF, 2001, BIOCHEMISTRY-US, V40, P10592, DOI 10.1021/bi010874d; Sibbesen O, 1996, J BIOL CHEM, V271, P22462, DOI 10.1074/jbc.271.37.22462; SLIGAR SG, 1974, P NATL ACAD SCI USA, V71, P3906, DOI 10.1073/pnas.71.10.3906; STAYTON PS, 1991, BIOCHEMISTRY-US, V30, P1845, DOI 10.1021/bi00221a017; Teixeira VH, 2004, BIOPHYS J, V86, P2773, DOI 10.1016/S0006-3495(04)74331-3; VAKSER IA, 1994, PROTEINS, V20, P320, DOI 10.1002/prot.340200405; Xia ZX, 2003, J BIOL INORG CHEM, V8, P843, DOI 10.1007/s00775-003-0485-0	50	40	43	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16135	16142		10.1074/jbc.M500771200	http://dx.doi.org/10.1074/jbc.M500771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15716266	hybrid			2022-12-25	WOS:000228444800081
J	Rouached, H; Berthomieu, P; El Kassis, E; Cathala, N; Catherinot, V; Labesse, G; Davidian, JC; Fourcroy, P				Rouached, H; Berthomieu, P; El Kassis, E; Cathala, N; Catherinot, V; Labesse, G; Davidian, JC; Fourcroy, P			Structural and functional analysis of the C-terminal STAS (sulfate transporter and anti-sigma antagonist) domain of the Arabidopsis thaliana sulfate transporter SULTR1.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SIGMA(F); REGULATORY DOMAIN; GENE; MUTATIONS; SPOIIAA; PROTEIN; PHOSPHORYLATION; YEAST; EXPRESSION; ENCODES	The C-terminal region of sulfate transporters from plants and animals belonging to the SLC26 family members shares a weak but significant similarity with the Bacillus sp. anti-anti-sigma protein SpoIIAA, thus defining the STAS domain ( sulfate transporter and anti-sigma antagonist). The present study is a structure/function analysis of the STAS domain of SULTR1.2, an Arabidopsis thaliana sulfate transporter. A three-dimensional model of the SULTR1.2 STAS domain was built which indicated that it shares the SpoIIAA folds. Moreover, the phosphorylation site, which is necessary for SpoIIAA activity, is conserved in the SULTR1.2 STAS domain. The model was used to direct mutagenesis studies using a yeast mutant defective for sulfate transport. Truncation of the whole SULTR1.2 STAS domain resulted in the loss of sulfate transport function. Analyses of small deletions and mutations showed that the C-terminal tail of the SULTR1.2 STAS domain and particularly two cysteine residues plays an important role in sulfate transport by SULTR1.2. All the substitutions made at the putative phosphorylation site Thr-587 led to a complete loss of the sulfate transport function of SULTR1.2. The reduction or suppression of sulfate transport of the SULTR1.2 mutants in yeast was not due to an incorrect targeting to the plasma membrane. Both our three-dimensional modeling and mutational analyses strengthen the hypothesis that the SULTR1.2 STAS domain is involved in protein-protein interactions that could control sulfate transport.	Univ Montpellier 2, INRA, Ecole Natl Super Agron Montpellier, CNRS,UMR 5004, F-34060 Montpellier, France; Univ Montpellier I, CNRS,UMR 5048, INSERM,U554, Ctr Biochim Struct, F-34060 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; Institut Agro; Montpellier SupAgro; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Fourcroy, P (corresponding author), Univ Montpellier 2, INRA, Ecole Natl Super Agron Montpellier, CNRS,UMR 5004, F-34060 Montpellier, France.	fourcroy@ensam.inra.fr	Kassis, Elie Girgis El/AAP-6511-2020	El Kassis, Elie Girgis/0000-0002-8397-9482; Berthomieu, Pierre/0000-0003-3358-2417; Labesse, Gilles/0000-0002-6861-3300; Rouached, Hatem/0000-0002-7751-0477				Aravind L, 2000, CURR BIOL, V10, pR53, DOI 10.1016/S0960-9822(00)00335-3; Bignell DRD, 2003, FEMS MICROBIOL LETT, V225, P93, DOI 10.1016/S0378-1097(03)00504-4; Cherest H, 1997, GENETICS, V145, P627; Chernova MN, 2003, J PHYSIOL-LONDON, V549, P3, DOI 10.1113/jphysiol.2003.039818; Clarkson J, 2003, BIOCHEM J, V372, P113, DOI 10.1042/BJ20021748; Clarkson J, 2001, J MOL BIOL, V314, P359, DOI 10.1006/jmbi.2001.5142; DIEDERICH B, 1994, GENE DEV, V8, P2653, DOI 10.1101/gad.8.21.2653; Douguet D, 2001, BIOINFORMATICS, V17, P752, DOI 10.1093/bioinformatics/17.8.752; Duncan L, 1996, J MOL BIOL, V260, P147, DOI 10.1006/jmbi.1996.0389; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Fizames C, 2004, PLANT PHYSIOL, V134, P67, DOI 10.1104/pp.103.030536; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; Hastbacka J, 1996, AM J HUM GENET, V58, P255; HAWKESFORD MJ, 1993, PLANTA, V190, P297, DOI 10.1007/BF00196957; Hedfalk K, 2004, J BIOL CHEM, V279, P14954, DOI 10.1074/jbc.M313126200; Johansson I, 1998, PLANT CELL, V10, P451, DOI 10.1105/tpc.10.3.451; Karniski LP, 2001, HUM MOL GENET, V10, P1485, DOI 10.1093/hmg/10.14.1485; Kitamura K, 2000, ACTA OTO-LARYNGOL, V120, P137, DOI 10.1080/000164800750000775; Ko SBH, 2004, NAT CELL BIOL, V6, P343, DOI 10.1038/ncb1115; Kovacs H, 1998, P NATL ACAD SCI USA, V95, P5067, DOI 10.1073/pnas.95.9.5067; Kroos L, 1999, MOL MICROBIOL, V31, P1285, DOI 10.1046/j.1365-2958.1999.01214.x; Liu KH, 2003, EMBO J, V22, P1005, DOI 10.1093/emboj/cdg118; Lopez-Bigas N, 2001, Hum Mutat, V18, P548, DOI 10.1002/humu.1238; Lord M, 1996, J BACTERIOL, V178, P6730, DOI 10.1128/jb.178.23.6730-6735.1996; Markovich D, 2001, PHYSIOL REV, V81, P1499, DOI 10.1152/physrev.2001.81.4.1499; Maruyama-Nakashita A, 2003, PLANT PHYSIOL, V132, P597, DOI 10.1104/pp.102.019802; Maudoux O, 2000, J BIOL CHEM, V275, P17762, DOI 10.1074/jbc.M909690199; Morsomme P, 1998, J BIOL CHEM, V273, P34837, DOI 10.1074/jbc.273.52.34837; Mount DB, 2004, PFLUG ARCH EUR J PHY, V447, P710, DOI 10.1007/s00424-003-1090-3; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Seavers PR, 2001, STRUCTURE, V9, P605, DOI 10.1016/S0969-2126(01)00623-2; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Shelden MC, 2001, BIOCHEM J, V356, P589, DOI 10.1042/0264-6021:3560589; Shibagaki N, 2004, J BIOL CHEM, V279, P30791, DOI 10.1074/jbc.M403248200; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1529, P203, DOI 10.1016/S1388-1981(00)00149-9; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SMITH FW, 1995, MOL GEN GENET, V247, P709, DOI 10.1007/BF00290402; Smith FW, 1997, PLANT J, V12, P875, DOI 10.1046/j.1365-313X.1997.12040875.x; SMITH FW, 1995, P NATL ACAD SCI USA, V92, P9373, DOI 10.1073/pnas.92.20.9373; SupertiFurga A, 1996, NAT GENET, V12, P100, DOI 10.1038/ng0196-100; Tamas MJ, 2003, J BIOL CHEM, V278, P6337, DOI 10.1074/jbc.M209792200; Vidmar JJ, 2000, FEBS LETT, V475, P65, DOI 10.1016/S0014-5793(00)01615-X; WANG YH, 1992, J BIOL CHEM, V267, P16759; Xie QH, 2002, AM J PHYSIOL-RENAL, V283, pF826, DOI 10.1152/ajprenal.00079.2002; Yoshimoto N, 2003, PLANT PHYSIOL, V131, P1511, DOI 10.1104/pp.014712	46	90	94	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15976	15983		10.1074/jbc.M501635200	http://dx.doi.org/10.1074/jbc.M501635200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15718229	hybrid, Green Published			2022-12-25	WOS:000228444800064
J	Shin, SW; Kokoza, V; Bian, GW; Cheon, HM; Kim, YJ; Raikhel, AS				Shin, SW; Kokoza, V; Bian, GW; Cheon, HM; Kim, YJ; Raikhel, AS			REL1, a homologue of Drosophila dorsal, regulates Toll antifungal immune pathway in the female mosquito Aedes aegypti	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDE GENES; ANOPHELES-GAMBIAE; HOST-DEFENSE; DIF; EXPRESSION; INDUCTION; RELISH; INFECTION; PROTEINS; SEQUENCE	Signaling by Drosophila Toll pathway activates two Rel/NF-kappa B transcription factors, Dorsal (Dl) and Dorsal-related immune factor (Dif). Dl plays a central role in the establishment of dorsoventral polarity during early embryogenesis, whereas Dif mediates the Toll receptor-dependent antifungal immune response in adult Drosophila. The absence of a Dif ortholog in mosquito genomes suggests that Dl may play its functional role in the mosquito Toll-mediated innate immune responses. We have cloned and molecularly characterized the gene homologous to Drosophila Dl and to Anopheles gambiae REL1 (Gambif1) from the yellow fever mosquito Aedes aegypti, named AaREL1. AaREL1 alternative transcripts encode two isoforms, AaREL1-A and AaREL1-B. Both transcripts are enriched during embryogenesis and are inducible by septic injury in larval and female mosquitoes. AaREL1 and AaREL2 ( Aedes Relish) selectively bind to different kappa B motifs from insect immune gene promoters. Ectopic expression of AaREL1-A in both Drosophila mbn-2 cells and transgenic flies specifically activates Drosomycin and results in increased resistance against the fungus Beauveria bassiana. AaREL1-B acted cooperatively with AaREL1-A to enhance the immune gene activation in Aag-2 cells. The RNA interference knock-outs revealed that AaREL1 affected the expression of Aedes homologue of Drosophila Serpin-27A and mediated specific antifungal immune response against B. bassiana. These results indicate that the homologue of Dl, but not that of Dif, is a key regulator of the Toll antifungal immune pathway in A. aegypti female mosquitoes.	Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA; Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Raikhel, AS (corresponding author), Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA.	alexander.raikhel@ucr.edu	Bian, Guowu/B-1572-2010	Shin, Sang Woon/0000-0001-9467-0803	NIAID NIH HHS [R01 AI059492] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beaty BJ, 2000, P NATL ACAD SCI USA, V97, P10295, DOI 10.1073/pnas.97.19.10295; Beier JC, 1998, ANNU REV ENTOMOL, V43, P519, DOI 10.1146/annurev.ento.43.1.519; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Brennan CA, 2004, ANNU REV IMMUNOL, V22, P457, DOI 10.1146/annurev.immunol.22.012703.104626; BRILLASMURY C, 1996, EMBO J, V15, P4691; CANTON Y, 2001, IMMUNOGENETICS, V52, P157; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; Curtis CF, 2000, PARASITOL TODAY, V16, P119, DOI 10.1016/S0169-4758(99)01605-1; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; Drier EA, 1997, SEMIN CANCER BIOL, V8, P83, DOI 10.1006/scbi.1997.0059; Enserink M, 2002, SCIENCE, V297, P1988, DOI 10.1126/science.297.5589.1988; Fallon AM, 2001, INSECT BIOCHEM MOLEC, V31, P263, DOI 10.1016/S0965-1748(00)00146-6; Gross I, 1999, GENE, V228, P233, DOI 10.1016/S0378-1119(98)00595-2; Han ZS, 1999, J BIOL CHEM, V274, P21355, DOI 10.1074/jbc.274.30.21355; Hedengren M, 1999, MOL CELL, V4, P827, DOI 10.1016/S1097-2765(00)80392-5; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; KAPPLER C, 1993, EMBO J, V12, P1561, DOI 10.1002/j.1460-2075.1993.tb05800.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Levashina EA, 1998, J MOL BIOL, V278, P515, DOI 10.1006/jmbi.1998.1705; Lindmark H, 2001, J IMMUNOL, V167, P6920, DOI 10.4049/jimmunol.167.12.6920; Lycett GJ, 2002, NATURE, V417, P387, DOI 10.1038/417387a; Manfruelli P, 1999, EMBO J, V18, P3380, DOI 10.1093/emboj/18.12.3380; Markstein M, 2002, P NATL ACAD SCI USA, V99, P763, DOI 10.1073/pnas.012591199; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; Nicolas E, 1998, J BIOL CHEM, V273, P10463, DOI 10.1074/jbc.273.17.10463; Osta MA, 2004, J EXP BIOL, V207, P2551, DOI 10.1242/jeb.01066; PAN D, 1992, EMBO J, V11, P1837, DOI 10.1002/j.1460-2075.1992.tb05235.x; Qiu P, 1998, DEVELOPMENT, V125, P1909; REICHHART JM, 1993, CR ACAD SCI III-VIE, V316, P1218; Rutschmann S, 2000, IMMUNITY, V12, P569, DOI 10.1016/S1074-7613(00)80208-3; SAMAKOVLIS C, 1992, BIOCHEM BIOPH RES CO, V188, P1169, DOI 10.1016/0006-291X(92)91354-S; Shin SW, 2002, P NATL ACAD SCI USA, V99, P9978, DOI 10.1073/pnas.162345999; Shin SW, 2003, P NATL ACAD SCI USA, V100, P2616, DOI 10.1073/pnas.0537347100; WATTAM AR, 1992, P NATL ACAD SCI USA, V89, P6502, DOI 10.1073/pnas.89.14.6502	41	92	94	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16499	16507		10.1074/jbc.M500711200	http://dx.doi.org/10.1074/jbc.M500711200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722339	hybrid			2022-12-25	WOS:000228444800124
J	Wei, Q; Miskimins, WK; Miskimins, R				Wei, Q; Miskimins, WK; Miskimins, R			Stage-specific expression of myelin basic protein in oligodendrocytes involves Nkx2.2-mediated repression that is relieved by the Sp1 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; PUR-ALPHA; BINDING-PROTEIN; PROTEOLIPID PROTEIN; GENE-TRANSCRIPTION; HOMEOBOX GENES; SONIC HEDGEHOG; NEURONAL FATE; RAT-BRAIN; NKX2.2	The homeodomain-containing protein Nkx2.2 is critical for the development of oligodendrocyte lineage cells, but the target genes of Nkx2.2 regulation have not been identified. In the present study, we found that the myelin basic protein gene is one of the genes that is regulated by Nkx2.2. Expression of Nkx2.2 represses the expression of myelin basic protein in oligodendrocyte progenitors. Two regulatory elements in the myelin basic protein promoter were identified and found to interact with Nkx2.2 in vitro. Despite their sequence divergence, both sites were involved in the Nkx2.2-mediated repression of the myelin basic protein promoter. Binding of Nkx2.2 also blocked and disrupted the binding of the transcriptional activator Pur alpha to the myelin basic protein promoter. Additionally Nkx2.2 recruited a histone deacetylase 1-mSin3A complex to the myelin basic protein promoter. We also found that the transcription factor Sp1 was able to compete off the binding of Nkx2.2 to its consensus binding site in vitro and reversed the repressive effect of Nkx2.2 in vivo. Our data revealed a novel role for Nkx2.2 in preventing the precocious expression of myelin basic protein in immature oligodendrocytes. Based on this study and our previous reports, a model for myelin basic protein gene control is proposed.	Univ S Dakota, Sch Med, Div Basic Biomed Sci, Vermillion, SD 57069 USA	University of South Dakota	Miskimins, R (corresponding author), Univ S Dakota, Sch Med, Div Basic Biomed Sci, 414 E Clark St, Vermillion, SD 57069 USA.	rmiskim@usd.edu	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016479] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AOYAMA A, 1990, BIOCHEM BIOPH RES CO, V167, P648, DOI 10.1016/0006-291X(90)92074-A; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Briscoe J, 2000, CELL, V101, P435, DOI 10.1016/S0092-8674(00)80853-3; Carlini LE, 2002, J BIOL CHEM, V277, P8682, DOI 10.1074/jbc.M109754200; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; Chepenik LG, 1998, GENE, V210, P37, DOI 10.1016/S0378-1119(98)00033-X; Cissell MA, 2003, J BIOL CHEM, V278, P751, DOI 10.1074/jbc.M205905200; Darbinian N, 2001, J CELL PHYSIOL, V189, P334, DOI 10.1002/jcp.10029; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; delosMonteros AE, 1997, J NEUROSCI RES, V50, P872; Dickinson PJ, 1996, NEUROPATH APPL NEURO, V22, P188; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; Fleischer TC, 2003, MOL CELL BIOL, V23, P3456, DOI 10.1128/MCB.23.10.3456-3467.2003; Fu H, 2001, DEV BRAIN RES, V129, P115, DOI 10.1016/S0165-3806(01)00178-X; Fu H, 2002, DEVELOPMENT, V129, P681; Gallia GL, 2001, J CELL BIOCHEM, V83, P355, DOI 10.1002/jcb.1247; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; Hartigan DJ, 1996, GENE, V168, P271, DOI 10.1016/0378-1119(95)00745-8; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Hessabi B, 2000, BIOCHEM BIOPH RES CO, V270, P695, DOI 10.1006/bbrc.2000.2491; Huang CJ, 2002, INT J DEV NEUROSCI, V20, P289, DOI 10.1016/S0736-5748(02)00022-9; JIMENEZ F, 1995, EMBO J, V14, P3487, DOI 10.1002/j.1460-2075.1995.tb07355.x; Kim DW, 2003, MOL CELL BIOL, V23, P8704, DOI 10.1128/MCB.23.23.8704-8717.2003; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; Kitamura K, 1997, MECH DEVELOP, V67, P83, DOI 10.1016/S0925-4773(97)00110-X; Kornberg Roger D., 1999, Trends in Cell Biology, V9, pM46, DOI 10.1016/S0962-8924(99)01679-7; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Le Lay J, 2004, J BIOL CHEM, V279, P22228, DOI 10.1074/jbc.M312673200; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; Lu YF, 2003, J BIOL CHEM, V278, P47792, DOI 10.1074/jbc.M305885200; Mallon BS, 2002, J NEUROSCI, V22, P876, DOI 10.1523/JNEUROSCI.22-03-00876.2002; Marin-Husstege M, 2002, J NEUROSCI, V22, P10333; Miskimins R, 2002, J NEUROSCI RES, V67, P100, DOI 10.1002/jnr.10080.abs; Miskimins R, 2001, INT J DEV NEUROSCI, V19, P85, DOI 10.1016/S0736-5748(00)00066-6; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Ohashi S, 2000, J NEUROCHEM, V75, P1781, DOI 10.1046/j.1471-4159.2000.0751781.x; Peng YW, 2002, BLOOD, V99, P2408, DOI 10.1182/blood.V99.7.2408; Peng YW, 2003, J BIOL CHEM, V278, P8385, DOI 10.1074/jbc.M213156200; Qi YC, 2001, DEVELOPMENT, V128, P2723; Sambrook J., 2001, MOL CLONING LAB MANU, V2, P81, DOI DOI 10.1093/nar/gku1003; SORG BA, 1987, J NEUROCHEM, V49, P1146, DOI 10.1111/j.1471-4159.1987.tb10005.x; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sun T, 2003, J NEUROSCI, V23, P9547; Sussel L, 1998, DEVELOPMENT, V125, P2213; TAMURA T, 1988, NUCLEIC ACIDS RES, V16, P11441, DOI 10.1093/nar/16.24.11441; Taveggia C, 1998, J BIOL CHEM, V273, P27741, DOI 10.1074/jbc.273.42.27741; Tretiakova A, 1999, J CELL PHYSIOL, V181, P160, DOI 10.1002/(SICI)1097-4652(199910)181:1<160::AID-JCP17>3.0.CO;2-H; Tretiakova A, 1998, J BIOL CHEM, V273, P22241, DOI 10.1074/jbc.273.35.22241; Wang JF, 2004, DEV BIOL, V266, P178, DOI 10.1016/j.ydbio.2003.10.018; Watada H, 2000, J BIOL CHEM, V275, P34224, DOI 10.1074/jbc.M004981200; Watada H, 2000, P NATL ACAD SCI USA, V97, P9443, DOI 10.1073/pnas.97.17.9443; Watanabe M, 2004, GLIA, V46, P311, DOI 10.1002/glia.20006; Wegner M, 2000, GLIA, V31, P1, DOI 10.1002/(SICI)1098-1136(200007)31:1<1::AID-GLIA10>3.0.CO;2-V; Wegner M, 2000, GLIA, V29, P118, DOI 10.1002/(SICI)1098-1136(20000115)29:2<118::AID-GLIA4>3.0.CO;2-Q; Wei Q, 2004, J NEUROSCI RES, V78, P796, DOI 10.1002/jnr.20342; Wei Q, 2003, GENE, V313, P161, DOI 10.1016/S0378-1119(03)00675-9; Wei Q, 2003, MOL CELL BIOL, V23, P4035, DOI 10.1128/MCB.23.12.4035-4045.2003; Wight PA, 1997, J NEUROSCI RES, V50, P917, DOI 10.1002/(SICI)1097-4547(19971215)50:6<917::AID-JNR2>3.0.CO;2-G; Wight PA, 1997, GENE, V201, P111, DOI 10.1016/S0378-1119(97)00435-6; Xu XH, 2000, MOL CELL NEUROSCI, V16, P740, DOI 10.1006/mcne.2000.0916; ZHANG XP, 1993, J NEUROCHEM, V60, P2010, DOI 10.1111/j.1471-4159.1993.tb03485.x; Zhou Q, 2001, NEURON, V31, P791, DOI 10.1016/S0896-6273(01)00414-7	68	56	60	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16284	16294		10.1074/jbc.M500491200	http://dx.doi.org/10.1074/jbc.M500491200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15695521	hybrid			2022-12-25	WOS:000228444800099
J	Zoccarato, F; Toscano, P; Alexandre, A				Zoccarato, F; Toscano, P; Alexandre, A			Dopamine-derived dopaminochrome promotes H2O2 release at mitochondrial complex I - Stimulation by rotenone, control by Ca2+, and relevance to Parkinson disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSPORT CHAIN; HUMAN SUBSTANTIA-NIGRA; HYDROGEN-PEROXIDE; ALPHA-SYNUCLEIN; NADPH OXIDASE; INDUCED DEGENERATION; BRAIN MITOCHONDRIA; SUPEROXIDE ANION; OXIDATIVE STRESS; MOUSE MODEL	Inhibitors of Complex I of the mitochondrial respiratory chain, such as rotenone, promote Parkinson disease-like symptoms and signs of oxidative stress. Dopamine (DA) oxidation products may be implicated in such a process. We show here that the o-quinone dopaminochrome (DACHR), a relatively stable DA oxidation product, promotes concentration (0.1 - 0.2 mu M)- and respiration-dependent generation of H2O2 at Complex I in brain mitochondria, with further stimulation by low concentrations of rotenone ( 5 - 30 nM). The rotenone effect required that contaminating Ca2+ ( 8 - 10 mu M) was not removed. DACHR apparently extracts an electron from the constitutively autoxidizable site in Complex I, producing a semiquinone, which then transfers an electron to O-2, generating O-2(radical anion) and then H2O2. Mitochondrial removal of H2O2, formed by either monoamine oxidase activity or DACHR, was performed largely by glutathione peroxidase and glutathione reductase, which were negatively regulated by low intramitochondrial Ca2+ levels. Thus, the H2O2 formed accumulated in the medium if contaminating Ca2+ was present; in the absence of Ca2+, H2O2 was completely removed if it originated from monoamine oxidase, but was less completely removed if it originated from DACHR. We propose that the primary action of rotenone is to promote extracellular O-2. release via activation of NADPH oxidase in the microglia. In turn, O-2. oxidizes DA to DACHR extracellularly. ( The reaction is favored by the lack of GSH, which would otherwise preferably produce GSH adducts of dopaminoquinone.) Once formed, DACHR ( which is resistant to GSH) enters neurons to activate the rotenone-stimulated redox cycle described.	Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy; Univ Padua, CNR, Ist Neurosci, Sez Biomembrane, I-35121 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Alexandre, A (corresponding author), Univ Padua, Dipartimento Chim Biol, Viale G Colombo 3, I-35121 Padua, Italy.	adolfo.alexandre@unipd.it						Benner EJ, 2004, P NATL ACAD SCI USA, V101, P9435, DOI 10.1073/pnas.0400569101; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BINDOLI A, 1990, BIOCHIM BIOPHYS ACTA, V1016, P349, DOI 10.1016/0005-2728(90)90168-4; BINDOLI A, 1992, FREE RADICAL BIO MED, V13, P391, DOI 10.1016/0891-5849(92)90182-G; CARSTAM R, 1991, BIOCHIM BIOPHYS ACTA, V1097, P152, DOI 10.1016/0925-4439(91)90100-N; CHIBA K, 1985, DRUG METAB DISPOS, V13, P342; Cooksey CJ, 1997, J BIOL CHEM, V272, P26226, DOI 10.1074/jbc.272.42.26226; Crocker SJ, 2003, J NEUROSCI, V23, P4081; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; FAHAN S, 2000, MERRITTS NEUROLOGY, P679; Fiskum G, 2003, ANN NY ACAD SCI, V991, P111; Floor E, 1998, J NEUROCHEM, V70, P268; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Gao HM, 2003, J NEUROSCI, V23, P6181; Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002; Gao HM, 2003, TRENDS PHARMACOL SCI, V24, P395, DOI 10.1016/S0165-6147(03)00176-7; Greenamyre JT, 2004, SCIENCE, V304, P1120, DOI 10.1126/science.1098966; HARTLEY A, 1994, J NEUROCHEM, V63, P1987; HASTINGS TG, 1995, J NEUROCHEM, V64, P919; Hornykiewicz O, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.2_Suppl_2.S2; Hudasek K, 2004, BIOCHEM BIOPH RES CO, V318, P135, DOI 10.1016/j.bbrc.2004.04.011; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Kalivendi SV, 2004, J BIOL CHEM, V279, P15240, DOI 10.1074/jbc.M312497200; Kalivendi SV, 2003, BIOCHEM J, V371, P151, DOI 10.1042/BJ20021525; Kamsler A, 2003, J NEUROSCI, V23, P269; Kaur D, 2002, AGING CELL, V1, P17, DOI 10.1046/j.1474-9728.2002.00001.x; KITAHAMA K, 1991, NEUROSCIENCE, V44, P185, DOI 10.1016/0306-4522(91)90260-U; Lavi R, 2003, J BIOL CHEM, V278, P40917, DOI 10.1074/jbc.M303034200; Li H, 1997, J NEUROCHEM, V69, P1530; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Lotharius J, 2000, J BIOL CHEM, V275, P38581, DOI 10.1074/jbc.M005385200; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MISRA HP, 1972, J BIOL CHEM, V247, P3170; ODH G, 1994, J NEUROCHEM, V62, P2030; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; Pearce RKB, 1997, J NEURAL TRANSM, V104, P661, DOI 10.1007/BF01291884; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Schmidt N, 2001, J NEURAL TRANSM, V108, P1263, DOI 10.1007/s007020100004; Sherer TB, 2003, NEUROSCI LETT, V341, P87, DOI 10.1016/S0304-3940(03)00172-1; Sherer TB, 2002, J NEUROSCI, V22, P7006; Smigrodzki R, 2004, NEUROBIOL AGING, V25, P1273, DOI 10.1016/j.neurobiolaging.2004.02.020; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; TSE DCS, 1976, J MED CHEM, V19, P37, DOI 10.1021/jm00223a008; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Vila M, 2003, NAT REV NEUROSCI, V4, P365, DOI 10.1038/nrn1100; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; ZHANG F, 1993, BIOORG CHEM, V21, P392, DOI 10.1006/bioo.1993.1033; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391; Zoccarato F, 2004, J BIOL CHEM, V279, P4166, DOI 10.1074/jbc.M308143200	56	77	79	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15587	15594		10.1074/jbc.M500657200	http://dx.doi.org/10.1074/jbc.M500657200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710606	hybrid			2022-12-25	WOS:000228444800017
J	Martin, MC; Allan, LA; Lickrish, M; Sampson, C; Morrice, N; Clarke, PR				Martin, MC; Allan, LA; Lickrish, M; Sampson, C; Morrice, N; Clarke, PR			Protein kinase A regulates caspase-9 activation by Apaf-1 downstream of cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; CYCLIC-AMP; NEUTROPHIL APOPTOSIS; CANCER CELLS; PHOSPHORYLATION; CAMP; BAD; PROCASPASE-9; INHIBITION; SITE	The cyclic AMP signal transduction pathway modulates apoptosis in diverse cell types, although the mechanism is poorly understood. A critical component of the intrinsic apoptotic pathway is caspase-9, which is activated by Apaf-1 in the apoptosome, a large complex assembled in response to release of cytochrome c from mitochondria. Caspase-9 cleaves and activates effector caspases, predominantly caspase-3, resulting in the demise of the cell. Here we identified a distinct mechanism by which cyclic AMP regulates this apoptotic pathway through activation of protein kinase A. We show that protein kinase A inhibits activation of caspase-9 and caspase-3 downstream of cytochrome c in Xenopus egg extracts and in a human cell-free system. Protein kinase A directly phosphorylates human caspase-9 at serines 99, 183, and 195. However, mutational analysis demonstrated that phosphorylation at these sites is not required for the inhibitory effect of protein kinase A on caspase-9 activation. Importantly, protein kinase A inhibits cytochrome c-dependent recruitment of procaspase-9 to Apaf-1 but not activation of caspase-9 by a constitutively activated form of Apaf-1. These data indicate that extracellular signals that elevate cyclic AMP and activate protein kinase A may suppress apoptosis by inhibiting apoptosome formation downstream of cytochrome c release from mitochondria.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Clarke, PR (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.	paul.clarke@cancer.org.uk	Clarke, Paul R./AAA-6803-2020; Clarke, Paul/B-1684-2009	Clarke, Paul/0000-0003-3525-2622; Martin, Morag/0000-0002-8667-6057				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Boucher MJ, 2001, BIOCHEM BIOPH RES CO, V285, P207, DOI 10.1006/bbrc.2001.5147; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CLARKE PR, 2002, APOPTOSIS MOL BIOL P, V40, P176; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Deming PB, 2004, MOL CELL BIOL, V24, P10289, DOI 10.1128/MCB.24.23.10289-10299.2004; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Duckworth BC, 2002, P NATL ACAD SCI USA, V99, P16794, DOI 10.1073/pnas.222661299; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hill MM, 2004, EMBO J, V23, P2134, DOI 10.1038/sj.emboj.7600210; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kwon G, 2004, J BIOL CHEM, V279, P8938, DOI 10.1074/jbc.M310330200; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Martin MC, 2001, J BIOL CHEM, V276, P45041, DOI 10.1074/jbc.M105197200; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; Orlov SN, 1999, CELL DEATH DIFFER, V6, P661, DOI 10.1038/sj.cdd.4400539; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Rossi AG, 1998, J IMMUNOL, V160, P3562; Rossi AG, 1995, BIOCHEM BIOPH RES CO, V217, P892, DOI 10.1006/bbrc.1995.2855; Shiozaki EN, 2004, TRENDS BIOCHEM SCI, V29, P486, DOI 10.1016/j.tibs.2004.07.003; Shiozaki EN, 2002, P NATL ACAD SCI USA, V99, P4197, DOI 10.1073/pnas.072544399; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Taylor SS, 2004, BBA-PROTEINS PROTEOM, V1697, P259, DOI 10.1016/j.bbapap.2003.11.029; Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960-9822(00)00702-8; von Knethen A, 2000, MOL CELL BIOCHEM, V212, P35, DOI 10.1023/A:1007124203607; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yusta B, 2000, J BIOL CHEM, V275, P35345, DOI 10.1074/jbc.M005510200; Zhang LZ, 2004, J BIOL CHEM, V279, P20858, DOI 10.1074/jbc.M310643200; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	43	71	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15449	15455		10.1074/jbc.M414325200	http://dx.doi.org/10.1074/jbc.M414325200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15703181	hybrid			2022-12-25	WOS:000228236800132
J	van der Wel, H; Ercan, A; West, CM				van der Wel, H; Ercan, A; West, CM			The Skp1 prolyl hydroxylase from Dictyostelium is related to the hypoxia-inducible factor-alpha class of animal prolyl 4-hydroxylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCF UBIQUITIN LIGASE; SPORE COAT; CYTOSOLIC GLYCOPROTEIN; PROLINE HYDROXYLATION; GLCNAC-TRANSFERASE; BINDING DOMAIN; MODIFIES SKP1; HIF; EXPRESSION; GLYCOSYLATION	Skp1 is a cytoplasmic and nuclear protein of eukaryotes best known as an adaptor in SCF ubiquitin-protein isopeptide ligases. In Dictyostelium, Skp1 is subject to 4-hydroxylation at Pro(143) and subsequent O-glycosylation by alpha-linked GlcNAc and other sugars. Soluble cytosolic extracts have Skp1 prolyl 4-hydroxylase (P4H) activity, which can be measured based on hydroxylation-dependent transfer of [H-3]GlcNAc to recombinant Skp1 by recombinant (Skp1-protein)-hydroxyproline alpha-N-acetyl-D-glucosaminyltransferase. The Dictyostelium Skp1 P4H gene (phyA) was predicted using a bioinformatics approach, and the expected enzyme activity was confirmed by expression of phyA cDNA in Escherichia coli. The purified recombinant enzyme (P4H1) was dependent on physiological concentrations of O-2, alpha-ketoglutarate, and ascorbate and was inhibited by CoCl2, 3,4-dihydroxybenzoate, and 3,4-dihydroxyphenyl acetate, as observed for known animal cytoplasmic P4Hs of the hypoxia-inducible factor-alpha (HIF alpha) class. Overexpression of phyA cDNA in Dictyostelium yielded increased enzyme activity in a soluble cytosolic extract. Disruption of the phyA locus by homologous recombination resulted in loss of detectable activity in extracts and blocked hydroxylation-dependent glycosylation of Skp1 based on molecular weight analysis by SDS-PAGE, demonstrating a requirement for P4H1 in vivo. The sequence and functional similarities of P4H1 to animal HIF alpha-type P4Hs suggest that hydroxylation of Skp1 may, like that of animal HIF alpha, be regulated by availability of O-2, alpha-ketoglutarate, and ascorbate, which might exert novel control over Skp1 glycosylation.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	West, CM (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, 940 Stanton L Young Blvd,BMSB 937, Oklahoma City, OK 73104 USA.	Cwest2@ouhsc.edu	Ercan, Altan/AGO-4238-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM37539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAVIND L, 2001, GENOME BIOL; Bochkareva E, 1998, J BIOL CHEM, V273, P3932, DOI 10.1074/jbc.273.7.3932; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Dalgard CL, 2004, BIOCHEM J, V380, P419, DOI 10.1042/BJ20031647; de Bruin Eric C., 2002, FEMS Yeast Research, V1, P291, DOI 10.1016/S1567-1356(01)00042-3; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; ERCAN A, 2005, IN PRESS GLYCOBIOLOG; Eriksson M, 1999, J BIOL CHEM, V274, P22131, DOI 10.1074/jbc.274.32.22131; Frei C, 2004, DEV CELL, V6, P241, DOI 10.1016/S1534-5807(03)00409-X; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Glockner G, 2002, NATURE, V418, P79, DOI 10.1038/nature00847; Hieta R, 2003, J BIOL CHEM, V278, P34966, DOI 10.1074/jbc.M303624200; Hieta R, 2002, J BIOL CHEM, V277, P23965, DOI 10.1074/jbc.M201865200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; KASKA DD, 1987, BIOCHEM J, V241, P483, DOI 10.1042/bj2410483; Ketcham C, 2004, J BIOL CHEM, V279, P29050, DOI 10.1074/jbc.M313858200; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Knowles HJ, 2003, CANCER RES, V63, P1764; KOZAROV E, 1995, J BIOL CHEM, V270, P3022, DOI 10.1074/jbc.270.7.3022; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Lando D, 2003, EUR J BIOCHEM, V270, P781, DOI 10.1046/j.1432-1033.2003.03445.x; Martin-Puig S, 2004, J BIOL CHEM, V279, P9504, DOI 10.1074/jbc.M310658200; McNeill LA, 2002, BIOORG MED CHEM LETT, V12, P1547, DOI 10.1016/S0960-894X(02)00219-6; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Mohanty S, 2001, GENE DEV, V15, P1435, DOI 10.1101/gad.871101; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Oehme F, 2004, ANAL BIOCHEM, V330, P74, DOI 10.1016/j.ab.2004.03.066; Pang KM, 1999, PLASMID, V41, P187, DOI 10.1006/plas.1999.1391; Pereira T, 2003, J BIOL CHEM, V278, P6816, DOI 10.1074/jbc.M209297200; Puta F, 1998, FOLIA BIOL-PRAGUE, V44, P185; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; SANDONA D, 1995, J BIOL CHEM, V270, P5587, DOI 10.1074/jbc.270.10.5587; Sassi S, 2001, GLYCOBIOLOGY, V11, P283, DOI 10.1093/glycob/11.4.283; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; STERNFELD J, 1977, P NATL ACAD SCI USA, V74, P268, DOI 10.1073/pnas.74.1.268; STERNFELD J, 1981, J CELL SCI, V50, P9; Teng-umnuay P, 1998, J BIOL CHEM, V273, P18242, DOI 10.1074/jbc.273.29.18242; Teng-umnuay P, 1999, J BIOL CHEM, V274, P36392, DOI 10.1074/jbc.274.51.36392; THURING RWJ, 1975, ANAL BIOCHEM, V66, P213, DOI 10.1016/0003-2697(75)90739-3; Tuckerman JR, 2004, FEBS LETT, V576, P145, DOI 10.1016/j.febslet.2004.09.005; van der Wel H, 2002, J BIOL CHEM, V277, P46527, DOI 10.1074/jbc.M208824200; van der Wel H, 2002, J BIOL CHEM, V277, P46328, DOI 10.1074/jbc.M208024200; van der Wel H, 2001, J BIOL CHEM, V276, P33952, DOI 10.1074/jbc.M102555200; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Vervoort EB, 2000, NUCLEIC ACIDS RES, V28, P2069, DOI 10.1093/nar/28.10.2069; Vranka JA, 2004, J BIOL CHEM, V279, P23615, DOI 10.1074/jbc.M312807200; Wang F, 2003, J BIOL CHEM, V278, P51395, DOI 10.1074/jbc.M308756200; West C. M., 2005, DICTYOSTELIUM GENOMI, P235; West CM, 1996, J BIOL CHEM, V271, P12024, DOI 10.1074/jbc.271.20.12024; West CM, 2004, BBA-GEN SUBJECTS, V1673, P29, DOI 10.1016/j.bbagen.2004.04.007; West CM, 2003, CELL MOL LIFE SCI, V60, P229, DOI 10.1007/s000180300018; West CM, 1997, GENE, V200, P1, DOI 10.1016/S0378-1119(97)00194-7; Zhang YY, 1998, BIOCHEMISTRY-US, V37, P10766, DOI 10.1021/bi9808013; Zhang YY, 1999, J CELL SCI, V112, P4367; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	62	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14645	14655		10.1074/jbc.M500600200	http://dx.doi.org/10.1074/jbc.M500600200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705570	hybrid			2022-12-25	WOS:000228236800039
J	Sakakida, Y; Miyamoto, Y; Nagoshi, E; Akashi, M; Nakamura, TJ; Mamine, T; Kasahara, M; Minami, Y; Yoneda, Y; Takumi, T				Sakakida, Y; Miyamoto, Y; Nagoshi, E; Akashi, M; Nakamura, TJ; Mamine, T; Kasahara, M; Minami, Y; Yoneda, Y; Takumi, T			Importin alpha/beta mediates nuclear transport of a mammalian circadian clock component, mCRY2, together with mPER2, through a bipartite nuclear localization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-TARGETING COMPLEX; ELEMENT-BINDING PROTEIN-2; 3 DISTINCT CLASSES; TRANSCRIPTION FACTOR; BETA-CATENIN; MOUSE; CRYPTOCHROME; CELLS; EXPRESSION; MANNER	Circadian rhythms, which period is approximately one day, are generated by endogenous biological clocks. These clocks are found throughout the animal kingdom, as well as in plants and even in prokaryotes. Molecular mechanisms for circadian rhythms are based on transcriptional oscillation of clock component genes, consisting of interwoven autoregulatory feedback loops. Among the loops, the nuclear transport of clock proteins is a crucial step for transcriptional regulation. In the present study, we showed that the nuclear entry of mCRY2, a mammalian clock component, is mediated by the importin alpha/beta system through a bipartite nuclear localization signal in its carboxyl end. In vitro transport assay using digitonin-permeabilized cells demonstrated that all three importin alpha s, alpha 1 (Rch1), alpha 3 (Qip-1), and alpha 7 (NPI-2), can mediate mCRY2 import. mCRY2 with the mutant nuclear localization signal failed to transport mPER2 into the nucleus of mammalian cultured cells, indicating that the nuclear localization signal identified in mCRY2 is physiologically significant. These results suggest that the importin alpha/beta system is involved in nuclear entry of mammalian clock components, which is indispensable to transcriptional oscillation of clock genes.	Osaka Biosci Inst, Osaka 5650874, Japan; Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Dept Frontier Biosci, Suita, Osaka 5650871, Japan; Sony Corp, Mat Labs, Life Sci Lab, Shinagawa Ku, Tokyo 1440001, Japan; Hyogo Univ Teachers Educ, Dept Genome Sci, Yashiro, Hyogo 6731494, Japan; Kobe Univ, Grad Sch Med, Fac Med Sci, Dept Genome Sci, Kobe, Hyogo 6500017, Japan	Osaka University; Osaka University; Sony Corporation; Hyogo University of Teacher Education; Kobe University	Takumi, T (corresponding author), Osaka Biosci Inst, 6-2-4 Furuedai, Osaka 5650874, Japan.	takumi@obi.or.jp		Nagoshi, Emi/0000-0002-6365-4074; Miyamoto, Yoichi/0000-0003-4016-1119				Allada R, 2001, ANNU REV NEUROSCI, V24, P1091, DOI 10.1146/annurev.neuro.24.1.1091; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Ems-McClung SC, 2004, MOL BIOL CELL, V15, P46, DOI 10.1091/mbc.E03-07-0454; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Harms E, 2004, J BIOL RHYTHM, V19, P361, DOI 10.1177/0748730404268111; Hastings MH, 2003, NAT REV NEUROSCI, V4, P649, DOI 10.1038/nrn1177; Hirayama J, 2003, J BIOL CHEM, V278, P35620, DOI 10.1074/jbc.M305028200; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; Kamei Y, 1999, J HISTOCHEM CYTOCHEM, V47, P363, DOI 10.1177/002215549904700310; Kobayashi K, 1998, NUCLEIC ACIDS RES, V26, P5086, DOI 10.1093/nar/26.22.5086; Kobayashi M, 2002, J BIOL CHEM, V277, P5816, DOI 10.1074/jbc.M108433200; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kohler M, 1997, FEBS LETT, V417, P104, DOI 10.1016/S0014-5793(97)01265-9; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee SJ, 2003, SCIENCE, V302, P1571, DOI 10.1126/science.1088372; Lindsay ME, 2002, CELL, V110, P349, DOI 10.1016/S0092-8674(02)00836-X; Maertens G, 2004, J BIOL CHEM, V279, P33421, DOI 10.1074/jbc.M404700200; Miyamoto Y, 2002, EMBO J, V21, P5833, DOI 10.1093/emboj/cdf569; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; Miyazaki K, 2001, MOL CELL BIOL, V21, P6651, DOI 10.1128/MCB.21.19.6651-6659.2001; Nachury MV, 1998, P NATL ACAD SCI USA, V95, P582, DOI 10.1073/pnas.95.2.582; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; Nagoshi E, 2001, MOL CELL BIOL, V21, P2779, DOI 10.1128/MCB.21.8.2779-2789.2001; Nishinaka Y, 2004, J BIOL CHEM, V279, P37559, DOI 10.1074/jbc.M405473200; Oster H, 2002, GENE DEV, V16, P2633, DOI 10.1101/gad.233702; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Sancar A, 2000, ANNU REV BIOCHEM, V69, P31, DOI 10.1146/annurev.biochem.69.1.31; Sancar A, 2004, J BIOL CHEM, V279, P34079, DOI 10.1074/jbc.R400016200; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Tachibana T, 2000, CELL STRUCT FUNCT, V25, P115, DOI 10.1247/csf.25.115; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; Takumi T, 1999, GENES CELLS, V4, P67, DOI 10.1046/j.1365-2443.1999.00238.x; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Tsuji L, 1997, FEBS LETT, V416, P30, DOI 10.1016/S0014-5793(97)01092-2; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Yamamoto T, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-18; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Zhu HS, 2003, CURR BIOL, V13, P1653, DOI 10.1016/j.cub.2003.08.033	54	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13272	13278		10.1074/jbc.M413236200	http://dx.doi.org/10.1074/jbc.M413236200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15689618	hybrid			2022-12-25	WOS:000228095500011
J	Viste, K; Kopperud, RK; Christensen, AE; Doskeland, SO				Viste, K; Kopperud, RK; Christensen, AE; Doskeland, SO			Substrate enhances the sensitivity of type I protein kinase a to cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CARDIAC-MUSCLE; TISSUE-SPECIFIC EXTINGUISHER; CYCLIC-AMP; REGULATORY SUBUNIT; CATALYTIC SUBUNIT; TYROSINE-HYDROXYLASE; CRYSTAL-STRUCTURE; BINDING-PROTEINS; TSE1 ENCODES; ADENOSINE	The functional significance of the presence of two major ( types I and II) isoforms of the cAMP-dependent protein kinase (PKA) is still enigmatic. The present study showed that peptide substrate enhanced the activation of PKA type I at low, physiologically relevant concentrations of cAMP through competitive displacement of the regulatory RI subunit. The effect was similar whether the substrate was a short peptide or the physiological 60-kDa protein tyrosine hydroxylase. In contrast, substrate failed to affect the cAMP-sensitivity of PKA type II. Size exclusion chromatography confirmed that substrate acted to physically enhance the dissociation of the RI alpha and C alpha subunits of PKA type I, but not the RII alpha and C alpha subunits of PKA type II. Substrate availability can therefore fine-tune the activation of PKA type I by cAMP, but not PKA type II. The cAMP-dissociated RII and C subunits of PKA type II reassociated much faster than the PKA type I subunits in the presence of substrate peptide. This suggests that only PKA type II is able to rapidly reverse its activation after a burst of cAMP when exposed to high substrate concentration. We propose this as a possible reason why PKA type II is preferentially found in complexes with substrates undergoing rapid phosphorylation cycles.	Univ Bergen, Dept Biomed, Sect Anat & Cell Biol, N-5009 Bergen, Norway; Haukeland Hosp, N-5021 Bergen, Norway	University of Bergen	Doskeland, SO (corresponding author), Univ Bergen, Dept Biomed, Sect Anat & Cell Biol, Jonas Lies Vei 91, N-5009 Bergen, Norway.	Stein.doskeland@biomed.uib.no		Doskeland, Stein Ove/0000-0002-4009-4756				Amieux PS, 2002, ANN NY ACAD SCI, V968, P75, DOI 10.1111/j.1749-6632.2002.tb04328.x; ARMSTRONG R, 1995, MOL CELL BIOL, V15, P1826; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; Cederberg A, 2001, CELL, V106, P563, DOI 10.1016/S0092-8674(01)00474-3; Cheng XD, 2001, J BIOL CHEM, V276, P4102, DOI 10.1074/jbc.M006447200; Croniger CM, 2001, J BIOL CHEM, V276, P629, DOI 10.1074/jbc.M007576200; DOSKELAND SO, 1977, BIOCHEM J, V165, P561, DOI 10.1042/bj1650561; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; DOSKELAND SO, 1981, INT J BIOCHEM, V13, P1, DOI 10.1016/0020-711X(81)90131-2; ERLICHMAN J, 1974, J BIOL CHEM, V249, P5000; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; FOSSBERG TM, 1978, ARCH BIOCHEM BIOPHYS, V189, P372, DOI 10.1016/0003-9861(78)90224-2; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Gangolli EA, 2000, MOL CELL BIOL, V20, P3442, DOI 10.1128/MCB.20.10.3442-3448.2000; GHARRETT AJ, 1976, NATURE, V264, P673, DOI 10.1038/264673a0; GJERTSEN BT, 1993, BIOCHEM J, V294, P497, DOI 10.1042/bj2940497; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095; Kopperud R, 2002, J BIOL CHEM, V277, P13443, DOI 10.1074/jbc.M109869200; Mani S, 2003, ANN NY ACAD SCI, V1002, P252, DOI 10.1196/annals.1281.028; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; MIYAMOTO E, 1973, J BIOL CHEM, V248, P179; Narayana N, 1997, BIOCHEMISTRY-US, V36, P4438, DOI 10.1021/bi961947+; OTTEN AD, 1991, J BIOL CHEM, V266, P23074; RANGELALDAO R, 1977, J BIOL CHEM, V252, P7140; RANGELALDAO R, 1976, J BIOL CHEM, V251, P7526; ROSEN OM, 1975, J BIOL CHEM, V250, P7788; SCOTT CW, 1989, MOL ENDOCRINOL, V3, P1815, DOI 10.1210/mend-3-11-1815; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Taylor SS, 2004, BBA-PROTEINS PROTEOM, V1697, P259, DOI 10.1016/j.bbapap.2003.11.029; Vigil D, 2004, BIOCHEMISTRY-US, V43, P5629, DOI 10.1021/bi0499157; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; YAMAUCHI T, 1979, J BIOL CHEM, V254, P503; Zhou J, 1997, BIOCHEMISTRY-US, V36, P15733, DOI 10.1021/bi971438n	43	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13279	13284		10.1074/jbc.M413065200	http://dx.doi.org/10.1074/jbc.M413065200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15691833	hybrid			2022-12-25	WOS:000228095500012
J	Manchanda, N; Lyubimova, A; Ho, HYH; James, MF; Gusella, JF; Ramesh, N; Snapper, SB; Ramesh, V				Manchanda, N; Lyubimova, A; Ho, HYH; James, MF; Gusella, JF; Ramesh, N; Snapper, SB; Ramesh, V			The NF2 tumor suppressor merlin and the ERM proteins interact with N-WASP and regulate its actin polymerization function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHIGELLA-FLEXNERI; ARP2/3 COMPLEX; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INTRACELLULAR MOTILITY; EPITHELIAL-CELLS; F-ACTIN; ASSOCIATION; MECHANISM; ACTIVATION; NUCLEATION	The function of the NF2 tumor suppressor merlin has remained elusive despite increasing evidence for its role in actin cytoskeleton reorganization. The closely related ERM proteins (ezrin, radixin, and moesin) act as linkers between the cell membrane and cytoskeleton, and have also been implicated as active actin reorganizers. We report here that merlin and the ERMs can interact with and regulate N-WASP, a critical regulator of actin dynamics. Merlin and moesin were found to inhibit N-WASP-mediated actin assembly in vitro, a function that appears independent of their ability to bind actin. Furthermore, exogenous expression of a constitutively active ERM inhibits N-WASP-dependent Shigella tail formation, suggesting that the ERMs may function as inhibitors of N- WASP function in vivo. This novel function of merlin and the ERMs illustrates a mechanism by which these proteins directly exert their effects on actin reorganization and also provides new insight into N-WASP regulation.	Massachusetts Gen Hosp, Mol Neurogenet Unit, Ctr Human Genet Res, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Gastrointestinal Unit, Med Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Inflammatory Bowel Dis, Boston, MA 02114 USA; Childrens Hosp, Div Immunol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital	Ramesh, V (corresponding author), Massachusetts Gen Hosp, Mol Neurogenet Unit, Ctr Human Genet Res, Bldg 149,13th St,Rm 6222, Charlestown, MA 02129 USA.	ramesh@helix.mgh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59561] Funding Source: Medline; NIAID NIH HHS [AI052354] Funding Source: Medline; NINDS NIH HHS [NS24279] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bashour AM, 2002, MOL CELL BIOL, V22, P1150, DOI 10.1128/MCB.22.4.1150-1157.2002; Brault E, 2001, J CELL SCI, V114, P1901; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Ho HYH, 2001, P NATL ACAD SCI USA, V98, P11306, DOI 10.1073/pnas.211420498; James MF, 2001, BIOCHEM J, V356, P377, DOI 10.1042/0264-6021:3560377; Kato M, 2002, BIOCHEM BIOPH RES CO, V291, P41, DOI 10.1006/bbrc.2002.6406; Lommel S, 2001, EMBO REP, V2, P850, DOI 10.1093/embo-reports/kve197; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Millard TH, 2004, BIOCHEM J, V380, P1, DOI 10.1042/BJ20040176; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Mounier J, 1999, J CELL SCI, V112, P2069; Paglini G, 1998, J CELL BIOL, V143, P443, DOI 10.1083/jcb.143.2.443; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Ramesh V, 2004, NAT REV NEUROSCI, V5, P462, DOI 10.1038/nrn1407; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Shibata T, 2002, CURR BIOL, V12, P341, DOI 10.1016/S0960-9822(02)00689-9; Skoudy A, 1999, J CELL SCI, V112, P2059; Snapper SB, 2001, NAT CELL BIOL, V3, P897, DOI 10.1038/ncb1001-897; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Wiederhold T, 2004, ONCOGENE, V23, P8815, DOI 10.1038/sj.onc.1208110	33	39	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12517	12522		10.1074/jbc.C400583200	http://dx.doi.org/10.1074/jbc.C400583200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15699051	hybrid			2022-12-25	WOS:000227922000055
J	Essafi, A; de Mattos, SF; Hassen, YAM; Soeiro, I; Mufti, GJ; Thomas, NSB; Medema, RH; Lam, EWF				Essafi, A; de Mattos, SF; Hassen, YAM; Soeiro, I; Mufti, GJ; Thomas, NSB; Medema, RH; Lam, EWF			Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells	ONCOGENE			English	Article						Bim; FoxO; Bcr-Abl; apoptosis; transcription	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE-ACTIVITY; FAMILY-MEMBER BIM; BCL-2 FAMILY; CYCLIN D2; IMATINIB MESYLATE; SIGNALING PATHWAY; BH3-ONLY PROTEIN; MAMMALIAN-CELLS	In this study, we have used the human BV173 and the mouse BaF3/Bcr-Abl-expressing cell lines as model systems to investigate the molecular mechanisms whereby STI571 and FoxO3a regulate Bim expression and apoptosis. FoxO3a lies downstream of Ber-Abl signalling and is constitutively phosphorylated in the Bcr-Abl-positive BV173 and BaF3/Bcr-Abl cells. Inhibition of Bcr-Abl kinase by STI571 results in FoxO3a activation, induction of Bim expression and apoptosis. Using reporter gene assays, we demonstrate that STI571 and FoxO3a activate Bim transcription through a FoxO-binding site (FHRE) located within the promoter. This was verified by DNA pull-down and chromatin immunoprecipitation analyses. We find that conditional activation of FoxO3a leads to induction of Bim expression and apoptosis. Conversely, silencing of FoxO3a in Bcr-Abl-expressing cells abolishes STI571-mediated Bim induction and apoptosis. Together, the results presented clearly confirm FoxO3a as a key regulator of apoptosis induced by ST1571, and show that Bim is a direct transcriptional target of FoxO3a that mediates the STI571-induced apoptosis. Thus, STI571 induces an accumulation of FoxO3a activity which in turn binds directly to an FHRE in the promoter to activate Bim expression and apoptosis.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Canc Med, Canc Res UK Labs, London W12 0NN, England; Univ London Kings Coll, Guys Kings & St Thomas Sch Med, Dept Haematol Med, Leukaemia Sci Labs,Rayne Inst, London SE5 9NU, England; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Cancer Research UK; Imperial College London; University of London; King's College London; Netherlands Cancer Institute	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Canc Med, Canc Res UK Labs, MRC Cyclotron Bldg,Du Cane Rd, London W12 0NN, England.	eric.lam@imperial.ac.uk	Essafi, Abdelkader/A-6602-2009; de Mattos, Silvia Fernández/K-5153-2014; Medema, Rene H/E-2981-2013; Medema, Rene H/G-5415-2011; Lam, Eric W-F/AAW-8566-2020	de Mattos, Silvia Fernández/0000-0003-4144-3687; Lam, Eric W-F/0000-0003-1274-3576; Medema, Rene/0000-0002-6754-0381				Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Borthakur G, 2004, INT J HEMATOL, V79, P411, DOI 10.1532/IJH97.04054; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Deininger MWN, 2001, CANCER RES, V61, P8005; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; EPNER DE, 1990, ANN INTERN MED, V113, P3, DOI 10.7326/0003-4819-113-1-3; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Ghaffari S, 2003, P NATL ACAD SCI USA, V100, P6523, DOI 10.1073/pnas.0731871100; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Harada Hisashi, 2003, Rev Clin Exp Hematol, V7, P117; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; Haskovec C, 1998, BRIT J HAEMATOL, V103, P1104, DOI 10.1046/j.1365-2141.1998.01098.x; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Komatsu N, 2003, J BIOL CHEM, V278, P6411, DOI 10.1074/jbc.M211562200; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kuribara R, 2004, MOL CELL BIOL, V24, P6172, DOI 10.1128/MCB.24.14.6172-6183.2004; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; NUSSINOV R, 1983, J THEOR BIOL, V100, P319, DOI 10.1016/0022-5193(83)90355-7; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; RAMAKRISHNAN L, 1989, BIOCHIM BIOPHYS ACTA, V989, P209, DOI 10.1016/0304-419X(89)90043-7; Scheijen B, 2004, ONCOGENE, V23, P3338, DOI 10.1038/sj.onc.1207456; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Seward RJ, 2003, MOL IMMUNOL, V39, P983, DOI 10.1016/S0161-5890(03)00047-6; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Strasser A, 2000, ANN NY ACAD SCI, V917, P541; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Tauchi T, 2004, INT J HEMATOL, V79, P434, DOI 10.1532/IJH97.04013; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	51	240	251	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2317	2329		10.1038/sj.onc.1208421	http://dx.doi.org/10.1038/sj.onc.1208421			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15688014				2022-12-25	WOS:000227877400005
J	Krick, S; Hanze, J; Eul, B; Savai, R; Seay, U; Grimminger, F; Lohmeyer, J; Klepetko, W; Seeger, W; Rose, F				Krick, S; Hanze, J; Eul, B; Savai, R; Seay, U; Grimminger, F; Lohmeyer, J; Klepetko, W; Seeger, W; Rose, F			Hypoxia-driven proliferation of human pulmonary artery fibroblasts: cross-talk between HIF-1 alpha and an autocrine angiotensin system	FASEB JOURNAL			English	Article						pulmonary hypertension; vascular remodeling	INDUCIBLE FACTOR-I; CONVERTING ENZYME; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; CELLULAR PROLIFERATION; RECEPTOR EXPRESSION; INDUCED APOPTOSIS; RNA INTERFERENCE; EPITHELIAL-CELLS; HYPERTROPHY	Pulmonary artery adventitial fibroblasts (FBPA) may play a central role in lung vascular remodeling under conditions of hypoxia and inflammation, the result being pulmonary hypertension and cor pulmonale. In cultured human FBPA, both angiotensin II (Ang II) and hypoxia promoted cell cycle progression and cell proliferation and suppressed apoptosis. These effects were further enhanced when both stimuli were applied simultaneously. Hypoxia elevated the expression of hypoxia-inducible factor 1 alpha (HIF-1 alpha) and increased the expression of genes regulated by the hypoxia-responsive element (HRE). Up-regulation of both angiotensin-converting enzyme (ACE) and Ang II receptor type 1 (AT1) was also observed. Exogenous Ang II further increased HIF/HRE-dependent signaling in FBPA, whereas suppression of the autocrine ACE-Ang II-AT1 loop with inhibitors of ACE, AT1, and phosphatidylinositol 3-kinase (PI3K) reduced the proliferative response to both hypoxia and exogenous Ang II. Overexpression of HIF-1 alpha by transient transfection caused the same proliferative effect and up-regulation of AT1 expression that were observed under hypoxic conditions. In contrast, small interfering RNA targeting HIF-1 alpha inhibited hypoxia-induced ACE and AT1 expression. Our studies indicate that the ACE-Ang II-AT1 system serves as a positive feedback loop and fosters FBPA proliferation under hypoxic conditions, with the PI3K-HIF-HRE axis as the central effector pathway. This pathway may thus facilitate vascular remodeling under hypoxic conditions.	Univ Giessen, Dept Internal Med 2, D-35392 Giessen, Germany; Vienna Univ Hosp, Dept Cardiothorac Surg, Vienna, Austria	Justus Liebig University Giessen; University Hospital Vienna	Krick, S (corresponding author), Univ Giessen, Dept Internal Med 2, Klinikstr 36, D-35392 Giessen, Germany.	Stefanie.Krick@innere.med.uni-giessen.de		Seeger, Werner/0000-0003-1946-0894; Grimminger, Friedrich/0000-0001-8725-6276; Savai, Rajkumar/0000-0003-1538-2091				AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; Adamy C, 2002, AM J PHYSIOL-HEART C, V283, pH733, DOI 10.1152/ajpheart.01088.2001; Belknap JK, 1997, AM J RESP CELL MOL, V16, P366, DOI 10.1165/ajrcmb.16.4.9115746; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Chassagne C, 2000, AM J RESP CELL MOL, V22, P323, DOI 10.1165/ajrcmb.22.3.3701; Chen EY, 2001, CANCER RES, V61, P2429; Durmowicz A G, 1999, Pediatr Rev, V20, pe91; DZAU VJ, 1984, J CARDIOVASC PHARM, V6, pS377, DOI 10.1097/00005344-198406002-00012; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; GIBBONS GH, 1990, CARDIOVASC DRUG THER, V4, P237, DOI 10.1007/BF01857638; Hanze J, 2003, BIOCHEM BIOPH RES CO, V312, P571, DOI 10.1016/j.bbrc.2003.10.153; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Lijnen PJ, 2003, METHOD FIND EXP CLIN, V25, P541, DOI 10.1358/mf.2003.25.7.778094; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; Marshall RP, 2003, CURR PHARM DESIGN, V9, P715, DOI 10.2174/1381612033455431; Marshall RP, 2000, AM J RESP CRIT CARE, V161, P1999, DOI 10.1164/ajrccm.161.6.9907004; Matsubara H, 1998, ENDOCR J, V45, P137, DOI 10.1507/endocrj.45.137; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Morrell NW, 1997, CARDIOVASC RES, V34, P393, DOI 10.1016/S0008-6363(97)00049-7; MORRELL NW, 1995, J CLIN INVEST, V96, P1823, DOI 10.1172/JCI118228; MURPHY JD, 1981, J PEDIATR-US, V98, P962, DOI 10.1016/S0022-3476(81)80605-1; Ohuchi N, 2004, COMP BIOCHEM PHYS C, V137, P281, DOI 10.1016/j.cca.2004.02.003; Orte C, 2000, J PATHOL, V192, P379, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH715>3.0.CO;2-Q; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Rose F, 2002, FASEB J, V16, P1660, DOI 10.1096/fj.02-0420fje; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; Schuttert JB, 2003, PFLUG ARCH EUR J PHY, V446, P387, DOI 10.1007/s00424-003-1026-y; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Stenmark KR, 2000, PHYSIOL RES, V49, P503; Stenmark KR, 2002, CHEST, V122, p326S, DOI 10.1378/chest.122.6_suppl.326S; Stenmark KR, 1997, ANNU REV PHYSIOL, V59, P89, DOI 10.1146/annurev.physiol.59.1.89; Stenmark KR, 1999, ADV EXP MED BIOL, V474, P231; Strauss BH, 2000, AM J RESP CELL MOL, V22, P1; Thomas WG, 2002, CIRC RES, V90, P135, DOI 10.1161/hh0202.104109; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang RG, 1999, AM J PHYSIOL-LUNG C, V277, pL1158, DOI 10.1152/ajplung.1999.277.6.L1158; Wang RQ, 2000, AM J PHYSIOL-LUNG C, V279, pL143, DOI 10.1152/ajplung.2000.279.1.L143; Wang RQ, 1999, AM J PHYSIOL-LUNG C, V277, pL1245, DOI 10.1152/ajplung.1999.277.6.L1245; Wang RQ, 1999, AM J PHYSIOL-LUNG C, V276, pL885, DOI 10.1152/ajplung.1999.276.5.L885; Wang RQ, 2000, J CELL PHYSIOL, V185, P253; Welsh DJ, 1998, AM J RESP CRIT CARE, V158, P1757, DOI 10.1164/ajrccm.158.6.9706054; Welsh DJ, 2001, AM J RESP CRIT CARE, V164, P282, DOI 10.1164/ajrccm.164.2.2008054; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wolf G, 2004, AM J NEPHROL, V24, P415, DOI 10.1159/000080086; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	54	69	74	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					857	+		10.1096/fj.04-2890fje	http://dx.doi.org/10.1096/fj.04-2890fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15718424				2022-12-25	WOS:000227591900028
J	Imamura, T; Imamura, C; Iwamoto, Y; Sandell, LJ				Imamura, T; Imamura, C; Iwamoto, Y; Sandell, LJ			Transcriptional co-activators CREB-binding protein/p300 increase chondrocyte Cd-rap gene expression by multiple mechanisms including sequestration of the repressor CCAAT/enhancer-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; COL2A1 PROMOTER ACTIVITY; II COLLAGEN GENE; MESSENGER-RNA; C/EBP-BETA; CAMPOMELIC DYSPLASIA; FACTOR SOX9; TGF-BETA; P300; CARTILAGE	Cartilage-derived retinoic acid-sensitive protein (CD-RAP) is a small secreted matrix protein expressed in developing and adult cartilage and by chondrocytes in culture. We have previously shown that the expression of Cd-rap, like many other cartilage matrix proteins, is repressed by interleukin 1 beta and that the transcription factor CCAAT/enhancer-binding protein (C/EBP) beta plays an important role in the interleukin 1 beta-induced repression ( Okazaki, K., Li, J., Yu, H., Fukui, N., and Sandell, L. J. ( 2002) J. Biol. Chem. 277, 31526 - 31533). The coactivators CREB-binding protein (CBP) and p300 are transcriptional co-regulators that participate in the activities of many different transcription factors including C/EBP. Here we show that CBP/p300 can reverse the inhibitory effect of C/EBP and moreover can stimulate expression of Cd-rap. The mechanism of this effect is shown to involve a unique synergy whereby CBP/p300 stimulate Cd-rap gene expression by at least two mechanisms. First, binding of CBP/p300 to C/EBP beta leads to sequestration of C/EBP eliminating DNA binding and subsequent repression; second, binding of CBP/p300 to the transcriptional activator Sox9 increases Sox9 DNA binding to the Cd-rap promoter leading to further stimulation of gene transcription. This is an example of a complementary transcriptional network whereby two very different mechanisms act together to confer a functional increase in transcription. This new paradigm is likely generally applicable to cartilage genes as Col2a1 cartilage collagen gene responds similarly.	Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Orthopaed Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Higashi Ku, Fukuoka 8128582, Japan	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Kyushu University	Sandell, LJ (corresponding author), Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Orthopaed Surg, 660 S Euclid Ave,Box 8233, St Louis, MO 63110 USA.	sandelll@wustl.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036994, R01AR045550] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR36994, R01 AR045550] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BLESCH A, 1994, CANCER RES, V54, P5695; Bosserhoff AK, 1999, J PATHOL, V187, P446, DOI 10.1002/(SICI)1096-9896(199903)187:4<446::AID-PATH267>3.0.CO;2-Y; Chen X, 1999, MOL CELL BIOL, V19, P4695; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Dietz UH, 1996, J BIOL CHEM, V271, P3311, DOI 10.1074/jbc.271.6.3311; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; Hou CH, 2002, CELL RES, V12, P79, DOI 10.1038/sj.cr.7290113; Huang SM, 2002, J VIROL, V76, P8710, DOI 10.1128/JVI.76.17.8710-8721.2002; Huang ZM, 2004, J BONE MINER RES, V19, P245, DOI 10.1359/jbmr.2004.19.2.245; Iioka T, 2003, J BONE MINER RES, V18, P1419, DOI 10.1359/jbmr.2003.18.8.1419; Jain R, 1999, BIOCHEM J, V338, P737, DOI 10.1042/0264-6021:3380737; Janknecht R, 1996, ONCOGENE, V12, P1961; Kondo SJ, 2001, J ORTHOP RES, V19, P712, DOI 10.1016/S0736-0266(00)00068-1; Kuang PP, 2003, AM J PHYSIOL-CELL PH, V285, pC1349, DOI 10.1152/ajpcell.00173.2003; Kypriotou M, 2003, DNA CELL BIOL, V22, P119, DOI 10.1089/104454903321515922; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Mochizuki K, 2002, GENE, V291, P271, DOI 10.1016/S0378-1119(02)00625-X; Murakami S, 2000, J BIOL CHEM, V275, P3687, DOI 10.1074/jbc.275.5.3687; Murray D, 2000, J BIOL CHEM, V275, P3610, DOI 10.1074/jbc.275.5.3610; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Okazaki K, 2002, J BIOL CHEM, V277, P31526, DOI 10.1074/jbc.M202815200; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Raval-Pandya M, 2001, MOL ENDOCRINOL, V15, P1035, DOI 10.1210/me.15.6.1035; RUBINSTEIN JH, 1990, AM J MED GENET, P3; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Sock E, 2003, HUM MOL GENET, V12, P1439, DOI 10.1093/hmg/ddg158; STRYER L, 1995, BIOCHEMISTRY-US, P581; Takahashi K, 2001, DEV DYNAM, V222, P252, DOI 10.1002/dvdy.1185; Tan LJ, 2003, J BIOL CHEM, V278, P17688, DOI 10.1074/jbc.M301676200; Tanaka K, 2000, MOL CELL BIOL, V20, P4428, DOI 10.1128/MCB.20.12.4428-4435.2000; Tsuda M, 2003, J BIOL CHEM, V278, P27224, DOI 10.1074/jbc.M303471200; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Watanabe M, 2003, AM J PATHOL, V163, P633, DOI 10.1016/S0002-9440(10)63690-5; Xie WF, 1999, J BONE MINER RES, V14, P757, DOI 10.1359/jbmr.1999.14.5.757; Zeng L, 2002, GENE DEV, V16, P1990, DOI 10.1101/gad.1008002	43	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16625	16634		10.1074/jbc.M411469200	http://dx.doi.org/10.1074/jbc.M411469200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722556	hybrid			2022-12-25	WOS:000228615500013
J	Moir, RD; Tseitlin, KA; Soscia, S; Hyman, BT; Irizarry, MC; Tanzi, RE				Moir, RD; Tseitlin, KA; Soscia, S; Hyman, BT; Irizarry, MC; Tanzi, RE			Autoantibodies to redox-modified oligomeric A beta are attenuated in the plasma of Alzheimer's disease patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBRAL AMYLOID ANGIOPATHY; CENTRAL-NERVOUS-SYSTEM; MOUSE MODEL; PROTEIN; ANTIBODIES; PEPTIDE; BRAIN; PATHOLOGY; DEMENTIA; SERUM	Accumulation of A beta protein in beta-amyloid deposits is a hallmark event in Alzheimer's disease ( AD). Recent findings suggest anti-A beta autoantibodies may have a role in AD pathology. However, a consensus has yet to emerge as to whether endogenous anti-A beta autoantibodies are elevated, depressed, or unchanged in AD patients. Whereas experiments to date have used synthetic unmodified monomeric A beta (A beta(mon)) to test autoimmunity, up to 40% of the A beta pool in AD brain consists of low molecular weight oligomeric cross-linked beta-amyloid protein species ( CAPS). Recent studies also suggest that CAPS may be the primary neurotoxic agent in AD. In the present study, AD and nondemented control plasma were analyzed for immunoreactivity to CAPS and A beta(mon). Plasma of both nondemented and AD patients were found to contain autoantibodies specific for soluble CAPS. Nondemented control and AD plasmas demonstrated similar immunoreactivity to A beta(mon). In contrast, anti-CAPS antibodies in AD plasma were found to be significantly reduced compared with nondemented controls ( p = 0.018). Furthermore, age at onset for AD correlated significantly ( p = 0.041) with plasma immunoreactivity to CAPS. These data suggest that autoantibodies to CAPS are depleted in AD patients and raise the prospect that immunization with anti-CAPS antibodies might provide therapeutic benefit for AD.	Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University	Tanzi, RE (corresponding author), Massachusetts Gen Hosp E, Genet & Aging Res Unit, Bldg 114,16th St, Charlestown, MA 02129 USA.	tanzi@helix.mgh.harvard.edu	Tanzi, Rudolph/AAE-9622-2019; Moir, Robert D./M-7612-2017	Tanzi, Rudolph/0000-0002-7032-1454; Moir, Robert D./0000-0001-5431-3553				Atwood CS, 2000, CELL MOL BIOL, V46, P777; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Atwood CS, 2004, BIOCHEMISTRY-US, V43, P560, DOI 10.1021/bi0358824; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bard F, 2003, P NATL ACAD SCI USA, V100, P2023, DOI 10.1073/pnas.0436286100; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BUSH AI, 1995, SCIENCE, V268, P1921, DOI 10.1126/science.268.5219.1921; Bush AI, 2002, P NATL ACAD SCI USA, V99, P7317, DOI 10.1073/pnas.122249699; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; CITRON M, 1993, NEUROBIOL AGING, V14, P571, DOI 10.1016/0197-4580(93)90041-9; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; Du Y, 2001, NEUROLOGY, V57, P801, DOI 10.1212/WNL.57.5.801; Fukumoto H, 2003, ARCH NEUROL-CHICAGO, V60, P958, DOI 10.1001/archneur.60.7.958; Galeazzi L, 1999, AMYLOID, V6, P7, DOI 10.3109/13506129908993282; Games D, 2000, ANN NY ACAD SCI, V920, P274; GASKIN F, 1993, J EXP MED, V177, P1181, DOI 10.1084/jem.177.4.1181; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P325; HAWKINS PN, 1994, BIOCHEM BIOPH RES CO, V201, P722, DOI 10.1006/bbrc.1994.1760; Hock C, 2002, NAT MED, V8, P1270, DOI 10.1038/nm783; Hyman BT, 2001, ANN NEUROL, V49, P808, DOI 10.1002/ana.1061; Iwatsubo T, 1998, NEUROBIOL AGING, V19, P161, DOI 10.1016/S0197-4580(98)00015-3; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kuo YM, 2000, BIOCHEM BIOPH RES CO, V268, P750, DOI 10.1006/bbrc.2000.2222; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lacroix-Desmazes S, 1998, J IMMUNOL METHODS, V216, P117, DOI 10.1016/S0022-1759(98)00074-X; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Leblhuber F, 1998, DEUT MED WOCHENSCHR, V123, P787, DOI 10.1055/s-2007-1024069; LEONARDI A, 1985, J NEUROL SCI, V67, P253, DOI 10.1016/0022-510X(85)90121-2; Matsuoka Y, 2003, J NEUROSCI, V23, P29; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; McLaurin J, 2002, NAT MED, V8, P1263, DOI 10.1038/nm790; Mehta PD, 1998, NEUROSCI LETT, V241, P13, DOI 10.1016/S0304-3940(97)00966-X; MONNING U, 1991, BASIC MECH DIAGNOSIS, P557; Myagkova MA, 2001, B EXP BIOL MED+, V131, P127, DOI 10.1023/A:1017527508878; Nath A, 2003, NEUROMOL MED, V3, P29, DOI 10.1385/NMM:3:1:29; Oppezzo P, 2003, PATHOL BIOL, V51, P297, DOI 10.1016/S0369-8114(02)00318-8; Rensink AAM, 2003, BRAIN RES REV, V43, P207, DOI 10.1016/j.brainresrev.2003.08.001; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SUZUKI N, 1994, AM J PATHOL, V145, P452; Tamaoka A, 1998, Nihon Ronen Igakkai Zasshi, V35, P273; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; Weksler ME, 2002, EXP GERONTOL, V37, P943, DOI 10.1016/S0531-5565(02)00029-3; Weksler ME, 2002, EXP GERONTOL, V37, P971, DOI 10.1016/S0531-5565(02)00091-8; Xu SH, 1997, MECH AGEING DEV, V94, P213, DOI 10.1016/S0047-6374(96)01861-1; Yoburn JC, 2003, CHEM RES TOXICOL, V16, P531, DOI 10.1021/tx025666g	55	83	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17458	17463		10.1074/jbc.M414176200	http://dx.doi.org/10.1074/jbc.M414176200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728175	hybrid			2022-12-25	WOS:000228615500112
J	Toh, WH; Kyo, S; Sabapathy, K				Toh, WH; Kyo, S; Sabapathy, K			Relief of p53-mediated telomerase suppression by p73	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; DOWN-REGULATION; CANCER-CELLS; TRANSCRIPTIONAL ACTIVATION; CONFERS RESISTANCE; SPONTANEOUS TUMORS; P53 HOMOLOG; DNA-BINDING; HTERT GENE; LIFE-SPAN	Reactivation of telomerase is a feature in many cancer cells. Telomerase activation inhibits telomere shortening, thereby preventing cell cycle arrest and apoptosis activated by shortened telomeres or chromosomal rearrangements. The tumor-suppressor gene product, p53, was previously shown to transcriptionally suppress the activation of the catalytic subunit of telomerase ( hTERT). Here we have evaluated the role of p73 in hTERT regulation. We found that ectoptic expression of p73 beta, in contrast to p73 alpha or p53, in p53 null H1299 cells does not lead to suppression of hTERT transcription. However co-expression of p73 alpha or p73 beta together with p53 abolished p53-mediated hTERT suppression. This phenomenon was found to be dependent on the DNA binding ability of p73. We also show that p53-mediated suppression of hTERT transcription requires a minimum threshold level of p53, and p73 abrogates p53-mediated suppression by reducing p53 levels through the activation of HDM2. Moreover, p53-mediated hTERT suppression was not relieved by p73 beta in cells depleted of HDM2 through small interfering RNA-mediated gene silencing. In addition, knockdown of HDM2 in MCF7 cells, which express moderately high levels of p73 and p53, resulted in the reduction of endogenous hTERT levels. Finally, knockdown of p73 in MCF7 cells resulted in increased p53 protein levels and a concomitant decrease in hTERT levels. Together, our data indicate a plausible way by which p73, through HDM2, can oppose p53 tumor suppressor function, thereby possibly contributing to tumorigenesis.	Natl Canc Ctr, Div Cellular & Mol Res, Mol Carcinogenesis Lab, Singapore 169610, Singapore; Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Natl Univ Singapore, Dept Biochem, Singapore 119260, Singapore	National Cancer Centre Singapore (NCCS); Kanazawa University; National University of Singapore	Sabapathy, K (corresponding author), Natl Canc Ctr, Div Cellular & Mol Res, Mol Carcinogenesis Lab, 11 Hosp Dr, Singapore 169610, Singapore.	cmrksb@nccs.com.sg						Akiyama M, 2002, CANCER RES, V62, P3876; Buschmann T, 2000, J MOL BIOL, V295, P1009, DOI 10.1006/jmbi.1999.3387; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dimri GP, 2002, CANCER RES, V62, P4736; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; El-Naggar AK, 2001, CARCINOGENESIS, V22, P729, DOI 10.1093/carcin/22.5.729; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Gu LB, 2002, BLOOD, V99, P3367, DOI 10.1182/blood.V99.9.3367; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishimoto O, 2002, CANCER RES, V62, P636; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Lee MK, 2005, J CELL SCI, V118, P819, DOI 10.1242/jcs.01673; Lin KW, 2004, NEOPLASIA, V6, P546, DOI 10.1593/neo.04205; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Luiten RM, 2003, BLOOD, V101, P4512, DOI 10.1182/blood-2002-07-2018; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Misawa M, 2002, INT J ONCOL, V21, P1087; Nakajima A, 2003, LEUKEMIA, V17, P560, DOI 10.1038/sj.leu.2402825; Ozaki T, 1999, CANCER RES, V59, P5902; Saito M, 2004, INT J ONCOL, V24, P1213; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667; Takakura M, 1999, CANCER RES, V59, P551; Teng LS, 2003, J CLIN ENDOCR METAB, V88, P1362, DOI 10.1210/jc.2002-021222; Toh WH, 2004, J BIOL CHEM, V279, P44713, DOI 10.1074/jbc.M407672200; Urquidi V, 2000, ANNU REV MED, V51, P65, DOI 10.1146/annurev.med.51.1.65; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Wang XQ, 2001, CANCER RES, V61, P1598; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan Zhang, 2002, Hematol J, V3, P201, DOI 10.1038/sj.thj.6200177; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhu JH, 1998, CANCER RES, V58, P5061	45	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17329	17338		10.1074/jbc.M500044200	http://dx.doi.org/10.1074/jbc.M500044200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15734740	hybrid			2022-12-25	WOS:000228615500097
J	Tripathi, MK; Misra, S; Khedkar, SV; Hamilton, N; Irvin-Wilson, C; Sharan, C; Sealy, L; Chaudhuri, G				Tripathi, MK; Misra, S; Khedkar, SV; Hamilton, N; Irvin-Wilson, C; Sharan, C; Sealy, L; Chaudhuri, G			Regulation of BRCA2 gene expression by the SLUG repressor protein in human breast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS SNAIL; DOWN-REGULATION; IN-VIVO; PROMOTER; BINDING; SILENCER; FAMILY; RNA	The expression of the breast cancer susceptibility protein BRCA2 is highly regulated in human breast, ovary, and pancreatic cells. BRCA2 is not expressed in the nondividing cells, and expression is cell cycle stage-dependent and is elevated in the sporadic cancer cells. Mutational analysis of the upstream sequence of the human BRCA2 gene revealed an E2-box-containing silencer at the - 701 to - 921 position. The E2-box is essential for the cell-cycle stage-dependent activity of the silencer. We affinity-purified a 29-kDa silencer-binding protein (SBP) from the nuclear extracts of human breast cells BT-549 and MDA-MB-231. We explored whether the E2-box- binding repressor protein SLUG, which is of similar molecular size, is involved in the silencing process. Supershift assay with the purified SBP and anti-SLUG antibody revealed the identity of the SBP as SLUG. We found that silencer is inactive in the human breast cancer cells such as MDA-MB-468 and MCF-7 that do not express SLUG, further suggesting the involvement of SLUG in the BRCA2 gene silencing. Inducible expression of human SLUG in the dividing MDA-MB-468 cells reduced BRCA2 RNA levels with the activation of the silencer. Furthermore, small interfering RNA-mediated knockdown of SLUG mRNA in the BT-549 cells caused inhibition of the silencer function. Chromatin immunoprecipitation assays suggested that SLUG mediates its action by recruiting C-terminal-binding protein-1 (CtBP-1) and histone deacetylase-1 (HDAC-1) at the silencer E2-box. The general HDAC inhibitor, trichostatin A, inhibited the SLUG-mediated regulation of the silencer function. It thus appears that SLUG is a negative regulator for BRCA2 gene expression.	Meharry Med Coll, Dept Biomed Sci, Div Canc Biol, Nashville, TN 37208 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37208 USA	Meharry Medical College; Vanderbilt University	Chaudhuri, G (corresponding author), Meharry Med Coll, Dept Biomed Sci, Div Canc Biol, 1005 DB Todd Jr Blvd, Nashville, TN 37208 USA.	gchaudhuri@mmc.edu			NATIONAL CANCER INSTITUTE [U54CA091408] Funding Source: NIH RePORTER; NCI NIH HHS [U54 CA091408-01, U54 CA091408, 1U54CA091408-010003] Funding Source: Medline; NIMHD NIH HHS [U54 MD007593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		Bertwistle D, 1997, CANCER RES, V57, P5485; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; CAMPBELL MJ, 1994, MED STAT COMMONSENSE; Chodosh LA, 1998, J MAMMARY GLAND BIOL, V3, P389, DOI 10.1023/A:1018784031651; Come C, 2004, J MAMMARY GLAND BIOL, V9, P183, DOI 10.1023/B:JOMG.0000037161.91969.de; Davis PL, 1999, ONCOGENE, V18, P6000, DOI 10.1038/sj.onc.1202990; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Hajra KM, 2002, CANCER RES, V62, P1613; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; Humphrey GW, 1996, GENE EXPRESSION, V6, P151; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Keen JC, 2003, CANCER-AM CANCER SOC, V97, P825, DOI 10.1002/cncr.11126; Kropotov A, 1999, EUR J BIOCHEM, V260, P336, DOI 10.1046/j.1432-1327.1999.00162.x; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Sambrook J, 2001, MOL CLONING LAB MANU; Scully R, 2004, J MAMMARY GLAND BIOL, V9, P237, DOI 10.1023/B:JOMG.0000048771.93906.3e; Sharan C, 1999, BIOCHEM BIOPH RES CO, V265, P285, DOI 10.1006/bbrc.1999.1652; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; SPECTOR DL, 1997, CELLS LAB MANUAL; Su LK, 1998, ONCOGENE, V17, P2377, DOI 10.1038/sj.onc.1202162; Tripathi MK, 2005, BIOCHEM BIOPH RES CO, V328, P43, DOI 10.1016/j.bbrc.2004.12.142; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wu K, 2000, J BIOL CHEM, V275, P35548, DOI 10.1074/jbc.M004390200; Wu KJ, 2003, J BIOL CHEM, V278, P15652, DOI 10.1074/jbc.M211297200; Zwijsen A, 2001, MOL CELL ENDOCRINOL, V180, P13, DOI 10.1016/S0303-7207(01)00505-6	31	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17163	17171		10.1074/jbc.M501375200	http://dx.doi.org/10.1074/jbc.M501375200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15734731	Green Accepted, hybrid			2022-12-25	WOS:000228615500077
J	Lee, MH; Rapti, M; Murphy, G				Lee, MH; Rapti, M; Murphy, G			Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting - Fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-alpha-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; ESCHERICHIA-COLI; APOPTOSIS; SEQUENCE; EXPRESSION; INVASION; DEATH	Tissue inhibitors of metalloproteinases (TIMPs) are the endogenous inhibitors of the matrix metalloproteinases, the ADAMs ( a disintegrin and metalloproteinase) and the ADAM-TS ( ADAM with thrombospondin repeats) proteinases. There are four mammalian TIMPs (TIMP-1 to -4), and each TIMP has its own profile of metalloproteinase inhibition. TIMP-4 is the latest member of the TIMPs to be cloned, and it has never been reported to be active against the tumor necrosis factor-alpha-converting enzyme ( TACE, ADAM-17). Here we examined the inhibitory properties of the full-length and the N-terminal domain form of TIMP-4 ( N-TIMP-4) with TACE and showed that N- TIMP-4 is a far superior inhibitor than its full-length counterpart. Although full-length TIMP-4 displayed negligible activity against TACE, N- TIMP-4 is a slow tight-binding inhibitor with low nanomolar binding affinity. Our findings suggested that the C-terminal subdomains of the TIMPs have a significant impact over their activities with the ADAMs. To elucidate further the molecular basis that underpins TIMP/TACE interactions, we sculpted N-TIMP-4 with the surface residues of TIMP-3, the only native TIMP inhibitor of the enzyme. Transplantation of only three residues, Pro-Phe-Gly, onto the AB-loop of N- TIMP-4 resulted in a 10-fold enhancement in binding affinity; the K-i values of the resultant mutant were almost comparable with that of TIMP-3. Further mutation at the EF-loop supported our earlier findings on the preference of TACE for leucine at this locus. Drawing together our previous experience in TACE-targeted mutagenesis by using TIMP-1 and -2 scaffolds, we have finally resolved the mystery of the selective sensitivity of TACE to TIMP-3.	Univ Cambridge, Dept Oncol, Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of Cambridge	Murphy, G (corresponding author), Univ Cambridge, Dept Oncol, Cambridge Inst Med Res, Wellcome Trust MRC Bldg, Cambridge CB2 2XY, England.	gm290@cam.ac.uk						Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Ahonen M, 1998, CANCER RES, V58, P2310; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Davis D, 2000, METH MOL B, V151, P267, DOI 10.1385/1-59259-046-2:267; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Hashimoto G, 2001, FEBS LETT, V494, P192, DOI 10.1016/S0014-5793(01)02323-7; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Kheradmand F, 2002, BIOESSAYS, V24, P8, DOI 10.1002/bies.10037; Leco KJ, 2001, J CLIN INVEST, V108, P817, DOI 10.1172/JCI12067; Lee MH, 2004, J BIOL CHEM, V279, P45121, DOI 10.1074/jbc.M406611200; Lee MH, 2004, J BIOL CHEM, V279, P17562, DOI 10.1074/jbc.M312589200; Lee MH, 2003, J BIOL CHEM, V278, P40224, DOI 10.1074/jbc.M305678200; Lee MH, 2002, BIOCHEM J, V364, P227, DOI 10.1042/bj3640227; Lee MH, 2001, BIOCHEM BIOPH RES CO, V280, P945, DOI 10.1006/bbrc.2000.4192; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; MORRISON JF, 1995, METHOD ENZYMOL, V248, P201; NEGRO A, 1995, FEBS LETT, V360, P52, DOI 10.1016/0014-5793(95)00073-I; Stracke JO, 2000, J BIOL CHEM, V275, P14809, DOI 10.1074/jbc.275.20.14809; Stratmann B, 2001, BIOL CHEM, V382, P987, DOI 10.1515/BC.2001.124; Troeberg L, 2002, BIOCHEMISTRY-US, V41, P15025, DOI 10.1021/bi026454l; Tuuttila A, 1998, J MOL BIOL, V284, P1133, DOI 10.1006/jmbi.1998.2223; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; Williamson RA, 2000, METH MOL B, V151, P257, DOI 10.1385/1-59259-046-2:257; Williamson RA, 2001, J BIOL CHEM, V276, P32966, DOI 10.1074/jbc.M101843200; WILLIAMSON RA, 1994, PROTEIN ENG, V7, P1035, DOI 10.1093/protein/7.8.1035	32	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15967	15975		10.1074/jbc.M500897200	http://dx.doi.org/10.1074/jbc.M500897200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713681	hybrid			2022-12-25	WOS:000228444800063
J	Brini, M; Manni, S; Pierobon, N; Du, GG; Sharma, P; MacLennan, DH; Carafoli, E				Brini, M; Manni, S; Pierobon, N; Du, GG; Sharma, P; MacLennan, DH; Carafoli, E			Ca2+ signaling in HEK-293 and skeletal muscle cells expressing recombinant ryanodine receptors harboring malignant hyperthermia and central core disease mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-FORMING SEGMENT; RELEASE CHANNEL; ENDOPLASMIC-RETICULUM; CALCIUM-ION; CAFFEINE; MITOCHONDRIA; SENSITIVITY; HOMEOSTASIS; HALOTHANE; AEQUORIN	Malignant hyperthermia (MH) and central core disease (CCD) are caused by mutations in the RYR1 gene encoding the skeletal muscle isoform of the ryanodine receptor (RyR1), a homotetrameric Ca2+ release channel. Rabbit RyR1 mutant cDNAs carrying mutations corresponding to those in human RyR1 that cause MH and CCD were expressed in HEK-293 cells, which do not have endogenous RyR, and in primary cultures of rat skeletal muscle, which express rat RyR1. Analysis of intracellular Ca2+ pools was performed using aequorin probes targeted to the lumen of the endo/sarcoplasmic reticulum (ER/SR), to the mitochondrial matrix, or to the cytosol. Mutations associated with MH caused alterations in intracellular Ca2+ homeostasis different from those associated with CCD. Measurements of luminal ER/SR Ca2+ revealed that the mutations generated leaky channels in all cases, but the leak was particularly pronounced in CCD mutants. Cytosolic and mitochondrial Ca2+ transients induced by caffeine stimulation were drastically augmented in the MH mutant, slightly reduced in one CCD mutant (Y523S) and completely abolished in another (I4898T). The results suggest that local Ca2+ derangements of different degrees account for the specific cellular phenotypes of the two disorders.	Univ Padua, Dept Biochem, I-35121 Padua, Italy; Univ Padua, CNR, Ctr Study Biomembranes, I-35121 Padua, Italy; VIMM, I-35129 Padua, Italy; Agripolis, Dept Expt Vet Sci, Legnaro, Italy; Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Veneto Institute Molecular Medicine; University of Toronto	Brini, M (corresponding author), Univ Padua, Dept Biochem, Viale G Colombo 3, I-35121 Padua, Italy.	brini@mail.bio.unipd.it	Brini, Marisa/K-5189-2016; Manni, Sabrina/AAE-9182-2021; Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094; Brini, Marisa/0000-0001-5141-0243; MANNI, SABRINA/0000-0001-6804-0680	Telethon [GP0193Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Avila G, 2001, P NATL ACAD SCI USA, V98, P4215, DOI 10.1073/pnas.071048198; Avila G, 2001, J GEN PHYSIOL, V118, P277, DOI 10.1085/jgp.118.3.277; Avila G, 2001, J BIOL CHEM, V276, P17732, DOI 10.1074/jbc.M009685200; Balshaw D, 1999, P NATL ACAD SCI USA, V96, P3345, DOI 10.1073/pnas.96.7.3345; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Brini M, 1997, MOL BIOL CELL, V8, P129, DOI 10.1091/mbc.8.1.129; CANTINI M, 1994, IN VITRO CELL DEV-AN, V30A, P131; Censier K, 1998, J CLIN INVEST, V101, P1233, DOI 10.1172/JCI993; Dirksen RT, 2002, TRENDS CARDIOVAS MED, V12, P189, DOI 10.1016/S1050-1738(02)00163-9; Dirksen RT, 2002, FRONT BIOSCI-LANDMRK, V7, pD659, DOI 10.2741/dirksen; Du GG, 2004, BIOCHEM J, V382, P557, DOI 10.1042/BJ20040580; Du GG, 2001, J BIOL CHEM, V276, P31760, DOI 10.1074/jbc.M102751200; Gao L, 2000, BIOPHYS J, V79, P828, DOI 10.1016/S0006-3495(00)76339-9; Loke J, 1998, AM J MED, V104, P470, DOI 10.1016/S0002-9343(98)00108-9; Lynch PJ, 1999, P NATL ACAD SCI USA, V96, P4164, DOI 10.1073/pnas.96.7.4164; MACLENNAN DH, 1992, SCIENCE, V256, P789, DOI 10.1126/science.1589759; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; MacLennan DH, 2003, NAT REV MOL CELL BIO, V4, P566, DOI 10.1038/nrm1151; MacLennan DH, 1999, CALCIUM AS A CELLULAR REGULATOR, P610; MACLENNAN DH, 1996, MOL BIOL MEMBRANE TR, P181; McCarthy TV, 2000, HUM MUTAT, V15, P410, DOI 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; OTSU K, 1994, J BIOL CHEM, V269, P9413; Rizzuto R, 1995, METHOD ENZYMOL, V260, P417, DOI 10.1016/0076-6879(95)60155-4; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Robert V, 1998, J BIOL CHEM, V273, P30372, DOI 10.1074/jbc.273.46.30372; Tong JF, 1999, J BIOL CHEM, V274, P693, DOI 10.1074/jbc.274.2.693; Tong JF, 1999, BIOCHEM J, V343, P39, DOI 10.1042/0264-6021:3430039; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; TREVES S, 1994, BIOCHEM J, V301, P661, DOI 10.1042/bj3010661; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971	35	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15380	15389		10.1074/jbc.M410421200	http://dx.doi.org/10.1074/jbc.M410421200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15689621	hybrid			2022-12-25	WOS:000228236800124
J	Charvet, C; Canonigo, AJ; Billadeau, DD; Altman, A				Charvet, C; Canonigo, AJ; Billadeau, DD; Altman, A			Membrane localization and function of Vav3 in T cells depend on its association with the adapter SLP-76	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; LYMPHOCYTE DEVELOPMENT; BIOLOGICAL-ACTIVITY; IMMUNE-RECOGNITION; PLASMA-MEMBRANE; FAMILY PROTEINS; GENE ACTIVATION; RHO-FAMILY; PKC-THETA; B-CELLS	The Vav family of guanine exchange factors plays a critical role in lymphocyte proliferation, cytoskeletal reorganization, and gene transcription upon immunoreceptor engagement. Although the role of Vav1 in T cells is well documented, the role of Vav3 is less clear. We investigated the subcellular localization of Vav3 during T cell activation. We report here that phosphorylation of Vav3 on tyrosine residue Tyr(173) is not required for T cell receptor (TCR)-induced Vav3 membrane translocation or immunological synapse (IS) recruitment, but mutation of this residue enhanced TCR-induced nuclear factor of activated T cells ( NFAT) activation. However, Vav3 mutants either containing an Src homology 2 (SH2)-disabled point mutation (R697L) or lacking its SH3-SH2-SH3 domains were unable to bind SLP-76 did not translocate to the membrane or to the IS and furthermore failed to activate NFAT. Importantly, the membrane translocation of Vav3 was abrogated in Lck, ZAP-70, LAT, and SLP-76-deficient T cells, where Vav3 binding to SLP-76 was disrupted. Finally, we confirmed and underlined the critical role of Vav3 in NFAT activation by knocking down Vav3 expression in Vav1-deficient T cells. Altogether, our data show that TCR-induced association of Vav3 with SLP-76 is required for its membrane/IS localization and function.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA; Mayo Clin & Mayo Fdn, Coll Med, Div Dev Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Immunol, Rochester, MN 55905 USA	La Jolla Institute for Immunology; Mayo Clinic; Mayo Clinic	Charvet, C (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA.	charvet@liai.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050819] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50819] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Altman A, 1999, ADV IMMUNOL, V72, P1, DOI 10.1016/S0065-2776(08)60017-6; Arudchandran R, 2000, J EXP MED, V191, P47, DOI 10.1084/jem.191.1.47; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Charvet C, 2002, J BIOL CHEM, V277, P15376, DOI 10.1074/jbc.M111627200; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Doody GM, 2000, EMBO J, V19, P6173, DOI 10.1093/emboj/19.22.6173; Fang N, 1999, J BIOL CHEM, V274, P16206, DOI 10.1074/jbc.274.23.16206; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Glimcher LH, 1999, CELL, V96, P13, DOI 10.1016/S0092-8674(00)80955-1; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hehner SP, 2000, J BIOL CHEM, V275, P18160, DOI 10.1074/jbc.275.24.18160; Inabe K, 2002, J EXP MED, V195, P189, DOI 10.1084/jem.20011571; Johmura S, 2003, IMMUNITY, V18, P777, DOI 10.1016/S1074-7613(03)00139-0; Kaminuma O, 2001, MOL CELL BIOL, V21, P3126, DOI 10.1128/MCB.21.9.3126-3136.2001; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Lin J, 2001, J CELL SCI, V114, P243; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Liu Y, 1997, J EXP MED, V185, P251, DOI 10.1084/jem.185.2.251; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Nishida M, 2001, EMBO J, V20, P2995, DOI 10.1093/emboj/20.12.2995; Raab M, 2001, IMMUNITY, V15, P921, DOI 10.1016/S1074-7613(01)00248-5; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Salojin KV, 2000, J BIOL CHEM, V275, P5966, DOI 10.1074/jbc.275.8.5966; Schuebel KE, 1996, ONCOGENE, V13, P363; Tamas P, 2001, CELL SIGNAL, V13, P475, DOI 10.1016/S0898-6568(01)00172-3; Tartare-Deckert S, 2001, J BIOL CHEM, V276, P20849, DOI 10.1074/jbc.M010588200; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Tybulewicz VLJ, 2003, IMMUNOL REV, V192, P42, DOI 10.1034/j.1600-065X.2003.00032.x; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Villalba M, 2002, J CELL BIOL, V157, P253, DOI 10.1083/jcb.200201097; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Zakaria S, 2004, J EXP MED, V199, P429, DOI 10.1084/jem.20031228; Zugaza JL, 2002, J BIOL CHEM, V277, P45377, DOI 10.1074/jbc.M208039200	46	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15289	15299		10.1074/jbc.M500275200	http://dx.doi.org/10.1074/jbc.M500275200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708849	hybrid			2022-12-25	WOS:000228236800114
J	Lin, JX; Liu, JL; Wang, Y; Zhu, JW; Zhou, K; Smith, N; Zhan, X				Lin, JX; Liu, JL; Wang, Y; Zhu, JW; Zhou, K; Smith, N; Zhan, X			Differential regulation of cortactin and N-WASP-mediated actin polymerization by missing in metastasis (MIM) protein	ONCOGENE			English	Article						MIM; cortactin; N-WASP; actin; cell motility; PDGF	FILAMENT NETWORK FORMATION; ARP2/3 COMPLEX; ESCHERICHIA-COLI; ACTIVATION; CELLS; EXPRESSION; NUCLEATION; SUBSTRATE; INTERACTS; DYNAMICS	Missing in metastasis (MIM) gene encodes an actin binding protein that is expressed at low levels in a subset of malignant cell lines. MIM protein tagged by green fluorescent protein (GFP) colocalizes with cortactin, an Arp2/3 complex activator, and interacts directly with the SH3 domain of cortactin. Recombinant full-length MIM promotes markedly cortactin and Arp2/3 complex-mediated actin polymerization in an SH3 dependent manner. In contrast, MIM-CT, a short splicing variant of MIM, binds poorly to cortactin in vitro and is unable to enhance actin polymerization. Full-length MIM binds to G-actin with a similar affinity as N-WASP-VCA, a constitutively active form of N-WASP, and inhibits N-WASP-VCA-mediated actin polymerization as analysed in vitro. The significance of the association of MIM with cortactin and G-actin was evaluated in NIH3T3 cells expressing several MIM constructs. Overexpression of full-length wild-type MIM-GFP inhibited markedly the motility of NIH3T3 cells induced by PDGF and that of human vein umbilical endothelial cells induced by sphingosine 1 phosphate. However, an MIM mutant with deletion of the WH2 domain, which is responsible for G-actin binding, enhanced cell motility. The motility inhibition imposed by MIM was compromised in the cells overexpressing N-WASP. In contrast, deletion of an MIM proline-rich domain, which is required for an optimal binding to cortactin, substantiated the MIM-mediated inhibition of cell motility. These data imply that MIM regulates cell motility by modulating different Arp2/3 activators in a distinguished manner.	Amer Red Cross, Holland Lab, Rockville, MD 20855 USA; Univ Maryland, Sch Med, Dept Pathol, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	American Red Cross; University System of Maryland; University of Maryland Baltimore	Zhan, X (corresponding author), Amer Red Cross, Holland Lab, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	szhan001@umaryland.edu						Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; BUBB MR, 1991, J BIOL CHEM, V266, P3820; Cheng L, 1997, GENE THER, V4, P1013, DOI 10.1038/sj.gt.3300507; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Kim K, 2004, BIOCHEMISTRY-US, V43, P2422, DOI 10.1021/bi036173t; Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Li YS, 2001, CANCER RES, V61, P6906; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; Mattila PK, 2003, J BIOL CHEM, V278, P8452, DOI 10.1074/jbc.M212113200; Millard TH, 2004, BIOCHEM J, V380, P1, DOI 10.1042/BJ20040176; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; SAFER D, 1991, J BIOL CHEM, V266, P4029; Schafer DA, 2002, CURR BIOL, V12, P1852, DOI 10.1016/S0960-9822(02)01228-9; Uruno T, 2003, J BIOL CHEM, V278, P26086, DOI 10.1074/jbc.M301997200; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; WEISS S, 1992, GENE, V121, P203, DOI 10.1016/0378-1119(92)90123-7; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yamagishi A, 2004, J BIOL CHEM, V279, P14929, DOI 10.1074/jbc.M309408200; ZHAN X, 1993, J BIOL CHEM, V268, P24427	27	75	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 17	2005	24	12					2059	2066		10.1038/sj.onc.1208412	http://dx.doi.org/10.1038/sj.onc.1208412			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688017				2022-12-25	WOS:000227681900010
J	Lemkine, GF; Raji, A; Alfama, G; Turque, N; Hassani, Z; Alegria-Prevot, O; Samarut, J; Levi, G; Demeneix, BA				Lemkine, GF; Raji, A; Alfama, G; Turque, N; Hassani, Z; Alegria-Prevot, O; Samarut, J; Levi, G; Demeneix, BA			Adult neural stem cell cycling in vivo requires thyroid hormone and its alpha receptor	FASEB JOURNAL			English	Article						subventricular zone; NSC; TH	CENTRAL-NERVOUS-SYSTEM; HISTONE H3; OLIGODENDROCYTE DIFFERENTIATION; XENOPUS-LAEVIS; GENE-TRANSFER; MOUSE-BRAIN; PHOSPHORYLATION; EXPRESSION; PROLIFERATION; MICE	Thyroid hormones (TH) are essential for brain development. However, information on if and how this key endocrine factor affects adult neurogenesis is fragmentary. We thus investigated the effects of TH on proliferation and apoptosis of stem cells in the subventricular zone(SVZ), as well as on migration of transgene-tagged neuroblasts out of the stem cell niche. Hypothyroidism significantly reduced all three of these processes, inhibiting generation of new cells. To determine the mechanisms relaying TH action in the SVZ, we analyzed which receptor was implicated and whether the effects were played out directly at the level of the stem cell population. The alpha TH receptor( TR alpha), but not TR beta, was found to be expressed in nestin positive progenitor cells of the SVZ. Further,use of TR alpha mutant mice showed TR alpha to be required to maintain full proliferative activity. Finally, a direct TH transcriptional effect, not mediated through other cell populations, was revealed by targeted gene transfer to stem cells in vivo. Indeed, TH directly modulated transcription from the c-myc promoter reporter construct containing a functional TH response element containing TRE but not from a mutated TRE sequence. We conclude that liganded-TR alpha is critical for neurogenesis in the adult mammalian brain.	Museum Natl Hist Nat, CNRS, UMR 5166, F-75231 Paris, France; Ecole Normale Super Lyon, Biol Cellulaire & Mol Lab, CNRS, UMR 5665, F-69364 Lyon, France	Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Demeneix, BA (corresponding author), Museum Natl Hist Nat, CNRS, UMR 5166, F-75231 Paris, France.	demeneix@mnhn.fr	Levi, Giovanni/B-4416-2013; Samarut, Jacques/AAD-2587-2019	Levi, Giovanni/0000-0002-7041-6787				Abdallah B, 1996, INT J DEV BIOL, V40, P507; Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; BAAS D, 1994, NEUROSCI LETT, V176, P47, DOI 10.1016/0304-3940(94)90868-0; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; BEARD MD, 1987, DEV BRAIN RES, V36, P181, DOI 10.1016/0165-3806(87)90022-8; Billon N, 2001, DEV BIOL, V235, P110, DOI 10.1006/dbio.2001.0293; BRICKMAN YG, 1995, J BIOL CHEM, V270, P24941, DOI 10.1074/jbc.270.42.24941; Brunner S, 2000, GENE THER, V7, P401, DOI 10.1038/sj.gt.3301102; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; D'Amour KA, 2003, P NATL ACAD SCI USA, V100, P11866, DOI 10.1073/pnas.1834200100; Davis Jennifer Duncan, 2003, Curr Psychiatry Rep, V5, P384, DOI 10.1007/s11920-003-0073-6; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Flamant F, 2003, TRENDS ENDOCRIN MET, V14, P85, DOI 10.1016/S1043-2760(02)00043-7; FORREST D, 1990, ONCOGENE, V5, P309; Forrest D, 2002, ENDOCRINOLOGY, V143, P2466, DOI 10.1210/en.143.7.2466; Forrest D, 2002, CURR OPIN NEUROBIOL, V12, P49, DOI 10.1016/S0959-4388(02)00289-1; Gauthier K, 1999, EMBO J, V18, P623, DOI 10.1093/emboj/18.3.623; Harpavat S, 2003, THYROID, V13, P1013, DOI 10.1089/105072503770867183; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; JACOBSON M, 2004, DEV NEUROBIOLOGY; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; LabatMoleur F, 1996, GENE THER, V3, P1010; Lemkine GF, 1999, J DRUG TARGET, V7, P305, DOI 10.3109/10611869909085513; Lemkine GF, 2002, MOL CELL NEUROSCI, V19, P165, DOI 10.1006/mcne.2001.1084; LEZOUALCH F, 1995, J BIOL CHEM, V270, P12100, DOI 10.1074/jbc.270.20.12100; Macchia PE, 2001, P NATL ACAD SCI USA, V98, P349, DOI 10.1073/pnas.011306998; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Marsh-Armstrong N, 1999, NEURON, V24, P871, DOI 10.1016/S0896-6273(00)81034-X; MORSHEAD CM, 1992, J NEUROSCI, V12, P249; Morte B, 2004, ENDOCRINOLOGY, V145, P1386, DOI 10.1210/en.2003-1123; Nait-Oumesmar B, 1999, EUR J NEUROSCI, V11, P4357, DOI 10.1046/j.1460-9568.1999.00873.x; Neurath AR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-6; Perez-Juste G, 2000, J BIOL CHEM, V275, P1307, DOI 10.1074/jbc.275.2.1307; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; Roth KA, 2000, P NATL ACAD SCI USA, V97, P466, DOI 10.1073/pnas.97.1.466; Saghatelyan A, 2004, NAT NEUROSCI, V7, P347, DOI 10.1038/nn1211; Samuels MH, 1998, THYROID, V8, P803, DOI 10.1089/thy.1998.8.803; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; Shi YH, 2004, NATURE, V427, P78, DOI 10.1038/nature02211; Shingo T, 2003, SCIENCE, V299, P117, DOI 10.1126/science.1076647; Tokumoto YM, 2001, EMBO J, V20, P5261, DOI 10.1093/emboj/20.18.5261	45	134	145	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					863	+		10.1096/fj.04-2916fje	http://dx.doi.org/10.1096/fj.04-2916fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15728663	Green Published			2022-12-25	WOS:000227591900010
J	Sherameti, I; Shahollari, B; Venus, Y; Altschmied, L; Varma, A; Oelmuller, R				Sherameti, I; Shahollari, B; Venus, Y; Altschmied, L; Varma, A; Oelmuller, R			The endophytic fungus Piriformospora indica stimulates the expression of nitrate reductase and the starch-degrading enzyme glucan-water dikinase in tobacco and Arabidopsis roots through a homeodomain transcription factor that binds to a conserved motif in their promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; GENE-EXPRESSION; DISEASE RESISTANCE; PROTEIN; BENZOTHIADIAZOLE; PHOSPHORYLATION; MEMBRANE; SUBUNIT; GROWTH; ACID	Piriformospora indica, an endophytic fungus of the Sebacinaceae family, promotes growth of Arabidopsis and tobacco seedlings and stimulates nitrogen accumulation and the expression of the genes for nitrate reductase and the starch-degrading enzyme glucan-water dikinase (SEX1) in roots. Neither growth promotion nor stimulation of the two enzymes requires heterotrimeric G proteins. P. indica also stimulates the expression of the uidA gene under the control of the Arabidopsis nitrate reductase (Nia2) promoter in transgenic tobacco seedlings. At least two regions (-470/-439 and -103/-89) are important for Nia2 promoter activity in tobacco roots. One of the regions contains an element, ATGATAGATAAT, that binds to a homeodomain transcription factor in vitro. The message for this transcription factor is up-regulated by P. indica. The transcription factor also binds to a CTGATAGATCT segment in the SEX1 promoter in vitro. We propose that the growth-promoting effect initiated by P. indica is accompanied by a co-regulated stimulation of enzymes involved in nitrate and starch metabolisms.	Univ Jena, Inst Gen Bot & Plant Physiol, D-07743 Jena, Germany; IPK, D-064566 Gatersleben, Germany; Jawaharlal Nehru Univ, Sch Life Sci, New Delhi 110067, India	Friedrich Schiller University of Jena; Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; Jawaharlal Nehru University, New Delhi	Oelmuller, R (corresponding author), Univ Jena, Inst Gen Bot & Plant Physiol, Dornburger Str 159, D-07743 Jena, Germany.	b7oera@hotmail.com		Altschmied, Lothar/0000-0002-7692-2971				BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Boukcim H, 2003, J PLANT PHYSIOL, V160, P1211, DOI 10.1078/0176-1617-00973; Chen H, 2003, PLANT PHYSIOL, V132, P1391, DOI 10.1104/pp.103.022434; Chen IP, 2003, PLANT J, V35, P771, DOI 10.1046/j.1365-313X.2003.01847.x; Esseling JJ, 2004, J MICROSC-OXFORD, V214, P104, DOI 10.1111/j.0022-2720.2004.01322.x; FIALA ES, 1989, CANCER RES, V49, P5518; FLIEGER K, 1993, PLANT J, V4, P9, DOI 10.1046/j.1365-313X.1993.04010009.x; Gage DJ, 2004, MICROBIOL MOL BIOL R, V68, P280, DOI 10.1128/MMBR.68.2.280-300.2004; Gorlach J, 1996, PLANT CELL, V8, P629, DOI 10.1105/tpc.8.4.629; Guescini M, 2003, MOL GENET GENOMICS, V269, P807, DOI 10.1007/s00438-003-0894-3; Hanawa F, 2000, PHYTOCHEMISTRY, V53, P55, DOI 10.1016/S0031-9422(99)00443-4; Hildebrandt U, 2002, PHYSIOL PLANTARUM, V115, P125, DOI 10.1034/j.1399-3054.2002.1150115.x; HITE M, 1979, ENVIRON MUTAGEN, V1, P383, DOI 10.1002/em.2860010411; Hoth S, 2002, J CELL SCI, V115, P4891, DOI 10.1242/jcs.00175; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; Jeon JS, 2000, PLANT CELL, V12, P871, DOI 10.1105/tpc.12.6.871; Kaldorf M, 1998, MOL PLANT MICROBE IN, V11, P439, DOI 10.1094/MPMI.1998.11.6.439; Kim MC, 2002, NATURE, V416, P447, DOI 10.1038/416447a; Kumari R, 2003, CURR SCI INDIA, V85, P1672; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawton KA, 1996, PLANT J, V10, P71, DOI 10.1046/j.1365-313X.1996.10010071.x; MARX DH, 1969, PHYTOPATHOLOGY, V59, P153; Mikaelian I, 1996, Methods Mol Biol, V57, P193; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; OELMULLER R, 1993, MOL GEN GENET, V237, P261, DOI 10.1007/BF00282808; OELMULLER R, 2004, ENDOCYT CELL RES, V15, P504; Peskan T, 2000, PLANT MOL BIOL, V42, P915, DOI 10.1023/A:1006477631166; Peskan-Berghofer T, 2005, PLANTA, V220, P737, DOI 10.1007/s00425-004-1393-4; Peskan-Berghofer T, 2004, PHYSIOL PLANTARUM, V122, P465, DOI 10.1111/j.1399-3054.2004.00424.x; Pham GH, 2004, PLANT SURFACE MICROBIOLOGY, P237; Reboutier D, 2002, MOL PLANT MICROBE IN, V15, P932, DOI 10.1094/MPMI.2002.15.9.932; Reimann R, 2004, PLANT PHYSIOL, V135, P121, DOI 10.1104/pp.103.036236; Ritte G, 2004, PLANT PHYSIOL, V135, P2068, DOI 10.1104/pp.104.041301; Ritte G, 2002, P NATL ACAD SCI USA, V99, P7166, DOI 10.1073/pnas.062053099; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sauerborn J, 2002, PHYTOPATHOLOGY, V92, P59, DOI 10.1094/PHYTO.2002.92.1.59; SHAHOLLARI B, 2005, IN PRESS J PLANT PHY; Sherameti I, 2004, PLANT J, V38, P578, DOI 10.1111/j.1365-313X.2004.02069.x; Sherameti I, 2002, J BIOL CHEM, V277, P46594, DOI 10.1074/jbc.M202924200; SINGH A, 2001, J ORCHID, V15, P89; Singh Anjana, 2003, Indian Journal of Biotechnology, V2, P65; Stauber EJ, 2003, EUKARYOT CELL, V2, P978, DOI 10.1128/EC.2.5.978-994.2003; Stockel J, 2004, J BIOL CHEM, V279, P10243, DOI 10.1074/jbc.M309246200; Varma A, 1999, APPL ENVIRON MICROB, V65, P2741; Verma S, 1998, MYCOLOGIA, V90, P896, DOI 10.2307/3761331	45	169	197	3	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26241	26247		10.1074/jbc.M500447200	http://dx.doi.org/10.1074/jbc.M500447200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15710607	hybrid			2022-12-25	WOS:000230386800039
J	Demine, R; Walden, P				Demine, R; Walden, P			Testing the role of gp96 as peptide chaperone in antigen processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK-PROTEIN GP96; MASS-SPECTROMETRY DATA; CLASS-I MOLECULES; ENDOPLASMIC-RETICULUM; BINDING-SITE; PROTEASOMAL CLEAVAGES; DENDRITIC CELLS; IDENTIFICATION; AMINOPEPTIDASE; GP96/GRP94	gp96 is a 96-kDa glycoprotein of the endoplasmic reticulum that is believed to be involved in antigen processing as an intermediate carrier of peptides for presentation by major histocompatibility complex (MHC) class I molecules. This function implies that gp96 carries a large array of different peptides that represent the antigenicity of the cell and can serve all MHC class I molecules. So far, the evidence regarding these peptides is largely indirect and based on experiments where mice immunized with gp96 from tumor or virus-infected cells developed T cellular immune responses with the corresponding specificities. We analyzed by mass spectrometry peptides isolated from gp96 and found a number of different peptides derived from the proteins of different cellular compartments but mostly cytoplasm and nucleus. The sequences of these peptides provide information on the specificity of antigen processing and reveal structural requirements for binding to gp96 that only partially correspond to those of peptides presented by MHC class I molecules. The yield of peptides extracted from gp96 was far substoichiometric with an estimated occupancy of this chaperone of between 0.1% and 0.4%. These results strongly argue against a regular role for gp96 as a peptide chaperone in antigen processing.	Humboldt Univ, Charite Univ Med Berlin, Dept Dermatol, D-10117 Berlin, Germany; Clin Res Grp Tumor Immunol, Dept Dermatol & Allergy, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Walden, P (corresponding author), Humboldt Univ, Charite Univ Med Berlin, Dept Dermatol, Schumannstr 20-21, D-10117 Berlin, Germany.	peter.walden@charite.de						Baker-LePain JC, 2002, J EXP MED, V196, P1447, DOI 10.1084/jem.20020436; Berwin B, 2002, J IMMUNOL, V168, P4282, DOI 10.4049/jimmunol.168.9.4282; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Binder RJ, 2004, P NATL ACAD SCI USA, V101, P6128, DOI 10.1073/pnas.0308180101; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Blythe MJ, 2002, BIOINFORMATICS, V18, P434, DOI 10.1093/bioinformatics/18.3.434; Breloer M, 1998, EUR J IMMUNOL, V28, P1016, DOI 10.1002/(SICI)1521-4141(199803)28:03<1016::AID-IMMU1016>3.0.CO;2-G; Chaurand P, 1999, J AM SOC MASS SPECTR, V10, P91, DOI 10.1016/S1044-0305(98)00145-7; Creasy DM, 2002, PROTEOMICS, V2, P1426, DOI 10.1002/1615-9861(200210)2:10<1426::AID-PROT1426>3.0.CO;2-5; Demine R, 2004, RAPID COMMUN MASS SP, V18, P907, DOI 10.1002/rcm.1420; Demine R, 2003, MOL BIOTECHNOL, V25, P71, DOI 10.1385/MB:25:1:71; FALK K, 1994, IMMUNOGENETICS, V39, P230; Fleischer K, 2004, J IMMUNOL, V172, P162, DOI 10.4049/jimmunol.172.1.162; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Gidalevitz T, 2004, J BIOL CHEM, V279, P16543, DOI 10.1074/jbc.M313060200; Holzhutter HG, 1999, J MOL BIOL, V286, P1251, DOI 10.1006/jmbi.1998.2530; Holzhutter HG, 2000, BIOPHYS J, V79, P1196, DOI 10.1016/S0006-3495(00)76374-0; Ishii T, 1999, J IMMUNOL, V162, P1303; KALTOFT K, 1992, IN VITRO CELL DEV-AN, V28A, P161; Kesmir C, 2002, PROTEIN ENG, V15, P287, DOI 10.1093/protein/15.4.287; Kloetzel PM, 2004, CURR OPIN IMMUNOL, V16, P76, DOI 10.1016/j.coi.2003.11.004; Kuttler C, 2000, J MOL BIOL, V298, P417, DOI 10.1006/jmbi.2000.3683; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; Linderoth NA, 2001, J BIOL CHEM, V276, P11049, DOI 10.1074/jbc.M010059200; Linderoth NA, 2000, J BIOL CHEM, V275, P5472, DOI 10.1074/jbc.275.8.5472; McSparron H, 2003, J CHEM INF COMP SCI, V43, P1276, DOI 10.1021/ci030461e; Meng SD, 2002, J IMMUNOL METHODS, V264, P29, DOI 10.1016/S0022-1759(02)00093-5; Meng SD, 2001, LANCET, V357, P528, DOI 10.1016/S0140-6736(00)04050-2; Menoret A, 2001, J BIOL CHEM, V276, P33313, DOI 10.1074/jbc.M103383200; Nagorsen D, 2004, CANCER IMMUNOL IMMUN, V53, P817, DOI 10.1007/s00262-004-0532-x; Nicchitta CV, 2004, CELL STRESS CHAPERON, V9, P325, DOI 10.1379/CSC-62.1; Nicchitta CV, 2003, NAT REV IMMUNOL, V3, P427, DOI 10.1038/nri1089; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; Nussbaum AK, 2001, IMMUNOGENETICS, V53, P87, DOI 10.1007/s002510100300; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Saric T, 2002, NAT IMMUNOL, V3, P1169, DOI 10.1038/ni859; Sastry S, 1999, J BIOL CHEM, V274, P12023, DOI 10.1074/jbc.274.17.12023; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Seifert U, 2003, NAT IMMUNOL, V4, P375, DOI 10.1038/ni905; Serwold T, 2001, NAT IMMUNOL, V2, P644, DOI 10.1038/89800; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860; Zheng H, 2001, J IMMUNOL, V167, P6731, DOI 10.4049/jimmunol.167.12.6731	46	42	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17573	17578		10.1074/jbc.M501233200	http://dx.doi.org/10.1074/jbc.M501233200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728573	hybrid			2022-12-25	WOS:000228807200002
J	Gao, NG; Shang, J; Lehrman, MA				Gao, NG; Shang, J; Lehrman, MA			Analysis of glycosylation in CDG-Ia fibroblasts by fluorophore-assisted carbohydrate electrophoresis - Implications for extracellular glucose and intracellular mannose 6-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENT GLYCOPROTEIN SYNDROME; CONGENITAL DISORDERS; LINKED OLIGOSACCHARIDES; ABNORMAL SYNTHESIS; N-GLYCOSYLATION; DEFECT; TRANSPORT; CORRECTS; SUPPLEMENTATION; GLYCOGEN	Phosphomannomutase (PMM) deficiency causes congenital disorder of glycosylation (CDG)-Ia, a broad spectrum disorder with developmental and neurological abnormalities. PMM converts mannose 6-phosphate (M6P) to mannose-1-phosphate, a precursor of GDP-mannose used to make Glc(3)Man(9)GlcNAc(2)-P-P-dolichol ( lipid-linked oligosaccharide; LLO). LLO, in turn, is the donor substrate of oligosaccharyltransferase for protein N-linked glycosylation. Hepatically produced N-linked glycoproteins in CDG-Ia blood are hypoglycosylated. Upon labeling with [H-3] mannose, CDG-Ia fibroblasts have been widely reported to accumulate [ 3H] LLO intermediates. Since these are thought to be poor oligosaccharyltransferase substrates, LLO intermediate accumulation has been the prevailing explanation for hypoglycosylation in patients. However, this is discordant with sporadic reports of specific glycoproteins ( detected with antibodies) from CDG-Ia fibroblasts being fully glycosylated. Here, fluorophore-assisted carbohydrate electrophoresis ( FACE, a nonradioactive technique) was used to analyze steady-state LLO compositions in CDG-Ia fibroblasts. FACE revealed that low glucose conditions accounted for previous observations of accumulated [H-3] LLO intermediates. Additional FACE experiments demonstrated abundant Glc(3)Man(9)GlcNAc(2)-P-P-dolichol, without hypoglycosylation, in CDG-Ia fibroblasts grown with physiological glucose. This suggested a "missing link" to explain hypoglycosylation in CDG-Ia patients. Because of the possibility of its accumulation, the effects of M6P on glycosylation were explored in vitro. Surprisingly, M6P was a specific activator for cleavage of Glc(3)Man(9)GlcNAc(2)-P-P-dolichol. This led to futile cycling of the LLO pathway, exacerbated by GDP-mannose/ PMM deficiency. The possibilities that M6P may accumulate in hepatocytes and that M6P-stimulated LLO cleavage may account for both hypoglycosylation and the clinical failure of dietary mannose therapy with CDG-Ia patients are discussed.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lehrman, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Blvd, Dallas, TX 75390 USA.	mark.lehrman@utsouthwestern.edu			NIGMS NIH HHS [GM38545, R01 GM038545, R56 GM038545] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM038545, R01GM038545] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand M, 2001, MOL BIOL CELL, V12, P487, DOI 10.1091/mbc.12.2.487; ASIKIN N, 1979, BIOCHEM BIOPH RES CO, V89, P279, DOI 10.1016/0006-291X(79)90975-6; Babovic-Vuksanovic D, 1999, J PEDIATR-US, V135, P775, DOI 10.1016/S0022-3476(99)70103-4; Bohles H, 2001, J INHERIT METAB DIS, V24, P858, DOI 10.1023/A:1013944308881; Chavan M, 2003, J BIOL CHEM, V278, P51441, DOI 10.1074/jbc.M310456200; Dupre T, 2000, GLYCOBIOLOGY, V10, P1277, DOI 10.1093/glycob/10.12.1277; Frank CG, 2004, AM J HUM GENET, V75, P146, DOI 10.1086/422367; Gao NG, 2003, GLYCOBIOLOGY, V13, p1G, DOI 10.1093/glycob/cwg009; Gao NG, 2002, GLYCOBIOLOGY, V12, P353, DOI 10.1093/glycob/12.5.353; Gao NG, 2002, J BIOL CHEM, V277, P39425, DOI 10.1074/jbc.M205195200; Grunewald S, 2001, AM J HUM GENET, V68, P347, DOI 10.1086/318199; Harms HK, 2002, ACTA PAEDIATR, V91, P1065, DOI 10.1080/080352502760311566; Jaeken J, 2001, ANNU REV GENOM HUM G, V2, P129, DOI 10.1146/annurev.genom.2.1.129; Karaoglu D, 2001, BIOCHEMISTRY-US, V40, P12193, DOI 10.1021/bi0111911; Kelleher DJ, 2003, MOL CELL, V12, P101, DOI 10.1016/S1097-2765(03)00243-0; KNAUER R, 1994, J INHERIT METAB DIS, V17, P541, DOI 10.1007/BF00711588; Korner C, 1998, GLYCOBIOLOGY, V8, P165, DOI 10.1093/glycob/8.2.165; Korner C, 1998, GLYCOCONJUGATE J, V15, P499, DOI 10.1023/A:1006939104442; Korner C, 1998, P NATL ACAD SCI USA, V95, P13200, DOI 10.1073/pnas.95.22.13200; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRASNEWICH DM, 1995, GLYCOBIOLOGY, V5, P503, DOI 10.1093/glycob/5.5.503; Lehrman MA, 2001, J BIOL CHEM, V276, P8623, DOI 10.1074/jbc.R100002200; Leuzzi R, 2001, BIOCHEM J, V357, P557, DOI 10.1042/0264-6021:3570557; Marquardt T, 1996, J INHERIT METAB DIS, V19, P246, DOI 10.1007/BF01799441; Marquardt T, 2001, BIOL CHEM, V382, P161, DOI 10.1515/BC.2001.024; MARQUARDT T, 1995, EUR J CELL BIOL, V66, P268; MARTYS JL, 1995, J BIOL CHEM, V270, P25976, DOI 10.1074/jbc.270.43.25976; Niehues R, 1998, J CLIN INVEST, V101, P1414, DOI 10.1172/JCI2350; Ohkura T, 1997, J BIOL CHEM, V272, P6868, DOI 10.1074/jbc.272.11.6868; Panneerselvam K, 1996, J CLIN INVEST, V97, P1478, DOI 10.1172/JCI118570; POWELL LD, 1994, J CLIN INVEST, V94, P1901, DOI 10.1172/JCI117540; Rush JS, 2000, GLYCOBIOLOGY, V10, P829, DOI 10.1093/glycob/10.8.829; Schenk B, 2001, GLYCOBIOLOGY, V11, p61R, DOI 10.1093/glycob/11.5.61R; Shang J, 2004, J BIOL CHEM, V279, P12076, DOI 10.1074/jbc.M400431200; Shang J, 2004, J BIOL CHEM, V279, P9703, DOI 10.1074/jbc.M310837200; Shang J, 2002, GLYCOBIOLOGY, V12, P307, DOI 10.1093/glycob/12.5.307	36	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17901	17909		10.1074/jbc.M500510200	http://dx.doi.org/10.1074/jbc.M500510200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15708848	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000228807200043
J	Fierobe, HP; Mingardon, F; Mechaly, A; Belaich, A; Rincon, MT; Pages, S; Lamed, R; Tardif, C; Belaich, JP; Bayer, EA				Fierobe, HP; Mingardon, F; Mechaly, A; Belaich, A; Rincon, MT; Pages, S; Lamed, R; Tardif, C; Belaich, JP; Bayer, EA			Action of designer cellulosomes on homogeneous versus complex substrates - Controlled incorporation of three distinct enzymes into a defined trifunctional scaffoldin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-CELLULOLYTICUM CELLULOSOME; THERMOCELLUM CELLULOSOME; SEQUENCE-ANALYSIS; ENDOGLUCANASE-A; COHESIN; CELLULASE; PURIFICATION; DEGRADATION; BINDING; PROTEIN	In recent work (Fierobe, H.- P., Bayer, E. A., Tardif, C., Czjzek, M., Mechaly, A., Belai " ch, A., Lamed, R., Shoham, Y., and Belaich, J.- P. ( 2002) J. Biol. Chem. 277, 49621 49630), we reported the self-assembly of a comprehensive set of defined " bifunctional" chimeric cellulosomes. Each complex contained the following: ( i) a chimeric scaffoldin possessing a cellulose-binding module and two cohesins of divergent specificity and (ii) two cellulases, each bearing a dockerin complementary to one of the divergent cohesins. This approach allowed the controlled integration of desired enzymes into a multiprotein complex of predetermined stoichiometry and topology. The observed enhanced synergy on recalcitrant substrates by the bifunctional designer cellulosomes was ascribed to two major factors: substrate targeting and proximity of the two catalytic components. In the present work, the capacity of the previously described chimeric cellulosomes was amplified by developing a third divergent cohesin-dockerin device. The resultant trifunctional designer cellulosomes were assayed on homogeneous and complex substrates ( microcrystalline cellulose and straw, respectively) and found to be considerably more active than the corresponding free enzyme or bifunctional systems. The results indicate that the synergy between two prominent cellulosomal enzymes ( from the family-48 and -9 glycoside hydrolases) plays a crucial role during the degradation of cellulose by cellulosomes and that one dominant family-48 processive endoglucanase per complex is sufficient to achieve optimal levels of synergistic activity. Furthermore cooperation within a cellulosome chimera between cellulases and a hemicellulase from different microorganisms was achieved, leading to a trifunctional complex with enhanced activity on a complex substrate.	CNRS, Inst Biol Struct & Microbiol, F-13402 Marseille, France; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Rowett Res Inst, Microbial Genet Grp, Aberdeen AB21 9SD, Scotland; Univ Aix Marseille 1, F-13331 Marseille, France; Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel	Centre National de la Recherche Scientifique (CNRS); Weizmann Institute of Science; University of Aberdeen; UDICE-French Research Universities; Aix-Marseille Universite; Tel Aviv University	Fierobe, HP (corresponding author), CNRS, Inst Biol Struct & Microbiol, 31 Chemin Joseph Aiguier, F-13402 Marseille, France.	hpfierob@ibsm.cnrs-mrs.fr	Rincon, Marco T/T-4798-2019; FIEROBE, Henri-Pierre/P-4372-2019					BAGNARATARDIF C, 1992, GENE, V119, P17, DOI 10.1016/0378-1119(92)90062-T; Bayer EA, 2004, ANNU REV MICROBIOL, V58, P521, DOI 10.1146/annurev.micro.57.030502.091022; BAYER EA, 1994, TRENDS BIOTECHNOL, V12, P379, DOI 10.1016/0167-7799(94)90039-6; BAYER EA, 2000, PROKARYOTES EVOLVING; Belaich A, 2002, J BACTERIOL, V184, P1378, DOI 10.1128/JB.184.5.1378-1384.2002; Blum DL, 2000, J BACTERIOL, V182, P1346, DOI 10.1128/JB.182.5.1346-1351.2000; FIEROBE HP, 1993, EUR J BIOCHEM, V217, P557, DOI 10.1111/j.1432-1033.1993.tb18277.x; FIEROBE HP, 1991, J BACTERIOL, V173, P7956, DOI 10.1128/jb.173.24.7956-7962.1991; Fierobe HP, 1999, BIOCHEMISTRY-US, V38, P12822, DOI 10.1021/bi9911740; Fierobe HP, 2002, J BIOL CHEM, V277, P49621, DOI 10.1074/jbc.M207672200; Fierobe HP, 2001, J BIOL CHEM, V276, P21257, DOI 10.1074/jbc.M102082200; Gal L, 1997, APPL ENVIRON MICROB, V63, P903, DOI 10.1128/AEM.63.3.903-909.1997; Gal L, 1997, J BACTERIOL, V179, P6595, DOI 10.1128/jb.179.21.6595-6601.1997; Gaudin C, 2000, J BACTERIOL, V182, P1910, DOI 10.1128/JB.182.7.1910-1915.2000; GERNGROSS UT, 1993, MOL MICROBIOL, V8, P325, DOI 10.1111/j.1365-2958.1993.tb01576.x; Hammel M, 2004, J BIOL CHEM, V279, P55985, DOI 10.1074/jbc.M408979200; HUGGETT ASG, 1957, LANCET, V2, P368; Jindou S, 2004, J BIOL CHEM, V279, P9867, DOI 10.1074/jbc.M308673200; LAMED R, 1983, J BACTERIOL, V156, P828, DOI 10.1128/JB.156.2.828-836.1983; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maamar H, 2004, MOL MICROBIOL, V51, P589, DOI 10.1046/j.1365-2958.2003.03859.x; Mohand-Oussaid O, 1999, J BACTERIOL, V181, P4035, DOI 10.1128/JB.181.13.4035-4040.1999; Pages S, 1999, J BACTERIOL, V181, P1801; Pages S, 1997, PROTEINS, V29, P517, DOI 10.1002/(SICI)1097-0134(199712)29:4<517::AID-PROT11>3.3.CO;2-I; PARK JT, 1949, J BIOL CHEM, V181, P149; Perret S, 2004, J BACTERIOL, V186, P6544, DOI 10.1128/JB.186.19.6544-6552.2004; RALET MC, 1994, CARBOHYD RES, V263, P257, DOI 10.1016/0008-6215(94)00177-4; ReverbelLeroy C, 1997, J BACTERIOL, V179, P46, DOI 10.1128/jb.179.1.46-52.1997; Rincon MT, 2004, J BACTERIOL, V186, P2576, DOI 10.1128/JB.186.9.2576-2585.2004; Rincon MT, 2003, J BACTERIOL, V185, P703, DOI 10.1128/JB.185.3.703-713.2003; Schaeffer F, 2002, BIOCHEMISTRY-US, V41, P2106, DOI 10.1021/bi011853m; YARON S, 1995, FEBS LETT, V360, P121, DOI 10.1016/0014-5793(95)00074-J; Yu PQ, 2003, J AGR FOOD CHEM, V51, P218, DOI 10.1021/jf020476x	33	199	211	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16325	16334		10.1074/jbc.M414449200	http://dx.doi.org/10.1074/jbc.M414449200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705576	hybrid			2022-12-25	WOS:000228444800104
J	Lemeshko, VV; Arias, M; Orduz, S				Lemeshko, VV; Arias, M; Orduz, S			Mitochondria permeabilization by a novel polycation peptide BTM-P1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THURINGIENSIS SUBSP-MEDELLIN; CANCER CELL-LINES; BACILLUS-THURINGIENSIS; CYTOCHROME-C; TRANSITION PORE; OXIDATIVE-PHOSPHORYLATION; ANTIMICROBIAL PEPTIDE; ANALOG PEPTIDES; MOSQUITO LARVAE; OUTER-MEMBRANE	Bacillus thuringiensis subsp. medellin is known to produce the Cry11Bb protein of 94 kDa, which is toxic for mosquito larvae due to permeabilization of the plasma membrane of midgut epithelial cells. Earlier we found that a 2.8-kDa novel peptide BTM-P1, which was artificially synthesized taking into account the primary structure of Cry11Bb endotoxin, is active against several species of bacteria. In this work we show that BTM-P1 induces cyclosporin A-insensitive swelling of rat liver mitochondria in various salt solutions but not in the sucrose medium. Inorganic phosphate and Ca2+ significantly increased this effect of the peptide. The uncoupling action of BTM-P1 on oxidative phosphorylation was stronger in the potassium-containing media and correlated with a decrease of the inner membrane potential of mitochondria. In isotonic KNO3, KCl, or NH4NO3 media, a complete drop of the inner membrane potential was observed at 1 - 2 mu g/ml of the peptide. The peptide-induced swelling was increased by energization of mitochondria in the potassium-containing media, but it was inhibited in the NaNO3, NH4NO3, and Tris-NO3 media. All mitochondrial effects of the peptide were completely prevented by adding a single N-terminal tryptophan residue to the peptide sequence. We suggest a mechanism of membrane permeabilization that includes a transmembrane- and surface potential-dependent insertion of the polycation peptide into the lipid bilayer and its oligomerization leading to formation of ion channels and also to the mitochondrial permeability transition pore opening in a cyclosporin A-insensitive manner.	Univ Nacl Colombia, Fac Ciencias, Escuela Fis, Medellin AA3840, Colombia; Corp Invest Biol, Unidad Biotecnol & Control Biol, Medellin AA7378, Colombia; Univ Pamplona, Fac Ciencias Basicas, Pamplona, Colombia	Universidad Nacional de Colombia	Lemeshko, VV (corresponding author), Univ Nacl Colombia, Fac Ciencias, Escuela Fis, Calle 65,Cra 64, Medellin AA3840, Colombia.	vvasilie@unalmed.edu.co	Orduz, Sergio/Q-7437-2017	Orduz, Sergio/0000-0001-7587-3816				BAKER MA, 1993, CANCER RES, V53, P3052; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; Borutaite V, 2003, FEBS LETT, V541, P1, DOI 10.1016/S0014-5793(03)00278-3; Braun P, 1999, BIOCHEMISTRY-US, V38, P9778, DOI 10.1021/bi990923a; Brumatti G, 2003, FEBS LETT, V541, P57, DOI 10.1016/S0014-5793(03)00299-0; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Cabrera MPD, 2004, J PEPT RES, V64, P95, DOI 10.1111/j.1399-3011.2004.00173.x; de Planque MRR, 2003, BIOCHEMISTRY-US, V42, P5341, DOI 10.1021/bi027000r; del Rio G, 2001, FEBS LETT, V494, P213, DOI 10.1016/S0014-5793(01)02348-1; Don AS, 2004, TRENDS MOL MED, V10, P372, DOI 10.1016/j.molmed.2004.06.005; Fujita N, 2000, DRUG RESIST UPDATE, V3, P149, DOI 10.1054/drup.2000.0142; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P1, DOI 10.1016/S0005-2728(03)00109-9; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; Gomez I, 2002, FEBS LETT, V513, P242, DOI 10.1016/S0014-5793(02)02321-9; Gottlieb RA, 2002, METHODS, V26, P341, DOI 10.1016/S1046-2023(02)00040-3; Gutierrez P, 2001, MEM I OSWALDO CRUZ, V96, P357, DOI 10.1590/S0074-02762001000300013; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; IBSEN KH, 1961, CANCER RES, V21, P829; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Ito A, 2004, J BIOL CHEM, V279, P21282, DOI 10.1074/jbc.M401881200; Iwai T, 2002, J MOL CELL CARDIOL, V34, P725, DOI 10.1006/jmcc.2002.2002; Killian JA, 2003, FEBS LETT, V555, P134, DOI 10.1016/S0014-5793(03)01154-2; Kim SK, 2003, PEPTIDES, V24, P945, DOI 10.1016/S0196-9781(03)00194-3; Kling K, 1999, AM J SURG, V178, P411, DOI 10.1016/S0002-9610(99)00209-3; Kushnareva YE, 1999, ARCH BIOCHEM BIOPHYS, V366, P107, DOI 10.1006/abbi.1999.1190; Le Mellay V, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-14; Lee DG, 2002, BBA-PROTEINS PROTEOM, V1598, P185, DOI 10.1016/S0167-4838(02)00373-4; Lemeshko SV, 2004, MOL CELL BIOCHEM, V256, P127, DOI 10.1023/B:MCBI.0000009864.77216.00; Lemeshko VV, 2000, FEBS LETT, V472, P5, DOI 10.1016/S0014-5793(00)01419-8; Lemeshko VV, 2003, ARCH BIOCHEM BIOPHYS, V412, P176, DOI 10.1016/S0003-9861(03)00034-1; Lemeshko VV, 2002, J BIOL CHEM, V277, P17751, DOI 10.1074/jbc.M201002200; Lemeshko VV, 2002, BIOPHYS J, V82, P684, DOI 10.1016/S0006-3495(02)75431-3; Lemeshko VV, 2001, ARCH BIOCHEM BIOPHYS, V388, P60, DOI 10.1006/abbi.2000.2214; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378; Liu CD, 1996, AM J SURG, V171, P192, DOI 10.1016/S0002-9610(99)80098-1; Mather M, 2001, BBA-BIOENERGETICS, V1503, P357, DOI 10.1016/S0005-2728(00)00231-0; Morin D, 2001, ADV DRUG DELIVER REV, V49, P151, DOI 10.1016/S0169-409X(01)00132-6; Nicholls D., 2002, BIOENERGETICS, V3; NORDENBERG J, 1987, BRIT J CANCER, V55, P41, DOI 10.1038/bjc.1987.9; OHSAKI Y, 1992, CANCER RES, V52, P3534; Orduz S, 1998, BBA-PROTEIN STRUCT M, V1388, P267, DOI 10.1016/S0167-4838(98)00168-X; ORDUZ S, 1992, J INVERTEBR PATHOL, V59, P99, DOI 10.1016/0022-2011(92)90118-N; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; Penso J, 2003, MOL GENET METAB, V78, P74, DOI 10.1016/S1096-7192(02)00203-2; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; Popova AV, 2002, BBA-BIOMEMBRANES, V1561, P109, DOI 10.1016/S0005-2736(01)00462-X; Raj PA, 2002, FEMS MICROBIOL LETT, V206, P9, DOI 10.1111/j.1574-6968.2002.tb10979.x; Rausell C, 2004, BIOCHEMISTRY-US, V43, P166, DOI 10.1021/bi035527d; Regula KM, 2003, J MOL CELL CARDIOL, V35, P559, DOI 10.1016/S0022-2828(03)00118-4; RIGOBELLO MP, 1995, BIOCHEM BIOPH RES CO, V217, P144, DOI 10.1006/bbrc.1995.2756; Rodriguez-Enriquez S, 2001, EUR J BIOCHEM, V268, P2512, DOI 10.1046/j.1432-1327.2001.02140.x; Ruiz LM, 2004, MEM I OSWALDO CRUZ, V99, P73, DOI 10.1590/S0074-02762004000100013; Schroder JM, 1999, BIOCHEM PHARMACOL, V57, P121, DOI 10.1016/S0006-2952(98)00226-3; Segura C, 2000, J INVERTEBR PATHOL, V76, P56, DOI 10.1006/jipa.2000.4945; Shinohara Y, 1997, BBA-BIOENERGETICS, V1319, P319, DOI 10.1016/S0005-2728(97)00002-9; Sokolove PM, 1996, ARCH BIOCHEM BIOPHYS, V336, P69, DOI 10.1006/abbi.1996.0533; Tatsumi T, 2003, CARDIOVASC RES, V59, P428, DOI 10.1016/S0008-6363(03)00391-2; WESTERHOFF HV, 1989, P NATL ACAD SCI USA, V86, P6597, DOI 10.1073/pnas.86.17.6597; White SH, 1998, BBA-REV BIOMEMBRANES, V1376, P339, DOI 10.1016/S0304-4157(98)00021-5; Wieckowski MR, 1998, FEBS LETT, V423, P339, DOI 10.1016/S0014-5793(98)00118-5; Wojtczak L, 1999, EUR J BIOCHEM, V263, P495, DOI 10.1046/j.1432-1327.1999.00522.x; Wolf BB, 2001, J BIOL CHEM, V276, P34244, DOI 10.1074/jbc.M011778200; Yamagiwa M, 2004, BIOSCI BIOTECH BIOCH, V68, P523, DOI 10.1271/bbb.68.523; Zakharov SD, 2002, BIOCHIMIE, V84, P465, DOI 10.1016/S0300-9084(02)01453-0; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	68	17	17	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15579	15586		10.1074/jbc.M414064200	http://dx.doi.org/10.1074/jbc.M414064200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713682	hybrid			2022-12-25	WOS:000228444800016
J	Lu, CF; Wang, AL; Dorsch, M; Tian, J; Nagashima, K; Coyle, AJ; Jaffee, B; Ocain, TD; Xu, YJ				Lu, CF; Wang, AL; Dorsch, M; Tian, J; Nagashima, K; Coyle, AJ; Jaffee, B; Ocain, TD; Xu, YJ			Participation of Rip2 in lipopolysaccharide signaling is independent of its kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TOLL-LIKE RECEPTORS; PROTEIN-KINASE; FAMILY-MEMBER; INNATE	Rip2 ( Rick, Cardiak, CCK2, and CARD3) is a serine/ threonine kinase containing a caspase recruitment domain ( CARD) at the C terminus. Previous reports have shown that Rip2 is involved in multiple receptor signaling pathways that are important for innate and adaptive immune responses. However, it is not known whether Rip2 kinase activity is required for its function. Here we confirm that Rip2 participates in lipopolysaccharide (LPS)/Toll-like receptor (TLR4) signaling and demonstrate that its kinase activity is not required. Upon LPS stimulation, Rip2 was transiently recruited to the TLR4 receptor complex and associated with key TLR signaling mediators IRAK1 and TRAF6. Furthermore, Rip2 kinase activity was induced by LPS treatment. These data indicate that Rip2 is directly involved in the LPS/ TLR4 signaling. Whereas macrophages from Rip2-deficient mice showed impaired NF-kappa B and p38 mitogen-activated protein kinase activation and reduced cytokine production in response to LPS stimulation, LPS signaling was intact in macrophages from mice that express Rip2 kinase-dead mutant. These results demonstrate that Rip2-mediated LPS signaling is independent of its kinase activity. Our findings strongly suggest that Rip2 functions as an adaptor molecule in transducing signals from immune receptors.	Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Lu, CF (corresponding author), Univ Calif Berkeley, 16 Barker Hall MC 3202, Berkeley, CA 94720 USA.	chafenlu@berkeley.edu						Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Jefferies C, 2001, MOL CELL BIOL, V21, P4544, DOI 10.1128/MCB.21.14.4544-4552.2001; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Navas TA, 1999, J BIOL CHEM, V274, P33684, DOI 10.1074/jbc.274.47.33684; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Ruefli-Brasse AA, 2004, J BIOL CHEM, V279, P1570, DOI 10.1074/jbc.C300460200; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeda K, 2001, GENES CELLS, V6, P733, DOI 10.1046/j.1365-2443.2001.00458.x; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1	19	52	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16278	16283		10.1074/jbc.M410114200	http://dx.doi.org/10.1074/jbc.M410114200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15691841	hybrid			2022-12-25	WOS:000228444800098
J	Raman, B; Ban, T; Yamaguchi, K; Sakai, M; Kawai, T; Naiki, H; Goto, Y				Raman, B; Ban, T; Yamaguchi, K; Sakai, M; Kawai, T; Naiki, H; Goto, Y			Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid beta peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMER A-BETA; INDUCED AGGREGATION; TRANSGENIC MICE; COPPER-BINDING; DISEASE; ZINC; PROTEIN; NEUROTOXICITY; COMPLEXES; INSIGHTS	Although metal ions such as Cu2+, Zn2+, and Fe3+ are implicated to play a key role in Alzheimer disease, their role is rather complex, and comprehensive understanding is not yet obtained. We show that Cu2+ and Zn2+ but not Fe3+ renders the amyloid beta peptide, A beta(1-40), non-fibrillogenic in nature. However, preformed fibrils of A beta(1-40) were stable when treated with these metal ions. Consequently, fibril growth of A beta(1-40) could be switched on/off by switching the molecule between its apo- and holo-forms. Clioquinol, a potential drug for Alzheimer disease, induced resumption of the Cu2+-suppressed but not the Zn2+-suppressed fibril growth of A beta(1-40). The observed synergistic effect of clioquinol and Zn2+ suggests that Zn2+-clioquinol complex effectively retards fibril growth. Thus, clioquinol has dual effects; although it disaggregates the metal ion-induced aggregates of A beta(1-40) through metal chelation, it further retards the fibril growth along with Zn2+. These results indicate the mechanism of metal ions in suppressing A beta amyloid formation, as well as providing information toward the use of metal ion chelators, particularly clioquinol, as potential drugs for Alzheimer disease.	Osaka Univ, Inst Prot Res, Osaka 5650871, Japan; Japan Sci & Technol Agcy, CREST, Osaka 5650871, Japan; Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; Osaka Univ, Inst Sci & Ind Res, Osaka 5670047, Japan; Univ Fukui, Fac Med Sci, Fukui 9101193, Japan; Japan Sci & Technol Agcy, CREST, Fukui 9101193, Japan	Osaka University; Japan Science & Technology Agency (JST); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Osaka University; University of Fukui; Japan Science & Technology Agency (JST)	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Yamadaoka 3-2, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Naiki, Hironobu/G-5599-2014					Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Ban T, 2004, J MOL BIOL, V344, P757, DOI 10.1016/j.jmb.2004.09.078; Ban T, 2003, J BIOL CHEM, V278, P16462, DOI 10.1074/jbc.C300049200; Bayer TA, 2003, P NATL ACAD SCI USA, V100, P14187, DOI 10.1073/pnas.2332818100; BUSCAGLIO J, 1993, P NATL ACAD SCI USA, V90, P2090; BUSH AI, 1994, J BIOL CHEM, V269, P12152; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cuajungco MP, 2000, ANN NY ACAD SCI, V920, P292; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Di Vaira M, 2004, INORG CHEM, V43, P3795, DOI 10.1021/ic0494051; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; Doraiswamy PM, 2004, LANCET NEUROL, V3, P431, DOI 10.1016/S1474-4422(04)00809-9; Esler WP, 1996, J NEUROCHEM, V66, P723; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gnjec A, 2002, FRONT BIOSCI, V7, pD1016, DOI 10.2741/gnjec; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Klug GMJA, 2003, EUR J BIOCHEM, V270, P4282, DOI 10.1046/j.1432-1033.2003.03815.x; Lane TJ, 1960, J AM CHEM SOC, V82, P4462, DOI 10.1021/ja01502a006; Liu ST, 1999, BIOCHEMISTRY-US, V38, P9373, DOI 10.1021/bi990205o; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Sparks DL, 2003, P NATL ACAD SCI USA, V100, P11065, DOI 10.1073/pnas.1832769100; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; Syme CD, 2004, J BIOL CHEM, V279, P18169, DOI 10.1074/jbc.M313572200; Wetzel R, 2002, STRUCTURE, V10, P1031, DOI 10.1016/S0969-2126(02)00809-2; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; Yoshiike Y, 2001, J BIOL CHEM, V276, P32293, DOI 10.1074/jbc.M010706200	41	143	151	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16157	16162		10.1074/jbc.M500309200	http://dx.doi.org/10.1074/jbc.M500309200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15718230	hybrid, Green Published			2022-12-25	WOS:000228444800084
J	Wei, Z; Lyon, M; Gallagher, JT				Wei, Z; Lyon, M; Gallagher, JT			Distinct substrate specificities of bacterial heparinases against N-unsubstituted glucosamine residues in heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICALLY-MODIFIED HEPARINS; FLAVOBACTERIUM-HEPARINUM; AMINO-GROUPS; PROTEOGLYCANS; GROWTH; DEGRADATION; HEPARITINASE; PURIFICATION; DIVERSITY; LYASES	The rare N- unsubstituted glucosamine ( GlcNH(3)(+)) residues in heparan sulfate have important biological and pathophysiological roles. In this study, four GlcNH(3)(+)-containing disaccharides were obtained from partially de- N- sulfated forms of heparin and the N- sulfated K5 polysaccharide by digestion with combined heparinases I, II, and III. These were identified as Delta HexA- GlcNH(3)(+), Delta HexA- GlcNH(3)(+)( 6S), Delta HexA(2S)- GlcNH(3)(+), and Delta HexA-( 2S)- GlcNH(3)(+) ( 6S). Digestions with individual enzymes revealed that heparinase I did not cleave at GlcNH(3)(+) residues; however, heparinases II and III showed selective and distinct activities. Heparinase II generated Delta HexA- GlcNH(3)(+)( 6S), Delta HexA( 2S)- GlcNH(3)(+), and Delta HexA( 2S)- GlcNH(3)(+) ( 6S) disaccharides, whereas heparinase III yielded only the Delta HexA- GlcNH(3)(+) unit. Thus, the action of heparinase II requires O- sulfation, whereas heparinase III acts only on the corresponding non- sulfated unit. These striking distinctions in substrate specificities of heparinases could be used to isolate oligosaccharides with novel sequences of GlcNH(3)(+) residues. Finally, heparinases were used to identify and quantify GlcNH(3)(+)-containing disaccharides in native bovine kidney and porcine intestinal mucosal heparan sulfates. The relatively high content of O- sulfated GlcNH(3)(+)- disaccharides in kidney HS raises questions about how these sequences are generated.	Christie Hosp NHS Trust, Canc Res UK, Manchester M20 4BX, Lancs, England; Univ Manchester, Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England	Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Lyon, M (corresponding author), Christie Hosp NHS Trust, Canc Res UK, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	MLyon@picr.man.ac.uk		Lyon, Malcolm/0000-0001-9575-6879				Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Chai WG, 2004, BIOCHEMISTRY-US, V43, P8590, DOI 10.1021/bi036250k; CONRAD HE, 1998, HEPARIN BINDING PROT, P10; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; DESAI UR, 1993, BIOCHEMISTRY-US, V32, P8140, DOI 10.1021/bi00083a012; Ding K, 2002, J BIOL CHEM, V277, P33353, DOI 10.1074/jbc.M203383200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; HOVINGH P, 1970, J BIOL CHEM, V245, P6170; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Leteux C, 2001, J BIOL CHEM, V276, P12539, DOI 10.1074/jbc.M010291200; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LINHARDT RJ, 1988, BIOCHEM J, V254, P781, DOI 10.1042/bj2540781; LINKER A, 1960, BIOCHIM BIOPHYS ACTA, V43, P366, DOI 10.1016/0006-3002(60)90460-1; Liu DF, 2002, P NATL ACAD SCI USA, V99, P568, DOI 10.1073/pnas.012578299; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Liu J, 2002, J BIOL CHEM, V277, P33456, DOI 10.1074/jbc.M202034200; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; LYON M, 1997, LAB GUIDE GLYCOCONJU, P61; MARCUM JA, 1986, AM J PHYSIOL, V250, pH879, DOI 10.1152/ajpheart.1986.250.5.H879; McBride PA, 1998, EXP NEUROL, V149, P447, DOI 10.1006/exnr.1997.6740; MOFFAT CF, 1991, EUR J BIOCHEM, V202, P531, DOI 10.1111/j.1432-1033.1991.tb16405.x; MOFFAT CF, 1991, EUR J BIOCHEM, V197, P449, DOI 10.1111/j.1432-1033.1991.tb15931.x; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; NADER HB, 1990, J BIOL CHEM, V265, P16807; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; PERLIN AS, 1971, CARBOHYD RES, V18, P185, DOI 10.1016/S0008-6215(00)80341-9; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P12232, DOI 10.1073/pnas.95.21.12232; Robinson CJ, 2001, J CELL SCI, V114, P853; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101; Westling C, 2002, J BIOL CHEM, V277, P49247, DOI 10.1074/jbc.M209139200	40	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15742	15748		10.1074/jbc.M501102200	http://dx.doi.org/10.1074/jbc.M501102200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705564	hybrid			2022-12-25	WOS:000228444800036
J	Haj, FG; Zabolotny, JM; Kim, YB; Kahn, BB; Neel, BG				Haj, FG; Zabolotny, JM; Kim, YB; Kahn, BB; Neel, BG			Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose Homeostasis of PTP1B-/- mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; AKT/PROTEIN KINASE-B; INSULIN-SENSITIVITY; GENE-THERAPY; PHOSPHOINOSITIDE 3-KINASE; IN-VIVO; ENDOPLASMIC-RETICULUM; ADENOVIRAL VECTORS; LEPTIN ACTION; OB/OB MICE	Protein-tyrosine phosphatase 1B (PTP1B) is an important negative regulator of insulin and leptin signaling in vivo. Mice lacking PTP1B ( PTP1B -/- mice) are hyperresponsive to insulin and leptin and resistant to diet-induced obesity. The tissue(s) that mediate these effects of global PTP1B deficiency remain controversial. We exploited the high degree of hepatotropism of adenoviruses to assess the role of PTP1B in the liver. Liver-specific re-expression of PTP1B in PTP1B -/- mice led to marked attenuation of their enhanced insulin sensitivity. This correlated with, and was probably caused by, decreased insulin-stimulated tyrosyl phosphorylation of the insulin receptor (IR) and IR substrate 2-associated phosphatidylinositide 3-kinase activity. Analysis using phospho-specific antibodies for the IR revealed preferential dephosphorylation of Tyr-1162/1163 compared with Tyr-972 by PTP1B in vivo. Our findings show that the liver is a major site of the peripheral action of PTP1B in regulating glucose homeostasis.	Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kahn, BB (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, 330 Brookline Ave,Res N 325 E, Boston, MA 02215 USA.	bkahn@bidmc.harvard.edu			NIDDK NIH HHS [DK09903, DK62212, R01 DK060839, DK060838] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060839, R01DK060838, F32DK009903] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Asilmaz E, 2004, J CLIN INVEST, V113, P414, DOI 10.1172/JCI200419511; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; Calera MR, 2000, J BIOL CHEM, V275, P6308, DOI 10.1074/jbc.275.9.6308; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Dadke S, 2000, J BIOL CHEM, V275, P23642, DOI 10.1074/jbc.M001063200; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Futagawa Y, 2000, RES EXP MED, V199, P263, DOI 10.1007/s004330050124; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; Gu F, 2003, MOL CELL BIOL, V23, P3753, DOI 10.1128/MCB.23.11.3753-3762.2003; Gum RJ, 2003, DIABETES, V52, P21, DOI 10.2337/diabetes.52.1.21; Gum RJ, 2003, MOL ENDOCRINOL, V17, P1131, DOI 10.1210/me.2002-0288; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Kaburagi Yasushi, 1999, Endocrine Journal, V46, pS25, DOI 10.1507/endocrj.46.Suppl_S25; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Lam NT, 2004, MOL ENDOCRINOL, V18, P1333, DOI 10.1210/me.2002-0193; LI QT, 1993, HUM GENE THER, V4, P403, DOI 10.1089/hum.1993.4.4-403; Lizcano JM, 2002, CURR BIOL, V12, pR236, DOI 10.1016/S0960-9822(02)00777-7; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Minokoshi Y, 2003, J BIOL CHEM, V278, P33609, DOI 10.1074/jbc.R300019200; MITTAL SK, 1993, VIRUS RES, V28, P67, DOI 10.1016/0168-1702(93)90090-A; Nandi A, 2004, PHYSIOL REV, V84, P623, DOI 10.1152/physrev.00032.2003; Rondinone CM, 2002, DIABETES, V51, P2405, DOI 10.2337/diabetes.51.8.2405; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; TONKS NK, 1991, METHOD ENZYMOL, V201, P442; Trapnell Bruce C., 1994, Current Opinion in Biotechnology, V5, P617, DOI 10.1016/0958-1669(94)90084-1; Ueki K, 2000, J CLIN INVEST, V105, P1437, DOI 10.1172/JCI7656; VanPatten S, 2004, BIOCHEM J, V379, P229, DOI 10.1042/BJ20040134; Venable CL, 2000, J BIOL CHEM, V275, P18318, DOI 10.1074/jbc.M908392199; Wang J, 2001, DIABETES OBES METAB, V3, P367, DOI 10.1046/j.1463-1326.2001.00173.x; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zabolotny JM, 2004, J BIOL CHEM, V279, P24844, DOI 10.1074/jbc.M310688200; Zinker BA, 2002, P NATL ACAD SCI USA, V99, P11357, DOI 10.1073/pnas.142298199	43	98	107	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15038	15046		10.1074/jbc.M413240200	http://dx.doi.org/10.1074/jbc.M413240200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15699041	hybrid			2022-12-25	WOS:000228236800086
J	Tourkina, E; Gooz, P; Pannu, J; Bonner, M; Scholz, D; Hacker, S; Silver, RM; Trojanowska, M; Hoffman, S				Tourkina, E; Gooz, P; Pannu, J; Bonner, M; Scholz, D; Hacker, S; Silver, RM; Trojanowska, M; Hoffman, S			Opposing effects of protein kinase C alpha and protein kinase C epsilon on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P42/44 MAP KINASE; ANCHORING PROTEINS; NULL MICE; SCLERODERMA; ACTIVATION; PATHWAY; STIMULATION; PULMONARY; MEMBRANE; ISOFORMS	The roles of MEK, ERK, the epsilon and alpha isoforms of protein kinase C (PKC), and caveolin-1 in regulating collagen expression were studied in normal lung fibroblasts. Knocking down caveolin-1 gave particularly striking results. A 70% decrease caused a 5-fold increase in MEK/ERK activation and collagen expression. The combined data reveal a branched signaling pathway. In its central portion MEK activates ERK, leading to increased collagen expression. Two branches converge on MEK/ERK. In one, increased PKC epsilon leads to MEK/ERK activation. In another, increased PKC alpha induces caveolin-1 expression, which in turn inhibits MEK/ERK activation and collagen expression. Lung fibroblasts from scleroderma patients with pulmonary fibrosis showed altered signaling. Consistent with their overexpression of collagen, scleroderma lung fibroblasts contain more activated MEK/ERK and less caveolin-1 than normal lung fibroblasts. Because cutaneous fibrosis is the hallmark of scleroderma, we also studied dermal fibroblasts. As in lung, there was more activated MEK/ERK in cells from scleroderma patients than in control cells, and MEK inhibition decreased collagen expression. However, the distinctive levels of PKC epsilon, PKC alpha, and caveolin-1 in lung and dermal fibroblasts from scleroderma patients and control subjects indicate that the links between these signaling proteins and MEK/ERK must function differently in the four cell types. Finally, we confirmed the relevance of these signaling cascades in vivo. The combined results demonstrate that a branched signaling pathway involving MEK, ERK, PKC epsilon, PKC alpha, and caveolin-1 regulates collagen expression in normal lung tissue and is perturbed during fibrosis.	Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA; The Citadel, Dept Biol, Charleston, SC 29409 USA	Medical University of South Carolina; Medical University of South Carolina	Tourkina, E (corresponding author), Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, 96 Jonathan Lucas St, Charleston, SC 29425 USA.	tourkine@musc.edu		Trojanowska, Maria/0000-0001-9550-7178	NCCIH NIH HHS [R21 AT00382] Funding Source: Medline; NHLBI NIH HHS [R01 HL73718] Funding Source: Medline; NIAMS NIH HHS [R01 AR44883, P60 AR049459] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT000382] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073718] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR049459, R01AR044883] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Atamas SP, 2003, AM J RESP CELL MOL, V29, P743, DOI 10.1165/rcmb.2003-0078OC; Besson A, 2001, ONCOGENE, V20, P7398, DOI 10.1038/sj.onc.1204899; Bogatkevich GS, 2001, J BIOL CHEM, V276, P45184, DOI 10.1074/jbc.M106441200; Clerk A, 2001, CIRC RES, V89, P847, DOI 10.1161/res.89.10.847; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V284, pC457, DOI 10.1152/ajpcell.00380.2002; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; ENDELMAN JA, 1998, FEBS LETT, V428, P205; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Gore-Hyer E, 2003, ARTHRITIS RHEUM-US, V48, P798, DOI 10.1002/art.10953; Jimenez SA, 2001, J CLIN INVEST, V108, P1395, DOI 10.1172/JCI200112347; Kasper M, 1998, HISTOCHEM CELL BIOL, V109, P41; LUDWICKA A, 1992, J RHEUMATOL, V19, P1716; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Nanjundan M, 2003, AM J PHYSIOL-LUNG C, V284, pL1, DOI 10.1152/ajplung.00029.2002; Newman GR, 1999, CELL TISSUE RES, V295, P111, DOI 10.1007/s004410051217; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Razani B, 2001, J BIOL CHEM, V276, P38121; Reunanen N, 2000, J BIOL CHEM, V275, P34634, DOI 10.1074/jbc.C000175200; Rybin VO, 1999, CIRC RES, V84, P980, DOI 10.1161/01.RES.84.9.980; Song JC, 2002, AM J PHYSIOL-CELL PH, V283, pC1548, DOI 10.1152/ajpcell.00105.2002; Tourkina E, 2004, AM J RESP CELL MOL, V31, P28, DOI 10.1165/rcmb.2003-0354OC; Tourkina E, 2001, ARTHRITIS RHEUM-US, V44, P1370, DOI 10.1002/1529-0131(200106)44:6<1370::AID-ART230>3.0.CO;2-2; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wu DQ, 2002, J BIOL CHEM, V277, P40449, DOI 10.1074/jbc.M206270200	31	94	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13879	13887		10.1074/jbc.M412551200	http://dx.doi.org/10.1074/jbc.M412551200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15691837	hybrid			2022-12-25	WOS:000228095500087
J	Ameyar-Zazoua, M; Wisniewska, MB; Bakiri, L; Wagner, EF; Yaniv, M; Weitzman, JB				Ameyar-Zazoua, M; Wisniewska, MB; Bakiri, L; Wagner, EF; Yaniv, M; Weitzman, JB			AP-1 dimers regulate transcription of the p14/p19(ARF) tumor suppressor gene	ONCOGENE			English	Article						AP1; p14(ARF); p19(ARF); RAS	C-JUN; CELL-PROLIFERATION; INK4A LOCUS; ARF; RAS; TRANSFORMATION; P53; ACTIVATION; P14(ARF); P19(ARF)	Evidence is accumulating about the role of individual AP-1 components in cell proliferation and transformation. Notably, Ras-mediated transformation is characterized by the upregulation of particular AP-1 members, such as c-Jun and Fra-1. The p14/p19(ARF) tumor suppressor gene is a key link between oncogenic Ras signaling and the p53 pathway. We explored the involvement of AP4 dimers in the transcriptional regulation of the P14/p19(ARF) gene. We demonstrate that both the human and mouse ARF promoters are transcriptional targets of selective AP-1 dimers. The ARF promoter is regulated specifically by AP-1 heterodimers containing Fra-1. Overexpression of e-Jun similar to Fra-1 dimers in primary murine fibroblast cells led to the upregulation of the endogenous ARF protein and growth arrest. Conversely, inhibition of c-Jun or Fra-1 protein levels resulted in decreased ARF expression. In addition, we show that AP-1 dimers cooperate with oncogenic Ras in the transcriptional activation of the p14/p19(ARF) promoter. Thus, AP-1 heterodimers may contribute to the regulation of ARF expression upon oncogenic signaling.	Inst Pasteur, Dept Dev Biol, Unit Gene Express & Dis, F-75724 Paris, France; Res Inst Mol Pathol, A-1030 Vienna, Austria	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Weitzman, JB (corresponding author), Inst Pasteur, Dept Dev Biol, Unit Gene Express & Dis, 25 Rue Dr Roux, F-75724 Paris, France.	jonathan.weitzman@pasteur.fr	Bakiri, Latifa/N-5780-2014; Bakiri, Latifa/AAP-1674-2020; Wisniewska, Marta B./A-6691-2009	Wisniewska, Marta B./0000-0002-1593-0361; Wagner, Erwin F/0000-0001-7872-0196; Weitzman, Jonathan/0000-0001-8445-0102; bakiri, latifa/0000-0002-6300-2420				Ameyar M, 2003, BIOCHIMIE, V85, P747, DOI 10.1016/j.biochi.2003.09.006; Ameyar M, 1998, J BIOL CHEM, V273, P29002, DOI 10.1074/jbc.273.44.29002; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Berkovich E, 2003, CELL CYCLE, V2, P127, DOI 10.4161/cc.2.2.293; BOS JL, 1989, CANCER RES, V49, P4682; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drayton S, 2003, CANCER CELL, V4, P301, DOI 10.1016/S1535-6108(03)00242-3; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kuo ML, 2003, CANCER RES, V63, P1046; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Modestou M, 2001, CANCER RES, V61, P3145; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; THIERRY F, 1987, J VIROL, V61, P134, DOI 10.1128/JVI.61.1.134-142.1987; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002	61	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2298	2306		10.1038/sj.onc.1208424	http://dx.doi.org/10.1038/sj.onc.1208424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15688012				2022-12-25	WOS:000227877400003
J	Burger, M; Hartmann, T; Burger, JA; Schraufstatter, I				Burger, M; Hartmann, T; Burger, JA; Schraufstatter, I			KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway	ONCOGENE			English	Article						chemokine receptor; signal transduction; CXCR2; KSHV-GPCR; STAT-3	PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; TRANSCRIPTIONAL ACTIVATION; INTERLEUKIN-8 RECEPTORS; ENDOTHELIAL-CELLS; SIGNAL TRANSDUCER; IN-VIVO; EXPRESSION; STAT3	The Kaposi's sarcoma herpesvirus encodes a G-protein-coupled chemokine receptor termed KSHV-GPCR. Expression of this constitutively active GPCR leads to cell transformation and vascular overgrowth characteristic of Kaposi's sarcoma. Previously, we have shown that CXCR2, the closest human homolog, is similarly able to transform cells if continuously stimulated or constitutively activated by amino-acid exchange D138V of the DRY sequence. Here, we demonstrate that STAT3 activation is a prerequisite for transformation in KSHV-GPCR and CXCR2 transfected NIH 3T3 cells. In KSHV-GPCR and D138V transfected cells, STAT-3 is constitutively phosphorylated on Tyr(705). In CXCR2 transfected NIH 3T3 cells and human microvascular endothelial cells (HMEC), which express the CXCR2 constitutively, STAT3 is phosphorylated upon stimulation with IL-8 (CXCL8). Focus formation in NIH 3T3 cells transfected with the KSHV-GPCR, CXCR2, or the D138V mutant, was blocked by the specific JAK2 inhibitor AG490. Typical functions of the CXCR2 including actin stress fiber formation, haptotaxis, and the angiogenic response in HMEC shown by tube formation in Matrigel were blocked by AG490. These data suggest that the transforming capacity and migratory responses that are involved in tumor development, metastasis, and angiogenesis in KSHV or CXCR2-expressing cells is at least partially mediated through a JAK2-STAT3 dependent pathway.	Freiburg Univ Hosp, Dept Internal Med, D-79106 Freiburg, Germany; La Jolla Inst Mol Med, Dept Canc Biol, San Diego, CA USA	University of Freiburg	Burger, M (corresponding author), Freiburg Univ Hosp, Dept Med, Div Hematol Oncol, Hugstetterstr 55, D-79106 Freiburg, Germany.	burgerm@mm11.ukl.uni-freiburg.de	Hartmann, Tanja Nicole/AAA-6735-2020; Hartmann, Tanja Nicole/C-9345-2017	Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-2633-7301	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Bellocq A, 1998, AM J PATHOL, V152, P83; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burger M, 1999, J IMMUNOL, V163, P2017; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Greene GF, 1997, AM J PATHOL, V150, P1571; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Korff T, 1999, J CELL SCI, V112, P3249; LEE J, 1992, J BIOL CHEM, V267, P16283; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Mellado M, 1998, J IMMUNOL, V161, P805; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Miller LJ, 1998, ANTICANCER RES, V18, P77; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Norgauer J, 1996, J IMMUNOL, V156, P1132; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Offermann MK, 1996, TRENDS MICROBIOL, V4, P383, DOI 10.1016/0966-842X(96)10060-3; Pelletier S, 2003, MOL CELL BIOL, V23, P1316, DOI 10.1128/MCB.23.4.1316-1333.2003; Richards BL, 1997, AM J SURG, V174, P507; Rodriguez-Frade JM, 2001, TRENDS IMMUNOL, V22, P612, DOI 10.1016/S1471-4906(01)02036-1; Scholz A, 2003, GASTROENTEROLOGY, V125, P891, DOI 10.1016/S0016-5085(03)01064-3; Schraufstatter IU, 2001, AM J PHYSIOL-LUNG C, V280, pL1094, DOI 10.1152/ajplung.2001.280.6.L1094; Schraufstatter IU, 2003, J IMMUNOL, V171, P6714, DOI 10.4049/jimmunol.171.12.6714; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shao H, 2003, CANCER RES, V63, P3923; Shepard LW, 2001, J BIOL CHEM, V276, P45979, DOI 10.1074/jbc.M104783200; Soriano SF, 2002, J EXP MED, V196, P311, DOI 10.1084/jem.20012041; Soriano SF, 2003, EUR J IMMUNOL, V33, P1328, DOI 10.1002/eji.200323897; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Takamori H, 2000, PANCREAS, V21, P52, DOI 10.1097/00006676-200007000-00051; Van Rompaey L, 2002, BIOCHEM BIOPH RES CO, V291, P820, DOI 10.1006/bbrc.2002.6513; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; WIGLER M, 1978, CANCER RES, V38, P1434; Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	54	77	81	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2067	2075		10.1038/SJ.ONC.1208442	http://dx.doi.org/10.1038/SJ.ONC.1208442			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688008				2022-12-25	WOS:000227681900011
J	Purohit, VS; Ramani, K; Sarkar, R; Kazazian, HH; Balasubramanian, SV				Purohit, VS; Ramani, K; Sarkar, R; Kazazian, HH; Balasubramanian, SV			Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; COAGULATION-FACTOR-VIII; C2 DOMAIN; MEMBRANE-BINDING; LIGHT-CHAIN; AGGREGATION; MODEL; PHOSPHATIDYLSERINE; IMMUNOGENICITY; STABILITY	Factor VIII is a multidomain protein composed of A1, A2, B, A3, C1, and C2 domains. Deficiency or dysfunction of factor VIII causes hemophilia A, a bleeding disorder. Administration of exogenous recombinant factor VIII as a replacement leads to development of inhibitory antibodies against factor VIII in 15-30% of hemophilia A patients. Hence, less immunogenic preparations of factor VIII are highly desirable. Inhibitory antibodies against factor VIII are mainly directed against immunodominant epitopes in C2, A3, and A2 domains. Further, several universal epitopes for CD4+ T-cells have been identified within the C2 domain. The C2 domain is also known to interact specifically with phosphatidyl-serine-rich lipid vesicles. Here, we have investigated the hypothesis that complexation of O-phospho-L-serine, the head group of phosphatidylserine, with the C2 domain can reduce the overall immunogenicity of factor VIII. The biophysical (circular dichroism and fluorescence) and biochemical studies (ELISA and size exclusion chromatography) showed that O-phospho-L-serine binds to the phospholipid-binding region in the C2 domain, and this interaction causes subtle changes in the tertiary structure of the protein. O-Phospho-L-serine also prevented aggregation of the protein under thermal stress. The immunogenicity of the factor VIII-O-phospho-L-serine complex was evaluated in hemophilia A mice. The total and inhibitory antibody titers were lower for factor VIII-O-phospho-L-serine complex compared with factor VIII alone. Moreover, factor VIII administered as a complex with O-phospho-L-serine retained in vivo activity in hemophilia A mice. Our results suggest that factor VIII-O-phospho-L-serine complex may be beneficial to increase the physical stability and reduce immunogenicity of recombinant factor VIII preparations.	SUNY Buffalo, Dept Pharmaceut Sci, Amherst, NY 14260 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Pennsylvania	Balasubramanian, SV (corresponding author), SUNY Buffalo, Dept Pharmaceut Sci, 527 Hochstetter Hall, Amherst, NY 14260 USA.	svb@acsu.buffalo.edu	Purohit, Vivek/GXH-0278-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070227] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL070227-02, R01 HL-70227, R01 HL070227] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ananyeva NM, 2004, BLOOD COAGUL FIBRIN, V15, P109, DOI 10.1097/00001721-200403000-00001; Behrmann M, 2002, THROMB HAEMOSTASIS, V88, P221; BI L, 1995, NAT GENET, V10, P119, DOI 10.1038/ng0595-119; Braun A, 1997, PHARMACEUT RES, V14, P1472, DOI 10.1023/A:1012193326789; Chirino AJ, 2004, DRUG DISCOV TODAY, V9, P82, DOI 10.1016/S1359-6446(03)02953-2; Crowther J. R., 2000, METHODS MOL BIOL, V149, DOI [10.1134/s000629790909017x, DOI 10.1134/S000629790909017X]; Derrick TS, 2004, J PHARM SCI-US, V93, P2549, DOI 10.1002/jps.20167; Doering CB, 2002, THROMB HAEMOSTASIS, V88, P450; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; Gensana M, 2001, HAEMOPHILIA, V7, P369, DOI 10.1046/j.1365-2516.2001.00526.x; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; GILBERT GE, 1990, J BIOL CHEM, V265, P815; Gilbert GE, 2002, J BIOL CHEM, V277, P6374, DOI 10.1074/jbc.M104732200; Grillo AO, 2001, BIOCHEMISTRY-US, V40, P586, DOI 10.1021/bi001547t; Ho AYL, 2000, DRUGS, V60, P547, DOI 10.2165/00003495-200060030-00003; Ingerslev J., 2000, Haematologica, V85, P15; Jacquemin MG, 1998, HAEMOPHILIA, V4, P552, DOI 10.1046/j.1365-2516.1998.440552.x; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KEMBALLCOOK G, 1992, THROMB RES, V67, P57, DOI 10.1016/0049-3848(92)90258-C; Kendrick BS, 1998, J PHARM SCI, V87, P1069, DOI 10.1021/js9801384; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Lollar P, 2001, ADV EXP MED BIOL, V489, P65; MATERA M, 1993, INT J CLIN PHARM RES, V13, P93; Pace CN, 1998, J MOL BIOL, V279, P271, DOI 10.1006/jmbi.1998.1760; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Pratt KP, 2004, THROMB HAEMOSTASIS, V92, P522, DOI 10.1160/TH03-12-0755; Purohit VS, 2003, BBA-BIOMEMBRANES, V1617, P31, DOI 10.1016/j.bbamem.2003.08.012; Qian JJ, 1999, THROMB HAEMOSTASIS, V81, P240, DOI 10.1055/s-0037-1614450; Raju R, 1995, EUR J IMMUNOL, V25, P3207, DOI 10.1002/eji.1830251202; RAMANI K, 2003, AAPS PHARMSCI, V5, pT2091; Reding MT, 2003, J THROMB HAEMOST, V1, P1777, DOI 10.1046/j.1538-7836.2003.00251.x; Reipert BM, 2000, THROMB HAEMOSTASIS, V84, P826, DOI 10.1055/s-0037-1614124; Remmele RL, 2000, BIOPHARM-APPL T BIO, V13, P36; SAENKO EL, 1995, J BIOL CHEM, V270, P13826, DOI 10.1074/jbc.270.23.13826; Saenko EL, 1997, J BIOL CHEM, V272, P18007, DOI 10.1074/jbc.272.29.18007; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; Sarkar R, 2003, J THROMB HAEMOST, V1, P220, DOI 10.1046/j.1538-7836.2003.00096.x; Scandella DH, 2001, THROMB RES, V101, P377, DOI 10.1016/S0049-3848(00)00418-7; Stoilova-McPhie S, 2002, BLOOD, V99, P1215, DOI 10.1182/blood.V99.4.1215; Taschner N, 2001, J MOL BIOL, V310, P169, DOI 10.1006/jmbi.2001.4736; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TSAI PK, 1993, PHARMACEUT RES, V10, P649, DOI 10.1023/A:1018939228201; VanAken WG, 1997, TRANSFUS MED REV, V11, P6, DOI 10.1016/S0887-7963(97)80005-3; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VERBRUGGEN B, 1995, THROMB HAEMOSTASIS, V73, P247; Vermeer AWP, 2000, BIOPHYS J, V78, P394, DOI 10.1016/S0006-3495(00)76602-1; Wang W, 2003, PHARM RES-DORDR, V20, P693, DOI 10.1023/A:1023271405005; Wu HY, 2001, THROMB HAEMOSTASIS, V85, P125, DOI 10.1055/s-0037-1612915; Zhai X, 2002, BIOCHEMISTRY-US, V41, P5675, DOI 10.1021/bi011844d	49	40	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17593	17600		10.1074/jbc.M500163200	http://dx.doi.org/10.1074/jbc.M500163200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728582	hybrid, Green Accepted			2022-12-25	WOS:000228807200005
J	Vyas, AA; Blixt, O; Paulson, JC; Schnaar, RL				Vyas, AA; Blixt, O; Paulson, JC; Schnaar, RL			Potent glycan inhibitors of myelin-associated glycoprotein enhance axon outgrowth in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL-CORD-INJURY; ADULT MAMMALIAN CNS; NOGO-66 RECEPTOR; FUNCTIONAL RECOVERY; NEURITE OUTGROWTH; SIGNALING PATHWAY; GROWTH-INHIBITORS; YOUNG-ADULT; REGENERATION; GANGLIOSIDES	Myelin-associated glycoprotein (MAG, Siglec-4) is one of several endogenous axon regeneration inhibitors that limit recovery from central nervous system injury and disease. Molecules that block such inhibitors may enhance axon regeneration and functional recovery. MAG, a member of the Siglec family of sialic acid-binding lectins, binds to sialoglycoconjugates on axons and particularly to gangliosides GD1a and GT1b, which may mediate some of the inhibitory effects of MAG. In a prior study (Blixt, O., Collins, B. E., van den Nieuwenhof, I. M., Crocker, P. R., and Paulson, J. C. ( 2003) J. Biol. Chem. 278, 31007 - 31019), we identified potent monovalent sialoside inhibitors of MAG using a novel screening platform. In the current study, the most potent of these were tested for their ability to reverse MAG-mediated inhibition of axon outgrowth from rat cerebellar granule neurons in vitro. Monovalent sialoglycans enhanced axon regeneration in proportion to their MAG binding affinities. The most potent glycoside was disialyl T antigen (NeuAc alpha 2 - 3Gal beta 1 - 3[NeuAc alpha 2 - 6] GalNAc-R), followed by 3-sialyl T antigen (NeuAc alpha 2 - 3Gal beta 1 - 3GalNAc-R), structures expressed on O-linked glycoproteins as well as on gangliosides. Prior studies indicated that blocking gangliosides reversed MAG inhibition (Vyas, A. A., Patel, H. V., Fromholt, S. E., Heffer-Lauc, M., Vyas, K. A., Dang, J., Schachner, M., and Schnaar, R. L. ( 2002) Proc. Natl. Acad. Sci. USA 99, 8412 - 8417). In the current study, blocking O-linked glycoprotein sialylation with benzyl-alpha GalNAc had no effect. The ability to reverse MAG inhibition with monovalent glycosides encourages further exploration of glycans and glycan mimetics as blockers of MAG-mediated axon outgrowth inhibition.	Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Johns Hopkins University; Johns Hopkins University; Scripps Research Institute; Scripps Research Institute	Schnaar, RL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.	schnaar@jhu.edu	Paulson, James/AAG-3565-2019; Schnaar, Ronald L/S-8967-2016	Schnaar, Ronald L/0000-0002-7701-5484; Blixt, Ola/0000-0003-4143-6276	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037096, R37NS037096] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60938] Funding Source: Medline; NINDS NIH HHS [R01 NS037096, NS37096] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO S, 1992, J BIOCHEM, V111, P287, DOI 10.1093/oxfordjournals.jbchem.a123751; Asher R A, 2001, Prog Brain Res, V132, P611; Blixt O, 2002, J AM CHEM SOC, V124, P5739, DOI 10.1021/ja017881+; Blixt O, 2001, J ORG CHEM, V66, P2442, DOI 10.1021/jo0057809; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Collins BE, 1999, J BIOL CHEM, V274, P37637, DOI 10.1074/jbc.274.53.37637; Collins BE, 1997, J BIOL CHEM, V272, P16889, DOI 10.1074/jbc.272.27.16889; Crocker PR, 1996, BIOCHEM SOC T, V24, P150, DOI 10.1042/bst0240150; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; DeBellard ME, 1996, MOL CELL NEUROSCI, V7, P89, DOI 10.1006/mcne.1996.0007; Dergham P, 2002, J NEUROSCI, V22, P6570; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fournier AE, 2001, CURR OPIN NEUROBIOL, V11, P89, DOI 10.1016/S0959-4388(00)00178-1; Gouyer V, 2001, FRONT BIOSCI, V6, pD1235, DOI 10.2741/gouyer; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; He ZG, 2004, ANNU REV NEUROSCI, V27, P341, DOI 10.1146/annurev.neuro.27.070203.144340; Heffer-Lauc M, 2005, BBA-MOL CELL BIOL L, V1686, P200, DOI 10.1016/j.bbalip.2004.10.002; HIRABAYASHI Y, 1992, J BIOL CHEM, V267, P12973; HIRABAYASHI Y, 1990, J BIOL CHEM, V265, P8144; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Hunt D, 2002, J NEUROCYTOL, V31, P93, DOI 10.1023/A:1023941421781; Josephson A, 2002, J COMP NEUROL, V453, P292, DOI 10.1002/cne.10408; Kim JE, 2003, NEURON, V38, P187, DOI 10.1016/S0896-6273(03)00147-8; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; KOTANI M, 1993, GLYCOBIOLOGY, V3, P137, DOI 10.1093/glycob/3.2.137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; McGee AW, 2003, TRENDS NEUROSCI, V26, P193, DOI 10.1016/S0166-2236(03)00062-6; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; Powell SK, 1997, J NEUROBIOL, V32, P223, DOI 10.1002/(SICI)1097-4695(199702)32:2<223::AID-NEU7>3.0.CO;2-A; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; Sato Y, 1998, GLYCOCONJUGATE J, V15, P1133, DOI 10.1023/A:1006911821339; Schafer M, 1996, NEURON, V16, P1107, DOI 10.1016/S0896-6273(00)80137-3; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P371; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P348; Simonen M, 2003, NEURON, V38, P201, DOI 10.1016/S0896-6273(03)00226-5; Spencer T, 2004, J ANAT, V204, P49, DOI 10.1111/j.1469-7580.2004.00259.x; Sun J, 2004, GLYCOBIOLOGY, V14, P851, DOI 10.1093/glycob/cwh107; SVENNERHOLM L, 1994, PROG BRAIN RES, V101, pR11; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Venkatesh K, 2005, J NEUROSCI, V25, P808, DOI 10.1523/JNEUROSCI.4464-04.2005; Vinson M, 2001, J BIOL CHEM, V276, P20280, DOI 10.1074/jbc.M100345200; Vyas AA, 2002, P NATL ACAD SCI USA, V99, P8412, DOI 10.1073/pnas.072211699; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Yang LJS, 1996, P NATL ACAD SCI USA, V93, P814, DOI 10.1073/pnas.93.2.814; Zaccai NR, 2003, STRUCTURE, V11, P557, DOI 10.1016/S0969-2126(03)00073-X; Zheng BH, 2005, P NATL ACAD SCI USA, V102, P1205, DOI 10.1073/pnas.0409026102; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3	51	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16305	16310		10.1074/jbc.M500250200	http://dx.doi.org/10.1074/jbc.M500250200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15701648	hybrid, Green Accepted			2022-12-25	WOS:000228444800101
J	Witting, PK; Wu, BJ; Raftery, M; Southwell-Keely, P; Stocker, R				Witting, PK; Wu, BJ; Raftery, M; Southwell-Keely, P; Stocker, R			Probucol protects against hypochlorite-induced endothelial dysfunction - Identification of a novel pathway of probucol oxidation to a biologically active intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NITRIC-OXIDE SYNTHASE; HERITABLE HYPERLIPIDEMIC RABBIT; HUMAN ATHEROSCLEROTIC LESIONS; SUPEROXIDE-PRODUCTION; FAMILIAL HYPERCHOLESTEROLEMIA; CARDIOVASCULAR EVENTS; CORONARY-ARTERIES; MODIFIED PROTEINS; BALLOON INJURY	Atherosclerosis is associated with endothelial dysfunction and a heightened state of inflammation characterized, in part, by an increase in vascular myeloperoxidase and proteins modified by its principal oxidant, hypochlorous acid (HOCl). Here we examined whether probucol could protect against endothelial dysfunction induced by the two-electron oxidant HOCl. Hypochlorous acid eliminated endothelium-dependent relaxation of rabbit aorta, whereas endothelial function and tissue cGMP was preserved and elevated, respectively, in animals pretreated with probucol. Exogenously added probucol also protected against HOCl-induced endothelial dysfunction. In vitro, HOCl oxidized probucol in a two-phase process with rate constants k(1) = 2.7 +/- 0.3 x 10(2) and k(2) = 0.7 +/- 0.2 x 10(2) M-1 s(-1) that resulted in a dose- and time-dependent accumulation of probucol-derived disulfoxide, 4,4'-dithiobis(2,6-di-tert-butyl-phenol) ( DTBP), DTBP-derived thiosulfonate, disulfone, and sulfonic acid, together with 3,3',5,5'-tetra-tert-butyl-4,4'-diphenoquinone (DPQ) as determined by high performance liquid chromatography and mass spectrometry. Like HOCl, selected one-electron oxidants converted probucol into DTBP and DPQ. Also, dietary and in vitro added DTBP protected aortic rings from HOCl-induced endothelial dysfunction and in vitro oxidation by HOCl gave rise to the thiosulfonate, disulfone, and sulfonic acid intermediates and DPQ. However, the product profiles of the in vitro oxidation systems were different from those in aortas of rabbits receiving dietary probucol or DTBP +/- HOCl treatment. Together, the results show that both probucol and DTBP react with HOCl and protect against HOCl-induced endothelial dysfunction, although direct scavenging of HOCl is unlikely to be responsible for the vascular protection by the two compounds.	Univ New S Wales, Sch Med Sci, Ctr Vasc Res, Sydney, NSW 2052, Australia; Univ New S Wales, Bioanalyt Mass Spectrometry Facil, Sydney, NSW 2052, Australia; Univ New S Wales, Sch Chem, Sydney, NSW 2052, Australia	University of New South Wales Sydney; University of New South Wales Sydney; University of New South Wales Sydney	Stocker, R (corresponding author), Univ New S Wales, Sch Med Sci, Ctr Vasc Res, Sydney, NSW 2052, Australia.	r.stocker@unsw.edu.au	Stocker, Roland/AAV-4489-2021; Witting, Paul/L-9786-2019; Witting, Paul/ABD-2053-2020	Witting, Paul/0000-0003-2237-7004; Wu, Ben/0000-0003-2826-4190				Abu-Soud HM, 2000, J BIOL CHEM, V275, P5425, DOI 10.1074/jbc.275.8.5425; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; Araki T, 2001, CHEM PHARM BULL, V49, P943, DOI 10.1248/cpb.49.943; Baldus S, 2001, J CLIN INVEST, V108, P1759; BARNHART RL, 1989, J LIPID RES, V30, P1703; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Braun A, 2003, P NATL ACAD SCI USA, V100, P7283, DOI 10.1073/pnas.1237725100; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; FERNS GAA, 1992, P NATL ACAD SCI USA, V89, P11312, DOI 10.1073/pnas.89.23.11312; Fleming I, 2001, CIRC RES, V88, P44, DOI 10.1161/01.RES.88.1.44; Gokce N, 2003, J AM COLL CARDIOL, V41, P1769, DOI 10.1016/S0735-1097(03)00333-4; Gokce N, 2002, CIRCULATION, V105, P1567, DOI 10.1161/01.CIR.0000012543.55874.47; Hattori Y, 2000, J CONTROL RELEASE, V69, P369, DOI 10.1016/S0168-3659(00)00338-2; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hollenberg SM, 2001, CIRCULATION, V104, P3091, DOI 10.1161/hc5001.100796; Kajinami K, 1996, ATHEROSCLEROSIS, V120, P181, DOI 10.1016/0021-9150(95)05699-8; KALYANARAMAN B, 1992, J BIOL CHEM, V267, P6789; KEANEY JF, 1995, J CLIN INVEST, V95, P2520, DOI 10.1172/JCI117953; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; Landmesser U, 2003, J CLIN INVEST, V111, P1201, DOI 10.1172/JCI200314172; Lau AK, 2003, CIRCULATION, V107, P2031, DOI 10.1161/01.CIR.0000062682.40051.43; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; MARCH J, 1977, ADV ORGANIC CHEM REA, P110; McNally JS, 2003, AM J PHYSIOL-HEART C, V285, pH2290, DOI 10.1152/ajpheart.00515.2003; Miller FJ, 1998, CIRC RES, V82, P1298, DOI 10.1161/01.RES.82.12.1298; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; NAGANO Y, 1992, ATHEROSCLEROSIS, V92, P131, DOI 10.1016/0021-9150(92)90272-I; Nuszkowski A, 2001, J BIOL CHEM, V276, P14212, DOI 10.1074/jbc.M007659200; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; Pattison DI, 2001, CHEM RES TOXICOL, V14, P1453, DOI 10.1021/tx0155451; PELTER A, 1988, TETRAHEDRON LETT, V29, P677, DOI 10.1016/S0040-4039(00)80182-3; RADI R, 1991, J BIOL CHEM, V266, P4244; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; SASAHARA M, 1994, J CLIN INVEST, V94, P155, DOI 10.1172/JCI117301; Sawayama Y, 2002, J AM COLL CARDIOL, V39, P610, DOI 10.1016/S0735-1097(01)01783-1; SCHNEIDER JE, 1993, CIRCULATION, V88, P628, DOI 10.1161/01.CIR.88.2.628; Stocker R, 2004, ARTERIOSCL THROM VAS, V24, P2028, DOI 10.1161/01.ATV.0000143388.20994.fa; SUARNA C, 1995, ARTERIOSCL THROM VAS, V15, P1616, DOI 10.1161/01.ATV.15.10.1616; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; White CR, 1996, P NATL ACAD SCI USA, V93, P8745, DOI 10.1073/pnas.93.16.8745; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5; Witting P, 1999, J CLIN INVEST, V104, P213, DOI 10.1172/JCI6391; Witting PK, 1999, FASEB J, V13, P667, DOI 10.1096/fasebj.13.6.667; Witting PK, 2002, BIOCHEMISTRY-US, V41, P11495, DOI 10.1021/bi025835w; Yan LJ, 1996, ARCH BIOCHEM BIOPHYS, V327, P330, DOI 10.1006/abbi.1996.0130; Zhang CX, 2001, J BIOL CHEM, V276, P27159, DOI 10.1074/jbc.M100191200; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442	54	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15612	15618		10.1074/jbc.M414256200	http://dx.doi.org/10.1074/jbc.M414256200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722355	hybrid			2022-12-25	WOS:000228444800020
J	Gao, CL; Schaefer, E; Lakkis, M; Blystone, SD				Gao, CL; Schaefer, E; Lakkis, M; Blystone, SD			beta(3) tyrosine phosphorylation and alpha(v)beta(3)-mediated adhesion are required for Vav1 association and Rho activation in leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; HEMATOPOIETIC-CELLS; BIOLOGICAL-ACTIVITY; PROTEINS; FAMILY; INTEGRINS; DOMAINS; GTPASES; KINASE; RAC	Integrin alpha(v)beta(3)-mediated adhesion of hematopoietic cells to vitronectin results in activation of the Rho GTPases. Mutation of beta(3) tyrosine residue 747, previously shown to disrupt cell adhesion, results in sustained activation of Cdc42 and diminished Rac and Rho activity. We investigated the role of the hematopoietically restricted guanine nucleotide exchange factor Vav1 in alpha(v)beta(3)-mediated adhesion. We find that Vav1, a guanine nucleotide exchange factor for Rac and Rho, associates with alpha(v)beta(3) upon cell adhesion to vitronectin and that this association requires beta(3) tyrosine phosphorylation. Expression of exogenous Vav1 demonstrates that Y160F, but not wild type or the Vav1Y174F mutant, inhibits Rac and Rho activation during alpha(v)beta(3)-mediated cell adhesion to vitronectin. Cells expressing Vav1Y160F exhibit a sustained Cdc42 activation similar to nonphosphorylatable beta(3) mutants. In addition, cytoskeletal reorganization and cell adhesion are severely suppressed in Vav1Y160F-transfected cells, and Vav1Y160F fails to associate with beta(3) integrins. Furthermore, Vav1 itself is selectively phosphorylated upon tyrosine 160 after alpha(v)beta(3)-mediated adhesion, and the association between Vav1 and beta(3) occurs in specific response to adhesion to substrate. These studies describe a phosphorylation-dependent association between beta(3) integrin and Vav1 which is essential for cell progression to a Rho-dominant phenotype during cell adhesion.	SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA; Bioresource Int, Hopkinton, MA 01748 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Blystone, SD (corresponding author), SUNY Upstate Med Univ, Dept Cell & Dev Biol, 750 E Adams St, Syracuse, NY 13210 USA.	Blystons@mail.upstate.edu			NIAID NIH HHS [AI 40602] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040602] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; Blystone SD, 2002, J BIOL CHEM, V277, P46886, DOI 10.1074/jbc.M209506200; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; Butler B, 2003, J BIOL CHEM, V278, P5264, DOI 10.1074/jbc.M206997200; Chandhoke SK, 2004, J CELL SCI, V117, P1431, DOI 10.1242/jcs.00987; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Groysman M, 2000, FEBS LETT, V467, P75, DOI 10.1016/S0014-5793(00)01121-2; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Movilla N, 2001, ONCOGENE, V20, P8057, DOI 10.1038/sj.onc.1205000; Movilla N, 1999, MOL CELL BIOL, V19, P7870; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Phillips DR, 2001, CURR OPIN CELL BIOL, V13, P546, DOI 10.1016/S0955-0674(00)00250-7; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Stebbins CC, 2003, MOL CELL BIOL, V23, P6291, DOI 10.1128/MCB.23.17.6291-6299.2003; Woodside DG, 2001, CURR BIOL, V11, P1799, DOI 10.1016/S0960-9822(01)00565-6; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; Yron I, 1999, CELL ADHES COMMUN, V7, P1, DOI 10.3109/15419069909034388; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431; Zugaza JL, 2002, J BIOL CHEM, V277, P45377, DOI 10.1074/jbc.M208039200	29	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15422	15429		10.1074/jbc.M414457200	http://dx.doi.org/10.1074/jbc.M414457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15699036	hybrid			2022-12-25	WOS:000228236800129
J	Johnson, KA; Terkeltaub, RA				Johnson, KA; Terkeltaub, RA			External GTP-bound transglutaminase 2 is a molecular switch for chondrocyte hypertrophic differentiation and calcification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TISSUE TRANSGLUTAMINASE; CELL MEMBRANE GLYCOPROTEIN-1; CROSS-LINKING; ARTICULAR CHONDROCYTES; STRUCTURAL BASIS; MATRIX VESICLES; X COLLAGEN; CARTILAGE; BINDING; EXPRESSION	Chondrocyte maturation to hypertrophy, associated with up-regulated transglutaminase 2 (TG2) expression, mediates not only physiologic growth plate mineralization but also pathologic matrix calcification and dysregulated matrix repair in osteoarthritic articular cartilage. TG2 -/- mouse chondrocytes demonstrate markedly inhibited progression to hypertrophic differentiation in response to both retinoic acid and the chemokine CXCL1. Here, our objectives were to test if up-regulated TG2 alone is sufficient to promote chondrocyte hypertrophic differentiation and to identify TG2 molecular determinants and potential downstream signals involved. TG2 activities, regulated by nucleotides and calcium, include cross-linking of cartilage matrix proteins, binding of fibronectin, and hydrolysis of GTP and ATP. Following transfection of TG2 site-directed mutants into chondrocytic cells, we observed that wild type TG2, and TG catalytic site and fibronectin-binding mutants promoted type X collagen expression and matrix calcification consistent with chondrocyte hypertrophic differentiation. In contrast, transfected mutants of TG2 GTP binding (K173L) and externalization (Y274A) sites did not stimulate chondrocyte hypertrophy. Recombinant TG2 treatment of bovine cartilage explants demonstrated that extracellular TG2 induced hypertrophy more robustly in the GTP-bound state, confirming an essential role of TG2 GTP binding. Finally, TG2 treatment induced type X collagen in a beta 1 integrin-mediated manner, associated with rapid phosphorylation of both Rac1 and p38 kinases that were inhibited by mutation of the TG2 GTP binding site. In conclusion, externalized GTP-bound TG2 serves as a molecular switch for differentiation of chondrocytes to a hypertrophic, calcifying phenotype in a manner that does not require either TG2 transamidation activity or fibronectin binding.	Univ Calif San Diego, Vet Affairs Med Ctr, San Diego, CA 92161 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Terkeltaub, RA (corresponding author), Univ Calif San Diego, Vet Affairs Med Ctr, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	rterkeltaub@ucsd.edu		Johnson, Kristen/0000-0003-0788-7217				ACHYUTHAN KE, 1995, J IMMUNOL METHODS, V180, P69, DOI 10.1016/0022-1759(94)00300-L; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; Aeschlimann D, 2000, CONNECT TISSUE RES, V41, P1, DOI 10.3109/03008200009005638; Ahvazi B, 2004, J BIOL CHEM, V279, P26716, DOI 10.1074/jbc.M403481200; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; ALINI M, 1994, J BONE MINER RES, V9, P1077; Bakker ENTP, 2005, CIRC RES, V96, P119, DOI 10.1161/01.RES.0000151333.56089.66; Balklava Z, 2002, J BIOL CHEM, V277, P16567, DOI 10.1074/jbc.M109836200; Borzi RM, 1999, FEBS LETT, V455, P238, DOI 10.1016/S0014-5793(99)00886-8; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; CUNY JF, 1989, ANN DERMATOL VENER, V116, P95; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Gaudry CA, 1999, EXP CELL RES, V252, P104, DOI 10.1006/excr.1999.4633; Gerstenfeld LC, 1996, J CELL BIOCHEM, V62, P1; Girkontaite I, 1996, MATRIX BIOL, V15, P231, DOI 10.1016/S0945-053X(96)90114-6; Heinkel D, 2004, FRONT BIOSCI-LANDMRK, V9, P3257, DOI 10.2741/1477; Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399; Iismaa SE, 2000, J BIOL CHEM, V275, P18259, DOI 10.1074/jbc.M000583200; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; Johnson K, 1999, ARTHRITIS RHEUM-US, V42, P1986, DOI 10.1002/1529-0131(199909)42:9<1986::AID-ANR26>3.0.CO;2-O; Johnson K, 2001, AM J PATHOL, V159, P149, DOI 10.1016/S0002-9440(10)61682-3; Johnson KA, 2003, J BIOL CHEM, V278, P18824, DOI 10.1074/jbc.M301055200; Kaartinen MT, 2002, J BONE MINER RES, V17, P2161, DOI 10.1359/jbmr.2002.17.12.2161; Kang SK, 2004, FEBS LETT, V577, P361, DOI 10.1016/j.febslet.2004.10.031; Kang SK, 2004, J BIOL CHEM, V279, P36593, DOI 10.1074/jbc.M402084200; KIRSCH T, 1992, BONE MINER, V18, P107, DOI 10.1016/0169-6009(92)90851-4; KIRSCH T, 1994, J BIOL CHEM, V269, P11462; Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149; Krane SM, 2001, J CLIN INVEST, V107, P31, DOI 10.1172/JCI11892; Lai TS, 1998, J BIOL CHEM, V273, P1776, DOI 10.1074/jbc.273.3.1776; LEE KN, 1993, BIOCHIM BIOPHYS ACTA, V1202, P1, DOI 10.1016/0167-4838(93)90055-V; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; LOTZ M, 1992, J IMMUNOL, V148, P466; Magne D, 2003, J BONE MINER RES, V18, P1430, DOI 10.1359/jbmr.2003.18.8.1430; Merz D, 2003, J IMMUNOL, V171, P4406, DOI 10.4049/jimmunol.171.8.4406; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nurminskaya M, 1998, J CELL BIOL, V142, P1135, DOI 10.1083/jcb.142.4.1135; Nurminskaya M, 1996, DEV DYNAM, V206, P260, DOI 10.1002/(SICI)1097-0177(199607)206:3<260::AID-AJA4>3.0.CO;2-G; Nurminskaya M, 2003, DEV BIOL, V263, P139, DOI 10.1016/S0012-1606(03)00445-7; Rosenthal AK, 1997, ARTHRITIS RHEUM, V40, P966, DOI 10.1002/art.1780400526; Sakai K, 2001, J BIOL CHEM, V276, P8740, DOI 10.1074/jbc.M008359200; Saoncella S, 2004, J BIOL CHEM, V279, P47172, DOI 10.1074/jbc.C400299200; SCHMID TM, 1985, J CELL BIOL, V100, P598, DOI 10.1083/jcb.100.2.598; Stephens P, 2004, J CELL SCI, V117, P3389, DOI 10.1242/jcs.01188; Summey BT, 2002, J ORTHOP RES, V20, P76, DOI 10.1016/S0736-0266(01)00064-X; Yoshimatsu T, 2001, INT J MOL MED, V8, P345; Zhen XC, 2001, J BIOL CHEM, V276, P4879, DOI 10.1074/jbc.M004990200	50	61	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15004	15012		10.1074/jbc.M500962200	http://dx.doi.org/10.1074/jbc.M500962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15691824	hybrid			2022-12-25	WOS:000228236800082
J	Katagiri, C; Masuda, K; Urano, T; Yamashita, K; Araki, Y; Kikuchi, K; Shima, H				Katagiri, C; Masuda, K; Urano, T; Yamashita, K; Araki, Y; Kikuchi, K; Shima, H			Phosphorylation of Ser-446 determines stability of MKP-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-MEDIATED PROTEOLYSIS; DUAL-SPECIFICITY PHOSPHATASES; PROTEIN-KINASE PHOSPHATASE; N-TERMINAL KINASE; MAP KINASE; PROTEASOME PATHWAY; DEGRADATION; ACTIVATION; DESTRUCTION; FAMILY	MAPK cascades can be negatively regulated by members of the MAPK phosphatase (MKP) family. However, how MKP activity is regulated is not well characterized. MKP-7, a JNK-specific phosphatase, possesses a unique COOH-terminal stretch (CTS) in addition to domains conserved among MKP family members. The CTS contains several motifs such as a nuclear localization signal, a nuclear export signal, PEST sequences, and a serine residue (Ser-446) that can be phosphorylated by activated ERK, suggesting an important regulatory role(s). S-35-pulse labeling experiments indicate that the half-life of MKP-7 is 1.5 h, a period significantly elongated by deleting the CTS. We also show that overexpressed MKP-7 is polyubiquitinated when co-expressed with ubiquitin and that proteasome inhibitors markedly inhibit MKP-7 degradation. We also determined that MKP-7 phosphorylated at Ser-446 has a longer half-life than unphosphorylated form of the wild type protein, as does a phospho-mimic mutant of MKP-7. These results indicate that activation of the ERK pathway strongly blocks JNK activation through stabilization of MKP-7 mediated by phosphorylation.	Hokkaido Univ, Div Biochem Oncol & Immunol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Nagoya Univ, Grad Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Kanazawa Univ, Div Life Sci, Grad Sch Nat Sci & Technol, Kanazawa, Ishikawa 9201192, Japan; Hokkaido Univ, Grad Sch Environm Earth Sci, Div Biosci, Sapporo, Hokkaido 0600810, Japan	Hokkaido University; Nagoya University; Kanazawa University; Hokkaido University	Shima, H (corresponding author), Hokkaido Univ, Div Biochem Oncol & Immunol, Inst Med Genet, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	hshima@igm.hokudai.ac.jp	Katagiri, Chiaki/AAW-6901-2020	Urano, Takeshi/0000-0003-3383-3554				Alonso A, 2004, TOP CURR GENET, V5, P333; Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Brodbeck D, 2001, J BIOL CHEM, V276, P29550, DOI 10.1074/jbc.M104633200; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Gilon T, 2000, MOL CELL BIOL, V20, P7214, DOI 10.1128/MCB.20.19.7214-7219.2000; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hoornaert I, 2003, ONCOGENE, V22, P7728, DOI 10.1038/sj.onc.1207089; Johnson TR, 2000, J BIOL CHEM, V275, P31755, DOI 10.1074/jbc.M004182200; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; Kibel AS, 2004, INT J CANCER, V109, P668, DOI 10.1002/ijc.20060; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lin YW, 2003, J BIOL CHEM, V278, P21534, DOI 10.1074/jbc.M301854200; Masuda K, 2003, J BIOL CHEM, V278, P32448, DOI 10.1074/jbc.M213254200; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Pfleger CM, 2000, GENE DEV, V14, P655; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rechsteiner MC, 2004, ADV EXP MED BIOL, V547, P49; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sasajima H, 2002, EUR J BIOCHEM, V269, P3596, DOI 10.1046/j.1432-1033.2002.03052.x; Sohaskey ML, 2002, MOL BIOL CELL, V13, P454, DOI 10.1091/mbc.01-11-0553; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Theodosiou A, 2002, ONCOGENE, V21, P2387, DOI 10.1038/sj.onc.1205309; Torres C, 2003, EXP CELL RES, V290, P195, DOI 10.1016/S0014-4827(03)00309-4; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Yasui Y, 2004, J BIOL CHEM, V279, P12997, DOI 10.1074/jbc.M311128200; Zur A, 2002, EMBO J, V21, P4500, DOI 10.1093/emboj/cdf452	36	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14716	14722		10.1074/jbc.M500200200	http://dx.doi.org/10.1074/jbc.M500200200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15689616	hybrid			2022-12-25	WOS:000228236800048
J	Li, ZG; Shi, HY; Zhang, M				Li, ZG; Shi, HY; Zhang, M			Targeted expression of maspin in tumor vasculatures induces endothelial cell apoptosis	ONCOGENE			English	Article						angiogenesis; maspin; endothelial cells; apoptosis; Bcl-2 family proteins	CYTOCHROME-C RELEASE; MEDIATED APOPTOSIS; BONE METASTASIS; ACTIVATION; PATHWAY; CANCER; ANGIOGENESIS; INHIBITION; DEATH; CASPASE-8	Angiogenesis, the formation of new blood vessels, is required for normal tissue development and pathological conditions such as tumorigenesis. Most solid tumors can not grow beyond a few millimeters without the recruitment of neovessels since cancer cells require access to blood vessels for nutrients and to escape the local environment and metastasize to other tissue and organ sites. Targeting tumor vessel endothelium therefore should serve as an effective therapy for cancers. Maspin is a serpin that exhibits antiangiogenic properties. In this report, we show that when maspin overexpression is targeted in vivo to endothelial cells, it actively induces endothelial cell apoptosis. Intravascular administration of adenovirus-maspin to mice bearing mammary tumors disrupts tumor-induced angiogenesis. Interestingly, tumor neovessels become leaky after maspin treatment, whereas normal mature vessels are not affected by maspin treatment. We further demonstrate that maspin directly induces endothelial cell apoptosis in vitro, and this effect is maspin specific. The induction of apoptosis is accompanied by changes in the expression of Bcl-2 family genes and is blocked by caspase inhibitors. In addition, the apoptotic effect is mediated by intracellular maspin and is dependent on the RSL region of maspin. Furthermore, we have shown that transient overexpression of Bcl-2 protected the HUVECs from maspin-mediated apoptosis, and the presence of both maspin and Bax accelerated the apoptosis process. These findings demonstrate that neovascular endothelial cells are highly sensitive to maspin level inside the cells. This property can be used for targeted therapy against tumor angiogenesis and metastasis.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Zhang, M (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	mzhang@bcm.tmc.edu			NCI NIH HHS [CA79736] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079736] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185; Choi WS, 2004, J BIOL CHEM, V279, P20451, DOI 10.1074/jbc.M311164200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Dickinson JL, 1998, CELL DEATH DIFFER, V5, P163, DOI 10.1038/sj.cdd.4400324; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1986, CANCER RES, V46, P467; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Gilot D, 2002, J BIOL CHEM, V277, P49220, DOI 10.1074/jbc.M207325200; Gurtu V, 1997, ANAL BIOCHEM, V251, P98, DOI 10.1006/abio.1997.2220; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; LaVallee TM, 2003, CANCER RES, V63, P468; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XY, 2001, CANCER RES, V61, P1699; Li YS, 2001, CANCER RES, V61, P6906; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McGettrick AF, 2001, EUR J BIOCHEM, V268, P5868, DOI 10.1046/j.0014-2956.2001.02535.x; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Shi HY, 2002, MOL THER, V5, P755, DOI 10.1006/mthe.2002.0602; Shi HY, 2001, CANCER RES, V61, P6945; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Suminami Y, 2000, BRIT J CANCER, V82, P981, DOI 10.1054/bjoc.1999.1028; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Tuxhorn JA, 2002, CANCER RES, V62, P6021; YANG J, 1997, SCIENCE, V275, P1132; Yuan YH, 2002, CIRCULATION, V105, P2653, DOI 10.1161/01.CIR.0000018947.95555.65; Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	46	48	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 17	2005	24	12					2008	2019		10.1038/sj.onc.1208449	http://dx.doi.org/10.1038/sj.onc.1208449			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688005				2022-12-25	WOS:000227681900005
J	Krasnova, IN; Ladenheim, B; Cadet, JL				Krasnova, IN; Ladenheim, B; Cadet, JL			Amphetamine induces apoptosis of medium spiny striatal projection neurons via the mitochondria-dependent pathway	FASEB JOURNAL			English	Article						striatum; caspase-3; Bax; striatal dopaminergic terminals	INNERVATED BRAIN-REGIONS; SUBSTITUTED AMPHETAMINES; DOPAMINE; DEATH; BAX; NEUROTOXICITY; ACTIVATION; CASPASE-3; MICE; P53	Amphetamine ( AMPH) is a psychostimulant whose chronic abuse may cause impairments in attention and memory in humans. These cognitive deficits might be related to neurotoxic effects of the drug. One such toxic effect is the well-described destruction of striatal dopaminergic terminals in mammals. In the present study, we investigated the possibility that AMPH might also cause neuronal apoptosis in the rodent striatum. Administration of a dose of the drug ( 10 mg/kg, 4 times, every 2 h) that is toxic to dopaminergic terminals resulted in the appearance of striatal cells that were positive for cleaved caspase-3 and for terminal deoxynucleotidyl transferase- mediated biotin- dUTP nick-end labeling ( TUNEL), observations that are indicative of an ongoing apoptotic process. Dual immunofluorescence staining revealed that cleaved caspase-3-positive cells express calbindin and DARPP-32, but not somatostatin, parvalbumin, or cholinergic markers. In addition, AMPH also caused increased expression of p53 and Bax at both transcript and protein levels; in contrast, Bcl-2 levels were decreased after the AMPH injections. Moreover, Bax knockout mice showed resistance to AMPH-induced apoptotic cell death but not to AMPH-induced destruction of dopaminergic terminals. When taken together, these observations indicate that injections of doses of AMPH that are known to destroy striatal dopamine terminals can also cause apoptotic death of postsynaptic medium spiny projection neurons via mitochondria-dependent mechanisms.	NIDA, Mol Neuropsychiat Branch, Intramural Res Program, DHHS,NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Cadet, JL (corresponding author), NIDA, Mol Neuropsychiat Branch, Intramural Res Program, DHHS,NIH, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.	JCADET@intra.nida.nih.gov			NATIONAL INSTITUTE ON DRUG ABUSE [Z01DA000174, Z01DA000153, ZIADA000174] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALLDREDGE BK, 1989, NEUROLOGY, V39, P1037, DOI 10.1212/WNL.39.8.1037; ANDERSSON M, 1991, J SMALL ANIM PRACT, V32, P1, DOI 10.1111/j.1748-5827.1991.tb00844.x; Bowyer JF, 1998, J PHARMACOL EXP THER, V286, P1074; Cadet JL, 2003, FASEB J, V17, P1775, DOI 10.1096/fj.03-0073rev; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cregan SP, 1999, J NEUROSCI, V19, P7860; Cyr M, 2003, P NATL ACAD SCI USA, V100, P11035, DOI 10.1073/pnas.1831768100; Deng XL, 1999, J NEUROSCI, V19, P10107; Deng XL, 2001, MOL BRAIN RES, V93, P64, DOI 10.1016/S0169-328X(01)00184-X; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Ekshyyan O, 2004, FRONT BIOSCI-LANDMRK, V9, P1567, DOI 10.2741/1357; ELLISON G, 1978, SCIENCE, V201, P276, DOI 10.1126/science.26975; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Fukumura M, 1998, BRAIN RES, V806, P1, DOI 10.1016/S0006-8993(98)00656-8; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; Huang NK, 1997, LIFE SCI, V61, P2219, DOI 10.1016/S0024-3205(97)00924-7; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Jakab RL, 2002, BRAIN RES, V958, P52, DOI 10.1016/S0006-8993(02)03439-X; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JANOWSKY DS, 1979, PSYCHOPHARMACOLOGY, V65, P73, DOI 10.1007/BF00491982; Jayanthi S, 2001, FASEB J, V15, P1745, DOI 10.1096/fj.01-0025com; Jayanthi S, 2004, FASEB J, V18, P238, DOI 10.1096/fj.03-0295com; KALANT H, 1975, CAN MED ASSOC J, V112, P299; Kawaguchi Y, 1997, NEUROSCI RES, V27, P1, DOI 10.1016/S0168-0102(96)01134-0; KAWAGUCHI Y, 1995, TRENDS NEUROSCI, V18, P527, DOI 10.1016/0166-2236(95)98374-8; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Krasnova IN, 2002, FASEB J, V16, P1379, DOI 10.1096/fj.01-0796com; Krasnova IN, 2001, NEUROSCIENCE, V107, P265, DOI 10.1016/S0306-4522(01)00351-7; Lotharius J, 2001, ANN NEUROL, V49, P79, DOI 10.1002/1531-8249(200101)49:1<79::AID-ANA11>3.0.CO;2-D; Marin O, 2000, J NEUROSCI, V20, P6063; MARTIN DL, 1993, J NEUROCHEM, V60, P395, DOI 10.1111/j.1471-4159.1993.tb03165.x; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; McKetin R, 1997, DRUG ALCOHOL DEPEN, V48, P235, DOI 10.1016/S0376-8716(97)00132-4; Melega WP, 1996, SYNAPSE, V22, P63, DOI 10.1002/(SICI)1098-2396(199601)22:1<63::AID-SYN7>3.0.CO;2-G; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILLER DB, 1994, J PHARMACOL EXP THER, V270, P752; Mitchell I, 2003, IUBMB LIFE, V55, P293, DOI 10.1080/1521654031000153012; Mitchell IJ, 1999, PROG NEUROBIOL, V59, P691, DOI 10.1016/S0301-0082(99)00019-2; Mitchell IJ, 1998, NEUROSCIENCE, V84, P489, DOI 10.1016/S0306-4522(97)00534-4; Mitchell IJ, 2002, NEUROSCIENCE, V109, P89, DOI 10.1016/S0306-4522(01)00455-9; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Morrill J, 2003, HIST TODAY, V53, P28; Murray JB, 1998, J PSYCHOL, V132, P227, DOI 10.1080/00223989809599162; Namura S, 1998, J NEUROSCI, V18, P3659; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; OCALLAGHAN JP, 1994, J PHARMACOL EXP THER, V270, P741; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ornstein TJ, 2000, NEUROPSYCHOPHARMACOL, V23, P113, DOI 10.1016/S0893-133X(00)00097-X; OUIMET CC, 1984, J NEUROSCI, V4, P111; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Qiu JH, 2002, J NEUROSCI, V22, P3504; RICAURTE GA, 1984, BRAIN RES, V303, P359, DOI 10.1016/0006-8993(84)91221-6; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8; Roth KA, 2001, MENT RETARD DEV D R, V7, P261, DOI 10.1002/mrdd.1036; RYAN LJ, 1990, BRAIN RES, V518, P67, DOI 10.1016/0006-8993(90)90955-B; Scheffel U, 1996, SYNAPSE, V23, P61; SCHOUSBOE A, 1992, PROG BRAIN RES, V94, P199; Stumm G, 1999, FASEB J, V13, P1065, DOI 10.1096/fasebj.13.9.1065; SULZER D, 1995, J NEUROSCI, V15, P4102; Svenningsson P, 2003, SCIENCE, V302, P1412, DOI 10.1126/science.1089681; Thiriet N, 2002, FASEB J, V16, P1887, DOI 10.1096/fj.02-0502com; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; WAGNER GC, 1980, NEUROLOGY, V30, P547; WALAAS SI, 1984, J NEUROSCI, V4, P84; Wu XW, 2002, FRONT BIOSCI, V7, pD151, DOI 10.2741/wu1; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131	71	54	55	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					851	+		10.1096/fj.04-2881fje	http://dx.doi.org/10.1096/fj.04-2881fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15731293				2022-12-25	WOS:000227591900006
J	Winn, RA; Marek, L; Han, SY; Rodriguez, K; Rodriguez, N; Hammond, M; Van Scoyk, M; Acosta, H; Mirus, J; Barry, N; Bren-Mattison, Y; Van Raay, TJ; Nemenoff, RA; Heasley, LE				Winn, RA; Marek, L; Han, SY; Rodriguez, K; Rodriguez, N; Hammond, M; Van Scoyk, M; Acosta, H; Mirus, J; Barry, N; Bren-Mattison, Y; Van Raay, TJ; Nemenoff, RA; Heasley, LE			Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-MESENCHYMAL TRANSITIONS; BETA-CATENIN; FACTOR RECEPTOR; C-JUN; CONVERGENT EXTENSION; MUTATIONS; PROTEIN; GENE; JNK; MOUSE	The Wnt signaling pathway is critical in normal development, and mutation of specific components is frequently observed in carcinomas of diverse origins. However, the potential involvement of this pathway in lung tumorigenesis has not been established. In this study, analysis of multiple Wnt mRNAs in non-small cell lung cancer (NSCLC) cell lines and primary lung tumors revealed markedly decreased Wnt-7a expression compared with normal short-term bronchial epithelial cell lines and normal uninvolved lung tissue. Wnt-7a transfection in NSCLC cell lines reversed cellular transformation, decreased anchorage-independent growth, and induced epithelial differentiation as demonstrated by soft agar and three-dimensional cell culture assays in a subset of the NSCLC cell lines. The action of Wnt-7a correlated with expression of the specific Wnt receptor Frizzled-9 (Fzd-9), and transfection of Fzd-9 into a Wnt-7a-insensitive NSCLC cell line established Wnt-7a sensitivity. Moreover, Wnt-7a was present in Fzd-9 immunoprecipitates, indicating a direct interaction of Wnt-7a and Fzd-9. In NSCLC cells, Wnt-7a and Fzd-9 induced both cadherin and Sprouty-4 expression and stimulated the JNK pathway, but not beta-catenin/T cell factor activity. In addition, transfection of gain-of-function JNK strongly inhibited anchorage-independent growth. Thus, this study demonstrates that Wnt-7a and Fzd-9 signaling through activation of the JNK pathway induces cadherin proteins and the receptor tyrosine kinase inhibitor Sprouty-4 and represents a novel tumor suppressor pathway in lung cancer that is required for maintenance of epithelial differentiation and inhibition of transformed cell growth in a subset of human NSCLCs.	Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care Med, Dept Med, Denver, CO 80262 USA; Vet Affairs Med Ctr, Denver, CO 80220 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vanderbilt University	Winn, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care Med, Dept Med, 4200 E 9th Ave, Denver, CO 80262 USA.	robert.winn@uchsc.edu	Bren-Mattison, Yvette/AAC-1137-2022; Acosta, Hector/GQP-3049-2022; Van Raay, Terry/AAA-7342-2021	Van Raay, Terence/0000-0003-0196-1041	NATIONAL CANCER INSTITUTE [P50CA058187, R01CA103618] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA58187, CA103618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beekman A, 1998, CANCER RES, V58, P910; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Fukuchi T, 1998, CANCER RES, V58, P3526; Garat C, 2000, J BIOL CHEM, V275, P22537, DOI 10.1074/jbc.M003000200; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Han SY, 2002, J BIOL CHEM, V277, P47167, DOI 10.1074/jbc.M204270200; Harden N, 2002, DIFFERENTIATION, V70, P181, DOI 10.1046/j.1432-0436.2002.700408.x; HEASLEY LE, 1998, BIOL LUNG CANC, P371; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; Hsieh ETK, 2000, LUNG CANCER, V29, P151, DOI 10.1016/S0169-5002(00)00116-1; Jonsson M, 2002, CANCER RES, V62, P409; Karasawa T, 2002, J BIOL CHEM, V277, P37479, DOI 10.1074/jbc.M205658200; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Lako M, 1998, GENE, V219, P101, DOI 10.1016/S0378-1119(98)00393-X; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LEVAYYOUNG BK, 1992, AM J PHYSIOL, V262, pL672, DOI 10.1152/ajplung.1992.262.6.L672; Li SF, 2001, J CLIN ENDOCR METAB, V86, P454, DOI 10.1210/jc.86.1.454; Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Murtagh J, 2004, J CELL BIOL, V166, P133, DOI 10.1083/jcb.200403020; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Ohsaki Y, 2000, ONCOL REP, V7, P603; Okegawa T, 2002, J UROLOGY, V167, P1836, DOI 10.1016/S0022-5347(05)65245-7; Olson DJ, 1998, TUMOR BIOL, V19, P244, DOI 10.1159/000030014; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perl AKT, 2003, DEV BIOL, V258, P154, DOI 10.1016/S0012-1606(03)00106-4; Polakis P, 2000, GENE DEV, V14, P1837; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Sassoon D, 1999, MOL CELL ENDOCRINOL, V158, P1, DOI 10.1016/S0303-7207(99)00170-7; Sato N, 2003, CANCER RES, V63, P3735; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; TENHAVEOPBROEK AAW, 1991, EXP LUNG RES, V17, P111, DOI 10.3109/01902149109064406; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Van Raay TJ, 2001, DEV GENES EVOL, V211, P453, DOI 10.1007/s004270100174; Wada M, 1997, J MOL MED-JMM, V75, P139, DOI 10.1007/s001090050098; Wallingford JB, 2002, DEV CELL, V2, P695, DOI 10.1016/S1534-5807(02)00197-1; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Zentrich E, 2002, J BIOL CHEM, V277, P4110, DOI 10.1074/jbc.M107824200; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	60	135	146	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19625	19634		10.1074/jbc.M409392200	http://dx.doi.org/10.1074/jbc.M409392200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15705594	hybrid			2022-12-25	WOS:000229113700026
J	Baumli, S; Hoeppner, S; Cramer, P				Baumli, S; Hoeppner, S; Cramer, P			A conserved mediator hinge revealed in the structure of the MED7 center dot MED21 (Med7 center dot Srb7) heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL REGULATION; PROTEIN-STRUCTURE; REPEAT DOMAIN; YEAST; ACTIVATOR; COMPLEX; REQUIREMENT; ORGANIZATION; ASSOCIATION	The Mediator of transcriptional regulation is the central coactivator that enables a response of RNA polymerase II (Pol II) to activators and repressors. We present the 3.0-angstrom crystal structure of a highly conserved part of the Mediator, the MED7 center dot MED21 (Med7 center dot Srb7) heterodimer. The structure is very extended, spanning one-third of the Mediator length and almost the diameter of Pol II. It shows a four-helix bundle domain and a coiled-coil protrusion connected by a flexible hinge. Four putative protein binding sites on the surface allow for assembly of the Mediator middle module and for binding of the conserved subunit MED6, which is shown to bridge to the Mediator head module. A flexible MED6 bridge and the MED7 center dot MED21 hinge could account for changes in overall Mediator structure upon binding to Pol II or activators. Our results support the idea that transcription regulation involves conformational changes within the general machinery.	Univ Munich, Dept Chem & Biochem, Gene Ctr, D-81377 Munich, Germany	University of Munich	Cramer, P (corresponding author), Univ Munich, Dept Chem & Biochem, Gene Ctr, Feodor Lynen Str 25, D-81377 Munich, Germany.	cramer@LMB.uni-muenchen.de						Asturias FJ, 1999, SCIENCE, V283, P985, DOI 10.1126/science.283.5404.985; Baek HJ, 2002, MOL CELL BIOL, V22, P2842, DOI 10.1128/MCB.22.8.2842-2852.2002; Bjorklund S, 2004, ADV PROTEIN CHEM, V67, P43; Boube M, 2002, CELL, V110, P143, DOI 10.1016/S0092-8674(02)00830-9; Bourbon HM, 2004, MOL CELL, V14, P553, DOI 10.1016/j.molcel.2004.05.011; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cantin GT, 2003, P NATL ACAD SCI USA, V100, P12003, DOI 10.1073/pnas.2035253100; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; Cosma MP, 2001, MOL CELL, V7, P1213, DOI 10.1016/S1097-2765(01)00266-0; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Davis JA, 2002, MOL CELL, V10, P409, DOI 10.1016/S1097-2765(02)00598-1; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dotson MR, 2000, P NATL ACAD SCI USA, V97, P14307, DOI 10.1073/pnas.260489497; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; Gromoller A, 2000, FEBS LETT, V484, P48, DOI 10.1016/S0014-5793(00)02123-2; Gromoller A, 2000, EMBO J, V19, P6845, DOI 10.1093/emboj/19.24.6845; Guglielmi B, 2004, NUCLEIC ACIDS RES, V32, P5379, DOI 10.1093/nar/gkh878; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; Kang JS, 2001, J BIOL CHEM, V276, P42003, DOI 10.1074/jbc.M105961200; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KELLER W, 1995, J MOL BIOL, V254, P657, DOI 10.1006/jmbi.1995.0645; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; Kwon JY, 2001, FEBS LETT, V508, P305, DOI 10.1016/S0014-5793(01)03072-1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee YC, 1998, MOL CELL BIOL, V18, P5364, DOI 10.1128/MCB.18.9.5364; Linder T, 2004, J BIOL CHEM, V279, P49455, DOI 10.1074/jbc.M409046200; Liu Y, 2001, J BIOL CHEM, V276, P7169, DOI 10.1074/jbc.M009586200; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lutzmann M, 2002, EMBO J, V21, P387, DOI 10.1093/emboj/21.3.387; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Meinhart A, 2003, J BIOL CHEM, V278, P48267, DOI 10.1074/jbc.M307874200; Mittler G, 2001, EMBO REP, V2, P808, DOI 10.1093/embo-reports/kve186; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Naar AM, 2002, GENE DEV, V16, P1339, DOI 10.1101/gad.987602; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; NONET ML, 1989, GENETICS, V123, P715; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Rost B, 1996, METHOD ENZYMOL, V266, P525; Taatjes DJ, 2002, SCIENCE, V295, P1058, DOI 10.1126/science.1065249; Taatjes DJ, 2004, NAT STRUCT MOL BIOL, V11, P664, DOI 10.1038/nsmb789; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Tudor M, 1999, GENE DEV, V13, P2365, DOI 10.1101/gad.13.18.2365; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603	53	56	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18171	18178		10.1074/jbc.M413466200	http://dx.doi.org/10.1074/jbc.M413466200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15710619	Green Published, hybrid			2022-12-25	WOS:000228807200075
J	Urizar, E; Claeysen, S; Deupi, X; Govaerts, C; Costagliola, S; Vassart, G; Pardo, L				Urizar, E; Claeysen, S; Deupi, X; Govaerts, C; Costagliola, S; Vassart, G; Pardo, L			An activation switch in the rhodopsin family of G protein-coupled receptors - The thyrotropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN HORMONE-RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; LUTROPIN RECEPTOR; CRYSTAL-STRUCTURE; FUNCTIONAL-ROLE; CONSERVED ASN; TSH RECEPTOR; SIDE-CHAIN; MUTATIONS; HELIX-7	We aimed at understanding molecular events involved in the activation of a member of the G protein-coupled receptor family, the thyrotropin receptor. We have focused on the transmembrane region and in particular on a network of polar interactions between highly conserved residues. Using molecular dynamics simulations and site-directed mutagenesis techniques we have identified residue Asn-7.49, of the NPxxY motif of TM 7, as a molecular switch in the mechanism of thyrotropin receptor (TSHr) activation. Asn-7.49 appears to adopt two different conformations in the inactive and active states. These two states are characterized by specific interactions between this Asn and polar residues in the transmembrane domain. The inactive gauche + conformation is maintained by interactions with residues Thr-6.43 and Asp-6.44. Mutation of these residues into Ala increases the constitutive activity of the receptor by factors of similar to 14 and similar to 10 relative to wild type TSHr, respectively. Upon receptor activation Asn-7.49 adopts the trans conformation to interact with Asp-2.50 and a putatively charged residue that remains to be identified. In addition, the conserved Leu-2.46 of the (N/S) LxxxD motif also plays a significant role in restraining the receptor in the inactive state because the L2.46A mutation increases constitutive activity by a factor of similar to 13 relative to wild type TSHr. As residues Leu-2.46, Asp-2.50, and Asn-7.49 are strongly conserved, this molecular mechanism of TSHr activation can be extended to other members of the rhodopsin-like family of G protein-coupled receptors.	Univ Autonoma Barcelona, Fac Med, Unitat Bioestadist, Lab Med Computac, Bellaterra 08193, Spain; Free Univ Brussels, Inst Rech Interdisciplinaire Biol Humaine & Nucl, B-1070 Brussels, Belgium; Univ Autonoma Barcelona, Inst Neurociencies, Bellaterra 08193, Spain; Univ Basque Country, Fac Farm, Dept Neurofarmacol, Vitoria 1006, Spain	Autonomous University of Barcelona; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Autonomous University of Barcelona; University of Basque Country	Pardo, L (corresponding author), Univ Autonoma Barcelona, Fac Med, Unitat Bioestadist, Lab Med Computac, Edifici M,Campus Univ, Bellaterra 08193, Spain.	Leonardo.Pardo@uab.es	Deupi, Xavier/B-2424-2009; costagliola, sabine/D-4864-2012; Claeysen, Sylvie/C-8599-2014	Deupi, Xavier/0000-0003-4572-9316; Claeysen, Sylvie/0000-0002-0576-5518; Pardo, Leonardo/0000-0003-1778-7420				Angelova K, 2000, MOL ENDOCRINOL, V14, P459, DOI 10.1210/me.14.4.459; Angelova K, 2002, J BIOL CHEM, V277, P32202, DOI 10.1074/jbc.M203272200; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; CASE D, 2003, AMBER 8; Claeysen S, 2002, FEBS LETT, V517, P195, DOI 10.1016/S0014-5793(02)02620-0; Costagliola S, 1998, J IMMUNOL, V160, P1458; Dunbrack RL, 1997, PROTEIN SCI, V6, P1661, DOI 10.1002/pro.5560060807; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Gales C, 2000, J BIOL CHEM, V275, P17321, DOI 10.1074/jbc.M909801199; Govaerts C, 2001, J BIOL CHEM, V276, P22991, DOI 10.1074/jbc.M102244200; Horn F, 2003, NUCLEIC ACIDS RES, V31, P294, DOI 10.1093/nar/gkg103; Kobilka B, 2004, MOL PHARMACOL, V65, P1060, DOI 10.1124/mol.65.5.1060; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002; Li B, 2005, J BIOL CHEM, V280, P5664, DOI 10.1074/jbc.M411623200; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Liapakis G, 2004, MOL PHARMACOL, V65, P1181, DOI 10.1124/mol.65.5.1181; Madabushi S, 2004, J BIOL CHEM, V279, P8126, DOI 10.1074/jbc.M312671200; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Montanelli L, 2004, MOL ENDOCRINOL, V18, P2061, DOI 10.1210/me.2004-0036; Neumann S, 2001, MOL ENDOCRINOL, V15, P1294, DOI 10.1210/me.15.8.1294; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okada T, 2001, CURR OPIN STRUC BIOL, V11, P420, DOI 10.1016/S0959-440X(00)00227-X; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parma J, 1997, J CLIN ENDOCR METAB, V82, P2695, DOI 10.1210/jc.82.8.2695; Prioleau C, 2002, J BIOL CHEM, V277, P36577, DOI 10.1074/jbc.M206223200; Ruprecht JJ, 2004, EMBO J, V23, P3609, DOI 10.1038/sj.emboj.7600374; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; SHI L, 2002, J BIOL CHEM, V277, P40989; Smits G, 2003, EMBO J, V22, P2692, DOI 10.1093/emboj/cdg260; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006; Vlaeminck-Guillem V, 2002, MOL ENDOCRINOL, V16, P736, DOI 10.1210/me.16.4.736; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Whistler JL, 2002, TRAFFIC, V3, P866, DOI 10.1034/j.1600-0854.2002.31203.x; Yu HB, 1999, BIOCHEMISTRY-US, V38, P12028, DOI 10.1021/bi990948+; ZHOU W, 1994, MOL PHARMACOL, V45, P165	46	100	107	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17135	17141		10.1074/jbc.M414678200	http://dx.doi.org/10.1074/jbc.M414678200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722344	Green Published, hybrid			2022-12-25	WOS:000228615500073
J	Urschel, S; Bassermann, F; Bai, RY; Munch, S; Peschel, C; Duyster, J				Urschel, S; Bassermann, F; Bai, RY; Munch, S; Peschel, C; Duyster, J			Phosphorylation of Grb10 regulates its interaction with 14-3-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN GRB10; INSULIN-RECEPTOR; SIGNALING PROTEINS; TYROSINE KINASE; BINDING; SUBSTRATE; IDENTIFICATION; AKT; LOCALIZATION; SPECIFICITY	Grb10 is a member of adapter proteins that are thought to play a role in receptor tyrosine kinase-mediated signal transduction. Grb10 expression levels can influence Akt activity, and Grb10 may act as an adapter involved in the relocalization of Akt to the cell membrane. Here we identified 14-3-3 as a binding partner of Grb10 by employing a yeast two-hybrid screen. The 14-3-3 center dot Grb10 interaction requires phosphorylation of Grb10, and only the phosphorylated form of Grb10 coimmunoprecipitates with endogenous 14-3-3. We could identify a putative phosphorylation site in Grb10, which is located in a classical 14-3-3 binding motif, RSVSEN. Mutation of this site in Grb10 diminished binding to 14-3-3. Thus, Grb10 exists in two different states of phosphorylation and complexes with 14-3-3 when phosphorylated on serine 428. We provide evidence that Akt directly binds Grb10 and is able to phosphorylate Grb10 in an in vitro kinase assay. Based on these findings, we propose a regulatory circuitry involving a phosphorylation-regulated complex formation of Grb10 with 14-3-3 and Akt.	Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, D-81675 Munich, Germany	Technical University of Munich; University of Munich	Duyster, J (corresponding author), Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, Ismanigerstr 22, D-81675 Munich, Germany.	justus.duyster@lrz.tum.de						Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deng YP, 2003, J BIOL CHEM, V278, P39311, DOI 10.1074/jbc.M304599200; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; Langlais P, 2000, ONCOGENE, V19, P2895, DOI 10.1038/sj.onc.1203616; Langlais P, 2004, MOL ENDOCRINOL, V18, P350, DOI 10.1210/me.2003-0117; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu F, 1998, MOL CELL BIOCHEM, V182, P73, DOI 10.1023/A:1006899832614; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nantel A, 1999, J BIOL CHEM, V274, P35719, DOI 10.1074/jbc.274.50.35719; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Powell DW, 2002, J BIOL CHEM, V277, P21639, DOI 10.1074/jbc.M203167200; Sato S, 2002, J BIOL CHEM, V277, P39360, DOI 10.1074/jbc.M205141200; Wang J, 1999, MOL CELL BIOL, V19, P6217; Wick KR, 2003, J BIOL CHEM, V278, P8460, DOI 10.1074/jbc.M208518200; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	30	17	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16987	16993		10.1074/jbc.M501477200	http://dx.doi.org/10.1074/jbc.M501477200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722337	hybrid			2022-12-25	WOS:000228615500055
J	Voss, OH; Kim, S; Wewers, MD; Doseff, AI				Voss, OH; Kim, S; Wewers, MD; Doseff, AI			Regulation of monocyte apoptosis by the protein kinase C delta-dependent phosphorylation of caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYTIC ACTIVATION; INHIBITOR; SURVIVAL; IDENTIFICATION; ENDOTOXIN; CLEAVAGE; CPP32; CELLS	Monocytes are central components of the innate immune response and normally circulate for a short period of time before undergoing spontaneous apoptosis. During inflammation, differentiation, or oncogenic transformation, the life span of monocytes is prolonged by preventing the activation of the apoptotic program. Here we showed that caspase-3, a cysteine protease required for monocyte apoptosis, is a phosphoprotein. We identified protein kinase C delta (PKC delta) as a member of the protein kinase C family that associates with and phosphorylates caspase-3. The PKC delta-dependent phosphorylation of caspase-3 resulted in an increase in the activity of caspase-3. This effect of PKC delta is specific to caspase-3, as evidenced by the absence of similar effects on caspase-9. The activity of PKC delta precedes the activation of caspase-3 during spontaneous monocyte apoptosis and in monocyte-induced apoptosis. We found that the overexpression of PKC delta resulted in an increase of apoptosis, whereas its inhibition blocked caspase-3 activity and decreased apoptosis. Our results provided evidence that the PKC delta-dependent phosphorylation of caspase-3 provided a novel pro-apoptotic mechanism involved in the regulation of monocyte life span.	Ohio State Univ, Heart & Lung Res Inst, Columbus, OH 43210 USA; Ohio State Univ, Div Pulm & Crit Care, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Doseff, AI (corresponding author), Ohio State Univ, Heart & Lung Res Inst 201, 473 W 12th Ave, Columbus, OH 43210 USA.	doseff-1@medctr.osu.edu	Doseff, Andrea/E-2991-2011; Kim, Sunghan/ABH-3874-2020; Wewers, Mark/AAB-6202-2021	Kim, Sunghan/0000-0002-4955-8780				Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CLINE MJ, 1978, ANN INTERN MED, V88, P78, DOI 10.7326/0003-4819-88-1-78; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Doseff AI, 2004, STEM CELLS DEV, V13, P473, DOI 10.1089/1547328042417255; Doseff AI, 2003, AM J RESP CELL MOL, V29, P367, DOI 10.1165/rcmb.2002-0158OC; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fahy RJ, 1999, J IMMUNOL, V163, P1755; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GEAHLEN RL, 1989, J NAT PROD, V52, P982, DOI 10.1021/np50065a011; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Goyal A, 2002, AM J RESP CELL MOL, V26, P224, DOI 10.1165/ajrcmb.26.2.4640; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Jang BC, 2004, BIOCHEM PHARMACOL, V67, P1819, DOI 10.1016/j.bcp.2004.01.018; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kelley TW, 1999, J BIOL CHEM, V274, P26393, DOI 10.1074/jbc.274.37.26393; Khwaja A, 1999, BLOOD, V94, P291, DOI 10.1182/blood.V94.1.291.413k10_291_301; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Leitges M, 2001, J CLIN INVEST, V108, P1505; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; MANGAN DF, 1993, J PERIODONTOL, V64, P461; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Merritt JE, 1997, CELL SIGNAL, V9, P53, DOI 10.1016/S0898-6568(96)00097-6; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Monick MM, 1998, AM J PHYSIOL-LUNG C, V275, pL389, DOI 10.1152/ajplung.1998.275.2.L389; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Page K, 2002, AM J RESP CELL MOL, V27, P204, DOI 10.1165/ajrcmb.27.2.20010016oc; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; SHAW MT, 1980, HUM PATHOL, V11, P215, DOI 10.1016/S0046-8177(80)80003-7; Shizukuda Y, 2002, AM J PHYSIOL-HEART C, V282, pH1625, DOI 10.1152/ajpheart.00783.2001; Smith L, 2000, J BIOL CHEM, V275, P40620, DOI 10.1074/jbc.M908517199; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tan SL, 2003, BIOCHEM J, V376, P545, DOI 10.1042/BJ20031406; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Zeigler MM, 2003, J BIOL CHEM, V278, P12894, DOI 10.1074/jbc.M213125200	53	69	72	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17371	17379		10.1074/jbc.M412449200	http://dx.doi.org/10.1074/jbc.M412449200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15716280	hybrid			2022-12-25	WOS:000228615500102
J	Han, J; Goldstein, LA; Gastman, BR; Rabinovitz, A; Rabinowich, H				Han, J; Goldstein, LA; Gastman, BR; Rabinovitz, A; Rabinowich, H			Disruption of Mcl-1 center dot Bim complex in granzyme B-mediated mitochondrial apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBERS; CELL-DEATH; BH4 DOMAIN; PHOSPHATIDYLSERINE EXPOSURE; NEUTROPHIL APOPTOSIS; CYTOSOLIC DELIVERY; MCL-1; EXPRESSION; CLEAVAGE	Recently, we reported the identification of a novel mitochondrial apoptotic pathway for granzyme B (GrB) (Han, J., Goldstein, L. A., Gastman, B. R., Froelich, C. J., Yin, X. M., and Rabinowich, H. ( 2004) J. Biol. Chem. 279, 22020 - 22029). The newly identified GrB-mediated mitochondrial cascade was initiated by the cleavage and subsequent degradation of Mcl-1, resulting in the release of mitochondrial Bim from Mcl-1 sequestration. To investigate the biological significance of Mcl-1 cleavage by GrB, we mapped the major GrB cleavage sites and evaluated the apoptotic potential of the cleavage products. GrB cleaves Mcl-1 after aspartic acid residues 117, 127, and 157, generating C-terminal fragments that all contain BH-1, BH-2, BH-3, and transmembrane domains. These fragments accumulate at an early apoptotic phase but are eliminated by further degradation during the apoptotic process. The major Mcl-1 C-terminal fragment generated by GrB ( residues 118 - 350) was unable to induce or enhance apoptosis when transfected into tumor cells. Instead, this Mcl-1 C-terminal fragment maintained a partial protective capability against GrB-mediated apoptosis via its lower affinity to Bim. In comparison with ectopically expressed full-length Mcl-1, the stably transfected C-terminal fragments of Mcl-1 were less efficiently localized to the mitochondria. Knockdown of Mcl-1, as achieved by transfection with Mcl-1-specific short interfering RNA, resulted in a significant level of apoptosis in the absence of external apoptotic stimulation and, in addition, enhanced the susceptibility of breast carcinoma cells to GrB cytotoxicity. The significance of Bim in this GrB apoptotic cascade was indicated by the marked protection against GrB-mediated apoptosis endowed on these cells through Bim knockdown. Our studies suggest that the disruption of the Mcl-1 center dot Bim complex by GrB initiates a major Bim-mediated cellular cytotoxic mechanism that requires the elimination of Mcl-1 following its initial cleavage.	Univ Pittsburgh, Pittsburgh Canc Inst, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Plast Surg, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rabinowich, H (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Hillman Canc Ctr, Res Pavill,Rm G17C,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	rabinow@pitt.edu			NATIONAL CANCER INSTITUTE [R01CA109285] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 109285] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; Browne KA, 1999, MOL CELL BIOL, V19, P8604; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Clohessy JG, 2004, BRIT J HAEMATOL, V125, P655, DOI 10.1111/j.1365-2141.2004.04949.x; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Denis GV, 2003, J BIOL CHEM, V278, P5775, DOI 10.1074/jbc.M210202200; Derouet M, 2004, J BIOL CHEM, V279, P26915, DOI 10.1074/jbc.M313875200; Droin NM, 2004, BBA-MOL CELL RES, V1644, P179, DOI 10.1016/j.bbamcr.2003.10.011; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P504, DOI 10.1006/bbrc.1999.1820; Froelich CJ, 2004, CELL DEATH DIFFER, V11, P369, DOI 10.1038/sj.cdd.4401381; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Gleiss B, 2002, FEBS LETT, V519, P153, DOI 10.1016/S0014-5793(02)02743-6; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang HM, 2000, BLOOD, V96, P1764, DOI 10.1182/blood.V96.5.1764.h8001764_1764_1771; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; Johnson DE, 2000, CANCER RES, V60, P1818; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lord SJ, 2003, IMMUNOL REV, V193, P31, DOI 10.1034/j.1600-065X.2003.00044.x; MacDonald G, 1999, J EXP MED, V189, P131, DOI 10.1084/jem.189.1.131; Matsko CM, 2001, BIOCHEM BIOPH RES CO, V287, P1112, DOI 10.1006/bbrc.2001.5696; Metkar SS, 2003, J CELL BIOL, V160, P875, DOI 10.1083/jcb.200210158; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Okita H, 1998, BBA-GENE STRUCT EXPR, V1398, P335, DOI 10.1016/S0167-4781(98)00059-1; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Pelletier M, 2002, FEBS LETT, V532, P164, DOI 10.1016/S0014-5793(02)03668-2; Rinkenberger JL, 2000, GENE DEV, V14, P23; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Sorenson CM, 2004, J BIOL CHEM, V279, P11368, DOI 10.1074/jbc.M310079200; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Thomas DA, 2001, P NATL ACAD SCI USA, V98, P14985, DOI 10.1073/pnas.261581498; Wang GQ, 2001, J EXP MED, V194, P1325, DOI 10.1084/jem.194.9.1325; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Yu A, 2000, BBA-MOL CELL BIOL L, V1487, P296, DOI 10.1016/S1388-1981(00)00100-1; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101	44	62	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16383	16392		10.1074/jbc.M411377200	http://dx.doi.org/10.1074/jbc.M411377200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713684	hybrid			2022-12-25	WOS:000228444800111
J	Tocilj, A; Schrag, JD; Li, YG; Schneider, BL; Reitzer, L; Matte, A; Cygler, M				Tocilj, A; Schrag, JD; Li, YG; Schneider, BL; Reitzer, L; Matte, A; Cygler, M			Crystal structure of N-succinylarginine dihydrolase AstB, bound to substrate and product, an enzyme from the arginine catabolic pathway of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINYLTRANSFERASE PATHWAY; DATABASE; DEIMINASE; AMINOTRANSFERASE; BIOSYNTHESIS; RECOGNITION; SUPERFAMILY; PSEUDOMONAS; HYDROLYSIS; MECHANISM	The ammonia-producing arginine succinyltransferase pathway is the major pathway in Escherichia coli and related bacteria for arginine catabolism as a sole nitrogen source. This pathway consists of five steps, each catalyzed by a distinct enzyme. Here we report the crystal structure of N-succinylarginine dihydrolase AstB, the second enzyme of the arginine succinyltransferase pathway, providing the first structural insight into enzymes from this pathway. The enzyme exhibits a pseudo 5-fold symmetric alpha/beta propeller fold of circularly arranged beta beta alpha beta modules enclosing the active site. The crystal structure indicates clearly that this enzyme belongs to the amidinotransferase ( AT) superfamily and that the active site contains a Cys-His-Glu triad characteristic of the AT superfamily. Structures of the complexes of AstB with the reaction product and a C365S mutant with bound the N-succinylarginine substrate suggest a catalytic mechanism that consists of two cycles of hydrolysis and ammonia release, with each cycle utilizing a mechanism similar to that proposed for arginine deiminases. Like other members of the AT superfamily of enzymes, AstB possesses a flexible loop that is disordered in the absence of substrate and assumes an ordered conformation upon substrate binding, shielding the ligand from the bulk solvent, thereby controlling substrate access and product release.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Montreal Joint Ctr Struct Biol, Montreal, PQ H4P 2R2, Canada; Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA	National Research Council Canada; University of Texas System; University of Texas Dallas	Cygler, M (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	mirek@bri.nrc.ca	Reitzer, Larry/A-2510-2016	Reitzer, Larry/0000-0002-4406-6090				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andreeva A, 2004, NUCLEIC ACIDS RES, V32, pD226, DOI 10.1093/nar/gkh039; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CUNIN R, 1986, MICROBIOL REV, V50, P314, DOI 10.1128/MMBR.50.3.314-352.1986; Das K, 2004, STRUCTURE, V12, P657, DOI 10.1016/j.str.2004.02.017; Fraley CD, 1998, J BACTERIOL, V180, P4287, DOI 10.1128/JB.180.16.4287-4290.1998; Galkin A, 2004, J BIOL CHEM, V279, P14001, DOI 10.1074/jbc.M313410200; Groft CM, 2000, NAT STRUCT BIOL, V7, P1156; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Humm A, 1997, EMBO J, V16, P3373, DOI 10.1093/emboj/16.12.3373; Itoh Y, 1997, J BACTERIOL, V179, P7280, DOI 10.1128/jb.179.23.7280-7290.1997; Karp PD, 2002, NUCLEIC ACIDS RES, V30, P56, DOI 10.1093/nar/30.1.56; Kiupakis AK, 2002, J BACTERIOL, V184, P2940, DOI 10.1128/JB.184.11.2940-2950.2002; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Liu WS, 2004, BIOCHEMISTRY-US, V43, P10896, DOI 10.1021/bi049218e; Lu XF, 2004, J AM CHEM SOC, V126, P5374, DOI 10.1021/ja049543p; Makarova KS, 1999, J MOL BIOL, V292, P11, DOI 10.1006/jmbi.1999.3059; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Murray-Rust J, 2001, NAT STRUCT BIOL, V8, P679, DOI 10.1038/90387; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pearl FMG, 2000, NUCLEIC ACIDS RES, V28, P277, DOI 10.1093/nar/28.1.277; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Reitzer L, 2003, ANNU REV MICROBIOL, V57, P155, DOI 10.1146/annurev.micro.57.030502.090820; Schneider BL, 1998, J BACTERIOL, V180, P4278, DOI 10.1128/JB.180.16.4278-4286.1998; Shah SA, 1997, STRUCTURE, V5, P1067, DOI 10.1016/S0969-2126(97)00258-X; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Shirai H, 2003, FEBS LETT, V555, P505, DOI 10.1016/S0014-5793(03)01314-0; Shirai H, 2001, TRENDS BIOCHEM SCI, V26, P465, DOI 10.1016/S0968-0004(01)01906-5; STALON V, 1987, J GEN MICROBIOL, V133, P2487; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766	36	20	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15800	15808		10.1074/jbc.M413833200	http://dx.doi.org/10.1074/jbc.M413833200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15703173	hybrid			2022-12-25	WOS:000228444800043
J	Barrett, CP; Noble, MEM				Barrett, CP; Noble, MEM			Molecular motions of human cyclin-dependent kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPUTER-SIMULATIONS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PROTEIN-KINASE; DYNAMICS; PHOSPHORYLATION; ACTIVATION; MECHANISM; INHIBITORS; REVEALS	We present a comprehensive description of the dynamic behavior of CDK2 in complex with cyclin A, arrived at by analysis of a total of 0.25 mu s of solvated molecular dynamics trajectories and 42 deposited CDK2 structures, and refined using other protein simulation algorithms. The CDK2-cyclin A dimer is a dynamic complex of 6 subdomains. Thermal motions are dominated by a relative twisting of the two monomers. The predominant motion within CDK2 is a "breathing" of the N-terminal and C-terminal lobes. The N-terminal lobe of cyclin A is tightly linked to the "PSTAIRE" helix of CDK2 to provide a rigid nucleus to the complex. By contrast, the "CDK-insert" region (residues 219-251) sometimes becomes highly mobile, a behavior that is observed in crystallographic analyses of CDK2 structures and that may relate to its role in recognizing diverse binding partners. We find that the three arginines that anchor phosphothreonine 160 of fully active CDK2 do not contribute equally to structural stabilization. This observation is supported by a survey of protein kinase sequences. We have also explored the physical basis of the role of the phosphate moiety in signaling by artificially modifying the charge of phosphothreonine 160 in molecular dynamics simulations. We find that phosphothreonine binding involves an active process of attraction in which both the receptor site (the arginine triad), and the phosphothreonine have a higher charge than is required to maintain an active conformation once formed. We have deposited our dynamics data to aid protein kinase inhibitor design.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England	University of Oxford	Noble, MEM (corresponding author), Univ Oxford, Dept Biochem, Lab Mol Biophys, S Parks Rd, Oxford OX1 3QU, England.	Martin.Noble@biop.ox.ac.uk		Noble, Martin/0000-0002-3595-9807				Barrett CP, 2004, ACTA CRYSTALLOGR D, V60, P2280, DOI 10.1107/S0907444904019171; Bartova I, 2004, PROTEIN SCI, V13, P1449, DOI 10.1110/ps.03578504; Berendsen HJC, 2000, CURR OPIN STRUC BIOL, V10, P165, DOI 10.1016/S0959-440X(00)00061-0; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; Davies TG, 2002, PHARMACOL THERAPEUT, V93, P125, DOI 10.1016/S0163-7258(02)00182-1; de Groot BL, 1999, J MOL BIOL, V286, P1241, DOI 10.1006/jmbi.1998.2568; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; deGroot BL, 1997, PROTEINS, V29, P240, DOI 10.1002/(SICI)1097-0134(199710)29:2<240::AID-PROT11>3.0.CO;2-O; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; GARCIA AE, 1992, PHYS REV LETT, V68, P2696, DOI 10.1103/PhysRevLett.68.2696; HERMANS J, 1984, BIOPOLYMERS, V23, P1513, DOI 10.1002/bip.360230807; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kaldis P, 2000, EUR J BIOCHEM, V267, P4213, DOI 10.1046/j.1432-1327.2000.01455.x; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Moraitakis G, 2003, REP PROG PHYS, V66, P383, DOI 10.1088/0034-4885/66/3/203; Morgan DO, 1996, CURR OPIN CELL BIOL, V8, P767, DOI 10.1016/S0955-0674(96)80076-7; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Otyepka M, 2002, J BIOMOL STRUCT DYN, V20, P141, DOI 10.1080/07391102.2002.10506830; ROUX B, 1995, COMPUT PHYS COMMUN, V91, P275, DOI 10.1016/0010-4655(95)00053-I; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sclafani RA, 1996, CURR OPIN CELL BIOL, V8, P788, DOI 10.1016/S0955-0674(96)80079-2; Stevenson LM, 2002, BIOCHEMISTRY-US, V41, P8528, DOI 10.1021/bi025812h; Tai K, 2001, BIOPHYS J, V81, P715, DOI 10.1016/S0006-3495(01)75736-0; Tarricone C, 2001, MOL CELL, V8, P657, DOI 10.1016/S1097-2765(01)00343-4; Tsigelny I, 1999, BIOPOLYMERS, V50, P513, DOI 10.1002/(SICI)1097-0282(19991015)50:5<513::AID-BIP5>3.0.CO;2-I; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4	35	40	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13993	14005		10.1074/jbc.M407371200	http://dx.doi.org/10.1074/jbc.M407371200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695825	hybrid			2022-12-25	WOS:000228095500102
J	Nash, JE; Johnston, TH; Collingridge, GL; Garner, CC; Brotchie, JM				Nash, JE; Johnston, TH; Collingridge, GL; Garner, CC; Brotchie, JM			Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia	FASEB JOURNAL			English	Article						synaptic plasticity; trafficking	LEVODOPA-INDUCED DYSKINESIAS; TUMOR-SUPPRESSOR PROTEIN; KINASE ANCHORING PROTEIN; NMDA RECEPTOR SUBUNITS; D-ASPARTATE RECEPTORS; RAT MODEL; 6-HYDROXYDOPAMINE-LESIONED RAT; GLUTAMATE RECEPTORS; STRIATAL NMDA; NIGROSTRIATAL FUNCTION	Abnormalities in subcellular localization and interaction between receptors and their signaling molecules occur within the striatum in Parkinson's disease (PD) and L-DOPA-induced dyskinesia ( LID). Synapse-associated proteins (SAPs), for example, PSD-95 and SAP97 organize the molecular architecture of synapses and regulate interactions between receptors and downstream-signaling molecules. Here, we show that expression and subcellular distribution of PSD-95 and SAP97 are altered in the striatum of unilateral 6-OHDA-lesioned rats following repeated vehicle ( a model of PD) or L-DOPA administration ( a model of L-DOPA-induced dyskinesia). Furthermore, following dopamine-depletion and development of behavioral deficits in Rotorod performance, indicative of parkinsonism, we observed a dramatic decrease in total striatal levels of PSD-95 and SAP97 ( to 25.6 +/- 9.9% and 19.0 +/- 5.0% of control, respectively). The remaining proteins were redistributed from the synapse into vesicular compartments. L-DOPA ( 6.5mg/ kg twice a day, 21 days) induced a rotational response, which became markedly enhanced with repeated treatment ( day 1: - 15.8 +/- 7.3 rotations cf day 21: 758.2 +/- 114.0 rotations). Post L-DOPA treatment, PSD-95 and SAP97 levels increased (367.4 +/- 43.2% and 159.9 +/- 9.5% from control values, respectively), with both being redistributed toward synaptic membranes from vesicular compartments. In situ hybridization showed that changes in total levels of PSD-95, but not SAP97, were accompanied by qualitatively similar changes in mRNA. These data highlight the potential role of abnormalities in the subcellular distribution of SAPs in the pathophysiology of a neurological disease.	Toronto Western Hosp, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada; Stanford Univ, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA; Univ Bristol, Sch Med Sci, Dept Anat, MRC,Ctr Synapt Plast, Bristol BS8 1TD, Avon, England	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Stanford University; University of Bristol	Nash, JE (corresponding author), 399 Bathurst St,MCL 11-419, Toronto, ON M5T 2Y4, Canada.	jnash@uhnres.utoronto.ca	Johnston, Tom H/D-2531-2018; Collingridge, Graham L/C-4605-2015; collingridge, graham/AAI-8362-2020	Johnston, Tom H/0000-0002-1537-8175; Collingridge, Graham L/0000-0002-9572-5359; Brotchie, Jonathan/0000-0003-2337-0816; Garner, Craig/0000-0003-1970-5417				ALTAR CA, 1987, J NEUROCHEM, V48, P390, DOI 10.1111/j.1471-4159.1987.tb04106.x; Alto NM, 2002, J CELL BIOL, V158, P659, DOI 10.1083/jcb.200204081; Bezard E, 2001, NAT REV NEUROSCI, V2, P577, DOI 10.1038/35086062; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROTCHIE JM, 2004, IN PRESS J NEURAL T; Calabresi P, 2000, ANN NEUROL, V47, pS60; Calon F, 2000, TRENDS NEUROSCI, V23, pS92, DOI 10.1016/S1471-1931(00)00026-4; Centonze D, 1999, J NEUROPHYSIOL, V82, P3575, DOI 10.1152/jn.1999.82.6.3575; Chase TN, 2001, ADV NEUROL, V86, P355; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Colledge M, 2003, NEURON, V40, P595, DOI 10.1016/S0896-6273(03)00687-1; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dunah AW, 2000, MOL PHARMACOL, V57, P342; Dunah AW, 2001, J NEUROSCI, V21, P5546, DOI 10.1523/JNEUROSCI.21-15-05546.2001; Duty S, 1998, EXP NEUROL, V150, P223, DOI 10.1006/exnr.1997.6771; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Gomez LL, 2002, J NEUROSCI, V22, P7027; Graybiel AM, 2000, TRENDS NEUROSCI, V23, pS71, DOI 10.1016/S1471-1931(00)00027-6; Henry B, 1998, EXP NEUROL, V151, P334, DOI 10.1006/exnr.1998.6819; Henry B, 2003, EXP NEUROL, V183, P458, DOI 10.1016/S0014-4886(03)00064-5; Henry B, 1998, Adv Neurol, V78, P53; Henry B, 1999, EXP NEUROL, V155, P204, DOI 10.1006/exnr.1998.6996; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; INGHAM CA, 1993, EXP BRAIN RES, V93, P17, DOI 10.1007/BF00227776; Ingham CA, 1998, J NEUROSCI, V18, P4732; INGHAM CA, 1989, BRAIN RES, V503, P334, DOI 10.1016/0006-8993(89)91686-7; JOHNSTON TH, IN PRESS EXP NEUROL; Konradi C, 2004, NEUROBIOL DIS, V17, P219, DOI 10.1016/j.nbd.2004.07.005; Kreienkamp HJ, 2002, BIOCHEM SOC T, V30, P464, DOI 10.1042/bst0300464; Leonard AS, 2002, J BIOL CHEM, V277, P48441, DOI 10.1074/jbc.M205164200; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Losi G, 2003, J PHYSIOL-LONDON, V548, P21, DOI 10.1113/jphysiol.2002.034918; Lundblad M, 2004, NEUROBIOL DIS, V16, P110, DOI 10.1016/j.nbd.2004.01.007; Lundblad M, 2002, EUR J NEUROSCI, V15, P120, DOI 10.1046/j.0953-816x.2001.01843.x; MARSDEN CA, 1989, HPLC MACROMOLECULES; Mok H, 2002, J NEUROSCI, V22, P5253; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muriel MP, 2002, MOVEMENT DISORD, V17, P1174, DOI 10.1002/mds.10256; Nash JE, 2000, J NEUROSCI, V20, P7782; Oh JD, 1999, BRAIN RES, V821, P433, DOI 10.1016/S0006-8993(99)01121-X; Okabe S, 2001, J NEUROSCI, V21, P6105, DOI 10.1523/JNEUROSCI.21-16-06105.2001; Oliveria SF, 2003, J CELL BIOL, V160, P101, DOI 10.1083/jcb.200209127; PAPA SM, 1995, BRAIN RES, V701, P13, DOI 10.1016/0006-8993(95)00924-3; PAPA SM, 1994, BRAIN RES, V662, P69, DOI 10.1016/0006-8993(94)90796-X; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Picconi B, 2004, J NEUROSCI, V24, P5283, DOI 10.1523/JNEUROSCI.1224-04.2004; Picconi B, 2003, NAT NEUROSCI, V6, P501, DOI 10.1038/nn1040; Prybylowski K, 2002, J NEUROSCI, V22, P8902; Rascol O, 2000, ANN NEUROL, V47, pS179; Ravenscroft P, 2004, EXP NEUROL, V185, P36, DOI 10.1016/j.expneurol.2003.09.001; Reuver SM, 1998, J CELL SCI, V111, P1071; Segovia G, 2003, MOVEMENT DISORD, V18, P138, DOI 10.1002/mds.10312; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Silverdale MA, 2003, ADV NEUROL, V91, P273; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Tahar AH, 2003, ADV NEUROL, V91, P51; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; UNGERSTEDT U, 1970, Brain Research, V24, P485, DOI 10.1016/0006-8993(70)90187-3; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x; Whishaw IQ, 2003, J NEUROSCI METH, V126, P13, DOI 10.1016/S0165-0270(03)00049-9; Winkler C, 2002, NEUROBIOL DIS, V10, P165, DOI 10.1006/nbdi.2002.0499; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4; ZIGMOND MJ, 1990, TRENDS NEUROSCI, V13, P290, DOI 10.1016/0166-2236(90)90112-N	65	61	63	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					583	+		10.1096/fj.04-1854fje	http://dx.doi.org/10.1096/fj.04-1854fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15703272				2022-12-25	WOS:000227591900019
J	Tanos, T; Marinissen, MJ; Leskow, FC; Hochbaum, D; Martinetto, H; Gutkind, JS; Coso, OA				Tanos, T; Marinissen, MJ; Leskow, FC; Hochbaum, D; Martinetto, H; Gutkind, JS; Coso, OA			Phosphorylation of c-fos by members of the p38 MAPK family - Role in the AP-1 response to UV light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; IMMEDIATE-EARLY GENE; N-TERMINAL KINASE; GROWTH-FACTOR; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; JUN PROMOTER; CELLULAR-TRANSFORMATION; MESSENGER-RNA	Exposure to sources of UV radiation, such as sunlight, induces a number of cellular alterations that are highly dependent on its ability to affect gene expression. Among them, the rapid activation of genes coding for two subfamilies of proto-oncoproteins, Fos and Jun, which constitute the AP-1 transcription factor, plays a key role in the subsequent regulation of expression of genes involved in DNA repair, cell proliferation, cell cycle arrest, death by apoptosis, and tissue and extracellular matrix remodeling proteases. Besides being regulated at the transcriptional level, Jun and Fos transcriptional activities are also regulated by phosphorylation as a result of the activation of intracellular signaling cascades. In this regard, the phosphorylation of c-Jun by UV-induced JNK has been readily documented, whereas a role for Fos proteins in UV-mediated responses and the identification of Fos-activating kinases has remained elusive. Here we identify p38 MAPKs as proteins that can associate with c-Fos and phosphorylate its transactivation domain both in vitro and in vivo. This phosphorylation is transduced into changes in its transcriptional ability as p38-activated c-Fos enhances AP1-driven gene expression. Our findings indicate that as a consequence of the activation of stress pathways induced by UV light, endogenous c-Fos becomes a substrate of p38 MAPKs and, for the first time, provide evidence that support a critical role for p38 MAPKs in mediating stress-induced c-Fos phosphorylation and gene transcription activation. Using a specific pharmacological inhibitor for p38 alpha and -beta, we found that most likely these two isoforms mediate UV-induced c-Fos phosphorylation in vivo. Thus, these newly described pathways act concomitantly with the activation of c-Jun by JNK/MAPKs, thereby contributing to the complexity of AP1-driven gene transcription regulation.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, Lab Fisiol & Biol Mol, Ifibyne Conicet, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Inst Invest & Ingn Genet, Ingebi Conicet, RA-1428 Buenos Aires, DF, Argentina; NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Coso, OA (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Lab Fisiol & Biol Mol, Ifibyne Conicet, RA-1428 Buenos Aires, DF, Argentina.	ocoso@fbmc.fcen.uba.ar	Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Tanos, Tamara/0000-0002-3217-3104; Hochbaum, Daniel/0000-0001-6387-7529	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abe MK, 2002, J BIOL CHEM, V277, P16733, DOI 10.1074/jbc.M112483200; Abe MK, 1999, MOL CELL BIOL, V19, P1301; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; BALL AR, 1988, COLD SPRING HARB SYM, V53, P687, DOI 10.1101/SQB.1988.053.01.078; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BODE AM, 2003, SCI STKE, pRE2; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen DB, 2003, MOL CELL ENDOCRINOL, V200, P141, DOI 10.1016/S0303-7207(02)00379-9; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1997, J BIOL CHEM, V272, P20691, DOI 10.1074/jbc.272.33.20691; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1995, BBA-MOL CELL RES, V1265, P224, DOI 10.1016/0167-4889(95)00002-A; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Higashi N, 2004, GENES CELLS, V9, P233, DOI 10.1111/j.1356-9597.2004.00715.x; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Isoherranen K, 1998, CELL SIGNAL, V10, P191, DOI 10.1016/S0898-6568(97)00100-9; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; Karla N, 2004, J BIOL CHEM, V279, P25313, DOI 10.1074/jbc.M400932200; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; MATSUI M, 1990, ONCOGENE, V5, P249; Mauviel A, 1996, J BIOL CHEM, V271, P24824, DOI 10.1074/jbc.271.40.24824; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; Oldenhof AD, 2002, AM J PHYSIOL-CELL PH, V283, pC1530, DOI 10.1152/ajpcell.00607.2001; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; Seo M, 2002, J BIOL CHEM, V277, P24197, DOI 10.1074/jbc.M201717200; Silvers AL, 2003, NEOPLASIA, V5, P319, DOI 10.1016/S1476-5586(03)80025-8; SMITH MF, 1992, J IMMUNOL, V149, P2000; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TAYLOR LK, 1993, P NATL ACAD SCI USA, V90, P368, DOI 10.1073/pnas.90.2.368; Terasawa K, 2003, GENES CELLS, V8, P263, DOI 10.1046/j.1365-2443.2003.00631.x; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	64	151	159	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18842	18852		10.1074/jbc.M500620200	http://dx.doi.org/10.1074/jbc.M500620200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15708845	hybrid			2022-12-25	WOS:000228932300036
J	Reguera, J; Grueso, E; Carreira, A; Sanchez-Martinez, C; Almendral, JM; Mateu, MG				Reguera, J; Grueso, E; Carreira, A; Sanchez-Martinez, C; Almendral, JM; Mateu, MG			Functional relevance of amino acid residues involved in interactions with ordered nucleic acid in a spherical virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARVOVIRUS MINUTE VIRUS; PROTEIN-RNA INTERACTIONS; BACTERIOPHAGE-MS2 COAT PROTEIN; CHLOROTIC MOTTLE VIRUS; TOBACCO-MOSAIC-VIRUS; CANINE PARVOVIRUS; 3-DIMENSIONAL STRUCTURE; OPERATOR FRAGMENTS; CRYSTAL-STRUCTURES; ICOSAHEDRAL VIRUS	In the spherical virion of the parvovirus minute virus of mice, several amino acid side chains of the capsid were previously found to be involved in interactions with the viral single-stranded DNA molecule. We have individually truncated by mutation to alanine many ( ten) of these side chains and analyzed the effects on capsid assembly, stability and conformation, viral DNA encapsidation, and virion infectivity. Mutation of residues Tyr-270, Asp-273, or Asp-474 led to a drastic reduction in infectivity. Mutant Y270A was defective in capsid assembly; mutant D273A formed stable capsids, but it was essentially unable to encapsidate the viral DNA or to externalize the N terminus of the capsid protein VP2, a connected conformational event. Mutation of residues Asp-58, Trp-60, Asn-183, Thr-267, or Lys-471 led to a moderate reduction in infectivity. None of these mutations had an effect on capsid assembly or stability, or on the DNA encapsidation process. However, those five mutant virions were substantially less stable than the parental virion in thermal inactivation assays. The results with this model spherical virus indicate that several capsid residues that are found to be involved in polar interactions or multiple hydrophobic contacts with the viral DNA molecule contribute to preserving the active conformation of the infectious viral particle. Their effect appears to be mediated by the non-covalent interactions they establish with the viral DNA. In addition, at least one acidic residue at each DNA-binding region is needed for DNA packaging.	Univ Autonoma Madrid, Consejo Super Invest Cient, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Mateu, MG (corresponding author), Univ Autonoma Madrid, Consejo Super Invest Cient, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	mgarcia@cbm.uam.es	Vidaechea, Juan J Reguera/G-7451-2012; Sanchez-Martinez, Maria/A-2948-2009; Grueso, Elia/F-3182-2012; Reguera, Juan/A-7551-2017; Mateu, Mauricio/ABF-2146-2021; Hierro, Esther Grueso/C-8107-2019; Almendral, Jose M/I-2510-2015	Sanchez-Martinez, Maria/0000-0002-2703-7511; Grueso, Elia/0000-0002-1397-6104; Reguera, Juan/0000-0003-4977-7948; Mateu, Mauricio/0000-0002-2915-1529; Grueso, Esther/0000-0002-5365-5129; Almendral, Jose M/0000-0003-3457-0389; Carreira, Aura/0000-0001-5489-4343				Agbandje-McKenna M, 1998, STRUCT FOLD DES, V6, P1369, DOI 10.1016/S0969-2126(98)00137-3; ASTELL CR, 1986, J VIROL, V57, P656, DOI 10.1128/JVI.57.2.656-669.1986; Bernal RA, 2004, J MOL BIOL, V337, P1109, DOI 10.1016/j.jmb.2004.02.033; Bink HHJ, 2002, ARCH VIROL, V147, P2261, DOI 10.1007/s00705-002-0891-6; Carreira A, 2004, J BIOL CHEM, V279, P6517, DOI 10.1074/jbc.M307662200; Casjens S., 1997, STRUCTURAL BIOL VIRU, P3; Chapman MS, 1996, ACTA CRYSTALLOGR D, V52, P129, DOI 10.1107/S0907444995007268; Chapman MS, 2003, ADV PROTEIN CHEM, V64, P125; CHAPMAN MS, 1995, STRUCTURE, V3, P151, DOI 10.1016/S0969-2126(01)00146-0; CHAPMAN MS, 1993, VIROLOGY, V194, P491, DOI 10.1006/viro.1993.1288; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; Cotmore SF, 1999, VIROLOGY, V254, P169, DOI 10.1006/viro.1998.9520; COTMORE SF, 1987, ADV VIRUS RES, V33, P91, DOI 10.1016/S0065-3527(08)60317-6; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; CURRY S, 1995, J VIROL, V69, P430, DOI 10.1128/JVI.69.1.430-438.1995; Da Poian AT, 2002, J BIOL CHEM, V277, P47596, DOI 10.1074/jbc.M209174200; DAPOIAN AT, 1994, BIOCHEMISTRY-US, V33, P8339, DOI 10.1021/bi00193a022; Dertinger D, 2001, J MOL BIOL, V314, P649, DOI 10.1006/jmbi.2001.5132; Dong XF, 1998, J VIROL, V72, P6024, DOI 10.1128/JVI.72.7.6024-6033.1998; Farr GA, 2004, VIROLOGY, V323, P243, DOI 10.1016/j.virol.2004.03.006; FISHER AJ, 1993, NATURE, V361, P176, DOI 10.1038/361176a0; GARDINER EM, 1988, J VIROL, V62, P2605, DOI 10.1128/JVI.62.8.2605-2613.1988; Hafenstein S, 2002, J VIROL, V76, P5350, DOI 10.1128/JVI.76.11.5350-5356.2002; Hernando E, 2000, VIROLOGY, V267, P299, DOI 10.1006/viro.1999.0123; HOHN T, 1969, J MOL BIOL, V43, P191, DOI 10.1016/0022-2836(69)90088-6; ILAG LL, 1993, J MOL BIOL, V229, P671, DOI 10.1006/jmbi.1993.1071; Johansson HE, 1998, P NATL ACAD SCI USA, V95, P9244, DOI 10.1073/pnas.95.16.9244; Johnson J. E., 1999, ENCY VIROLOGY, P1946; JOHNSON JE, 1997, STRUCTURAL BIOL VIRU, P269; Jones S, 2001, NUCLEIC ACIDS RES, V29, P943, DOI 10.1093/nar/29.4.943; Larson SB, 1998, J MOL BIOL, V277, P37, DOI 10.1006/jmbi.1997.1570; LARSON SB, 1993, NATURE, V361, P179, DOI 10.1038/361179a0; LI TS, 1992, BIOCHEMISTRY-US, V31, P6673, DOI 10.1021/bi00144a006; LILJAS L, 1986, PROG BIOPHYS MOL BIO, V48, P1, DOI 10.1016/0079-6107(86)90008-8; Lima SMB, 2004, EUR J BIOCHEM, V271, P135, DOI 10.1046/j.1432-1033.2003.03911.x; LlamasSaiz AL, 1997, ACTA CRYSTALLOGR D, V53, P93, DOI 10.1107/S0907444996010566; Lombardo E, 2000, J VIROL, V74, P3804, DOI 10.1128/JVI.74.8.3804-3814.2000; Lombardo E, 2002, J VIROL, V76, P7049, DOI 10.1128/JVI.76.14.7049-7059.2002; Lopez-Bueno A, 2003, J VIROL, V77, P2701, DOI 10.1128/JVI.77.4.2701-2708.2003; Maroto B, 2004, J VIROL, V78, P10685, DOI 10.1128/jvi.78.19.10685-10694.2004; Mateo R, 2003, J BIOL CHEM, V278, P41019, DOI 10.1074/jbc.M304990200; MCKENNA R, 1992, NATURE, V355, P137, DOI 10.1038/355137a0; MCKENNA R, 1994, J MOL BIOL, V237, P517, DOI 10.1006/jmbi.1994.1253; PEABODY DS, 1993, EMBO J, V12, P595, DOI 10.1002/j.1460-2075.1993.tb05691.x; RAMIREZ JC, 1995, VIROLOGY, V206, P57, DOI 10.1016/S0042-6822(95)80019-0; Reguera J, 2004, P NATL ACAD SCI USA, V101, P2724, DOI 10.1073/pnas.0307748101; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; SACHER R, 1989, J VIROL, V63, P4545, DOI 10.1128/JVI.63.11.4545-4552.1989; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SPEIR JA, 1995, STRUCTURE, V3, P63, DOI 10.1016/S0969-2126(01)00135-6; STOCKLEY PG, 1992, CURR OPIN STRUC BIOL, V2, P143; STUBBS G, 1989, PROTEIN NUCLEIC ACID, P87; Tang L, 2001, NAT STRUCT BIOL, V8, P77, DOI 10.1038/83089; TATTERSALL P, 1983, J VIROL, V46, P944, DOI 10.1128/JVI.46.3.944-955.1983; TATTERSALL P, 1977, J MOL BIOL, V111, P375, DOI 10.1016/S0022-2836(77)80060-0; Tihova M, 2004, J VIROL, V78, P2897, DOI 10.1128/JVI.78.6.2897-2905.2004; TIMMINS PA, 1994, STRUCTURE, V2, P1191, DOI 10.1016/S0969-2126(94)00121-9; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420; Valegard K, 1997, J MOL BIOL, V270, P724, DOI 10.1006/jmbi.1997.1144; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; van den Worm SHE, 1998, NUCLEIC ACIDS RES, V26, P1345, DOI 10.1093/nar/26.5.1345; VIRUDACHALAM R, 1985, VIROLOGY, V146, P138, DOI 10.1016/0042-6822(85)90060-1; VRIEND G, 1986, J MOL BIOL, V191, P453, DOI 10.1016/0022-2836(86)90140-3; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WERY JP, 1994, J MOL BIOL, V235, P565, DOI 10.1006/jmbi.1994.1014; WHITERELL GW, 1991, PROGR NUCL ACIDS RES, V40, P185; WU H, 1993, J MOL BIOL, V233, P231, DOI 10.1006/jmbi.1993.1502; Xie Q, 1996, J MOL BIOL, V264, P497, DOI 10.1006/jmbi.1996.0657	68	22	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17969	17977		10.1074/jbc.M500867200	http://dx.doi.org/10.1074/jbc.M500867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728575	hybrid			2022-12-25	WOS:000228807200051
J	Kessl, JJ; Ha, KH; Merritt, AK; Lange, BB; Hill, P; Meunier, B; Meshnick, SR; Trumpower, BL				Kessl, JJ; Ha, KH; Merritt, AK; Lange, BB; Hill, P; Meunier, B; Meshnick, SR; Trumpower, BL			Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc(1) complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; ATOVAQUONE RESISTANCE; IN-VITRO; MALARIA PROPHYLAXIS; MOLECULAR-BASIS; Q(O) SITE; HYDROXYNAPHTHOQUINONE; PROGUANIL; 566C80; VIVO	Atovaquone is a new anti-malarial agent that specifically targets the cytochrome bc(1) complex and inhibits parasite respiration. A growing number of failures of this drug in the treatment of malaria have been genetically linked to point mutations in the mitochondrial cytochrome b gene. To better understand the molecular basis of atovaquone resistance in malaria, we introduced five of these mutations, including the most prevalent variant found in Plasmodium falciparum (Y268S), into the cytochrome b gene of the budding yeast Saccharomyces cerevisiae and thus obtained cytochrome bc(1) complexes resistant to inhibition by atovaquone. By modeling the variations in cytochrome b structure and atovaquone binding with the mutated bc(1) complexes, we obtained the first quantitative explanation for the molecular basis of atovaquone resistance in malaria parasites.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	Dartmouth College; University of London; University College London; University of North Carolina; University of North Carolina Chapel Hill	Trumpower, BL (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.	Trumpower@Dartmouth.edu	Kessl, Jacques/AAV-2526-2021; Kessl, Jacques/J-6073-2015	Meunier, Brigitte/0000-0002-6988-4663				ARAUJO FG, 1991, ANTIMICROB AGENTS CH, V35, P293, DOI 10.1128/AAC.35.2.293; Atlante A, 2000, J BIOL CHEM, V275, P37159, DOI 10.1074/jbc.M002361200; Billington OJ, 1999, ANTIMICROB AGENTS CH, V43, P1866, DOI 10.1128/AAC.43.8.1866; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Camus D, 2004, CLIN INFECT DIS, V38, P1716, DOI 10.1086/421086; Crofts AR, 2000, BBA-BIOENERGETICS, V1459, P456, DOI 10.1016/S0005-2728(00)00184-5; David KP, 2003, SCAND J INFECT DIS, V35, P897, DOI 10.1080/00365540310016862; Devereux HL, 2001, J MED VIROL, V65, P218, DOI 10.1002/jmv.2023; Farnert A, 2003, BMJ-BRIT MED J, V326, P628, DOI 10.1136/bmj.326.7390.628; Fisher N, 2004, J BIOL CHEM, V279, P12951, DOI 10.1074/jbc.M313866200; Fivelman Quinton L, 2002, Malar J, V1, P1; FRY M, 1992, BIOCHEM PHARMACOL, V43, P1545, DOI 10.1016/0006-2952(92)90213-3; Gao XG, 2002, BIOCHEMISTRY-US, V41, P11692, DOI 10.1021/bi026252p; Gil JP, 2003, MOL CELL PROBE, V17, P85, DOI 10.1016/S0890-8508(03)00006-9; Hill P, 2003, ANTIMICROB AGENTS CH, V47, P2725, DOI 10.1128/AAC.47.9.2725-2731.2003; HUDSON AT, 1993, PARASITOL TODAY, V9, P66, DOI 10.1016/0169-4758(93)90040-M; HUGHES WT, 1995, J INFECT DIS, V172, P1042, DOI 10.1093/infdis/172.4.1042; HUGHES WT, 1990, ANTIMICROB AGENTS CH, V34, P225, DOI 10.1128/AAC.34.2.225; Kessl JJ, 2004, J BIOL CHEM, V279, P2817, DOI 10.1074/jbc.M309984200; Kessl JJ, 2003, J BIOL CHEM, V278, P31312, DOI 10.1074/jbc.M304042200; Korsinczky M, 2000, ANTIMICROB AGENTS CH, V44, P2100, DOI 10.1128/AAC.44.8.2100-2108.2000; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; Palsdottir H, 2003, J BIOL CHEM, V278, P31303, DOI 10.1074/jbc.M302195200; Peters JM, 2002, ANTIMICROB AGENTS CH, V46, P2435, DOI 10.1128/AAC.46.8.2435-2441.2002; Petersen E, 2003, J TRAVEL MED, V10, pS13; Schwartz E, 2003, CLIN INFECT DIS, V37, P450, DOI 10.1086/375599; Schwobel B, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-5; Snyder CH, 1999, J BIOL CHEM, V274, P31209, DOI 10.1074/jbc.274.44.31209; Srivastava IK, 1999, MOL MICROBIOL, V33, P704, DOI 10.1046/j.1365-2958.1999.01515.x; Suswam E, 2001, EXP PARASITOL, V98, P180, DOI 10.1006/expr.2001.4639; Syafruddin D, 1999, MOL BIOCHEM PARASIT, V104, P185, DOI 10.1016/S0166-6851(99)00148-6; Wibrand F, 2001, ANN NEUROL, V50, P540, DOI 10.1002/ana.1224; Wichmann O, 2004, J INFECT DIS, V190, P1541, DOI 10.1086/424469	33	62	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17142	17148		10.1074/jbc.M500388200	http://dx.doi.org/10.1074/jbc.M500388200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15718226	hybrid, Green Published			2022-12-25	WOS:000228615500074
J	Yamamoto, T; Suzuki, N				Yamamoto, T; Suzuki, N			Expression and function of cGMP-dependent protein kinase type I during medaka fish embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REQUIRES NUCLEAR TRANSLOCATION; SOLUBLE GUANYLYL CYCLASE; CREB PHOSPHORYLATION; GENE-EXPRESSION; GLI PROTEINS; HEDGEHOG; PROTEOLYSIS; ACTIVATION; PROMOTER; SUBUNIT	We isolated and characterized cDNA clones (PKG I alpha and PKG I beta) for medaka fish cGMP-dependent protein kinase ( PKG) I alpha and I beta, and demonstrated that both are expressed in the embryos after late gastrula stage. Whole-mount in situ hybridization using each isoform-specific probe revealed that the transcripts of the PKG I alpha gene were present in the spinal cord and gill arch, whereas those of the PKG I beta gene were only weakly expressed in these organs, but highly expressed in the otic vesicles. Injection of PKG I alpha-specific morpholino antisense oligonucleotides (I alpha-MO) into two-cell stage medaka fish embryos caused severe abnormalities in the developing embryos, such as the development of a hammer-like head, fusion of the developing eyes, and degeneration of cells around the eyes, whereas injection of PKG I alpha-specific morpholino antisense oligonucleotides ( I beta-MO) caused fewer abnormalities in the embryos, even when injected at higher concentrations than I alpha-MO. The PKG I-overexpressing embryos exhibited smaller eyes and enlargement of the forebrain, a phenotype similar to that observed in the cAMP-dependent protein kinase (PKA)-depressed embryos. In the PKG-deficient embryos, a sonic hedgehog (shh)-target gene, HNF-3 beta, was expressed weakly, and this phenotype was similar to that observed in the PKA-overexpressing embryos suggesting that the cGMP/PKG signaling pathway is involved in some steps of shh signaling. We also demonstrated that Gli proteins, shh-downstream molecules, are phosphorylated by the NO/cGMP signaling pathway, probably by PKG in NG108-15 neuroblastoma cells. These results imply that PKG and PKA share common substrates and work in an opposite manner during the early embryogenesis of medaka fish.	Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan	Hokkaido University	Yamamoto, T (corresponding author), Keio Univ, Sch Med, Dept Biochem & Integrat Med Biol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	take-y@sc.itc.keio.ac.jp						Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Amieux PS, 2002, J BIOL CHEM, V277, P27294, DOI 10.1074/jbc.M200302200; Butt E, 2003, J BIOL CHEM, V278, P15601, DOI 10.1074/jbc.M209009200; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dontchev VD, 2003, J HISTOCHEM CYTOCHEM, V51, P435, DOI 10.1177/002215540305100405; Epstein DJ, 1996, DEVELOPMENT, V122, P2885; Gendron L, 2002, NEUROENDOCRINOLOGY, V75, P70, DOI 10.1159/000048222; Goldberg N D, 1975, Adv Cyclic Nucleotide Res, V5, P307; Gudi T, 2000, ONCOGENE, V19, P6324, DOI 10.1038/sj.onc.1204007; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; IWAMATSU T, 1994, ZOOL SCI, V11, P825; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Joore J, 1998, MECH DEVELOP, V79, P5, DOI 10.1016/S0925-4773(98)00152-X; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Koebernick K, 2002, DIFFERENTIATION, V70, P69, DOI 10.1046/j.1432-0436.2002.700201.x; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; Lefers MA, 2002, CURR BIOL, V12, pR422, DOI 10.1016/S0960-9822(02)00914-4; Lu YF, 1999, J NEUROSCI, V19, P10250; Lucas KA, 2000, PHARMACOL REV, V52, P375; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Mikami T, 1999, J BIOL CHEM, V274, P18567, DOI 10.1074/jbc.274.26.18567; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Qian YF, 1996, J NEUROSCI, V16, P3130; Robertson CP, 2001, DEV BIOL, V238, P157, DOI 10.1006/dbio.2001.0392; Rubenstein JLR, 1998, CURR OPIN NEUROBIOL, V8, P18, DOI 10.1016/S0959-4388(98)80004-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Schmidt H, 2002, J CELL BIOL, V159, P489, DOI 10.1083/jcb.200207058; SOKOLOWSKI MB, 1980, BEHAV GENET, V10, P291, DOI 10.1007/BF01067774; Song BH, 2003, DEV DYNAM, V227, P91, DOI 10.1002/dvdy.10296; Tamura N, 1996, HYPERTENSION, V27, P552, DOI 10.1161/01.HYP.27.3.552; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Waschek JA, 1998, P NATL ACAD SCI USA, V95, P9602, DOI 10.1073/pnas.95.16.9602; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WOLFE L, 1989, J BIOL CHEM, V264, P7734; Yamagami S, 2001, J BIOCHEM-TOKYO, V130, P39, DOI 10.1093/oxfordjournals.jbchem.a002960; Yamamoto T, 2002, BIOCHEM J, V361, P337, DOI 10.1042/0264-6021:3610337; Yamamoto T, 2003, ZOOL SCI, V20, P181, DOI 10.2108/zsj.20.181	45	7	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16979	16986		10.1074/jbc.M412433200	http://dx.doi.org/10.1074/jbc.M412433200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15710621	hybrid			2022-12-25	WOS:000228615500054
J	Baldwin, SA; Yao, SYM; Hyde, RJ; Ng, AML; Foppolo, S; Barnes, K; Ritzel, MWL; Cass, CE; Young, JD				Baldwin, SA; Yao, SYM; Hyde, RJ; Ng, AML; Foppolo, S; Barnes, K; Ritzel, MWL; Cass, CE; Young, JD			Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOBASE TRANSPORTERS; RECOMBINANT HUMAN; ANTICANCER DRUGS; CELLULAR UPTAKE; PROTEINS; FAMILY; CELLS; IDENTIFICATION; EXPRESSION; LYSOSOMES	The first mammalian examples of the equilibrative nucleoside transporter family to be characterized, hENT1 and hENT2, were passive transporters located predominantly in the plasma membranes of human cells. We now report the functional characterization of members of a third subgroup of the family, from human and mouse, which differ profoundly in their properties from previously characterized mammalian nucleoside transporters. The 475-residue human and mouse proteins, designated hENT3 and mENT3, respectively, are 73% identical in amino acid sequence and possess long N-terminal hydrophilic domains that bear typical ( DE) XXXL(LI) endosomal/lysosomal targeting motifs. ENT3 transcripts and proteins are widely distributed in human and rodent tissues, with a particular abundance in placenta. However, in contrast to ENT1 and ENT2, the endogenous and green fluorescent protein-tagged forms of the full-length hENT3 protein were found to be predominantly intracellular proteins that co-localized, in part, with lysosomal markers in cultured human cells. Truncation of the hydrophilic N-terminal region or mutation of its dileucine motif to alanine caused the protein to be relocated to the cell surface both in human cells and in Xenopus oocytes, allowing characterization of its transport activity in the latter. The protein proved to be a broad selectivity, low affinity nucleoside transporter that could also transport adenine. Transport activity was relatively insensitive to the classical nucleoside transport inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep and was sodium ion-independent. However, it was strongly dependent upon pH, and the optimum pH value of 5.5 probably reflected the location of the transporter in acidic, intracellular compartments.	Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England; Univ Alberta, Dept Physiol, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Oncol, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Cross Canc Inst, Edmonton, AB T6G 2H7, Canada	University of Leeds; University of Alberta; University of Alberta; University of Alberta	Baldwin, SA (corresponding author), Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England.	s.a.baldwin@leeds.ac.uk						Acimovic Y, 2002, MOL BIOL EVOL, V19, P2199, DOI 10.1093/oxfordjournals.molbev.a004044; Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; Boll M, 2004, PFLUG ARCH EUR J PHY, V447, P776, DOI 10.1007/s00424-003-1073-4; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; Damaraju VL, 2003, ONCOGENE, V22, P7524, DOI 10.1038/sj.onc.1206952; DAVIES A, 1990, BIOCHEM J, V266, P799; Engel K, 2004, J BIOL CHEM, V279, P50042, DOI 10.1074/jbc.M407913200; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; Gray JH, 2004, PFLUG ARCH EUR J PHY, V447, P728, DOI 10.1007/s00424-003-1107-y; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HEYDRICK SJ, 1991, J BIOL CHEM, V266, P8790; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; Lai YR, 2004, J BIOL CHEM, V279, P4490, DOI 10.1074/jbc.M307938200; Landfear SM, 2004, EUKARYOT CELL, V3, P245, DOI 10.1128/EC.3.2.245-254.2004; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Mani RS, 1998, J BIOL CHEM, V273, P30818, DOI 10.1074/jbc.273.46.30818; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; Musa H, 2002, J HISTOCHEM CYTOCHEM, V50, P305, DOI 10.1177/002215540205000302; Pastor-Anglada M, 1998, TRENDS PHARMACOL SCI, V19, P424, DOI 10.1016/S0165-6147(98)01253-X; PISONI RL, 1989, J BIOL CHEM, V264, P4850; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Towler MC, 2000, EXP CELL RES, V259, P167, DOI 10.1006/excr.2000.4958; Vickers MF, 2000, J BIOL CHEM, V275, P25931, DOI 10.1074/jbc.M000239200; Visser F, 2002, J BIOL CHEM, V277, P395, DOI 10.1074/jbc.M105324200; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; Yao SYM, 2002, J BIOL CHEM, V277, P24938, DOI 10.1074/jbc.M200966200; Yao SYM, 2001, MOL MEMBR BIOL, V18, P161, DOI 10.1080/09687680110048318	37	250	259	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15880	15887		10.1074/jbc.M414337200	http://dx.doi.org/10.1074/jbc.M414337200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15701636	hybrid			2022-12-25	WOS:000228444800053
J	Gan, YH; Shen, YH; Wang, J; Wang, XW; Utama, B; Wang, J; Wang, XL				Gan, YH; Shen, YH; Wang, J; Wang, XW; Utama, B; Wang, J; Wang, XL			Role of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESS TRANSCRIPTION; GENE-EXPRESSION; DNA METHYLATION; BINDING PROTEIN; SP1 SITE; PROMOTER; INHIBITORS; ACETYLATION; COMPLEX; HTERT	Histone acetylation plays an important role in chromatin remodeling and gene expression. The molecular mechanisms involved in cell-specific expression of endothelial nitric-oxide synthase ( eNOS) are not fully understood. In this study we investigated whether histone deacetylation was involved in repression of eNOS expression in non-endothelial cells. Induction of eNOS expression by histone deacetylase ( HDAC) inhibitors trichostatin A (TSA) and sodium butyrate was observed in all four different types of non-endothelial cells examined. Chromatin immunoprecipitation assays showed that the induction of eNOS expression by TSA was accompanied by a remarkable increase of acetylation of histone H3 associated with the eNOS 5'-flanking region in the non-endothelial cells. Moreover, DNA methylation-mediated repression of eNOS promoter activity was partially reversed by TSA treatment, and combined treatment of TSA and 5-aza-2'-deoxycytidine (AzadC) synergistically induced eNOS expression in non-endothelial cells. The proximal Sp1 site is critical for basal activity of eNOS promoter. The induction of eNOS by inhibition of HDACs in non-endothelial cells, however, appeared not mediated by the changes in Sp1 DNA binding activity. We further showed that Sp1 bound to the endogenous eNOS promoter and associated with HDAC1 in non-endothelial HeLa cells. Combined TSA and AzadC treatment increased Sp1 binding to the endogenous eNOS promoter but decreased the association between HDAC1 and Sp1 in HeLa cells. Our data suggest that HDAC1 plays a critical role in eNOS repression, and the proximal Sp1 site may serve a key target for HDCA1-mediated eNOS repression in non-endothelial cells.	Baylor Coll Med, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, Houston, TX 77030 USA; Peking Univ, Sch Stomatol, Ctr TMJ Disorders, Beijing 100081, Peoples R China	Baylor College of Medicine; Peking University	Wang, XL (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, MS NAB 2010, Houston, TX 77030 USA.	xlwang@bcm.tmc.edu	shen, ying/HHS-5635-2022		NHLBI NIH HHS [R01 HL066053-04, R01-HL066053, R01 HL066053] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066053] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown Robert, 2004, Expert Rev Anticancer Ther, V4, P501, DOI 10.1586/14737140.4.4.501; Camarero N, 2003, NUCLEIC ACIDS RES, V31, P1693, DOI 10.1093/nar/gkg262; Chan Y, 2004, J BIOL CHEM, V279, P35087, DOI 10.1074/jbc.M405063200; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Davie JR, 1999, J CELL BIOCHEM, P141; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286; Guillot PV, 2000, PHYSIOL GENOMICS, V2, P77, DOI 10.1152/physiolgenomics.2000.2.2.77; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Kim HS, 2003, BIOCHEM BIOPH RES CO, V312, P950, DOI 10.1016/j.bbrc.2003.11.012; Laumonnier Y, 2000, J BIOL CHEM, V275, P40732, DOI 10.1074/jbc.M004696200; Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941; Li HG, 2002, NITRIC OXIDE-BIOL CH, V7, P149, DOI 10.1016/S1089-8603(02)00111-8; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Qiu P, 2002, CIRC RES, V90, P858, DOI 10.1161/01.RES.0000016504.08608.B9; Rossig L, 2002, CIRC RES, V91, P837, DOI 10.1161/01.RES.0000037983.07158.B1; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Teichert AM, 2000, AM J PHYSIOL-HEART C, V278, pH1352, DOI 10.1152/ajpheart.2000.278.4.H1352; van Haperen R, 2003, AM J PATHOL, V163, P1677, DOI 10.1016/S0002-9440(10)63524-9; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wang R, 2002, ARTERIOSCL THROM VAS, V22, pE1, DOI 10.1161/01.ATV.0000016248.51577.1F; Warnecke PM, 2002, METHODS, V27, P101, DOI 10.1016/S1046-2023(02)00060-9; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200; Zhao SJ, 2003, CANCER RES, V63, P2624	31	81	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16467	16475		10.1074/jbc.M412960200	http://dx.doi.org/10.1074/jbc.M412960200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722551	Green Accepted, hybrid			2022-12-25	WOS:000228444800121
J	Hambsch, B; Grinevich, V; Seeburg, PH; Schwarz, MK				Hambsch, B; Grinevich, V; Seeburg, PH; Schwarz, MK			gamma-Protocadherins, presenilin-mediated release of C-terminal fragment promotes locus expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CELL-ADHESION; E-CADHERIN; INTRACELLULAR DOMAIN; SECRETASE ACTIVITY; N-CADHERIN; DIVERSITY; CLEAVAGE; MICE; PROTEOLYSIS	gamma-Protocadherins (gamma-pcdhs) are type I membrane-spanning glycoproteins, widely expressed in the mammal and required for survival. These cell adhesion molecules are expressed from a complex locus comprising 22 functional variable exons arranged in tandem, each encoding extracellular, transmembrane and intracellular sequence, and three exons for an invariant C-terminal domain (gamma-ICD). However, the signaling mechanisms that lie downstream of gamma-pcdhs have not been elucidated. Here we report that gamma-pcdhs are subject to presenilin-dependent intramembrane cleavage (PS-IP), accompanied by shedding of the extracellular domain. The cleaved intracellular domain (gamma-ICD) translocates to the cell nucleus and was detected in subsets of cortical neurons. Notably, gene-targeted mice lacking functional gamma-ICD sequence showed severely reduced gamma-pcdh mRNA levels and neonatal lethality. Most importantly, inhibition of gamma-secretase decreased gamma-pcdh locus expression. Luciferase reporter assays demonstrated that gamma-pcdh promoter activity is increased by gamma-ICD. These results reveal an intracellular signaling mechanism for gamma-pcdhs and identify a novel vital target for the gamma-secretase complex.	Max Planck Inst Med Res, Dept Mol Neurobiol, D-69120 Heidelberg, Germany	Max Planck Society	Seeburg, PH (corresponding author), Max Planck Inst Med Res, Dept Mol Neurobiol, Jahnstr 29, D-69120 Heidelberg, Germany.	seeburg@mpimf-heidelberg.mpg.de						Angst BD, 2001, J CELL SCI, V114, P629; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; DE SB, 1999, NATURE, V398, P518; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Feng RB, 2004, P NATL ACAD SCI USA, V101, P8162, DOI 10.1073/pnas.0402733101; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Mack V, 2001, SCIENCE, V292, P2501, DOI 10.1126/science.1059365; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; MURATA Y, 2004, J BIOL CHEM; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Phillips GR, 2003, J NEUROSCI, V23, P5096; Phillips GR, 2001, NEURON, V32, P63, DOI 10.1016/S0896-6273(01)00450-0; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Shapiro L, 1999, NEURON, V23, P427, DOI 10.1016/S0896-6273(00)80796-5; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Silver RA, 2003, SCIENCE, V302, P1981, DOI 10.1126/science.1087160; Suchanek B, 1997, BIOL CHEM, V378, P929; Suzuki ST, 1996, J CELL SCI, V109, P2609; Tanaka H, 2000, NEURON, V25, P93, DOI 10.1016/S0896-6273(00)80874-0; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Togashi H, 2002, NEURON, V35, P77, DOI 10.1016/S0896-6273(02)00748-1; Wang XZ, 2002, GENE DEV, V16, P1890, DOI 10.1101/gad.1004802; Wang XZ, 2002, NEURON, V36, P843, DOI 10.1016/S0896-6273(02)01090-5; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; WISDEN W, 2002, IN SITU HYBRIDIZATIO, V47; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wu Q, 2001, GENOME RES, V11, P389, DOI 10.1101/gr.167301; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; ZABORSZKY L, 1989, NEUROANATOMICAL TRAC, V2, P49; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	49	68	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15888	15897		10.1074/jbc.M414359200	http://dx.doi.org/10.1074/jbc.M414359200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15711011	hybrid			2022-12-25	WOS:000228444800054
J	Reversi, A; Rimoldi, V; Marrocco, T; Cassoni, P; Bussolati, G; Parenti, M; Chini, B				Reversi, A; Rimoldi, V; Marrocco, T; Cassoni, P; Bussolati, G; Parenti, M; Chini, B			The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAVEOLIN-1 ENRICHED DOMAINS; G-PROTEINS; IN-VITRO; VASOPRESSIN RECEPTOR; CANCER CELLS; ACTIVATION; BINDING; LIGAND; PROLIFERATION; DESIGN	In human myometrial cells, the promiscuous coupling of the oxytocin receptors (OTRs) to G(q) and G(i) leads to contraction. However, the activation of OTRs coupled to different G protein pathways can also trigger opposite cellular responses, e.g. OTR coupling to G(i) inhibits, whereas its coupling to G(q) stimulates, cell proliferation. Drug analogues capable of promoting a selective receptor-G protein coupling may be of great pharmacological and clinical importance because they may target only one specific signal transduction pathway. Here, we report that atosiban, an oxytocin derivative that acts as a competitive antagonist on OTR/G(q) coupling, displays agonistic properties on OTR/G(i) coupling, as shown by specific S-35-labeled guanosine 5'-3-O-(thio) trisphosphate ([S-35] GTP gamma S) binding. Moreover, atosiban, by acting on a G(i)-mediated pathway, inhibits cell growth of HEK293 and Madin-Darby canine kidney cells stably transfected with OTRs and of DU145 prostate cancer cells expressing endogenous OTRs. Notably, atosiban leads to persistent ERK1/2 activation and p21(WAF1/CIP1) induction, the same signaling events leading to oxytocin-mediated cell growth inhibition via a Gi pathway. Finally, atosiban exposure did not cause OTR internalization and led to only a modest decrease (20%) in the number of high affinity cell membrane OTRs, two observations consistent with the finding that atosiban did not lead to any desensitization of the oxytocin-induced activation of the G(q)-phospholipase C pathway. Taken together, these observations indicate that atosiban acts as a "biased agonist" of the human OTRs and thus belongs to the class of compounds capable of selectively discriminating only one among the multiple possible active conformations of a single G protein-coupled receptor, thereby leading to the selective activation of a unique intracellular signal cascade.	CNR, Inst Neurosci, Cellular & Mol Pharmacol Sect, I-20129 Milan, Italy; Univ Turin, Dept Biomed Sci & Human Oncol, I-10126 Turin, Italy; Univ Milano Bicocca, Dept Expt & Environm Med & Med Biotechnol, I-20052 Monza, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Turin; University of Milano-Bicocca	Chini, B (corresponding author), CNR, Inst Neurosci, Cellular & Mol Pharmacol Sect, Via Vanvitelli 32, I-20129 Milan, Italy.	B.Chini@in.cnr.it	Cassoni, Paola/I-8544-2018; Rimoldi, Valeria/AAB-4865-2020	Rimoldi, Valeria/0000-0002-5598-3986; Chini, Bice/0000-0002-1686-284X; Reversi, Alessandra/0000-0002-9934-5636				AKERLUND M, 1987, BRIT J OBSTET GYNAEC, V94, P1040, DOI 10.1111/j.1471-0528.1987.tb02287.x; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; BERDE B, 1968, HDB EXPERIMENTAL PHA, V23, P802; Bestervelt L, 2000, CELL SIGNAL, V12, P53, DOI 10.1016/S0898-6568(99)00067-4; BOSSMAR T, 1994, AM J OBSTET GYNECOL, V171, P1634, DOI 10.1016/0002-9378(94)90415-4; Breton C, 2002, J CLIN ENDOCR METAB, V87, P1415, DOI 10.1210/jc.87.3.1415; Cassoni P, 2004, INT J ONCOL, V25, P899; Cassoni P, 2001, ENDOCRINOLOGY, V142, P1130, DOI 10.1210/en.142.3.1130; Cassoni P, 1996, INT J CANCER, V66, P817, DOI 10.1002/(SICI)1097-0215(19960611)66:6<817::AID-IJC18>3.0.CO;2-#; Chan DC, 2002, CLIN CANCER RES, V8, P1280; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; Chini B, 2000, EXP PHYSIOL, V85, p59S, DOI 10.1111/j.1469-445X.2000.tb00008.x; Coomarasamy Aravinthan, 2002, Med Sci Monit, V8, pRA268; Drube S, 2000, BRIT J PHARMACOL, V131, P1553, DOI 10.1038/sj.bjp.0703764; ELANDS J, 1988, EUR J PHARMACOL, V147, P197, DOI 10.1016/0014-2999(88)90778-9; Gimpl G, 2001, PHYSIOL REV, V81, P629, DOI 10.1152/physrev.2001.81.2.629; Guzzi F, 2002, ONCOGENE, V21, P1658, DOI 10.1038/sj.onc.1205219; Harrison C, 2003, LIFE SCI, V74, P489, DOI 10.1016/j.lfs.2003.07.005; Hasbi A, 2004, MOL ENDOCRINOL, V18, P1277, DOI 10.1210/me.2003-0440; Jarpe MB, 1998, J BIOL CHEM, V273, P3097, DOI 10.1074/jbc.273.5.3097; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P256, DOI 10.1016/S0165-6147(00)89037-9; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P188, DOI 10.1016/S0165-6147(00)89020-3; Kenakin T, 2003, TRENDS PHARMACOL SCI, V24, P346, DOI 10.1016/S0165-6147(03)00167-6; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KIRK CJ, 1986, BIOCHEM J, V240, P197, DOI 10.1042/bj2400197; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacKinnon AC, 2001, J BIOL CHEM, V276, P28083, DOI 10.1074/jbc.M009772200; MANNING M, 1993, J RECEPTOR RES, V13, P195, DOI 10.3109/10799899309073655; MANNING M, 1995, INT J PEPT PROT RES, V46, P244; Milligan G, 2003, TRENDS PHARMACOL SCI, V24, P87, DOI 10.1016/S0165-6147(02)00027-5; Moody TW, 2001, PEPTIDES, V22, P109, DOI 10.1016/S0196-9781(00)00362-4; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Paquin J, 2002, P NATL ACAD SCI USA, V99, P9550, DOI 10.1073/pnas.152302499; PHANEUF S, 1994, AM J OBSTET GYNECOL, V171, P1627, DOI 10.1016/0002-9378(94)90414-6; PHANEUF S, 1993, J ENDOCRINOL, V136, P497, DOI 10.1677/joe.0.1360497; Rimoldi V, 2003, ONCOGENE, V22, P6054, DOI 10.1038/sj.onc.1206612; Sanborn BM, 2001, EXP PHYSIOL, V86, P223, DOI 10.1113/eph8602179; Slusarz MJ, 2003, PROTEIN PEPTIDE LETT, V10, P295, DOI 10.2174/0929866033478898; Stirnweis J, 2002, PEPTIDES, V23, P1503, DOI 10.1016/S0196-9781(02)00089-X; Strakova Z, 1997, AM J PHYSIOL-ENDOC M, V272, pE870, DOI 10.1152/ajpendo.1997.272.5.E870; Takasu H, 1999, BIOCHEMISTRY-US, V38, P13453, DOI 10.1021/bi990437n; Thornton S, 2001, EXP PHYSIOL, V86, P297, DOI 10.1113/eph8602186; Tomizawa K, 2003, NAT NEUROSCI, V6, P384, DOI 10.1038/nn1023; Tong WG, 2002, CLIN CANCER RES, V8, P3232; WIELAND T, 1994, METHOD ENZYMOL, V237, P3	45	95	97	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16311	16318		10.1074/jbc.M409945200	http://dx.doi.org/10.1074/jbc.M409945200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705593	hybrid			2022-12-25	WOS:000228444800102
J	Yik, JHN; Chen, RC; Pezda, AC; Zhou, Q				Yik, JHN; Chen, RC; Pezda, AC; Zhou, Q			Compensatory contributions of HEXIM1 and HEXIM2 in maintaining the balance of active and inactive positive transcription elongation factor b complexes for control of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; P-TEFB; 7SK SNRNA; CLP-1 GENE; TAT; KINASE; INHIBITION; ACTIVATION; EXPRESSION; MECHANISM	Human positive transcriptional elongation factor b (P-TEFb), consisting of a cyclin-dependent kinase 9-cyclin T heterodimer, stimulates general and disease-specific transcriptional elongation by phosphorylating RNA polymerase II. The HEXIM1 protein, aided by the 7SK snRNA, sequesters P-TEFb into an inactive 7SK center dot HEXIM1 center dot P-TEFb small nuclear ribonucleic acid particle for inhibition of transcription and, consequently, cell proliferation. Here we show that, like HEXIM1, a highly homologous protein named HEXIM2 also possesses the ability to inactivate P-TEFb to suppress transcription through a 7SK-mediated interaction with P-TEFb. Furthermore, HEXIM1 and HEXIM2 can form stable homo- and hetero-oligomers ( most likely dimers), which may nucleate the formation of the 7SK small nuclear ribonucleic acid particle. Despite their similar functions, HEXIM1 and HEXIM2 exhibit distinct expression patterns in various human tissues and established cell lines. In HEXIM1-knocked down cells, HEXIM2 can functionally and quantitatively compensate for the loss of HEXIM1 to maintain a constant level of the 7SK/ HEXIM-bound P-TEFb. Our results demonstrate that there is a tightly regulated cellular process to maintain the balance between active and inactive P-TEFb complexes, which controls global transcription as well as cell growth and differentiation.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Xiamen Univ, Sch Life Sci, Xiamen 361005, Peoples R China	University of California System; University of California Berkeley; Xiamen University	Zhou, Q (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 622 Barker Hall 3202, Berkeley, CA 94720 USA.	qzhou@uclink4.berkeley.edu	Chen, Ruichuan/G-4618-2010; Yik, Jasper/C-7343-2009	Yik, Jasper/0000-0001-7532-629X	NIAID NIH HHS [AI41757, AI058400] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041757, F32AI058400] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; Chen RC, 2004, J BIOL CHEM, V279, P4153, DOI 10.1074/jbc.M310044200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Huang F, 2004, MECH DEVELOP, V121, P559, DOI 10.1016/j.mod.2004.04.012; Huang FC, 2002, GENE, V292, P245, DOI 10.1016/S0378-1119(02)00596-6; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; MARKS PA, 1994, P NATL ACAD SCI USA, V91, P10251, DOI 10.1073/pnas.91.22.10251; Michels AA, 2004, EMBO J, V23, P2608, DOI 10.1038/sj.emboj.7600275; Michels AA, 2003, MOL CELL BIOL, V23, P4859, DOI 10.1128/MCB.23.14.4859-4869.2003; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Ouchida R, 2003, GENES CELLS, V8, P95, DOI 10.1046/j.1365-2443.2003.00618.x; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Wittmann BM, 2003, CANCER RES, V63, P5151; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Yik JHN, 2004, MOL CELL BIOL, V24, P5094, DOI 10.1128/MCB.24.12.5094-5105.2004; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x	25	84	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16368	16376		10.1074/jbc.M500912200	http://dx.doi.org/10.1074/jbc.M500912200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713661	hybrid			2022-12-25	WOS:000228444800109
J	Berg, DT; Myers, LJ; Richardson, MA; Sandusky, G; Grinnell, BW				Berg, DT; Myers, LJ; Richardson, MA; Sandusky, G; Grinnell, BW			Smad6s regulates plasminogen activator inhibitor-1 through a protein kinase C-beta-dependent up-regulation of transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TGF-BETA; RESPONSIVE ELEMENT; GENE-EXPRESSION; INDUCIBLE ELEMENTS; ENDOTHELIAL-CELLS; DIRECT BINDING; MESSENGER-RNA; TYPE-1 GENE; PKC-BETA	Plasminogen activator inhibitor-1 (PAI-1) is a serpin class protease inhibitor that plays a central role in the regulation of vascular function and tissue remodeling by modulating thrombosis, inflammation, and the extracellular matrix. A central mediator controlling PAI-1 is transforming growth factor-beta(TGF-beta), which induces its expression and promotes fibrosis. We have found that a unique member of the Smad family of signal transduction molecules, Smad6s, modulates the expression of PAI-1. Overexpression of Smad6s in endothelial cells increases promoter activity and PAI-1 secretion, and an antisense to Smad6s suppresses the induction of PAI-1 by TGF-beta. The effect of Smad6s on the PAI-1 promoter appeared to be the result of increase binding of the forkhead winged helix factor FoxD1 to a TGF-beta-responsive element. Furthermore, the effect of Smad6s on PAI-1 up-regulation and on FoxD1 binding was found to result from up-regulation of TGF-beta and could be inhibited by the blocking TGF-beta signaling with Smad7. The ability of Smad6s to regulate the TGF-beta promoter and subsequent PAI-1 induction was suppressed by a selective protein kinase C-beta (PKC-beta) inhibitor. Consistent with the in vitro data, we found that increased Smad6s in diseased vessels correlated with increased TGF-beta and PAI-1 levels. Overall, our results demonstrate that the level of Smad6s can alter the level of TGF-beta and the subsequent induction of PAI-1 via a FoxD1 transcription site. Furthermore, our data suggest that this process, which is up-regulated in diseased vessels, can be modulated by the inhibition of PKC-beta.	Lilly Corp Ctr, Lilly Res Labs, Div Biotechnol Discovery Res, Indianapolis, IN 46285 USA	Eli Lilly	Grinnell, BW (corresponding author), Lilly Corp Ctr, Lilly Res Labs, Div Biotechnol Discovery Res, Indianapolis, IN 46285 USA.	bgrinnell@lilly.com						Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; ALLAN EH, 1995, CLIN ORTHOP RELAT R, P54; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bard J, 1996, BIOESSAYS, V18, P705, DOI 10.1002/bies.950180905; Bobik A, 1999, CIRCULATION, V99, P2883, DOI 10.1161/01.CIR.99.22.2883; Brown NJ, 2002, SEMIN NEPHROL, V22, P399, DOI 10.1053/snep.2002.34725; Cederberg A, 1999, J BIOL CHEM, V274, P165, DOI 10.1074/jbc.274.1.165; Chen YQ, 2001, THROMB HAEMOSTASIS, V86, P1563, DOI 10.1055/s-0037-1616763; Chorostowska-Wynimko J, 2004, INT J MOL MED, V13, P759; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dong C, 2002, J HEART LUNG TRANSPL, V21, P999, DOI 10.1016/S1053-2498(02)00403-5; Dong G, 1996, J BIOL CHEM, V271, P29969, DOI 10.1074/jbc.271.47.29969; Eddy AA, 2002, AM J PHYSIOL-RENAL, V283, pF209, DOI 10.1152/ajprenal.00032.2002; Ernstsson S, 1996, J BIOL CHEM, V271, P21094, DOI 10.1074/jbc.271.35.21094; Fay WP, 2004, TRENDS CARDIOVAS MED, V14, P196, DOI 10.1016/j.tcm.2004.03.002; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; Gomez-Skarmeta JL, 1999, MECH DEVELOP, V80, P15, DOI 10.1016/S0925-4773(98)00190-7; GRINNELL BW, 1986, MOL CELL BIOL, V6, P3596, DOI 10.1128/MCB.6.11.3596; Hatini V, 1996, GENE DEV, V10, P1467, DOI 10.1101/gad.10.12.1467; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hou BD, 2004, J BIOL CHEM, V279, P18127, DOI 10.1074/jbc.M310438200; Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Khatib AM, 2001, INT J CANCER, V91, P300, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1055>3.3.CO;2-E; KIM SJ, 1989, J BIOL CHEM, V264, P402; Koya D, 2000, FASEB J, V14, P439, DOI 10.1096/fasebj.14.3.439; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; Krishnan P, 2001, DEV GROWTH DIFFER, V43, P115; Kutz SM, 2001, CELL MOTIL CYTOSKEL, V48, P163, DOI 10.1002/1097-0169(200103)48:3<163::AID-CM1006>3.0.CO;2-C; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; Lopez S, 1999, THROMB HAEMOSTASIS, V81, P415, DOI 10.1055/s-0037-1614488; Loskutoff DJ, 1997, CIRCULATION, V96, P2772; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; Margaglione M, 1998, ARTERIOSCL THROM VAS, V18, P152, DOI 10.1161/01.ATV.18.2.152; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; McCaffrey TA, 2000, CYTOKINE GROWTH F R, V11, P103, DOI 10.1016/S1359-6101(99)00034-9; Mur C, 2004, LIFE SCI, V75, P611, DOI 10.1016/j.lfs.2003.12.026; Nakayama T, 1998, GENES CELLS, V3, P387, DOI 10.1046/j.1365-2443.1998.00196.x; REIFELMILLER AE, 1991, J BIOL CHEM, V266, P13873; Ren S, 2000, AM J PHYSIOL-ENDOC M, V278, pE656, DOI 10.1152/ajpendo.2000.278.4.E656; Richardson MA, 2000, ENDOCRINOLOGY, V141, P3908, DOI 10.1210/en.141.10.3908; Rosenberg RD, 1999, NEW ENGL J MED, V340, P1555, DOI 10.1056/NEJM199905203402007; Rossini M., 2004, DRUG DISCOV TODAY, V1, P65; SANDLER MA, 1994, J BIOL CHEM, V269, P21500; Sandusky G, 2002, J BIOL CHEM, V277, P49815, DOI 10.1074/jbc.C200543200; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; Schoenhard JA, 2003, J MOL CELL CARDIOL, V35, P473, DOI 10.1016/S0022-2828(03)00051-8; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Vervloet MG, 1998, SEMIN THROMB HEMOST, V24, P33, DOI 10.1055/s-2007-995821; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; Westendorp RGJ, 1999, LANCET, V354, P561, DOI 10.1016/S0140-6736(98)09376-3; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; Wileman SM, 2000, BRIT J OPHTHALMOL, V84, P417, DOI 10.1136/bjo.84.4.417; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	58	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14943	14947		10.1074/jbc.C400579200	http://dx.doi.org/10.1074/jbc.C400579200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15716278	hybrid			2022-12-25	WOS:000228236800074
J	Cole, SH; Carney, GE; McClung, CA; Willard, SS; Taylor, BJ; Hirsh, J				Cole, SH; Carney, GE; McClung, CA; Willard, SS; Taylor, BJ; Hirsh, J			Two functional but noncomplementing Drosophila tyrosine decarboxylase genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID DECARBOXYLASE; INSECT VISCERAL MUSCLE; CENTRAL-NERVOUS-SYSTEM; LOCUSTA-MIGRATORIA; JUVENILE-HORMONE; DOPA DECARBOXYLASE; STRESS CONDITIONS; OCTOPAMINE; MELANOGASTER; TYRAMINE	The trace biogenic amine tyramine is present in the nervous systems of animals ranging in complexity from nematodes to mammals. Tyramine is synthesized from tyrosine by the enzyme tyrosine decarboxylase (TDC), a member of the aromatic amino acid family, but this enzyme has not been identified in Drosophila or in higher animals. To further clarify the roles of tyramine and its metabolite octopamine, we have cloned two TDC genes from Drosophila melanogaster, dTdc1 and dTdc2. Although both gene products have TDC activity in vivo, dTdc1 is expressed nonneurally, whereas dTdc2 is expressed neurally. Flies with a mutation in dTdc2 lack neural tyramine and octopamine and are female sterile due to egg retention. Although other Drosophila mutants that lack octopamine retain eggs completely within the ovaries, dTdc2 mutants release eggs into the oviducts but are unable to deposit them. This specific sterility phenotype can be partially rescued by driving the expression of dTdc2 in a dTdc2-specific pattern, whereas driving the expression of dTdc1 in the same pattern results in a complete rescue. The disparity in rescue efficiencies between the ectopically expressed Tdc genes may reflect the differential activities of these gene products. The egg retention phenotype of the dTdc2 mutant and the phenotypes associated with ectopic dTdc expression contribute to a model in which octopamine and tyramine have distinct and separable neural activities.	Univ Virginia, Dept Biol, Charlottesville, VA 22903 USA; Univ Virginia, Grad Program Neurosci, Charlottesville, VA 22903 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA	University of Virginia; University of Virginia; Texas A&M University System; Texas A&M University College Station; Oregon State University	Hirsh, J (corresponding author), Univ Virginia, Dept Biol, Rm 262,Gilmer Hall,POB 400328, Charlottesville, VA 22903 USA.	jh6u@virginia.edu	McClung, Colleen/AAA-5943-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027318, R01GM056920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F31DA006063, F31DA015265] Funding Source: NIH RePORTER; NIDA NIH HHS [1 F31 DA15265-03, 1 F31 DA06063-01] Funding Source: Medline; NIGMS NIH HHS [R01 GM 56920A, R01 GM27318] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERT VR, 1992, P NATL ACAD SCI USA, V89, P12053, DOI 10.1073/pnas.89.24.12053; Berry MD, 1996, NEUROCHEM RES, V21, P1075, DOI 10.1007/BF02532418; BIRMAN S, 1994, J BIOL CHEM, V269, P26559; Blumenthal EM, 2003, AM J PHYSIOL-CELL PH, V284, pC718, DOI 10.1152/ajpcell.00359.2002; Borowsky B, 2001, P NATL ACAD SCI USA, V98, P8966, DOI 10.1073/pnas.151105198; Branchek TA, 2003, CURR OPIN PHARMACOL, V3, P90, DOI 10.1016/S1471-4892(02)00028-0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Bunzow JR, 2001, MOL PHARMACOL, V60, P1181, DOI 10.1124/mol.60.6.1181; Clark J, 2003, J COMP PHYSIOL A, V189, P105, DOI 10.1007/s00359-002-0375-x; Clark J, 2000, J INSECT PHYSIOL, V46, P191, DOI 10.1016/S0022-1910(99)00116-X; COOK BJ, 1992, COMP BIOCHEM PHYS C, V102, P273, DOI 10.1016/0742-8413(92)90111-J; CUMMINGS CA, 1994, DEVELOPMENT, V120, P381; DAVENPORT AP, 1984, INSECT BIOCHEM, V14, P135, DOI 10.1016/0020-1790(84)90021-0; DeZazzo J, 2000, NEURON, V27, P145, DOI 10.1016/S0896-6273(00)00016-7; Donini A, 2004, J INSECT PHYSIOL, V50, P351, DOI 10.1016/j.jinsphys.2004.02.005; DOWNER RGH, 1993, NEUROCHEM RES, V18, P1245, DOI 10.1007/BF00975042; Fitzpatrick PF, 1999, ANNU REV BIOCHEM, V68, P355, DOI 10.1146/annurev.biochem.68.1.355; FITZPATRICK PF, 1990, J BIOL CHEM, V265, P2042; Gilbert LI, 2000, INSECT BIOCHEM MOLEC, V30, P617, DOI 10.1016/S0965-1748(00)00034-5; Gong ZF, 2004, J NEUROSCI, V24, P9059, DOI 10.1523/JNEUROSCI.1645-04.2004; Gruntenko N, 2004, ARCH INSECT BIOCHEM, V55, P55, DOI 10.1002/arch.10123; Gruntenko N E, 2001, Dokl Biol Sci, V379, P382, DOI 10.1023/A:1011672801835; Gruntenko NE, 2000, INSECT BIOCHEM MOLEC, V30, P775, DOI 10.1016/S0965-1748(00)00049-7; Hirashima A, 2000, BIOCHEM GENET, V38, P167, DOI 10.1023/A:1001925613951; Hirashima A, 1999, GEN COMP ENDOCR, V116, P373, DOI 10.1006/gcen.1999.7378; Hirashima A, 2000, BIOSCI BIOTECH BIOCH, V64, P2625, DOI 10.1271/bbb.64.2625; JUORIO AV, 1983, NEUROPHARMACOLOGY, V22, P71, DOI 10.1016/0028-3908(83)90262-9; KAATZ H, 1994, J INSECT PHYSIOL, V40, P865, DOI 10.1016/0022-1910(94)90020-5; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KRIEGER M, 1991, P NATL ACAD SCI USA, V88, P2161, DOI 10.1073/pnas.88.6.2161; LANGE AB, 1984, J NEUROBIOL, V15, P441, DOI 10.1002/neu.480150605; Lee HG, 2003, DEV BIOL, V264, P179, DOI 10.1016/j.ydbio.2003.07.018; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; McClung C, 1999, CURR BIOL, V9, P853, DOI 10.1016/S0960-9822(99)80389-3; *MOL PROB INC, 1993, BIOPR, V17, P1; Monastirioti M, 1999, MICROSC RES TECHNIQ, V45, P106, DOI 10.1002/(SICI)1097-0029(19990415)45:2<106::AID-JEMT5>3.3.CO;2-V; Monastirioti M, 1996, J NEUROSCI, V16, P3900; Monastirioti M, 2003, DEV BIOL, V264, P38, DOI 10.1016/j.ydbio.2003.07.019; MORGAN BA, 1986, EMBO J, V5, P3335, DOI 10.1002/j.1460-2075.1986.tb04648.x; Nykamp DA, 2000, J INSECT PHYSIOL, V46, P809, DOI 10.1016/S0022-1910(99)00170-5; ODELL K, 1987, CR ACAD SCI III-VIE, V305, P199; OLDENDORF WH, 1971, AM J PHYSIOL, V221, P1629, DOI 10.1152/ajplegacy.1971.221.6.1629; ORCHARD I, 1985, J NEUROBIOL, V16, P171, DOI 10.1002/neu.480160303; ORCHARD I, 1986, J NEUROBIOL, V17, P359, DOI 10.1002/neu.480170502; PARKER EM, 1988, J PHARMACOL EXP THER, V245, P199; Rauschenbach IY, 2004, J INSECT PHYSIOL, V50, P323, DOI 10.1016/j.jinsphys.2004.02.001; RAUSCHENBACH IY, 1993, J INSECT PHYSIOL, V39, P761, DOI 10.1016/0022-1910(93)90051-R; Roeder T, 1999, PROG NEUROBIOL, V59, P533, DOI 10.1016/S0301-0082(99)00016-7; Roeder T, 2003, ARCH INSECT BIOCHEM, V54, P1, DOI 10.1002/arch.10102; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHUPBACH T, 1991, GENETICS, V129, P1119; Thummel CS, 1992, DROS INF SERV, V71, P150; Walther DJ, 2003, BIOCHEM PHARMACOL, V66, P1673, DOI 10.1016/S0006-2952(03)00556-2; ZHU MY, 1995, GEN PHARMACOL-VASC S, V26, P681, DOI 10.1016/0306-3623(94)00223-A	54	227	236	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14948	14955		10.1074/jbc.M414197200	http://dx.doi.org/10.1074/jbc.M414197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15691831	hybrid			2022-12-25	WOS:000228236800075
J	Goncalves, I; Nesbitt, WS; Yuan, YP; Jackson, SP				Goncalves, I; Nesbitt, WS; Yuan, YP; Jackson, SP			Importance of temporal flow gradients and integrin alpha(IIb)beta(3) mechanotransduction for shear activation of platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; CAROTID BIFURCATION; INTEGRIN ALPHA(IIB)BETA(3); ADHESIVE INTERACTIONS; GLYCOPROTEIN IB/V/IX; CALCIUM SIGNALS; DISTINCT ROLES; PULSATILE FLOW; STRESS; AGGREGATION	Disturbances of blood flow play an important role in promoting platelet activation and arterial thrombus formation in stenosed, injured, atherosclerotic arteries. To date, glycoprotein Ib ( GPIb) has been considered the primary platelet mechanosensory receptor, responding to increased shear with enhanced adhesive and signaling function. We demonstrate here that von Willebrand factor-GPIb interaction is inefficient at inducing platelet activation even when platelets are exposed to very high wall shear stresses (60 dyn/cm(2)). Rapid platelet activation under flow was only observed under experimental conditions in which transiently adherent platelets were exposed to sudden accelerations in blood flow. Platelet responsiveness to temporal shear gradients was integrin alpha(IIb)beta(3)-dependent and occurred only on a von Willebrand factor substrate, as platelets forming integrin alpha(IIb)beta(3) adhesive contacts with immobilized fibrinogen were unresponsive to sudden increases in shear. The calcium response induced by temporal shear gradients was distinct from previously identified integrin alpha(IIb)beta(3) calcium responses in terms of its transient nature, its requirement for platelet co-stimulation by the P2Y(1) purinergic ADP receptor, and its dependence on the influx of extracellular calcium. Our studies demonstrate a key role for temporal shear gradients in promoting platelet activation. Moreover, they define for the first time the involvement of P2Y receptors in integrin mechanotransduction.	Monash Univ, Dept Med, Australian Ctr Blood Dis, Alfred Med Res & Educ Precinct, Prahran, Vic 3181, Australia	Monash University	Jackson, SP (corresponding author), Monash Univ, Dept Med, Australian Ctr Blood Dis, Alfred Med Res & Educ Precinct, 6th Floor,Burnet Tower,Commercial Rd, Prahran, Vic 3181, Australia.	shaun.jackson@med.monash.edu.au	Goncalves, Isaac/AAO-8371-2020	Nesbitt, Warwick/0000-0001-5644-7053; Jackson, Shaun/0000-0002-4750-1991				ALENGHAT FJ, 2002, SCI STKE; Bao XP, 1999, ARTERIOSCL THROM VAS, V19, P996, DOI 10.1161/01.ATV.19.4.996; Boyer JL, 1996, MOL PHARMACOL, V50, P1323; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; JAKOBSEN E, 1973, Thrombosis Research, V3, P145, DOI 10.1016/0049-3848(73)90065-0; Jarvis GE, 2000, BRIT J PHARMACOL, V129, P275, DOI 10.1038/sj.bjp.0703046; Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200; Kroll MH, 1996, BLOOD, V88, P1525; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; KU DN, 1983, ARTERIOSCLEROSIS, V3, P31, DOI 10.1161/01.ATV.3.1.31; Lehoux S, 2003, J BIOMECH, V36, P631, DOI 10.1016/S0021-9290(02)00441-4; MAILHAC A, 1994, CIRCULATION, V90, P988, DOI 10.1161/01.CIR.90.2.988; Mazzucato M, 2004, BLOOD, V104, P3221, DOI 10.1182/blood-2004-03-1145; Mazzucato M, 2002, BLOOD, V100, P2793, DOI 10.1182/blood-2002-02-0514; Meyer CJ, 2000, NAT CELL BIOL, V2, P666, DOI 10.1038/35023621; MOAKE JL, 1988, BLOOD, V71, P1366; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; Moog S, 2001, BLOOD, V98, P1038, DOI 10.1182/blood.V98.4.1038; Nesbitt WS, 2003, J CELL BIOL, V160, P1151, DOI 10.1083/jcb.200207119; Nesbitt WS, 2002, J BIOL CHEM, V277, P2965, DOI 10.1074/jbc.M110070200; Putney JW, 2001, J CELL SCI, V114, P2223; Ruggeri ZM, 1999, BLOOD, V94, P172, DOI 10.1182/blood.V94.1.172.413k17_172_178; Sage SO, 1997, EXP PHYSIOL, V82, P807, DOI 10.1113/expphysiol.1997.sp004066; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; STRONY J, 1993, AM J PHYSIOL, V265, pH1787; Waitkus-Edwards KR, 2002, CIRC RES, V90, P473, DOI 10.1161/hh0402.105899; White CR, 2001, CIRCULATION, V103, P2508; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; Yap CL, 2000, J BIOL CHEM, V275, P41377, DOI 10.1074/jbc.M005590200; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847; Yuan YP, 1999, J BIOL CHEM, V274, P36241, DOI 10.1074/jbc.274.51.36241; ZARINS CK, 1983, CIRC RES, V53, P502, DOI 10.1161/01.RES.53.4.502	34	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15430	15437		10.1074/jbc.M410235200	http://dx.doi.org/10.1074/jbc.M410235200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701653	hybrid			2022-12-25	WOS:000228236800130
J	Gronert, K; Maheshwari, N; Khan, N; Hassan, IR; Dunn, M; Schwartzman, ML				Gronert, K; Maheshwari, N; Khan, N; Hassan, IR; Dunn, M; Schwartzman, ML			A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGGERED 15-EPI-LIPOXIN A(4); BOVINE CORNEAL EPITHELIUM; NECROSIS-FACTOR-ALPHA; INDUCED LIPOXIN A(4); DOCOSAHEXAENOIC ACID; GENE-EXPRESSION; ARACHIDONATE 15-LIPOXYGENASE; SUPPRESSES INFLAMMATION; NEUTROPHIL RECRUITMENT; TARGETED DISRUPTION	The surface of the eye actively suppresses inflammation while maintaining a remarkable capacity for epithelial wound repair. Our understanding of mechanisms that balance inflammatory/reparative responses to provide effective host defense while preserving tissue function is limited, in particular, in the cornea. Lipoxin A(4) (LXA(4)) and docosahexaenoic acid-derived neuroprotectin D1 (NPD1) are lipid autacoids formed by 12/15-lipoxy-genase (LOX) pathways that exhibit anti-inflammatory and neuroprotective properties. Here, we demonstrate that mouse corneas generate endogenous LXA(4) and NPD1. 12/15-LOX (Alox15) and LXA(4) receptor mRNA expression as well as LXA(4) formation were abrogated by epithelial removal and restored during wound healing. Amplification of these pathways by topical treatment with LXA(4) or NPD1 (1 mu g) increased the rate of re-epithelialization (65-90%, n = 6-10, p < 0.03) and attenuated the sequelae of thermal injury. In contrast, the proinflammatory eicosanoids, LTB4 and 12R-hydroxyeicosatrienoic acid, had no impact on corneal re-epithelialization. Epithelial removal induced a temporally defined influx of neutrophils into the stroma as well as formation of the proinflammatory chemokine KC. Topical treatment with LXA(4) and NPD1 significantly increased PMNs in the cornea while abrogating KC formation by 60%. More importantly, Alox15-deficient mice exhibited a defect in both corneal re-epithelialization and neutrophil recruitment that correlated with a 43% reduction in endogenous LXA(4) formation. Collectively, these results identify a novel action for the mouse 12/15-LOX ( Alox15) and its products, LXA(4) and NPD1, in wound healing that is distinct from their well established anti-inflammatory properties.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA	New York Medical College	Gronert, K (corresponding author), New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA.	karsten_gronert@nymc.edu			NATIONAL EYE INSTITUTE [R01EY016136, R01EY006513] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY016136, EY06513, R01 EY016136-02] Funding Source: Medline; NIDDK NIH HHS [DK6053] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aliberti J, 2002, J EXP MED, V196, P1253, DOI 10.1084/jem.20021183; Ariel A, 2003, J IMMUNOL, V170, P6266, DOI 10.4049/jimmunol.170.12.6266; Bannenberg GL, 2004, J EXP MED, V199, P515, DOI 10.1084/jem.20031325; Bazan HEP, 1997, INVEST OPHTH VIS SCI, V38, P2492; BAZAN HEP, 1985, CURR EYE RES, V4, P175, DOI 10.3109/02713688509000847; BAZAN NG, 1997, SURV OPHTHALMOL, V41, P23; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Canny G, 2002, P NATL ACAD SCI USA, V99, P3902, DOI 10.1073/pnas.052533799; CHEN XS, 1994, J BIOL CHEM, V269, P13979; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Conners MS, 1997, INVEST OPHTH VIS SCI, V38, P1963; CUBITT CL, 1993, INVEST OPHTH VIS SCI, V34, P3199; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; De Caterina R, 2000, AM J CLIN NUTR, V71, p213S, DOI 10.1093/ajcn/71.1.213S; DECATERINA R, 1993, N3 FATTY ACIDS VASCU; Devchand PR, 2003, FASEB J, V17, P652, DOI 10.1096/fj.02-0770com; Fraunfelder F., 2001, DRUG INDUCED OCULAR, V5th ed.; Funk CD, 1996, J BIOL CHEM, V271, P23338, DOI 10.1074/jbc.271.38.23338; Funk CD, 2002, PROSTAG OTH LIPID M, V68-9, P303, DOI 10.1016/S0090-6980(02)00036-9; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gan L, 1999, INVEST OPHTH VIS SCI, V40, P575; Gewirtz AT, 1998, J CLIN INVEST, V101, P1860, DOI 10.1172/JCI1339; Gronert K, 1998, J EXP MED, V187, P1285, DOI 10.1084/jem.187.8.1285; Gronert K, 1999, METH MOL B, V120, P119; Hamrah P, 2003, J LEUKOCYTE BIOL, V74, P172, DOI 10.1189/jlb.1102544; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; HURST JS, 1991, J BIOL CHEM, V266, P6726; Johnson EN, 1999, J INVEST DERMATOL, V112, P861, DOI 10.1046/j.1523-1747.1999.00595.x; Kelavkar Uddhav, 2002, Curr Urol Rep, V3, P207, DOI 10.1007/s11934-002-0066-8; Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985; KROMANN N, 1980, ACTA MED SCAND, V208, P401; Kumar V., 2004, ROBBINS COTRAN PATHO, P47; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748; LEVY BD, 1993, LIPIDS, V28, P1047, DOI 10.1007/BF02537069; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Liminga M, 1999, BBA-MOL CELL BIOL L, V1437, P124, DOI 10.1016/S1388-1981(99)00004-9; LIMINGA M, 1994, BBA-LIPID LIPID MET, V1210, P288, DOI 10.1016/0005-2760(94)90231-3; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; McDonnell M, 2001, PROSTAG OTH LIPID M, V63, P93, DOI 10.1016/S0090-6980(00)00100-3; McMahon B, 2001, TRENDS PHARMACOL SCI, V22, P391, DOI 10.1016/S0165-6147(00)01771-5; Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; Munger KA, 1999, P NATL ACAD SCI USA, V96, P13375, DOI 10.1073/pnas.96.23.13375; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Niederkorn JY, 2003, J LEUKOCYTE BIOL, V74, P167, DOI 10.1189/jlb.1102543; Ono SJ, 2003, J LEUKOCYTE BIOL, V74, P149, DOI 10.1189/jlb.0403191; ROSENBAUM JT, 1995, INVEST OPHTH VIS SCI, V36, P2151; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schottelius AJ, 2002, J IMMUNOL, V169, P7063, DOI 10.4049/jimmunol.169.12.7063; Schwartzman ML, 1997, ADVANCES IN OCULAR TOXICOLOGY, P3; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; SERHAN CN, 1989, BIOCHIM BIOPHYS ACTA, V1004, P158, DOI 10.1016/0005-2760(89)90264-6; Shappell SB, 2003, CANCER RES, V63, P2256; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Simopoulos Artemis P., 1999, Journal of the American College of Nutrition, V18, P487, DOI 10.1046/j.1440-6047.1999.00123.x; SIMPSON DM, 1972, J CLIN INVEST, V51, P2009, DOI 10.1172/JCI107007; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Spandau UHM, 2003, ARCH OPHTHALMOL-CHIC, V121, P825, DOI 10.1001/archopht.121.6.825; Streilein JW, 2003, J LEUKOCYTE BIOL, V74, P179, DOI 10.1189/jlb.1102574; STRIETER RM, 1992, AM J PATHOL, V141, P1279; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Takano T, 1998, J CLIN INVEST, V101, P819, DOI 10.1172/JCI1578; Taylor CT, 1998, GASTROENTEROLOGY, V114, P657, DOI 10.1016/S0016-5085(98)70579-7; Tomobe YI, 2000, LIPIDS, V35, P61, DOI 10.1007/s11745-000-0495-0; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; Vance RE, 2004, P NATL ACAD SCI USA, V101, P2135, DOI 10.1073/pnas.0307308101; VERBEY NLJ, 1990, INVEST OPHTH VIS SCI, V31, P1526; WEIMAR V, 1957, J EXP MED, V105, P141, DOI 10.1084/jem.105.2.141	71	236	265	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15267	15278		10.1074/jbc.M410638200	http://dx.doi.org/10.1074/jbc.M410638200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708862	hybrid			2022-12-25	WOS:000228236800112
J	Kneass, ZT; Marchase, RB				Kneass, ZT; Marchase, RB			Protein O-GlcNAc modulates motility-associated signaling intermediates in neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; PLATELET-ACTIVATING-FACTOR; PANCREATIC BETA-CELLS; P38 MAP KINASE; INSULIN-RESISTANCE; SMOOTH-MUSCLE; NUCLEOCYTOPLASMIC PROTEINS; HEXOSAMINE PATHWAY; MURINE NEUTROPHILS; POTENTIAL ROLE	The modification of serine/threonine residues on cytoplasmic and nuclear proteins by N-acetylglucosamine (O-GlcNAc) is suggested to play a role in the regulation of a variety of signal transduction pathways. We have previously shown that glucosamine (GlcNH(2)), a metabolic precursor of O-GlcNAcylation, increases O-GlcNAc and enhances motility in neutrophils. Here, we extend this correlation by showing that a mechanistically distinct means of increasing O-GlcNAc, achieved by inhibition of O-GlcNAc removal with O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc), increases basal cellular motility and directional migration induced by the chemoattractant formyl-methionine-leucine-phenylalanine ( fMLP). Furthermore, we demonstrate that O- GlcNAc modulates the activities of signaling intermediates known to regulate neutrophil movement. GlcNH(2) and PUGNAc increase both the basal and fMLP-induced activity of a central mediator of cellular motility, the small GTPase Rac. Phosphoinositide 3-kinase, an important regulator of Rac activity and neutrophil motility, is shown to regulate the signaling pathway on which GlcNH(2) and PUGNAc act. Rac is an important upstream regulatory element in p38 and p44/42 mitogen-activated protein kinase ( MAPK) signaling in neutrophils, and these MAPKs are implicated in chemotactic signal transduction. We show that GlcNH(2) and PUGNAc treatment increases p42/44 and p38 MAPK activities and that these increases are associated with activation of upstream MAPK kinases. These data indicate that O-GlcNAcylation is an important signaling element in neutrophils that modulates the activities of several critical signaling intermediates involved in the regulation of cellular movement.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Marchase, RB (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, MCLM 690, Birmingham, AL 35294 USA.	rbmarchase@uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055647] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55647] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreozzi F, 2004, ENDOCRINOLOGY, V145, P2845, DOI 10.1210/en.2003-0939; Anello M, 2004, AM J PHYSIOL-ENDOC M, V287, pE602, DOI 10.1152/ajpendo.00320.2003; Arias EB, 2004, DIABETES, V53, P921, DOI 10.2337/diabetes.53.4.921; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Burt DJ, 2003, DIABETOLOGIA, V46, P531, DOI 10.1007/s00125-003-1075-y; Campbell M, 2004, CIRC RES, V95, P380, DOI 10.1161/01.RES.0000138019.82184.5d; Coffer PJ, 1998, BIOCHEM J, V329, P121; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Coxon PY, 2003, CELL SIGNAL, V15, P993, DOI 10.1016/S0898-6568(03)00074-3; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Drost EM, 2002, EUR J IMMUNOL, V32, P393, DOI 10.1002/1521-4141(200202)32:2<393::AID-IMMU393>3.0.CO;2-5; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; ERIKSSON G, 1984, ARCH BIOCHEM BIOPHYS, V235, P692, DOI 10.1016/0003-9861(84)90245-5; Filippi MD, 2004, NAT IMMUNOL, V5, P744, DOI 10.1038/ni1081; Frevert CW, 1998, J IMMUNOL METHODS, V213, P41, DOI 10.1016/S0022-1759(98)00016-7; Fujita T, 2005, CELL SIGNAL, V17, P167, DOI 10.1016/j.cellsig.2004.06.008; Gao Y, 2003, ARCH BIOCHEM BIOPHYS, V415, P155, DOI 10.1016/S0003-9861(03)00234-0; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; GRIFFITH LS, 1995, J NEUROSCI RES, V41, P270, DOI 10.1002/jnr.490410214; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Hannigan M, 2001, J LEUKOCYTE BIOL, V69, P497; Hannigan MO, 2001, J IMMUNOL, V167, P3953, DOI 10.4049/jimmunol.167.7.3953; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Hii CS, 2004, J BIOL CHEM, V279, P49825, DOI 10.1074/jbc.M406892200; Hii CST, 1999, INFECT IMMUN, V67, P1297, DOI 10.1128/IAI.67.3.1297-1302.1999; Hirano S, 2004, CELL STRESS CHAPERON, V9, P29, DOI 10.1379/1466-1268(2004)009<0029:HRFAMA>2.0.CO;2; Hiromura M, 2003, J BIOL CHEM, V278, P14046, DOI 10.1074/jbc.M300789200; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HORSCH M, 1991, EUR J BIOCHEM, V197, P815, DOI 10.1111/j.1432-1033.1991.tb15976.x; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; Hsieh TJ, 2003, ENDOCRINOLOGY, V144, P4338, DOI 10.1210/en.2003-0220; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3; Kawamura H, 2004, ARTERIOSCL THROM VAS, V24, P276, DOI 10.1161/01.ATV.0000112012.33770.2a; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; Kim C, 2001, J IMMUNOL, V166, P1223, DOI 10.4049/jimmunol.166.2.1223; Kneass ZT, 2004, J BIOL CHEM, V279, P45759, DOI 10.1074/jbc.M407911200; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehman JA, 2001, AM J PHYSIOL-CELL PH, V280, pC183, DOI 10.1152/ajpcell.2001.280.1.C183; Li SJ, 2002, J IMMUNOL, V169, P5043, DOI 10.4049/jimmunol.169.9.5043; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; Marshall S, 2004, J BIOL CHEM, V279, P35313, DOI 10.1074/jbc.M404133200; Nagata T, 2001, BRIT J ANAESTH, V86, P853, DOI 10.1093/bja/86.6.853; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Niggli V, 2000, FEBS LETT, V473, P217, DOI 10.1016/S0014-5793(00)01534-9; OKADA T, 1994, J BIOL CHEM, V269, P3563; Okuyama R, 2001, BIOCHEM BIOPH RES CO, V287, P366, DOI 10.1006/bbrc.2001.5607; Parker GJ, 2003, J BIOL CHEM, V278, P10022, DOI 10.1074/jbc.M207787200; Pichon S, 2004, J CELL SCI, V117, P2569, DOI 10.1242/jcs.01110; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Sun CX, 2004, BLOOD, V104, P3758, DOI 10.1182/blood-2004-03-0781; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Wang CJ, 2002, J IMMUNOL, V169, P415, DOI 10.4049/jimmunol.169.1.415; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Wells L, 2003, BIOCHEM BIOPH RES CO, V302, P435, DOI 10.1016/S0006-291X(03)00175-X; Wells L, 2003, FEBS LETT, V546, P154, DOI 10.1016/S0014-5793(03)00641-0; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; Wu Y, 2004, BIOCHEM BIOPH RES CO, V316, P666, DOI 10.1016/j.bbrc.2004.02.107; Yao PJ, 1998, J NEUROSCI, V18, P2399; Zachara NE, 2004, J BIOL CHEM, V279, P30133, DOI 10.1074/jbc.M403773200; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zu YL, 1998, J IMMUNOL, V160, P1982	85	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14579	14585		10.1074/jbc.M414066200	http://dx.doi.org/10.1074/jbc.M414066200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15703172	hybrid			2022-12-25	WOS:000228236800030
J	Zampieri, N; Xu, CF; Neubert, TA; Chao, MV				Zampieri, N; Xu, CF; Neubert, TA; Chao, MV			Cleavage of p75 neurotrophin receptor by alpha-secretase and gamma-secretase requires specific receptor domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PROTEIN-ECTODOMAIN; NOGO RECEPTOR; CELL-SURFACE; DEATH DOMAIN; IN-VITRO; TNF; METALLOPROTEASE; PROTEOLYSIS; P75(NTR)	The p75 neurotrophin receptor (p75(NTR)), a member of the tumor necrosis factor superfamily of receptors, undergoes multiple proteolytic cleavage events. These events are initiated by an alpha-secretase-mediated release of the extracellular domain followed by a gamma-secretase-mediated intramembrane cleavage. However, the specific determinants of p75(NTR) cleavage events are unknown. Many other substrates of gamma-secretase cleavage have been identified, including Notch, amyloid precursor protein, and ErbB4, indicating there is broad substrate recognition by gamma-secretase. Using a series of deletion mutations and chimeric receptors of p75(NTR) and the related Fas receptor, we have identified domains that are essential for p75(NTR) proteolysis. The initial alpha-secretase cleavage was extracellular to the transmembrane domain. Unfortunately, deletion mutants were not capable of defining the requirements of ectodomain shedding. Although this cleavage is promiscuous with respect to amino acid sequence, its position with respect to the transmembrane domain is invariant. The generation of chimeric receptors exchanging different domains of noncleavable Fas receptor with p75(NTR), however, revealed that a discrete domain above the membrane is sufficient for efficient cleavage of p75(NTR). Mass spectrometric analysis confirmed the cleavage can occur with a truncated p75(NTR) displaying only 15 extracellular amino acids in the stalk region.	NYU, Sch Med, Skirball Inst Biomol Med, Mol Neurobiol Program, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, Struct Biol Program, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	New York University; New York University; New York University; New York University	Chao, MV (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Mol Neurobiol Program, 540 1st Ave, New York, NY 10016 USA.	chao@saturn.med.nyu.edu		Chao, Moses/0000-0002-6969-3744; Zampieri, Niccolo/0000-0002-2228-9453	NCI NIH HHS [CA56490] Funding Source: Medline; NCRR NIH HHS [S10 RR01-7990] Funding Source: Medline; NICHD NIH HHS [HD23315] Funding Source: Medline; NINDS NIH HHS [NS21072] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD023315] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA056490] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BANDTLOW C, 2004, SCI STKE, V235, pPE24; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Barker PA, 2004, NEURON, V42, P529, DOI 10.1016/j.neuron.2004.04.001; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; DISTEFANO PS, 1993, J NEUROSCI, V13, P2405, DOI 10.1523/JNEUROSCI.13-06-02405.1993; DISTEFANO PS, 1990, BRAIN RES, V534, P340, DOI 10.1016/0006-8993(90)90154-4; DISTEFANO PS, 1988, J NEUROSCI, V8, P231; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Frade JM, 1996, NATURE, V383, P166; GALARDY RE, 1994, CANCER RES, V54, P4715; He XL, 2004, SCIENCE, V304, P870, DOI 10.1126/science.1095190; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; Jung KM, 2003, J BIOL CHEM, V278, P42161, DOI 10.1074/jbc.M306028200; Kanning KC, 2003, J NEUROSCI, V23, P5425, DOI 10.1523/jneurosci.23-13-05425.2003; KLEITMAN N, 1991, CULTURING NERVE CELL; Kong H, 1999, CELL DEATH DIFFER, V6, P1133, DOI 10.1038/sj.cdd.4400587; LEMKE G, 1988, DEVELOPMENT, V102, P499; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wong ST, 2002, NAT NEUROSCI, V5, P1302, DOI 10.1038/nn975; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Zhao LC, 2001, J BIOL CHEM, V276, P30631, DOI 10.1074/jbc.M103748200	47	82	88	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14563	14571		10.1074/jbc.M412957200	http://dx.doi.org/10.1074/jbc.M412957200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701642	hybrid			2022-12-25	WOS:000228236800028
J	Yu, C; Markan, K; Temple, KA; Deplewski, D; Brady, MJ; Cohen, RN				Yu, C; Markan, K; Temple, KA; Deplewski, D; Brady, MJ; Cohen, RN			The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAUSES INSULIN-RESISTANCE; PPAR-GAMMA; HORMONE-RECEPTORS; CO-REPRESSOR; COFACTOR RECRUITMENT; GLYCOGEN-SYNTHASE; N-COR; ADIPOCYTES; COMPLEXES; DIFFERENTIATION	The peroxisome proliferator-activated receptor gamma (PPAR gamma) is a central regulator of adipogenesis and recruits coactivator proteins in response to ligand. However, the role of another class of nuclear cofactors, the nuclear receptor corepressors, in modulating PPAR gamma transcriptional activity is less clear. Such corepressors include the nuclear receptor corepressor (NCoR) and the silencing mediator of retinoid and thyroid hormone receptors (SMRT). Our data suggest that PPAR gamma recruits SMRT and NCoR in the absence of ligand and that these corepressors are capable of down-regulating PPAR gamma-mediated transcriptional activity. The addition of the PPAR gamma ligand pioglitazone results in dissociation of the PPAR gamma-corepressor complex. To define the role of SMRT and NCoR in PPAR gamma action, 3T3-L1 cells deficient in SMRT or NCoR were generated by RNA interference. When these cells are exposed to differentiation media, they exhibit increased expression of adipocyte-specific genes and increased production of lipid droplets, as compared with control cells. These data suggest that the nuclear receptor corepressors decrease PPAR gamma transcriptional activity and repress the adipogenic program in 3T3-L1 cells.	Univ Chicago, Dept Med, Endocrinol Sect, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Sect Pediat Endocrinol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Cohen, RN (corresponding author), 5841 S Maryland Ave,MC 1027, Chicago, IL 60637 USA.	roncohen@medicine.bsd.uchicago.edu		Markan, Kathleen/0000-0002-3732-5525	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60 DK20595] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agostini M, 2004, ENDOCRINOLOGY, V145, P1527, DOI 10.1210/en.2003-1271; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Brady MJ, 1999, J BIOL CHEM, V274, P27497, DOI 10.1074/jbc.274.39.27497; Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cohen RN, 1998, MOL ENDOCRINOL, V12, P1567, DOI 10.1210/me.12.10.1567; Cohen RN, 2001, MOL ENDOCRINOL, V15, P1049, DOI 10.1210/me.15.7.1049; Cohen RN, 2000, MOL ENDOCRINOL, V14, P900, DOI 10.1210/me.14.6.900; Gurnell M, 2003, J CLIN ENDOCR METAB, V88, P2412, DOI 10.1210/jc.2003-030435; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jepsen K, 2002, J CELL SCI, V115, P689; Koutnikova H, 2003, P NATL ACAD SCI USA, V100, P14457, DOI 10.1073/pnas.2336090100; Krogsdam AM, 2002, BIOCHEM J, V363, P157, DOI 10.1042/0264-6021:3630157; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Li AC, 2002, NAT MED, V8, P1235, DOI 10.1038/nm1102-1235; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Park Y, 2003, DIABETOLOGIA, V46, P365, DOI 10.1007/s00125-003-1037-4; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Ruse MD, 2002, MOL CELL BIOL, V22, P1626, DOI 10.1128/MCB.22.6.1626-1638.2002; Sohn YC, 2003, MOL ENDOCRINOL, V17, P366, DOI 10.1210/me.2002-0150; Tzameli I, 2004, J BIOL CHEM, V279, P36093, DOI 10.1074/jbc.M405346200; Wang LH, 2004, IMMUNITY, V20, P205, DOI 10.1016/S1074-7613(04)00030-5; Wang Q, 2004, MOL ENDOCRINOL, V18, P1376, DOI 10.1210/me.2003-0421; Webb P, 2000, MOL ENDOCRINOL, V14, P1976, DOI 10.1210/me.14.12.1976; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835	39	173	179	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13600	13605		10.1074/jbc.M409468200	http://dx.doi.org/10.1074/jbc.M409468200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15691842	hybrid			2022-12-25	WOS:000228095500053
J	Yang, HY; Asaad, N; Held, KD				Yang, HY; Asaad, N; Held, KD			Medium-mediated intercellular communication is involved in bystander responses of X-ray-irradiated normal human fibroblasts	ONCOGENE			English	Article						bystander responses; X-ray; fibroblasts; transwell system; reactive oxygen species	INDUCED GENOMIC INSTABILITY; STRAND BREAK REPAIR; SISTER-CHROMATID EXCHANGES; ALPHA-PARTICLES; MAMMALIAN-CELLS; UNIRRADIATED CELLS; IONIZING-RADIATION; DAMAGE SIGNALS; DNA-DAMAGE; INDUCTION	Although radiation-induced bystander effects have been demonstrated in a number of cell types, the studies have largely been performed using high linear energy transfer (LET) radiation, such as alpha-particles. The literature is contradictory on whether fibroblasts show bystander responses, especially after low LET radiation such as X- or gamma-rays and whether the same signal transmission pathways are involved. Herein, a novel transwell insert culture dish method is used to show that X- irradiation induces medium-mediated bystander effects in AGO1522 normal human fibroblasts. The frequency of micronuclei formation in unirradiated bystander cells increases from a background of about 6.5% to about 9-13% at all doses from 0.1 to 10Gy to the irradiated cells. Induction of p21(Waf1) protein and foci of gamma-H(2)AX in bystander cells is also independent of dose to the irradiated cells above 0.1 Gy. In addition, levels of reactive oxygen species (ROS) were increased persistently in directly irradiated cells up to 60 h after irradiation and in bystander cells for 30 h. Adding Cu-Zn superoxide dismutase ( SOD) and catalase to the medium decreases the formation of micronuclei and induction of p21(Waf1) and gamma-H(2)AX foci in bystander cells, suggesting oxidative metabolism plays a role in the signaling pathways in bystander cells. The results of clonogenic assay of bystander cells showed that survival of bystander cells decreases from 0 to 0.5 Gy, and then is independent of the dose to irradiated cells from 0.5 to 10 Gy. Unlike the response with p21(Waf1) expression, gamma-H(2)AX foci and micronuclei, adding SOD and catalase has no effect on the survival of bystander cells. The data suggest that irradiated cells release toxic factors other than ROS into the medium.	Harvard Univ, Sch Med, Dept Radiat Oncol, Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Held, KD (corresponding author), Harvard Univ, Sch Med, Dept Radiat Oncol, Massachusetts Gen Hosp, COX 302,Fruit St, Boston, MA 02114 USA.	kheld@partners.org						Azzam EI, 2002, CANCER RES, V62, P5436; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Ballarini F, 2002, MUTAT RES-FUND MOL M, V501, P1, DOI 10.1016/S0027-5107(02)00010-6; Baverstock K, 2000, MUTAT RES-FUND MOL M, V454, P89, DOI 10.1016/S0027-5107(00)00100-7; Belyakov OV, 2001, BRIT J CANCER, V84, P674, DOI 10.1054/bjoc.2000.1665; Bishayee A, 2001, RADIAT RES, V155, P335, DOI 10.1667/0033-7587(2001)155[0335:FRIAGJ]2.0.CO;2; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Deshpande A, 1996, RADIAT RES, V145, P260, DOI 10.2307/3578980; EMERIT I, 1994, FREE RADICAL BIO MED, V16, P99, DOI 10.1016/0891-5849(94)90246-1; FENECH M, 1986, MUTAT RES, V161, P193, DOI 10.1016/0027-5107(86)90010-2; Fimognari C, 1997, MUTAGENESIS, V12, P91, DOI 10.1093/mutage/12.2.91; GOH KO, 1968, RADIAT RES, V35, P171, DOI 10.2307/3572443; Hall EJ, 2003, ONCOGENE, V22, P7034, DOI 10.1038/sj.onc.1206900; HOLLOWELL JG, 1968, P SOC EXP BIOL MED, V129, P240; HOLLOWELL JG, 1967, J S C MED ASS, V63, P437; Huo LH, 2001, RADIAT RES, V156, P521, DOI 10.1667/0033-7587(2001)156[0521:HMIIBC]2.0.CO;2; Iyer R, 2000, CANCER RES, V60, P1290; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Khan MA, 1998, INT J RADIAT ONCOL, V40, P467, DOI 10.1016/S0360-3016(97)00736-0; Lehnert BE, 1997, CANCER RES, V57, P2164; Little JB, 2003, ONCOGENE, V22, P6978, DOI 10.1038/sj.onc.1206988; Little JB, 2003, RADIAT RES, V159, P262, DOI 10.1667/0033-7587(2003)159[0262:IOTNEJ]2.0.CO;2; Little JB, 2002, RADIAT PROT DOSIM, V99, P159, DOI 10.1093/oxfordjournals.rpd.a006751; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; Mothersill C, 2000, BRIT J CANCER, V82, P1740; Mothersill C, 2003, ONCOGENE, V22, P7028, DOI 10.1038/sj.onc.1206882; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Nagasawa H, 2003, INT J RADIAT BIOL, V79, P35, DOI 10.1080/0955300021000019230; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Narayanan PK, 1999, RADIAT RES, V152, P57, DOI 10.2307/3580049; Olive PL, 1997, ONCOL RES, V9, P287; PARSONS WB, 1954, CANCER, V7, P170; Prise KM, 2003, ONCOGENE, V22, P7043, DOI 10.1038/sj.onc.1206991; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Rugo RE, 2002, RADIAT RES, V158, P210, DOI 10.1667/0033-7587(2002)158[0210:XRCAPI]2.0.CO;2; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; Seymour C, 1999, RADIAT RES, V151, P505, DOI 10.2307/3579842; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Seymour CB, 2000, RADIAT RES, V153, P508, DOI 10.1667/0033-7587(2000)153[0508:RCOBAT]2.0.CO;2; Shao C, 2003, CANCER RES, V63, P8437; Shao C, 2002, INT J RADIAT BIOL, V78, P837, DOI 10.1080/09553000210149786; SOUTO J, 1962, NATURE, V195, P1317, DOI 10.1038/1951317a0; Wang B, 2004, RADIAT RES, V161, P9, DOI 10.1667/RR3106; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; Zhou HN, 2002, MUTAT RES-FUND MOL M, V499, P135, DOI 10.1016/S0027-5107(01)00285-8	52	190	205	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2096	2103		10.1038/sj.onc.1208439	http://dx.doi.org/10.1038/sj.onc.1208439			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688009				2022-12-25	WOS:000227681900014
J	Lucas, R; Warner, TD; Vojnovic, I; Mitchell, JA				Lucas, R; Warner, TD; Vojnovic, I; Mitchell, JA			Cellular mechanisms of acetaminophen: role of cyclooxygenase	FASEB JOURNAL			English	Article						cyclooxygenase-2; nonsteroidal anti-inflammatory drugs; rofecoxib; lipid peroxide	PROSTAGLANDIN H-2 SYNTHASES; H SYNTHASE; INHIBITION; CYCLO-OXYGENASE-2; SPECIFICITY; PARACETAMOL; PEROXIDASE; SYNTHETASE; ACTIVATION; SALICYLATE	Acetaminophen is one of the most commonly used drugs for the safe and effective treatment of pain and fever. Acetaminophen works by lowering cyclo-oxygenase products preferentially in the central nervous system, where oxidant stress is strictly limited. However, the precise mechanism of action for acetaminophen on cyclo-oxygenase activity is debated. Two theories prevail. First, it is suggested that acetaminophen selectively inhibits a distinct form of cyclooxygenase, cyclo-oxygenase-3. Second, it is suggested that acetaminophen has no affinity for the active site of cyclo-oxygenase but instead blocks activity by reducing the active oxidized form of cyclo-oxygenase to an inactive form. Here, we have used an in vitro model of cyclo-oxygenase-2 activity (A549 cells stimulated with IL-1 beta) to show that acetaminophen is an effective inhibitor of cyclo-oxygenase activity in intact cells. However, acetaminophen, unlike nonsteroidal antiinflammatory drugs ( NSAIDs), cannot inhibit activity in broken cell preparations. The inhibitory effects of acetaminophen were abolished by increasing intracellular oxidation conditions with the cell-permeable hydroperoxide t-butylOOH. Similarly the inhibitory effects of the cyclooxygenase-2 selective inhibitor rofecoxib or the mixed cyclo-oxygenase-1/cyclo-oxygenase-2 inhibitors ibuprofen and naproxen were significant reduced by t-butylOOH. By contrast, the inhibitory effects of indomethacin or diclofenac, which also inhibit both cyclo- oxygenase-1 and cyclo- oxygenase-2, were unaffected by t-butylOOH. These observations dispel the notion that cyclo- oxygenase-3 is involved in the actions of acetaminophen and provide evidence that supports the theory that acetaminophen interferes with the oxidation state of cyclo- oxygease. Moreover, they suggest for the first time that the inhibitory effects of some NSAIDs, including the newly introduced cyclo- oxygenase-2 selective inhibitor rofecoxib, owe part of their inhibitory actions to effects on oxidation state of cyclo- oxygenase. Our data with t-butylOOH and NSAIDs illustrates an, as yet, undeveloped therapeutic window for the "cyclo-oxygenase inhibitor". Specifically, combining active site selectively with actions on enzyme oxidation state would allow for a broader range of tissue selective drugs.	Univ London Imperial Coll Sci Technol & Med, NHLI, Royal Brompton Hosp, UCCM, London SW3 6LY, England; Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England	Imperial College London; Royal Brompton Hospital; University of London; Queen Mary University London	Mitchell, JA (corresponding author), Univ London Imperial Coll Sci Technol & Med, NHLI, Royal Brompton Hosp, UCCM, Dovehouse St, London SW3 6LY, England.	j.a.mitchell@imperial.ac.uk	Lucas, Rut/H-6050-2015; Warner, Timothy D/A-1980-2009; Mitchell, Jane A/A-1991-2009	Lucas, Rut/0000-0002-4697-7832; Warner, Timothy D/0000-0003-3988-4408; 				Aronoff DM, 2003, J PHARMACOL EXP THER, V304, P589, DOI 10.1124/jpet.102.042853; Bambai B, 2000, J BIOL CHEM, V275, P27608; Boutaud O, 2002, P NATL ACAD SCI USA, V99, P7130, DOI 10.1073/pnas.102588199; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Dinchuk JE, 2003, IMMUNOL LETT, V86, P121, DOI 10.1016/S0165-2478(02)00268-7; FLOWER RJ, 1972, NATURE, V240, P410, DOI 10.1038/240410a0; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; HANEL AM, 1982, BIOCHEM PHARMACOL, V31, P3307, DOI 10.1016/0006-2952(82)90565-2; Kis B, 2003, J CEREBR BLOOD F MET, V23, P1287, DOI 10.1097/01.WCB.0000090681.07515.81; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; Mitchell JA, 1997, MOL PHARMACOL, V51, P907, DOI 10.1124/mol.51.6.907; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MOLDEUS P, 1982, BIOCHEM PHARMACOL, V31, P1363, DOI 10.1016/0006-2952(82)90029-6; Ouellet M, 2001, ARCH BIOCHEM BIOPHYS, V387, P273, DOI 10.1006/abbi.2000.2232; Perini RF, 2003, CURR PHARM DESIGN, V9, P2207, DOI 10.2174/1381612033454027; Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03-0645rev; WARNER TD, 2004, IN PRESS J PHARM EXP	18	90	96	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					635	+		10.1096/fj.04-2437fje	http://dx.doi.org/10.1096/fj.04-2437fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15705740				2022-12-25	WOS:000227591900013
J	Ait-Mamar, B; Cailleret, M; Rucker-Martin, C; Bouabdallah, A; Candiani, G; Adamy, C; Duvaldestin, P; Pecker, F; Defer, N; Pavoine, C				Ait-Mamar, B; Cailleret, M; Rucker-Martin, C; Bouabdallah, A; Candiani, G; Adamy, C; Duvaldestin, P; Pecker, F; Defer, N; Pavoine, C			The cytosolic phospholipase A(2) pathway, a safeguard of beta(2)-adrenergic cardiac effects in rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAT ATRIAL MYOCYTES; ARACHIDONIC-ACID PATHWAY; NITRIC-OXIDE; G-PROTEIN; PHOSPHOLAMBAN PHOSPHORYLATION; VENTRICULAR CARDIOMYOCYTES; PHYSIOLOGICAL RELEVANCE; SARCOPLASMIC-RETICULUM; CAVEOLAE MICRODOMAINS; ADENYLYL-CYCLASE	We have recently demonstrated that in human heart, beta(2)-adrenergic receptors (beta(2)-ARs) are biochemically coupled not only to the classical adenylyl cyclase (AC) pathway but also to the cytosolic phospholipase A(2) (cPLA(2)) pathway (Pavoine, C., Behforouz, N., Gauthier, C., Le Gouvello, S., Roudot-Thoraval, F., Martin, C. R., Pawlak, A., Feral, C., Defer, N., Houel, R., Magne, S., Amadou, A., Loisance, D., Duvaldestin, P., and Pecker, F. (2003) Mol. Pharmacol. 64, 1117-1125). In this study, using Fura-2-loaded cardiomyocytes isolated from adult rats, we showed that stimulation of beta(2)-ARs triggered an increase in the amplitude of electrically stimulated [Ca2+](i) transients and contractions. This effect was abolished with the PKA inhibitor, H89, but greatly enhanced upon addition of the selective cPLA(2) inhibitor, AACOCF(3). The beta(2)-AR/cPLA(2) inhibitory pathway involved G(i) and MSK1. Potentiation of beta(2)-AR/AC/PKA-induced Ca2+ responses by AACOCF3 did not rely on the enhancement of AC activity but was associated with eNOS phosphorylation (Ser(1177)) and L-NAME-sensitive NO production. This was correlated with PKA-dependent phosphorylation of PLB (Ser(16)). The constraint exerted by the beta(2)-AR/cPLA(2) pathway on the beta(2)-AR/AC/PKA-induced Ca2+ responses required integrity of caveolar structures and was impaired by Filipin III treatment. Immunoblot analyses demonstrated zinterol-induced translocation of cPLA(2) and its cosedimentation with MSK1, eNOS, PLB, and sarcoplasmic reticulum Ca2+ pump (SERCA) 2a in a low density caveolin-3-enriched membrane fraction. This inferred the gathering of beta(2)-AR signaling effectors around caveolae/sarcoplasmic reticulum (SR) functional platforms. Taken together, these data highlight cPLA(2) as a cardiac beta(2)-AR signaling pathway that limits beta(2)-AR/AC/PKA-induced Ca2+ responses in adult rat cardiomyocytes through the impairment of eNOS activation and PLB phosphorylation.	Univ Paris 12, INSERM, U581, F-94010 Creteil, France; Hop Henri Mondor, Serv Anesthesie & Reanimat, F-94010 Creteil, France; Hop Marie Lannelongue, CNRS, UMR 8078, F-92350 Le Plessis Robinson, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Centre National de la Recherche Scientifique (CNRS); Hopital Marie Lannelongue	Pavoine, C (corresponding author), Hop Henri Mondor, INSERM, U581, F-94010 Creteil, France.	pavoine@im3.inserm.fr	Candiani, Gabriele/A-9744-2009; Pavoine, Catherine/N-4405-2018	Candiani, Gabriele/0000-0003-0575-068X; Pavoine, Catherine/0000-0002-0598-5545; Rucker-Martin, Catherine/0000-0002-1593-7432				Aimond F, 2000, J BIOL CHEM, V275, P39110, DOI 10.1074/jbc.M008192200; Amadou A, 2002, AM J PHYSIOL-CELL PH, V282, pC1339, DOI 10.1152/ajpcell.00471.2001; Bergdahl A, 2004, CAN J PHYSIOL PHARM, V82, P289, DOI 10.1139/Y04-033; Bisognano JD, 2000, J MOL CELL CARDIOL, V32, P817, DOI 10.1006/jmcc.2000.1123; Bolte S, 2004, J CELL SCI, V117, P943, DOI 10.1242/jcs.00920; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Brodde OE, 1999, PHARMACOL REV, V51, P651; Brown WJ, 2003, TRAFFIC, V4, P214, DOI 10.1034/j.1600-0854.2003.00078.x; Cailleret M, 2004, CIRCULATION, V109, P406, DOI 10.1161/01.CIR.0000109499.00587.FF; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Dedkova EN, 2003, CIRC RES, V93, P1233, DOI 10.1161/01.RES.0000106133.92737.27; Dedkova EN, 2002, J PHYSIOL-LONDON, V542, P711, DOI 10.1113/jphysiol.2002.023341; DELCAYRE C, 1988, J CLIN INVEST, V82, P460, DOI 10.1172/JCI113619; Evans JH, 2004, J BIOL CHEM, V279, P6005, DOI 10.1074/jbc.M311246200; Foerster K, 2003, P NATL ACAD SCI USA, V100, P14475, DOI 10.1073/pnas.1936026100; Gaudreault SB, 2004, J BIOL CHEM, V279, P356, DOI 10.1074/jbc.M304777200; Greene AL, 2000, J BIOL CHEM, V275, P24722, DOI 10.1074/jbc.M001783200; Hagemann D, 2000, J BIOL CHEM, V275, P22532, DOI 10.1074/jbc.C000253200; Hagemann D, 2002, TRENDS CARDIOVAS MED, V12, P51, DOI 10.1016/S1050-1738(01)00145-1; Haq S, 2003, NAT MED, V9, P944, DOI 10.1038/nm891; Hare JM, 2003, J MOL CELL CARDIOL, V35, P719, DOI 10.1016/S0022-2828(03)00143-3; Harrison JG, 2004, BBA-MOL CELL RES, V1644, P17, DOI 10.1016/j.bbamcr.2003.10.008; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Itoh Y, 2000, ANAL BIOCHEM, V287, P203, DOI 10.1006/abio.2000.4859; Jo SH, 2002, CIRC RES, V91, P46, DOI 10.1161/01.RES.0000024115.67561.54; JORGENSEN AO, 1982, J CELL BIOL, V93, P883, DOI 10.1083/jcb.93.3.883; Kuo KH, 2003, RESP PHYSIOL NEUROBI, V137, P197, DOI 10.1016/S1569-9048(03)00147-2; Kuschel M, 1999, J BIOL CHEM, V274, P22048, DOI 10.1074/jbc.274.31.22048; Leslie CC, 2004, PROSTAG LEUKOTR ESS, V70, P373, DOI 10.1016/j.plefa.2003.12.012; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Liggett SB, 2000, CIRCULATION, V101, P1707; Magne S, 2001, J BIOL CHEM, V276, P39539, DOI 10.1074/jbc.M100954200; Markou T, 2002, BIOCHEM J, V365, P757, DOI 10.1042/BJ20011828; Markou T, 2003, MOL CELL BIOCHEM, V242, P163, DOI 10.1023/A:1021110300652; Massion PB, 2003, J PHYSIOL-LONDON, V546, P63, DOI 10.1113/jphysiol.2002.025973; Massion PB, 2003, CIRC RES, V93, P388, DOI 10.1161/01.RES.0000088351.58510.21; MERY PF, 1993, J BIOL CHEM, V268, P26286; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; Nagase T, 2002, NAT MED, V8, P480, DOI 10.1038/nm0502-480; Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200; Palomba L, 2004, FREE RADICAL BIO MED, V36, P319, DOI 10.1016/j.freeradbiomed.2003.10.026; Pavoine C, 2005, CELL SIGNAL, V17, P141, DOI 10.1016/j.cellsig.2004.09.001; Pavoine C, 2003, MOL PHARMACOL, V64, P1117, DOI 10.1124/mol.64.5.1117; Pavoine C, 1999, J BIOL CHEM, V274, P628, DOI 10.1074/jbc.274.2.628; Petroff MGV, 2001, NAT CELL BIOL, V3, P867, DOI 10.1038/ncb1001-867; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Rucker-Martin C, 2002, CARDIOVASC RES, V55, P38, DOI 10.1016/S0008-6363(02)00338-3; Rybin VO, 2003, MOL PHARMACOL, V63, P1338, DOI 10.1124/mol.63.6.1338; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sambrano GR, 2002, NATURE, V420, P712, DOI 10.1038/nature01306; Sauvadet A, 1996, CIRC RES, V78, P102, DOI 10.1161/01.RES.78.1.102; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Steinberg SF, 1999, CIRC RES, V85, P1101; Thomas MJ, 2003, J MOL CELL CARDIOL, V35, P1325, DOI 10.1016/j.yjmcc.2003.08.005; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Vangheluwe P, 2003, CELL CALCIUM, V34, P457, DOI 10.1016/S0143-4160(03)00126-X; Wang YG, 2002, J GEN PHYSIOL, V119, P69, DOI 10.1085/jgp.119.1.69; Xiao RP, 2004, J MOL CELL CARDIOL, V36, P7, DOI 10.1016/j.yjmcc.2003.10.013; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234	66	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18881	18890		10.1074/jbc.M410305200	http://dx.doi.org/10.1074/jbc.M410305200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15728587	hybrid			2022-12-25	WOS:000228932300040
J	Banno, T; Gazel, A; Blumenberg, M				Banno, T; Gazel, A; Blumenberg, M			Pathway-specific profiling identifies the NF-kappa B-dependent tumor necrosis factor alpha-regulated genes in epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; CASPASE-8 ACTIVATION; SIGNAL-TRANSDUCTION; SKIN-CANCER; TNF-ALPHA; IKK-ALPHA; APOPTOSIS; KINASE; DISEASE; COMPLEX	Identification of tumor necrosis factor alpha (TNF alpha) as the key agent in inflammatory disorders led to new therapies specifically targeting TNF alpha and avoiding many side effects of earlier anti-inflammatory drugs. However, because of the wide spectrum of systems affected by TNF alpha, drugs targeting TNF alpha have a potential risk of delaying wound healing, secondary infections, and cancer. Indeed, increased risks of tuberculosis and carcinogenesis have been reported as side effects after anti-TNF alpha therapy. TNF alpha regulates many processes (e.g. immune response, cell cycle, and apoptosis) through several signal transduction pathways that convey the TNF alpha signals to the nucleus. Hypothesizing that specific TNF alpha-dependent pathways control specific processes and that inhibition of a specific pathway may yield even more precisely targeted therapies, we used oligonucleotide microarrays and parthenolide, an NF-kappa B-specific inhibitor, to identify the NF-kappa B-dependent set of the TNF alpha-regulated genes in human epidermal keratinocytes. Expression of similar to 40% of all TNF alpha-regulated genes depends on NF-kappa B; 17% are regulated early (1-4 h post-treatment), and 23% are regulated late (24-48 h). Cytokines and apoptosis-related and cornification proteins belong to the "early" NF-kappa B-dependent group, and antigen presentation proteins belong to the "late" group, whereas most cell cycle, RNA-processing, and metabolic enzymes are not NF-kappa B-dependent. Therefore, inflammation, immunomodulation, apoptosis, and differentiation are on the NF-kappa B pathway, and cell cycle, metabolism, and RNA processing are not. Most early genes contain consensus NF-kappa B binding sites in their promoter DNA and are, presumably, directly regulated by NF-kappa B, except, curiously, the cornification markers. Using siRNA silencing, we identified cFLIP/CFLAR as an essential NF-kappa B-dependent antiapoptotic gene. The results confirm our hypothesis, suggesting that inhibiting a specific TNF alpha-dependent signaling pathway may inhibit a specific TNF alpha-regulated process, leaving others unaffected. This could lead to more specific anti-inflammatory agents that are both more effective and safer.	NYU, Sch Med, Dept Dermatol, New York, NY 10016 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY USA; Univ Tsukuba, Inst Clin Med, Dept Dermatol, Ibaraki 3058575, Japan	New York University; New York University; New York University; University of Tsukuba	Blumenberg, M (corresponding author), NYU, Sch Med, Dept Dermatol, 550 1st Ave, New York, NY 10016 USA.	blumem01@med.nyu.edu		Blumenberg, Miroslav/0000-0002-8672-7774	NIAMS NIH HHS [AR41850] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041850] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adachi M, 2003, DNA CELL BIOL, V22, P665, DOI 10.1089/104454903770238148; Ahn SG, 2002, EXP MOL MED, V34, P243, DOI 10.1038/emm.2002.34; Antoni C, 2002, CLIN EXP RHEUMATOL, V20, pS152; Banno T, 2003, ANTIVIR THER, V8, P541; Banno T, 2004, J BIOL CHEM, V279, P32633, DOI 10.1074/jbc.M400642200; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1996, SCIENCE, V274, P784; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hirsch DS, 2001, J BIOL CHEM, V276, P875, DOI 10.1074/jbc.M007039200; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kassner A, 2003, MATRIX BIOL, V22, P131, DOI 10.1016/S0945-053X(03)00008-8; Kataoka T, 1998, J IMMUNOL, V161, P3936; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Komine M, 2000, J BIOL CHEM, V275, P32077, DOI 10.1074/jbc.M001253200; Legg J, 2003, DEVELOPMENT, V130, P6049, DOI 10.1242/dev.00837; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lind MH, 2004, P NATL ACAD SCI USA, V101, P4972, DOI 10.1073/pnas.0307106101; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McDermott MF, 2001, CELL MOL BIOL, V47, P619; Nahar IK, 2003, ANN PHARMACOTHER, V37, P1256, DOI 10.1345/aph.1C039; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; O'Neill GM, 2001, MOL CELL BIOL, V21, P5094, DOI 10.1128/MCB.21.15.5094-5108.2001; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Smahi A, 2000, NATURE, V405, P466; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XJ, 1999, P NATL ACAD SCI USA, V96, P8483, DOI 10.1073/pnas.96.15.8483; Wolf R, 2002, CLIN DERMATOL, V20, P522, DOI 10.1016/S0738-081X(02)00273-0; Won YK, 2004, CARCINOGENESIS, V25, P1449, DOI 10.1093/carcin/bgh151; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904	44	84	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18973	18980		10.1074/jbc.M411758200	http://dx.doi.org/10.1074/jbc.M411758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15722350	hybrid			2022-12-25	WOS:000228932300051
J	Langlois, MA; Boniface, C; Wang, G; Alluin, J; Salvaterra, PM; Puymirat, J; Rossi, JJ; Lee, NS				Langlois, MA; Boniface, C; Wang, G; Alluin, J; Salvaterra, PM; Puymirat, J; Rossi, JJ; Lee, NS			Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRINUCLEOTIDE REPEAT; ARGONAUTE FAMILY; MAMMALIAN-CELLS; GENE DELIVERY; PROTEIN; TRANSCRIPTS; EXPRESSION; LOCALIZATION; ELEGANS; BINDING	Small interfering RNA ( siRNA) duplexes induce the specific cleavage of target RNAs in mammalian cells. Their involvement in down-regulation of gene expression is termed RNA interference (RNAi). It is widely believed that RNAi predominates in the cytoplasm. We report here the co-existence of cytoplasmic and nuclear RNAi phenomena in primary human myotonic dystrophy type 1 (DM1) cells by targeting myotonic dystrophy protein kinase ( DMPK) mRNAs. Heterozygote DM1 myoblasts from a human DM1 fetus produce a nuclear retained mutant DMPK transcript with large CUG repeats ( similar to 3,200) from one allele of the DMPK gene and a wild type transcript with 18 CUG repeats, thus providing for both a nuclear and cytoplasmic expression profile to be evaluated. We demonstrate here for the first time downregulation of the endogenous nuclear retained mutant DMPK mRNAs targeted with lentivirus-delivered short hairpin RNAs (shRNAs). This nuclear RNAi(-like) phenomenon was not observed when synthetic siRNAs were delivered by cationic lipids, suggesting either a link between processing of the shRNA and nuclear import or a separate pathway for processing shRNAs in the nuclei. Our observation of simultaneous RNAi on both cytoplasmic and nuclear retained DMPK has important implications for post-transcriptional gene regulation in both compartments of mammalian cells.	City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Grad Sch Biol Sci, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Neurosci, Grad Sch Biol Sci, Duarte, CA 91010 USA; Univ Laval, Med Res Ctr, Lab Human Genet, CHUQ, Ste Foy, PQ G1V 7P4, Canada	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; Laval University	Lee, NS (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Grad Sch Biol Sci, Duarte, CA 91010 USA.	nlee@coh.org	Langlois, Marc-Andre/J-2103-2012	Langlois, Marc-Andre/0000-0003-4652-3029				Astriab-Fisher A, 2004, BIOCHEM PHARMACOL, V68, P403, DOI 10.1016/j.bcp.2004.03.040; Bosher JM, 1999, GENETICS, V153, P1245; BROOK, 1992, CELL, V69, P385; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; DESHAYES S, 1967, BIOCHIM BIOPHYS ACTA, P141; Dudley NR, 2003, CURR OPIN MOL THER, V5, P113; Dudley NR, 2002, P NATL ACAD SCI USA, V99, P4191, DOI 10.1073/pnas.062605199; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fardaei M, 2001, NUCLEIC ACIDS RES, V29, P2766, DOI 10.1093/nar/29.13.2766; Furling D, 2001, NEUROMUSCULAR DISORD, V11, P728, DOI 10.1016/S0960-8966(01)00226-7; Furling D, 2003, AM J PATHOL, V162, P1001, DOI 10.1016/S0002-9440(10)63894-1; Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889; Langlois MA, 2003, MOL THER, V7, P670, DOI 10.1016/S1525-0016(03)00068-6; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Mankodi A, 2002, CURR OPIN NEUROL, V15, P545, DOI 10.1097/00019052-200210000-00005; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Robb GB, 2005, NAT STRUCT MOL BIOL, V12, P133, DOI 10.1038/nsmb886; Sasaki T, 2003, GENOMICS, V82, P323, DOI 10.1016/S0888-7543(03)00129-0; Shinagawa T, 2003, GENE DEV, V17, P1340, DOI 10.1101/gad.1073003; Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Taneja KL, 1998, BIOTECHNIQUES, V24, P472, DOI 10.2144/98243rr02; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Waddington SN, 2003, GENE THER, V10, P1234, DOI 10.1038/sj.gt.3301991; Yam PY, 2002, MOL THER, V5, P479, DOI 10.1006/mthe.2002.0558; Zeng Y, 2002, RNA, V8, P855, DOI 10.1017/S1355838202020071	35	92	102	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16949	16954		10.1074/jbc.M501591200	http://dx.doi.org/10.1074/jbc.M501591200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722335	hybrid			2022-12-25	WOS:000228615500050
J	Rauch, BH; Millette, E; Kenagy, RD; Daum, G; Fischer, JW; Clowes, AW				Rauch, BH; Millette, E; Kenagy, RD; Daum, G; Fischer, JW; Clowes, AW			Syndecan-4 is required for thrombin-induced migration and proliferation in human vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; PROTEIN-KINASE-C; EGF RECEPTOR TRANSACTIVATION; FOCAL ADHESION FORMATION; CYTOPLASMIC DOMAIN; ALPHA; ATHEROSCLEROSIS; PROTEOGLYCANS; MODULATION; ACTIVATION	Thrombin is a mitogen and chemoattractant for vascular smooth muscle cells (SMCs) and may contribute to vascular lesion formation. We have previously shown that human SMCs, when stimulated with thrombin, release basic fibroblast growth factor ( bFGF), causing phosphorylation of FGF receptor-1 (FGFR-1). Treatment with bFGF-neutralizing antibodies (anti-bFGF) or heparin inhibits thrombin-induced DNA synthesis. We concluded that thrombin may stimulate entry into the cell cycle via bFGF release and FGFR-1 activation. In the present study, we demonstrate a requirement for not only FGFR-1 but also syndecan-4, a transmembrane heparan-sulfate proteoglycan. Inhibition of syndecan-4 expression using small interfering RNA ( siRNA) resulted in reduced DNA synthesis by human SMCs after stimulation with thrombin ( 10 nmol/liter). Anti-bFGF antibody, which inhibits DNA synthesis in control cells, had no inhibitory effect when syndecan-4 expression was reduced by siRNA. Thrombin- or bFGF-induced SMC migration, determined in Boyden chamber assays, was reduced in cells treated with syndecan-4 or FGFR-1 siRNA or by anti-bFGF. Thrombin induced phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 in a biphasic pattern. Although thrombin-mediated ERK phosphorylation at 5 min was not affected by syndecan-4 or FGFR-1 siRNA, ERK phosphorylation at later time points was reduced. We conclude that thrombin-released bFGF binds to syndecan-4 and FGFR-1, which is required for thrombin-induced mitogenesis and migration.	Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Rauch, BH (corresponding author), Univ Klinikum Dusseldorf, Inst Pharmakol & Klin Pharmakol, Univ Str1, D-40225 Dusseldorf, Germany.	rauchb@uni-duesseldorf.de	Rauch, Bernhard/Q-6205-2018	Rauch, Bernhard/0000-0002-6003-4662; Kenagy, Richard/0000-0002-2021-5565	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-18645] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bass MD, 2002, BIOCHEM J, V368, P1, DOI 10.1042/BJ20021228; Bellin R, 2002, GLYCOCONJUGATE J, V19, P295, DOI 10.1023/A:1025352501148; Chu CL, 2004, BIOCHEM J, V379, P331, DOI 10.1042/BJ20031082; Debey S, 2003, BIOCHEM PHARMACOL, V65, P979, DOI 10.1016/S0006-2952(02)01661-1; Deroanne C, 2003, J CELL SCI, V116, P1367, DOI 10.1242/jcs.00308; Dobra K, 2000, EXP CELL RES, V258, P12, DOI 10.1006/excr.2000.4915; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; Horowitz A, 1998, J BIOL CHEM, V273, P25548, DOI 10.1074/jbc.273.40.25548; Horowitz A, 2002, J CELL BIOL, V157, P715, DOI 10.1083/jcb.200112145; Ishiguro K, 2000, J BIOL CHEM, V275, P5249, DOI 10.1074/jbc.275.8.5249; Jayson GC, 1999, INT J CANCER, V82, P298, DOI 10.1002/(SICI)1097-0215(19990719)82:2<298::AID-IJC23>3.3.CO;2-0; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; Longley RL, 1999, J CELL SCI, V112, P3421; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rauch BH, 2004, CIRC RES, V94, P340, DOI 10.1161/01.RES.0000111805.09592.D8; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; Simons M, 2001, CELL SIGNAL, V13, P855, DOI 10.1016/S0898-6568(01)00190-5; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Thodeti CK, 2003, J BIOL CHEM, V278, P9576, DOI 10.1074/jbc.M208937200; Volk R, 1999, J BIOL CHEM, V274, P24417, DOI 10.1074/jbc.274.34.24417; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Wilcox-Adelman SA, 2002, GLYCOCONJUGATE J, V19, P305, DOI 10.1023/A:1025304602057; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4	29	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17507	17511		10.1074/jbc.M410848200	http://dx.doi.org/10.1074/jbc.M410848200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731100	hybrid			2022-12-25	WOS:000228615500118
J	AbuJarour, RJ; Dalal, S; Hanson, PI; Draper, RK				AbuJarour, RJ; Dalal, S; Hanson, PI; Draper, RK			p97 is in a complex with cholera toxin and influences the transport of cholera toxin and related toxins to the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A-CHAIN; ENDOPLASMIC-RETICULUM; RETROGRADE TRANSPORT; PSEUDOMONAS EXOTOXIN; EUKARYOTIC RIBOSOMES; PROTEIN DISLOCATION; SECRETORY PATHWAY; PLASMA-MEMBRANE; GOLGI-COMPLEX; TRANSLOCATION	Certain protein toxins, including cholera toxin, ricin, and Pseudomonas aeruginosa exotoxin A, are transported to the lumen of the endoplasmic reticulum where they retro-translocate across the endoplasmic reticulum membrane to enter the cytoplasm. The mechanism of retrotranslocation is poorly understood but may involve the endoplasmic reticulum-associated degradation pathway. The AAA ATPase p97 ( also called valosin-containing protein) participates in the retro-translocation of cellular endoplasmic reticulum-associated degradation substrates and is therefore a candidate to participate in the retrotranslocation of protein toxins. To investigate whether p97 functions in toxin delivery to the cytoplasm, we measured the sensitivity to toxins of cells expressing either wild-type p97 or a dominant ATPase-defective p97 mutant under control of a tetracycline-inducible promoter. The rate at which cholera toxin and related toxins entered the cytoplasm was reduced in cells expressing the ATPase-defective p97, suggesting that the toxins might interact with p97. To detect interaction, the cholera toxin A chain was immunoprecipitated from cholera toxin-treated Vero cells, and co-immunoprecipitation of p97 was assessed by immunoblotting. The immunoprecipitates contained both cholera toxin A chain and p97, evidence that the two proteins are in a complex. Altogether, these results provide functional and structural evidence that p97 participates in the transport of cholera toxin to the cytoplasm.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	University of Texas System; University of Texas Dallas; Washington University (WUSTL)	Draper, RK (corresponding author), Univ Texas, Dept Mol & Cell Biol, FO31,Box 830688, Richardson, TX 75083 USA.	draper@utdallas.edu	Hanson, Phyllis/E-9420-2012					BAU MY, 1993, J BIOL CHEM, V268, P19939; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Brunger AT, 2003, FEBS LETT, V555, P126, DOI 10.1016/S0014-5793(03)01107-4; Chaudry GJ, 2002, TRENDS MICROBIOL, V10, P58, DOI 10.1016/S0966-842X(01)02294-6; Chen A, 2003, J CELL SCI, V116, P3503, DOI 10.1242/jcs.00641; Chen A, 2002, BBA-MOL CELL RES, V1589, P124, DOI 10.1016/S0167-4889(02)00163-5; Dalal S, 2004, MOL BIOL CELL, V15, P637, DOI 10.1091/mbc.E03-02-0097; Deeks ED, 2002, BIOCHEMISTRY-US, V41, P3405, DOI 10.1021/bi011580v; EIDELS L, 1988, HDB NATURAL TOXINS, P217; Elkabetz Y, 2004, J BIOL CHEM, V279, P3980, DOI 10.1074/jbc.M309938200; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1987, J BIOL CHEM, V262, P5908; Fujinaga Y, 2003, MOL BIOL CELL, V14, P4783, DOI 10.1091/mbc.E03-06-0354; Hazes B, 1997, BIOCHEMISTRY-US, V36, P11051, DOI 10.1021/bi971383p; Hu TH, 1999, MOL BIOL CELL, V10, P921, DOI 10.1091/mbc.10.4.921; Jackson ME, 1999, J CELL SCI, V112, P467; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Jarosch E, 2003, INT REV CYTOL, V223, P39; Jarosch E, 2002, TRAFFIC, V3, P530, DOI 10.1034/j.1600-0854.2002.30803.x; Koopmann JO, 2000, IMMUNITY, V13, P117, DOI 10.1016/S1074-7613(00)00013-3; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; Lencer WI, 2003, TRENDS BIOCHEM SCI, V28, P639, DOI 10.1016/j.tibs.2003.10.002; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Lord JM, 2003, BIOCHEM SOC T, V31, P1260; Lord JM, 1998, J CELL BIOL, V140, P733; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; NEVILLE DM, 1986, ANNU REV BIOCHEM, V55, P195, DOI 10.1146/annurev.biochem.55.1.195; Rodighiero C, 2002, EMBO REP, V3, P1222, DOI 10.1093/embo-reports/kvf239; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; Sandvig K, 2002, ANNU REV CELL DEV BI, V18, P1, DOI 10.1146/annurev.cellbio.18.011502.142107; Sannerud R, 2003, CURR OPIN CELL BIOL, V15, P438, DOI 10.1016/S0955-0674(03)00077-2; Schmitz A, 2000, J CELL BIOL, V148, P1203, DOI 10.1083/jcb.148.6.1203; SPANGLER BD, 1992, MICROBIOL REV, V56, P622, DOI 10.1128/MMBR.56.4.622-647.1992; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Wesche J, 1999, J BIOL CHEM, V274, P34443, DOI 10.1074/jbc.274.48.34443; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656	40	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15865	15871		10.1074/jbc.M406316200	http://dx.doi.org/10.1074/jbc.M406316200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15691847	hybrid			2022-12-25	WOS:000228444800051
J	Cuthbertson, BJ; Yang, YS; Bachere, E; Bullesbach, EE; Gross, PS; Aumelas, A				Cuthbertson, BJ; Yang, YS; Bachere, E; Bullesbach, EE; Gross, PS; Aumelas, A			Solution structure of synthetic penaeidin-4 with structural and functional comparisons with penaeidin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-STATE NMR; ANTIMICROBIAL PEPTIDES; INNATE IMMUNITY; PROTEINS; SHRIMP; SPECTROSCOPY; PROTEGRIN-1; ASSIGNMENT; DROSOPHILA; PEXIGANAN	Antimicrobial peptide structure has direct implications for the complexity of functions and mechanisms of action. The penaeidin antimicrobial peptide family from shrimp is divided into multiple class designations based on primary structure. The penaeidin classes are not only characterized by variability in primary sequence but also by variation in target specificity and effectiveness. Whereas class 4 exhibits low isoform diversity within species and is highly conserved between species, the primary sequence of penaeidin class 3 is less conserved between species and exhibits considerable isoform diversity within species. All penaeidins, regardless of class or species, are composed of two dramatically different domains: an unconstrained proline-rich domain and a disulfide bond-stabilized cysteine-rich domain. The proline-rich domain varies in length and is generally less conserved, whereas the spacing and specific residue content of the cysteine-rich domain is more conserved. The structure of the synthetic penaeidin class 4 (PEN4-1) from Litopenaeus setiferus was analyzed using several approaches, including chemical mapping of disulfide bonds, circular dichroism analysis of secondary structural characteristics, and complete characterization of the solution structure of the peptide by proton NMR. L. setiferus PEN4-1 was then compared with the previously characterized structure of penaeidin class 3 from Litopenaeus vannamei. Moreover, the specificity of these antimicrobial peptides was examined through direct comparison of activity against a panel of microbes. The penaeidin classes differ in microbial target specificity, which correlates to variability in specific domain sequence. However, the tertiary structure of the cysteine-rich domain and indeed the overall structure of penaeidins are conserved across classes.	Univ Montpellier I, Ctr Biochim Struct, CNRS,UMR 5048,INSERM U414, Fac Pharm, F-34093 Montpellier, France; Univ Montpellier 2, IFREMER, CNRS, UMR 5171, F-34095 Montpellier, France; Med Univ S Carolina, Charleston, SC 29412 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Clemson Univ, Genome Inst, Proteom Facil, Clemson, SC 29634 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Ifremer; Universite de Montpellier; Medical University of South Carolina; Medical University of South Carolina; Clemson University	Aumelas, A (corresponding author), Univ Montpellier I, Ctr Biochim Struct, CNRS,UMR 5048,INSERM U414, Fac Pharm, 15 Ave Charles Flahault, F-34093 Montpellier, France.	A.Aumelas@cbs.cnrs.fr	Bachere, Evelyne/O-6117-2014					Bachere E, 2004, IMMUNOL REV, V198, P149, DOI 10.1111/j.0105-2896.2004.00115.x; Bachere E, 2000, AQUACULTURE, V191, P71, DOI 10.1016/S0044-8486(00)00419-1; Buffy JJ, 2003, BIOCHEMISTRY-US, V42, P13725, DOI 10.1021/bi035187w; Buffy JJ, 2003, BIOPHYS J, V85, P2363, DOI 10.1016/S0006-3495(03)74660-8; CHAN AWE, 1993, PROTEIN SCI, V2, P1574, DOI 10.1002/pro.5560021004; Cuthbertson BJ, 2004, BIOCHEM J, V381, P79, DOI 10.1042/BJ20040330; Cuthbertson BJ, 2002, IMMUNOGENETICS, V54, P442, DOI 10.1007/s00251-002-0487-z; CUTHBERTSON BJ, 2004, THESIS MED U S CAROL; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; Destoumieux D, 1997, J BIOL CHEM, V272, P28398, DOI 10.1074/jbc.272.45.28398; Destoumieux D, 1999, EUR J BIOCHEM, V266, P335, DOI 10.1046/j.1432-1327.1999.00855.x; Ding L, 2003, BIOCHEMISTRY-US, V42, P12251, DOI 10.1021/bi035130+; Ding Y, 2001, GENOMICS, V74, P142, DOI 10.1006/geno.2001.6547; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Ge YG, 1999, ANTIMICROB AGENTS CH, V43, P782, DOI 10.1128/AAC.43.4.782; Ge YG, 1999, DIAGN MICR INFEC DIS, V35, P45, DOI 10.1016/S0732-8893(99)00056-5; Hamamoto K, 2002, MICROBIOL IMMUNOL, V46, P741, DOI 10.1111/j.1348-0421.2002.tb02759.x; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Iwanaga S, 2002, CURR OPIN IMMUNOL, V14, P87, DOI 10.1016/S0952-7915(01)00302-8; JACOB L, 1994, CIBA F SYMP, V186, P197; JACOB L, 1994, CIBA F SYMP, V186, P216; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; Patch JA, 2003, J AM CHEM SOC, V125, P12092, DOI 10.1021/ja037320d; Patch JA, 2002, CURR OPIN CHEM BIOL, V6, P872, DOI 10.1016/S1367-5931(02)00385-X; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RANCE M, 1987, J MAGN RESON, V74, P557, DOI 10.1016/0022-2364(87)90277-0; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; SRINIVASAN N, 1990, INT J PEPT PROT RES, V36, P147; Tam JP, 1995, P NATL ACAD SCI USA, V92, P12485, DOI 10.1073/pnas.92.26.12485; Volkman BF, 1997, BIOPOLYMERS, V41, P451, DOI 10.1002/(SICI)1097-0282(19970405)41:4<451::AID-BIP9>3.3.CO;2-7; Wishart DS, 2001, METHOD ENZYMOL, V338, P3; Wu J, 1997, PROTEIN SCI, V6, P391; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang YS, 2003, J BIOL CHEM, V278, P36859, DOI 10.1074/jbc.M305450200; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	43	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16009	16018		10.1074/jbc.M412420200	http://dx.doi.org/10.1074/jbc.M412420200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15699044	hybrid			2022-12-25	WOS:000228444800068
J	Jin, ZJ; Xin, MG; Deng, XM				Jin, ZJ; Xin, MG; Deng, XM			Survival function of protein kinase C iota as a novel nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-activated Bad kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INDUCED APOPTOSIS; LUNG-CARCINOMA CELLS; SRC TYROSINE KINASE; BH3 DOMAIN; PHOSPHORYLATION; PATHWAY; DEATH; NICOTINE; RECEPTOR; CANCER	Nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is formed by nitrosation of nicotine and has been identified as the most potent carcinogen in cigarette smoke. NNK cannot only induce DNA damage but also promotes the survival of human lung cancer cells. Protein kinase C (PKC) iota is an atypical PKC isoform and plays an important role in cell survival, but the downstream survival substrate(s) is not yet identified. Bad, a proapoptotic BH3-only member of Bcl2 family, is co-expressed with PKC iota in both small cell lung cancer and non-small cell lung cancer cells. We discovered that NNK potently induces multisite Bad phosphorylation at Ser-112, Ser-136, and Ser-155 via activation of PKC iota in association with increased survival of human lung cancer cells. Purified, active PKC iota can directly phosphorylate both endogenous and recombinant Bad at these three sites and disrupt Bad/Bcl-XL binding in vitro. Overexpression of PKC iota results in an enhancement of Bad phosphorylation. NNK also stimulates activation of c-Src, which is a known PKC iota upstream kinase. Treatment of cells with the PKC inhibitor (staurosporine) or a Src-specific inhibitor (PP2) can block NNK-induced Bad phosphorylation and promote apoptotic cell death. The beta-adrenergic receptor inhibitor propranolol blocks both NNK-induced activation of PKC iota and Bad phosphorylation, indicating that NNK-induced Bad phosphorylation occurs at least in part through the upstream beta-adrenergic receptor. Mechanistically, NNK-induced Bad phosphorylation prevents its interaction with Bcl-XL. Because the specific depletion of PKC iota by RNA interference inhibits both NNK-induced Bad phosphorylation and survival, this confirms that PKC iota is a necessary component in NNK-mediated survival signaling. Collectively, these findings reveal a novel role for PKC iota as an NNK-activated physiological Bad kinase that can directly phosphorylate and inactivate this proapoptotic BH3-only protein, which leads to enhanced survival and chemoresistance of human lung cancer cells.	Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), Univ Florida, Shands Canc Ctr, Dept Med, 1600 SW Archer Rd,Acad Res Bldg,R4-216,POB 100232, Gainesville, FL 32610 USA.	xdeng@ufscc.ufl.edu	Jin, Zhaohui/AAI-5562-2020; Jin, Zhaohui/AAQ-2893-2021	Jin, Zhaohui/0000-0001-7844-5833; 	NATIONAL CANCER INSTITUTE [R01CA112183] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA112183-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; *AM CANC SOC, 2003, CANC FACTS FIG, P13; Bergmann A, 2002, DEV CELL, V3, P607, DOI 10.1016/S1534-5807(02)00328-3; Bhagwat SV, 1998, BIOCHEM PHARMACOL, V56, P831, DOI 10.1016/S0006-2952(98)00228-7; Cloutier JF, 2001, J MOL BIOL, V313, P539, DOI 10.1006/jmbi.2001.4997; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Ding L, 2002, J BIOL CHEM, V277, P35305, DOI 10.1074/jbc.M201460200; DUMONT JA, 1994, BIOCHEM BIOPH RES CO, V204, P264, DOI 10.1006/bbrc.1994.2454; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Gescher A, 2000, CRIT REV ONCOL HEMAT, V34, P127, DOI 10.1016/S1040-8428(00)00058-5; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Hirai I, 2001, BIOCHEM J, V359, P345, DOI 10.1042/0264-6021:3590345; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang JY, 2004, J BIOL CHEM, V279, P21637, DOI 10.1074/jbc.M400956200; IKEGAKI N, 1994, CANCER RES, V54, P6; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Jin ZH, 2004, J BIOL CHEM, V279, P40209, DOI 10.1074/jbc.M404056200; Jin ZH, 2004, J BIOL CHEM, V279, P23837, DOI 10.1074/jbc.M402566200; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Kelly A, 2001, J WOMEN HEALTH GEN-B, V10, P515, DOI 10.1089/15246090152543085; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; PARK PG, 1995, CANCER RES, V55, P3504; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schuller HM, 1999, CANCER RES, V59, P4510; Schuller HM, 2002, NAT REV CANCER, V2, P455, DOI 10.1038/nrc824; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Shopland DR, 1995, ENVIRON HEALTH PERSP, V103, P131, DOI 10.2307/3432300; Spitaler M, 2000, J BIOL CHEM, V275, P33289, DOI 10.1074/jbc.M002742200; Suemaru K, 1997, N-S ARCH PHARMACOL, V355, P571, DOI 10.1007/PL00004985; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Trombino S, 2004, CANCER RES, V64, P135, DOI 10.1158/0008-5472.CAN-03-1672; Uchida S, 2002, AUTON NEUROSCI-BASIC, V96, P126, DOI 10.1016/S1566-0702(02)00004-8; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Wooten MW, 2001, MOL CELL BIOL, V21, P8414, DOI 10.1128/MCB.21.24.8414-8427.2001; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200; Zheng TZ, 1996, INT J CANCER, V68, P172, DOI 10.1002/(SICI)1097-0215(19961009)68:2<172::AID-IJC5>3.0.CO;2-V; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	51	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16045	16052		10.1074/jbc.M413488200	http://dx.doi.org/10.1074/jbc.M413488200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705582	hybrid			2022-12-25	WOS:000228444800072
J	Tran, NH; Wu, XC; Frost, JA				Tran, NH; Wu, XC; Frost, JA			B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; A-RAF; PHOSPHATIDYLINOSITOL 3-KINASE; SERINE/THREONINE KINASE; ONCOGENIC MUTATIONS; NEGATIVE REGULATION; GROWTH-FACTOR; MAP KINASE; C-TERMINUS; SERINE 338	B-Raf is a key regulator of the ERK pathway and is mutationally activated in two-thirds of human melanomas. In this work, we have investigated the activation mechanism of B-Raf and characterized the roles of Ras and of B-Raf phosphorylation in this regulation. Raf-1 is regulated by an N-terminal autoinhibitory domain whose actions are blocked by interaction with Ras and subsequent phosphorylation of Ser(338). We observed that B-Raf also contains an N-terminal autoinhibitory domain and that the interaction of this domain with the catalytic domain was inhibited by binding to active H-Ras. However, unlike Raf-1, the phosphorylation of B-Raf at Ser(445) was constitutive and was only moderately increased by expression of constitutively active H-Ras or constitutively active PAK1. Ser(445) phosphorylation is important to the B-Raf activation mechanism, however, because mutation of this site to alanine increased the affinity of the regulatory domain for the catalytic domain and increased autoinhibition. Similarly, expression of constitutively active PAK1 also decreased autoinhibition. B-Raf autoinhibition was negatively regulated by acidic substitutions at phosphorylation sites within the activation loop of B-Raf and by the oncogenic substitution V599E. However, these substitutions did not affect the ability of the regulatory domain to co-immunoprecipitate with the catalytic domain. These data demonstrate that B-Raf activity is autoregulated, that constitutive phosphorylation of Ser(445) primes B-Raf for activation, and that a key feature of phosphorylation within the activation loop or of oncogenic mutations within this region is to block autoinhibition.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Frost, JA (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, 6431 Fannin St, Houston, TX 77030 USA.	jeffrey.a.frost@uth.tmc.edu		Frost, Jeffrey/0000-0001-9722-1536				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Brose MS, 2002, CANCER RES, V62, P6997; Brummer T, 2003, ONCOGENE, V22, P8823, DOI 10.1038/sj.onc.1207185; CATLING AD, 1994, J BIOL CHEM, V269, P30014; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Chong HR, 2003, J BIOL CHEM, V278, P36269, DOI 10.1074/jbc.M212803200; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Dong JL, 2003, CANCER RES, V63, P3883; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; King AJ, 2001, FEBS LETT, V497, P6, DOI 10.1016/S0014-5793(01)02425-5; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mercer K, 2002, ONCOGENE, V21, P347, DOI 10.1038/sj.onc.1205101; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber CK, 2001, CANCER RES, V61, P3595; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Xu XL, 2003, CANCER RES, V63, P4561; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; Zang MW, 2001, J BIOL CHEM, V276, P25157, DOI 10.1074/jbc.M100152200; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang BH, 2001, EXP LUNG RES, V27, P269, DOI 10.1080/019021401300054046; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	50	100	107	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16244	16253		10.1074/jbc.M501185200	http://dx.doi.org/10.1074/jbc.M501185200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710605	hybrid			2022-12-25	WOS:000228444800094
J	Balland, V; Bouzhir-Sima, L; Kiger, L; Marden, MC; Vos, MH; Liebl, U; Mattioli, TA				Balland, V; Bouzhir-Sima, L; Kiger, L; Marden, MC; Vos, MH; Liebl, U; Mattioli, TA			Role of arginine 220 in the oxygen sensor FixL from Bradyrhizobium japonicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN; LIGAND-BINDING; ESCHERICHIA-COLI; HEME DOMAIN; PAS DOMAINS; SIGNAL-TRANSDUCTION; CARBON-MONOXIDE; KINASE-ACTIVITY; PROTEIN; DOS	In the heme-based oxygen sensor protein FixL, conformational changes induced by oxygen binding to the heme sensor domain regulate the activity of a neighboring histidine kinase, eventually restricting expression of specific genes to hypoxic conditions. The conserved arginine 220 residue is suggested to play a key role in the signal transduction mechanism. To obtain detailed insights into the role of this residue, we replaced Arg(220) by histidine (R220H), glutamine (R220Q), glutamate (R220E), and isoleucine (R220I) in the heme domain FixLH from Bradyrhizobium japonicum. These mutations resulted in dramatic changes in the O-2 affinity with K-d values in the order R220I < R220Q < wild type < R220H. For the R220H and R220Q mutants, residue 220 interacts with the bound O-2 or CO ligands, as seen by resonance Raman spectroscopy. For the oxy-adducts, this H-bond modifies the pi acidity of the O-2 ligand, and its strength is correlated with the back-bonding-sensitive nu(4) frequency, the k(off) value for O-2 dissociation, and heme core-size conformational changes. This effect is especially strong for the wild-type protein where Arg(220) is, in addition, positively charged. These observations strongly suggest that neither strong ligand fixation nor the displacement of residue 220 into the heme distal pocket are solely responsible for the reported heme conformational changes associated with kinase activity regulation, but that a significant decrease of the heme pi* electron density because of strong back-bonding toward the oxygen ligand also plays a key role.	CEA Saclay, Dept Biol Joliot Curie, Serv Bioenerget, Lab Biophys Stress Oxydant, F-91191 Gif Sur Yvette, France; CEA Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; Ecole Polytech, CNRS, INSERM, U451,UMR 7645ENSTA,Lab Opt & Biosci, F-91128 Palaiseau, France; INSERM, U473, F-94275 Le Kremlin Bicetre, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	Mattioli, TA (corresponding author), CEA Saclay, Dept Biol Joliot Curie, Serv Bioenerget, Lab Biophys Stress Oxydant, F-91191 Gif Sur Yvette, France.	tony.mattioli@cea.fr	Marden, Michael/AAA-5923-2020; Marden, Michael C/G-3139-2012; Balland, Véronique/AAD-7548-2022; Balland, Véronique/D-2479-2013	Marden, Michael C/0000-0002-5254-6385; Balland, Véronique/0000-0001-9534-9659; Vos, Marten/0000-0003-0493-4831; LIEBL, Ursula/0000-0003-0869-4388				Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; Aono S, 2002, J BIOL CHEM, V277, P13528, DOI 10.1074/jbc.M112256200; Chang AL, 2001, BIOCHEMISTRY-US, V40, P3420, DOI 10.1021/bi0100236; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Das TK, 2001, P NATL ACAD SCI USA, V98, P479, DOI 10.1073/pnas.98.2.479; Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; DESBOIS A, 1989, INORG CHEM, V28, P825, DOI 10.1021/ic00304a007; Dioum EM, 2002, SCIENCE, V298, P2385, DOI 10.1126/science.1078456; Dunham CM, 2003, BIOCHEMISTRY-US, V42, P7701, DOI 10.1021/bi0343370; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GILLESGONZALEZ MA, 1995, BIOCHEMISTRY-US, V34, P232, DOI 10.1021/bi00001a027; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Gong WM, 2000, BIOCHEMISTRY-US, V39, P3955, DOI 10.1021/bi992346w; Hao B, 2002, BIOCHEMISTRY-US, V41, P12952, DOI 10.1021/bi020144l; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; HIROTA S, 1994, J AM CHEM SOC, V116, P10564, DOI 10.1021/ja00102a025; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; KERR EA, 1985, J BIOL CHEM, V260, P8360; LI T, 1994, BIOCHEMISTRY-US, V33, P1344; Liebl U, 2002, P NATL ACAD SCI USA, V99, P12771, DOI 10.1073/pnas.192311699; LukatRodgers GS, 1997, BIOCHEMISTRY-US, V36, P4178, DOI 10.1021/bi9628230; Nellen-Anthamatten D, 1998, J BACTERIOL, V180, P5251, DOI 10.1128/JB.180.19.5251-5255.1998; Park HJ, 2004, BIOCHEMISTRY-US, V43, P2738, DOI 10.1021/bi035980p; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P12301, DOI 10.1021/bi980752u; RAMDSEN J, 1989, BIOCHEMISTRY-US, V28, P3125; ROUSSEAU DL, 1983, ANNU REV BIOPHYS BIO, V12, P357, DOI 10.1146/annurev.bb.12.060183.002041; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Sciotti MA, 2003, J BACTERIOL, V185, P5639, DOI 10.1128/JB.185.18.5639-5642.2003; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Taguchi S, 2004, J BIOL CHEM, V279, P3340, DOI 10.1074/jbc.M301013200; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; Tamura K, 1996, J AM CHEM SOC, V118, P9434, DOI 10.1021/ja9543457; Tomita T, 2002, BIOCHEMISTRY-US, V41, P4819, DOI 10.1021/bi0158831; Tuckerman JR, 2002, BIOCHEMISTRY-US, V41, P6170, DOI 10.1021/bi025628w; Uzan J, 2004, BIOPHYS J, V87, P1196, DOI 10.1529/biophysj.104.042168; Vreede J, 2003, J BIOL CHEM, V278, P18434, DOI 10.1074/jbc.M301701200; WALTERS MA, 1982, BIOCHEMISTRY-US, V21, P6989, DOI 10.1021/bi00269a057	42	32	32	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15279	15288		10.1074/jbc.M413928200	http://dx.doi.org/10.1074/jbc.M413928200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15711013	hybrid			2022-12-25	WOS:000228236800113
J	Doppler, H; Storz, P; Li, J; Comb, MJ; Toker, A				Doppler, H; Storz, P; Li, J; Comb, MJ; Toker, A			A phosphorylation state-specific antibody recognizes Hsp27, a novel substrate of protein kinase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTACT-CELLS; ACTIVATION; PATHWAY; MOTIFS; IDENTIFICATION	The use of phosphorylation state-specific antibodies has revolutionized the field of cellular signaling by Ser/ Thr protein kinases. A more recent application of this technology is the development of phospho-specific antibodies that specifically recognize the consensus substrate phosphorylated motif of a given protein kinase. Here, we describe the development and use of such an antibody which is directed against the optimal phosphorylation motif of protein kinase D (PKD). A degenerate phosphopeptide library with fixed residues corresponding to the consensus LXR(Q/K/E/M)(M/L/K/E/Q/ A) S*XXXX was used as an antigen to generate an antibody that recognizes this motif. We characterized the antibody by enzyme-linked immunosorbent assay and with immobilized peptide arrays and also detected immunoreactive phosphoproteins in HeLa cells stimulated with agonists known to activate PKD. Silencing PKD expression using RNA interference validated the specificity of this antibody immunoreactive against putative substrates. The antibody also detected the PKD substrates RIN1 and HDAC5. Knowledge of the PKD consensus motif also enabled us to identify Ser(82) in the human heat shock protein Hsp27 as a novel substrate for PKD. We term this antibody anti-PKD pMOTIF and predict that it will enable the discovery of novel PKD substrate proteins in cells.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA; Cell Signaling Technol, Beverly, MA 01915 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Toker, A (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, 330 Brookline Ave,RN-237, Boston, MA 02215 USA.	atoker@bidmc.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA075134] Funding Source: NIH RePORTER; NCI NIH HHS [CA75134] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cohen P, 2002, NAT CELL BIOL, V4, pE127, DOI 10.1038/ncb0502-e127; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; Hutti JE, 2004, NAT METHODS, V1, P27, DOI 10.1038/NMETH708; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; MANNING BD, 2002, SCI STKE; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; PERLMANN H, 1994, CELL BIOL LAB HDB; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, J BIOL CHEM, V278, P17969, DOI 10.1074/jbc.M213224200; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200; Zhou SY, 2001, METHOD ENZYMOL, V332, P171; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	23	134	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15013	15019		10.1074/jbc.C400575200	http://dx.doi.org/10.1074/jbc.C400575200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15728188	hybrid			2022-12-25	WOS:000228236800083
J	Nie, LP; Feng, WH; Diaz, R; Gratton, MA; Doyle, KJ; Yamoah, EN				Nie, LP; Feng, WH; Diaz, R; Gratton, MA; Doyle, KJ; Yamoah, EN			Functional consequences of polyamine synthesis inhibition by L-alpha-difluoromethylornithine (DFMO) - Cellular mechanisms for DFMO-mediated ototoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING POTASSIUM CHANNEL; RECTIFIER K+ CHANNEL; COCHLEAR STRIA VASCULARIS; INNER-EAR; ORNITHINE-DECARBOXYLASE; NULL MUTATION; INWARD RECTIFICATION; TARGETED DISRUPTION; INTERMEDIATE CELLS; MARGINAL CELLS	L-alpha-Difluoromethylornithine (DFMO) is a chemopreventive agent for colon cancer in clinical trials. Yet, the drug produces an across-frequency elevation of the hearing threshold, suggesting that DFMO may affect a common trait along the cochlear spiral. The mechanism for the ototoxic effects of DFMO remains uncertain. The cochlear duct is exclusively endowed with endocochlear potential (EP). EP is a requisite for normal sound transduction, as it provides the electromotive force that determines the magnitude of the receptor potential of hair cells. EP is generated by the high throughput of K+ across cells of the stria vascularis, conferred partly by the activity of Kir4.1 channels. Here, we show that the ototoxicity of DFMO may be mediated by alteration of the inward rectification of Kir4.1 channels, resulting in a marked reduction in EP. These findings are surprising given that the present model for EP generation asserts that Kir4.1 confers the outflow of K+ in the stria vascularis. We have proposed an alternative model. These findings should also enable the rational design of new pharmaceuticals devoid of the untoward effect of DFMO.	Univ Calif Davis, Dept Otolaryngol, Ctr Neurosci, Davis, CA 95616 USA; Univ Penn, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA	University of California System; University of California Davis; University of Pennsylvania	Yamoah, EN (corresponding author), Univ Calif Davis, Dept Otolaryngol, Ctr Neurosci, 1544 Newton Ct, Davis, CA 95616 USA.	enyamoah@ucdavis.edu			NIDCD NIH HHS [DC006442, DC007592, DC004523] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC004523, R01DC006442, R01DC007592] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Ando M, 1999, CELL TISSUE RES, V298, P179, DOI 10.1007/s004419900066; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bianchi L, 1996, J BIOL CHEM, V271, P6114, DOI 10.1074/jbc.271.11.6114; BREDT DS, 1995, P NATL ACAD SCI USA, V92, P6753, DOI 10.1073/pnas.92.15.6753; BROCK M, 1994, HEARING RES, V72, P37, DOI 10.1016/0378-5955(94)90203-8; Casimiro MC, 2001, P NATL ACAD SCI USA, V98, P2526, DOI 10.1073/pnas.041398998; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; Choe S, 2002, NAT REV NEUROSCI, V3, P115, DOI 10.1038/nrn727; COLQUHOUN D, 1995, SINGLE CHANNEL RECOR, P191; DALLOS P, 2001, COCHLEA, V8, P1; DAVIS H, 1957, PHYSIOL REV, V37, P1; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; Dou HV, 2004, JARO-J ASSOC RES OTO, V5, P215, DOI 10.1007/s10162-003-4020-3; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; Doyle KJ, 2001, LARYNGOSCOPE, V111, P781, DOI 10.1097/00005537-200105000-00005; Doyle KJ, 2001, ARCH OTOLARYNGOL, V127, P553, DOI 10.1001/archotol.127.5.553; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; Furuta H, 1998, HEARING RES, V123, P10, DOI 10.1016/S0378-5955(98)00091-4; Gratton M A, 1996, Hear Res, V102, P181, DOI 10.1016/S0378-5955(96)90017-9; Hayashi M, 2003, J PHYSIOL-LONDON, V547, P255, DOI 10.1113/jphysiol.2002.035857; HENLEY CM, 1995, HEARING RES, V84, P99, DOI 10.1016/0378-5955(95)00017-X; Hibino H, 1997, J NEUROSCI, V17, P4711; HILLE B, 1992, IONIC CHANNELS EXCIT, P131; Ishii M, 1997, J NEUROSCI, V17, P7725; Ishii M, 2003, AM J PHYSIOL-CELL PH, V285, pC260, DOI 10.1152/ajpcell.00560.2002; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Kozel PJ, 1998, J BIOL CHEM, V273, P18693, DOI 10.1074/jbc.273.30.18693; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Kubo Y, 1996, J BIOL CHEM, V271, P15729, DOI 10.1074/jbc.271.26.15729; Lee MP, 2000, J CLIN INVEST, V106, P1447, DOI 10.1172/JCI10897; Li LY, 2001, GLIA, V33, P57, DOI 10.1002/1098-1136(20010101)33:1<57::AID-GLIA1006>3.0.CO;2-0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; Marcus DC, 2002, AM J PHYSIOL-CELL PH, V282, pC403, DOI 10.1152/ajpcell.00312.2001; MARKS SC, 1991, HEARING RES, V53, P230, DOI 10.1016/0378-5955(91)90057-G; Meyskens FL, 1999, CLIN CANCER RES, V5, P945; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; NICHOLS CG, 1994, J PHYSIOL-LONDON, V476, P399, DOI 10.1113/jphysiol.1994.sp020141; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Nicolas MT, 2003, HEARING RES, V181, P20, DOI 10.1016/S0378-5955(03)00162-X; NIE L, 2004, 27 ANN MIDW RES M AS; OFFNER FF, 1987, HEARING RES, V29, P117, DOI 10.1016/0378-5955(87)90160-2; Orias M, 1997, AM J PHYSIOL-RENAL, V273, pF663, DOI 10.1152/ajprenal.1997.273.4.F663; Pasic TR, 1997, ARCH OTOLARYNGOL, V123, P1281; Pessia M, 2001, J PHYSIOL-LONDON, V532, P359, DOI 10.1111/j.1469-7793.2001.0359f.x; Rozengurt N, 2003, HEARING RES, V177, P71, DOI 10.1016/S0378-5955(02)00799-2; Sage CL, 2001, HEARING RES, V160, P1, DOI 10.1016/S0378-5955(01)00308-2; SALT AN, 1987, LARYNGOSCOPE, V97, P984; SALZER SJ, 1990, HEARING RES, V46, P101, DOI 10.1016/0378-5955(90)90143-D; Schmiedt RA, 2002, J NEUROSCI, V22, P9643; SCHULTE BA, 1992, HEARING RES, V61, P35, DOI 10.1016/0378-5955(92)90034-K; SEWELL WF, 1984, J PHYSIOL-LONDON, V347, P685, DOI 10.1113/jphysiol.1984.sp015090; Shyng SL, 1996, P NATL ACAD SCI USA, V93, P12014, DOI 10.1073/pnas.93.21.12014; Smith MK, 1998, CARCINOGENESIS, V19, P1409, DOI 10.1093/carcin/19.8.1409; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; STEEL KP, 1989, DEVELOPMENT, V107, P453; Tachibana M, 1999, PIGM CELL RES, V12, P344, DOI 10.1111/j.1600-0749.1999.tb00518.x; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; Takeuchi S, 1996, HEARING RES, V101, P181, DOI 10.1016/S0378-5955(96)00151-7; Takeuchi S, 1998, NEUROSCI LETT, V247, P175, DOI 10.1016/S0304-3940(98)00318-8; Takeuchi S, 2000, BIOPHYS J, V79, P2572, DOI 10.1016/S0006-3495(00)76497-6; TAKUMI T, 1995, J BIOL CHEM, V270, P16339, DOI 10.1074/jbc.270.27.16339; Talley EM, 2001, J NEUROSCI, V21, P7491, DOI 10.1523/JNEUROSCI.21-19-07491.2001; Tanemoto M, 2000, J PHYSIOL-LONDON, V525, P587, DOI 10.1111/j.1469-7793.2000.00587.x; TASAKI I, 1959, J NEUROPHYSIOL, V22, P149, DOI 10.1152/jn.1959.22.2.149; Tucker SJ, 2000, J BIOL CHEM, V275, P16404, DOI 10.1074/jbc.C000127200; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; Yang ZJ, 2000, J GEN PHYSIOL, V116, P33, DOI 10.1085/jgp.116.1.33	71	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15097	15102		10.1074/jbc.M409856200	http://dx.doi.org/10.1074/jbc.M409856200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15718247	hybrid			2022-12-25	WOS:000228236800092
J	Shi, DS; Morizono, H; Yu, XL; Roth, L; Caldovic, L; Allewell, NM; Malamy, MH; Tuchman, M				Shi, DS; Morizono, H; Yu, XL; Roth, L; Caldovic, L; Allewell, NM; Malamy, MH; Tuchman, M			Crystal structure of N-acetylornithine Transcarbamylase from Xanthomonas campestris - A novel enzyme in a new arginine biosynthetic pathway found in several eubacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE TRANSCARBAMYLASE; PROTEIN; PROGRAM	We have identified in Xanthomonas campestris a novel N-acetylornithine transcarbamylase that replaces ornithine transcarbamylase in the canonic arginine biosynthetic pathway of several Eubacteria. The crystal structures of the protein in the presence and absence of the reaction product, N-acetylcitrulline, were determined. This new family of transcarbamylases lacks the DxxSMG motif that is characteristic of all ornithine transcarbamylases (OTCases) and contains a novel proline-rich loop that forms part of the active site. The specificity for N-acetylornithine is conferred by hydrogen bonding with residues in the proline- rich loop via water molecules and by hydrophobic interactions with residues from the adjacent 80' s, 120' s, and proline- rich loops. This novel protein structure provides a starting point for rational design of specific analogs that may be useful in combating human and plant pathogens that utilize acetylornithine transcarbamylase rather than ornithine transcarbamylase.	Childrens Natl Med Ctr, Childrens Res Inst, Washington, DC 20010 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Univ Maryland, Coll Life Sci, Dept Chem & Biochem, College Pk, MD 20742 USA	Children's National Health System; Tufts University; University System of Maryland; University of Maryland College Park	Shi, DS (corresponding author), Childrens Natl Med Ctr, Childrens Res Inst, 111 Michigan Ave NW, Washington, DC 20010 USA.	dshi@cnmcresearch.org	Morizono, Hiroki/E-9737-2013	Morizono, Hiroki/0000-0002-9678-5564; Shi, Dashuang/0000-0002-5491-1104; Caldovic, Ljubica/0000-0002-9140-5585	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD032652] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047870, K01DK067935] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-01646] Funding Source: Medline; NICHD NIH HHS [HD-32652] Funding Source: Medline; NIDDK NIH HHS [DK-067935, DK-47870] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRADFORD M, 1976, ANAL BIOCHEM, V72, P1219; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; da Silva ACR, 2002, NATURE, V417, P459, DOI 10.1038/417459a; Ha Y, 1997, P NATL ACAD SCI USA, V94, P9550, DOI 10.1073/pnas.94.18.9550; Jin L, 1997, NAT STRUCT BIOL, V4, P622, DOI 10.1038/nsb0897-622; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Massant J, 2003, ACTA CRYSTALLOGR D, V59, P2140, DOI 10.1107/S0907444903019231; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Shi DS, 2002, J MOL BIOL, V320, P899, DOI 10.1016/S0022-2836(02)00539-9; Shi DS, 2001, BIOCHEM J, V354, P501, DOI 10.1042/0264-6021:3540501	19	32	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14366	14369		10.1074/jbc.C500005200	http://dx.doi.org/10.1074/jbc.C500005200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15731101	hybrid			2022-12-25	WOS:000228236800003
J	Hoffert, JD; Chou, CL; Fenton, RA; Knepper, MA				Hoffert, JD; Chou, CL; Fenton, RA; Knepper, MA			Calmodulin is required for vasopressin-stimulated increase in cyclic AMP production in inner medullary collecting duct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLFACTORY ADENYLYL-CYCLASE; WATER CHANNELS; UREA TRANSPORTER; RAT-KIDNEY; KINASE-II; CELLS; CALCIUM; PHOSPHORYLATION; MEMBRANE; AQUAPORIN-2	Calmodulin plays a critical role in regulation of renal collecting duct water permeability by vasopressin. However, specific targets for calmodulin action have not been thoroughly addressed. In the present study, we investigated whether Ca2+/calmodulin regulates adenylyl cyclase activity in the renal inner medullary collecting duct. Rat inner medullary collecting duct suspensions were incubated in the presence or absence of 0.1 nM vasopressin and the calmodulin inhibitors, monodansylcadaverine, W-7, and trifluoperazine, followed by measurement of cAMP. Vasopressin-stimulated cAMP elevation was significantly attenuated in the presence of calmodulin inhibitors. Analysis of transglutaminase 2 knock-out mice confirmed that these compounds were not acting through inhibition of transglutaminase 2 activity. Calmodulin inhibitors also blocked both cholera toxin- and forskolin-stimulated cAMP accumulation. In isolated perfused tubules, W-7 reversibly blocked vasopressin-stimulated urea permeability, a process that requires a rise in intracellular cAMP but does not appear to involve protein trafficking to the apical plasma membrane. These results suggest that calmodulin is required for vasopressin-stimulated adenylyl cyclase activity in the intact inner medullary collecting duct. Reverse transcription-PCR, immunoblotting, and immunohistochemistry revealed the presence of the calmodulin-sensitive adenylyl cyclase type 3 in the rat collecting duct, an isoform previously not known to be expressed in the collecting duct. Long-term treatment of Brattleboro rats with a vasopressin analog markedly decreased adenylyl cyclase type 3 protein abundance, providing an explanation for long-term down-regulation of vasopressin response in the collecting duct. These studies demonstrate the importance of calmodulin in the regulation of collecting duct adenylyl cyclase activity and transport function.	NHLBI, Kidney & Electrolyte Metab Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Knepper, MA (corresponding author), NHLBI, Kidney & Electrolyte Metab Lab, NIH, Bldg 10,Rm 6N260,10 Ctr Dr,MSC 1603, Bethesda, MD 20892 USA.	knep@helix.nih.gov	Knepper, Mark/AAF-8412-2020; Fenton, Robert A/ABD-9824-2021; Fenton, Robert/AFR-6983-2022	Fenton, Robert/0000-0003-1623-199X	Intramural NIH HHS [Z99 HL999999, Z01 HL001285-21] Funding Source: Medline; NHLBI NIH HHS [Z01-HL-01282-KE] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL001282, Z01HL001285] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSIELLO DA, 1981, J BIOL CHEM, V256, P9796; Chabardes D, 1996, J BIOL CHEM, V271, P19264, DOI 10.1074/jbc.271.32.19264; Chaudhry A, 1996, AM J PHYSIOL-REG I, V270, pR755, DOI 10.1152/ajpregu.1996.270.4.R755; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOU CL, 1995, AM J PHYSIOL-RENAL, V269, pF78, DOI 10.1152/ajprenal.1995.269.1.F78; Chou CL, 2004, J BIOL CHEM, V279, P49026, DOI 10.1074/jbc.M408565200; Chou CL, 2000, J BIOL CHEM, V275, P36839, DOI 10.1074/jbc.M005552200; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; CORNWELL MM, 1983, BIOCHIM BIOPHYS ACTA, V762, P414, DOI 10.1016/0167-4889(83)90006-X; DAVIS JQ, 1984, J BIOL CHEM, V259, P3550; Defer N, 1998, FEBS LETT, V424, P216, DOI 10.1016/S0014-5793(98)00178-1; Defer N, 2000, AM J PHYSIOL-RENAL, V279, pF400, DOI 10.1152/ajprenal.2000.279.3.F400; DEVINCENZO L, 2001, MOL CELL BIOL, V21, P148; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V270, pF623, DOI 10.1152/ajprenal.1996.270.4.F623; Ecelbarger CA, 1998, AM J PHYSIOL-RENAL, V274, pF1161, DOI 10.1152/ajprenal.1998.274.6.F1161; GRANTHAM JJ, 1966, AM J PHYSIOL, V211, P255, DOI 10.1152/ajplegacy.1966.211.1.255; Helies-Toussaint C, 2000, AM J PHYSIOL-RENAL, V279, pF185, DOI 10.1152/ajprenal.2000.279.1.F185; Hoffert JD, 2004, AM J PHYSIOL-RENAL, V286, pF170, DOI 10.1152/ajprenal.00223.2003; Imbert-Teboul Martine, 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P151; Inoue T, 1999, AM J PHYSIOL-RENAL, V276, pF559, DOI 10.1152/ajprenal.1999.276.4.F559; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KNEPPER MA, 1994, SEMIN NEPHROL, V14, P302; Kusano E, 2001, TOHOKU J EXP MED, V193, P207, DOI 10.1620/tjem.193.207; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu CY, 1999, BRAIN RES, V826, P253, DOI 10.1016/S0006-8993(99)01269-X; Mamluk R, 1999, ENDOCRINOLOGY, V140, P4601, DOI 10.1210/en.140.10.4601; Mhaouty-Kodja S, 1997, J BIOL CHEM, V272, P31100, DOI 10.1074/jbc.272.49.31100; Morris RG, 2002, J GEN PHYSIOL, V120, P71, DOI 10.1085/jgp.20018547; Nickols HH, 2004, J BIOL CHEM, V279, P46969, DOI 10.1074/jbc.M407351200; NIELSEN S, 1993, AM J PHYSIOL, V265, pF204, DOI 10.1152/ajprenal.1993.265.2.F204; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; NISHIKAWA M, 1980, NATURE, V287, P863, DOI 10.1038/287863a0; STAR RA, 1988, J CLIN INVEST, V81, P1879, DOI 10.1172/JCI113534; Stewart GS, 2004, AM J PHYSIOL-RENAL, V286, pF979, DOI 10.1152/ajprenal.00334.2003; STOKES JB, 1987, AM J PHYSIOL, V253, pF251, DOI 10.1152/ajprenal.1987.253.2.F251; SUGDEN MC, 1979, FEBS LETT, V105, P95, DOI 10.1016/0014-5793(79)80894-7; SUNDAN A, 1983, BIOCHEM BIOPH RES CO, V117, P562, DOI 10.1016/0006-291X(83)91237-8; TAKAICHI K, 1988, AM J PHYSIOL, V255, pF834, DOI 10.1152/ajprenal.1988.255.5.F834; Terris J, 1996, AM J PHYSIOL-RENAL, V271, pF414, DOI 10.1152/ajprenal.1996.271.2.F414; van Balkom BWM, 2004, AM J PHYSIOL-RENAL, V286, pF216, DOI 10.1152/ajprenal.00307.2003; WAYMAN GA, 1995, J BIOL CHEM, V270, P24108, DOI 10.1074/jbc.270.41.24108; Wei J, 1998, NEURON, V21, P495, DOI 10.1016/S0896-6273(00)80561-9; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; XIA ZG, 1992, NEUROSCI LETT, V144, P169, DOI 10.1016/0304-3940(92)90742-P; YAMAKI M, 1992, AM J PHYSIOL, V262, P957; Yip KP, 2002, J PHYSIOL-LONDON, V538, P891, DOI 10.1113/jphysiol.2001.012606; Zhang C, 2002, AM J PHYSIOL-RENAL, V282, pF85, DOI 10.1152/ajprenal.0054.2001	50	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13624	13630		10.1074/jbc.M500040200	http://dx.doi.org/10.1074/jbc.M500040200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15710610	Green Accepted, hybrid			2022-12-25	WOS:000228095500056
J	Hwang, SG; Yu, SS; Ryu, JH; Jeon, HB; Yoo, YJ; Eom, SH; Chun, JS				Hwang, SG; Yu, SS; Ryu, JH; Jeon, HB; Yoo, YJ; Eom, SH; Chun, JS			Regulation of beta-catenin signaling and maintenance of chondrocyte differentiation by ubiquitin-independent proteasomal degradation of alpha-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE-INDUCED APOPTOSIS; PROTEIN-KINASE-C; ARTICULAR CHONDROCYTES; ORNITHINE-DECARBOXYLASE; PLAKOGLOBIN; INHIBITION; PHENOTYPE; PATHWAY; P53; DEDIFFERENTIATION	Accumulation of beta-catenin and subsequent stimulation of beta-catenin-T cell-factor (Tcf)/lymphoid-enhancer-factor (Lef) transcriptional activity causes dedifferentiation of articular chondrocytes, which is characterized by decreased type II collagen expression and initiation of type I collagen expression. This study examined the mechanisms of alpha-catenin degradation, the role of alpha-catenin in beta-catenin signaling, and the physiological significance of beta-catenin regulation of beta-catenin signaling in articular chondrocytes. We found that both alpha- and beta-catenin accumulated during dedifferentiation of chondrocytes by escaping from proteasomal degradation. beta-Catenin degradation was ubiquitination-dependent, whereas alpha-catenin was proteasomally degraded in a ubiquitination-independent fashion. The accumulated alpha- and beta-catenin existed as complexes in the cytosol and nucleus. The complex formation between alpha- and beta-catenin blocked proteasomal degradation of alpha-catenin and also inhibited beta-catenin- Tcf/Lef transcriptional activity and the suppression of type II collagen expression associated with ectopic expression of beta-catenin, the inhibition of proteasome, or Wnt signaling. Collectively, our results indicate that ubiquitin-independent degradation of alpha-catenin regulates beta-catenin signaling and maintenance of the differentiated phenotype of articular chondrocytes.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea	Gwangju Institute of Science & Technology (GIST)	Chun, JS (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea.	jschun@gist.ac.kr						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Asher G, 2002, P NATL ACAD SCI USA, V99, P13125, DOI 10.1073/pnas.202480499; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Benaroudj N, 2001, BIOCHIMIE, V83, P311, DOI 10.1016/S0300-9084(01)01244-5; Dantuma NP, 2002, FEBS LETT, V529, P22, DOI 10.1016/S0014-5793(02)03252-0; Giannini AL, 2000, EXP CELL RES, V255, P207, DOI 10.1006/excr.1999.4785; Giannini AL, 2000, J BIOL CHEM, V275, P21883, DOI 10.1074/jbc.M001929200; Hoyt MA, 2003, J BIOL CHEM, V278, P12135, DOI 10.1074/jbc.M211802200; Hwang SG, 2004, J BIOL CHEM, V279, P26597, DOI 10.1074/jbc.M401401200; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Kim SJ, 2002, BIOCHEM BIOPH RES CO, V296, P221, DOI 10.1016/S0006-291X(02)00824-0; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Kim SJ, 2002, J BIOL CHEM, V277, P30375, DOI 10.1074/jbc.M205193200; MAHAFFEY D, 1993, J BIOL CHEM, V268, P21205; Murakami Y, 2000, BIOCHEM BIOPH RES CO, V267, P1, DOI 10.1006/bbrc.1999.1706; Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Sehgal RNM, 1997, J CELL BIOL, V139, P1033, DOI 10.1083/jcb.139.4.1033; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Takahashi N, 2000, BIOCHEM BIOPH RES CO, V277, P691, DOI 10.1006/bbrc.2000.3748; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Yoon JB, 2003, J BIOL CHEM, V278, P15319, DOI 10.1074/jbc.M212520200; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200	27	78	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12758	12765		10.1074/jbc.M413367200	http://dx.doi.org/10.1074/jbc.M413367200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15695815	hybrid			2022-12-25	WOS:000227922000083
J	Weber, HO; Ludwig, RL; Morrison, D; Kotlyarov, A; Gaestel, M; Vousden, KH				Weber, HO; Ludwig, RL; Morrison, D; Kotlyarov, A; Gaestel, M; Vousden, KH			HDM2 phosphorylation by MAPKAP kinase 2	ONCOGENE			English	Article						HDM2; MAPKAP kinase 2; p53; phosphorylation	CELL-CYCLE ARREST; UBIQUITIN-PROTEIN LIGASE; RING-FINGER DOMAIN; NUCLEAR EXPORT; P53 STABILITY; ONCOPROTEIN MDM2; UV-RADIATION; DNA-DAMAGE; DEGRADATION; PATHWAY	p53 stability is regulated by HDM2, a RING domain protein that acts as an E3 ligase to ubiquitinate p53 and target its degradation. Phosphorylation of HDM2 on serine 166 by AKT has been shown to enhance HDM2 activity and promote the degradation of p53. Here, we show that MAPKAP kinase 2 ( MK2) can phosphorylate HDM2 on serine 157 and 166 in vitro. Treatment of cells with anisomycin, which activates MK2, also results in phosphorylation of HDM2 on serine 157 and 166 in vivo. Mutation of the MK2 phosphorylation sites in HDM2 to aspartic acid renders HDM2 slightly more active in the degradation of p53, and mouse cells deficient for MK2 show reduced Mdm2 phosphorylation and elevated levels of p53 protein. Together, our results suggest that MK2 may act to dampen the extent and duration of the p53 response.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; NCI, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Hannover Med Sch, Inst Biochem Physiol Chem, D-30625 Hannover, Germany	Beatson Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Hannover Medical School	Vousden, KH (corresponding author), Beatson Inst Canc Res, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.	k.vousden@beatson.gla.ac.uk	Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652	NATIONAL CANCER INSTITUTE [ZIABC010329, Z01BC010329] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bates S, 1999, MOL CARCINOGEN, V24, P7, DOI 10.1002/(SICI)1098-2744(199901)24:1<7::AID-MC2>3.0.CO;2-5; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brignone C, 2004, ONCOGENE, V23, P4121, DOI 10.1038/sj.onc.1207540; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Burch LR, 2004, J MOL BIOL, V337, P115, DOI 10.1016/j.jmb.2003.10.081; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; LUNA RMD, 1995, NATURE, V378, P203; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2003, MOL CANCER RES, V1, P1017; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Perry ME, 2004, MOL CANCER RES, V2, P9; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	49	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					1965	1972		10.1038/sj.onc.1208389	http://dx.doi.org/10.1038/sj.onc.1208389			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688025				2022-12-25	WOS:000227681900001
J	Winter, AG; Dorgan, C; Melton, DW				Winter, AG; Dorgan, C; Melton, DW			Expression of a splicing variant in the 5'-UTR of the human ERCC1 gene is not cancer related	ONCOGENE			English	Article						ERCC1; nucleotide excision repair; ovarian cancer; cisplatin; splicing	NUCLEOTIDE EXCISION-REPAIR; CELL LUNG-CANCER; OVARIAN-CANCER; MESSENGER-RNA; COMBINATION CHEMOTHERAPY; CISPLATIN RESISTANCE; LINES; POLYMORPHISMS; PLATINUM; REMOVAL	Cisplatin is the most commonly used chemotherapeutic agent in the treatment of ovarian cancer. One of the mechanisms of resistance of ovarian tumours to cisplatin is increased nucleotide excision repair activity, in particular increased levels of the endonuclease ERCC1. Since 30-40% of ovarian cancers develop resistance to cisplatin after treatment and these tumours are usually incurable, ERCC1 expression is potentially useful as a predictive marker for the effectiveness of cisplatin-based chemotherapy. Using RT-PCR and Northern blotting, we have examined the expression of a 42 bp differentially spliced sequence in exon 1 of the human ERCC1 gene, loss of which has previously been reported to be correlated with higher levels of ERCC1 mRNA in ovarian cancer cell lines. We report here that this alternate transcript is ubiquitous in human tissues and cancer cell lines, is absent in mouse and thus does not appear to be cancer related.	Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie Canc Res UK Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Melton, DW (corresponding author), Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie Canc Res UK Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland.	david.melton@ed.ac.uk						DABHOLKAR M, 1994, J CLIN INVEST, V94, P703, DOI 10.1172/JCI117388; Damia G, 1996, INT J CANCER, V66, P779, DOI 10.1002/(SICI)1097-0215(19960611)66:6<779::AID-IJC12>3.0.CO;2-Z; Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X; HOY CA, 1985, CANCER RES, V45, P1737; Isla D, 2004, ANN ONCOL, V15, P1194, DOI 10.1093/annonc/mdh319; JOHNSON SW, 1994, BIOCHEM PHARMACOL, V47, P689, DOI 10.1016/0006-2952(94)90132-5; LANGDON SP, 1988, CANCER RES, V48, P6166; Li QD, 1999, BIOCHEM PHARMACOL, V57, P347, DOI 10.1016/S0006-2952(98)00291-3; Li TY, 2004, INT J ONCOL, V25, P1105; MASUDA H, 1990, CANCER RES, V50, P1863; MASUDA H, 1988, CANCER RES, V48, P5713; McGuire WP, 1998, SEMIN ONCOL, V25, P340; PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080; Ryu JS, 2004, LUNG CANCER, V44, P311, DOI 10.1016/j.lungcan.2003.11.019; Stoehlmacher J, 2004, BRIT J CANCER, V91, P344, DOI 10.1038/sj.bjc.6601975; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; Yu JJ, 2001, ONCOGENE, V20, P7694, DOI 10.1038/sj.onc.1204977	17	4	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2110	2113		10.1038/sj.onc.1208400	http://dx.doi.org/10.1038/sj.onc.1208400			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688021				2022-12-25	WOS:000227681900016
J	Lahiri, DK; Ge, YW; Maloney, B				Lahiri, DK; Ge, YW; Maloney, B			Characterization of the APP proximal promoter and 5 '-untranslated regions: identification of cell-type specific domains and implications in APP gene expression and Alzheimer's disease	FASEB JOURNAL			English	Article						amyloid; beta protein; cytokine; interleukin; TGF beta-1	AMYLOID PRECURSOR PROTEIN; MESSENGER-RNA; TRANSGENIC MICE; TRANSFORMING GROWTH-FACTOR-BETA-1; REGULATORY ELEMENTS; RESPONSIVE ELEMENT; TGF-BETA; INTERLEUKIN-1; LINES; TRANSLATION	Alzheimer's disease is characterized by brain deposition of toxic amyloid beta-peptide (A beta), generated from the A beta precursor protein (APP). APP gene expression is regulated via the proximal promoter region (PPR; - 46/- 1 in the human sequence; + 1 transcription start) and the 5'- untranslated region (5'-UTR; + 1/+ 147). We have recently identified a unique CAGA sequence, "amyloid," (+83/+86) present only in the APP gene from amyloid plaque-forming species, absent in all APP-like-proteins' (APLP1 and APLP2) genes. To assay functional activity of PPR + UTR and 5'- UTR regions that either contain or lack the " amyloid" box, we tested nine constructs in transient transfection studies. We observed significantly high reporter gene activity with - 46/144, - 46/100, - 46/54, and 54/144 constructs. The 54/100 fragment, which contains a transforming growth factor-beta/"amyloid"/interleukin-1 acute box cassette, showed different activity depending on cell type. Electrophoretic mobility shift assay ( EMSA) showed distinct DNA-nuclear protein interaction in all fragments, differing among both cell types and specific fragment. Reporter gene expression corroborates with the DNA-protein binding pattern. To directly examine the " amyloid" box, we generated oligomers for CAGA mutants or mutated adjacent nucleotides. EMSA results showed that altering " amyloid" or adjacent sequence alters specific DNA-nuclear protein interaction in both mutation- and cell-type-specific manners. Reporter gene assay reveals mutant-specific expression effects. Therefore, the - 46/54 region appears to be essential for basal expression of the APP gene, the 54/100 and 100/144 regions may have tissue-specific activity, and the " amyloid" CAGA box plays a role in APP gene regulation.	Indiana Univ, Sch Med, Inst Psychiat Res, Dept Psychiat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Lahiri, DK (corresponding author), Indiana Univ, Sch Med, Inst Psychiat Res, Dept Psychiat, 791 Union Dr, Indianapolis, IN 46202 USA.	dlahiri@iupui.edu	Maloney, Bryan J/C-4924-2011; Lahiri, Debomoy/AAZ-3322-2020	Maloney, Bryan J/0000-0003-2364-9649; 	NATIONAL INSTITUTE ON AGING [R01AG018379, R01AG018884] Funding Source: NIH RePORTER; NIA NIH HHS [AG18884, AG18379] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arango D, 2001, AM J MED GENET, V103, P138, DOI 10.1002/1096-8628(20011001)103:2<138::AID-AJMG1529>3.0.CO;2-8; Bellingham SA, 2004, J BIOL CHEM, V279, P20378, DOI 10.1074/jbc.M400805200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ge YW, 2004, J NEUROCHEM, V90, P1432, DOI 10.1111/j.1471-4159.2004.02608.x; Ghosh C, 2000, MOL BIOL REP, V27, P113, DOI 10.1023/A:1007173906990; Ghosh C, 1999, J MOL NEUROSCI, V13, P77, DOI 10.1385/JMN:13:1-2:77; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; Kongsvik TL, 2002, J BIOL CHEM, V277, P16484, DOI 10.1074/jbc.M201583200; Kumar VB, 2000, PEPTIDES, V21, P1769, DOI 10.1016/S0196-9781(00)00339-9; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; Lahiri DK, 2003, J ALZHEIMERS DIS, V5, P81, DOI 10.3233/JAD-2003-5203; LAHIRI DK, 1991, MOL BRAIN RES, V9, P253, DOI 10.1016/0169-328X(91)90009-M; Lahiri DK, 2003, CURR DRUG TARGETS, V4, P97, DOI 10.2174/1389450033346957; Lahiri DK, 2004, ANN NY ACAD SCI, V1030, P282, DOI 10.1196/annals.1329.035; LAHIRI DK, 1995, MOL BRAIN RES, V32, P233, DOI 10.1016/0169-328X(95)00078-7; Leong GM, 2001, J BIOL CHEM, V276, P18243, DOI 10.1074/jbc.M010815200; Lesne S, 2003, J BIOL CHEM, V278, P18408, DOI 10.1074/jbc.M300819200; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maloney B, 2004, FASEB J, V18, P1288, DOI 10.1096/fj.03-1703fje; Perez RG, 1997, J NEUROSCI, V17, P9407; Roberts AB, 2003, ANN NY ACAD SCI, V995, P1, DOI 10.1111/j.1749-6632.2003.tb03205.x; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Rogers JT, 1999, J BIOL CHEM, V274, P6421, DOI 10.1074/jbc.274.10.6421; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; Schug JaOGC, 1998, TECHNICAL REPORTS CO, P1; Selkoe DJ, 2002, ANNU REV GENOM HUM G, V3, P67, DOI 10.1146/annurev.genom.3.022502.103022; SHAPIRO BA, 1988, COMPUT APPL BIOSCI, V4, P387; Shaw KTY, 2001, P NATL ACAD SCI USA, V98, P7605, DOI 10.1073/pnas.131152998; Song WH, 1998, GENE, V217, P165, DOI 10.1016/S0378-1119(98)00340-0; Song WH, 1998, GENE, V217, P151, DOI 10.1016/S0378-1119(98)00337-0; SPARKS DL, 2003, P NATL ACAD SCI USA, V100, P11193; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; White AR, 2002, J NEUROSCI, V22, P365, DOI 10.1523/JNEUROSCI.22-02-00365.2002; Wyss-Coray T, 2000, AM J PATHOL, V156, P139, DOI 10.1016/S0002-9440(10)64713-X; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	41	38	40	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					653	+		10.1096/fj.04-2900fje	http://dx.doi.org/10.1096/fj.04-2900fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15703276				2022-12-25	WOS:000227591900018
J	Hari-Dass, R; Shah, C; Meyer, DJ; Raynes, JG				Hari-Dass, R; Shah, C; Meyer, DJ; Raynes, JG			Serum amyloid A protein binds to outer membrane protein A of Gram-negative bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; COUPLED RECEPTOR; OMPA PROTEIN; EXPRESSION; INDUCTION; IDENTIFICATION; ADHESION; ANTIGEN; DOMAIN	Serum amyloid A (SAA) is the major acute phase protein in man and most mammals. We observed SAA binding to a surprisingly large number of Gram-negative bacteria, including Escherichia coli, Salmonella typhimurium, Shigella flexneri, Klebsiella pneumoniae, Vibrio cholerae, and Pseudomonas aeruginosa. The binding was found to be high affinity and rapid. Importantly, this binding was not inhibited by high density lipoprotein with which SAA is normally complexed in serum. Binding was also observed when bacteria were offered serum containing SAA. Ligand blots following SDS-PAGE or two-dimensional gels revealed two major ligands of 29 and 35 kDa that bound SAA when probing with radiolabeled SAA or SAA and monoclonal anti-SAA. Following fractionation the ligand was found in the outer membrane fraction of E. coli and was identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry to be outer membrane protein A ( OmpA). OmpA-deficient E. coli did not bind SAA, and following purification of OmpA the protein retained binding activity. The ligands on other bacteria were likely to be homologues of OmpA because wild type, but not OprF-deficient, P. aeruginosa bound SAA.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Immunol Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Raynes, JG (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Immunol Unit, Keppel St, London WC1E 7HT, England.	john.raynes@lshtm.ac.uk	Raynes, John G/G-7932-2011	Raynes, John G/0000-0002-8536-1328				Ancsin JB, 1997, J BIOL CHEM, V272, P406; Ancsin JB, 1999, J BIOL CHEM, V274, P7172, DOI 10.1074/jbc.274.11.7172; Arora A, 2001, NAT STRUCT BIOL, V8, P334, DOI 10.1038/86214; BADOLATO R, 1994, J EXP MED, V180, P203, DOI 10.1084/jem.180.1.203; Baranova IN, 2005, J BIOL CHEM, V280, P8031, DOI 10.1074/jbc.M405009200; BEHER MG, 1980, J BACTERIOL, V143, P906, DOI 10.1128/JB.143.2.906-913.1980; Belaaouaj AA, 2000, SCIENCE, V289, P1185, DOI 10.1126/science.289.5482.1185; BENDITT EP, 1977, P NATL ACAD SCI USA, V74, P4025, DOI 10.1073/pnas.74.9.4025; BRINCKERHOFF CE, 1989, SCIENCE, V243, P655, DOI 10.1126/science.2536953; Cai L, 2005, J BIOL CHEM, V280, P2954, DOI 10.1074/jbc.M411555200; He R, 2003, BLOOD, V101, P1572, DOI 10.1182/blood-2002-05-1431; Jeannin P, 2000, NAT IMMUNOL, V1, P502, DOI 10.1038/82751; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; MORROW JF, 1981, P NATL ACAD SCI-BIOL, V78, P4718, DOI 10.1073/pnas.78.8.4718; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Ogawa H, 2000, AM J PHYSIOL-GASTR L, V279, pG492, DOI 10.1152/ajpgi.2000.279.3.G492; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; Prasadarao NV, 2002, J IMMUNOL, V169, P6352, DOI 10.4049/jimmunol.169.11.6352; Prasadarao NV, 2002, INFECT IMMUN, V70, P4556, DOI 10.1128/IAI.70.8.4556-4563.2002; PRASADARO NV, 2000, INFECT IMMUN, V71, P1680; PreciadoPatt L, 1996, J IMMUNOL, V156, P1189; PRUZANSKI W, 1995, BIOCHEM J, V309, P461, DOI 10.1042/bj3090461; RAYNES JG, 1988, ANAL BIOCHEM, V173, P116, DOI 10.1016/0003-2697(88)90168-6; Santiago-Cardona PG, 2003, DEV COMP IMMUNOL, V27, P105, DOI 10.1016/S0145-305X(02)00068-X; SCHWEIZER M, 1978, EUR J BIOCHEM, V82, P211, DOI 10.1111/j.1432-1033.1978.tb12013.x; Singh SP, 2003, INFECT IMMUN, V71, P3937, DOI 10.1128/IAI.71.7.3937-3946.2003; SINN HJ, 1988, ANAL BIOCHEM, V170, P186, DOI 10.1016/0003-2697(88)90107-8; Soulas C, 2000, J IMMUNOL, V165, P2335, DOI 10.4049/jimmunol.165.5.2335; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; SUGAWARA E, 1994, J BIOL CHEM, V269, P17981; Sukumaran SK, 2003, INFECT IMMUN, V71, P5951, DOI 10.1128/IAI.71.10.5951-5961.2003; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; Urieli-Shoval S, 2002, BLOOD, V99, P1224, DOI 10.1182/blood.V99.4.1224; Urieli-Shoval S, 1998, J HISTOCHEM CYTOCHEM, V46, P1377, DOI 10.1177/002215549804601206; Walder K, 2002, DIABETES, V51, P1859, DOI 10.2337/diabetes.51.6.1859; Wang Y, 2002, BIOCHEM BIOPH RES CO, V292, P396, DOI 10.1006/bbrc.2002.6657; Yan SD, 2000, NAT MED, V6, P643, DOI 10.1038/76216	37	100	106	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18562	18567		10.1074/jbc.M500490200	http://dx.doi.org/10.1074/jbc.M500490200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15705572	hybrid			2022-12-25	WOS:000228932300003
J	Kwade, Z; Swiatek, A; Azmi, A; Goossens, A; Inze, D; Van Onckelen, H; Roef, L				Kwade, Z; Swiatek, A; Azmi, A; Goossens, A; Inze, D; Van Onckelen, H; Roef, L			Identification of four adenosine kinase Isoforms in tobacco BY-2 cells and their putative role in the cell cycle-regulated cytokinin metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS CYTOKININS; QUANTITATIVE-ANALYSIS; MESSENGER-RNA; BIOSYNTHESIS; PURIFICATION; ARABIDOPSIS; GENE; PHOSPHORYLATION; EXPRESSION; INDUCTION	Adenosine kinase (ADK), a key enzyme in the regulation of the intracellular level of adenosine is also speculated to be responsible for the conversion of cytokinin ribosides to their respective nucleotides. To elucidate the role of ADK in the cytokinin metabolism of tobacco BY-2 cells ( Nicotiana tabacum cv. "Bright Yellow-2"; TBY-2), we have identified and characterized the full-length cDNAs encoding four ADK isoforms of N. tabacum and determined their catalytic properties. The four TBY-2 ADK isoforms ( designated 1S, 2S, 1T, and 2T) display a high affinity for both adenosine ( K-m 1.88 - 7.30 mu M) and three distinct types of cytokinin ribosides: isopentenyladenosine; zeatin riboside; and dihydrozeatin riboside (K-m 0.30 - 8.71 mu M). The V-max/K-m values suggest that ADK2S exhibits in vitro an overall higher efficiency in the metabolism of cytokinin ribosides than the other three isoforms. The expression pattern of NtADK genes is modulated significantly during the cell cycle. We suggest that the increased transcript accumulation of NtADK coupled to an increased ADK activity just prior to mitosis is associated with a very active cytokinin metabolism at that phase of the cell cycle of synchronized TBY-2 cells.	Univ Antwerp, Dept Biol, Lab Plant Biochem & Physiol, B-2610 Antwerp, Belgium; State Univ Ghent VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium	University of Antwerp; Flanders Institute for Biotechnology (VIB); Ghent University	Van Onckelen, H (corresponding author), Univ Antwerp, Dept Biol, Lab Plant Biochem & Physiol, Univ Pl 1, B-2610 Antwerp, Belgium.	harry.vanonckelen@ua.ac.be	Inzé, Dirk/AAW-6381-2021; Ding, Cheng-Qiang/B-6287-2011	Inzé, Dirk/0000-0002-3217-8407; Goossens, Alain/0000-0002-1599-551X; Swiatek, Agnieszka/0000-0003-0744-888X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Astot C, 2000, P NATL ACAD SCI USA, V97, P14778, DOI 10.1073/pnas.260504097; Auer CA, 2002, J PLANT GROWTH REGUL, V21, P24, DOI 10.1007/s003440010044; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Azmi A, 2001, PLANTA, V213, P29, DOI 10.1007/s004250000476; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BIELESKI RL, 1964, ANAL BIOCHEM, V9, P431, DOI 10.1016/0003-2697(64)90204-0; Breyne P, 2002, P NATL ACAD SCI USA, V99, P14825, DOI 10.1073/pnas.222561199; CHEN CM, 1977, PLANT PHYSIOL, V59, P443, DOI 10.1104/pp.59.3.443; Chen CM, 1997, PHYSIOL PLANTARUM, V101, P665, DOI 10.1111/j.1399-3054.1997.tb01051.x; Craigon DJ, 2004, NUCLEIC ACIDS RES, V32, pD575, DOI 10.1093/nar/gkh133; Cronn RC, 2003, BIOTECHNIQUES, V34, P726, DOI 10.2144/03344st01; CROWELL DN, 1992, PLANT PHYSIOL, V100, P2090, DOI 10.1104/pp.100.4.2090; Davies Peter J., 1995, P1; Faye F, 1997, PLANT PHYSIOL BIOCH, V35, P15; Goossens A, 2003, P NATL ACAD SCI USA, V100, P8595, DOI 10.1073/pnas.1032967100; GURANOWSKI A, 1979, ARCH BIOCHEM BIOPHYS, V196, P220, DOI 10.1016/0003-9861(79)90569-1; Haberer G, 2002, PLANT PHYSIOL, V128, P354, DOI 10.1104/pp.010773; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hammerton RD, 1996, PHYSIOL PLANTARUM, V96, P77, DOI 10.1111/j.1399-3054.1996.tb00186.x; Hedtke B, 2002, PLANT J, V30, P625, DOI 10.1046/j.1365-313X.2002.01318.x; Hoth S, 2003, FEBS LETT, V554, P373, DOI 10.1016/S0014-5793(03)01194-3; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; Jameson P.E., 1994, CYTOKININS CHEM ACTI, P113; KAMINEK M, 1992, TRENDS BIOTECHNOL, V10, P159, DOI 10.1016/0167-7799(92)90204-9; Laukens K, 2003, FEBS LETT, V533, P63, DOI 10.1016/S0014-5793(02)03750-X; Laureys F, 1998, FEBS LETT, V426, P29, DOI 10.1016/S0014-5793(98)00297-X; LETHAM DS, 1983, ANNU REV PLANT PHYS, V34, P163, DOI 10.1146/annurev.pp.34.060183.001115; Long MC, 2003, J BACTERIOL, V185, P6548, DOI 10.1128/JB.185.22.6548-6555.2003; Maj MC, 2000, BIOCHEM BIOPH RES CO, V275, P386, DOI 10.1006/bbrc.2000.3307; McGaw Brian A., 1995, P98; McNally T, 1997, BIOCHEM BIOPH RES CO, V231, P645, DOI 10.1006/bbrc.1997.6157; Mlejnek P, 2003, PLANT CELL ENVIRON, V26, P1723, DOI 10.1046/j.1365-3040.2003.01090.x; Mlejnek P, 2002, PLANTA, V215, P158, DOI 10.1007/s00425-002-0733-5; Moffatt BA, 2002, PLANT PHYSIOL, V128, P812, DOI 10.1104/pp.010880; Moffatt BA, 2000, PLANT PHYSIOL, V124, P1775, DOI 10.1104/pp.124.4.1775; Mok DWS, 2001, ANNU REV PLANT PHYS, V52, P89, DOI 10.1146/annurev.arplant.52.1.89; Mok DWS, 1994, CYTOKININS CHEM ACTI, P129; Mok MC., 1994, CYTOKININS CHEM ACTI, P155, DOI DOI 10.1201/9781351071284; NAGATA T, 1992, INT REV CYTOL, V132, P1, DOI 10.1016/S0074-7696(08)62452-3; OKAMURO JK, 1985, MOL GEN GENET, V198, P290, DOI 10.1007/BF00383009; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PHILLIPS IDJ, 1975, ANNU REV PLANT PHYS, V26, P341, DOI 10.1146/annurev.pp.26.060175.002013; PRINSEN E, 1995, RAPID COMMUN MASS SP, V9, P948, DOI 10.1002/rcm.1290091016; RAES J, 1999, EMBNET NEWS EUROPEAN, V61; Redig P, 1996, FEBS LETT, V391, P175, DOI 10.1016/0014-5793(96)00728-4; Rock Christopher D., 1995, P671; Sambrook J, 2001, MOL CLONING LAB MANU; Schorlemmer HU, 1997, INT J IMMUNOTHER, V13, P9; Schulz PA, 2001, PLANT PHYSIOL, V126, P1224, DOI 10.1104/pp.126.3.1224; SKOOG F, 1957, Symp Soc Exp Biol, V11, P118; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; Spychala J, 1996, P NATL ACAD SCI USA, V93, P1232, DOI 10.1073/pnas.93.3.1232; Staden J. Van, 1979, Plant, Cell and Environment, V2, P93, DOI 10.1111/j.1365-3040.1979.tb00780.x; Stasolla C, 2003, J PLANT PHYSIOL, V160, P1271, DOI 10.1078/0176-1617-01169; Tanguay RL, 1996, MOL CELL BIOL, V16, P146; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDEPEER Y, 1993, COMPUT APPL BIOSCI, V9, P177; Veselov D, 2003, PLANTA, V216, P512, DOI 10.1007/s00425-002-0883-5; von Schwartzenberg K, 1998, PLANT J, V13, P249, DOI 10.1046/j.1365-313X.1998.00011.x; Wang H, 2003, PLANT CELL, V15, P3020, DOI 10.1105/tpc.015180; Werner T, 2003, PLANT CELL, V15, P2532, DOI 10.1105/tpc.014928; Yamaguchi M, 2003, P NATL ACAD SCI USA, V100, P8019, DOI 10.1073/pnas.1332637100	63	34	35	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17512	17519		10.1074/jbc.M411428200	http://dx.doi.org/10.1074/jbc.M411428200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731114	hybrid			2022-12-25	WOS:000228615500119
J	Lee, YS; Kim, HK; Chung, SM; Kim, KS; Dutta, A				Lee, YS; Kim, HK; Chung, SM; Kim, KS; Dutta, A			Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the downregulation of putative targets during differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL TEMPORAL RNAS; C-ELEGANS; INTERFERENCE; EXPRESSION; IDENTIFICATION; PROTEIN; DICER; CONSERVATION; SEQUENCE; LIN-28	Micro-RNAs are small non-coding RNAs that regulate target gene expression post-transcriptionally through base pairing with the target messenger RNA. Functional characterization of micro-RNAs awaits robust experimental methods to knock-down a micro-RNA as well as to assay its function in vivo. In addition to the recently developed method to sequester micro-RNA with 2'-O-methyl antisense oligonucleotide, we report that small interfering RNA against the loop region of a micro-RNA precursor can be used to deplete the micro-RNA. The depletion of miR-125b by this method had a profound effect on the proliferation of adult differentiated cancer cells, and this proliferation defect was rescued by cotransfected mature micro-RNA. This technique has unique advantages over the 2'-O-methyl antisense oligonucleotide and can be used to determine micro-RNA function, assay micro-RNAs in vivo, and identify the contribution of a predicted micro-RNA precursor to the pool of mature micro-RNA in a given cell. miR-125b and let-7 micro-RNAs are induced, whereas their putative targets, lin-28 and lin-41, are decreased during in vitro differentiation of Tera-2 or embryonic stem cells. Experimental increase or decrease of micro-RNA concentrations did not, however, affect the levels of the targets, a finding that is explained by the fact that the down-regulation of the targets appears to be mostly at the transcriptional level in these in vitro differentiation systems. Collectively these results reveal the importance of micro-RNA depletion strategies for directly determining micro-RNA function in vivo.	Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Seoul Natl Univ, Sch Biol Sci, Inst Mol Biol & Genet, Seoul 151742, South Korea; Harvard Univ, McLean Hosp, Sch Med, Mol Neurobiol Lab, Belmont, MA 02478 USA	University of Virginia; Seoul National University (SNU); Harvard University; McLean Hospital	Dutta, A (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Dutta, Anindya/P-3203-2016; Huang, H/E-9490-2010	Dutta, Anindya/0000-0002-4319-0073	NCI NIH HHS [R01 CA89406] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089406] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; Aravin AA, 2003, DEV CELL, V5, P337, DOI 10.1016/S1534-5807(03)00228-4; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Bashirullah A, 2003, DEV BIOL, V259, P1, DOI 10.1016/S0012-1606(03)00063-0; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Dostie J, 2003, RNA, V9, P180, DOI 10.1261/rna.2141503; Feinbaum R, 1999, DEV BIOL, V210, P87, DOI 10.1006/dbio.1999.9272; Grad Y, 2003, MOL CELL, V11, P1253, DOI 10.1016/S1097-2765(03)00153-9; GREENBERG ME, 2002, SHORT PROTOCOLS MOL, V1, P4; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264; Kawasaki H, 2003, NATURE, V426, P100, DOI 10.1038/nature02141; Kawasaki H, 2003, NATURE, V423, P838, DOI 10.1038/nature01730; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Llave C, 2002, PLANT CELL, V14, P1605, DOI 10.1105/tpc.003210; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Moss EG, 2003, DEV BIOL, V258, P432, DOI 10.1016/S0012-1606(03)00126-X; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Nelson PT, 2004, RNA, V10, P387, DOI 10.1261/rna.5181104; Park W, 2002, CURR BIOL, V12, P1484, DOI 10.1016/S0960-9822(02)01017-5; Pasquinelli AE, 2002, ANNU REV CELL DEV BI, V18, P495, DOI 10.1146/annurev.cellbio.18.012502.105832; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; PERTOVAARA L, 1993, BIOCHEM BIOPH RES CO, V191, P149, DOI 10.1006/bbrc.1993.1196; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Sernpere LF, 2003, DEV BIOL, V259, P9, DOI 10.1016/S0012-1606(03)00208-2; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; THOMPSON S, 1984, J CELL SCI, V72, P37; Vella MC, 2004, GENE DEV, V18, P132, DOI 10.1101/gad.1165404	48	277	321	5	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16635	16641		10.1074/jbc.M412247200	http://dx.doi.org/10.1074/jbc.M412247200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722555	hybrid			2022-12-25	WOS:000228615500014
J	Schoenemeyer, A; Barnes, BJ; Mancl, ME; Latz, E; Goutagny, N; Pitha, PM; Fitzgerald, KA; Golenbock, DT				Schoenemeyer, A; Barnes, BJ; Mancl, ME; Latz, E; Goutagny, N; Pitha, PM; Fitzgerald, KA; Golenbock, DT			The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TOLL-LIKE RECEPTORS; DOMAIN-CONTAINING ADAPTER; SINGLE-STRANDED RNA; TRANSCRIPTION FACTORS; GENE-EXPRESSION; IKK-EPSILON; RESPONSE ELEMENT; VIRUS-INFECTION; ALPHA GENES	Interferon regulatory factors (IRFs) are critical components of virus-induced immune activation and type I interferon regulation. IRF3 and IRF7 are activated in response to a variety of viruses or after engagement of Toll-like receptor (TLR) 3 and TLR4 by double-stranded RNA and lipopolysaccharide, respectively. The activation of IRF5, is much more restricted. Here we show that in contrast to IRF3 and IRF7, IRF5 is not a target of the TLR3 signaling pathway but is activated by TLR7 or TLR8 signaling. We also demonstrate that MyD88, interleukin 1 receptor-associated kinase 1, and tumor necrosis factor receptor-associated factor 6 are required for the activation of IRF5 and IRF7 in the TLR7 signaling pathway. Moreover, ectopic expression of IRF5 enabled type I interferon production in response to TLR7 signaling, whereas knockdown of IRF5 by small interfering RNA reduced type I interferon induction in response to the TLR7 ligand, R-848. IRF5 and IRF7, therefore, emerge from these studies as critical mediators of TLR7 signaling.	Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	University of Massachusetts System; University of Massachusetts Worcester; Johns Hopkins University; Johns Hopkins Medicine	Fitzgerald, KA (corresponding author), 364 Plantat St,LRB 308-9, Worcester, MA 01605 USA.	Kate.Fitzgerald@umassmed.edu	Latz, Eicke/H-3951-2014; Fitzgerald, Katherine/ABE-6317-2020	Latz, Eicke/0000-0003-1488-5666; Fitzgerald, Kate/0000-0003-3175-609X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI052455, R01AI052455, R01AI049309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054060, R37GM054060] Funding Source: NIH RePORTER; NCI NIH HHS [R01A1/CA19737-19A1] Funding Source: Medline; NIAID NIH HHS [AI49309, AI52455] Funding Source: Medline; NIGMS NIH HHS [GM54060] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Barnes BJ, 2004, J BIOL CHEM, V279, P45194, DOI 10.1074/jbc.M400726200; Barnes BJ, 2003, J BIOL CHEM, V278, P16630, DOI 10.1074/jbc.M212609200; Barnes BJ, 2002, MOL CELL BIOL, V22, P5721, DOI 10.1128/MCB.22.16.5721-5740.2002; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chariot A, 2002, J BIOL CHEM, V277, P37029, DOI 10.1074/jbc.M205069200; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Dent CL, 1996, EUR J BIOCHEM, V236, P895, DOI 10.1111/j.1432-1033.1996.t01-1-00895.x; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Du X, 2000, EUR CYTOKINE NETW, V11, P362; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Genin P, 2000, J IMMUNOL, V164, P5352, DOI 10.4049/jimmunol.164.10.5352; Gibson SJ, 2002, CELL IMMUNOL, V218, P74, DOI 10.1016/S0008-8749(02)00517-8; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Izaguirre A, 2003, J LEUKOCYTE BIOL, V74, P1125, DOI 10.1189/jlb.0603255; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jarrossay D, 2001, EUR J IMMUNOL, V31, P3388, DOI 10.1002/1521-4141(200111)31:11<3388::AID-IMMU3388>3.0.CO;2-Q; Jiang ZF, 2004, P NATL ACAD SCI USA, V101, P3533, DOI 10.1073/pnas.0308496101; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Krug A, 2004, IMMUNITY, V21, P107, DOI 10.1016/j.immuni.2004.06.007; Krug A, 2004, BLOOD, V103, P1433, DOI 10.1182/blood-2003-08-2674; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li XX, 1999, MOL CELL BIOL, V19, P4643; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; MANIATIS T, 1988, HARVEY LECT, V82, P71; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; MEGYERI K, 1995, MOL CELL BIOL, V15, P2207; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nomura F, 2000, GENES CELLS, V5, P191; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Reich NC, 2002, J INTERF CYTOK RES, V22, P103, DOI 10.1089/107999002753452719; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Stanley MA, 2002, CLIN EXP DERMATOL, V27, P571, DOI 10.1046/j.1365-2230.2002.01151.x; Suzuki N, 2003, J IMMUNOL, V171, P6065, DOI 10.4049/jimmunol.171.11.6065; TESTERMAN TL, 1995, J LEUKOCYTE BIOL, V58, P365, DOI 10.1002/jlb.58.3.365; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Von Krogh G, 2001, EUR J DERMATOL, V11, P598; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; YEH TJ, 1982, J CLIN MICROBIOL, V16, P413, DOI 10.1128/JCM.16.2.413-415.1982; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M, 2002, J INTERF CYTOK RES, V22, P73, DOI 10.1089/107999002753452674	72	299	318	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17005	17012		10.1074/jbc.M412584200	http://dx.doi.org/10.1074/jbc.M412584200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15695821	hybrid			2022-12-25	WOS:000228615500057
J	Charriere, F; Tan, THP; Schneider, A				Charriere, F; Tan, THP; Schneider, A			Mitochondrial initiation factor 2 of Trypanosoma brucei binds imported formylated elongator-type tRNA(Met)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATOR TRANSFER-RNA; PROTEIN-SYNTHESIS; FACTOR IF2; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; MESSENGER-RNA; FACTOR-II; TRANSLATION; FORMYLTRANSFERASE; INTERFERENCE	The mitochondrion of Trypanosoma brucei lacks tRNA genes. Its translation system therefore depends on the import of nucleus-encoded tRNAs. Thus, except for the cytosol-specific initiator tRNA(Met), all trypanosomal tRNAs function in both the cytosol and the mitochondrion. The only tRNA(Met) present in T. brucei mitochondria is therefore the one which, in the cytosol, is involved in translation elongation. Mitochondrial translation initiation depends on an initiator tRNA(Met) carrying a formylated methionine. This tRNA is then recognized by initiation factor 2, which brings it to the ribosome. To guarantee mitochondrial translation initiation, T. brucei has an unusual methionyl-tRNA formyltransferase that formylates elongator tRNA(Met). In the present study, we have identified initiation factor 2 of T. brucei and shown that its carboxyl-terminal domain specifically binds formylated trypanosomal elongator tRNA(Met). Furthermore, the protein also recognizes the structurally very different Escherichia coli initiator tRNA(Met), suggesting that the main determinant recognized is the formylated methionine. In vivo studies using stable RNA interference cell lines showed that knockdown of initiation factor 2, depending on which construct was used, causes slow growth or even growth arrest. Moreover, concomitantly with ablation of the protein, a loss of oxidative phosphorylation was observed. Finally, although ablation of the methionyl-tRNA formyltransferase on its own did not impair growth, a complete growth arrest was observed when it was combined with the initiation factor 2 RNA interference cell line showing the slow growth phenotype. Thus, these experiments illustrate the importance of mitochondrial translation initiation for growth of procyclic T. brucei.	Univ Fribourg, Dept Biol Zool, CH-1700 Fribourg, Switzerland	University of Fribourg	Schneider, A (corresponding author), Univ Fribourg, Dept Biol Zool, Chemin Musee 10, CH-1700 Fribourg, Switzerland.	andre.schneider@unifr.ch						Allemann N, 2000, MOL BIOCHEM PARASIT, V111, P87, DOI 10.1016/S0166-6851(00)00303-0; Beverley S M, 1993, Methods Mol Biol, V21, P333; Blanquet S, 2000, CURR OPIN STRUC BIOL, V10, P95, DOI 10.1016/S0959-440X(99)00055-X; Bochud-Allemann N, 2002, J BIOL CHEM, V277, P32849, DOI 10.1074/jbc.M205776200; Boelens R, 2002, CURR PROTEIN PEPT SC, V3, P107, DOI 10.2174/1389203023380765; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Esseiva AC, 2004, MOL BIOL CELL, V15, P2750, DOI 10.1091/mbc.E03-11-0821; Garofalo C, 2003, ARCH BIOCHEM BIOPHYS, V413, P243, DOI 10.1016/S0003-9861(03)00119-X; Guenneugues M, 2000, EMBO J, V19, P5233, DOI 10.1093/emboj/19.19.5233; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; Horvath A, 2000, J BIOL CHEM, V275, P17160, DOI 10.1074/jbc.M907246199; Horvath A, 2000, SCIENCE, V287, P1639, DOI 10.1126/science.287.5458.1639; Kapp LD, 2004, ANNU REV BIOCHEM, V73, P657, DOI 10.1146/annurev.biochem.73.030403.080419; Li Y, 2000, J BACTERIOL, V182, P2886, DOI 10.1128/JB.182.10.2886-2892.2000; LIAO HX, 1991, J BIOL CHEM, V266, P20714; LIAO HX, 1990, J BIOL CHEM, V265, P13618; Martin NC, 2002, P NATL ACAD SCI USA, V99, P1110, DOI 10.1073/pnas.042011199; Meunier S, 2000, EMBO J, V19, P1918, DOI 10.1093/emboj/19.8.1918; Newton DT, 1999, J BIOL CHEM, V274, P22143, DOI 10.1074/jbc.274.32.22143; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; Spremulli LL, 2004, PROG NUCLEIC ACID RE, V77, P211, DOI 10.1016/S0079-6603(04)77006-3; Spurio R, 2000, J BIOL CHEM, V275, P2447, DOI 10.1074/jbc.275.4.2447; Steiner-Mosonyi M, 2004, J BIOL CHEM, V279, P52262, DOI 10.1074/jbc.M408086200; Takeuchi N, 2001, J BIOL CHEM, V276, P20064, DOI 10.1074/jbc.M101007200; Tan THP, 2002, P NATL ACAD SCI USA, V99, P1152, DOI 10.1073/pnas.022522299; Tan THP, 2002, MOL CELL BIOL, V22, P3707, DOI 10.1128/MCB.22.11.3707-3716.2002; Tibbetts AS, 2003, J BIOL CHEM, V278, P31774, DOI 10.1074/jbc.M304962200; Vial L, 2003, BIOCHEMISTRY-US, V42, P932, DOI 10.1021/bi026901x; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WIRTZ E, 1995, SCIENCE, V268, P1179, DOI 10.1126/science.7761835	34	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15659	15665		10.1074/jbc.M411581200	http://dx.doi.org/10.1074/jbc.M411581200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15731104	hybrid			2022-12-25	WOS:000228444800026
J	Vainauskas, S; Menon, AK				Vainauskas, S; Menon, AK			Endoplasmic reticulum localization of Gaa1 and PIG-T, subunits of the glycosylphosphatidylinositol transamidase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPII-DEPENDENT EXPORT; GPI ANCHOR ATTACHMENT; SUBCELLULAR-LOCALIZATION; TRANSMEMBRANE DOMAIN; MEMBRANE-PROTEINS; RETENTION SIGNAL; ER RETENTION; BULK-FLOW; RECEPTOR; MOTIF	After integration into the endoplasmic reticulum ( ER) membrane, ER-resident membrane proteins must be segregated from proteins that are exported to post-ER compartments. Here we analyze how human Gaa1 and PIG-T, two of the five subunits of the ER-localized glycosylphosphatidylinositol transamidase complex, are retained in the ER. Neither protein contains a known ER localization signal. Gaa1 is a polytopic membrane glycoprotein with a cytoplasmic N terminus and a large luminal loop between its first two transmembrane spans; PIG-T is a type I membrane glycoprotein. To simplify our analyses, we studied Gaa1 and PIG-T constructs that could not interact with other subunits of the transamidase. We now show that Gaa1(282), a truncated protein consisting of the first TM domain and luminal loop of Gaa1, is correctly oriented, N-glycosylated, and ER-localized. Removal of a potential ER localization signal in the form of a triple arginine cluster near the N terminus of Gaa1 or Gaa1(282) had no effect on ER localization. Fusion proteins consisting of different elements of Gaa1(282) appended to alpha 2,6-sialyltransferase or transferrin receptor could exit the ER, indicating that Gaa1(282), and by implication Gaa1, does not contain any dominant ER-sorting determinants. The data suggest that Gaa1 is passively retained in the ER by a signalless mechanism. In contrast, similar analyses of PIG-T revealed that it is ER-localized because of information in its transmembrane span; fusion of the PIG-T transmembrane span to Tac antigen, a plasma membrane-localized protein, caused the fusion protein to remain in the ER. These data are discussed in the context of models that have been proposed to account for retention of ER membrane proteins.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Vainauskas, S (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	saulius@biochem.wisc.edu		Menon, Anant Kumar/0000-0001-6924-2698	NIGMS NIH HHS [GM55427] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; Chen C, 2000, GLYCOBIOLOGY, V10, P531, DOI 10.1093/glycob/10.5.531; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; De Beeck AO, 2004, J VIROL, V78, P12591, DOI 10.1128/JVI.78.22.12591-12602.2004; Eisen TG, 2000, ONCOLOGY-NY, V14, P17; Eisenhaber B, 2003, BIOESSAYS, V25, P367, DOI 10.1002/bies.10254; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Fraering P, 2001, MOL BIOL CELL, V12, P3295, DOI 10.1091/mbc.12.10.3295; Fu J, 2000, J BIOL CHEM, V275, P3984, DOI 10.1074/jbc.275.6.3984; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; GRIFFITHS G, 1995, TRENDS CELL BIOL, V5, P9, DOI 10.1016/S0962-8924(00)88926-6; Grimme SJ, 2004, MOL BIOL CELL, V15, P2758, DOI 10.1091/mbc.E04-01-0035; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; Hong YJ, 2003, MOL BIOL CELL, V14, P1780, DOI 10.1091/mbc.E02-12-0794; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Letourneur F, 1998, J BIOL CHEM, V273, P33273, DOI 10.1074/jbc.273.50.33273; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; Malkus P, 2002, J CELL BIOL, V159, P915, DOI 10.1083/jcb.200208074; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nikonov AV, 2002, J CELL BIOL, V158, P497, DOI 10.1083/jcb.200201116; Ohishi K, 2003, J BIOL CHEM, V278, P13959, DOI 10.1074/jbc.M300586200; Ohishi K, 2001, EMBO J, V20, P4088, DOI 10.1093/emboj/20.15.4088; Parker AKT, 2004, J BIOL CHEM, V279, P23797, DOI 10.1074/jbc.M402098200; Pentcheva T, 2002, J IMMUNOL, V168, P1538, DOI 10.4049/jimmunol.168.4.1538; Pottekat A, 2004, J BIOL CHEM, V279, P15743, DOI 10.1074/jbc.M313537200; Robert J, 2005, J BIOL CHEM, V280, P2300, DOI 10.1074/jbc.M410655200; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; Sharma DK, 1999, J BIOL CHEM, V274, P16479, DOI 10.1074/jbc.274.23.16479; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Vainauskas S, 2004, J BIOL CHEM, V279, P6540, DOI 10.1074/jbc.M312191200; Vainauskas S, 2002, J BIOL CHEM, V277, P30535, DOI 10.1074/jbc.M205402200; Wang XD, 2004, J CELL BIOL, V167, P65, DOI 10.1083/jcb.200401035; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Wrzeszczynski KO, 2004, CELL MOL LIFE SCI, V61, P1341, DOI 10.1007/s00018-004-4005-3; Xia H, 2001, NEUROPHARMACOLOGY, V41, P714, DOI 10.1016/S0028-3908(01)00103-4; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198	51	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16402	16409		10.1074/jbc.M414253200	http://dx.doi.org/10.1074/jbc.M414253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713669	hybrid			2022-12-25	WOS:000228444800113
J	Butler, B; Blystone, SD				Butler, B; Blystone, SD			Tyrosine phosphorylation of beta(3) integrin provides a binding site for Pyk2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADHESION KINASE; ALPHA(V)BETA(3) INTEGRIN; DEPENDENT ACTIVATION; SRC; RECEPTOR; ASSOCIATION; CELLS; AUTOPHOSPHORYLATION; STIMULATION	Integrins expressed on leukocytes possess the ability to maintain themselves in a non-adhesive state, thus preventing unwarranted adhesion and uncontrolled inflammation. Leukocyte adhesion is regulated through the modulation of integrin receptors such as alpha(V)beta(3). Firm adhesion to the extracellular matrix and directed cellular motility requires the reorganization of the actin cytoskeleton. The ability of beta(3) to recruit signaling and scaffolding molecules to propagate alpha(V)beta(3)-mediated signals is regulated in part by the phosphorylation of the beta(3) cytoplasmic tail. The identities of integrin-associated signaling molecules within alpha(V)beta(3) podosomes and in particular the proximal binding partners of the beta(3) cytoplasmic tail are not completely known. Here we show that alpha(V)beta(3) ligation induces Pyk2-Tyr-402 phosphorylation and its association with the beta(3) cytoplasmic tail in a beta(3)-Tyr-747 phosphorylation-dependent manner. Pyk2 binding to the beta(3) cytoplasmic tail is direct and dependent upon Pyk2-Tyr-402 and beta(3)-Tyr-747 phosphorylations. These data identify Pyk2 as a phosphorylated beta(3) binding partner, providing a potential structural and signaling platform to achieve alpha(V)beta(3)-mediated remodeling of the actin cytoskeleton.	SUNY Syracuse, Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Blystone, SD (corresponding author), SUNY Syracuse, Upstate Med Univ, Dept Cell & Dev Biol, 750 E Adams St, Syracuse, NY 13210 USA.	Blystons@upstate.edu			NIAID NIH HHS [R01AI40602, K02AI57384] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040602, K02AI057384] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; ANESKIEVICH BJ, 1991, ONCOGENE, V6, P1381; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Astier A, 1997, J BIOL CHEM, V272, P228; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; BALLARD LL, 1991, CLIN EXP IMMUNOL, V84, P336; Bayer AL, 2003, J MOL CELL CARDIOL, V35, P1121, DOI 10.1016/S0022-2828(03)00228-1; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; Butler B, 2003, J BIOL CHEM, V278, P5264, DOI 10.1074/jbc.M206997200; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; CARLOS TM, 1994, BLOOD, V84, P2068; Chandhoke SK, 2004, J CELL SCI, V117, P1431, DOI 10.1242/jcs.00987; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Doucey MA, 2003, J BIOL CHEM, V278, P26983, DOI 10.1074/jbc.M302709200; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; Duong LT, 2000, CELL MOTIL CYTOSKEL, V47, P174, DOI 10.1002/1097-0169(200011)47:3<174::AID-CM2>3.0.CO;2-N; Fuortes M, 1999, J CLIN INVEST, V104, P327, DOI 10.1172/JCI6018; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Gavrilovskaya IN, 1998, P NATL ACAD SCI USA, V95, P7074, DOI 10.1073/pnas.95.12.7074; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; Koziak K, 2001, BRIT J HAEMATOL, V114, P134, DOI 10.1046/j.1365-2141.2001.02894.x; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Litvak V, 2000, J BIOL CHEM, V275, P32736, DOI 10.1074/jbc.M004200200; Neff S, 1998, J VIROL, V72, P3587, DOI 10.1128/JVI.72.5.3587-3594.1998; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Okigaki M, 2003, P NATL ACAD SCI USA, V100, P10740, DOI 10.1073/pnas.1834348100; Park SY, 2004, J BIOL CHEM, V279, P33315, DOI 10.1074/jbc.M313527200; Pfaff M, 2001, J CELL SCI, V114, P2775; Phillips DR, 2001, THROMB HAEMOSTASIS, V86, P246; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; ROIVAINEN M, 1994, VIROLOGY, V203, P357, DOI 10.1006/viro.1994.1494; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; Sancho D, 2002, J IMMUNOL, V169, P292, DOI 10.4049/jimmunol.169.1.292; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Sayed MR, 2000, J CELL PHYSIOL, V183, P314, DOI 10.1002/(SICI)1097-4652(200006)183:3<314::AID-JCP3>3.0.CO;2-J; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Smyth SS, 2001, BLOOD, V98, P1055, DOI 10.1182/blood.V98.4.1055; Smyth SS, 2001, CIRCULATION, V103, P2501; Tsuchida M, 2000, J BIOL CHEM, V275, P1344, DOI 10.1074/jbc.275.2.1344; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036; Wrenn RW, 2001, BIOCHEM BIOPH RES CO, V282, P882, DOI 10.1006/bbrc.2001.4657	51	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14556	14562		10.1074/jbc.M411765200	http://dx.doi.org/10.1074/jbc.M411765200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15695828	hybrid			2022-12-25	WOS:000228236800027
J	Graille, M; Zhou, CZ; Receveur-Brechot, V; Collinet, B; Declerck, N; van Tilbeurgh, H				Graille, M; Zhou, CZ; Receveur-Brechot, V; Collinet, B; Declerck, N; van Tilbeurgh, H			Activation of the LicT transcriptional antiterminator involves a domain swing/lock mechanism provoking massive structural changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING DOMAIN; CATABOLITE REPRESSION; CRYSTAL-STRUCTURE; PROTEIN BGLG; SCATTERING; PHOSPHORYLATION; RECOGNITION; SYSTEM; OPERON; FAMILY	The transcriptional antiterminator protein LicT regulates the expression of Bacillus subtilis operons involved in beta-glucoside metabolism. It consists of an N-terminal RNA-binding domain (co-antiterminator (CAT)) and two phosphorylatable phosphotransferase system regulation domains (PRD1 and PRD2). In the activated state, each PRD forms a dimeric unit with the phosphorylation sites totally buried at the dimer interface. Here we present the 1.95 angstrom resolution structure of the inactive LicT PRDs as well as the molecular solution structure of the full-length protein deduced from small angle x-ray scattering. Comparison of native (inactive) and mutant (constitutively active) PRD crystal structures shows massive tertiary and quaternary rearrangements of the entire regulatory domain. In the inactive state, a wide swing movement of PRD2 results in dimer opening and brings the phosphorylation sites to the protein surface. This movement is accompanied by additional structural rearrangements of both the PRD1-PRD1' interface and the CAT-PRD1 linker. Small angle x-ray scattering experiments indicate that the amplitude of the PRD2 swing might even be wider in solution than in the crystals. Our results suggest that PRD2 is highly mobile in the native protein, whereas it is locked upon activation by phosphorylation.	Lab Enzymol & Biochim Struct, CNRS, UPR9063, F-91198 Gif Sur Yvette, France; Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, CNRS, UMR8619, F-91405 Orsay, France; Univ Aix Marseille 1, CNRS, UMR6098, F-13402 Marseille, France; Univ Aix Marseille 2, CNRS, UMR6098, F-13402 Marseille, France; Univ Montpellier I, Ctr Biochim Struct, CNRS, UMR9955,INSERM,U414, F-34090 Montpellier, France; INRA, INA PG, CNRS, UMR2585, F-78850 Thiverval Grignon, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay	van Tilbeurgh, H (corresponding author), Lab Enzymol & Biochim Struct, CNRS, UPR9063, Batiment 34,1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	Herman.Van-Tilbeurgh@ibbmc.u-psud.fr	Zhou, Cong-Zhao/E-9174-2011; GRAILLE, Marc/D-3242-2014	Zhou, Cong-Zhao/0000-0002-6881-7151; GRAILLE, Marc/0000-0002-7853-5852; Declerck, Nathalie/0000-0003-1551-1607; Receveur-Brechot, Veronique/0000-0002-7464-6192				AYMERICH S, 1992, P NATL ACAD SCI USA, V89, P10410, DOI 10.1073/pnas.89.21.10410; Bachem S, 1998, J BACTERIOL, V180, P5319, DOI 10.1128/JB.180.20.5319-5326.1998; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Declerck N, 2001, J MOL BIOL, V314, P671, DOI 10.1006/jmbi.2001.5185; Declerck N, 1999, J MOL BIOL, V294, P389, DOI 10.1006/jmbi.1999.3256; Fux L, 2003, J BIOL CHEM, V278, P50978, DOI 10.1074/jbc.M308085200; Gorke B, 1999, EMBO J, V18, P3370, DOI 10.1093/emboj/18.12.3370; Gorke B, 2003, J BIOL CHEM, V278, P46219, DOI 10.1074/jbc.M308002200; HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; KRUGER S, 1995, J BACTERIOL, V177, P5590; Leslie A., 1992, JOINT CCP4 EACMB NEW; Lindner C, 2002, J BACTERIOL, V184, P4819, DOI 10.1128/JB.184.17.4819-4828.2002; Lindner C, 1999, MOL MICROBIOL, V31, P995, DOI 10.1046/j.1365-2958.1999.01262.x; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Lopian L, 2003, P NATL ACAD SCI USA, V100, P7099, DOI 10.1073/pnas.1037608100; MAHADEVAN S, 1987, CELL, V50, P485, DOI 10.1016/0092-8674(87)90502-2; Manival X, 1997, EMBO J, V16, P5019, DOI 10.1093/emboj/16.16.5019; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Schmalisch MH, 2003, J BIOL CHEM, V278, P51108, DOI 10.1074/jbc.M309972200; Schnetz K, 1996, J BACTERIOL, V178, P1971, DOI 10.1128/jb.178.7.1971-1979.1996; Stulke J, 1998, MOL MICROBIOL, V28, P865, DOI 10.1046/j.1365-2958.1998.00839.x; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Tortosa P, 2001, MOL MICROBIOL, V41, P1381, DOI 10.1046/j.1365-2958.2001.02608.x; van Tilbeurgh H, 2001, CURR OPIN STRUC BIOL, V11, P685, DOI 10.1016/S0959-440X(01)00267-6; van Tilbeurgh H, 2001, EMBO J, V20, P3789, DOI 10.1093/emboj/20.14.3789; vanTilbeurgh H, 1997, EMBO J, V16, P5030, DOI 10.1093/emboj/16.16.5030; Yang YS, 2002, EMBO J, V21, P1987, DOI 10.1093/emboj/21.8.1987	32	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14780	14789		10.1074/jbc.M414642200	http://dx.doi.org/10.1074/jbc.M414642200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15699035	hybrid, Green Published			2022-12-25	WOS:000228236800055
J	Misra, V; Rapin, N; Akhova, O; Bainbridge, M; Korchinski, P				Misra, V; Rapin, N; Akhova, O; Bainbridge, M; Korchinski, P			Zhangfei is a potent and specific inhibitor of the host cell factor-binding transcription factor luman	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-INDUCING FACTOR; SIMPLEX-VIRUS VP16; ACTIVATION DOMAIN; MESSENGER-RNA; ER STRESS; K-BZIP; PROTEIN; DNA; HCF-1; CHOP	Host cell factor (HCF) was initially discovered as a cellular co-factor required for the activation of herpes simplex virus immediate early gene expression by the virion associated transactivator VP16. HCF also participates in a variety of cellular processes, although the mechanism of its action is not known. VP16 binds to HCF through a 4-amino acid motif (EHAY), which closely resembles the HCF binding domain of two cellular basic leucine-zipper proteins, Luman and Zhangfei. Luman is a powerful transcription factor that, in transient expression assays, activates promoters containing cAMP or unfolded protein response elements (UPRE). In contrast, Zhangfei neither binds consensus recognition elements for basic leucine-zipper proteins nor does it activate promoters containing them. Here we show that Zhangfei suppresses the ability of Luman to activate transcription. HCF appeared to be required for efficient suppression. A mutant of Zhangfei, which was unable to bind HCF, was impaired in its ability to suppress Luman. Zhangfei did not suppress ATF6, a transcription factor closely related to Luman but that does not bind HCF, unless the HCF binding motif of Luman was grafted onto it. Zhangfei inhibited the HCF-dependent activation of a UPRE-containing promoter by a Gal4-Luman fusion protein but was unable to inhibit the HCF-independent activation by Gal4-Luman of a promoter that contained Gal4 binding motifs. Binding of HCF by Zhangfei was required for the co-localization of Luman and Zhangfei to nuclear domains, suggesting that HCF might target the proteins to a common location.	Univ Saskatchewan, Western Coll Vet Med, Dept Microbiol, Saskatoon, SK S7N 5B4, Canada; Univ Saskatchewan, Dept Comp Sci, Saskatoon, SK S7N 5B4, Canada	University of Saskatchewan; University of Saskatchewan	Misra, V (corresponding author), Univ Saskatchewan, Western Coll Vet Med, Dept Microbiol, Saskatoon, SK S7N 5B4, Canada.	vikram.misra@usask.ca	Misra, Vikram/AAC-4266-2020	Misra, Vikram/0000-0001-6818-7156				Ajuh P, 2002, EMBO J, V21, P6590, DOI 10.1093/emboj/cdf652; Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Draghici S, 2003, GENOMICS, V81, P98, DOI 10.1016/S0888-7543(02)00021-6; Draghici S, 2003, NUCLEIC ACIDS RES, V31, P3775, DOI 10.1093/nar/gkg624; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; GOTO H, 1907, GENE DEV, V11, P726; HITT M, 1995, METH MOL G, V7, P13; Izumiya Y, 2003, J VIROL, V77, P1441, DOI 10.1128/JVI.77.2.1441-1451.2003; Julien E, 2003, EMBO J, V22, P2360, DOI 10.1093/emboj/cdg242; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; Khurana B, 2004, J BIOL CHEM, V279, P33673, DOI 10.1074/jbc.M401255200; La Boissiere S, 1999, EMBO J, V18, P480; Liao W, 2003, J VIROL, V77, P3809, DOI 10.1128/JVI.77.6.3809-3815.2003; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 2000, J VIROL, V74, P934, DOI 10.1128/JVI.74.2.934-943.2000; Lu R, 2000, NUCLEIC ACIDS RES, V28, P2446, DOI 10.1093/nar/28.12.2446; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Luciano RL, 2000, P NATL ACAD SCI USA, V97, P10757, DOI 10.1073/pnas.190062797; Luciano RL, 2003, J BIOL CHEM, V278, P51116, DOI 10.1074/jbc.M303470200; Luciano RL, 2002, P NATL ACAD SCI USA, V99, P13403, DOI 10.1073/pnas.202200399; Mahajan SS, 2002, J BIOL CHEM, V277, P44292, DOI 10.1074/jbc.M205440200; Mahajan SS, 2000, MOL CELL BIOL, V20, P919, DOI 10.1128/MCB.20.3.919-928.2000; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; MISRA V, 1995, J VIROL, V69, P5209, DOI 10.1128/JVI.69.9.5209-5216.1995; Misra V, 1996, MOL CELL BIOL, V16, P4404; Moore DD, 1995, GLOB MOB SURV; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; Raggo C, 2002, MOL CELL BIOL, V22, P5639, DOI 10.1128/MCB.22.16.5639-5649.2002; Reilly PT, 2002, MOL CELL BIOL, V22, P6767, DOI 10.1128/MCB.22.19.6767-6778.2002; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Sambrook J, 2001, MOL CLONING LAB MANU; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Ubeda M, 2003, J BIOL CHEM, V278, P40514, DOI 10.1074/jbc.M306404200; Ubeda M, 2000, NUCLEIC ACIDS RES, V28, P4987, DOI 10.1093/nar/28.24.4987; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Vogel JL, 2000, EMBO J, V19, P683, DOI 10.1093/emboj/19.4.683; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Wang Y, 2000, J BIOL CHEM, V275, P27013; Wysocka J, 2003, TRENDS BIOCHEM SCI, V28, P294, DOI 10.1016/S0968-0004(03)00088-4; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0	50	32	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15257	15266		10.1074/jbc.M500728200	http://dx.doi.org/10.1074/jbc.M500728200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705566	hybrid			2022-12-25	WOS:000228236800111
J	Patchell, VB; Gallon, CE; Evans, JS; Gao, Y; Perry, SV; Levine, BA				Patchell, VB; Gallon, CE; Evans, JS; Gao, Y; Perry, SV; Levine, BA			The regulatory effects of tropomyosin and troponin-I on the interaction of myosin loop regions with F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; PROTEIN-PROTEIN INTERACTIONS; HYPERTROPHIC CARDIOMYOPATHY; BINDING-SITE; BETA-MYOSIN; MUSCLE-CONTRACTION; ACTOMYOSIN COMPLEX; 50/20-KDA JUNCTION; ATPASE ACTIVITY; ADP RELEASE	The N terminus of skeletal myosin light chain 1 and the cardiomyopathy loop of human cardiac myosin have been shown previously to bind to actin in the presence and absence of tropomyosin (Patchell, V. B., Gallon, C. E., Hodgkin, M. A., Fattoum, A., Perry, S. V., and Levine, B. A. ( 2002) Eur. J. Biochem. 269, 5088 - 5100). We have extended this work and have shown that segments corresponding to other regions of human cardiac beta-myosin, presumed to be sites of interaction with F-actin ( residues 554 - 584, 622 - 646, and 633 - 660), likewise bind independently to actin under similar conditions. The binding to F-actin of a peptide spanning the minimal inhibitory segment of human cardiac troponin I ( residues 134 - 147) resulted in the dissociation from F-actin of all the myosin peptides bound to it either individually or in combination. Troponin C neutralized the effect of the inhibitory peptide on the binding of the myosin peptides to F-actin. We conclude that the binding of the inhibitory region of troponin I to actin, which occurs during relaxation in muscle when the calcium concentration is low, imposes conformational changes that are propagated to different locations on the surface of actin. We suggest that the role of tropomyosin is to facilitate the transmission of structural changes along the F-actin filament so that the monomers within a structural unit are able to interact with myosin.	Univ Birmingham, Sch Med, Div Med Sci, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham	Levine, BA (corresponding author), Univ Birmingham, Sch Med, Div Med Sci, Birmingham B15 2TT, W Midlands, England.	S.V.Perry@bham.ac.uk						Bartegi A, 1997, EUR J BIOCHEM, V250, P484, DOI 10.1111/j.1432-1033.1997.0484a.x; Cuda G, 1997, J MUSCLE RES CELL M, V18, P275, DOI 10.1023/A:1018613907574; CUDA G, 1993, J CLIN INVEST, V91, P2861, DOI 10.1172/JCI116530; EATON BL, 1976, SCIENCE, V192, P1337, DOI 10.1126/science.131972; GALLON CE, 2003, J MUSCLE CELL MOTIL, V24, P327; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GRABAREK Z, 1987, ACTA BIOCHIM BIOPHYS, V22, P307; Holmes KC, 2004, PHILOS T ROY SOC B, V359, P1819, DOI 10.1098/rstb.2004.1566; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; Houdusse A, 2000, P NATL ACAD SCI USA, V97, P11238, DOI 10.1073/pnas.200376897; Jardetzky O., 1981, NMR MOL BIOL; Joel PB, 2003, BIOCHEMISTRY-US, V42, P9160, DOI 10.1021/bi034415j; Joel PB, 2001, J BIOL CHEM, V276, P2998, DOI 10.1074/jbc.M006930200; Knetsch MLW, 1999, J BIOL CHEM, V274, P20133, DOI 10.1074/jbc.274.29.20133; Lehman W, 2001, J MOL BIOL, V307, P739, DOI 10.1006/jmbi.2001.4514; LEVINE BA, 1988, EUR J BIOCHEM, V172, P389, DOI 10.1111/j.1432-1033.1988.tb13899.x; Lian L. Y., 1993, NMR MACROMOLECULES P, P153; Luo Y, 2002, J MOL BIOL, V316, P429, DOI 10.1006/jmbi.2001.5358; MIKI M, 1987, EUR J BIOCHEM, V168, P339, DOI 10.1111/j.1432-1033.1987.tb13425.x; Milligan RA, 1996, P NATL ACAD SCI USA, V93, P21, DOI 10.1073/pnas.93.1.21; Morano I, 1997, FEBS LETT, V408, P71, DOI 10.1016/S0014-5793(97)00390-6; MORNET D, 1979, BIOCHEM BIOPH RES CO, V89, P925, DOI 10.1016/0006-291X(79)91867-9; Onishi H, 1995, P NATL ACAD SCI USA, V92, P11965, DOI 10.1073/pnas.92.26.11965; Patchell VB, 2002, EUR J BIOCHEM, V269, P5088, DOI 10.1046/j.1432-1033.2002.03227.x; Rarick HM, 1996, J BIOL CHEM, V271, P27039, DOI 10.1074/jbc.271.43.27039; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Sasaki N, 1999, J BIOL CHEM, V274, P37840, DOI 10.1074/jbc.274.53.37840; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Timson DJ, 1997, FEBS LETT, V400, P31, DOI 10.1016/S0014-5793(96)01314-2; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; Van Dijk J, 1999, BIOCHEMISTRY-US, V38, P15078, DOI 10.1021/bi991595h; Volkmann N, 2000, NAT STRUCT BIOL, V7, P1147; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; Woo A, 2003, HEART, V89, P1179, DOI 10.1136/heart.89.10.1179; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v; Yengo CM, 1999, BIOCHEMISTRY-US, V38, P14515, DOI 10.1021/bi991226l; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	39	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14469	14475		10.1074/jbc.M414202200	http://dx.doi.org/10.1074/jbc.M414202200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15695827	hybrid			2022-12-25	WOS:000228236800016
J	Murakami, M; Masuda, S; Ueda-Semmyo, K; Yoda, E; Kuwata, H; Takanezawa, Y; Aoki, J; Arai, H; Sumimoto, H; Ishikawa, Y; Ishii, T; Nakatani, Y; Kudo, I				Murakami, M; Masuda, S; Ueda-Semmyo, K; Yoda, E; Kuwata, H; Takanezawa, Y; Aoki, J; Arai, H; Sumimoto, H; Ishikawa, Y; Ishii, T; Nakatani, Y; Kudo, I			Group VIBCa2+-independent phospholipase A(2)gamma promotes cellular membrane hydrolysis and prostaglandin production in a manner distinct from other intracellular phospholipases A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; SMOOTH-MUSCLE-CELLS; KINASE-C-ALPHA; INTESTINAL POLYPOSIS; REDUCED FERTILITY; P388D(1) CELLS; KNOCKOUT MICE; E SYNTHASE-1; A(2); GENERATION	Although group VIA Ca2+-independent phospholipase A(2)beta (iPLA(2)beta) has been implicated in various cellular events, the functions of other iPLA(2) isozymes remain largely elusive. In this study, we examined the cellular functions of group VIB iPLA(2)gamma. Lentiviral transfection of iPLA(2)gamma into HEK293 cells resulted in marked increases in spontaneous, stimulus-coupled, and cell death-associated release of arachidonic acid ( AA), which was converted to prostaglandin E-2 with preferred cyclooxygenase (COX)-1 coupling. Conversely, treatment of HEK293 cells with iPLA(2)gamma small interfering RNA significantly reduced AA release, indicating the participation of endogenous iPLA(2)gamma. iPLA(2)gamma protein appeared in multiple sizes according to cell types, and a 63-kDa form was localized mainly in peroxisomes. Electrospray ionization mass spectrometry of cellular phospholipids revealed that iPLA(2)gamma and other intracellular PLA(2) enzymes acted on different phospholipid subclasses. Transfection of iPLA(2)gamma into HCA-7 cells also led to increased AA release and prostaglandin E-2 synthesis via both COX-1 and COX-2, with a concomitant increase in cell growth. Immunohistochemistry of human colorectal cancer tissues showed elevated expression of iPLA(2)gamma in adenocarcinoma cells. These results collectively suggest distinct roles for iPLA(2 beta) and iPLA(2)gamma in cellular homeostasis and signaling, a functional link between peroxisomal AA release and eicosanoid generation, and a potential contribution of iPLA(2)gamma to tumorigenesis.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo 1130033, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Biol Mol & Struct, Higashi Ku, Fukuoka 8128582, Japan; Toho Univ, Sch Med, Dept Pathol, Ohta Ku, Tokyo 1438540, Japan	Showa University; University of Tokyo; Kyushu University	Murakami, M (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	mako@pharm.showa-u.ac.jp	Kuwata, Hiro/N-2023-2019	Kuwata, Hiro/0000-0002-5023-1777; Aoki, Junken/0000-0001-9435-1896; Takanezawa, Yasukazu/0000-0002-9220-5825				Akiba S, 2002, BIOCHEM PHARMACOL, V63, P1969, DOI 10.1016/S0006-2952(02)00988-7; Akiba S, 1999, J BIOL CHEM, V274, P19906, DOI 10.1074/jbc.274.28.19906; Asai K, 2003, J BIOL CHEM, V278, P8809, DOI 10.1074/jbc.M212117200; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Balboa MA, 2003, J IMMUNOL, V170, P5276, DOI 10.4049/jimmunol.170.10.5276; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Bambai B, 2004, J BIOL CHEM, V279, P4084, DOI 10.1074/jbc.M304762200; Bao SZ, 2004, J BIOL CHEM, V279, P38194, DOI 10.1074/jbc.M406489200; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Carey MA, 2003, AM J RESP CRIT CARE, V167, P1509, DOI 10.1164/rccm.200211-1383OC; Chiba H, 2004, J BIOL CHEM, V279, P12890, DOI 10.1074/jbc.M305801200; Chulada PC, 2000, CANCER RES, V60, P4705; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Das S, 2002, J BIOL CHEM, V277, P23838, DOI 10.1074/jbc.M202322200; DOLE VP, 1960, J BIOL CHEM, V235, P2595; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Kamei D, 2003, J BIOL CHEM, V278, P19396, DOI 10.1074/jbc.M213290200; Kamei D, 2004, J BIOL CHEM, V279, P33684, DOI 10.1074/jbc.M400199200; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lio YC, 1998, BBA-LIPID LIPID MET, V1392, P320, DOI 10.1016/S0005-2760(98)00049-6; Mancuso DJ, 2003, J BIOL CHEM, V278, P22231, DOI 10.1074/jbc.C300033200; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; MASUDA S, 2004, BIOCHIM BIOPHYS ACTA, V1686, P15; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200; Murakami M, 2003, J BIOL CHEM, V278, P10657, DOI 10.1074/jbc.M211325200; Murakami M, 2003, BIOCHEM J, V372, P695, DOI 10.1042/BJ20030061; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 2002, J BIOL CHEM, V277, P19145, DOI 10.1074/jbc.M112385200; Murakami M, 2002, EUR J BIOCHEM, V269, P2698, DOI 10.1046/j.1432-1033.2002.02938.x; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Ramanadham S, 2004, BIOCHEMISTRY-US, V43, P918, DOI 10.1021/bi035536m; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; Roshak AK, 2000, J BIOL CHEM, V275, P35692, DOI 10.1074/jbc.M002273200; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Seegers HC, 2002, J PHARMACOL EXP THER, V302, P918, DOI 10.1124/jpet.302.3.918; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Shinzawa K, 2003, J CELL BIOL, V163, P1219, DOI 10.1083/jcb.200306159; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Stahelin RV, 2003, J BIOL CHEM, V278, P12452, DOI 10.1074/jbc.M212864200; Steer SA, 2002, AM J PHYSIOL-CELL PH, V283, pC1621, DOI 10.1152/ajpcell.00109.2002; Stewart A, 2002, J BIOL CHEM, V277, P29526, DOI 10.1074/jbc.M204856200; Su X, 2004, J BIOL CHEM, V279, P21740, DOI 10.1074/jbc.M314166200; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; Tanaka H, 2000, BIOCHEM BIOPH RES CO, V272, P320, DOI 10.1006/bbrc.2000.2776; Tanaka H, 2004, BIOCHEM BIOPH RES CO, V320, P1284, DOI 10.1016/j.bbrc.2004.05.225; Tanaka M, 2004, FEBS LETT, V571, P197, DOI 10.1016/j.febslet.2004.06.083; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tay HK, 2004, J BIOL CHEM, V279, P22505, DOI 10.1074/jbc.M308788200; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; van Tienhoven M, 2002, J BIOL CHEM, V277, P20942, DOI 10.1074/jbc.M200330200; Williams CS, 2000, CANCER RES, V60, P6045; Wu G, 2003, BIOCHEMISTRY-US, V42, P13772, DOI 10.1021/bi035415m; Yang JY, 2003, FEBS LETT, V546, P247, DOI 10.1016/S0014-5793(03)00581-7; Yellaturu CR, 2003, J BIOL CHEM, V278, P43831, DOI 10.1074/jbc.M301472200	77	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14028	14041		10.1074/jbc.M413766200	http://dx.doi.org/10.1074/jbc.M413766200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695510	hybrid			2022-12-25	WOS:000228095500105
J	Pascreau, G; Delcros, JG; Cremet, JY; Prigent, C; Arlot-Bonnemains, Y				Pascreau, G; Delcros, JG; Cremet, JY; Prigent, C; Arlot-Bonnemains, Y			Phosphorylation of maskin by Aurora-A participates in the control of sequential protein synthesis during Xenopus laevis oocyte maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B1 MESSENGER-RNA; CYTOPLASMIC POLYADENYLATION; MEIOTIC MATURATION; TRANSLATIONAL CONTROL; MAP KINASE; II TRANSITION; MEIOSIS-II; CELL-CYCLE; D-TACC; MOS	At the end of oogenesis, Xenopus laevis stage VI oocytes are arrested at the G(2)/M transition (prophase) waiting for progesterone to release the block and begin maturation. Progesterone triggers a cascade of phosphorylation events such as a decrease of pK(a) and an increase of maturating-promoting factor activity. Progression through meiosis was controlled by the sequential synthesis of several proteins. For instance, the MAPK kinase kinase c-Mos is the very first protein to be produced, whereas cyclin B1 appears only after meiosis I. After the meiotic cycles, the oocyte arrests at metaphase of meiosis II with an elevated c-Mos kinase activity (cytostatic factor). By using a two-hybrid screen, we have identified maskin, a protein involved in the control of mRNA sequential translation, as a binding partner of Aurora-A, a protein kinase necessary for oocyte maturation. Here we showed that, in vitro, Aurora-A directly binds to maskin and that both proteins can be co-immunoprecipitated from oocyte extracts, suggesting that they do associate in vivo. We also demonstrated that Aurora-A phosphorylates maskin on a Ser residue conserved in transforming acidic coiled coil proteins from Drosophila to human. When the phosphorylation of this Ser was inhibited in vivo by microinjection of synthetic peptides that mimic the maskin-phosphorylated sequence, we observed a premature maturation. Under these conditions, proteins such as cyclin B1 and Cdc6, which are normally detected only in meiosis II, were massively produced in meiosis I before the occurrence of the nuclear envelope breakdown. This result strongly suggests that phosphorylation of maskin by Aurora-A prevents meiosis II proteins from being produced during meiosis I.	Univ Rennes 1, CNRS, UMR Genet & Dev 6061, Grp Cycle Cellulaire,IFR97 Genom Fonct,Fac Med, 2 Av Pr Leon Bernard, F-35043 Rennes, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Arlot-Bonnemains, Y (corresponding author), Univ Rennes 1, CNRS, UMR Genet & Dev 6061, Grp Cycle Cellulaire,IFR97 Genom Fonct,Fac Med, 2 Av Pr Leon Bernard, F-35043 Rennes, France.	yannick.arlot-bonnemains@univ-rennes1.fr	delcros, jean-guy/N-5813-2017	delcros, jean-guy/0000-0002-9593-4046; Pascreau, Gaetan/0000-0002-1654-4032				Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Barkoff A, 1998, EMBO J, V17, P3168, DOI 10.1093/emboj/17.11.3168; Barkoff AF, 2000, DEV BIOL, V220, P97, DOI 10.1006/dbio.2000.9613; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Cao QP, 2002, EMBO J, V21, P3852, DOI 10.1093/emboj/cdf353; Castro A, 2003, J BIOL CHEM, V278, P2236, DOI 10.1074/jbc.M207894200; Charlesworth A, 2002, EMBO J, V21, P2798, DOI 10.1093/emboj/21.11.2798; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Chen RH, 1997, METHOD ENZYMOL, V283, P572; de Moor CH, 1999, EMBO J, V18, P2294, DOI 10.1093/emboj/18.8.2294; deMoor CH, 1997, MOL CELL BIOL, V17, P6419, DOI 10.1128/MCB.17.11.6419; Dupre A, 2002, EMBO J, V21, P4026, DOI 10.1093/emboj/cdf400; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; Frank-Vaillant M, 2000, J CELL SCI, V113, P1127; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; Hake LE, 1997, BBA-REV CANCER, V1332, pM31, DOI 10.1016/S0304-419X(96)00039-X; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hochegger H, 2001, DEVELOPMENT, V128, P3795; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lemaitre JM, 2002, NATURE, V419, P718, DOI 10.1038/nature01046; Ma CQ, 2003, MOL CELL BIOL, V23, P1703, DOI 10.1128/MCB.23.5.1703-1716.2003; Macdonald PM, 1996, CURR OPIN GENET DEV, V6, P403, DOI 10.1016/S0959-437X(96)80060-8; Maton G, 2003, J BIOL CHEM, V278, P21439, DOI 10.1074/jbc.M300811200; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; MERRIAM RW, 1971, EXP CELL RES, V68, P75, DOI 10.1016/0014-4827(71)90588-X; Nakajo N, 2000, GENE DEV, V14, P328; Osborne H B, 1997, Prog Mol Subcell Biol, V18, P173; PAYNTON BV, 1994, MOL REPROD DEV, V37, P172, DOI 10.1002/mrd.1080370208; Peter M, 2002, DEVELOPMENT, V129, P2129; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Roghi C, 1998, J CELL SCI, V111, P557; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Scrittori L, 2001, J BIOL CHEM, V276, P30002, DOI 10.1074/jbc.M102701200; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; Tian JD, 1997, P NATL ACAD SCI USA, V94, P10729, DOI 10.1073/pnas.94.20.10729; Whitmire E, 2002, NATURE, V419, P722, DOI 10.1038/nature01032	52	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13415	13423		10.1074/jbc.M410584200	http://dx.doi.org/10.1074/jbc.M410584200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15687499	hybrid			2022-12-25	WOS:000228095500029
J	Spender, LC; Whiteman, HJ; Karstegl, CE; Farrell, PJ				Spender, LC; Whiteman, HJ; Karstegl, CE; Farrell, PJ			Transcriptional cross-regulation of RUNX1 by RUNX3 in human B cells	ONCOGENE			English	Article						RUNX3/ RUNX1/EBNA-2; Epstein-Barr virus; B cells	EPSTEIN-BARR-VIRUS; ACUTE MYELOID-LEUKEMIA; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; VIRAL NUCLEAR ANTIGEN-2; ACTIVATED NOTCH1; GENE-EXPRESSION; FAMILY-MEMBERS; GASTRIC-CANCER; AML1; REPRESSION	RUNX transcription factors are important in development and in numerous types of human cancer. They act as either transcriptional activators or repressors and can be proto-oncogenes or tumour suppressors. Understanding their regulation and interaction may explain how RUNX factors contribute to such different and often opposing biological processes. We show that RUNX3 regulates RUNX1 expression, contributing to the mutually exclusive expression of RUNX3 and RUNX1 in human B lymphoid cell lines. RUNX3 repressed the RUNX1 P1 promoter by binding specifically to conserved RUNX sites near the transcription start of the promoter. siRNA inhibition of RUNX3 in lymphoblastoid cells resulted in increased RUNX1 expression, indicating that continuous expression of physiological levels of RUNX3 is required to maintain repression. Furthermore, expression of RUNX3 was required for efficient proliferation of B cells immortalized by Epstein-Barr virus. Cross-regulation between different RUNX family members is therefore a means of controlling RUNX protein expression and must now be considered in the interpretation of pathological changes due to loss of RUNX3 tumour suppressor function or following gene duplication or translocation events.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research	Farrell, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.	p.farrell@imperial.ac.uk		Farrell, Paul/0000-0002-6754-9351; Whiteman, Hannah/0000-0001-6275-6135				Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; Bernardin F, 2002, CANCER BIOL THER, V1, P492, DOI 10.4161/cbt.1.5.163; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Hofelmayr H, 1999, J VIROL, V73, P2770; Hofelmayr H, 2001, J VIROL, V75, P2033, DOI 10.1128/JVI.75.5.2033-2040.2001; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Javed A, 2000, J CELL SCI, V113, P2221; Kato N, 2003, AM J PATHOL, V163, P387, DOI 10.1016/S0002-9440(10)63668-1; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Lebestky T, 2003, GENE DEV, V17, P348, DOI 10.1101/gad.1052803; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; Martensson A, 2001, EUR J IMMUNOL, V31, P3165, DOI 10.1002/1521-4141(200111)31:11<3165::AID-IMMU3165>3.0.CO;2-N; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Rini D, 2001, GENE, V273, P13, DOI 10.1016/S0378-1119(01)00579-0; Shi MJ, 1998, J IMMUNOL, V161, P6751; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; Spender LC, 2002, J VIROL, V76, P4919, DOI 10.1128/JVI.76.10.4919-4927.2002; Strobl LJ, 2000, J VIROL, V74, P1727, DOI 10.1128/JVI.74.4.1727-1735.2000; Strobl LJ, 1997, IMMUNOBIOLOGY, V198, P299, DOI 10.1016/S0171-2985(97)80050-2; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Wada M, 2004, ONCOGENE, V23, P2401, DOI 10.1038/sj.onc.1207395; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Wotton S, 2002, CANCER RES, V62, P7181; Xiao WH, 2004, WORLD J GASTROENTERO, V10, P376; Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200	49	74	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1873	1881		10.1038/sj.onc.1208404	http://dx.doi.org/10.1038/sj.onc.1208404			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688019				2022-12-25	WOS:000227542000006
J	Atherton, PJ; Babraj, JA; Smith, K; Singh, J; Rennie, MJ; Wackerhage, H				Atherton, PJ; Babraj, JA; Smith, K; Singh, J; Rennie, MJ; Wackerhage, H			Selective activation of AMPK-PGC-1 alpha or PKB-TSC2-mTOR signaling can explain specific adaptive responses to endurance or resistance training-like electrical muscle stimulation	FASEB JOURNAL			English	Article						PKB(Akt); signal transduction; skeletal muscle	PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; SKELETAL-MUSCLE; MAMMALIAN TARGET; MITOCHONDRIAL BIOGENESIS; ELONGATION-FACTOR-2 KINASE; EXERCISE; PHOSPHORYLATION; RAPAMYCIN; TRANSCRIPTION	Endurance training induces a partial fast-to-slow muscle phenotype transformation and mitochondrial biogenesis but no growth. In contrast, resistance training mainly stimulates muscle protein synthesis resulting in hypertrophy. The aim of this study was to identify signaling events that may mediate the specific adaptations to these types of exercise. Isolated rat muscles were electrically stimulated with either high frequency (HFS; 6x10 repetitions of 3 s-bursts at 100 Hz to mimic resistance training) or low frequency (LFS; 3 h at 10 Hz to mimic endurance training). HFS significantly increased myofibrillar and sarcoplasmic protein synthesis 3 h after stimulation 5.3- and 2.7-fold, respectively. LFS had no significant effect on protein synthesis 3 h after stimulation but increased UCP3 mRNA 11.7-fold, whereas HFS had no significant effect on UCP3 mRNA. Only LFS increased AMPK phosphorylation significantly at Thr172 by approximate to 2-fold and increased PGC-1 alpha protein to 1.3 times of control. LFS had no effect on PKB phosphorylation but reduced TSC2 phosphorylation at Thr1462 and deactivated translational regulators. In contrast, HFS acutely increased phosphorylation of PKB at Ser473 5.3-fold and the phosphorylation of TSC2, mTOR, GSK-3 beta at PKB-sensitive sites. HFS also caused a prolonged activation of the translational regulators p70 S6k, 4E-BP1, eIF-2B, and eEF2. These data suggest that a specific signaling response to LFS is a specific activation of the AMPK-PGC-1 alpha signaling pathway which may explain some endurance training adaptations. HFS selectively activates the PKB-TSC2-mTOR cascade causing a prolonged activation of translational regulators, which is consistent with increased protein synthesis and muscle growth. We term this behavior the "AMPK-PKB switch." We hypothesize that the AMPK-PKB switch is a mechanism that partially mediates specific adaptations to endurance and resistance training, respectively.	Univ Cent Lancashire, Dept Biol Sci, Preston PR1 2HE, Lancs, England; Univ Dundee, Sch Life Sci, Dundee, Scotland; Univ Nottingham, Clin Physiol Lab, Nottingham, England	University of Central Lancashire; University of Dundee; University of Nottingham	Singh, J (corresponding author), Univ Cent Lancashire, Dept Biol Sci, Preston PR1 2HE, Lancs, England.	jsingh3@uclan.ac.uk	Rennie, Michael J/B-1762-2008	Babraj, John/0000-0002-7427-7841; Smith, Ken/0000-0001-8971-6635	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049869] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 49869] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Baar K, 1999, AM J PHYSIOL-CELL PH, V276, pC120, DOI 10.1152/ajpcell.1999.276.1.C120; Baar Keith, 2000, Molecular Cell Biology Research Communications, V4, P76, DOI 10.1006/mcbr.2000.0257; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Bolster DR, 2003, J PHYSIOL-LONDON, V553, P213, DOI 10.1113/jphysiol.2003.047019; BONEN A, 1994, AM J PHYSIOL, V266, pE1, DOI 10.1152/ajpendo.1994.266.1.E1; Browne GJ, 2004, J BIOL CHEM, V279, P12220, DOI 10.1074/jbc.M309773200; CHENG SW, 2004, IN PRESS J BOIL CHEM; Cheng SWY, 2004, J BIOL CHEM, V279, P15719, DOI 10.1074/jbc.C300534200; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dubbelhuis PF, 2002, FEBS LETT, V521, P39, DOI 10.1016/S0014-5793(02)02815-6; Garlick PJ, 1997, BAILLIERE CLIN ENDOC, V11, P629, DOI 10.1016/S0950-351X(97)80910-X; Gautsch TA, 1998, AM J PHYSIOL-CELL PH, V274, pC406, DOI 10.1152/ajpcell.1998.274.2.C406; Hernandez JM, 2000, J APPL PHYSIOL, V88, P1142, DOI 10.1152/jappl.2000.88.3.1142; Higginson J, 2002, PFLUG ARCH EUR J PHY, V445, P437, DOI 10.1007/s00424-002-0939-1; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Hudson ER, 2003, CURR BIOL, V13, P861, DOI 10.1016/S0960-9822(03)00249-5; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kubukeli ZN, 2002, SPORTS MED, V32, P489, DOI 10.2165/00007256-200232080-00002; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Martineau LC, 2001, J APPL PHYSIOL, V91, P693, DOI 10.1152/jappl.2001.91.2.693; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; MILLER RG, 1987, MUSCLE NERVE, V10, P810, DOI 10.1002/mus.880100906; Murgia M, 2000, NAT CELL BIOL, V2, P142, DOI 10.1038/35004013; Nader GA, 2001, J APPL PHYSIOL, V90, P1936, DOI 10.1152/jappl.2001.90.5.1936; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; Proud CG, 2003, CURR TOP MICROBIOL, V279, P215; Rennie MJ, 2004, ANNU REV PHYSIOL, V66, P799, DOI 10.1146/annurev.physiol.66.052102.134444; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Saitoh M, 2002, J BIOL CHEM, V277, P20104, DOI 10.1074/jbc.M201745200; Sakamoto K, 2003, AM J PHYSIOL-ENDOC M, V285, pE1081, DOI 10.1152/ajpendo.00228.2003; SAKAMOTO K, 2004, IN PRESS AM J PHYSIO; SALMONS S, 1981, MUSCLE NERVE, V4, P94, DOI 10.1002/mus.880040204; SCHWENK WF, 1984, ANAL BIOCHEM, V141, P101; Stoppani J, 2002, AM J PHYSIOL-ENDOC M, V283, pE1239, DOI 10.1152/ajpendo.00278.2002; Taylor PM, 1996, J EXP BIOL, V199, P923; Terada S, 2002, BIOCHEM BIOPH RES CO, V296, P350, DOI 10.1016/S0006-291X(02)00881-1; Tipton KD, 2001, INT J SPORT NUTR EXE, V11, P109, DOI 10.1123/ijsnem.11.1.109; VANDENBURGH H, 1979, SCIENCE, V203, P265, DOI 10.1126/science.569901; Vyas DR, 2002, AM J PHYSIOL-CELL PH, V283, pC545, DOI 10.1152/ajpcell.00049.2002; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Williamson DL, 2001, J APPL PHYSIOL, V91, P1955, DOI 10.1152/jappl.2001.91.5.1955; Wojtaszewski JFP, 2003, AM J PHYSIOL-ENDOC M, V284, pE813, DOI 10.1152/ajpendo.00436.2002; Wretman C, 2001, J PHYSIOL-LONDON, V535, P155, DOI 10.1111/j.1469-7793.2001.00155.x; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yang SY, 1996, J MUSCLE RES CELL M, V17, P487, DOI 10.1007/BF00123364; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	60	336	361	0	47	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					786	+		10.1096/fj.04-2179fje	http://dx.doi.org/10.1096/fj.04-2179fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15716393				2022-12-25	WOS:000227591900026
J	Wang, Q; Downey, GP; Abreu, M; Bajenova, E; Kapus, A; McCulloch, CA				Wang, Q; Downey, GP; Abreu, M; Bajenova, E; Kapus, A; McCulloch, CA			Mitochondrial function is a critical determinant of IL-1-induced ERK activation	FASEB JOURNAL			English	Article						Ca2+ signals; gingival fibroblasts; mitochondria	OPERATED CA2+ ENTRY; NF-KAPPA-B; GENE-EXPRESSION; ENDOPLASMIC-RETICULUM; CALCIUM; STORE; RECEPTOR; KINASE; INTERLEUKIN-1-BETA; FIBROBLASTS	Interleukin-1 (IL-1) is a potent, proinflammatory cytokine, but local environmental factors in inflamed sites or in sepsis may affect cell metabolism and energetics, including the amplitude and duration of IL-1-induced signals, thereby leading to loss of tissue homeostasis. Currently, the mechanisms by which disruption of cell energetics affects inflammatory signaling are incompletely understood. Here, we examined the impact of cell energetics and mitochondrial function on the regulation of IL-1-induced Ca2+ signals and ERK activation in human gingival fibroblasts, cells that are important targets for IL-1-induced destruction of extracellular matrix in inflamed connective tissues. In untreated cells, IL-1 induced a prolonged increase of free intracellular calcium, which was required for ERK activation. Inhibition of cellular energetics by selective depolarization of mitochondria blocked Ca2+ uptake and almost completely abolished IL-1-induced cytosolic Ca2+ signals and ERK activation. IL-1 caused rapid Ca2+ release from the endoplasmic reticulum ( ER), concomitant with mitochondrial Ca2+ uptake from ER and non-ER stores. Disruption of mitochondrial energetics abrogated IL-1 induced Ca2+ release from the ER but left other vital cellular functions intact. The negative effect of mitochondrial depolarization on ER release was bypassed by BAPTA/AM, indicating that mitochondrial Ca2+ buffering is the key mechanism in regulating ER release. Thus, in gingival fibroblasts, mitochondrial Ca2+ uptake is essential not only for shaping the kinetics and duration, but also the generation of, IL-1-induced Ca2+ signals. Consequently, mitochondria regulate key downstream effectors of IL-1, including MAP kinases.	Univ Toronto, CIHR Grp Matrix Dynam, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Med, Div Respirol, Toronto, ON, Canada; Univ Hlth Network Res Inst, Toronto Gen Div, Res Inst, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Toronto Gen Hosp, Div Surg, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	McCulloch, CA (corresponding author), Univ Toronto, CIHR Grp Matrix Dynam, Room 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	christopher.mcculloch@utoronto.ca		Downey, Gregory P/0000-0003-3253-5862				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARORA PD, 1995, J BIOL CHEM, V270, P6042, DOI 10.1074/jbc.270.11.6042; Arora PD, 2001, J BIOL CHEM, V276, P14100, DOI 10.1074/jbc.M010298200; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bhat-Nakshatri P, 1998, P NATL ACAD SCI USA, V95, P6971, DOI 10.1073/pnas.95.12.6971; Boyle DL, 1997, ARTHRITIS RHEUM, V40, P1772, DOI 10.1002/art.1780401008; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Brealey David, 2003, Curr Infect Dis Rep, V5, P365, DOI 10.1007/s11908-003-0015-9; Camello C, 2002, CELL CALCIUM, V32, P355, DOI 10.1016/S0143416002001926; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Gilabert JA, 2001, EMBO J, V20, P2672, DOI 10.1093/emboj/20.11.2672; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; Hajnoczky G, 2000, J PHYSIOL-LONDON, V529, P69, DOI 10.1111/j.1469-7793.2000.00069.x; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hardingham GE, 1998, CELL CALCIUM, V23, P131, DOI 10.1016/S0143-4160(98)90111-7; HONIG J, 1989, J PERIODONTAL RES, V24, P362, DOI 10.1111/j.1600-0765.1989.tb00883.x; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Lo YYC, 1998, J BIOL CHEM, V273, P7059, DOI 10.1074/jbc.273.12.7059; Lomax RB, 2002, J BIOL CHEM, V277, P26479, DOI 10.1074/jbc.M201845200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Mogensen TH, 2003, J IMMUNOL, V170, P6224, DOI 10.4049/jimmunol.170.12.6224; O'Neill LAJ, 2000, IMMUNOL TODAY, V21, P206, DOI 10.1016/S0167-5699(00)01611-X; Parekh AB, 2003, J PHYSIOL-LONDON, V547, P333, DOI 10.1113/jphysiol.2002.034140; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Putney JW, 2001, J CELL SCI, V114, P2223; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; RICHARDS D, 1988, ARCH ORAL BIOL, V33, P237, DOI 10.1016/0003-9969(88)90184-7; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rosado JA, 2000, TRENDS CARDIOVAS MED, V10, P327, DOI 10.1016/S1050-1738(01)00073-1; Szabadkai G, 2003, J BIOL CHEM, V278, P15153, DOI 10.1074/jbc.M300180200; Trollinger DR, 2000, BIOPHYS J, V79, P39, DOI 10.1016/S0006-3495(00)76272-2; van den Berg WB, 1999, Z RHEUMATOL, V58, P136, DOI 10.1007/s003930050163; Wang Q, 2003, FASEB J, V17, pA1072	40	12	12	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					837	+		10.1096/fj.04-2657fje	http://dx.doi.org/10.1096/fj.04-2657fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15728661				2022-12-25	WOS:000227591900008
J	Mathieu, M; Debousker, G; Vincent, S; Viviani, F; Bamas-Jacques, N; Mikol, V				Mathieu, M; Debousker, G; Vincent, S; Viviani, F; Bamas-Jacques, N; Mikol, V			Escherichia coli FolC structure reveals an unexpected dihydrofolate binding site providing an attractive target for anti-microbial therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMATE SYNTHETASE; FOLYLPOLYGLUTAMATE SYNTHETASE; CRYSTAL-STRUCTURE; BIOSYNTHESIS; REPLACEMENT; CLONING; LIGASE; MURD; GENE	In some bacteria, such as Escherichia coli, the addition of L-glutamate to dihydropteroate ( dihydrofolate synthetase activity) and the subsequent additions of L-glutamate to tetrahydrofolate ( folylpolyglutamate synthetase (FPGS) activity) are catalyzed by the same enzyme, FolC. The crystal structure of E. coli FolC is described in this paper. It showed strong similarities to that of the FPGS enzyme of Lactobacillus casei within the ATP binding site and the catalytic site, as do all other members of the Mur synthethase superfamily. FolC structure revealed an unexpected dihydropteroate binding site very different from the folate site identified previously in the FPGS structure. The relevance of this site is exemplified by the presence of phosphorylated dihydropteroate, a reaction intermediate in the DHFS reaction. L. casei FPGS is considered a relevant model for human FPGS. As such, the presence of a folate binding site in E. coli FolC, which is different from the one seen in FPGS enzymes, provides avenues for the design of specific inhibitors of this enzyme in antimicrobial therapy.	Aventis Pharma, Dept Biol Struct, F-94403 Vitry Sur Seine, France	Sanofi-Aventis; Sanofi France	Mathieu, M (corresponding author), Aventis Pharma, Dept Biol Struct, 13 Quai J Guesde, F-94403 Vitry Sur Seine, France.	magali.mathieu@sanofi-aventis.com						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bertrand JA, 2000, J MOL BIOL, V301, P1257, DOI 10.1006/jmbi.2000.3994; Bertrand JA, 1997, EMBO J, V16, P3416, DOI 10.1093/emboj/16.12.3416; BOGNAR AL, 1985, J BIOL CHEM, V260, P5625; Bricogne G, 1997, METHOD ENZYMOL, V276, P361, DOI 10.1016/S0076-6879(97)76069-5; BRICOGNE G, 1993, ACTA CRYSTALLOGR D, V49, P37, DOI 10.1107/S0907444992010400; Burger A, 1998, FEMS MICROBIOL LETT, V159, P283, DOI 10.1016/S0378-1097(97)00540-5; Cherest H, 2000, J BIOL CHEM, V275, P14056, DOI 10.1074/jbc.275.19.14056; Costi MP, 2001, CURR DRUG TARGETS, V2, P135, DOI 10.2174/1389450013348669; Dementin S, 2001, EUR J BIOCHEM, V268, P5800, DOI 10.1046/j.0014-2956.2001.02524.x; Fussenegger M, 1996, MOL GEN GENET, V250, P277; Gordon E, 2001, J BIOL CHEM, V276, P10999, DOI 10.1074/jbc.M009835200; KESHAVJEE K, 1991, J BIOL CHEM, V266, P19925; Moran RG, 1999, SEMIN ONCOL, V26, P24; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; PYNE C, 1992, J BACTERIOL, V174, P1750, DOI 10.1128/jb.174.6.1750-1759.1992; Ravanel S, 2001, P NATL ACAD SCI USA, V98, P15360, DOI 10.1073/pnas.261585098; Rosowsky A, 1999, J MED CHEM, V42, P3510, DOI 10.1021/jm9807205; Roversi P, 2000, ACTA CRYSTALLOGR D, V56, P1316, DOI 10.1107/S0907444900008490; SHANE B, 1980, J BIOL CHEM, V255, P5663; Sun XL, 1998, P NATL ACAD SCI USA, V95, P6647, DOI 10.1073/pnas.95.12.6647; Sun XL, 2001, J MOL BIOL, V310, P1067, DOI 10.1006/jmbi.2001.4815	22	39	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18916	18922		10.1074/jbc.M413799200	http://dx.doi.org/10.1074/jbc.M413799200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15705579	hybrid			2022-12-25	WOS:000228932300044
J	Changela, A; Martins, A; Shuman, S; Mondragon, A				Changela, A; Martins, A; Shuman, S; Mondragon, A			Crystal structure of baculovirus RNA triphosphatase complexed with phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPPING ENZYME LEF4; MUTATIONAL ANALYSIS; TUMOR-SUPPRESSOR; DIFFRACTION DATA; ACTIVE-SITE; PROTEIN; 5'-TRIPHOSPHATASE; POLYMERASE; MECHANISM; PROGRAM	Baculovirus RNA 5'-triphosphatase (BVP) exemplifies a family of RNA-specific cysteine phosphatases that includes the RNA triphosphatase domains of metazoan and plant mRNA capping enzymes. Here we report the crystal structure of BVP in a phosphate-bound state at 1.5 angstrom resolution. BVP adopts the characteristic cysteine-phosphatase alpha/beta fold and binds two phosphate ions in the active site region, one of which is proposed to mimic the phosphate of the product complex after hydrolysis of the covalent phosphoenzyme intermediate. The crystal structure highlights the role of backbone amides and side chains of the P-loop motif (118)HCTHGXNRT(126) in binding the cleavable phosphate and stabilizing the transition state. Comparison of the BVP structure to the apoenzyme of mammalian RNA triphosphatase reveals a concerted movement of the Arg-125 side chain ( to engage the phosphate directly) and closure of an associated surface loop over the phosphate in the active site. The structure highlights a direct catalytic role of Asn-124, which is the signature P-loop residue of the RNA triphosphatase family and a likely determinant of the specificity of BVP for hydrolysis of phosphoanhydride linkages.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Northwestern University; Memorial Sloan Kettering Cancer Center	Mondragon, A (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2205 Tech Dr, Evanston, IL 60208 USA.	a-mondragon@northwestern.edu	Martins, Alexandra/J-9592-2013	Martins, Alexandra/0000-0003-4322-8497	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498, R01GM051350] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM051350, GM42498, GM51350] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Deshpande T, 1999, J BIOL CHEM, V274, P16590, DOI 10.1074/jbc.274.23.16590; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Gong CL, 2003, VIROLOGY, V309, P125, DOI 10.1016/S0042-6822(03)00002-3; Gray CH, 2003, EMBO J, V22, P3524, DOI 10.1093/emboj/cdg348; Gross CH, 1998, J VIROL, V72, P7057, DOI 10.1128/JVI.72.9.7057-7063.1998; Guarino LA, 1998, J VIROL, V72, P7985, DOI 10.1128/JVI.72.10.7985-7991.1998; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; LI YH, 1995, J VIROL, V69, P4533, DOI 10.1128/JVI.69.7.4533-4537.1995; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Martins A, 2003, NUCLEIC ACIDS RES, V31, P1455, DOI 10.1093/nar/gkg244; Martins A, 2002, VIROLOGY, V304, P167, DOI 10.1006/viro.2002.1606; Martins A, 2002, BIOCHEMISTRY-US, V41, P13403, DOI 10.1021/bi0265426; Martins A, 2001, J BIOL CHEM, V276, P45522, DOI 10.1074/jbc.M107615200; Martins A, 2000, J BIOL CHEM, V275, P35070, DOI 10.1074/jbc.M005748200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; Shuman S, 2001, COLD SPRING HARB SYM, V66, P301, DOI 10.1101/sqb.2001.66.301; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8; Takagi T, 1998, P NATL ACAD SCI USA, V95, P9808, DOI 10.1073/pnas.95.17.9808; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328	37	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17848	17856		10.1074/jbc.M500885200	http://dx.doi.org/10.1074/jbc.M500885200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15713658	hybrid			2022-12-25	WOS:000228807200037
J	Ling, M; Troller, U; Zeidman, R; Stensman, H; Schultz, A; Larsson, C				Ling, M; Troller, U; Zeidman, R; Stensman, H; Schultz, A; Larsson, C			Identification of conserved amino acids N-terminal of the PKC epsilon C1b domain crucial for protein kinase C epsilon-mediated induction of neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTORS; NERVE GROWTH-FACTOR; PKC-EPSILON; REGULATORY DOMAINS; CATALYTIC DOMAIN; PHOSPHOLIPASE-D; BINDING DOMAIN; DELTA; NEUROBLASTOMA; GOLGI	We have shown previously that protein kinase C (PKC) epsilon can induce neurite outgrowth independently of its catalytic activity via a region encompassing its C1 domains. In this study we aimed at identifying specific amino acids in this region crucial for induction of neurite outgrowth. Deletion studies demonstrated that only 4 amino acids N-terminal and 20 residues C-terminal of the C1 domains are necessary for neurite induction. The corresponding regions from all other novel isoforms but not from PKC alpha were also neuritogenic. Further mutation studies indicated that amino acids immediately N-terminal of the C1a domain are important for plasma membrane localization and thereby for neurite induction. Addition of phorbol ester made this construct neurite-inducing. However, mutation of amino acids flanking the C1b domain reduced the neurite-inducing capacity even in the presence of phorbol esters. Sequence alignment highlighted an 8-amino acid-long sequence N-terminal of the C1b domain that is conserved in all novel PKC isoforms. Specifically, we found that mutations of either Phe-237, Val-239, or Met-241 in PKC epsilon completely abolished the neurite-inducing capacity of PKC epsilon C1 domains. Phorbol ester treatment could not restore neurite induction but led to a plasma membrane translocation. Furthermore, if 12 amino acids were included N-terminal of the C1b domain, the C1a domain was dispensable for neurite induction. In conclusion, we have identified a highly conserved sequence N-terminal of the C1b domain that is crucial for neurite induction by PKC epsilon, indicating that this motif may be critical for some morphological effects of PKC.	Lund Univ, Malmo Univ Hosp, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Larsson, C (corresponding author), Lund Univ, UMAS, Entrance 78,3rd Floor, SE-20502 Malmo, Sweden.	Christer.Larsson@molmed.mas.lu.se						Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; Caloca MJ, 2001, J BIOL CHEM, V276, P18303, DOI 10.1074/jbc.M011368200; Chen D, 2004, J BIOL CHEM, V279, P4829, DOI 10.1074/jbc.M311196200; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; Goerke A, 2002, J BIOL CHEM, V277, P32054, DOI 10.1074/jbc.M203734200; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Hernandez RM, 2001, J CELL BIOCHEM, V83, P532, DOI 10.1002/jcb.1246; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; HUNDLE B, 1995, J BIOL CHEM, V270, P30134; Hurley JH, 1997, PROTEIN SCI, V6, P477; Johannes FJ, 1999, FEBS LETT, V461, P68, DOI 10.1016/S0014-5793(99)01424-6; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; Kiss Z, 1999, ARCH BIOCHEM BIOPHYS, V363, P121, DOI 10.1006/abbi.1998.1066; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; Ling M, 2004, EXP CELL RES, V292, P135, DOI 10.1016/j.yexcr.2003.08.013; Ma BY, 2003, P NATL ACAD SCI USA, V100, P5772, DOI 10.1073/pnas.1030237100; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; Mikule K, 2003, J BIOL CHEM, V278, P21168, DOI 10.1074/jbc.M211828200; Oka M, 2003, FEBS LETT, V554, P179, DOI 10.1016/S0014-5793(03)01158-X; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Raghunath A, 2003, BIOCHEM J, V370, P901, DOI 10.1042/BJ20021420; Rosdahl JA, 2002, MOL CELL NEUROSCI, V19, P292, DOI 10.1006/mcne.2001.1071; Schultz A, 2004, J BIOL CHEM, V279, P31750, DOI 10.1074/jbc.M313017200; Schultz A, 2004, J NEUROCHEM, V89, P1427, DOI 10.1111/j.1471-4159.2004.02431.x; Schultz A, 2003, CELL DEATH DIFFER, V10, P662, DOI 10.1038/sj.cdd.4401235; Singer WD, 1996, J BIOL CHEM, V271, P4504; Troller U, 2004, CELL SIGNAL, V16, P245, DOI 10.1016/S0898-6568(03)00135-9; Wang HB, 2002, J BIOL CHEM, V277, P4541, DOI 10.1074/jbc.M107150200; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Zeidman R, 1999, J CELL BIOL, V145, P713, DOI 10.1083/jcb.145.4.713; Zeidman R, 2002, MOL BIOL CELL, V13, P12, DOI 10.1091/mbc.01-04-0210; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	37	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17910	17919		10.1074/jbc.M412036200	http://dx.doi.org/10.1074/jbc.M412036200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15718244	hybrid			2022-12-25	WOS:000228807200044
J	Marshall, CB; Chakrabartty, A; Davies, PL				Marshall, CB; Chakrabartty, A; Davies, PL			Hyperactive antifreeze protein from winter flounder is a very long rod-like dimer of alpha-helices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM ELLIPTICITIES; ICE CRYSTAL MORPHOLOGY; SMELT OSMERUS-MORDAX; I ANTIFREEZE; FREEZING RESISTANCE; THERMAL HYSTERESIS; COILED-COILS; BINDING; ADSORPTION; PEPTIDES	The winter flounder ( Pseudopleuronectes americanus) produces short, monomeric alpha-helical antifreeze proteins ( type I AFP), which adsorb to and inhibit the growth of ice crystals. These proteins alone are not sufficiently active to protect this fish against freezing at -1.9 degrees C, the freezing point of seawater. We have recently isolated a hyperactive antifreeze protein from the plasma of the flounder with activity 10 - 100-fold higher than type I AFP. It is comparable in activity to the AFPs produced by insects, and is capable of conferring freeze resistance to the flounder. This novel AFP has a molecular mass of 16,683 Da and a remarkable amino acid composition that is > 60% alanine. CD spectra indicate that the protein is almost entirely alpha-helical at 4 degrees C but partially denatures at 20 degrees C, resulting in a species with a moderately reduced helix content that is stable at up to 50 degrees C. This transformation correlates with irreversible loss of activity. Analytical ultracentrifugation ( sedimentation velocity and equilibrium) indicates that the predominant species in solution is dimeric ( molecular weight, 32,275). Size-exclusion chromatography reveals a 2-fold higher apparent molecular weight suggesting that this molecule has an unusually large Stokes radius. The axial ratio of the dimer calculated from the sedimentation velocity data is 18: 1, confirming that this protein has an extraordinarily long, rod-like structure, consistent with a novel dimeric alpha-helical arrangement. The structural model that best fits these data is one in which the similar to 195 amino acids of each monomer form one similar to 290-angstrom long alpha-helix and associate via a unique dimerization motif that is distinct from that of the leucine zipper and any other coiled-coil.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	Queens University - Canada; University of Toronto	Davies, PL (corresponding author), Queens Univ, Dept Biochem, Botterell Hall, Kingston, ON K7L 3N6, Canada.	daviesp@post.queensu.ca	Marshall, Christopher/K-8943-2019	Marshall, Christopher/0000-0002-7571-5700; Chakrabartty, Avi/0000-0001-7002-8381				Achenbach JC, 2002, EUR J BIOCHEM, V269, P1219, DOI 10.1046/j.1432-1033.2002.02761.x; Baardsnes J, 1999, FEBS LETT, V463, P87, DOI 10.1016/S0014-5793(99)01588-4; Baardsnes J, 2003, J BIOL CHEM, V278, P38942, DOI 10.1074/jbc.M306776200; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BURCHAM TS, 1984, BIOPOLYMERS, V23, P1379, DOI 10.1002/bip.360230720; CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; Chao H, 1996, PROTEIN SCI, V5, P1150; Chao HM, 1997, BIOCHEMISTRY-US, V36, P14652, DOI 10.1021/bi970817d; COOPER TM, 1990, BIOPOLYMERS, V30, P657, DOI 10.1002/bip.360300703; Davies PL, 2002, PHILOS T R SOC B, V357, P927, DOI 10.1098/rstb.2002.1081; DAVIES PL, 1992, GENE, V112, P171, DOI 10.1016/0378-1119(92)90373-W; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DeLuca CI, 1998, BIOPHYS J, V74, P1502, DOI 10.1016/S0006-3495(98)77862-2; DEVRIES AL, 1977, BIOCHIM BIOPHYS ACTA, V495, P388, DOI 10.1016/0005-2795(77)90395-6; DUMAN JG, 1974, NATURE, V247, P237, DOI 10.1038/247237a0; Evans RP, 2001, BBA-PROTEIN STRUCT M, V1547, P235, DOI 10.1016/S0167-4838(01)00190-X; EWART KV, 1990, CAN J ZOOL, V68, P1652, DOI 10.1139/z90-245; FEENEY RE, 1986, ANNU REV BIOPHYS BIO, V15, P59; Fletcher GL, 2001, ANNU REV PHYSIOL, V63, P359, DOI 10.1146/annurev.physiol.63.1.359; Graham LA, 1997, NATURE, V388, P727, DOI 10.1038/41908; Gronwald W, 1996, BIOCHEMISTRY-US, V35, P16698, DOI 10.1021/bi961934w; Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462; Houston ME, 1998, J BIOL CHEM, V273, P11714, DOI 10.1074/jbc.273.19.11714; Jia ZC, 2002, TRENDS BIOCHEM SCI, V27, P101, DOI 10.1016/S0968-0004(01)02028-X; Job GE, 2004, ANGEW CHEM INT EDIT, V43, P5649, DOI 10.1002/anie.200460536; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; Kuiper MJ, 2003, BIOCHEM BIOPH RES CO, V300, P645, DOI 10.1016/S0006-291X(02)02900-5; LAU SYM, 1984, J BIOL CHEM, V259, P3253; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Leinala EK, 2002, J BIOL CHEM, V277, P33349, DOI 10.1074/jbc.M205575200; Liou YC, 2000, NATURE, V406, P322, DOI 10.1038/35018604; Marshall CB, 2004, BIOCHEMISTRY-US, V43, P11637, DOI 10.1021/bi0488909; Marshall CB, 2004, NATURE, V429, P153, DOI 10.1038/429153a; Marshall CB, 2004, BIOCHEMISTRY-US, V43, P148, DOI 10.1021/bi035605x; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P1591, DOI 10.1021/bi00220a021; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P4245, DOI 10.1021/bi00231a020; NEMETHY G, 1967, NATURE, V214, P363, DOI 10.1038/214363a0; Nishimiya Y, 2003, J BIOL CHEM, V278, P32307, DOI 10.1074/jbc.M304390200; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SCOTT GK, 1988, J MOL EVOL, V27, P29, DOI 10.1007/BF02099727; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; Starzyk A, 2005, BIOCHEMISTRY-US, V44, P369, DOI 10.1021/bi0481444; Tyshenko MG, 1997, NAT BIOTECHNOL, V15, P887, DOI 10.1038/nbt0997-887; Wallimann P, 1999, ANGEW CHEM INT EDIT, V38, P1290, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1290::AID-ANIE1290>3.0.CO;2-E; Wallimann P, 2003, J AM CHEM SOC, V125, P1203, DOI 10.1021/ja0275360; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zhang W, 1999, FEBS LETT, V455, P372, DOI 10.1016/S0014-5793(99)00906-0; ZHOU NE, 1992, J BIOL CHEM, V267, P2664	50	66	71	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17920	17929		10.1074/jbc.M500622200	http://dx.doi.org/10.1074/jbc.M500622200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15716269	hybrid			2022-12-25	WOS:000228807200045
J	DiRusso, CC; Li, H; Darwis, D; Watkins, PA; Berger, J; Black, PN				DiRusso, CC; Li, H; Darwis, D; Watkins, PA; Berger, J; Black, PN			Comparative biochemical studies of the murine fatty acid transport proteins (FATP) expressed in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; SACCHAROMYCES-CEREVISIAE; MOUSE; GENE; DISRUPTION; ACTIVATION; CLONING; GROWTH; IDENTIFICATION; LOCALIZATION	The fatty acid transport protein ( FATP) family is a group of proteins that are predicted to be components of specific fatty acid trafficking pathways. In mammalian systems, six different isoforms have been identified, which function in the import of exogenous fatty acids or in the activation of very long-chain fatty acids. This has led to controversy as to whether these proteins function as membrane-bound fatty acid transporters or as acyl-CoA synthetases, which activate long-chain fatty acids concomitant with transport. The yeast FATP orthologue, Fat1p, is a dual functional protein and is required for both the import of long-chain fatty acids and the activation of very long-chain fatty acids; these activities intrinsic to Fat1p are separable functions. To more precisely define the roles of the different mammalian isoforms in fatty acid trafficking, the six murine proteins (mmFATP1-6) were expressed and characterized in a genetically defined yeast strain, which cannot transport long-chain fatty acids and has reduced long-chain acyl-CoA synthetase activity (fat1 Delta faa1 Delta). Each isoform was evaluated for fatty acid transport, fatty acid activation (using C-18: 1, C-20: 4, and C-24: 0 as substrates), and accumulation of very long-chain fatty acids. Murine FATP1, - 2, and - 4 complemented the defects in fatty acid transport and very long-chain fatty acid activation associated with a deletion of the yeast FAT1 gene; mmFATP3, - 5, and - 6 did not complement the transport function even though each was localized to the yeast plasma membrane. Both mmFATP3 and - 6 activated C20: 4 and C24: 0, while the expression of mmFATP5 did not substantially increase acyl-CoA synthetases activities using the substrates tested. These data support the conclusion that the different mmFATP isoforms play unique roles in fatty acid trafficking, including the transport of exogenous long-chain fatty acids.	Ordway Res Inst, Ctr Metab Dis, Albany, NY 12208 USA; Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; Kennedy Krieger Res Inst, Baltimore, MD 21205 USA; Med Univ Vienna, Brain Res Inst, A-1090 Vienna, Austria	Ordway Research Institute; Albany Medical College; Kennedy Krieger Institute; Medical University of Vienna	Black, PN (corresponding author), Ordway Res Inst, Ctr Med Sci, 150 New Scotland Ave, Albany, NY 12208 USA.	pblack@ordwayresearch.org	Berger, Johannes/A-9122-2014; DiRusso, Concetta C/M-1884-2014	Berger, Johannes/0000-0003-0182-2658; Watkins, Paul A./0000-0002-3246-1405; Black, Paul/0000-0002-6272-6881; DiRusso, Concetta/0000-0001-7388-9152	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037355] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56850] Funding Source: Medline; NINDS NIH HHS [NS37355] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Berger J, 1998, FEBS LETT, V425, P305, DOI 10.1016/S0014-5793(98)00255-5; Berger J, 1998, BIOCHEM BIOPH RES CO, V247, P255, DOI 10.1006/bbrc.1998.8770; Berk PD, 1997, J BIOL CHEM, V272, P8830, DOI 10.1074/jbc.272.13.8830; Campbell FM, 1998, PLACENTA, V19, P409, DOI 10.1016/S0143-4004(98)90081-9; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; Cupp D, 2004, BIOCHEMISTRY-US, V43, P4473, DOI 10.1021/bi036335l; DiRusso CC, 2000, EUR J BIOCHEM, V267, P4422, DOI 10.1046/j.1432-1327.2000.01489.x; ESFAHANI M, 1981, J SUPRAMOL STR CELL, V15, P119, DOI 10.1002/jsscb.1981.380150203; Faergeman NJ, 2001, J BIOL CHEM, V276, P37051, DOI 10.1074/jbc.M100884200; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; Frohnert BI, 1999, J BIOL CHEM, V274, P3970, DOI 10.1074/jbc.274.7.3970; Gargiulo CE, 1999, J LIPID RES, V40, P881; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gimeno RE, 2003, J BIOL CHEM, V278, P49512, DOI 10.1074/jbc.M309759200; Gimeno RE, 2003, J BIOL CHEM, V278, P16039, DOI 10.1074/jbc.M211412200; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Hall AM, 2005, J BIOL CHEM, V280, P11948, DOI 10.1074/jbc.M412629200; Hall AM, 2003, J BIOL CHEM, V278, P43008, DOI 10.1074/jbc.M306575200; Hamilton JA, 2002, MOL CELL BIOCHEM, V239, P17, DOI 10.1023/A:1020542220599; Hamilton JA, 2001, J MOL NEUROSCI, V16, P99, DOI 10.1385/JMN:16:2-3:99; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; Heinzer AK, 2003, HUM MOL GENET, V12, P1145, DOI 10.1093/hmg/ddg126; Heinzer AK, 2002, J BIOL CHEM, V277, P28765, DOI 10.1074/jbc.M203053200; Herrmann T, 2003, J CELL BIOL, V161, P1105, DOI 10.1083/jcb.200207080; Herrmann T, 2001, GENE, V270, P31, DOI 10.1016/S0378-1119(01)00489-9; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; Kampf JP, 2004, J BIOL CHEM, V279, P35775, DOI 10.1074/jbc.M403630200; Kim JK, 2004, J CLIN INVEST, V113, P756, DOI 10.1172/JCI200418917; Kleinfeld AM, 2000, J MEMBRANE BIOL, V175, P79, DOI 10.1007/s002320001056; LANDS W E M, 1980, Biochemical Society Transactions, V8, P25; Lee JR, 2002, J BIOCHEM, V131, P541, DOI 10.1093/oxfordjournals.jbchem.a003132; Li H, 2005, ANAL BIOCHEM, V336, P11, DOI 10.1016/j.ab.2004.09.025; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Memon RA, 1999, DIABETES, V48, P121, DOI 10.2337/diabetes.48.1.121; Mihalik SJ, 2002, J BIOL CHEM, V277, P24771, DOI 10.1074/jbc.M203295200; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Moulson CL, 2003, P NATL ACAD SCI USA, V100, P5274, DOI 10.1073/pnas.0431186100; Pei ZT, 2004, J BIOL CHEM, V279, P54454, DOI 10.1074/jbc.M410091200; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Richards MR, 2003, J BIOL CHEM, V278, P10477, DOI 10.1074/jbc.M212469200; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Stahl A, 2004, PFLUG ARCH EUR J PHY, V447, P722, DOI 10.1007/s00424-003-1106-z; Stahl A, 2001, TRENDS ENDOCRIN MET, V12, P266, DOI 10.1016/S1043-2760(01)00427-1; Steinberg SJ, 2000, J BIOL CHEM, V275, P15605, DOI 10.1074/jbc.C000015200; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; Stuhlsatz-Krouper SM, 1999, PROSTAG LEUKOTR ESS, V60, P285, DOI 10.1016/S0952-3278(99)80001-5; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; Watkins PA, 1999, PROSTAG LEUKOTR ESS, V60, P323, DOI 10.1016/S0952-3278(99)80007-6; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; Watkins PA, 2000, CELL BIOCHEM BIOPHYS, V32, P333, DOI 10.1385/CBB:32:1-3:333; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602; Zou ZY, 2003, J BIOL CHEM, V278, P16414, DOI 10.1074/jbc.M210557200; Zou ZY, 2002, J BIOL CHEM, V277, P31062, DOI 10.1074/jbc.M205034200	55	107	115	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16829	16837		10.1074/jbc.M409598200	http://dx.doi.org/10.1074/jbc.M409598200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15699031	hybrid			2022-12-25	WOS:000228615500036
J	Fu, MF; Rao, M; Bouras, T; Wang, CG; Wu, KM; Zhang, XP; Li, ZP; Yao, TP; Pestell, RG				Fu, MF; Rao, M; Bouras, T; Wang, CG; Wu, KM; Zhang, XP; Li, ZP; Yao, TP; Pestell, RG			Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOCYTE DIFFERENTIATION; CELL-CYCLE; ANDROGEN RECEPTOR; ESTROGEN-RECEPTOR; PPAR-GAMMA; TUMOR-ANTIGEN; D1; COMPLEX; TRANSACTIVATION; TRANSCRIPTION	The cyclin D1 gene encodes the labile serum-inducible regulatory subunit of a holoenzyme that phosphorylates and inactivates the retinoblastoma protein. Overexpression of cyclin D1 promotes cellular proliferation and normal physiological levels of cyclin D1 function to inhibit adipocyte differentiation in vivo. We have previously shown that cyclin D1 inhibits peroxisome proliferator-activated receptor ( PPAR) gamma-dependent activity through a cyclin-dependent kinase- and retinoblastoma protein-binding-independent mechanism. In this study, we determined the molecular mechanism by which cyclin D1 regulated PPAR gamma function. Herein, murine embryonic fibroblast (MEF) differentiation by PPAR gamma ligand was associated with a reduction in histone deacetylase (HDAC1) activity. Cyclin D1(-/-) MEFs showed an increased propensity to undergo differentiation into adipocytes. Genetic deletion of cyclin D1 reduced HDAC1 activity. Reconstitution of cyclin D1 into the cyclin D1(-/-) MEFs increased HDAC1 activity and blocked PPAR gamma-mediated adipogenesis. PPAR gamma activity was enhanced in cyclin D1(-/-) cells. Reintroduction of cyclin D1 inhibited basal and ligand-induced PPAR gamma activity and enhanced HDAC repression of PPAR gamma activity. Cyclin D1 bound HDAC in vivo and preferentially physically associated with HDAC1, HDAC2, HDAC3, and HDAC5. Chromatin immunoprecipitation assay demonstrated that cyclin D1 enhanced recruitment of HDAC1 and HDAC3 and histone methyltransferase SUV39H1 to the PPAR response element of the lipoprotein lipase promoter and decreased acetylation of total histone H3 and histone H3 lysine 9. Collectively, these studies suggest an important role of cyclin D1 in regulation of PPAR gamma-mediated adipocyte differentiation through recruitment of HDACs to regulate PPAR response element local chromatin structure and PPAR gamma function.	Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Res Ctr, Washington, DC 20057 USA; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Georgetown University; Duke University	Pestell, RG (corresponding author), Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Res Ctr, Res Bldg,Rm E501,3970 Reservoir Rd NW,Box 571468, Washington, DC 20057 USA.	pestell@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA086072, R01CA107382, R01CA070896, R01CA075503, R01CA093596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK065220] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA93596, R01CA75503, R01CA70896, R01CA86072, R01CA107382] Funding Source: Medline; NIDDK NIH HHS [1 R21DK065220-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Alexander DL, 1998, J CELL SCI, V111, P3311; Beckstead R, 2001, MOL CELL, V7, P753, DOI 10.1016/S1097-2765(01)00220-9; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bouzahzah B, 2000, CANCER RES, V60, P4531; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Fu MF, 2002, CYTOKINE GROWTH F R, V13, P259, DOI 10.1016/S1359-6101(02)00003-5; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; Higgins C, 1996, J VIROL, V70, P745, DOI 10.1128/JVI.70.2.745-752.1996; Holnthoner W, 2002, J BIOL CHEM, V277, P45847, DOI 10.1074/jbc.M209354200; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Knudsen KE, 1999, CANCER RES, V59, P2297; Koutnikova H, 2001, ANN MED, V33, P556, DOI 10.3109/07853890108995966; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lagace DC, 2004, J BIOL CHEM, V279, P18851, DOI 10.1074/jbc.M312795200; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lazaro JB, 2002, GENE DEV, V16, P1792, DOI 10.1101/gad.U-9988R; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Neumeister P, 2003, MOL BIOL CELL, V14, P2005, DOI 10.1091/mbc.02-07-0102; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Ratineau C, 2002, J BIOL CHEM, V277, P8847, DOI 10.1074/jbc.M110747200; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Shih HH, 2001, MOL CELL BIOL, V21, P5723, DOI 10.1128/MCB.21.17.5723-5732.2001; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Tang QQ, 2004, BIOCHEM BIOPH RES CO, V319, P235, DOI 10.1016/j.bbrc.2004.04.176; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Wei Q, 2001, FEBS LETT, V490, P171, DOI 10.1016/S0014-5793(01)02120-2; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	47	226	232	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16934	16941		10.1074/jbc.M500403200	http://dx.doi.org/10.1074/jbc.M500403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15713663	hybrid			2022-12-25	WOS:000228615500048
J	Mancheno, JM; Tateno, H; Goldstein, IJ; Martinez-Ripoll, M; Hermoso, JA				Mancheno, JM; Tateno, H; Goldstein, IJ; Martinez-Ripoll, M; Hermoso, JA			Structural analysis of the Laetiporus sulphureus hemolytic pore-forming lectin in complex with sugars	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING DOMAIN; HEAT-LABILE ENTEROTOXIN; C-TYPE LECTIN; CRYSTAL-STRUCTURE; PROGENITOR TOXIN; IDENTIFICATION; BINDING; CRYSTALLOGRAPHY; HEMAGGLUTININ; ASSOCIATION	LSL is a lectin produced by the parasitic mushroom Laetiporus sulphureus, which exhibits hemolytic and hemagglutinating activities. Here, we report the crystal structure of LSL refined to 2.6-angstrom resolution determined by the single isomorphous replacement method with the anomalous scatter (SIRAS) signal of a platinum derivative. The structure reveals that LSL is hexameric, which was also shown by analytical ultracentrifugation. The monomeric protein (35 kDa) consists of two distinct modules: an N-terminal lectin module and a pore-forming module. The lectin module has a beta-trefoil scaffold that bears structural similarities to those present in toxins known to interact with galactose-related carbohydrates such as the hemagglutinin component (HA1) of the progenitor toxin from Clostridium botulinum, abrin, and ricin. On the other hand, the C-terminal pore-forming module (composed of domains 2 and 3) exhibits three-dimensional structural resemblances with domains 3 and 4 of the beta-pore-forming toxin aerolysin from the Gram-negative bacterium Aeromonas hydrophila, and domains 2 and 3 from the epsilon-toxin from Clostridium perfringens. This finding reveals the existence of common structural elements within the aerolysin-like family of toxins that could be directly involved in membrane-pore formation. The crystal structures of the complexes of LSL with lactose and N-acetyllactosamine reveal two dissacharide-binding sites per subunit and permits the identification of critical residues involved in sugar binding.	CSIC, Inst Rocasolano, Grp Cristalog Macromol & Biol Estructural, E-28006 Madrid, Spain; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); University of Michigan System; University of Michigan	Mancheno, JM (corresponding author), CSIC, Inst Rocasolano, Grp Cristalog Macromol & Biol Estructural, Serrano 119, E-28006 Madrid, Spain.	xjosemi@iqfr.csic.es	Hermoso, Juan/J-3433-2012; Mancheno, Jose/K-4984-2014; Martinez-Ripoll, Martin/A-8313-2012; Tateno, Hiroaki/M-2706-2018	Hermoso, Juan/0000-0002-1862-8950; Mancheno, Jose/0000-0001-6943-3291; Martinez-Ripoll, Martin/0000-0002-4019-0529; Tateno, Hiroaki/0000-0003-3006-1659	NIGMS NIH HHS [GM29477] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALLARD J, 1992, INFECT IMMUN, V60, P784, DOI 10.1128/IAI.60.3.784-790.1992; Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; Blundell TL, 1996, P NATL ACAD SCI USA, V93, P14243, DOI 10.1073/pnas.93.25.14243; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cioci G, 2003, FEBS LETT, V555, P297, DOI 10.1016/S0014-5793(03)01249-3; Cole AR, 2004, NAT STRUCT MOL BIOL, V11, P797, DOI 10.1038/nsmb804; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fujinaga Y, 1997, MICROBIOL-UK, V143, P3841, DOI 10.1099/00221287-143-12-3841; Fujinaga Y, 2000, FEBS LETT, V467, P179, DOI 10.1016/S0014-5793(00)01147-9; HABAZETTL J, 1992, NATURE, V359, P855, DOI 10.1038/359855a0; Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805; Heuck AP, 2001, BIOCHEMISTRY-US, V40, P9065, DOI 10.1021/bi0155394; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Inoue K, 2003, MICROBIOL-SGM, V149, P3361, DOI 10.1099/mic.0.26586-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Knapp M., 1998, AM CRYSTALLOGR ASS, V25, P90; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laue TM, 1992, BIOCH POLYM SCI; Liu Y, 2000, J EXP MED, V191, P1105, DOI 10.1084/jem.191.7.1105; Mancheno JM, 2004, ACTA CRYSTALLOGR D, V60, P1139, DOI 10.1107/S0907444904007991; MCLACHLAN AD, 1979, J MOL BIOL, V133, P557, DOI 10.1016/0022-2836(79)90408-X; Melton JA, 2004, J BIOL CHEM, V279, P14315, DOI 10.1074/jbc.M313758200; MERRITT EA, 1994, PROTEIN SCI, V3, P166; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nooren IMA, 2003, J MOL BIOL, V325, P991, DOI 10.1016/S0022-2836(02)01281-0; Nooren IMA, 2003, EMBO J, V22, P3486, DOI 10.1093/emboj/cdg359; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Poget SF, 1999, J MOL BIOL, V290, P867, DOI 10.1006/jmbi.1999.2910; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TAHIROV TH, 1995, J MOL BIOL, V250, P354, DOI 10.1006/jmbi.1995.0382; Tateno H, 2003, J BIOL CHEM, V278, P40455, DOI 10.1074/jbc.M306836200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Transue TR, 1997, NAT STRUCT BIOL, V4, P779, DOI 10.1038/nsb1097-779; Uchida T, 2004, J BIOL CHEM, V279, P37133, DOI 10.1074/jbc.M404065200; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; Walker JR, 2004, BIOCHEMISTRY-US, V43, P3783, DOI 10.1021/bi035871a; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842	55	89	93	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17251	17259		10.1074/jbc.M413933200	http://dx.doi.org/10.1074/jbc.M413933200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15687495	hybrid			2022-12-25	WOS:000228615500088
J	Ma, MC; Qian, H; Ghassemi, F; Zhao, P; Xia, Y				Ma, MC; Qian, H; Ghassemi, F; Zhao, P; Xia, Y			Oxygen-sensitive delta-opioid receptor-regulated survival and death signals - Novel insights into neuronal preconditioning and protection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAT CORTICAL-NEURONS; GENE-EXPRESSION; IN-VITRO; MOLECULAR PHARMACOLOGY; ISCHEMIC TOLERANCE; P38 INHIBITOR; BRAIN; MU; STRESS	The detrimental effect of severe hypoxia (SH) on neurons can be mitigated by hypoxic preconditioning (HPC), but the molecular mechanisms involved remain unclear, and an understanding of these may provide novel solutions for hypoxic/ischemic disorders ( e. g. stroke). Here, we show that the delta-opioid receptor (DOR), an oxygen-sensitive membrane protein, mediates the HPC protection through specific signaling pathways. Although SH caused a decrease in DOR expression and neuronal injury, HPC induced an increase in DOR mRNA and protein levels and reversed the reduction in levels of the endogenous DOR peptide, leucine enkephalin, normally seen during SH, thus protecting the neurons from SH insult. The HPC-induced protection could be blocked by DOR antagonists. The DOR-mediated HPC protection depended on an increase in ERK and Bcl 2 activity, which counteracted the SH-induced increase in p38 MAPK activities and cytochrome c release. The cross-talk between ERK and p38 MAPKs displays a "yin-yang" antagonism under the control of the DOR-G protein-protein kinase C pathway. Our findings demonstrate a novel mechanism of HPC neuroprotection (i.e. the intracellular up-regulation of DOR-regulated survival signals).	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA	Yale University	Xia, Y (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St,LMP 3107, New Haven, CT 06520 USA.	ying.xia@yale.edu			NCCIH NIH HHS [AT-01094] Funding Source: Medline; NICHD NIH HHS [HD-34852] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034852] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT001094] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; Benedict PE, 1999, CIRCULATION, V100, P357; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bossenmeyer-Pourie C, 1998, MOL BRAIN RES, V58, P237, DOI 10.1016/S0169-328X(98)00123-5; Boutin H, 1999, STROKE, V30, P1271, DOI 10.1161/01.STR.30.6.1271; Bruer U, 1997, FEBS LETT, V414, P117, DOI 10.1016/S0014-5793(97)00954-X; Burt AR, 1996, BIOCHEM J, V320, P227, DOI 10.1042/bj3200227; Buzas B, 1997, NEUROSCIENCE, V76, P479, DOI 10.1016/S0306-4522(96)00242-4; Chen Y, 2001, J CEREBR BLOOD F MET, V21, P34, DOI 10.1097/00004647-200101000-00005; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Drolet G, 2001, PROG NEURO-PSYCHOPH, V25, P729, DOI 10.1016/S0278-5846(01)00161-0; Fukuda K, 1996, J NEUROCHEM, V67, P1309; FUKUSHIMA N, 1994, NEUROSCI LETT, V176, P55, DOI 10.1016/0304-3940(94)90870-2; Gage AT, 1996, BRAIN RES, V719, P172, DOI 10.1016/0006-8993(96)00092-3; Hayashi T, 2002, SYNAPSE, V43, P86, DOI 10.1002/syn.10019; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hislop JN, 2004, J BIOL CHEM, V279, P22522, DOI 10.1074/jbc.M311062200; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; Legos JJ, 2002, EUR J PHARMACOL, V447, P37, DOI 10.1016/S0014-2999(02)01890-3; Legos JJ, 2001, BRAIN RES, V892, P70, DOI 10.1016/S0006-8993(00)03228-5; Liu J, 2000, AM J PHYSIOL-CELL PH, V278, pC144, DOI 10.1152/ajpcell.2000.278.1.C144; Lou LG, 1997, BIOCHEM BIOPH RES CO, V236, P626, DOI 10.1006/bbrc.1997.7027; Ma MC, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341008; Mai HQ, 2003, J BIOL CHEM, V278, P1886, DOI 10.1074/jbc.M209044200; Mayfield KP, 1996, NEUROSCIENCE, V72, P785, DOI 10.1016/0306-4522(95)00585-4; MAYFIELD KP, 1995, BRAIN RES, V676, P358, DOI 10.1016/0006-8993(95)00089-9; MAYFIELD KP, 1994, J PHARMACOL EXP THER, V268, P683; MAYFIELD KP, 1994, J PHARMACOL EXP THER, V268, P74; Meloni BP, 2002, BRAIN RES, V928, P69, DOI 10.1016/S0006-8993(01)03361-3; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nandagopal K, 2001, J PHARMACOL EXP THER, V297, P474; Park EM, 2004, NEUROSCIENCE, V123, P147, DOI 10.1016/j.neuroscience.2003.08.023; PerezPinzon MA, 1996, NEUROSCIENCE, V75, P687; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Quock RM, 1999, PHARMACOL REV, V51, P503; Raeburn CD, 2001, ARCH SURG-CHICAGO, V136, P1263, DOI 10.1001/archsurg.136.11.1263; SAKAKI T, 1995, NEUROSCI RES, V23, P289, DOI 10.1016/0168-0102(95)00954-X; Satoh M, 1995, PHARMACOL THERAPEUT, V68, P343, DOI 10.1016/0163-7258(95)02011-X; Satoh T, 2000, NEUROSCI LETT, V288, P163, DOI 10.1016/S0304-3940(00)01229-5; Su TP, 2000, J BIOMED SCI, V7, P195, DOI 10.1007/BF02255466; Takeda K, 2002, GENES CELLS, V7, P1099, DOI 10.1046/j.1365-2443.2002.00591.x; Tauskela JS, 1999, BRAIN RES, V827, P143, DOI 10.1016/S0006-8993(99)01322-0; Torocsik B, 2000, EUR J NEUROSCI, V12, P527, DOI 10.1046/j.1460-9568.2000.00933.x; Tso PH, 2000, J NEUROCHEM, V74, P1685, DOI 10.1046/j.1471-4159.2000.0741685.x; Tubbs RJ, 2002, ACAD EMERG MED, V9, P555, DOI 10.1111/j.1553-2712.2002.tb02291.x; XIA J, 1992, AM J PHYSIOL, V262, pR595; XIA Y, 1991, BRAIN RES, V549, P181, DOI 10.1016/0006-8993(91)90457-7; Xia Y, 2001, J COMP NEUROL, V436, P202; Yenari MA, 2003, ANN NY ACAD SCI, V993, P54, DOI 10.1111/j.1749-6632.2003.tb07511.x; Zhang JH, 2002, AM J PHYSIOL-CELL PH, V282, pC1225, DOI 10.1152/ajpcell.00226.2001; Zhang JH, 2000, BRAIN RES, V885, P143, DOI 10.1016/S0006-8993(00)02906-1; Zhang WB, 2003, J NEUROCHEM, V86, P1213, DOI 10.1046/j.1471-4159.2003.01930.x; Zhang Z, 1999, J NEUROCHEM, V73, P1502, DOI 10.1046/j.1471-4159.1999.0731502.x	55	127	139	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16208	16218		10.1074/jbc.M408055200	http://dx.doi.org/10.1074/jbc.M408055200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15687501	hybrid			2022-12-25	WOS:000228444800090
J	Nemoto, S; Fergusson, MM; Finkel, T				Nemoto, S; Fergusson, MM; Finkel, T			SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIFE-SPAN EXTENSION; CALORIE RESTRICTION; SACCHAROMYCES-CEREVISIAE; CELL-SURVIVAL; NAD(+)-DEPENDENT DEACETYLASES; MITOCHONDRIAL BIOGENESIS; PROTEIN DEACETYLASES; GAMMA COACTIVATOR-1; NAD; LONGEVITY	In lower organisms, increased expression of the NAD-dependent deacetylase Sir2 augments lifespan. The mechanism through which this life extension is mediated remains incompletely understood. Here we have examined the cellular effects of overexpression of SIRT1, the closest mammalian ortholog of Sir2. In PC12 cells, increased expression of the NAD-dependent deacetylase SIRT1 reduces cellular oxygen consumption by similar to 25%. We further demonstrate that SIRT1 expression can alter the transcriptional activity of the mitochondrial biogenesis coactivator PGC-1 alpha. In addition, SIRT1 and PGC-1 alpha directly interact and can be co-immunoprecipitated as a molecular complex. A single amino acid mutation in the putative ADP-ribosyltransferase domain of SIRT1 inhibits the interaction of SIRT1 with PGC-1 alpha but does not effect the interaction of SIRT1 with either p53 or Foxo3a. We further show that PGC-1 alpha is acetylated in vivo. This acetylation is augmented by treatment with the SIRT1 inhibitor nicotinamide or by expression of the transcriptional coactivator p300. Finally we demonstrate that SIRT1 catalyzes PGC-1 alpha deacetylation both in vitro and in vivo. These results provide a direct link between the sirtuins, a family of proteins linked to lifespan determination and PGC-1 alpha, a coactivator that regulates cellular metabolism.	NHLBI, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Finkel, T (corresponding author), NHLBI, Cardiovasc Branch, NIH, Bldg 10 CRC,Rm 5-3330, Bethesda, MD 20892 USA.	Finkelt@nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005012, ZIAHL005012] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RM, 2003, SCIENCE, V302, P2124, DOI 10.1126/science.1088697; Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Bitterman KJ, 2003, MICROBIOL MOL BIOL R, V67, P376, DOI 10.1128/MMBR.67.3.376-399.2003; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Borra MT, 2002, J BIOL CHEM, V277, P12632, DOI 10.1074/jbc.M111830200; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Denu JM, 2003, TRENDS BIOCHEM SCI, V28, P41, DOI 10.1016/S0968-0004(02)00005-1; Dumble M, 2004, ANN NY ACAD SCI, V1019, P171, DOI 10.1196/annals.1297.027; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; TRAN H, 2003, SCI STKE; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	37	801	826	0	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16456	16460		10.1074/jbc.M501485200	http://dx.doi.org/10.1074/jbc.M501485200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15716268	hybrid			2022-12-25	WOS:000228444800119
J	Shorer, H; Amar, N; Meerson, A; Elazar, Z				Shorer, H; Amar, N; Meerson, A; Elazar, Z			Modulation of N-ethylmaleimide-sensitive factor activity upon amino acid deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; SYNTAXIN HOMOLOG; SNARE COMPLEX; PROTEIN; GOLGI; TRANSPORT; NSF; ATPASE; EXOCYTOSIS; PATHWAY	Adaptation of eukaryotic cells to changing environmental conditions entails rapid regulation of protein targeting and transport to specific organelles. Such adaptation is well exemplified in mammalian cells exposed to nitrogen starvation that are triggered to form and transport autophagosomes to lysosomes, thus constituting an inducible intracellular trafficking pathway. Here we investigated the relationship between the general secretory machinery and the autophagic pathway in Chinese hamster ovary cells grown in the absence of amino acid. Utilizing VSVG-YFP ( vesicular stomatitis virus G protein fused to yellow fluorescent protein) and norepinephrine as markers for constitutive and regulated exocytosis, respectively, we found that secretion is attenuated in cells grown in media lacking amino acid. Such decrease in exocytosis stems from partial inhibition of N-ethylmaleimide-sensitive factor ATPase activity, which in turn causes an accumulation of SNARE complexes at both the Golgi apparatus and the plasma membrane of the starved cells. These findings expose a novel cellular strategy to attenuate secretion of proteins under conditions of limited amino acid supply.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elazar, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	bmzevi@wicc.weizmann.ac.il	Meerson, Ari/N-2338-2019	Meerson, Ari/0000-0002-5811-7952				Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Cuervo AM, 2000, J BIOL CHEM, V275, P33329, DOI 10.1074/jbc.M005655200; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Grusovin J, 2003, FRONT BIOSCI-LANDMRK, V8, pD620, DOI 10.2741/1052; Han SY, 2000, BIOCHEM J, V352, P165, DOI 10.1042/0264-6021:3520165; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; Isahara K, 1999, NEUROSCIENCE, V91, P233, DOI 10.1016/S0306-4522(98)00566-1; Ishihara N, 2001, MOL BIOL CELL, V12, P3690, DOI 10.1091/mbc.12.11.3690; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kunz JB, 2004, J BIOL CHEM, V279, P9987, DOI 10.1074/jbc.M307905200; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LEAF DS, 1990, DEV BIOL, V141, P1, DOI 10.1016/0012-1606(90)90097-3; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1; May AP, 2001, J BIOL CHEM, V276, P21991, DOI 10.1074/jbc.R100013200; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Mirnics K, 2000, NEURON, V28, P53, DOI 10.1016/S0896-6273(00)00085-4; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Muller JMM, 2002, J CELL BIOL, V157, P1161, DOI 10.1083/jcb.200202082; Munafo DB, 2002, TRAFFIC, V3, P472, DOI 10.1034/j.1600-0854.2002.30704.x; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Nara A, 2002, CELL STRUCT FUNCT, V27, P29, DOI 10.1247/csf.27.29; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593; Ollinger K, 1997, J BIOL CHEM, V272, P23707, DOI 10.1074/jbc.272.38.23707; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Parlati F, 2002, P NATL ACAD SCI USA, V99, P5424, DOI 10.1073/pnas.082100899; Presley JF, 1998, MOL BIOL CELL, V9, P1617, DOI 10.1091/mbc.9.7.1617; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sollner TH, 2003, MOL MEMBR BIOL, V20, P209, DOI 10.1080/0968768031000104953; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Waters MG, 2000, TRAFFIC, V1, P588, DOI 10.1034/j.1600-0854.2000.010802.x; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Whiteheart SW, 2001, INT REV CYTOL, V207, P71; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	45	14	14	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16219	16226		10.1074/jbc.M500554200	http://dx.doi.org/10.1074/jbc.M500554200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15708857	hybrid			2022-12-25	WOS:000228444800091
J	Birgander, PL; Bug, S; Kasrayan, A; Dahlroth, SL; Westman, MA; Gordon, E; Sjoberg, BM				Birgander, PL; Bug, S; Kasrayan, A; Dahlroth, SL; Westman, MA; Gordon, E; Sjoberg, BM			Nucleotide-dependent formation of catalytically competent dimers from engineered monomeric ribonucleotide reductase protein R1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY REGULATION; ESCHERICHIA-COLI; ALLOSTERIC REGULATION; SUBUNIT INTERACTION; DIPHOSPHATE REDUCTASE; COMPREHENSIVE MODEL; EFFECTOR-BINDING; CELL-CYCLE; ENZYME; MOUSE	Each catalytic turnover by aerobic ribonucleotide reductase requires the assembly of the two proteins, R1 (alpha(2)) and R2 (beta(2)), to produce deoxyribonucleotides for DNA synthesis. The R2 protein forms a tight dimer, whereas the strength of the R1 dimer differs between organisms, being monomeric in mouse R1 and dimeric in Escherichia coli. We have used the known E. coli R1 structure as a framework for design of eight different mutations that affect the helices and proximal loops that comprise the dimer interaction area. Mutations in loop residues did not affect dimerization, whereas mutations in the helices had very drastic effects on the interaction resulting in monomeric proteins with very low or no activity. The monomeric N238A protein formed an interesting exception, because it unexpectedly was able to reduce ribonucleotides with a comparatively high capacity. Gel filtration studies revealed that N238A was able to dimerize when bound by both substrate and effector, a result in accordance with the monomeric R1 protein from mouse. The effects of the N238A mutation, fit well with the notion that E. coli protein R1 has a comparatively small dimer interaction surface in relation to its size, and the results illustrate the stabilization effects of substrates and effectors in the dimerization process. The identification of key residues in the dimerization process and the fact that there is little sequence identity between the interaction areas of the mammalian and the prokaryotic enzymes may be of importance in drug design, similar to the strategy used in treatment of HSV infection.	Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden	Stockholm University	Sjoberg, BM (corresponding author), Stockholm Univ, Dept Mol Biol & Funct Genom, Svante Arrhenius Vag 16, SE-10691 Stockholm, Sweden.	britt-marie.sjoberg@molbio.su.se		Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; CORY JG, 1978, J BIOL CHEM, V253, P2898; EKBERG M, 2000, THESIS SWEDISH U AGR; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; Himo F, 2003, CHEM REV, V103, P2421, DOI 10.1021/cr020436s; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; Jordan A, 1996, MOL MICROBIOL, V19, P777, DOI 10.1046/j.1365-2958.1996.424950.x; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kashlan OB, 2003, BIOCHEMISTRY-US, V42, P1696, DOI 10.1021/bi020634d; Kashlan OB, 2002, BIOCHEMISTRY-US, V41, P462, DOI 10.1021/bi011653a; Kasrayan A, 2004, J BIOL CHEM, V279, P31050, DOI 10.1074/jbc.M400693200; Larsson KM, 2004, NAT STRUCT MOL BIOL, V11, P1142, DOI 10.1038/nsmb838; Larsson KM, 2001, STRUCTURE, V9, P739, DOI 10.1016/S0969-2126(01)00627-X; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; Poole AM, 2002, J MOL EVOL, V55, P180, DOI 10.1007/s00239-002-2315-3; Reichard P, 2000, J BIOL CHEM, V275, P33021, DOI 10.1074/jbc.M005337200; Reichard P, 2002, ARCH BIOCHEM BIOPHYS, V397, P149, DOI 10.1006/abbi.2001.2637; Scott CP, 2001, BIOCHEMISTRY-US, V40, P1651, DOI 10.1021/bi002335z; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; Stubble J, 2003, CURR OPIN CHEM BIOL, V7, P183, DOI 10.1016/S1367-5931(03)00025-5; SUN L, 1994, J BACTERIOL, V176, P2415, DOI 10.1128/JB.176.8.2415-2426.1994; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1980, J BIOL CHEM, V255, P7426; THELANDER L, 1973, J BIOL CHEM, V248, P4591; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; Uhlin U, 1996, J MOL BIOL, V262, P358, DOI 10.1006/jmbi.1996.0519; UPPSTEN M, 2004, THESIS SWEDISH U AGR, P52	34	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14997	15003		10.1074/jbc.M500565200	http://dx.doi.org/10.1074/jbc.M500565200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15699052	hybrid			2022-12-25	WOS:000228236800081
J	Bullesbach, EE; Schwabe, C				Bullesbach, EE; Schwabe, C			LGR8 signal activation by the relaxin-like factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-LIKE PEPTIDE; RECEPTOR; CRYPTORCHIDISM; LINKS	The relaxin-like factor (RLF) is thought to be responsible for the intra-abdominal migration of the testis during mammalian development. Our latest studies of RLF and LGR8 have revealed that the N-terminal region of the A chain is not required for receptor binding but is indispensable for cyclic AMP generation. RLF derivatives with six residues deleted from the N terminus of the A chain are active, whereas further truncation, up to the first A chain cysteine (A-10), yields tightly binding ligands devoid of signaling activity. These derivatives are specific competitive inhibitors (RLFi) of RLF. Although receptor binding is dependent upon B chain residues, the N-terminal region of the A chain is a generic trigger of the trans-membrane signaling activity.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Bullesbach, EE (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	bullesee@musc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD040406] Funding Source: NIH RePORTER; NICHD NIH HHS [1-R01-HD40406] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADHAM IM, 1993, J BIOL CHEM, V268, P26668; Adler A J, 1973, Methods Enzymol, V27, P675; Biron Z, 2002, BIOCHEMISTRY-US, V41, P12687, DOI 10.1021/bi026261y; Bogatcheva NV, 2003, MOL ENDOCRINOL, V17, P2639, DOI 10.1210/me.2003-0096; Bullesbach EE, 2004, BIOCHEMISTRY-US, V43, P8021, DOI 10.1021/bi049601j; Bullesbach EE, 1999, J BIOL CHEM, V274, P22354, DOI 10.1074/jbc.274.32.22354; Bullesbach EE, 2002, BIOCHEMISTRY-US, V41, P274, DOI 10.1021/bi0117302; Bullesbach EE, 1999, BIOCHEMISTRY-US, V38, P3073, DOI 10.1021/bi982687u; BURKHARDT E, 1994, GENOMICS, V20, P13, DOI 10.1006/geno.1994.1121; Drapeau G R, 1977, Methods Enzymol, V47, P189; Gorlov IP, 2002, HUM MOL GENET, V11, P2309, DOI 10.1093/hmg/11.19.2309; Hsu SYT, 2003, MOL CELL ENDOCRINOL, V202, P165, DOI 10.1016/S0303-7207(03)00078-9; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; Kumagai J, 2002, J BIOL CHEM, V277, P31283, DOI 10.1074/jbc.C200398200; MARUYAMA K, 1992, J PROTEIN CHEM, V11, P1, DOI 10.1007/BF01025086; Nef S, 1999, NAT GENET, V22, P295, DOI 10.1038/10364; Overbeek PA, 2001, GENESIS, V30, P26, DOI 10.1002/gene.1029; STEINER AL, 1979, METHOD HORM RADIOIMM, P3; Sudo S, 2003, J BIOL CHEM, V278, P7855, DOI 10.1074/jbc.M212457200; Truong A, 2003, BIOL REPROD, V69, P1658, DOI 10.1095/biolreprod.103.019166; Zimmermann S, 1999, MOL ENDOCRINOL, V13, P681, DOI 10.1210/me.13.5.681	22	48	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14586	14590		10.1074/jbc.M414443200	http://dx.doi.org/10.1074/jbc.M414443200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708846	hybrid			2022-12-25	WOS:000228236800031
J	Fraley, TS; Pereira, CB; Tran, TC; Singleton, C; Greenwood, JA				Fraley, TS; Pereira, CB; Tran, TC; Singleton, C; Greenwood, JA			Phosphoinositide binding regulates alpha-actinin dynamics - Mechanism for modulating cytoskeletal remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN MUTANTS; GREEN FLUORESCENT PROTEIN; FOCAL ADHESIONS; STRESS FIBERS; PI 3-KINASE; IN-VIVO; KINASE; ACTIVATION; LINK; RAS	The active association-dissociation of dynamic protein-protein interactions is critical for the ability of the actin cytoskeleton to remodel. To determine the influence of phosphoinositide binding on the dynamic interaction of alpha-actinin with actin filaments and integrin adhesion receptors, fluorescence recovery after photobleaching (FRAP) microscopy was carried out comparing wild-type green fluorescent protein (GFP)-alpha-actinin and a GFP-alpha-actinin mutant with a decreased affinity for phosphoinositides (Fraley, T. S., Tran, T. C., Corgan, A. M., Nash, C. A., Hao, J., Critchley, D. R., and Greenwood, J. A. (2003) J. Biol. Chem. 278, 24039-24045). In fibroblasts, recovery of the mutant alpha-actinin protein was 2.2 times slower than the wild type along actin stress fibers and 1.5 times slower within focal adhesions. FRAP was also measured in U87MG glioblastoma cells, which have higher levels of 3-phosphorylated phosphoinositides. As expected, alpha-actinin turnover for both the stress fiber and focal adhesion populations was faster in U87MG cells compared with fibroblasts with recovery of the mutant protein slower than the wild type along actin stress fibers. To understand the influence of alpha-actinin turnover on the modulation of the actin cytoskeleton, wild-type or mutant alpha-actinin was co-expressed with constitutively active phosphoinositide (PI) 3-kinase. Co-expression with the alpha-actinin mutant inhibited actin reorganization with the appearance of enlarged alpha-actinin containing focal adhesions. These results demonstrate that the binding of phosphoinositides regulates the association-dissociation rate of alpha-actinin with actin filaments and integrin adhesion receptors and that the dynamics of alpha-actinin is important for PI 3-kinase-induced reorganization of the actin cytoskeleton. In conclusion, phosphoinositide regulation of alpha-actinin dynamics modulates the plasticity of the actin cytoskeleton influencing remodeling.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Oregon State Univ, Dept Stat, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Greenwood, JA (corresponding author), Oregon State Univ, Dept Biochem & Biophys, ALS 2011, Corvallis, OR 97331 USA.	jeffrey.greenwood@orst.edu		Greenwood, Juliet/0000-0001-6438-964X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063711] Funding Source: NIH RePORTER; NCRR NIH HHS [1S10RR107903-01] Funding Source: Medline; NIEHS NIH HHS [P30 ES00210] Funding Source: Medline; NIGMS NIH HHS [GM63711] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhatt A, 2002, J CELL SCI, V115, P3415; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; Corgan AM, 2004, BIOCHEM J, V378, P1067, DOI 10.1042/BJ20031124; Edlund M, 2001, CELL MOTIL CYTOSKEL, V48, P190, DOI 10.1002/1097-0169(200103)48:3<190::AID-CM1008>3.0.CO;2-C; Fraley TS, 2003, J BIOL CHEM, V278, P24039, DOI 10.1074/jbc.M213288200; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; Gillham H, 1999, J CELL BIOL, V146, P869, DOI 10.1083/jcb.146.4.869; Greene DK, 2003, J BIOL CHEM, V278, P7617, DOI 10.1074/jbc.M207123200; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Lyman S, 1997, J BIOL CHEM, V272, P22538, DOI 10.1074/jbc.272.36.22538; Otey CA, 2004, CELL MOTIL CYTOSKEL, V58, P104, DOI 10.1002/cm.20007; PAVALKO FM, 1991, BIOCHEM SOC T, V19, P1065, DOI 10.1042/bst0191065; Peterson LJ, 2004, MOL BIOL CELL, V15, P3497, DOI 10.1091/mbc.E03-09-0696; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; Rajfur Z, 2002, NAT CELL BIOL, V4, P286, DOI 10.1038/ncb772; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Shimizu Y, 1996, IMMUNOL TODAY, V17, P565, DOI 10.1016/S0167-5699(96)10061-X; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Tsuruta D, 2002, FASEB J, V16, P866, DOI 10.1096/fj.01-0878fje; van Drogen Frank, 2004, Methods Mol Biol, V284, P287; von Wichert G, 2003, EMBO J, V22, P5023, DOI 10.1093/emboj/cdg492; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	28	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15479	15482		10.1074/jbc.M500631200	http://dx.doi.org/10.1074/jbc.M500631200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15710624	hybrid			2022-12-25	WOS:000228236800136
J	Higuchi, M; Tomioka, M; Takano, J; Shirotani, K; Iwata, N; Masumoto, H; Maki, M; Itohara, S; Saido, TC				Higuchi, M; Tomioka, M; Takano, J; Shirotani, K; Iwata, N; Masumoto, H; Maki, M; Itohara, S; Saido, TC			Distinct mechanistic roles of calpain and caspase activation in neurodegeneration as revealed in mice overexpressing their specific inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL PROTEINASE CALPAIN; ISCHEMIC NEURONAL DEATH; SMALL-SUBUNIT GENE; ALZHEIMERS-DISEASE; RAT-BRAIN; PHOSPHORYLATION STATE; PROTEASE FAMILIES; CELL-DEATH; APOPTOSIS; TAU	Enzymatic proteolysis has been implicated in diverse neuropathological conditions, including acute/subacute ischemic brain injuries and chronic neurodegeneration such as Alzheimer disease and Parkinson disease. Calcium-dependent proteases, calpains, have been intensively analyzed in relation to these pathological conditions, but in vivo experiments have been hampered by the lack of appropriate experimental systems for a selective regulation of the calpain activity in animals. Here we have generated transgenic (Tg) mice that overexpress human calpastatin, a specific and the only natural inhibitor of calpains. In order to clarify the distinct roles of these cell death-associated cysteine proteases, we dissected neurodegenerative changes in these mice together with Tg mice overexpressing a viral inhibitor of caspases after intrahippocampal injection of kainic acid (KA), an inducer of neuronal excitotoxicity. Immunohistochemical analyses using endo-specific antibodies against calpain- and caspase-cleaved cytoskeletal components revealed that preclusion of KA-induced calpain activation can rescue the hippocampal neurons from disruption of the neuritic cytoskeletons, whereas caspase suppression has no overt effect on the neuritic pathologies. In addition, progressive neuronal loss between the acute and subacute phases of KA-induced injury was largely halted only in human calpastatin Tg mice. The animal models and experimental paradigm employed here unequivocally demonstrate their usefulness for clarifying the distinct contribution of calpain and caspase systems to molecular mechanisms governing neurodegeneration in adult brains, and our results indicate the potentials of specific calpain inhibitors in ameliorating excitotoxic neuronal damages.	RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan; Nagoya Univ, Sch Agr Sci, Dept Appl Biol Sci, Lab Mol & Cellular Regulat,Chikusa Ku, Nagoya, Aichi 4648601, Japan; RIKEN, Brain Sci Inst, Lab Behav Genet, Wako, Saitama 3510198, Japan	RIKEN; Nagoya University; RIKEN	Higuchi, M (corresponding author), RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan.	mhiguchi@brain.riken.jp; saido@brain.riken.jp	Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015; Maki, Masatoshi/AAM-6839-2021; Itohara, Shigeyoshi/I-8769-2012	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903; Maki, Masatoshi/0000-0001-9144-5491; Itohara, Shigeyoshi/0000-0002-2410-9989				Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Asada K, 1989, J Enzyme Inhib, V3, P49, DOI 10.3109/14756368909030363; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; Canu N, 1998, J NEUROSCI, V18, P7061; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Crocker SJ, 2003, J NEUROSCI, V23, P4081; EMORI Y, 1987, P NATL ACAD SCI USA, V84, P3590, DOI 10.1073/pnas.84.11.3590; FISCHER I, 1991, NEUROCHEM RES, V16, P891, DOI 10.1007/BF00965538; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; GOEDERT M, 1993, P NATL ACAD SCI USA, V90, P5066, DOI 10.1073/pnas.90.11.5066; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Higuchi M, 2002, NEUROMOL MED, V2, P131, DOI 10.1385/NMM:2:2:131; Hitomi K, 1998, BIOSCI BIOTECH BIOCH, V62, P136, DOI 10.1271/bbb.62.136; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lubisch W, 2000, BIOORG MED CHEM LETT, V10, P2187, DOI 10.1016/S0960-894X(00)00430-3; Manya H, 2002, J BIOL CHEM, V277, P35503, DOI 10.1074/jbc.M206033200; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; NAGAO S, 1994, J BIOCHEM, V115, P1178, DOI 10.1093/oxfordjournals.jbchem.a124476; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; Pang Z, 2003, J NEUROPATH EXP NEUR, V62, P633, DOI 10.1093/jnen/62.6.633; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; Rami A, 2003, NEUROBIOL DIS, V13, P75, DOI 10.1016/S0969-9961(03)00018-4; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; SAHYOUN N, 1985, BIOCHEM BIOPH RES CO, V132, P878, DOI 10.1016/0006-291X(85)91889-3; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108; Takano J, 2005, J BIOL CHEM, V280, P16175, DOI 10.1074/jbc.M414552200; Tomioka M, 2002, MOL BRAIN RES, V108, P18, DOI 10.1016/S0169-328X(02)00486-2; TU PH, 1995, J CELL BIOL, V129, P1629, DOI 10.1083/jcb.129.6.1629; Wang GJ, 1999, METHODS, V18, P459, DOI 10.1006/meth.1999.0813; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WANG KKW, 1999, CALPAIN PHARM TOXICO, P77; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; Yang FS, 1998, AM J PATHOL, V152, P379; Zimmerman UJP, 2000, IUBMB LIFE, V50, P63	54	131	142	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15229	15237		10.1074/jbc.M500939200	http://dx.doi.org/10.1074/jbc.M500939200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15699033	hybrid			2022-12-25	WOS:000228236800108
J	Mayr, BM; Guzman, E; Montminy, M				Mayr, BM; Guzman, E; Montminy, M			Glutamine rich and basic region/leucine zipper (bZIP) domains stabilize cAMP-response element-binding protein (CREB) binding to chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER IN-VIVO; TRANSCRIPTIONAL ACTIVATION; DEPENDENT ACTIVATOR; TFIID COMPLEX; REVEALS; PHOSPHORYLATION; SITES; EXPRESSION; SUBDOMAINS; INDUCTION	We have examined the dynamics of cAMP-response element-binding protein ( CREB) binding to chromatin in live cells using fluorescence recovery after photobleaching ( FRAP). CREB was found to bind to target sites with a residence time of 100 s, and exposure to a cAMP agonist had no effect on these kinetics. In addition to the basic region/leucine zipper ( bZIP) domain, a glutamine-rich trans-activation domain in CREB called Q2 also appeared to be critical for promoter occupancy. Indeed, mutations in Q2 that reduced residence time by FRAP assay disrupted target gene activation via CREB in cells exposed to a cAMP agonist. Notably, insertion of the glutamine-rich B trans-activation domain of SP1 into a mutant CREB polypeptide lacking Q2 stabilized CREB occupancy and rescued target gene activation. These results suggest a novel mechanism by which the family of glutamine-rich activators promotes cellular gene expression.	Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA 92037 USA	Salk Institute	Montminy, M (corresponding author), Salk Inst Biol Studies, Peptide Biol Labs, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	montminy@salk.edu	Mayr, Bernhard M/F-6936-2012	Mayr, Bernhard M/0000-0002-8973-4494	NIGMS NIH HHS [R01 GM037828] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037828] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Dundr M, 2002, SCIENCE, V298, P1623, DOI 10.1126/science.1076164; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; Felinski EA, 1999, J BIOL CHEM, V274, P11672, DOI 10.1074/jbc.274.17.11672; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Halder SK, 2002, MOL ENDOCRINOL, V16, P1853, DOI 10.1210/me.2001-0262; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Phair RD, 2004, METHOD ENZYMOL, V375, P393; Rojo-Niersbach E, 1999, J BIOL CHEM, V274, P33778, DOI 10.1074/jbc.274.47.33778; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Schumacher MA, 2000, J BIOL CHEM, V275, P35242, DOI 10.1074/jbc.M007293200; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; Wolfl S, 1999, MOL ENDOCRINOL, V13, P659, DOI 10.1210/me.13.5.659; Zou MX, 2004, ONCOGENE, V23, P330, DOI 10.1038/sj.onc.1207053	29	29	29	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15103	15110		10.1074/jbc.M414144200	http://dx.doi.org/10.1074/jbc.M414144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15703171	hybrid			2022-12-25	WOS:000228236800093
J	Shenoy, SK; Lefkowitz, RJ				Shenoy, SK; Lefkowitz, RJ			Receptor-specific ubiquitination of beta-arrestin directs assembly and targeting of seven-transmembrane receptor signalosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CLATHRIN-MEDIATED ENDOCYTOSIS; BETA(2)-ADRENERGIC RECEPTOR; REGULATED KINASES; MAP KINASE; DEPENDENT DEGRADATION; ADRENERGIC-RECEPTOR; ERK ACTIVATION; GENE; TRANSDUCTION	Angiotensin II type 1a (AT1a), vasopressin V2, and neurokinin 1 (NK1) receptors are seven-transmembrane receptors (7TMRs) that bind and co-internalize with the multifunctional adaptor protein, beta-arrestin. These receptors also lead to robust and persistent activation of extracellular-signal regulated kinase 1/2 (ERK1/2) localized on endosomes. Recently, the co-trafficking of receptor-beta-arrestin complexes to endosomes was demonstrated to require stable beta-arrestin ubiquitination (Shenoy, S. K., and Lefkowitz, R. J. (2003) J. Biol. Chem. 278, 14498-14506). We now report that lysines at positions 11 and 12 in beta-arrestin2 are specific and required sites for its AngII-mediated sustained ubiquitination. Thus, upon AngII stimulation the mutant beta-arrestin2(K11,12R) is only transiently ubiquitinated, does not form stable endocytic complexes with the AT1aR, and is impaired in scaffolding-activated ERK1/2. Fusion of a ubiquitin moiety in-frame to beta-arrestin2(K11,12R) restores AngII-mediated trafficking and signaling. Wild type beta-arrestin2 and beta-arrestin2(K11R),(K12R)-Ub, but not beta-arrestin2(K11R,K12R), prevent nuclear translocation of pERK. These findings imply that sustained beta-arrestin ubiquitination not only directs co-trafficking of receptor-beta-arrestin complexes but also orchestrates the targeting of "7TMR signalosomes" to microcompartments within the cell. Surprisingly, binding of beta-arrestin2(K11R,K12R) to V2R and NK1R is indistinguishable from that of wild type beta-arrestin2. Moreover, ubiquitination patterns and ERK scaffolding of beta-arrestin2(K11,12R) are unimpaired with respect to V2R stimulation. In contrast, a quintuple lysine mutant (beta-arrestin2(K18R,K107R,K108R,K207R,K296R)) is impaired in endosomal trafficking in response to V2R but not AT1aR stimulation. Our findings delineate a novel regulatory mechanism for 7TMR signaling, dictated by the ubiquitination of beta-arrestin on specific lysines that become accessible for modification due to the specific receptor-bound conformational states of beta-arrestin2.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Lefkowitz, Robert/AAW-2649-2021; Shenoy, Sudha/AAN-4075-2021	Shenoy, Sudha/0000-0002-2565-4663	NHLBI NIH HHS [HL16037, HL 70631] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL070631, R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Day FL, 1999, J BIOL CHEM, V274, P23726, DOI 10.1074/jbc.274.34.23726; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Elorza A, 2003, J BIOL CHEM, V278, P29164, DOI 10.1074/jbc.M304314200; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Gonzallez-Gaitan M, 2003, NAT REV MOL CELL BIO, V4, P213, DOI 10.1038/nrm1053; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Guillemot L, 2001, J BIOL CHEM, V276, P39394, DOI 10.1074/jbc.M103862200; HERSHKO A, 1981, J BIOL CHEM, V256, P1525; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LEE RM, 1992, J BIOL CHEM, V267, P1088; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; McKay S, 1998, AM J RESP CELL MOL, V18, P823, DOI 10.1165/ajrcmb.18.6.2924; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Teis D, 2003, CELL MOL LIFE SCI, V60, P2020, DOI 10.1007/s00018-003-3010-2; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Vines CM, 2003, J BIOL CHEM, V278, P41581, DOI 10.1074/jbc.C300291200; Vishnivetskiy SA, 2004, J BIOL CHEM, V279, P1262, DOI 10.1074/jbc.M308834200; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563	46	118	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15315	15324		10.1074/jbc.M412418200	http://dx.doi.org/10.1074/jbc.M412418200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15699045	hybrid			2022-12-25	WOS:000228236800117
J	Wisniewski, HG; Snitkin, ES; Mindrescu, C; Sweet, MH; Vilcek, J				Wisniewski, HG; Snitkin, ES; Mindrescu, C; Sweet, MH; Vilcek, J			TSG-6 protein binding to glycosaminoglycans - Formation of stable complexes with hyaluronan and binding to chondroitin sulfates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TRYPSIN INHIBITOR; COLLAGEN-INDUCED ARTHRITIS; FACTOR-STIMULATED GENE-6; T-CELL EXTRAVASATION; SMOOTH-MUSCLE-CELLS; LINK MODULE; EXTRACELLULAR-MATRIX; PRIMARY ADHESION; HEAVY-CHAIN; DBA/1J MICE	TSG-6 protein, up-regulated in inflammatory lesions and in the ovary during ovulation, shows anti-inflammatory activity and plays an essential role in female fertility. Studies in murine models of acute inflammation and experimental arthritis demonstrated that TSG-6 has a strong anti-inflammatory and chondroprotective effect. TSG-6 protein is composed of the N-terminal link module that binds hyaluronan and a C-terminal CUB domain, present in a variety of proteins. Interactions between the isolated link module and hyaluronan have been studied extensively, but little is known about the binding of full-length TSG-6 protein to hyaluronan and other glycosaminoglycans. We show that TSG-6 protein and hyaluronan, in a temperature-dependent fashion, form a stable complex that is resistant to dissociating agents. The formation of such stable complexes may underlie the activities of TSG-6 protein in inflammation and fertility, e. g. the TSG-6-dependent cross-linking of hyaluronan in the cumulus cell-oocyte complex during ovulation. Because adhesion to hyaluronan is involved in cell trafficking in inflammatory processes, we also studied the effect of TSG-6 on cell adhesion. TSG-6 binding to immobilized hyaluronan did not interfere with subsequent adhesion of lymphoid cells. In addition to immobilized hyaluronan, full-length TSG-6 also binds free hyaluronan and all chondroitin sulfate isoforms under physiological conditions. These interactions may contribute to the localization of TSG-6 in cartilage and to its chondroprotective and anti-inflammatory effects in models of arthritis.	NYU Med Ctr, Dept Microbiol, Sch Med, New York, NY 10016 USA	New York University	Wisniewski, HG (corresponding author), NYU Med Ctr, Dept Microbiol, Sch Med, 550 1st Ave, New York, NY 10016 USA.	hans-georg.wisniewski@med.nyu.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044351] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-44351] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bardos T, 2002, J IMMUNOL, V168, P6013, DOI 10.4049/jimmunol.168.12.6013; Bardos T, 2001, AM J PATHOL, V159, P1711, DOI 10.1016/S0002-9440(10)63018-0; Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P42, DOI 10.1053/joca.2000.0348; Blundell CD, 2003, J BIOL CHEM, V278, P49261, DOI 10.1074/jbc.M309623200; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Calvete JJ, 1996, FEBS LETT, V379, P207, DOI 10.1016/0014-5793(95)01513-2; Carrette O, 2001, BIOL REPROD, V65, P301, DOI 10.1095/biolreprod65.1.301; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; de la Motte CA, 1999, J BIOL CHEM, V274, P30747, DOI 10.1074/jbc.274.43.30747; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975; Estess P, 1999, J EXP MED, V190, P9, DOI 10.1084/jem.190.1.9; Frost GI, 1997, ANAL BIOCHEM, V251, P263, DOI 10.1006/abio.1997.2262; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Getting SJ, 2002, J BIOL CHEM, V277, P51068, DOI 10.1074/jbc.M205121200; Glant TT, 2002, ARTHRITIS RHEUM-US, V46, P2207, DOI 10.1002/art.10555; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HUANG L, 1993, J BIOL CHEM, V268, P26725; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; Lesley J, 2004, J BIOL CHEM, V279, P25745, DOI 10.1074/jbc.M313319200; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; Majors AK, 2003, J BIOL CHEM, V278, P47223, DOI 10.1074/jbc.M304871200; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; Mindrescu C, 2002, ARTHRITIS RHEUM, V46, P2453, DOI 10.1002/art.10503; Mindrescu C, 2000, ARTHRITIS RHEUM, V43, P2668, DOI 10.1002/1529-0131(200012)43:12<2668::AID-ANR6>3.0.CO;2-E; Mukhopadhyay D, 2004, J BIOL CHEM, V279, P11119, DOI 10.1074/jbc.M313471200; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Odum L, 2002, REPRODUCTION, V124, P249, DOI 10.1530/reprod/124.2.249; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; Parkar AA, 1997, FEBS LETT, V410, P413, DOI 10.1016/S0014-5793(97)00621-2; PERIN JP, 1987, J BIOL CHEM, V262, P13269; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Richards JS, 2002, ANNU REV PHYSIOL, V64, P69, DOI 10.1146/annurev.physiol.64.081501.131029; SANZ L, 1993, MOL REPROD DEV, V35, P37, DOI 10.1002/mrd.1080350107; Sato H, 2001, BIOCHEM BIOPH RES CO, V281, P1154, DOI 10.1006/bbrc.2001.4475; SCOTT JE, 1961, BIOCHEM J, V81, P418, DOI 10.1042/bj0810418; Siegelman MH, 1999, J LEUKOCYTE BIOL, V66, P315, DOI 10.1002/jlb.66.2.315; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; Topfer-Petersen E, 1998, ANDROLOGIA, V30, P217; Varani S, 2002, MOL ENDOCRINOL, V16, P1154, DOI 10.1210/me.16.6.1154; Wisniewski HG, 2004, CYTOKINE GROWTH F R, V15, P129, DOI 10.1016/j.cytogfr.2004.01.005; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; Zhuo LS, 2004, J BIOL CHEM, V279, P38079, DOI 10.1074/jbc.R300039200; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	58	34	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14476	14484		10.1074/jbc.M411734200	http://dx.doi.org/10.1074/jbc.M411734200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15699048	hybrid			2022-12-25	WOS:000228236800017
J	Sellers, JA; Hou, L; Schoenberg, DR; de Medeiros, SRB; Wahli, W; Shelness, GS				Sellers, JA; Hou, L; Schoenberg, DR; de Medeiros, SRB; Wahli, W; Shelness, GS			Microsomal triglyceride transfer protein promotes the secretion of Xenopus laevis vitellogenin A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CONTAINING LIPOPROTEINS; APOLIPOPROTEIN-B; ENDOPLASMIC-RETICULUM; APOLIPOPHORIN-II/I; EXPRESSION; LIPOVITELLIN; CELLS; GENE; ABETALIPOPROTEINEMIA; METABOLISM	Vitellogenins (Vtg) are ancient lipid transport and storage proteins and members of the large lipid transfer protein (LLTP) gene family, which includes insect apolipophorin II/I, apolipoprotein B ( apoB), and the microsomal triglyceride transfer protein (MTP). Lipidation of Vtg occurs at its site of synthesis in vertebrate liver, insect fat body, and nematode intestine; however, the mechanism of Vtg lipid acquisition is unknown. To explore whether Vtg biogenesis requires the apoB cofactor and LLTP family member, MTP, Vtg was expressed in COS cells with and without coexpression of the 97-kDa subunit of human MTP. Expression of Vtg alone gave rise to a similar to 220-kDa apoprotein, which was predominantly confined to an intracellular location. Coexpression of Vtg with human MTP enhanced Vtg secretion by 5-fold, without dramatically affecting its intracellular stability. A comparison of wild type and a triglyceride transfer-defective form of MTP revealed that both were capable of promoting Vtg secretion, whereas only wild type MTP could promote the secretion of apoB41 (amino-terminal 41% of apoB). These studies demonstrate that the biogenesis of Vtg is MTP-dependent and that MTP is the likely ancestral member of the LLTP gene family.	Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Univ Lausanne, Ctr Integrat Genom, CH-10015 Lausanne, Switzerland	Wake Forest University; Wake Forest Baptist Medical Center; University System of Ohio; Ohio State University; University of Lausanne	Shelness, GS (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	gshelnes@wfubmc.edu	Wahli, Walter/B-1398-2009; Batistuzzo de Medeiros, Silvia/H-2117-2015; DE MEDEIROS, SILVIA REGINA BATISTUZZO/ABC-2811-2020; Wahli, Walter/I-3194-2019; Schoenberg, Daniel/J-3423-2019	Wahli, Walter/0000-0002-5966-9089; Batistuzzo de Medeiros, Silvia/0000-0003-2431-0479; DE MEDEIROS, SILVIA REGINA BATISTUZZO/0000-0003-2431-0479; Schoenberg, Daniel/0000-0003-4570-1946	NHLBI NIH HHS [HL49373, HL07867] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Babin PJ, 1999, J MOL EVOL, V49, P150, DOI 10.1007/PL00006528; Brozovic S, 2004, NAT MED, V10, P535, DOI 10.1038/nm1043; BYRNE BM, 1989, PROG BIOPHYS MOL BIO, V53, P33, DOI 10.1016/0079-6107(89)90005-9; Canavoso LE, 2001, ANNU REV NUTR, V21, P23, DOI 10.1146/annurev.nutr.21.1.23; CHAPMAN MJ, 1980, J LIPID RES, V21, P789; DEMEDEIROS SRB, 1993, THESIS U LAUSANNE LA; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002; Hui TY, 2002, J LIPID RES, V43, P785; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; NARDELLI D, 1987, J BIOL CHEM, V262, P15377; Ohashi K, 2000, J LIPID RES, V41, P1199; Park JJ, 2004, P NATL ACAD SCI USA, V101, P1022, DOI 10.1073/pnas.0307847100; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Read J, 2000, J BIOL CHEM, V275, P30372, DOI 10.1074/jbc.C000364200; Segrest JP, 1999, J LIPID RES, V40, P1401; Sellers JA, 2003, J BIOL CHEM, V278, P20367, DOI 10.1074/jbc.M300271200; Sellers JA, 2001, J LIPID RES, V42, P1897; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; Shelness GS, 2003, J BIOL CHEM, V278, P44702, DOI 10.1074/jbc.M307562200; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; Shibata Y, 2003, SCIENCE, V302, P1779, DOI 10.1126/science.1087167; Smolenaars MMW, 2005, J LIPID RES, V46, P412, DOI 10.1194/jlr.M400374-JLR200; Thompson JR, 2002, BIOCHEMISTRY-US, V41, P9398, DOI 10.1021/bi025674w; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277	32	28	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13902	13905		10.1074/jbc.M500769200	http://dx.doi.org/10.1074/jbc.M500769200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15701598	hybrid			2022-12-25	WOS:000228095500090
J	Wang, CG; Hou, XH; Mohapatra, S; Ma, YH; Cress, WD; Pledger, WJ; Chen, JD				Wang, CG; Hou, XH; Mohapatra, S; Ma, YH; Cress, WD; Pledger, WJ; Chen, JD			Activation of p27(Kip1) expression by E2F1 - A negative feedback mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; GENE P27(KIP1); APOPTOSIS; MEDIATE; MICE; P27; FIBROBLASTS; INHIBITORS; INDUCTION; P21(CIP1)	The E2F1 transcription factor is a critical regulator of cell cycle due to its ability to promote S phase entry. However, E2F1 overexpression also sensitizes cells to apoptosis and E2F1-null mice are predisposed to tumor development, suggesting that it also has properties of a growth suppressor. E2F1 transcription function is regulated by interaction with hypophosphorylated pRb. Cdk inhibitors such as p16(INK4a) and p27(Kip1) inhibit pRb phosphorylation by the cyclin D/Cdk4 and cyclin E/Cdk2 complexes, thus keeping E2F1 in an inactive state. We found that E2F1 binds to the p27 promoter in vivo and activates p27 mRNA and protein expression. Depletion of endogenous E2F1 by siRNA causes a reduction in basal p27 expression level. Inhibition of endogenous p27 expression by siRNA increases E2F1 transcriptional activity and permits accelerated cell cycle progression by exogenous E2F1. These observations suggest that induction of p27 acts as a negative feedback mechanism for E2F1 and may also contribute to other functions of E2F1.	H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA		Chen, JD (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, MRC3057A,12902 Magnolia Dr, Tampa, FL 33612 USA.	jchen@moffitt.usf.edu	Mohapatra, Subhra/A-1381-2012					Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Carneiro C, 2003, ONCOGENE, V22, P361, DOI 10.1038/sj.onc.1206163; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Ciaparrone M, 1998, CANCER RES, V58, P114; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; HARVEY M, 1993, ONCOGENE, V8, P2457; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; Ma YH, 2003, J BIOL CHEM, V278, P16770, DOI 10.1074/jbc.M212702200; Ma YH, 2003, MOL CANCER THER, V2, P73; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Tsihlias J, 1999, ANNU REV MED, V50, P401; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	30	69	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12339	12343		10.1074/jbc.C400536200	http://dx.doi.org/10.1074/jbc.C400536200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15713665	hybrid			2022-12-25	WOS:000227922000034
J	Savchenko, A; Krogan, N; Cort, JR; Evdokimova, E; Lew, JM; Yee, AA; Sanchez-Pulido, L; Andrade, MA; Bochkarev, A; Watson, JD; Kennedy, MA; Greenblatt, J; Hughes, T; Arrowsmith, CH; Rommens, JM; Edwards, AM				Savchenko, A; Krogan, N; Cort, JR; Evdokimova, E; Lew, JM; Yee, AA; Sanchez-Pulido, L; Andrade, MA; Bochkarev, A; Watson, JD; Kennedy, MA; Greenblatt, J; Hughes, T; Arrowsmith, CH; Rommens, JM; Edwards, AM			The Shwachman-Bodian-Diamond syndrome protein family is involved in RNA metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; YEAST NSR1 PROTEIN; SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-PROTEINS; GENETIC-ANALYSIS; SPLICING FACTORS; NUCLEAR-PROTEIN; FISSION YEAST; NMR; SIMILARITY	A combination of structural, biochemical, and genetic studies in model organisms was used to infer a cellular role for the human protein (SBDS) responsible for Shwachman-Bodian-Diamond syndrome. The crystal structure of the SBDS homologue in Archaeoglobus fulgidus, AF0491, revealed a three domain protein. The N-terminal domain, which harbors the majority of disease-linked mutations, has a novel three-dimensional fold. The central domain has the common winged helix-turn-helix motif, and the C-terminal domain shares structural homology with known RNA-binding domains. Proteomic analysis of the SBDS sequence homologue in Saccharomyces cerevisiae, YLR022C, revealed an association with over 20 proteins involved in ribosome biosynthesis. NMR structural genomics revealed another yeast protein, YHR087W, to be a structural homologue of the AF0491 N-terminal domain. Sequence analysis confirmed them as distant sequence homologues, therefore related by divergent evolution. Synthetic genetic array analysis of YHR087W revealed genetic interactions with proteins involved in RNA and rRNA processing including Mdm20/Nat3, Nsr1, and Npl3. Our observations, taken together with previous reports, support the conclusion that SBDS and its homologues play a role in RNA metabolism.	Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Ontario Ctr Struct Proteom, Toronto, ON M5G 1L6, Canada; Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Pacific NW Natl Lab, NE Struct Genom Consortium, Richland, WA 99352 USA; Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99352 USA; Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; CSIC, Ctr Nacl Biotecnol, Prot Design Grp, E-28049 Madrid, Spain; Ottawa Hlth Res Inst, Ontario Genom Innovat Ctr, Bioinformat Grp, Ottawa, ON K1H 8L6, Canada; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; European Bioinformat Inst, European Mol Biol Lab, Cambridge CB10 1SD, England; Hosp Sick Children, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Toronto; University of Toronto; Structural Genomics Consortium; University of Toronto; United States Department of Energy (DOE); Pacific Northwest National Laboratory; United States Department of Energy (DOE); Pacific Northwest National Laboratory; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); University of Ottawa; Ottawa Hospital Research Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center; European Molecular Biology Laboratory (EMBL); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Edwards, AM (corresponding author), Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	aled.edwards@utoronto.ca	Andrade, Miguel A/B-6565-2008; Kennedy, Michael/ABE-6002-2021; Rommens, Johanna/AAT-7465-2021; Kennedy, Michael/M-2578-2019	Andrade, Miguel A/0000-0001-6650-1711; Arrowsmith, Cheryl/0000-0002-4971-3250; Sanchez Pulido, Luis/0000-0002-2300-8502; Edwards, Aled/0000-0002-4782-6016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062413, P50GM062414] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50-GM62413-02, P50-GM62414] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P4658, DOI 10.1093/nar/27.23.4658; Arnold RJ, 1999, J BIOL CHEM, V274, P37035, DOI 10.1074/jbc.274.52.37035; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BODIAN M, 1964, ACTA PAEDIATR, V53, P282, DOI 10.1111/j.1651-2227.1964.tb07237.x; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Boocock GRB, 2003, NAT GENET, V33, P97, DOI 10.1038/ng1062; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bu DB, 2003, NUCLEIC ACIDS RES, V31, P2443, DOI 10.1093/nar/gkg340; CAVANAGH J, 1996, PROTEIN NMR SPECTROS, P411; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Cummings L, 2002, FEMS MICROBIOL LETT, V216, P133, DOI 10.1016/S0378-1097(02)00955-2; DEANGELO DJ, 1995, MOL CELL BIOL, V15, P1254; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dror Y, 2002, BRIT J HAEMATOL, V118, P701, DOI 10.1046/j.1365-2141.2002.03585.x; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Ginzberg H, 2000, AM J HUM GENET, V66, P1413, DOI 10.1086/302856; Gottschalk A, 1998, RNA, V4, P374; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Inoue K, 2000, J BIOL CHEM, V275, P32793, DOI 10.1074/jbc.M004560200; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KONDO K, 1992, J BIOL CHEM, V267, P16259; KONDO K, 1992, J BIOL CHEM, V267, P16252; Koonin EV, 2001, GENOME RES, V11, P240, DOI 10.1101/gr.162001; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lecompte O, 2002, NUCLEIC ACIDS RES, V30, P5382, DOI 10.1093/nar/gkf693; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Luscombe NM, 2000, GENOME BIOL, V1; Mata J, 2002, NAT GENET, V32, P143, DOI 10.1038/ng951; Nakashima E, 2004, HUM GENET, V114, P345, DOI 10.1007/s00439-004-1081-2; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicholls A., 1992, GRASP GRAPHICAL REPR; NIERHAUS KH, 1991, BIOCHIMIE, V73, P739, DOI 10.1016/0300-9084(91)90054-5; Omer AD, 2003, MOL MICROBIOL, V48, P617, DOI 10.1046/j.1365-2958.2003.03483.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park J, 1997, J MOL BIOL, V273, P349, DOI 10.1006/jmbi.1997.1288; Peng WT, 2003, CELL, V113, P919, DOI 10.1016/S0092-8674(03)00466-5; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; RUSSELL ID, 1992, J CELL BIOL, V119, P737, DOI 10.1083/jcb.119.4.737; Sanchez-Pulido L, 2000, BIOINFORMATICS, V16, P656, DOI 10.1093/bioinformatics/16.7.656; Schade M, 1999, EMBO J, V18, P470, DOI 10.1093/emboj/18.2.470; SCHLENSTEDT G, 1993, J CELL BIOL, V123, P785, DOI 10.1083/jcb.123.4.785; SCHWACHMAN H, 1964, J PEDIATR-US, V65, P645; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Selenko P, 2003, MOL CELL, V11, P965, DOI 10.1016/S1097-2765(03)00115-1; Shammas C, 2005, J BIOL CHEM, V280, P19221, DOI 10.1074/jbc.M414656200; SINGLETON DR, 1995, J CELL SCI, V108, P265; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Wolf YI, 1999, GENOME RES, V9, P689; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906; Xing YY, 1997, NAT STRUCT BIOL, V4, P24, DOI 10.1038/nsb0197-24; Yee A, 2002, P NATL ACAD SCI USA, V99, P1825, DOI 10.1073/pnas.042684599; Zenklusen D, 2001, MOL CELL BIOL, V21, P4219, DOI 10.1128/MCB.21.13.4219-4232.2001; Zhang RG, 2002, J BIOL CHEM, V277, P19183, DOI 10.1074/jbc.M112171200	68	84	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19213	19220		10.1074/jbc.M414421200	http://dx.doi.org/10.1074/jbc.M414421200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15701634	hybrid			2022-12-25	WOS:000228932300078
J	Cohen, DM; Chen, H; Johnson, RP; Choudhury, B; Craig, SW				Cohen, DM; Chen, H; Johnson, RP; Choudhury, B; Craig, SW			Two distinct head-tail interfaces cooperate to suppress activation of vinculin by talin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING-SITE; ALPHA-ACTININ; N-WASP; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INTRAMOLECULAR ASSOCIATION; CYTOSKELETAL PROTEINS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; CELL MECHANICS; ADHESION	Vinculin is autoinhibited by an intramolecular interaction that masks binding sites for talin and F-actin. Although a recent structural model explains autoinhibition solely in terms of the interaction between vinculin tail (V-t) and residues 1 - 258 (D1), we find an absolute requirement for an interface involving the D4 domain of head (V-h residues 710 - 836) and V-t. Charge-to-alanine mutations in V-t revealed a class of mutants, T12 and T19, distal to the V-(1-258) binding site, which showed increases in their K-d values for head binding of 100- and 42-fold, respectively. Reciprocal mutation of residues in the D4 domain that contact V-t yielded a head-tail interaction mutant of comparable magnitude to T19. These findings account for the approximately 120-fold difference in K-d values between V-t binding to V-( 1 - 258), as opposed to full-length V-h-( 1 - 851). The significance of a bipartite autoinhibitory site is evidenced by its effects on talin binding to V-h. Whereas V-t fails to compete with the talin rod domain for binding to V-( 1 - 258), competition occurs readily with full-length V-h, and this requires the D4 interface. Moreover in intact vinculin, mutations in the D4-V-t interface stabilize association of vinculin and talin rod. In cells, these head-tail interaction mutants induce hypertrophy and elongation of focal adhesions. Definition of a second autoinhibitory site, the D4-V-t interface, supports the competing model of vinculin activation that invokes cooperative action of ligands at two sites. Together the D1-V-t and D4-V-t interfaces provide the high affinity ( similar to 10(-9)) autoinhibition observed in full-length vinculin.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Johns Hopkins University; Northwestern University	Craig, SW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	scraig@jhmi.edu		Cohen, Daniel/0000-0002-7963-668X	NIGMS NIH HHS [GM41605] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM041605, R01GM041605] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alenghat FJ, 2000, BIOCHEM BIOPH RES CO, V277, P93, DOI 10.1006/bbrc.2000.3636; Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; Bakolitsa C, 2004, NATURE, V430, P583, DOI 10.1038/nature02610; Balaban NQ, 2001, NAT CELL BIOL, V3, P466, DOI 10.1038/35074532; BARSTEAD RJ, 1991, J CELL BIOL, V114, P715, DOI 10.1083/jcb.114.4.715; Bass MD, 2002, BIOCHEM J, V362, P761, DOI 10.1042/0264-6021:3620761; BELKIN AM, 1987, FEBS LETT, V220, P291, DOI 10.1016/0014-5793(87)80832-3; Benesch S, 2002, J BIOL CHEM, V277, P37771, DOI 10.1074/jbc.M204145200; Borgon RA, 2004, STRUCTURE, V12, P1189, DOI 10.1016/j.str.2004.05.009; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; Calderwood DA, 2004, J BIOL CHEM, V279, P28889, DOI 10.1074/jbc.M402161200; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COHEN DM, 2004, MOL BIOL CELL S, V15, P81; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043; Dueber JE, 2003, SCIENCE, V301, P1904, DOI 10.1126/science.1085945; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Goldmann WH, 2002, BIOCHEM BIOPH RES CO, V290, P749, DOI 10.1006/bbrc.2001.6243; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Isenberg G, 1996, FEBS LETT, V397, P316, DOI 10.1016/S0014-5793(96)01203-3; Izard T, 2004, J BIOL CHEM, V279, P27667, DOI 10.1074/jbc.M403076200; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; JOCKUSCH BM, 1981, P NATL ACAD SCI-BIOL, V78, P3005, DOI 10.1073/pnas.78.5.3005; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; KROEMKER M, 1994, FEBS LETT, V355, P259, DOI 10.1016/0014-5793(94)01216-4; Lee HS, 2004, J MOL BIOL, V343, P771, DOI 10.1016/j.jmb.2004.08.069; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Miller GJ, 2001, J BIOL CHEM, V276, P11729, DOI 10.1074/jbc.M008646200; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; OHALLORAN T, 1986, METHOD ENZYMOL, V134, P69; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Prehoda KE, 2002, CURR OPIN CELL BIOL, V14, P149, DOI 10.1016/S0955-0674(02)00307-1; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; SILICIANO JD, 1986, METHOD ENZYMOL, V134, P78; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Steimle PA, 1999, J BIOL CHEM, V274, P18414, DOI 10.1074/jbc.274.26.18414; Subauste MC, 2004, J CELL BIOL, V165, P371, DOI 10.1083/jcb.200308011; Tan JL, 2003, P NATL ACAD SCI USA, V100, P1484, DOI 10.1073/pnas.0235407100; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Xing BD, 2001, J BIOL CHEM, V276, P44373, DOI 10.1074/jbc.M108587200; Xu WM, 1998, DEVELOPMENT, V125, P327; Zemljic-Harpf AE, 2004, AM J PATHOL, V165, P1033, DOI 10.1016/S0002-9440(10)63364-0; Zhang ZY, 2004, MOL BIOL CELL, V15, P4234, DOI 10.1091/mbc.E04-03-0264	55	124	124	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17109	17117		10.1074/jbc.M414704200	http://dx.doi.org/10.1074/jbc.M414704200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728584	hybrid			2022-12-25	WOS:000228615500070
J	Cohen, E; Goldshleger, R; Shainskaya, A; Tal, DM; Ebel, C; le Maire, M; Karlish, SJD				Cohen, E; Goldshleger, R; Shainskaya, A; Tal, DM; Ebel, C; le Maire, M; Karlish, SJD			Purification of Na+,K+-ATPase expressed in Pichia pastoris reveals an essential role of phospholipid-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; ATPASE ACTIVITY; BETA-SUBUNIT; SARCOPLASMIC-RETICULUM; CONFORMATIONAL-CHANGES; OXIDATIVE CLEAVAGE; MEMBRANE-PROTEINS; RENAL NA,K-ATPASE; CRYSTAL-STRUCTURE; MAMMALIAN KIDNEY	Na+, K+-ATPase ( porcine alpha/his(10)-beta) has been expressed in Pichia Pastoris, solubilized in n-dodecyl-beta-maltoside and purified to 70 - 80% purity by nickel-nitrilotriacetic acid chromatography combined with size exclusion chromatography. The recombinant protein is inactive if the purification is done without added phospholipids. The neutral phospholipid, dioleoylphosphatidylcholine, preserves Na+, K+-ATPase activity of protein prepared in a Na+-containing medium, but activity is lost in a K+-containing medium. By contrast, the acid phospholipid, dioleoylphosphatidylserine, preserves activity in either Na+- or K+-containing media. In optimal conditions activity is preserved for about 2 weeks at 0 degrees C. Both recombinant Na+, K+-ATPase and native pig kidney Na+, K+-ATPase, dissolved in n-dodecyl-beta-maltoside, appear to be mainly stable monomers (alpha/beta) as judged by size exclusion chromatography and sedimentation velocity. Na+, K+-ATPase activities at 37 degrees C of the size exclusion chromatography-purified recombinant and renal Na+, K+-ATPase are comparable but are lower than that of membrane-bound renal Na+, K+-ATPase. The beta subunit is expressed in Pichia Pastoris as two lightly glycosylated polypeptides and is quantitatively deglycosylated by endoglycosidase- H at 0 degrees C, to a single polypeptide. Deglycosylation inactivates Na+, K+-ATPase prepared with dioleoylphosphatidylcholine, whereas dioleoylphosphatidylserine protects after deglycosylation, and Na+, K+-ATPase activity is preserved. This work demonstrates an essential role of phospholipid interactions with Na+, K+-ATPase, including a direct interaction of dioleoylphosphatidylserine, and possibly another interaction of either the neutral or acid phospholipid. Additional lipid effects are likely. A role for the beta subunit in stabilizing conformations of Na+, K+-ATPase ( or H+, K+-ATPase) with occluded K+ ions can also be inferred. Purified recombinant Na+, K+-ATPase could become an important experimental tool for various purposes, including, hopefully, structural work.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Biol Mass Spectrometry Facil, IL-76100 Rehovot, Israel; Univ Paris 11, CEA Saclay, DBJC SBFM, CNRS,URA 2096, F-91191 Gif Sur Yvette, France; Univ Paris 11, CEA Saclay, LRD17V, F-91191 Gif Sur Yvette, France; UJF, CNRS,UMR 5075, CEA, Inst Biol Struct JP Ebel,Lab Biophys Mol, F-38027 Grenoble, France	Weizmann Institute of Science; Weizmann Institute of Science; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Steven.Karlish@weizmann.ac.il		Ebel, Christine/0000-0002-6912-500X				Bar Shimon M, 1998, J BIOL CHEM, V273, P34190, DOI 10.1074/jbc.273.51.34190; Beaudet L, 1998, METHOD ENZYMOL, V292, P397; Beggah AT, 1997, J BIOL CHEM, V272, P10318; Bretthauer RK, 1999, BIOTECHNOL APPL BIOC, V30, P193; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; Cereghino JL, 2000, FEMS MICROBIOL REV, V24, P45, DOI 10.1111/j.1574-6976.2000.tb00532.x; Champeil P, 2000, J BIOL CHEM, V275, P18623, DOI 10.1074/jbc.M000470200; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; CORNELIUS F, 1984, BIOCHIM BIOPHYS ACTA, V772, P357, DOI 10.1016/0005-2736(84)90153-6; Cornelius F, 2003, BIOCHEMISTRY-US, V42, P8541, DOI 10.1021/bi034532e; CORNELIUS F, 1995, BBA-BIOMEMBRANES, V1235, P205, DOI 10.1016/0005-2736(95)80006-2; Cornelius F, 2001, BIOCHEMISTRY-US, V40, P8842, DOI 10.1021/bi010541g; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; Hakansson KO, 2003, J MOL BIOL, V332, P1175, DOI 10.1016/j.jmb.2003.07.012; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; Hilge M, 2003, NAT STRUCT BIOL, V10, P468, DOI 10.1038/nsb924; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; JOHANNSSON A, 1981, BIOCHIM BIOPHYS ACTA, V641, P416, DOI 10.1016/0005-2736(81)90498-3; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V527, P115, DOI 10.1016/0005-2744(78)90261-9; KATES M, 1972, LABORATORY TECHNIQUE, V3, P347; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; Laughery M, 2004, J BIOL CHEM, V279, P36339, DOI 10.1074/jbc.M402778200; le Maire M, 2000, BBA-BIOMEMBRANES, V1508, P86, DOI 10.1016/S0304-4157(00)00010-1; Lee AG, 2003, BBA-BIOMEMBRANES, V1612, P1, DOI 10.1016/S0005-2736(03)00056-7; LEMAIRE M, 1989, ANAL BIOCHEM, V177, P50, DOI 10.1016/0003-2697(89)90012-2; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; MARCUS MM, 1986, BIOCHIM BIOPHYS ACTA, V854, P270, DOI 10.1016/0005-2736(86)90120-3; Montigny C, 2004, J BIOL CHEM, V279, P43971, DOI 10.1074/jbc.M407142200; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Or E, 1999, J BIOL CHEM, V274, P2802, DOI 10.1074/jbc.274.5.2802; Pedersen PA, 1996, J BIOL CHEM, V271, P2514, DOI 10.1074/jbc.271.5.2514; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; Rice WJ, 2001, BIOPHYS J, V80, P2187, DOI 10.1016/S0006-3495(01)76191-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Shinji N, 2003, ANN NY ACAD SCI, V986, P235, DOI 10.1111/j.1749-6632.2003.tb07168.x; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Strugatsky D, 2003, J BIOL CHEM, V278, P46064, DOI 10.1074/jbc.M308303200; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; Taniguchi K, 2001, J BIOCHEM, V129, P335, DOI 10.1093/oxfordjournals.jbchem.a002862; Toustrup-Jensen M, 2003, J BIOL CHEM, V278, P11402, DOI 10.1074/jbc.M212136200; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; Winstone TL, 2005, BIOCHEM BIOPH RES CO, V327, P437, DOI 10.1016/j.bbrc.2004.11.164; YEAGLE PL, 1988, BIOCHEMISTRY-US, V27, P6449, DOI 10.1021/bi00417a037; Zhang HM, 2003, P NATL ACAD SCI USA, V100, P5160, DOI 10.1073/pnas.0931431100	58	54	59	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16610	16618		10.1074/jbc.M414290200	http://dx.doi.org/10.1074/jbc.M414290200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15708860	hybrid			2022-12-25	WOS:000228615500011
J	Fasciano, S; Patel, RC; Handy, I; Patel, CV				Fasciano, S; Patel, RC; Handy, I; Patel, CV			Regulation of vascular smooth muscle proliferation by heparin - Inhibition of cyclin-dependent kinase 2 activity by p27(kip1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DOUBLE-STRANDED-RNA; RAT CAROTID-ARTERY; MYC MESSENGER-RNA; CELL-CYCLE; C-FOS; GROWTH-FACTOR; IN-VITRO; S PHASE; POSTTRANSCRIPTIONAL REGULATION	Uncontrolled proliferation of vascular smooth muscle cells ( VSMCs) contribute to intimal hyperplasia during atherosclerosis and restenosis. Heparin is an antiproliferative agent for VSMCs and has been shown to block VSMC proliferation both in tissue culture systems and in animals. Despite the well documented antiproliferative actions of heparin, its cellular targets largely remain unknown. In an effort to characterize the mechanism of the antiproliferative property of heparin, we have analyzed the effect of heparin on cell cycle in VSMC. Our results indicate that the heparin- induced block in G(1) to S phase transition is imposed by p27(kip1) -mediated inhibition of cyclin- dependent kinase 2 activity. Further analysis of p27(kip1) mRNA levels showed that the increase in p27(kip1) protein levels in heparin- treated VSMC occurs at posttranscriptional levels. We present evidence that heparin causes stabilization of p27(kip1) protein during G(1) phase and thereby prevents activation of cyclin- dependent kinase 2.	Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Patel, RC (corresponding author), Univ S Carolina, Dept Biol Sci, 700 Sumter St, Columbia, SC 29208 USA.	patelr@sc.edu	Patel, Rekha/M-7123-2015	Patel, Rekha/0000-0001-9434-4880	NHLBI NIH HHS [R01 HL063359, R01 HL63359] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063359] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AU YPT, 1992, CIRC RES, V70, P1062, DOI 10.1161/01.RES.70.5.1062; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Boehm Manfred, 2003, Prog Cell Cycle Res, V5, P19; Braun-Dullaeus RC, 1999, J CLIN INVEST, V104, P815, DOI 10.1172/JCI5339; Braun-Dullaeus RC, 1998, CIRCULATION, V98, P82, DOI 10.1161/01.CIR.98.1.82; Braun-Dullaeus RC, 2001, ARTERIOSCL THROM VAS, V21, P1152, DOI 10.1161/hq0701.092104; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CASTELLOT JJ, 1989, J CELL BIOL, V109, P3147, DOI 10.1083/jcb.109.6.3147; CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; Castro C, 2004, ATHEROSCLEROSIS, V172, P31, DOI 10.1016/j.atherosclerosis.2003.09.003; Castro C, 2003, J BIOL CHEM, V278, P4482, DOI 10.1074/jbc.M204716200; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; CLOWES AW, 1989, TRANSPLANT P, V21, P3700; CLOWES AW, 1987, INT ANGIOL, V6, P45; Coleman J, 2001, BMC Mol Biol, V2, P12, DOI 10.1186/1471-2199-2-12; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Daum G, 1997, CIRC RES, V81, P17, DOI 10.1161/01.RES.81.1.17; Deng XB, 2004, J BIOL CHEM, V279, P22498, DOI 10.1074/jbc.M400479200; Desdouets C, 1995, Prog Cell Cycle Res, V1, P115; Diez-Juan A, 2004, BLOOD, V103, P158, DOI 10.1182/blood-2003-07-2319; Diez-Juan A, 2001, FASEB J, V15, P1989, DOI 10.1096/fj.01-0130com; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Gallo R, 1999, CIRCULATION, V99, P2164, DOI 10.1161/01.CIR.99.16.2164; Gerlitz G, 2002, EUR J BIOCHEM, V269, P2810, DOI 10.1046/j.1432-1033.2002.02974.x; Gopfert U, 2003, HUM MOL GENET, V12, P1767, DOI 10.1093/hmg/ddg177; Goukassian D, 2001, FASEB J, V15, P1877, DOI 10.1096/fj.01-0065com; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; Hedin U, 1998, J VASC SURG, V27, P512, DOI 10.1016/S0741-5214(98)70326-X; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Herbert JM, 1996, J BIOL CHEM, V271, P25928; Horiuchi A, 1999, MOL HUM REPROD, V5, P139, DOI 10.1093/molehr/5.2.139; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; KENAGY RD, 1995, THROMB RES, V77, P55, DOI 10.1016/0049-3848(95)90864-C; KENAGY RD, 1994, J CLIN INVEST, V93, P1987, DOI 10.1172/JCI117191; Kleiman N S, 2000, J Invasive Cardiol, V12 Suppl F, p20F; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Kouzarides Tony, 1993, Trends in Cell Biology, V3, P211, DOI 10.1016/0962-8924(93)90113-F; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Marks AR, 2003, TRANSPLANT P, V35, p231S, DOI 10.1016/S0041-1345(03)00243-4; Marra DE, 2000, CIRCULATION, V102, P2124, DOI 10.1161/01.CIR.102.17.2124; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Miralem T, 1996, J BIOL CHEM, V271, P17100, DOI 10.1074/jbc.271.29.17100; Miralem T, 1996, AM J PHYSIOL-RENAL, V270, pF960, DOI 10.1152/ajprenal.1996.270.6.F960; Mishra-Gorur K, 2002, AM J PATHOL, V161, P1893, DOI 10.1016/S0002-9440(10)64465-3; Mishra-Gorur K, 2002, J BIOL CHEM, V277, P33537, DOI 10.1074/jbc.C200342200; Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morris TA, 1998, EXP CELL RES, V240, P218, DOI 10.1006/excr.1997.3925; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Nho Richard Seonghun, 2003, Prog Cell Cycle Res, V5, P249; NIKKARI ST, 1994, AM J PATHOL, V144, P1348; Noble MEM, 1997, TRENDS BIOCHEM SCI, V22, P482, DOI 10.1016/S0968-0004(97)01144-4; OLASHAW N, 2002, SCI STKE; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; OTTLINGER ME, 1993, J BIOL CHEM, V268, P19173; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; Patel RC, 2002, ARTERIOSCL THROM VAS, V22, P1439, DOI 10.1161/01.ATV.0000028817.20351.FE; Pukac L, 1998, EXP CELL RES, V242, P548, DOI 10.1006/excr.1998.4138; PUKAC LA, 1990, CELL REGUL, V1, P435, DOI 10.1091/mbc.1.5.435; PUKAC LA, 1992, J BIOL CHEM, V267, P3707; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Roque M, 2001, LAB INVEST, V81, P895, DOI 10.1038/labinvest.3780298; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Silva AM, 2004, J BIOL CHEM, V279, P37670, DOI 10.1074/jbc.M406554200; SNOW AD, 1990, AM J PATHOL, V137, P313; Sun J, 2001, CIRCULATION, V103, P2967, DOI 10.1161/01.CIR.103.24.2967; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; Tokumoto YM, 2002, DEV BIOL, V245, P224, DOI 10.1006/dbio.2002.0626; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; VINDELOV LL, 1983, CYTOMETRY, V3, P328, DOI 10.1002/cyto.990030504; Wang G, 2003, J CELL BIOCHEM, V90, P548, DOI 10.1002/jcb.10621; Woods TC, 2002, J BIOL CHEM, V277, P1924, DOI 10.1074/jbc.M108189200; WRIGHT TC, 1989, P NATL ACAD SCI USA, V86, P3199, DOI 10.1073/pnas.86.9.3199; Young J J, 2000, J Invasive Cardiol, V12 Suppl E, pE14; YOUNG JJ, 2000, J INVASIVE CARDIO SE, V12, pE25; Zhang YW, 2001, ONCOGENE, V20, P4138, DOI 10.1038/sj.onc.1204563; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	100	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15682	15689		10.1074/jbc.M411458200	http://dx.doi.org/10.1074/jbc.M411458200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15731113	Green Accepted, hybrid			2022-12-25	WOS:000228444800029
J	Marraffini, LA; Schneewind, O				Marraffini, LA; Schneewind, O			Anchor structure of staphylococcal surface proteins - V. Anchor structure of the sortase B substrate IsdC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; AUREUS STRAIN COPENHAGEN; SENSITIVE ENZYMATIC REACTIONS; D-ALANINE CARBOXYPEPTIDASE; CELL-WALL; ESCHERICHIA-COLI; SORTING REACTION; CROSS-LINKING; LPXTG MOTIF; PEPTIDOGLYCAN	Staphylococcus aureus sortase A cleaves surface protein precursors bearing C-terminal LPXTG motif sorting signals between the threonine and glycine residues. Using lipid II precursor as cosubstrate, sortase A catalyzes the amide linkage between the carboxyl group of threonine and the amino group of pentaglycine cross-bridges, thereby tethering C-terminal ends of surface proteins to the bacterial cell wall envelope. Staphylococcal sortase B also anchors its only known substrate, the IsdC precursor with a C-terminal NPQTN motif sorting signal, to the cell wall envelope. Herein, we determined the cell wall anchor structure of IsdC. The sorting signal of IsdC is cleaved between threonine and asparagine of the NPQTN motif, and the carboxyl group of threonine is amide-linked to the amino group of pentaglycine cross-bridges. In contrast to sortase A substrates, the anchor structure of IsdC displays shorter glycan strands and significantly less cell wall cross-linking. A model is proposed whereby sortases A and B recognize unique features of sorting signals and peptidoglycan substrates to deposit proteins with distinct topologies in the cell wall envelope.	Univ Chicago, Dept Microbiol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Schneewind, O (corresponding author), Univ Chicago, Dept Microbiol, 920 E 58th St, Chicago, IL 60637 USA.	oschnee@bsd.uchicago.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052474, R01AI038897] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38897, AI52474] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHMSEN L, 1985, EMBO J, V4, P3901, DOI 10.1002/j.1460-2075.1985.tb04164.x; Arbeloa A, 2004, J BIOL CHEM, V279, P41546, DOI 10.1074/jbc.M407149200; Bae T, 2003, J BACTERIOL, V185, P2910, DOI 10.1128/JB.185.9.2910-2919.2003; Bera A, 2005, MOL MICROBIOL, V55, P778, DOI 10.1111/j.1365-2958.2004.04446.x; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; Bierne H, 2004, J BACTERIOL, V186, P1972, DOI 10.1128/JB.186.7.1972-1982.2004; Boneca IG, 2000, J BIOL CHEM, V275, P9910, DOI 10.1074/jbc.275.14.9910; CALANDRA GB, 1980, INFECT IMMUN, V28, P1033; CHATTERJEE AN, 1964, P NATL ACAD SCI USA, V51, P9, DOI 10.1073/pnas.51.1.9; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; COLE RM, 1962, SCIENCE, V135, P722, DOI 10.1126/science.135.3505.722; Cossart P, 2000, P NATL ACAD SCI USA, V97, P5013, DOI 10.1073/pnas.97.10.5013; DUTHIE ES, 1952, J GEN MICROBIOL, V6, P95, DOI 10.1099/00221287-6-1-2-95; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; GALLY D, 1993, J GEN MICROBIOL, V139, P1907, DOI 10.1099/00221287-139-8-1907; GHUYSEN JM, 1963, BIOCHEMISTRY-US, V2, P1119, DOI 10.1021/bi00905a036; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; Giesbrecht P, 1998, MICROBIOL MOL BIOL R, V62, P1371, DOI 10.1128/MMBR.62.4.1371-1414.1998; IZAKI K, 1966, P NATL ACAD SCI USA, V55, P656, DOI 10.1073/pnas.55.3.656; JENSEN KLAUS, 1958, ACTA PATHOL ET MICROBIOL SCAND, V44, P421; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; MATSUHAS.M, 1967, J BIOL CHEM, V242, P3191; MATSUHASHI M, 1965, P NATL ACAD SCI USA, V54, P587, DOI 10.1073/pnas.54.2.587; Matsuhashi M., 1994, BACTERIAL CELL WALL, P55; Mazmanian SK, 2002, P NATL ACAD SCI USA, V99, P2293, DOI 10.1073/pnas.032523999; Mazmanian SK, 2000, P NATL ACAD SCI USA, V97, P5510, DOI 10.1073/pnas.080520697; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; MAZMANIAN SK, 2002, BACILLUS SUBTILIS IT, P57; MUNOZ E, 1966, BIOCHEMISTRY-US, V5, P3748, DOI 10.1021/bi00876a004; NAKAGAWA J, 1984, J BIOL CHEM, V259, P3937; Navarre WW, 1999, J BIOL CHEM, V274, P15847, DOI 10.1074/jbc.274.22.15847; Navarre WW, 1998, J BIOL CHEM, V273, P29135, DOI 10.1074/jbc.273.44.29135; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; Perry AM, 2002, J BIOL CHEM, V277, P16241, DOI 10.1074/jbc.M109194200; PETIT JF, 1968, J BIOL CHEM, V243, P757; Rivas JM, 2004, CURR OPIN DRUG DISC, V7, P223; Ruzin A, 2002, J BACTERIOL, V184, P2141, DOI 10.1128/JB.184.8.2141-2147.2002; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Skaar EP, 2004, J BIOL CHEM, V279, P436, DOI 10.1074/jbc.M307952200; SNOWDEN MA, 1989, J GEN MICROBIOL, V135, P3015; STEERS E, 1965, J BIOL CHEM, V240, P2478; Strominger J L, 1968, Harvey Lect, V64, P179; STROMINGER JL, 1967, FED PROC, V26, P9; SYDNER AP, 2000, INTERPRETING PROTEIN; TIPPER DJ, 1967, BIOCHEMISTRY-US, V6, P906, DOI 10.1021/bi00855a035; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; TIPPER DJ, 1965, BIOCHEMISTRY-US, V4, P468, DOI 10.1021/bi00879a015; TIPPER DJ, 1968, BIOCHEMISTRY-US, V7, P1441, DOI 10.1021/bi00844a029; Ton-That H, 1999, J BIOL CHEM, V274, P24316, DOI 10.1074/jbc.274.34.24316; Ton-That H, 2002, J BIOL CHEM, V277, P7447, DOI 10.1074/jbc.M109945200; Ton-That H, 1999, P NATL ACAD SCI USA, V96, P12424, DOI 10.1073/pnas.96.22.12424; TonThat H, 1997, J BIOL CHEM, V272, P22285, DOI 10.1074/jbc.272.35.22285; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Xiong AM, 2000, MICROBIOL-UK, V146, P659, DOI 10.1099/00221287-146-3-659; YOKOGAWA K, 1974, ANTIMICROB AGENTS CH, V6, P156, DOI 10.1128/AAC.6.2.156; Zhang RG, 2004, STRUCTURE, V12, P1147, DOI 10.1016/j.str.2004.06.001; Zong YN, 2004, STRUCTURE, V12, P105, DOI 10.1016/j.str.2003.11.021	62	59	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16263	16271		10.1074/jbc.M500071200	http://dx.doi.org/10.1074/jbc.M500071200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15718231	hybrid			2022-12-25	WOS:000228444800096
J	Rottmann, S; Menkel, AR; Bouchard, C; Mertsching, J; Loidl, P; Kremmer, E; Eilers, M; Luscher-Firzlaff, J; Lilischkis, R; Luscher, B				Rottmann, S; Menkel, AR; Bouchard, C; Mertsching, J; Loidl, P; Kremmer, E; Eilers, M; Luscher-Firzlaff, J; Lilischkis, R; Luscher, B			Mad1 function in cell proliferation and transcriptional repression is antagonized by cyclin E/CDK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATES CENTROSOME DUPLICATION; TRANSFORMATION; PROGRESSION; INHIBITION; COMPLEXES; PROTEINS; FAMILY; GROWTH; CANCER; E-CDK2	The transcription factors of the Myc/Max/Mad network play essential roles in the regulation of cellular behavior. Mad1 inhibits cell proliferation by recruiting an mSin3-corepressor complex that contains histone deacetylase activity. Here we demonstrate that Mad1 is a potent inhibitor of the G(1) to S phase transition, a function that requires Mad1 to heterodimerize with Max and to bind to the corepressor complex. Cyclin E/CDK2, but not cyclin D and cyclin A complexes, fully restored S phase progression. In addition inhibition of colony formation and gene repression by Mad1 were also efficiently antagonized by cyclin E/CDK2. This was the result of cyclin E/CDK2 interfering with the interaction of Mad1 with HDAC1 and reducing HDAC activity. Our findings define a novel interplay between the cell cycle regulator cyclin E/CDK2 and Mad1 and its associated repressor complex and suggests an additional mechanism how cyclin E/CDK2 affects the G1 to S phase transition.	Klinikum RWTH, Abt Biochem & Mol Biol, Inst Biochem, D-52057 Aachen, Germany; Klinikum RWTH, Inst Arbeitsmed, D-52057 Aachen, Germany; Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany; Inst Mol Tumorforsch, D-35033 Marburg, Germany; Med Univ Innsbruck, Inst Mol Biol, A-6020 Innsbruck, Austria; GSF Munich, Inst Mol Immunol, D-81377 Munich, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; Hannover Medical School; Medical University of Innsbruck; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Luscher, B (corresponding author), Klinikum RWTH, Abt Biochem & Mol Biol, Inst Biochem, D-52057 Aachen, Germany.	luescher@rwth-aachen.de	Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709; Eilers, Martin/0000-0002-0376-6533				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; CERNI C, 1995, ONCOGENE, V11, P587; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Ho A, 2002, CURR OPIN GENET DEV, V12, P47, DOI 10.1016/S0959-437X(01)00263-5; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; ROTTMANN S, 2005, IN PRESS CURR TOP MI; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700	24	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15489	15492		10.1074/jbc.C400611200	http://dx.doi.org/10.1074/jbc.C400611200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722557	hybrid			2022-12-25	WOS:000228444800004
J	Sun, YP; Leaman, DW				Sun, YP; Leaman, DW			Involvement of Noxa in cellular apoptotic responses to interferon, double-stranded RNA, and virus infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GENE FACTOR-3; ALPHA-INDUCED APOPTOSIS; PROSTATE-CANCER CELLS; BCL-2 FAMILY; REGULATORY FACTOR-3; BH3-ONLY PROTEINS; IMMUNE-RESPONSE; DEATH AGONIST; FACTOR DRAF1; VIRAL BCL-2	Double-stranded RNA ( dsRNA) accumulates in virally infected cells, leading to induction of genes encoding proteins involved in signaling, apoptosis, protein synthesis/ processing, and cell metabolism. Noxa is a BH3-containing mitochondrial protein that contributes to apoptosis by disrupting mitochondrial outer membrane integrity. Here we demonstrate potent induction of Noxa expression by exposure of cells to dsRNA, interferon (IFN), and virus. Noxa induction was confirmed by using reverse transcriptase-PCR and immunoblot analyses in multiple human tumor cell lines. Importantly, Noxa regulation by IFN and dsRNA was independent of p53, thereby identifying a novel mechanism of Noxa induction. Ectopic expression of Noxa in HT1080 fibrosarcoma cells enhanced cellular sensitivity to viral or dsRNA/actinomycin D-induced apoptosis, typified by enhanced cytochrome c release from the mitochondrial to the cytosolic fraction and increased cleavage of caspases 3 and 9. Point and deletion mutations of Noxa confirmed that both the BH3 domain and the mitochondrial-targeting domain were necessary for enhanced cellular apoptotic responses to dsRNA, IFN, or virus. Treatment of cells with dsRNA or virus, but not etoposide, induced interaction between Noxa and Bax that required an intact Noxa BH3 domain. Interestingly, the Noxa mitochondrial-targeting domain deletion mutant interacted with Bax in a dsRNA-dependent manner and redirected Bax away from the mitochondria, thus acting as a dominant-negative protein. Together, these data suggest that Noxa is an important component of the innate immune response of cells to viral infection, leading to enhanced cellular apoptosis that may play a role in limiting viral dissemination.	Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA	University System of Ohio; University of Toledo	Leaman, DW (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.	dleaman@utnet.utoledo.edu			NATIONAL CANCER INSTITUTE [R01CA090837] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA90837] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; BANDYOPADHYAY SK, 1995, J BIOL CHEM, V270, P19624, DOI 10.1074/jbc.270.33.19624; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; Brassard DL, 2004, J INTERF CYTOK RES, V24, P455, DOI 10.1089/1079990041689638; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Colletier PJ, 2000, INT J RADIAT ONCOL, V48, P1507, DOI 10.1016/S0360-3016(00)01409-7; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Everett H, 1999, TRENDS MICROBIOL, V7, P160, DOI 10.1016/S0966-842X(99)01487-0; Gangappa S, 2002, J EXP MED, V195, P931, DOI 10.1084/jem.20011825; Ghosh A, 2001, J BIOL CHEM, V276, P25447, DOI 10.1074/jbc.M100496200; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65; HIJIKATA M, 1990, J VIROL, V64, P4632, DOI 10.1128/JVI.64.10.4632-4639.1990; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; ISAACS WB, 1991, CANCER RES, V51, P4716; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Kaiser WJ, 2004, J IMMUNOL, V172, P1699, DOI 10.4049/jimmunol.172.3.1699; Kalai M, 2002, CELL DEATH DIFFER, V9, P981, DOI 10.1038/sj.cdd.4401051; Kelly JD, 2004, BRIT J CANCER, V91, P164, DOI 10.1038/sj.bjc.6601895; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; LASTELLI J, 1998, BIOMED PHARMACOTHER, V52, P386; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Leaman DW, 2003, J INTERF CYTOK RES, V23, P745, DOI 10.1089/107999003772084860; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Matsumoto M, 2004, MICROBIOL IMMUNOL, V48, P147, DOI 10.1111/j.1348-0421.2004.tb03500.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Panaretakis T, 2003, ONCOGENE, V22, P4543, DOI 10.1038/sj.onc.1206503; Polster BM, 2004, BBA-MOL CELL RES, V1644, P211, DOI 10.1016/j.bbamcr.2003.11.001; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Sledz CA, 2004, BIOCHEM SOC T, V32, P952, DOI 10.1042/BST0320952; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Suk K, 2001, FEBS LETT, V495, P66, DOI 10.1016/S0014-5793(01)02335-3; Sun YP, 2004, J INTERF CYTOK RES, V24, P350, DOI 10.1089/107999004323142213; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Tamura T, 1996, BIOCHEM BIOPH RES CO, V229, P21, DOI 10.1006/bbrc.1996.1752; tenOever BR, 2004, J VIROL, V78, P10636, DOI 10.1128/JVI.78.19.10636-10649.2004; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Weaver BK, 2001, FASEB J, V15, P501, DOI 10.1096/fj.00-0222com; Wei MC, 2000, GENE DEV, V14, P2060; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	56	53	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15561	15568		10.1074/jbc.m412630200	http://dx.doi.org/10.1074/jbc.m412630200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705586	hybrid			2022-12-25	WOS:000228444800014
J	Ayalon, G; Segev, E; Elgavish, S; Stern-Bach, Y				Ayalon, G; Segev, E; Elgavish, S; Stern-Bach, Y			Two regions in the N-terminal domain of ionotropic glutamate receptor 3 form the subunit oligomerization interfaces that control subtype-specific receptor assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; LIGAND-BINDING PROPERTIES; FOLD-RECOGNITION; ION CHANNELS; MOLECULAR DETERMINANTS; LOCAL-STRUCTURE; PROTEIN; MUTATION; SITE; MICE	The N-terminal domain (NTD) of alpha-amino-3-hydroxy-5- methylisoxazolepropionate ( AMPA) and kainate glutamate receptors plays an important role in controlling subtype specific receptor assembly. To identify NTD subdomains involved in this process we generated AMPA glutamate receptor 3 (GluR3) mutants having intra-NTD substitutions with the corresponding regions of the kainate receptor GluR6 and tested their ability to form functional heteromers with wild-type subunits. The chimeric design was based on the homology of the NTD to the NTD of the metabotropic GluR1, shown to form two globular lobes and to assemble in dimers. Accordingly, the NTD was divided into four regions, termed here N1 - N4, of which N1 and N3 correspond to the regions forming lobe-1 and N2 and N4 to those forming lobe-2. Substituting N1 or N3 impaired functional heteromerization but allowed protein-protein interactions. Conversely, exchanging N2 or N4 preserved functional heteromerization, although it significantly decreased homomeric activity, indicating a role in subunit folding. Moreover, a deletion in GluR3 corresponding to the hotfoot mouse mutation of the glutamate receptor delta 2, covering part of N2, N3, and N4, impaired both homomeric and heteromeric oligomerization, thus explaining the null-like mouse phenotype. Finally, computer modeling suggested that the dimer interface, largely formed by N1, is highly hydrophobic in GluR3, whereas in GluR6 it contains electrostatic interactions, hence offering an explanation for the subtype assembly specificity conferred by this region. N3, however, is positioned perpendicular to the dimer interface and therefore may be involved in secondary interactions between dimers in the assembled tetrameric receptor.	Hebrew Univ Jerusalem, Hadassah Dent Sch, Inst Basic Dent Sci, Dept Anat & Cell Biol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Struct Biol Bioinformat Unit, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Stern-Bach, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Dent Sch, Inst Basic Dent Sci, Dept Anat & Cell Biol, IL-91120 Jerusalem, Israel.	yaelb@cc.huji.ac.il						ARAKI K, 1993, BIOCHEM BIOPH RES CO, V197, P1267, DOI 10.1006/bbrc.1993.2614; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; Dingledine R, 1999, PHARMACOL REV, V51, P7; Fischer D, 1999, PROTEINS, P209; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Karchin R, 2003, PROTEINS, V51, P504, DOI 10.1002/prot.10369; Karplus K, 2001, PROTEINS, P86, DOI 10.1002/prot.10021; Karplus K, 2003, PROTEINS, V53, P491, DOI 10.1002/prot.10540; KASHIWABUCHI N, 1995, CELL, V81, P245, DOI 10.1016/0092-8674(95)90334-8; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kniazeff J, 2004, NAT STRUCT MOL BIOL, V11, P706, DOI 10.1038/nsmb794; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Kuusinen A, 1999, J BIOL CHEM, V274, P28937, DOI 10.1074/jbc.274.41.28937; Lalouette A, 1998, GENOMICS, V50, P9, DOI 10.1006/geno.1998.5314; Leuschner WD, 1999, J BIOL CHEM, V274, P16907, DOI 10.1074/jbc.274.24.16907; LOMELI H, 1993, FEBS LETT, V315, P318, DOI 10.1016/0014-5793(93)81186-4; Low CM, 2000, P NATL ACAD SCI USA, V97, P11062, DOI 10.1073/pnas.180307497; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Matsuda S, 2002, EUR J NEUROSCI, V16, P1507, DOI 10.1046/j.1460-9568.2002.02219.x; Mayer ML, 2004, ANNU REV PHYSIOL, V66, P161, DOI 10.1146/annurev.physiol.66.050802.084104; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Paoletti P, 2000, NEURON, V28, P911, DOI 10.1016/S0896-6273(00)00163-X; Papadakis M, 2004, J BIOL CHEM, V279, P14703, DOI 10.1074/jbc.M313446200; Pasternack A, 2002, J BIOL CHEM, V277, P49662, DOI 10.1074/jbc.M208349200; Perin-Dureau F, 2002, J NEUROSCI, V22, P5955; Robert A, 2002, NEUROSCIENCE, V115, P1199, DOI 10.1016/S0306-4522(02)00534-1; SAPER MA, 1983, J BIOL CHEM, V258, P1057; Seeburg PH, 1996, J NEUROCHEM, V66, P1; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Tsuchiya D, 2002, P NATL ACAD SCI USA, V99, P2660, DOI 10.1073/pnas.052708599; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; Wells GB, 2001, J BIOL CHEM, V276, P3031, DOI 10.1074/jbc.M006668200; Yuzaki M, 2003, NEUROSCI RES, V46, P11, DOI 10.1016/S0168-0102(03)00036-1; Zheng F, 2001, NAT NEUROSCI, V4, P894, DOI 10.1038/nn0901-894; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	42	51	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15053	15060		10.1074/jbc.M408413200	http://dx.doi.org/10.1074/jbc.M408413200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15703162	hybrid			2022-12-25	WOS:000228236800088
J	Baisamy, L; Jurisch, N; Diviani, D				Baisamy, L; Jurisch, N; Diviani, D			Leucine zipper-mediated homo-oligomerization regulates the Rho-GEF activity of AKAP-Lbc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTORS; DEPENDENT PROTEIN-KINASE; DBL HOMOLOGY DOMAIN; GUANOSINE TRIPHOSPHATASES; ANCHORING PROTEINS; BCR-ABL; OLIGOMERIZATION; PHOSPHORYLATION; AUTOINHIBITION; ACTIVATION	AKAP-Lbc is a novel member of the A-kinase anchoring protein (AKAPs) family, which functions as a cAMP-dependent protein kinase (PKA)-targeting protein as well as a guanine nucleotide exchange factor (GEF) for RhoA. We recently demonstrated that AKAP-Lbc Rho-GEF activity is stimulated by the alpha-subunit of the heterotrimeric G protein G(12), whereas phosphorylation of AKAP-Lbc by the anchored PKA induces the recruitment of 14-3-3, which inhibits its GEF function. In the present report, using co-immunoprecipitation approaches, we demonstrated that AKAP-Lbc can form homo-oligomers inside cells. Mutagenesis studies revealed that oligomerization is mediated by two adjacent leucine zipper motifs located in the C-terminal region of the anchoring protein. Most interestingly, disruption of oligomerization resulted in a drastic increase in the ability of AKAP-Lbc to stimulate the formation of Rho-GTP in cells under basal conditions, suggesting that oligomerization maintains AKAP-Lbc in a basal-inactive state. Based on these results and on our previous findings showing that AKAP-Lbc is inactivated through the association with 14-3-3, we investigated the hypothesis that AKAP-Lbc oligomerization might be required for the regulatory action of 14-3-3. Most interestingly, we found that mutants of AKAP-Lbc impaired in their ability to undergo oligomerization were completely resistant to the inhibitory effect of PKA and 14-3-3. This suggests that 14-3-3 can negatively regulate the Rho-GEF activity of AKAP-Lbc only when the anchoring protein is in an oligomeric state. Altogether, these findings provide a novel mechanistic explanation of how oligomerization can regulate the activity of exchange factors of the Dbl family.	Fac Med, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Geneva	Diviani, D (corresponding author), Fac Med, Dept Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	Dario.diviani@ipharm.unil.ch	Jurisch-Yaksi, Nathalie/A-3219-2019	Jurisch-Yaksi, Nathalie/0000-0002-8767-6120; Diviani, Dario/0000-0003-4375-3718				Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; CARR DW, 1991, J BIOL CHEM, V266, P14188; Chikumi H, 2004, ONCOGENE, V23, P233, DOI 10.1038/sj.onc.1207012; Diviani D, 2001, J BIOL CHEM, V276, P44247, DOI 10.1074/jbc.M106629200; Diviani D, 2004, EMBO J, V23, P2811, DOI 10.1038/sj.emboj.7600287; Eisenhaure TM, 2003, J BIOL CHEM, V278, P30975, DOI 10.1074/jbc.M303277200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feng QY, 2004, EMBO J, V23, P3492, DOI 10.1038/sj.emboj.7600331; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Newlon MG, 1997, J BIOL CHEM, V272, P23637, DOI 10.1074/jbc.272.38.23637; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zhang XW, 2001, MOL CELL BIOL, V21, P840, DOI 10.1128/MCB.21.3.840-853.2001; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zhu KJ, 2001, MOL CELL BIOL, V21, P425, DOI 10.1128/MCB.21.2.425-437.2001	30	56	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15405	15412		10.1074/jbc.M414440200	http://dx.doi.org/10.1074/jbc.M414440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15691829	hybrid			2022-12-25	WOS:000228236800127
J	Romero, JR; Rivera, A; Lanca, V; Bicho, MDP; Conlin, PR; Ricupero, DA				Romero, JR; Rivera, A; Lanca, V; Bicho, MDP; Conlin, PR; Ricupero, DA			Na+/Ca2+ exchanger activity modulates connective tissue growth factor mRNA expression in transforming growth factor beta 1- and Des-Arg(10)-kallidin-stimulated myofibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE-EXPRESSION; IDIOPATHIC PULMONARY-FIBROSIS; SODIUM-CALCIUM EXCHANGE; HUMAN LUNG FIBROBLASTS; CARDIAC MYOCYTES; MESANGIAL CELLS; IN-VIVO; RECEPTOR; BRADYKININ; KINASE	Transforming growth factor (TGF)-beta and des-Arg(10)-kallidin stimulate the expression of connective tissue growth factor ( CTGF), a matrix signaling molecule that is frequently overexpressed in fibrotic disorders. Because the early signal transduction events regulating CTGF expression are unclear, we investigated the role of Ca2+ homeostasis in CTGF mRNA expression in TGF-beta 1- and des-Arg(10)-kallidin-stimulated human lung myofibroblasts. Activation of the kinin B1 receptor with des-Arg(10)-kallidin stimulated a rise in cytosolic Ca2+ that was extracellular Na+-dependent and extracellular Ca2+ dependent. The des-Arg(10)-kallidin-stimulated increase of cytosolic Ca2+ was blocked by KB-R7943, a specific inhibitor of Ca2+ entry mode operation of the plasma membrane Na+/Ca2+ exchanger. TGF-beta 1 similarly stimulated a KB-R7943-sensitive increase of cytosolic Ca2+ with kinetics distinct from the des-Arg(10)-kallidin- stimulated Ca2+ response. We also found that KB-R7943 or 2', 4'-dichlorobenzamil, an amiloride analog that inhibits the Na+/Ca2+ exchanger activity, blocked the TGF-beta 1- and des-Arg(10)-kallidin- stimulated increases of CTGF mRNA. Pretreatment with KB-R7943 also reduced the basal and TGF-beta 1-stimulated levels of alpha 1( I) collagen and alpha smooth muscle actin mRNAs. These data suggest that, in addition to regulating ion homeostasis, Na+/Ca2+ exchanger acts as a signal transducer regulating CTGF, alpha 1( I) collagen, and alpha smooth muscle actin expression. Consistent with a more widespread role for Na+/Ca2+ exchanger in fibrogenesis, we also observed that KB-R7943 likewise blocked TGF-beta 1-stimulated levels of CTGF mRNA in human microvascular endothelial and human osteoblast-like cells. We conclude that Ca2+ entry mode operation of the Na+/Ca2+ exchanger is required for des- Arg(10)-kallidin- and TGF-beta 1-stimulated fibrogenesis and participates in the maintenance of the myofibroblast phenotype.	Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA; Childrens Hosp Boston, Dept Med, Boston, MA 02115 USA; Childrens Hosp Boston, Dept Lab Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Lisbon, Fac Med, Genet Lab, Ctr Metab & Endocrinol, P-1200 Lisbon, Portugal; Vet Affairs Boston Healthcare Syst, Boston, MA 02130 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Universidade de Lisboa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Boston University; Boston University	Romero, JR (corresponding author), Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA.	jromero@rics.bwh.harvard.edu		Bicho, Manuel/0000-0002-5773-5687; Romero, Jose Ricardo/0000-0001-8225-0772; Lanca, Vasco/0000-0001-9996-5088	NHLBI NIH HHS [HL67699] Funding Source: Medline; NIDDK NIH HHS [DK064841, DK002817, DK63214] Funding Source: Medline; NIEHS NIH HHS [ES11443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL067699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK064841, K01DK002817, K24DK063214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R03ES011443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Carrillo C, 1998, CELL MOL BIOL, V44, P543; Chen YJ, 2002, KIDNEY INT, V62, P1149, DOI 10.1111/j.1523-1755.2002.kid567.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Condrescu M, 2002, ANN NY ACAD SCI, V976, P214; CRESPO LM, 1990, NATURE, V345, P618, DOI 10.1038/345618a0; DAVIS AJ, 1994, NEUROPHARMACOLOGY, V33, P127, DOI 10.1016/0028-3908(94)90107-4; DEBLOIS D, 1989, IMMUNOPHARMACOLOGY, V17, P187, DOI 10.1016/0162-3109(89)90047-7; Ehler E, 1996, CELL MOTIL CYTOSKEL, V34, P288, DOI 10.1002/(SICI)1097-0169(1996)34:4<288::AID-CM4>3.0.CO;2-4; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; GARCIA ML, 1990, J BIOL CHEM, V265, P3763; Gooch JL, 2004, J BIOL CHEM, V279, P15561, DOI 10.1074/jbc.M308759200; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Iwamoto T, 1996, J BIOL CHEM, V271, P22391, DOI 10.1074/jbc.271.37.22391; Kang TM, 2004, NATURE, V427, P544, DOI 10.1038/nature02271; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; Kimchi-Sarfaty C, 2002, J BIOL CHEM, V277, P2505, DOI 10.1074/jbc.M109154200; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Kucich U, 2001, ARCH BIOCHEM BIOPHYS, V395, P103, DOI 10.1006/abbi.2001.2571; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; KUHN C, 1991, AM J PATHOL, V138, P1257; Li L, 2000, J BIOL CHEM, V275, P20903, DOI 10.1074/jbc.M000995200; LOW RB, 1985, J CELL BIOL, V101, P500, DOI 10.1083/jcb.101.2.500; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; Mashburn NA, 1999, AM J PHYSIOL-RENAL, V276, pF574, DOI 10.1152/ajprenal.1999.276.4.F574; McGowan TA, 2002, AM J PHYSIOL-RENAL, V282, pF910, DOI 10.1152/ajprenal.00252.2001; Nakamura T, 1998, P NATL ACAD SCI USA, V95, P5389, DOI 10.1073/pnas.95.9.5389; Nesti LJ, 2002, ANN NY ACAD SCI, V961, P178, DOI 10.1111/j.1749-6632.2002.tb03078.x; Oemar BS, 1997, CIRCULATION, V95, P831; PERKINS MN, 1995, CAN J PHYSIOL PHARM, V73, P832, DOI 10.1139/y95-113; Phagoo SB, 2001, J PHARMACOL EXP THER, V298, P77; REGOLI D, 1980, PHARMACOL REV, V32, P1; Ricupero DA, 2000, J BIOL CHEM, V275, P12475, DOI 10.1074/jbc.275.17.12475; Schulze DH, 2003, J BIOL CHEM, V278, P28849, DOI 10.1074/jbc.M300754200; SIMONSSON BG, 1973, RESPIRATION, V30, P378, DOI 10.1159/000193051; Stains JP, 2001, J BONE MINER RES, V16, P1434, DOI 10.1359/jbmr.2001.16.8.1434; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; ZHANG K, 1994, AM J PATHOL, V145, P114	45	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14378	14384		10.1074/jbc.M410052200	http://dx.doi.org/10.1074/jbc.M410052200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15703175	hybrid			2022-12-25	WOS:000228236800005
J	Salmon, KA; Hung, S; Steffen, NR; Krupp, R; Baldi, P; Hatfield, GW; Gunsalus, RP				Salmon, KA; Hung, S; Steffen, NR; Krupp, R; Baldi, P; Hatfield, GW; Gunsalus, RP			Global gene expression profiling in Escherichia coli K12 - Effects of oxygen availability and ArcA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDASE CYDAB OPERON; PROTON-TRANSLOCATING NADH; AEROBIC REGULATION; ACID RESISTANCE; COLI K-12; TRANSCRIPTIONAL REGULATION; ELECTRON-ACCEPTORS; HEME AVAILABILITY; GROWTH-CONDITIONS; FUMARASE FUMA	The ArcAB two-component system of Escherichia coli regulates the aerobic/anaerobic expression of genes that encode respiratory proteins whose synthesis is coordinated during aerobic/anaerobic cell growth. A genomic study of E. coli was undertaken to identify other potential targets of oxygen and ArcA regulation. A group of 175 genes generated from this study and our previous study on oxygen regulation ( Salmon, K., Hung, S. P., Mekjian, K., Baldi, P., Hatfield, G. W., and Gunsalus, R. P. ( 2003) J. Biol. Chem. 278, 29837 - 29855), called our gold standard gene set, have p values < 0.00013 and a posterior probability of differential expression value of 0.99. These 175 genes clustered into eight expression patterns and represent genes involved in a large number of cell processes, including small molecule biosynthesis, macromolecular synthesis, and aerobic/anaerobic respiration and fermentation. In addition, 119 of these 175 genes were also identified in our previous study of the fnr allele. A MEME/weight matrix method was used to identify a new putative ArcA-binding site for all genes of the E. coli genome. 16 new sites were identified upstream of genes in our gold standard set. The strict statistical analyses that we have performed on our data allow us to predict that 1139 genes in the E. coli genome are regulated either directly or indirectly by the ArcA protein with a 99% confidence level.	Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Irvine, Dept Informat & Comp Sci, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Chem Engn & Mat Sci, Irvine, CA 92697 USA; Univ Calif Irvine, Inst Genom & Bioinformat, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Gunsalus, RP (corresponding author), Univ Calif Irvine, Dept Microbiol & Mol Genet, Campus Dr, Irvine, CA 92697 USA.	robg@microbio.ucla.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068903] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007443] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21678] Funding Source: Medline; NIGMS NIH HHS [GM49694, GM68903] Funding Source: Medline; NLM NIH HHS [T15 LM-07443] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Bailey TL, 1998, BIOINFORMATICS, V14, P48, DOI 10.1093/bioinformatics/14.1.48; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Baldi P, 2002, DNA MICROARRAYS GENE; Bauer CE, 1999, ANNU REV MICROBIOL, V53, P495, DOI 10.1146/annurev.micro.53.1.495; BELL AI, 1990, MOL MICROBIOL, V4, P1753, DOI 10.1111/j.1365-2958.1990.tb00553.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BONGAERTS J, 1995, MOL MICROBIOL, V16, P521, DOI 10.1111/j.1365-2958.1995.tb02416.x; Chao GL, 1997, J BACTERIOL, V179, P4299, DOI 10.1128/jb.179.13.4299-4304.1997; COMPAN I, 1994, MOL MICROBIOL, V11, P955, DOI 10.1111/j.1365-2958.1994.tb00374.x; COTTER PA, 1990, J BACTERIOL, V172, P6333, DOI 10.1128/jb.172.11.6333-6338.1990; COTTER PA, 1989, J BACTERIOL, V171, P3817, DOI 10.1128/jb.171.7.3817-3823.1989; Cotter PA, 1997, MOL MICROBIOL, V25, P605, DOI 10.1046/j.1365-2958.1997.5031860.x; COTTER PA, 1992, FEMS MICROBIOL LETT, V91, P31; DRAPAL N, 1995, MOL MICROBIOL, V16, P597, DOI 10.1111/j.1365-2958.1995.tb02422.x; Govantes F, 2000, MOL MICROBIOL, V37, P1456, DOI 10.1046/j.1365-2958.2000.02100.x; Govantes F, 2000, MOL MICROBIOL, V38, P1061, DOI 10.1046/j.1365-2958.2000.02215.x; Guest John R., 1996, P317; Guest JR, 1997, MICROBIOL-SGM, V143, P457, DOI 10.1099/00221287-143-2-457; GUNSALUS RP, 1994, RES MICROBIOL, V145, P437, DOI 10.1016/0923-2508(94)90092-2; Hatfield GW, 2003, MOL MICROBIOL, V47, P871, DOI 10.1046/j.1365-2958.2003.03298.x; HIRSHFIELD IN, 1984, J BACTERIOL, V158, P615, DOI 10.1128/JB.158.2.615-620.1984; Hung SP, 2002, J BIOL CHEM, V277, P40309, DOI 10.1074/jbc.M204044200; IUCHI S, 1990, J BACTERIOL, V172, P6020, DOI 10.1128/jb.172.10.6020-6025.1990; JAYARAMAN PS, 1989, NUCLEIC ACIDS RES, V17, P135, DOI 10.1093/nar/17.1.135; Jeong JY, 2004, J BIOL CHEM, V279, P38513, DOI 10.1074/jbc.M406667200; JONES HM, 1987, J BACTERIOL, V169, P3340, DOI 10.1128/jb.169.7.3340-3349.1987; LEVEQUE F, 1991, J BACTERIOL, V173, P7903, DOI 10.1128/jb.173.24.7903-7910.1991; Liu XQ, 2004, J BIOL CHEM, V279, P12588, DOI 10.1074/jbc.M313454200; Long AD, 2001, J BIOL CHEM, V276, P19937, DOI 10.1074/jbc.M010192200; Lynch AS, 1996, J BACTERIOL, V178, P6238, DOI 10.1128/JB.178.21.6238-6249.1996; LYNCH AS, 1996, REGULATION GENE EXPR, P362; LYNCH AS, 1996, ESCHERICHIA COLI SAL, V1, P1526; Ma Z, 2003, J BACTERIOL, V185, P6852, DOI 10.1128/JB.185.23.6852-6859.2003; Ma Z, 2002, J BACTERIOL, V184, P7001, DOI 10.1128/JB.184.24.7001-7012.2002; Masuda N, 2003, MOL MICROBIOL, V48, P699, DOI 10.1046/j.1365-2958.2003.03477.x; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; PARK SJ, 1995, J BACTERIOL, V177, P6255, DOI 10.1128/jb.177.21.6255-6262.1995; PARK SJ, 1995, J BACTERIOL, V177, P6652, DOI 10.1128/jb.177.22.6652-6656.1995; PARK SJ, 1995, MOL MICROBIOL, V15, P473, DOI 10.1111/j.1365-2958.1995.tb02261.x; Park SJ, 1997, J BACTERIOL, V179, P4138, DOI 10.1128/jb.179.13.4138-4142.1997; PARK SJ, 1994, J BACTERIOL, V176, P5086, DOI 10.1128/jb.176.16.5086-5092.1994; Salgado H, 2004, NUCLEIC ACIDS RES, V32, pD303, DOI 10.1093/nar/gkh140; Salmon K, 2003, J BIOL CHEM, V278, P29837, DOI 10.1074/jbc.M213060200; SAWERS G, 1992, J BACTERIOL, V174, P3474, DOI 10.1128/JB.174.11.3474-3478.1992; Shen J, 1997, MOL MICROBIOL, V26, P223, DOI 10.1046/j.1365-2958.1997.5561923.x; Silhavy T.J., 1984, EXPT GENE FUSIONS; Tramonti A, 2002, J BACTERIOL, V184, P2603, DOI 10.1128/JB.184.10.2603-2613.2002; Tseng CP, 1996, J BACTERIOL, V178, P1094, DOI 10.1128/jb.178.4.1094-1098.1996; Tseng CP, 1997, FEMS MICROBIOL LETT, V157, P67, DOI 10.1016/S0378-1097(97)00455-2; Tseng CP, 2001, J BACTERIOL, V183, P461, DOI 10.1128/JB.183.2.461-467.2001; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488	53	153	183	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15084	15096		10.1074/jbc.M414030200	http://dx.doi.org/10.1074/jbc.M414030200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15699038	hybrid			2022-12-25	WOS:000228236800091
J	Connor, JH; Lyles, DS				Connor, JH; Lyles, DS			Inhibition of host and viral translation during vesicular stomatitis virus infection - eIF2 is responsible for the inhibition of viral but not host translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED GENE-EXPRESSION; PROTEIN-KINASE PKR; MATRIX PROTEIN; MALIGNANT-TRANSFORMATION; INNATE IMMUNITY; INITIATION; RNA; PHOSPHORYLATION; CELLS; RESISTANCE	In cells that allow replication of vesicular stomatitis virus (VSV), there are two phases of translation inhibition: an early block of host translation and a later inhibition of viral translation. We investigated the phosphorylation of the alpha subunit of the eIF2 complex during these two phases of viral infection. In VSV-infected cells, the accumulation of phosphorylated (inactivated) eIF2 alpha did not begin until well after host protein synthesis was inhibited, suggesting that it only plays a role in blocking viral translation later after infection. Consistent with this, cells expressing an unphosphorylatable eIF2 alpha showed prolonged viral protein synthesis without an effect on host protein synthesis inhibition. Induction of eIF2 alpha phosphorylation at early times of viral infection by treatment with thapsigargin showed that virus and host translation are similarly inhibited, demonstrating that viral and host messages are similarly sensitive to eIF2 alpha phosphorylation. A recombinant virus that expresses a mutant matrix protein and is defective in the inhibition of host and virus protein synthesis showed an altered phosphorylation of eIF2 alpha, demonstrating an involvement of viral protein function in inducing this antiviral response. This analysis of eIF2 alpha phosphorylation, coupled with earlier findings that the eIF4F complex is modified earlier during VSV infection, supports a temporal/kinetic model of translation control, where at times soon after infection, changes in the eIF4F complex result in the inhibition of host protein synthesis; at later times, inactivation of the eIF2 complex blocks VSV protein synthesis.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University	Connor, JH (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	jconnor@wfubmc.edu		Lyles, Douglas/0000-0002-8401-3073; Connor, John/0000-0002-8867-7256	NCI NIH HHS [CA09422] Funding Source: Medline; NIAID NIH HHS [R01 AI052304, AI051805, R01 AI032983, AI052304, AI32983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032983, R21AI052304, F32AI051805, R01AI052304] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmed M, 2003, J VIROL, V77, P4646, DOI 10.1128/JVI.77.8.4646-4657.2003; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Baltzis D, 2004, J VIROL, V78, P12747, DOI 10.1128/JVI.78.23.12747-12761.2004; Bushell M, 2002, J CELL BIOL, V158, P395, DOI 10.1083/jcb.200205044; CENTRELLA M, 1982, J VIROL, V41, P781, DOI 10.1128/JVI.41.3.781-791.1982; Chesler DA, 2002, CYTOKINE GROWTH F R, V13, P441, DOI 10.1016/S1359-6101(02)00044-8; Connor JH, 2004, J VIROL, V78, P8960, DOI 10.1128/JVI.78.17.8960-8970.2004; Connor JH, 2002, J VIROL, V76, P10177, DOI 10.1128/JVI.76.20.10177-10187.2002; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; DRATEWKAKOS E, 1984, BIOCHEMISTRY-US, V23, P6184, DOI 10.1021/bi00320a045; Durbin RK, 2002, VIRAL IMMUNOL, V15, P41, DOI 10.1089/088282402317340224; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Gale M, 2000, MICROBIOL MOL BIOL R, V64, P239, DOI 10.1128/MMBR.64.2.239-280.2000; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; JAYE MC, 1982, VIROLOGY, V116, P148, DOI 10.1016/0042-6822(82)90410-X; Kopecky SA, 2003, J VIROL, V77, P5524, DOI 10.1128/JVI.77.9.5524-5528.2003; Kopecky SA, 2001, J VIROL, V75, P12169, DOI 10.1128/JVI.75.24.12169-12181.2001; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Lyles DS, 2000, MICROBIOL MOL BIOL R, V64, P709, DOI 10.1128/MMBR.64.4.709-724.2000; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Perkins DJ, 2004, MOL CELL BIOL, V24, P2025, DOI 10.1128/MCB.24.5.2025-2040.2004; Petersen JM, 2000, MOL CELL BIOL, V20, P8590, DOI 10.1128/MCB.20.22.8590-8601.2000; Rose JK, 2001, FIELDS VIROLOGY, P1221; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schneider RJ, 2003, TRENDS BIOCHEM SCI, V28, P130, DOI 10.1016/S0968-0004(03)00029-X; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6	32	66	69	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13512	13519		10.1074/jbc.M501156200	http://dx.doi.org/10.1074/jbc.M501156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15705563	hybrid			2022-12-25	WOS:000228095500042
J	Ichimura, T; Watanabe, S; Sakamoto, Y; Aoto, T; Fujita, N; Nakao, M				Ichimura, T; Watanabe, S; Sakamoto, Y; Aoto, T; Fujita, N; Nakao, M			Transcriptional repression and heterochromatin formation by MBD1 and MCAF/AM family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG BINDING-PROTEIN; HISTONE H3 METHYLTRANSFERASE; DNA METHYLATION; LYSINE 9; CHROMATIN; DOMAIN; HP1; MAINTENANCE; INTERACTS; PATTERNS	DNA methylation cooperates with methylation at lysine 9 of histone H3 (H3-K9), a modified histone molecule that is targeted by heterochromatin protein 1, to form a transcriptionally silent chromatin. Methyl CpG-binding protein MBD1 recognizes methylated CpG dinucleotide and recruits H3-K9 methyltransferases such as SETDB1 to genomic regions. Here we show that MBD1-containing chromatin-associated factor (MCAF) 1, also known as the human homologue of murine ATFa-associated modulator (AM), is required for transcriptional repression and heterochromatin formation by MBD1, together with the involvement of SETDB1. Moreover, the amino acid sequence of MCAF1 shows similarity to a number of sequences of the MCAF/AM-related proteins, resulting in the identification of a new member of the protein family, termed MCAF2. Immunoprecipitation and in vitro binding analyses reveal that both MCAF proteins interact with MBD1, SETDB1, and Sp1 via two evolutionarily conserved distinct domains. Furthermore, MCAF1 enhances transcriptional repression by MBD1 together with SETDB1, and exogenous expression of MCAF2 partly compensates for the repressive activity in MCAF1 knockdown HeLa cells. The expression of MBD1 mutant, which lacks interaction with MCAF proteins, perturbs heterochromatin protein 1-enriched heterochromatin formation at the MBD1-containing chromosomal loci. These data suggest that MBD1.MCAF1.SETDB1 complex facilitates the formation of heterochromatic domains, emphasizing the role of MCAF/AM family proteins in epigenetic control.	Kumamoto Univ, Inst Mol Embryol & Genet, Dept Regenerat Med, Kumamoto 8600811, Japan	Kumamoto University	Nakao, M (corresponding author), Kumamoto Univ, Inst Mol Embryol & Genet, Dept Regenerat Med, 2-2-1 Honjo, Kumamoto 8600811, Japan.	mnakao@gpo.kumamoto-u.ac.jp	Watanabe, Sugiko/Q-6201-2019	Watanabe, Sugiko/0000-0002-2120-9546				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; De Graeve F, 2000, ONCOGENE, V19, P1807, DOI 10.1038/sj.onc.1203492; Dodge JE, 2004, MOL CELL BIOL, V24, P2478, DOI 10.1128/MCB.24.6.2478-2486.2004; Espada J, 2004, J BIOL CHEM, V279, P37175, DOI 10.1074/jbc.M404842200; Fahrner JA, 2003, GENE DEV, V17, P1805, DOI 10.1101/gad.1123303; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Fujita N, 2003, MOL CELL BIOL, V23, P2834, DOI 10.1128/MCB.23.8.2834-2843.2003; Goll MG, 2002, GENE DEV, V16, P1739, DOI 10.1101/gad.1013902; Hendrich B, 2003, TRENDS GENET, V19, P269, DOI 10.1016/S0168-9525(03)00080-5; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jorgensen HF, 2004, MOL CELL BIOL, V24, P3387, DOI 10.1128/MCB.24.8.3387-3395.2004; Kadonaga JT, 2004, CELL, V116, P247, DOI 10.1016/S0092-8674(03)01078-X; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Kouzminova E, 2001, EMBO J, V20, P4309, DOI 10.1093/emboj/20.15.4309; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Malagnac F, 2002, EMBO J, V21, P6842, DOI 10.1093/emboj/cdf687; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ohki I, 2001, CELL, V105, P487, DOI 10.1016/S0092-8674(01)00324-5; Reese BE, 2003, MOL CELL BIOL, V23, P3226, DOI 10.1128/MCB.23.9.3226-3236.2003; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tariq M, 2004, TRENDS GENET, V20, P244, DOI 10.1016/j.tig.2004.04.005; Tariq M, 2003, P NATL ACAD SCI USA, V100, P8823, DOI 10.1073/pnas.1432939100; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wang HB, 2003, MOL CELL, V12, P475, DOI 10.1016/j.molcel.2003.08.007; Watanabe S, 2003, P NATL ACAD SCI USA, V100, P12859, DOI 10.1073/pnas.2131819100; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Yamada K, 2003, BIOCHEM J, V373, P167, DOI 10.1042/BJ20021866; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhao XY, 2003, P NATL ACAD SCI USA, V100, P6777, DOI 10.1073/pnas.1131928100	46	92	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13928	13935		10.1074/jbc.M413654200	http://dx.doi.org/10.1074/jbc.M413654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15691849	hybrid			2022-12-25	WOS:000228095500094
J	Kamath, K; Wilson, L; Cabral, F; Jordan, MA				Kamath, K; Wilson, L; Cabral, F; Jordan, MA			beta III-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; INDIVIDUAL MICROTUBULES; ANTIMITOTIC DRUGS; MITOTIC BLOCK; TAXOL; ISOTYPES; PROTEIN; EXPRESSION; BINDING; TAU	The development of resistance to paclitaxel in tumors is one of the most significant obstacles to successful therapy. Overexpression of the beta III-tubulin isotype has been associated with paclitaxel resistance in a number of cancer cell lines and in tumors, but the mechanism of resistance has remained unclear. Paclitaxel inhibits cancer cell proliferation by binding to the beta-subunit of tubulin in microtubules and suppressing microtubule dynamic instability, leading to mitotic arrest and cell death. We hypothesized that beta III-tubulin overexpression induces resistance to paclitaxel either by constitutively enhancing microtubule dynamic instability in resistant cells or by rendering the microtubules less sensitive to the suppression of dynamics by paclitaxel. Using Chinese hamster ovary cells that inducibly overexpress either beta I- or beta III-tubulin, we analyzed microtubule dynamic instability during interphase by microinjection of rhodamine-labeled tubulin and time-lapse fluorescence microscopy. In the absence of paclitaxel, there were no differences in any aspect of dynamic instability between the two beta-tubulin-overexpressing cell types. However, in the presence of 150 nM paclitaxel, dynamic instability was suppressed to a significantly lesser extent (suppressed only 12%) in cells overexpressing beta III-tubulin than in cells overexpressing similar levels of beta I-tubulin (suppressed 47%). The results suggest that overexpression of beta III-tubulin induces paclitaxel resistance by reducing the ability of paclitaxel to suppress microtubule dynamics. The results also suggest that endogenous regulators of microtubule dynamics may differentially interact with individual tubulin isotypes, supporting the idea that differential expression of tubulin isotypes has functional consequences in cells.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of Texas System	Jordan, MA (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	jordan@lifesci.ucsb.edu			NATIONAL CANCER INSTITUTE [R01CA057291] Funding Source: NIH RePORTER; NCI NIH HHS [CA57291] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P252, DOI 10.1016/0167-4781(91)90112-Y; BANERJEE A, 1994, J BIOL CHEM, V269, P2041; Barlow SB, 2002, J CELL SCI, V115, P3469; Bunker JM, 2004, MOL BIOL CELL, V15, P2720, DOI 10.1091/mbc.E04-01-0062; Cabral F, 2001, DRUG RESIST UPDATE, V4, P3, DOI 10.1054/drup.2000.0172; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200; CROSS D, 1991, BIOCHEMISTRY-US, V30, P4362, DOI 10.1021/bi00231a036; Derry WB, 1997, BIOCHEMISTRY-US, V36, P3554, DOI 10.1021/bi962724m; DERRY WB, 1995, BIOCHEMISTRY-US, V34, P2203, DOI 10.1021/bi00007a014; Downing KH, 1998, CURR OPIN CELL BIOL, V10, P16, DOI 10.1016/S0955-0674(98)80082-3; Dozier JH, 2003, BREAST CANCER RES, V5, pR157, DOI 10.1186/bcr631; Goncalves A, 2001, P NATL ACAD SCI USA, V98, P11737, DOI 10.1073/pnas.191388598; GONZALEZGARAY ML, 1995, CELL MOTIL CYTOSKEL, V31, P259, DOI 10.1002/cm.970310403; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hari M, 2003, CELL MOTIL CYTOSKEL, V56, P45, DOI 10.1002/cm.10132; Honore S, 2004, CANCER RES, V64, P4957, DOI 10.1158/0008-5472.CAN-04-0693; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; Jordan M. A., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P1, DOI 10.2174/1568011023354290; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Kamath K, 2003, CANCER RES, V63, P6026; Kar S, 2003, EMBO J, V22, P70, DOI 10.1093/emboj/cdg001; Kavallaris M, 1999, BRIT J CANCER, V80, P1020, DOI 10.1038/sj.bjc.6690507; KAVALLERIS M, 1997, J CLIN INVEST, V100, P1; Laing N, 1997, BIOCHEMISTRY-US, V36, P871, DOI 10.1021/bi961445w; LUDNENA RF, 1993, MOL BIOL CELL, V4, P445; Luduena RF, 1998, INT REV CYTOL, V178, P207; MACCIONI RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P568, DOI 10.1016/0003-9861(89)90403-7; Martello LA, 2003, CANCER RES, V63, P1207; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358; SAWADA T, 1989, J BIOL CHEM, V264, P3013; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SHARMA J, 1994, J PROTEIN CHEM, V13, P165, DOI 10.1007/BF01891975; Valiron O, 2001, CELL MOL LIFE SCI, V58, P2069, DOI 10.1007/PL00000837; Verdier-Pinard P, 2003, BIOCHEMISTRY-US, V42, P5349, DOI 10.1021/bi027293o; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947	40	202	218	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12902	12907		10.1074/jbc.M414477200	http://dx.doi.org/10.1074/jbc.M414477200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15695826	hybrid			2022-12-25	WOS:000227922000099
J	Tarrade, A; Bastien, J; Bruck, N; Bauer, A; Gianni, M; Rochette-Egly, C				Tarrade, A; Bastien, J; Bruck, N; Bauer, A; Gianni, M; Rochette-Egly, C			Retinoic acid and arsenic trioxide cooperate for apoptosis through phosphorylated RXR alpha	ONCOGENE			English	Article						arsenic; retinoic acic; phosphorylation; apoptosis; stress-kinases; RXR	OXIDATIVE DNA-DAMAGE; HISTONE H3 PHOSPHOACETYLATION; IMMEDIATE-EARLY GENE; N-TERMINAL KINASE; RECEPTOR-ALPHA; RAR-ALPHA; NUCLEAR RECEPTORS; CARCINOMA-CELLS; ACTIVATION; TRANSCRIPTION	Arsenite trioxide (AS(2)O(3)) induces apoptosis in several cell lines by disturbing key signal transduction pathways through its oxidative properties. Here, we report that AS(2)O(3) also induces the phosphorylation of the retinoid receptor RXR alpha, subsequent to oxidative damages and the activation of the stress-activated protein kinases cascade (JNKs). We also report that RA amplifies both AS(2)O(3)-induced phosphorylation of RXR alpha and apoptosis. Taking advantage of 'rescue' F9 cell lines expressing RXR alpha mutated at its phosphorylation sites, in an RXR alpha a null background, we provide evidence that RXR alpha is a key element involved in that potentiating effect. Finally, we demonstrate that AS(2)O(3) also abrogates the transactivation of RA-target genes.	IGBMC, CNRS, INSERM, ULP, F-67404 Illkirch Graffenstaden, France; Ist Ric Farmacol Mario Negri, Lab Biol Mol, I-20157 Milan, Italy	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Rochette-Egly, C (corresponding author), IGBMC, CNRS, INSERM, ULP, BP 10142, F-67404 Illkirch Graffenstaden, France.	cegly@igbmc.u-strasbg.fr	Gianni, Maurizio/ABG-6322-2020	Gianni, Maurizio/0000-0002-6945-708X				Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; Altucci L, 2001, TRENDS ENDOCRIN MET, V12, P460, DOI 10.1016/S1043-2760(01)00502-1; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Bastien J., 2002, J BIOL CHEM, V24, P24; Bebien M, 2003, ONCOGENE, V22, P1836, DOI 10.1038/sj.onc.1206334; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Bernstam L, 2000, J TOXICOL ENV HEAL B, V3, P293, DOI 10.1080/109374000436355; Boudjelal M, 2002, EXP CELL RES, V274, P130, DOI 10.1006/excr.2001.5450; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; Ghosh R, 1999, NUCLEIC ACIDS RES, V27, P3213, DOI 10.1093/nar/27.15.3213; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; GIANNI M, 2003, J BIOL CHEM, V5, P389; Hayakawa F, 2004, CANCER CELL, V5, P389, DOI 10.1016/S1535-6108(04)00082-0; He ZW, 2003, J BIOL CHEM, V278, P10588, DOI 10.1074/jbc.M208581200; Hong SH, 2001, MOL CELL BIOL, V21, P7172, DOI 10.1128/MCB.21.21.7172-7182.2001; Huang CS, 2004, MOL CELL BIOCHEM, V255, P57, DOI 10.1023/B:MCBI.0000007261.04684.78; Iordanov MS, 1999, J BIOL CHEM, V274, P25801, DOI 10.1074/jbc.274.36.25801; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Keriel A, 2002, CELL, V109, P125, DOI 10.1016/S0092-8674(02)00692-X; Kessel M, 2002, MOL CELL BIOCHEM, V234, P301, DOI 10.1023/A:1015927406142; Kitchin KT, 2003, TOXICOL LETT, V137, P3, DOI 10.1016/S0378-4274(02)00376-4; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Laudet V., 2001, NUCL RECEPTOR FACTSB; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Lerner L, 2003, GENE DEV, V17, P2564, DOI 10.1101/gad.1135003; Li J, 2003, J BIOL CHEM, V278, P13183, DOI 10.1074/jbc.M300269200; Li J, 2002, J BIOL CHEM, V277, P49504, DOI 10.1074/jbc.M207836200; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; Liu Q, 2003, BLOOD, V101, P4078, DOI 10.1182/blood-2002-10-3231; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Mologni L, 1999, BLOOD, V93, P1045, DOI 10.1182/blood.V93.3.1045.403k22_1045_1061; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Nesnow S, 2002, CHEM RES TOXICOL, V15, P1627, DOI 10.1021/tx025598y; Oridate N, 1996, ONCOGENE, V12, P2019; Puccetti E, 2003, ONCOGENE, V22, P6900, DOI 10.1038/sj.onc.1206747; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rochette-Egly C, 2003, CELL SIGNAL, V15, P355, DOI 10.1016/S0898-6568(02)00115-8; Rochette-Egly C, 2001, HISTOL HISTOPATHOL, V16, P909, DOI 10.14670/HH-16.909; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; Roussel MJS, 2001, ONCOGENE, V20, P7287, DOI 10.1038/sj.onc.1204863; Sakaue M, 2001, CELL DEATH DIFFER, V8, P411, DOI 10.1038/sj.cdd.4400818; Schwerdtle T, 2003, CARCINOGENESIS, V24, P967, DOI 10.1093/carcin/bgg018; Shen ZX, 2004, P NATL ACAD SCI USA, V101, P5328, DOI 10.1073/pnas.0400053101; Shi HL, 2004, MOL CELL BIOCHEM, V255, P67, DOI 10.1023/B:MCBI.0000007262.26044.e8; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Theodosiou A, 2002, ONCOGENE, V21, P2387, DOI 10.1038/sj.onc.1205309; Verma A, 2002, J BIOL CHEM, V277, P44988, DOI 10.1074/jbc.M207176200; Xi HK, 2003, J IMMUNOL, V170, P315, DOI 10.4049/jimmunol.170.1.315; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu J, 2002, NAT REV CANCER, V2, P705, DOI 10.1038/nrc887; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852; Zhu Q, 2002, BLOOD, V99, P1014	67	21	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2277	2288		10.1038/sj.onc.1208402	http://dx.doi.org/10.1038/sj.onc.1208402			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15688020				2022-12-25	WOS:000227877400001
J	Philippova, M; Ivanov, D; Allenspach, R; Takuwa, Y; Erne, P; Resink, T				Philippova, M; Ivanov, D; Allenspach, R; Takuwa, Y; Erne, P; Resink, T			RhoA and Rac mediate endothelial cell polarization and detachment induced by T-cadherin	FASEB JOURNAL			English	Article						adhesion molecules; cytoskeleton; cell phenotype; small GTPases; signaling	SMOOTH-MUSCLE-CELLS; N-CADHERIN; PHOSPHATIDYLINOSITOL 3-KINASE; VASCULAR CELLS; FAMILY GTPASES; GROWTH-FACTOR; UP-REGULATION; BETA-CATENIN; IN-VITRO; ADHESION	T-cadherin (T-cad) is an atypical GPI- anchored member of the cadherin superfamily. Ligation of T-cad receptors on endothelial cells prevents cell spreading, promotes elongation and polarization, decreases adhesion to the matrix, and facilitates migration. This study investigates involvement of Rho GTPases in T-cad signaling. Human umbilical vein endothelial cells were infected with adenoviral vectors expressing dominant-negative and/or constitutively active mutants of RhoA (N19RhoA/RhoA63), ROCK (RB/PH(TT)/CAT), and Rac1 (N17RAC). Mutant-infected and empty vector-infected cells were compared with respect to their ability to detach and polarize when plated on substratum containing recombinant T-cad protein used as a ligand mimicking homophilic T-cad interactions. ROCK involvement was also studied using specific inhibitor Y-27632. Adhesion assays, analysis of cell phenotype, and actin cytoskeleton organization using TRITC-labeled phalloidin demonstrated that T-cad-induced cell polarization includes two complementary components: RhoA/ROCK pathway is necessary for cell contraction, stress fiber assembly, and inhibition of spreading, whereas Rac is required for formation of actin-rich lamellipodia at the leading edges of polarized cells. Individual repression of either pathway only partially prevented cell polarization and detachment, while simultaneous repression of RhoA and Rac pathways fully eliminated responses to homophilic T-cad ligation. In conclusion, these data suggest that T-cad induces cell deadhesion and polarization via RhoA-ROCK and Rac-dependent mechanisms.	Univ Basel Hosp, Dept Res, Cardiovasc Labs, CH-4031 Basel, Switzerland; Kanazawa Univ, Sch Med, Div Physiol, Kanazawa, Ishikawa 9208640, Japan; Luzern Kantonsspital, Div Cardiol, CH-6000 Luzern, Switzerland	University of Basel; Kanazawa University; Lucerne Cantonal Hospital	Resink, T (corresponding author), Univ Basel Hosp, Dept Res, Cardiovasc Labs, Hebelstr 20, CH-4031 Basel, Switzerland.	Therese-J.Resink@unibas.ch	Filippova, Maria/GXH-7313-2022	Filippova, Maria/0000-0003-3124-3155				Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amerongen GPV, 2003, ARTERIOSCL THROM VAS, V23, P211, DOI 10.1161/01.ATV.0000054198.68894.88; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Angst BD, 2001, J CELL SCI, V114, P629; Blindt R, 2004, CARDIOVASC RES, V62, P212, DOI 10.1016/j.cardiores.2004.01.004; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Cheng N, 2002, CYTOKINE GROWTH F R, V13, P75, DOI 10.1016/S1359-6101(01)00031-4; Connolly JO, 2002, MOL BIOL CELL, V13, P2474, DOI 10.1091/mbc.E02-01-0006; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Deroanne C, 2003, J CELL SCI, V116, P1367, DOI 10.1242/jcs.00308; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; Eto Y, 2000, AM J PHYSIOL-HEART C, V278, pH1744, DOI 10.1152/ajpheart.2000.278.6.H1744; Fredette BJ, 1996, DEVELOPMENT, V122, P3163; Fujiwara H, 2004, EXP CELL RES, V292, P67, DOI 10.1016/j.yexcr.2003.08.010; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Gerhardt H, 2000, DEV DYNAM, V218, P472, DOI 10.1002/1097-0177(200007)218:3<472::AID-DVDY1008>3.0.CO;2-#; Gerhardt H, 1999, EUR J NEUROSCI, V11, P1191, DOI 10.1046/j.1460-9568.1999.00526.x; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; Guan JL, 2004, SCIENCE, V303, P773, DOI 10.1126/science.1094376; Hoang MV, 2004, P NATL ACAD SCI USA, V101, P1874, DOI 10.1073/pnas.0308525100; Hu HL, 2001, NEURON, V32, P39, DOI 10.1016/S0896-6273(01)00453-6; Iso T, 2003, ARTERIOSCL THROM VAS, V23, P543, DOI 10.1161/01.ATV.0000060892.81529.8F; Ivanov D, 2004, CARDIOVASC RES, V64, P132, DOI 10.1016/j.cardiores.2004.06.010; Ivanov D, 2004, EXP CELL RES, V293, P207, DOI 10.1016/j.yexcr.2003.09.030; Ivanov D, 2001, HISTOCHEM CELL BIOL, V115, P231; Jones M, 2002, ARTERIOSCL THROM VAS, V22, P1972, DOI 10.1161/01.ATV.0000036416.14084.5A; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Koller E, 1996, J BIOL CHEM, V271, P30061, DOI 10.1074/jbc.271.47.30061; Kudrjashova E, 2002, HISTOCHEM CELL BIOL, V118, P281, DOI 10.1007/s00418-002-0463-6; Kuhn TB, 1999, J NEUROSCI, V19, P1965; Kuzmenko YS, 1998, FEBS LETT, V434, P183, DOI 10.1016/S0014-5793(98)00977-6; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; Liao F, 2000, CANCER RES, V60, P6805; Liu YQ, 2004, FASEB J, V18, P457, DOI 10.1096/fj.03-0948com; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Ming XF, 2002, MOL CELL BIOL, V22, P8467, DOI 10.1128/MCB.22.24.8467-8477.2002; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; Pearce JD, 2004, J VASC SURG, V39, P223, DOI 10.1016/S0741-5214(03)01037-1; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Philippova M, 2003, HISTOCHEM CELL BIOL, V120, P353, DOI 10.1007/s00418-003-0584-6; Philippova MP, 1998, FEBS LETT, V429, P207, DOI 10.1016/S0014-5793(98)00598-5; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Shima DT, 2000, CURR OPIN GENET DEV, V10, P536, DOI 10.1016/S0959-437X(00)00124-6; Soga N, 2001, CELL COMMUN ADHES, V8, P1, DOI 10.3109/15419060109080703; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451; Vouret-Craviari V, 2002, J CELL SCI, V115, P2475; Wojciak-Stothard B, 2003, J CELL BIOL, V161, P429, DOI 10.1083/jcb.200210135; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Wyder L, 2000, CANCER RES, V60, P4682; Xue W, 1997, CANCER RES, V57, P1682; Yu TW, 2001, NAT NEUROSCI, V4, P1169, DOI 10.1038/nn748	59	44	47	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					588	+		10.1096/fj.04-2430fje	http://dx.doi.org/10.1096/fj.04-2430fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15703273				2022-12-25	WOS:000227591900015
J	Cooper, DS; Saxena, NC; Yang, HS; Lee, HJ; Moring, AG; Lee, A; Choi, IY				Cooper, DS; Saxena, NC; Yang, HS; Lee, HJ; Moring, AG; Lee, A; Choi, IY			Molecular and functional characterization of the electroneutral Na/HCO3 cotransporter NBCn1 in rat hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-BICARBONATE COTRANSPORTER; CYTOPLASMIC DOMAIN; PYRAMIDAL NEURONS; INTRACELLULAR PH; EXTERNAL PH; TRANSPORTER; CLONING; ASTROCYTES; KIDNEY; BRAIN	We examined molecular and electrophysiological properties of the electroneutral sodium/bicarbonate cotransporter (NBCn1) that is present in rat hippocampal neurons. By PCR, a deletion variant (NBCn1-E) that lacks 123 amino acids in the cytoplasmic N-terminal domain was found in adult neurons. The previously characterized NBCn1-B, which does not have the deletion, was detected in embryonic neurons. In Xenopus oocytes, NBCn1-E raised the intracellular pH in the presence of HCO3 without significantly affecting the membrane potential. Despite this electroneutral cotransport activity, the transporter mediated a steady-state current that positively shifted the resting potential by almost 30 mV. The mean reversal potential of the steady-state current was - 21.2 mV, close to the resting potential of - 21.4 mV. The reversal potential shifted 26 mV in response to a 10-fold increase of external Na+ for concentrations above 10 mM. The current activity mediated by the transporter was unaffected by K+, Mg2+, Ca2+, or Cl-. Stable expression of NBCn1-E in human embryonic kidney cells also evoked an inward current that shifted the resting potentials more positive compared with the sham-transfected controls. In primary cultures of embryonic hippocampal neurons, the NBCn1 protein was localized in somatodendrites and synapses. NBCn1 protein was partially colocalized with the postsynaptic density protein PSD-95. Single-cell PCR showed that NBCn1 mRNA expression was present in both gamma-aminobutyric acid ( GABA) ergic and non-GABAergic neurons. We propose that NBCn1 in hippocampal neurons may affect neuronal activity by regulating local pH as well as steady-state inward currents at synapses.	Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Choi, IY (corresponding author), Emory Univ, Sch Med, Dept Physiol, 615 Michael St, Atlanta, GA 30322 USA.	ichoi@physio.emory.edu	choi, inyeong/AAM-4826-2021	Lee, Amy/0000-0001-8021-0443	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044922] Funding Source: NIH RePORTER; NINDS NIH HHS [NS044922] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baxter KA, 1996, J PHYSIOL-LONDON, V493, P457, DOI 10.1113/jphysiol.1996.sp021396; BENSON DL, 1994, J NEUROCYTOL, V23, P279, DOI 10.1007/BF01188497; Bevensee Mark O., 1998, P211; BEVENSEE MO, 1995, FASEB J, V9, pA308; Bok D, 2003, NAT GENET, V34, P313, DOI 10.1038/ng1176; Boron W F, 2001, JOP, V2, P176; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; Choi I, 1997, FEBS LETT, V405, P133, DOI 10.1016/S0014-5793(97)00155-5; Choi I, 1999, AM J PHYSIOL-CELL PH, V276, pC576, DOI 10.1152/ajpcell.1999.276.3.C576; Choi I, 2000, NATURE, V405, P571, DOI 10.1038/35014615; COOPER DS, 2004, SOC NEUR 2004 ABSTR; Deitmer JW, 2002, J NEUROCHEM, V80, P721, DOI 10.1046/j.0022-3042.2002.00765.x; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; Freedman JC, 1997, J GEN PHYSIOL, V109, P201, DOI 10.1085/jgp.109.2.201; Giffard RG, 2000, J NEUROSCI, V20, P1001, DOI 10.1523/JNEUROSCI.20-03-01001.2000; Goslin K., 1998, CULTURING NERVE CELL, P339; GRICHTCHENKO II, 1994, NEUROSCIENCE, V62, P1071, DOI 10.1016/0306-4522(94)90344-1; IIJIMA T, 1986, P NATL ACAD SCI USA, V83, P654, DOI 10.1073/pnas.83.3.654; Kang TC, 2002, MOL BRAIN RES, V109, P226, DOI 10.1016/S0169-328X(02)00559-4; Katsura K., 1998, P563; Kwon TH, 2002, AM J PHYSIOL-RENAL, V282, pF341, DOI 10.1152/ajprenal.00104.2001; Loiselle FB, 2003, MOL MEMBR BIOL, V20, P307, DOI 10.1080/0968768031000122520; OCONNOR ER, 1994, J NEUROPHYSIOL, V72, P2580, DOI 10.1152/jn.1994.72.6.2580; Odgaard E, 2004, J PHYSIOL-LONDON, V555, P205, DOI 10.1113/jphysiol.2003.046474; Park M, 2002, J BIOL CHEM, V277, P50503, DOI 10.1074/jbc.M201862200; Parker MD, 2001, BIOCHEM BIOPH RES CO, V282, P1103, DOI 10.1006/bbrc.2001.4692; PASTERNACK M, 1993, ACTA PHYSIOL SCAND, V148, P229, DOI 10.1111/j.1748-1716.1993.tb09553.x; Pushkin A, 1999, J BIOL CHEM, V274, P16569, DOI 10.1074/jbc.274.23.16569; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; RANSOM BR, 1992, PROG BRAIN RES, V94, P37; Romero MF, 2004, PFLUG ARCH EUR J PHY, V447, P495, DOI 10.1007/s00424-003-1180-2; Romero MF, 2000, J BIOL CHEM, V275, P24552, DOI 10.1074/jbc.M003476200; Schmitt BM, 2000, J NEUROSCI, V20, P6839, DOI 10.1523/JNEUROSCI.20-18-06839.2000; SCHWIENING CJ, 1994, J PHYSIOL-LONDON, V475, P59, DOI 10.1113/jphysiol.1994.sp020049; Soleimani M, 2001, J MEMBRANE BIOL, V183, P71, DOI 10.1007/s00232-001-0055-8; TRAYNELIS SF, 1991, J PHYSIOL-LONDON, V433, P727, DOI 10.1113/jphysiol.1991.sp018453; Vorum H, 2000, AM J PHYSIOL-RENAL, V279, pF901, DOI 10.1152/ajprenal.2000.279.5.F901; VYKLICKY L, 1990, J PHYSIOL-LONDON, V430, P497, DOI 10.1113/jphysiol.1990.sp018304; WYBORSKI RJ, 1990, MOL BRAIN RES, V8, P193, DOI 10.1016/0169-328X(90)90016-7; Zhang DC, 2000, BLOOD, V96, P2925	40	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17823	17830		10.1074/jbc.M408646200	http://dx.doi.org/10.1074/jbc.M408646200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15718246	hybrid			2022-12-25	WOS:000228807200034
J	Levinson, JN; Chery, N; Huang, K; Wong, TP; Gerrow, K; Kang, R; Prange, O; Wang, YT; El-Husseini, A				Levinson, JN; Chery, N; Huang, K; Wong, TP; Gerrow, K; Kang, R; Prange, O; Wang, YT; El-Husseini, A			Neuroligins mediate excitatory and inhibitory synapse formation - Involvement of PSD-95 and neurexin-1 beta in neuroligin-induced synaptic specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; HIPPOCAMPAL-NEURONS; MENTAL-RETARDATION; BETA-NEUREXINS; AUTISM; PROTEINS; SYNAPTOGENESIS; PLASTICITY; MOLECULES; BINDING	The balance between excitatory and inhibitory synapses is a tightly regulated process that requires differential recruitment of proteins that dictate the specificity of newly formed contacts. However, factors that control this process remain unidentified. Here we show that members of the neuroligin (NLG) family, including NLG1, NLG2, and NLG3, drive the formation of both excitatory and inhibitory presynaptic contacts. The enrichment of endogenous NLG1 at excitatory contacts and NLG2 at inhibitory synapses supports an important in vivo role for these proteins in the development of both types of contacts. Immunocytochemical and electrophysiological analysis showed that the effects on excitatory and inhibitory synapses can be blocked by treatment with a fusion protein containing the extracellular domain of neurexin-1 beta. We also found that overexpression of PSD-95, a postsynaptic binding partner of NLGs, resulted in a shift in the distribution of NLG2 from inhibitory to excitatory synapses. These findings reveal a critical role for NLGs and their synaptic partners in controlling the number of inhibitory and excitatory synapses. Furthermore, relative levels of PSD-95 alter the ratio of excitatory to inhibitory synaptic contacts by sequestering members of the NLG family to excitatory synapses.	Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	El-Husseini, A (corresponding author), Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada.	alaa@interchange.ubc.ca	Wang, Yu Tian/A-4729-2008; Wang, Yu Tian/J-8255-2015	Wong, Tak Pan/0000-0001-8611-4911				Bao JX, 2004, NAT NEUROSCI, V7, P1250, DOI 10.1038/nn1342; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brose N, 1999, NATURWISSENSCHAFTEN, V86, P516, DOI 10.1007/s001140050666; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; CHIH B, 2004, HUM MOL GENET; Craig AM, 2001, NAT NEUROSCI, V4, P569, DOI 10.1038/88388; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; El-Hussein AE, 2000, SCIENCE, V290, P1364; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; El-Husseini AE, 2002, CELL, V108, P849, DOI 10.1016/S0092-8674(02)00683-9; Graf ER, 2004, CELL, V119, P1013, DOI 10.1016/j.cell.2004.11.035; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Laumonnier F, 2004, AM J HUM GENET, V74, P552, DOI 10.1086/382137; Lee SH, 2000, CURR OPIN NEUROBIOL, V10, P125, DOI 10.1016/S0959-4388(99)00046-X; Levi S, 2004, J NEUROSCI, V24, P207, DOI 10.1523/JNEUROSCI.1661-03.2004; Luscher B, 2004, PHARMACOL THERAPEUT, V102, P195, DOI 10.1016/j.pharmthera.2004.04.003; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Prange O, 2004, P NATL ACAD SCI USA, V101, P13915, DOI 10.1073/pnas.0405939101; Rao A, 2000, NAT NEUROSCI, V3, P747, DOI 10.1038/77636; Risch N, 1999, AM J HUM GENET, V65, P493, DOI 10.1086/302497; Rubenstein JLR, 2003, GENES BRAIN BEHAV, V2, P255, DOI 10.1034/j.1601-183X.2003.00037.x; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; Todd PK, 2003, P NATL ACAD SCI USA, V100, P14374, DOI 10.1073/pnas.2336265100; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; Varoqueaux F, 2004, EUR J CELL BIOL, V83, P449, DOI 10.1078/0171-9335-00410; Washbourne P, 2004, J NEUROSCI, V24, P9244, DOI 10.1523/JNEUROSCI.3339-04.2004; Yao WD, 2004, NEURON, V41, P625, DOI 10.1016/S0896-6273(04)00048-0; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4; Ziv NE, 2001, NEUROSCIENTIST, V7, P365, DOI 10.1177/107385840100700505	38	207	224	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17312	17319		10.1074/jbc.M413812200	http://dx.doi.org/10.1074/jbc.M413812200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15723836	hybrid			2022-12-25	WOS:000228615500095
J	Otto, BR; Sijbrandi, R; Luirink, J; Oudega, B; Heddle, JG; Mizutani, K; Park, SY; Tame, JRH				Otto, BR; Sijbrandi, R; Luirink, J; Oudega, B; Heddle, JG; Mizutani, K; Park, SY; Tame, JRH			Crystal structure of hemoglobin protease, a heme binding autotransporter protein from pathogenic Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTEROIDES-FRAGILIS; TSH AUTOTRANSPORTER; SHIGELLA-FLEXNERI; SECRETION PATHWAY; SERINE-PROTEASE; IRON UPTAKE; VIRULENCE; GENE; FAMILY; DOMAIN	The acquisition of iron is essential for the survival of pathogenic bacteria, which have consequently evolved a wide variety of uptake systems to extract iron and heme from host proteins such as hemoglobin. Hemoglobin protease (Hbp) was discovered as a factor involved in the symbiosis of pathogenic Escherichia coli and Bacteroides fragilis, which cause intra-abdominal abscesses. Released from E. coli, this serine protease autotransporter degrades hemoglobin and delivers heme to both bacterial species. The crystal structure of the complete passenger domain of Hbp (110 kDa) is presented, which is the first structure from this class of serine proteases and the largest parallel beta-helical structure yet solved.	Yokohama City Univ, Prot Design Lab, Yokohama, Kanagawa 2300045, Japan; Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Mol Microbiol, NL-1081 HV Amsterdam, Netherlands	Yokohama City University; Vrije Universiteit Amsterdam	Tame, JRH (corresponding author), Yokohama City Univ, Prot Design Lab, Suehiro Cho 1-7-29, Yokohama, Kanagawa 2300045, Japan.	jtame@tsurumi.yokohama-cu.ac.jp	Luirink, Joen/AAB-8658-2021; Heddle, Jonathan/AAP-7167-2020; Heddle, Jonathan G/H-4586-2014	Luirink, J./0000-0001-8431-0804				ALDRIDGE KE, 1995, AM J SURG, V169, pS2; Arnoux P, 1999, NAT STRUCT BIOL, V6, P516; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benjelloun-Touimi Z, 1998, MICROBIOL-SGM, V144, P1815, DOI 10.1099/00221287-144-7-1815; Brunder W, 1997, MOL MICROBIOL, V24, P767, DOI 10.1046/j.1365-2958.1997.3871751.x; BRUNGER AT, 1996, XPLOR VERSION 3 85; Clantin B, 2004, P NATL ACAD SCI USA, V101, P6194, DOI 10.1073/pnas.0400291101; Dozois CM, 2000, INFECT IMMUN, V68, P4145, DOI 10.1128/IAI.68.7.4145-4154.2000; Dutta PR, 2002, INFECT IMMUN, V70, P7105, DOI 10.1128/IAI.70.12.7105-7113.2002; Emsley P, 1996, NATURE, V381, P90, DOI 10.1038/381090a0; Eslava C, 1998, INFECT IMMUN, V66, P3155, DOI 10.1128/IAI.66.7.3155-3163.1998; Farthmann EH, 1998, INFECTION, V26, P329, DOI 10.1007/BF02962266; Guyer DM, 2000, MOL MICROBIOL, V38, P53, DOI 10.1046/j.1365-2958.2000.02110.x; Henderson IR, 2004, MICROBIOL MOL BIOL R, V68, P692, DOI 10.1128/MMBR.68.4.692-744.2004; Henderson IR, 2001, INFECT IMMUN, V69, P1231, DOI 10.1128/IAI.69.3.1231-1243.2001; Henderson IR, 1999, INFECT IMMUN, V67, P5587, DOI 10.1128/IAI.67.11.5587-5596.1999; Henderson IR, 2000, TRENDS MICROBIOL, V8, P529, DOI 10.1016/S0966-842X(00)01853-9; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Jenkins J, 2001, PROG BIOPHYS MOL BIO, V77, P111, DOI 10.1016/S0079-6107(01)00013-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSE J, 1995, MOL MICROBIOL, V18, P378, DOI 10.1111/j.1365-2958.1995.mmi_18020378.x; KLAUSER T, 1993, BIOESSAYS, V15, P799, DOI 10.1002/bies.950151205; Kostakioti M, 2004, INFECT IMMUN, V72, P5548, DOI 10.1128/IAI.72.10.5548-5554.2004; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Navarro-Garcia F, 2001, INFECT IMMUN, V69, P1053, DOI 10.1128/IAI.69.2.1053-1060.2001; Oliver DC, 2003, MOL MICROBIOL, V47, P1367, DOI 10.1046/j.1365-2958.2003.03377.x; Oomen CJ, 2004, EMBO J, V23, P1257, DOI 10.1038/sj.emboj.7600148; OTTO BR, 1988, MICROB PATHOGENESIS, V4, P279, DOI 10.1016/0882-4010(88)90088-5; Otto BR, 1998, J EXP MED, V188, P1091, DOI 10.1084/jem.188.6.1091; Otto BR, 2002, INFECT IMMUN, V70, P5, DOI 10.1128/IAI.70.1.5-10.2002; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parreira VR, 2003, INFECT IMMUN, V71, P5087, DOI 10.1128/IAI.71.9.5087-5096.2003; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; PROVENCE DL, 1994, INFECT IMMUN, V62, P1369, DOI 10.1128/IAI.62.4.1369-1380.1994; ROTSTEIN OD, 1989, J MED MICROBIOL, V29, P269, DOI 10.1099/00222615-29-4-269; Roussel A., 1989, TURBO FRODO; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Scott DJ, 2002, J MOL BIOL, V315, P1179, DOI 10.1006/jmbi.2001.5306; Sijbrandi R, 2003, J BIOL CHEM, V278, P4654, DOI 10.1074/jbc.M211630200; Stathopoulos C, 1999, INFECT IMMUN, V67, P772, DOI 10.1128/IAI.67.2.772-781.1999; Stein M, 1996, J BACTERIOL, V178, P6546, DOI 10.1128/jb.178.22.6546-6554.1996; Tame JRH, 2002, ACTA CRYSTALLOGR D, V58, P843, DOI 10.1107/S0907444902003499; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Veiga E, 2002, EMBO J, V21, P2122, DOI 10.1093/emboj/21.9.2122; WILLIAMS PH, 1979, INFECT IMMUN, V26, P925, DOI 10.1128/IAI.26.3.925-932.1979	47	137	144	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17339	17345		10.1074/jbc.M412885200	http://dx.doi.org/10.1074/jbc.M412885200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728184	Green Published, hybrid			2022-12-25	WOS:000228615500098
J	Genes, O; Ilbert, M; Mejean, V; Iobbi-Nivol, C				Genes, O; Ilbert, M; Mejean, V; Iobbi-Nivol, C			TorD, an essential chaperone for TorA molybdoenzyme maturation at high temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEADER-BINDING-PROTEIN; N-OXIDE REDUCTASE; ESCHERICHIA-COLI; NITRATE REDUCTASE; SHEWANELLA-MASSILIA; INVOLVEMENT; BIOSYNTHESIS; PATHWAY; FORMS; DMSD	TorD has been recognized as an accessory protein that improves maturation of TorA, the molybdenum cofactor-containing trimethylamine oxide reductase of Escherichia coli. In this study, we show that at 42 degrees C and in the absence of TorD TorA is poorly matured and almost completely degraded. Strikingly, TorD restores TorA maturation to the same level whatever the growth temperature. In vitro experiments in which apoTorA was incubated with or without TorD at various temperatures confirm that TorD is an essential chaperone for TorA at elevated temperatures preventing apoTorA misfolding before cofactor insertion.	CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, F-13402 Marseille, France	Centre National de la Recherche Scientifique (CNRS)	Iobbi-Nivol, C (corresponding author), CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, 31 Chemin Joseph Aiguier, F-13402 Marseille, France.	iobbi@ibsm.cnrs-mrs.fr	Ilbert, marianne/ABG-5015-2021; Genest, Olivier/GQZ-3215-2022	Genest, Olivier/0000-0003-1240-2827; ilbert, marianne/0000-0002-9070-2334; Mejean, Vincent/0000-0001-6533-5846				CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; Gon S, 2001, J BIOL CHEM, V276, P11545, DOI 10.1074/jbc.M008875200; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HILLE R, 2000, SUBCELLULAR BIOCH EN, P445; Ilbert M, 2004, MICROBIOL-SGM, V150, P935, DOI 10.1099/mic.0.26909-0; Ilbert M, 2003, J BIOL CHEM, V278, P28787, DOI 10.1074/jbc.M302730200; Jack RL, 2004, EMBO J, V23, P3962, DOI 10.1038/sj.emboj.7600409; Kuchar J, 2004, CHEM REV, V104, P509, DOI 10.1021/cr020613p; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; Mendel RR, 2002, MET IONS BIOL SYST, V39, P317; Miller J.H., 1972, EXPT MOL GENETICS; Oresnik IJ, 2001, MOL MICROBIOL, V40, P323, DOI 10.1046/j.1365-2958.2001.02391.x; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; Pommier J, 1998, J BIOL CHEM, V273, P16615, DOI 10.1074/jbc.273.26.16615; Ray N, 2003, FEBS LETT, V534, P156, DOI 10.1016/S0014-5793(02)03839-5; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sarfo KJ, 2004, BIOCHEM BIOPH RES CO, V315, P397, DOI 10.1016/j.bbrc.2004.01.070; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; Tranier S, 2003, STRUCTURE, V11, P165, DOI 10.1016/S0969-2126(03)00008-X; Tranier S, 2002, PROTEIN SCI, V11, P2148, DOI 10.1110/ps.0202902; Turner RJ, 2004, CAN J MICROBIOL, V50, P225, DOI 10.1139/W03-117; Vergnes A, 2004, J BIOL CHEM, V279, P41398, DOI 10.1074/jbc.M407087200	22	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15644	15648		10.1074/jbc.M501119200	http://dx.doi.org/10.1074/jbc.M501119200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15723832	hybrid			2022-12-25	WOS:000228444800024
J	Gibbons, JA; Weiser, DC; Shenolikar, S				Gibbons, JA; Weiser, DC; Shenolikar, S			Importance of a surface hydrophobic pocket on protein phosphatase-1 catalytic subunit in recognizing cellular regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE PHOSPHATASES; PHOSPHORYLASE-PHOSPHATASE; AFFINITY-CHROMATOGRAPHY; TARGETING SUBUNITS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; STRUCTURAL BASIS; SKELETAL-MUSCLE; GROWTH ARREST; NEURABIN-I	Cellular functions of protein phosphatase-1 (PP1), a major eukaryotic serine/threonine phosphatase, are defined by the association of PP1 catalytic subunits with endogenous protein inhibitors and regulatory subunits. Many PP1 regulators share a consensus RVXF motif, which docks within a hydrophobic pocket on the surface of the PP1 catalytic subunit. Although these regulatory proteins also possess additional PP1-binding sites, mutations of the RVXF sequence established a key role of this PP1-binding sequence in the function of PP1 regulators. WT PP1 alpha, the C-terminal truncated PP1 alpha- ( 1 - 306), a chimeric PP1 alpha containing C-terminal sequences from PP2A, another phosphatase, PP1 alpha- ( 1 - 306) with the RVXF-binding pocket substitutions L289R, M290K, and C291R, and PP2A were analyzed for their regulation by several mammalian proteins. These studies established that modifications of the RVXF-binding pocket had modest effects on the catalytic activity of PP1, as judged by recognition of substrates and sensitivity to toxins. However, the selected modifications impaired the sensitivity of PP1 to the inhibitor proteins, inhibitor-1 and inhibitor-2. In addition, they impaired the ability of PP1 to bind neurabin-I, the neuronal regulatory subunit, and GM, the skeletal muscle glycogen-targeting subunit. These data suggested that differences in RVXF interactions with the hydrophobic pocket dictate the affinity of PP1 for cellular regulators. Substitution of a distinct RVXF sequence in inhibitor-1 that enhanced its binding and potency as a PP1 inhibitor emphasized the importance of the RVXF sequence in defining the function of this and other PP1 regulators. Our studies suggest that the diversity of RVXF sequences provides for dynamic physiological regulation of PP1 functions in eukaryotic cells.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Shenolikar, S (corresponding author), Pfizer Global Res & Dev, Cardiovasc Mol Sci, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.	shirish.shenolikar@Pfizer.com			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007031] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52054] Funding Source: Medline; NIEHS NIH HHS [T32-ES-07031] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ansai T, 1996, J BIOL CHEM, V271, P24401, DOI 10.1074/jbc.271.40.24401; Baker SH, 1997, GENETICS, V145, P615; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; Brush MH, 2003, MOL CELL BIOL, V23, P1292, DOI 10.1128/MCB.23.4.1292-1303.2003; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; Carmody LC, 2004, J BIOL CHEM, V279, P21714, DOI 10.1074/jbc.M402261200; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; Connor JH, 1998, METH MOL B, V93, P41; Connor JH, 2000, J BIOL CHEM, V275, P18670, DOI 10.1074/jbc.M909312199; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DESDOUITS F, 1995, BIOCHEM BIOPH RES CO, V206, P652, DOI 10.1006/bbrc.1995.1092; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; Kita A, 2002, STRUCTURE, V10, P715, DOI 10.1016/S0969-2126(02)00764-5; Kloeker S, 2003, PROTEIN EXPRES PURIF, V31, P19, DOI 10.1016/S1046-5928(03)00141-4; Liu J, 2000, BIOCHEM J, V346, P77, DOI 10.1042/0264-6021:3460077; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; MACKINTOSH RW, 1990, FEBS LETT, V276, P156, DOI 10.1016/0014-5793(90)80531-M; Maynes JT, 2001, J BIOL CHEM, V276, P44078, DOI 10.1074/jbc.M107656200; McAvoy T, 1999, BIOCHEMISTRY-US, V38, P12943, DOI 10.1021/bi991227d; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; Morishita W, 2001, NEURON, V32, P1133, DOI 10.1016/S0896-6273(01)00554-2; PARK IK, 1994, J BIOL CHEM, V269, P944; RICHARDSON DC, 1992, PROTEIN SCI, V1, P3; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHLENDER KK, 1989, BIOCHEM BIOPH RES CO, V159, P72, DOI 10.1016/0006-291X(89)92406-6; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; Terrak M, 2004, NATURE, V429, P780, DOI 10.1038/nature02582; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P27716, DOI 10.1074/jbc.M203365200; Terry-Lorenzo RT, 2000, J BIOL CHEM, V275, P2439, DOI 10.1074/jbc.275.4.2439; VILLAMORUZZI E, 1986, ARCH BIOCHEM BIOPHYS, V247, P155, DOI 10.1016/0003-9861(86)90544-8; Wakula P, 2003, J BIOL CHEM, V278, P18817, DOI 10.1074/jbc.M300175200; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; Watanabe T, 2001, P NATL ACAD SCI USA, V98, P3080, DOI 10.1073/pnas.051003898; Weiser DC, 2004, J BIOL CHEM, V279, P48904, DOI 10.1074/jbc.M404416200; Word JM, 1999, J MOL BIOL, V285, P1711, DOI 10.1006/jmbi.1998.2400; Wu XL, 2001, BIOCHEMISTRY-US, V40, P7410, DOI 10.1021/bi002796k; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200; ZHANG ZJ, 1994, J BIOL CHEM, V269, P13766; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484	50	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15903	15911		10.1074/jbc.M500871200	http://dx.doi.org/10.1074/jbc.M500871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15703180	hybrid			2022-12-25	WOS:000228444800056
J	Horton, JK; Stefanick, DF; Naron, JM; Kedar, PS; Wilson, SH				Horton, JK; Stefanick, DF; Naron, JM; Kedar, PS; Wilson, SH			Poly(ADP-ribose) polymerase activity prevents signaling pathways for cell cycle arrest after DNA methylating agent exposure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; S-PHASE; MAMMALIAN-CELLS; INDUCED CYTOTOXICITY; DAMAGE CHECKPOINT; ATR; REPLICATION; BETA; CHK1; ACTIVATION	Mouse fibroblasts, deficient in DNA polymerase beta, are hypersensitive to monofunctional DNA methylating agents such as methyl methanesulfonate ( MMS). Both wild- type and, in particular, repair- deficient DNA polymerase beta null cells are highly sensitized to the cytotoxic effects of MMS by 4- amino- 1,8- naphthalimide ( 4-AN), an inhibitor of poly( ADP- ribose) polymerase ( PARP) activity. Experiments with synchronized cells suggest that exposure during S- phase of the cell cycle is required for the 4- AN effect. 4- AN elicits a similar extreme sensitization to the thymidine analog, 5- hydroxymethyl-2' -deoxyuridine, implicating the requirement for an intermediate of DNA repair. In PARP- 1- expressing fibroblasts treated with a combination of MMS and 4- AN, a complete inhibition of DNA synthesis is apparent after 4 h, and by 24 h, all cells are arrested in S- phase of the cell cycle. Continuous incubation with 4- AN is required to maintain the cell cycle arrest. Caffeine, an inhibitor of the upstream checkpoint kinases ATM ( ataxia telangiectasia-mutated) and ATR ( ATM and Rad3- related), has no effect on the early inhibition of DNA synthesis, but cells are no longer able to maintain the block after 8 h. Instead, the addition of caffeine leads to arrest of cells in G(2)/ M rather than S- phase after 24 h. Analysis of signaling pathways in cell extracts reveals an activation of Chk1 after treatment with MMS and 4- AN, which can be suppressed by caffeine. Our results suggest that inhibition of PARP activity results in sensitization to MMS through maintenance of an ATR and Chk1- dependent S- phase checkpoint.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001500] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036119, ZIADK036119, Z01DK060004, ZIADK061000, Z01DK061000, ZIADK060004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050159, Z01ES061060, ZIAES050159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000311, Z01AG000294, ZIAAG000294, ZIAAG000311] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; BANASIK M, 1992, J BIOL CHEM, V267, P1569; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; BOORSTEIN RJ, 1984, J CELL PHYSIOL, V120, P345, DOI 10.1002/jcp.1041200313; BOORSTEIN RJ, 1992, MOL CELL BIOL, V12, P5536, DOI 10.1128/MCB.12.12.5536; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; BOULTON S, 1995, BRIT J CANCER, V72, P849, DOI 10.1038/bjc.1995.423; BUTLER WB, 1984, ANAL BIOCHEM, V141, P70, DOI 10.1016/0003-2697(84)90426-3; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Cortez D, 2003, J BIOL CHEM, V278, P37139, DOI 10.1074/jbc.M307088200; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 2000, J BIOL CHEM, V275, P11809, DOI 10.1074/jbc.275.16.11809; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Fortini P, 2000, NUCLEIC ACIDS RES, V28, P3040, DOI 10.1093/nar/28.16.3040; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Guo N, 2002, CELL GROWTH DIFFER, V13, P77; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Horton JK, 2003, DNA REPAIR, V2, P27, DOI 10.1016/S1568-7864(02)00184-2; Horton JK, 2002, DNA REPAIR, V1, P317, DOI 10.1016/S1568-7864(02)00008-3; Hyrien O, 2000, BIOCHIMIE, V82, P5, DOI 10.1016/S0300-9084(00)00344-8; Izumi T, 2003, TOXICOLOGY, V193, P43, DOI 10.1016/S0300-483X(03)00289-0; Jeong SY, 2003, J BIOL CHEM, V278, P46782, DOI 10.1074/jbc.M304551200; Joerges C, 2003, ONCOGENE, V22, P6119, DOI 10.1038/sj.onc.1206613; Kaufmann WK, 2003, MUTAT RES-FUND MOL M, V532, P85, DOI 10.1016/j.mrfmmm.2003.08.012; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Lavrik OI, 2001, J BIOL CHEM, V276, P25541, DOI 10.1074/jbc.M102125200; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Liu L, 1999, CLIN CANCER RES, V5, P2908; Liu QH, 2000, GENE DEV, V14, P1448; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Mazurek N, 2000, J BIOL CHEM, V275, P36311, DOI 10.1074/jbc.M003831200; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Newlands ES, 1997, CANCER TREAT REV, V23, P35, DOI 10.1016/S0305-7372(97)90019-0; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Pascucci B, 2002, NUCLEIC ACIDS RES, V30, P2124, DOI 10.1093/nar/30.10.2124; Rothstein R, 2000, GENE DEV, V14, P1; Ruf A, 1998, BIOCHEMISTRY-US, V37, P3893, DOI 10.1021/bi972383s; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schlicker A, 1999, INT J RADIAT BIOL, V75, P91, DOI 10.1080/095530099140843; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Tentori L, 2002, GLIA, V40, P44, DOI 10.1002/glia.10113; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Ward IM, 2004, J BIOL CHEM, V279, P9677, DOI 10.1074/jbc.C300554200; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	57	60	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15773	15785		10.1074/jbc.M413841200	http://dx.doi.org/10.1074/jbc.M413841200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15701627	hybrid			2022-12-25	WOS:000228444800040
J	Kitiphongspattana, K; Mathews, CE; Leiter, EH; Gaskins, HR				Kitiphongspattana, K; Mathews, CE; Leiter, EH; Gaskins, HR			Proteasome inhibition alters glucose-stimulated (pro) insulin secretion and turnover in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; NEWLY SYNTHESIZED PROTEINS; TRANSLATIONAL CONTROL; QUALITY-CONTROL; ISLET FUNCTION; MUTANT PROINSULIN; CYSTEINE PROTEASE; RAPID DEGRADATION; MEMBRANE-PROTEIN	Metabolic labeling studies were conducted in freshly isolated mouse islets and a beta- cell line ( MIN6) to examine the effects of proteasome inhibition on glucose- stimulated ( pro) insulin synthesis and secretion. Glucose- stimulated ( pro) insulin synthesis, as determined by the incorporation of [ H-3] tyrosine, decreased significantly by 90% in islets and 71% in MIN6 cells pretreated with the proteasome inhibitor lactacystin ( 10 mu M) for 2 h. To follow the fate of newly synthesized ( pro) insulin, islets were pulse- labeled with [H-3] tyrosine ( 40 mu Ci) for 20 min and chased +/- lactacystin ( 10 mu M) for up to 4 h. The release of newly synthesized ( pro) insulin ([H-3] tyrosine-labeled) was similar between lactacystin- treated and control islets despite a 51% decrease ( p < 0.05) in total immunoreactive ( pro) insulin secretion by lactacystin-treated islets. The specific radioactivity of [H-3] tyrosine-labeled ( pro) insulin in the extracellular medium of lactacystin-treated islets ( 0.52 +/- 0.16 cpm/ microunits) was 2- fold greater relative to control islets ( 0.25 +/- 0.06 cpm/ microunits). Induction of the unfolded protein response by lactacystin, as evidenced by the up- regulation of endoplasmic reticulum ( ER) chaperones ( GRP78/ BiP, GRP94, protein disulfide isomerase) and induction of the stress- inducible transcription factor C/ EBP- homologous protein/ GADD153 ( CHOP/ GADD153), likely contributed to the release of newly synthesized ( pro) insulin to relieve ER stress. The present data indicate proteasome inhibition did not prevent, but increased ( p < 0.05), the intracellular degradation of [H-3] tyrosine- labeled ( pro) insulin from 8 to 24% in islets. Collectively, these data indicate beta- cells may balance glucose- stimulated ( pro) insulin synthesis and secretion with the activity of the proteasome to regulate protein concentrations in the ER.	Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Vet Pathobiol, Urbana, IL 61801 USA; Univ Illinois, Inst Genom Biol, Urbana, IL 61801 USA; Univ Pittsburgh, Rangos Res Ctr, Inst Diabet, Pittsburgh, PA 15213 USA; Jackson Lab, Bar Harbor, ME 04609 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Jackson Laboratory	Gaskins, HR (corresponding author), Univ Illinois, Div Nutr Sci, 1207 W Gregory Dr, Urbana, IL 61801 USA.	hgaskins@uiuc.edu		Gaskins, H. Rex/0000-0002-1249-535X	NIDDK NIH HHS [DK27722, DK49192, 5T32 DK59802, DK365175, DK09864] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049192, R37DK027722, T32DK059802, R01DK027722] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ablamunits V, 1999, CLIN EXP IMMUNOL, V115, P260, DOI 10.1046/j.1365-2249.1999.00802.x; Baldeon ME, 1997, DIABETES, V46, P770, DOI 10.2337/diabetes.46.5.770; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Cardozo C, 2002, BIOCHEMISTRY-US, V41, P10105, DOI 10.1021/bi025749w; CARROLL RJ, 1988, P NATL ACAD SCI USA, V85, P8943, DOI 10.1073/pnas.85.23.8943; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; Fleming JV, 1997, MOL REPROD DEV, V48, P310, DOI 10.1002/(SICI)1098-2795(199711)48:3&lt;310::AID-MRD2&gt;3.0.CO;2-U; GOLD G, 1982, SCIENCE, V218, P56, DOI 10.1126/science.6181562; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; GROSS DJ, 1989, P NATL ACAD SCI USA, V86, P4107, DOI 10.1073/pnas.86.11.4107; HALBAN PA, 1991, DIABETOLOGIA, V34, P767, DOI 10.1007/BF00408349; HALBAN PA, 1980, BIOCHEM PHARMACOL, V29, P2625, DOI 10.1016/0006-2952(80)90077-5; HALBAN PA, 1983, DIABETES, V32, P254, DOI 10.2337/diabetes.32.3.254; Halban PA, 2003, MOL BIOL CELL, V14, P1195, DOI 10.1091/mbc.E02-05-0299; HALBAN PA, 1987, DIABETOLOGIA, V30, P348, DOI 10.1007/BF00299029; HALBAN PA, 1982, ENDOCRINOLOGY, V110, P1183, DOI 10.1210/endo-110-4-1183; HALBAN PA, 1980, J BIOL CHEM, V255, P6003; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2002, DIABETES, V51, pS455, DOI 10.2337/diabetes.51.2007.S455; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Jarosch E, 2003, INT REV CYTOL, V223, P39; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Kopito RR, 2000, EMBO REP, V1, P225, DOI 10.1093/embo-reports/kvd052; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LANDSTROM AHS, 1988, DIABETES, V37, P309, DOI 10.2337/diabetes.37.3.309; LANDSTROM AHS, 1991, METABOLISM, V40, P399, DOI 10.1016/0026-0495(91)90151-L; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MORAN CR, 1963, DIABETES, V12, P115; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Okamoto T, 2001, J BIOL CHEM, V276, P742, DOI 10.1074/jbc.M003078200; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; PERMUTT MA, 1972, J BIOL CHEM, V247, P1194; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; QUINN D, 1991, J CELL BIOL, V113, P987, DOI 10.1083/jcb.113.5.987; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; SCHNELL AH, 1988, CELL TISSUE RES, V252, P9; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; SCHUIT FC, 1988, P NATL ACAD SCI USA, V85, P3865, DOI 10.1073/pnas.85.11.3865; Shi YG, 1999, J BIOL CHEM, V274, P5723, DOI 10.1074/jbc.274.9.5723; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; Urade R, 1999, BIOSCI BIOTECH BIOCH, V63, P610, DOI 10.1271/bbb.63.610; URADE R, 1993, J BIOL CHEM, V268, P22004; Wang J, 1999, J CLIN INVEST, V103, P27, DOI 10.1172/JCI4431; Welihinda AA, 1999, GENE EXPRESSION, V7, P293; WHEATLEY DN, 1982, J THEOR BIOL, V98, P283, DOI 10.1016/0022-5193(82)90265-X; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yoshioka M, 1997, DIABETES, V46, P887, DOI 10.2337/diabetes.46.5.887	65	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15727	15734		10.1074/jbc.M410876200	http://dx.doi.org/10.1074/jbc.M410876200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705591	hybrid			2022-12-25	WOS:000228444800034
J	Li, SG; Zhou, H; Luo, YP; Zhang, P; Qu, LH				Li, SG; Zhou, H; Luo, YP; Zhang, P; Qu, LH			Identification and functional analysis of 20 box H/ACA small nucleolar RNAs (snoRNAs) from Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							U6 SPLICEOSOMAL RNA; NON-MESSENGER RNAS; RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; 2'-O-RIBOSE METHYLATION; PRERIBOSOMAL RNA; GUIDE SNORNAS; PSEUDOURIDINE; GENE; YEAST	Considering all small nucleolar RNAs (snoRNAs) enriched in the nucleolus, we generated a specialized cDNA library of small nuclear RNAs from Schizosaccharomyces pombe and isolated, for the first time, 20 novel box H/ACA snoRNAs. Thirteen of these were characterized as novel guides that were predicted to direct 19 pseudouridylations in 18 S and 25 S rRNAs. The remaining seven snoRNAs were considered as orphan guides that lack sequence complementarity to either rRNAs or snRNAs. We have experimentally demonstrated the function of the 10 novel snoRNAs by gene deletion in the fission yeast. The snoRNAs were shown to be dispensable for the viability of S. pombe, although an impact of snR94 depletion on yeast growth, especially at 23 degrees C, was revealed. A total of 30 pseudouridylation sites were precisely mapped in the S. pombe rRNAs, showing a distinctive pseudouridylation pattern in the budding yeast. Interestingly, the absence of pseudouridylation on U2347 in S. pombe 25 S rRNA pointed out a critical role for Psi 2345 in conferring a growth advantage for yeast. In contrast to the intron-encoded box C/D snoRNAs in yeast, all box H/ACA snoRNAs appeared to be transcribed independently from intergenic regions between two protein-coding genes, except for snR35, which was nested in an open reading frame encoding for a hypothetical protein, although expressed from the opposite strand. Remarkably, snR90 was cotranscribed with an intron-encoded box C/D snoRNA, and this is the first demonstration of a non-coding RNA gene that encodes two different types of snoRNAs by its exon and intron. A detailed comparison of the S. pombe snoRNAs, with their functional homologues in diverse organisms, suggests a mechanism by which the snoRNAs have evolved in coordination with rRNAs to preserve the post-transcriptional modification sites among distant eukaryotes.	Zhongshan Univ, Biotechnol Res Ctr, Key Lab Gene Engn, Minist Educ, Guangzhou 510275, Peoples R China	Sun Yat Sen University	Qu, LH (corresponding author), Zhongshan Univ, Biotechnol Res Ctr, Key Lab Gene Engn, Minist Educ, Guangzhou 510275, Peoples R China.	lsbrc04@zsu.edu.cn	Zhang, Peng/F-9664-2013	Qu, Liang-Hu/0000-0003-3657-2863				Atzorn V, 2004, MOL CELL BIOL, V24, P1769, DOI 10.1128/MCB.24.4.1769-1778.2004; Bachellerie JP, 2002, BIOCHIMIE, V84, P775, DOI 10.1016/S0300-9084(02)01402-5; Badis G, 2003, RNA, V9, P771, DOI 10.1261/rna.5240503; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; Brown JWS, 2003, TRENDS PLANT SCI, V8, P42, DOI 10.1016/S1360-1385(02)00007-9; Cavaille J, 2002, HUM MOL GENET, V11, P1527, DOI 10.1093/hmg/11.13.1527; Cavaille J, 2000, P NATL ACAD SCI USA, V97, P14311, DOI 10.1073/pnas.250426397; Chen CL, 2003, NUCLEIC ACIDS RES, V31, P2601, DOI 10.1093/nar/gkg373; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; d'Orval BC, 2001, NUCLEIC ACIDS RES, V29, P4518, DOI 10.1093/nar/29.22.4518; Darzacq X, 2002, EMBO J, V21, P2746, DOI 10.1093/emboj/21.11.2746; Dove JE, 1998, METHOD CELL BIOL, V53, P33; Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; Ganot P, 1999, MOL CELL BIOL, V19, P6906; Huang ZP, 2004, J MOL BIOL, V341, P669, DOI 10.1016/j.jmb.2004.06.041; Huttenhofer A, 2002, CURR OPIN CHEM BIOL, V6, P835, DOI 10.1016/S1367-5931(02)00397-6; Huttenhofer A, 2001, EMBO J, V20, P2943, DOI 10.1093/emboj/20.11.2943; Jady BE, 2001, EMBO J, V20, P541, DOI 10.1093/emboj/20.3.541; King TH, 2003, MOL CELL, V11, P425, DOI 10.1016/S1097-2765(03)00040-6; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Kruszka K, 2003, EMBO J, V22, P621, DOI 10.1093/emboj/cdg040; Lowe TM, 1999, SCIENCE, V283, P1168, DOI 10.1126/science.283.5405.1168; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; Ofengand J, 1997, J MOL BIOL, V266, P246, DOI 10.1006/jmbi.1996.0737; Ofengand J, 2002, FEBS LETT, V514, P17, DOI 10.1016/S0014-5793(02)02305-0; Qu LH, 1999, MOL CELL BIOL, V19, P1144; Schattner P, 2004, NUCLEIC ACIDS RES, V32, P4281, DOI 10.1093/nar/gkh768; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; Tollervey D, 1996, EXP CELL RES, V229, P226, DOI 10.1006/excr.1996.0364; Tycowski KT, 1998, MOL CELL, V2, P629, DOI 10.1016/S1097-2765(00)80161-6; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; Vitali P, 2003, NUCLEIC ACIDS RES, V31, P6543, DOI 10.1093/nar/gkg849; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Zhou H, 2002, NUCLEIC ACIDS RES, V30, P894, DOI 10.1093/nar/30.4.894; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	45	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16446	16455		10.1074/jbc.M500326200	http://dx.doi.org/10.1074/jbc.M500326200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15716270	hybrid			2022-12-25	WOS:000228444800118
J	Mukherjee, A; Prasad, TK; Rao, NM; Banerjee, R				Mukherjee, A; Prasad, TK; Rao, NM; Banerjee, R			Haloperidol-associated stealth liposomes - A potent carrier for delivering genes to human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGMA-RECEPTOR LIGAND; PHARMACOLOGICAL CHARACTERIZATION; BINDING; IMMUNOLIPOSOMES; PRODRUGS; CALCIUM; TUMORS; LIVER; LINES	Sigma receptors are membrane-bound proteins that are overexpressed in certain human malignancies including breast cancer. These receptors show very high affinity for various sigma ligands including neuroleptics like haloperidol. We hypothesized that in associating haloperidol-linked lipid into the cationic lipid-DNA complex, we can specifically target and deliver genes to breast cancer cells that overexpress sigma receptors. In the present study, haloperidol was chemically modified to conjugate at the distal end of the polyethylene glycol-linked phospholipid, which was then incorporated into the cationic liposome known to condense and deliver genes inside cells. The resulting haloperidol-conjugated targeted lipoplex showed at least 10-fold higher ( p < 0.001) reporter gene expression in MCF-7 cells than control lipoplex. The reporter gene expression of the targeted lipoplex was significantly blocked by haloperidol ( p < 0.001) and by another sigma ligand, 1,3-ditolylguanidine ( p < 0.001) in the majority of cationic lipid to DNA charge ratios (+/-). Spironolactone-mediated sigma receptor down-regulation enabled MCF-7 to show 10-fold lower transgene expression with targeted lipoplex compared with that obtained in spironolactone-untreated cells. The targeted lipoplex generated nonspecific gene expression in sigma receptor-nonexpressing human cancer cells such as Hela, KB, HepG2, and Chinese hamster ovary cells. Moreover, the transgene expression remained unabated in physiologically relevant serum concentrations. This is the first study to demonstrate that haloperidol-targeted gene delivery systems can mediate efficient targeting of genes to sigma receptor-overexpressing breast cancer cells, thereby becoming a novel class of therapeutics for the treatment of human cancers.	Indian Inst Chem Technol, Div Lipid Sci & Technol, Hyderabad 500007, Andhra Pradesh, India; Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Technology (IICT); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Banerjee, R (corresponding author), Indian Inst Chem Technol, Div Lipid Sci & Technol, Rm 345, Hyderabad 500007, Andhra Pradesh, India.	rkbanerjee@yahoo.com	Banerjee, Rajkumar/AAC-2699-2020	Banerjee, Rinti/0000-0002-6400-5906; Banerjee, Rajkumar/0000-0003-2336-6294				Aydar E, 2004, CANCER RES, V64, P5029, DOI 10.1158/0008-5472.CAN-03-2329; Banerjee R, 2004, INT J CANCER, V112, P693, DOI 10.1002/ijc.20452; Brent PJ, 1996, BIOCHEM BIOPH RES CO, V219, P219, DOI 10.1006/bbrc.1996.0208; Crawford KW, 2002, CANCER RES, V62, P313; Ganapathy ME, 1999, J PHARMACOL EXP THER, V289, P251; Greenwald RB, 1996, J MED CHEM, V39, P424, DOI 10.1021/jm950475e; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HELLEWELL SB, 1994, EUR J PHARM-MOLEC PH, V268, P9, DOI 10.1016/0922-4106(94)90115-5; HO RJY, 1986, BIOCHEMISTRY-US, V25, P5500, DOI 10.1021/bi00367a023; HUANG A, 1983, J BIOL CHEM, V258, P4034; HUANG A, 1980, J BIOL CHEM, V255, P8015; John CS, 1999, CANCER RES, V59, P4578; John CS, 1999, NUCL MED BIOL, V26, P377, DOI 10.1016/S0969-8051(98)00104-8; JOHN CS, 1993, J NUCL MED, V34, P2169; JOHN CS, 1995, CANCER RES, V55, P3022; JOHN CS, 1994, J MED CHEM, V37, P1737, DOI 10.1021/jm00038a002; John CS, 1996, NUCL MED BIOL, V23, P761, DOI 10.1016/0969-8051(96)00070-4; KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H; KNIGHT AR, 1991, NEUROPHARMACOLOGY, V30, P923, DOI 10.1016/0028-3908(91)90128-X; Majeti BK, 2004, CHEM BIOL, V11, P427, DOI 10.1016/j.chembiol.2004.03.015; MARUYAMA K, P NATL ACAD SCI US, V87, P5744; Mei JF, 2001, BIOCHEM PHARMACOL, V62, P349, DOI 10.1016/S0006-2952(01)00666-9; MORI A, 1993, PHARMACEUT RES, V10, P507, DOI 10.1023/A:1018933632318; SHEFFIELD JB, 1987, ANAL BIOCHEM, V166, P49, DOI 10.1016/0003-2697(87)90544-6; Singh RS, 2002, CHEM-EUR J, V8, P900, DOI 10.1002/1521-3765(20020215)8:4<900::AID-CHEM900>3.0.CO;2-X; VILNER BJ, 1993, EUR J PHARM-MOLEC PH, V244, P199, DOI 10.1016/0922-4106(93)90029-9; VILNER BJ, 1995, J NEUROSCI, V15, P117; Vilner BJ, 2000, J PHARMACOL EXP THER, V292, P900; VILNER BJ, 1995, CANCER RES, V55, P408; WOLFE SA, 1989, ENDOCRINOLOGY, V124, P1160, DOI 10.1210/endo-124-3-1160; ZALIPSKY S, 1994, FEBS LETT, V353, P71, DOI 10.1016/0014-5793(94)01013-7	31	48	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15619	15627		10.1074/jbc.M409723200	http://dx.doi.org/10.1074/jbc.M409723200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15695518	hybrid			2022-12-25	WOS:000228444800021
J	Poppelmann, B; Klimmek, K; Strozyk, E; Voss, R; Schwarz, T; Kulms, D				Poppelmann, B; Klimmek, K; Strozyk, E; Voss, R; Schwarz, T; Kulms, D			NF kappa B-dependent down-regulation of tumor necrosis factor receptor-associated proteins contributes to interleukin-1-mediated enhancement of ultraviolet B-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTECTS TRANSFORMED KERATINOCYTES; RADIATION-INDUCED APOPTOSIS; ALPHA-INDUCED APOPTOSIS; INDUCED CELL-DEATH; IN-VIVO; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; JNK ACTIVATION; LIGAND; TRAF1	Activation of the transcription factor nuclear factor-kappa B (NF kappa B) by inflammatory cytokines like tumor necrosis (TNF) factor and interleukin-1 (IL-1) is generally associated with the induction of antiapoptotic pathways. Therefore, NF kappa B inhibits both intrinsically and extrinsically induced apoptosis and thus is regarded to act universally in an antiapoptotic fashion. Accordingly, activation of NF kappa B by IL-1 was shown to result in reduction of death ligand-induced apoptosis via up-regulation of antiapoptotic inhibitor of apoptosis proteins (IAPs). In contrast, apoptosis induced by ultraviolet-B radiation (UVB) was shown to be enhanced in an NF kappa B-dependent manner, indicating that NF kappa B can also act in a proapoptotic fashion. This study investigates the molecular mechanisms underlying IL-1-mediated enhancement of UVB-induced apoptosis. We show that NF kappa B activation in costimulation with UVB treatment results in repression of antiapoptotic genes and consequently in down-regulation of the respective proteins, like c-IAP, FLICE-inhibitory protein ( FLIP), and some members of the TNF receptor-associated ( TRAF) 2 protein family. In parallel, TNF alpha is released, leading to activation of signaling pathways mediated by TNF receptor-1 (TNF-R1). Although TNF is well known to induce both proapoptotic and antiapoptotic effects, the down-regulated levels of TRAF-1, -2, and -6 proteins by IL-1 plus UVB action leads to a shift toward promotion of the proapoptotic pathway. In concert with the down-regulation of IAPs and FLIP, TNF-R1 activation as an additional proapoptotic stimulus now results in significant enhancement of UVB-induced apoptosis. Taken together, elucidation of the molecular mechanisms underlying IL-1-mediated enhancement of UVB-induced apoptosis revealed that NF kappa B does not exclusively act in an antiapoptotic fashion but may also mediate proapoptotic effects.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Univ Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Munster, Dept Integrated Funct Genom, D-48149 Munster, Germany; Univ Munster, Inst Clin Chem & Lab Med, D-48149 Munster, Germany; Univ Kiel, Dept Dermatol, D-24105 Kiel, Germany	University of Stuttgart; University of Munster; University of Munster; University of Munster; University of Kiel	Kulms, D (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	Dagmar.Kulms@izi.uni-stuttgart.de	Kulms, Dagmar/H-1653-2014; Schwarz, Thomas/A-9148-2010					Aota K, 2002, EXP CELL RES, V276, P111, DOI 10.1006/excr.2002.5515; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Arron JR, 2002, J EXP MED, V196, P923, DOI 10.1084/jem.20020774; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Duffey DC, 1999, CANCER RES, V59, P3468; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Irmler M, 2000, FEBS LETT, V468, P129, DOI 10.1016/S0014-5793(00)01206-0; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jang HD, 2001, BIOCHEM BIOPH RES CO, V281, P499, DOI 10.1006/bbrc.2001.4369; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Kulms D, 2000, PHOTODERMATOL PHOTO, V16, P195, DOI 10.1034/j.1600-0781.2000.160501.x; Kulms D, 2002, ONCOGENE, V21, P5844, DOI 10.1038/sj.onc.1205743; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Leo E, 2001, J BIOL CHEM, V276, P8087, DOI 10.1074/jbc.M009450200; Leverkus M, 2003, J INVEST DERMATOL, V121, P149, DOI 10.1046/j.1523-1747.2003.12332.x; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LUGER TA, 1992, PHARM SKIN, P283; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; Muhlenbeck F, 2000, J BIOL CHEM, V275, P32208, DOI 10.1074/jbc.M000482200; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	48	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15635	15643		10.1074/jbc.M413006200	http://dx.doi.org/10.1074/jbc.M413006200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15723831	hybrid			2022-12-25	WOS:000228444800023
J	Tang, L; Stith, L; Jaffe, EK				Tang, L; Stith, L; Jaffe, EK			Substrate-induced interconversion of protein quaternary structure isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIC LIGHT-SCATTERING; X-RAY-STRUCTURE; MAMMALIAN RIBONUCLEOTIDE REDUCTASE; 5-AMINOLEVULINIC ACID DEHYDRATASE; SYNTHASE CATALYZED REACTION; PORPHOBILINOGEN SYNTHASE; ESCHERICHIA-COLI; ALLOSTERIC REGULATION; COMPREHENSIVE MODEL; MECHANISM	Human porphobilinogen synthase ( PBGS) can exist in two dramatically different quaternary structure isoforms, which have been proposed to be in dynamic equilibrium ( Breinig, S., Kervinen, J., Stith, L., Wasson, A. S., Fairman, R., Wlodawer, A., Zdanov, A., and Jaffe, E. K. ( 2003) Nat. Struct. Biol. 10, 757 - 763). The quaternary structure isoforms of PBGS result from two alternative conformations of the monomer; one monomer structure assembles into a high activity octamer, whereas the other monomer structure assembles into a low activity hexamer. The kinetic behavior of these oligomers led to the hypothesis that turnover facilitates the interconversion of the oligomeric structures. The current work demonstrates that the interactions of ligands at the enzyme active site promote the structural interconversion between human PBGS quaternary structure isoforms, favoring formation of the octamer. This observation illustrates that the assembly and disassembly of oligomeric proteins can be facilitated by the protein motions that accompany enzymatic catalysis.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Jaffe, EK (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Eileen.Jaffe@fccc.edu			NCI NIH HHS [CA006927] Funding Source: Medline; NIEHS NIH HHS [ES03654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Battersby AR, 2000, NAT PROD REP, V17, P507, DOI 10.1039/b002635m; BERU N, 1985, J BIOL CHEM, V260, P9251; Breinig S, 2003, NAT STRUCT BIOL, V10, P757, DOI 10.1038/nsb963; Erskine PT, 2003, BIOCHEM J, V373, P733, DOI 10.1042/BJ20030513; Erskine PT, 1997, NAT STRUCT BIOL, V4, P1025, DOI 10.1038/nsb1297-1025; Erskine PT, 2001, J MOL BIOL, V312, P133, DOI 10.1006/jmbi.2001.4947; FerreDAmare AR, 1997, METHOD ENZYMOL, V276, P157, DOI 10.1016/S0076-6879(97)76056-7; Frankenberg N, 1999, J MOL BIOL, V289, P591, DOI 10.1006/jmbi.1999.2808; Gast K, 1997, FEBS LETT, V403, P245, DOI 10.1016/S0014-5793(97)00058-6; Jaffe EK, 2004, BIOORG CHEM, V32, P316, DOI 10.1016/j.bioorg.2004.05.010; Jaffe EK, 2003, CHEM BIOL, V10, P25, DOI 10.1016/S1074-5521(02)00296-X; JAFFE EK, 1995, BIOCHEMISTRY-US, V34, P244, DOI 10.1021/bi00001a029; JAFFE EK, 1990, BIOCHEMISTRY-US, V29, P8345, DOI 10.1021/bi00488a021; JAFFE EK, 1986, J BIOL CHEM, V261, P9348; Jaffe EK, 2000, ACTA CRYSTALLOGR D, V56, P115, DOI 10.1107/S0907444999014894; Jaffe EK, 2002, J BIOL CHEM, V277, P19792, DOI 10.1074/jbc.M201486200; Jaffe EK, 2001, J BIOL CHEM, V276, P1531, DOI 10.1074/jbc.M007663200; JORDAN PM, 1985, BIOCHEM J, V227, P1015, DOI 10.1042/bj2271015; Kashlan OB, 2003, BIOCHEMISTRY-US, V42, P1696, DOI 10.1021/bi020634d; Kashlan OB, 2002, BIOCHEMISTRY-US, V41, P462, DOI 10.1021/bi011653a; Kervinen J, 2001, BIOCHEMISTRY-US, V40, P8227, DOI 10.1021/bi010656k; Kervinen J, 2000, BIOCHEMISTRY-US, V39, P9018, DOI 10.1021/bi000620c; Kundrat L, 2003, J BIOL CHEM, V278, P31325, DOI 10.1074/jbc.M304124200; MILLSDAVIES NL, 2000, THESIS U SOUTHAMPTON; MITCHELL LW, 1993, ARCH BIOCHEM BIOPHYS, V300, P169, DOI 10.1006/abbi.1993.1024; Moradian-Oldak J, 1998, J STRUCT BIOL, V122, P320, DOI 10.1006/jsbi.1998.4008; Schonfeld HJ, 1998, BIOCHEM SOC T, V26, P753, DOI 10.1042/bst0260753; SEGEL IH, 1975, ENZYME KINETICS, P64; Senior NM, 1996, BIOCHEM J, V320, P401; SHEMIN D, 1976, PHILOS T ROY SOC B, V273, P109, DOI 10.1098/rstb.1976.0004; STELLA AM, 1977, MOL CELL BIOCHEM, V16, P97, DOI 10.1007/BF01732049; TSCHUDY DP, 1981, J BIOL CHEM, V256, P9915; Van Holde KKE, 1998, PRINCIPLES PHYS BIOC, P312; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0	34	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15786	15793		10.1074/jbc.M500218200	http://dx.doi.org/10.1074/jbc.M500218200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710608	hybrid			2022-12-25	WOS:000228444800041
J	Tie, JK; Nicchitta, C; von Heijne, G; Stafford, DW				Tie, JK; Nicchitta, C; von Heijne, G; Stafford, DW			Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; GAMMA-GLUTAMYL CARBOXYLASE; 2,3-EPOXIDE REDUCTASE; ACTIVE-SITE; RAT-LIVER; DEPENDENT CARBOXYLASE; THIOREDOXIN SYSTEM; PROTEIN TOPOLOGY; PURIFICATION; PREDICTION	Vitamin K epoxide reductase (VKOR) catalyzes the conversion of vitamin K 2,3-epoxide into vitamin K in the vitamin K redox cycle. Recently, the gene encoding the catalytic subunit of VKOR was identified as a 163-amino acid integral membrane protein. In this study we report the experimentally derived membrane topology of VKOR. Our results show that four hydrophobic regions predicted as the potential transmembrane domains in VKOR can individually insert across the endoplasmic reticulum membrane in vitro. However, in the intact enzyme there are only three transmembrane domains, residues 10 - 29, 101 - 123, and 127 - 149, and membrane-integration of residues 75 - 97 appears to be suppressed by the surrounding sequence. Results of N-linked glycosylation-tagged full-length VKOR shows that the N terminus of VKOR is located in the endoplasmic reticulum lumen, and the C terminus is located in the cytoplasm. Further evidence for this topological model of VKOR was obtained with freshly prepared intact microsomes from insect cells expressing HPC4-tagged full-length VKOR. In these experiments an HPC4 tag at the N terminus was protected from proteinase K digestion, whereas an HPC4 tag at the C terminus was susceptible. Altogether, our results suggest that VKOR is a type III membrane protein with three transmembrane domains, which agrees well with the prediction by the topology prediction program TMHMM.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Duke Univ, Dept Cell Biol, Durham, NC 27710 USA; Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden	University of North Carolina; University of North Carolina Chapel Hill; Duke University; Stockholm University	Stafford, DW (corresponding author), Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA.	dws@E-mail.unc.edu	von Heijne, Gunnar/F-5576-2011; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; Tie, Jian-Ke/0000-0002-8447-3408	NHLBI NIH HHS [HL48318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Begent LA, 2001, J PHARM PHARMACOL, V53, P481, DOI 10.1211/0022357011775776; BELL R G, 1970, Archives of Biochemistry and Biophysics, V141, P473, DOI 10.1016/0003-9861(70)90164-5; Cain D, 1997, J BIOL CHEM, V272, P29068, DOI 10.1074/jbc.272.46.29068; Furie B, 1999, BLOOD, V93, P1798, DOI 10.1182/blood.V93.6.1798.406k22_1798_1808; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Goder V, 2001, FEBS LETT, V504, P87, DOI 10.1016/S0014-5793(01)02712-0; Goodstadt L, 2004, TRENDS BIOCHEM SCI, V29, P289, DOI 10.1016/j.tibs.2004.04.004; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; Kim H, 2003, J BIOL CHEM, V278, P10208, DOI 10.1074/jbc.M300163200; LEE JJ, 1985, BIOCHEMISTRY-US, V24, P7063, DOI 10.1021/bi00346a007; LEE JJ, 1984, BIOCHEMISTRY-US, V23, P2246, DOI 10.1021/bi00305a024; Li T, 2004, NATURE, V427, P541, DOI 10.1038/nature02254; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Melen K, 2003, J MOL BIOL, V327, P735, DOI 10.1016/S0022-2836(03)00182-7; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; MUKHARJI I, 1985, P NATL ACAD SCI USA, V82, P2713, DOI 10.1073/pnas.82.9.2713; Mutucumarana VP, 2000, J BIOL CHEM, V275, P32572, DOI 10.1074/jbc.M006808200; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Nilsson J, 2000, FEBS LETT, V486, P267, DOI 10.1016/S0014-5793(00)02321-8; Presnell SR, 2002, THROMB HAEMOSTASIS, V87, P937, DOI 10.1055/s-0037-1613115; PREUSCH PC, 1990, FREE RADICAL RES COM, V8, P401, DOI 10.3109/10715769009053374; PREUSCH PC, 1992, FEBS LETT, V305, P257, DOI 10.1016/0014-5793(92)80681-6; PRICE PA, 1988, ANNU REV NUTR, V8, P565, DOI 10.1146/annurev.nu.08.070188.003025; Rost S, 2004, NATURE, V427, P537, DOI 10.1038/nature02214; Saxena SP, 2001, APOPTOSIS, V6, P57, DOI 10.1023/A:1009624111275; SILVERMAN RB, 1988, BIOCHEM BIOPH RES CO, V155, P1248, DOI 10.1016/S0006-291X(88)81274-9; SOUTE BAM, 1992, BIOCHEM J, V281, P255, DOI 10.1042/bj2810255; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; SUTTIE JW, 1986, HAEMOSTASIS, V16, P193; Taylor PD, 2003, NUCLEIC ACIDS RES, V31, P3698, DOI 10.1093/nar/gkg554; THIJSSEN HHW, 1994, BIOCHEM J, V297, P277, DOI 10.1042/bj2970277; Tie J, 2000, BLOOD, V96, P973, DOI 10.1182/blood.V96.3.973.015k55_973_978; Wajih N, 2005, J BIOL CHEM, V280, P10540, DOI 10.1074/jbc.M413982200; Wallin R, 2002, THROMB RES, V108, P221, DOI 10.1016/S0049-3848(03)00060-4; WALLIN R, 1987, INT J BIOCHEM, V19, P1063, DOI 10.1016/0020-711X(87)90307-7; Wallin R, 1997, METHOD ENZYMOL, V282, P395; Wallin R, 2001, FASEB J, V15, P2542, DOI 10.1096/fj.01-0337fje; WALTER P, 1983, METHOD ENZYMOL, V96, P84	39	86	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16410	16416		10.1074/jbc.M500765200	http://dx.doi.org/10.1074/jbc.M500765200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15716279	Green Published, hybrid			2022-12-25	WOS:000228444800114
J	Davoodpour, P; Landstrom, M				Davoodpour, P; Landstrom, M			2-methoxyestradiol-induced apoptosis in prostate cancer cells requires Smad7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; (TGF-BETA)-INDUCED APOPTOSIS; RECEPTOR; BIM; BAX; PHOSPHORYLATION; PROLIFERATION; ANGIOGENESIS; MECHANISMS; INDUCTION	Prostate cancer is the second most common cause of death related to cancer in Western society. 2-Methoxyestradiol (2-ME), an endogenous metabolite of estradiol-17 beta, inhibits tumor angiogenesis while also exerting potent cytotoxic effects on various cancer cells. 2-ME has been shown to activate the p38 MAPK and JNK pathways and to induce apoptosis in cells, although the underlying molecular mechanisms for this are unknown. Here we report that the expression of Smad7, an adaptor molecule required to activate p38 MAPK in the transforming growth factor beta signaling pathway, is also required for 2-ME-induced p38 activation and apoptosis in human prostate cancer cells (PC-3U). PC-3U/AS-S7 cells stably transfected with an antisense Smad7 construct, or PC-3U cells transiently transfected with short interfering RNA for Smad7, were protected against 2-ME-induced apoptosis. 2-ME-induced apoptosis was found to involve p38 MAPK and JNK, because simultaneous treatments with 2-ME and a specific p38 inhibitor (SB203580) or an inhibitor of JNK (L-JNK1) prevented 2-ME-induced apoptosis. Most interestingly, Smad7 was shown by both antisense and short interfering RNA techniques to affect levels of beta-catenin, which has been implicated previously in the regulation of apoptosis. Moreover, Smad7 was found to be important for the basal expression of Bim, a pro-apoptotic Bcl-2 family member, and for 2-ME-induced expression of Bim. These results suggest that expression of Smad7 is crucial for 2-ME-induced apoptosis in human prostate cancer cells.	Uppsala Univ, Biomed Ctr, Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden; Uppsala Univ, Imanet, SE-75185 Uppsala, Sweden	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University	Landstrom, M (corresponding author), Uppsala Univ, Biomed Ctr, Ludwig Inst Canc Res, Box 595, SE-75124 Uppsala, Sweden.	Marene.Landstrom@licr.uu.se		Landstrom, Marene/0000-0001-6737-7230				Barker N, 2000, BIOESSAYS, V22, P961; Bu SZ, 2002, FEBS LETT, V531, P141, DOI 10.1016/S0014-5793(02)03478-6; Burns TF, 2003, CANCER BIOL THER, V2, P431, DOI 10.4161/cbt.2.4.478; Crawford ED, 2003, UROLOGY, V62, P3, DOI 10.1016/j.urology.2003.10.013; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Davoodpour P, 2004, NUCL MED BIOL, V31, P867, DOI 10.1016/j.nucmedbio.2004.03.015; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Edlund S, 2005, MOL CELL BIOL, V25, P1475, DOI 10.1128/MCB.25.4.1475-1488.2005; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Harris CA, 2001, J BIOL CHEM, V276, P37754; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kent EC, 2003, UROLOGY, V62, P134, DOI 10.1016/j.urology.2003.09.005; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; LaVallee TM, 2002, CANCER RES, V62, P3691; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; MacCarthy-Morrogh L, 2000, CANCER RES, V60, P5441; Mazars A, 2001, J BIOL CHEM, V276, P36797, DOI 10.1074/jbc.M101672200; Moustakas A, 2001, J CELL SCI, V114, P4359; Olmeda D, 2003, MOL BIOL CELL, V14, P2844, DOI 10.1091/mbc.E03-01-0865; Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Qadan LR, 2001, BIOCHEM BIOPH RES CO, V285, P1259, DOI 10.1006/bbrc.2001.5320; Quan TH, 2005, J BIOL CHEM, V280, P8079, DOI 10.1074/jbc.M409647200; Quan TH, 2001, J BIOL CHEM, V276, P26349, DOI 10.1074/jbc.M010835200; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Schumacher G, 2001, J CANCER RES CLIN, V127, P405, DOI 10.1007/s004320000233; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shimada K, 2003, CARCINOGENESIS, V24, P1067, DOI 10.1093/carcin/bgg058; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391	46	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14773	14779		10.1074/jbc.M414470200	http://dx.doi.org/10.1074/jbc.M414470200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708859	hybrid			2022-12-25	WOS:000228236800054
J	Saavalainen, K; Pasonen-Seppanen, S; Dunlop, TW; Tammi, R; Tammi, MI; Carlberg, C				Saavalainen, K; Pasonen-Seppanen, S; Dunlop, TW; Tammi, R; Tammi, MI; Carlberg, C			The human hyaluronan synthase 2 gene is a primary retinoic acid and epidermal growth factor responding gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; VITAMIN-D; HEPARIN-BINDING; CELL-GROWTH; IN-VITRO; IDENTIFICATION; ELEMENTS; KERATINOCYTES; ACTIVATION; TRANSCRIPTION	Hyaluronan is an abundant and rapidly turned over matrix molecule between the vital cell layers of the epidermis and subject to large concentration changes associated with keratinocyte proliferation, migration, and differentiation induced by paracrine and endocrine factors like epidermal growth factor (EGF) and all-trans-retinoic acid ( RA). We found that in REK cells EGF and all-trans-RA up-regulated hyaluronan synthase 2 (Has2) gene expression within 2 h 4-fold each and in HaCaT human immortal keratinocytes 8- and 33-fold, respectively. The first 10 kb of the human Has2 promoter were scanned in silico and in vitro for potential response elements of signal transducer and activator of transcription ( STAT) or RA receptor (RAR) proteins. We identified a STAT-response element in the proximal promoter region and confirmed its functionality in response to EGF by chromatin immunoprecipitation (ChIP) assays. Direct in vitro binding of RARs to four RARE candidates within the Has2 promoter could not be observed at stringent gel shift conditions, but reporter gene assays demonstrated functionality of a complex of two of these RAREs located similar to 1200 bp upstream of the transcription start site. Moreover, ChIP assays using antibodies against nine nuclear proteins monitored all-trans-RA-dependent binding of RAR, retinoid X receptor, mediator protein, and RNA polymerase II and also histone 4 acetylation to a promoter region containing the complex RARE. Taken together, the human Has2 gene is a potent primary EGF and all-trans-RA responding gene with a complex regulation.	Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Anat, FIN-70211 Kuopio, Finland	Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland	Carlberg, C (corresponding author), Univ Kuopio, Dept Biochem, POB 1627, FIN-70211 Kuopio, Finland.	carlberg@messi.uku.fi	Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Glass CK, 2000, GENE DEV, V14, P121; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hiltunen ELJ, 2002, CANCER RES, V62, P6410; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jurka J, 1996, COMPUT CHEM, V20, P119, DOI 10.1016/S0097-8485(96)80013-1; Makinen JM, 2002, MOL PHARMACOL, V62, P366, DOI 10.1124/mol.62.2.366; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Monslow J, 2004, J BIOL CHEM, V279, P20576, DOI 10.1074/jbc.M312666200; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nishida Y, 1999, J BIOL CHEM, V274, P21893, DOI 10.1074/jbc.274.31.21893; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Pasonen-Seppanen S, 2001, J INVEST DERMATOL, V117, P1322, DOI 10.1046/j.0022-202x.2001.01529.x; Pasonen-Seppanen S, 2003, J INVEST DERMATOL, V120, P1038, DOI 10.1046/j.1523-1747.2003.12249.x; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; Piepkorn M, 1998, J INVEST DERMATOL, V111, P715, DOI 10.1046/j.1523-1747.1998.00390.x; Quack M, 2000, J MOL BIOL, V296, P743, DOI 10.1006/jmbi.2000.3499; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rilla K, 2002, J CELL SCI, V115, P3633, DOI 10.1242/jcs.00042; SCHRADER M, 1993, NUCLEIC ACIDS RES, V21, P1231, DOI 10.1093/nar/21.5.1231; Shaffer PL, 2002, EMBO J, V21, P2242, DOI 10.1093/emboj/21.9.2242; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; TAMMI R, 1989, J INVEST DERMATOL, V92, P326, DOI 10.1111/1523-1747.ep12277125; TAMMI R, 1994, PROG HISTOCHEM CYTOC, V29, P1; Toell A, 2000, BIOCHEM J, V352, P301, DOI 10.1042/0264-6021:3520301; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Xiao JH, 1999, EMBO J, V18, P1539, DOI 10.1093/emboj/18.6.1539	38	87	89	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14636	14644		10.1074/jbc.M500206200	http://dx.doi.org/10.1074/jbc.M500206200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15722343	hybrid			2022-12-25	WOS:000228236800038
J	Madonna, R; Di Napoli, P; Massaro, M; Grilli, A; Felaco, M; De Caterina, A; Tang, DM; De Caterina, R; Geng, YJ				Madonna, R; Di Napoli, P; Massaro, M; Grilli, A; Felaco, M; De Caterina, A; Tang, DM; De Caterina, R; Geng, YJ			Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; COA REDUCTASE INHIBITOR; ENDOTHELIAL PROGENITOR CELLS; NECROSIS-FACTOR-ALPHA; COENZYME-A REDUCTASE; HEART-FAILURE; PRIMARY ASTROCYTES; INTERFERON-GAMMA; APOPTOTIC DEATH; STATIN THERAPY	Cardiac stem cells or myoblasts are vulnerable to inflammatory stimulation in hearts with infarction or ischemic injury. Widely used for the prevention and treatment of atherosclerotic heart disease, the cholesterol-lowering drugs statins may exert anti-inflammatory effects. In this study, we examined the impact of inhibition of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase with simvastatin on the expression of inducible nitric-oxide synthase (iNOS) in embryonic cardiac myoblasts stimulated with the proinflammatory cytokines, interleukin-1 or tumor necrosis factor. Treatment with simvastatin significantly reduced the levels of iNOS mRNA and protein in cytokine-treated rat H9c2 cardiac embryonic myoblasts. Addition of the HMG-CoA reductase product, L-mevalonate, and the by-product of cholesterol synthesis, geranylgeranyl pyrophosphate, could reverse the statin inhibitory effect on iNOS expression. Simvastatin treatment lowered the Rho GTPase activities, whereas the Rho-associated kinase inhibitor Y27632 partially blocked the statin inhibitory effect on nitrite production in the cytokine-treated H9c2 cells. Treatment with simvastatin led to inactivation of NF-kappa B by elevation of the NF-kappa B inhibitor I kappa B and reduction of the NF-kappa B nuclear contents in the cytokine-stimulated H9c2 cells. Hence, treatment with simvastatin can attenuate iNOS expression and NO synthesis in cytokine-stimulated embryonic cardiac myoblasts. The statin inhibitory effect may occur through isoprenoid-mediated intracellular signal transduction, which involves several key signal proteins, such as Rho kinase and I kappa B/NF-kappa B. These data suggest that statin therapy may protect the cardiac myocyte progenitors against the cytotoxicity of cytokine-induced high output of NO production in infarcted or ischemic hearts with inflammation.	Univ G DAnnunzio, Inst Cardiol, I-66100 Chieti, Italy; Univ G DAnnunzio, Ctr Excellence Aging, I-66100 Chieti, Italy; Univ G DAnnunzio, Dept Biomorphol, I-66100 Chieti, Italy; CNR, Inst Clin Physiol, I-73100 Lecce, Italy; Univ Texas, Hlth Sci Ctr, Houston, TX 77030 USA	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Texas System; University of Texas Health Science Center Houston	De Caterina, R (corresponding author), Univ G DAnnunzio, Osped S Camillo de Lellis, Dept Cardiol, Via Forlanini 50, I-66100 Chieti, Italy.	rdcater@unich.it; yong-jian.geng@uth.tmc.edu	massaro, marika/AAQ-1204-2020; De Caterina, Raffaele/K-3857-2016	massaro, marika/0000-0001-6124-5077; De Caterina, Raffaele/0000-0003-1637-574X; grilli, alfredo/0000-0002-5746-5007; Madonna, Rosalinda/0000-0001-6455-2777	NHLBI NIH HHS [R01HL69509, R01HL59249] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059249, R01HL069509] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Birks EJ, 2000, TRANSPLANTATION, V70, P1498, DOI 10.1097/00007890-200011270-00018; Birks EJ, 1997, CORONARY ARTERY DIS, V8, P389, DOI 10.1097/00019501-199706000-00007; Bloch W, 2001, MICROSC RES TECHNIQ, V55, P259, DOI 10.1002/jemt.1175; Bloch W, 1999, CARDIOVASC RES, V43, P675, DOI 10.1016/S0008-6363(99)00160-1; Desager JP, 1996, CLIN PHARMACOKINET, V31, P348, DOI 10.2165/00003088-199631050-00003; Di Napoli P, 2001, CARDIOVASC RES, V51, P283, DOI 10.1016/S0008-6363(01)00306-6; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; GENG Y, 1992, CIRC RES, V71, P1268, DOI 10.1161/01.RES.71.5.1268; Geng YJ, 2003, ANN NY ACAD SCI, V1010, P687, DOI 10.1196/annals.1299.126; Geng YJ, 1996, ARTERIOSCL THROM VAS, V16, P19, DOI 10.1161/01.ATV.16.1.19; Geng YJ, 1996, CANCER RES, V56, P866; GENG YJ, 1994, BBA-GENE STRUCT EXPR, V1218, P421, DOI 10.1016/0167-4781(94)90196-1; GENG YJ, 1994, EXP CELL RES, V214, P418, DOI 10.1006/excr.1994.1275; Gotto AM, 2001, AM J CARDIOL, V87, p13B; Gotto AM, 2001, AM J CARDIOL, V88, p36F; Guijarro C, 1998, CIRC RES, V83, P490, DOI 10.1161/01.RES.83.5.490; Hattori Y, 2002, CARDIOVASC RES, V54, P649, DOI 10.1016/S0008-6363(02)00266-3; HESCHELER J, 1991, CIRC RES, V69, P1476, DOI 10.1161/01.RES.69.6.1476; Hescheler J, 1999, CELLS TISSUES ORGANS, V165, P153, DOI 10.1159/000016695; Ikeda Y, 2003, J CARDIOVASC PHARM, V41, P649, DOI 10.1097/00005344-200304000-00019; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Kaneta S, 2003, ATHEROSCLEROSIS, V170, P237, DOI 10.1016/S0021-9150(03)00301-0; Kim SJ, 2002, AM J PHYSIOL-HEART C, V282, pH423, DOI 10.1152/ajpheart.00609.2001; Kraynack NC, 2002, AM J PHYSIOL-LUNG C, V283, pL604, DOI 10.1152/ajplung.00459.2001; Laufs U, 2000, CIRCULATION, V102, P3104; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Laufs U, 2002, CARDIOVASC RES, V53, P911, DOI 10.1016/S0008-6363(01)00540-5; Llevadot J, 2001, J CLIN INVEST, V108, P399, DOI 10.1172/JCI200113131; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Massion PB, 2003, CIRC RES, V93, P388, DOI 10.1161/01.RES.0000088351.58510.21; Ogata Y, 2002, J CARDIOVASC PHARM, V40, P907, DOI 10.1097/00005344-200212000-00012; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; Rasmussen LM, 2001, BIOCHEM J, V360, P363, DOI 10.1042/0264-6021:3600363; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Vasa M, 2001, CIRCULATION, V103, P2885, DOI 10.1161/hc2401.092816; Vincent L, 2001, FEBS LETT, V495, P159, DOI 10.1016/S0014-5793(01)02337-7; von Haehling S, 2003, HEART FAIL REV, V8, P99, DOI 10.1023/A:1022103222857; Wassmann S, 2001, HYPERTENSION, V37, P1450, DOI 10.1161/01.HYP.37.6.1450; XIE QW, 1994, J BIOL CHEM, V269, P4705	41	75	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13503	13511		10.1074/jbc.M411859200	http://dx.doi.org/10.1074/jbc.M411859200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15705589	hybrid, Green Published			2022-12-25	WOS:000228095500041
J	Courter, DL; Lomas, L; Scatena, M; Giachelli, CM				Courter, DL; Lomas, L; Scatena, M; Giachelli, CM			Src kinase activity is required for integrin alpha(V)beta(3)-mediated activation of nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; HUMAN-MELANOMA CELLS; SMOOTH-MUSCLE-CELLS; C-SRC; PROMATRIX METALLOPROTEINASE-2; CYTOPLASMIC DOMAIN; OSTEOPONTIN; MIGRATION; GROWTH; PHOSPHORYLATION	Integrin adhesion to extracellular matrix proteins protects adhesion-dependent cells from suspension-induced apoptosis. Previous studies indicate that activation of the transcription factor nuclear factor-kappa B was necessary for the integrin alpha(v)beta(3) ligand osteopontin to protect endothelial cells from apoptosis caused by serum withdrawal. In this study, beta(3) integrins were over-expressed in smooth muscle cells. When plated on osteopontin, cells overexpressing wild-type beta(3) had enhanced cell adhesion, cell spreading, and nuclear factor-kappa B activation compared with vector control. Removal of four amino acids (759X) from the C terminus of beta(3) eliminated the ability of the integrin to promote these processes. Single amino acid substitutions indicated that phosphorylation at tyrosine 759 was not required for activation of the transcription factor, however this residue appeared to play a structural role, because mutation to alanine significantly inhibited nuclear factor-kappa B activation. The Src family of tyrosine kinases represents important transducers during integrin signaling, and the C terminus of beta(3) has been implicated as the binding site for Src. Immunoprecipitations demonstrated that Src associated with wild-type beta(3) integrins, but Src and integrins lacking the C terminus (759X) did not form a complex. Pharmacological inhibition with the Src inhibitor PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) or overexpression of kinase-dead c-Src blocked nuclear factor-kappa B activation. Mouse embryonic fibroblasts deficient for Src failed to activate nuclear factor-kappa B when plated on osteopontin, in contrast to control fibroblasts. Together, these experiments indicate that the C terminus of beta(3) and Src activity are required for integrin alpha(v)beta(3)-mediated nuclear factor-kappa B activation.	Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA	University of Washington; University of Washington Seattle; University of Southern California	Giachelli, CM (corresponding author), Univ Washington, Dept Bioengn, Box 351720,Bagley 460, Seattle, WA 98195 USA.	ceci@u.washington.edu			NHLBI NIH HHS [HL18645, HL07312] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; Chellaiah M, 1996, ENDOCRINOLOGY, V137, P2432, DOI 10.1210/en.137.6.2432; Das R, 2004, J BIOL CHEM, V279, P11051, DOI 10.1074/jbc.M310256200; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Ferri N, 2003, J BIOL CHEM, V278, P19757, DOI 10.1074/jbc.M212714200; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Garton KJ, 2002, BIOTECHNIQUES, V32, P830, DOI 10.2144/02324rr01; HRUSKA KA, 1995, ENDOCRINOLOGY, V136, P2984, DOI 10.1210/en.136.7.2984; Huang S, 2000, CLIN CANCER RES, V6, P2573; Huang WC, 2003, J IMMUNOL, V170, P4767, DOI 10.4049/jimmunol.170.9.4767; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LEMIRE JM, 1994, AM J PATHOL, V144, P1068; LIAW L, 1995, CIRC RES, V77, P665, DOI 10.1161/01.RES.77.4.665; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Malyankar UM, 2000, J BIOL CHEM, V275, P20959, DOI 10.1074/jbc.C000290200; Martin SM, 2003, J BIOMED MATER RES A, V67A, P334, DOI 10.1002/jbm.a.10060; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Petitclerc E, 1999, CANCER RES, V59, P2724; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Philip S, 2003, J BIOL CHEM, V278, P14487, DOI 10.1074/jbc.M207309200; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Woodside DG, 2001, CURR BIOL, V11, P1799, DOI 10.1016/S0960-9822(01)00565-6; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	35	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12145	12151		10.1074/jbc.M412555200	http://dx.doi.org/10.1074/jbc.M412555200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15695822	hybrid			2022-12-25	WOS:000227922000012
J	Fan, SJ; Gao, M; Meng, QH; Laterra, JJ; Symons, MH; Coniglio, S; Pestell, RG; Goldberg, ID; Rosen, AM				Fan, SJ; Gao, M; Meng, QH; Laterra, JJ; Symons, MH; Coniglio, S; Pestell, RG; Goldberg, ID; Rosen, AM			Role of NF-kappa B signaling in hepatocyte growth factor scatter factor-mediated cell protection	ONCOGENE			English	Article						NF-kappa B; I kappa B; p65; super-repressor; hepatocyte growth factor (HGF); scatter factor (SF)	TUMOR-NECROSIS-FACTOR; BREAST-CANCER CELLS; FACTOR/SCATTER FACTOR; FACTOR RECEPTOR; CARCINOMA-CELLS; ACTIVATION; EXPRESSION; APOPTOSIS; PROTEIN; PATHWAY	The cytokine scatter factor/hepatocyte growth factor (HGF/SF) protects epithelial, carcinoma, and other cell types against cytotoxicity and apoptosis induced by DNA-damaging agents such as ionizing radiation and adriamycin (ADR, a topoisomerase IIalpha inhibitor). We investigated the role of nuclear factor kappa B (NF-kappaB) signaling in HGF/SF-mediated protection of human prostate cancer (DU-145) and Madin-Darby canine kidney (MDCK) epithelial cells against ADR. HGF/SF caused the rapid nuclear translocation of the p65 ( RelA) subunit of NF-kappaB associated with the transient loss of the inhibitory subunit IkappaB-alpha. Exposure to HGF/SF caused the activation of an NF-kappaB luciferase reporter that was blocked or attenuated by the expression of a mutant 'super-repressor' IkappaB-alpha. Electrophoretic mobility shift assay supershift assays revealed that HGF/SF treatment induced the transient binding of various NF-kappaB family proteins ( p65, p50, c-Rel, and RelB) with radiolabeled NF-kappaB-binding oligonucleotides. The HGF/SF-mediated protection of DU-145 and MDCK cells against ADR ( demonstrated using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays) was abrogated by the IkappaB-alpha super-repressor. The ability of HGF/SF to activate NF-kappaB signaling was dependent on c-Akt-->Pak1 (p21-associated kinase-1) signaling ( with Pak1 downstream of c-Akt) and was inhibited by the tumor suppressor PTEN ( phosphatase and tensin homolog). Inhibitors of phosphatidylinositol-3'-kinase and Src family kinases significantly inhibited HGF/SF-mediated activation of NF-kappaB, while inhibitors of MEK, protein kinase C, and p70 S6 kinase had a modest effect or no effect on NF-kappaB activity. HGF/SF induced the expression of several known NF-kappaB target genes (cIAP-1 ( cellular inhibitor of apoptosis-1), cIAP-2, and TRAF-2 (TNF receptor-associated factor- 2)) in an NF-kappaB-dependent manner; HGF/SF blocked the inhibition of expression of these genes by ADR. Experimental manipulation of expression of these genes suggests that they ( particularly TRAF-2 and cIAP-2) contribute to the protection against ADR by HGF/SF. These findings suggest that HGF/SF activates NF-kappaB through a c-Akt-->Pak1 signaling pathway that is also dependent on Src, and that NF-kappaB contributes to HGF/SF-mediated protection against ADR.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20057 USA; Long Isl Jewish Med Ctr, N Shore Long Isl Jewish Res Inst, Dept Radiat Oncol, New Hyde Pk, NY 11040 USA; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; N Shore Long Isl Jewish Res Inst, N Shore Long Isl Jewish Hlth Syst, Manhasset, NY 11030 USA	Georgetown University; Northwell Health; Johns Hopkins University; Kennedy Krieger Institute; Northwell Health	Rosen, AM (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, 3970 Reservoir Rd,NW Box 571469, Washington, DC 20057 USA.	emr36@georgetown.edu	Meng, Q./GSI-6185-2022		NATIONAL CANCER INSTITUTE [R01CA080000, R01CA082599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA013122] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA80000, R01-CA82599] Funding Source: Medline; NIAAA NIH HHS [R21AA13122] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NINDS NIH HHS [R01-NS43987] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; ALLEY MC, 1988, CANCER RES, V48, P589; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Bell S, 2003, CELL SIGNAL, V15, P1, DOI 10.1016/S0898-6568(02)00080-3; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bouzahzah B, 2001, MOL MED, V7, P816, DOI 10.1007/BF03401974; Bowers DC, 2000, CANCER RES, V60, P4277; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Carter KB, 2000, J BIOL CHEM, V275, P27858; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Davis ME, 2004, J BIOL CHEM, V279, P163, DOI 10.1074/jbc.M307528200; DeMeester SL, 2001, FASEB J, V15, P270, DOI 10.1096/fj.00-0170hyp; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Foryst-Ludwig A, 2000, J BIOL CHEM, V275, P39779, DOI 10.1074/jbc.M007617200; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Gao M, 2001, J BIOL CHEM, V276, P47257, DOI 10.1074/jbc.M106791200; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Guiet C, 2002, CELL DEATH DIFFER, V9, P138, DOI 10.1038/sj/cdd/4400947; Gupta S, 2003, INT J ONCOL, V22, P15; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hellerbrand C, 1998, AM J PHYSIOL-GASTR L, V275, pG269, DOI 10.1152/ajpgi.1998.275.2.G269; Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; KAWAMATA S, 1998, P NATL ACAD SCI USA, V95, P565; Kurland JF, 2003, J BIOL CHEM, V278, P32465, DOI 10.1074/jbc.M212919200; Lee SY, 1998, J EXP MED, V188, P1381, DOI 10.1084/jem.188.7.1381; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liu R, 2001, J LEUKOCYTE BIOL, V70, P961; Magnani M., 2000, Current Drug Targets, V1, P387, DOI 10.2174/1389450003349056; Matteucci E, 2003, ONCOGENE, V22, P4062, DOI 10.1038/sj.onc.1206519; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Muller M, 2002, MOL CELL BIOL, V22, P1060, DOI 10.1128/MCB.22.4.1060-1072.2002; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Ozes ON, 1999, NATURE, V401, P82; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; Rahmani M, 2001, ONCOGENE, V20, P5132, DOI 10.1038/sj.onc.1204678; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; Rosen EM, 1998, NATO ADV SCI I A-LIF, V298, P415; Saijo K, 2003, NAT IMMUNOL, V4, P274, DOI 10.1038/ni893; Shen BJ, 1997, DNA CELL BIOL, V16, P703, DOI 10.1089/dna.1997.16.703; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yuan RQ, 2001, CANCER RES, V61, P8022; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200	64	101	106	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1749	1766		10.1038/sj.onc.1208327	http://dx.doi.org/10.1038/sj.onc.1208327			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15688034				2022-12-25	WOS:000227345100011
J	El Omari, K; Bird, LE; Nicholes, CE; Ren, JS; Stammers, DK				El Omari, K; Bird, LE; Nicholes, CE; Ren, JS; Stammers, DK			Crystal structure of CC3 (TIP30) - Implications for its role as a tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAT-ACTIVATED TRANSCRIPTION; SHORT-CHAIN DEHYDROGENASES/REDUCTASES; HIV-1 TAT; CARBONYL REDUCTASE; NUCLEAR IMPORT; PROTEIN; COMPLEX; KINASE; COACTIVATOR; METASTASIS	CC3 (TIP30) is a protein with pro-apoptotic and anti-metastatic properties. The tumor suppressor effect of CC3 has been suggested to result from inhibition of nuclear transport by binding to importin beta s or by regulating transcription through interaction in a complex with co-activator independent of AF-2 function (CIA) and the c-myc gene. Previous biochemical studies indicated that CC3 has protein kinase activity, and a structural similarity to cAMP-dependent protein kinase catalytic subunit was proposed. By contrast, bioinformatics studies suggested a relationship of CC3 to the short chain dehydrogenase reductase family. To clarify details of the CC3 structural family and ligand binding properties, we have determined the crystal structure of CC3 at 1.7-angstrom resolution. CC3 has a short chain dehydrogenase reductase fold and binding specificity for NADPH, yet it is unlikely to be normally enzymatically active because it is monomeric. These structural results, in conjunction with data from earlier mutagenesis work on the nucleotide binding motif, suggest that NADPH binding is important for the biological activity of CC3, including interaction with importins and with the CIA/c-myc system. CC3 provides an example of the adaptation of a metabolic enzyme fold to include a regulatory role, as also seen in the case of the NADH-binding co-repressor CtBP.	Univ Oxford, Struct Biol Div, Oxford OX3 7BN, England; Univ Oxford, Oxford Prot Prod Facil, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics	Stammers, DK (corresponding author), Univ Oxford, Struct Biol Div, Roosevelt Dr, Oxford OX3 7BN, England.	daves@strubi.ox.ac.uk	Ren, Jingshan/AAT-7729-2021	Ren, Jingshan/0000-0003-4015-1404; El Omari, Kamel/0000-0003-3506-6045; Bird, Louise/0000-0002-9846-5716				Baker ME, 2000, CELL MOL LIFE SCI, V57, P851, DOI 10.1007/s000180050047; Baker ME, 1999, CURR BIOL, V9, pR471, DOI 10.1016/S0960-9822(99)80297-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Ghosh D, 2001, J BIOL CHEM, V276, P18457, DOI 10.1074/jbc.M100538200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ito M, 2003, CANCER RES, V63, P8763; Jiang C, 2004, J BIOL CHEM, V279, P27781, DOI 10.1074/jbc.M401809200; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; King FW, 2004, MOL CELL BIOL, V24, P7091, DOI 10.1128/MCB.24.16.7091-7101.2004; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Lee SJ, 2003, SCIENCE, V302, P1571, DOI 10.1126/science.1088372; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1089/108705701753364922; Pereira PJB, 2001, NAT STRUCT BIOL, V8, P215, DOI 10.1038/84948; Saikumar P, 1999, AM J MED, V107, P489, DOI 10.1016/S0002-9343(99)00259-4; Salim M, 2001, J BIOL CHEM, V276, P10929, DOI 10.1074/jbc.M010753200; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Shi YJ, 2004, TRENDS GENET, V20, P445, DOI 10.1016/j.tig.2004.07.004; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; Stammers DK, 2001, EMBO J, V20, P6619, DOI 10.1093/emboj/20.23.6619; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Walter TS, 2003, J APPL CRYSTALLOGR, V36, P308, DOI 10.1107/S0021889803001997; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xiao H, 2000, EMBO J, V19, P956, DOI 10.1093/emboj/19.5.956; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146	32	23	24	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18229	18236		10.1074/jbc.M501113200	http://dx.doi.org/10.1074/jbc.M501113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728189	hybrid			2022-12-25	WOS:000228807200081
J	Burns, KL; Gelbaum, LT; Sullards, MC; Bostwick, DE; May, SW				Burns, KL; Gelbaum, LT; Sullards, MC; Bostwick, DE; May, SW			Iso-coenzyme A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONYL-COA MUTASE; CHOLINE-ACETYLTRANSFERASE; THIAZOLINE INTERMEDIATE; ACID; NUCLEOTIDE; ANALOGS; INTERCONVERSION; IDENTIFICATION; CONFORMATION; PHOSPHATE	Iso-coenzyme A is an isomer of coenzyme A in which the monophosphate is attached to the 2'-carbon of the ribose ring. Although iso-CoA was first reported in 1959 (Moffatt, J. G., and Khorana, H. G. ( 1959) J. Am. Chem. Soc. 81, 1265 - 1265) to be a by-product of the chemical synthesis of CoA, relatively little attention has been focused on iso-CoA or on acyl-iso-CoA compounds in the literature. We now report structural characterizations of iso-CoA, acetyl-iso-CoA, acetoacetyl-iso-CoA, and beta-hydroxybutyryl-iso-CoA using mass spectrometry ( MS), tandem MS, and homonuclear and heteronuclear NMR analyses. Although the 2'-phosphate isomer of malonyl-CoA was recently identified in commercial samples, previous characterizations of iso-CoA itself have been based on chromatographic analyses, which ultimately rest on comparisons with the degradation products of CoA and NADPH or have been based on assumptions regarding enzyme specificity. We describe a high performance liquid chromatography methodology for separating the isomers of several CoA-containing compounds. We also report here the first examples of iso-CoA-containing compounds acting as substrates in enzymatic acyl transfer reactions. Finally, we describe a simple synthesis of iso-CoA from CoA, which utilizes beta-cyclodextrin to produce iso-CoA with high regioselectivity, and we demonstrate a plausible mechanism that accounts for the existence of iso-CoA isomers in commercial preparations of CoA-containing compounds. We anticipate that these results will provide methodology and impetus for investigating iso-CoA compounds as potential pseudo-substrates or inhibitors of the > 350 known CoA-utilizing enzymes.	Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA; Georgia Inst Technol, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology	May, SW (corresponding author), Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA.	sheldon.may@chemistry.gatech.edu			NCRR NIH HHS [1S10RR012008-01A1] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR012008] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BEINERT H, 1953, J BIOL CHEM, V200, P385; BEINERT H, 1952, J AM CHEM SOC, V74, P854, DOI 10.1021/ja01123a531; BRENDELBERGER G, 1988, ANGEW CHEM INT EDIT, V27, P1089, DOI 10.1002/anie.198810891; BRENDELBERGER V, 1989, ISRAEL J CHEM, V29, P195; BROWN DM, 1951, J CHEM SOC, P2952; BUYSKE DM, 1951, J BIOL CHEM, V193, P307; CIARDELLI TL, 1981, LIEBIGS ANN CHEM, V5, P828; Cobas JC, 2003, CONCEPT MAGN RESON A, V19A, P80, DOI 10.1002/cmr.a.10089; DORDINE RL, 1995, BIOORG CHEM, V23, P169, DOI 10.1006/bioo.1995.1014; HASHIMOTO M, 1972, CHEM LETT, P595, DOI 10.1246/cl.1972.595; INGEBRETSEN OC, 1979, ANAL BIOCHEM, V96, P181, DOI 10.1016/0003-2697(79)90571-2; Iyer PP, 2001, J BACTERIOL, V183, P4244, DOI 10.1128/JB.183.14.4244-4250.2001; KHYM JX, 1954, J AM CHEM SOC, V76, P5523, DOI 10.1021/ja01650a075; KOMIYAMA M, 1992, J AM CHEM SOC, V114, P1070, DOI 10.1021/ja00029a040; Kozlov G, 2003, J BIOL CHEM, V278, P46021, DOI 10.1074/jbc.M305176200; KUROOKA S, 1967, CHEM PHARM BULL, V15, P944; LEE CH, 1975, J AM CHEM SOC, V97, P1225, DOI 10.1021/ja00838a043; Lee J, 2001, J BIOL CHEM, V276, P14804, DOI 10.1074/jbc.M009434200; LIPMANN F, 1950, J BIOL CHEM, V186, P235; MAUTNER HG, 1981, P NATL ACAD SCI-BIOL, V78, P7449, DOI 10.1073/pnas.78.12.7449; Mazumder R, 2002, NUCLEIC ACIDS RES, V30, P5229, DOI 10.1093/nar/gkf645; MICHELSON A, 1961, BIOCHIM BIOPHYS ACTA, V50, P605, DOI 10.1016/0006-3002(61)90033-6; MICHELSON AM, 1964, BIOCHIM BIOPHYS ACTA, V93, P71, DOI 10.1016/0304-4165(64)90261-2; MICHENFELDER M, 1986, ANGEW CHEM INT EDIT, V25, P366, DOI 10.1002/anie.198603661; MICHENFELDER M, 1987, EUR J BIOCHEM, V168, P659, DOI 10.1111/j.1432-1033.1987.tb13467.x; MIEYAL JJ, 1974, J BIOL CHEM, V249, P2633; MIKHAILOV SN, 1992, J ORG CHEM, V57, P4122, DOI 10.1021/jo00041a014; MILLER TL, 1966, J AM CHEM SOC, V88, P2299, DOI 10.1021/ja00962a037; Minkler PE, 2004, ANAL BIOCHEM, V328, P203, DOI 10.1016/j.ab.2004.01.015; MOFFATT JG, 1959, J AM CHEM SOC, V81, P1265, DOI 10.1021/ja01514a073; MOFFATT JG, 1961, J AM CHEM SOC, V83, P663, DOI 10.1021/ja01464a036; NORWOOD DL, 1990, J CHROMATOGR-BIOMED, V527, P289, DOI 10.1016/S0378-4347(00)82113-1; OIVANEN M, 1989, J ORG CHEM, V54, P2556, DOI 10.1021/jo00272a018; OIVANEN M, 1991, J ORG CHEM, V56, P3623, DOI 10.1021/jo00011a032; PATEL SS, 1988, ANAL BIOCHEM, V170, P355, DOI 10.1016/0003-2697(88)90642-2; Rosenfeld S, 1997, J AM CHEM SOC, V119, P8395, DOI 10.1021/ja9759048; ROSSIER J, 1977, BIOCHEM J, V165, P321, DOI 10.1042/bj1650321; SAWATA S, 1992, J PHYS ORG CHEM, V5, P502, DOI 10.1002/poc.610050812; Schomburg I, 2004, NUCLEIC ACIDS RES, V32, pD431, DOI 10.1093/nar/gkh081; Shimazu M, 2004, ANAL BIOCHEM, V328, P51, DOI 10.1016/j.ab.2004.01.025; SHIMIZU M, 1965, CHEM PHARM BULL, V13, P1142; SHIMIZU M, 1967, CHEM PHARM BULL, V15, P655; SHUSTER L, 1955, J BIOL CHEM, V215, P183; SOGIN DC, 1976, J NEUROCHEM, V27, P1333, DOI 10.1111/j.1471-4159.1976.tb02612.x; STADTMAN ER, 1953, J BIOL CHEM, V203, P47; STEWART CJ, 1978, LIEBIGS ANN CHEM, V1, P57; Tachibana A, 1998, J FERMENT BIOENG, V86, P523, DOI 10.1016/S0922-338X(98)80166-9; TAGUCHI Y, 1976, B CHEM SOC JPN, V49, P1122, DOI 10.1246/bcsj.49.1122; THORPE C, 1981, EUR J BIOCHEM, V118, P279; Vogel KW, 2000, BIOORGAN MED CHEM, V8, P2451, DOI 10.1016/S0968-0896(00)00189-9; WAGNER AP, 1991, EUR J BIOCHEM, V195, P699, DOI 10.1111/j.1432-1033.1991.tb15756.x; WANG HY, 1991, ARCH BIOCHEM BIOPHYS, V289, P274, DOI 10.1016/0003-9861(91)90472-U; WANG TP, 1952, J AM CHEM SOC, V74, P3204, DOI 10.1021/ja01132a542; WANG TP, 1954, J BIOL CHEM, V206, P299; WANG TP, 1954, J BIOL CHEM, V206, P311; WILSON GE, 1975, J AM CHEM SOC, V97, P2907, DOI 10.1021/ja00843a053; WU DH, 1995, J BIOL CHEM, V270, P29111, DOI 10.1074/jbc.270.49.29111; ZHAO YM, 1994, CAN J CHEM, V72, P164, DOI 10.1139/v94-025	58	20	21	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16550	16558		10.1074/jbc.M411898200	http://dx.doi.org/10.1074/jbc.M411898200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15708855	hybrid			2022-12-25	WOS:000228615500004
J	Doss-Pepe, EW; Chen, L; Madura, K				Doss-Pepe, EW; Chen, L; Madura, K			alpha-Synuclein and Parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DOPAMINE TRANSPORTER; PLASMA-MEMBRANE; DOWN-REGULATION; DNA-REPAIR; IN-VITRO; SACCHAROMYCES-CEREVISIAE; MULTIVESICULAR BODIES; POLYUBIQUITIN CHAINS; CONJUGATING ENZYMES; PROTEOLYTIC PATHWAY	Mutations in alpha-synuclein, Parkin, and UCH-L1 cause heritable forms of Parkinson disease. Unlike alpha-synuclein, for which no precise biochemical function has been elucidated, Parkin functions as a ubiquitin E3 ligase, and UCH-L1 is a deubiquitinating enzyme. The E3 ligase activity of Parkin in Parkinson disease is poorly understood and is further obscured by the fact that multiubiquitin chains can be formed through distinct types of linkages that regulate diverse cellular processes. For instance, ubiquitin lysine 48-linked multiubiquitin chains target substrates to the proteasome, whereas ubiquitin lysine 63-linked chains control ribosome function, protein sorting and trafficking, and endocytosis of membrane proteins. It is notable in this regard that ubiquitin lysine 63-linked chains promote the degradation of membrane proteins by the lysosome. Because both Parkin and alpha-synuclein can regulate the activity of the dopamine transporter, we investigated whether they influenced ubiquitin lysine 63-linked chain assembly. These studies revealed novel biochemical activities for both Parkin and alpha-synuclein. We determined that Parkin functions with UbcH13/Uev1a, a dimeric ubiquitin-conjugating enzyme, to assemble ubiquitin lysine 63-linked chains. Our results and the results of others indicate that Parkin can promote both lysine 48- and lysine 63-linked ubiquitin chains. alpha-Synuclein also stimulated the assembly of lysine 63-linked ubiquitin chains. Because UCH-L1, a ubiquitin hydrolase, was recently reported to form lysine 63-linked conjugates, it is evident that three proteins that are genetically linked to Parkinson disease can contribute to lysine 63 multiubiquitin chain formation.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Doss-Pepe, EW (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 683 Hoes Lane,Rm 372, Piscataway, NJ 08854 USA.	dosspeew@umdnj.edu; maduraki@umdnj.edu			NCI NIH HHS [CA83875] Funding Source: Medline; NIA NIH HHS [AG01047] Funding Source: Medline; NINDS NIH HHS [NS044081] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083875] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K01AG001047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; BANIAHMAD C, 1994, BIOTECHNIQUES, V16, P194; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Buckley KM, 2000, J PHYSIOL-LONDON, V525, P11, DOI 10.1111/j.1469-7793.2000.t01-2-00011.x; Burbea M, 2002, NEURON, V35, P107, DOI 10.1016/S0896-6273(02)00749-3; Buttner C, 2001, J BIOL CHEM, V276, P42978, DOI 10.1074/jbc.M102121200; Cabin DE, 2002, J NEUROSCI, V22, P8797; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Dalfo E, 2004, NEUROBIOL DIS, V16, P92, DOI 10.1016/j.nbd.2004.01.001; Dalfo E, 2004, J NEUROPATH EXP NEUR, V63, P302, DOI 10.1093/jnen/63.4.302; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Elsasser S, 2004, J BIOL CHEM, V279, P26817, DOI 10.1074/jbc.M404020200; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hegde AN, 2002, NAT REV NEUROSCI, V3, P854, DOI 10.1038/nrn961; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jiang HB, 2004, J BIOL CHEM, V279, P54380, DOI 10.1074/jbc.M409282200; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kubo S, 2001, J NEUROCHEM, V78, P42, DOI 10.1046/j.1471-4159.2001.00364.x; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lehmensiek V, 2002, NEUROREPORT, V13, P1279, DOI 10.1097/00001756-200207190-00013; Liani E, 2004, P NATL ACAD SCI USA, V101, P5500, DOI 10.1073/pnas.0401081101; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Lotharius J, 2002, HUM MOL GENET, V11, P2395, DOI 10.1093/hmg/11.20.2395; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; Melikian HE, 1999, J NEUROSCI, V19, P7699; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Reggiori F, 2000, MOL BIOL CELL, V11, P3737, DOI 10.1091/mbc.11.11.3737; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Reggiori F, 2002, NAT CELL BIOL, V4, P117, DOI 10.1038/ncb743; Roth AF, 2000, J BIOL CHEM, V275, P8143, DOI 10.1074/jbc.275.11.8143; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Springael JY, 1999, J CELL SCI, V112, P1375; Tan PK, 1996, J CELL BIOL, V135, P1789, DOI 10.1083/jcb.135.6.1789; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; Wersinger C, 2003, NEUROSCI LETT, V340, P189, DOI 10.1016/S0304-3940(03)00097-1; Wersinger C, 2004, BIOCHEMISTRY-US, V43, P1242, DOI 10.1021/bi035308s; Wersinger C, 2003, FASEB J, V17, P2151, DOI 10.1096/fj.03-0152fje; Wersinger C, 2003, MOL CELL NEUROSCI, V24, P91, DOI 10.1016/S1044-7431(03)00124-6; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	68	103	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16619	16624		10.1074/jbc.M413591200	http://dx.doi.org/10.1074/jbc.M413591200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15718234	hybrid			2022-12-25	WOS:000228615500012
J	Jones, LH; Pearson, AR; Tang, Y; Wilmot, CM; Davidson, VL				Jones, LH; Pearson, AR; Tang, Y; Wilmot, CM; Davidson, VL			Active site aspartate residues are critical for tryptophan tryptophylquinone biogenesis in methylamine dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOHEMOPROTEIN AMINE DEHYDROGENASE; QUINONE COFACTOR BIOGENESIS; CRYSTAL-STRUCTURE; PARACOCCUS-DENITRIFICANS; SUBSTRATE-SPECIFICITY; ENZYME; MUTAGENESIS; PROTEIN; OXIDASE; MAUG	The biosynthesis of methylamine dehydrogenase ( MADH) requires formation of six intrasubunit disulfide bonds, incorporation of two oxygens into residue beta Trp(57) and covalent cross-linking of beta Trp(57) to beta Trp(108) to form the protein-derived cofactor tryptophan tryptophylquinone (TTQ). Residues beta Asp(76) and beta Asp(32) are located in close proximity to the quinone oxygens of TTQ in the enzyme active site. These residues are structurally conserved in quinohemoprotein amine dehydrogenase, which possesses a cysteine tryptophylquinone cofactor. Relatively conservative beta D76N and beta D32N mutations resulted in very low levels of MADH expression. Analysis of the isolated proteins by mass spectrometry revealed that each mutation affected TTQ biogenesis. beta D76N MADH possessed the six disulfides but had no oxygen incorporated into beta Trp(57) and was completely inactive. The beta D32N MADH preparation contained a major species with six disulfides but no oxygen incorporated into beta Trp(57) and a minor species with both oxygens incorporated, which was active. The steady-state kinetic parameters for the beta D32N mutant were significantly altered by the mutation and exhibited a 1000-fold increase in the K-m value for methylamine. These results have allowed us to more clearly define the sequence of events that lead to TTQ biogenesis and to define novel roles for aspartate residues in the biogenesis of a protein-derived cofactor.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Mississippi; University of Mississippi Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Davidson, VL (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, 2500 N State St, Jackson, MS 39216 USA.	vdavidson@biochem.umsmed.edu		Pearson, Arwen/0000-0001-8499-7490; Wilmot, Carrie/0000-0002-8706-0000; Davidson, Victor/0000-0002-1966-7302	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041574, R01GM066569, R37GM041574] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-66569, GM-41574, R01 GM066569] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOKS HB, 1993, BIOCHEMISTRY-US, V32, P2725, DOI 10.1021/bi00061a034; Chen LY, 1998, J MOL BIOL, V276, P131, DOI 10.1006/jmbi.1997.1511; Chistoserdov AY, 2001, MICROBIOL-SGM, V147, P2195, DOI 10.1099/00221287-147-8-2195; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; DAVIDSON VL, 1990, METHOD ENZYMOL, V188, P241; Davidson VL, 2001, ADV PROTEIN CHEM, V58, P95; Dove JE, 2001, ADV PROTEIN CHEM, V58, P141; Firbank SJ, 2001, P NATL ACAD SCI USA, V98, P12932, DOI 10.1073/pnas.231463798; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GOVINDARAJ S, 1994, J BACTERIOL, V176, P2922, DOI 10.1128/JB.176.10.2922-2929.1994; Graichen ME, 1999, J BACTERIOL, V181, P4216, DOI 10.1128/JB.181.14.4216-4222.1999; Hevel JM, 1999, BIOCHEMISTRY-US, V38, P3683, DOI 10.1021/bi982199m; HUSAIN M, 1985, J BIOL CHEM, V260, P4626; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; Okeley NM, 2000, CHEM BIOL, V7, pR159, DOI 10.1016/S1074-5521(00)00140-X; Pearson AR, 2004, BIOCHEMISTRY-US, V43, P5494, DOI 10.1021/bi049863l; Pearson AR, 2003, BIOCHEMISTRY-US, V42, P3224, DOI 10.1021/bi027073a; Satoh A, 2002, J BIOL CHEM, V277, P2830, DOI 10.1074/jbc.M109090200; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sun DP, 2001, PROTEIN ENG, V14, P675, DOI 10.1093/protein/14.9.675; Wang YT, 2003, BIOCHEMISTRY-US, V42, P7318, DOI 10.1021/bi034243q; Wang YT, 2002, J BIOL CHEM, V277, P4119, DOI 10.1074/jbc.M109270200; Zhu ZY, 2000, BIOCHEMISTRY-US, V39, P11184, DOI 10.1021/bi001568n; Zhu ZY, 1998, J BIOL CHEM, V273, P14254, DOI 10.1074/jbc.273.23.14254	24	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17392	17396		10.1074/jbc.M500943200	http://dx.doi.org/10.1074/jbc.M500943200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15734739	hybrid			2022-12-25	WOS:000228615500104
J	Koolpe, M; Burgess, R; Dail, M; Pasquale, EB				Koolpe, M; Burgess, R; Dail, M; Pasquale, EB			EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAUSE CRANIOFRONTONASAL SYNDROME; CRYSTAL-STRUCTURE; TYROSINE KINASES; PROTEIN HORMONE; TUMOR-GROWTH; LIGANDS; AGONIST; POTENT; CELLS; EMBRYOGENESIS	The Eph receptor tyrosine kinases are overexpressed in many pathologic tissues and have therefore emerged as promising drug target candidates. However, there are few molecules available that can selectively bind to a single Eph receptor and not other members of this large receptor family. Here we report the identification by phage display of peptides that bind selectively to different receptors of the EphB class, including EphB1, EphB2, and EphB4. Peptides with the same EphB receptor specificity compete with each other for binding, suggesting that they have partially overlapping binding sites. In addition, several of the peptides contain amino acid motifs found in the G-H loop of the ephrin-B ligands, which is the region that mediates high-affinity interaction with the EphB receptors. Consistent with targeting the ephrin-binding site, the higher affinity peptides antagonize ephrin binding to the EphB receptors. We also designed an optimized EphB4-binding peptide with affinity comparable with that of the natural ligand, ephrin-B2. These peptides should be useful as selective inhibitors of the pathological activities of EphB receptors and as targeting agents for imaging probes and therapeutic drugs.	Burnham Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	elenap@burnham.org			NCI NIH HHS [CA82713] Funding Source: Medline; NICHD NIH HHS [HD25938] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA082713] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aasland R, 2002, FEBS LETT, V513, P141, DOI 10.1016/S0014-5793(01)03295-1; Adams RH, 2000, TRENDS CARDIOVAS MED, V10, P183, DOI 10.1016/S1050-1738(00)00046-3; Aoki M, 2004, J BIOL CHEM, V279, P32643, DOI 10.1074/jbc.M313247200; Ballinger MD, 1999, NAT BIOTECHNOL, V17, P1199, DOI 10.1038/70746; Battaglia AA, 2003, NAT NEUROSCI, V6, P339, DOI 10.1038/nn1034; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; Blanco F, 1998, CURR OPIN STRUC BIOL, V8, P107, DOI 10.1016/S0959-440X(98)80017-1; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Brantley-Sieders Dana M., 2004, Angiogenesis, V7, P17, DOI 10.1023/B:AGEN.0000037340.33788.87; Conover JC, 2000, NAT NEUROSCI, V3, P1091, DOI 10.1038/80606; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Fairbrother WJ, 1998, BIOCHEMISTRY-US, V37, P17754, DOI 10.1021/bi981931e; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Goldshmit Y, 2004, J NEUROSCI, V24, P10064, DOI 10.1523/JNEUROSCI.2981-04.2004; Hajduk PJ, 1997, SCIENCE, V278, P497, DOI 10.1126/science.278.5337.497; Himanen JP, 1998, NATURE, V396, P486, DOI 10.1038/24904; Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; Koolpe M, 2002, J BIOL CHEM, V277, P46974, DOI 10.1074/jbc.M208495200; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lackmann M, 1997, J BIOL CHEM, V272, P16521, DOI 10.1074/jbc.272.26.16521; Landon LA, 2003, J PROTEIN CHEM, V22, P193, DOI 10.1023/A:1023483232397; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Lowman HB, 1998, BIOCHEMISTRY-US, V37, P8870, DOI 10.1021/bi980426e; Mao WG, 2004, CANCER RES, V64, P781, DOI 10.1158/0008-5472.CAN-03-1047; Martiny-Baron G, 2004, NEOPLASIA, V6, P248, DOI 10.1593/neo.03457; McConnell SJ, 1999, COMB CHEM HIGH T SCR, V2, P155; Moore KB, 2004, DEV CELL, V6, P55, DOI 10.1016/S1534-5807(03)00395-2; Murai KK, 2003, MOL CELL NEUROSCI, V24, P1000, DOI 10.1016/j.mcn.2003.08.006; Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625; Nakamoto M, 2002, MICROSC RES TECHNIQ, V59, P58, DOI 10.1002/jemt.10177; Neidigh JW, 2002, NAT STRUCT BIOL, V9, P425, DOI 10.1038/nsb798; Noren NK, 2004, P NATL ACAD SCI USA, V101, P5583, DOI 10.1073/pnas.0401381101; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; PASQUALE EB, 2005, IN PRESS NAT REV MOL; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; Smith FM, 2004, J BIOL CHEM, V279, P9522, DOI 10.1074/jbc.M309326200; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; Song JX, 2002, BIOCHEMISTRY-US, V41, P10942, DOI 10.1021/bi025815u; Twigg SRF, 2004, P NATL ACAD SCI USA, V101, P8652, DOI 10.1073/pnas.0402819101; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; Wieland I, 2004, AM J HUM GENET, V74, P1209, DOI 10.1086/421532; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Wrighton NC, 1997, NAT BIOTECHNOL, V15, P1261, DOI 10.1038/nbt1197-1261	50	117	125	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17301	17311		10.1074/jbc.M500363200	http://dx.doi.org/10.1074/jbc.M500363200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722342	hybrid			2022-12-25	WOS:000228615500094
J	Koyanagi, M; Haendeler, J; Badorff, C; Brandes, RP; Hoffmann, J; Pandur, P; Zeiher, AM; Kuhl, M; Dimmeler, S				Koyanagi, M; Haendeler, J; Badorff, C; Brandes, RP; Hoffmann, J; Pandur, P; Zeiher, AM; Kuhl, M; Dimmeler, S			Non-canonical Wnt signaling enhances differentiation of human circulating progenitor cells to cardiomyogenic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC STEM-CELLS; ENDOTHELIAL-CELLS; CARDIAC MYOCYTES; IN-VITRO; CARDIOMYOCYTES; MYOCARDIUM; PATHWAY; MUSCLE; TRANSDIFFERENTIATION; REGENERATION	Human endothelial circulating progenitor cells (CPCs) can differentiate to cardiomyogenic cells during co-culture with neonatal rat cardiomyocytes. Wnt proteins induce myogenic specification and cardiac myogenesis. Here, we elucidated the effect of Wnts on differentiation of CPCs to cardiomyogenic cells. CPCs from peripheral blood mononuclear cells were isolated from healthy volunteers and co-cultured with neonatal rat cardiomyocytes. 6 - 10 days after co-culture, cardiac differentiation was determined by alpha-sarcomeric actinin staining of human lymphocyte antigen-positive cells (fluorescence-activated cell-sorting analysis) and mRNA expression of human myosin heavy chain and atrial natriuretic peptide. Supplementation of co-cultures with Wnt11-conditioned medium significantly enhanced the differentiation of CPCs to cardiomyocytes (1.7 +/- 0.3-fold), whereas Wnt3A-conditioned medium showed no effect. Cell fusion was not affected by Wnt11-conditioned medium. Because Wnts inhibit glycogen synthase kinase-3 beta, we further determined whether the glycogen synthase kinase-3 beta inhibitor LiCl also enhanced cardiac differentiation of CPCs. However, LiCl ( 10 mM) did not affect CPC differentiation. In contrast, Wnt11-conditioned medium time-dependently activated protein kinase C (PKC). Moreover, the PKC inhibitors bisindolylmaleimide I and III significantly blocked differentiation of CPCs to cardiomyocytes. PKC activation by phorbol 12-myristate 13-acetate significantly increased CPC differentiation to a similar extent as compared with Wnt11-conditioned medium. Our data demonstrate that Wnt11, but not Wnt3A, augments cardiomyogenic differentiation of human CPCs. Wnt11 promotes cardiac differentiation via the non-canonical PKC-dependent signaling pathway.	Univ Frankfurt, Dept Mol Cardiol, D-60590 Frankfurt, Germany; Univ Frankfurt, Inst Cardiovasc Physiol, D-60590 Frankfurt, Germany; Univ Ulm, Dept Biochem, D-89081 Ulm, Germany	Goethe University Frankfurt; Goethe University Frankfurt; Ulm University	Dimmeler, S (corresponding author), Univ Frankfurt, Dept Mol Cardiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Dimmeler@em.uni-frankfurt.de	Brandes, Ralf P/L-3058-2017	Brandes, Ralf P/0000-0002-8035-0048; Dimmeler, Stefanie/0000-0002-1045-2436; Haendeler, Judith/0000-0001-8507-4540				Badorff C, 2003, CIRCULATION, V107, P1024, DOI 10.1161/01.CIR.0000051460.85800.BB; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P10733, DOI 10.1073/pnas.191217898; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI200113152; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; Muller M, 2000, FASEB J, V14, P2540, DOI 10.1096/fj.00-0002com; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nakamura T, 2003, P NATL ACAD SCI USA, V100, P5834, DOI 10.1073/pnas.0935626100; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Olson EN, 2003, GENE DEV, V17, P1937, DOI 10.1101/gad.1110103; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Terami H, 2004, BIOCHEM BIOPH RES CO, V325, P968, DOI 10.1016/j.bbrc.2004.10.103; Toyofuku T, 2000, J CELL BIOL, V150, P225, DOI 10.1083/jcb.150.1.225; Yeh ETH, 2003, CIRCULATION, V108, P2070, DOI 10.1161/01.CIR.0000099501.52718.70	25	108	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16838	16842		10.1074/jbc.M500323200	http://dx.doi.org/10.1074/jbc.M500323200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15701629	hybrid			2022-12-25	WOS:000228615500037
J	Phelps, M; Phillips, A; Darley, M; Blaydes, JP				Phelps, M; Phillips, A; Darley, M; Blaydes, JP			MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR-ALPHA; TRANSCRIPTIONAL ACTIVATION; TRANSLATIONAL CONTROL; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; FEEDBACK LOOP; P53 FUNCTION; MDM2; PROTEIN; PHOSPHORYLATION	The physical and functional interaction between the transcription factor p53 and its negative regulatory partner protein Hdm2 (Mdm2 in mouse) is a key point of convergence of multiple signaling pathways that regulates cell proliferation and survival. hdm2 mRNA transcription is induced by p53, forming the basis of an auto-regulatory feedback loop. Growth and survival factor-activated Ras-Raf-MEK-ERK signaling can also regulate Hdm2 expression independently of p53, contributing to the pro-survival effect of these factors. In murine fibroblasts, this occurs through the regulation of mdm2 mRNA transcription. Here we show that, in human breast cancer epithelial cells, MEK-dependent regulation of Hdm2 expression also occurs at a post-transcriptional level. Pharmacological blockade of MEK activity in T47D cells inhibits Hdm2 protein synthesis by 80 - 90%. This occurs in the absence of changes in the expression of the major hdm2-P1 mRNA transcript and only an similar to 40% reduction in hdm2-P2 transcript levels. The amounts of both transcripts that are associated with polyribosomes and are, hence, being actively translated are reduced by > 80% by the MEK inhibitor, U0126. We show here that this is due to the inhibition of hdm2 mRNA export from the nucleus when MEK activity is inhibited. In MCF-7 breast cancer cells that express wild-type p53, Hdm2 is required to suppress p53-dependent transcription when MEK kinase is active. Regulation of the nuclear export of hdm2 mRNA provides, therefore, a mechanism whereby mitogen-stimulated cells avoid p53-dependent cell cycle arrest or apoptosis by maintaining the dynamic equilibrium of the Hdm2-p53 feedback loop.	Univ Southampton, Southampton Gen Hosp, Sch Med, Canc Sci Div, Southampton SO16 6YD, Hants, England	University of Southampton	Blaydes, JP (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, Canc Sci Div, MP 824, Southampton SO16 6YD, Hants, England.	j.p.blaydes@soton.ac.uk	Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				Agarwal ML, 2001, ONCOGENE, V20, P2527, DOI 10.1038/sj.onc.1204353; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Boldt S, 2002, CARCINOGENESIS, V23, P1831, DOI 10.1093/carcin/23.11.1831; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; BREWER G, 1990, METHOD ENZYMOL, V181, P202; Brown CY, 1999, ONCOGENE, V18, P5631, DOI 10.1038/sj.onc.1202949; BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Toledo SM, 2000, ONCOGENE, V19, P6185, DOI 10.1038/sj.onc.1204020; DENOME RM, 1989, NUCLEIC ACIDS RES, V17, P2081, DOI 10.1093/nar/17.5.2081; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erkmann JA, 2004, EXP CELL RES, V296, P12, DOI 10.1016/j.yexcr.2004.03.015; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gupta AK, 2001, CANCER RES, V61, P4278; Halaschek-Wiener J, 2004, CELL SIGNAL, V16, P1319, DOI 10.1016/j.cellsig.2004.04.003; HERRERA R, 2002, TRENDS MOL MED S, V8, P27, DOI DOI 10.1016/S1471-4914(02)02307-9; Hori M, 2002, BREAST CANCER RES TR, V71, P77, DOI 10.1023/A:1013350419426; Hui L, 2004, MOL CELL BIOL, V24, P5677, DOI 10.1128/MCB.24.13.5677-5686.2004; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Keene JD, 2003, NAT GENET, V33, P111, DOI 10.1038/ng0203-111; KOMMINOTH P, 2002, RADIOACTIVE IN SITU, P149; Lane DP, 2002, TRENDS MOL MED, V8, pS38, DOI 10.1016/S1471-4914(02)02309-2; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; LUNA RMD, 1995, NATURE, V378, P203; MARAIA RJ, 1994, NUCLEIC ACIDS RES, V22, P3045, DOI 10.1093/nar/22.15.3045; MARCHETTI A, 1995, J PATHOL, V175, P31, DOI 10.1002/path.1711750106; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOSNER J, 1994, ONCOGENE, V9, P3321; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Onel K, 2004, MOL CANCER RES, V2, P1; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Phelps M, 2003, CANCER RES, V63, P2616; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	67	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16651	16658		10.1074/jbc.M412334200	http://dx.doi.org/10.1074/jbc.M412334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15723837	Green Accepted, hybrid			2022-12-25	WOS:000228615500016
J	Takada, Y; Kobayashi, Y; Aggarwal, BB				Takada, Y; Kobayashi, Y; Aggarwal, BB			Evodiamine abolishes constitutive and inducible NF-kappa B activation by inhibiting I kappa B alpha kinase activation, thereby suppressing NF-kappa B-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION; CYCLIN D1; TRANSCRIPTIONAL REGULATION; DEPENDENT INDUCTION; P65 PHOSPHORYLATION; MEDIATED INDUCTION; ENDOTHELIAL-CELLS; TNF-ALPHA; CYCLOOXYGENASE-2	Evodiamine, an alkaloidal component extracted from the fruit of Evodiae fructus (Evodia rutaecarpa Benth., Rutaceae), exhibits antiproliferative, antimetastatic, and apoptotic activities through a poorly defined mechanism. Because several genes that regulate cellular proliferation, carcinogenesis, metastasis, and survival are regulated by nuclear factor-kappa B (NF-kappa B), we postulated that evodiamine mediates its activity by modulating NF-kappa B activation. In the present study, we investigated the effect of evodiamine on NF-kappa B and NF-kappa B-regulated gene expression activated by various carcinogens. We demonstrate that evodiamine was a highly potent inhibitor of NF-kappa B activation, and it abrogated both inducible and constitutive NF-kappa B activation. The inhibition corresponded with the sequential suppression of I kappa B alpha kinase activity, I kappa B alpha phosphorylation, I kappa B alpha degradation, p65 phosphorylation, p65 nuclear translocation, and p65 acetylation. Evodiamine also inhibited tumor necrosis factor (TNF)-induced Akt activation and its association with IKK. Suppression of Akt activation was specific, because it had no effect on JNK or p38 MAPK activation. Evodiamine also inhibited the NF-kappa B-dependent reporter gene expression activated by TNF, TNFR1, TRADD, TRAF2, NIK, and IKK but not that activated by the p65 subunit of NF-kappa B. NF-kappa B-regulated gene products such as Cyclin D1, c-Myc, COX-2, MMP-9, ICAM-1, MDR1, Survivin, XIAP, IAP1, IAP2, FLIP, Bcl-2, Bcl-x(L), and Bfl-1/A1 were all down-regulated by evodiamine. This down-regulation potentiated the apoptosis induced by cytokines and chemotherapeutic agents and suppressed TNF-induced invasive activity. Overall, our results indicated that evodiamine inhibits both constitutive and induced NF-kappa B activation and NF-kappa B-regulated gene expression and that this inhibition may provide a molecular basis for the ability of evodiamine to suppress proliferation, induce apoptosis, and inhibit metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Immunol, Houston, TX 77030 USA; Niigata Univ Pharm & Appl Sci, Fac Appl Life Sci, Niigata 9568603, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Niigata University	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013	Kobayashi, Yoshinori/0000-0002-4289-7392	NCI NIH HHS [P50 CA97007, P01 CA91844, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA091844, P30CA016672, P50CA097007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; ALBINI A, 1987, CANCER RES, V47, P3239; Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Bentires-Alj M, 2003, ONCOGENE, V22, P90, DOI 10.1038/sj.onc.1206056; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chiou WF, 1997, J NAT PROD, V60, P708, DOI 10.1021/np960495z; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Fei XF, 2003, CANCER SCI, V94, P92, DOI 10.1111/j.1349-7006.2003.tb01358.x; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hirschowitz E, 2002, GENE THER, V9, P81, DOI 10.1038/sj.gt.3301621; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang YC, 2004, LIFE SCI, V75, P35, DOI 10.1016/j.lfs.2003.11.025; Kan SF, 2004, INT J CANCER, V110, P641, DOI 10.1002/ijc.20138; KING CL, 1980, J NAT PROD, V43, P577, DOI 10.1021/np50011a008; Kobayashi Y, 2003, PLANTA MED, V69, P425, DOI 10.1055/s-2003-39701; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Morris KR, 2003, INFECT IMMUN, V71, P1442, DOI 10.1128/IAI.71.3.1442-1452.2003; Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Ogasawara M, 2004, BIOL PHARM BULL, V27, P578, DOI 10.1248/bpb.27.578; Ogasawara M, 2002, BIOL PHARM BULL, V25, P1491, DOI 10.1248/bpb.25.1491; Ogasawara M, 2001, BIOL PHARM BULL, V24, P917, DOI 10.1248/bpb.24.917; Ogasawara M, 2001, BIOL PHARM BULL, V24, P720, DOI 10.1248/bpb.24.720; Ozes ON, 1999, NATURE, V401, P82; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; Richardson MA, 2002, SEMIN ONCOL, V29, P531, DOI 10.1053/sonc.2002.50002; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shiraga M, 2002, CANCER RES, V62, P5967; SHOJI N, 1986, J PHARM SCI, V75, P612, DOI 10.1002/jps.2600750619; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; Takada Y, 2004, ONCOGENE, V23, P9247, DOI 10.1038/sj.onc.1208169; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weinstein IB, 2000, CARCINOGENESIS, V21, P857, DOI 10.1093/carcin/21.5.857; YAMAHARA J, 1989, J ETHNOPHARMACOL, V27, P185, DOI 10.1016/0378-8741(89)90090-1; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zhang Y, 2003, BIOL PHARM BULL, V26, P1543, DOI 10.1248/bpb.26.1543; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; [No title captured]	66	156	173	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17203	17212		10.1074/jbc.M500077200	http://dx.doi.org/10.1074/jbc.M500077200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15710601	hybrid			2022-12-25	WOS:000228615500082
J	Gemmill, TR; Wu, XY; Hanes, SD				Gemmill, TR; Wu, XY; Hanes, SD			Vanishingly low levels of Ess1 prolyl-isomerase activity are sufficient for growth in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; PRE-MESSENGER-RNA; C-TERMINAL DOMAIN; CIS/TRANS-ISOMERASE; 3'-END FORMATION; CYCLOPHILIN-A; IN-VIVO; POL-II; TRANSCRIPTION; BINDING	Ess1 is an essential peptidylprolyl-cis/trans-isomerase in the yeast Saccharomyces cerevisiae. Ess1 and its human homolog, Pin1, bind to phospho-Ser-Pro sites within proteins, including the carboxyl-terminal domain (CTD) of Rpb1, the largest subunit of RNA polymerase II (pol II). Ess1 and Pin1 are thought to control mRNA synthesis by catalyzing conformational changes in Rpb1 that affect interaction of cofactors with the pol II transcription complex. Here we have characterized wild-type and mutant Ess1 proteins in vitro and in vivo. We found that Ess1 preferentially binds and isomerizes CTD heptad-repeat (YSPTSPS) peptides that are phosphorylated on Ser5. Binding by the mutant proteins in vitro was essentially normal, and the proteins were largely stable in vivo. However, their catalytic activities were reduced > 1,000-fold. These data along with results of in vivo titration experiments indicate that Ess1 isomerase activity is required for growth, but only at vanishingly low levels. We found that although wildtype cells contain about similar to 200,000 molecules of Ess1, a level of fewer than 400 molecules per cell is sufficient for growth. In contrast, higher levels of Ess1 were required for growth in the presence of certain metabolic inhibitors, suggesting that Ess1 is important for tolerance to environmental challenge.	New York State Dept Hlth, Wadsworth Ctr, Ctr Med Sci, Albany, NY 12208 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12208 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Hanes, SD (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Ctr Med Sci, 120 New Scotland Ave, Albany, NY 12208 USA.	hanes@wadsworth.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055108] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM55108] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arevalo-Rodriguez M, 2004, FRONT BIOSCI-LANDMRK, V9, P2420, DOI 10.2741/1405; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; Burz DS, 1998, EMBO J, V17, P5998, DOI 10.1093/emboj/17.20.5998; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Devasahayam G, 2002, GENETICS, V160, P37; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; DOLINSKI K, 1997, GUIDEBOOK MOL CHAPER, P359; Fischer G, 1998, FEBS LETT, V426, P17, DOI 10.1016/S0014-5793(98)00242-7; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Fujimori F, 2001, BIOCHEM BIOPH RES CO, V289, P181, DOI 10.1006/bbrc.2001.5925; Hampsey M, 1997, YEAST, V13, P1099, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1099::AID-YEA177>3.3.CO;2-Z; Hanes S.D., 1988, THESIS BROWN U PROVI; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; Huang HK, 2001, J CELL SCI, V114, P3779; Joseph JD, 2004, J BIOL CHEM, V279, P32373, DOI 10.1074/jbc.M405415200; KERN D, 1993, FEBS LETT, V323, P198, DOI 10.1016/0014-5793(93)81338-Z; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1111/j.1574-6976.2002.tb00613.x; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kops O, 2002, FEBS LETT, V513, P305, DOI 10.1016/S0014-5793(02)02288-3; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Lin PS, 2003, CHEM REC, V3, P235, DOI 10.1002/tcr.10063; LOUVION JF, 1993, GENE, V131, P129, DOI 10.1016/0378-1119(93)90681-R; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2003, BIOESSAYS, V25, P174, DOI 10.1002/bies.10223; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; Morris DP, 1999, J BIOL CHEM, V274, P31583, DOI 10.1074/jbc.274.44.31583; Palancade B, 2004, J MOL BIOL, V335, P415, DOI 10.1016/j.jmb.2003.10.036; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; RUDD KE, 1995, TRENDS BIOCHEM SCI, V20, P12, DOI 10.1016/S0968-0004(00)88940-9; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SCHMID FX, 1993, ADV PROTEIN CHEM, V44, P25, DOI 10.1016/S0065-3233(08)60563-X; Stafford GA, 1998, J BIOL CHEM, V273, P34240, DOI 10.1074/jbc.273.51.34240; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Wilcox CB, 2004, GENETICS, V167, P93, DOI 10.1534/genetics.167.1.93; Wu XY, 2000, EMBO J, V19, P3727, DOI 10.1093/emboj/19.14.3727; Wu XY, 2003, GENETICS, V165, P1687; Xu YX, 2003, GENE DEV, V17, P2765, DOI 10.1101/gad.1135503; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	47	49	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15510	15517		10.1074/jbc.M412172200	http://dx.doi.org/10.1074/jbc.M412172200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15728580	hybrid			2022-12-25	WOS:000228444800008
J	Tong, X; Yin, L; Joshi, S; Rosenberg, DW; Giardina, C				Tong, X; Yin, L; Joshi, S; Rosenberg, DW; Giardina, C			Cyclooxygenase-2 regulation in colon cancer cells - Modulation of RNA polymerase II elongation by histone deacetylase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN FATTY-ACIDS; NF-KAPPA-B; TUMOR VIRUS PROMOTER; MESSENGER-RNA; SODIUM-BUTYRATE; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; COLORECTAL-CANCER; GROWTH-INHIBITION; EPITHELIAL-CELLS	We are interested in the mechanism of cyclooxygenase-2 (Cox-2) regulation in colon cancer cells because this knowledge could provide insight into colon carcinogenesis and suggest ways to suppress Cox-2 expression in colon tumors. Studying the HT-29 colon cancer cell line as a model, we found that Cox-2 mRNA and protein levels were activated over 10-fold by the inflammatory cytokine tumor necrosis factor (TNF)-alpha. Moreover, we found that the histone deacetylase inhibitors butyrate and trichostatin A could block Cox-2 activation in a gene-specific manner. TNF-alpha and butyrate did not significantly affect Cox-2 promoter activity, mRNA stability, or negative regulation by the Cox-2 3'-untranslated RNA region. A nuclear run-on assay showed that TNF-alpha increased Cox-2 transcription, whereas butyrate was suppressive. Because butyrate has been reported to suppress polymerase elongation on the c-myc gene, we employed the chromatin immunoprecipitation assay to determine the influence of butyrate and trichostatin A on polymerase distribution on the Cox-2 gene. These data indicated that butyrate restricted polymerase elongation from exon 1 to 2 on both the c-myc and Cox-2 genes. We propose that histone deacetylases regulate a transcriptional block on the Cox-2 and c- myc genes and that this block may be a potential target for pharmacological intervention.	Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA; Univ Penn, Sch Med, Dept Endocrinol & Metab, Philadelphia, PA 19104 USA; Univ Connecticut, Ctr Hlth, Dept Mol Med, Farmington, CT 06030 USA	University of Connecticut; University of Pennsylvania; University of Connecticut	Giardina, C (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, 91 N Eagleville Rd, Storrs, CT 06269 USA.	Giardina@uconnvm.uconn.edu		TONG, XIN/0000-0002-4832-8940	NCI NIH HHS [R29 CA79656-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA079656] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; AZUMA M, 1986, CANCER RES, V46, P770; BARNARD JA, 1993, CELL GROWTH DIFFER, V4, P495; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chen ZY, 2004, J NUTR, V134, P792, DOI 10.1093/jn/134.4.792; Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S; Dehm SM, 2004, MOL CELL BIOL, V24, P2296, DOI 10.1128/MCB.24.6.2296-2307.2004; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; FREDSTROM SB, 1994, JPEN-PARENTER ENTER, V18, P14, DOI 10.1177/014860719401800114; Gou Q, 1998, BIOCHEM BIOPH RES CO, V242, P508, DOI 10.1006/bbrc.1997.7994; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; HEERDT BG, 1994, CANCER RES, V54, P3288; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HERUTH DP, 1993, J BIOL CHEM, V268, P20466; Hinnebusch BF, 2002, J NUTR, V132, P1012, DOI 10.1093/jn/132.5.1012; Hodin RA, 1996, CELL GROWTH DIFFER, V7, P647; Inan MS, 2000, GASTROENTEROLOGY, V118, P724, DOI 10.1016/S0016-5085(00)70142-9; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; Klampfer L, 2004, J BIOL CHEM, V279, P30358, DOI 10.1074/jbc.M401359200; Klampfer L, 2003, MOL CANCER RES, V1, P855; Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427; Kostyniuk CL, 2002, ONCOGENE, V21, P6340, DOI 10.1038/sj.onc.1205787; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Mariadason JM, 2000, CANCER RES, V60, P4561; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Mulholland NM, 2003, ONCOGENE, V22, P4807, DOI 10.1038/sj.onc.1206722; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; O'Leary KA, 2004, MUTAT RES-FUND MOL M, V551, P245, DOI 10.1016/j.mrfmmm.2004.01.015; Ogawa H, 2003, BIOCHEM BIOPH RES CO, V309, P512, DOI 10.1016/j.bbrc.2003.08.026; Osada H, 2001, CANCER RES, V61, P8331; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; Patrone G, 2000, BIOTECHNIQUES, V29, P1012, DOI 10.2144/00295st02; Ramsay RG, 2003, INT J IMMUNOPATH PH, V16, P59; Rascle A, 2003, MOL CELL BIOL, V23, P4162, DOI 10.1128/MCB.23.12.4162-4173.2003; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Rosenkranz HS, 2003, ONCOL RES, V13, P529, DOI 10.3727/000000003108748054; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Segain JP, 2000, GUT, V47, P397, DOI 10.1136/gut.47.3.397; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sheldon LA, 2001, J BIOL CHEM, V276, P32423, DOI 10.1074/jbc.C100315200; Siavoshian S, 1997, CELL BIOL INT, V21, P281, DOI 10.1006/cbir.1997.0153; Singh B, 1997, CARCINOGENESIS, V18, P1265, DOI 10.1093/carcin/18.6.1265; SOULEIMANI A, 1993, FEBS LETT, V326, P45, DOI 10.1016/0014-5793(93)81758-R; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Tabuchi Y, 2002, BIOCHEM BIOPH RES CO, V293, P1287, DOI 10.1016/S0006-291X(02)00365-0; Tong X, 2004, BIOCHEM BIOPH RES CO, V317, P463, DOI 10.1016/j.bbrc.2004.03.066; Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03-0645rev; Wilson AJ, 2002, CANCER RES, V62, P6006; Wilson MA, 2002, J BIOL CHEM, V277, P15171, DOI 10.1074/jbc.M200349200; Wu GD, 1999, J LEUKOCYTE BIOL, V66, P1049, DOI 10.1002/jlb.66.6.1049; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Yin L, 2001, J BIOL CHEM, V276, P44641, DOI 10.1074/jbc.M105170200; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	62	28	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15503	15509		10.1074/jbc.M411978200	http://dx.doi.org/10.1074/jbc.M411978200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713675	hybrid			2022-12-25	WOS:000228444800007
J	Wang, DK; Li, ZB; Messing, EM; Wu, G				Wang, DK; Li, ZB; Messing, EM; Wu, G			The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with MET and enhances the hepatocyte growth factor-induced Erk-Elk-1-serum response element pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIF-ALPHA; RAS; DEGRADATION; RANBPM; ACTIVATION; EFFECTORS; GAP; PHOSPHORYLATION; HYDROXYLATION; DESTRUCTION	The suppressor of cytokine signaling ( SOCS) protein family includes a SPRY ( repeats in splA and RyR) domain-containing SOCS box protein (SSB) subfamily, which consists of four members, SSB-1, SSB-2, SSB-3, and SSB-4. These proteins contain a central SPRY domain and a C-terminal SOCS box. Although some of the SOCS protein subfamilies function as adaptors for a large family of ubiquitin-protein isopeptide ligases to regulate certain signaling pathways, the function of the SSB subfamily remains to be determined. In our previous studies, we have found that two SPRY domain-containing proteins, RanBP9 and RanBP10, interact with MET through the SPRY domain. In the present study, we explored the function of SSB proteins in the regulation of the hepatocyte growth factor (HGF)-MET signaling. Our results showed that all four SSB proteins also interacted with the MET. The MET interaction with SSB-1 was further investigated. We demonstrated that SSB-1 bound to MET tyrosine kinase domain through its SPRY domain. MET interacted with SSB-1 in both the absence and the presence of HGF, but HGF treatment resulted in the recruitment of more SSB-1 by MET. We showed that overexpression of SSB-1 but not other SSB proteins enhanced the HGF-induced serum response element (SRE)-luciferase activity. Overexpression of SSB-1 exhibited no effect on the basal level or epidermal growth factor-induced SRE-luciferase activity. SSB-1 also enhanced HGF-induced Erk phosphorylation. Suppression of SSB-1 by the RNA interference method down-regulated HGF-induced SRE-luciferase activity and decreased Elk-1 activation. These results suggest that SSB-1 may play an important role in enhancing the HGF-induced Erk-Elk-1-SRE pathway. Furthermore, we demonstrated that in response to HGF stimulation, the SSB-1 protein became phosphorylated at tyrosine residue 31. The phosphorylated SSB-1 protein bound to p120Ras-GTPase-activating protein ( GAP) but did not promote the degradation of p120RasGAP, indicating that enhanced HGF-MET signaling by overexpression of SSB-1 was not dependent on p120RasGAP degradation.	Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Wu, G (corresponding author), Univ Rochester, Med Ctr, Dept Urol, 601 Elmwood Ave,Box 656, Rochester, NY 14642 USA.	Guan_Wu@urmc.rochester.edu						BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Herrmann C, 1996, PROG BIOPHYS MOL BIO, V66, P1, DOI 10.1016/S0079-6107(96)00015-6; Ideguchi H, 2002, BIOCHEM J, V367, P87, DOI 10.1042/BJ20011851; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kashige N, 2000, P NATL ACAD SCI USA, V97, P2093, DOI 10.1073/pnas.040547997; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Midgley RS, 2002, CRIT REV ONCOL HEMAT, V44, P109, DOI 10.1016/S1040-8428(01)00189-5; Mikolajczyk M, 2003, BIOCHEM BIOPH RES CO, V310, P14, DOI 10.1016/j.bbrc.2003.08.116; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; Rao MA, 2002, J BIOL CHEM, V277, P48020, DOI 10.1074/jbc.M209741200; Stella MC, 1999, INT J BIOCHEM CELL B, V31, P1357, DOI 10.1016/S1357-2725(99)00089-8; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; Wang DK, 2004, BIOCHEM BIOPH RES CO, V313, P320, DOI 10.1016/j.bbrc.2003.11.124; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	28	42	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16393	16401		10.1074/jbc.M413897200	http://dx.doi.org/10.1074/jbc.M413897200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713673	hybrid			2022-12-25	WOS:000228444800112
J	Guo, Q; Sousa, R				Guo, Q; Sousa, R			Weakening of the T7 promoter-polymerase interaction facilitates promoter release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTISUBUNIT RNA-POLYMERASES; INITIAL BUBBLE COLLAPSE; ELONGATION COMPLEX; TRANSCRIPTION INITIATION; STRUCTURAL BASIS; DNA; BACTERIOPHAGE-T7; STABILITY; TERMINATION; TRANSITION	During transcription initiation, RNA polymerases retain interactions with their promoters until the RNA is extended to 8-13 nucleotides, at which point the polymerase releases the promoter and moves downstream. It has been shown that release of the T7 promoter is inhibited when the T7 RNA polymerase-promoter interaction is strengthened. Here we asked whether release would be facilitated when the T7 promoter-polymerase interaction is weakened by the introduction of promoter mutations known to reduce promoter activity. Using chemical and enzymatic probes to monitor the position of the polymerase as a function of RNA length, we found that promoter mutations upstream of -4 facilitated release of the polymerase from the promoter, but more downstream mutations did not have such effects. We also found that released complexes turn over more slowly than promoter-bound complexes, indicating that retention of promoter interactions contributes to the dissociation of short RNAs during initial transcription.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Sousa, R (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	sousa@biochem.uthscsa.edu		Sousa, Rui/0000-0003-4314-121X	NIGMS NIH HHS [R01 GM052522, GM52522] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brieba LG, 2001, EMBO J, V20, P6826, DOI 10.1093/emboj/20.23.6826; Brieba LG, 2001, J BIOL CHEM, V276, P10306, DOI 10.1074/jbc.M009866200; CHAPMAN KA, 1987, NUCLEIC ACIDS RES, V15, P5413, DOI 10.1093/nar/15.13.5413; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Cramer P, 2002, CURR OPIN STRUC BIOL, V12, P89, DOI 10.1016/S0959-440X(02)00294-4; Esposito EA, 2004, J BIOL CHEM, V279, P44270, DOI 10.1074/jbc.M407688200; Gong P, 2004, J BIOL CHEM, V279, P44277, DOI 10.1074/jbc.M409118200; Gopal V, 1999, J MOL BIOL, V290, P411, DOI 10.1006/jmbi.1999.2836; Guo Q, 2005, J BIOL CHEM, V280, P3474, DOI 10.1074/jbc.M412287200; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Imburgio D, 2000, BIOCHEMISTRY-US, V39, P10419, DOI 10.1021/bi000365w; Liu CH, 2002, J BIOL CHEM, V277, P2725, DOI 10.1074/jbc.M108856200; MARTIN CT, 1987, BIOCHEMISTRY-US, V26, P2690, DOI 10.1021/bi00384a006; Mentesana PE, 2000, J MOL BIOL, V302, P1049, DOI 10.1006/jmbi.2000.4114; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Mukherjee S, 2003, EMBO J, V22, P6483, DOI 10.1093/emboj/cdg618; Mukherjee S, 2002, CELL, V110, P81, DOI 10.1016/S0092-8674(02)00815-2; Mukherjee Srabani, 2003, Biological Procedures Online, V5, P78, DOI 10.1251/bpo49; Place C, 1999, BIOCHEMISTRY-US, V38, P4948, DOI 10.1021/bi982689e; SHI YB, 1988, J BIOL CHEM, V263, P527; Sousa R, 2003, PROG NUCLEIC ACID RE, V73, P1, DOI 10.1016/S0079-6603(03)01001-8; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; TINTUT Y, 1995, J BIOL CHEM, V270, P24392, DOI 10.1074/jbc.270.41.24392; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464	27	10	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14956	14961		10.1074/jbc.M500518200	http://dx.doi.org/10.1074/jbc.M500518200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15711016	hybrid			2022-12-25	WOS:000228236800076
J	Hoashi, T; Watabe, H; Muller, J; Yamaguchi, Y; Vieira, WD; Hearing, VJ				Hoashi, T; Watabe, H; Muller, J; Yamaguchi, Y; Vieira, WD; Hearing, VJ			MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCULOCUTANEOUS ALBINISM TYPE-1; SUBCELLULAR-LOCALIZATION; ENDOPLASMIC-RETICULUM; MELANOGENIC COMPLEX; MOUSE MELANOMA; TYROSINASE; BIOGENESIS; GP100; DIFFERENTIATION; TRAFFICKING	More than 125 genes that regulate pigmentation have been identified to date. Of those, MART-1 has been widely studied as a melanoma-specific antigen and as a melanosome-specific marker. Whereas the functions of other melanosomal proteins, such as tyrosinase, tyrosinase-related protein-1, dopachrome tautomerase, and Pmel17, are known, the function of MART-1 in melanogenesis, is unclear. A role for MART-1 in pigmentation is expected because its expression pattern and subcellular distribution is quite similar to the other melanosomal proteins and usually correlates with melanin content. We investigated the function of MART-1 using a multi-disciplinary approach, including the use of siRNA to inhibit MART-1 function and the use of transfection to re-express MART-1 in MART-1-negative cells. We show that MART-1 forms a complex with Pmel17 and affects its expression, stability, trafficking, and the processing which is required for melanosome structure and maturation. We conclude that MART-1 is indispensable for Pmel17 function and thus plays an important role in regulating mammalian pigmentation.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Div Viral Prod, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 2132, Bethesda, MD 20892 USA.	hearingv@nih.gov	Yamaguchi, Yuji/X-6681-2019; Yamaguchi, Yuji/B-9312-2008	Yamaguchi, Yuji/0000-0003-4338-2662	DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; Basrur V, 2003, J PROTEOME RES, V2, P69, DOI 10.1021/pr025562r; Bennett DC, 2003, PIGM CELL RES, V16, P333, DOI 10.1034/j.1600-0749.2003.00067.x; Berson JF, 2003, J CELL BIOL, V161, P521, DOI 10.1083/jcb.200302072; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; De Maziere AM, 2002, TRAFFIC, V3, P678, DOI 10.1034/j.1600-0854.2002.30909.x; Dusseljee S, 1998, J CELL SCI, V111, P2217; Fetsch PA, 1999, CANCER CYTOPATHOL, V87, P37, DOI 10.1002/(SICI)1097-0142(19990225)87:1<37::AID-CNCR7>3.0.CO;2-7; Hearing VJ, 2005, J DERMATOL SCI, V37, P3, DOI 10.1016/j.jdermsci.2004.08.014; Hoashi T, 2001, BIOCHEM BIOPH RES CO, V288, P371, DOI 10.1006/bbrc.2001.5789; Jimbow K, 2000, PIGM CELL RES, V13, P222, DOI 10.1034/j.1600-0749.2000.130403.x; Jimenez-Cervantes C, 1998, BIOCHEM BIOPH RES CO, V253, P761, DOI 10.1006/bbrc.1998.9817; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; Kawakami Y, 1997, J IMMUNOL METHODS, V202, P13, DOI 10.1016/S0022-1759(96)00211-6; Kawakami Y, 1998, J IMMUNOTHER, V21, P237, DOI 10.1097/00002371-199807000-00001; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kobayashi T, 1998, J BIOL CHEM, V273, P31801, DOI 10.1074/jbc.273.48.31801; Kushimoto T, 2003, PIGM CELL RES, V16, P237, DOI 10.1034/j.1600-0749.2003.00034.x; Kushimoto T, 2001, P NATL ACAD SCI USA, V98, P10698, DOI 10.1073/pnas.191184798; KWON BS, 1995, NUCLEIC ACIDS RES, V23, P154, DOI 10.1093/nar/23.1.154; Nakamura N, 2000, J BIOL CHEM, V275, P6523, DOI 10.1074/jbc.275.9.6523; ORLOW SJ, 1994, J INVEST DERMATOL, V103, P196, DOI 10.1111/1523-1747.ep12392743; ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291; Rakhmilevich AL, 2001, CLIN CANCER RES, V7, P952; Rimoldi D, 2001, J BIOL CHEM, V276, P43189, DOI 10.1074/jbc.M103221200; SEIJI M, 1963, NATURE, V197, P1082, DOI 10.1038/1971082a0; Toyofuku K, 2001, FASEB J, V15, P2149, DOI 10.1096/fj.01-0216com; Toyofuku K, 2001, BIOCHEM J, V355, P259, DOI 10.1042/0264-6021:3550259; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Virador V, 2001, PIGM CELL RES, V14, P289, DOI 10.1034/j.1600-0749.2001.140410.x; Watabe H, 2004, J BIOL CHEM, V279, P7971, DOI 10.1074/jbc.M309714200; Xu XW, 2002, AM J SURG PATHOL, V26, P82, DOI 10.1097/00000478-200201000-00010; Yasumoto K, 2004, J BIOL CHEM, V279, P28330, DOI 10.1074/jbc.M401269200	34	115	125	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14006	14016		10.1074/jbc.M413692200	http://dx.doi.org/10.1074/jbc.M413692200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695812	hybrid			2022-12-25	WOS:000228095500103
J	Liu, M; Li, YL; Cavener, D; Arvan, P				Liu, M; Li, YL; Cavener, D; Arvan, P			Proinsulin disulfide maturation and misfolding in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AKITA DIABETIC MOUSE; TRANSLATIONAL CONTROL; SECRETORY PATHWAY; KINETIC TRAP; C-PEPTIDE; INSULIN; PROTEIN; INSULIN-LIKE-GROWTH-FACTOR-1; DYSFUNCTION; BEHAVIOR	Upon nonreducing Tris-Tricine-urea-SDS-PAGE, newly synthesized proinsulin from pancreatic islets of normal rodents forms a band fast mobility representing the native disulfide isomer, which is efficiently secreted. In addition at least two slower migrating "isomer 1 and 2" bands are recovered, not discernible under reducing conditions, which represent minor species that exhibit less efficient secretion. Although rats and mice have two proinsulin genes, three distinct migrating species are also produced upon proinsulin expression from a single wildtype human proinsulin cDNA. The "Akita-type" proinsulin mutation, which causes dominant-negative diabetes mellitus due to point mutation C(A7)Y that leaves B7-cysteine without its disulfide pairing partner, is recovered as a form that near quantitatively co-migrates with the aberrant isomer 1 band of proinsulin. Anomalous migration is also demonstrated for several other mutants lacking a single cysteine. In islets from PERK-/- mice, which exhibit premature loss of pancreatic beta cells, hypersynthesis of proinsulin increases the amount of nonnative proinsulin isomers. Such findings appear consistent with an hypothesis that supranormal production of nonnative proinsulin may predispose to pancreatic beta cell toxicity.	Univ Michigan, Med Ctr, Sch Med, Div Endocrinol Diabet & Metab, Ann Arbor, MI 48109 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA	University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Arvan, P (corresponding author), Univ Michigan, Med Ctr, Sch Med, Div Endocrinol Diabet & Metab, MSRB2 Rm 5560,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	parvan@umich.edu	Cavener, Douglas R/E-3524-2010	Liu, Ming/0000-0003-2665-4072	NIDDK NIH HHS [R01 DK048280, DK 48280, R01 DK048280-12A2] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048280] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DAI Y, 1994, BIOCHEM MOL BIOL INT, V33, P1049; Guo ZY, 2002, BIOCHEMISTRY-US, V41, P1556, DOI 10.1021/bi011166v; Guo ZY, 2002, BIOCHEMISTRY-US, V41, P10585, DOI 10.1021/bi020165f; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; HUA QX, 1995, NAT STRUCT BIOL, V2, P129, DOI 10.1038/nsb0295-129; Hua QX, 2002, BIOCHEMISTRY-US, V41, P14700, DOI 10.1021/bi0202981; Hua QX, 2002, J BIOL CHEM, V277, P43443, DOI 10.1074/jbc.M206107200; HUANG XF, 1995, J BIOL CHEM, V270, P20417, DOI 10.1074/jbc.270.35.20417; Izumi T, 2003, DIABETES, V52, P409, DOI 10.2337/diabetes.52.2.409; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu M, 2003, J BIOL CHEM, V278, P14798, DOI 10.1074/jbc.M212070200; Min CY, 2004, EUR J BIOCHEM, V271, P1737, DOI 10.1111/j.1432-1033.2004.04079.x; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Qiao ZS, 2003, J BIOL CHEM, V278, P17800, DOI 10.1074/jbc.M300906200; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; Ron D, 2002, J CLIN INVEST, V109, P443, DOI 10.1172/JC1200215020; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Wang J, 1999, J CLIN INVEST, V103, P27, DOI 10.1172/JCI4431; Yoshioka M, 1997, DIABETES, V46, P887, DOI 10.2337/diabetes.46.5.887; Zhang BY, 2003, J BIOL CHEM, V278, P3687, DOI 10.1074/jbc.M209474200; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zuber C, 2004, FASEB J, V18, P917, DOI 10.1096/fj.03-1210fje	23	89	91	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13209	13212		10.1074/jbc.C400475200	http://dx.doi.org/10.1074/jbc.C400475200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15705595	hybrid, Green Accepted			2022-12-25	WOS:000228095500003
J	Raboni, S; Bettati, S; Mozzarelli, A				Raboni, S; Bettati, S; Mozzarelli, A			Identification of the geometric requirements for allosteric communication between the alpha- and beta-subunits of tryptophan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIENZYME COMPLEX; INTERSUBUNIT COMMUNICATION; SALMONELLA-TYPHIMURIUM; FLEXIBLE LOOP; ALPHA(2)BETA(2) COMPLEX; ALPHA-2-BETA-2 COMPLEX; MONOVALENT CATIONS; CONFORMATIONAL-CHANGES; SUBSTRATE-SPECIFICITY; MULTIENZYME COMPLEX	The pyridoxal 5'-phosphate-dependent tryptophan synthase alpha(2)beta(2) complex is a paradigmatic protein for substrate channeling and allosteric regulation. The enzymatic activity is modulated by a ligand-mediated equilibrium between open (inactive) and closed (active) conformations of the alpha- and beta-subunit, predominantly involving the mobile alpha loop 6 and the beta-COMM domain that contains beta helix 6. The alpha ligand-triggered intersubunit communication seems to rely on a single hydrogen bond formed between the carbonyl oxygen of beta Ser-178 of beta helix 6 and the NH group of alpha Gly-181 of alpha loop 6. We investigated whether and to what extent mutations of alpha Gly-181 and beta Ser-178 affect allosteric regulation by the replacement of beta Ser-178 with Pro or Ala and of alpha Gly-181 with either Pro to remove the amidic proton that forms the hydrogen bond or Ala, Val, and Phe to analyze the dependence on steric hindrance of the open-closed conformational transition. The alpha and beta activity assays and the equilibrium distribution of beta-subunit catalytic intermediates indicate that mutations do not significantly influence the intersubunit catalytic activation but completely abolish ligand-induced alpha- to beta-subunit signaling, demonstrating distinct pathways for alpha-beta-site communication. Limited proteolysis experiments indicate that the removal of the interaction between beta Ser-178 and alpha Gly-181 strongly favors the more trypsin-accessible open conformation of the alpha-active site. When the hydrogen bond cannot be formed, the alpha-subunit is unable to attain the closed conformation, and consequently, the allosteric signal is aborted at the subunit interface.	Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Parma, Dept Publ Hlth, I-43100 Parma, Italy; Univ Parma, Ist Nazl Fis Mat, I-43100 Parma, Italy; Univ Parma, Ist Nazl Biostrutture & Biosistemi, I-43100 Parma, Italy	University of Parma; University of Parma; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Padua; University of Parma; University of Parma	Mozzarelli, A (corresponding author), Univ Parma, Dept Biochem & Mol Biol, Parco Area Sci 23-A, I-43100 Parma, Italy.	biochim@unipr.it	Bettati, Stefano/V-9975-2018; RABONI, Samanta/P-7823-2018; Mozzarelli, Andrea/C-3615-2014	Bettati, Stefano/0000-0001-6787-0594; RABONI, Samanta/0000-0003-3068-3714; Mozzarelli, Andrea/0000-0003-3762-0062				AHMED SA, 1991, J BIOL CHEM, V266, P21548; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BRZOVIC PS, 1992, J BIOL CHEM, V267, P13028; BRZOVIC PS, 1993, BIOCHEMISTRY-US, V32, P10404, DOI 10.1021/bi00090a016; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P1180, DOI 10.1021/bi00119a030; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P390, DOI 10.1073/pnas.51.3.390; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; Fan YX, 2000, BIOCHEMISTRY-US, V39, P4692, DOI 10.1021/bi9921586; Ferrari D, 2003, BIOCHEMISTRY-US, V42, P7807, DOI 10.1021/bi034291a; Ferrari D, 2001, BIOCHEMISTRY-US, V40, P7421, DOI 10.1021/bi002892l; Gutteridge A, 2004, FEBS LETT, V567, P67, DOI 10.1016/j.febslet.2004.03.067; HIGGINS W, 1979, BIOCHEMISTRY-US, V18, P4827, DOI 10.1021/bi00589a010; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; Kulik V, 2002, J MOL BIOL, V324, P677, DOI 10.1016/S0022-2836(02)01109-9; KUMAGAI H, 1971, BIOCHEM BIOPH RES CO, V44, P1271, DOI 10.1016/S0006-291X(71)80223-1; Marabotti A, 2001, J BIOL CHEM, V276, P17747, DOI 10.1074/jbc.M011781200; Miles E W, 1995, Subcell Biochem, V24, P207; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1978, J BIOL CHEM, V253, P6266; Miles EW, 2001, CHEM REC, V1, P140; MILES EW, 1991, J BIOL CHEM, V266, P10715; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; Nishio K, 2005, BIOCHEMISTRY-US, V44, P1184, DOI 10.1021/bi047927m; OGASAHARA K, 1992, J BIOL CHEM, V267, P5222; Osborne A, 2003, J BIOL CHEM, V278, P44083, DOI 10.1074/jbc.M308276200; PERACCHI A, 1995, BIOCHEMISTRY-US, V34, P9459, DOI 10.1021/bi00029a022; Peracchi A, 1996, BIOCHEMISTRY-US, V35, P1872, DOI 10.1021/bi951889c; Pioselli B, 2004, PROTEIN SCI, V13, P913, DOI 10.1110/ps.03492904; Raboni S, 2003, BBA-PROTEINS PROTEOM, V1647, P157, DOI 10.1016/S1570-9639(03)00084-0; Rhee S, 1998, BIOCHEMISTRY-US, V37, P10653, DOI 10.1021/bi980779d; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Rowlett R, 1998, BIOCHEMISTRY-US, V37, P2961, DOI 10.1021/bi972286z; RUVINOV SB, 1992, FEBS LETT, V299, P197, DOI 10.1016/0014-5793(92)80246-D; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; Weber-Ban E, 2001, BIOCHEMISTRY-US, V40, P3497, DOI 10.1021/bi002690p; Weyand M, 2002, J BIOL CHEM, V277, P10653, DOI 10.1074/jbc.M111031200; Weyand M, 2002, J BIOL CHEM, V277, P10647, DOI 10.1074/jbc.M111285200; Weyand M, 2000, J BIOL CHEM, V275, P41058, DOI 10.1074/jbc.C000479200; WOEHL EU, 1995, BIOCHEMISTRY-US, V34, P9466, DOI 10.1021/bi00029a023; XIE G, 2002, GENOME BIOL; Yang LH, 1996, PROTEIN EXPRES PURIF, V8, P126, DOI 10.1006/prep.1996.0082; YANG XJ, 1992, J BIOL CHEM, V267, P7520; YANG XJ, 1993, J BIOL CHEM, V268, P22269	45	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13450	13456		10.1074/jbc.M414521200	http://dx.doi.org/10.1074/jbc.M414521200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15691828	hybrid			2022-12-25	WOS:000228095500033
J	Robitaille, H; Proulx, R; Robitaille, K; Blouin, R; Germain, L				Robitaille, H; Proulx, R; Robitaille, K; Blouin, R; Germain, L			The mitogen-activated protein kinase kinase kinase dual leucine zipper-bearing kinase (DLK) acts as a key regulator of keratinocyte terminal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; CORNIFIED CELL-ENVELOPE; C-JUN; EPIDERMAL-KERATINOCYTES; TISSUE TRANSGLUTAMINASE; STRATUM-CORNEUM; GOLGI-APPARATUS; UP-REGULATION; IN-VITRO; SKIN	In the skin, epithelial cells undergo a terminal differentiation program leading to the formation of the stratum corneum. Although it is expected that the last phases of this process must be tightly regulated since it results in cell death, the signaling pathways involved in this induction remain ill defined. We now report that a single kinase, the mitogen-activated protein kinase kinase kinase dual leucine zipper-bearing kinase (DLK), acts in the epidermis to promote the terminal differentiation of human keratinocytes. In support of this notion, we showed that DLK expression was restricted to the granular layer in situ. In addition, cultured keratinocytes infected with a recombinant adenovirus expressing DLK exhibited morphological and biochemical changes, including a suprabasal localization, altered cell shape, compacted cytoplasm, DNA fragmentation, and the up-regulation of filaggrin, that are reminiscent of a terminally differentiated phenotype. Moreover the expression of wild-type DLK in keratinocytes stimulated transglutaminase activity and the consequent formation of the cornified cell envelope, while a kinase-inactive variant of DLK did not. Together these results identify DLK as a signaling molecule implicated in the regulation of keratinocyte terminal differentiation and cornification.	Univ Sherbrooke, Fac Sci, Dept Biol, Sherbrooke, PQ J1K 2R1, Canada; Ctr Hosp Univ Quebec, Lab Rech Grand Brules, Lab Orgnogenese Expt, Quebec City, PQ G1S 4L8, Canada; Univ Laval, Dept Chirurg, Ste Foy, PQ G1K 7P4, Canada	University of Sherbrooke; Laval University; Laval University	Germain, L (corresponding author), Univ Sherbrooke, Fac Sci, Dept Biol, 2500,Blvd Univ, Sherbrooke, PQ J1K 2R1, Canada.	lucie.germain@chg.ulaval.ca		Germain, Lucie/0000-0001-8883-6491				Akiyama M, 2002, BRIT J DERMATOL, V146, P968, DOI 10.1046/j.1365-2133.2002.04869.x; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Bergeron P, 1997, BIOCHEM BIOPH RES CO, V231, P153, DOI 10.1006/bbrc.1997.6073; Broome AM, 2004, J INVEST DERMATOL, V122, P29, DOI 10.1046/j.0022-202X.2003.22105.x; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; Chen YR, 2000, INT J ONCOL, V16, P651; CLINE PR, 1983, CANCER RES, V43, P3203; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; DALE BA, 1978, NATURE, V276, P729, DOI 10.1038/276729a0; Dashti SR, 2001, J BIOL CHEM, V276, P27214, DOI 10.1074/jbc.M100465200; Dashti SR, 2001, J BIOL CHEM, V276, P8059, DOI 10.1074/jbc.C000862200; Denning MF, 2004, INT J BIOCHEM CELL B, V36, P1141, DOI 10.1016/j.biocel.2003.12.004; Douziech M, 1999, J HISTOCHEM CYTOCHEM, V47, P1287, DOI 10.1177/002215549904701008; Eckert RL, 2002, J INVEST DERM SYMP P, V7, P36, DOI 10.1046/j.1523-1747.2002.19634.x; Eckert RL, 2003, J INVEST DERMATOL, V120, P823, DOI 10.1046/j.1523-1747.2003.12120.x; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Fabre-Jonca N, 1999, J INVEST DERMATOL, V112, P216, DOI 10.1046/j.1523-1747.1999.00500.x; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Fuchs E, 1990, CURR OPIN CELL BIOL, V2, P1028, DOI 10.1016/0955-0674(90)90152-5; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; Gartel AL, 2002, MOL CANCER THER, V1, P639; Germain L, 2000, J INVEST DERMATOL, V115, P860, DOI 10.1046/j.1523-1747.2000.00024.x; Harvat BL, 1998, J CELL SCI, V111, P1185; Hirai S, 1996, ONCOGENE, V12, P641; Hobbs RM, 2004, J INVEST DERMATOL, V123, P503, DOI 10.1111/j.0022-202X.2004.23225.x; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jeon S, 1998, P NATL ACAD SCI USA, V95, P687, DOI 10.1073/pnas.95.2.687; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; Maatta A, 2004, J INVEST DERMATOL, V122, pXII, DOI 10.1046/j.0022-202X.2003.22139.x; Madison KC, 1996, J INVEST DERMATOL, V106, P1030, DOI 10.1111/1523-1747.ep12338596; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Michel M, 1996, J CELL SCI, V109, P1017; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robitaille K, 2004, CELL DEATH DIFFER, V11, P542, DOI 10.1038/sj.cdd.4401392; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Takahashi H, 2002, J DERMATOL SCI, V30, P94, DOI 10.1016/S0923-1811(02)00064-6; Takahashi H, 2001, J BIOL CHEM, V276, P36632, DOI 10.1074/jbc.M102021200; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; Weinberg WC, 2002, CRIT REV ORAL BIOL M, V13, P453, DOI 10.1177/154411130201300603; Welter JF, 1995, ONCOGENE, V11, P2681; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288	55	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12732	12741		10.1074/jbc.M411619200	http://dx.doi.org/10.1074/jbc.M411619200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15695824	hybrid			2022-12-25	WOS:000227922000080
J	Wang, M; Futamura, M; Wang, Y; You, M				Wang, M; Futamura, M; Wang, Y; You, M			Pas1c1 is a candidate for the mouse pulmonary adenoma susceptibility 1 locus	ONCOGENE			English	Article						mouse; Pas1 locus; lung tumor; susceptibility; alternative splicing	LUNG-TUMOR SUSCEPTIBILITY; LAMIN-A; MICE; LOCUS; GENES	Pas1 candidate 1 (Pas1c1) gene (also named Lmna-rs1) was found to encode two alternatively spliced mRNA transcripts (i.e. Pas1c1-Va and Pas1c1-Vb). In this study, we identified three additional mRNA transcripts encoded by the Pas1c1 gene, which were designated as Pas1c1-Vc, Pas1c1-Vd, and Pas1c1-Ve, respectively. Similar to Pas1c1-Vb, the newly identified transcripts were only expressed in mouse lung tissues from strains carrying the Pas1-susceptible (Pas1/s) allele. Pas1c1 transcripts were also detected in heart, testis, or brain but not in liver, spleen, or kidney. An 11-nucleotide polymorphism was found within the 3'-acceptor splice site of exon 8, which cosegregates with mouse strain Pas1 alleles and may underlie the strain-specific exon 8 skipping. We also found that ectopic expression of the Pas1c1-Va and Pas1c1-Vb in COS7 and NIH3T3 cells exhibited distinct intracellular distributions. These results support that Pas1c1 as a candidate for the Pas1 locus and the strain-specific isoforms may have differential effects on cell proliferation.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave,Campus Box 8109, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA058554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012063] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58554] Funding Source: Medline; NIEHS NIH HHS [R01ES012063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Favreau C, 2004, MOL CELL BIOL, V24, P1481, DOI 10.1128/MCB.24.4.1481-1492.2004; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Lammerding J, 2004, J CLIN INVEST, V113, P370, DOI 10.1172/JCI200419670; Lin L, 1998, EXP LUNG RES, V24, P481, DOI 10.3109/01902149809087382; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; Manenti G, 2004, ONCOGENE, V23, P4495, DOI 10.1038/sj.onc.1207584; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Wang M, 2003, CANCER RES, V63, P3317; Zhang ZQ, 2003, P NATL ACAD SCI USA, V100, P12642, DOI 10.1073/pnas.2133947100	13	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1958	1963		10.1038/sj.onc.1208295	http://dx.doi.org/10.1038/sj.onc.1208295			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688036				2022-12-25	WOS:000227542000014
J	Crimi, M; Bordoni, A; Menozzi, G; Riva, L; Fortunato, F; Galbiati, S; Del Bo, R; Pozzoli, U; Bresolin, N; Comi, GP				Crimi, M; Bordoni, A; Menozzi, G; Riva, L; Fortunato, F; Galbiati, S; Del Bo, R; Pozzoli, U; Bresolin, N; Comi, GP			Skeletal muscle gene expression profiling in mitochondrial disorders	FASEB JOURNAL			English	Article						mt DNA; MELAS; PEO; real-time PCR; microarray	CLUSTER-ANALYSIS; DNA MUTATIONS; TRANSCRIPTION; NUCLEAR; VARIABILITY; BIOGENESIS; METABOLISM; ACTIVATION; MECHANISMS; APOPTOSIS	Extremely variable clinic and genetic features characterize mitochondrial encephalomyopathy (ME M). Pathogenic mitochondrial DNA(mtDNA) defects can be divided into large-scale rearrangements and single point mutations. Clinical manifestations become evident when a threshold percentage of the total mtDNA is mutated. In some MEM, the "mutant load" in an affected tissue is directly related to the severity of the phenotype. However, the clinical phenotype is not simply a direct consequence of the relative abundance of mutated mtDNA. Other factors, such as nuclear background, can contribute to the disease process, resulting in a wide range of phenotypes caused by the same mutation. Using Affymetrix oligonucleotide cDNA microarrays(HG-U133A), we studied the gene expression profile of muscle tissue biopsies obtained from 12 MEM patients[4 common 4977 bp deleted mtDNA and 8 A3243G:4 progressive external ophthalmoplegia (PEO) and 4 mitochondrial myopathy,encephalopathy, lactic cidosis, and stroke-like episodes syndrome (MELAS) phenotypes] compared with age matched healthy individuals. We found several differentially expressed genes: 35 were markedly up-regulated in the mtDNA macro-deletion group(vs. the control group) and 4 decreased; 56 genes were dysregulated in A3243G-related disorders(53 down-regulated in PEO and 3 upregulated in MELAS). Finally, 12 genes were similarly regulated in the majority of the MEM patients under study. Amongst these, we identified an increased expression of genes related to the metabolism of the amino groups, as well as of several genes involved in genetic information processing. Moreover, few genes were similarly decreased in MEM patients vs. the control group. Real-time PCR demonstrated excellent reproducibility of the microarray-based findings. The observed expression changes are likely to represent a molecular signature for mitochondrial disorders. Furthermore,the differential expression profile of MELAS(A3243G) vs. PEOA3243G may support a role of nuclear background in contributing to these different clinical phenotypes. MEM microarray data are available from GEO database (http://www.ncbi.nlm.nih.gov/geo/) wit h the access ion number: GSE1462.	Univ Milan, Dept Neurol Sci, I-20122 Milan, Italy; IRCCS, Osped Maggiore Policlin, Dino Ferrari Ctr, I-20122 Milan, Italy; CEND, I-20122 Milan, Italy; IRCCS E Medea La Nostra Famiglia, I-23842 Bosisio Parini, LC, Italy; Polytech Univ, Dept Biomed Engn, I-20133 Milan, Italy	University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Eugenio Medea; Polytechnic University of Milan	Crimi, M (corresponding author), Univ Milan, Dept Neurol Sci, Pad Ne Ponti,Via F Sforza 35, I-20122 Milan, Italy.	marcreamy@tiscali.it	Galbiati, Sara/AAA-7115-2020; Pozzoli, Uberto/AAH-5492-2019; Riva, Laura/R-2562-2016	Galbiati, Sara/0000-0001-6810-359X; Pozzoli, Uberto/0000-0003-0670-7106; Bresolin, Nereo/0000-0001-6694-3595; Crimi, Marco/0000-0001-6903-9163; Comi, Giacomo/0000-0002-1383-5248; Riva, Laura/0000-0001-5688-4915				ALESSI DR, 1993, ONCOGENE, V8, P2015; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Augenlicht LH, 1999, ANN NY ACAD SCI, V889, P20, DOI 10.1111/j.1749-6632.1999.tb08720.x; Bakay M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-4; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Camasamudram V, 2003, EUR J BIOCHEM, V270, P1128, DOI 10.1046/j.1432-1033.2003.03461.x; Colleluori DM, 2001, ARCH BIOCHEM BIOPHYS, V389, P135, DOI 10.1006/abbi.2001.2324; DELSITE R, 2002, MOL CANCER, V12, P6; Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109; Garnier A, 2003, J PHYSIOL-LONDON, V551, P491, DOI 10.1113/jphysiol.2003.045104; Gommans IMP, 2002, J MUSCLE RES CELL M, V23, P59, DOI 10.1023/A:1019984714528; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721; Hansson A, 2004, P NATL ACAD SCI USA, V101, P3136, DOI 10.1073/pnas.0308710100; Hauptmann N, 1996, ARCH BIOCHEM BIOPHYS, V335, P295, DOI 10.1006/abbi.1996.0510; Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jacobs HT, 2000, HUM MOL GENET, V9, P463, DOI 10.1093/hmg/9.4.463; Jiang DW, 2003, J BIOL CHEM, V278, P4763, DOI 10.1074/jbc.M210410200; Kaufmann P, 1996, ANN NEUROL, V40, P172, DOI 10.1002/ana.410400208; KOGA Y, 1988, ACTA NEUROPATHOL, V76, P135, DOI 10.1007/BF00688097; Koga Y, 2002, NEUROLOGY, V58, P827, DOI 10.1212/WNL.58.5.827; Li RH, 2003, BBA-GENE STRUCT EXPR, V1629, P53, DOI 10.1016/S0167-4781(03)00160-X; Li XM, 2002, J BIOL CHEM, V277, P27256, DOI 10.1074/jbc.M203267200; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q; Morris SM, 1997, GENE, V193, P157, DOI 10.1016/S0378-1119(97)00099-1; NAKASE H, 1990, AM J HUM GENET, V46, P418; PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; RAO VLR, 1994, NEUROSCI LETT, V170, P27, DOI 10.1016/0304-3940(94)90230-5; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Rowland LP, 1983, MITOCHONDRIAL PATHOL, P141; Rusanen H, 2000, BBA-MOL BASIS DIS, V1500, P10, DOI 10.1016/S0925-4439(99)00081-2; Sciacco M, 2001, NEUROLOGY, V56, P1070, DOI 10.1212/WNL.56.8.1070; SCRIVER CR, 1995, METABOLIC BASIS INHE; SEIDEL U, 1988, GENE, V66, P135, DOI 10.1016/0378-1119(88)90231-4; Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482; Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277; Silvestri G, 1997, MUSCLE NERVE, V20, P221; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; Wiesinger H, 2001, PROG NEUROBIOL, V64, P365, DOI 10.1016/S0301-0082(00)00056-3; Yamamoto J, 2004, J BIOL CHEM, V279, P16954, DOI 10.1074/jbc.M312079200; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48	55	48	50	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					866	+		10.1096/fj.04-3045fje	http://dx.doi.org/10.1096/fj.04-3045fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15728662				2022-12-25	WOS:000227591900009
J	Stokes, DL; Delavoie, F; Rice, WJ; Champeil, P; McIntosh, DB; Lacapere, JJ				Stokes, DL; Delavoie, F; Rice, WJ; Champeil, P; McIntosh, DB; Lacapere, JJ			Structural studies of a stabilized phosphoenzyme intermediate of Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; P-TYPE ATPASES; CALCIUM-PUMP; FLUORESCEIN ISOTHIOCYANATE; CROSS-LINKING; ACTIVE-SITE; ATP BINDING; CA-ATPASE; CRYOELECTRON MICROSCOPY; ELECTRON-MICROSCOPY	Ca2+-ATPase belongs to the family of P-type ATPases and maintains low concentrations of intracellular Ca2+. Its reaction cycle consists of four main intermediates that alternate ion binding in the transmembrane domain with phosphorylation of an aspartate residue in a cytoplasmic domain. Previous work characterized an ultrastable phosphoenzyme produced first by labeling with fluorescein isothiocyanate, then by allowing this labeled enzyme to establish a maximal Ca2+ gradient, and finally by removing Ca2+ from the solution. This phosphoenzyme is characterized by very low fluorescence and has specific enzymatic properties suggesting the existence of a high energy phosphoryl bond. To study the structural properties of this phosphoenzyme, we used cryoelectron microscopy of two-dimensional crystals formed in the presence of decavanadate and determined the structure at 8-angstrom resolution. To our surprise we found that at this resolution the low fluorescence phosphoenzyme had a structure similar to that of the native enzyme crystallized under equivalent conditions. We went on to use glutaraldehyde cross-linking and proteolysis for independent structural assessment and concluded that, like the unphosphorylated native enzyme, Ca2+ and vanadate exert a strong influence over the global structure of this low fluorescence phosphoenzyme. Based on a structural model with fluorescein isothiocyanate bound at the ATP site, we suggest that the stability as well as the low fluorescence of this phosphoenzyme is due to a fluorescein-mediated cross-link between two cytoplasmic domains that prevents hydrolysis of the aspartyl phosphate. Finally, we consider the alternative possibility that phosphate transfer to fluorescein itself could explain the properties of this low fluorescence species.	Univ Paris 07, INSERM, U410, F-75870 Paris, France; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10012 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10012 USA; New York Struct Biol Ctr, New York, NY 10027 USA; CNRS, URA 2096, F-91191 Gif Sur Yvette, France; CEA Saclay, SBPM DBCM, F-91191 Gif Sur Yvette, France; Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; New York University; New York University; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Cape Town	Stokes, DL (corresponding author), Univ Paris 07, INSERM, U410, 16 Rue Henri Huchard,BP 416, F-75870 Paris, France.	stokes@saturn.med.nyu.edu; Jean-Jacques.Lacapere@bichat.inserm.fr	DELAVOIE, Franck/AAP-3126-2021	DELAVOIE, Franck/0000-0001-9692-0386; Rice, William/0000-0002-5187-255X	NIGMS NIH HHS [R01-GM56960] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056960] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; Beroukhim R, 1997, ULTRAMICROSCOPY, V70, P57, DOI 10.1016/S0304-3991(97)00070-3; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; Champeil P, 2001, J BIOL CHEM, V276, P5795, DOI 10.1074/jbc.M006980200; Chen ZH, 2003, J BIOL CHEM, V278, P48348, DOI 10.1074/jbc.M309545200; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; CSERMELY P, 1985, EUR J BIOCHEM, V150, P455, DOI 10.1111/j.1432-1033.1985.tb09043.x; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; Delavoie F, 2003, ANN NY ACAD SCI, V986, P17, DOI 10.1111/j.1749-6632.2003.tb07133.x; DELAVOIE F, 2001, BIOL CELL, V93, P363; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; EVERTS ME, 1989, BIOCHEM J, V260, P443, DOI 10.1042/bj2600443; FAGAN MJ, 1994, J MOL EVOL, V38, P57; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Henao F, 2001, J BIOL CHEM, V276, P24284, DOI 10.1074/jbc.M103905200; HIGHSMITH S, 1985, BIOCHIM BIOPHYS ACTA, V817, P123, DOI 10.1016/0005-2736(85)90074-4; Hua SM, 2000, J BIOL CHEM, V275, P30546, DOI 10.1074/jbc.M003218200; Huang SH, 1998, BIOCHEMISTRY-US, V37, P18064, DOI 10.1021/bi981997+; Huang Z, 1999, J BIOMOL SCREEN, V4, P327, DOI 10.1177/108705719900400608; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; Korndorfer IP, 2003, PROTEINS, V53, P121, DOI 10.1002/prot.10497; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; Lenoir G, 2004, J BIOL CHEM, V279, P9156, DOI 10.1074/jbc.M311411200; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MCINTOSH DB, 1994, J BIOL CHEM, V269, P21587; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; ROSS DC, 1991, J BIOL CHEM, V266, P4613; ROSS DC, 1987, J BIOL CHEM, V262, P2042; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; Seekoe T, 2001, J BIOL CHEM, V276, P46737, DOI 10.1074/jbc.M106320200; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Stokes DL, 2000, BIOPHYS J, V78, P1765, DOI 10.1016/S0006-3495(00)76727-0; Stokes DL, 2003, ANNU REV BIOPH BIOM, V32, P445, DOI 10.1146/annurev.biophys.32.110601.142433; Tani K, 1996, ULTRAMICROSCOPY, V65, P31, DOI 10.1016/S0304-3991(96)00052-6; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; WARREN GB, 1974, P NATL ACAD SCI USA, V71, P622, DOI 10.1073/pnas.71.3.622; WHITLOW M, 1995, PROTEIN ENG, V8, P749, DOI 10.1093/protein/8.8.749; Wriggers W, 1999, J STRUCT BIOL, V125, P185, DOI 10.1006/jsbi.1998.4080; Xu C, 2002, J MOL BIOL, V316, P201, DOI 10.1006/jmbi.2001.5330; Young HS, 2001, J MOL BIOL, V308, P231, DOI 10.1006/jmbi.2001.4558; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	56	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18063	18072		10.1074/jbc.M500031200	http://dx.doi.org/10.1074/jbc.M500031200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15734741	Green Published, hybrid			2022-12-25	WOS:000228807200063
J	Allen, DL; Weber, JN; Sycuro, LK; Leinwand, LA				Allen, DL; Weber, JN; Sycuro, LK; Leinwand, LA			Myocyte enhancer factor-2 and serum response factor binding elements regulate fast myosin heavy chain transcription in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; GENE-EXPRESSION; SKELETAL; MUSCLE; CALCINEURIN; MEF2; SLOW; SEQUENCES; ACTIVATION; PROTEINS	Adult fast muscle fibers express distinct myosin heavy chains (MyHC) in differing proportions, but the mechanisms underlying their differential expression remain undefined. We used a variety of in vitro and in vivo approaches to explore the contribution of transcriptional regulation to adult fast MyHC expression. Here we show that 800 - 1000 bp of a sequence upstream of the three mouse adult fast MyHC genes (Ia, IIb, and IId/x) are sufficient to drive muscle-specific and fiber-specific expression in vivo. We show that the upstream promoter region of the gene most abundantly expressed in mouse skeletal muscles, IIb MyHC, retains binding activity and transcriptional activation for three positive transcription factors, the serum response factor, Oct-1, and myocyte enhancer factor-2, whereas the other two genes (IIa and IId/x) have nucleotide substitutions in these sites that reduce binding and transcriptional activation. Finally, we demonstrate that regions upstream of 300 bp modulate the effects of these elements. Together, these data demonstrate that the quantitative differences in MyHC expression in mouse skeletal muscle have evolved at least in part through the elimination of positive-acting transcription factor binding sites.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Leinwand, LA (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Campus Box 347, Boulder, CO 80309 USA.	leinwand@stripe.colorado.edu	Weber, Jesse N/I-8685-2019	Weber, Jesse N/0000-0003-4839-6684; LEINWAND, LESLIE/0000-0003-1470-4810; Sycuro, Laura/0000-0002-2011-6305	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029090] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen DL, 2002, J BIOL CHEM, V277, P45323, DOI 10.1074/jbc.M208302200; Allen DL, 2001, J BIOL CHEM, V276, P43524, DOI 10.1074/jbc.M108017200; ALLEN DL, 2000, AM J PHYSIOL, V280, pC637; BASSELDUBY R, 1994, MOL CELL BIOL, V14, P4596, DOI 10.1128/MCB.14.7.4596; Calvo S, 1999, MOL CELL BIOL, V19, P515; Calvo S, 2001, MOL CELL BIOL, V21, P8490, DOI 10.1128/MCB.21.24.8490-8503.2001; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; Esser K, 1999, J BIOL CHEM, V274, P12095, DOI 10.1074/jbc.274.17.12095; Gordon SE, 2001, J APPL PHYSIOL, V90, P1174, DOI 10.1152/jappl.2001.90.3.1174; Grayson J, 1998, J CELL BIOCHEM, V70, P366, DOI 10.1002/(SICI)1097-4644(19980901)70:3<366::AID-JCB10>3.3.CO;2-T; Hayes A, 1996, J APPL PHYSIOL, V80, P670, DOI 10.1152/jappl.1996.80.2.670; Lakich MM, 1998, J BIOL CHEM, V273, P15217, DOI 10.1074/jbc.273.24.15217; Lucas CA, 2000, BIOCHEM BIOPH RES CO, V272, P303, DOI 10.1006/bbrc.2000.2768; Maeda T, 2002, J BIOL CHEM, V277, P48889, DOI 10.1074/jbc.M206858200; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; REGGIANI C, 1992, MUSCLE NERVE, V15, P199, DOI 10.1002/mus.880150212; Sakuma K, 2004, ACTA NEUROPATHOL, V108, P241, DOI 10.1007/s00401-004-0884-5; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; TAKEDA S, 1992, J BIOL CHEM, V267, P16957; Talmadge Robert J., 1993, Current Opinion in Rheumatology, V5, P695; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Weiss A, 1996, ANNU REV CELL DEV BI, V12, P417, DOI 10.1146/annurev.cellbio.12.1.417; WELLS DJ, 1993, FEBS LETT, V332, P179, DOI 10.1016/0014-5793(93)80508-R; Wheeler MT, 1999, AM J PHYSIOL-CELL PH, V276, pC1069, DOI 10.1152/ajpcell.1999.276.5.C1069; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963	34	42	44	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17126	17134		10.1074/jbc.M501207200	http://dx.doi.org/10.1074/jbc.M501207200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728583	hybrid			2022-12-25	WOS:000228615500072
J	Das, BB; Sen, N; Dasgupta, SB; Ganguly, A; Majumder, HK				Das, BB; Sen, N; Dasgupta, SB; Ganguly, A; Majumder, HK			N-terminal region of the large subunit of leishmania donovani bisubunit topoisomerase I is involved in DNA relaxation and interaction with the smaller subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CRYSTAL-STRUCTURES; CAMPTOTHECIN; DOMAIN; RECONSTITUTION; MECHANISM; TRYPANOSOMES; INHIBITOR; FRAGMENT; COMPLEX	Leishmania donovani topoisomerase I is an unusual bisubunit enzyme. We have demonstrated earlier that the large and small subunit could be reconstituted in vitro to show topoisomerase I activity. We extend our biochemical study to evaluate the role of the large subunit in topoisomerase activity. The large subunit (LdTOP1L) shows a substantial degree of homology with the core DNA binding domain of the topoisomerase IB family. Two N-terminal truncation constructs, LdTOP1 Delta 39L ( lacking amino acids 1 - 39) and LdTOP1 Delta 99L ( lacking amino acids 1 - 99) of the large subunit were generated and mixed with intact small subunit (LdTOP1S). Our observations reveal that residues within amino acids 1 - 39 of the large subunit have significant roles in modulating topoisomerase I activity (i.e. in vitro DNA relaxation, camptothecin sensitivity, cleavage activity, and DNA binding affinity). Interestingly, the mutant LdTOP1 Delta 99LS was unable to show topoisomerase I activity. Investigation of the loss of activity indicates that LdTOP1 Delta 99L was unable to pull down glutathione S-transferase-LdTOP1S in an Ni2+-nitrilotriacetic acid co-immobilization experiment. For further analysis, we co-expressed LdTOP1L and LdTOP1S in Escherichia coli BL21(DE3) pLysS cells. The lysate shows topoisomerase I activity. Immunoprecipitation revealed that LdTOP1L could interact with LdTOP1S, indicating the subunit interaction in bacterial cells, whereas immunoprecipitation of bacterial lysate co-expressing LdTOP1 Delta 99L and LdTOP1S reveals that LdTOP1 Delta 99L was significantly deficient at interacting with LdTOP1S to reconstitute topoisomerase I activity. This study demonstrates that heterodimerization between the large and small subunits of the bisubunit enzyme appears to be an absolute requirement for topoisomerase activity. The residue within amino acids 1 - 39 from the N-terminal end of the large subunit regulates DNA topology during relaxation by controlling noncovalent DNA binding or by coordinating DNA contacts by other parts of the enzyme.	Indian Inst Chem Biol, Dept Mol Parasitol, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Majumder, HK (corresponding author), Indian Inst Chem Biol, Dept Mol Parasitol, 4 Raja Sc Mullick Rd, Kolkata 700032, W Bengal, India.	hkmajumder@iicb.res.in	Das, Benu Brata/AAC-3452-2022; DAS, BENU BRATA BRATA/AAX-4347-2021; Sen, Nilkantha/AAW-9788-2020	DAS, BENU BRATA BRATA/0000-0003-2519-7105; 				Bodley AL, 2003, P NATL ACAD SCI USA, V100, P7539, DOI 10.1073/pnas.1330762100; BODLEY AL, 1995, P NATL ACAD SCI USA, V92, P3726, DOI 10.1073/pnas.92.9.3726; CAREY J, 1991, METHOD ENZYMOL, V208, P103; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1998, J BIOL CHEM, V273, P11589, DOI 10.1074/jbc.273.19.11589; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; Das A, 2004, TRENDS PARASITOL, V20, P381, DOI 10.1016/j.pt.2004.06.005; Das BB, 2004, FEBS LETT, V565, P81, DOI 10.1016/j.febslet.2004.03.078; Frohlich RF, 2004, J MOL BIOL, V336, P93, DOI 10.1016/j.jmb.2003.12.007; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; LI CJ, 1993, J BIOL CHEM, V268, P22463; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Lisby M, 2001, J BIOL CHEM, V276, P20220, DOI 10.1074/jbc.M010991200; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; Redinbo Matthew R., 1999, Current Opinion in Structural Biology, V9, P29, DOI 10.1016/S0959-440X(99)80005-0; Redinbo MR, 1999, J MOL BIOL, V292, P685, DOI 10.1006/jmbi.1999.3065; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; Sen N, 2004, J BIOL CHEM, V279, P52366, DOI 10.1074/jbc.M406705200; Sen N, 2004, CELL DEATH DIFFER, V11, P924, DOI 10.1038/sj.cdd.4401435; Sengupta T, 2003, NUCLEIC ACIDS RES, V31, P5305, DOI 10.1093/nar/gkg727; Stewart L, 1999, J BIOL CHEM, V274, P32950, DOI 10.1074/jbc.274.46.32950; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Villa H, 2003, J BIOL CHEM, V278, P3521, DOI 10.1074/jbc.M203991200; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yang Z, 2002, J BIOL CHEM, V277, P30815, DOI 10.1074/jbc.M205302200; Yao N, 2003, J BIOL CHEM, V278, P50744, DOI 10.1074/jbc.M309206200	33	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16335	16344		10.1074/jbc.M412417200	http://dx.doi.org/10.1074/jbc.M412417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15711017	hybrid			2022-12-25	WOS:000228444800105
J	Gupta, N; Zahn, MM; Coppens, I; Joiner, KA; Voelker, DR				Gupta, N; Zahn, MM; Coppens, I; Joiner, KA; Voelker, DR			Selective disruption of phosphatidylcholine metabolism of the intracellular parasite Toxoplasma gondii arrests its growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLSERINE DECARBOXYLASE; PHOSPHOLIPID-METABOLISM; PARASITOPHOROUS VACUOLE; ANTIMALARIAL ACTIVITY; CULTURED FIBROBLASTS; ESCHERICHIA-COLI; HOST; BIOSYNTHESIS; MEMBRANE; ERYTHROCYTES	Toxoplasma gondii is an intracellular protozoan parasite capable of causing devastating infections in immunocompromised and immunologically immature individuals. In this report, we demonstrate the relative independence of T. gondii from its host cell for aminoglycerophospholipid synthesis. The parasite can acquire the lipid precursors serine, ethanolamine, and choline from its environment and use them for the synthesis of its major lipids, phosphatidylserine ( PtdSer), phosphatidylethanolamine (PtdEtn), and phosphatidylcholine (PtdCho), respectively. Dimethylethanolamine (Etn(Me)(2)), a choline analog, dramatically interfered with the PtdCho metabolism of T. gondii and caused a marked inhibition of its growth within human foreskin fibroblasts. In tissue culture medium supplemented with 2 mM Etn(Me)(2), the parasite-induced lysis of the host cells was dramatically attenuated, and the production of parasites was inhibited by more than 99%. The disruption of parasite growth was paralleled by structural abnormalities in its membranes. In contrast, no negative effect on host cell growth and morphology was observed. The data also reveal that the Etn(Me)(2)-supplemented parasite had a time-dependent decrease in its PtdCho content and an equivalent increase in phosphatidyldimethylethanolamine, whereas other major lipids, PtdSer, PtdEtn, and PtdIns, remained largely unchanged. Relative to host cells, the parasites incorporated more than 7 times as much Etn( Me)(2) into their phospholipid. These findings reveal that Etn( Me)(2) selectively alters parasite lipid metabolism and demonstrate how selective inhibition of PtdCho synthesis is a powerful approach to arresting parasite growth.	Natl Jewish Med & Res Ctr, Cell Biol Program, Dept Med, Denver, CO 80206 USA; Johns Hopkins Univ, Blomberg Sch Publ Hlth, Baltimore, MD 21205 USA; Yale Univ, Sch Med, Infect Dis Sect, Investigat Med Program, New Haven, CT 06520 USA	National Jewish Health; Johns Hopkins University; Yale University	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Cell Biol Program, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	voelkerd@njc.org	Joiner, Keith/AAH-1059-2021	Joiner, Keith/0000-0003-3062-823X; Gupta, Nishith/0000-0003-1452-5126	NIAID NIH HHS [AI030060] Funding Source: Medline; NIGMS NIH HHS [2R37GM32453] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ancelin ML, 1998, BLOOD, V91, P1426, DOI 10.1182/blood.V91.4.1426; Calas M, 1997, J MED CHEM, V40, P3557, DOI 10.1021/jm9701886; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; Charron AJ, 2002, J CELL SCI, V115, P3049; Coppens I, 2003, MOL BIOL CELL, V14, P3804, DOI 10.1091/mbc.E02-12-0830; Coppens I, 2000, J CELL BIOL, V149, P167, DOI 10.1083/jcb.149.1.167; DOWHAN W, 1974, J BIOL CHEM, V249, P3079; Elabbadi N, 1997, BIOCHEM J, V324, P435, DOI 10.1042/bj3240435; HJELMSTAD RH, 1992, METHOD ENZYMOL, V209, P272; KUGE O, 1991, J BIOL CHEM, V266, P6370; LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403; MAZIERE C, 1986, BIOCHEM BIOPH RES CO, V137, P43, DOI 10.1016/0006-291X(86)91173-3; OHTA A, 1981, J BIOL CHEM, V256, P2219; Pessi G, 2004, P NATL ACAD SCI USA, V101, P6206, DOI 10.1073/pnas.0307742101; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHROEDER F, 1976, J BIOL CHEM, V251, P5015; Sinai AP, 2001, J CELL BIOL, V154, P95, DOI 10.1083/jcb.200101073; Sinai AP, 1997, ANNU REV MICROBIOL, V51, P415, DOI 10.1146/annurev.micro.51.1.415; SussToby E, 1996, P NATL ACAD SCI USA, V93, P8413, DOI 10.1073/pnas.93.16.8413; Tenter AM, 2000, INT J PARASITOL, V30, P1217, DOI 10.1016/S0020-7519(00)00124-7; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073; VIAL HJ, 1990, BLOOD CELLS, V16, P531; WONG SY, 1994, CLIN INFECT DIS, V18, P853, DOI 10.1093/clinids/18.6.853	26	64	67	4	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16345	16353		10.1074/jbc.M501523200	http://dx.doi.org/10.1074/jbc.M501523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15708856	hybrid			2022-12-25	WOS:000228444800106
J	Nobta, M; Tsukazaki, T; Shibata, Y; Xin, C; Moriishi, T; Sakano, S; Shindo, H; Yamaguchi, A				Nobta, M; Tsukazaki, T; Shibata, Y; Xin, C; Moriishi, T; Sakano, S; Shindo, H; Yamaguchi, A			Critical regulation of bone morphogenetic protein-induced osteoblastic differentiation by Delta1/Jagged1-activated Notch1 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIFFERENTIATION; PROGENITOR CELLS; CROSS-TALK; PATHWAYS; INHIBITION; ACTIVATION; GENE; TRANSFORMATION; EXPRESSION; MYOGENESIS	Functional involvement of the Notch pathway in osteoblastic differentiation has been previously investigated using the truncated intracellular domain, which mimics Notch signaling by interacting with the DNA-binding protein CBF-1. However, it is unclear whether Notch ligands Delta1 and Jagged1 also induce an identical cellular response in osteoblastic differentiation. We have shown that both Delta1 and Jagged1 were expressed concomitantly with Notch1 in maturating osteoblastic cells during bone regeneration and that overexpressed and immobilized recombinant Delta1 and Jagged1 alone did not alter the differentiated state of MC3T3-E1 and C2C12 cells. However, they augmented bone morphogenetic protein-2 (BMP2)-induced alkaline phosphatase activity and the expression of several differentiation markers, except for osteocalcin, and ultimately enhanced calcified nodule and in vivo ectopic bone formation of MC3T3-E1. In addition, both ligands transmitted signal through the CBF-1-dependent pathway and stimulated the expression of HES-1, a direct target of Notch pathway. To test the necessity of Notch signaling in BMP2-induced differentiation, Notch signaling was inhibited by the dominant negative extracellular domain of Notch1, specific inhibitor, or small interference RNA. These treatments decreased alkaline phosphatase activity as well as the expression of other differentiation markers and inhibited the promoter activity of Id-1, a target gene of the BMP pathway. These results indicate the functional redundancy between Delta1 and Jagged1 in osteoblastic differentiation whereby Delta1/Jagged1-activated Notch1 enhances BMP2-induced differentiation through the identical signaling pathway. Furthermore, our data also suggest that functional Notch signaling is essential not only for BMP2-induced osteoblast differentiation but also for BMP signaling itself.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Oral Pathol & Bone Metab, Nagasaki 8528588, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Orthopaed Pathomech, Nagasaki 8528588, Japan; Life Sci Fundamental Res Lab, Shizuoka 4168501, Japan; Tokyo Med & Dent Univ, Grad Sch, Div Oral Pathol, Tokyo 1138549, Japan	Nagasaki University; Nagasaki University; Tokyo Medical & Dental University (TMDU)	Tsukazaki, T (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Oral Pathol & Bone Metab, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.	ttsuka@net.nagasaki-u.ac.jp						Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; Beck CW, 2003, DEV CELL, V5, P429, DOI 10.1016/S1534-5807(03)00233-8; Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Cheng PY, 2001, J IMMUNOL, V167, P4458, DOI 10.4049/jimmunol.167.8.4458; Dahlqvist C, 2003, DEVELOPMENT, V130, P6089, DOI 10.1242/dev.00834; de Jong DS, 2004, BIOCHEM BIOPH RES CO, V320, P100, DOI 10.1016/j.bbrc.2004.05.150; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Hansson EM, 2004, SEMIN CANCER BIOL, V14, P320, DOI 10.1016/j.semcancer.2004.04.011; Hirata K, 2003, BONE, V32, P502, DOI 10.1016/S8756-3282(03)00054-1; Iioka T, 2003, J BONE MINER RES, V18, P1419, DOI 10.1359/jbmr.2003.18.8.1419; Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065; Karanu FN, 2001, BLOOD, V97, P1960, DOI 10.1182/blood.V97.7.1960; Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365-2443.2002.00573.x; Kuroda K, 1999, J BIOL CHEM, V274, P7238, DOI 10.1074/jbc.274.11.7238; Lindsell CE, 1996, MOL CELL NEUROSCI, V8, P14, DOI 10.1006/mcne.1996.0040; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Sciaudone M, 2003, ENDOCRINOLOGY, V144, P5631, DOI 10.1210/en.2003-0463; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Shindo K, 2003, EXP CELL RES, V290, P370, DOI 10.1016/S0014-4827(03)00349-5; Small D, 2003, J BIOL CHEM, V278, P16405, DOI 10.1074/jbc.M300464200; SMALL D, 2000, J BIOL CHEM, V19, P32022; Swiatek P. J., 1991, GENE DEV, V113, P707; Takizawa T, 2003, NUCLEIC ACIDS RES, V31, P5723, DOI 10.1093/nar/gkg778; Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231; Trifonova R, 2004, J BIOL CHEM, V279, P13285, DOI 10.1074/jbc.C300564200; Wada Y, 1998, BONE, V22, P479, DOI 10.1016/S8756-3282(98)00039-8; Watanabe N, 2003, J BONE MINER METAB, V21, P344, DOI 10.1007/s00774-003-0428-4; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Yamada T, 2003, BLOOD, V101, P2227, DOI 10.1182/blood-2002-06-1740; Zamurovic N, 2004, J BIOL CHEM, V279, P37704, DOI 10.1074/jbc.M403813200	34	156	173	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15842	15848		10.1074/jbc.M412891200	http://dx.doi.org/10.1074/jbc.M412891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15695512	hybrid			2022-12-25	WOS:000228444800048
J	Wilson, R; Freddi, S; Chan, D; Cheah, KSE; Bateman, JF				Wilson, R; Freddi, S; Chan, D; Cheah, KSE; Bateman, JF			Misfolding of collagen X chains harboring Schmid metaphyseal chondrodysplasia mutations results in aberrant disulfide bond formation, intracellular retention, and activation of the unfolded protein response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOMERIC MATRIX PROTEIN; CARBOXYL-TERMINAL DOMAIN; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; IN-VITRO; TRANSFECTED CELLS; MOLECULAR-BASIS; CARTILAGE; NC1; MICE	Collagen X is a short chain collagen expressed specifically by the hypertrophic chondrocytes of the cartilage growth plate during endochondral bone formation. Accordingly, COL10A1 mutations disrupt growth plate function and cause Schmid metaphyseal chondrodysplasia (SMCD). SMCD mutations are almost exclusively located in the NC1 domain, which is crucial for both trimer formation and extracellular assembly. Several mutations are expected to reduce the level of functional collagen X due to NC1 domain misfolding or exclusion from stable trimer formation. However, other mutations may be tolerated within the structure of the assembled NC1 trimer, allowing mutant chains to exert a dominant-negative impact within the extracellular matrix. To address this, we engineered SMCD mutations that are predicted either to prohibit subunit folding and assembly (NC1del10 and Y598D, respectively) or to allow trimerization (N617K and G618V) and transfected these constructs into 293-EBNA and SaOS-2 cells. Although expected to form stable trimers, G618V and N617K chains ( like Y598D and NC1del10 chains) were secreted very poorly compared with wild- type collagen X. Interestingly, all mutations resulted in formation of an unusual SDS-stable dimer, which dissociated upon reduction. As the NC1 domain sulfhydryl group is not solvent-exposed in the correctly folded NC1 monomer, disulfide bond formation would result only from a dramatic conformational change. In cells expressing mutant collagen X, we detected significantly increased amounts of the spliced form of X-box DNA-binding protein mRNA and up-regulation of BiP, two key markers for the unfolded protein response. Our data provide the first clear evidence for misfolding of SMCD collagen X mutants, and we propose that solvent exposure of the NC1 thiol may trigger the recognition and degradation of mutant collagen X chains.	Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Matrix Biol Res Unit, Parkville, Vic 3052, Australia; Univ Melbourne, Royal Childrens Hosp, Dept Pediat, Parkville, Vic 3052, Australia; Univ Hong Kong, Fac Med, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; University of Hong Kong	Bateman, JF (corresponding author), Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Matrix Biol Res Unit, Parkville, Vic 3052, Australia.	john.bateman@mcri.edu.au	Cheah, Kathryn/C-4222-2009; Wilson, Richard/H-8429-2012; Chan, Danny/C-4203-2009	Wilson, Richard/0000-0003-0152-4394; Bateman, John/0000-0001-8542-0730; Chan, Danny/0000-0003-3824-5778				Allen RL, 1999, J IMMUNOL, V162, P5045; Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Anelli T, 2003, EMBO J, V22, P5015, DOI 10.1093/emboj/cdg491; Bateman JF, 2003, HUM MOL GENET, V12, P217, DOI 10.1093/hmg/ddg054; Bateman JF, 2004, HUM MUTAT, V23, P396, DOI 10.1002/humu.9222; Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200; Bogin O, 2002, STRUCTURE, V10, P165, DOI 10.1016/S0969-2126(02)00697-4; Briggs MD, 2002, HUM MUTAT, V19, P465, DOI 10.1002/humu.10066; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CAPPS GG, 1993, J IMMUNOL, V151, P159; Chan D, 1998, MATRIX BIOL, V17, P169, DOI 10.1016/S0945-053X(98)90056-7; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; Chan D, 1999, J BIOL CHEM, V274, P13091, DOI 10.1074/jbc.274.19.13091; Chan D, 1998, J CLIN INVEST, V101, P1490, DOI 10.1172/JCI1976; Chan D, 2001, J BIOL CHEM, V276, P7992, DOI 10.1074/jbc.M003361200; Dangoria NS, 2002, J BIOL CHEM, V277, P23459, DOI 10.1074/jbc.M110336200; Delot E, 1998, J BIOL CHEM, V273, P26692, DOI 10.1074/jbc.273.41.26692; DHARMAVARAM RM, 1994, HUM MOL GENET, V3, P507, DOI 10.1093/hmg/3.3.507; Dinser R, 2002, J CLIN INVEST, V110, P505, DOI 10.1172/JCI200214386; Dublet B, 1999, J BIOL CHEM, V274, P18909, DOI 10.1074/jbc.274.27.18909; Elamaa H, 2003, MATRIX BIOL, V22, P427, DOI 10.1016/S0945-053X(03)00073-8; Fichard A, 1997, J BIOL CHEM, V272, P30083, DOI 10.1074/jbc.272.48.30083; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; Gress CJ, 2000, J CELL BIOL, V149, P983, DOI 10.1083/jcb.149.4.983; Hashimoto Y, 2003, AM J PATHOL, V163, P101, DOI 10.1016/S0002-9440(10)63634-6; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; Jacenko O, 2002, AM J PATHOL, V160, P2019, DOI 10.1016/S0002-9440(10)61152-2; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Klatt AR, 2001, J BIOL CHEM, V276, P17267, DOI 10.1074/jbc.M100587200; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; Kwan KM, 1997, J CELL BIOL, V136, P459, DOI 10.1083/jcb.136.2.459; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; Mann HH, 2004, J BIOL CHEM, V279, P25294, DOI 10.1074/jbc.M403778200; Marks DS, 1999, J BIOL CHEM, V274, P3632, DOI 10.1074/jbc.274.6.3632; McLaughlin SH, 1999, J BIOL CHEM, V274, P7570, DOI 10.1074/jbc.274.11.7570; Mear JP, 1999, J IMMUNOL, V163, P6665; Piecha D, 2002, BIOCHEM J, V367, P715, DOI 10.1042/BJ20021069; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; SCHMID TM, 1990, ANN NY ACAD SCI, V580, P64, DOI 10.1111/j.1749-6632.1990.tb17918.x; SCHMID TM, 1984, BIOCHEMISTRY-US, V23, P553, DOI 10.1021/bi00298a024; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; Svensson L, 2002, MOL CELL BIOL, V22, P4366, DOI 10.1128/MCB.22.12.4366-4371.2002; THOMAS JT, 1991, BIOCHEM SOC T, V19, P804, DOI 10.1042/bst0190804; TILLET E, 1995, EUR J BIOCHEM, V228, P160, DOI 10.1111/j.1432-1033.1995.tb20245.x; TILLET E, 1994, EUR J BIOCHEM, V221, P177, DOI 10.1111/j.1432-1033.1994.tb18727.x; Vranka J, 2001, MATRIX BIOL, V20, P439, DOI 10.1016/S0945-053X(01)00148-2; WALLIS GA, 1994, AM J HUM GENET, V54, P169; Wallis GA, 1996, J MED GENET, V33, P450, DOI 10.1136/jmg.33.6.450; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79; Wilson R, 2002, J BIOL CHEM, V277, P12516, DOI 10.1074/jbc.M112044200; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zhang Y, 1999, J BIOL CHEM, V274, P22409, DOI 10.1074/jbc.274.32.22409	58	54	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15544	15552		10.1074/jbc.M410758200	http://dx.doi.org/10.1074/jbc.M410758200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15695517	hybrid			2022-12-25	WOS:000228444800012
J	Aquilina, JA; Benesch, JLP; Ding, LL; Yaron, O; Horwitz, J; Robinson, CV				Aquilina, JA; Benesch, JLP; Ding, LL; Yaron, O; Horwitz, J; Robinson, CV			Subunit exchange of polydisperse proteins - Mass spectrometry reveals consequences of alpha A-crystallin truncation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; HUMAN LENS CRYSTALLINS; AGE-RELATED-CHANGES; C-TERMINAL REGION; POSTTRANSLATIONAL MODIFICATION; LIGHT-SCATTERING; B-CRYSTALLIN; CALPAIN LP82; CHAPERONE; BOVINE	The small heat shock protein, alpha-crystallin, plays a key role in maintaining lens transparency by chaperoning structurally compromised proteins. This is of particular importance in the human lens, where proteins are exposed to post-translational modifications over the lifetime of an individual. Here, we examine the structural and functional consequences of one particular modification of alpha A-crystallin involving the truncation of 5 C-terminal residues (alpha A(1-168)). Using novel mass spectrometry approaches and established biophysical techniques, we show that alpha A(1-168) forms oligomeric assemblies with a lower average molecular mass than wild-type alpha A-crystallin (alpha A(WT)). Also apparent from the mass spectra of both alpha A(WT) and alpha A(1-168) assemblies is the predominance of oligomers containing even numbers of subunits; interestingly, this preference is more marked for alpha A(1-168). To examine the rate of exchange of subunits between assemblies, we mixed alpha B crystallin with either alpha A(WT) or alpha A(1-168) and monitored in a real-time mass spectrometry experiment the formation of heteroligomers. The results show that there is a significant decrease in the rate of exchange when alpha A(1-168) is involved. These reduced exchange kinetics, however, have no effect upon chaperone efficiency, which is found to be closely similar for both alpha A(WT) and alpha A(1-168). Overall, therefore, our results allow us to conclude that, in contrast to mechanisms established for analogous proteins from plants, yeast, and bacteria, the rate of subunit exchange is not the critical parameter in determining efficient chaperone behavior for mammalian alpha A-crystallin.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA	University of Cambridge; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Robinson, CV (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cvr24@cam.ac.uk	Aquilina, John Andrew/AGF-4013-2022; Benesch, Justin/A-4250-2008; Aquilina, J. Andrew/A-5366-2013	Benesch, Justin/0000-0002-1507-3742; robinson, carol/0000-0001-7829-5505	NATIONAL EYE INSTITUTE [R01EY003897, R37EY003897] Funding Source: NIH RePORTER; NEI NIH HHS [EY-3897] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aquilina JA, 2004, J BIOL CHEM, V279, P28675, DOI 10.1074/jbc.M403348200; Aquilina JA, 2003, P NATL ACAD SCI USA, V100, P10611, DOI 10.1073/pnas.1932958100; ASSELBERGS FAM, 1978, EUR J BIOCHEM, V91, P65, DOI 10.1111/j.1432-1033.1978.tb20937.x; Benesch JLP, 2003, ANAL CHEM, V75, P2208, DOI 10.1021/ac034132x; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; Carver JA, 1996, EXP EYE RES, V63, P639, DOI 10.1006/exer.1996.0158; Colvis C, 2002, ARCH BIOCHEM BIOPHYS, V397, P319, DOI 10.1006/abbi.2001.2669; de Jong W W, 1974, Eur J Biochem, V48, P271; EHRNSPERGER M, 1997, MOL CHAPERONES LIFE, P533; Fougerousse F, 2000, HUM MOL GENET, V9, P165, DOI 10.1093/hmg/9.2.165; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Harding J., 1991, CATARACT BIOCH EPIDE; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Horwitz J, 1999, EYE, V13, P403, DOI 10.1038/eye.1999.114; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; Kamei A, 2001, BIOL PHARM BULL, V24, P96, DOI 10.1248/bpb.24.96; Lund AL, 1996, EXP EYE RES, V63, P661, DOI 10.1006/exer.1996.0160; Ma H, 1998, EXP EYE RES, V67, P221, DOI 10.1006/exer.1998.0515; Ma H, 1998, INVEST OPHTH VIS SCI, V39, P454; Ma ZX, 1998, EXP EYE RES, V67, P21, DOI 10.1006/exer.1998.0482; MIESBAUER LR, 1994, J BIOL CHEM, V269, P12494; Moroni M, 2001, BBA-PROTEIN STRUCT M, V1546, P282, DOI 10.1016/S0167-4838(01)00154-6; Nakamura Y, 2000, INVEST OPHTH VIS SCI, V41, P1460; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; PALMER WG, 1969, P NATL ACAD SCI USA, V64, P404, DOI 10.1073/pnas.64.1.404; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; Sharma KK, 1996, BIOCHEM BIOPH RES CO, V218, P365, DOI 10.1006/bbrc.1996.0064; Sobott F, 2002, ANAL CHEM, V74, P1402, DOI 10.1021/ac0110552; Sobott F, 2002, J BIOL CHEM, V277, P38921, DOI 10.1074/jbc.M206060200; Takemoto LJ, 1997, INT J BIOCHEM CELL B, V29, P311, DOI 10.1016/S1357-2725(96)00111-2; TAKEMOTO LJ, 1995, CURR EYE RES, V14, P837, DOI 10.3109/02713689508995806; Thampi P, 2003, BIOCHEMISTRY-US, V42, P11857, DOI 10.1021/bi030129w; Thampi P, 2002, INVEST OPHTH VIS SCI, V43, P3265; Treweek TM, 2005, FEBS J, V272, P711, DOI 10.1111/j.1742-4658.2004.04507.x; Treweek TM, 2003, AUST J CHEM, V56, P357, DOI 10.1071/CH03031; Ueda Y, 2001, EXP EYE RES, V73, P625, DOI 10.1006/exer.2001.1071; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; Vanhoudt J, 1998, INT J BIOL MACROMOL, V22, P229, DOI 10.1016/S0141-8130(98)00020-8; VANKLEEF FSM, 1975, NATURE, V258, P264, DOI 10.1038/258264a0; WALSH MT, 1991, J BIOL CHEM, V266, P20079; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S	47	91	92	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14485	14491		10.1074/jbc.M500135200	http://dx.doi.org/10.1074/jbc.M500135200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701626	hybrid			2022-12-25	WOS:000228236800018
J	Funa, N; Funabashi, M; Yoshimura, E; Horinouchi, S				Funa, N; Funabashi, M; Yoshimura, E; Horinouchi, S			A novel quinone-forming monooxygenase family involved in modification of aromatic polyketides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-COELICOLOR A3(2); COMBINATORIAL BIOSYNTHESIS; ACTINORHODIN BIOSYNTHESIS; TETRACENOMYCIN-C; GENOME SEQUENCE; SYNTHASE; EXPRESSION; RECONSTITUTION; PURIFICATION; SUPERFAMILY	RppA is a type III polyketide synthase (PKS) that catalyzes condensation of five molecules of malonyl-CoA to form 1,3,6,8-tetrahydroxynaphthalene (THN). In Streptomyces antibioticus IFO13271 and several other Streptomyces species, an open reading frame, named momA, is present as a neighbor of rppA. MomA belonged to the "cupin" superfamily because it contained a set of two motifs that is responsible for binding one equivalent of metal ions. MomA catalyzed monooxygenation of the THN produced from malonyl-CoA by the action of RppA to form flaviolin. In addition, it used several polyketides as substrates and formed the corresponding quinones. MomA required redox-active transition metal ions (Ni2+, Cu2+, Fe3+, Fe2+, Mn2+, and Co2+) for its activity, whereas it was inhibited by a redox-inert transition metal ion (Zn2+). MomA neither possessed any flavin prosthetic group nor required nicotinamide cofactors for monooxygenation, which shows that MomA as a member of the cupin superfamily is a novel monooxygenase. Consistent with the catalytic property of MomA, WhiE-ORFII showing similarity in amino acid sequence to MomA and containing a cupin domain also catalyzed monooxygenation of THN. whiE-ORFII is located immediately upstream of the "minimal PKS" gene within the whiE type II PKS gene cluster for biosynthesis of a gray spore pigment in Streptomyces coelicolor A3(2), and a number of whiE-ORFII homologues are present in the biosynthetic gene cluster for polyketides of type II in various Streptomyces species. These findings show that a novel class of quinone-forming monooxygenases is involved in modification of aromatic polyketides synthesized by PKSs of types II and III.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo; University of Tokyo	Horinouchi, S (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan.	asuhori@mail.ecc.u-tokyo.ac.jp						Anand R, 2002, BIOCHEMISTRY-US, V41, P7659, DOI 10.1021/bi0200965; Austin MB, 2003, NAT PROD REP, V20, P79, DOI 10.1039/b100917f; Bao WL, 1998, BIOCHEMISTRY-US, V37, P8132, DOI 10.1021/bi980466i; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Carreras CW, 1998, BIOCHEMISTRY-US, V37, P2084, DOI 10.1021/bi972919+; Chung JY, 2002, J BACTERIOL, V184, P6115, DOI 10.1128/JB.184.22.6115-6122.2002; Cortes J, 2002, MOL MICROBIOL, V44, P1213, DOI 10.1046/j.1365-2958.2002.02975.x; DAVIS NK, 1990, MOL MICROBIOL, V4, P1679, DOI 10.1111/j.1365-2958.1990.tb00545.x; Dunwell JM, 2004, PHYTOCHEMISTRY, V65, P7, DOI 10.1016/j.phytochem.2003.08.016; FALK H, 1993, MONATSH CHEM, V124, P339, DOI 10.1007/BF00810594; Fetzner S, 2002, APPL MICROBIOL BIOT, V60, P243, DOI 10.1007/s00253-002-1123-4; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; Funa N, 2002, BIOCHEM J, V367, P781, DOI 10.1042/BJ20020953; Gaisser S, 1997, J BACTERIOL, V179, P6271, DOI 10.1128/jb.179.20.6271-6278.1997; Hayaishi O., 1974, MOL MECH OXYGEN ACTI; HOPWOOD DA, 1985, GENETIC MANIPULATION, P1; Hutchinson CR, 1997, CHEM REV, V97, P2525, DOI 10.1021/cr960022x; Hutchinson CR, 1998, CURR OPIN MICROBIOL, V1, P319, DOI 10.1016/S1369-5274(98)80036-2; Ichinose K, 2001, CHEM PHARM BULL, V49, P192, DOI 10.1248/cpb.49.192; Maniatis T., 1982, MOL CLONING LAB MANU; OHAGEN D, 1991, POLYKETIDE METABOLIT; Omura S, 2001, P NATL ACAD SCI USA, V98, P12215, DOI 10.1073/pnas.211433198; Pochapsky TC, 2002, NAT STRUCT BIOL, V9, P966, DOI 10.1038/nsb863; Rawlings BJ, 2001, NAT PROD REP, V18, P231, DOI 10.1039/b100191o; Rawlings BJ, 1999, NAT PROD REP, V16, P425, DOI 10.1039/a900566h; Rix U, 2002, NAT PROD REP, V19, P542, DOI 10.1039/b103920m; Sciara G, 2003, EMBO J, V22, P205, DOI 10.1093/emboj/cdg031; SHEN B, 1993, BIOCHEMISTRY-US, V32, P6656, DOI 10.1021/bi00077a019; Swan MK, 2003, J BIOL CHEM, V278, P47261, DOI 10.1074/jbc.M308603200; TAKANO E, 1995, GENE, V166, P133, DOI 10.1016/0378-1119(95)00545-2; Yu TW, 1998, J AM CHEM SOC, V120, P7749, DOI 10.1021/ja9803658; YU TW, 1995, MICROBIOL-UK, V141, P2779, DOI 10.1099/13500872-141-11-2779	32	43	52	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14514	14523		10.1074/jbc.M500190200	http://dx.doi.org/10.1074/jbc.M500190200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701630	hybrid			2022-12-25	WOS:000228236800022
J	Sturla, LM; Amorino, G; Alexander, MS; Mikkelsen, RB; Valerie, K; Schmidt-Ullrich, RK				Sturla, LM; Amorino, G; Alexander, MS; Mikkelsen, RB; Valerie, K; Schmidt-Ullrich, RK			Requirement of Tyr-992 and Tyr-1173 in phosphorylation of the epidermal growth factor receptor by ionizing radiation and modulation by SHP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SQUAMOUS CARCINOMA-CELLS; PHOSPHOLIPASE-C; BINDING-SITES; EGF RECEPTOR; ACTIVATION; KINASES; SHC; DEPHOSPHORYLATION; IDENTIFICATION	The epidermal growth factor receptor ( EGFR) is activated by ionizing radiation (IR) in many human carcinomas, mediating a cytoprotective response and subsequent radioresistance. The underlying molecular mechanisms remain to be understood, and we propose here a specific role for the Tyr-992 residue of EGFR and examine its regulation by the phosphatase, SHP2. The -fold increase in phosphorylation of Tyr-992 in response to IR is twice that seen with ligand (EGF) binding. Mutation of Tyr-992 blocked completely IR-induced EGFR phosphorylation and reduced activation of the downstream signaling molecule, phospholipase C gamma. IR has previously been demonstrated to inhibit activity of protein-tyrosine phosphatases. Following protein-tyrosine phosphatase inhibition by sodium vanadate both EGFR expressing Chinese hamster ovary (CHO) and A431 exhibited up to an 8-fold increase in the basal level of Tyr-992 phosphorylation, significantly higher than that seen with Tyr-1173, Tyr-1068, and total EGFR Tyr. CHO cells expressing a SHP2 mutant also demonstrated up to an 8-fold increase in the basal level of Tyr-992 phosphorylation. In this study we show the unique association of SHP2 with EGFR in response to IR, with up to a 2.5-fold increase in the direct association of endogenous SHP2 with EGFR-wt in response to 2 gray of IR in both CHO and A431 cells. Mutation of Tyr-992 abolished this response. In conclusion we have identified several differentially activated Tyr residues, one of which is not only more sensitive to activation by IR, translating into differential activation of downstream signaling, but uniquely modulated by the phosphatase SHP2.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA	Virginia Commonwealth University	Mikkelsen, RB (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, POB 980058, Richmond, VA 23298 USA.	RMIKKELS@VCU.EDU	Valerie, Kristoffer/AAL-8299-2021		NCI NIH HHS [CA90881, R01CA65896, P01CA72955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072955, R01CA065896, R01CA090881] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Agazie YM, 2003, J BIOL CHEM, V278, P13952, DOI 10.1074/jbc.M210670200; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Contessa JN, 1999, CLIN CANCER RES, V5, P405; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRIGALE A, 2004, HUM MUTAT, V23, P267; Hagg M, 2002, INT J MOL MED, V10, P655; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Holmes Matthew, 2003, Methods Mol Biol, V234, P1; Kamata H, 2000, EUR J BIOCHEM, V267, P1933, DOI 10.1046/j.1432-1327.2000.01194.x; Kavanagh BD, 1998, RADIAT RES, V149, P579, DOI 10.2307/3579904; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Leach JK, 2002, J BIOL CHEM, V277, P15400, DOI 10.1074/jbc.M110309200; Leach JK, 2001, CANCER RES, V61, P3894; Mikkelsen RB, 2003, ONCOGENE, V22, P5734, DOI 10.1038/sj.onc.1206663; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; Reynolds AR, 2003, NAT CELL BIOL, V5, P447, DOI 10.1038/ncb981; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; Schmidt-Ullrich RK, 2003, ONCOGENE, V22, P5855, DOI 10.1038/sj.onc.1206698; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SULLIVAN SG, 1994, FREE RADICAL BIO MED, V16, P399, DOI 10.1016/0891-5849(94)90042-6; Tiganis T, 2002, IUBMB LIFE, V53, P3, DOI 10.1080/15216540210811; TODD DG, 1994, CANCER RES, V54, P5224; Todd DG, 1999, J RECEPT SIGNAL TR R, V19, P885, DOI 10.3109/10799899909038430; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; Zhang ZY, 1996, J BIOL CHEM, V271, P5386, DOI 10.1074/jbc.271.10.5386	41	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14597	14604		10.1074/jbc.M413287200	http://dx.doi.org/10.1074/jbc.M413287200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708852	hybrid			2022-12-25	WOS:000228236800033
J	Govindarajan, B; Shah, A; Cohen, C; Arnold, RS; Schechner, J; Chung, J; Mercurio, AM; Alani, R; Ryu, B; Fan, CY; Cuezva, JM; Martinez, M; Arbiser, JL				Govindarajan, B; Shah, A; Cohen, C; Arnold, RS; Schechner, J; Chung, J; Mercurio, AM; Alani, R; Ryu, B; Fan, CY; Cuezva, JM; Martinez, M; Arbiser, JL			Malignant transformation of human cells by constitutive expression of platelet-derived growth factor-BB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN SARCOMA-VIRUS; DERMATOFIBROSARCOMA PROTUBERANS; TUBEROUS SCLEROSIS; TYROSINE KINASE; RECEPTOR-BETA; HUMAN GLIOMA; FACTOR PDGF; MAP KINASE; IN-VIVO; PROTEIN	Platelet-derived growth factors (PDGFs) comprise a family of growth factors strongly implicated in human oncogenesis. A number of human tumors overexpress PDGF family members or have translocations activating PDGF receptors. Whereas the epidemiologic evidence implicating PDGF in human tumors is strong, malignant transformation of human cells by overexpression of PDGF has not been demonstrated. We have previously developed a human cell line by the sequential introduction of large T cells and telomerase, and we have demonstrated that these cells express functionally active PDGF receptor (PDGFR) beta. In order to determine whether growth factor-mediated transformation of human cells could occur, these cells were transduced with a retrovirus encoding PDGF-BB. Constitutive expression of PDGF-BB led to malignant transformation in nude mice. This is the first demonstration of constitutive signaling causing malignant transformation of human cells. Some of the changes that occur because of constitutive growth factor expression can be reversed by the clinically approved tyrosine kinase inhibitor Glivec, whereas other changes are not reversible by tyrosine kinase inhibitors. Our model allows the assessment of epigenetic changes that occur during human carcinogenesis. In addition, these studies provide insight into the clinical failure of tyrosine kinase inhibitors as monotherapy for advanced malignancy.	Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Lab Med, Atlanta, GA 30322 USA; Vet Affairs Hosp, Atlanta, GA 30322 USA; Yale Univ, Dept Dermatol, New Haven, CT 06511 USA; Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21224 USA; Johns Hopkins Univ, Dept Dermatol, Baltimore, MD 21224 USA; Harvard Univ, Sch Med, Beth Israel Deaconness Hosp, Div Signal Transduct, Cambridge, MA 02138 USA; Univ Arkansas Med Sci, Little Rock, AR 72205 USA; Vet Affairs Med Ctr, Little Rock, AR 72205 USA; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Dept Biol Mol, E-28049 Madrid, Spain; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Dept Matemat, E-28049 Madrid, Spain	Emory University; Emory University; Emory University; Yale University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Harvard University; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Arbiser, JL (corresponding author), Emory Univ, Sch Med, Dept Dermatol, WMB 5309,1639 Pierce Dr, Atlanta, GA 30322 USA.	jarbise@emory.edu	Cuezva, Jose M/F-8381-2011; Cuezva, Jose M/AAR-5392-2020	Cuezva Marcos, Jose Manuel/0000-0003-1118-248X; Martinez-Diez, Marta/0000-0002-4095-8673; Alani, Rhoda/0000-0003-2741-2665; Ryu, Byungwoo/0000-0001-6334-6787	NIAMS NIH HHS [R01 AR47901] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047901] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Arbiser JL, 2004, J INVEST DERMATOL, V123, P788, DOI 10.1111/j.0022-202X.2004.23418.x; Arbiser JL, 2004, SEMIN CANCER BIOL, V14, P81, DOI 10.1016/j.semcancer.2003.09.013; Arbiser JL, 2002, AM J PATHOL, V161, P781, DOI 10.1016/S0002-9440(10)64237-X; Arbiser JL, 2001, AM J PATHOL, V159, P483, DOI 10.1016/S0002-9440(10)61720-8; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Arbiser JL, 1998, J AM ACAD DERMATOL, V38, P950, DOI 10.1016/S0190-9622(98)70158-6; BECKER D, 1992, ONCOGENE, V7, P2303; BETSHOLTZ C, 1983, BIOCHEM BIOPH RES CO, V117, P176, DOI 10.1016/0006-291X(83)91557-7; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Cohen C, 2002, CLIN CANCER RES, V8, P3728; Cuezva JM, 2002, CANCER RES, V62, P6674; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Enis DR, 2002, J INVEST DERMATOL, V119, P209; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Govindarajan B, 2003, CLIN CANCER RES, V9, P3469; Govindarajan B, 2003, J BIOL CHEM, V278, P9790, DOI 10.1074/jbc.M212929200; Govindarajan B, 2002, MOL MED, V8, P1; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HAMMACHER A, 1988, EUR J BIOCHEM, V176, P179, DOI 10.1111/j.1432-1033.1988.tb14266.x; HUANG JS, 1984, IN VITRO CELL DEV B, V20, P280; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Klafter R, 2000, J INVEST DERM SYMP P, V5, P79, DOI 10.1046/j.1087-0024.2000.00007.x; Le Goffe C, 2002, BIOCHEM J, V364, P349, DOI 10.1042/BJ20011856; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; McLaughlin ER, 2000, J INVEST DERMATOL, V114, P1209, DOI 10.1046/j.1523-1747.2000.00005-3.x; RACKER E, 1981, SCIENCE, V213, P303, DOI 10.1126/science.6264596; RACKER E, 1981, SCIENCE, V213, P1313, DOI 10.1126/science.6765631; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; Shimizu A, 1999, CANCER RES, V59, P3719; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Unwin RD, 2003, PROTEOMICS, V3, P1620, DOI 10.1002/pmic.200300464	38	23	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13936	13943		10.1074/jbc.M500411200	http://dx.doi.org/10.1074/jbc.M500411200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695519	hybrid			2022-12-25	WOS:000228095500095
J	Hanai, J; Mammoto, T; Seth, P; Mori, K; Karumanchi, SA; Barasch, J; Sukhatme, VP				Hanai, J; Mammoto, T; Seth, P; Mori, K; Karumanchi, SA; Barasch, J; Sukhatme, VP			Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATINASE-ASSOCIATED LIPOCALIN; E-CADHERIN; TUMOR PROGRESSION; CANCER-CELLS; EXPRESSION; IRON; PROTEIN; ADHESION; KINASE; NGAL	Lipocalin 2, an iron-siderophore-binding protein, converts embryonic kidney mesenchyme to epithelia. We found that lipocalin 2 could also convert 4T1-Ras-transformed mesenchymal tumor cells to an epithelial phenotype, increase E-cadherin expression, and suppress cell invasiveness in vitro and tumor growth and lung metastases in vivo. The Ras-MAPK pathway mediated the epithelial to mesenchymal transition in part by increasing E-cadherin phosphorylation and degradation. Lipocalin 2 antagonized these effects at a point upstream of Raf activation. Lipocalin 2 action was enhanced by iron-siderophore. These data characterize lipocalin 2 as an epithelial inducer in Ras malignancy and a suppressor of metastasis.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Nephrol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Hematol Oncol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Study Tumor Microenvironm, Boston, MA 02215 USA; Columbia Univ Coll Phys & Surg, Dept Med & Anat & Cell Biol, New York, NY 10032 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Columbia University	Sukhatme, VP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Nephrol, 330 Brookline Ave,RW 563, Boston, MA 02215 USA.	vsukhatm@bidmc.harvard.edu	Mori, Kiyoshi/N-1267-2014; Karumanchi, Subbian Ananth/AAI-1694-2021; Sukhatme, Vikas/W-2776-2019	Mori, Kiyoshi/0000-0002-7285-8351; 				Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Asai T, 1998, INT J CANCER, V76, P418, DOI 10.1002/(SICI)1097-0215(19980504)76:3<418::AID-IJC21>3.3.CO;2-E; Bilello JP, 2003, AM J PATHOL, V162, P1323, DOI 10.1016/S0002-9440(10)63928-4; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; Boussadia O, 2002, MECH DEVELOP, V115, P53, DOI 10.1016/S0925-4773(02)00090-4; Bratt T, 2000, BBA-PROTEIN STRUCT M, V1482, P318, DOI 10.1016/S0167-4838(00)00154-0; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cowland JB, 1997, GENOMICS, V45, P17, DOI 10.1006/geno.1997.4896; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P327, DOI 10.1016/S0167-4838(00)00169-2; Flower DR, 1996, BIOCHEM J, V318, P1; Friedl A, 1999, HISTOCHEM J, V31, P433, DOI 10.1023/A:1003708808934; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; GarayRojas E, 1996, GENE, V170, P173, DOI 10.1016/0378-1119(95)00896-9; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064; Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200; Hay ED, 1995, ACTA ANAT, V154, P8; Islam S, 2000, J CELL BIOCHEM, V78, P141, DOI 10.1002/(SICI)1097-4644(20000701)78:1<141::AID-JCB13>3.0.CO;2-R; Kim BS, 2002, CELL IMMUNOL, V220, P96, DOI 10.1016/S0008-8749(03)00031-5; LEHMANMCKEEMAN LD, 1992, TOXICOL APPL PHARM, V116, P170, DOI 10.1016/0041-008X(92)90296-5; Li EM, 2003, ACTA BIOCH BIOPH SIN, V35, P247; Li JY, 2004, AM J PHYSIOL-CELL PH, V287, pC1547, DOI 10.1152/ajpcell.00260.2004; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; LOOMIS LD, 1991, INORG CHEM, V30, P906, DOI 10.1021/ic00005a008; Mammoto T, 2002, CANCER LETT, V184, P165, DOI 10.1016/S0304-3835(02)00210-0; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Nielsen BS, 1996, GUT, V38, P414, DOI 10.1136/gut.38.3.414; Ory S, 2004, CURR BIOL, V14, pR277, DOI 10.1016/j.cub.2004.03.023; PALLER MS, 1988, KIDNEY INT, V34, P474, DOI 10.1038/ki.1988.205; Seth P, 2002, CANCER RES, V62, P4540; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Strong RK, 1998, ACTA CRYSTALLOGR D, V54, P93, DOI 10.1107/S0907444997010615; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004; Tsukamoto T, 1999, J BIOL CHEM, V274, P24579, DOI 10.1074/jbc.274.35.24579; Vanderburg CR, 1996, ACTA ANAT, V157, P87; Wojnar P, 2001, J BIOL CHEM, V276, P20206, DOI 10.1074/jbc.M101762200; Yang J, 2003, AM J PHYSIOL-RENAL, V285, pF9, DOI 10.1152/ajprenal.00008.2003; Yang J, 2002, MOL CELL, V10, P1045, DOI 10.1016/S1097-2765(02)00710-4	45	97	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13641	13647		10.1074/jbc.M413047200	http://dx.doi.org/10.1074/jbc.M413047200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15691834	hybrid			2022-12-25	WOS:000228095500058
J	Dahm-Daphi, J; Hubbe, P; Horvath, F; El-Awady, RA; Bouffard, KE; Powell, SN; Willers, H				Dahm-Daphi, J; Hubbe, P; Horvath, F; El-Awady, RA; Bouffard, KE; Powell, SN; Willers, H			Nonhomologous end-joining of site-specic but not of radiation-induced DNA double-strand breaks is reduced in the presence of wild-type p53	ONCOGENE			English	Article						p53; double-strand break; nonhomologous end-joining; radiation; I-SceI	HOMOLOGOUS RECOMBINATION; POTENTIAL MECHANISM; GENOMIC STABILITY; IN-VITRO; REPAIR; SUPPRESSION; RADIOSENSITIVITY; PROTEINS; FIDELITY; CELLS	Nonhomologous end-joining (NHEJ) of DNA double-strand breaks (DSBs) entails two principal mechanisms: modi. cation of DNA ends prior to ligation (error-prone rejoining) or precise ligation without modi. cation if the DNA ends are complementary (error-free repair). Error-prone rejoining is mutagenic, because it can lead to destruction of coding sequence or to chromosomal aberrations, and therefore must be tightly regulated. Previous studies on the role of the p53 tumor suppressor in the regulation of NHEJ have yielded conflicting results, but a rigorous analysis of NHEJ proficiency and fidelity in a purely chromosomal context has not been carried out. To this end, we created novel repair plasmid substrates that integrate into the genome. DSBs generated by the I-SceI endonuclease within these substrates were repaired by either error-prone rejoining or precise ligation. We found that the expression of wild-type p53 inhibited any repair-associated DNA sequence deletion, including a more than 250-fold inhibition of error-prone rejoining events compared to p53-null cells, while any promoting effect of p53 on precise ligation could not be directly evaluated. The role of p53 in NHEJ appeared to involve a direct transactivation-independent mechanism, possibly restricting DNA end-modi. cation by blocking the annealing of single strands along flanking stretches of microhomology. The inhibition of error-prone rejoining by p53 did not apply to the rejoining of DSBs induced by ionizing radiation. In conclusion, our data suggest that p53 restricts the mutagenic effects of NHEJ without compromising repair proficiency or cell survival, thereby maintaining genomic stability.	Univ Hamburg, Hosp Eppendorf, Dept Radiotherapy & Radiat Oncol, Expt Radiat Oncol Lab, D-20246 Hamburg, Germany; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Lab Mol & Cellular Radiat Biol, Charlestown, MA 02129 USA	University of Hamburg; Harvard University; Massachusetts General Hospital	Dahm-Daphi, J (corresponding author), Univ Klinikum Hamburg Eppendorf, Klin Strahlentherapie & Radioonkol, Martinstr 52, D-20246 Hamburg, Germany.	dahm@uke.uni-hamburg.de			NATIONAL CANCER INSTITUTE [R01CA058985] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achanta G, 2001, CANCER RES, V61, P8723; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Allen C, 2003, DNA REPAIR, V2, P1147, DOI 10.1016/S1568-7864(03)00139-3; Bill CA, 1997, MUTAT RES-DNA REPAIR, V385, P21, DOI 10.1016/S0921-8777(97)00040-2; Boehden GS, 2003, ONCOGENE, V22, P4111, DOI 10.1038/sj.onc.1206632; Bohnke A, 2004, INT J RADIAT BIOL, V80, P53, DOI 10.1080/09553000310001642902; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; BRYANT PE, 1987, INT J RADIAT BIOL, V52, P537, DOI 10.1080/09553008714552041; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; CHANG C, 1993, CANCER RES, V53, P1244; Dahm-Daphi J, 2000, STRAHLENTHER ONKOL, V176, P278, DOI 10.1007/s000660050010; DahmDaphi J, 1997, INT J RADIAT BIOL, V72, P171, DOI 10.1080/095530097143392; DiBiase SJ, 1999, INT J RADIAT ONCOL, V45, P743, DOI 10.1016/S0360-3016(99)00229-1; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dikomey E, 1998, INT J RADIAT BIOL, V73, P269, DOI 10.1080/095530098142365; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; El-Awady RA, 2003, BRIT J CANCER, V89, P593, DOI 10.1038/sj.bjc.6601133; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Guirouilh-Barbat J, 2004, MOL CELL, V14, P611, DOI 10.1016/j.molcel.2004.05.008; HENNER WD, 1983, J BIOL CHEM, V258, P711; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Iwabuchi K, 2003, J BIOL CHEM, V278, P36487, DOI 10.1074/jbc.M304066200; Izumi T, 2003, TOXICOLOGY, V193, P43, DOI 10.1016/S0300-483X(03)00289-0; Lee JW, 2004, J BIOL CHEM, V279, P805, DOI 10.1074/jbc.M307913200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lieber MR, 2004, DNA REPAIR, V3, P817, DOI 10.1016/j.dnarep.2004.03.015; Lin YF, 2003, DNA REPAIR, V2, P1, DOI 10.1016/S1568-7864(02)00183-0; LIU LF, 1983, J BIOL CHEM, V258, P5365; Ma JL, 2003, MOL CELL BIOL, V23, P8820, DOI 10.1128/MCB.23.23.8820-8828.2003; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Okorokov AL, 2002, CARCINOGENESIS, V23, P549, DOI 10.1093/carcin/23.4.549; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; Pfeiffer P, 2000, MUTAGENESIS, V15, P289, DOI 10.1093/mutage/15.4.289; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; POWELL SN, 1995, CANCER RES, V55, P1643; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Rogers-Bald M, 2000, INT J RADIAT BIOL, V76, P23, DOI 10.1080/095530000138970; Romanova LY, 2004, ONCOGENE, V23, P9025, DOI 10.1038/sj.onc.1207982; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; Tang W, 1999, CANCER RES, V59, P2562; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; Willers H, 2004, BRIT J CANCER, V90, P1297, DOI 10.1038/sj.bjc.6601729; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Willers H, 2001, CARCINOGENESIS, V22, P1757, DOI 10.1093/carcin/22.11.1757; Yang TT, 1997, ONCOGENE, V14, P1511, DOI 10.1038/sj.onc.1200979; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004	54	49	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1663	1672		10.1038/sj.onc.1208396	http://dx.doi.org/10.1038/sj.onc.1208396			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15688024				2022-12-25	WOS:000227345100002
J	Nomura, T; Kushiro, T; Yokota, T; Kamiya, Y; Bishop, GJ; Yamaguchi, S				Nomura, T; Kushiro, T; Yokota, T; Kamiya, Y; Bishop, GJ; Yamaguchi, S			The last reaction producing brassinolide is catalyzed by cytochrome P-450s, CYP85A3 in tomato and CYP85A2 in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRASSINOSTEROID SIGNAL-TRANSDUCTION; PLANT-GROWTH; GENE; EXPRESSION; STEPS; CASTASTERONE; ELONGATION; RECEPTOR; ENCODES; PATHWAY	Brassinosteroids are steroidal hormones essential for the growth and development of plants. Brassinolide, the most biologically active brassinosteroid, has a seven-membered lactone ring that is formed by a Baeyer-Villiger oxidation of its immediate precursor castasterone. Despite its potential key role in controlling plant development, brassinolide synthase has not been identified. Previous work has shown that the formation of castasterone from 6-deoxocastasterone is catalyzed by members of the CYP85A family of cytochrome P-450 monooxygenases. A null mutation in the tomato Dwarf (CYP85A1) gene, extreme dwarf (d(x)), causes severe dwarfism due to brassinosteroid deficiency, but the dx mutant still produces fruits. Here, we show that dx fruits contain brassinolide at a higher level than wild-type fruits and that a new CYP85A gene, CYP85A3, is preferentially expressed in tomato fruits. Tomato CYP85A3 catalyzed the Baeyer-Villiger oxidation to produce brassinolide from castasterone in yeast, in addition to the conversion of 6-deoxocastasterone to castasterone. We also show that Arabidopsis CYP85A2, which was initially characterized as castasterone synthase, also has brassinolide synthase activity. Exogenous application of castasterone and brassinolide to the Arabidopsis cyp85a1/cyp85a2 double mutant suggests that castasterone can function as an active brassinosteroid but that its conversion into brassinolide is necessary for normal vegetative development in Arabidopsis. We postulate that castasterone is the major active brassinosteroid during vegetative growth in tomato, whereas brassinolide may play an organ-specific role in fruit development in this species.	RIKEN, Inst Phys & Chem Res, Plant Sci Ctr, Tsurumi Ku, Kanagawa 2300045, Japan; Teikyo Univ, Dept Biosci, Utsunomiya, Tochigi 3208551, Japan; Univ Wales, Inst Biol Sci, Aberystwyth SY23 3DA, Dyfed, Wales	RIKEN; Teikyo University; Aberystwyth University	Bishop, GJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Biol, Wye Campus, Ashford TN25 5AH, Kent, England.	g.bishop@imperial.ac.uk	Kamiya, Yuji/F-9420-2010; Yamaguchi, Shinjiro/F-9684-2010; Nomura, Takahito/C-7327-2012	Kamiya, Yuji/0000-0003-4415-520X; Kushiro, Tetsuo/0000-0002-7598-4791; Nomura, Takahito/0000-0002-3655-3243				AKHTAR M, 1993, J STEROID BIOCHEM, V44, P375, DOI 10.1016/0960-0760(93)90241-N; Bajguz A, 2003, PHYTOCHEMISTRY, V62, P1027, DOI 10.1016/S0031-9422(02)00656-8; Bancos S, 2002, PLANT PHYSIOL, V130, P504, DOI 10.1104/pp.005439; Bishop GJ, 1996, PLANT CELL, V8, P959, DOI 10.1105/tpc.8.6.959; Bishop GJ, 1999, P NATL ACAD SCI USA, V96, P1761, DOI 10.1073/pnas.96.4.1761; Castle J, 2005, PLANT MOL BIOL, V57, P129, DOI 10.1007/s11103-004-6851-7; Choe SW, 1998, PLANT CELL, V10, P231, DOI 10.1105/tpc.10.2.231; Clouse SD, 2002, MOL CELL, V10, P973, DOI 10.1016/S1097-2765(02)00744-X; Clouse SD, 1998, ANNU REV PLANT PHYS, V49, P427, DOI 10.1146/annurev.arplant.49.1.427; FISCHER RT, 1991, J BIOL CHEM, V266, P6124; Fujioka S, 2003, ANNU REV PLANT BIOL, V54, P137, DOI 10.1146/annurev.arplant.54.031902.134921; GROVE MD, 1979, NATURE, V281, P216, DOI 10.1038/281216a0; Helliwell CA, 1999, PLANT PHYSIOL, V119, P507, DOI 10.1104/pp.119.2.507; Hong Z, 2003, PLANT CELL, V15, P2900, DOI 10.1105/tpc.014712; Hong Z, 2002, PLANT J, V32, P495, DOI 10.1046/j.1365-313X.2002.01438.x; Kim TW, 2004, PHYTOCHEMISTRY, V65, P679, DOI 10.1016/j.phytochem.2004.01.007; MAK AY, 1992, J AM CHEM SOC, V114, P8309, DOI 10.1021/ja00047a063; Mihovilovic MD, 2002, EUR J ORG CHEM, V2002, P3711; Montoya T, 2005, PLANT J, V42, P262, DOI 10.1111/j.1365-313X.2005.02376.x; Montoya T, 2002, PLANT CELL, V14, P3163, DOI 10.1105/tpc.006379; Mori M, 2002, PLANT PHYSIOL, V130, P1152, DOI 10.1104/pp.007179; Nomura T, 2001, PHYTOCHEMISTRY, V57, P171, DOI 10.1016/S0031-9422(00)00440-4; Peng P, 2003, J PLANT GROWTH REGUL, V22, P298, DOI 10.1007/s00344-003-0059-y; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; Sakurai A, 1999, PLANT PHYSIOL BIOCH, V37, P351, DOI 10.1016/S0981-9428(99)80041-2; Shimada Y, 2003, PLANT PHYSIOL, V131, P287, DOI 10.1104/pp.013029; Shimada Y, 2001, PLANT PHYSIOL, V126, P770, DOI 10.1104/pp.126.2.770; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; Wang ZY, 2001, NATURE, V410, P380, DOI 10.1038/35066597; Yokota T, 1999, N COMP BIOC, V33, P277; YOKOTA T, 1990, AGR BIOL CHEM TOKYO, V54, P1107, DOI 10.1080/00021369.1990.10870046	31	147	168	2	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17873	17879		10.1074/jbc.M414592200	http://dx.doi.org/10.1074/jbc.M414592200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15710611	hybrid			2022-12-25	WOS:000228807200040
J	Debidda, M; Wang, L; Zang, H; Poli, V; Zheng, Y				Debidda, M; Wang, L; Zang, H; Poli, V; Zheng, Y			A role of STAT3 in rho GTPase-regulated cell migration and proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; FAMILY GTPASES; IL-6 RESPONSE; ACTIVATION; BINDING; PATHWAYS; PROTEIN; GROWTH; CDC42; TRANSCRIPTION	Rho family GTPases and STAT3 act as mediators of cytokine and growth factor signaling in a variety of cellular functions involved in inflammation, tumorigenesis, and development. In the course of searching for their functional connections, we found by using STAT3 knock-out mouse embryonic fibroblasts that RhoA, Rac1, and Cdc42 could cause nonspecific activation of STAT3 promoter-driven luciferase reporter in the absence of STAT3, raising concerns to a body of literature where STAT3 was associated with Rho GTPases based on the reporter system. We also found that although active RhoA, Rac1, and Cdc42 could all mediate Ser-727 and Tyr-705 phosphorylation and nuclear translocation of STAT3, the Rho GTPases were able to induce STAT3 activation independently of the interleukin-6 autocrine pathway, and active RhoA, Rac1, or Cdc42 could not form a stable complex with STAT3 as previously suggested, indicating an unappreciated mechanism of STAT3 activation by the Rho GTPases. The RhoA-induced STAT3 activation partly depended on Rho-associated kinase (ROK) and involved multiple effector signals as revealed by the examination of effector domain mutants of RhoA. Genetic deletion of STAT3 led to a loss of response to RhoA in myosin light chain phosphorylation and actin stress fiber induction but sensitized the cells to RhoA or ROK-stimulated cell migration. STAT3 was required for the RhoA-induced NF-kappa B and cyclin D1 transcription and was involved in NF-kappa B nuclear translocation. Furthermore, loss of STAT3 expression inhibited RhoA-promoted cell proliferation and blocked RhoA or ROK induced anchorage-independent growth. These phenotypic changes in STAT3(-/-) cells could be rescued by reconstituting STAT3 gene. Our studies carried out in STAT3 null cells demonstrate unambiguously that STAT3 represents an essential effector pathway of Rho GTPases in regulating multiple cellular functions including actin cytoskeleton reorganization, cell migration, gene activation, and proliferation.	Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA; Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University of Turin	Zheng, Y (corresponding author), Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA.	yi.zheng@chmcc.org	Zheng, Yi/J-7235-2015; Poli, Valeria/A-9215-2012	Zheng, Yi/0000-0001-7089-6074; Poli, Valeria/0000-0002-3739-3966	NIGMS NIH HHS [GM 53943, GM 60523] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; Aznar S, 2001, MOL BIOL CELL, V12, P3282, DOI 10.1091/mbc.12.10.3282; Benitah SA, 2003, MOL BIOL CELL, V14, P3041, DOI 10.1091/mbc.E03-01-0016; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Guo FK, 2004, MOL CELL BIOL, V24, P1426, DOI 10.1128/MCB.24.3.1426-1438.2004; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Kamakura S, 2004, NAT CELL BIOL, V6, P547, DOI 10.1038/ncb1138; Kira M, 2002, J BIOL CHEM, V277, P12931, DOI 10.1074/jbc.M110795200; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Pfeffer LM, 2004, J BIOL CHEM, V279, P31304, DOI 10.1074/jbc.M308975200; Roovers K, 2003, MOL CELL BIOL, V23, P4283, DOI 10.1128/MCB.23.12.4283-4294.2003; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sartor CI, 1997, CANCER RES, V57, P978; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Sivko GS, 2004, J CELL BIOCHEM, V93, P844, DOI 10.1002/jcb.20224; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Takeda T, 1998, J ENDOCRINOL, V159, P323, DOI 10.1677/joe.0.1590323; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VAN AL, 1997, GENE DEV, V11, P2295; Wang L, 2004, BIOCHEMISTRY-US, V43, P14584, DOI 10.1021/bi048574u	39	112	116	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17275	17285		10.1074/jbc.M413187200	http://dx.doi.org/10.1074/jbc.M413187200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15705584	hybrid			2022-12-25	WOS:000228615500091
J	He, QY; Shu, HJ; Cheng, P; Chen, S; Wang, LX; Liu, Y				He, QY; Shu, HJ; Cheng, P; Chen, S; Wang, LX; Liu, Y			Light-independent phosphorylation of WHITE COLLAR-1 regulates its function in the Neurospora circadian negative feedback loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOCK PROTEIN FREQUENCY; KINASE-I-EPSILON; BLUE-LIGHT; DEPENDENT PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PERIOD PROTEIN; GENE-FREQUENCY; DOUBLE-TIME; CRASSA; TRANSCRIPTION	Phosphorylation is a major regulatory mechanism controlling circadian clocks. In the Neurospora circadian clock, the PER-ARNT-SIM ( PAS) domain-containing transcription factor, WHITE COLLAR (WC)-1, acts both as the blue light photoreceptor of the clock and as a positive element in the circadian negative feedback loop in constant darkness, by activating the transcription of the frequency (frq) gene. To understand the role of WC-1 phosphorylation, five in vivo WC-1 phosphorylation sites, located immediately downstream of the WC-1 zinc finger DNA binding domain, were identified by tandem mass spectrometry using biochemically purified endogenous WC-1 protein. Mutations of these phosphorylation sites suggest that they are major WC-1 phosphorylation sites under constant conditions but are not responsible for the light-induced hyperphosphorylation of WC-1. Although phosphorylation of these sites does not affect the light function of WC-1, strains carrying mutations of these sites show short period, low amplitude, or arrhythmic conidiation rhythms in constant darkness. Furthermore, normal or slightly higher levels of frq mRNA and FRQ proteins were observed in a mutant strain containing mutations of all five sites despite its low WC-1 levels. Together, these data suggest that phosphorylation of these sites negatively regulates the function of WC-1 in the circadian negative feedback loop and is important for the function of the Neurospora circadian clock.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Liu, Y (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, Rm L4-235,5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Yi.Liu@UTsouthwestern.edu	He, qiyang/AAT-5826-2021; He, qiyang/GQA-4070-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062591, R01GM068496] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM068496, GM062591] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akten B, 2003, NAT NEUROSCI, V6, P251, DOI 10.1038/nn1007; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Arpaia G, 1999, MOL GEN GENET, V262, P314, DOI 10.1007/s004380051089; Ballario P, 1996, EMBO J, V15, P1650, DOI 10.1002/j.1460-2075.1996.tb00510.x; Cheng P, 2005, GENE DEV, V19, P234, DOI 10.1101/gad.1266805; Cheng P, 2003, P NATL ACAD SCI USA, V100, P5938, DOI 10.1073/pnas.1031791100; Cheng P, 2003, J BIOL CHEM, V278, P3801, DOI 10.1074/jbc.M209592200; Cheng P, 2002, MOL CELL BIOL, V22, P517, DOI 10.1128/MCB.22.2.517-524.2002; Cheng P, 2001, P NATL ACAD SCI USA, V98, P7408, DOI 10.1073/pnas.121170298; Cheng P, 2001, EMBO J, V20, P101, DOI 10.1093/emboj/20.1.101; Christie JM, 1998, SCIENCE, V282, P1698, DOI 10.1126/science.282.5394.1698; Collett MA, 2002, GENETICS, V160, P149; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Denault DL, 2001, EMBO J, V20, P109, DOI 10.1093/emboj/20.1.109; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Froehlich AC, 2003, P NATL ACAD SCI USA, V100, P5914, DOI 10.1073/pnas.1030057100; Froehlich AC, 2002, SCIENCE, V297, P815, DOI 10.1126/science.1073681; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; Gorl M, 2001, EMBO J, V20, P7074, DOI 10.1093/emboj/20.24.7074; He Q, 2003, EMBO J, V22, P4421, DOI 10.1093/emboj/cdg425; He QY, 2002, SCIENCE, V297, P840, DOI 10.1126/science.1072795; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; Lee K, 2000, SCIENCE, V289, P107, DOI 10.1126/science.289.5476.107; Lee K, 2003, GENETICS, V163, P103; Lin JM, 2002, NATURE, V420, P816, DOI 10.1038/nature01235; Linden H, 1997, FUNGAL GENET BIOL, V22, P141, DOI 10.1006/fgbi.1997.1013; Linden H, 1997, EMBO J, V16, P98, DOI 10.1093/emboj/16.1.98; Liu Y, 2000, P NATL ACAD SCI USA, V97, P234, DOI 10.1073/pnas.97.1.234; Liu Y, 2003, CELL MOL LIFE SCI, V60, P2131, DOI 10.1007/s00018-003-3109-5; Liu Y, 1997, CELL, V89, P477, DOI 10.1016/S0092-8674(00)80228-7; Liu Y, 2003, J BIOL RHYTHM, V18, P195, DOI 10.1177/0748730403018003002; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; Merrow M, 2001, EMBO J, V20, P307, DOI 10.1093/emboj/20.3.307; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Roenneberg T, 2000, METHOD ENZYMOL, V305, P104; Sasaki T, 2002, J BIOL CHEM, V277, P36032, DOI 10.1074/jbc.M206674200; Schwerdtfeger C, 2000, EUR J BIOCHEM, V267, P414, DOI 10.1046/j.1432-1327.2000.01016.x; Shalitin D, 2002, NATURE, V417, P763, DOI 10.1038/nature00815; SHU H, 2003, AFCS RES REPORTS; Sugano S, 1998, P NATL ACAD SCI USA, V95, P11020, DOI 10.1073/pnas.95.18.11020; Talora C, 1999, EMBO J, V18, P4961, DOI 10.1093/emboj/18.18.4961; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Yang YH, 2004, GENE DEV, V18, P255, DOI 10.1101/gad.1152604; Yang YH, 2003, MOL CELL BIOL, V23, P6221, DOI 10.1128/MCB.23.17.6221-6228.2003; Yang YH, 2002, GENE DEV, V16, P994, DOI 10.1101/gad.965102; Yang YH, 2001, J BIOL CHEM, V276, P41064, DOI 10.1074/jbc.M106905200; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576	53	83	86	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17526	17532		10.1074/jbc.M414010200	http://dx.doi.org/10.1074/jbc.M414010200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731099	hybrid			2022-12-25	WOS:000228615500121
J	Taha, TA; Kitatani, K; Bielawski, J; Cho, W; Hannun, YA; Obeid, LM				Taha, TA; Kitatani, K; Bielawski, J; Cho, W; Hannun, YA; Obeid, LM			Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED HEPATOCYTE APOPTOSIS; CELL-DEATH; TNF-ALPHA; LYSOSOMAL PERMEABILIZATION; PROTEASE PATHWAYS; SPHINGOSINE-1-PHOSPHATE; ACTIVATION; RELEASE; CASPASE	Sphingosine kinase-1 (SK1) has emerged as a key component of cytokine responses, including roles in apoptosis, yet the specific mechanisms by which cytokines regulate SK1 in the apoptotic responses have not been studied. In this study, we show that prolonged treatment of MCF-7 cells with tumor necrosis factor (TNF) induces a dose- and time-dependent decrease in SK1 protein. Inhibition of the upstream caspase 8 by IETD significantly rescued TNF effects on SK1, yet the caspase 7 inhibitor DEVD failed to have any effect, suggesting that the decline in SK1 occurs downstream of the initiator caspase but upstream of the effector caspase. In addition to caspase activation, TNF caused disruption of lysosomes with relocation of the cysteine protease cathepsin B into the cytosol. Down-regulation of cathepsin B using small interfering RNA significantly restored SK1 levels following exposure to TNF, suggesting that SK1 loss was dependent on cathepsin B activity. The regulation of SK1 by the lysosomal protease was further supported by the colocalization of SK1 with the lysosome and cathepsin B in cells and the loss of the colocalization following exposure to TNF. The ability of cathepsin B to regulate SK1 was further corroborated by an in vitro approach where recombinant cathepsin B cleaved SK1 at multiple sites to produce several cleavage fragments. Therefore, these studies show that SK1 down-regulation by TNF is dependent on the "lysosomal pathway" of apoptosis and specifically on cathepsin B, which functions as an SK1 protease in cells.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Ralph H Johnson Vet Adm Hosp, Div Gen Internal Med, Charleston, SC 29401 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Univ Illinois, Dept Chem, Chicago, IL 60607 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA.	obeidl@musc.edu	Kitatani, Kazuyuki/H-7100-2019	Kitatani, Kazuyuki/0000-0002-8516-6135; obeid, lina/0000-0002-0734-0847	NCI NIH HHS [P01 CA097132] Funding Source: Medline; NIDDK NIH HHS [DK59340] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA097132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059340] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dietrich N, 2004, CELL DEATH DIFFER, V11, P301, DOI 10.1038/sj.cdd.4401353; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Foghsgaard L, 2002, J BIOL CHEM, V277, P39499, DOI 10.1074/jbc.M206669200; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; Heinrich M, 2004, CELL DEATH DIFFER, V11, P550, DOI 10.1038/sj.cdd.4401382; Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Liu N, 2003, EMBO J, V22, P5313, DOI 10.1093/emboj/cdg510; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Taha TA, 2004, J BIOL CHEM, V279, P20546, DOI 10.1074/jbc.M401259200; Werneburg N, 2004, AM J PHYSIOL-GASTR L, V287, pG436, DOI 10.1152/ajpgi.00019.2004; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499	21	74	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17196	17202		10.1074/jbc.M413744200	http://dx.doi.org/10.1074/jbc.M413744200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15710602	hybrid			2022-12-25	WOS:000228615500081
J	Toledo, MS; Suzuki, E; Handa, K; Hakomori, S				Toledo, MS; Suzuki, E; Handa, K; Hakomori, S			Effect of ganglioside and tetraspanins in microdomains on interaction of integrins with fibroblast growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; CELL-ADHESION; SIGNAL-TRANSDUCTION; GM3 GANGLIOSIDE; GLUCOSYLCERAMIDE SYNTHASE; IMMUNOLOGICAL SYNAPSE; MEDIATED MODULATION; CAVEOLAE MEMBRANE; PHOSPHORYLATION; GLYCOSYLATION	The functional interaction ("cross-talk") of integrins with growth factor receptors has become increasingly clear as a basic mechanism in cell biology, defining cell growth, adhesion, and motility. However, no studies have addressed the microdomains in which such interaction takes place nor the effect of gangliosides and tetraspanins (TSPs) on such interaction. Growth of human embryonal WI38 fibroblasts is highly dependent on fibroblast growth factor (FGF) and its receptor ( FGFR), stably associated with ganglioside GM3 and TSPs CD9 and CD81 in the ganglioside-enriched microdomain. Adhesion and motility of these cells are mediated by laminin-5 ((LN5) and fibronectin (FN) through alpha 3 beta 1 and alpha 5 beta 1 integrin receptors, respectively. When WI38 cells or its transformant VA13 cells were adhered to LN5 or FN, alpha 3 beta 1 or alpha 5 beta 1 were stimulated, giving rise to signaling to activate FGFR through tyrosine phosphorylation and inducing cell proliferation under serum-free conditions without FGF addition. Types and intensity of signaling during the time course differed significantly depending on the type of integrin stimulated (alpha 3 beta 1 versus alpha 5 beta 1), and on cell type ( WI38 versus VA13). Such effect of cross-talk between integrins and FGFR was influenced strongly by the change of GM3 and TSPs. (i) GM3 depletion by P4 caused enhanced tyrosine phosphorylation of FGFR and Akt followed by MAPK activation, without significant change of ceramide level. GM3 depletion also caused enhanced co-immunoprecipitation of FGFR with alpha 3/alpha 5/beta 1 and of these integrins with CD9/CD81. (ii) LN5- or FN-dependent proliferation of both WI38 and VA13 was strongly enhanced by GM3 depletion and by CD9/ CD81 knockdown by siRNA. Thus, integrin-FGFR crosstalk is strongly influenced by GM3 and/or TSPs within the ganglioside-enriched microdomain.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Hakomori, S (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	hakomori@u.washington.edu	de Toledo, Marcos Sergio/M-7185-2019; Toledo, Marcos S/B-6243-2008; Suzuki, Erika/B-3456-2008	de Toledo, Marcos Sergio/0000-0002-6605-0874; Suzuki, Erika/0000-0002-4010-8716	NCI NIH HHS [R01 CA80054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bektas M, 2003, ANAL BIOCHEM, V320, P259, DOI 10.1016/S0003-2697(03)00388-9; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; COHEN S, 1980, J BIOL CHEM, V255, P4834; DITTMER JC, 1964, J LIPID RES, V5, P126; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Hakomori S, 2004, AN ACAD BRAS CIENC, V76, P553, DOI 10.1590/S0001-37652004000300010; Hakomori S, 2002, FEBS LETT, V531, P88, DOI 10.1016/S0014-5793(02)03479-8; HANNUN YA, 1997, SPHINGOLIPID MEDIATE, P188; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kawakami Y, 2002, J BIOL CHEM, V277, P34349, DOI 10.1074/jbc.M200771200; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Li RX, 2000, J BIOL CHEM, V275, P34213, DOI 10.1074/jbc.M906368199; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mannion BA, 1996, J IMMUNOL, V157, P2039; Marchesini N, 2004, J BIOL CHEM, V279, P25101, DOI 10.1074/jbc.M313662200; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; Odintsova E, 2003, J CELL SCI, V116, P4557, DOI 10.1242/jcs.00793; Ono M, 2001, BIOCHEMISTRY-US, V40, P6414, DOI 10.1021/bi0101998; Ono M, 2000, BIOCHEM BIOPH RES CO, V279, P744, DOI 10.1006/bbrc.2000.4030; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; Selzner M, 2001, CANCER RES, V61, P1233; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; Shu LM, 2002, J BIOL CHEM, V277, P18447, DOI 10.1074/jbc.M111363200; Signorelli P, 2002, METHOD ENZYMOL, V345, P275; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Suzuki E, 2004, P NATL ACAD SCI USA, V101, P14788, DOI 10.1073/pnas.0406536101; Tagami S, 2002, J BIOL CHEM, V277, P3085, DOI 10.1074/jbc.M103705200; Toledo MS, 2004, J BIOL CHEM, V279, P34655, DOI 10.1074/jbc.M403857200; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Yates AJ, 1998, ANN NY ACAD SCI, V845, P57, DOI 10.1111/j.1749-6632.1998.tb09662.x; Zhang J, 2004, J VIROL, V78, P1448, DOI 10.1128/JVI.78.3.1448-1455.2004; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	54	81	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16227	16234		10.1074/jbc.M413713200	http://dx.doi.org/10.1074/jbc.M413713200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710618	hybrid			2022-12-25	WOS:000228444800092
J	Wang, L; Li, G; Sugita, S				Wang, L; Li, G; Sugita, S			A central kinase domain of type I phosphatidylinositol phosphate kinases is sufficient to prime exocytosis - Isoform specificity and its underlying mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRACKED PC12 CELLS; PLASMA-MEMBRANE; CA2+-ACTIVATED SECRETION; VESICLE EXOCYTOSIS; CA2+ SENSOR; PROTEIN; FAMILY; 5-KINASES; BINDING; CLONING	Exocytosis, a critical process for neuronal communication and hormonal regulation, involves several distinct steps including MgATP-dependent priming ( which involves the synthesis of phosphatidylinositol 4,5-bisphosphate). Type I phosphatidylinositol phosphate kinases (PIPKIs) were purified biochemically as a priming factor. PIPKI consists of three domains: the N-terminal region, the central kinase domain, and the C-terminal region. Three isoforms (alpha, beta, and gamma) of PIPKI have been identified, and each is alternatively spliced at the C-terminal region. In the present study, we conducted a structure/function analysis of PIPKIs in the priming of exocytosis, and we found that recombinant PIPKI alpha and PIPKI gamma had priming activity. However, an unexpected finding of these results was that PIPKI beta did not prime exocytosis. The N- or C-terminal region of PIPKI alpha and PIPKI gamma was not required for priming, which indicates that the central kinase domain is sufficient for this process. Alternative splicing in each isoform did not affect the isoform specificity in priming. Priming activity by isoforms is strongly correlated with their phosphatidylinositol phosphate kinase activity because PIPKI alpha and PIPKI gamma had higher kinase activity than PIPKI beta. These results suggest that PIPKI alpha and PIPKI gamma are the critical priming factors for exocytosis; it also suggests that the levels of phosphatidylinositol phosphate kinase activity in producing phosphatidylinositol 4,5-bisphosphate specify the function of PIPKI isoforms in priming.	Univ Hlth Network, Div Cellular & Mol Biol, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Sugita, S (corresponding author), Univ Hlth Network, Div Cellular & Mol Biol, Toronto Western Res Inst, MC 11-432,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	ssugita@uhnres.utoronto.ca		Sugita, Shuzo/0000-0002-9182-873X; Wang, Li/0000-0002-3460-2080				Aikawa Y, 2003, J CELL BIOL, V162, P647, DOI 10.1083/jcb.200212142; Barbieri MA, 2001, J BIOL CHEM, V276, P47212, DOI 10.1074/jbc.C100490200; Barylko B, 2001, J BIOL CHEM, V276, P7705, DOI 10.1074/jbc.C000861200; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Di Paolo G, 2004, NATURE, V431, P415, DOI 10.1038/nature02896; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Grishanin RN, 2002, J BIOL CHEM, V277, P22025, DOI 10.1074/jbc.M201614200; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Holz RW, 2002, ANN NY ACAD SCI, V971, P232, DOI 10.1111/j.1749-6632.2002.tb04467.x; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Shin OH, 2003, NEURON, V37, P99, DOI 10.1016/S0896-6273(02)01145-5; Shin OH, 2002, NAT NEUROSCI, V5, P649, DOI 10.1038/nn869; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Sugita S, 2002, EMBO J, V21, P270, DOI 10.1093/emboj/21.3.270; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; Tucker WC, 2003, J CELL BIOL, V162, P199, DOI 10.1083/jcb.200302060; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; Wang L, 2004, J BIOL CHEM, V279, P19875, DOI 10.1074/jbc.M400522200; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1	29	13	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16522	16527		10.1074/jbc.M413263200	http://dx.doi.org/10.1074/jbc.M413263200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15728183	hybrid			2022-12-25	WOS:000228444800127
J	Rabie, T; Strehl, A; Ludwig, A; Nieswandt, B				Rabie, T; Strehl, A; Ludwig, A; Nieswandt, B			Evidence for a role of ADAM17 (TACE) in the regulation of platelet glycoprotein V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN RESPONSIVENESS; CYTOPLASMIC DOMAIN; ALPHA; RECEPTOR; CALMODULIN; ADHESION; IX; ACTIVATION; CLEAVAGE; COLLAGEN	Glycoprotein V (GPV) is a subunit of the GPIb-IX-V receptor for von Willebrand factor and thrombin and has been shown to modulate platelet responses to the two strongest physiological agonists, thrombin and collagen. Thrombin directly cleaves GPV from the platelet surface, yielding a 69-kDa fragment GPV f1 of unknown function. We show here that a similar to 82-kDa fragment of GPV is shed from the platelet surface upon cellular activation with phorbol 12-myristate 13-acetate or the collagen-related peptide. This shedding was inhibited by the broad range metalloproteinase inhibitor GM6001, the two potent ADAM17 inhibitors GW280264X and TAPI-2, and was absent in mice lacking functional ADAM17 (ADAM17 lacking Zn-binding domain; ADAM17(Delta Zn/Delta Zn)). Furthermore, we show that recombinant ADAM17 ectodomain efficiently releases GPV from the platelet surface. GPV is known to be associated with the intracellular regulatory protein calmodulin, which has previously been shown to be involved in ADAM17-mediated shedding of L-selectin from the surface of leukocytes. As in these reports, inhibition of calmodulin led to rapid GPV shedding from the platelet surface, a process that was again blocked by GM6001 or ADAM17 inhibitors and that was absent in ADAM17(Delta Zn/Delta Zn) mice. Inhibition of outside-in signaling through GPIIb/IIIa did not significantly affect GPV shedding, excluding an essential role of this pathway for the regulation of ADAM17 activity. These results demonstrate that GPV is cleaved upon agonist-induced platelet activation and show that ADAM17 is the major enzyme mediating this process.	Univ Wurzburg, Deutsch Forschungsgemeinschaft Res Ctr Expt Biome, Rudolf Virchow Ctr, D-97078 Wurzburg, Germany; Univ Kiel, Inst Biochem, D-24098 Kiel, Germany	University of Wurzburg; University of Kiel	Nieswandt, B (corresponding author), Univ Wurzburg, Deutsch Forschungsgemeinschaft Res Ctr Expt Biome, Rudolf Virchow Ctr, D-97078 Wurzburg, Germany.	bernhard.nieswandt@virchow.uni-uerzburg.de	Rabie, Tamer/C-7886-2013; Ludwig, Andreas/I-5685-2012	Ludwig, Andreas/0000-0001-8536-4986; Rabie, Tamer/0000-0001-9060-8797				Abel S, 2004, J IMMUNOL, V172, P6362, DOI 10.4049/jimmunol.172.10.6362; Andre P, 2002, NAT MED, V8, P247, DOI 10.1038/nm0302-247; Andrews RK, 2003, INT J BIOCHEM CELL B, V35, P1170, DOI 10.1016/S1357-2725(02)00280-7; Andrews RK, 2001, BLOOD, V98, P681, DOI 10.1182/blood.V98.3.681; Azorsa DO, 1999, THROMB HAEMOSTASIS, V81, P131; Bennett TA, 2000, J IMMUNOL, V164, P4120, DOI 10.4049/jimmunol.164.8.4120; Bergmeier W, 2000, BLOOD, V95, P886, DOI 10.1182/blood.V95.3.886.003k45_886_893; Bergmeier W, 2004, CIRC RES, V95, P677, DOI 10.1161/01.RES.0000143899.73453.11; Bergmeier W, 2002, CYTOMETRY, V48, P80, DOI 10.1002/cyto.10114; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; BLACK RA, 2003, BIOCH SOC S, V39; Blobel CP, 2002, INFLAMM RES, V51, P83, DOI 10.1007/BF02684007; Cazenave Jean-Pierre, 2004, Methods Mol Biol, V272, P13; Chakravarthy B, 1999, TRENDS NEUROSCI, V22, P12, DOI 10.1016/S0166-2236(98)01288-0; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; FOX JEB, 1994, BLOOD COAGUL FIBRIN, V5, P291, DOI 10.1097/00001721-199404000-00020; GARDINER EE, 2004, BLOOD; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; HIDAKA H, 1983, METHOD ENZYMOL, V102, P185; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; Kahn ML, 1999, BLOOD, V94, P4112, DOI 10.1182/blood.V94.12.4112.424k40_4112_4121; Kato K, 2004, BLOOD, V104, P2339, DOI 10.1182/blood-2004-03-1127; Kehrel B, 1998, BLOOD, V91, P491; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Matala E, 2001, J IMMUNOL, V167, P1617, DOI 10.4049/jimmunol.167.3.1617; Moog S, 2001, BLOOD, V98, P1038, DOI 10.1182/blood.V98.4.1038; Moss ML, 2002, ESSAYS BIOCHEM, V38, P141, DOI 10.1042/bse0380141; Nieswandt B, 2000, BLOOD, V96, P2520; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Prasad KSS, 2003, P NATL ACAD SCI USA, V100, P12367, DOI 10.1073/pnas.2032886100; Ramakrishnan V, 1999, P NATL ACAD SCI USA, V96, P13336, DOI 10.1073/pnas.96.23.13336; Ramakrishnan V, 2001, P NATL ACAD SCI USA, V98, P1823, DOI 10.1073/pnas.98.4.1823; TANAKA T, 1983, PHARMACOLOGY, V26, P249, DOI 10.1159/000137808; Walcheck B, 2003, J LEUKOCYTE BIOL, V74, P389, DOI 10.1189/jlb.0403141; Ware J, 2000, P NATL ACAD SCI USA, V97, P2803, DOI 10.1073/pnas.050582097	40	95	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14462	14468		10.1074/jbc.M500041200	http://dx.doi.org/10.1074/jbc.M500041200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15691827	hybrid			2022-12-25	WOS:000228236800015
J	Valineva, T; Yang, J; Palovuori, R; Silvennoinen, O				Valineva, T; Yang, J; Palovuori, R; Silvennoinen, O			The transcriptional co-activator protein p100 recruits histone acetyltransferase activity to STAT6 and mediates interaction between the CREB-binding protein and STAT6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLUCOCORTICOID-RECEPTOR; SYNERGISTIC ACTIVATION; IL-4; P300/CBP; CBP; INTERLEUKIN-4; ACETYLATION; COOPERATION; INDUCTION	STAT6 is a critical regulator of transcription for interleukin-4 (IL-4)-induced genes. Activation of gene expression involves recruitment of coactivator proteins that function as bridging factors connecting sequence-specific transcription factors to the basal transcription machinery, and as chromatin-modifying enzymes. Coactivator proteins CBP/p300 have been implicated in regulation of transcription in all STATs. CBP is also required for STAT6-mediated gene activation, but the underlying molecular mechanisms are still elusive. In this study we investigated the mechanisms by which STAT6 recruits CBP and chromatin-modifying activities to the promoter. Our results indicate that while STAT1-interacted directly with CBP, the interaction between STAT6 and CBP was found to be mediated through p100 protein, a coactivator protein that has previously been shown to stimulate the transcription of IL-4-induced genes. The staphylococcal nuclease-like (SN)-domains of p100 directly interacted with amino acids 1099-1758 of CBP, while p100 did not associate with SRC-1, another coactivator of STAT6. p100 was found to recruit histone acetyltransferase (HAT) activity to STAT6 in vivo. Chromatin immunoprecipitation studies demonstrated that p100 increases the STAT6-p100-CBP ternary complex formation in the human Ig epsilon promoter. p100 also increased the amount of acetylated histone H4 at the Ig epsilon promoter, and siRNAs directed against p100 effectively inhibited Ig epsilon reporter gene expression. Our results suggest that p100 has an important role in the assembly of STAT6 transcriptosome, and that p100 stimulates IL-4-dependent transcription by mediating interaction between STAT6 and CBP and recruiting chromatin modifying activities to STAT6-responsive promoters.	Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland; Tampere Univ Hosp, Dept Clin Microbiol, FIN-33521 Tampere, Finland; Tianjin Med Univ, Dept Immunol, Tianjin 300070, Peoples R China	Tampere University; Tampere University; Tampere University Hospital; Tianjin Medical University	Silvennoinen, O (corresponding author), Univ Tampere, Inst Med Technol, Biokatu 8, FIN-33014 Tampere, Finland.	olli.silvennoinen@uta.fi						Aittomaki S, 2000, J IMMUNOL, V164, P5689, DOI 10.4049/jimmunol.164.11.5689; Arimura A, 2004, J BIOL CHEM, V279, P31105, DOI 10.1074/jbc.M404428200; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Callebaut I, 1997, BIOCHEM J, V321, P125, DOI 10.1042/bj3210125; Chan HM, 2001, J CELL SCI, V114, P2363; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Goenka S, 2003, J BIOL CHEM, V278, P50362, DOI 10.1074/jbc.M305854200; Gupta S, 1999, J EXP MED, V190, P1837, DOI 10.1084/jem.190.12.1837; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Litterst CM, 2003, J BIOL CHEM, V278, P45340, DOI 10.1074/jbc.M303644200; Litterst CM, 2001, J BIOL CHEM, V276, P45713, DOI 10.1074/jbc.M108132200; McDonald C, 1999, J INTERF CYTOK RES, V19, P711, DOI 10.1089/107999099313550; Mikita T, 1998, J IMMUNOL, V161, P1822; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Ohmori Y, 1998, J BIOL CHEM, V273, P29202, DOI 10.1074/jbc.273.44.29202; Paukku K, 2003, MOL ENDOCRINOL, V17, P1805, DOI 10.1210/me.2002-0256; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Pesu M, 2000, BLOOD, V95, P494, DOI 10.1182/blood.V95.2.494; Pesu M, 2003, EUR J IMMUNOL, V33, P1727, DOI 10.1002/eji.200323680; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; ROUSSET F, 1988, J IMMUNOL, V140, P2625; Shankaranarayanan P, 2001, J BIOL CHEM, V276, P42753, DOI 10.1074/jbc.M102626200; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Stutz AM, 1999, J IMMUNOL, V163, P4383; Thienes CP, 1997, J IMMUNOL, V158, P5874; TONG X, 1995, MOL CELL BIOL, V15, P4735; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; WARREN WD, 1995, J IMMUNOL, V155, P5637; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; Yang J, 2002, EMBO J, V21, P4950, DOI 10.1093/emboj/cdf463; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	46	87	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14989	14996		10.1074/jbc.M410465200	http://dx.doi.org/10.1074/jbc.M410465200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15695802	hybrid			2022-12-25	WOS:000228236800080
J	Wang, YN; Johnson, P				Wang, YN; Johnson, P			Expression of CD45 lacking the catalytic protein tyrosine phosphatase domain modulates Lck phosphorylation and T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SIGNAL-TRANSDUCTION; SRC-FAMILY KINASES; ANTIGEN RECEPTOR; NEGATIVE REGULATION; INTERLEUKIN-2 SECRETION; CYTOPLASMIC DOMAIN; LYMPHOCYTES; P56(LCK); LINE; DEPHOSPHORYLATION	The function of the second protein tyrosine phosphatase domain (D2) in two-domain protein tyrosine phosphatases (PTP) is not well understood. In CD45, D2 can interact with the catalytic domain (D1) and stabilize its activity. Although D2 itself has no detectable catalytic activity, it can bind substrate and may influence the substrate specificity of CD45. To further explore the function of D2 in T cells, a full-length construct of CD45 lacking the D1 catalytic domain (CD45RABC-D2) was expressed in CD45(+) and CD45(-) Jurkat T cells. In CD45(-) Jurkat T cells, CD45RABC-D2 associated with Lck but, unlike its active counterpart CD45RABC, did not restore the induction of tyrosine phosphorylation or CD69 expression upon T cell receptor (TCR) stimulation. Expression of CD45RABC-D2 in CD45(-) Jurkat T cells resulted in its association with Lck, increased the phosphorylation state of Lck, and reduced T cell activation. TCR-induced tyrosine phosphorylation was delayed, and although MAPK phosphorylation and CD69 expression were not significantly affected, the calcium signal and IL2 production were severely reduced. This indicates that the non-catalytic domains of CD45 can interact with Lck in T cells. CD45RABC-D2 acts as a dominant negative resulting in an increase in Lck phosphorylation and a preferential loss of the calcium signaling pathway, but not the MAPK pathway, upon TCR signaling. This finding suggests that, in addition to their established roles in the initiation of TCR signaling, CD45 and Lck may also influence the type of TCR signal generated.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Johnson, P (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 300-6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	pauline@interchange.ubc.ca	Johnson, Pauline/G-9659-2019	Johnson, Pauline/0000-0001-7367-4653				Abraham RT, 2004, NAT REV IMMUNOL, V4, P301, DOI 10.1038/nri1330; Alexander DR, 2000, SEMIN IMMUNOL, V12, P349, DOI 10.1006/smim.2000.0218; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Ashwell JD, 1999, IMMUNOL TODAY, V20, P412, DOI 10.1016/S0167-5699(99)01505-4; Cantrell DA, 2003, IMMUNOL REV, V192, P122, DOI 10.1034/j.1600-065X.2003.00028.x; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Dornan S, 2002, J BIOL CHEM, V277, P1912, DOI 10.1074/jbc.M108386200; Duplay P, 1996, J BIOL CHEM, V271, P17896, DOI 10.1074/jbc.271.30.17896; Ebinu JO, 2000, BLOOD, V95, P3199; Felberg J, 2000, BIOCHEM BIOPH RES CO, V271, P292, DOI 10.1006/bbrc.2000.2623; Felberg J, 2004, J BIOL CHEM, V279, P3455, DOI 10.1074/jbc.M309537200; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; Greer SF, 2001, J IMMUNOL, V166, P7208, DOI 10.4049/jimmunol.166.12.7208; Hermiston ML, 2003, ANNU REV IMMUNOL, V21, P107, DOI 10.1146/annurev.immunol.21.120601.140946; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; JOHNSON P, 2000, MOD ASP IMMUNOBIOL, V1, P156; JOHNSON P, 1997, WEIRS HDB EXPT IMMUN, V2; JUSTEMENT LB, 1990, J IMMUNOL, V144, P3272; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; Kashio N, 1998, J BIOL CHEM, V273, P33856, DOI 10.1074/jbc.273.50.33856; KITAMURA K, 1995, J BIOL CHEM, V270, P21151, DOI 10.1074/jbc.270.36.21151; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; Lefebvre DC, 2003, BBA-PROTEINS PROTEOM, V1650, P40, DOI 10.1016/S1570-9639(03)00190-0; Leitenberg D, 1996, J EXP MED, V183, P249, DOI 10.1084/jem.183.1.249; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Li RH, 2001, J BIOL CHEM, V276, P28767, DOI 10.1074/jbc.M100158200; Majeti R, 2000, CELL, V103, P1059, DOI 10.1016/S0092-8674(00)00209-9; MCKENNEY DW, 1995, J BIOL CHEM, V270, P24949, DOI 10.1074/jbc.270.42.24949; Mustelin T, 2003, IMMUNOL REV, V191, P139, DOI 10.1034/j.1600-065X.2003.00014.x; MUSTELIN T, 1995, EUR J IMMUNOL, V25, P942, DOI 10.1002/eji.1830250413; Mustelin T, 2003, BIOCHEM J, V371, P15, DOI 10.1042/BJ20021637; Ng DHW, 1997, BIOCHEM J, V327, P867; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110; Seavitt JR, 1999, MOL CELL BIOL, V19, P4200; Shenoi H, 1999, J IMMUNOL, V162, P7120; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Veillette A, 1999, J BIOL CHEM, V274, P14392, DOI 10.1074/jbc.274.20.14392; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; Wang Y, 2000, J IMMUNOL, V164, P2557, DOI 10.4049/jimmunol.164.5.2557; Weil R, 1996, CURR TOP MICROBIOL, V205, P63; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205	54	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14318	14324		10.1074/jbc.M413265200	http://dx.doi.org/10.1074/jbc.M413265200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15687496	hybrid			2022-12-25	WOS:000228095500136
J	Yang, WC; Bancroft, L; Augenlicht, LH				Yang, WC; Bancroft, L; Augenlicht, LH			Methylation in the p21(WAF1/cip1) promoter of Apc(+/-), p21(+/-) mice and lack of response to sulindac	ONCOGENE			English	Article						Apc; p21(WAF1/cip1); methylation	FAMILIAL ADENOMATOUS POLYPOSIS; HIGH-RISK DIET; DNA METHYLATION; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; TARGETED INACTIVATION; CELL-PROLIFERATION; GENE-EXPRESSION; 5-AZA-2'-DEOXYCYTIDINE; DECITABINE	p21(WAF1/cip1) plays a critical role in regulating intestinal cell proliferation, maturation and tumorigenesis. Our previous work demonstrated that inactivation of a single p21 allele in Apc1638(+/-) mice was sufficient to accelerate Apc-initiated tumor formation, and that inactivation of only one p21 allele was also sufficient to abrogate duodenal tumor inhibition by sulindac, a nonsteroidal anti-inflammatory drug. To dissect the role of p21 in sulindac inhibition of intestinal tumor development in Apc1638(+/-) mice, we quantified p21 expression from Apc(+/-), p21(+/+), (+/-) or (-/-) mice fed sulindac. In Apc(+/-), p21 wild-type mice fed the sulindac supplemental diet, both p21 mRNA and protein were significantly increased in the. at mucosa and tumors of the duodenum. However, p21 was not induced by sulindac in the duodenal. at mucosa and tumors of Apc(+/-) mice in which one or both p21 alleles had been inactivated. Further investigation revealed that the cytosine residues in a CpG cluster in the promoter region of the mouse p21 gene displayed hypermethylation in the Apc(+/-), p21(+/-) mice. This suggested that although the p21(+/-) mice retained a wild-type allele, this allele was functionally modulated by hypermethylation, and that the inability of sulindac to inhibit tumor formation in Apc(+/-), p21(+/-) mice is likely due to the inability to induce expression of the wild-type, but differentially methylated, p21 allele.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Yang, WC (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	wyang@montefiore.org	Yang, Wancai/G-3750-2010; Yang, Wancai/O-7655-2019	Yang, Wancai/0000-0001-7437-9197	NCI NIH HHS [CA100926, CA96605, CA87559] Funding Source: Medline; PHS HHS [P01 13330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA100926, R01CA096605, R01CA087559] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Boolbol SK, 1996, CANCER RES, V56, P2556; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Davis CD, 2003, J NUTR, V133, P2907, DOI 10.1093/jn/133.9.2907; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Esteller M, 2002, SCIENCE, V297, P1807; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Goldberg Y, 1996, ONCOGENE, V12, P893; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lavelle D, 2003, LEUKEMIA RES, V27, P999, DOI 10.1016/S0145-2126(03)00068-7; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; NUGENT KP, 1993, BRIT J SURG, V80, P1618, DOI 10.1002/bjs.1800801244; Pohlmann P, 2002, AM J CLIN ONCOL-CANC, V25, P496, DOI 10.1097/00000421-200210000-00015; Polyak K, 1996, AM J PATHOL, V149, P381; Pretlow TP, 2003, AM J PATHOL, V163, P1757, DOI 10.1016/S0002-9440(10)63535-3; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Shiff SJ, 1997, GASTROENTEROLOGY, V113, P1992, DOI 10.1016/S0016-5085(97)99999-6; Soh JW, 2003, PROG EXP TUMOR RES, V37, P261; Subbaramaiah K, 1997, P SOC EXP BIOL MED, V216, P201; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; Xian J, 2004, CANCER RES, V64, P6432, DOI 10.1158/0008-5472.CAN-04-2561; Yang WC, 2003, CANCER RES, V63, P4990; Yang WC, 2001, CANCER RES, V61, P6297; Yang WC, 2001, CANCER RES, V61, P565; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200	37	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 17	2005	24	12					2104	2109		10.1038/sj.onc.1208444	http://dx.doi.org/10.1038/sj.onc.1208444			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688007				2022-12-25	WOS:000227681900015
J	Bianchi, P; Pimentel, DR; Murphy, MP; Colucci, WS; Parini, A				Bianchi, P; Pimentel, DR; Murphy, MP; Colucci, WS; Parini, A			A new hypertrophic mechanism of serotonin in cardiac myocytes: receptor-independent ROS generation	FASEB JOURNAL			English	Article						monoamine oxidases; hypertrophy; oxidative stress; heart; MAPK	RAT VENTRICULAR MYOCYTES; MONOAMINE-OXIDASE-A; ACTIVATED PROTEIN-KINASE; RENAL EPITHELIAL-CELLS; HEART-FAILURE; OXIDATIVE STRESS; STIMULATED HYPERTROPHY; ANGIOTENSIN-II; NADPH OXIDASE; INCREASES	Reactive oxygen species (ROS) play a critical role in cardiac hypertrophy. We have recently shown that the serotonin-degrading enzyme monoamine oxidase A (MAO A) is an important source of hydrogen peroxide in rat heart. In the present study, we investigated the potential role of hydrogen peroxide generated by MAO A in cardiomyocyte hypertrophy by serotonin. Serotonin (5 mu M, 48 h) induced hypertrophy in cultured adult rat ventricular myocytes, as reflected by increased (3)H-leucine incorporation (+ 43%, P< 0.001) and total protein content (+ 22%, P< 0.001). Serotonin also increased intracellular hydrogen peroxide and oxidative stress production, measured respectively by DCF fluorescence intensity and GSH/GSSG ratio, and promoted ERK1/2 phosphorylation ( P< 0.001). Serotonin effects were only partially inhibited by the 5-HT(2B) receptor antagonist SB 206553. In contrast, they were extensively (> 80%) prevented by the amine uptake inhibitor imipramine, the MAO inhibitor pargyline and the MEK inhibitor PD 98059. Cardiomyocyte hypertrophy and ERK activation were also inhibited by decreasing intracellular ROS by adenoviral overexpression of catalase or cardiomyocytes treatment with the iron chelator deferoxamine. These data suggest that part of cardiac hypertrophic effect of serotonin requires hydrogen peroxide production by MAO A and ERK1/2 activation. This newly recognized, receptor-independent mechanism of serotonin may contribute to myocardial remodeling and failure.	CHU Rangueil, Inst Louis Bugnard, INSERM, U388, F-31059 Toulouse, France; Boston Univ, Med Ctr, Cardiovasc Med Sect, Boston, MA USA; MRC, Dunn Human Nutr Unit, Cambridge, England	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Boston University; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Parini, A (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U388, Bat L3,TSA 50032, F-31059 Toulouse, France.	parini@toulouse.inserm.fr	Murphy, Michael P/C-2120-2009	Murphy, Michael P/0000-0003-1115-9618; Colucci, Wilson/0000-0002-0576-9420; Parini, Angelo/0000-0002-9848-8838; Pimentel, David/0000-0002-0537-7195	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061639] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20612, HL61639] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amin JK, 2001, J MOL CELL CARDIOL, V33, P131, DOI 10.1006/jmcc.2000.1285; Bianchi P, 2003, J AM SOC NEPHROL, V14, P855, DOI 10.1097/01.ASN.0000058909.00567.5C; CALDERONE A, 1995, CIRCULATION, V92, P2385, DOI 10.1161/01.CIR.92.9.2385; Calderone A, 1998, J CLIN INVEST, V101, P812, DOI 10.1172/JCI119883; Cohen G, 1999, J NEUROCHEM, V73, P2310, DOI 10.1046/j.1471-4159.1999.0732310.x; Dhalla AK, 1996, J AM COLL CARDIOL, V28, P506, DOI 10.1016/0735-1097(96)00140-4; Ekelund UEG, 1999, CIRC RES, V85, P437, DOI 10.1161/01.RES.85.5.437; ELLINGSEN O, 1993, AM J PHYSIOL, V265, pH747, DOI 10.1152/ajpheart.1993.265.2.H747; Fu LW, 2002, J PHYSIOL-LONDON, V544, P897, DOI 10.1113/jphysiol.2002.023374; Greene EL, 2000, AM J PHYSIOL-RENAL, V278, pF650, DOI 10.1152/ajprenal.2000.278.4.F650; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GUFFROY C, 1984, LIFE SCI, V34, P535, DOI 10.1016/0024-3205(84)90486-7; He XS, 1996, GENE, V175, P121, DOI 10.1016/0378-1119(96)00136-9; Hill MF, 1996, AM J PATHOL, V148, P291; Holschneider DP, 2002, AM J PHYSIOL-HEART C, V282, pH1751, DOI 10.1152/ajpheart.00600.2001; Ide T, 1999, CIRC RES, V85, P357, DOI 10.1161/01.RES.85.4.357; Lee SL, 2001, AM J PHYSIOL-LUNG C, V281, pL646, DOI 10.1152/ajplung.2001.281.3.L646; Lee SL, 1999, AM J PHYSIOL-LUNG C, V277, pL282, DOI 10.1152/ajplung.1999.277.2.L282; Li JM, 2002, HYPERTENSION, V40, P477, DOI 10.1161/01.HYP.0000032031.30374.32; Mallat Z, 1998, CIRCULATION, V97, P1536, DOI 10.1161/01.CIR.97.16.1536; Marcos E, 2003, AM J RESP CRIT CARE, V168, P487, DOI 10.1164/rccm.200210-1212OC; Maurel A, 2003, AM J PHYSIOL-HEART C, V284, pH1460, DOI 10.1152/ajpheart.00700.2002; Metais C, 1999, CIRCULATION, V100, P328; Nakamura K, 1998, CIRCULATION, V98, P794, DOI 10.1161/01.CIR.98.8.794; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P9508, DOI 10.1073/pnas.97.17.9508; Nebigil CG, 2003, CIRCULATION, V107, P3223, DOI 10.1161/01.CIR.0000074224.57016.01; Nebigil CG, 2003, FASEB J, V17, P1373, DOI 10.1096/fj.02-1122fje; Pimentel DR, 2001, CIRC RES, V89, P453, DOI 10.1161/hh1701.096615; Raasch W, 2002, J PHARMACOL EXP THER, V300, P428, DOI 10.1124/jpet.300.2.428; Sawyer DB, 2002, J MOL CELL CARDIOL, V34, P379, DOI 10.1006/jmcc.2002.1526; Sorescu Dan, 2002, Congest Heart Fail, V8, P132, DOI 10.1111/j.1527-5299.2002.00717.x; Vindis C, 2001, KIDNEY INT, V59, P76, DOI 10.1046/j.1523-1755.2001.00468.x; Xiao L, 2001, J MOL CELL CARDIOL, V33, P779, DOI 10.1006/jmcc.2001.1348; YOUDIM MBH, 1991, BIOCHEM PHARMACOL, V41, P155, DOI 10.1016/0006-2952(91)90471-G	34	81	87	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					641	+		10.1096/fj.04-2518fje	http://dx.doi.org/10.1096/fj.04-2518fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15703274				2022-12-25	WOS:000227591900016
J	Bogan, MJ; Agnes, GR; Pio, F; Cornell, RB				Bogan, MJ; Agnes, GR; Pio, F; Cornell, RB			Interdomain and membrane interactions of CTP : phosphocholine cytidylyltransferase revealed via limited proteolysis and mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CTP; BINDING DOMAIN; IDENTIFICATION; ENZYME; ALPHA; PEPTIDES; HELIX	CTP:phosphocholine cytidylyltransferase (CCT) is a multi-domain enzyme that regulates phosphatidylcholine synthesis. It converts to an active form upon binding cell membranes, and interdomain dissociations have been hypothesized to accompany this process. To identify these interdomain and membrane interactions, the tertiary structures of three forms of CCT alpha were probed by monitoring accessibility to proteases. Time-limited digestion with chymotrypsin or arginine C of soluble CCT alpha (CCTsol), phospholipid vesicle-bound CCT (CCTmem), and a soluble constitutively active CCT truncated at amino acid 236 generated complex mixtures of peptides that were resolved and identified by gel electrophoresis/immunoblotting and by matrix-assisted laser desorption/ionization-mass spectrometry, with or without coupling to capillary liquid chromatography. Identification of cleavage sites enabled assembly of peptide bond accessibility maps for each CCT form. Our results reveal a similar to 80-residue core within the catalytic domain (domain C) as the most inaccessible region in all three forms and the C- terminal phosphorylation domain as the most accessible. Membrane binding has little effect on the protease accessibility of these domains. To map the protease sites onto the catalytic domain, its three-dimensional structure was modeled from the atomic coordinates of glycerolphosphate cytidylyltransferase (Protein Data Bank code 1COZ). The protease inaccessibility of most sites in domain C could be explained by burial or location within secondary structural elements. The accessibility of the N-terminal domain (domain N) was enhanced upon membrane binding. Residues Phe(234)-Leu(303) were inaccessible in CCTmem, suggesting burial in the membrane. Surprisingly, residues Leu(274)-Leu(303) of this domain were also inaccessible in CCTsol. We propose that this region is buried by interdomain contacts with domain N in CCTsol. Membrane binding and burial of domain M in the lipid bilayer may disrupt this interaction, leading to increased exposure of sites in domain N.	Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada	Simon Fraser University; Simon Fraser University	Cornell, RB (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.	cornell@sfu.ca	Bogan, Mike/I-6962-2012	Bogan, Mike/0000-0001-9318-3333; pio, frederic/0000-0003-2050-847X				Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; Arnold RS, 1997, BIOCHEMISTRY-US, V36, P6149, DOI 10.1021/bi970023z; Bujnicki JM, 2001, PROTEIN SCI, V10, P352, DOI 10.1110/ps.40501; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; CORNELL RB, 1995, BIOCHEM J, V310, P699, DOI 10.1042/bj3100699; Cornell RB, 1998, BIOCHEM SOC T, V26, P539, DOI 10.1042/bst0260539; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; CRAIG L, 1994, J BIOL CHEM, V269, P3311; Davies SMA, 2001, BIOCHEMISTRY-US, V40, P10522, DOI 10.1021/bi010904c; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; Friesen JA, 1999, J BIOL CHEM, V274, P13384, DOI 10.1074/jbc.274.19.13384; Helmink BA, 2003, BIOCHEMISTRY-US, V42, P5043, DOI 10.1021/bi027431+; Johnson JE, 1997, BBA-BIOMEMBRANES, V1324, P273, DOI 10.1016/S0005-2736(96)00233-7; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; Johnson JE, 2003, J BIOL CHEM, V278, P514, DOI 10.1074/jbc.M206072200; Johnson JE, 1998, BIOCHEMISTRY-US, V37, P9509, DOI 10.1021/bi980340l; Karim M, 2003, BBA-MOL CELL BIOL L, V1633, P1, DOI 10.1016/S1388-1981(03)00067-2; KEIL B, 1992, SPECIFICIYT PROTEOLY; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Knochenmuss R, 2003, CHEM REV, V103, P441, DOI 10.1021/cr0103773; Kratzer R, 1998, ELECTROPHORESIS, V19, P1910, DOI 10.1002/elps.1150191109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laskowski RA, 2001, NUCLEIC ACIDS RES, V29, P221, DOI 10.1093/nar/29.1.221; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Lykidis A, 2001, BIOCHEMISTRY-US, V40, P494, DOI 10.1021/bi002140r; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; McMaster CR, 2001, BIOCHEM CELL BIOL, V79, P681, DOI 10.1139/bcb-79-6-681; Pattridge KA, 2003, J BIOL CHEM, V278, P51863, DOI 10.1074/jbc.M306174200; POEHLING HM, 1981, ELECTROPHORESIS, V2, P141, DOI 10.1002/elps.1150020304; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; Taneva S, 2003, BIOCHEMISTRY-US, V42, P11768, DOI 10.1021/bi035234k; van Meer G, 2004, CURR OPIN CELL BIOL, V16, P373, DOI 10.1016/j.ceb.2004.06.004; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; Wall DB, 2002, ELECTROPHORESIS, V23, P3193, DOI 10.1002/1522-2683(200209)23:18<3193::AID-ELPS3193>3.0.CO;2-Y; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; Weber CH, 1999, STRUCTURE, V7, P1113, DOI 10.1016/S0969-2126(99)80178-6; Xie MT, 2004, J BIOL CHEM, V279, P28817, DOI 10.1074/jbc.M403311200	38	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19613	19624		10.1074/jbc.M414028200	http://dx.doi.org/10.1074/jbc.M414028200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15713672	hybrid			2022-12-25	WOS:000229113700025
J	Crouch, E; Tu, YZ; Briner, D; McDonald, B; Smith, K; Holmskov, U; Hartshorn, K				Crouch, E; Tu, YZ; Briner, D; McDonald, B; Smith, K; Holmskov, U; Hartshorn, K			Ligand specificity of human surfactant protein D - Expression of a mutant trimeric collectin that shows enhanced interactions with influenza a virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAIN; C-TYPE LECTIN; MANNOSE-BINDING PROTEINS; PULMONARY HOST-DEFENSE; HELICAL COILED-COIL; INNATE IMMUNITY; SERUM LECTIN; LUNG; CL-43; CONGLUTININ	Surfactant protein D is a pattern recognition molecule that plays diverse roles in immune regulation and antimicrobial host defense. Its interactions with known ligands are calcium-dependent and involve binding to the trimeric, C-type carbohydrate recognition domain. Surfactant protein D preferentially binds to glucose and related sugars. However, CL-43, a bovine serum lectin, which evolved through duplication of the surfactant protein D gene in ruminants, prefers mannose and mannose-rich polysaccharides. Surfactant protein D is characterized by two relatively conserved motifs at the binding face, along the edges of the shallow carbohydrate-binding groove. For CL-43, sequence alignments demonstrate a basic insertion, Arg-Ala-Lys (RAK), immediately N-terminal to the first motif. We hypothesized that this insertion contributes to the differences in saccharide selectivity and host defense function and compared the activities of recombinant trimeric neck + carbohydrate recognition domains of human surfactant protein D (NCRD) with CL-43 (RCL-43-NCRD) and selected NCRD mutants. Insertion of the CL-43 RAK sequence or a control Ala-Ala-Ala sequence ( AAA) into the corresponding position in NCRD increased the efficiency of binding to mannan and changed the inhibitory potencies of competing saccharides to more closely resemble those of CL-43. In addition, RAK resembled CL-43 in its greater capacity to inhibit the infectivity of influenza A virus and to increase uptake of influenza by neutrophils.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Univ So Denmark, Inst Med Biol, Odense, Denmark; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Washington University (WUSTL); University of Southern Denmark; Boston University	Crouch, E (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	crouch@path.wustl.edu	Holmskov, Uffe/AAA-3056-2022	Holmskov, Uffe/0000-0002-2391-9445; Hartshorn, Kevan/0000-0002-7196-7433	NHLBI NIH HHS [HL-44015, HL-69031, HL-29594] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069031, P01HL029594, R01HL044015] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen MJ, 2004, GLYCOBIOLOGY, V14, P693, DOI 10.1093/glycob/cwh088; Allen MJ, 2001, BIOCHEMISTRY-US, V40, P7789, DOI 10.1021/bi002901q; Bouyain S, 2001, GLYCOBIOLOGY, V11, P989, DOI 10.1093/glycob/11.11.989; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; CROUCH E, 1993, AM J PATHOL, V142, P241; Crouch E, 2000, IMMUNOL REV, V173, P52, DOI 10.1034/j.1600-065X.2000.917311.x; Crouch E C, 2000, Respir Res, V1, P93; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; CROUCH EC, 2002, INNATE IMMUNITY; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Epstein J, 1996, CURR OPIN IMMUNOL, V8, P29, DOI 10.1016/S0952-7915(96)80101-4; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; Hansen S, 2002, IMMUNOBIOLOGY, V205, P498, DOI 10.1078/0171-2985-00150; Hartshorn K, 1996, AM J PHYSIOL-LUNG C, V271, pL753, DOI 10.1152/ajplung.1996.271.5.L753; Hartshorn KL, 2000, BIOCHEM J, V351, P449, DOI 10.1042/0264-6021:3510449; Hartshorn KL, 2002, BIOCHEM J, V366, P87, DOI 10.1042/BJ20011868; Hawgood S, 2004, J VIROL, V78, P8565, DOI 10.1128/JVI.78.16.8565-8572.2004; Hawgood S, 2001, ANNU REV PHYSIOL, V63, P495, DOI 10.1146/annurev.physiol.63.1.495; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; Holmskov U, 1996, FEBS LETT, V393, P314, DOI 10.1016/0014-5793(96)00915-5; Holmskov UL, 2000, APMIS, V108, P7; HOPPE HJ, 1994, STRUCTURE, V2, P1129, DOI 10.1016/S0969-2126(94)00115-4; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; Kishore U, 2001, Results Probl Cell Differ, V33, P225; LeVine AM, 2001, MICROBES INFECT, V3, P161, DOI 10.1016/S1286-4579(00)01363-0; LeVine AM, 2001, J IMMUNOL, V167, P5868, DOI 10.4049/jimmunol.167.10.5868; LIM BL, 1994, J BIOL CHEM, V269, P11820; LIM BL, 1994, BIOCHEM BIOPH RES CO, V202, P1674, DOI 10.1006/bbrc.1994.2127; LOVELESS RW, 1995, IMMUNOLOGY, V85, P651; LU JH, 1992, BIOCHEM J, V284, P795, DOI 10.1042/bj2840795; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Ng KKS, 2002, J BIOL CHEM, V277, P16088, DOI 10.1074/jbc.M200493200; OGASAWARA Y, 1995, J BIOL CHEM, V270, P14725, DOI 10.1074/jbc.270.24.14725; PERSSON A, 1990, J BIOL CHEM, V265, P5755; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; Sahly H, 2002, J IMMUNOL, V169, P3267, DOI 10.4049/jimmunol.169.6.3267; Shrive AK, 2003, J MOL BIOL, V331, P509, DOI 10.1016/S0022-2836(03)00761-7; van Eijk M, 2003, J IMMUNOL, V171, P1431, DOI 10.4049/jimmunol.171.3.1431; Vuk-Pavlovic Z, 2001, AM J RESP CELL MOL, V24, P475, DOI 10.1165/ajrcmb.24.4.3504; Zhang LQ, 2002, J BIOL CHEM, V277, P22453, DOI 10.1074/jbc.M201632200; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200	43	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17046	17056		10.1074/jbc.M413932200	http://dx.doi.org/10.1074/jbc.M413932200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15711012	hybrid			2022-12-25	WOS:000228615500062
J	Lee, KW; Ma, LQ; Yan, XM; Liu, BR; Zhang, XK; Cohen, P				Lee, KW; Ma, LQ; Yan, XM; Liu, BR; Zhang, XK; Cohen, P			Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXR alpha/Nur77	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-3; BREAST-CANCER CELLS; ORPHAN RECEPTOR TR3; PROSTATE-CANCER; RETINOIC ACID; LUNG-CANCER; NUCLEAR EXPORT; NGFI-B; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAY	Insulin-like growth factor-binding protein-3 (IGFBP-3) induces apoptosis by its ability to bind insulin-like growth factors (IGFs) as well as its IGF-independent effects involving binding to other molecules including the retinoid X receptor-alpha (RXR alpha). Here we describe that in response to IGFBP-3, the RXR alpha binding partner nuclear receptor Nur77 rapidly undergoes translocation from the nucleus to the mitochondria, initiating an apoptotic cascade resulting in caspase activation within 6 h. This translocation is a type 1 IGF receptor-signaling independent event as IGFBP-3 induces Nur77 translocation in R-cells. IGFBP-3 and Nur77 are additive in inducing apoptosis. GFP-Nur77 transfection into RXR alpha wildtype and knock-out mouse embryonic fibroblasts and subsequent treatment with IGFBP-3 show that RXR alpha is required for IGFBP-3-induced Nur77 translocation and apoptosis. Addition of IGFBP-3 to 22RV1 cell lysates enhanced the ability of GST-RXR alpha to "pull down" Nur77, and overexpression of IGFBP-3 enhanced the accumulation of mitochondrial RXR alpha. This unique nongenotropic nuclear pathway supports an emerging role for IGFBP-3 as a novel, multicompartmental signaling molecule involved in induction of apoptosis in malignant cells.	Univ Calif Los Angeles, Div Pediat Endocrinol, Mattel Childrens Hosp, David Geffen Sch Med, Los Angeles, CA 90095 USA; Burnham Inst, Ctr Canc, La Jolla, CA 92037 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Sanford Burnham Prebys Medical Discovery Institute	Cohen, P (corresponding author), Univ Calif Los Angeles, Div Pediat Endocrinol, Mattel Childrens Hosp, David Geffen Sch Med, Los Angeles, CA 90095 USA.	hassy@mednet.ucla.edu			NCI NIH HHS [R01CA100938, P50CA92131] Funding Source: Medline; NIA NIH HHS [R01AG20954] Funding Source: Medline; NICHD NIH HHS [2K12HD34610] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD034610] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA092131, R01CA100938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ali O, 2003, HORM METAB RES, V35, P726; Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; Boyle BJ, 2001, J UROLOGY, V165, P1319, DOI 10.1016/S0022-5347(01)69892-6; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Butt AJ, 2002, ENDOCRINOLOGY, V143, P2693, DOI 10.1210/en.143.7.2693; Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; Chang YS, 2004, ONCOGENE, V23, P6569, DOI 10.1038/sj.onc.1207882; Cheung CW, 2004, KIDNEY INT, V65, P1272, DOI 10.1111/j.1523-1755.2004.00535.x; Dawson MI, 2001, CANCER RES, V61, P4723; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Franklin SL, 2003, J CLIN ENDOCR METAB, V88, P900, DOI 10.1210/jc.2002-020472; Granata R, 2004, FASEB J, V18, P1456, DOI 10.1096/fj.04-1618fje; Gucev ZS, 1996, CANCER RES, V56, P1545; Hampel OZ, 1998, J UROLOGY, V159, P2220, DOI 10.1016/S0022-5347(01)63309-3; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HINTZ RL, 1991, J UROLOGY, V146, P1160, DOI 10.1016/S0022-5347(17)38031-X; Holmes WF, 2003, J CELL BIOCHEM, V89, P262, DOI 10.1002/jcb.10505; Hwa V, 1997, ENDOCRINE, V6, P235, DOI 10.1007/BF02820498; Ikezoe T, 2004, BLOOD, V104, P237, DOI 10.1182/blood-2003-07-2203; Ikonen M, 2003, P NATL ACAD SCI USA, V100, P13042, DOI 10.1073/pnas.2135111100; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Kaplan PJ, 1999, CANCER RES, V59, P2203; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kim HS, 2004, CANCER RES, V64, P2229, DOI 10.1158/0008-5472.CAN-03-1675; Kirman I, 2004, SURGERY, V136, P205, DOI 10.1016/j.surg.2004.04.020; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Labelle Y, 1999, ONCOGENE, V18, P3303, DOI 10.1038/sj.onc.1202675; Lee HY, 2004, JNCI-J NATL CANCER I, V96, P1536, DOI 10.1093/jnci/djh286; Lee JM, 2002, P NATL ACAD SCI USA, V99, P11878, DOI 10.1073/pnas.182552499; Lee KW, 2004, J BIOL CHEM, V279, P469, DOI 10.1074/jbc.M307316200; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Lin XF, 2004, J CELL SCI, V117, P5609, DOI 10.1242/jcs.01474; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; London SJ, 2002, JNCI-J NATL CANCER I, V94, P749, DOI 10.1093/jnci/94.10.749; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Mu XM, 2003, J BIOL CHEM, V278, P42840, DOI 10.1074/jbc.M305594200; Nickerson T, 1998, ENDOCRINOLOGY, V139, P807, DOI 10.1210/en.139.2.807; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Perks CM, 2002, BIOCHEM BIOPH RES CO, V294, P988, DOI 10.1016/S0006-291X(02)00569-7; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; QINGNAN Y, 2003, AM ASS CANC RES WASH; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Rajah R, 2002, CELL GROWTH DIFFER, V13, P163; Rajpal A, 2003, EMBO J, V22, P6526, DOI 10.1093/emboj/cdg620; Ramachandran S, 2005, ONCOGENE, V24, P188, DOI 10.1038/sj.onc.1207906; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Schedlich LJ, 2004, BIOCHEM BIOPH RES CO, V314, P83, DOI 10.1016/j.bbrc.2003.12.049; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Schwarze SR, 2002, J BIOL CHEM, V277, P14877, DOI 10.1074/jbc.M200373200; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; Wilson AJ, 2003, CANCER RES, V63, P5401; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Wu Q, 2002, CARCINOGENESIS, V23, P1583, DOI 10.1093/carcin/23.10.1583; Wu Q, 1997, MOL CELL BIOL, V17, P6598, DOI 10.1128/MCB.17.11.6598; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151; Zhang YX, 2002, BLOOD, V100, P2917, DOI 10.1182/blood.V100.8.2917	68	130	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16942	16948		10.1074/jbc.M412757200	http://dx.doi.org/10.1074/jbc.M412757200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731112	hybrid			2022-12-25	WOS:000228615500049
J	Pederson, BA; Cope, CR; Schroeder, JM; Smith, MW; Irimia, JM; Thurberg, BL; DePaoli-Roach, AA; Roach, PJ				Pederson, BA; Cope, CR; Schroeder, JM; Smith, MW; Irimia, JM; Thurberg, BL; DePaoli-Roach, AA; Roach, PJ			Exercise capacity of mice genetically lacking muscle glycogen synthase - In mice, muscle glycogen is not essential for exercise	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CARBOHYDRATE; DIET; INTERLEUKIN-6; HOMEOSTASIS; LIVER; HEART	The glucose storage polymer glycogen is generally considered to be an important source of energy for skeletal muscle contraction and a factor in exercise endurance. A genetically modified mouse model lacking muscle glycogen was used to examine whether the absence of the polysaccharide affects the ability of mice to run on a treadmill. The MGSKO mouse has the GYS1 gene, encoding the muscle isoform of glycogen synthase, disrupted so that skeletal muscle totally lacks glycogen. The morphology of the soleus and quadriceps muscles from MGSKO mice appeared normal. MGSKO-null mice, along with wild type littermates, were exercised to exhaustion. There were no significant differences in the work performed by MGSKO mice as compared with their wild type littermates. The amount of liver glycogen consumed during exercise was similar for MGSKO and wild type animals. Fasting reduced exercise endurance, and after overnight fasting, there was a trend to reduced exercise endurance for the MGSKO mice. These studies provide genetic evidence that in mice muscle glycogen is not essential for strenuous exercise and has relatively little effect on endurance.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Ctr Diabet Res, Indianapolis, IN 46202 USA; Genzyme Corp, Dept Pathol, Framingham, MA 01701 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Sanofi-Aventis; Genzyme Corporation	Roach, PJ (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.	proach@iupui.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027221, R37DK027221, U24DK059637] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aschenbach WG, 2001, J BIOL CHEM, V276, P39959, DOI 10.1074/jbc.M105518200; BALDWIN KM, 1973, AM J PHYSIOL, V225, P1045, DOI 10.1152/ajplegacy.1973.225.5.1045; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BERGSTROM J, 1967, ACTA PHYSIOL SCAND, V71, P140, DOI 10.1111/j.1748-1716.1967.tb03720.x; BERGSTROM J, 1966, NATURE, V210, P309, DOI 10.1038/210309a0; Febbraio MA, 2004, DIABETES, V53, P1643, DOI 10.2337/diabetes.53.7.1643; Gleeson M, 2000, IMMUNOL CELL BIOL, V78, P554, DOI 10.1046/j.1440-1711.2000.00953.x; Hawley JA, 1997, SPORTS MED, V24, P73, DOI 10.2165/00007256-199724020-00001; HERMANSE.L, 1967, ACTA PHYSIOL SCAND, V71, P129, DOI 10.1111/j.1748-1716.1967.tb03719.x; Holloszy JO, 1998, FRONT BIOSCI, V3, pD1011, DOI DOI 10.2741/A342; Hribal ML, 2002, AM J PHYSIOL-ENDOC M, V282, pE977, DOI 10.1152/ajpendo.00561.2001; Ivy JL, 1999, CLIN SPORT MED, V18, P469, DOI 10.1016/S0278-5919(05)70162-9; KARLSSON J, 1971, J APPL PHYSIOL, V31, P203, DOI 10.1152/jappl.1971.31.2.203; Kasuga M, 2003, J CLIN INVEST, V111, P1282, DOI 10.1172/JCI200318526; Lightfoot JT, 2004, PHYSIOL GENOMICS, V19, P270, DOI 10.1152/physiolgenomics.00125.2004; Mason SD, 2004, PLOS BIOL, V2, P1540, DOI 10.1371/journal.pbio.0020288; MCARDLE B, 1951, CLIN SCI, V10, P12; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; Orho M, 1998, J CLIN INVEST, V102, P507, DOI 10.1172/JCI2890; Pedersen BK, 2003, J MUSCLE RES CELL M, V24, P113, DOI 10.1023/A:1026070911202; Pederson BA, 2004, MOL CELL BIOL, V24, P7179, DOI 10.1128/MCB.24.16.7179-7187.2004; REITMAN J, 1973, P SOC EXP BIOL MED, V142, P628; ROACH PJ, 2001, ENDOCRINE PANCREAS R; SHERMAN WM, 1981, INT J SPORTS MED, V2, P114, DOI 10.1055/s-2008-1034594; Shulman RG, 2001, P NATL ACAD SCI USA, V98, P457, DOI 10.1073/pnas.98.2.457; Steensberg A, 2001, J PHYSIOL-LONDON, V537, P633, DOI 10.1111/j.1469-7793.2001.00633.x; Suzuki Y, 2001, MOL CELL BIOL, V21, P2683, DOI 10.1128/MCB.21.8.2683-2694.2001; Tamashiro KLK, 2002, NAT MED, V8, P262, DOI 10.1038/nm0302-262; TERJUNG RL, 1972, AM J PHYSIOL, V223, P549, DOI 10.1152/ajplegacy.1972.223.3.549; Wallberg-Henriksson H, 2001, MOL MEMBR BIOL, V18, P205; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294	31	84	85	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17260	17265		10.1074/jbc.M410448200	http://dx.doi.org/10.1074/jbc.M410448200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15711014	hybrid			2022-12-25	WOS:000228615500089
J	Rishal, I; Porozov, Y; Yakubovich, D; Varon, D; Dascal, N				Rishal, I; Porozov, Y; Yakubovich, D; Varon, D; Dascal, N			G beta gamma-dependent and G beta gamma-independent basal activity of G protein-activated K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; POTASSIUM CHANNEL; XENOPUS-OOCYTES; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; SUBUNITS; RECEPTOR; GIRK1; IDENTIFICATION; BINDING; MODULATION	Cardiac and neuronal G protein-activated K+ channels (GIRK; Kir3) open following the binding of G beta gamma subunits, released from G(i/o) proteins activated by neurotransmitters. GIRKs also possess basal activity contributing to the resting potential in neurons. It appears to depend largely on free G beta gamma, but a G beta gamma-independent component has also been envisaged. We investigated G beta gamma dependence of the basal GIRK activity (A(GIRK,basal)) quantitatively, by titrated expression of G beta gamma scavengers, in Xenopus oocytes expressing GIRK1/2 channels and muscarinic m2 receptors. The widely used G beta gamma scavenger, myristoylated C terminus of beta-adrenergic kinase (m-c beta ARK), reduced A(GIRK,basal) by 70 - 80% and eliminated the acetylcholine-evoked current (I-ACh). However, we found that m-c beta ARK directly binds to GIRK, complicating the interpretation of physiological data. Among several newly constructed G beta gamma scavengers, phosducin with an added myristoylation signal (m-phosducin) was most efficient in reducing GIRK currents. m-phosducin relocated to the membrane fraction and did not bind GIRK. Titrated expression of m-phosducin caused a reduction of A(GIRK, basal) by up to 90%. Expression of GIRK was accompanied by an increase in the level of G beta gamma and G alpha in the plasma membrane, supporting the existence of preformed complexes of GIRK with G protein subunits. Increased expression of G beta gamma and its constitutive association with GIRK may underlie the excessively high AGIRK, basal observed at high expression levels of GIRK. Only 10 - 15% of A(GIRK, basal) persisted upon expression of both m-phosducin and c beta ARK. These results demonstrate that a major part of I-basal is G beta gamma-dependent at all levels of channel expression, and only a small fraction (< 10%) may be G beta gamma-independent.	Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Dascal, N (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.	dascaln@post.tau.ac.il	Porozov, Yuri/AAD-5285-2019; Porozov, Yuri/N-9088-2016; Dascal, Nathan/O-3915-2015; RISHAL, IDA/K-1691-2012	Porozov, Yuri/0000-0002-5450-3135; Dascal, Nathan/0000-0002-5397-4146; 	NIGMS NIH HHS [R01 GM68493] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068493] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bauer PH, 1998, J BIOL CHEM, V273, P9465, DOI 10.1074/jbc.273.16.9465; Blackmer T, 2001, SCIENCE, V292, P293, DOI 10.1126/science.1058803; Blanchet C, 2002, P NATL ACAD SCI USA, V99, P4674, DOI 10.1073/pnas.072075399; Carman CV, 2000, J BIOL CHEM, V275, P10443, DOI 10.1074/jbc.275.14.10443; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; DASCAL N, 1995, P NATL ACAD SCI USA, V92, P6758, DOI 10.1073/pnas.92.15.6758; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; Finley M, 2004, J PHYSIOL-LONDON, V555, P643, DOI 10.1113/jphysiol.2003.056101; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; He C, 2002, J BIOL CHEM, V277, P6088, DOI 10.1074/jbc.M104851200; HILGEMANN DW, 2001, SCI STKE; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x; Ho IHM, 1999, J BIOL CHEM, V274, P8639, DOI 10.1074/jbc.274.13.8639; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; ITO H, 1994, J PHYSIOL-LONDON, V476, P55; Ivanina T, 2004, J BIOL CHEM, V279, P17260, DOI 10.1074/jbc.M313425200; Ivanina T, 2003, J BIOL CHEM, V278, P29174, DOI 10.1074/jbc.M304518200; Jing J, 1999, EMBO J, V18, P1245, DOI 10.1093/emboj/18.5.1245; Kenakin T, 2004, MOL PHARMACOL, V65, P2, DOI 10.1124/mol.65.1.2; KIM CM, 1993, J BIOL CHEM, V268, P15412; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; Kurachi Y, 2004, J PHYSIOL-LONDON, V554, P285, DOI 10.1113/jphysiol.2003.048439; Leaney JL, 2001, J PHYSIOL-LONDON, V534, P367, DOI 10.1111/j.1469-7793.2001.00367.x; Lei WB, 2001, J BIOL CHEM, V276, P16720, DOI 10.1074/jbc.M100207200; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Logothetis DE, 1999, J PHYSIOL-LONDON, V520, P630, DOI 10.1111/j.1469-7793.1999.00630.x; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; Meyer T, 2001, J BIOL CHEM, V276, P5650, DOI 10.1074/jbc.M009179200; MIRSHAHI T, 2003, SCI STKE; Nikolov EN, 2004, J BIOL CHEM, V279, P23630, DOI 10.1074/jbc.M312861200; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; Petit-Jacques J, 1999, J GEN PHYSIOL, V114, P673, DOI 10.1085/jgp.114.5.673; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Prybylowski K, 2004, J BIOL CHEM, V279, P9673, DOI 10.1074/jbc.R300029200; Rebois RV, 2003, RECEPTOR CHANNEL, V9, P169, DOI 10.1080/10606820308243; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Rishal I, 2003, J BIOL CHEM, V278, P3840, DOI 10.1074/jbc.C200605200; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; Ruiz-Velasco V, 1998, J PHYSIOL-LONDON, V513, P761, DOI 10.1111/j.1469-7793.1998.761ba.x; Sarvazyan NA, 1998, J BIOL CHEM, V273, P7934, DOI 10.1074/jbc.273.14.7934; Savage JR, 2000, J BIOL CHEM, V275, P30399, DOI 10.1074/jbc.M005120200; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; Schulz R, 2001, PHARMACOL RES, V43, P1, DOI 10.1006/phrs.2000.0757; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Singer-Lahat D, 2000, PFLUG ARCH EUR J PHY, V440, P627, DOI 10.1007/s004240000341; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; Stanfield PR, 2002, REV PHYSIOL BIOCH P, V145, P47, DOI 10.1007/BFb0116431; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; Takigawa T, 2002, J PHYSIOL-LONDON, V539, P67, DOI 10.1113/jphysiol.2001.012883; Torrecilla M, 2002, J NEUROSCI, V22, P4328, DOI 10.1523/JNEUROSCI.22-11-04328.2002; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Vorobiov D, 1998, PFLUG ARCH EUR J PHY, V436, P56, DOI 10.1007/s004240050604; Vorobiov D, 2000, J BIOL CHEM, V275, P4166, DOI 10.1074/jbc.275.6.4166; Yakubovich D, 2005, J MOL NEUROSCI, V25, P7, DOI 10.1385/JMN:25:1:007; Yevenes GE, 2003, NAT NEUROSCI, V6, P819, DOI 10.1038/nn1095; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; Zhang QL, 2002, J PHYSIOL-LONDON, V545, P355, DOI 10.1113/jphysiol.2002.032151	62	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16685	16694		10.1074/jbc.M412196200	http://dx.doi.org/10.1074/jbc.M412196200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728579	hybrid			2022-12-25	WOS:000228615500020
J	Baghdoyan, S; Lamartine, J; Castel, D; Pitaval, A; Roupioz, Y; Franco, N; Duarte, M; Martin, MT; Gidrol, X				Baghdoyan, S; Lamartine, J; Castel, D; Pitaval, A; Roupioz, Y; Franco, N; Duarte, M; Martin, MT; Gidrol, X			Id2 reverses cell cycle arrest induced by gamma-irradiation in human HaCaT keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; MAMMALIAN-CELLS; RNA INTERFERENCE; C-MYC; GENES; DIFFERENTIATION; INDUCTION; GROWTH; TUMORIGENESIS; TRANSCRIPTION	Id2 plays a key role in epithelial cells, regulating differentiation, the cell cycle, and proliferation. Because human skin constantly renews itself and is the first target of irradiation, it is of primary interest to evaluate whether such a gene may be regulated in keratinocytes exposed to ionizing radiation. We show here that Id2 is induced in response to gamma-irradiation and have investigated the consequence of this regulation on cell fate. Using RNA interference, we observed that Id2 extinction significantly reduces cell growth in human keratinocytes through the control of the G(1)-S transition of the cell cycle. We have investigated whether the impact of Id2 on the cell cycle may have a physiological role on the cell's ability to cope with radiative stress. Indeed, when Id2 is down-regulated through interfering RNA, cells are more sensitive to irradiation. Conversely, when Id2 is overexpressed, this somehow protects the cell. We propose that Id2 favors reentering the cell cycle after radiation-induced cell cycle arrest to permit the recovery of keratinocytes exposed to ionizing radiation.	Commissariat Energie Atom Evry, Serv Genom Fonct, F-91057 Evry, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Gidrol, X (corresponding author), Commissariat Energie Atom Evry, Serv Genom Fonct, 2 Rue Gaston Cremieux,CP22, F-91057 Evry, France.	xavier.gidrol@cea.fr	Castel, David/D-5353-2018; Martin, Michele T/C-5554-2008	Castel, David/0000-0003-0247-080X; Martin, Michele T/0000-0003-0530-6466; PITAVAL, Amandine/0000-0002-0279-2553; Gidrol, Xavier/0000-0002-4233-3749; Baghdoyan, Sandrine/0000-0002-5904-7394; Lamartine, Jerome/0000-0003-2322-1618				BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Flatt PM, 1998, CELL GROWTH DIFFER, V9, P535; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; HARA E, 1994, J BIOL CHEM, V269, P2139; Karlsson A, 2003, P NATL ACAD SCI USA, V100, P9974, DOI 10.1073/pnas.1732638100; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Lemaitre G, 2004, J CELL BIOCHEM, V93, P1048, DOI 10.1002/jcb.20212; Liu K, 1996, INT J RADIAT BIOL, V69, P763, DOI 10.1080/095530096145508; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; Norton JD, 2000, J CELL SCI, V113, P3897; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PRASAD AV, 1995, RADIAT RES, V143, P263, DOI 10.2307/3579212; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SHUNG B, 1994, MUTAT RES, V307, P43, DOI 10.1016/0027-5107(94)90276-3; Song HJ, 1998, INT J RADIAT ONCOL, V41, P897, DOI 10.1016/S0360-3016(98)00143-6; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	24	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15836	15841		10.1074/jbc.M414216200	http://dx.doi.org/10.1074/jbc.M414216200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15691830	hybrid			2022-12-25	WOS:000228444800047
J	Efendiev, R; Chen, ZP; Krmar, RT; Uhles, S; Katz, AI; Pedemonte, CH; Bertorello, AM				Efendiev, R; Chen, ZP; Krmar, RT; Uhles, S; Katz, AI; Pedemonte, CH; Bertorello, AM			The 14-3-3 protein translates the NA(+),K+-ATPase alpha(1)-subunit phosphorylation signal into binding and activation of phosphoinositide 3-kinase during endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+,K+-ATPASE ALPHA-SUBUNIT; NA+-K+-ATPASE; PROXIMAL TUBULE NA+,K+-ATPASE; PLASMA-MEMBRANE; SARCOPLASMIC-RETICULUM; PKC-BETA; DOPAMINE; CELLS; RECEPTOR; KINASE	Clathrin-dependent endocytosis of Na+, K+-ATPase molecules in response to G protein-coupled receptor signals is triggered by phosphorylation of the alpha-subunit and the binding of phosphoinositide 3-kinase. In this study, we describe a molecular mechanism linking phosphorylation of Na+, K+-ATPase alpha-subunit to binding and activation of phosphoinositide 3-kinase. Co-immunoprecipitation studies, as well as experiments using confocal microscopy, revealed that dopamine favored the association of 14-3-3 protein with the basolateral plasma membrane and its co-localization with the Na+, K+-ATPase alpha-subunit. The functional relevance of this interaction was established in opossum kidney cells expressing a 14-3-3 dominant negative mutant, where dopamine failed to decrease Na+, K+-ATPase activity and to promote its endocytosis. The phosphorylated Ser-18 residue within the alpha-subunit N terminus is critical for 14-3-3 binding. Activation of phosphoinositide 3-kinase by dopamine during Na+, K+-ATPase endocytosis requires the binding of the kinase to a proline-rich domain within the alpha-subunit, and this effect was blocked by the presence of a 14-3-3 dominant negative mutant. Thus, the 14-3-3 protein represents a critical linking mechanism for recruiting phosphoinositide 3-kinase to the site of Na+, K+-ATPase endocytosis.	Karolinska Univ Hosp Solna, King Gustaf V Res Inst, Karolinska Inst,Dept Med, Atherosclerosis Res Unit, S-17176 Stockholm, Sweden; Karolinska Univ Hosp Solna, Karolinska Inst, Dept Mol Med, S-17176 Stockholm, Sweden; Univ Houston, Coll Pharm, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77204 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; University of Houston System; University of Houston; University of Chicago	Bertorello, AM (corresponding author), Karolinska Univ Hosp Solna, King Gustaf V Res Inst, Karolinska Inst,Dept Med, Atherosclerosis Res Unit, M1-01, S-17176 Stockholm, Sweden.	alejandro.bertorello@medks.ki.se		Uhles, Sabine/0000-0002-2836-8726	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062195] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK62195] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Aperia AC, 2000, ANNU REV PHYSIOL, V62, P621, DOI 10.1146/annurev.physiol.62.1.621; BERTORELLO AM, 1992, J CELL SCI, V101, P343; Bertorello AM, 2003, MOL BIOL CELL, V14, P1149, DOI 10.1091/mbc.E02-06-0367; Bertorello AM, 1999, AM J PHYSIOL-LUNG C, V276, pL20, DOI 10.1152/ajplung.1999.276.1.L20; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budu CE, 2002, BRIT J PHARMACOL, V137, P1380, DOI 10.1038/sj.bjp.0704962; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Chibalin AV, 1998, J BIOL CHEM, V273, P8814, DOI 10.1074/jbc.273.15.8814; Chibalin AV, 1997, AM J PHYSIOL-CELL PH, V273, pC1458, DOI 10.1152/ajpcell.1997.273.5.C1458; Chibalin AV, 1998, MOL BIOL CELL, V9, P1209, DOI 10.1091/mbc.9.5.1209; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; Cornelius F, 2003, ANN NY ACAD SCI, V986, P579, DOI 10.1111/j.1749-6632.2003.tb07256.x; Done SC, 2002, J BIOL CHEM, V277, P17108, DOI 10.1074/jbc.M201326200; Efendiev R, 1999, FEBS LETT, V456, P45, DOI 10.1016/S0014-5793(99)00925-4; Efendiev R, 2000, BIOCHEMISTRY-US, V39, P9884, DOI 10.1021/bi0007831; Efendiev R, 2003, J BIOL CHEM, V278, P28719, DOI 10.1074/jbc.M303741200; Efendiev R, 2002, J BIOL CHEM, V277, P44108, DOI 10.1074/jbc.M205173200; Efendiev R, 2002, J BIOL CHEM, V277, P11489, DOI 10.1074/jbc.M108182200; Guthridge MA, 2000, MOL CELL, V6, P99, DOI 10.1016/S1097-2765(00)00011-3; Kagan A, 2002, EMBO J, V21, P1889, DOI 10.1093/emboj/21.8.1889; Khundmiri SJ, 2002, AM J PHYSIOL-RENAL, V282, pF512, DOI 10.1152/ajprenal.00111.2000; Kimura MT, 2001, J BIOL CHEM, V276, P17291, DOI 10.1074/jbc.M005453200; Krook A, 1997, J BIOL CHEM, V272, P30208, DOI 10.1074/jbc.272.48.30208; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Ogimoto G, 2000, P NATL ACAD SCI USA, V97, P3242, DOI 10.1073/pnas.060025597; Pagel P, 2003, ANN NY ACAD SCI, V986, P360, DOI 10.1111/j.1749-6632.2003.tb07215.x; Pedemonte CH, 2001, J BIOENERG BIOMEMBR, V33, P439, DOI 10.1023/A:1010675708820; SERI I, 1990, AM J PHYSIOL, V258, pF52, DOI 10.1152/ajprenal.1990.258.1.F52; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Teixeira VL, 2003, ANN NY ACAD SCI, V986, P587, DOI 10.1111/j.1749-6632.2003.tb07257.x; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297	39	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16272	16277		10.1074/jbc.M500486200	http://dx.doi.org/10.1074/jbc.M500486200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722354	hybrid			2022-12-25	WOS:000228444800097
J	Lengner, CJ; Hassan, MQ; Serra, RW; Lepper, C; van Wijnen, AJ; Stein, JL; Lian, JB; Stein, GS				Lengner, CJ; Hassan, MQ; Serra, RW; Lepper, C; van Wijnen, AJ; Stein, JL; Lian, JB; Stein, GS			Nkx3.2-mediated repression of Runx2 promotes chondrogenic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; DENSITY MICROMASS CULTURES; IN-VITRO MODEL; SONIC HEDGEHOG; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTOR; CHONDROCYTE DIFFERENTIATION; MESENCHYMAL CELLS; SOMITIC CHONDROGENESIS; GENE-EXPRESSION	Runx2, a transcription factor known to be essential for osteoblast maturation and skeletogenesis, is also expressed in pre-cartilaginous mesenchymal condensations in the developing embryo. It is therefore necessary to understand the control and consequential regulatory activity of the Runx2 gene within the context of chondrogenic differentiation of a mesenchymal progenitor cell. We identify the homeodomain protein Nkx3.2 as a potent sequence-specific repressor of the Runx2 promoter that acts through a regulatory element 0.1 kb upstream from the site of transcriptional initiation. The biological significance of this repression is established by utilizing bone morphogenic protein 2 (BMP-2)-induced chondrogenic differentiation of pluripotent C3H10T1/2 cells as a model for the initial events of mesenchymal chondrogenesis. We demonstrate that induction of the chondrogenic phenotype and endogenous Nkx3.2 expression is accompanied by a repression of Runx2 gene activity. Bypassing Runx2 repression by adenoviral-mediated introduction of Runx2 into C3H10T1/2 cells can prevent the induction of chondrogenesis, but cannot reverse the chondrogenic phenotype once it has been initiated, as evidenced by Sox9 and type II collagen expression and extracellular matrix deposition. Our results demonstrate that Runx2 is a direct transcriptional target of Nkx3.2, and that repression of Runx2 at the onset of chondrogenesis is a prerequisite for the activation of a chondrocyte-specific program of gene expression. We postulate that Runx2 is a critical link in BMP-2-mediated initiation of mesenchymal chondrogenesis that results in activation of Sox9 at least in part through the Nkx3.2-dependent repression of Runx2.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Lian, JB (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	jane.lian@umassmed.edu	Hassan, Mohammad/GZA-7507-2022; van Wijnen, Andre J./AAG-3578-2019	Hassan, Mohammad/0000-0002-1712-0004; van Wijnen, Andre J./0000-0002-4458-0946; Lengner, Christopher/0000-0002-0574-5189	NIAMS NIH HHS [AR39588, P01 AR48818, R01 AR049069] Funding Source: Medline; NIDDK NIH HHS [P30 DK32520] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039588, R01AR049069, P01AR048818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; Akazawa H, 2000, GENES CELLS, V5, P499, DOI 10.1046/j.1365-2443.2000.00339.x; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Chan GK, 2003, ENDOCRINOLOGY, V144, P5511, DOI 10.1210/en.2003-0273; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; Denker AE, 1999, DIFFERENTIATION, V64, P67, DOI 10.1046/j.1432-0436.1999.6420067.x; Drissi H, 2002, J CELL BIOCHEM, V86, P403, DOI 10.1002/jcb.10238; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Drissi H, 2002, EXP CELL RES, V274, P323, DOI 10.1006/excr.2002.5474; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Eames BF, 2004, DEV BIOL, V274, P188, DOI 10.1016/j.ydbio.2004.07.006; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; Enomoto-Iwamoto M, 2001, OSTEOARTHR CARTILAGE, V9, pS76, DOI 10.1053/joca.2001.0448; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; Gerstenfeld LC, 1996, J CELL BIOCHEM, V62, P1; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Haas AR, 2000, METH MOL B, V137, P383; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; Kim DW, 2003, MOL CELL BIOL, V23, P8704, DOI 10.1128/MCB.23.23.8704-8717.2003; Kim DW, 2003, J BIOL CHEM, V278, P27532, DOI 10.1074/jbc.M301461200; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 2003, J BONE MINER METAB, V21, P193, DOI 10.1007/s00774-002-0408-0; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937; Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058; Lengner CJ, 2004, J CELL PHYSIOL, V200, P327, DOI 10.1002/jcp.20118; Lengner CJ, 2002, MECH DEVELOP, V114, P167, DOI 10.1016/S0925-4773(02)00050-3; Lettice LA, 1999, P NATL ACAD SCI USA, V96, P9695, DOI 10.1073/pnas.96.17.9695; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1; Marcelle C, 1999, DEV BIOL, V214, P277, DOI 10.1006/dbio.1999.9389; Marcelle C, 1997, DEVELOPMENT, V124, P3955; Mello MA, 1999, IN VITRO CELL DEV-AN, V35, P262; Murtaugh LC, 2001, DEV CELL, V1, P411, DOI 10.1016/S1534-5807(01)00039-9; Murtaugh LC, 1999, GENE DEV, V13, P225, DOI 10.1101/gad.13.2.225; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; North T, 1999, DEVELOPMENT, V126, P2563; Ohyama Y, 2004, ENDOCRINOLOGY, V145, P4685, DOI 10.1210/en.2003-1492; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Rabie ABM, 2004, ARCH ORAL BIOL, V49, P109, DOI 10.1016/j.archoralbio.2003.09.006; Singh R, 2003, ENDOCRINOLOGY, V144, P5081, DOI 10.1210/en.2003-0741; Spinella-Jaegle S, 2001, J CELL SCI, V114, P2085; Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640; Takamoto M, 2003, J ENDOCRINOL, V177, P413, DOI 10.1677/joe.0.1770413; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Tribioli C, 1999, DEVELOPMENT, V126, P5699; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Yagi K, 2003, J CELL BIOCHEM, V88, P1077, DOI 10.1002/jcb.10467; Yamashiro T, 2002, MECH DEVELOP, V119, pS107, DOI 10.1016/S0925-4773(03)00101-1; Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705; Zehentner BK, 2000, DNA CELL BIOL, V19, P275, DOI 10.1089/10445490050021186; Zeng L, 2002, GENE DEV, V16, P1990, DOI 10.1101/gad.1008002	56	68	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15872	15879		10.1074/jbc.M411144200	http://dx.doi.org/10.1074/jbc.M411144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15703179	hybrid			2022-12-25	WOS:000228444800052
J	Zhu, CB; Carneiro, AM; Dostmann, WR; Hewlett, WA; Blakely, RD				Zhu, CB; Carneiro, AM; Dostmann, WR; Hewlett, WA; Blakely, RD			p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOGENIC-AMINE TRANSPORTERS; HUMAN DOPAMINE TRANSPORTER; LONG-TERM POTENTIATION; NECROSIS-FACTOR-ALPHA; NOREPINEPHRINE TRANSPORTER; SYNTAXIN 1A; SURFACE EXPRESSION; GABA TRANSPORTERS; KINASE; CELLS	Presynaptic, plasma membrane serotonin (5-hydroxytryptamine; 5-HT) transporters (SERTs) clear 5-HT following vesicular release and are regulated through trafficking-dependent pathways. Recently, we (Zhu, C.- B., Hewlett, W. A., Feoktistov, I., Biaggioni, I., and Blakely, R. D. ( 2004) Mol. Pharmacol. 65, 1462 - 1474) provided evidence for a trafficking-independent mode of SERT regulation downstream of adenosine receptor (AR) activation that is sensitive to p38 MAPK inhibitors. Here, we probe this pathway in greater detail, demonstrating elevation of 5-HT transport by multiple p38 MAPK activators (anisomycin, H2O2, and UV radiation), in parallel with p38 MAPK phosphorylation, as well as suppression of anisomycin stimulation by p38 MAPK siRNA treatments. Studies with transporter-transfected Chinese hamster ovary cells reveal that SERT stimulation is shared with the human norepinephrine transporter but not the human dopamine transporter. Saturation kinetic analyses of anisomycin-SERT activity reveal a selective reduction in 5-HT Km supported by a commensurate increase in 5-HT potency (K-i) for displacing surface antagonist binding. Anisomycin treatments that stimulate SERT activity do not elevate surface SERT surface density whereas stimulation is lost with preexposure of cells to the surface-SERT inactivating reagent, 2-(trimethylammonium) ethyl methane thiosulfonate. Guanylyl cyclase (1H-( 1,2,4)- oxadiazolo[4,3-a]quinoxalin- 1-one) and protein kinase G inhibitors (H8, DT-2) block AR stimulation of SERT yet fail to antagonize SERT stimulation by anisomycin. We thus place p38 MAPK activation downstream of protein kinase G in a SERT-catalytic regulatory pathway, distinct from events controlling SERT surface density. In contrast, the activity of protein phosphatase 2A inhibitors ( fostriecin and calyculin A) to attenuate anisomycin stimulation of 5-HT transport suggests that protein phosphatase 2A is a critical component of the pathway responsible for p38 MAPK up-regulation of SERT catalytic activity.	Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Vermont	Blakely, RD (corresponding author), Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Suite 7140 MRBIII, Nashville, TN 37232 USA.	randy.blakely@vanderbilt.edu		Marin Dias Carneiro, Ana/0000-0002-1204-9202; Zhu, Chongbin/0000-0003-4530-7949; MD Carneiro, Ana/0000-0002-7470-7047	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH065782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68991] Funding Source: Medline; NIDA NIH HHS [DA07390] Funding Source: Medline; NIMH NIH HHS [T32-MH65782-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Anisman H, 2003, ANN MED, V35, P2, DOI 10.1080/07853890310004075; Ansah TA, 2003, J PHARMACOL EXP THER, V305, P956, DOI 10.1124/jpet.102.047134; Apparsundaram S, 2001, J PHARMACOL EXP THER, V299, P666; Barros LF, 1997, J PHYSIOL-LONDON, V504, P517, DOI 10.1111/j.1469-7793.1997.517bd.x; Bauman AL, 2000, J NEUROSCI, V20, P7571; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Blakely RD, 1998, BIOL PSYCHIAT, V44, P169, DOI 10.1016/S0006-3223(98)00124-3; Bunyard P, 2003, MOL IMMUNOL, V39, P815, DOI 10.1016/S0161-5890(02)00262-6; Carneiro AM, 2002, J NEUROSCI, V22, P7045; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Cook Edwin H. Jr., 1996, Current Opinion in Pediatrics, V8, P348, DOI 10.1097/00008480-199608000-00008; Daws LC, 2000, J NEUROCHEM, V75, P2113, DOI 10.1046/j.1471-4159.2000.0752113.x; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; Deken SL, 2003, J NEUROSCI, V23, P1563; Dostmann WRG, 2000, P NATL ACAD SCI USA, V97, P14772, DOI 10.1073/pnas.97.26.14772; Eaton M, 1996, EXP NEUROL, V140, P105, DOI 10.1006/exnr.1996.0121; Flattem NL, 2000, MOL PSYCHIATR, V5, P110, DOI 10.1038/sj.mp.4000585; Furtado LM, 2002, BIOCHEM CELL BIOL, V80, P569, DOI 10.1139/O02-156; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GIROS B, 1992, MOL PHARMACOL, V42, P383; Haase J, 2001, BIOCHEM SOC T, V29, P722, DOI 10.1042/BST0290722; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Holmes A, 2003, BIOL PSYCHIAT, V54, P953, DOI 10.1016/j.biopsych.2003.09.003; Horschitz S, 2003, J NEUROCHEM, V86, P958, DOI 10.1046/j.1471-4159.2003.01899.x; Jayanthi LD, 2004, J BIOL CHEM, V279, P19315, DOI 10.1074/jbc.M311172200; Kelly A, 2003, J BIOL CHEM, V278, P19453, DOI 10.1074/jbc.M301938200; Kilic F, 2003, MOL PHARMACOL, V64, P440, DOI 10.1124/mol.64.2.440; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LAUNAY JM, 1994, AM J PHYSIOL, V266, P526; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Liu QH, 2003, AM J PHYSIOL-HEART C, V285, pH97, DOI 10.1152/ajpheart.00956.2002; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Magnani F, 2004, J BIOL CHEM, V279, P38770, DOI 10.1074/jbc.M400831200; McNicol A., 1996, PRACT APPROACH SER, P1; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Murphy DL, 2003, GENES BRAIN BEHAV, V2, P350, DOI 10.1046/j.1601-1848.2003.00049.x; Murphy DL, 2004, MOL INTERV, V4, P109, DOI 10.1124/mi.4.2.8; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; Nestler EJ, 2001, MOL NEUROPHARMACOLOG, P191; New LG, 1998, TRENDS CARDIOVAS MED, V8, P220, DOI 10.1016/S1050-1738(98)00012-7; OWENS MJ, 1994, CLIN CHEM, V40, P288; Ozaki N, 2003, MOL PSYCHIATR, V8, P933, DOI 10.1038/sj.mp.4001365; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Pampolina C, 1999, THROMB RES, V96, P27, DOI 10.1016/S0049-3848(99)00062-6; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Quick MW, 2002, INT J DEV NEUROSCI, V20, P219, DOI 10.1016/S0736-5748(02)00021-7; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; RAMAMOORTHY S, 1993, PLACENTA, V14, P449, DOI 10.1016/S0143-4004(05)80465-5; Ramamoorthy Sammanda, 2002, P1; Reith MEA., 1997, NEUROTRANSMITTER TRA, P29, DOI 10.1007/978-1-59259-470-2_2; RUDNICK G, 1978, BIOCHEMISTRY-US, V17, P5300, DOI 10.1021/bi00617a033; Sakai N, 1997, J NEUROCHEM, V68, P2618; Samuvel DJ, 2005, J NEUROSCI, V25, P29, DOI 10.1523/JNEUROSCI.3754-04.2005; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; Somwar R, 2001, BIOCHEM J, V359, P639, DOI 10.1042/0264-6021:3590639; Sung U, 2003, J NEUROSCI, V23, P1697; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Wang QW, 2004, J NEUROSCI, V24, P3370, DOI 10.1523/JNEUROSCI.1633-03.2004; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; White S, 2002, CRIT REV BIOTECHNOL, V22, P1, DOI 10.1080/07388550490465817; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397; Zhu CB, 2004, MOL PHARMACOL, V65, P1462, DOI 10.1124/mol.65.6.1462; Zhu CB, 2004, EUR J PHARMACOL, V504, P1, DOI 10.1016/j.ejphar.2004.09.023	69	165	168	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15649	15658		10.1074/jbc.M410858200	http://dx.doi.org/10.1074/jbc.M410858200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15728187	hybrid			2022-12-25	WOS:000228444800025
J	Hasegawa, M; Imamura, R; Kinoshita, T; Matsumoto, N; Masumoto, J; Inohara, N; Suda, T				Hasegawa, M; Imamura, R; Kinoshita, T; Matsumoto, N; Masumoto, J; Inohara, N; Suda, T			ASC-mediated NF-kappa B activation leading to interleukin-8 production requires caspase-8 and is inhibited by CLARP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL MEDITERRANEAN FEVER; CONTAINING APAF1-LIKE PROTEIN; REGULATES ACTIVATION; HOST RECOGNITION; FAS LIGAND; T-CELLS; APOPTOSIS; PYRIN; GENE; MEMBER	ASC is an adaptor molecule that mediates apoptotic and inflammatory signals from several Apaf-1-like molecules, including CARD12/Ipaf, cryopyrin/PYPAF1, PYPAF5, PYPAF7, and NALP1. To characterize the signaling pathway mediated by ASC, we established cell lines in which muramyl dipeptide, the bacterial component recognized by another Apaf-1-like molecule, Nod2, induced an interaction between a CARD12-Nod2 chimeric protein and ASC, and elicited cell autonomous NF-kappa B activation. This response required caspase-8, and was suppressed by CLARP/FLIP, an inhibitor of caspase-8. The catalytic activity of caspase-8 was required for the ASC-mediated NF-kappa B activation when caspase-8 was expressed at an endogenous level, although it was not essential when caspase-8 was overexpressed. In contrast, FADD, the adaptor protein linking Fas and caspase-8, was not required for this response. Consistently, ASC recruited caspase-8 and CLARP but not FADD and Nod2 to its speck-like aggregates in cells. Finally, muramyl dipeptide induced interleukin-8 production in MAIL8 cells. These results are the first to indicate that caspase-8 plays an important role in the ASC-mediated NF-kappa B activation, and that the ASC-mediated NF-kappa B activation actually induces physiologically relevant gene expression.	Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	Kanazawa University; University of Michigan System; University of Michigan	Suda, T (corresponding author), Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.	sudat@kenroku.kanazawa-u.ac.jp	IMAMURA, Ryu/D-8433-2015; KINOSHITA, Takeshi/D-8436-2015					Aksentijevich I, 1997, CELL, V90, P797; Bernot A, 1997, NAT GENET, V17, P25; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Chae JJ, 2003, MOL CELL, V11, P591, DOI 10.1016/S1097-2765(03)00056-X; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Conway KE, 2000, CANCER RES, V60, P6236; Dowds TA, 2003, BIOCHEM BIOPH RES CO, V302, P575, DOI 10.1016/S0006-291X(03)00221-3; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Imamura R, 2004, J BIOL CHEM, V279, P46415, DOI 10.1074/jbc.M403226200; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lee ZH, 2001, J LEUKOCYTE BIOL, V69, P490; Leo E, 2001, J BIOL CHEM, V276, P8087, DOI 10.1074/jbc.M009450200; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7; Meylan E, 2002, EMBO REP, V3, P1201, DOI 10.1093/embo-reports/kvf236; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Stoven S, 2003, P NATL ACAD SCI USA, V100, P5991, DOI 10.1073/pnas.1035902100; Suda T, 1996, J IMMUNOL, V157, P3918; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Wang YT, 2004, INT IMMUNOL, V16, P777, DOI 10.1093/intimm/dxh081; Zhang YK, 1999, J BIOL CHEM, V274, P34657, DOI 10.1074/jbc.274.49.34657	42	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15122	15130		10.1074/jbc.M412284200	http://dx.doi.org/10.1074/jbc.M412284200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701651	hybrid, Green Submitted			2022-12-25	WOS:000228236800095
J	Kikuchi, S; Griffin, CT; Wang, SS; Bissell, DM				Kikuchi, S; Griffin, CT; Wang, SS; Bissell, DM			Role of CD44 in epithelial wound repair - Migration of rat hepatic stellate cells utilizes hyaluronic acid and CD44v6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-INJURY; TGF-BETA; EXPRESSION; LIPOCYTES; GROWTH; PROLIFERATION; ACTIVATION; FIBROSIS; ADHESION; ISOFORMS	The hyaluronic acid receptor, CD44, exists as multiple splice variants that appear to have a role in migration of tumor cells. The role of this receptor and its variants in normal wound repair is poorly understood. A central feature of wound repair in the liver is activation and migration of perisinusoidal stellate cells. We have examined CD44 expression by stellate cells from normal or injured rat liver, finding that it increases with injury and involves a distinct set of CD44 splice variants. Among the latter, variants containing the v6 exon (CD44v6) are strikingly increased. Analysis of migration of primary cells on transwell filter inserts reveals that only cells isolated from injured liver are migratory. Also, they move more rapidly on hyaluronic acid than on collagen I or collagen IV. A polyclonal antibody to recombinant CD44v6 blocks migration by 50%, whereas antibody to CD44v4 has no effect. The inhibition is specific for cells migrating on hyaluronic acid and is reversed by synthetic peptide representing the N terminus of the v6 protein. In conclusion, activated stellate cells use CD44v6 and hyaluronic acid for migration. Given the evidence that migration is required for progression of injury with scar formation, blockers of CD44v6 expression or function are candidates for preventing the deleterious effects of chronic fibrosis.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bissell, DM (corresponding author), Univ Calif San Francisco, Dept Med, Box 0538, San Francisco, CA 94143 USA.	dmbiss@itsa.ucsf.edu			NIDDK NIH HHS [P30DK26743, R39DK31198] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031198, R01DK031198, P30DK026743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTHUR MJP, 1989, J CLIN INVEST, V84, P1076, DOI 10.1172/JCI114270; Bissell DM, 2001, EXP MOL MED, V33, P179, DOI 10.1038/emm.2001.31; Carloni V, 1997, GASTROENTEROLOGY, V112, P522, DOI 10.1053/gast.1997.v112.pm9024306; Cuff CA, 2001, J CLIN INVEST, V108, P1031, DOI 10.1172/JCI12455; Della Fazia MA, 2001, J HEPATOL, V34, P555, DOI 10.1016/S0168-8278(00)00065-9; DOUGHERTY GJ, 1994, J BIOL CHEM, V269, P9074; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; Failli P, 2000, GASTROENTEROLOGY, V119, P479, DOI 10.1053/gast.2000.9354; Friedman SL, 1997, J GASTROENTEROL, V32, P424, DOI 10.1007/BF02934504; HORN T, 1986, J HEPATOL, V3, P333, DOI 10.1016/S0168-8278(86)80486-X; Ikeda K, 1999, HEPATOLOGY, V29, P1760, DOI 10.1002/hep.510290640; Jain M, 1996, J CLIN INVEST, V97, P596, DOI 10.1172/JCI118455; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; Kinnman N, 2000, LAB INVEST, V80, P697, DOI 10.1038/labinvest.3780073; Marra F, 1999, HEPATOLOGY, V29, P140, DOI 10.1002/hep.510290107; Racine-Samson L, 1997, J BIOL CHEM, V272, P30911, DOI 10.1074/jbc.272.49.30911; RALL CJN, 1995, CANCER RES, V55, P1831; Reeder JA, 1998, CANCER RES, V58, P3719; ROCKEY DC, 1993, J CLIN INVEST, V92, P1795, DOI 10.1172/JCI116769; Satoh T, 2000, J GASTROEN HEPATOL, V15, P402, DOI 10.1046/j.1440-1746.2000.02164.x; Sleeman J, 1996, J CELL BIOL, V135, P1139, DOI 10.1083/jcb.135.4.1139; Tangkijvanich P, 2003, J BIOMED SCI, V10, P352, DOI 10.1159/000070101; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Vrochides D, 1996, HEPATOLOGY, V23, P1650, DOI 10.1053/jhep.1996.v23.pm0008675189; Yang CQ, 2003, GASTROENTEROLOGY, V124, P147, DOI 10.1053/gast.2003.50012; Yu Q, 2000, GENE DEV, V14, P163	27	45	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15398	15404		10.1074/jbc.M414048200	http://dx.doi.org/10.1074/jbc.M414048200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15691832	hybrid			2022-12-25	WOS:000228236800126
J	Pon, YL; Auersperg, N; Wong, AST				Pon, YL; Auersperg, N; Wong, AST			Gonadotropins regulate N-cadherin-mediated human ovarian surface epithelial cell survival at both post-translational and transcriptional levels through a cyclic AMP/protein kinase a pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; PERFUSED RAT OVARY; EXTRACELLULAR-MATRIX; LUTEINIZING-HORMONE; GRANULOSA-CELLS; IN-VITRO; SIGNALING PATHWAYS; BETA-CATENIN; EXPRESSION; OVULATION	Gonadotropins are the major regulators of ovarian function and may be involved in the etiology of ovarian cancer. In this study, we report a new mechanism whereby gonadotropins regulate the survival of human ovarian surface epithelium (OSE), the tissue of origin of epithelial ovarian carcinomas. Our results indicate that disruption of N-cadherin-mediated cell-cell adhesion is an important molecular event in the apoptosis of human OSE. Treatment with surge serum concentrations of gonadotropins reduced the amount of N-cadherin with a concomitant induction of apoptosis, and this effect was mediated by a cAMP/protein kinase A pathway but not the ERK1/2 and protein kinase C cascades. We further demonstrated that activation of the gonadotropins/cAMP signaling pathway in human OSE led to a rapid down-regulation of N-cadherin protein level followed by a reduction at the level of N-cadherin mRNA, indicating that expression of N-cadherin was regulated by post-translational and transcriptional mechanisms. The former mechanism was mediated by increased turnover of N-cadherin protein and could be reversed by inhibition of proteasomal or matrix metalloproteinase (MMP-2) activity. On the other hand, at the transcriptional level, the addition of actinomycin D abolished the cAMP-mediated decrease in N-cadherin mRNA but did not change its stability. Inhibition of protein kinase A or expressing a dominant negative mutant of cAMP-response element-binding protein blocked this decrease of N-cadherin mRNA. Together, the combined operation of post-translational and transcriptional mechanisms suggests that regulation of N-cadherin is a crucial event and emphasizes the important role that N-cadherin has in controlling the survival capability of human OSE.	Univ Hong Kong, Dept Zool, Hong Kong, Hong Kong, Peoples R China; Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V6H 3V5, Canada	University of Hong Kong; University of British Columbia	Wong, AST (corresponding author), Univ Hong Kong, Dept Zool, 4S-14 Kadoorie Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	awong1@hku.hk	Wong, Alice/AFJ-4595-2022	Wong, Alice/0000-0002-0676-6475				AHARONI D, 1995, EXP CELL RES, V218, P271, DOI 10.1006/excr.1995.1156; AKTIPIS S, 1981, BIOCHIM BIOPHYS ACTA, V655, P278, DOI 10.1016/0005-2787(81)90038-1; Amsterdam A, 2003, MOL CELL ENDOCRINOL, V202, P77, DOI 10.1016/S0303-7207(03)00066-2; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; Auersperg N, 2003, GYNECOL ONCOL, V88, pS47, DOI 10.1006/gyno.2002.6683; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; BJERSING L, 1975, EXPERIENTIA, V31, P605, DOI 10.1007/BF01932485; BRABANT G, 1995, ENDOCRINOLOGY, V136, P3113, DOI 10.1210/en.136.7.3113; BRANNSTROM M, 1988, ENDOCRINOLOGY, V122, P1715; Breckwoldt M, 1996, Zentralbl Gynakol, V118, P176; BUTLER TA, 1991, BIOL REPROD, V44, P1183, DOI 10.1095/biolreprod44.6.1183; Campbell BK, 1998, J REPROD FERTIL, V112, P69, DOI 10.1530/jrf.0.1120069; Chamson-Reig A, 2003, ENDOCRINOLOGY, V144, P2957, DOI 10.1210/en.2003-0011; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; Colgin DC, 1997, ANIM REPROD SCI, V47, P197, DOI 10.1016/S0378-4320(97)00011-0; D'Ascenzo S, 2004, EUR J ENDOCRINOL, V151, P87, DOI 10.1530/eje.0.1510087; Davies BR, 1999, GYNECOL ENDOCRINOL, V13, P75, DOI 10.3109/09513599909167536; Emonard H, 1999, ANN NY ACAD SCI, V878, P647, DOI 10.1111/j.1749-6632.1999.tb07751.x; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; GRAG PP, 1998, GYNECOLOGY, V92, P472; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; HOFFMAN AG, 1993, INT J CANCER, V54, P828, DOI 10.1002/ijc.2910540518; HUNTER MG, 1981, J REPROD FERTIL, V63, P285; Ivarsson K, 2001, HUM REPROD, V16, P18, DOI 10.1093/humrep/16.1.18; Julie PM, 2003, ENDOCR RES, V29, P327, DOI 10.1081/ERC-120025040; KERENTAL I, 1995, EXP CELL RES, V218, P283, DOI 10.1006/excr.1995.1157; Konishi I, 1999, ONCOLOGY-BASEL, V57, P45, DOI 10.1159/000055274; KRUK PA, 1994, IN VITRO CELL DEV-AN, V30A, P217; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; Machell NH, 2003, REPRODUCTION, V125, P791, DOI 10.1530/rep.0.1250791; MACLACHLAN NJ, 1987, ENVIRON HEALTH PERSP, V73, P27, DOI 10.2307/3430595; MAINESBANDIERA SL, 1992, AM J OBSTET GYNECOL, V167, P729, DOI 10.1016/S0002-9378(11)91579-8; MainesBandiera SL, 1997, INT J GYNECOL PATHOL, V16, P250, DOI 10.1097/00004347-199707000-00010; Makrigiannakis A, 1999, AM J PATHOL, V154, P1391, DOI 10.1016/S0002-9440(10)65393-X; Mandai M, 1997, EUR J CANCER, V33, P1501, DOI 10.1016/S0959-8049(97)00166-4; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; MURDOCH WJ, 1995, J REPROD FERTIL, V105, P161, DOI 10.1530/jrf.0.1050161; Murdoch WJ, 2004, EXP BIOL MED, V229, P546, DOI 10.1177/153537020422900613; OSTERHOLZER HO, 1985, BIOL REPROD, V33, P247, DOI 10.1095/biolreprod33.1.247; PARADIES NE, 1993, J NEUROSCI RES, V36, P33, DOI 10.1002/jnr.490360105; Parrott JA, 2001, MOL CELL ENDOCRINOL, V172, P213, DOI 10.1016/S0303-7207(00)00340-3; Peluso JJ, 2000, BIOL SIGNAL RECEPT, V9, P115; REVILLION F, 1993, ANTICANCER RES, V13, P1625; Richards JS, 2002, RECENT PROG HORM RES, V57, P195, DOI 10.1210/rp.57.1.195; Riley SC, 2004, ANIM REPROD SCI, V81, P329, DOI 10.1016/j.anireprosci.2003.10.011; Rowlands TM, 2000, REV REPROD, V5, P53; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shushan A, 1996, FERTIL STERIL, V65, P13, DOI 10.1016/S0015-0282(16)58020-0; Sundfeldt K, 2000, J REPROD FERTIL, V118, P375, DOI 10.1530/reprod/118.2.375; Sundfeldt K, 1997, INT J CANCER, V74, P275, DOI 10.1002/(SICI)1097-0215(19970620)74:3<275::AID-IJC7>3.3.CO;2-V; Syed V, 2001, CANCER RES, V61, P6768; Thomas FH, 2005, ENDOCRINOLOGY, V146, P941, DOI 10.1210/en.2004-0826; Trolice MP, 1997, ENDOCRINOLOGY, V138, P107, DOI 10.1210/en.138.1.107; Tsafriri A, 1999, EXP CLIN ENDOCR DIAB, V107, P1, DOI 10.1055/s-0029-1212066; Wong AST, 1999, INT J CANCER, V81, P180; Zheng WX, 2000, GYNECOL ONCOL, V76, P80, DOI 10.1006/gyno.1999.5628	58	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15438	15448		10.1074/jbc.M410766200	http://dx.doi.org/10.1074/jbc.M410766200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701645	hybrid			2022-12-25	WOS:000228236800131
J	Browne, RJ; Stitt, BL				Browne, RJ; Stitt, BL			Active site occupancy required for catalytic cooperativity by Escherichia coli transcription termination factor Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE NUCLEOSIDE PHOSPHORYLASE; ATP HYDROLYSIS; PROTEIN RHO; NUCLEOTIDE-BINDING; AMP DEAMINASE; RAPID QUENCH; MECHANISM; F-1-ATPASE; ENZYME; YEAST	Escherichia coli transcription termination factor Rho exhibits the phenomenon of catalytic cooperativity. The catalytic rate per site is 30-fold faster when all three sites are filled with substrate ATP than when only a single site is occupied (Stitt, B. L., and Xu, Y. (1998) J. Biol. Chem. 273, 26477-26486). Experiments presented here investigate whether all three active sites must be filled or whether only two occupied sites are required for catalytic cooperativity. The results indicate that all three Rho catalytic sites must be filled with substrate to achieve the enhanced catalytic rate, both in pre-steady-state and in steady-state hydrolysis. They further suggest that, once the enzyme is saturated with ATP, a V-max enzyme conformation is achieved that is stable for at least three catalytic cycles.	Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Stitt, BL (corresponding author), Temple Univ, Sch Med, Dept Biochem, 3420 N Broad St, Philadelphia, PA 19140 USA.	stitt@temple.edu			NIGMS NIH HHS [GM60247] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060247] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Amano T, 1996, J BIOL CHEM, V271, P18128, DOI 10.1074/jbc.271.30.18128; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Browne RJ, 2005, J BIOL CHEM, V280, P13292, DOI 10.1074/jbc.M500221200; Cao H, 2002, BIOCHEMISTRY-US, V41, P3520, DOI 10.1021/bi012148g; CROSS RL, 1982, J BIOL CHEM, V257, P2101; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; GEISELMANN J, 1992, PROTEIN SCI, V1, P850, DOI 10.1002/pro.5560010703; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Kim DE, 1999, J BIOL CHEM, V274, P11623, DOI 10.1074/jbc.274.17.11623; MERKLER DJ, 1990, J BIOL CHEM, V265, P4420; MERKLER DJ, 1989, J BIOL CHEM, V264, P21422; Miles RW, 1998, BIOCHEMISTRY-US, V37, P8615, DOI 10.1021/bi980658d; Milgrom YM, 1998, BIOCHEM J, V330, P1037; OPPERMAN T, 1994, J BACTERIOL, V176, P5033, DOI 10.1128/jb.176.16.5033-5043.1994; Richardson JP, 2002, BBA-GENE STRUCT EXPR, V1577, P251, DOI 10.1016/S0167-4781(02)00456-6; Rose I A, 1980, Methods Enzymol, V64, P47; ROSE IA, 1995, METHOD ENZYMOL, V249, P315; Skordalakes E, 2005, STRUCTURE, V13, P99, DOI 10.1016/j.str.2004.10.013; Skordalakes E, 2003, CELL, V114, P135, DOI 10.1016/S0092-8674(03)00512-9; Stitt BL, 1998, J BIOL CHEM, V273, P26477, DOI 10.1074/jbc.273.41.26477; Stitt BL, 2001, BIOCHEMISTRY-US, V40, P2276, DOI 10.1021/bi002253a; STITT BL, 1988, J BIOL CHEM, V263, P11130; STITT BL, 1986, J BIOL CHEM, V261, P5906; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 2001, J BIOL CHEM, V276, P35422, DOI 10.1074/jbc.M104946200; WILKINSON KD, 1979, J BIOL CHEM, V254, P2567	31	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13300	13303		10.1074/jbc.M500222200	http://dx.doi.org/10.1074/jbc.M500222200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15703177	hybrid			2022-12-25	WOS:000228095500015
J	Cheng, JK; Yu, L; Zhang, DY; Huang, QJ; Spencer, D; Su, B				Cheng, JK; Yu, L; Zhang, DY; Huang, QJ; Spencer, D; Su, B			Dimerization through the catalytic domain is essential for MEKK2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; T-CELL-RECEPTOR; BETA SIGNAL-TRANSDUCTION; PROTEIN-KINASE; MOLECULAR-CLONING; GENE-EXPRESSION; GROWTH-FACTOR; PB1 DOMAINS; MAST-CELLS; IN-VIVO	Mitogen-activated protein kinase (MAPK) cascades are the central components of the intracellular signaling networks that eukaryotic cells use to respond to a wide spectrum of extracellular stimuli. MAPKs are activated through a module consisting of a MAPK, a MAPK kinase (MKK), and a MKK kinase (MAP3K). Because of its unique position in the MAPK module, a MAP3K is crucial in relaying the upstream receptor-mediated signals through the MAPK cascades to induce physiological responses. Yet, the underlying molecular mechanism of MAP3K regulation and activation remains largely unknown. In this study, we demonstrated that MAP3K MEKK2 activation requires dimerization. We mapped the MEKK2 dimerization motif in its catalytic domain and showed that the NH2-terminal region is not required for MEKK2 dimer formation. We also found that the inactive, non-phosphorylated MEKK2 formed significantly more dimers than the phosphorylated and, hence, active MEKK2. Moreover, prevention of MEKK2 dimer formation inhibited MEKK2-mediated JNK activation. Using a chemical-induced dimerization system, we further demonstrated that MEKK2 dimer formation in vivo augmented MEKK2-dependent JNK activation and JNK/AP-1 reporter gene transcription. Together, these results suggest a novel mechanism underlying MEKK2 regulation and activation.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Su, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	bsu@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044016] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; NHLBI NIH HHS [HL070225] Funding Source: Medline; NIAID NIH HHS [AI44016] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Chayama K, 2001, P NATL ACAD SCI USA, V98, P4599, DOI 10.1073/pnas.081021898; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; Fan LF, 1999, HUM GENE THER, V10, P2273, DOI 10.1089/10430349950016924; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Freeman KW, 2003, CANCER RES, V63, P6237; Garrington TP, 2000, EMBO J, V19, P5387, DOI 10.1093/emboj/19.20.5387; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Goetz CA, 2003, J BIOL CHEM, V278, P51184, DOI 10.1074/jbc.M309183200; Guo ZJ, 2002, MOL CELL BIOL, V22, P5761, DOI 10.1128/MCB.22.16.5761-5768.2002; Hammaker DR, 2004, J IMMUNOL, V172, P1612, DOI 10.4049/jimmunol.172.3.1612; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kesavan K, 2004, J CELL PHYSIOL, V199, P140, DOI 10.1002/jcp.10457; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Noda Y, 2003, J BIOL CHEM, V278, P43516, DOI 10.1074/jbc.M306330200; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Schaefer BC, 1999, IMMUNITY, V11, P411, DOI 10.1016/S1074-7613(00)80116-8; Schlesinger TK, 1998, FRONT BIOSCI, V3, P1181; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Su B, 2001, J BIOL CHEM, V276, P14784, DOI 10.1074/jbc.M010134200; Sun WY, 2003, MOL CELL BIOL, V23, P2298, DOI 10.1128/MCB.23.7.2298-2308.2003; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yang JH, 1998, GENE, V212, P95, DOI 10.1016/S0378-1119(98)00158-9	36	41	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13477	13482		10.1074/jbc.M414258200	http://dx.doi.org/10.1074/jbc.M414258200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695508	hybrid			2022-12-25	WOS:000228095500037
J	Massa, PE; Li, X; Hanidu, A; Siamas, J; Pariali, M; Pareja, J; Savitt, AG; Catron, KM; Li, J; Marcu, KB				Massa, PE; Li, X; Hanidu, A; Siamas, J; Pariali, M; Pareja, J; Savitt, AG; Catron, KM; Li, J; Marcu, KB			Gene expression profiling in conjunction with physiological rescues of IKK alpha-null cells with wild type or mutant IKK alpha reveals distinct classes of IKK alpha/NF-kappa B-dependent genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ACTIVATING TRANSCRIPTION FACTOR-3; N-TERMINAL KINASE; HELIX-LOOP-HELIX; INDUCED APOPTOSIS; LEUCINE-ZIPPER; TNF-ALPHA; RELA/P65 SUBUNIT; PROLIFERIN GENE; TAX INDUCTION	Cellular responses to stress-like stimuli require the I kappa B kinase (IKK) signalsome (IKK alpha, IKK beta, and NEMO/IKK gamma) to activate NF-kappa B-dependent genes. IKK beta and NEMO/IKK gamma are required to release NF-kappa B p65/p50 heterodimers from I kappa B alpha, resulting in their nuclear migration and sequence-specific DNA binding; but IKK alpha was found to be dispensable for this initial phase of canonical NF-kappa B activation. Nevertheless, IKK alpha(-/-) mouse embryonic fibroblasts (MEFs) fail to express NF-kappa B targets in response to proinflammatory stimuli, uncovering a nuclear role for IKK alpha in NF-kappa B activation. However, it remains unknown whether the global defect in NF-kappa B-dependent gene expression of IKK alpha(-/-) cells is caused by the absence of IKK alpha kinase activity. We show by gene expression profiling that rescue of near physiological levels of wild type IKK alpha in IKK alpha(-/-) MEFs globally restores expression of their canonical NF-kappa B target genes. To prove that the kinase activity of IKK alpha was required on a genomic scale, the same physiological rescue was performed with a kinase-dead, ATP binding domain IKK alpha mutant (IKK alpha(K44M)). Remarkably, the IKK alpha(K44M) protein rescued similar to 28% of these genes, albeit in a largely stimulus-independent manner with the notable exception of several genes that also acquired tumor necrosis factor-alpha responsiveness. Thus the IKK alpha-containing signalsome unexpectedly functions in the presence and absence of extracellular signals in both kinase-dependent and -independent modes to differentially modulate the expression of five distinct classes of IKK alpha/NF-kappa B-dependent genes.	Boehringer Ingelheim Pharmaceut Inc, Dept Immunol & Inflammat, Ridgefield, CT 06877 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Grad Program Genet, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Dept Microbiol, Stony Brook, NY 11794 USA; Univ Bologna, San Orsola Hosp, Ctr Appl Biomed Res, I-40138 Bologna, Italy	Boehringer Ingelheim; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna	Li, J (corresponding author), Boehringer Ingelheim Pharmaceut Inc, Dept Immunol & Inflammat, 900 Ridgebury Rd,POB 368, Ridgefield, CT 06877 USA.	jli@rdg.boehringer-ingelheim.com; kmarcu@ms.cc.sunysb.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066882] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM066882-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Amir RE, 2004, ONCOGENE, V23, P2540, DOI 10.1038/sj.onc.1207366; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Anest V, 2004, J BIOL CHEM, V279, P31183, DOI 10.1074/jbc.M404380200; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; CONNOR AM, 1989, BIOCHIM BIOPHYS ACTA, V1009, P75, DOI 10.1016/0167-4781(89)90081-X; Corbacho AM, 2002, J ENDOCRINOL, V173, P219, DOI 10.1677/joe.0.1730219; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fassett JT, 2001, ENDOCRINOLOGY, V142, P2129, DOI 10.1210/en.142.5.2129; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Grey ST, 1999, J EXP MED, V190, P1135, DOI 10.1084/jem.190.8.1135; Groskopf JC, 1997, ENDOCRINOLOGY, V138, P2835, DOI 10.1210/en.138.7.2835; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Hai T, 1999, GENE EXPRESSION, V7, P321; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kato T, 2003, MOL CELL, V12, P829, DOI 10.1016/S1097-2765(03)00358-7; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Liacini A, 2003, EXP CELL RES, V288, P208, DOI 10.1016/S0014-4827(03)00180-0; Liebermann DA, 1998, ONCOGENE, V17, P3319, DOI 10.1038/sj.onc.1202574; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; Malewicz M, 2003, J BIOL CHEM, V278, P32825, DOI 10.1074/jbc.M304000200; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; McKenzie FR, 2000, MOL CELL BIOL, V20, P2635, DOI 10.1128/MCB.20.8.2635-2649.2000; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakagomi S, 2003, J NEUROSCI, V23, P5187; Nawa T, 2000, BIOCHEM BIOPH RES CO, V275, P406, DOI 10.1006/bbrc.2000.3332; Nawa T, 2002, ATHEROSCLEROSIS, V161, P281, DOI 10.1016/S0021-9150(01)00639-6; Nobori K, 2002, J MOL CELL CARDIOL, V34, P1387, DOI 10.1006/jmcc.2002.2091; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; Ohazama A, 2004, DEV CELL, V6, P219, DOI 10.1016/S1534-5807(04)00024-3; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Patke A, 2004, CURR OPIN IMMUNOL, V16, P251, DOI 10.1016/j.coi.2004.01.007; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Razmara M, 2002, J BIOL CHEM, V277, P13952, DOI 10.1074/jbc.M107811200; Renard P, 2001, Nucleic Acids Res, V29, pE21, DOI 10.1093/nar/29.4.e21; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sil AK, 2004, NATURE, V428, P660, DOI 10.1038/nature02421; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tergaonkar V, 2003, MOL CELL BIOL, V23, P8070, DOI 10.1128/MCB.23.22.8070-8083.2003; Toft DJ, 2001, P NATL ACAD SCI USA, V98, P13055, DOI 10.1073/pnas.231364798; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Weih F, 2003, IMMUNOL REV, V195, P91, DOI 10.1034/j.1600-065X.2003.00064.x; Weil R, 2004, CURR OPIN IMMUNOL, V16, P374, DOI 10.1016/j.coi.2004.03.003; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Zazzeroni F, 2003, BLOOD, V102, P3270, DOI 10.1182/blood-2003-03-0689; Zhang H, 2002, INT J ONCOL, V20, P1035; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	94	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14057	14069		10.1074/jbc.M414401200	http://dx.doi.org/10.1074/jbc.M414401200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695520	Green Accepted, hybrid			2022-12-25	WOS:000228095500108
J	Suzuki, T; Nakanishi, K; Tsutsui, H; Iwai, H; Akira, S; Inohara, N; Chamaillard, M; Nunez, G; Sasakawa, C				Suzuki, T; Nakanishi, K; Tsutsui, H; Iwai, H; Akira, S; Inohara, N; Chamaillard, M; Nunez, G; Sasakawa, C			A novel caspase-1/toll-like receptor 4-independent pathway of cell death induced by cytosolic Shigella in infected macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE-DERIVED MACROPHAGES; TOLL-LIKE RECEPTOR-4; INTESTINAL EPITHELIAL-CELLS; NF-KAPPA-B; INDUCED APOPTOSIS; BACTERIAL PEPTIDOGLYCAN; CASPASE-1 ACTIVATION; CONVERTING-ENZYME; DENDRITIC CELLS; FLEXNERI	Shigella-induced macrophage cell death is an important step in the induction of acute inflammatory responses that ultimately lead to bacillary dysentery. Cell death was previously reported to be dependent upon the activation of caspase-1 via interaction with IpaB secreted by intracellular Shigella, but in this study, we show that Shigella infection of macrophages can also induce cell death independent of caspase-1 or IpaB activity. Time-lapse imaging and electron microscopic analyses indicated that caspase-1-dependent and -independent cell death is morphologically indistinguishable and that both resemble necrosis. Analyses of Shigella mutants or Escherichia coli using co-infection with Listeria suggested that a component common to Gram-negative bacteria is involved in inducing caspase-1-independent cell death. Further studies revealed that translocation of bacterial lipid A into the cytosol of macrophages potentially mediates cell death. Notably, cell death induced by cytosolic bacteria was TLR4-independent. These results identify a novel cell death pathway induced by intracellular Gram-negative bacteria that may play a role in microbial-host interactions and inflammatory responses.	Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Minato Ku, Tokyo 1088639, Japan; Hyogo Med Univ, Dept Immunol & Med Zool, Nishinomiya, Hyogo 6638501, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Japan Sci & Technol Agcy, PRESTO, Kawaguchi 3320012, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan; Japan Sci & Technol Agcy, ERATO, Kawaguchi 3320012, Japan	University of Tokyo; Hyogo College of Medicine; University of Hyogo; Osaka University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Suzuki, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	t-suzuki@ims.u-tokyo.ac.jp	Nuñez, Gabriel/A-7160-2014; Akira, Shizuo/C-3134-2009; Chamaillard, Mathias/L-6542-2013	Chamaillard, Mathias/0000-0002-0243-9717; Tsutsui, Hiroko/0000-0001-7928-4875				Akashi S, 2001, INT IMMUNOL, V13, P1595, DOI 10.1093/intimm/13.12.1595; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bannerman DD, 2003, AM J PHYSIOL-LUNG C, V284, pL899, DOI 10.1152/ajplung.00338.2002; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; Boise LH, 2001, TRENDS MICROBIOL, V9, P64, DOI 10.1016/S0966-842X(00)01937-5; Brennan MA, 2000, MOL MICROBIOL, V38, P31, DOI 10.1046/j.1365-2958.2000.02103.x; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chen LM, 1996, MOL MICROBIOL, V21, P1101, DOI 10.1046/j.1365-2958.1996.471410.x; Chen YJ, 1996, EMBO J, V15, P3853, DOI 10.1002/j.1460-2075.1996.tb00759.x; d'Hauteville H, 2002, J IMMUNOL, V168, P5240, DOI 10.4049/jimmunol.168.10.5240; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Edgeworth JD, 2002, EUR J IMMUNOL, V32, P1464, DOI 10.1002/1521-4141(200205)32:5<1464::AID-IMMU1464>3.0.CO;2-G; Fernandez-Prada C, 1998, INFECT IMMUN, V66, P3918, DOI 10.1128/IAI.66.8.3918-3924.1998; FernandezPrada CM, 1997, INFECT IMMUN, V65, P1486, DOI 10.1128/IAI.65.4.1486-1496.1997; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Hernandez LD, 2003, J CELL BIOL, V163, P1123, DOI 10.1083/jcb.200309161; Hilbi H, 1997, INFECT IMMUN, V65, P5165, DOI 10.1128/IAI.65.12.5165-5170.1997; Hilbi H, 1998, J BIOL CHEM, V273, P32895, DOI 10.1074/jbc.273.49.32895; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Hornef MW, 2003, J EXP MED, V198, P1225, DOI 10.1084/jem.20022194; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hueffer K, 2004, CELL MICROBIOL, V6, P1019, DOI 10.1111/j.1462-5822.2004.00451.x; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Jarvelainen HA, 2003, TRENDS CELL BIOL, V13, P204, DOI 10.1016/S0962-8924(03)00032-1; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Kuwae A, 2001, J BIOL CHEM, V276, P32230, DOI 10.1074/jbc.M103831200; Monack DM, 2001, CELL MICROBIOL, V3, P825, DOI 10.1046/j.1462-5822.2001.00162.x; Monack DM, 1996, P NATL ACAD SCI USA, V93, P9833, DOI 10.1073/pnas.93.18.9833; Navarre WW, 2000, CELL MICROBIOL, V2, P265, DOI 10.1046/j.1462-5822.2000.00056.x; Nonaka T, 2003, MICROBIOL-SGM, V149, P2513, DOI 10.1099/mic.0.26341-0; Nonaka T, 1999, FEMS MICROBIOL LETT, V174, P89, DOI 10.1111/j.1574-6968.1999.tb13553.x; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Sansonetti PJ, 2000, IMMUNITY, V12, P581, DOI 10.1016/S1074-7613(00)80209-5; SASAKAWA C, 1986, INFECT IMMUN, V51, P470, DOI 10.1128/IAI.51.2.470-475.1986; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; Stockbauer KE, 2003, CELL MICROBIOL, V5, P123, DOI 10.1046/j.1462-5822.2003.00260.x; Suzuki T, 2000, J EXP MED, V191, P1905, DOI 10.1084/jem.191.11.1905; Suzuki T, 2002, CELL MICROBIOL, V4, P223, DOI 10.1046/j.1462-5822.2002.00185.x; Suzuki T, 2001, INFECT IMMUN, V69, P5959, DOI 10.1128/IAI.69.10.5959-5966.2001; TOBE T, 1994, MOL MICROBIOL, V12, P267, DOI 10.1111/j.1365-2958.1994.tb01015.x; VANNHIEU GT, 2000, CELL MICROBIOL, V2, P187, DOI DOI 10.1046/J.1462-5822.2000.00046.X; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WASSEF JS, 1989, INFECT IMMUN, V57, P858, DOI 10.1128/IAI.57.3.858-863.1989; WATARAI M, 1995, EMBO J, V14, P2461, DOI 10.1002/j.1460-2075.1995.tb07243.x; Weinrauch Y, 1999, ANNU REV MICROBIOL, V53, P155, DOI 10.1146/annurev.micro.53.1.155; ZYCHLINSKY A, 1994, MOL MICROBIOL, V11, P619, DOI 10.1111/j.1365-2958.1994.tb00341.x	50	54	56	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14042	14050		10.1074/jbc.M414671200	http://dx.doi.org/10.1074/jbc.M414671200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695506	hybrid			2022-12-25	WOS:000228095500106
J	Kim, KM; Gainetdinov, RR; Laporte, SA; Caron, MG; Barak, LS				Kim, KM; Gainetdinov, RR; Laporte, SA; Caron, MG; Barak, LS			G protein-coupled receptor kinase regulates dopamine D-3 receptor signaling by modulating the stability of a receptor-filamin-beta-arrestin complex - A case of autoreceptor regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; DESENSITIZATION; PHOSPHORYLATION; SEQUESTRATION; ASSOCIATION; ENDOCYTOSIS	In addition to its postsynaptic role, the dopamine D-3 receptor (D3R) serves as a presynaptic autoreceptor, where it provides continuous feedback regulation of dopamine release at nerve terminals for processes as diverse as emotional tone and locomotion. D3R signaling ability is supported by an association with filamin (actin-binding protein 280), which localizes the receptor with G proteins in plasma membrane lipid rafts but is not appreciably antagonized in a classical sense by the ligand-mediated activation of G protein-coupled receptor kinases (GRKs) and beta-arrestins. In this study, we investigate GRK-mediated regulation of D(3)R(.)filamin complex stability and its effect on D(3)R(.)G protein signaling potential. Studies in HEK-293 cells show that in the absence of agonist the D3R immunoprecipitates in a complex containing both filamin A and beta-arrestin2. Moreover, the filamin directly interacts with beta-arrestin2 as assessed by immunoprecipitation and yeast two-hybrid studies. With reductions in basal GRK2/3 activity, an increase in the basal association of filamin A and beta-arrestin2 with D3R is observed. Conversely, increases in the basal GRK2/3 activity result in a reduction in the interaction between the D3R and filamin but a relative increase in the agonist-mediated interaction between beta-arrestin2 and the D3R. Our data suggest that the D3R, filamin A, and beta-arrestin form a signaling complex that is destabilized by agonist- or expression-mediated increases in GRK2/3 activity. These findings provide a novel GRK-based mechanism for regulating D3R signaling potential and provide insight for interpreting D3R autoreceptor behavior.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Chonnam Natl Univ, Coll Pharm, Dept Pharmacol, Kwangju 500757, South Korea	Duke University; Chonnam National University	Caron, MG (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3287, Durham, NC 27710 USA.	caron002@mc.duke.edu	Laporte, Stephane/ABC-4228-2021; Laporte, Stephane A/F-3282-2012; Gainetdinov, Raul R/G-5875-2011	Laporte, Stephane/0000-0002-0633-543X; Gainetdinov, Raul R/0000-0003-2951-6038	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019573] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-61365] Funding Source: Medline; NINDS NIH HHS [NS19573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMLAIKY N, 1984, FEBS LETT, V176, P436, DOI 10.1016/0014-5793(84)81213-2; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Diaz J, 2000, J NEUROSCI, V20, P8677; Enz R, 2002, FEBS LETT, V514, P184, DOI 10.1016/S0014-5793(02)02361-X; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Gainetdinov RR, 2003, NEURON, V38, P291, DOI 10.1016/S0896-6273(03)00192-2; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Gurevich EV, 1999, NEUROPSYCHOPHARMACOL, V20, P60, DOI 10.1016/S0893-133X(98)00066-9; Jones SR, 1999, NAT NEUROSCI, V2, P649, DOI 10.1038/10204; Joseph JD, 2002, NEUROSCIENCE, V112, P39, DOI 10.1016/S0306-4522(02)00067-2; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; Kim OJ, 2004, J BIOL CHEM, V279, P7999, DOI 10.1074/jbc.M308281200; Krueger KM, 1997, J BIOL CHEM, V272, P5; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; Li M, 2002, BIOCHEM PHARMACOL, V63, P859, DOI 10.1016/S0006-2952(01)00932-7; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Luttrell LM, 2002, J CELL SCI, V115, P455; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Onoprishvili I, 2003, MOL PHARMACOL, V64, P1092, DOI 10.1124/mol.64.5.1092; Robinson SW, 1996, J NEUROCHEM, V67, P212; Seck T, 2003, J BIOL CHEM, V278, P10408, DOI 10.1074/jbc.M209655200; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6	31	75	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12774	12780		10.1074/jbc.M408901200	http://dx.doi.org/10.1074/jbc.M408901200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15687500	hybrid			2022-12-25	WOS:000227922000085
J	Patrussi, L; Savino, MT; Pellegrini, M; Paccani, SR; Migliaccio, E; Plyte, S; Lanfrancone, L; Pelicci, PG; Baldari, CT				Patrussi, L; Savino, MT; Pellegrini, M; Paccani, SR; Migliaccio, E; Plyte, S; Lanfrancone, L; Pelicci, PG; Baldari, CT			Cooperation and selectivity of the two Grb2 binding sites of p52Shc in T-cell antigen receptor signaling to Ras family GTPases and Myc-dependent survival	ONCOGENE			English	Article						TCR signaling; T-cell activation; T-cell survival; MAP kinases; stress activated kinases; Rac	PROTEIN-PROTEIN INTERACTIONS; ADAPTER PROTEIN; PHOSPHOTYROSINE-BINDING; SHC ADAPTER; TYROSINE KINASE; GENE ACTIVATION; MEMBRANE RAFTS; COLLAGEN SHC; ZETA-CHAIN; IN-VIVO	Shc proteins participate in a variety of processes regulating cell proliferation, survival and apoptosis. The two ubiquitously expressed isoforms, p52Shc/p46Shc, couple tyrosine kinase receptors to Ras by recruiting Grb2/Sos complexes to a membrane-proximal localization. Tyrosine residues 239/240 and 317 become phosphorylated following receptor engagement and, as such, form two Grb2 binding sites, which have been proposed to be differentially coupled to Myc-dependent survival and to fos-dependent proliferation, respectively. Here, we have addressed the individual function of YY239/240 and Y317 in T-cell antigen receptor (TCR) signaling. We show that p52Shc is phosphorylated on both YY239/240 and Y317 following TCR engagement. Mutation of either YY239/240 or Y317 results in impaired interaction with Grb2 and inhibition of Ras/MAP kinase activation and CD69 induction, supporting a role for both Grb2 binding sites in this function. Substitution of either YY239/240 or Y317 also results in a defective activation of Rac and the coupled stress kinases JNK and p38. Furthermore, mutation of Y317 or, to a larger extent, of YY239/240, results in increased activation-induced cell death, which in cells expressing the FF239/240 mutant is accompanied by impaired TCR-dependent c-myc transcription. The data underline a pleiotropic and nonredundant role of Shc, mediated by both YY239/240 and Y317, in T-cell activation and survival.	Univ Siena, Dept Evolutionary Biol, I-53100 Siena, Italy; European Inst Oncol, I-20141 Milan, Italy; Discovery Res Oncol, Nerviano, Italy	University of Siena; IRCCS European Institute of Oncology (IEO)	Baldari, CT (corresponding author), Univ Siena, Dept Evolutionary Biol, Via Aldo Moro 2, I-53100 Siena, Italy.	baldari@unisi.it	Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019; Migliaccio, Enrica/AAQ-8880-2020; Patrussi, Laura/AAD-4332-2020	Lanfrancone, Luisa/0000-0002-4523-3815; Baldari, Cosima/0000-0002-4414-6744; Patrussi, Laura/0000-0003-1542-6955				Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Alcover A, 2000, CRIT REV IMMUNOL, V20, P325; Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; Baron V, 1998, ENDOCRINOLOGY, V139, P3034, DOI 10.1210/en.139.6.3034; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cantrell DA, 2003, IMMUNOL REV, V192, P122, DOI 10.1034/j.1600-065X.2003.00028.x; D'Oro U, 2002, J IMMUNOL, V169, P6269, DOI 10.4049/jimmunol.169.11.6269; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fruman DA, 2002, SEMIN IMMUNOL, V14, P7, DOI 10.1006/smim.2001.0337; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; Hashimoto A, 1999, J BIOL CHEM, V274, P20139, DOI 10.1074/jbc.274.29.20139; Iwashima M, 2002, P NATL ACAD SCI USA, V99, P4544, DOI 10.1073/pnas.082647499; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Koretzky GA, 1997, IMMUNOL TODAY, V18, P401, DOI 10.1016/S0167-5699(97)01088-8; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Magistrelli G, 1999, EUR J BIOCHEM, V266, P1166, DOI 10.1046/j.1432-1327.1999.00973.x; Matsui K, 2000, J IMMUNOL, V164, P3002, DOI 10.4049/jimmunol.164.6.3002; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Milia E, 1996, ONCOGENE, V13, P767; Nelson BH, 2003, J IMMUNOL, V170, P5563, DOI 10.4049/jimmunol.170.11.5563; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; Pacini S, 2004, MOL CELL BIOL, V24, P1747, DOI 10.1128/MCB.24.4.1747-1757.2004; Pacini S, 1998, J BIOL CHEM, V273, P20487, DOI 10.1074/jbc.273.32.20487; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; Plyte S, 2001, J BIOL CHEM, V276, P14350, DOI 10.1074/jbc.M007854200; Plyte S, 2000, ONCOGENE, V19, P1529, DOI 10.1038/sj.onc.1203451; Pratt JC, 1999, J IMMUNOL, V163, P2586; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Rodman JS, 2000, J CELL SCI, V113, P183; Roose JP, 2003, PLOS BIOL, V1, P271, DOI 10.1371/journal.pbio.0000053; Sakaguchi K, 2001, BIOCHEM BIOPH RES CO, V282, P1154, DOI 10.1006/bbrc.2001.4680; SALCINI AE, 1994, ONCOGENE, V9, P2827; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; Valitutti S, 1997, IMMUNOL TODAY, V18, P299, DOI 10.1016/S0167-5699(97)01075-X; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Ventura A, 2002, J BIOL CHEM, V277, P22370, DOI 10.1074/jbc.M200280200; Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521-4141(199808)28:08<2265::AID-IMMU2265>3.0.CO;2-P; Zhang L, 2002, NAT IMMUNOL, V3, P749, DOI 10.1038/ni820; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	54	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2218	2228		10.1038/sj.onc.1208384	http://dx.doi.org/10.1038/sj.onc.1208384			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15688026				2022-12-25	WOS:000227857900009
J	Hayashi, K; Kaufman, L; Ross, MD; Klotman, PE				Hayashi, K; Kaufman, L; Ross, MD; Klotman, PE			Definition of the critical domains required for homophilic targeting of mouse sidekick molecules	FASEB JOURNAL			English	Article						adhesion molecule; immunoglobulin domain; podocyte; HIV-associated nephropathy	HIV-ASSOCIATED NEPHROPATHY; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; COLLAPSING GLOMERULOPATHIES; IMMUNOGLOBULIN SUPERFAMILY; PODOCYTE PHENOTYPE; IGA NEPHROPATHY; PROLIFERATION; DISEASE; EXPRESSION; EPITHELIUM	Sidekick-1, a cell adhesion molecule of the immunoglobulin superfamily, is up-regulated in glomerular podocytes in the collapsing glomerulopathy of HIV-associated nephropathy (HIVAN). Sidekick-1 and its ortholog sidekick-2 have also been shown to function as neuronal targeting molecules, guiding developing neurons to specific synapses. In the current work, we overexpress mouse sidekick-1 and - 2 in HEK 293 T cells in order to characterize their binding specificities. Cells transiently transfected with either sidekick-1 or - 2 cDNA formed separate aggregates when mixed together, demonstrating that sidekicks are homophilic adhesion molecules. The transfection of the short splice variant ( lacking the first two Ig domains) or a construct encoding sidekick-1 with the second Ig domain deleted both resulted in nearly abolished adhesion. A beta-sheet strand peptide containing the sequence QLVILA corresponding to an amino acid sequence in the second Ig domain of sidekick-1 showed specific interaction with the recombinant first Ig domain-His protein of sidekick-1. Cells expressing a mutant sidekick-1 where the binding sequence QLVILA is deleted failed to mediate significant adhesion. Furthermore, cells transfected with a chimeric sidekick, where the first two Ig domains of sidekick-2 are replaced with the corresponding two Ig domains of sidekick-1, form aggregates with sidekick-1-transfected cells. The reverse chimera, where the first two Ig domains of sidekick-2 are substituted onto sidekick-1, was similarly able to form aggregates with sidekick-2-transfected cells. These results establish that the first and second Ig domains of sidekick-1 and - 2 are necessary and sufficient to mediate and target homophilic adhesion, and the QLVILA sequence is critical to the interaction. Understanding these functional domains has widespread implications in normal development and HIVAN pathogenesis.	CUNY Mt Sinai Sch Med, Div Nephrol, New York, NY 10029 USA; Juntendo Univ, Sch Med, Dept Internal Med, Div Nephrol, Tokyo 113, Japan	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Juntendo University	Hayashi, K (corresponding author), CUNY Mt Sinai Sch Med, Div Nephrol, Annenberg Bldg,Room 23-38,1 Gustave L Levy Pl, New York, NY 10029 USA.	kayo.hayashi@mssm.edu			NIDDK NIH HHS [1 PO1 DK56492] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056492] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA Y, 1998, P 9 GEN INF WORKSH G, P131; Barclay AN, 2003, SEMIN IMMUNOL, V15, P215, DOI 10.1016/S1044-5323(03)00047-2; Barisoni L, 2002, MICROSC RES TECHNIQ, V57, P254, DOI 10.1002/jemt.10084; Barisoni L, 1999, J AM SOC NEPHROL, V10, P51; Barisoni L, 2000, KIDNEY INT, V58, P137, DOI 10.1046/j.1523-1755.2000.00149.x; Barisoni L, 2000, KIDNEY INT, V58, P173, DOI 10.1046/j.1523-1755.2000.00152.x; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Bruggeman LA, 2000, J AM SOC NEPHROL, V11, P2079, DOI 10.1681/ASN.V11112079; FRIES JWU, 1989, LAB INVEST, V60, P205; Hara M, 1998, AM J NEPHROL, V18, P35, DOI 10.1159/000013302; Hishiki T, 2001, KIDNEY BLOOD PRESS R, V24, P99, DOI 10.1159/000054214; Husain M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000019642.55998.69; Kaufman L, 2004, J AM SOC NEPHROL, V15, P1721, DOI 10.1097/01.ASN.0000128975.28958.C2; Kim YH, 2001, KIDNEY INT, V60, P957, DOI 10.1046/j.1523-1755.2001.060003957.x; Lemley KV, 2002, KIDNEY INT, V61, P1475, DOI 10.1046/j.1523-1755.2002.00269.x; Lin YF, 2001, DEVELOPMENT, V128, P1573; Marras D, 2002, NAT MED, V8, P522, DOI 10.1038/nm0502-522; Nakamura T, 2000, AM J NEPHROL, V20, P175, DOI 10.1159/000013580; Nguyen DNT, 1997, DEVELOPMENT, V124, P3303; SALZER JL, 1989, DEV NEUROSCI-BASEL, V11, P377, DOI 10.1159/000111914; Schwartz EJ, 2001, J AM SOC NEPHROL, V12, P1677, DOI 10.1681/ASN.V1281677; Shankland SJ, 2000, KIDNEY INT, V58, P674, DOI 10.1046/j.1523-1755.2000.00213.x; Shirato I, 1996, VIRCHOWS ARCH, V429, P255; White KE, 2002, DIABETES, V51, P3083, DOI 10.2337/diabetes.51.10.3083; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Yamagata M, 2002, CELL, V110, P649, DOI 10.1016/S0092-8674(02)00910-8; Yu J, 2002, DEVELOPMENT, V129, P5301	27	19	21	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					614	+		10.1096/fj.04-2947fje	http://dx.doi.org/10.1096/fj.04-2947fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15703275				2022-12-25	WOS:000227591900017
J	Melchionna, R; Porcelli, D; Mangoni, A; Carlini, D; Liuzzo, G; Spinetti, G; Antonini, A; Capogrossi, MC; Napolitano, M				Melchionna, R; Porcelli, D; Mangoni, A; Carlini, D; Liuzzo, G; Spinetti, G; Antonini, A; Capogrossi, MC; Napolitano, M			Laminar shear stress inhibits CXCR4 expression on endothelial cells: functional consequences for atherogenesis	FASEB JOURNAL			English	Article						chemokine; atherosclerosis; apoptosis	NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; CHEMOKINE RECEPTOR CXCR4; SIGNAL-REGULATED KINASE; VASCULAR SMOOTH-MUSCLE; FACTOR-I; ATHEROSCLEROTIC PLAQUES; HEMODYNAMIC FORCES; FLOW CONDITIONS; GROWTH-FACTOR	Laminar shear stress (LSS) represents a major athero-protective stimulus. However, the mechanisms for this effect are poorly characterized. As chemokine receptors modulate endothelial cell functions, we hypothesized that at least some LSS effects on endothelial cells (ECs) may be due to LSS-dependent changes in chemokine receptor expression and function. Exposure of Human umbilical vein endothelial cells (HUVECs) to 15 dynes/cm(2)/sec(-1) LSS strongly inhibited CXC chemokine receptor 4 (CXCR4) expression at the transcriptional level and impaired stromal-derived factor (SDF)-1/CXCL12-driven chemotaxis. On the contrary, low shear stress (SS; 4 dynes/cm(2)/sec(-1)) only marginally affected CXCR4 expression when compared with static control cells. Differently from CXCR4, the expression of SDF-1 mRNA was not affected by LSS treatment. CXCR4 overexpression induced a dose-dependent endothelial cell apoptosis that was enhanced by SDF-1 treatment and was caspase- dependent. CXCR4 overexpression inhibited the LSS-mediated antiapoptotic effect on ECs and was associated to impairment of LSS-induced ERK1/2 phosphorylation. These findings suggest that LSS-induced CXCR4 down-regulation may contribute to endothelial cell survival. Interestingly, the expression of the proatherogenic chemokines MCP-1 and IL-8 was induced by SDF-1 treatment and by CXCR4 overexpression in HUVECs. Further, the known LSS-induced inhibition of MCP-1 expression was impaired in CXCR4 overexpressing ECs. Finally, CXCR4 was abundantly expressed by human atherosclerotic plaque endothelium that is exposed to low/absent shear stress, while it was poorly expressed by minimally diseased carotid artery endothelium. In conclusion, LSS-dependent CXCR4 down-regulation may contribute to atheroprotection by favoring the integrity of the endothelial barrier and by inhibiting MCP-1 and IL-8 expression.	IRCCS, Ist Dermopat Immacolata, Lab Patol Vasc, I-00167 Rome, Italy; IRCCS, Ctr Cardiol Fdn I Monzino, Lab Biol Vasc & Terapia Genica, Rome, Italy; Univ Sacred Heart, Osped Gemelli, Inst Cardiol, I-00168 Rome, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Centro Cardiologico Monzino; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Napolitano, M (corresponding author), IRCCS, Ist Dermopat Immacolata, Lab Patol Vasc, Via Monti di Creta 104, I-00167 Rome, Italy.	m.napolitano@idi.it	melchionna, Roberta/G-2479-2011; Antonini, Angelo/H-9726-2019; Napolitano, Monica/AAB-3982-2021; Spinetti, Gaia/T-8245-2018; Melchionna, Roberta/AAZ-4111-2021; LIUZZO, GIOVANNA/J-8090-2018	Antonini, Angelo/0000-0003-1040-2807; Spinetti, Gaia/0000-0001-7996-6809; Melchionna, Roberta/0000-0002-8410-9681; LIUZZO, GIOVANNA/0000-0002-5714-0907				Abi-Younes S, 2000, CIRC RES, V86, P131, DOI 10.1161/01.RES.86.2.131; Akimoto S, 2000, CIRC RES, V86, P185, DOI 10.1161/01.RES.86.2.185; Aurrand-Lions M, 2002, NAT IMMUNOL, V3, P116, DOI 10.1038/ni0202-116; Berk BC, 2001, ANN NY ACAD SCI, V947, P93; Bernardini G, 2000, BLOOD, V96, P4039, DOI 10.1182/blood.V96.13.4039.h8004039_4039_4045; Berndt C, 1998, P NATL ACAD SCI USA, V95, P12556, DOI 10.1073/pnas.95.21.12556; Boisvert WA, 2000, IMMUNOL RES, V21, P129, DOI 10.1385/IR:21:2-3:129; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Chiu JJ, 1999, CIRC RES, V85, P238, DOI 10.1161/01.RES.85.3.238; Damas JK, 2002, CIRCULATION, V106, P36, DOI 10.1161/01.CIR.0000020001.09990.90; DAVIES PF, 1986, P NATL ACAD SCI USA, V83, P2114, DOI 10.1073/pnas.83.7.2114; Davis ME, 2001, CIRC RES, V89, P1073, DOI 10.1161/hh2301.100806; Dimmeler S, 1996, FEBS LETT, V399, P71, DOI 10.1016/S0014-5793(96)01289-6; Dimmeler S, 1999, ARTERIOSCL THROM VAS, V19, P656, DOI 10.1161/01.ATV.19.3.656; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fernandis AZ, 2002, J BIOL CHEM, V277, P18111, DOI 10.1074/jbc.M200750200; Garcia-Cardena G, 2001, P NATL ACAD SCI USA, V98, P4478, DOI 10.1073/pnas.071052598; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Gimbrone MA, 1999, THROMB HAEMOSTASIS, V82, P722; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; Haque NS, 2001, BLOOD, V97, P39, DOI 10.1182/blood.V97.1.39; Hayes IM, 1998, ARTERIOSCL THROM VAS, V18, P397, DOI 10.1161/01.ATV.18.3.397; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; Hermann C, 1997, ARTERIOSCL THROM VAS, V17, P3588, DOI 10.1161/01.ATV.17.12.3588; Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Kaiser D, 1997, BIOCHEM BIOPH RES CO, V231, P586, DOI 10.1006/bbrc.1997.6146; Kanda S, 2003, J BIOL CHEM, V278, P257, DOI 10.1074/jbc.M204771200; Lataillade JJ, 2000, BLOOD, V95, P756, DOI 10.1182/blood.V95.3.756; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lin K, 2000, P NATL ACAD SCI USA, V97, P9385, DOI 10.1073/pnas.170282597; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035; Malek AM, 1996, J CELL SCI, V109, P713; Mirshahi F, 2000, THROMB RES, V99, P587, DOI 10.1016/S0049-3848(00)00292-9; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Moriuchi M, 1997, J IMMUNOL, V159, P4322; Murdoch C, 2000, J VASC RES, V37, P1, DOI 10.1159/000025707; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nguyen DH, 2002, J IMMUNOL, V168, P4121, DOI 10.4049/jimmunol.168.8.4121; Odemis V, 2002, J BIOL CHEM, V277, P39801, DOI 10.1074/jbc.M200472200; Palumbo R, 2000, CIRCULATION, V102, P225, DOI 10.1161/01.CIR.102.2.225; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Reape TJ, 1999, ATHEROSCLEROSIS, V147, P213, DOI 10.1016/S0021-9150(99)00346-9; Salcedo R, 2000, FASEB J, V14, P2055, DOI 10.1096/fj.99-0963com; Salcedo R, 2003, BLOOD, V102, P1966, DOI 10.1182/blood-2002-11-3400; Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5; Salcedo R, 2003, MICROCIRCULATION, V10, P359, DOI 10.1038/sj.mn.7800200; Salvucci O, 2002, BLOOD, V99, P2703, DOI 10.1182/blood.V99.8.2703; Schecter AD, 2003, MICROCIRCULATION, V10, P265, DOI 10.1038/sj.mn.7800192; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Terkeltaub R, 1998, CURR OPIN LIPIDOL, V9, P397, DOI 10.1097/00041433-199810000-00003; Tricot O, 2000, CIRCULATION, V101, P2450, DOI 10.1161/01.CIR.101.21.2450; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; Ullrich CK, 2000, BLOOD, V96, P1438, DOI 10.1182/blood.V96.4.1438.h8001438_1438_1442; Urbich C, 2000, CIRC RES, V87, P683, DOI 10.1161/01.RES.87.8.683; Vlahakis SR, 2002, J IMMUNOL, V169, P5546, DOI 10.4049/jimmunol.169.10.5546; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200	69	40	44	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					629	+		10.1096/fj.04-2219fje	http://dx.doi.org/10.1096/fj.04-2219fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15705741				2022-12-25	WOS:000227591900014
J	Cabral, WA; Makareeva, E; Colige, A; Letocha, AD; Ty, JM; Yeowell, HN; Pals, G; Leikin, S; Marini, JC				Cabral, WA; Makareeva, E; Colige, A; Letocha, AD; Ty, JM; Yeowell, HN; Pals, G; Leikin, S; Marini, JC			Mutations near amino end of alpha 1(I) collagen cause combined osteogenesis imperfecta/Ehlers-Danlos syndrome by interference with N-propeptide processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME TYPE-VII; SPLICE ACCEPTOR SITE; I PROCOLLAGEN; PRO-ALPHA-1(I) CHAIN; COL1A2 GENE; CLINICAL-FEATURES; BASE SUBSTITUTION; THERMAL-STABILITY; ALPHA-2(I) CHAIN; PROTEINASE	Patients with OI/EDS form a distinct subset of osteogenesis imperfecta (OI) patients. In addition to skeletal fragility, they have characteristics of Ehlers-Danlos syndrome (EDS). We identified 7 children with types III or IV OI, plus severe large and small joint laxity and early progressive scoliosis. In each child with OI/EDS, we identified a mutation in the first 90 residues of the helical region of alpha 1(I) collagen. These mutations prevent or delay removal of the procollagen N-propeptide by purified N-proteinase (ADAMTS-2) in vitro and in pericellular assays. The mutant pN-collagen which results is efficiently incorporated into matrix by cultured fibroblasts and osteoblasts and is prominently present in newly incorporated and immaturely cross-linked collagen. Dermal collagen fibrils have significantly reduced cross-sectional diameters, corroborating incorporation of pN-collagen into fibrils in vivo. Differential scanning calorimetry revealed that these mutant collagens are less stable than the corresponding procollagens, which is not seen with other type I collagen helical mutations. These mutations disrupt a distinct folding region of high thermal stability in the first 90 residues at the amino end of type I collagen and alter the secondary structure of the adjacent N-proteinase cleavage site. Thus, these OI/EDS collagen mutations are directly responsible for the bone fragility of OI and indirectly responsible for EDS symptoms, by interference with N-propeptide removal.	NICHD, Bone & Extracellular Matrix Branch, NIH, Bethesda, MD 20892 USA; NICHD, Sect Phys Biochem, NIH, Bethesda, MD 20892 USA; Univ Liege, Lab Connect Tissue Biol, B-4000 Liege, Belgium; Duke Univ, Med Ctr, Div Dermatol, Durham, NC 27710 USA; VU Med Ctr, NL-1007 MB Amsterdam, Netherlands	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Liege; Duke University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Marini, JC (corresponding author), NICHD, Bone & Extracellular Matrix Branch, NIH, Bldg 10,Rm 9s239,9000 Rockville Pike, Bethesda, MD 20892 USA.	oidoc@helix.nih.gov	Makareeva, Elena/F-5183-2011; Leikin, Sergey/A-5518-2008	Makareeva, Elena/0000-0002-5815-0760; Leikin, Sergey/0000-0001-7095-0739; Pals, Gerard/0000-0003-4091-7115	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000408, ZIAHD000256] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000408, Z01HD000256] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BATEMAN JF, 1994, MATRIX BIOL, V14, P251, DOI 10.1016/0945-053X(94)90189-9; Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.3.CO;2-P; BONADIO J, 1985, J BIOL CHEM, V260, P1734; Byers P, 2002, CONNECTIVE TISSUE IT, P385, DOI DOI 10.1002/0471221929.CH8; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; Byers PH, 1997, AM J MED GENET, V72, P94, DOI 10.1002/(SICI)1096-8628(19971003)72:1<94::AID-AJMG20>3.0.CO;2-O; Cabral WA, 2003, J BIOL CHEM, V278, P10006, DOI 10.1074/jbc.M212523200; CARR AJ, 1994, J MED GENET, V31, P306, DOI 10.1136/jmg.31.4.306; CHIODO AA, 1992, J BIOL CHEM, V267, P6361; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; COLE WG, 1986, J BIOL CHEM, V261, P5496; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; DALESSIO M, 1991, AM J HUM GENET, V49, P400; DOMBROWSKI KE, 1989, BIOCHEMISTRY-US, V28, P7107, DOI 10.1021/bi00443a048; DOMBROWSKI KE, 1988, J BIOL CHEM, V263, P16545; EYRE DR, 1985, J BIOL CHEM, V260, P1322; FESHCHENKO S, 1997, HUM MUTAT, V12, P138; Giunta C, 1999, J BONE JOINT SURG AM, V81A, P225, DOI 10.2106/00004623-199902000-00010; HELSETH DL, 1979, BIOPOLYMERS, V18, P3005, DOI 10.1002/bip.1979.360181208; HO KKY, 1994, HUM MUTAT, V3, P358, DOI 10.1002/humu.1380030406; HOLMES DF, 1993, J BIOL CHEM, V268, P15758; JONES EY, 1987, BIOPOLYMERS, V26, P463, DOI 10.1002/bip.360260403; Kuznetsova NV, 2003, J MOL BIOL, V331, P191, DOI 10.1016/S0022-2836(03)00715-0; LEHMANN HW, 1994, ARCH DERMATOL RES, V286, P425, DOI 10.1007/BF00371566; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; MARINI JC, 1993, J BIOL CHEM, V268, P2667; Marini JC, 2004, NELSON TXB PEDIAT, P2336; MORIKAWA T, 1980, BIOCHEMISTRY-US, V19, P2646, DOI 10.1021/bi00553a017; Nicholls A C, 2000, J Med Genet, V37, pE33, DOI 10.1136/jmg.37.11.e33; NICHOLLS AC, 1991, HUM GENET, V87, P193, DOI 10.1007/BF00204180; NICHOLLS AC, 1992, HUM GENET, V88, P627, DOI 10.1007/BF02265286; OTTER A, 1989, BIOCHEMISTRY-US, V28, P8003, DOI 10.1021/bi00446a006; Pace JM, 2001, J MED GENET, V38, P443, DOI 10.1136/jmg.38.7.443; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Raff ML, 2000, HUM GENET, V106, P19, DOI 10.1007/s004390051004; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sarafova AP, 1998, HUM MUTAT, V11, P395, DOI 10.1002/(SICI)1098-1004(1998)11:5<395::AID-HUMU7>3.3.CO;2-W; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; SIPPOLA M, 1984, J BIOL CHEM, V259, P4094; TANZAWA K, 1985, J BIOL CHEM, V260, P1120; TORREBLANCO A, 1992, J BIOL CHEM, V267, P2650; TUDERMAN L, 1978, BIOCHEMISTRY-US, V17, P2948, DOI 10.1021/bi00608a002; VASAN NS, 1991, AM J HUM GENET, V48, P305; WATSON RB, 1992, J BIOL CHEM, V267, P9093; WEIL D, 1989, J BIOL CHEM, V264, P16804; WILLING MC, 1994, AM J HUM GENET, V55, P638; WIRTZ MK, 1987, J BIOL CHEM, V262, P16376	49	90	94	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19259	19269		10.1074/jbc.M414698200	http://dx.doi.org/10.1074/jbc.M414698200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15728585	hybrid			2022-12-25	WOS:000228932300083
J	Dhakshinamoorthy, S; Jain, AK; Bloom, DA; Jaiswal, AK				Dhakshinamoorthy, S; Jain, AK; Bloom, DA; Jaiswal, AK			Bach1 competes with Nrf2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H : quinone oxidoreductase 1 gene expression and induction in response to antioxidants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME OXYGENASE-1 GENE; MAF RECOGNITION ELEMENT; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; MEDIATED EXPRESSION; FUNCTIONAL-CHARACTERIZATION; NUCLEAR EXPORT; ACTIVATION; REPRESSOR; NAD(P)H	The antioxidant response element ( ARE) and Nrf2 are known to regulate the expression and coordinated induction of genes encoding detoxifying enzymes including NAD( P) H: quinone oxidoreductase1 (NQO1) in response to antioxidants. In this report, we demonstrate that overexpression of the transcription factor Bach1 in Hep-G2 cells negatively regulated NQO1 gene expression and induction in response to antioxidant t-BHQ. Bandshift and supershift assays revealed that Bach1 binds to the ARE as a heterodimer with small Maf proteins but not as a homodimer or heterodimer with Nrf2. The transfection and ChIP assays revealed that Bach1 and Nrf2 competed with each other to regulate ARE-mediated gene expression. Heme, a negative regulator of Bach1 relieved the Bach1 repression of NQO1 gene expression in transfected cells. The transcription of Bach1 and Nrf2 did not change in response to t-BHQ. Immunofluorescence assays and Western blot analysis revealed that both Bach1 and Nrf2 localized in the cytoplasm and nucleus of the untreated cells. The treatment of cells with t-BHQ resulted in the nuclear accumulation of both Bach1 and Nrf2. Interestingly, the t-BHQ-induced nuclear accumulation of Bach1 was significantly delayed over that of Nrf2. These results led to the conclusion that a balance of Nrf2 versus Bach1 inside the nucleus influences up- or down-regulation of ARE-mediated gene expression. The results further suggest that antioxidant-induced delayed accumulation of Bach1 contributes to the down-regulation of ARE-regulated genes, presumably to reduce the antioxidant enzymes to normal levels.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.	ajaiswal@bcm.tmc.edu	Jain, Abhinav K/A-2540-2013	Jain, Abhinav/0000-0003-3268-514X	NIGMS NIH HHS [GM47466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466, R29GM047466] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHOI SY, 1996, J PARODONTOL IMPLANT, V15, P19; de Macario EC, 2000, FRONT BIOSCI-LANDMRK, V5, pD780; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; JAISWAL AK, 1988, J BIOL CHEM, V263, P13572; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; Kanezaki R, 2001, J BIOL CHEM, V276, P7278, DOI 10.1074/jbc.M004227200; KANNAN S, 2004, J BIOL CHEM, V279, P50810; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MULKAHY RT, 1997, J BIOL CHEM, V272, P7445; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Ogawa K, 2001, EMBO J, V20, P2835, DOI 10.1093/emboj/20.11.2835; Oyake T, 1996, MOL CELL BIOL, V16, P6083; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Radjendirane Venugopal, 1997, P441; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Suzuki H, 2003, J BIOL CHEM, V278, P49246, DOI 10.1074/jbc.M306764200; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894	37	298	316	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16891	16900		10.1074/jbc.M500166200	http://dx.doi.org/10.1074/jbc.M500166200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15734732	hybrid			2022-12-25	WOS:000228615500043
J	Planavila, A; Laguna, JC; Vazquez-Carrera, M				Planavila, A; Laguna, JC; Vazquez-Carrera, M			Nuclear factor-kappa B activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CARDIOMYOCYTE HYPERTROPHY; SKELETAL-MUSCLE; RECEPTOR-ALPHA; PPAR-ALPHA; EXPRESSION; RAT; GROWTH; HEART; DELTA; BETA	Little is known about the mechanisms responsible for the fall in fatty acid oxidation during the development of cardiac hypertrophy. We focused on the effects of nuclear factor (NF)-kappa B activation during cardiac hypertrophy on the activity of peroxisome proliferator-activated receptor (PPAR) beta/delta, which is the predominant PPAR subtype in cardiac cells and plays a prominent role in the regulation of cardiac lipid metabolism. Phenylephrine-induced cardiac hypertrophy in neonatal rat cardiomyocytes caused a reduction in the expression of pyruvate dehydrogenase kinase 4 (Pdk4), a target gene of PPAR beta/delta involved in fatty acid utilization, and a fall in palmitate oxidation that was reversed by NF-kappa B inhibitors. Lipopolysaccharide stimulation of NF-kappa B in embryonic rat heart-derived H9c2 myotubes, which only express PPAR beta/delta, caused both a reduction in Pdk4 expression and DNA binding activity of PPAR beta/delta to its response element, effects that were reversed by NF-kappa B inhibitors. Coimmunoprecipitation studies demonstrated that lipopolysaccharide strongly stimulated the physical interaction between the p65 subunit of NF-kappa B and PPAR beta/delta, providing an explanation for the reduced activity of PPAR beta/delta. Finally, we assessed whether this mechanism was present in vivo in pressure overload-induced cardiac hypertrophy. In hypertrophied hearts of banded rats the reduction in the expression of Pdk4 was accompanied by activation of NF-kappa B and enhanced interaction between p65 and PPAR beta/delta. These results indicate that NF-kappa B activation during cardiac hypertrophy down-regulates PPAR beta/delta activity, leading to a fall in fatty acid oxidation, through a mechanism that involves enhanced protein-protein interaction between the p65 subunit of NF-kappa B and PPAR beta/delta.	Univ Barcelona, Fac Pharm, Dept Pharmacol & Therapeut Chem, Pharmacol Unit, E-08028 Barcelona, Spain	University of Barcelona	Vazquez-Carrera, M (corresponding author), Univ Barcelona, Fac Pharm, Dept Pharmacol & Therapeut Chem, Pharmacol Unit, Diagonal 643, E-08028 Barcelona, Spain.	mvazquezcarrera@ub.edu	Laguna, JCLaguna - Juan C./C-5481-2017; Vázquez-Carrera, Manuel/H-2612-2015	Laguna, JCLaguna - Juan C./0000-0002-7082-0704; Vázquez-Carrera, Manuel/0000-0001-7138-8207; Anna, Planavila Porta/0000-0001-5474-4724				Auwerx J, 1999, CELL, V97, P161; Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; Binas B, 1999, FASEB J, V13, P805, DOI 10.1096/fasebj.13.8.805; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Cabrero A, 2002, J BIOL CHEM, V277, P10100, DOI 10.1074/jbc.M110321200; Cabrero A, 2001, DIABETES, V50, P1883, DOI 10.2337/diabetes.50.8.1883; Cheng LH, 2004, NAT MED, V10, P1245, DOI 10.1038/nm1116; Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Force T, 2002, CIRCULATION, V105, P402, DOI 10.1161/circ.105.4.402; Gilde AJ, 2003, CIRC RES, V92, P518, DOI 10.1161/01.RES.0000060700.55247.7C; Gupta S, 2002, J CELL BIOL, V159, P1019, DOI 10.1083/jcb.200207149; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Higuchi Y, 2002, J MOL CELL CARDIOL, V34, P233, DOI 10.1006/jmcc.2001.1505; Hirotani S, 2002, CIRCULATION, V105, P509, DOI 10.1161/hc0402.102863; KELLY DP, 1994, NEW ENGL J MED, V330, P913; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KIMURA Y, 1994, J MOL CELL CARDIOL, V26, P1145, DOI 10.1006/jmcc.1994.1133; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lorell BH, 2000, CIRCULATION, V102, P470; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; Purcell NH, 2001, P NATL ACAD SCI USA, V98, P6668, DOI 10.1073/pnas.111155798; Sack MN, 1996, CIRCULATION, V94, P2837, DOI 10.1161/01.CIR.94.11.2837; Shin WS, 2002, ATHEROSCLEROSIS, V160, P91, DOI 10.1016/S0021-9150(01)00571-8; TAEGTMEYER H, 1988, HYPERTENSION, V11, P416, DOI 10.1161/01.HYP.11.5.416; Takano H, 2000, CIRC RES, V87, P596, DOI 10.1161/01.RES.87.7.596; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; THAIK CM, 1995, J CLIN INVEST, V96, P1093, DOI 10.1172/JCI118095; Westergaard M, 2003, J INVEST DERMATOL, V121, P1104, DOI 10.1046/j.1523-1747.2003.12536.x; Wu P, 1997, FASEB J, V11, pA1355	33	105	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17464	17471		10.1074/jbc.M414220200	http://dx.doi.org/10.1074/jbc.M414220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728586	hybrid			2022-12-25	WOS:000228615500113
J	Bare, DJ; Kettlun, CS; Liang, M; Bers, DM; Mignery, GA				Bare, DJ; Kettlun, CS; Liang, M; Bers, DM; Mignery, GA			Cardiac type 2 inositol 1,4,5-trisphosphate receptor - Interaction and modulation by calcium/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNELS; CA2+ RELEASE; RYANODINE RECEPTOR; NUCLEAR-ENVELOPE; SARCOPLASMIC-RETICULUM; EXPRESSION; INSP(3); BINDING; LOCALIZATION; MYOCYTES	The type 2 inositol 1,4,5-trisphosphate receptor (InsP(3)R2) was identified previously as the predominant isoform in cardiac ventricular myocytes. Here we reported the subcellular localization of InsP(3)R2 to the cardiomyocyte nuclear envelope (NE). The other major known endo/sarcoplasmic reticulum calcium-release channel ( ryanodine receptor) was not localized to the NE, indicating functional segregation of these channels and possibly a unique role for InsP(3)R2 in regulating nuclear calcium dynamics. Immunoprecipitation experiments revealed that the NE InsP(3)R2 associates with Ca2+/calmodulin-dependent protein kinase II delta (CaMKII delta), the major isoform expressed in cardiac myocytes. Recombinant InsP(3)R2 and CaMKII delta(B) also coimmunoprecipitated after co-expression in COS-1 cells. Additionally, the amino-terminal 1078 amino acids of the InsP(3)R2 were sufficient for interaction with CaMKII delta(B) and associated upon mixing following separate expression. CaMKII can also phosphorylate InsP(3)R2, as demonstrated by P-32 labeling. Incorporation of CaMKII-treated InsP(3)R2 into planar lipid bilayers revealed that InsP(3)-mediated channel open probability is significantly reduced ( similar to 11 times) by phosphorylation via CaMKII. We concluded that the InsP(3)R2 and CaMKII delta likely represent two central components of a multiprotein signaling complex, and this raises the possibility that calcium release via InsP(3)R2 in the myocyte NE may activate local CaMKII signaling, which may feedback on InsP(3)R2 function.	Loyola Univ, Dept Physiol, Maywood, IL 60153 USA; Loyola Univ, Cardiovasc Inst, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago	Mignery, GA (corresponding author), Loyola Univ, Dept Physiol, 2160 S 1st Ave, Maywood, IL 60153 USA.	gmigner@lumc.edu	Bers, Donald M/C-4507-2012	Bers, Donald/0000-0002-2237-9483	NHLBI NIH HHS [HL30077] Funding Source: Medline; NIMH NIH HHS [MH53367] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030077, R01HL030077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053367, R29MH053367] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BASSANI RA, 1992, J PHYSIOL-LONDON, V453, P591, DOI 10.1113/jphysiol.1992.sp019246; Bootman MD, 2000, CELL MOL LIFE SCI, V57, P371, DOI 10.1007/PL00000699; Czubryt MP, 1996, J MOL CELL CARDIOL, V28, P455, DOI 10.1006/jmcc.1996.0042; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Echevarria W, 2003, NAT CELL BIOL, V5, P440, DOI 10.1038/ncb980; Felzen B, 1998, CIRC RES, V82, P438, DOI 10.1161/01.RES.82.4.438; Furuichi T, 1999, CALCIUM AS A CELLULAR REGULATOR, P200; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GO LO, 1995, J CLIN INVEST, V95, P888, DOI 10.1172/JCI117739; Guihard G, 1997, FEBS LETT, V414, P89, DOI 10.1016/S0014-5793(97)00949-6; Huh YH, 2003, FEBS LETT, V555, P411, DOI 10.1016/S0014-5793(03)01273-0; JORGENSEN AO, 1993, J CELL BIOL, V120, P969, DOI 10.1083/jcb.120.4.969; Kapiloff MS, 2001, J CELL SCI, V114, P3167; KAUFMANN SH, 1981, EXP CELL RES, V132, P105, DOI 10.1016/0014-4827(81)90088-4; Kaznacheyeva E, 1998, J GEN PHYSIOL, V111, P847, DOI 10.1085/jgp.111.6.847; Kockskamper J, 2001, BIOPHYS J, V81, P2590, DOI 10.1016/S0006-3495(01)75903-6; Laflamme K, 2002, J CELL BIOCHEM, V85, P219, DOI 10.1002/jcb.10124; Lipp P, 2000, CURR BIOL, V10, P939, DOI 10.1016/S0960-9822(00)00624-2; Mackenzie L, 2002, J PHYSIOL-LONDON, V541, P395, DOI 10.1113/jphysiol.2001.013411; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; Marks AR, 2000, CIRC RES, V87, P8, DOI 10.1161/01.RES.87.1.8; Matifat F, 2001, PFLUG ARCH EUR J PHY, V441, P796, DOI 10.1007/s004240000479; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MOSCHELLA MC, 1993, J CELL BIOL, V120, P1137, DOI 10.1083/jcb.120.5.1137; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Perez PJ, 1997, J BIOL CHEM, V272, P23961, DOI 10.1074/jbc.272.38.23961; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; Ramos-Franco J, 2000, BIOPHYS J, V79, P1388, DOI 10.1016/S0006-3495(00)76391-0; Ramos-Franco J, 1998, BIOPHYS J, V75, P2783, DOI 10.1016/S0006-3495(98)77721-5; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; Sugiyama T, 2000, FEBS LETT, V466, P29, DOI 10.1016/S0014-5793(99)01732-9; Tasker PN, 2000, BIOCHEM BIOPH RES CO, V273, P907, DOI 10.1006/bbrc.2000.3036; Wu X, 2004, CIRCULATION, V110, P285; Yang JC, 1998, J CELL BIOL, V142, P511, DOI 10.1083/jcb.142.2.511; Zhu DM, 1996, BIOCHEMISTRY-US, V35, P7214, DOI 10.1021/bi952471h; ZIMA A, 2005, BIOPHYS J S, V88, P433; Zima AV, 2004, J PHYSIOL-LONDON, V555, P607, DOI 10.1113/jphysiol.2003.058529; Zima AV, 2003, J PHYSIOL-LONDON, V550, P765, DOI 10.1113/jphysiol.2003.040345	42	141	144	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15912	15920		10.1074/jbc.M414212200	http://dx.doi.org/10.1074/jbc.M414212200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710625	hybrid			2022-12-25	WOS:000228444800057
J	Liu, MZ; Durfee, T; Cabrera, JE; Zhao, K; Jin, DJ; Blattner, FR				Liu, MZ; Durfee, T; Cabrera, JE; Zhao, K; Jin, DJ; Blattner, FR			Global transcriptional programs reveal a carbon source foraging strategy by Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE LIFETIME IMAGES; RATE-DEPENDENT REGULATION; LAC OPERON EXPRESSION; GROWTH-RATE; RNA-POLYMERASE; CATABOLITE REPRESSION; SALMONELLA-TYPHIMURIUM; REGULATORY MECHANISMS; SIGMA(S) SUBUNIT; TEXTURE ANALYSIS	By exploring global gene expression of Escherichia coli growing on six different carbon sources, we discovered a striking genome transcription pattern: as carbon substrate quality declines, cells systematically increase the number of genes expressed. Gene induction occurs in a hierarchical manner and includes many factors for uptake and metabolism of better but currently unavailable carbon sources. Concomitantly, cells also increase their motility. Thus, as the growth potential of the environment decreases, cells appear to devote progressively more energy on the mere possibility of improving conditions. This adaptation is not what would be predicated by classic regulatory models alone. We also observe an inverse correlation between gene activation and rRNA synthesis suggesting that reapportioning RNA polymerase ( RNAP) contributes to the expanded genome activation. Significant differences in RNAP distribution in vivo, monitored using an RNAP-green fluorescent protein fusion, from energy-rich and energy-poor carbon source cultures support this hypothesis. Together, these findings represent the integration of both substrate-specific and global regulatory systems, and may be a bacterial approximation to metazoan risk-prone foraging behavior.	Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; NCI, Transcript Control Sect, Gene Regulat & Crhomosome Biol Lab, Ctr Canc Res,NIH, Frederick, MD 21702 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Blattner, FR (corresponding author), Univ Wisconsin, Dept Genet, 445 Henry Mall, Madison, WI 53706 USA.	fred@genome.wisc.edu			NATIONAL CANCER INSTITUTE [Z01BC010632, ZIABC010632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035682] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35682-17S1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ades SE, 2004, CURR OPIN MICROBIOL, V7, P157, DOI 10.1016/j.mib.2004.02.010; Anthony LC, 2003, METHOD ENZYMOL, V370, P181; Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327; Bockhorst J, 2003, BIOINFORMATICS, V19, P1227, DOI 10.1093/bioinformatics/btg147; BOTSFORD JL, 1975, J BACTERIOL, V124, P380, DOI 10.1128/JB.124.1.380-390.1975; Bremer H., 1996, E COLI SALMONELLA CE, V2, P1553; Bruckner R, 2002, FEMS MICROBIOL LETT, V209, P141; Cabrera JE, 2003, MOL MICROBIOL, V50, P1493, DOI 10.1046/j.1365-2958.2003.03805.x; CASHEL M, 1996, ESCHERICHIA COLI SAL, V1, P1458; Crasnier M, 1996, RES MICROBIOL, V147, P479, DOI 10.1016/0923-2508(96)84002-2; Cunning C, 1999, J BACTERIOL, V181, P4853, DOI 10.1128/JB.181.16.4853-4862.1999; Gentry DR, 1996, MOL MICROBIOL, V19, P1373, DOI 10.1111/j.1365-2958.1996.tb02480.x; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; HARALICK RM, 1973, IEEE T SYST MAN CYB, VSMC3, P610, DOI 10.1109/TSMC.1973.4309314; HASTJARJO T, 1990, J EXP ANAL BEHAV, V53, P155, DOI 10.1901/jeab.1990.53-155; Hengge-Aronis R, 2002, MICROBIOL MOL BIOL R, V66, P373, DOI 10.1128/MMBR.66.3.373-395.2002; Hengge-Aronis R, 2002, J MOL MICROB BIOTECH, V4, P341; Hua Q, 2004, APPL ENVIRON MICROB, V70, P2354, DOI 10.1128/AEM.70.4.2354-2366.2004; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; Karp PD, 2002, NUCLEIC ACIDS RES, V30, P56, DOI 10.1093/nar/30.1.56; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Kuo JT, 2003, FEBS LETT, V553, P397, DOI 10.1016/S0014-5793(03)01071-8; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; LENDENMANN U, 1995, MICROBIOL-SGM, V141, P71, DOI 10.1099/00221287-141-1-71; MANDELSTAM J, 1962, BIOCHEM J, V82, P489, DOI 10.1042/bj0820489; MIURA A, 1981, CELL, V25, P773, DOI 10.1016/0092-8674(81)90185-9; Muffler A, 1996, EMBO J, V15, P1333, DOI 10.1002/j.1460-2075.1996.tb00475.x; Murata S, 2001, CYTOMETRY, V43, P94, DOI 10.1002/1097-0320(20010201)43:2<94::AID-CYTO1023>3.0.CO;2-4; Murata S, 2001, J HISTOCHEM CYTOCHEM, V49, P1443, DOI 10.1177/002215540104901112; NEIDHARDT FC, 1957, J BACTERIOL, V73, P260, DOI 10.1128/JB.73.2.260-263.1957; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NORRIS TE, 1972, J MOL BIOL, V64, P633, DOI 10.1016/0022-2836(72)90088-5; Oh MK, 2002, J BIOL CHEM, V277, P13175, DOI 10.1074/jbc.M110809200; Rosenow C, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.22.e112; Ruiz N, 2003, J BACTERIOL, V185, P5984, DOI 10.1128/JB.185.20.5984-5992.2003; Saier MH, 1998, BIOTECHNOL BIOENG, V58, P170, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<170::AID-BIT9>3.0.CO;2-I; Salgado H, 2004, NUCLEIC ACIDS RES, V32, pD303, DOI 10.1093/nar/gkh140; Schauder S, 2001, GENE DEV, V15, P1468, DOI 10.1101/gad.899601; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; Sperandio V, 2002, MOL MICROBIOL, V43, P809, DOI 10.1046/j.1365-2958.2002.02803.x; Taga ME, 2003, MOL MICROBIOL, V50, P1411, DOI 10.1046/j.1365-2958.2003.03781.x; TSENG CP, 1994, J BACTERIOL, V176, P6599, DOI 10.1128/JB.176.21.6599-6605.1994; VanBogelen RA, 1996, J BACTERIOL, V178, P4344, DOI 10.1128/jb.178.15.4344-4366.1996; WANNER BL, 1978, J BACTERIOL, V136, P947, DOI 10.1128/JB.136.3.947-954.1978; Weyn B, 2000, ANAL QUANT CYTOL, V22, P373; Wick LM, 2001, ENVIRON MICROBIOL, V3, P588, DOI 10.1046/j.1462-2920.2001.00231.x; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Zhi HJ, 2003, J BIOL CHEM, V278, P47340, DOI 10.1074/jbc.M305430200; Zhou YN, 1998, P NATL ACAD SCI USA, V95, P2908, DOI 10.1073/pnas.95.6.2908; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401	51	152	156	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15921	15927		10.1074/jbc.M414050200	http://dx.doi.org/10.1074/jbc.M414050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705577	hybrid			2022-12-25	WOS:000228444800058
J	Okura, M; Fang, JM; Salto, ML; Singer, RS; Docampo, R; Moreno, SNJ				Okura, M; Fang, JM; Salto, ML; Singer, RS; Docampo, R; Moreno, SNJ			A lipid-modified phosphoinositide-specific phospholipase C (TcPI-PLC) is involved in differentiation of trypomastigotes to amastigotes of Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MAMMALIAN-CELLS; INVASION; EXPRESSION; OLIGONUCLEOTIDES; OVEREXPRESSION; PALMITOYLATION; DIACYLGLYCEROL; TRANSFORMATION; LEISHMANIA	The phosphoinositide-specific phospholipase C ( PIPLC) is an important component of the inositol phosphate/ diacylglycerol signaling pathway. A newly discovered Trypanosoma cruzi PI-PLC (TcPI-PLC) is lipid modified in its N terminus, targeted to its plasma membrane, and believed to play a role in differentiation of the parasite because its expression increases during the differentiation of trypomastigote to amastigote stages. To determine whether TcPI-PLC is involved in this differentiation step, antisense inhibition using phosphorothioate-modified oligonucleotides, and overexpression of the gene were performed. Antisense oligonucleotide-treated parasites showed a reduced rate of differentiation in comparison to controls, as well as accumulation of intermediate forms. Overexpression of TcPI-PLC led to a faster differentiation rate. In contrast, overexpression of a mutant TcPI-PLC that lacked the lipid modification at its N terminus did not affect the differentiation rate. Therefore, TcPI-PLC is involved, when expressed in the plasma membrane, in the differentiation of trypomastigotes to amastigotes, an essential step for the intracellular replication of these parasites.	Univ Georgia, Ctr Trop & Global Emerging Dis, Athens, GA 30602 USA; Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA; Univ Illinois, Ctr Zoonoses Res, Urbana, IL 61802 USA; Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University System of Georgia; University of Georgia	Moreno, SNJ (corresponding author), Univ Georgia, Ctr Trop & Global Emerging Dis, Athens, GA 30602 USA.	s-moreno@cb.uga.edu			NCRR NIH HHS [C06 RR16515-01] Funding Source: Medline; NIAID NIH HHS [AI-48039] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR016515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI048039] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHKTAR S, 1991, LIFE SCI, V49, P1793; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BIZZOZERO OA, 1995, METHOD ENZYMOL, V250, P361; BONE GJ, 1956, NATURE, V178, P308, DOI 10.1038/178308a0; BURLEIGH BA, 1995, ANNU REV MICROBIOL, V49, P175, DOI 10.1146/annurev.mi.49.100195.001135; Caler EV, 1998, EMBO J, V17, P4975, DOI 10.1093/emboj/17.17.4975; COOPER R, 1993, J CELL BIOL, V122, P149, DOI 10.1083/jcb.122.1.149; DOCAMPO R, 1991, BIOCHEM J, V275, P407, DOI 10.1042/bj2750407; DOCAMPO R, 1993, MOL BIOCHEM PARASIT, V59, P305, DOI 10.1016/0166-6851(93)90228-P; Furuya T, 2000, J BIOL CHEM, V275, P6428, DOI 10.1074/jbc.275.9.6428; Godsel LM, 1999, EMBO J, V18, P2057, DOI 10.1093/emboj/18.8.2057; Gomez ML, 1999, INT J PARASITOL, V29, P981, DOI 10.1016/S0020-7519(99)00041-7; GOMEZ ML, 1989, MOL BIOCHEM PARASIT, V36, P101, DOI 10.1016/0166-6851(89)90182-5; Gonzalez J, 2003, BIOCHEM J, V374, P647, DOI 10.1042/BJ20030215; Grellier P, 1999, MOL BIOCHEM PARASIT, V98, P239, DOI 10.1016/S0166-6851(98)00172-8; Hall B. Fenton, 1993, Seminars in Cell Biology, V4, P323, DOI 10.1006/scel.1993.1039; HALLAK H, 1994, J BIOL CHEM, V269, P4571; HOSMER DW, 1991, AM J PUBLIC HEALTH, V81, P1630, DOI 10.2105/AJPH.81.12.1630; IRVINE R, 1996, NATURE, V380, P582; KANBARA H, 1990, Japanese Journal of Parasitology, V39, P226; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; KENDALL G, 1990, EMBO J, V9, P2751, DOI 10.1002/j.1460-2075.1990.tb07462.x; Malaga S, 2001, INFECT IMMUN, V69, P353, DOI 10.1128/IAI.69.1.353-359.2001; Minning TA, 2003, MOL BIOCHEM PARASIT, V131, P55, DOI 10.1016/S0166-6851(03)00189-0; Mortara RA, 2001, J EUKARYOT MICROBIOL, V48, P27, DOI 10.1111/j.1550-7408.2001.tb00413.x; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Nozaki T, 1999, MOL BIOCHEM PARASIT, V102, P283, DOI 10.1016/S0166-6851(99)00108-5; RAMAZEILLES C, 1994, P NATL ACAD SCI USA, V91, P7859, DOI 10.1073/pnas.91.17.7859; ROTHMAN KJ, 1986, ANN INTERN MED, V105, P445, DOI 10.7326/0003-4819-105-3-445; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMATZ DM, 1982, PARASITOLOGY, V85, P115, DOI 10.1017/S0031182000054202; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; TEIXEIRA SMR, 1994, J BIOL CHEM, V269, P20509; Temperton NJ, 1998, MOL BIOCHEM PARASIT, V96, P167, DOI 10.1016/S0166-6851(98)00127-3; Tomas AM, 1997, EUR J BIOCHEM, V244, P596, DOI 10.1111/j.1432-1033.1997.t01-1-00596.x; TOMLINSON S, 1995, PARASITOLOGY, V110, P547, DOI 10.1017/S0031182000065264; Woolsey AM, 2003, J CELL SCI, V116, P3611, DOI 10.1242/jcs.00666; Zar J. H., 1984, BIOSTAT ANAL, P718	40	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16235	16243		10.1074/jbc.M414535200	http://dx.doi.org/10.1074/jbc.M414535200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710612	hybrid			2022-12-25	WOS:000228444800093
J	Burden, AF; Manley, NC; Clark, AD; Gartler, SM; Laird, CD; Hansen, RS				Burden, AF; Manley, NC; Clark, AD; Gartler, SM; Laird, CD; Hansen, RS			Hemimethylation and non-CpG methylation levels in a promoter region of human LINE-1 (L1) repeated elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIRPIN-BISULFITE PCR; DNA METHYLATION; GENE; PATTERNS; SITES; DEMETHYLATION; INHERITANCE; KINETICS; CELLS	DNA methylation within the promoter region of human LINE1 (L1) transposable elements is important for maintaining transcriptional inactivation and for inhibiting L1 transposition. Determining methylation patterns on the complementary strands of repeated sequences is difficult using standard bisulfite methylation analysis. Evolutionary changes in each repeat and the variations between cells or alleles of the same repeat lead to a heterogeneous population of sequences. Potential sequence biases can arise during analyses that are different for the converted sense and antisense strands. These problems can be avoided with hairpin-bisulfite PCR, a double-stranded PCR method in which complementary strands of individual molecules are attached by a hairpin linker ligated to genomic DNA. Using human L1 elements to study methylation of repeated sequences, (i) we distinguish valid L1 sequences from redundant and contaminant sequences by applying the powerful new method of molecular barcodes, (ii) we resolve a controversy on the level of hemimethylation of L1 sequences in fetal fibroblasts in favor of relatively little hemimethylation, (iii) we report that human L1 sequences in different cell types also have primarily concordant CpG methylation patterns on complementary strands, and (iv) we provide evidence that non-CpG cytosines within the regions analyzed are rarely methylated.	Univ Washington, Dept Biol, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Burden, AF (corresponding author), Univ Washington, Dept Biol, Box 351800, Seattle, WA 98195 USA.	afb4@u.washington.edu; cdlaird@u.washington.edu	Hu, Ruogu/B-2203-2008		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD002274] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016659, R01HD016659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053805] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 02274, HD 16659] Funding Source: Medline; NIGMS NIH HHS [GM 53805] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; Edwards Matthew J., 1992, Human Mutation, V1, P47, DOI 10.1002/humu.1380010108; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; Hansen RS, 2003, HUM MOL GENET, V12, P2559, DOI 10.1093/hmg/ddg268; Hata K, 1997, GENE, V189, P227, DOI 10.1016/S0378-1119(96)00856-6; Hermann A, 2004, J BIOL CHEM, V279, P48350, DOI 10.1074/jbc.M403427200; Laird CD, 2004, P NATL ACAD SCI USA, V101, P204, DOI 10.1073/pnas.2536758100; Miner BE, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh132; OTTO SP, 1990, GENETICS, V124, P429; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; PONCZ M, 1982, HEMOGLOBIN, V6, P27, DOI 10.3109/03630268208996930; SALUZ HP, 1986, P NATL ACAD SCI USA, V83, P7167, DOI 10.1073/pnas.83.19.7167; Singal R, 2001, BLOOD, V98, P3441, DOI 10.1182/blood.V98.12.3441; Stirzaker C, 1997, CANCER RES, V57, P2229; THAYER RE, 1993, GENE, V133, P273, DOI 10.1016/0378-1119(93)90651-I; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422; WIGLER MH, 1981, CELL, V24, P285, DOI 10.1016/0092-8674(81)90317-2; Woodcock DM, 1997, J BIOL CHEM, V272, P7810, DOI 10.1074/jbc.272.12.7810; Zhou YX, 1998, GENOME, V41, P23, DOI 10.1139/gen-41-1-23	19	39	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14413	14419		10.1074/jbc.M413836200	http://dx.doi.org/10.1074/jbc.M413836200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15710616	hybrid			2022-12-25	WOS:000228236800009
J	Chen, CC; Wu, HY				Chen, CC; Wu, HY			LeuO protein delimits the transcriptionally active and repressive domains on the bacterial chromosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER RELAY MECHANISM; P1 PLASMID CENTROMERE; COLI BGL PROMOTER; ESCHERICHIA-COLI; LAC REPRESSOR; H-NS; SALMONELLA-TYPHIMURIUM; SACCHAROMYCES-CEREVISIAE; CHROMATIN INSULATOR; BOUNDARY ELEMENTS	LeuO protein relieves bacterial gene silencer AT8-mediated transcriptional repression as part of a promoter relay mechanism found in the ilvIH-leuO-leuABCD gene cluster. The gene silencing activity has recently been characterized as a nucleoprotein filament initiated at the gene silencer. In this gene locus, the nucleoprotein filament cis-spreads toward the target leuO promoter and results in the repression of the leuO gene. Although the cis-spreading nature of the transcriptionally repressive nucleoprotein filament has been revealed, the mechanism underlying LeuO-mediated gene silencing relief remains unknown. We have demonstrated here that LeuO functions analogously to the eukaryotic boundary element that delimits the transcriptionally active and repressive domains on the chromosome by blocking the cis-spreading pathway of the transcriptionally repressive heterochromatin. Given that one LeuO-binding site is positioned between the gene silencer and the target promoter, the simultaneous presence of a second LeuO-binding site synergistically enhances the blockade, resulting in a cooperative increase in LeuO-mediated gene silencing relief. A known DNA loop-forming protein, the lac repressor (LacI), was used to confirm that cooperative protein binding via DNA looping is responsible for the blocking synergy. Indeed, a distal LeuO site located downstream cooperates with the LeuO sites located upstream of the leuO gene, resulting in synergistic relief for the repressed leuO gene via looping out the intervening DNA between LeuO sites in the ilvIH-leuO-leuABCD gene cluster.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Chen, CC (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave, Detroit, MI 48201 USA.	haiwu@med.wayne.edu			NIGMS NIH HHS [GM-53617] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053617, R01GM053617] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bell AC, 1999, CURR OPIN GENET DEV, V9, P191, DOI 10.1016/S0959-437X(99)80029-X; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; BESSE M, 1986, EMBO J, V5, P1377, DOI 10.1002/j.1460-2075.1986.tb04370.x; Bi X, 1999, P NATL ACAD SCI USA, V96, P11934, DOI 10.1073/pnas.96.21.11934; Blanton J, 2003, GENE DEV, V17, P664, DOI 10.1101/gad.1052003; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; Capelson M, 2004, BIOL CELL, V96, P617, DOI 10.1016/j.biolcel.2004.06.004; Caramel A, 1998, J MOL BIOL, V284, P875, DOI 10.1006/jmbi.1998.2191; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Chen CC, 2005, J BIOL CHEM, V280, P5101, DOI 10.1074/jbc.M411840200; Chen CC, 2003, J BIOL CHEM, V278, P38094, DOI 10.1074/jbc.M300461200; Chen CC, 2003, FRONT BIOSCI, V8, pD430, DOI 10.2741/968; Chen CC, 2001, J BIOL CHEM, V276, P9478, DOI 10.1074/jbc.M010501200; CHEN J, 1994, J BIOL CHEM, V269, P12482; CHEN J, 1994, BIOCHEMISTRY-US, V33, P1234, DOI 10.1021/bi00171a025; Chen SQ, 2001, GENETICS, V159, P1649; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Donze D, 2002, BIOESSAYS, V24, P344, DOI 10.1002/bies.10072; Dorman CJ, 2004, NAT REV MICROBIOL, V2, P391, DOI 10.1038/nrmicro883; Fang M, 1998, J BIOL CHEM, V273, P29929, DOI 10.1074/jbc.273.45.29929; Fang M, 1998, J BACTERIOL, V180, P626, DOI 10.1128/JB.180.3.626-633.1998; Fernandez-Mora M, 2004, J BACTERIOL, V186, P2909, DOI 10.1128/JB.186.10.2909-2920.2004; Festenstein R, 2000, CURR OPIN GENET DEV, V10, P199, DOI 10.1016/S0959-437X(00)00060-5; Fourel G, 1999, EMBO J, V18, P2522, DOI 10.1093/emboj/18.9.2522; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; Hanai R, 1996, J BIOL CHEM, V271, P17469, DOI 10.1074/jbc.271.29.17469; Hao JJ, 2002, J BACTERIOL, V184, P4857, DOI 10.1128/JB.184.17.4857-4867.2002; Harmer T, 2001, P NATL ACAD SCI USA, V98, P427, DOI 10.1073/pnas.98.2.427; HENDRICH BD, 1995, HUM MOL GENET, V4, P1765, DOI 10.1093/hmg/4.suppl_1.1765; Ishii K, 2003, MOL CELL, V11, P237, DOI 10.1016/S1097-2765(03)00010-8; Ishii K, 2002, CELL, V109, P551, DOI 10.1016/S0092-8674(02)00756-0; Jordi BJAM, 1997, J BIOL CHEM, V272, P12083, DOI 10.1074/jbc.272.18.12083; Jordi JAM, 2000, J BIOL CHEM, V275, P12123, DOI 10.1074/jbc.275.16.12123; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; Kamakaka RT, 2003, CURR BIOL, V13, pR317, DOI 10.1016/S0960-9822(03)00236-7; Kamakaka RT, 2002, CURR BIOL, V12, pR535, DOI 10.1016/S0960-9822(02)01032-1; KANIA J, 1976, P NATL ACAD SCI USA, V73, P3529, DOI 10.1073/pnas.73.10.3529; Kim SK, 1999, P NATL ACAD SCI USA, V96, P8557, DOI 10.1073/pnas.96.15.8557; Klauck E, 1997, MOL MICROBIOL, V25, P559, DOI 10.1046/j.1365-2958.1997.4911852.x; KRAMER H, 1988, EMBO J, V7, P547, DOI 10.1002/j.1460-2075.1988.tb02844.x; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; LEHMING N, 1987, EMBO J, V6, P3145, DOI 10.1002/j.1460-2075.1987.tb02625.x; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; LYNCH AS, 1995, P NATL ACAD SCI USA, V92, P1896, DOI 10.1073/pnas.92.6.1896; Mukerji M, 1997, MOL MICROBIOL, V24, P617, DOI 10.1046/j.1365-2958.1997.3621725.x; Murphy TD, 1998, CELL, V93, P317, DOI 10.1016/S0092-8674(00)81158-7; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; Oki M, 2004, MOL CELL BIOL, V24, P1956, DOI 10.1128/MCB.24.5.1956-1967.2004; Oki M, 2002, CURR OPIN CELL BIOL, V14, P299, DOI 10.1016/S0955-0674(02)00327-7; Perrod S, 2003, CELL MOL LIFE SCI, V60, P2303, DOI 10.1007/s00018-003-3246-x; Pryde FE, 1999, EMBO J, V18, P2538, DOI 10.1093/emboj/18.9.2538; Repoila F, 2001, J BACTERIOL, V183, P4012, DOI 10.1128/JB.183.13.4012-4023.2001; Rimsky S, 2004, CURR OPIN MICROBIOL, V7, P109, DOI 10.1016/j.mib.2004.02.001; Rodionov O, 1999, SCIENCE, V283, P546, DOI 10.1126/science.283.5401.546; Schnetz K, 1996, NUCLEIC ACIDS RES, V24, P2422, DOI 10.1093/nar/24.12.2422; SCHNETZ K, 1995, EMBO J, V14, P2545, DOI 10.1002/j.1460-2075.1995.tb07252.x; SHI XL, 1995, J BACTERIOL, V177, P810, DOI 10.1128/jb.177.3.810-814.1995; Tham WH, 2002, ONCOGENE, V21, P512, DOI 10.1038/sj.onc.1205078; Ueguchi C, 1998, J BACTERIOL, V180, P190, DOI 10.1128/JB.180.1.190-193.1998; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; WANG Q, 1993, MOL MICROBIOL, V7, P883, DOI 10.1111/j.1365-2958.1993.tb01179.x; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; WU HY, 1995, CELL, V82, P445, DOI 10.1016/0092-8674(95)90433-6; Wu HY, 2003, PROG NUCLEIC ACID RE, V73, P43, DOI 10.1016/S0079-6603(03)01002-X; Yarmolinsky M, 2000, CURR OPIN MICROBIOL, V3, P138, DOI 10.1016/S1369-5274(00)00065-5; Zhimulev I. F., 2003, Genetika, V39, P187	70	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15111	15121		10.1074/jbc.M414544200	http://dx.doi.org/10.1074/jbc.M414544200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15711009	hybrid			2022-12-25	WOS:000228236800094
J	Dietrich, LEP; LaGrassa, TJ; Rohde, J; Cristodero, M; MEiringer, CTA; Ungermann, C				Dietrich, LEP; LaGrassa, TJ; Rohde, J; Cristodero, M; MEiringer, CTA; Ungermann, C			ATP-independent control of Vac8 palmitoylation by a SNARE subcomplex on yeast vacuoles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO REACTIONS; SACCHAROMYCES-CEREVISIAE; FUSION REQUIRES; EARLY-STAGE; ALPHA-SNAP; R-SNARE; PROTEIN; COMPLEX; MEMBRANE; DOCKING	Yeast vacuole fusion requires palmitoylated Vac8. We previously showed that Vac8 acylation occurs early in the fusion reaction, is blocked by antibodies against Sec18 (yeast N-ethylmaleimide-sensitive fusion protein (NSF)), and is mediated by the R-SNARE Ykt6. Here we analyzed the regulation of this reaction on purified vacuoles. We show that Vac8 acylation is restricted to a narrow time window, is independent of ATP hydrolysis by Sec18, and is stimulated by the ion chelator EDTA. Analysis of vacuole protein complexes indicated that Ykt6 is part of a complex distinct from the second R-SNARE, Nyv1. We speculate that during vacuole fusion, Nyv1 is the classical R-SNARE, whereas the Ykt6-containing complex has a novel function in Vac8 palmitoylation.	Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Ungermann, C (corresponding author), Heidelberg Univ, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	cu2@ix.urz.uni-heidelberg.de	Cristodero, Marina/AAK-5703-2021; Cristodero, Marina/AAC-8824-2022	Dietrich, Lars/0000-0003-2049-1137				Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Brachmann CB, 1998, YEAST, V14, P115; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; Dietrich LEP, 2005, EMBO REP, V6, P245, DOI 10.1038/sj.embor.7400350; Dietrich LEP, 2004, EMBO J, V23, P45, DOI 10.1038/sj.emboj.7600015; Dilcher M, 2001, J BIOL CHEM, V276, P34537, DOI 10.1074/jbc.M101551200; El-Husseini AED, 2002, NAT REV NEUROSCI, V3, P791, DOI 10.1038/nrn940; Fleckenstein D, 1998, J CELL SCI, V111, P3109; Fukasawa M, 2004, P NATL ACAD SCI USA, V101, P4815, DOI 10.1073/pnas.0401183101; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; Giles NM, 2003, CHEM BIOL, V10, P677, DOI 10.1016/S1074-5521(03)00174-1; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; Horsnell WGC, 2002, BIOCHEMISTRY-US, V41, P5230, DOI 10.1021/bi0160359; Ishikawa K, 2003, J CELL BIOL, V160, P887, DOI 10.1083/jcb.200210139; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kweon Y, 2003, MOL BIOL CELL, V14, P1868, DOI 10.1091/mbc.E02-10-0687; Lewis MJ, 2002, TRAFFIC, V3, P922, DOI 10.1034/j.1600-0854.2002.31207.x; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; MORGAN A, 1994, J BIOL CHEM, V269, P29347; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Pan XZ, 2000, MOL BIOL CELL, V11, P2445, DOI 10.1091/mbc.11.7.2445; Pan XZ, 1998, J CELL SCI, V111, P2137; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Price A, 2000, J CELL BIOL, V148, P1231, DOI 10.1083/jcb.148.6.1231; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Steel GJ, 2000, MOL BIOL CELL, V11, P1345, DOI 10.1091/mbc.11.4.1345; Tang FS, 2003, NATURE, V422, P87, DOI 10.1038/nature01453; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Ungermann C, 1998, EMBO J, V17, P3269, DOI 10.1093/emboj/17.12.3269; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Veit M, 2003, FEBS LETT, V540, P101, DOI 10.1016/S0014-5793(03)00232-1; Veit M, 2001, EMBO J, V20, P3145, DOI 10.1093/emboj/20.12.3145; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wang CW, 2003, J CELL BIOL, V163, P973, DOI 10.1083/jcb.200308071; Wang YX, 2001, J BIOL CHEM, V276, P35133, DOI 10.1074/jbc.M103937200; Wang YX, 1998, J CELL BIOL, V140, P1063, DOI 10.1083/jcb.140.5.1063; Weisman LS, 2003, ANNU REV GENET, V37, P435, DOI 10.1146/annurev.genet.37.050203.103207; Zhang T, 2001, J BIOL CHEM, V276, P27480, DOI 10.1074/jbc.M102786200	47	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15348	15355		10.1074/jbc.M410582200	http://dx.doi.org/10.1074/jbc.M410582200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701652	Green Accepted, hybrid			2022-12-25	WOS:000228236800120
J	Ren, LP; Feoktistova, A; McDonald, WH; Den Haese, G; Morrell, JL; Gould, KL				Ren, LP; Feoktistova, A; McDonald, WH; Den Haese, G; Morrell, JL; Gould, KL			Analysis of the role of phosphorylation in fission yeast Cdc13p/cyclinB function*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-TYPE CYCLIN; ANAPHASE-PROMOTING COMPLEX; WD-REPEAT PROTEIN; SCHIZOSACCHAROMYCES-POMBE; CELL-CYCLE; DNA-DAMAGE; NUCLEAR-LOCALIZATION; S-PHASE; CDC2; MITOSIS	The Cdk1p-cyclin B complex drives entry into mitosis in all eukaryotes. Cdc13p is the single essential cyclin in Schizosaccharomyces pombe and a member of the cyclin B family. Cdc13p abundance rises during G(2)-phase and falls as cells progress through mitosis and G(1). Cdc13p degradation, mediated by the anaphase-promoting complex, is an important mechanism of Cdk1p inhibition and mitotic exit. Cdk1p-cyclin B1 complexes shuttle between the nucleus and cytoplasm, and preventing nuclear accumulation of Cdk1p-cyclin B1 in mammalian cells appears to be one mechanism of preventing entry into mitosis during a DNA damage-induced checkpoint delay. In vertebrates, phosphorylation plays a key role in regulating the intracellular distribution of cyclins. Previous mass spectrometric analysis identified sites of Cdc13p phosphorylation. Here, we have confirmed that these sites are the sole in vivo Cdc13p phosphorylation sites and have studied the role that phosphorylation plays in Cdc13p localization and function. Our data indicate that Cdc13p accumulates in the nucleolus in response to G(2) checkpoint delays, rather than in the cytoplasm, and that phosphorylation plays no role in Cdc13p localization or function.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Gould, KL (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, 221 Kirkland Hall, Nashville, TN 37232 USA.	Kathy.gould@vanderbilt.edu	Morrell-Falvey, Jennifer L/A-6615-2011; McDonald, W. Hayes/B-4109-2016	Morrell-Falvey, Jennifer L/0000-0002-9362-7528; McDonald, W. Hayes/0000-0002-3510-426X; Gould, Kathleen/0000-0002-3810-4070	NIGMS NIH HHS [GM47728] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047728] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFA CE, 1989, J CELL SCI, P9; ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; Asakawa H, 2001, MOL GENET GENOMICS, V265, P424, DOI 10.1007/s004380000429; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Balasubramanian MK, 1997, METHOD ENZYMOL, V283, P494; Berry LD, 1999, MOL CELL BIOL, V19, P2535; Berry LD, 1996, MOL GEN GENET, V251, P635; Blanco MA, 2001, J CELL SCI, V114, P2135; Blanco MA, 2000, EMBO J, V19, P3945, DOI 10.1093/emboj/19.15.3945; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; Borgne A, 1999, J BIOL CHEM, V274, P11977, DOI 10.1074/jbc.274.17.11977; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chang L, 2001, MOL CELL BIOL, V21, P6681, DOI 10.1128/MCB.21.19.6681-6694.2001; Creanor J, 1996, J CELL SCI, V109, P1647; Decottignies A, 2001, J CELL SCI, V114, P2627; DENHAESE GJ, 1995, MOL BIOL CELL, V6, P371, DOI 10.1091/mbc.6.4.371; Dunaway S, 2004, METHODS, V33, P260, DOI 10.1016/j.ymeth.2003.11.022; FISHER D, 1995, SEMIN CELL BIOL, V6, P73, DOI 10.1016/1043-4682(95)90003-9; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; GALLAGHER IM, 1993, MOL BIOL CELL, V4, P1087, DOI 10.1091/mbc.4.11.1087; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; Martin-Castellanos C, 1996, EMBO J, V15, P839, DOI 10.1002/j.1460-2075.1996.tb00419.x; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; Mondesert O, 1996, MOL CELL BIOL, V16, P1527; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; RUSSELL P, 1989, MOL BIOL FISSION YEA; SMEETS MFMA, 1994, RADIOTHER ONCOL, V33, P217, DOI 10.1016/0167-8140(94)90357-3; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Yamada HY, 2000, J CELL SCI, V113, P3989; Yamaguchi S, 1997, MOL BIOL CELL, V8, P2475, DOI 10.1091/mbc.8.12.2475; Yamaguchi S, 2000, EMBO J, V19, P3968, DOI 10.1093/emboj/19.15.3968; Yamano H, 1996, EMBO J, V15, P5268, DOI 10.1002/j.1460-2075.1996.tb00912.x; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200	50	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14591	14596		10.1074/jbc.M500560200	http://dx.doi.org/10.1074/jbc.M500560200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705571	hybrid			2022-12-25	WOS:000228236800032
J	Briggs, GS; Mahdi, AA; Wen, Q; Lloyd, RG				Briggs, GS; Mahdi, AA; Wen, Q; Lloyd, RG			DNA binding by the substrate specificity (Wedge) domain of RecG helicase suggests a role in processivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINATION PROTEIN RECG; DAMAGED REPLICATION FORKS; ESCHERICHIA-COLI K-12; SINGLE-STRANDED-DNA; HOLLIDAY JUNCTIONS; CRYSTAL-STRUCTURES; BRANCH MIGRATION; RECBCD ENZYME; REP HELICASE; RESOLVASE	RecG differs from most helicases acting on branched DNA in that it is thought to catalyze unwinding via translocation of a monomer on dsDNA, with a wedge domain facilitating strand separation. Conserved phenylalanines in the wedge are shown to be critical for DNA binding. When detached from the helicase domains, the wedge bound a Holliday junction with high affinity but failed to bind a replication fork structure. Further stabilizing contacts are identified in full-length RecG, which may explain fork binding. Detached from the wedge, the helicase region unwound junctions but had extremely low substrate affinity, arguing against the "classical inchworm" mode of translocation. We propose that the processivity of RecG on branched DNA substrates is dependent on the ability of the wedge to establish strong binding at the branch point. This keeps the helicase motor in contact with the substrate, enabling it to drive dsDNA translocation with high efficiency.	Univ Nottingham, Queens Med Ctr, Inst Genet, Nottingham NG7 2UH, England	University of Nottingham	Lloyd, RG (corresponding author), Univ Nottingham, Queens Med Ctr, Inst Genet, Nottingham NG7 2UH, England.	bob.lloyd@nottingham.ac.uk		Briggs, Geoff/0000-0002-4149-8752				AlDeib AA, 1996, J BACTERIOL, V178, P6782, DOI 10.1128/jb.178.23.6782-6789.1996; BACHMANN BJ, 1996, ESCHERICHIA COLI SAL, P2460; Bolt EL, 2002, MOL CELL, V10, P187, DOI 10.1016/S1097-2765(02)00560-9; Briggs GS, 2004, PHILOS T R SOC B, V359, P49, DOI 10.1098/rstb.2003.1364; Chan SN, 1997, J BIOL CHEM, V272, P14873, DOI 10.1074/jbc.272.23.14873; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; Kaplan DL, 2002, MOL CELL, V10, P647, DOI 10.1016/S1097-2765(02)00642-1; Kaplan DL, 2004, MOL CELL, V15, P453, DOI 10.1016/j.molcel.2004.06.039; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1991, J BACTERIOL, V173, P1004, DOI 10.1128/jb.173.3.1004-1011.1991; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Mahdi AA, 1997, NUCLEIC ACIDS RES, V25, P3875, DOI 10.1093/nar/25.19.3875; Mahdi AA, 2003, EMBO J, V22, P724, DOI 10.1093/emboj/cdg043; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; McGlynn P, 2000, NUCLEIC ACIDS RES, V28, P2324, DOI 10.1093/nar/28.12.2324; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; McGlynn P, 2000, CELL, V101, P35, DOI 10.1016/S0092-8674(00)80621-2; McGlynn P, 2002, TRENDS GENET, V18, P413, DOI 10.1016/S0168-9525(02)02720-8; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; McGlynn P, 1999, NUCLEIC ACIDS RES, V27, P3049, DOI 10.1093/nar/27.15.3049; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8235, DOI 10.1073/pnas.121007798; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Phillips RJ, 1997, MOL GEN GENET, V254, P319, DOI 10.1007/PL00008605; Posfai G, 1997, J BACTERIOL, V179, P4426, DOI 10.1128/jb.179.13.4426-4428.1997; Schmidt KH, 2002, J BIOL CHEM, V277, P45331, DOI 10.1074/jbc.M207263200; Shuttleworth G, 2004, J MOL BIOL, V337, P621, DOI 10.1016/j.jmb.2004.01.021; Singleton MR, 2004, NATURE, V432, P187, DOI 10.1038/nature02988; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; Soultanas P, 2000, CURR OPIN STRUC BIOL, V10, P124, DOI 10.1016/S0959-440X(99)00059-7; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Vincent SD, 1996, J MOL BIOL, V264, P713, DOI 10.1006/jmbi.1996.0671; Yu M, 1998, P NATL ACAD SCI USA, V95, P981, DOI 10.1073/pnas.95.3.981	38	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13921	13927		10.1074/jbc.M412054200	http://dx.doi.org/10.1074/jbc.M412054200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695524	hybrid			2022-12-25	WOS:000228095500093
J	Li, ZG; McNulty, DE; Marler, KJM; Lim, L; Hall, C; Annan, RS; Sacks, DB				Li, ZG; McNulty, DE; Marler, KJM; Lim, L; Hall, C; Annan, RS; Sacks, DB			IQGAP1 promotes neurite outgrowth in a phosphorylation-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ACTIN-BINDING; MASS-SPECTROMETRY; CELL-MIGRATION; SELECTIVE DETECTION; NEURONAL POLARITY; CDC42; CALMODULIN; CYTOSKELETON; GTPASES	In eukaryotic cells IQGAP1 binds to and alters the function of several proteins, including actin, E-cadherin, beta-catenin, Cdc42, and Rac1. Yeast IQGAP1 homologues have an important role in cytoskeletal organization, suggesting that modulation of the cytoskeleton is a fundamental role of IQGAP1. Phosphorylation is a common mechanism by which cells regulate protein function. Here we demonstrate that endogenous IQGAP1 is highly phosphorylated in MCF-7 human breast epithelial cells. Moreover, incubation of cells with phorbol 12-myristate 13-acetate (PMA) stimulated phosphate incorporation into IQGAP1. By using mass spectrometry, Ser-1443 was identified as the major site phosphorylated on IQGAP1 in intact cells treated with PMA. Ser-1441 was also phosphorylated but to a lesser extent. In vitro analysis with purified proteins documented that IQGAP1 is a substrate for protein kinase C epsilon, which catalyzes phosphorylation on Ser-1443. Consistent with these findings, inhibition of cellular protein kinase C via bisindolymaleimide abrogated Ser-1443 phosphorylation in response to PMA. To elucidate the biological sequelae of phosphorylation, Ser-1441 and Ser-1443 were converted either to alanine, to create a non-phosphorylatable construct, or to glutamic acid and aspartic acid, respectively, to generate a phosphomimetic IQGAP1. Although overexpression of wild type IQGAP1 promoted neurite outgrowth in N1E-115 neuroblastoma cells, the nonphosphorylatable IQGAP1 S1441A/S1443A had no effect. In contrast, the S1441E/S1443D mutation markedly enhanced the ability of IQGAP1 to induce neurite outgrowth. Our data disclose that IQGAP1 is phosphorylated at multiple sites in intact cells and that phosphorylation of IQGAP1 will alter its ability to regulate the cytoskeleton of neuronal cells.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; GlaxoSmithKline, Dept Computat Analyt & Struct Sci, Prote & Biol Mass Spectrometry Lab, King Of Prussia, PA 19406 USA; UCL, Inst Neurol, Dept Mol Neurosci, London WC1N 1PJ, England; Natl Univ Singapore, Inst Mol & Cell Biol, GSK IMCB Grp, Singapore 138673, Singapore	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; GlaxoSmithKline; University of London; University College London; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; National University of Singapore	Sacks, DB (corresponding author), Brigham & Womens Hosp, Dept Pathol, Thorn 530,75 Francis St, Boston, MA 02115 USA.	dsacks@rics.bwh.harvard.edu	Hall, Christine/C-8390-2009	Sacks, David/0000-0003-3100-0735				Ballestrem C, 2000, MOL BIOL CELL, V11, P2999, DOI 10.1091/mbc.11.9.2999; BARTLETT WP, 1984, J NEUROSCI, V4, P1944; BENZEEV A, 1984, BIOCHIM BIOPHYS ACTA, V780, P197, DOI 10.1016/0304-419X(85)90003-4; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Briggs MW, 2003, EMBO REP, V4, P571, DOI 10.1038/sj.embor.embor867; Briggs MW, 2003, FEBS LETT, V542, P7, DOI 10.1016/S0014-5793(03)00333-8; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Cory GOC, 2002, J BIOL CHEM, V277, P45115, DOI 10.1074/jbc.M203346200; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Govind S, 2001, J CELL BIOL, V152, P579, DOI 10.1083/jcb.152.3.579; Grohmanova K, 2004, J BIOL CHEM, V279, P48495, DOI 10.1074/jbc.M408113200; Hager JW, 2003, RAPID COMMUN MASS SP, V17, P1056, DOI 10.1002/rcm.1020; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall C, 2001, J NEUROSCI, V21, P5191, DOI 10.1523/JNEUROSCI.21-14-05191.2001; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; HUDDLESTON MJ, 1993, J AM SOC MASS SPECTR, V4, P710, DOI 10.1016/1044-0305(93)80049-5; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; Kermorgant S, 2004, EMBO J, V23, P3721, DOI 10.1038/sj.emboj.7600396; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Li ZG, 2003, J BIOL CHEM, V278, P4347, DOI 10.1074/jbc.M208579200; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Ling M, 2004, EXP CELL RES, V292, P135, DOI 10.1016/j.yexcr.2003.08.013; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Loureiro JJ, 2002, MOL BIOL CELL, V13, P2533, DOI 10.1091/mbc.E01-10-0102; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200; McCallum SJ, 1998, J BIOL CHEM, V273, P22537, DOI 10.1074/jbc.273.35.22537; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Nishimura T, 2004, NAT CELL BIOL, V6, P328, DOI 10.1038/ncb1118; Price LS, 2003, J BIOL CHEM, V278, P39413, DOI 10.1074/jbc.M302083200; Ramesh V, 2004, NAT REV NEUROSCI, V5, P462, DOI 10.1038/nrn1407; Roy M, 2004, J BIOL CHEM, V279, P17329, DOI 10.1074/jbc.M308405200; Schwamborn JC, 2004, NAT NEUROSCI, V7, P923, DOI 10.1038/nn1295; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Winder SJ, 2003, CURR OPIN CELL BIOL, V15, P14, DOI 10.1016/S0955-0674(02)00002-9; Zappacosta F, 2002, ANAL CHEM, V74, P3221, DOI 10.1021/ac025538x	49	63	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13871	13878		10.1074/jbc.M413482200	http://dx.doi.org/10.1074/jbc.M413482200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695813	hybrid			2022-12-25	WOS:000228095500086
J	Mohapatra, DP; Nau, C				Mohapatra, DP; Nau, C			Regulation of Ca2+-dependent desensitization in the vanilloid receptor TRPV1 by calcineurin and cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSAICIN-ACTIVATED CURRENTS; ROOT GANGLION NEURONS; CA2+-SENSITIVE INACTIVATION; DIRECT PHOSPHORYLATION; THERMAL HYPERALGESIA; CALCIUM-CHANNELS; CA2+ CHANNELS; INHIBITION; VR1; CALMODULIN	he vanilloid receptor TRPV1 is a polymodal nonselective cation channel of nociceptive sensory neurons involved in the perception of inflammatory pain. TRPV1 exhibits desensitization in a Ca2+-dependent manner upon repeated activation by capsaicin or protons. The cAMP-dependent protein kinase (PKA) decreases desensitization of TRPV1 by directly phosphorylating the channel presumably at sites Ser(116) and Thr(370). In the present study we investigated the influence of protein phosphatase 2B (calcineurin) on Ca2+-dependent desensitization of capsaicin- and proton-activated currents. By using site-directed mutagenesis, we generated point mutations at PKA and protein kinase C consensus sites and studied wild type (WT) and mutant channels transiently expressed in HEK293t or HeLa cells under whole cell voltage clamp. We found that intracellular application of the cyclosporin A.cyclophilin A complex (CsA.CyP), a specific inhibitor of calcineurin, significantly decreased desensitization of capsaicin- or proton-activated TRPV1-WT currents. This effect was similar to that obtained by extracellular application of forskolin (FSK), an indirect activator of PKA. Simultaneous applications of CsA.CyP and FSK in varying concentrations suggested that these substances acted independently from each other. In mutation T370A, application of CsA.CyP did not reduce desensitization of capsaicin- activated currents as compared with WT and to mutant channels S116A and T144A. In a double mutation at candidate protein kinase C phosphorylation sites, application of CsA.CyP or FSK decreased desensitization of capsaicin- activated currents similar to WT channels. We conclude that Ca2+-dependent desensitization of TRPV1 might be in part regulated through channel dephosphorylation by calcineurin and channel phosphorylation by PKA possibly involving Thr(370) as a key amino acid residue.	Univ Erlangen Nurnberg, Dept Anesthesiol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Nau, C (corresponding author), Univ Erlangen Nurnberg, Dept Anesthesiol, Krankenhausstr 12, D-91054 Erlangen, Germany.	Carla.Nau@kfa.imed.uni-erlangen.de	Durga, Mohapatra/B-3620-2008; Mohapatra, Durga/M-2133-2017	Mohapatra, Durga/0000-0001-5016-1281				Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Docherty RJ, 1996, PFLUG ARCH EUR J PHY, V431, P828, DOI 10.1007/BF02332166; Gunthorpe NJ, 2001, PFLUG ARCH EUR J PHY, V442, P668; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; IMREDY JP, 1994, NEURON, V12, P1301, DOI 10.1016/0896-6273(94)90446-4; Jin L, 2002, P NATL ACAD SCI USA, V99, P13522, DOI 10.1073/pnas.212504399; Jung JY, 2004, J BIOL CHEM, V279, P7048, DOI 10.1074/jbc.M311448200; Khiroug L, 1998, J NEUROSCI, V18, P2458; King B, 1997, NEUROREPORT, V8, P1099, DOI 10.1097/00001756-199703240-00007; Koplas PA, 1997, J NEUROSCI, V17, P3525; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Lopshire JC, 1998, J NEUROSCI, V18, P6081; Mohapatra DP, 2003, J BIOL CHEM, V278, P50080, DOI 10.1074/jbc.M306619200; Mohapatra DP, 2003, MOL CELL NEUROSCI, V23, P314, DOI 10.1016/S1044-7431(03)00054-X; Numazaki M, 2003, P NATL ACAD SCI USA, V100, P8002, DOI 10.1073/pnas.1337252100; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Rathee PK, 2002, J NEUROSCI, V22, P4740, DOI 10.1523/JNEUROSCI.22-11-04740.2002; Rosenbaum T, 2004, J GEN PHYSIOL, V123, P53, DOI 10.1085/jgp.200308906; Santana LF, 2002, J PHYSIOL-LONDON, V544, P57, DOI 10.1113/jphysiol.2002.020552; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; TONG G, 1994, J NEUROPHYSIOL, V72, P754, DOI 10.1152/jn.1994.72.2.754; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Trevisani M, 2002, NAT NEUROSCI, V5, P546, DOI 10.1038/nn852; Trudeau MC, 2002, P NATL ACAD SCI USA, V99, P8424, DOI 10.1073/pnas.122015999; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	34	222	234	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13424	13432		10.1074/jbc.M410917200	http://dx.doi.org/10.1074/jbc.M410917200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15691846	hybrid			2022-12-25	WOS:000228095500030
J	Park, H; Adsit, FG; Boyington, JC				Park, H; Adsit, FG; Boyington, JC			The 1.4 angstrom crystal structure of the human oxidized low density lipoprotein receptor Lox-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECTIN-LIKE DOMAIN; OX-LDL RECEPTOR-1; ENDOTHELIAL RECEPTOR; SUPPORTS ADHESION; UP-REGULATION; CELLS; BINDING; PROTEIN; EXPRESSION; RESIDUES	The lectin-like oxidized low density lipoprotein receptor-1 (Lox-1) mediates the recognition and internalization of oxidatively modified low density lipoprotein by vascular endothelial cells. This interaction results in a number of pro-atherogenic cellular responses that probably play a significant role in the pathology of atherosclerosis. The 1.4 angstrom crystal structure of the extracellular C-type lectin-like domain of human Lox-1 reveals a heart-shaped homodimer with a ridge of six basic amino acids extending diagonally across the apolar top of Lox-1, a central hydrophobic tunnel that extends through the entire molecule, and an electrostatically neutral patch of 12 charged residues that resides next to the tunnel at each opening. Based on the arrangement of critical binding residues on the Lox-1 structure, we propose a binding mode for the recognition of modified low density lipoprotein and other Lox-1 ligands.	NIEHS, Biomol Crystallog Grp, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Boyington, JC (corresponding author), NIEHS, Biomol Crystallog Grp, Struct Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	boyingt1@niehs.nih.gov		ADSIT, FLOYD/0000-0002-1971-3604	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101563] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353; Chen MY, 2001, FEBS LETT, V499, P215, DOI 10.1016/S0014-5793(01)02557-1; Chen MY, 2001, BIOCHEM J, V355, P289, DOI 10.1042/0264-6021:3550289; Cominacini L, 2001, J BIOL CHEM, V276, P13750, DOI 10.1074/jbc.M010612200; Cominacini L, 2000, J BIOL CHEM, V275, P12633, DOI 10.1074/jbc.275.17.12633; DeLano WL, 2004, PYMOL MOL GRAPHICS S; Delneste Y, 2002, IMMUNITY, V17, P353, DOI 10.1016/S1074-7613(02)00388-6; Esterbauer H, 1996, REV PHYSIOL BIOCH P, V127, P31, DOI 10.1007/BFb0048264; Gillotte KL, 2000, J LIPID RES, V41, P824; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Greenberg JW, 1996, INFECT IMMUN, V64, P3318, DOI 10.1128/IAI.64.8.3318-3325.1996; Hayashida K, 2002, FEBS LETT, V511, P133, DOI 10.1016/S0014-5793(01)03297-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jono T, 2002, FEBS LETT, V511, P170, DOI 10.1016/S0014-5793(01)03325-7; Kataoka H, 1999, CIRCULATION, V99, P3110, DOI 10.1161/01.CIR.99.24.3110; Kawai Y, 2003, J BIOL CHEM, V278, P21040, DOI 10.1074/jbc.M212426200; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Li DY, 2000, ARTERIOSCL THROM VAS, V20, P1116, DOI 10.1161/01.ATV.20.4.1116; Li DY, 2003, CIRCULATION, V107, P612, DOI 10.1161/01.CIR.0000047276.52039.FB; Li DY, 2000, CIRCULATION, V101, P2889, DOI 10.1161/01.CIR.101.25.2889; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Moriwaki H, 1998, ARTERIOSCL THROM VAS, V18, P1541, DOI 10.1161/01.ATV.18.10.1541; Murase T, 1998, CIRC RES, V83, P328, DOI 10.1161/01.RES.83.3.328; Nagase M, 2001, BIOCHEM BIOPH RES CO, V281, P720, DOI 10.1006/bbrc.2001.4374; Oka K, 1998, P NATL ACAD SCI USA, V95, P9535, DOI 10.1073/pnas.95.16.9535; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parasassi T, 2001, FREE RADICAL BIO MED, V31, P82, DOI 10.1016/S0891-5849(01)00555-X; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shi XH, 2001, J CELL SCI, V114, P1273; Shi Xiaohua, 2001, Molecular Cell Biology Research Communications, V4, P292, DOI 10.1006/mcbr.2001.0296; Shimaoka T, 2001, J IMMUNOL, V166, P5108, DOI 10.4049/jimmunol.166.8.5108; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Xie QH, 2004, DNA CELL BIOL, V23, P111, DOI 10.1089/104454904322759920; Zelensky AN, 2003, PROTEINS, V52, P466, DOI 10.1002/prot.10626	41	70	71	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13593	13599		10.1074/jbc.M500768200	http://dx.doi.org/10.1074/jbc.M500768200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695803	hybrid			2022-12-25	WOS:000228095500052
J	Maschler, S; Wirl, G; Spring, H; Bredow, DV; Sordat, I; Beug, H; Reichmann, E				Maschler, S; Wirl, G; Spring, H; Bredow, DV; Sordat, I; Beug, H; Reichmann, E			Tumor cell invasiveness correlates with changes in integrin expression and localization	ONCOGENE			English	Article						TGF beta; Ras; EMT; invasion; fibronectin receptor; laminin receptor	EPITHELIAL-MESENCHYMAL TRANSITIONS; EXTRACELLULAR-MATRIX PROTEINS; ALPHA-6-BETA-4 INTEGRIN; MOLECULAR-MECHANISMS; SIGNALING PATHWAYS; CANCER-CELLS; IN-VIVO; CARCINOMA; PROGRESSION; METASTASIS	In nontumorigenic mammary epithelial cells (EpH4), transforming growth factor-beta (TGF beta 1) causes cell cycle arrest/apoptosis, but induces epitheliomesenchymal transition (EMT) in Ha-Ras-transformed EpH4 cells (EpRas). EMT is closely correlated with late-stage tumor progression and results in fibroblastic, migratory cells displaying a mesenchymal gene expression program (FibRas). EpRas and FibRas cells showed strongly increased cell substrate adhesion to fibronectin, collagens I/IV and laminin 1. Furthermore, Ras transformation caused enhanced or de-novo expression of the integrin subunits beta 1, alpha 2 and alpha 3, or alpha 5 and alpha 6, respectively, the latter subunits being even more strongly expressed in FibRas cells. Importantly, polarized EpRas cells expressed integrin subunits beta 1 and beta 6 at distinct (apical and lateral) membrane domains, while FibRas cells coexpressed these integrins and alpha 5 at the entire plasma membrane. During EMT, EpRas cells formed an alpha 5 beta 1 complex and deposited its ligand fibronectin into the extracellular matrix. Function-blocking alpha 5 antibodies attenuated migration, and caused massive apoptosis in EpRas cells undergoing TGF beta 1-induced EMT in collagen gels, but failed to affect EpRas- or FibRas-derived structures. We conclude that functional alpha 5b1 integrin is centrally implicated in EMT induction. Importantly, FibRas cells also failed to deposit the alpha 6 beta 4 ligand laminin 5, suggesting that alpha 6 beta 4 is no longer functional after EMT and replaced by mesenchymal integrins such as alpha 5 beta 1.	Res Inst Mol Pathol, A-1030 Vienna, Austria; German Canc Inst, Heidelberg, Germany; Swiss Canc Res Inst, Lausanne, Switzerland; Univ Childrens Hosp, Dept Surg, Zurich, Switzerland	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University Children's Hospital Zurich	Maschler, S (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	maschler@imp.univie.ac.at						ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; Birchmeier C, 1996, ACTA ANAT, V156, P217; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Defilippi P, 1997, ONCOGENE, V14, P1933, DOI 10.1038/sj.onc.1201027; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Harabayashi T, 1999, J UROLOGY, V161, P1364, DOI 10.1016/S0022-5347(01)61685-9; Henning K, 1999, HISTOPATHOLOGY, V34, P305; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; JUHASZ I, 1993, AM J PATHOL, V143, P1458; Maschler S, 2004, ONCOGENE, V23, P3622, DOI 10.1038/sj.onc.1207403; Miller KA, 2001, J BIOL CHEM, V276, P42863, DOI 10.1074/jbc.M108130200; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Palecek SP, 1996, J CELL SCI, V109, P941; PELLEGRINI G, 1992, J CLIN INVEST, V89, P1783, DOI 10.1172/JCI115782; Putz E, 1999, CANCER RES, V59, P241; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; Saulnier R, 1996, EXP CELL RES, V222, P360, DOI 10.1006/excr.1996.0045; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sheppard D, 1996, BIOESSAYS, V18, P655, DOI 10.1002/bies.950180809; STREULI CH, 1993, J CELL BIOL, V120, P253, DOI 10.1083/jcb.120.1.253; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WIRL G, 1995, J CELL SCI, V108, P2445; Witkowski CM, 2000, CARCINOGENESIS, V21, P325, DOI 10.1093/carcin/21.2.325; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853; ZUK A, 1994, DEV DYNAM, V201, P378, DOI 10.1002/aja.1002010409	38	132	133	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 17	2005	24	12					2032	2041		10.1038/sj.onc.1208423	http://dx.doi.org/10.1038/sj.onc.1208423			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688013				2022-12-25	WOS:000227681900007
J	Yoon, YS; Lee, JH; Hwang, SC; Choi, KS; Yoon, G				Yoon, YS; Lee, JH; Hwang, SC; Choi, KS; Yoon, G			TGF beta 1 induces prolonged mitochondrial ROS generation through decreased complex IV activity with senescent arrest in Mv1Lu cells	ONCOGENE			English	Article						mitochondrial dysfunction; TGF beta 1; senescence; reactive oxygen species; complex IV defect	GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; MESENCHYMAL TRANSDIFFERENTIATION; OXIDATIVE STRESS; DOWN-REGULATION; CANCER; ACTIVATION; APOPTOSIS; TRIGGERS; ACCUMULATION	Transforming growth factor beta 1 (TGF beta 1) is a well-characterized cytokine that suppresses epithelial cell growth. We report here that TGF beta 1 arrested lung epithelial Mv1Lu cells at G1 phase of the cell cycle with acquisition of senescent phenotypes in the presence of 10% serum, whereas it gradually induced apoptosis with lower concentrations of serum. The senescent arrest was accompanied by prolonged generation of reactive oxygen species (ROS) and persistent disruption of mitochondrial membrane potential (Delta psi m). We demonstrated that the sustained ROS overproduction was derived from mitochondrial respiratory defect via decreased complex IV activity and was involved in the arrest. Moreover, we verified that hepatocyte growth factor released Mv1Lu cells from the arrest by protecting mitochondrial respiration, thereby preventing both the Delta psi m disruption and the ROS generation. Our present results suggest the TGF beta 1-induced senescent arrest as another plausible mechanism to suppress cellular growth in vivo and provide a new biochemical association between the mitochondrial functional defects and the cytokine-induced senescent arrest, emphasizing the importance of maintenance of mitochondrial function in cellular protection from the arrest.	Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 443721, South Korea; Ajou Univ, Sch Med, Dept Pulm & Crit Care Med, Suwon 443721, South Korea; Ajou Univ, Sch Med, Inst Med Sci, Suwon 443721, South Korea	Ajou University; Ajou University; Ajou University	Yoon, G (corresponding author), Ajou Univ, Sch Med, Dept Biochem & Mol Biol, San 5,Wonchon Dong, Suwon 443721, South Korea.	ypeace@ajou.ac.kr		Choi, Kyeong Sook/0000-0003-2331-0856; Hwang, Sung Chul/0000-0003-2401-619X				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4; BOVERIS A, 1999, OXIDAT STRESS DIS, V2, P1; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Chang BD, 1999, CANCER RES, V59, P3761; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ellenrieder V, 2001, CANCER RES, V61, P4222; Esposti MD, 2001, METHOD CELL BIOL, V65, P75; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Frippiat C, 2001, J BIOL CHEM, V276, P2531, DOI 10.1074/jbc.M006809200; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Islam KN, 1997, FREE RADICAL BIO MED, V22, P1007, DOI 10.1016/S0891-5849(96)00493-5; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lee HC, 2001, BIOGERONTOLOGY, V2, P231, DOI 10.1023/A:1013270512172; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mathon NE, 2001, NAT REV CANCER, V1, P203, DOI 10.1038/35106045; Parekh TV, 1998, CELL GROWTH DIFFER, V9, P423; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SASTRE J, 1999, OXIDAT STRESS DIS, V2, P181; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Suh Y, 2002, NAT MED, V8, P3, DOI 10.1038/nm0102-3; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; Taipale J, 1996, J BIOL CHEM, V271, P4342; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; Untergasser G, 2003, EXP GERONTOL, V38, P1179, DOI 10.1016/j.exger.2003.08.008; Villani G, 2001, METHOD CELL BIOL, V65, P119, DOI 10.1016/S0091-679X(01)65007-6; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Yoon G, 2002, BIOCHEM J, V366, P613, DOI 10.1042/BJ20011445; Yoon YS, 2003, J BIOL CHEM, V278, P51577, DOI 10.1074/jbc.M308489200; Zhao H, 2002, BIOCHEM BIOPH RES CO, V294, P464, DOI 10.1016/S0006-291X(02)00484-9	48	135	138	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1895	1903		10.1038/sj.onc.1208262	http://dx.doi.org/10.1038/sj.onc.1208262			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688038				2022-12-25	WOS:000227542000008
J	Diaz-Moreno, I; Diaz-Quintana, A; De la Rosa, MA; Ubbink, M				Diaz-Moreno, I; Diaz-Quintana, A; De la Rosa, MA; Ubbink, M			Structure of the complex between plastocyanin and cytochrome f from the cyanobacterium Nostoc sp PCC 7119 as determined by paramagnetic NMR - The balance between electrostatic and hydrophobic interactions within the transient complex determines the relative orientation of the two proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWNIAN DYNAMICS; ESCHERICHIA-COLI; HEME; RESIDUES; PATCH; B(6)F; RECOGNITION; ASSOCIATION; SIMULATION; EXPRESSION	The complex between cytochrome f and plastocyanin from the cyanobacterium Nostoc has been characterized by NMR spectroscopy. The binding constant is 16 mM(-1), and the lifetime of the complex is much less than 10 ms. Intermolecular pseudo-contact shifts observed for the plastocyanin amide nuclei, caused by the heme iron, as well as the chemical-shift perturbation data were used as the sole experimental restraints to determine the orientation of plastocyanin relative to cytochrome f with a precision of 1.3. The data show that the hydrophobic patch surrounding tyrosine 1 in cytochrome f docks the hydrophobic patch of plastocyanin. Charge complementarities are found between the rims of the respective recognition sites of cytochrome f and plastocyanin. Significant differences in the relative orientation of both proteins are found between this complex and those previously reported for plants and Phormidium, indicating that electrostatic and hydrophobic interactions are balanced differently in these complexes.	Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands; Univ Seville, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; CSIC, Seville 41092, Spain	Leiden University; Leiden University - Excl LUMC; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC)	Ubbink, M (corresponding author), Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, POB 9502, NL-2300 RA Leiden, Netherlands.	m.ubbink@chem.leidenuniv.nl	De la Rosa, Miguel/B-2545-2014; Ubbink, Marcellus/E-2158-2011; Díaz-Moreno, Irene/E-7181-2010; Díaz-Quintana, Antonio/A-1946-2011	De la Rosa, Miguel/0000-0003-1187-5737; Ubbink, Marcellus/0000-0002-2615-6914; Díaz-Moreno, Irene/0000-0002-5318-7644; Díaz-Quintana, Antonio/0000-0001-8973-8009				ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; Allen JF, 2004, TRENDS PLANT SCI, V9, P130, DOI 10.1016/j.tplants.2004.01.009; Andersson P, 1998, J BIOMOL NMR, V11, P279, DOI 10.1023/A:1008227631084; [Anonymous], 2002, PHOTOSYNTHETICA; Badsberg U, 1996, BIOCHEMISTRY-US, V35, P7021, DOI 10.1021/bi960621y; Bendall D. S., 1996, P43; BLUNDELL T, 1988, EUR J BIOCHEM, V172, P513, DOI 10.1111/j.1432-1033.1988.tb13917.x; BRUNGER AT, 1992, X PLOR 3 1 MANUAL; Carrell CJ, 1999, BIOCHEMISTRY-US, V38, P9590, DOI 10.1021/bi9903190; Castenholz R.W., 1970, SCHWEIZ Z HYDROL, V32, P538; Chakrabarti P, 2002, PROTEINS, V47, P334, DOI 10.1002/prot.10085; COLEMAN PM, 1978, J MOL BIOL, V211, P617; Crowley PB, 2003, ACCOUNTS CHEM RES, V36, P723, DOI 10.1021/ar0200955; Crowley PB, 2004, BIOCHEM J, V378, P45, DOI 10.1042/BJ20031423; Crowley PB, 2002, BIOCHEMISTRY-US, V41, P15698, DOI 10.1021/bi026349b; Crowley PB, 2001, J AM CHEM SOC, V123, P10444, DOI 10.1021/ja0112700; Crowley PB, 2004, PROTEINS, V55, P603, DOI 10.1002/prot.20043; De Rienzo F, 2001, BIOPHYS J, V81, P3090, DOI 10.1016/S0006-3495(01)75947-4; Diaz-Moreno I, 2005, BIOCHEMISTRY-US, V44, P3176, DOI 10.1021/bi047855z; Gong XS, 2000, EUR J BIOCHEM, V267, P1732, DOI 10.1046/j.1432-1327.2000.01168.x; Gong XS, 2000, EUR J BIOCHEM, V267, P3461, DOI 10.1046/j.1432-1327.2000.01366.x; GRAY JC, 1992, PHOTOSYNTH RES, V34, P359, DOI 10.1007/BF00029811; Gross EL, 2003, BIOPHYS J, V85, P2055, DOI 10.1016/S0006-3495(03)74633-5; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hart SE, 2003, BIOCHEMISTRY-US, V42, P4829, DOI 10.1021/bi020674h; Helgstrand M, 2000, J BIOMOL NMR, V18, P329, DOI 10.1023/A:1026729404698; Hope AB, 2000, BBA-BIOENERGETICS, V1456, P5, DOI 10.1016/S0005-2728(99)00101-2; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; Illerhaus J, 2000, J BIOL CHEM, V275, P17590, DOI 10.1074/jbc.275.23.17590; Jones S, 1997, J MOL BIOL, V272, P121, DOI 10.1006/jmbi.1997.1234; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kallas T, 1994, MOL BIOL CYANOBACTER, V1, P259, DOI DOI 10.1007/978-94-011-0227-8_9; Kannt A, 1996, BBA-BIOENERGETICS, V1277, P115, DOI 10.1016/S0005-2728(96)00090-4; KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; LANGE C, 2005, IN PRESS BIOENERGETI; LEE BH, 1995, J BIOCHEM, V117, P1209; Martinez SE, 1996, PROTEIN SCI, V5, P1081; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; Molina-Heredia FP, 1998, BIOCHEM BIOPH RES CO, V243, P302, DOI 10.1006/bbrc.1997.7953; Molina-Heredia FP, 2001, J BIOL CHEM, V276, P601, DOI 10.1074/jbc.M007081200; Pearson DC, 1998, BIOPHYS J, V75, P2698, DOI 10.1016/S0006-3495(98)77714-8; Pearson DC, 1996, BIOPHYS J, V71, P64, DOI 10.1016/S0006-3495(96)79236-6; Prudencio M, 2004, J MOL RECOGNIT, V17, P524, DOI 10.1002/jmr.686; REDINBO MR, 1994, J BIOENERG BIOMEMBR, V26, P49, DOI 10.1007/BF00763219; REGAN JJ, 1994, GREENPATH SOFTWARE V; SANDMANN G, 1983, ARCH MICROBIOL, V134, P23, DOI 10.1007/BF00429401; Schlarb-Ridley BG, 2002, BIOCHEMISTRY-US, V41, P3279, DOI 10.1021/bi0116588; Schulz H, 1999, P NATL ACAD SCI USA, V96, P6462, DOI 10.1073/pnas.96.11.6462; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SKOURTIS SS, 1993, CHEM PHYS LETT, V209, P171, DOI 10.1016/0009-2614(93)87219-S; Soriano GM, 1996, BIOCHEMISTRY-US, V35, P14590, DOI 10.1021/bi9616211; Soriano GM, 1998, BIOCHEMISTRY-US, V37, P15120, DOI 10.1021/bi9807714; Soriano GM, 1997, BIOPHYS J, V73, P3265, DOI 10.1016/S0006-3495(97)78351-6; Stroebel D, 2003, NATURE, V426, P413, DOI 10.1038/nature02155; SYKES AG, 1985, CHEM SOC REV, V14, P283, DOI 10.1039/cs9851400283; Ubbink M, 1998, STRUCTURE, V6, P323, DOI 10.1016/S0969-2126(98)00035-5; UBBINK M, 1992, J BACTERIOL, V174, P3707, DOI 10.1128/JB.174.11.3707-3714.1992; Ubbink M, 1996, EUR J BIOCHEM, V242, P132, DOI 10.1111/j.1432-1033.1996.0132r.x; UBBINK M, 2001, HDB METALLOPROTEINS, P182; Ullmann GM, 1997, J AM CHEM SOC, V119, P42, DOI 10.1021/ja962237u; Wodak SJ, 2003, ADV PROTEIN CHEM, V61, P9; Worrall JAR, 2002, BIOCHEMISTRY-US, V41, P11721, DOI 10.1021/bi026296y	65	68	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18908	18915		10.1074/jbc.M413298200	http://dx.doi.org/10.1074/jbc.M413298200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15705583	hybrid, Green Published			2022-12-25	WOS:000228932300043
J	Feige, JN; Gelman, L; Tudor, C; Engelborghs, Y; Wahli, W; Desvergne, B				Feige, JN; Gelman, L; Tudor, C; Engelborghs, Y; Wahli, W; Desvergne, B			Fluorescence imaging reveals the nuclear behavior of peroxisome proliferator-activated receptor retinoid X receptor heterodimers in the absence and presence of ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D RECEPTORS; LIVING CELLS; GLUCOCORTICOID-RECEPTOR; HORMONE-RECEPTORS; CORRELATION SPECTROSCOPY; INTRANUCLEAR MOBILITY; MOLECULAR-DYNAMICS; ANDROGEN RECEPTOR; LIVE CELLS; IN-VIVO	In a global approach combining fluorescence recovery after photobleaching ( FRAP), fluorescence correlation spectroscopy (FCS), and fluorescence resonance energy transfer ( FRET), we address the behavior in living cells of the peroxisome proliferator-activated receptors (PPARs), a family of nuclear receptors involved in lipid and glucose metabolism, inflammation control, and wound healing. We first demonstrate that unlike several other nuclear receptors, PPARs do not form speckles upon ligand activation. The subnuclear structures that may be observed under some experimental conditions result from overexpression of the protein and our immunolabeling experiments suggest that these structures are subjected to degradation by the proteasome. Interestingly and in contrast to a general assumption, PPARs readily heterodimerize with retinoid X receptor (RXR) in the absence of ligand in living cells. PPAR diffusion coefficients indicate that all the receptors are engaged in complexes of very high molecular masses and/or interact with relatively immobile nuclear components. PPARs are not immobilized by ligand binding. However, they exhibit a ligand-induced reduction of mobility, probably due to enhanced interactions with cofactors and/or chromatin. Our study draws attention to the limitations and pitfalls of fluorescent chimera imaging and demonstrates the usefulness of the combination of FCS, FRAP, and FRET to assess the behavior of nuclear receptors and their mode of action in living cells.	Univ Lausanne, NCCR Frontiers Genet, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland; Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Louvain, Belgium	University of Lausanne; KU Leuven	Desvergne, B (corresponding author), Univ Lausanne, NCCR Frontiers Genet, Ctr Integrat Genom, Batiment Biol, CH-1015 Lausanne, Switzerland.	beatrice.desvergne@unil.ch	Wahli, Walter/B-1398-2009; Wahli, Walter/I-3194-2019; Desvergne, Beatrice/C-8892-2016	Wahli, Walter/0000-0002-5966-9089; Desvergne, Beatrice/0000-0001-5483-288X; Gelman, Laurent/0000-0003-3277-3115				Akiyama TE, 2002, MOL ENDOCRINOL, V16, P707, DOI 10.1210/me.16.4.707; Auwerx J, 1999, CELL, V97, P161; Bai YL, 2003, MOL ENDOCRINOL, V17, P589, DOI 10.1210/me.2002-0351; Baumann CT, 2001, J BIOL CHEM, V276, P11237, DOI 10.1074/jbc.M011112200; Brock R, 1998, BIOPHYS J, V75, P2547, DOI 10.1016/S0006-3495(98)77699-4; Bunn CF, 2001, MOL ENDOCRINOL, V15, P512, DOI 10.1210/mend.15.4.0619; DeFranco DB, 2002, MOL ENDOCRINOL, V16, P1449, DOI 10.1210/me.16.7.1449; Dittrich P, 2001, BIOL CHEM, V382, P491, DOI 10.1515/BC.2001.061; Dong S, 2004, MOL CELL BIOL, V24, P4465, DOI 10.1128/MCB.24.10.4465-4475.2004; Dowell P, 1999, J BIOL CHEM, V274, P15901, DOI 10.1074/jbc.274.22.15901; Elbi C, 2004, P NATL ACAD SCI USA, V101, P2876, DOI 10.1073/pnas.0400116101; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Grande MA, 1997, J CELL SCI, V110, P1781; Hihi AK, 2002, CELL MOL LIFE SCI, V59, P790, DOI 10.1007/s00018-002-8467-x; Hinojos CAD, 2005, TRENDS ENDOCRIN MET, V16, P12, DOI 10.1016/j.tem.2004.11.006; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; IJpenberg A, 2004, EMBO J, V23, P2083, DOI 10.1038/sj.emboj.7600209; Krouglova T, 2004, BIOPHYS J, V87, P2635, DOI 10.1529/biophysj.104.040717; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; Lemberger T, 1996, J BIOL CHEM, V271, P1764, DOI 10.1074/jbc.271.3.1764; Lim CS, 1999, MOL ENDOCRINOL, V13, P366, DOI 10.1210/me.13.3.366; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Llopis J, 2000, P NATL ACAD SCI USA, V97, P4363, DOI 10.1073/pnas.97.8.4363; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Maruvada P, 2003, J BIOL CHEM, V278, P12425, DOI 10.1074/jbc.M202752200; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Oesterreich S, 2000, MOL ENDOCRINOL, V14, P369, DOI 10.1210/me.14.3.369; Patel H, 2005, J CELL SCI, V118, P175, DOI 10.1242/jcs.01600; Pederson T, 2001, CELL, V104, P635, DOI 10.1016/S0092-8674(02)01455-1; Phair RD, 2004, MOL CELL BIOL, V24, P6393, DOI 10.1128/MCB.24.14.6393-6402.2004; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Prufer K, 2000, J BIOL CHEM, V275, P41114, DOI 10.1074/jbc.M003791200; Racz A, 1999, J BIOL CHEM, V274, P19352, DOI 10.1074/jbc.274.27.19352; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Schaaf MJM, 2003, MOL CELL BIOL, V23, P1922, DOI 10.1128/MCB.23.6.1922-1934.2003; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Stavreva DA, 2004, MOL CELL BIOL, V24, P2682, DOI 10.1128/MCB.24.7.2682-2697.2004; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Stenoien DL, 2002, NAT CELL BIOL, V4, P806, DOI 10.1038/ncb859; Stenoien DL, 2000, J CELL BIOCHEM, P99; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Wachsmuth M, 2000, J MOL BIOL, V298, P677, DOI 10.1006/jmbi.2000.3692; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	55	92	99	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17880	17890		10.1074/jbc.M500786200	http://dx.doi.org/10.1074/jbc.M500786200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15731109	hybrid			2022-12-25	WOS:000228807200041
J	Maiti, B; Li, J; de Bruin, A; Gordon, F; Timmers, C; Opavsky, R; Patil, K; Tuttle, J; Cleghorn, W; Leone, G				Maiti, B; Li, J; de Bruin, A; Gordon, F; Timmers, C; Opavsky, R; Patil, K; Tuttle, J; Cleghorn, W; Leone, G			Cloning and characterization of mouse E2F8, a novel mammalian E2F family member capable of blocking cellular proliferatio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; HISTONE DEACETYLASE; S-PHASE; REPRESS TRANSCRIPTION; CYCLE; COMPLEX; BINDING; GENES; RB	The E2F transcription factor family plays a crucial and well established role in cell cycle progression. Deregulation of E2F activities in vivo leads to developmental defects and cancer. Based on current evidence in the field, mammalian E2Fs can be functionally categorized into either transcriptional activators ( E2F1, E2F2, and E2F3a) or repressors (E2F3b, E2F4, E2F5, E2F6, and E2F7). We have identified a novel E2F family member, E2F8, which is conserved in mice and humans and has its counterpart in Arabidopsis thaliana (E2Ls). Interestingly, E2F7 and E2F8 share unique structural features that distinguish them from other mammalian E2F repressor members, including the presence of two distinct DNA-binding domains and the absence of DP-dimerization, retinoblastoma-binding, and transcriptional activation domains. Similar to E2F7, overexpression of E2F8 significantly slows down the proliferation of primary mouse embryonic fibroblasts. These observations, together with the fact that E2F7 and E2F8 can homodimerize and are expressed in the same adult tissues, suggest that they may have overlapping and perhaps synergistic roles in the control of cellular proliferation.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Genet Comprehens Canc Ctr, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Leone, G (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA.	Leone-1@medctr.osu.edu	de Bruin, Alain/AAL-9195-2020; Martin, Faye/I-1759-2012; LI, JING/F-5318-2011	de Bruin, Alain/0000-0001-8579-2649	PHS HHS [T32] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beaudoing E, 2000, GENOME RES, V10, P1001, DOI 10.1101/gr.10.7.1001; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202; Kosugi S, 2002, J BIOL CHEM, V277, P16553, DOI 10.1074/jbc.M200913200; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Mariconti L, 2002, J BIOL CHEM, V277, P9911, DOI 10.1074/jbc.M110616200; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Stevaux O, 2002, EMBO J, V21, P4927, DOI 10.1093/emboj/cdf501; Suzuki A, 2000, MOL CELL, V5, P217, DOI 10.1016/S1097-2765(00)80418-9; Takahashi Y, 2000, GENE DEV, V14, P804; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	32	146	153	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18211	18220		10.1074/jbc.M501410200	http://dx.doi.org/10.1074/jbc.M501410200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15722552	hybrid			2022-12-25	WOS:000228807200079
J	Velkov, T; Chuang, S; Wielens, J; Sakellaris, H; Charman, WN; Porter, CJH; Scanlon, MJ				Velkov, T; Chuang, S; Wielens, J; Sakellaris, H; Charman, WN; Porter, CJH; Scanlon, MJ			The interaction of lipophilic drugs with intestinal fatty acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; ESCHERICHIA-COLI; DIFFERENT MECHANISMS; SERUM-ALBUMIN; MODEL SYSTEM; LIVER; RAT; EXPRESSION; TRANSPORT; NMR	Intestinal fatty acid-binding protein (I-FABP) is a small protein that binds long-chain dietary fatty acids in the cytosol of the columnar absorptive epithelial cells (enterocytes) of the intestine. The binding cavity of IFABP is much larger than is necessary to bind a fatty acid molecule, which suggests that the protein may be able to bind other hydrophobic and amphipathic ligands such as lipophilic drugs. Herein we describe the binding of three structurally diverse lipophilic drugs, bezafibrate, ibuprofen (both R- and S-isomers) and nitrazepam to I-FABP. The rank order of affinity for I-FABP determined for these compounds was found to be R- ibuprofen approximate to bezafibrate > S-ibuprofen >> nitrazepam. The binding affinities were not directly related to aqueous solubility or partition coefficient of the compounds; however, the freely water-soluble drug diltiazem showed no affinity for I-FABP. Drug-I-FABP interaction interfaces were defined by analysis of chemical shift perturbations in NMR spectra, which revealed that the drugs bound within the central fatty acid binding cavity. Each drug participated in a different set of interactions within the cavity; however, a number of common contacts were observed with residues also involved in fatty acid binding. These data suggest that the binding of non-fatty acid lipophilic drugs to I-FABP may increase the cytosolic solubility of these compounds and thereby facilitate drug transport from the intestinal lumen across the enterocyte to sites of distribution and metabolism.	Monash Univ, Victorian Coll Pharm, Dept Med Chem, Parkville, Vic 3052, Australia; Monash Univ, Dept Pharmaceut, Parkville, Vic 3052, Australia; Monash Univ, Dept Microbiol, Parkville, Vic 3052, Australia	Monash University; Monash University; Monash University	Scanlon, MJ (corresponding author), Monash Univ, Victorian Coll Pharm, Dept Med Chem, 381 Royal Parade, Parkville, Vic 3052, Australia.	Martin.Scanlon@vcp.monash.edu.au	Porter, Christopher JH/C-6333-2011	Porter, Christopher JH/0000-0003-3474-7551; Scanlon, Martin/0000-0002-9230-7506; Charman, William/0000-0002-7051-2023; Chuang, Sara/0000-0001-7738-5613; Wielens, Jerome/0000-0003-3406-4136; velkov, tony/0000-0002-0017-7952				Arighi CN, 2003, BIOCHEMISTRY-US, V42, P7539, DOI 10.1021/bi020680d; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BASS NM, 1986, BIOCHEM BIOPH RES CO, V137, P929, DOI 10.1016/0006-291X(86)90314-1; BURRIER RE, 1986, BIOCHIM BIOPHYS ACTA, V879, P229; EADS J, 1993, J BIOL CHEM, V268, P26375; GLATZ JFC, 1988, NEWS PHYSIOL SCI, V3, P41; GORDON JI, 1985, J BIOL CHEM, V260, P1995; Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164; Hidalgo Ismael J., 2001, Current Topics in Medicinal Chemistry, V1, P385, DOI 10.2174/1568026013395010; HILLGREN KM, 1995, MED RES REV, V15, P83, DOI 10.1002/med.2610150202; Hodsdon ME, 1996, J MOL BIOL, V264, P585, DOI 10.1006/jmbi.1996.0663; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P2278, DOI 10.1021/bi962018l; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P1450, DOI 10.1021/bi961890r; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; HUBBELL T, 1994, BIOCHEMISTRY-US, V33, P3327, DOI 10.1021/bi00177a025; Jenkins-Kruchten AE, 2003, J BIOL CHEM, V278, P47636, DOI 10.1074/jbc.M307680200; KAIKAUS RM, 1990, EXPERIENTIA, V46, P617, DOI 10.1007/BF01939701; KANDA T, 1990, BIOCHEM BIOPH RES CO, V168, P1053, DOI 10.1016/0006-291X(90)91136-G; Kane CD, 1996, ANAL BIOCHEM, V233, P197, DOI 10.1006/abio.1996.0028; Kirk WR, 1996, BIOPHYS J, V70, P69, DOI 10.1016/S0006-3495(96)79592-9; KOCHWESER J, 1976, NEW ENGL J MED, V294, P526, DOI 10.1056/NEJM197603042941005; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kurian E, 1996, BIOCHEMISTRY-US, V35, P3865, DOI 10.1021/bi952589y; LACHAU S, 1992, J PHARM SCI, V81, P287, DOI 10.1002/jps.2600810319; Li Y, 1996, J BIOL CHEM, V271, P28038, DOI 10.1074/jbc.271.45.28038; LOWE JB, 1987, J BIOL CHEM, V262, P5931; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; Motulsky H, 2003, PRACTICAL GUIDE CURV; Newcomer ME, 1998, SUB CELL BIOCHEM, V30, P53; Ory JJ, 1999, BIOPHYS J, V77, P1107, DOI 10.1016/S0006-3495(99)76961-4; Pastukhov AV, 2003, PROTEINS, V53, P607, DOI 10.1002/prot.10401; PAULUSSEN RJA, 1990, INT J BIOCHEM, V22, P393, DOI 10.1016/0020-711X(90)90142-P; Porter CJH, 2001, ADV DRUG DELIVER REV, V50, P61, DOI 10.1016/S0169-409X(01)00151-X; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SACCHETTINI JC, 1990, MOL CELL BIOCHEM, V98, P81; Shen DD, 1997, ADV DRUG DELIV REV, V27, P99; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Thompson J, 1999, BBA-MOL CELL BIOL L, V1441, P117, DOI 10.1016/S1388-1981(99)00146-8; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; Thumser AEA, 2000, J LIPID RES, V41, P647; THUMSER AEA, 1994, BIOCHEM J, V301, P801, DOI 10.1042/bj3010801; VAHOUNY GV, 1987, ADV LIPID RES, V22, P83; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; VINCENT SH, 1985, J BIOL CHEM, V260, P4521; Vorum H, 1999, DAN MED BULL, V46, P379; Weisiger RA, 2002, MOL CELL BIOCHEM, V239, P35, DOI 10.1023/A:1020550405578; Wolfrum C, 2000, BIOCHEMISTRY-US, V39, P1469, DOI 10.1021/bi991638u	50	49	52	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17769	17776		10.1074/jbc.M410193200	http://dx.doi.org/10.1074/jbc.M410193200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15722357	hybrid			2022-12-25	WOS:000228807200027
J	Bour, G; Plassat, JL; Bauer, A; Lalevee, S; Rochette-Egly, C				Bour, G; Plassat, JL; Bauer, A; Lalevee, S; Rochette-Egly, C			Vinexin beta interacts with the non-phosphorylated AF-1 domain of retinoid receptor gamma(RAR gamma) and represses RAR gamma-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; ACTIVATION FUNCTIONS AF-1; EPIDERMAL-GROWTH-FACTOR; F9 CELLS; TRANSACTIVATION FUNCTIONS; ACID; PHOSPHORYLATION; PROTEIN; ALPHA; COMPLEX	Nuclear retinoic acid receptors (RARs) are ligand-dependent transcription factors that regulate the expression of retinoic acid target genes. Although the importance of RAR phosphorylation in their N-terminal domain is clearly established, the underlying mechanism for the phosphorylation-dependent transcriptional activity of the receptors had not been elucidated yet. Here, using a yeast two-hybrid system, we report the isolation of vinexin beta as a new cofactor that interacts with the N-terminal A/B domain of the RAR gamma isotype. Vinexin beta is a multiple SH3 motif-containing protein associated with the cytoskeleton and also present in the nucleus. We demonstrate that vinexin beta colocalizes with RAR gamma in the nucleus and interacts with the non-phosphorylated form of the AF-1 domain of RAR gamma. We also show that this interaction is prevented upon phosphorylation of the AF-1 domain. Using F9 cells stably overexpressing vinexin beta or vinexin knockdown by RNA interference, we demonstrate that vinexin beta is an inhibitor of RAR gamma-mediated transcription. We propose a model in which phosphorylation of the AF-1 domain controls RAR gamma-mediated transcription through triggering the dissociation of vinexin beta.	Univ Strasbourg 1, Dept Cell Biol & Signal Transduct, IGBMC, INSERM,CNRS,UMR 7104, F-67404 Illkirch Graffenstaden, Communaute Urba, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Rochette-Egly, C (corresponding author), Univ Strasbourg 1, Dept Cell Biol & Signal Transduct, IGBMC, INSERM,CNRS,UMR 7104, BP 10142, F-67404 Illkirch Graffenstaden, Communaute Urba, France.	cegly@igbmc.u-strasbg.fr						Akamatsu M, 1999, J BIOL CHEM, V274, P35933, DOI 10.1074/jbc.274.50.35933; Altucci L, 2001, TRENDS ENDOCRIN MET, V12, P460, DOI 10.1016/S1043-2760(01)00502-1; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Beitel LK, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290041; Bommer M, 2002, J BIOL CHEM, V277, P37961, DOI 10.1074/jbc.M206001200; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Germain P, 2003, PURE APPL CHEM, V75, P1619, DOI 10.1351/pac200375111619; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Glass CK, 2000, GENE DEV, V14, P121; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Keriel A, 2002, CELL, V109, P125, DOI 10.1016/S0092-8674(02)00692-X; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Kumar R, 2003, MOL ENDOCRINOL, V17, P1, DOI 10.1210/me.2002-0258; Laudet V., 2001, NUCL RECEPTOR FACTSB; Le Douarin B, 2001, METH MOL B, V176, P227; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Loinder K, 2003, J STEROID BIOCHEM, V84, P15, DOI 10.1016/S0960-0760(03)00007-4; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Metivier R, 2001, MOL ENDOCRINOL, V15, P1953, DOI 10.1210/me.15.11.1953; Mitsushima M, 2004, J BIOL CHEM, V279, P34570, DOI 10.1074/jbc.M402304200; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Rochette-Egly C, 2001, HISTOL HISTOPATHOL, V16, P909, DOI 10.14670/HH-16.909; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; Sohn YC, 2003, MOL ENDOCRINOL, V17, P366, DOI 10.1210/me.2002-0150; Suwa A, 2002, J BIOL CHEM, V277, P13053, DOI 10.1074/jbc.M108644200; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Townson SM, 2003, J BIOL CHEM, V278, P20059, DOI 10.1074/jbc.M212988200; Tujague M, 2004, J BIOL CHEM, V279, P9255, DOI 10.1074/jbc.M312160200; vom Baur E, 1998, GENE DEV, V12, P1278, DOI 10.1101/gad.12.9.1278; VOM BE, 1996, EMBO J, V15, P110; Warnmark A, 2003, MOL ENDOCRINOL, V17, P1901, DOI 10.1210/me.2002-0384; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Zarrinpar A, 2000, NAT STRUCT BIOL, V7, P611, DOI 10.1038/77891	49	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17027	17037		10.1074/jbc.M501344200	http://dx.doi.org/10.1074/jbc.M501344200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15734736	hybrid			2022-12-25	WOS:000228615500060
J	Furukawa, Y; O'Halloran, TV				Furukawa, Y; O'Halloran, TV			Amyotrophic lateral sclerosis mutations have the greatest destabilizing effect on the Apo- and reduced form of SOD1, leading to unfolding and oxidative aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU/ZN SUPEROXIDE-DISMUTASE; ALS-LINKED SOD1; SPINAL-CORD MITOCHONDRIA; COPPER CHAPERONE; MOTOR-NEURONS; CU,ZN-SUPEROXIDE DISMUTASE; DISULFIDE REDUCTION; AXONAL-TRANSPORT; TRANSGENIC MICE; IN-VITRO	Mutant forms of Cu, Zn-superoxide dismutase (SOD1) that cause familial amyotrophic lateral sclerosis (ALS) exhibit toxicity that promotes the death of motor neurons. Proposals for the toxic properties typically involve aberrant catalytic activities or protein aggregation. The striking thermodynamic stability of mature forms of the ALS mutant SOD1 (T-m > 70 degrees C) is not typical of protein aggregation models that involve unfolding. Over 44 states of the polypeptide are possible, depending upon metal occupancy, disulfide status, and oligomeric state; however, it is not clear which forms might be responsible for toxicity. Recently the intramolecular disulfide has been shown to be required for SOD1 activity, leading us to examine these states of several disease-causing SOD1 mutants. We find that ALS mutations have the greatest effect on the most immature form of SOD1, destabilizing the metal-free and disulfide-reduced polypeptide to the point that it is unfolded at physiological temperatures (T-m < 37 degrees C). We also find that immature states of ALS mutant ( but not wild type) proteins readily form oligomers at physiological concentrations. Furthermore, these oligomers are more susceptible to mild oxidative stress, which promotes incorrect disulfide cross-links between conserved cysteines and drives aggregation. Thus it is the earliest disulfide-reduced polypeptides in the SOD1 assembly pathway that are most destabilized with respect to unfolding and oxidative aggregation by ALS-causing mutations.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University; Northwestern University	O'Halloran, TV (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	t-ohalloran@northwestern.edu	O'Halloran, Thomas/ABE-6125-2021; Furukawa, Yoshiaki/F-2871-2014	O'Halloran, Thomas/0000-0001-8732-5059; Furukawa, Yoshiaki/0000-0002-1918-372X	NIGMS NIH HHS [GM 54111, R01 GM054111] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054111] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnesano F, 2004, J BIOL CHEM, V279, P47998, DOI 10.1074/jbc.M406021200; Bartnikas TB, 2003, J BIOL CHEM, V278, P33602, DOI 10.1074/jbc.M305435200; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Borchelt DR, 1998, NEUROBIOL DIS, V5, P27, DOI 10.1006/nbdi.1998.0178; BORDO D, 1994, J MOL BIOL, V238, P366, DOI 10.1006/jmbi.1994.1298; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Carroll MC, 2004, P NATL ACAD SCI USA, V101, P5964, DOI 10.1073/pnas.0308298101; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHLEBOWSKI JF, 1977, J BIOL CHEM, V252, P7042; Crow JP, 1997, J NEUROCHEM, V69, P1936; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Eaton WA, 1998, ACCOUNTS CHEM RES, V31, P745, DOI 10.1021/ar9700825; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Field LS, 2003, J BIOL CHEM, V278, P28052, DOI 10.1074/jbc.M304296200; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hough MA, 2004, P NATL ACAD SCI USA, V101, P5976, DOI 10.1073/pnas.0305143101; Jonsson PA, 2004, BRAIN, V127, P73, DOI 10.1093/brain/awh005; Kabashi E, 2004, J NEUROCHEM, V89, P1325, DOI 10.1111/j.1471-4159.2004.02453.x; Khare SD, 2004, P NATL ACAD SCI USA, V101, P15094, DOI 10.1073/pnas.0406650101; KUROBE N, 1990, CLIN CHIM ACTA, V187, P11, DOI 10.1016/0009-8981(90)90257-S; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Leinweber B, 2004, FREE RADICAL BIO MED, V36, P911, DOI 10.1016/j.freeradbiomed.2003.12.021; LEPOCK JR, 1990, J BIOL CHEM, V265, P21612; Lindberg MJ, 2002, P NATL ACAD SCI USA, V99, P16607, DOI 10.1073/pnas.262527099; Lindberg MJ, 2004, P NATL ACAD SCI USA, V101, P15893, DOI 10.1073/pnas.0403979101; Lindenau J, 2000, GLIA, V29, P25, DOI 10.1002/(SICI)1098-1136(20000101)29:1<25::AID-GLIA3>3.0.CO;2-G; Linding R, 2004, J MOL BIOL, V342, P345, DOI 10.1016/j.jmb.2004.06.088; Liu J, 2004, NEURON, V43, P5, DOI 10.1016/j.neuron.2004.06.016; Lyons TJ, 1998, J BIOL INORG CHEM, V3, P650, DOI 10.1007/s007750050279; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; Pasinelli P, 2004, NEURON, V43, P19, DOI 10.1016/j.neuron.2004.06.021; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rae TD, 2001, J BIOL CHEM, V276, P5166, DOI 10.1074/jbc.M008005200; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; Ray SS, 2004, BIOCHEMISTRY-US, V43, P4899, DOI 10.1021/bi030246r; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SHIBATA N, 1994, NEUROSCI LETT, V179, P149, DOI 10.1016/0304-3940(94)90956-3; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Subramaniam JR, 2002, NAT NEUROSCI, V5, P301, DOI 10.1038/nn823; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Wang J, 2003, HUM MOL GENET, V12, P2753, DOI 10.1093/hmg/ddg312; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Zhang H, 2003, J BIOL CHEM, V278, P24078, DOI 10.1074/jbc.M302051200; Zhang QH, 2003, BIOCHEMISTRY-US, V42, P8756, DOI 10.1021/bi030077a	62	198	203	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17266	17274		10.1074/jbc.M500482200	http://dx.doi.org/10.1074/jbc.M500482200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15691826	hybrid			2022-12-25	WOS:000228615500090
J	Fushinobu, S; Hidaka, M; Honda, Y; Wakagi, T; Shoun, H; Kitaoka, M				Fushinobu, S; Hidaka, M; Honda, Y; Wakagi, T; Shoun, H; Kitaoka, M			Structural basis for the specificity of the reducing end xylose-releasing exo-oligoxylanase from Bacillus halodurans C-125	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; XYLANASE; PROGRAM; GLYCOSIDASE; EXPRESSION; HYDROLASE; COMPLEX; PROTEIN; CLONING	Reducing end xylose-releasing exo-oligoxylanase from Bacillus halodurans C-125 (Rex) hydrolyzes xylooligosaccharides whose degree of polymerization is greater than or equal to 3, releasing the xylose unit at the reducing end. It is a unique exo-type glycoside hydrolase that recognizes the xylose unit at the reducing end in a very strict manner, even discriminating the beta-anomeric hydroxyl configuration from the alpha-anomer or 1-deoxyxylose. We have determined the crystal structures of Rex in unliganded and complex forms at 1.35 - 2.20-angstrom resolution and revealed the structural aspects of its three subsites ranging from - 2 to + 1. The structure of Rex was compared with those of endo-type enzymes in glycoside hydrolase subfamily 8a (GH-8a). The catalytic machinery of Rex is basically conserved with other GH-8a enzymes. However, subsite + 2 is blocked by a barrier formed by a kink in the loop before helix alpha(10). His-319 in this loop forms a direct hydrogen bond with the beta-hydroxyl of xylose at subsite + 1, contributing to the specific recognition of anomers at the reducing end.	Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan	University of Tokyo; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan	Fushinobu, S (corresponding author), Univ Tokyo, Dept Biotechnol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	asfushi@mail.ecc.u-tokyo.ac.jp	Fushinobu, Shinya/E-4987-2011; Wakagi, Takayoshi/AAJ-4145-2021; Kitaoka, Motomitsu/R-1536-2019	Fushinobu, Shinya/0000-0003-1346-6435; Kitaoka, Motomitsu/0000-0002-0083-1838				Adachi W, 2004, J MOL BIOL, V343, P785, DOI 10.1016/j.jmb.2004.08.028; Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barr BK, 1996, BIOCHEMISTRY-US, V35, P586, DOI 10.1021/bi9520388; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Christopher JA, 1998, J MOL GRAPH MODEL, V16, P285; Divne C, 1998, J MOL BIOL, V275, P309, DOI 10.1006/jmbi.1997.1437; Fujimoto Z, 2004, J BIOL CHEM, V279, P9606, DOI 10.1074/jbc.M312293200; Guerin DMA, 2002, J MOL BIOL, V316, P1061, DOI 10.1006/jmbi.2001.5404; Guimaraes BG, 2002, J MOL BIOL, V320, P587, DOI 10.1016/S0022-2836(02)00497-7; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HONDA H, 1985, J BACTERIOL, V161, P784, DOI 10.1128/JB.161.2.784-785.1985; HONDA H, 1985, CAN J MICROBIOL, V31, P538, DOI 10.1139/m85-100; Honda Y, 2005, ACTA CRYSTALLOGR F, V61, P291, DOI 10.1107/S1744309105003635; Honda Y, 2004, J BIOL CHEM, V279, P55097, DOI 10.1074/jbc.M409832200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee MH, 2002, BIOCHEM BIOPH RES CO, V295, P818, DOI 10.1016/S0006-291X(02)00748-9; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parsiegla G, 1998, EMBO J, V17, P5551, DOI 10.1093/emboj/17.19.5551; Pell G, 2004, J BIOL CHEM, V279, P11777, DOI 10.1074/jbc.M311947200; Pell G, 2004, J BIOL CHEM, V279, P9597, DOI 10.1074/jbc.M312278200; TAPIO S, 1991, J BIOL CHEM, V266, P19450; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Van Petegem F, 2003, J BIOL CHEM, V278, P7531, DOI 10.1074/jbc.M206862200; Yaoi K, 2004, STRUCTURE, V12, P1209, DOI 10.1016/j.str.2004.04.020; Yaoi K, 2002, J BIOL CHEM, V277, P48276, DOI 10.1074/jbc.M208443200	30	50	53	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17180	17186		10.1074/jbc.M413693200	http://dx.doi.org/10.1074/jbc.M413693200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15718242	hybrid			2022-12-25	WOS:000228615500079
J	Lee, DW; Zhao, XH; Scarselletta, S; Schweinsberg, PJ; Eisenberg, E; Grant, BD; Greene, LE				Lee, DW; Zhao, XH; Scarselletta, S; Schweinsberg, PJ; Eisenberg, E; Grant, BD; Greene, LE			ATP binding regulates oligomerization and endosome association of RME-1 family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE MYOSIN ATPASE; MEMBRANE; EHD1; COMPARTMENT; MECHANISM; RECEPTOR	Members of the RME-1/mRme-1/EHD1 protein family have recently been shown to function in the recycling of membrane proteins from recycling endosomes to the plasma membrane. RME-1 family proteins are normally found in close association with recycling endosomes and the vesicles and tubules emanating from these endosomes, consistent with the proposal that these proteins directly participate in endosomal transport. RME-1 family proteins contain a C-terminal EH (eps15 homology) domain thought to be involved in linking RME-1 to other endocytic proteins, a coiled-coil domain thought to be involved in homo-oligomerization and an N-terminal P-loop domain thought to mediate nucleotide binding. In the present study, we show that both Caenorhabditis elegans and mouse RME-1 proteins bind and hydrolyze ATP. No significant GTP binding or hydrolysis was detected. Mutation or deletion of the ATP-binding P-loop prevented RME-1 oligomerization and at the same time dissociated RME-1 from endosomes. In addition, ATP depletion caused RME-1 to lose its endosome association in the cell, resulting in cytosolic localization. Taken together, these results indicate that ATP binding is required for oligomerization of mRme-1/EHD1, which in turn is required for its association with endosomes.	NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Rutgers State University New Brunswick	Greene, LE (corresponding author), NHLBI, Cell Biol Lab, NIH, 50 South Dr,Rm 2537,MSC 8017, Bethesda, MD 20892 USA.	greenel@helix.nih.gov		Grant, Barth/0000-0002-5943-8336	NIGMS NIH HHS [R01 GM067237-02, R01 GM067237, GM67237-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000449] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Caplan S, 2002, EMBO J, V21, P2557, DOI 10.1093/emboj/21.11.2557; CHOCK SP, 1979, J BIOL CHEM, V254, P3236; CHOCK SP, 1979, J BIOL CHEM, V254, P3229; Galperin E, 2002, TRAFFIC, V3, P575, DOI 10.1034/j.1600-0854.2002.30807.x; Guilherme A, 2004, J BIOL CHEM, V279, P40062, DOI 10.1074/jbc.M401918200; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; Lin SX, 2001, NAT CELL BIOL, V3, P567, DOI 10.1038/35078543; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Naslavsky N, 2004, MOL BIOL CELL, V15, P2410, DOI 10.1091/mbc.E03-10-0733; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Rotem-Yehudar R, 2001, J BIOL CHEM, V276, P33054, DOI 10.1074/jbc.M009913200; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Wendland B, 2001, NAT CELL BIOL, V3, pE133, DOI 10.1038/35078592; Wenk MR, 2004, P NATL ACAD SCI USA, V101, P8262, DOI 10.1073/pnas.0401874101; Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085; Zeng XC, 2004, J CELL SCI, V117, P4991, DOI 10.1242/jcs.01373; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	23	68	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17213	17220		10.1074/jbc.M412751200	http://dx.doi.org/10.1074/jbc.M412751200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15710626	hybrid			2022-12-25	WOS:000228615500083
J	Zheng, ZY; Bay, BH; Aw, SE; Lin, VCL				Zheng, ZY; Bay, BH; Aw, SE; Lin, VCL			A novel antiestrogenic mechanism in progesterone receptor-transfected breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; ESTROGEN-RECEPTOR; CROSS-TALK; IN-VIVO; GROWTH; MCF-7; 4-HYDROXYLATION; PROLIFERATION; PROGESTINS; METABOLISM	The expression of progesterone receptor ( PR) is normally estrogen-dependent, and progesterone is only active in target cells following estrogen exposure. This study revealed that the effect of estrogen was markedly disrupted by estrogen-independent expression of PR. Transfection of PR in estrogen receptor (ER)-positive MCF-7 cells abolished the estradiol-17 beta growth stimulatory effect that was observed in the parental cells and the vector-transfected controls in a ligand-independent manner. The antiestrogenic effect was also observed at the level of gene transcription. Estradiol-17 beta (E2)-induced gene expression of pS2 and GREB1 was impaired by 50 - 75% after 24 - 72 h of E2 treatment in PR-transfected cells. Promoter interference assay revealed that PR transfection drastically inhibited E2-mediated ER binding to estrogen response elements ( ERE). The antiestrogenic effects of transfected PR are associated with enhanced metabolism of E2. HPLC analysis of [H-3] E2 in the samples indicated that the percentage of [H-3] E2 metabolized by PR-transfected cells in 6 h is similar to that by vector-transfected control cells in 24 h ( 77 and 80%, respectively). The increased metabolism of E2 may, in turn, be caused by increased cellular uptake of E2, as demonstrated by whole cell binding of [H-3] E2. The findings open up a new window for a hitherto unknown functional relationship between the PR and ER. The antiestrogenic effect of transfected PR also provides a potential therapeutic strategy for estrogen-dependent breast cancer.	Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore; Natl Univ Singapore, Fac Med, Dept Anat, Singapore 117597, Singapore; Singapore Gen Hosp, Dept Clin Res, Singapore 169608, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore; Singapore General Hospital	Lin, VCL (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	cllin@ntu.edu.sg	LIU, JIANG Jimmy/AHB-8921-2022; Chun Ling, Valerie Lin/A-2188-2011	LIU, JIANG Jimmy/0000-0001-6281-6505; 				Berstein LM, 2003, ENDOCR-RELAT CANCER, V10, P267, DOI 10.1677/erc.0.0100267; BRUEGGEMEIER RW, 1989, MOL CELL ENDOCRINOL, V64, P161, DOI 10.1016/0303-7207(89)90142-1; Brueggemeier RW, 2001, ANN NY ACAD SCI, V948, P51; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; DEHENNIN L, 1984, J STEROID BIOCHEM, V20, P465, DOI 10.1016/0022-4731(84)90255-3; DRUEGE PM, 1986, NUCLEIC ACIDS RES, V14, P9329, DOI 10.1093/nar/14.23.9329; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; Gass EK, 1998, ENDOCRINOLOGY, V139, P1905, DOI 10.1210/en.139.4.1905; GOTTARDIS MM, 1989, CANCER RES, V49, P4765; Graham JD, 1995, J BIOL CHEM, V270, P30693, DOI 10.1074/jbc.270.51.30693; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; JENG MH, 1992, CANCER RES, V52, P6539; Jensen EV, 2001, P NATL ACAD SCI USA, V98, P15197, DOI 10.1073/pnas.211556298; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Katzenellenbogen BS, 2000, J SOC GYNECOL INVEST, V7, pS33, DOI 10.1177/1071557600007001S10; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; Lakhani NJ, 2003, CURR DRUG METAB, V4, P505, DOI 10.2174/1389200033489244; Lavigne JA, 2001, CANCER RES, V61, P7488; LIN CL, 1991, J ENDOCRINOL, V130, P251, DOI 10.1677/joe.0.1300251; Lin VCL, 2001, CLIN CANCER RES, V7, P2880; Lin VCL, 2000, MOL ENDOCRINOL, V14, P348, DOI 10.1210/me.14.3.348; Lin VCL, 1999, CLIN CANCER RES, V5, P395; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MCGUIRE W, 1975, ESTROGEN HUMAN BREAS; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Osborne CK, 2003, BREAST, V12, P362, DOI 10.1016/S0960-9776(03)00137-1; Pasqualini J R, 2001, Gynecol Endocrinol, V15 Suppl 6, P44; Ratajczak T, 2003, CURR TOP MED CHEM, V3, P1348, DOI 10.2174/1568026033451934; REDDEL RR, 1987, CANCER RES, V47, P5323; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; Sartorius CA, 2003, BREAST CANCER RES TR, V79, P287, DOI 10.1023/A:1024031731269; SUTHERLAND RL, 1998, CANCER RES, V48, P5084; Thornton JW, 2003, SCIENCE, V301, P1714, DOI 10.1126/science.1086185; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; WILD MJ, 1991, J STEROID BIOCHEM, V39, P535, DOI 10.1016/0960-0760(91)90248-4; Wilson AM, 2001, CARCINOGENESIS, V22, P257, DOI 10.1093/carcin/22.2.257	37	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17480	17487		10.1074/jbc.M501261200	http://dx.doi.org/10.1074/jbc.M501261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728178	hybrid			2022-12-25	WOS:000228615500115
J	Liu, J; DeYoung, SM; Zhang, M; Dold, LH; Saltiel, AR				Liu, J; DeYoung, SM; Zhang, M; Dold, LH; Saltiel, AR			The stomatin/prohibitin/flotillin/HflK/C domain of flotillin-1 contains distinct sequences that direct plasma membrane localization and protein interactions in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINCULIN-BINDING PROTEIN; LIPID RAFTS; CELL-SURFACE; CYTOSKELETAL ORGANIZATION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ANCHORED PROTEINS; GOLGI-COMPLEX; RECEPTOR; ACTIN	Flotillin-1 is a lipid raft-associated protein that has been implicated in various cellular processes. We examined the subcellular distribution of flotillin-1 in different cell types and found that localization is cell type-specific. Flotillin-1 relocates from a cytoplasmic compartment to the plasma membrane upon the differentiation of 3T3-L1 adipocytes. To delineate the structural determinants necessary for its localization, we generated a series of truncation mutants of flotillin-1. Wild type flotillin-1 has two putative hydrophobic domains and is localized to lipid raft microdomains at the plasma membrane. Flotillin-1 fragments lacking the N-terminal hydrophobic stretch are excluded from the lipid raft compartments but remain at the plasma membrane. On the other hand, mutants with the second hydrophobic region deleted fail to traffic to the plasma membrane but are instead found in intracellular granule-like structures. Flotillin-1 specifically interacts with the adaptor protein CAP, the Src family kinase Fyn, and cortical F-actin in lipid raft microdomains in adipocytes. Furthermore, CAP and Fyn associate with different regions in the N-terminal sequences of flotillin-1. These results furthered our understanding for how flotillin-1 can function as a molecular link between lipid rafts of the plasma membrane and a multimeric signaling complex at the actin cytoskeleton.	Univ Michigan, Inst Life Sci, Dept Internal Med, Med Ctr, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Life Sci, Dept Physiol, Med Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Saltiel, AR (corresponding author), Univ Michigan, Inst Life Sci, Dept Internal Med, Med Ctr, 210 Washtenaw Ave,3rd Floor 2216, Ann Arbor, MI 48109 USA.	saltiel@umich.edu	Zhang, Mei/O-6070-2015; Saltiel, Alan/L-3632-2019	Zhang, Mei/0000-0002-3960-9978; Saltiel, Alan/0000-0002-9726-9828	NIDDK NIH HHS [DK60591, F32 DK064551, DK61618] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061618, R01DK060591, F32DK064551] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Baumann CA, 2000, J BIOL CHEM, V275, P9131, DOI 10.1074/jbc.275.13.9131; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brunton VG, 2004, BBA-MOL CELL RES, V1692, P121, DOI 10.1016/j.bbamcr.2004.04.010; Dermine JF, 2001, J BIOL CHEM, V276, P18507, DOI 10.1074/jbc.M101113200; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Gkantiragas I, 2001, MOL BIOL CELL, V12, P1819, DOI 10.1091/mbc.12.6.1819; Haglund K, 2004, J CELL SCI, V117, P2557, DOI 10.1242/jcs.01148; Harris TJC, 2002, BIOESSAYS, V24, P996, DOI 10.1002/bies.10172; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Hwang JB, 1999, J BIOL CHEM, V274, P22813, DOI 10.1074/jbc.274.32.22813; Kawabe H, 1999, J BIOL CHEM, V274, P30914, DOI 10.1074/jbc.274.43.30914; Kimura A, 2002, J BIOL CHEM, V277, P30153, DOI 10.1074/jbc.M203375200; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Kwik J, 2003, P NATL ACAD SCI USA, V100, P13964, DOI 10.1073/pnas.2336102100; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; Liu J, 2000, J BIOL CHEM, V275, P15940, DOI 10.1074/jbc.M909303199; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Muller G, 2001, MOL CELL BIOL, V21, P4553, DOI 10.1128/MCB.21.14.4553-4567.2001; Neumann-Giesen C, 2004, BIOCHEM J, V378, P509, DOI 10.1042/BJ20031100; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; Schulte T, 1997, DEVELOPMENT, V124, P577; Sevlever D, 1999, BIOCHEM J, V343, P627, DOI 10.1042/0264-6021:3430627; Shumay E, 2002, MOL BIOL CELL, V13, P3943, DOI 10.1091/mbc.E02-03-0174; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Solomon S, 2002, IMMUNOBIOLOGY, V205, P108, DOI 10.1078/0171-2985-00114; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stuermer CAO, 2001, MOL BIOL CELL, V12, P3031, DOI 10.1091/mbc.12.10.3031; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; Tavernarakis N, 1999, TRENDS BIOCHEM SCI, V24, P425, DOI 10.1016/S0968-0004(99)01467-X; Tu XL, 2004, J PROTEOME RES, V3, P445, DOI 10.1021/pr0340779; Zhang M, 2003, MOL MED, V9, P18, DOI 10.1007/BF03402103	41	42	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16125	16134		10.1074/jbc.M500940200	http://dx.doi.org/10.1074/jbc.M500940200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713660	hybrid			2022-12-25	WOS:000228444800080
J	Li, XH; Zhang, R; Luo, DH; Park, SJ; Wang, Q; Kim, Y; Min, W				Li, XH; Zhang, R; Luo, DH; Park, SJ; Wang, Q; Kim, Y; Min, W			Tumor necrosis factor alpha-induced desumoylation and cytoplasmic translocation of homeodomain-interacting protein kinase 1 are critical for apoptosis signal-regulating kinase 1-JNK/p38 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED ASK1 ACTIVATION; CELL-DEATH; ASK1-MEDIATED APOPTOSIS; SERINE/THREONINE KINASE; INDEPENDENT MANNER; PROTEIN KINASE-2; INHIBITOR 14-3-3; MAP KINASES; STRESS; SUMO-1	The apoptosis signal-regulating kinase 1 (ASK1)-JNK/ p38 signaling pathway is pivotal component in cell apoptosis and can be activated by a variety of death stimuli including tumor necrosis factor (TNF) alpha and oxidative stress ( reactive oxygen species). However, the mechanism for ASK1 activation is not fully understood. We have recently identified ASK1-interacting protein (AIP1) as novel signal transducer in TNF alpha-induced ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3. In the present study, we employed yeast two-hybrid system using the N-terminal domain of AIP1 as bait and identified homeodomain-interacting protein kinase 1 (HIPK1) as an AIP1-associated protein. Interestingly, we showed that TNF alpha induced HIPK1 desumoylation concomitant with a translocation from nucleus to cytoplasm at 15 min followed by a return to nucleus by 60 min. The kinetics of HIPK1 translocation correlates with those of stress-induced ASK1-JNK/P38 activation. A specific JNK inhibitor blocked the reverse but not the initial translocation of HIPK1, suggesting that the initial translocation is an upstream event of ASK1-JNK/p38 signaling and JNK activation regulates the reverse translocation as a feedback mechanism. Consistently, expression of HIPK1 increased, whereas expression of a kinase-inactive form (HIPK1-D315N) or small interference RNA of HIPK1 decreased stress-induced ASK1-JNK/P38 activation without effects on IKK-NF-kappa B signaling. Moreover, a sumoylation-defective mutant of HIPK1 (KR5) localizes to the cytoplasm and is constitutively active in ASK1-JNK/P38 activation. Furthermore, HIPK1-KR5 induces dissociation of ASK1 from its inhibitors 14-3-3 and thioredoxin and synergizes with AIP1 to induce ASK1 activation. Our study suggests that TNF alpha-induced desumoylation and cytoplasmic translocation of HIPK1 are critical in TNF alpha-induced ASK1-JNK/p38 activation.	Yale Univ, Sch Med, Dept Pathol,Boyer Ctr Mol Med, Interdept Program Vasc Biol & Transplantat, New Haven, CT 06510 USA; NHLBI, Lab Res Program, NIH, Bethesda, MD 20892 USA; Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Guangzhou 510080, Peoples R China	Yale University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Sun Yat Sen University	Min, W (corresponding author), Yale Univ, Sch Med, Dept Pathol,Boyer Ctr Mol Med, Interdept Program Vasc Biol & Transplantat, BCMM 454,295 Congress Ave, New Haven, CT 06510 USA.	wang.min@yale.edu			NHLBI NIH HHS [HL-65978] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065978] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bailey D, 2004, J BIOL CHEM, V279, P692, DOI 10.1074/jbc.M306195200; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ecsedy JA, 2003, MOL CELL BIOL, V23, P950, DOI 10.1128/MCB.23.3.950-960.2003; GOLDMAN EH, 2003, J BIOL CHEM; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hay RT, 2004, NAT CELL BIOL, V6, P89, DOI 10.1038/ncb0204-89; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kadoya T, 2002, MOL CELL BIOL, V22, P3803, DOI 10.1128/MCB.22.11.3803-3819.2002; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kondo S, 2003, P NATL ACAD SCI USA, V100, P5431, DOI 10.1073/pnas.0530308100; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Li X, 2000, BIOCHEM BIOPH RES CO, V277, P513, DOI 10.1006/bbrc.2000.3700; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rochat-Steiner V, 2000, J EXP MED, V192, P1165, DOI 10.1084/jem.192.8.1165; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; Song JJ, 2003, J BIOL CHEM, V278, P47245, DOI 10.1074/jbc.M213201200; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790	44	62	68	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15061	15070		10.1074/jbc.M414262200	http://dx.doi.org/10.1074/jbc.M414262200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701637	hybrid			2022-12-25	WOS:000228236800089
J	Sakakibara, K; Sato, K; Yoshino, K; Oshiro, N; Hirahara, S; Hasan, AKMM; Iwasaki, T; Ueda, Y; Iwao, Y; Yonezawa, K; Fukami, Y				Sakakibara, K; Sato, K; Yoshino, K; Oshiro, N; Hirahara, S; Hasan, AKMM; Iwasaki, T; Ueda, Y; Iwao, Y; Yonezawa, K; Fukami, Y			Molecular identification and characterization of Xenopus egg uroplakin III, an egg raft-associated transmembrane protein that is tyrosine-phosphorylated upon fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-DEPENDENT ACTIVATION; PHOSPHOLIPASE C-GAMMA; LIPID RAFTS; MEMBRANE MICRODOMAIN; BLADDER EPITHELIUM; CD9-DEFICIENT MICE; ESCHERICHIA-COLI; CALCIUM-RELEASE; SPERM FACTOR; SRC	Here we describe mass spectrometric identification, molecular cloning, and biochemical characterization of a lipid/membrane raft-associated protein that is tyrosine-phosphorylated upon Xenopus egg fertilization. This protein is homologous to mammalian uroplakin III, a member of the uroplakin family proteins (UPs) that constitute asymmetric unit membranes in the mammalian urothelial tissues, thus termed Xenopus uroplakin III (xUPIII). xUPIII contains N-linked sugars and is highly expressed in Xenopus eggs, ovary, urinary tract, and kidney. In unfertilized eggs, xUPIII is predominantly localized to the lipid/membrane rafts and exposed on the cell surface, as judged by surface biotinylation experiments and indirect immunofluorescent studies. After fertilization or hydrogen peroxide-induced egg activation, xUPIII becomes rapidly phosphorylated on tyrosine residue-249, which locates in the carboxyl-terminal cytoplasmic tail of the molecule. Raft localization and tyrosine phosphorylation of xUPIII can be reconstituted in HEK293 cells by coexpression of xUPIII, and Xenopus c-Src, a tyrosine kinase whose fertilization-induced activation in egg rafts is required for initiation of development. In mammals, UPIII is forming a complex with a tetraspanin molecule uroplakin Ib. As another tetraspanin, CD9, is known to be a critical component for sperm-egg fusion in the mouse, we have assumed that xUPIII is involved in sperm-egg interaction. An antibody against the extracellular domain of xUPIII blocks sperm-egg interaction, as judged by the occurrence of egg activation and first cell cleavage. Thus, xUPIII represents an egg raft-associated protein that is likely involved in sperm-egg interaction as well as subsequent Src-dependent intracellular events of egg activation in Xenopus.	Kobe Univ, Res Ctr Environm Genom, Nada Ku, Kobe, Hyogo 6578501, Japan; Kobe Univ, Grad Sch Sci & Technol, Nada Ku, Kobe, Hyogo 6578501, Japan; Kobe Univ, Biosignal Res Ctr, Nada Ku, Kobe, Hyogo 6578501, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan; Yamaguchi Univ, Fac Sci, Dept Biol Sci, Yamaguchi 7538512, Japan	Kobe University; Kobe University; Kobe University; Japan Science & Technology Agency (JST); Yamaguchi University	Sato, K (corresponding author), Kobe Univ, Res Ctr Environm Genom, Nada Ku, Kobe, Hyogo 6578501, Japan.	kksato@kobe-u.ac.jp						Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bodin S, 2003, BBA-BIOMEMBRANES, V1610, P247, DOI 10.1016/S0005-2736(03)00022-1; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Deng FM, 2002, J CELL BIOL, V159, P685, DOI 10.1083/jcb.200204102; Duncan MJ, 2004, J BIOL CHEM, V279, P18944, DOI 10.1074/jbc.M400769200; Evans JP, 2002, NAT CELL BIOL, V4, pS57, DOI 10.1038/ncb-nm-fertilityS57; Harder T, 2004, TRAFFIC, V5, P265, DOI 10.1111/j.1600-0854.2003.00163.x; Harlow E., 1988, ANTIBODIES LAB MANUA; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Hu P, 2000, J CELL BIOL, V151, P961, DOI 10.1083/jcb.151.5.961; Hu P, 2002, AM J PHYSIOL-RENAL, V283, pF1200, DOI 10.1152/ajprenal.00043.2002; Kachar B, 1999, J MOL BIOL, V285, P595, DOI 10.1006/jmbi.1998.2304; Kaji K, 2004, REPRODUCTION, V127, P423, DOI 10.1530/rep.1.00163; Kaji K, 2000, NAT GENET, V24, P279, DOI 10.1038/73502; Kurokawa M, 2004, BIOL CELL, V96, P37, DOI 10.1016/j.biolcel.2003.11.003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; Liang FX, 2001, BIOCHEM J, V355, P13, DOI 10.1042/0264-6021:3550013; Maekawa S, 2003, BBA-BIOMEMBRANES, V1610, P261, DOI 10.1016/S0005-2736(03)00023-3; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Mizote A, 1999, DEV BIOL, V208, P79, DOI 10.1006/dbio.1999.9195; Olsburgh J, 2003, J PATHOL, V199, P41, DOI 10.1002/path.1252; Primakoff P, 2002, SCIENCE, V296, P2183, DOI 10.1126/science.1072029; Rossi P, 2003, ANDROLOGIA, V35, P71, DOI 10.1046/j.1439-0272.2003.00539.x; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; Santella L, 2004, TRENDS BIOCHEM SCI, V29, P400, DOI 10.1016/j.tibs.2004.06.009; Sato K, 2004, BBA-PROTEINS PROTEOM, V1697, P103, DOI 10.1016/j.bbapap.2003.11.017; Sato K, 2003, J BIOL CHEM, V278, P38413, DOI 10.1074/jbc.M302617200; Sato K, 1999, DEV BIOL, V209, P308, DOI 10.1006/dbio.1999.9255; Sato K, 1998, FEBS LETT, V424, P113, DOI 10.1016/S0014-5793(98)00123-9; Sato K, 2002, DEVELOPMENT, V129, P885; Sato K, 2001, DEV GROWTH DIFFER, V43, P55; Sato KI, 2000, DEV BIOL, V224, P453, DOI 10.1006/dbio.2000.9782; SCHULTZ RM, 1995, CURR TOP DEV BIOL, V30, P21, DOI 10.1016/S0070-2153(08)60563-3; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Swann K, 2004, REPRODUCTION, V127, P431, DOI 10.1530/rep.1.00169; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tokmakov AA, 2002, CELL CALCIUM, V32, P11, DOI 10.1016/S0143-4160(02)00078-7; Tu LY, 2002, MOL BIOL CELL, V13, P4221, DOI 10.1091/mbc.E02-04-0211; Williams CJ, 2002, HUM REPROD UPDATE, V8, P313, DOI 10.1093/humupd/8.4.313; WU XR, 1993, J CELL SCI, V106, P31; WU XR, 1995, J BIOL CHEM, V270, P29752; Wu XR, 1996, P NATL ACAD SCI USA, V93, P9630, DOI 10.1073/pnas.93.18.9630; WU XR, 1994, J BIOL CHEM, V269, P13716; YU J, 1994, J CELL BIOL, V125, P171, DOI 10.1083/jcb.125.1.171; Zhou G, 2001, J CELL SCI, V114, P4095	49	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15029	15037		10.1074/jbc.M410538200	http://dx.doi.org/10.1074/jbc.M410538200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15699050	hybrid			2022-12-25	WOS:000228236800085
J	Zhao, TJ; Ou, WB; Xie, Q; Liu, Y; Yan, YB; Zhou, HM				Zhao, TJ; Ou, WB; Xie, Q; Liu, Y; Yan, YB; Zhou, HM			Catalysis of creatine kinase refolding by protein disulfide isomerase involves disulfide cross-link and dimer to tetramer switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-CHAPERONE ACTIVITY; PEPTIDE-BINDING-SITE; SUBSTRATE-BINDING; ACTIVE-SITE; OLIGOMERIZATION; THIOREDOXIN; DOMAINS; REACTIVATION; AGGREGATION; BONDS	Protein disulfide isomerase (PDI) functions as an isomerase to catalyze thiol: disulfide exchange, as a chaperone to assist protein folding, and as a subunit of prolyl-4-hydroxylase and microsomal triglyceride transfer protein. At a lower concentration of 0.2 mu M, PDI facilitated the aggregation of unfolded rabbit muscle creatine kinase (CK) and exhibited anti-chaperone activity, which was shown to be mainly due to the hydrophobic interactions between PDI and CK and was independent of the cross-linking of disulfide bonds. At concentrations above 1 mu M, PDI acted as a protector against aggregation but an inhibitor of reactivation during CK refolding. The inhibition effect of PDI on CK reactivation was further characterized as due to the formation of PDI-CK complexes through intermolecular disulfide bonds, a process involving Cys-36 and Cys-295 of PDI. Two disulfide-linked complexes containing both PDI and CK were obtained, and the large, soluble aggregates around 400 kDa were composed of 1 molecule of tetrameric PDI and 2 molecules of inactive intermediate dimeric CK, whereas the smaller one, around 200 kDa, was formed by 1 dimeric PDI and 1 dimeric CK. To our knowledge this is the first study revealing that PDI could switch its conformation from dimer to tetramer in its functions as a foldase. According to the observations in this research and our previous study of the folding pathways of CK, a working model was proposed for the molecular mechanism of CK refolding catalyzed by PDI.	Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China; Tsinghua Univ, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China	Tsinghua University; Tsinghua University	Yan, YB (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China.	ybyan@tsinghua.edu.cn; zhm-dbs@tsinghua.edu.cn	Zhao, Tong-Jin/AFH-2915-2022; Yan, Yong-Bin/A-4282-2008; Ou, Wen-Bin/J-1142-2019	Yan, Yong-Bin/0000-0002-8565-3558; , Wenbin/0000-0002-6311-9442				Bulleid NJ, 2003, CURR BIOL, V13, pR380, DOI 10.1016/S0960-9822(03)00314-2; CAI H, 1994, J BIOL CHEM, V269, P24550; Chadli A, 1999, J BIOL CHEM, V274, P4133, DOI 10.1074/jbc.274.7.4133; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; Freedman RB, 1998, BIOL CHEM, V379, P321, DOI 10.1515/bchm.1998.379.3.321; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GAO Y, 1999, J BIOTECHNOL, V15, P349; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; HU CH, 1988, CHIN BIOCH J, V4, P61; Jorgensen CS, 2003, EUR J BIOCHEM, V270, P4140, DOI 10.1046/j.1432-1033.2003.03808.x; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Klappa P, 1997, EUR J BIOCHEM, V248, P37, DOI 10.1111/j.1432-1033.1997.t01-1-00037.x; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Klappa P, 2001, BIOCHEM J, V354, P553, DOI 10.1042/0264-6021:3540553; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; Leydier C, 1998, BIOCHEMISTRY-US, V37, P17579, DOI 10.1021/bi981828p; Li S, 2001, INT J BIOCHEM CELL B, V33, P279, DOI 10.1016/S1357-2725(01)00003-6; LYLES MM, 1994, J BIOL CHEM, V269, P30946; Ow WB, 2001, PROTEIN SCI, V10, P2346, DOI 10.1110/ps.23301; Park YD, 2001, BIOCHEM CELL BIOL, V79, P479, DOI 10.1139/bcb-79-4-479; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Primm TP, 1996, J BIOL CHEM, V271, P33664, DOI 10.1074/jbc.271.52.33664; PUIG A, 1994, J BIOL CHEM, V269, P19128; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; Ruddock LW, 2000, PROTEIN SCI, V9, P758; Song JL, 1997, BIOCHEM J, V328, P841, DOI 10.1042/bj3280841; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; Wang CC, 2002, METHOD ENZYMOL, V348, P66, DOI 10.1016/S0076-6879(02)48627-2; Wang ZF, 1995, BIOCHIMIE, V77, P953, DOI 10.1016/0300-9084(95)80007-7; Wearsch PA, 1996, BIOCHEMISTRY-US, V35, P16760, DOI 10.1021/bi962068q; YAO QZ, 1982, SCI SIN B-CHEM B A M, V25, P1296; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651; YU XC, 1994, BBA-PROTEIN STRUCT M, V1207, P109, DOI 10.1016/0167-4838(94)90058-2	38	43	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13470	13476		10.1074/jbc.M413882200	http://dx.doi.org/10.1074/jbc.M413882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695804	hybrid			2022-12-25	WOS:000228095500036
J	Jin, SG; Jiang, CL; Rauch, T; Li, HW; Pfeifer, GP				Jin, SG; Jiang, CL; Rauch, T; Li, HW; Pfeifer, GP			MBD3L2 interacts with MBD3 and components of the NuRD complex and can oppose MBD2-MeCP1-mediated methylation silencing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG-BINDING-PROTEINS; HISTONE DEACETYLASE COMPLEX; TRANSCRIPTIONAL REPRESSOR; DNA METHYLATION; CHROMOSOMAL-PROTEIN; MAMMALIAN PROTEIN; GENE ACTIVATION; CHROMATIN; MECP2; DOMAIN	MBD2 and MBD3 are two proteins that contain methyl-CpG binding domains and have a transcriptional repression function. Both proteins are components of a large CpG-methylated DNA binding complex named MeCP1, which consists of the nucleosome remodeling and histone deacetylase complex Mi2-NuRD and MBD2. MBD3L2 ( methyl-CpG-binding protein 3-like 2) is a protein with substantial homology to MBD2 and MBD3, but it lacks the methyl-CpG-binding domain. Unlike MBD3L1, which is specifically expressed in haploid male germ cells, MBD3L2 expression is more widespread. MBD3L2 interacts with MBD3 in vitro and in vivo, colocalizes with MBD3 but not MBD2, and does not localize to methyl-CpG-rich regions in the nucleus. In glutathione S-transferase pull-down assays, MBD3L2 is found associated with several known components of the Mi2-NuRD complex, including HDAC1, HDAC2, MTA1, MBD3, p66, RbAp46, and RbAp48. Gel shift experiments with nuclear extracts and a CpG-methylated DNA probe indicate that recombinant MBD3L2 can displace a form of the MeCP1 complex from methylated DNA. MBD3L2 acts as a transcriptional repressor when tethered to a GAL4-DNA binding domain. Repression by GAL4MBD3L2 is relieved by MBD2 and vice versa, and repression by MBD2 from a methylated promoter is relieved by MBD3L2. The data are consistent with a role of MBD3L2 as a transcriptional modulator that can interchange with MBD2 as an MBD3-interacting component of the NuRD complex. Thus, MBD3L2 has the potential to recruit the MeCP1 complex away from methylated DNA and reactivate transcription.	Beckman Res Inst City Hope, Div Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Pfeifer, GP (corresponding author), Beckman Res Inst City Hope, Div Biol, Duarte, CA 91010 USA.	gpfeifer@coh.org		Jin, Seung-Gi/0000-0001-5041-0559	NATIONAL CANCER INSTITUTE [R01CA104967] Funding Source: NIH RePORTER; NCI NIH HHS [CA104967] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Feng Q, 2001, GENE DEV, V15, P827; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; Jiang CL, 2004, J BIOL CHEM, V279, P52456, DOI 10.1074/jbc.M409149200; Jiang CL, 2002, GENOMICS, V80, P621, DOI 10.1006/geno.2002.7001; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Li HW, 2004, J BIOL CHEM, V279, P4212, DOI 10.1074/jbc.M311374200; Macleod D, 1999, NAT GENET, V23, P139, DOI 10.1038/13767; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Stancheva I, 2000, GENE DEV, V14, P313; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; TOH Y, 1994, J BIOL CHEM, V269, P22958; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yao YL, 2003, J BIOL CHEM, V278, P42560, DOI 10.1074/jbc.M302955200; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	38	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12700	12709		10.1074/jbc.M413492200	http://dx.doi.org/10.1074/jbc.M413492200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15701600	hybrid			2022-12-25	WOS:000227922000077
J	Sithanandam, G; Fornwald, LW; Fields, J; Anderson, LM				Sithanandam, G; Fornwald, LW; Fields, J; Anderson, LM			Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549	ONCOGENE			English	Article						lung adenocarcinoma; ErbB3; siRNA; Akt; apoptosis; invasion	BREAST-CANCER CELLS; NF-KAPPA-B; C-ERBB-3 PROTEIN EXPRESSION; FACTOR RECEPTOR; KINASE-B; ENHANCES MOTILITY; AKT ACTIVATION; IN-VITRO; HEREGULIN; OVEREXPRESSION	The ErbB3 receptor and the downstream signaling kinase Akt are implicated in proliferation of lung adenocarcinoma cells. Inhibition by siRNAs to ErbB3 and Akt isoforms 1, 2 and 3 was utilized to investigate the contribution of these molecules to tumor survival, spreading and invasiveness, and the roles of specific Akt isoforms. ErbB3 siRNA stably and dose-dependently suppressed ErbB3 protein for 2 days or more, and reduced cell numbers, by both suppressing cell cycle and causing apoptosis and necrosis. It also inhibited soft agar growth, cell motility and migration, and invasiveness. Akt1, 2 and 3 siRNAs had similar suppressive effects on cell number, apoptosis/ necrosis and soft agar growth. However, although Akt1 siRNA had no effect on cell migration or invasion, Akt2 siRNA effectively suppressed both activities, and Akt3 siRNA had moderate effectiveness. In A549 cells, ErbB3 is indicated as having major effects on cell division, survival, motility, migration and invasiveness. All three Akt isoforms are to varying degrees involved in these cell behaviors, with Akt2 especially implicated in migration and invasion. ErbB3 and the Akts are promising targets for therapy, and siRNAs may be useful for this purpose.	NCI, SAIC Frederick, Basic Res Program, Frederick, MD 21702 USA; NCI, Comparat Carcinogenesis Lab, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sithanandam, G (corresponding author), NCI, SAIC Frederick, Basic Res Program, Frederick, MD 21702 USA.	sithanan@mail.ncifcrf.gov			NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arboleda MJ, 2003, CANCER RES, V63, P196; Balsara BR, 2004, CARCINOGENESIS, V25, P2053, DOI 10.1093/carcin/bgh226; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Bellacosa A, 2004, CANCER BIOL THER, V3, P268, DOI 10.4161/cbt.3.3.703; Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; Brognard J, 2001, CANCER RES, V61, P3986; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Cho HJ, 2003, AM J PHYSIOL-GASTR L, V284, pG996, DOI 10.1152/ajpgi.00347.2002; Chun KH, 2003, JNCI-J NATL CANCER I, V95, P291, DOI 10.1093/jnci/95.4.291; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Conus NM, 2002, J BIOL CHEM, V277, P38021, DOI 10.1074/jbc.M203387200; David O, 2004, CHEST, V125, p152S, DOI 10.1378/chest.125.5_suppl.152S; Gilmour LMR, 2002, CLIN CANCER RES, V8, P3933; Gollamudi M, 2004, LUNG CANCER, V43, P135, DOI 10.1016/j.lungcan.2003.08.027; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hauck CR, 2001, CANCER RES, V61, P7079; Hijazi MM, 2000, INT J ONCOL, V17, P629; Hilbe W, 2003, J CLIN PATHOL, V56, P736, DOI 10.1136/jcp.56.10.736; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Jackson JG, 2004, CANCER RES, V64, P2601, DOI 10.1158/0008-5472.CAN-03-3106; Krystal GW, 2002, MOL CANCER THER, V1, P913; Lai WW, 2001, ANN THORAC SURG, V72, P1868, DOI 10.1016/S0003-4975(01)03207-6; Lee KY, 2002, EXP MOL MED, V34, P462, DOI 10.1038/emm.2002.64; Liu XS, 2001, NEOPLASIA, V3, P278, DOI 10.1038/sj.neo.7900163; Luo J, 2000, BREAST CANCER RES TR, V63, P61, DOI 10.1023/A:1006436315284; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mukohara T, 2004, ANTICANCER RES, V24, P11; Munster PN, 2002, CANCER RES, V62, P3132; Natale RB, 2004, INT J RADIAT ONCOL, V59, P39, DOI 10.1016/j.ijrobp.2004.02.037; Noguchi H, 1999, GASTROENTEROLOGY, V117, P1119, DOI 10.1016/S0016-5085(99)70397-5; Okudela K, 2004, AM J PATHOL, V164, P91, DOI 10.1016/S0002-9440(10)63100-8; Ono M, 2004, MOL CANCER THER, V3, P465; Ozes ON, 1999, NATURE, V401, P82; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Patel NV, 2000, AM J RESP CELL MOL, V22, P432, DOI 10.1165/ajrcmb.22.4.3854; POLLER DN, 1992, J PATHOL, V168, P275, DOI 10.1002/path.1711680306; Raben D, 2004, INT J RADIAT ONCOL, V59, P27, DOI 10.1016/j.ijrobp.2004.01.054; Ritch PA, 2003, J BIOL CHEM, V278, P20971, DOI 10.1074/jbc.M213074200; Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201; Sandirasegarane L, 2001, BIOCHEM BIOPH RES CO, V283, P158, DOI 10.1006/bbrc.2001.4739; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; Sithanandam G, 2003, CARCINOGENESIS, V24, P1581, DOI 10.1093/carcin/bgg125; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Sundaresan S, 1998, ENDOCRINOLOGY, V139, P4756, DOI 10.1210/en.139.12.4756; TATEISHI M, 1991, EUR J CANCER, V27, P1372, DOI 10.1016/0277-5379(91)90012-3; Taylor JM, 2004, EXP CELL RES, V300, P463, DOI 10.1016/j.yexcr.2004.07.018; Tsao AS, 2003, CANCER EPIDEM BIOMAR, V12, P660; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; VAN AD, 1996, SCIENCE, V274, P787; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; Venkateswarlu S, 2002, ONCOGENE, V21, P78, DOI 10.1038/sj.onc.1205011; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Vijapurkar U, 2003, EXP CELL RES, V284, P291, DOI 10.1016/S0014-4827(02)00040-X; Way TD, 2004, J BIOL CHEM, V279, P4479, DOI 10.1074/jbc.M305529200; West KA, 2004, CANCER RES, V64, P446, DOI 10.1158/0008-5472.CAN-03-3241; Xu FJ, 1997, CLIN CANCER RES, V3, P1629; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yi ES, 1997, MODERN PATHOL, V10, P142; Zhou H, 2002, ONCOGENE, V21, P8732, DOI 10.1038/sj.onc.1205984; Zinda MJ, 2001, CLIN CANCER RES, V7, P2475	62	65	78	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1847	1859		10.1038/sj.onc.1208381	http://dx.doi.org/10.1038/sj.onc.1208381			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688028				2022-12-25	WOS:000227542000004
J	Karst, AM; Dai, DL; Martinka, M; Li, G				Karst, AM; Dai, DL; Martinka, M; Li, G			PUMA expression is significantly reduced in human cutaneous melanomas	ONCOGENE			English	Article						PUMA; tissue microarray; melanoma; gene expression	COLORECTAL-CANCER CELLS; MALIGNANT-MELANOMA; APOPTOSIS; CHEMORESISTANCE; RESISTANCE; MECHANISMS; SIGNALS; DEATH; GENE; P53	Cutaneous malignant melanoma is an aggressive form of skin cancer, characterized by strong chemoresistance and poor patient prognosis. The molecular mechanisms underlying its resistance to chemotherapy remain unclear but are speculated to involve the dysregulation of apoptotic pathways. In this study, we sought to determine whether PUMA (p53 upregulated modulator of apoptosis) contributes to human melanoma formation, tumor progression, and survival. We used tissue microarray and immunohistochemistry to examine PUMA expression in 107 primary melanomas, 51 metastatic melanomas, and 64 dysplastic nevi. Here we report that PUMA expression is significantly weaker in primary melanomas compared to dysplastic nevi ( P<0.0001), and is further reduced in metastatic melanomas compared to primary tumors ( P = 0.001). We show that weak PUMA expression in melanoma correlates with poorer overall and disease-specific 5-year survival ( P<0.005 and P<0.001, respectively) of melanoma patients and that PUMA expression in tumor tissue is an independent predictor of both overall and disease-specific 5-year survival ( P = 0.05). Additionally, we show that exogenous PUMA expression in human melanoma cell lines ( both wild type and mutant p53) results in significant apoptotic cell death. Our results suggest that PUMA expression may be an important prognostic marker for human melanoma and that adenoviral delivery of PUMA sensitizes melanoma cells to apoptosis.	Univ British Columbia, Dept Med, Div Dermatol, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Vancouver Coastal Hlth Res Inst, Div Anat Pathol, Vancouver, BC, Canada	University of British Columbia; Vancouver Coastal Health Research Institute	Li, G (corresponding author), Univ British Columbia, Dept Med, Div Dermatol, Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	gangli@interchange.ubc.ca	Li, Gang/A-8257-2011					Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; Bowen AR, 2003, J INVEST DERMATOL, V120, P48, DOI 10.1046/j.1523-1747.2003.12010.x; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Grossman D, 2001, CANCER METAST REV, V20, P3, DOI 10.1023/A:1013123532723; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Houghton AN, 2002, CANCER CELL, V2, P275, DOI 10.1016/S1535-6108(02)00161-7; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jemal A, 2001, JNCI-J NATL CANCER I, V93, P678, DOI 10.1093/jnci/93.9.678; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Serrone L, 1999, MELANOMA RES, V9, P51, DOI 10.1097/00008390-199902000-00007; Serrone L, 2000, J EXP CLIN CANC RES, V19, P21; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; STAUNTON MJ, 1995, AM J CLIN PATHOL, V103, P300, DOI 10.1093/ajcp/103.3.300; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	21	71	84	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1111	1116		10.1038/sj.onc.1208374	http://dx.doi.org/10.1038/sj.onc.1208374			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15690057				2022-12-25	WOS:000226749200018
J	Dan, Z; Popov, Y; Patsenker, E; Preimel, D; Liu, C; Wang, XD; Seitz, HK; Schuppan, D; Stickel, F				Dan, Z; Popov, Y; Patsenker, E; Preimel, D; Liu, C; Wang, XD; Seitz, HK; Schuppan, D; Stickel, F			Hepatotoxicity of alcohol-induced polar retinol metabolites involves apoptosis via loss of mitochondrial membrane potential	FASEB JOURNAL			English	Article						alcoholic liver disease; cytochrome P4502E1; hypervitaminosis A; mitochondrial damage; vitamin A	ETHANOL-INDUCED APOPTOSIS; BETA-CAROTENE; VITAMIN-A; PERMEABILITY TRANSITION; CYTOCHROME P-4502E1; ACID CONCENTRATION; RAT HEPATOCYTES; LIVER-INJURY; C-JUN; CARCINOGENESIS	Chronic alcohol consumption depletes hepatic vitamin A stores. However, vitamin A supplementation is hepatotoxic,which is further potentiated by concomitant alcohol consumption. It was suggested that polar retinol metabolites generated by alcohol-inducible cytochrome P4502E1 aggravate liver damage. However, experimental evidence supporting this hypothesis is lacking. To elucidate the effects of polar retinol metabolites on cultured HepG2 cells and primary rat hepatocytes, polar retinol metabolites were extracted from liver tissues of rats fed either an alcoholic or isocaloric control Lieber-DeCarli diet. Cell toxicity assays included morphology assessment, trypan blue exclusion test,and LDH/AST leakage. Staining for DAPI and acridine orange, FACS analysis, and Western blot for cleaved caspase-9 and-3 were used to detect apoptosis. Polar retinol metabolites caused marked cytotoxicity in a concentration- and time-dependent manner in both cell types reflected by morphological changes, a dramatic increase in trypan blue positive cells, and LDH/AST leakage. Toxicity was due to apoptosis, as demonstrated by a time-dependent increase of sub-G1 cellular events,a rapid loss of mitochondrial membrane potential, and a time-dependent activation of caspase-9 and-3. No toxicity was found with equivalent doses of the control extract from nonalcoholic rats. We demonstrate that polar retinol metabolites cause marked hepatocyte death through the induction of apoptosis.	Univ Heidelberg, Salem Med Ctr, Dept Med, Lab Alcohol Res & Liver Dis, D-69121 Heidelberg, Germany; Univ Erlangen Nuremberg, Dept Med 1, Lab Liver Res, Erlangen, Germany; Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Gastroenterol, Wuhan 430074, Peoples R China; Tufts Univ, Human Nutr Res Ctr Aging, Nutr & Canc Biol Lab, Boston, MA 02111 USA	Ruprecht Karls University Heidelberg; University of Erlangen Nuremberg; Huazhong University of Science & Technology; Tufts University; United States Department of Agriculture (USDA)	Stickel, F (corresponding author), Univ Heidelberg, Salem Med Ctr, Dept Med, Lab Alcohol Res & Liver Dis, Zeppelinstr 11-33, D-69121 Heidelberg, Germany.	felix.stickel@stadtmission-hd.de	Popov, Yury V./A-7781-2008	Popov, Yury V./0000-0001-7973-942X				Adachi M, 2002, FREE RADICAL BIO MED, V32, P487, DOI 10.1016/S0891-5849(02)00740-2; Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560; Badger TM, 2003, ALCOHOL CLIN EXP RES, V27, P336, DOI 10.1097/01.ALC.0000052583.87673.37; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 1996, J IMMUNOL, V157, P512; Chung JG, 2001, CARCINOGENESIS, V22, P1213, DOI 10.1093/carcin/22.8.1213; Chung JY, 2002, ONCOGENE, V21, P1539, DOI 10.1038/sj.onc.1205023; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Crabb DW, 2001, ALCOHOL CLIN EXP RES, V25, p207S, DOI 10.1097/00000374-200105051-00034; Deltour L, 1996, FASEB J, V10, P1050, DOI 10.1096/fasebj.10.9.8801166; Eguchi Y, 1997, CANCER RES, V57, P1835; GARCIARUIZ C, 1994, J CLIN INVEST, V94, P193, DOI 10.1172/JCI117306; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; Higuchi H, 2001, HEPATOLOGY, V34, P320, DOI 10.1053/jhep.2001.26380; Kessova IG, 2001, ALCOHOL CLIN EXP RES, V25, P1368, DOI 10.1111/j.1530-0277.2001.tb02360.x; LEO MA, 1992, HEPATOLOGY, V15, P883, DOI 10.1002/hep.1840150522; Leo MA, 1999, AM J CLIN NUTR, V69, P1071; Leo MA, 1997, AM J CLIN NUTR, V66, P1461, DOI 10.1093/ajcn/66.6.1461; Lieber CS, 1999, ALCOHOL CLIN EXP RES, V23, P991, DOI 10.1111/j.1530-0277.1999.tb04217.x; Lieber CS, 1997, PHYSIOL REV, V77, P517, DOI 10.1152/physrev.1997.77.2.517; Liu C, 2002, ALCOHOL CLIN EXP RES, V26, P1703, DOI 10.1097/01.ALC.0000037135.09289.69; Liu C, 2001, GASTROENTEROLOGY, V120, P179, DOI 10.1053/gast.2001.20877; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MINUK GY, 1988, HEPATOLOGY, V8, P272, DOI 10.1002/hep.1840080214; Neuman MG, 2002, ALCOHOL, V28, P117, DOI 10.1016/S0741-8329(02)00243-4; Neuman MG, 1999, CLIN BIOCHEM, V32, P547, DOI 10.1016/S0009-9120(99)00054-5; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pastorino JG, 1999, BIOCHEM BIOPH RES CO, V265, P405, DOI 10.1006/bbrc.1999.1696; Patek AJ, 1939, J CLIN INVEST, V18, P609, DOI 10.1172/JCI101075; RUSSELL RM, 1974, NEW ENGL J MED, V291, P435, DOI 10.1056/NEJM197408292910903; SEGLEN PO, 1979, J TOXICOL ENV HEALTH, V5, P551, DOI 10.1080/15287397909529766; Seitz H. K., 2002, Nutritional toxicology, P122; Stickel F, 2003, ALIMENT PHARM THER, V18, P357, DOI 10.1046/j.1365-2036.2003.01660.x; Stickel F, 2002, GUT, V51, P132, DOI 10.1136/gut.51.1.132; Wang XD, 1998, HEPATOLOGY, V28, P744, DOI 10.1002/hep.510280321; WORNER TM, 1988, AM J CLIN NUTR, V48, P1431, DOI 10.1093/ajcn/48.6.1431; Wu DF, 1999, ALCOHOL CLIN EXP RES, V23, P67	38	49	51	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					845	+		10.1096/fj.04-2809fje	http://dx.doi.org/10.1096/fj.04-2809fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15731294				2022-12-25	WOS:000227591900005
J	Turner, NA; O'Regan, DJ; Ball, SG; Porter, KE				Turner, NA; O'Regan, DJ; Ball, SG; Porter, KE			Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels	FASEB JOURNAL			English	Article						statins; signal transduction pathways; matrix metalloproteinase-9	HMG-COA REDUCTASE; IV COLLAGENASE EXPRESSION; ARTERY BYPASS GRAFTS; NITRIC-OXIDE; MATRIX-METALLOPROTEINASE-9 EXPRESSION; DEGRADING METALLOPROTEINASES; NEOINTIMA FORMATION; MONONUCLEAR-CELLS; CAROTID-ARTERY; IN-VIVO	Increased matrix metalloproteinase-9 (MMP-9) expression is associated with intimal hyperplasia in saphenous vein (SV) bypass grafts. Recent evidence suggests that HMG-CoA reductase inhibitors (statins) can prevent the progression of vein graft failure. Here we investigated whether statins inhibited MMP-9 secretion from cultured human SV smooth muscle cells (SMC) and examined the underlying mechanisms. SV-SMC from different patients were exposed to phorbol ester (TPA) or PDGF-BB plus interleukin- 1 alpha (IL-1). MMP-9 secretion and mRNA expression were analyzed using gelatin zymography and RT-PCR, respectively. Specific signal transduction pathways were investigated by immunoblotting and pharmacological inhibition. Simvastatin reduced TPA- and PDGF/IL-1-induced MMP-9 secretion and mRNA levels, effects reversed by geranylgeranyl pyrophosphate and mimicked by inhibiting Rho geranylgeranylation or Rho-kinase ( ROCK). MMP-9 secretion induced by PDGF/IL-1 was mediated via the ERK, p38 MAPK, and NF kappa B pathways, whereas that induced by TPA was mediated specifically via the ERK pathway. Simvastatin failed to inhibit activation of these signaling pathways. Moreover, simvastatin did not affect MMP-9 mRNA stability. Together these data suggest that simvastatin reduces MMP-9 secretion from human SV-SMC by inhibiting the RhoA/ROCK pathway and decreasing MMP-9 mRNA levels independently of effects on signaling pathways required for MMP-9 gene expression.	Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England; Leeds Gen Infirm, Yorkshire Heart Ctr, Dept Cardiac Surg, Leeds, W Yorkshire, England	University of Leeds; Leeds General Infirmary; University of Leeds	Porter, KE (corresponding author), Univ Leeds, Inst Cardiovasc Res, Worsley Bldg, Leeds LS2 9JT, W Yorkshire, England.	medkep@leeds.ac.uk		Turner, Neil/0000-0002-4957-5433				Akool ES, 2003, MOL CELL BIOL, V23, P4901, DOI 10.1128/MCB.23.14.4901-4916.2003; Amin ARMR, 2003, GENES CELLS, V8, P515, DOI 10.1046/j.1365-2443.2003.00652.x; ANGELINI GD, 1989, EUR HEART J, V10, P273, DOI 10.1093/oxfordjournals.eurheartj.a059476; Bellosta S, 1998, ARTERIOSCL THROM VAS, V18, P1671, DOI 10.1161/01.ATV.18.11.1671; Bond M, 2001, CARDIOVASC RES, V50, P556, DOI 10.1016/S0008-6363(01)00220-6; Campeau L, 1997, NEW ENGL J MED, V336, P153; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Cho A, 2002, CIRC RES, V91, P845, DOI 10.1161/01.RES.0000040420.17366.2E; Chong PH, 2002, ANN PHARMACOTHER, V36, P1907, DOI 10.1345/aph.1C116; Christenson JT, 2001, AM J CARDIOL, V88, P896, DOI 10.1016/S0002-9149(01)01901-4; Denoyelle C, 2003, CELL SIGNAL, V15, P327, DOI 10.1016/S0898-6568(02)00124-9; Dichtl W, 2003, ARTERIOSCL THROM VAS, V23, P58, DOI 10.1161/01.ATV.0000043456.48735.20; Doggrell SA, 2001, EXPERT OPIN INV DRUG, V10, P1755, DOI 10.1517/13543784.10.9.1755; Dotani MI, 2000, AM J CARDIOL, V86, P1128, DOI 10.1016/S0002-9149(00)01172-3; Eberhardt W, 2002, J BIOL CHEM, V277, P33518, DOI 10.1074/jbc.M202008200; Flaker GC, 1999, J AM COLL CARDIOL, V34, P106, DOI 10.1016/S0735-1097(99)00145-X; Galis ZS, 2002, CIRC RES, V91, P852, DOI 10.1161/01.RES.0000041036.86977.14; George SJ, 1997, CARDIOVASC RES, V33, P447, DOI 10.1016/S0008-6363(96)00211-8; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hausding M, 2000, BRIT J PHARMACOL, V131, P553, DOI 10.1038/sj.bjp.0703607; Igarashi M, 1997, BRIT J PHARMACOL, V120, P1172, DOI 10.1038/sj.bjp.0701018; Indolfi C, 2000, J AM COLL CARDIOL, V35, P214, DOI 10.1016/S0735-1097(99)00526-4; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; Kamiyama Masumi, 2003, J Atheroscler Thromb, V10, P117; Kraynack NC, 2002, AM J PHYSIOL-LUNG C, V283, pL604, DOI 10.1152/ajplung.00459.2001; Leville CD, 2000, J SURG RES, V90, P183, DOI 10.1006/jsre.2000.5887; Luan ZX, 2003, ARTERIOSCL THROM VAS, V23, P769, DOI 10.1161/01.ATV.0000068646.76823.AE; Negre-Aminou P, 2001, BIOCHEM PHARMACOL, V61, P991, DOI 10.1016/S0006-2952(01)00566-4; Noa M, 2001, PHARMACOL RES, V43, P31, DOI 10.1006/phrs.2000.0736; Ortego M, 1999, ATHEROSCLEROSIS, V147, P253, DOI 10.1016/S0021-9150(99)00193-8; Ortego M, 2002, EUR J PHARMACOL, V448, P113, DOI 10.1016/S0014-2999(02)01938-6; PAULY RR, 1994, CIRC RES, V75, P41, DOI 10.1161/01.RES.75.1.41; Porter KE, 2004, CARDIOVASC RES, V61, P745, DOI 10.1016/j.cardiores.2003.11.032; Porter KE, 2002, J VASC SURG, V36, P150, DOI 10.1067/mva.2002.122029; Porter KE, 2002, BIOCHEM SOC T, V30, P120, DOI 10.1042/bst0300120; Porter KE, 1998, BRIT J SURG, V85, P1373; Porter KE, 1999, EUR J VASC ENDOVASC, V17, P404, DOI 10.1053/ejvs.1998.0761; Sessa WC, 2001, TRENDS MOL MED, V7, P189, DOI 10.1016/S1471-4914(01)01985-2; Shin M, 2002, BBA-MOL CELL RES, V1589, P311, DOI 10.1016/S0167-4889(02)00195-7; Simon C, 2001, EXP CELL RES, V271, P344, DOI 10.1006/excr.2001.5374; SOUTHGATE KM, 1992, BIOCHEM J, V288, P93, DOI 10.1042/bj2880093; Southgate KM, 1999, ARTERIOSCL THROM VAS, V19, P1640, DOI 10.1161/01.ATV.19.7.1640; Suma H, 1999, Ann Thorac Cardiovasc Surg, V5, P141; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Turner NA, 2003, CARDIOVASC RES, V57, P784, DOI 10.1016/S0008-6363(02)00729-0; Turner NA, 2001, CELL SIGNAL, V13, P269, DOI 10.1016/S0898-6568(01)00135-8; Viedt C, 2003, BASIC RES CARDIOL, V98, P353, DOI 10.1007/s00395-003-0437-4; von Haehling S, 2003, HEART FAIL REV, V8, P99, DOI 10.1023/A:1022103222857; Wang IK, 2000, ONCOLOGY-BASEL, V59, P245, DOI 10.1159/000012168; Werba JP, 2003, ANN THORAC SURG, V76, P2132, DOI 10.1016/S0003-4975(03)00820-8; Werner N, 2002, BASIC RES CARDIOL, V97, P105, DOI 10.1007/s003950200000; Yamakawa Tadashi, 2003, J Atheroscler Thromb, V10, P37	53	122	134	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					804	+		10.1096/fj.04-2852fje	http://dx.doi.org/10.1096/fj.04-2852fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15728660				2022-12-25	WOS:000227591900007
J	Vellaichamy, E; Khurana, ML; Fink, J; Pandey, KN				Vellaichamy, E; Khurana, ML; Fink, J; Pandey, KN			Involvement of the NF-kappa B/matrix metalloproteinase pathway in cardiac fibrosis of mice lacking guanylyl cyclase/natriuretic peptide receptor A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ADULT-RAT CARDIOMYOCYTES; CONGESTIVE-HEART-FAILURE; SMOOTH-MUSCLE-CELLS; NITRIC-OXIDE; ACTIVATOR PROTEIN-1; TISSUE INHIBITORS; GENE-EXPRESSION; TRANSGENIC MICE; CYCLIC-GMP	Mice carrying a targeted disruption of the Npr1 gene (coding for guanylyl cyclase/natriuretic peptide receptor A (NPRA)) exhibit increased blood pressure, cardiac hypertrophy, and congestive heart failure, similar to untreated human hypertensive patients. The objective of this study was to determine whether permanent ablation of NPRA signaling in mice alters the expression of matrix metalloproteinase (MMP)-2 and MMP-9 and pro-inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), leading to myocardial collagen remodeling. Here, we report that expression levels of the MMP-2 and MMP-9 genes were increased by 3-5-fold and that the expression of the TNF-alpha gene was enhanced by 8-fold in Npr1 homozygous null mutant (Npr1(-/-)) mouse hearts compared with wild-type (Npr1(+/+)) control mouse hearts. Myocardial fibrosis, total collagen, and the collagen type I/III ratio (p < 0.01) were dramatically increased in adult Npr1(-/-) mice compared with age-matched wild-type counterparts. Hypertrophic marker genes, including the beta-myosin heavy chain and transforming growth factor-beta 1, were significantly up-regulated (3-5-fold) in both young and adult Npr1(-/-) mouse hearts. NF-kappa B binding activity in ventricular tissues was enhanced by 4-fold with increased translocation of the p65 subunit from the cytoplasmic to nuclear fraction in Npr1(-/-) mice. Our results show that reduced NPRA signaling activates MMP, transforming growth factor-beta 1, and TNF-alpha expression in Npr1(-/-) mouse hearts. The findings of this study demonstrate that disruption of NPRA/cGMP signaling promotes hypertrophic growth and extracellular matrix remodeling, leading to the development of cardiac hypertrophy, myocardial fibrosis, and congestive heart failure.	Tulane Univ, Hlth Sci Ctr, Sch Med, Dept Physiol & Hypertens, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Sch Med, Renal Ctr Excellence, New Orleans, LA 70112 USA	Tulane University; Tulane University	Pandey, KN (corresponding author), Tulane Univ, Hlth Sci Ctr, Sch Med, Dept Physiol, SL-39,1430 Tulane Ave, New Orleans, LA 70112 USA.	kpandey@tulane.edu			NHLBI NIH HHS [HL 62147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Calderone A, 1998, J CLIN INVEST, V101, P812, DOI 10.1172/JCI119883; CAO L, 1995, HYPERTENSION, V25, P227, DOI 10.1161/01.HYP.25.2.227; Collard CD, 1999, ARTERIOSCL THROM VAS, V19, P2623, DOI 10.1161/01.ATV.19.11.2623; COLUCCI WS, 1997, AM J CARDIOL, V80, P15; Cowan KN, 1999, CIRC RES, V84, P1223, DOI 10.1161/01.RES.84.10.1223; Davia K, 1999, PHYSIOL GENOMICS, V1, P41, DOI 10.1152/physiolgenomics.1999.1.2.41; DEBOLD AJ, 1985, SCIENCE, V230, P767, DOI 10.1126/science.2932797; DENT CL, 1999, TRANSCRIPTION FACTOR, P1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dixon IMC, 1997, J MOL CELL CARDIOL, V29, P1837, DOI 10.1006/jmcc.1997.0420; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; Eagleton MJ, 2002, J SURG RES, V104, P15, DOI 10.1006/jsre.2002.6396; Ellmers LJ, 2002, AM J PHYSIOL-HEART C, V283, pH707, DOI 10.1152/ajpheart.00677.2001; Frantz S, 2003, CARDIOVASC RES, V57, P749, DOI 10.1016/S0008-6363(02)00723-X; HOLTWICK R, 2003, J CLIN INVEST, V111, P1275; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; Kapoun AM, 2004, CIRC RES, V94, P453, DOI 10.1161/01.RES.0000117070.86556.9F; Kiemer AK, 2002, BIOCHEM BIOPH RES CO, V295, P1068, DOI 10.1016/S0006-291X(02)00807-0; Kishimoto I, 2001, P NATL ACAD SCI USA, V98, P2703, DOI 10.1073/pnas.051625598; KLINGER JR, 1993, J APPL PHYSIOL, V75, P198, DOI 10.1152/jappl.1993.75.1.198; Knipp BS, 2004, J SURG RES, V116, P70, DOI 10.1016/S0022-4804(03)00306-8; Knowles JW, 2001, J CLIN INVEST, V107, P975, DOI 10.1172/JCI11273; Kuwahara F, 2002, CIRCULATION, V106, P130, DOI 10.1161/01.CIR.0000020689.12472.E0; Levin ER, 1998, NEW ENGL J MED, V339, P321; Li CF, 2001, AM J PHYSIOL-HEART C, V280, pH1264, DOI 10.1152/ajpheart.2001.280.3.H1264; Li YY, 2000, CARDIOVASC RES, V46, P214, DOI 10.1016/S0008-6363(00)00003-1; Li YY, 2000, P NATL ACAD SCI USA, V97, P12746, DOI 10.1073/pnas.97.23.12746; Li YY, 2002, AM J PHYSIOL-HEART C, V282, pH983, DOI 10.1152/ajpheart.00233.2001; Manabe I, 2002, CIRC RES, V91, P1103, DOI 10.1161/01.RES.0000046452.67724.B8; MAQUART FX, 1993, J CLIN INVEST, V92, P2368, DOI 10.1172/JCI116842; MARTIN AF, 1982, CIRC RES, V50, P117, DOI 10.1161/01.RES.50.1.117; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; MUKHERJEE D, 1991, J CLIN INVEST, V88, P1141, DOI 10.1172/JCI115414; Oliver PM, 1998, P NATL ACAD SCI USA, V95, P2547, DOI 10.1073/pnas.95.5.2547; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; Pandey KN, 2000, BIOCHEM BIOPH RES CO, V271, P374, DOI 10.1006/bbrc.2000.2627; Pandey KN, 2000, MOL PHARMACOL, V57, P259; Peterson JT, 2001, CIRCULATION, V103, P2303; Polyakova V, 2004, J AM COLL CARDIOL, V44, P1609, DOI 10.1016/j.jacc.2004.07.023; Ritchie RH, 1998, AM J PHYSIOL-HEART C, V275, pH1370, DOI 10.1152/ajpheart.1998.275.4.H1370; Rosenkranz AC, 2003, CARDIOVASC RES, V57, P515, DOI 10.1016/S0008-6363(02)00667-3; Sharma GD, 2002, MOL CELL BIOCHEM, V233, P165, DOI 10.1023/A:1015882302796; Shi SJ, 2003, AM J PHYSIOL-RENAL, V285, pF694, DOI 10.1152/ajprenal.00097.2003; Shi SJ, 2001, AM J PHYSIOL-RENAL, V281, pF665, DOI 10.1152/ajprenal.2001.281.4.F665; Spinale FG, 1998, CIRC RES, V82, P482, DOI 10.1161/01.RES.82.4.482; Spinale FG, 2002, CIRC RES, V90, P520, DOI 10.1161/01.RES.0000013290.12884.A3; Spinale FG, 1999, CIRC RES, V85, P364, DOI 10.1161/01.RES.85.4.364; Strauss BH, 1996, CIRC RES, V79, P541, DOI 10.1161/01.RES.79.3.541; Thomas CV, 1998, CIRCULATION, V97, P1708, DOI 10.1161/01.CIR.97.17.1708; Tsuruda T, 2002, CIRC RES, V91, P1127, DOI 10.1161/01.RES.0000046234.73401.70; VANBUREN P, 1995, CIRC RES, V77, P439, DOI 10.1161/01.RES.77.2.439; VILLARREAL FJ, 1992, AM J PHYSIOL, V262, pH1861, DOI 10.1152/ajpheart.1992.262.6.H1861; WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849; Zahabi A, 2003, J BIOL CHEM, V278, P47694, DOI 10.1074/jbc.M309661200	58	79	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19230	19242		10.1074/jbc.M411373200	http://dx.doi.org/10.1074/jbc.M411373200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15710627	hybrid			2022-12-25	WOS:000228932300080
J	Wilker, EW; Grant, RA; Artim, SC; Yaffe, MB				Wilker, EW; Grant, RA; Artim, SC; Yaffe, MB			A structural basis for 14-3-3 sigma functional specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; CRYSTAL-STRUCTURE; SIGMA GENE; KINASE; HYPERMETHYLATION; PHOSPHORYLATION; PROTEINS; ISOFORMS; BINDING; 14-3-3-PROTEINS	The 14-3-3 family of proteins includes seven isotypes in mammalian cells that play numerous diverse roles in intracellular signaling. Most 14-3-3 proteins form homodimers and mixed heterodimers between different isotypes, with overlapping roles in ligand binding. In contrast, one mammalian isoform, 14-3-3 sigma, expressed primarily in epithelial cells, appears to play a unique role in the cellular response to DNA damage and in human oncogenesis. The biological and structural basis for these 14-3-3-specific functions is unknown. We demonstrate that endogenous 14-3-3 sigma preferentially forms homodimers in cells. We have solved the x-ray crystal structure of 14-3-3 sigma bound to an optimal phosphopeptide ligand at 2.4 angstrom resolution. The structure reveals the presence of stabilizing ring-ring and salt bridge interactions unique to the 14-3-3 sigma homodimer structure and potentially destabilizing electrostatic interactions between subunits in 14-3-3 sigma-containing heterodimers, rationalizing preferential homodimerization of 14-3-3 sigma in vivo. The interaction of the phosphopeptide with 14-3-3 reveals a conserved mechanism for phospho-dependent ligand binding, implying that the phosphopeptide binding cleft is not the critical determinant of the unique biological properties of 14-3-3 sigma. Instead, the structure suggests a second ligand binding site involved in 14-3-3 sigma-specific ligand discrimination. We have confirmed this by site-directed mutagenesis of three sigma-specific residues that uniquely define this site. Mutation of these residues to the alternative sequence that is absolutely conserved in all other 14-3-3 isotypes confers upon 14-3-3 sigma the ability to bind to Cdc25C, a ligand that is known to bind to other 14-3-3 proteins but not to sigma.	MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA; MIT, Div Biol Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Yaffe, MB (corresponding author), MIT, Ctr Canc Res, Dept Biol, 77 Massachusetts Ave,E18-580, Cambridge, MA 02139 USA.	myaffe@mit.edu		/0000-0003-4503-9024	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060594, P50GM068762] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM68762, GM60594] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Chaudhri M, 2003, BIOCHEM BIOPH RES CO, V300, P679, DOI 10.1016/S0006-291X(02)02902-9; Dalal SN, 2004, CELL CYCLE, V3, P672; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Nguyen A, 2004, NAT BIOTECHNOL, V22, P993, DOI 10.1038/nbt997; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Powell DW, 2003, MOL CELL BIOL, V23, P5376, DOI 10.1128/MCB.23.15.5376-5387.2003; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Suzuki H, 2000, CANCER RES, V60, P4353; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; Wilker E, 2004, J MOL CELL CARDIOL, V37, P633, DOI 10.1016/j.yjmcc.2004.04.015; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	40	183	187	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18891	18898		10.1074/jbc.M500982200	http://dx.doi.org/10.1074/jbc.M500982200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15731107	hybrid			2022-12-25	WOS:000228932300041
J	Bai, XC; Lu, D; Liu, AL; Zhang, ZM; Li, XM; Zou, ZP; Zeng, WS; Cheng, BL; Luo, SQ				Bai, XC; Lu, D; Liu, AL; Zhang, ZM; Li, XM; Zou, ZP; Zeng, WS; Cheng, BL; Luo, SQ			Reactive oxygen species stimulates receptor activator of NF-kappa B ligand expression in osteoblast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; OSTEOCLASTIC BONE-RESORPTION; NECROSIS-FACTOR-ALPHA; OXIDATIVE STRESS; ESTROGEN-DEFICIENCY; HYDROGEN-PEROXIDE; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-SURVIVAL; HEAT-SHOCK; P38 MAPK	It has been established that reactive oxygen species (ROS) such as H2O2 or superoxide anion is involved in bone loss-related diseases by stimulating osteoclast differentiation and bone resorption and that receptor activator of NF-kappa B ligand ( RANKL) is a critical osteoclastogenic factor expressed on stromal/osteoblastic cells. However, the roles of ROS in RANKL expression and signaling mechanisms through which ROS regulates RANKL genes are not known. Here we report that increased intracellular ROS levels by H2O2 or xanthine/ xanthine oxidase-generated superoxide anion stimulated RANKL mRNA and protein expression in human osteoblast-like MG63 cell line and primary mouse bone marrow stromal cells and calvarial osteoblasts. Further analysis revealed that ROS promoted phosphorylation of cAMP response element-binding protein (CREB)/ ATF2 and its binding to CRE-domain in the murine RANKL promoter region. Moreover, the results of protein kinase A (PKA) inhibitor KT5720 and CREB1 RNA interference transfection clearly showed that PKA-CREB signaling pathway was necessary for ROS stimulation of RANKL in mouse osteoblasts. In human MG63 cells, however, we found that ROS promoted heat shock factor 2 (HSF2) binding to heat shock element in human RANKL promoter region and that HSF2, but not PKA, was required for ROS up-regulation of RANKL as revealed by KT5720 and HSF2 RNA interference transfection. We also found that ROS stimulated phosphorylation of extracellular signal-regulated kinases ( ERKs) and that PD98059, the inhibitor for ERKs suppressed ROS-induced RANKL expression either in mouse osteoblasts or in MG63 cells. These results demonstrate that ROS stimulates RANKL expression via ERKs and PKA-CREB pathway in mouse osteoblasts and via ERKs and HSF2 in human MG63 cells.	So Med Univ, Dept Cell Biol, Guangzhou 510515, Peoples R China; Kunming Med Coll, Inst Neurosci, Kunming 650032, Peoples R China; Nanfang Hosp, Dept Orthopaed & Spinal Surg, Saoguan 510515, Guangzhou, Peoples R China; Saoguan Coll, Dept Biol, Saoguan 512005, Guangzhou, Peoples R China	Southern Medical University - China; Kunming Medical University; Southern Medical University - China	Bai, XC (corresponding author), So Med Univ, Dept Cell Biol, Guangzhou 510515, Peoples R China.	baixc15@fimmu.com		Bai, Xiaochun/0000-0001-9631-4781				Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073; Bai XC, 2002, BIOCHEM J, V363, P395, DOI 10.1042/0264-6021:3630395; Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747; BAX BE, 1992, BIOCHEM BIOPH RES CO, V183, P1153, DOI 10.1016/S0006-291X(05)80311-0; Bedogni B, 2003, J BIOL CHEM, V278, P16510, DOI 10.1074/jbc.M301089200; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Cao J, 2003, J BONE MINER RES, V18, P270, DOI 10.1359/jbmr.2003.18.2.270; Cao LH, 2003, J CELL BIOCHEM, V89, P152, DOI 10.1002/jcb.10486; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fraser JHE, 1996, BONE, V19, P223, DOI 10.1016/8756-3282(96)00177-9; Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200; GARRETT JR, 1990, J CLIN INVEST, V85, P632; Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222-6233.2002; Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503; Golden LH, 2004, BONE, V34, P3, DOI 10.1016/j.bone.2003.09.005; Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035; HALL TJ, 1995, BIOCHEM BIOPH RES CO, V207, P280, DOI 10.1006/bbrc.1995.1184; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; Henriksen K, 2003, J BIOL CHEM, V278, P48745, DOI 10.1074/jbc.M309193200; Ichiki T, 2003, HYPERTENSION, V42, P177, DOI 10.1161/01.HYP.0000079791.26014.04; Ishida A, 2002, J BIOL CHEM, V277, P26217, DOI 10.1074/jbc.M111093200; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Karsdal MA, 2003, J BIOL CHEM, V278, P44975, DOI 10.1074/jbc.M303905200; Kodama I, 2004, J BONE MINER RES, V19, P200, DOI 10.1359/JBMR.0301229; Komarova SV, 2003, J BIOL CHEM, V278, P8286, DOI 10.1074/jbc.M206421200; Kondo H, 2002, J BONE MINER RES, V17, P1667, DOI 10.1359/jbmr.2002.17.9.1667; Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859; Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3; Li XT, 2003, ENDOCRINOLOGY, V144, P4999, DOI 10.1210/en.2003-0166; Maggio D, 2003, J CLIN ENDOCR METAB, V88, P1523, DOI 10.1210/jc.2002-021496; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891-5849(01)00610-4; Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378-1119(03)00841-2; O'Brien CA, 2002, BONE, V30, P453, DOI 10.1016/S8756-3282(01)00692-5; Roccisana JL, 2004, J BIOL CHEM, V279, P10500, DOI 10.1074/jbc.M303727200; Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756-3282(01)00682-2; SONTAKKE AN, 1992, CLIN CHIM ACTA, V318, P145; Steinbeck MJ, 1998, J CELL PHYSIOL, V176, P574, DOI 10.1002/(SICI)1097-4652(199809)176:3<574::AID-JCP14>3.0.CO;2-#; SUDA N, 1993, BIOCHIM BIOPHYS ACTA, V1157, P318, DOI 10.1016/0304-4165(93)90116-P; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Troen BR, 2003, EXP GERONTOL, V38, P605, DOI 10.1016/S0531-5565(03)00069-X; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vinals F, 2002, FEBS LETT, V510, P99, DOI 10.1016/S0014-5793(01)03236-7; Walsh MC, 2003, CYTOKINE GROWTH F R, V14, P251, DOI 10.1016/S1359-6101(03)00027-3; Weitzmann MN, 2002, J CLIN INVEST, V110, P1643, DOI 10.1172/JCI200215687; WONG GL, 1975, P NATL ACAD SCI USA, V72, P3167, DOI 10.1073/pnas.72.8.3167; Yoneda T, 2004, ENDOCRINOLOGY, V145, P2384, DOI 10.1210/en.2003-1536; Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599	51	247	266	2	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17497	17506		10.1074/jbc.M409332200	http://dx.doi.org/10.1074/jbc.M409332200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731115	hybrid			2022-12-25	WOS:000228615500117
J	Connor, KM; Subbaram, S; Regan, KJ; Nelson, KK; Mazurkiewicz, JE; Bartholomew, PJ; Aplin, AE; Tai, YT; Aguirre-Ghiso, J; Flores, SC; Melendez, JA				Connor, KM; Subbaram, S; Regan, KJ; Nelson, KK; Mazurkiewicz, JE; Bartholomew, PJ; Aplin, AE; Tai, YT; Aguirre-Ghiso, J; Flores, SC; Melendez, JA			Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR PTEN; MATRIX-METALLOPROTEINASE EXPRESSION; PROTEIN-TYROSINE PHOSPHATASES; INDUCIBLE FACTOR 1-ALPHA; HYDROGEN-PEROXIDE; PHOSPHATIDYLINOSITOL 3-KINASE; REDOX REGULATION; IN-VITRO; ACTIVATION	Recent studies have demonstrated that the tumor suppressor PTEN ( phosphatase and tensin homolog deleted from chromosome 10), the antagonist of the phosphosphoinositol-3- kinase ( PI3K) signaling cascade, is susceptible to H2O2-dependent oxidative inactivation. This study describes the use of redox-engineered cell lines to identify PTEN as sensitive to oxidative inactivation by mitochondrial H2O2. Increases in the steady state production of mitochondrial derived H2O2, as a result of manganese superoxide dismutase ( Sod2) overexpression, led to PTEN oxidation that was reversed by the coexpression of the H2O2- detoxifying enzyme catalase. The accumulation of an oxidized inactive fraction of PTEN favored the formation of phosphatidylinositol 3,4,5-triphosphate at the plasma membrane, resulting in increased activation of Akt and modulation of its downstream targets. PTEN oxidation in response to mitochondrial H2O2 enhanced PI3K signaling, leading to increased expression of the key regulator of angiogenesis, vascular endothelial growth factor. Overexpression of PTEN prevented the H2O2- dependent increase in vascular endothelial growth factor promoter activity and immunoreactive protein, whereas a mutant PTEN (G129R), lacking phosphatase activity, did not. Furthermore, mitochondrial generation of H2O2 by Sod2 promoted endothelial cell sprouting in a three-dimensional in vitro angiogenesis assay that was attenuated by catalase coexpression or the PI3K inhibitor LY2949002. Moreover, Sod2 overexpression resulted in increased in vivo blood vessel formation that was H2O2- dependent as assessed by the chicken chorioallantoic membrane assay. Our findings provide the first evidence for the involvement of mitochondrial H2O2 in regulating PTEN function and the angiogenic switch, indicating that Sod2 can serve as an alternative physiological source of the potent signaling molecule, H2O2.	Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA; Albany Med Coll, Ctr Neuropharmacol & Neurosci, Albany, NY 12208 USA; Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; SUNY Albany, Dept Biomed Sci, Sch Publ Hlth, Rensselaer, NY 12144 USA; Univ Colorado, Hlth Sci Ctr, Webb Waring Inst Canc Aging & Antioxidant Res, Denver, CO 80262 USA	Albany Medical College; Albany Medical College; Albany Medical College; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Albany; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Melendez, JA (corresponding author), Albany Med Coll, Ctr Immunol & Microbial Dis, MC 151,47 New Scotland Ave, Albany, NY 12208 USA.	melenda@mail.amc.edu		Melendez, Juan/0000-0001-8021-3097; Aguirre-Ghiso, Julio/0000-0002-6694-6507; Connor, Kip/0000-0002-2048-9080	NATIONAL CANCER INSTITUTE [K22CA095011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI049822] Funding Source: NIH RePORTER; NCI NIH HHS [CA095011, CA77068] Funding Source: Medline; NIAID NIH HHS [AI49822] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Bijur GN, 2003, J NEUROCHEM, V87, P1427, DOI 10.1046/j.1471-4159.2003.02113.x; Blancher C, 2001, CANCER RES, V61, P7349; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brauchle M, 1996, J BIOL CHEM, V271, P21793, DOI 10.1074/jbc.271.36.21793; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Cheng HL, 2000, MOL CELL ENDOCRINOL, V170, P211, DOI 10.1016/S0303-7207(00)00324-5; Chiarugi P, 2003, TRENDS BIOCHEM SCI, V28, P509, DOI 10.1016/S0968-0004(03)00174-9; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; Cho M, 2001, AM J PHYSIOL-HEART C, V280, pH2357, DOI 10.1152/ajpheart.2001.280.5.H2357; Dickinson ME, 2001, BIOTECHNIQUES, V31, P1272, DOI 10.2144/01316bt01; DIMINO MJ, 1987, BIOL REPROD, V36, P97, DOI 10.1095/biolreprod36.1.97; Downes CP, 2004, BIOCHEM SOC T, V32, P338, DOI 10.1042/BST0320338; Finkel T, 2001, IUBMB LIFE, V52, P3, DOI 10.1080/15216540252774694; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gao N, 2002, J BIOL CHEM, V277, P31963, DOI 10.1074/jbc.M200082200; Gomez-Manzano C, 2003, ANN NEUROL, V53, P109, DOI 10.1002/ana.10396; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lansford R, 2001, J BIOMED OPT, V6, P311, DOI 10.1117/1.1383780; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Marshall JG, 2001, J CELL BIOL, V153, P1369, DOI 10.1083/jcb.153.7.1369; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Monte M, 1997, EUR J CANCER, V33, P676, DOI 10.1016/S0959-8049(96)00506-0; Nakatsu MN, 2003, LAB INVEST, V83, P1873, DOI 10.1097/01.LAB.0000107160.81875.33; Nelson KK, 2003, CLIN CANCER RES, V9, P424; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Qin SF, 2003, BIOCHEMISTRY-US, V42, P2995, DOI 10.1021/bi0205911; Qin SF, 2000, P NATL ACAD SCI USA, V97, P7118, DOI 10.1073/pnas.130198197; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Ranganathan AC, 2001, J BIOL CHEM, V276, P14264, DOI 10.1074/jbc.M100199200; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; RHEE SG, 2000, SCI STKE, pE1; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sato Y, 2001, ANN NY ACAD SCI, V947, P117; Schafer G, 2003, J BIOL CHEM, V278, P8190, DOI 10.1074/jbc.M211999200; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Sen CK, 2002, J BIOL CHEM, V277, P33284, DOI 10.1074/jbc.M203391200; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Tai YT, 2002, BLOOD, V99, P1419, DOI 10.1182/blood.V99.4.1419; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Tsugawa K, 2002, FRONT BIOSCI-LANDMRK, V7, pE245, DOI 10.2741/tsugawa; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Werner E, 2002, J CELL BIOL, V158, P357, DOI 10.1083/jcb.200111028; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu YL, 1998, FEBS LETT, V440, P111, DOI 10.1016/S0014-5793(98)01415-X; Yamada KM, 2001, J CELL SCI, V114, P2375; Yasuda M, 1998, LIFE SCI, V64, P249, DOI 10.1016/S0024-3205(98)00560-8; Zhong H, 2000, CANCER RES, V60, P1541	65	190	196	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16916	16924		10.1074/jbc.M410690200	http://dx.doi.org/10.1074/jbc.M410690200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15701646	hybrid			2022-12-25	WOS:000228615500046
J	Desai, SA; Alkhalil, A; Kang, M; Ashfaq, U; Nguyen, ML				Desai, SA; Alkhalil, A; Kang, M; Ashfaq, U; Nguyen, ML			Plasmodial surface anion channel-independent phloridzin resistance in Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITE; HUMAN ERYTHROCYTES; TRANSPORT; MEMBRANE; PERMEATION; TRANSFECTION; NA+	The plasmodial surface anion channel (PSAC) is an unusual ion channel induced on the human red blood cell membrane after infection with the malaria parasite, Plasmodium falciparum. Because PSAC is permeant to small metabolic precursors essential for parasite growth and is present on red blood cells infected with geographically divergent parasite isolates, it may be an ideal target for future antimalarial development. Here, we used chemically induced mutagenesis and known PSAC antagonists that inhibit in vitro parasite growth to examine whether resistance mutations in PSAC can be readily induced. Stable mutants resistant to phloridzin were generated and selected within 3 weeks after treatment with 1-methyl-3-nitro-1-nitrosoguanidine. These mutants were evaluated with osmotic lysis and electrophysiological transport assays, which indicate that PSAC inhibition by phloridzin is complex with at least two different modes of inhibition. Mutants resistant to the growth inhibitory effects of phloridzin expressed PSAC activity indistinguishable from that on sensitive parasites, indicating selection of resistance via mutations in one or more other parasite targets. Failure to induce mutations in PSAC activity is consistent with a highly constrained channel protein less susceptible to resistance mutations; whether this protein is parasiteor host-encoded remains to be determined.	NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Desai, SA (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, Rm 3W-01,12735 Twinbrook Pkwy, Rockville, MD 20852 USA.	sdesai@niaid.nih.gov	Desai, Sanjay A/B-7110-2009	Desai, Sanjay/0000-0003-2150-2483	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000882] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000882-07] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ALEY SB, 1984, J EXP MED, V160, P1585, DOI 10.1084/jem.160.5.1585; Alkhalil A, 2004, BLOOD, V104, P4279, DOI 10.1182/blood-2004-05-2047; Anderson PAV, 2001, COMP BIOCHEM PHYS B, V129, P17, DOI 10.1016/S1096-4959(01)00376-1; CABANTCHIK ZI, 1990, BLOOD CELLS, V16, P421; CHULAY JD, 1983, EXP PARASITOL, V55, P138, DOI 10.1016/0014-4894(83)90007-3; Cohn JV, 2003, MOL BIOCHEM PARASIT, V132, P27, DOI 10.1016/j.molbiopara.2003.08.001; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; Cooper RA, 2002, MOL PHARMACOL, V61, P35, DOI 10.1124/mol.61.1.35; Crabb BS, 2004, METH MOL B, V270, P263; Desai SA, 2000, NATURE, V406, P1001, DOI 10.1038/35023000; Desai SA, 1997, P NATL ACAD SCI USA, V94, P2045, DOI 10.1073/pnas.94.5.2045; DESAI SA, 1993, NATURE, V362, P643, DOI 10.1038/362643a0; DESAI SA, 2005, IN PRESS NANOMEDICIN; DIVO AA, 1985, J PROTOZOOL, V32, P59, DOI 10.1111/j.1550-7408.1985.tb03013.x; Egee S, 2002, J PHYSIOL-LONDON, V542, P795, DOI 10.1113/jphysiol.2002.022970; Elliott JL, 2001, BIOCHEM J, V355, P733, DOI 10.1042/bj3550733; Gardiner DL, 2003, TRENDS PARASITOL, V19, P381, DOI 10.1016/S1471-4922(03)00187-9; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; GINSBURG H, 1985, MOL BIOCHEM PARASIT, V14, P313, DOI 10.1016/0166-6851(85)90059-3; HADLEY T, 1983, EXP PARASITOL, V55, P306, DOI 10.1016/0014-4894(83)90027-9; Huber SM, 2002, EMBO J, V21, P22, DOI 10.1093/emboj/21.1.22; INSELBURG J, 1984, MOL BIOCHEM PARASIT, V10, P89, DOI 10.1016/0166-6851(84)90021-5; KIRK K, 1993, FEBS LETT, V323, P123, DOI 10.1016/0014-5793(93)81462-9; KIRK K, 1994, J BIOL CHEM, V269, P3339; KUTNER S, 1987, BIOCHEM PHARMACOL, V36, P123, DOI 10.1016/0006-2952(87)90389-3; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; MELNIK E, 1977, J GEN PHYSIOL, V69, P243, DOI 10.1085/jgp.69.2.243; Rokitskaya TI, 2002, BIOPHYS J, V82, P865, DOI 10.1016/S0006-3495(02)75448-9; Saliba KJ, 1998, J BIOL CHEM, V273, P10190, DOI 10.1074/jbc.273.17.10190; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Staines HM, 2000, BBA-BIOMEMBRANES, V1463, P88, DOI 10.1016/S0005-2736(99)00187-X; Staines HM, 2001, AM J PHYSIOL-CELL PH, V280, pC1576, DOI 10.1152/ajpcell.2001.280.6.C1576; UPSTON JM, 1995, BBA-BIOMEMBRANES, V1236, P249, DOI 10.1016/0005-2736(95)00055-8; Verloo P, 2004, J BIOL CHEM, V279, P10316, DOI 10.1074/jbc.M311540200; Wagner MA, 2003, BIOPHYS J, V84, P116, DOI 10.1016/S0006-3495(03)74836-X; Wang Z, 2003, MUTAT RES-FUND MOL M, V528, P29, DOI 10.1016/S0027-5107(03)00079-4; Wickham ME, 2003, J BIOL CHEM, V278, P37658, DOI 10.1074/jbc.M305252200	37	25	25	2	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16861	16867		10.1074/jbc.M414629200	http://dx.doi.org/10.1074/jbc.M414629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15701633	hybrid			2022-12-25	WOS:000228615500040
J	Hanamoto, T; Ozaki, T; Furuya, H; Hosoda, M; Hayashi, S; Nakanshi, M; Yamamoto, H; Kikuchi, H; Todo, S; Nakagawara, A				Hanamoto, T; Ozaki, T; Furuya, H; Hosoda, M; Hayashi, S; Nakanshi, M; Yamamoto, H; Kikuchi, H; Todo, S; Nakagawara, A			Identification of protein kinase A catalytic subunit beta as a novel binding partner of p73 and regulation of p73 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; C-ABL; DNA-DAMAGE; APOPTOTIC RESPONSE; TRANSCRIPTIONAL ACTIVATION; P53-RELATED PROTEIN; SPLICE VARIANTS; P53; DELTA-NP73; PHOSPHORYLATION	Post-translational modifications play a crucial role in regulation of the protein stability and pro-apoptotic function of p53 as well as its close relative p73. Using a yeast two-hybrid screening based on the Sos recruitment system, we identified protein kinase A catalytic subunit beta (PKA-C beta) as a novel binding partner of p73. Co-immunoprecipitation and glutathione S-transferase pull-down assays revealed that p73 alpha associated with PKA-C beta in mammalian cells and that their interaction was mediated by both the N- and C-terminal regions of p73 alpha. In contrast, p53 failed to bind to PKA-C beta. In vitro phosphorylation assay demonstrated that glutathione S-transferase-p73 alpha- ( 1 - 130), which has one putative PKA phosphorylation site, was phosphorylated by PKA. Enforced expression of PKA-C beta resulted in significant inhibition of the transactivation function and pro-apoptotic activity of p73 alpha, whereas a kinase-deficient mutant of PKA-C beta had no detectable effect. Consistent with this notion, treatment with H-89 ( an ATP analog that functions as a PKA inhibitor) reversed the dibutyryl cAMP-mediated inhibition of p73 alpha. Of particular interest, PKA-C beta facilitated the intramolecular interaction of p73 alpha, thereby masking the N- terminal transactivation domain with the C-terminal inhibitory domain. Thus, our findings indicate a PKA-C beta-mediated inhibitory mechanism of p73 function.	Chiba Canc Ctr Res Inst, Div Biochem, Chuo Ku, Chiba 2608717, Japan; Hokkaido Univ, Sch Med, Dept Gen Surg, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Chiba Cancer Center; Hokkaido University	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp	Hosoda, Mitsuchika/A-7534-2012					Agami R, 1999, NATURE, V399, P809; Anderson CNG, 1999, J NEUROSCI, V19, P664; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Filippa N, 1999, MOL CELL BIOL, V19, P4989; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Gaiddon C, 2003, J BIOL CHEM, V278, P27421, DOI 10.1074/jbc.M300251200; Gong JG, 1999, NATURE, V399, P806; Gonzalez S, 2003, MOL CELL BIOL, V23, P8161, DOI 10.1128/MCB.23.22.8161-8171.2003; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Higuchi H, 2003, EMBO J, V22, P1790, DOI 10.1093/emboj/cdg177; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Ishimoto O, 2002, CANCER RES, V62, P636; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Liu QH, 2000, GENE DEV, V14, P1448; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nakamura Y, 1997, EUR J CANCER, V33, P1986, DOI 10.1016/S0959-8049(97)00333-X; Orstavik S, 2001, EUR J BIOCHEM, V268, P5066, DOI 10.1046/j.0014-2956.2001.02429.x; Ozaki T, 1999, CANCER RES, V59, P5902; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; SMETS LA, 1987, J CELL PHYSIOL, V133, P395, DOI 10.1002/jcp.1041330227; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stiewe T, 2002, CANCER RES, V62, P3598; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; UHLER MD, 1986, J BIOL CHEM, V261, P5360; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Wu KJ, 2002, ONCOGENE, V21, P7872, DOI 10.1038/sj.onc.1205986; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	57	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16665	16675		10.1074/jbc.M414323200	http://dx.doi.org/10.1074/jbc.M414323200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15723830	hybrid			2022-12-25	WOS:000228615500018
J	Anand, P; Gruppuso, PA				Anand, P; Gruppuso, PA			The regulation of hepatic protein synthesis during fasting in the rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; BRANCHED-CHAIN AMINO; S6 PHOSPHORYLATION; LIVER DEVELOPMENT; GROWTH-FACTOR; RAPAMYCIN; ACTIVATION; INITIATION; STARVATION; KINASE	We have studied translational control in the model of 48 h of fasting in the rat. Our initial observations showed a paradoxical increase in ribosomal protein S6 (rpS6) phosphorylation and a decrease in eukaryotic initiation factor 2 alpha (eIF2 alpha) phosphorylation. These effects, which would favor an increase in protein synthesis, could be attributed to increased circulating concentrations of branched-chain amino acids in fasting. To determine what mechanisms might account for decreased hepatic translation in fasting, we examined the cap binding complex. eIF4E-bound 4E-BP1 did not increase. However, eIF4E-bound eIF4G and total cellular eIF4G were profoundly decreased in fasted liver. eIF4G mRNA levels were not lower after fasting. Based on the hypothesis that decreased eIF4G translation might account for the reduced eIF4G content, we fractionated ribosomes by sucrose density centrifugation. Immunoblotting for rpS6 showed modest polysomal disaggregation upon fasting. PCR analysis of polysome profiles revealed that a spectrum of mRNAs undergo different translational regulation in the fasted state. In particular, eIF4G was minimally affected by fasting. This indicated that reduced eIF4G abundance in fasting may be a function of its stability, whereas its recovery upon refeeding is necessarily independent of its own involvement in the cap binding complex. Western immunoblotting of polysome fractions showed that phosphorylated rpS6 was disproportionately present in translating polysomes in fed and fasted animals, consistent with a role in translational control. However, the translation of rpS8, an mRNA with a 5'-oligopyrimidine tract, did not coincide with rpS6 phosphorylation, thus dissociating rpS6 phosphorylation from the translational control of this subset of mRNAs.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA; Brown Univ, Dept Pediat, Providence, RI 02912 USA	Brown University; Brown University	Gruppuso, PA (corresponding author), Rhode Isl Hosp, Div Pediat Endocrinol & Metab, 593 Eddy St, Providence, RI 02903 USA.	Philip_Gruppuso@brown.edu			NICHD NIH HHS [HD35831, HD24455] Funding Source: Medline; NIDDK NIH HHS [DK59815] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD024455] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059815] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADIBI SA, 1976, METABOLISM, V25, P1287, DOI 10.1016/S0026-0495(76)80012-1; Anand P, 2002, AM J PHYSIOL-ENDOC M, V283, pE844, DOI 10.1152/ajpendo.00111.2002; Awad MM, 2000, FEBS LETT, V483, P160, DOI 10.1016/S0014-5793(00)02108-6; Awad MM, 2000, CELL GROWTH DIFFER, V11, P325; Barth-Baus D, 2002, NUCLEIC ACIDS RES, V30, P1919, DOI 10.1093/nar/30.9.1919; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; Boylan JM, 2001, J BIOL CHEM, V276, P44457, DOI 10.1074/jbc.M103457200; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; CURRAN TR, 1993, EXP CELL RES, V209, P53, DOI 10.1006/excr.1993.1284; DARNELL J, 1990, MOL CELL BIOL, P261; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DUNCAN R, 1982, EUR J BIOCHEM, V123, P535; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gruppuso PA, 2000, BBA-GENE STRUCT EXPR, V1494, P242, DOI 10.1016/S0167-4781(00)00244-X; Gruppuso PA, 2005, PEDIATR RES, V57, P185, DOI 10.1203/01.PDR.0000151646.55587.0F; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HOWARD G, 1986, P SOC EXP BIOL MED, V181, P312; HUTSON NJ, 1982, J BIOL CHEM, V257, P9548; HUTSON SM, 1981, AM J CLIN NUTR, V34, P173, DOI 10.1093/ajcn/34.2.173; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jenniskens FA, 2002, PEDIATR RES, V52, P437, DOI 10.1203/00006450-200209000-00022; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; KRIEG J, 1988, J BIOL CHEM, V263, P11473; Kubota H, 2003, J BIOL CHEM, V278, P20457, DOI 10.1074/jbc.C300133200; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; Park IH, 2002, J BIOL CHEM, V277, P31423, DOI 10.1074/jbc.M204080200; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; PREEDY VR, 1988, BIOCHEM J, V250, P179, DOI 10.1042/bj2500179; PRINCEN JMG, 1983, ANN NUTR METAB, V27, P182, DOI 10.1159/000176651; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sachs AB, 2000, NAT STRUCT BIOL, V7, P356, DOI 10.1038/75120; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SCHULLER E, 1995, TRANSFUS CLIN BIOL, V2, P57, DOI 10.1016/S1246-7820(05)80023-0; Shigemitsu K, 1999, FEBS LETT, V447, P303, DOI 10.1016/S0014-5793(99)00304-X; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; TAS PWL, 1987, EUR J BIOCHEM, V163, P561, DOI 10.1111/j.1432-1033.1987.tb10904.x; WEBER G, 1957, AM J PHYSIOL, V190, P229, DOI 10.1152/ajplegacy.1957.190.2.229; Wool I. G., 1996, TRANSLATIONAL CONTRO, P685; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	50	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16427	16436		10.1074/jbc.M410576200	http://dx.doi.org/10.1074/jbc.M410576200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15716276	hybrid			2022-12-25	WOS:000228444800116
J	Stepan, V; Ramamoorthy, S; Nitsche, H; Zavros, Y; Merchant, JL; Todisco, A				Stepan, V; Ramamoorthy, S; Nitsche, H; Zavros, Y; Merchant, JL; Todisco, A			Regulation and function of the sonic hedgehog signal transduction pathway in isolated gastric parietal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT GENE-EXPRESSION; EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE-B; FLOOR PLATE; TRANSGENIC MICE; TGF-ALPHA; GLI2; MOUSE; AKT; DIFFERENTIATION	Shh ( Sonic hedgehog) regulates gastric epithelial cell differentiation. We reported that incubation of purified canine parietal cells with epidermal growth factor ( EGF) for 6 - 16 h, stimulates H+/ K+- ATPase alpha- subunit gene expression through the activation of Akt. We explored if Shh mediates some of the actions of EGF in the parietal cells. EGF induced a 6- fold increase in Shh expression, measured by Western blots, after 5 h of incubation. This effect was inhibited by both the phosphatidylinositol 3- kinase inhibitor LY294002 and by transduction of the cells with an adenoviral vector expressing dominant negative Akt. EGF stimulated the release of Shh- like immunoreactivity from the parietal cells, after 16 h of incubation. Shh induced H+/ K+-ATPase alpha- subunit gene expression, assessed by Northern blots, it stimulated a luciferase reporter plasmid containing the EGF- responsive sequence ( ERE) of the canine H+/ K+- ATPase alpha- subunit gene promoter, and it induced parietal cell nuclear protein binding to the ERE. Gli transcription factors mediate the intracellular actions of Shh. Co- transfection of the parietal cells with the H+(/) K+- luc plasmid together with one expressing Gli2, induced H+/ K+- luciferase activity 5- fold, whereas co- transfection of the cells with the H+/ K+- luc plasmid together with one expressing dominant negative Gli2, inhibited EGF induction of H+/ K+- luciferase activity. Identical results were observed in the presence of the Shh signal transduction pathway inhibitor, cyclopamine. Transfection of the cells with dominant negative Akt inhibited EGF, but not Shh stimulation of H+/ K+-ATPase- luciferase activity. Thus, EGF but not Shh signals through Akt. Preincubation of the cells for 16 h with either Shh or EGF enhanced histamine- stimulated [ C-14] aminopyrine uptake by 50%. In conclusions, some of the actions of EGF in the parietal cells are mediated by the sequential activation of the Akt and the Shh signal transduction pathways. These effects might represent novel mechanisms mediating the actions of growth factors on gastric epithelial cell differentiation.	Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Todisco, A (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, 6520 MSRB I, Ann Arbor, MI 48109 USA.	atodisco@umich.edu	Merchant, Juanita/AAF-8277-2019	Merchant, Juanita/0000-0002-6559-8184	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK062041, R01DK058312, P30DK034933] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30-DK-34933, R01-DK-058312, DK-34933, P01-DK-062041, R01-DK-1410] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Askari FK, 1996, GENE THER, V3, P381; BABYATSKY MW, 1997, TXB GASTROENTEROLOGY, P547; BEAUCHAMP RD, 1989, J CLIN INVEST, V84, P1017, DOI 10.1172/JCI114223; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Canfield V, 1996, P NATL ACAD SCI USA, V93, P2431, DOI 10.1073/pnas.93.6.2431; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEN MC, 1993, AM J PHYSIOL, V264, P390; CHEW CS, 1989, AM J PHYSIOL, V256, pG254, DOI 10.1152/ajpgi.1989.256.1.G254; CHEW CS, 1994, AM J PHYSIOL-GASTR L, V267, pG818, DOI 10.1152/ajpgi.1994.267.5.G818; DELVALLE J, 1994, TXB GASTROENTEROLOGY, P278; DEMBINSKI AB, 1985, ENDOCRINOLOGY, V116, P90, DOI 10.1210/endo-116-1-90; Ding Q, 1998, DEVELOPMENT, V125, P2533; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Goetz JA, 2002, BIOESSAYS, V24, P157, DOI 10.1002/bies.10056; Goldenring JR, 2000, GASTROENTEROLOGY, V118, P1080, DOI 10.1016/S0016-5085(00)70361-1; Gooz M, 2000, AM J PHYSIOL-GASTR L, V278, pG981, DOI 10.1152/ajpgi.2000.278.6.G981; Hardcastle Z, 1998, DEVELOPMENT, V125, P2803; Jeong J, 2002, J CLIN INVEST, V110, P591, DOI 10.1172/JCI200216506; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Judd LM, 1999, AM J PHYSIOL-GASTR L, V277, pG209, DOI 10.1152/ajpgi.1999.277.1.G209; KAISE M, 1995, J BIOL CHEM, V270, P18637, DOI 10.1074/jbc.270.31.18637; Kanda S, 2003, J BIOL CHEM, V278, P8244, DOI 10.1074/jbc.M210635200; Kirton CM, 2002, AM J PHYSIOL-GASTR L, V283, pG787, DOI 10.1152/ajpgi.00538.2001; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kusayanagi S, 2002, BIOCHEM BIOPH RES CO, V290, P1289, DOI 10.1006/bbrc.2002.6339; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Li QT, 1996, J BIOL CHEM, V271, P3671, DOI 10.1074/jbc.271.7.3671; Matise MP, 1998, DEVELOPMENT, V125, P2759; Mo R, 1997, DEVELOPMENT, V124, P113; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Muraoka A, 1996, AM J PHYSIOL-GASTR L, V271, pG1104, DOI 10.1152/ajpgi.1996.271.6.G1104; Nagahara A, 1998, AM J PHYSIOL-GASTR L, V275, pG740, DOI 10.1152/ajpgi.1998.275.4.G740; Nybakken K, 2002, CURR OPIN GENET DEV, V12, P503, DOI 10.1016/S0959-437X(02)00333-7; Park HL, 2000, DEVELOPMENT, V127, P1593; Podolsky Daniel K., 1994, P129; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Scarff KL, 1999, GASTROENTEROLOGY, V117, P605, DOI 10.1016/S0016-5085(99)70453-1; SOLL AH, 1978, J CLIN INVEST, V61, P370, DOI 10.1172/JCI108947; SOROKA CJ, 1993, EUR J CELL BIOL, V60, P76; Stepan V, 2004, GASTROENTEROLOGY, V127, P1150, DOI 10.1053/j.gastro.2004.06.059; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Takeuchi Y, 1999, AM J PHYSIOL-GASTR L, V276, pG1484, DOI 10.1152/ajpgi.1999.276.6.G1484; Todisco A, 2001, J BIOL CHEM, V276, P46436, DOI 10.1074/jbc.M009645200; Troyer KL, 2001, GASTROENTEROLOGY, V121, P68, DOI 10.1053/gast.2001.25478; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Uribe JM, 1997, GASTROENTEROLOGY, V112, P255; van den Brink GR, 2001, GASTROENTEROLOGY, V121, P317, DOI 10.1053/gast.2001.26261; van den Brink GR, 2002, GUT, V51, P628, DOI 10.1136/gut.51.5.628; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648	55	79	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15700	15708		10.1074/jbc.M413037200	http://dx.doi.org/10.1074/jbc.M413037200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15691835	hybrid			2022-12-25	WOS:000228444800031
J	Chou, TF; Bieganowski, P; Shilinski, K; Cheng, JL; Brenner, C; Wagner, CR				Chou, TF; Bieganowski, P; Shilinski, K; Cheng, JL; Brenner, C; Wagner, CR			P-31 NMR and genetic analysis establish hinT as the only Escherchia coli purine nucleoside phosphoramidase and as essential for growth under high salt conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE TRIAD SUPERFAMILY; NUCLEOTIDE-BINDING PROTEINS; AVIAN SEX DETERMINATION; DIHYDROFOLATE-REDUCTASE; ESCHERICHIA-COLI; BIOLOGICAL-ACTIVITY; HIT FAMILY; MECHANISM; FHIT; DECOMPOSITION	Eukaryotic cells encode AMP-lysine (AMP-N-epsilon-(N-alpha-acetyl lysine methyl ester) 5'-phosphoramidate) hydrolases related to the rabbit histidine triad nucleotide-binding protein 1 (Hint1) sequence. Bacterial and archaeal cells have Hint homologs annotated in a variety of ways, but the enzymes have not been characterized, nor have phenotypes been described due to loss of enzymatic activity. We developed a quantitative P-31 NMR assay to determine whether Escherichia coli possesses an adenosine phosphoramidase activity. Indeed, soluble lysates prepared from wild-type laboratory E. coli exhibited activity on the model substrate adenosine 5'-monophosphoramidate (AMP-NH2). The E. coli Hint homolog, which had been comprehensively designated ycfF and is here named hinT, was cloned, overexpressed, purified, and characterized with respect to purine nucleoside phosphoramidate substrates. Bacterial hinT was several times more active than human or rabbit Hint1 on five model substrates. In addition, bacterial and mammalian enzymes preferred guanosine versus adenosine phosphoramidates as substrates. Analysis of the lysates from a constructed hinT knock-out strain of E. coli demonstrated that all of the cellular purine nucleoside phosphoramidase activity is due to hinT. Physiological analysis of this mutant revealed that the loss of hinT results in failure to grow in media containing 0.75 M KCl, 0.9 M NaCl, 0.5 M NaOAc, or 10 mM MnCl2. Thus, cation-resistant bacterial cell growth may be dependent on the hydrolysis of adenylylated and/or guanylylated phosphoramidate substrates by hinT.	Univ Minnesota, Dept Med Chem, Coll Pharm, Minneapolis, MN 55455 USA; Dartmouth Coll Sch Med, Dept Genet, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Biochem, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA	University of Minnesota System; University of Minnesota Twin Cities; Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Wagner, CR (corresponding author), Univ Minnesota, Dept Med Chem, Coll Pharm, 8-174 Weaver Densford Hall,308 Harvard St SE, Minneapolis, MN 55455 USA.	wagne003@umn.edu	Bieganowski, Pawel/ABC-8554-2021; Brenner, Charles/D-6339-2014	Bieganowski, Pawel/0000-0002-1169-4517; Brenner, Charles/0000-0002-4955-3226	NCI NIH HHS [CA075954, R01 CA075954, R01 CA075954-08, CA55334] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055334, R55CA055334, R01CA075954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham TW, 1996, J MED CHEM, V39, P4569, DOI 10.1021/jm9603680; Abraham TW, 1997, NUCLEOS NUCLEOT NUCL, V16, P2079, DOI 10.1080/07328319708002557; Balzarini J, 1996, P NATL ACAD SCI USA, V93, P7295, DOI 10.1073/pnas.93.14.7295; Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Brenner C, 1999, J CELL PHYSIOL, V181, P179, DOI 10.1002/(SICI)1097-4652(199911)181:2<179::AID-JCP1>3.0.CO;2-8; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; BUSTOS SA, 1990, J BACTERIOL, V172, P1998, DOI 10.1128/jb.172.4.1998-2004.1990; Chang SL, 2001, J MED CHEM, V44, P223, DOI 10.1021/jm000260r; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Drontle DP, 2004, MINI-REV MED CHEM, V4, P409; DUDKIN SM, 1971, FEBS LETT, V16, P48, DOI 10.1016/0014-5793(71)80682-8; Gilmour J, 1997, BIOCHEM J, V326, P471, DOI 10.1042/bj3260471; Jaggi R, 1997, EMBO J, V16, P5562, DOI 10.1093/emboj/16.18.5562; Kim J, 2004, MOL PHARMACEUT, V1, P102, DOI 10.1021/mp0340338; Korsisaari N, 2000, J BIOL CHEM, V275, P34837, DOI 10.1074/jbc.C000505200; Korsisaari N, 2003, MOL CELL BIOL, V23, P3929, DOI 10.1128/MCB.23.11.3929-3935.2003; Krakowiak A, 2004, J BIOL CHEM, V279, P18711, DOI 10.1074/jbc.M314271200; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kwasnicka DA, 2003, J BIOL CHEM, V278, P39051, DOI 10.1074/jbc.M306355200; LEDNEVA RK, 1970, DOKL AKAD NAUK SSSR+, V193, P1308; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Liu HD, 2002, EMBO J, V21, P4699, DOI 10.1093/emboj/cdf448; McGuigan C, 1996, BIOORG MED CHEM LETT, V6, P1183, DOI 10.1016/0960-894X(96)00195-3; MCGUIGAN C, 1993, BIOORG MED CHEM LETT, V3, P1207, DOI 10.1016/S0960-894X(00)80316-9; McIntee EJ, 1997, J MED CHEM, V40, P3323, DOI 10.1021/jm960694f; MOFFATT JG, 1961, J AM CHEM SOC, V83, P649, DOI 10.1021/ja01464a034; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; MORRISON JF, 1988, BIOCHEMISTRY-US, V27, P5499, DOI 10.1021/bi00415a017; Pace HC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r18; Parks KP, 2004, PHYSIOL GENOMICS, V20, P12, DOI 10.1152/physiolgenomics.00204.2004; Salehi Z, 2002, MOL MICROBIOL, V46, P49, DOI 10.1046/j.1365-2958.2002.03151.x; Song H, 2003, PHARMACEUT RES, V20, P448, DOI 10.1023/A:1022616523678; Sticha KRK, 1997, PROTEIN EXPRES PURIF, V10, P141, DOI 10.1006/prep.1997.0734; STONE SR, 1982, BIOCHEMISTRY-US, V21, P3757, DOI 10.1021/bi00259a006; Su T, 2003, P NATL ACAD SCI USA, V100, P7824, DOI 10.1073/pnas.1332160100; Trapasso F, 2003, P NATL ACAD SCI USA, V100, P1592, DOI 10.1073/pnas.0437915100; Wagner CR, 2000, MED RES REV, V20, P417, DOI 10.1002/1098-1128(200011)20:6<417::AID-MED1>3.0.CO;2-Z	39	45	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15356	15361		10.1074/jbc.M500434200	http://dx.doi.org/10.1074/jbc.M500434200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15703176	Green Accepted, hybrid			2022-12-25	WOS:000228236800121
J	Tsubota, Y; Yasuda, C; Kariya, Y; Ogawa, T; Hirosaki, T; Mizushima, H; Miyazaki, K				Tsubota, Y; Yasuda, C; Kariya, Y; Ogawa, T; Hirosaki, T; Mizushima, H; Miyazaki, K			Regulation of biological activity and matrix assembly of laminin-5 by COOH-terminal, LG4-5 domain of alpha 3 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-ADHESION; NEURITE OUTGROWTH; ALPHA-3-BETA-1 INTEGRIN; RECOMBINANT LAMININ-5; EXTRACELLULAR-MATRIX; PROTEOLYTIC FRAGMENT; EPITHELIAL-CELLS; SCATTER FACTOR; GAMMA-2 CHAIN; MIGRATION	The basement membrane protein laminin-5 (LN5; alpha 3 beta 3 gamma 2) undergoes specific proteolytic processing of the 190-kDa alpha 3 chain to the 160-kDa form after the secretion, releasing its COOH-terminal, LG4 - 5 domain. To clarify the biological significance of this processing, we tried to express a recombinant precursor LN5 with a 190-kDa alpha 3 chain (pre-LN5), in which the cleavage sequence Gln-Asp was changed to Ala-Ala by point mutation. When the wild-type and mutated LN5 heterotrimers were expressed in HEK293 cells, the wild-type alpha 3 chain was completely cleaved, whereas the mutated alpha 3 chain was partially cleaved at the same cleavage site (Ala-Ala). pre-LN5 was preferentially deposited on the extracellular matrix, but this deposition was effectively blocked by exogenous heparin. This suggests that interaction between the LG4 - 5 domain and heparan sulfate proteoglycans on the cell surface and/or extracellular matrix is important in the matrix assembly of LN5. Next, we purified both pre-LN5 and the mature LN5 with the processed, 160-kDa alpha 3 chain (mat-LN5) from the conditioned medium of the HEK293 cells and compared their biological activities. mat-LN5 showed higher activities to promote cell adhesion, cell scattering, cell migration, and neurite outgrowth than pre-LN5. These results indicate that the proteolytic removal of LG4 - 5 from the 190-kDa alpha 3 chain converts the precursor LN5 from a less active form to a fully active form. Furthermore, the released LG4 - 5 fragment stimulated the neurite outgrowth in the presence of mat-LN5, suggesting that LG4 - 5 synergistically enhances integrin signaling as it is released from the precursor LN5.	Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Kihara Mem Yokohama Fdn Advancement Life Sci, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan	Yokohama City University	Miyazaki, K (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, 641-12 Maioka Cho, Yokohama, Kanagawa 2440813, Japan.	miyazaki@yokohama-cu.ac.jp						ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Baker SE, 1996, J CELL SCI, V109, P2509; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CARTER BZ, 1991, LAB INVEST, V65, P610; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Culley B, 2001, NEUROSCI LETT, V301, P83, DOI 10.1016/S0304-3940(01)01615-9; DeHart GW, 2003, EXP CELL RES, V283, P67, DOI 10.1016/S0014-4827(02)00028-9; Frank DE, 2004, J CELL SCI, V117, P1351, DOI 10.1242/jcs.01003; Fukushima Y, 1998, INT J CANCER, V76, P63, DOI 10.1002/(SICI)1097-0215(19980330)76:1<63::AID-IJC11>3.0.CO;2-H; Gagnoux-Palacios L, 2001, J CELL BIOL, V153, P835, DOI 10.1083/jcb.153.4.835; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Hirosaki T, 2000, J BIOL CHEM, V275, P22495, DOI 10.1074/jbc.M001326200; Hirosaki T, 2002, J BIOL CHEM, V277, P49287, DOI 10.1074/jbc.M111096200; IIZUKA H, 1992, BRAIN RES, V599, P1, DOI 10.1016/0006-8993(92)90844-Y; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Kariya Y, 2002, J BIOCHEM, V132, P607, DOI 10.1093/oxfordjournals.jbchem.a003263; Kariya Y, 2003, J CELL BIOCHEM, V88, P506, DOI 10.1002/jcb.10350; Kariya Y, 2004, EXP CELL RES, V297, P508, DOI 10.1016/j.yexcr.2004.03.044; Kariya Y, 2004, J BIOL CHEM, V279, P24774, DOI 10.1074/jbc.M400670200; Kato K, 2002, BIOCHEMISTRY-US, V41, P10747, DOI 10.1021/bi020180k; KIKKAWA Y, 1994, J BIOCHEM-TOKYO, V116, P862, DOI 10.1093/oxfordjournals.jbchem.a124608; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Kunneken K, 2004, J BIOL CHEM, V279, P5184, DOI 10.1074/jbc.M310424200; Lampe PD, 1998, J CELL BIOL, V143, P1735, DOI 10.1083/jcb.143.6.1735; Libby RT, 2000, J NEUROSCI, V20, P6517, DOI 10.1523/JNEUROSCI.20-17-06517.2000; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MATSUI C, 1995, J BIOL CHEM, V270, P23496, DOI 10.1074/jbc.270.40.23496; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; Mizushima H, 1996, J BIOCHEM-TOKYO, V120, P1196; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; Nievers MG, 1999, MATRIX BIOL, V18, P5, DOI 10.1016/S0945-053X(98)00003-1; Ogawa T, 2004, J CELL BIOCHEM, V92, P701, DOI 10.1002/jcb.20112; Okamoto O, 2003, J BIOL CHEM, V278, P44168, DOI 10.1074/jbc.M300726200; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Shang ML, 2001, J BIOL CHEM, V276, P33045, DOI 10.1074/jbc.M100798200; Sigle RO, 2004, J CELL SCI, V117, P4481, DOI 10.1242/jcs.01310; Smith BE, 1996, CELL ADHES COMMUN, V3, P451, DOI 10.3109/15419069609081022; Stipp CS, 2000, J CELL SCI, V113, P1871; Tsubota Y, 2000, BIOCHEM BIOPH RES CO, V278, P614, DOI 10.1006/bbrc.2000.3851; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; Yoneda A, 2003, MATRIX BIOL, V22, P25, DOI 10.1016/S0945-053X(03)00010-6	47	29	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14370	14377		10.1074/jbc.M413051200	http://dx.doi.org/10.1074/jbc.M413051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15695818	hybrid			2022-12-25	WOS:000228236800004
J	Criswell, T; Beman, M; Araki, S; Leskov, K; Cataldo, E; Mayo, LD; Boothman, DA				Criswell, T; Beman, M; Araki, S; Leskov, K; Cataldo, E; Mayo, LD; Boothman, DA			Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; PROSTATE-CANCER; FACTOR RECEPTOR; CARCINOMA-CELLS; CLUSTERIN/APOLIPOPROTEIN-J; TRANSCRIPTION FACTORS; IONIZING-RADIATION; ANTIAPOPTOTIC GENE; APOLIPOPROTEIN J; IGF-I	Secretory clusterin protein ( sCLU) is a general genotoxic stress- induced, pro- survival gene product implicated in aging, obesity, heart disease, and cancer. However, the regulatory signal transduction processes that control sCLU expression remain undefined. Here, we report that induction of sCLU is delayed, peaking 72 h after low doses of ionizing radiation, and is dependent on the up- regulation of insulin- like growth factor- 1 as well as phosphorylation- dependent activation of its receptor ( IGF- 1 and IGF- 1R, respectively). Activated IGF- 1R then stimulates the downstream Src- Mek- Erk signal transduction cascade to ultimately transactivate the early growth response- 1 ( Egr- 1) transcription factor, required for sCLU expression. Thus, ionizing radiation exposure causes stress- induced activation of IGF- 1R-Src-Mek- Erk- Egr- 1 signaling that regulates the sCLU pro- survival cascade pathway, important for radiation resistance in cancer therapy.	Case Comprehens Canc Ctr, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Comprehens Canc Ctr, Lab Mol Stress Responses, Program Mol & Cellular Basis Dis, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Mayo, LD (corresponding author), Case Comprehens Canc Ctr, Dept Radiat Oncol, 10900 Euclid Ave,WRB-3, Cleveland, OH 44106 USA.	lindsey.mayo@case.edu; david.boothman@case.edu	Leskov, Konstantin S/J-2339-2017; Boothman, David/Q-7776-2019	Leskov, Konstantin S/0000-0001-6201-5660; 	NCI NIH HHS [P30 CA142543, R01 CA078530, P30 CA43703] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA142543, P30CA043703, R01CA078530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad T, 2004, J BIOL CHEM, V279, P1713, DOI 10.1074/jbc.M306156200; ARTEAGA CL, 2003, CANCER BIOL THER, V2, P79; Bayon Y, 2004, CANCER RES, V64, P5905, DOI 10.1158/0008-5472.CAN-03-3657; Bettuzzi Saverio, 2003, Acta Biomed, V74, P101; BOOTHMAN DA, 1993, P NATL ACAD SCI USA, V90, P7200, DOI 10.1073/pnas.90.15.7200; Burgaud JL, 1996, EXP CELL RES, V223, P412, DOI 10.1006/excr.1996.0096; Cervellera M, 2000, J BIOL CHEM, V275, P21055, DOI 10.1074/jbc.M002055200; Chen XD, 2003, P NATL ACAD SCI USA, V100, P9530, DOI 10.1073/pnas.1233633100; Chung J, 2004, CANCER LETT, V203, P155, DOI 10.1016/j.canlet.2003.07.008; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Criswell T, 2003, CANCER BIOL THER, V2, P372, DOI 10.4161/cbt.2.4.430; DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Dricu A, 1999, GLYCOBIOLOGY, V9, P571, DOI 10.1093/glycob/9.6.571; FREED KA, 1989, J MOL ENDOCRINOL, V3, P183, DOI 10.1677/jme.0.0030183; Gleave ME, 2001, UROLOGY, V58, P39, DOI 10.1016/S0090-4295(01)01241-9; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Grana TM, 2003, CANCER RES, V63, P7807; Gruden G, 2003, KIDNEY INT, V63, P1249, DOI 10.1046/j.1523-1755.2003.00857.x; Hough CD, 2001, CANCER RES, V61, P3869; Ishikawa Y, 1998, ARTERIOSCL THROM VAS, V18, P665, DOI 10.1161/01.ATV.18.4.665; IWAMURA M, 1993, PROSTATE, V22, P243, DOI 10.1002/pros.2990220307; Jin G, 1999, EUR J BIOCHEM, V263, P534, DOI 10.1046/j.1432-1327.1999.00533.x; Kim KU, 2003, RADIAT RES, V160, P224, DOI 10.1667/RR3040; KRISHNAN S, 2003, FRONT BIOSCI, V8, P1; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LeBedis C, 2002, INT J CANCER, V100, P2, DOI 10.1002/ijc.10481; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Lo LW, 2001, J CELL PHYSIOL, V188, P304, DOI 10.1002/jcp.1124; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Meyer RG, 2002, EUR J BIOCHEM, V269, P337, DOI 10.1046/j.0014-2956.2001.02658.x; Milas L, 2004, INT J RADIAT ONCOL, V58, P966, DOI 10.1016/j.ijrobp.2003.08.035; Miyake H, 2000, CANCER RES, V60, P2547; Newkirk MM, 1999, J RHEUMATOL, V26, P597; Petropoulou C, 2001, FEBS LETT, V509, P287, DOI 10.1016/S0014-5793(01)03150-7; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Saffer H, 2002, MODERN PATHOL, V15, P1221, DOI 10.1097/01.MP.0000036386.87517.AA; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sekharam M, 2003, ANTICANCER RES, V23, P1517; Steinberg J, 1997, CLIN CANCER RES, V3, P1707; Trougakos IP, 2004, CANCER RES, V64, P1834, DOI 10.1158/0008-5472.CAN-03-2664; Wen B, 2001, BRIT J CANCER, V85, P2017, DOI 10.1054/bjoc.2001.2171; Wilson MR, 2000, TRENDS BIOCHEM SCI, V25, P95, DOI 10.1016/S0968-0004(99)01534-0; Xie MJ, 2002, PANCREAS, V25, P234, DOI 10.1097/00006676-200210000-00004; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Zellweger T, 2002, CLIN CANCER RES, V8, P3276; Zhou H, 2004, INT J RADIAT ONCOL, V58, P344, DOI 10.1016/j.ijrobp.2003.09.046	50	125	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14212	14221		10.1074/jbc.M412569200	http://dx.doi.org/10.1074/jbc.M412569200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15689620	hybrid			2022-12-25	WOS:000228095500124
J	Flatten, K; Dai, NT; Vroman, BT; Loegering, D; Erlichman, C; Karnitz, LM; Kaufmann, SH				Flatten, K; Dai, NT; Vroman, BT; Loegering, D; Erlichman, C; Karnitz, LM; Kaufmann, SH			The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE CHECKPOINT; DNA-DAMAGE CHECKPOINT; CANCER CELL-LINES; IONIZING-RADIATION; CAMPTOTHECIN CYTOTOXICITY; REPLICATION FORKS; POLYMERASE-ALPHA; MAMMALIAN-CELLS; PROTECTS CELLS; STRAND BREAKS	Agents that target topoisomerase I are widely utilized to treat human cancer. Previous studies have indicated that both the ataxia telangiectasia mutated (ATM)/checkpoint kinase (Chk) 2 and ATM- and Rad 3-related (ATR)/Chk1 checkpoint pathways are activated after treatment with these agents. The relative contributions of these two pathways to survival of cells after treatment with topoisomerase I poisons are currently unknown. To address this issue, we assessed the roles of ATR, Chk1, ATM, and Chk2 in cells treated with the topoisomerase I poisons camptothecin and 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan. Colony forming assays demonstrated that down-regulation of ATR or Chk1 sensitized cells to SN-38 and camptothecin. In contrast, ATM and Chk2 had minimal effect of sensitivity to SN-38 or camptothecin. Additional experiments demonstrated that the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin, which down-regulates Chk1, also sensitized a variety of human carcinoma cell lines to SN-38. Collectively, these results show that the ATR/Chk1 pathway plays a predominant role in the response to topoisomerase I inhibitors in carcinoma cells and identify a potential approach for enhancing the efficacy of these drugs.	Mayo Clin & Mayo Fdn, Coll Med, Div Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Med Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Div Oncol Res, Guggenheim 1301,200 1st St SW, Rochester, MN 55905 USA.	Karnitz.Larry@Mayo.edu; Kaufmann.Scott@Mayo.edu		Kaufmann, Scott/0000-0002-4900-7145	NCI NIH HHS [CA104378, R01 CA073709, CA90390, CA73709] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adjei AA, 1997, CLIN CANCER RES, V3, P761; Adjei AA, 2001, CLIN CANCER RES, V7, P1438; Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Bible KC, 1997, CANCER RES, V57, P3375; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Busby EC, 2000, CANCER RES, V60, P2108; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; COVEY JM, 1989, CANCER RES, V49, P5016; DAVIES SM, 1989, NUCLEIC ACIDS RES, V17, P1337, DOI 10.1093/nar/17.4.1337; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Fiorani P, 2004, J BIOL CHEM, V279, P21271, DOI 10.1074/jbc.M312338200; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goetz MP, 2005, J CLIN ONCOL, V23, P1078, DOI 10.1200/JCO.2005.09.119; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kaufmann SH, 1997, BLOOD, V89, P2098, DOI 10.1182/blood.V89.6.2098; Kaufmann SH, 2001, ANAL BIOCHEM, V296, P283, DOI 10.1006/abio.2001.5313; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Loegering D, 2004, J BIOL CHEM, V279, P18641, DOI 10.1074/jbc.M313536200; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; MATTERN MR, 1987, CANCER RES, V47, P1793; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; Sagata N, 2002, SCIENCE, V298, P1905, DOI 10.1126/science.1079225; Sato S, 2004, J BIOL CHEM, V279, P33759, DOI 10.1074/jbc.M402055200; Shao RG, 1997, CANCER RES, V57, P4029; Shimuta K, 2002, EMBO J, V21, P3694, DOI 10.1093/emboj/cdf357; Siu WY, 2004, MOL CANCER THER, V3, P621; SLICHENMYER WJ, 1993, JNCI-J NATL CANCER I, V85, P271, DOI 10.1093/jnci/85.4.271; SMITH PJ, 1989, INT J RADIAT BIOL, V55, P217, DOI 10.1080/09553008914550271; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Solit DB, 2003, CANCER RES, V63, P2139; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; TAKIMOTO CH, 2001, CANC CHEMOTHERAPY BI, V20, P579; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Wang HY, 2002, CANCER RES, V62, P2483; Wang X, 2004, NUCLEIC ACIDS RES, V32, P767, DOI 10.1093/nar/gkh243; Wang Y, 2003, P NATL ACAD SCI USA, V100, P15387, DOI 10.1073/pnas.2536810100; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	71	86	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14349	14355		10.1074/jbc.M411890200	http://dx.doi.org/10.1074/jbc.M411890200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15699047	Green Published, hybrid			2022-12-25	WOS:000228095500140
J	Gwizdek, C; Hobeika, M; Kus, B; Ossareh-Nazari, B; Dargemont, C; Rodriguez, MS				Gwizdek, C; Hobeika, M; Kus, B; Ossareh-Nazari, B; Dargemont, C; Rodriguez, MS			The mRNA nuclear export factor Hpr1 is regulated by Rsp5-mediated ubiquitylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE RSP5P; SACCHAROMYCES-CEREVISIAE; WW DOMAIN; FUNCTIONAL INTERACTION; PROTEIN LIGASE; POLYMERASE-II; YEAST; TRANSCRIPTION; PROTEASOME; TRANSPORT	Ubiquitin conjugation and in particular two distinct HECT ubiquitin ligases, Rsp5p and Tom1p, have been shown to participate in the regulation of mRNA export in Saccharomyces cerevisiae. The identification of the ubiquitin ligase substrates represents a major challenge in understanding how this modification may modulate mRNA export. Here, we identified Hpr1p, a member of the THO/TREX (transcription/export) complex that couples mRNA transcription to nuclear export as a target of the ubiquitin-proteasome pathway. Hpr1p degradation is enhanced at high temperature and appears linked to on-going RNA-polymeraseII-mediated transcription. Interestingly, the stability of the other THO complex components is not affected under these conditions indicating that Hpr1p turnover could control the formation of the THO/TREX complex and consequently mRNA export. Using in vivo and in vitro approaches we demonstrate that Rsp5p is responsible for the ubiquitylation of Hpr1p that also involves the ubiquitin-conjugating enzyme Ubc4p. Thus, Hpr1p represents the first nuclear export factor regulated by ubiquitylation, strongly suggesting that this post-translational modification participates in the coordination of transcription and mRNA export processes.	Univ Paris 06, CNRS, Unite Mixte Rech 7592, Inst Jacques Monod, F-75251 Paris, France; Univ Paris 07, CNRS, Unite Mixte Rech 7592, Inst Jacques Monod, F-75251 Paris, France; Univ Toronto, Toronto, ON M5G 1L6, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; University of Toronto	Dargemont, C (corresponding author), Univ Paris 06, CNRS, Unite Mixte Rech 7592, Inst Jacques Monod, 2 Pl Jussieu,Tour 43, F-75251 Paris, France.	dargemont@ijm.jussieu.fr						Azad AK, 1997, MOL BIOL CELL, V8, P825, DOI 10.1091/mbc.8.5.825; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Chavez S, 2000, EMBO J, V19, P5824, DOI 10.1093/emboj/19.21.5824; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Cohen M, 2003, NAT CELL BIOL, V5, P661, DOI 10.1038/ncb1003; Duncan K, 2000, CURR BIOL, V10, P687, DOI 10.1016/S0960-9822(00)00527-3; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; Jensen TH, 2001, CURR BIOL, V11, P1711, DOI 10.1016/S0960-9822(01)00529-2; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kim M, 2004, EMBO J, V23, P354, DOI 10.1038/sj.emboj.7600053; Kus BM, 2004, PROTEINS, V54, P455, DOI 10.1002/prot.10620; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lei EP, 2001, GENE DEV, V15, P1771, DOI 10.1101/gad.892401; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; Moreau V, 1997, MOL BIOL CELL, V8, P1361, DOI 10.1091/mbc.8.7.1361; Neumann S, 2003, EMBO REP, V4, P1156, DOI 10.1038/sj.embor.7400026; Nuber U, 1999, J BIOL CHEM, V274, P7576, DOI 10.1074/jbc.274.11.7576; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rodriguez MS, 2004, BIOL CELL, V96, P639, DOI 10.1016/j.biolcel.2004.04.014; Rodriguez MS, 2003, TRAFFIC, V4, P566, DOI 10.1034/j.1600-0854.2003.00115.x; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Shcherbik N, 2004, J BIOL CHEM, V279, P53892, DOI 10.1074/jbc.M410325200; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Stutz G, 2000, ARCH ANDROLOGY, V44, P117; Utsugi T, 1999, GENE, V234, P285, DOI 10.1016/S0378-1119(99)00197-3; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zenklusen D, 2001, MOL CELL BIOL, V21, P4219, DOI 10.1128/MCB.21.13.4219-4232.2001	40	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13401	13405		10.1074/jbc.C500040200	http://dx.doi.org/10.1074/jbc.C500040200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15713680	Green Published, hybrid			2022-12-25	WOS:000228095500027
J	Wang, RP; Su, JD; Wang, XR; Piao, HL; Zhang, XL; Adams, CY; Cui, NG; Jiang, C				Wang, RP; Su, JD; Wang, XR; Piao, HL; Zhang, XL; Adams, CY; Cui, NG; Jiang, C			Subunit stoichiometry of the Kir1.1 channel in proton-dependent gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+ CHANNELS; POTASSIUM CHANNEL; PH SENSITIVITY; SURFACE EXPRESSION; INTRACELLULAR PH; BARTTER-SYNDROME; ROMK CHANNEL; ATP CHANNELS; BINDING; MODULATION	Kir1.1 channel regulates membrane potential and K+ secretion in renal tubular cells. This channel is gated by intracellular protons, in which a lysine residue (Lys(80)) plays a critical role. Mutation of the Lys(80) to a methionine (K80M) disrupts pH-dependent channel gating. To understand how an individual subunit in a tetrameric channel is involved in pH-dependent channel gating, we performed these studies by introducing K80M-disrupted subunits to tandem tetrameric channels. The pH sensitivity was studied in whole-cell voltage clamp and inside-out patches. Homomeric tetramers of the wild-type (wt) and K80M-disrupted channels showed a pH sensitivity almost identical to that of their monomeric counterparts. In heteromeric tetramers and dimers, pH sensitivity was a function of the number of wt subunits. Recruitment of the first single wt subunit shifts the pK(a) greatly, whereas additions of any extra wt subunit had smaller effects. Single-channel analysis revealed that the tetrameric channel with two or more wt subunits showed one substate conductance at similar to 40% of the full conductance, suggesting that four subunits act as two pairs. However, three and four substates of conductance were seen in the tetrameric wt-3K80M and 4K80M channels. Acidic pH increased long-time closures when there were two or more wt subunits. Disruption of more than two subunits led to flicking activity with appearance of a new opening event and loss of the long period of closures. Interestingly, the channel with two wt subunits at diagonal and adjacent configurations showed the same pH sensitivity, substate conductance, and long-time closure. These results thus suggest that one functional subunit is sufficient to act in the pH-dependent gating of the Kir1.1 channel, the channel sensitivity to pH increases with additional subunits, the full pH sensitivity requires contributions of all four subunits, and two subunits may be coordinated in functional dimers of either trans or cis configuration.	Georgia State Univ, Dept Biol, Atlanta, GA 30302 USA	University System of Georgia; Georgia State University	Jiang, C (corresponding author), Georgia State Univ, Dept Biol, 24 Peachtree Ctr Ave, Atlanta, GA 30302 USA.	cjiang@gsu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067890, R01HL058410] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL058410, HL067890, R01 HL067890, HL058410] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bichet D, 2003, NAT REV NEUROSCI, V4, P957, DOI 10.1038/nrn1244; Chanchevalap S, 2000, J BIOL CHEM, V275, P7811, DOI 10.1074/jbc.275.11.7811; Choe H, 1997, AM J PHYSIOL-RENAL, V273, pF516, DOI 10.1152/ajprenal.1997.273.4.F516; Dorschner H, 1999, MOL PHARMACOL, V55, P1060; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; Flagg TP, 1999, J GEN PHYSIOL, V114, P685, DOI 10.1085/jgp.114.5.685; Flagg TP, 2002, J PHYSIOL-LONDON, V544, P351, DOI 10.1113/jphysiol.2002.027581; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; Hebert SC, 2003, CURR OPIN NEPHROL HY, V12, P527, DOI 10.1097/00041552-200309000-00008; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Huang CL, 2001, CURR OPIN NEPHROL HY, V10, P693, DOI 10.1097/00041552-200109000-00022; Kahle KT, 2003, NAT GENET, V35, P372, DOI 10.1038/ng1271; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Kunzelmann K, 2000, CELL PHYSIOL BIOCHEM, V10, P117, DOI 10.1159/000016342; Kuzhikandathil EV, 2000, J GEN PHYSIOL, V115, P697, DOI 10.1085/jgp.115.6.697; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; Leipziger J, 2000, AM J PHYSIOL-RENAL, V279, pF919, DOI 10.1152/ajprenal.2000.279.5.F919; Leung YM, 2000, J BIOL CHEM, V275, P10182, DOI 10.1074/jbc.275.14.10182; Lin DH, 2002, J BIOL CHEM, V277, P44278, DOI 10.1074/jbc.M203702200; Liu DT, 1998, NEURON, V21, P235, DOI 10.1016/S0896-6273(00)80530-9; MacGregor GG, 2002, P NATL ACAD SCI USA, V99, P2726, DOI 10.1073/pnas.042688899; McLerie M, 2003, J MOL CELL CARDIOL, V35, P367, DOI 10.1016/S0022-2828(03)00014-2; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; McNicholas CM, 1998, AM J PHYSIOL-RENAL, V275, pF972, DOI 10.1152/ajprenal.1998.275.6.F972; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Pessia M, 2001, J PHYSIOL-LONDON, V532, P359, DOI 10.1111/j.1469-7793.2001.0359f.x; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Ruiz M, 1997, NATURE, V389, P389, DOI 10.1038/38744; Sadja R, 2002, P NATL ACAD SCI USA, V99, P10783, DOI 10.1073/pnas.162346199; Schonherr R, 1999, J BIOL CHEM, V274, P5362, DOI 10.1074/jbc.274.9.5362; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; Ulens C, 2003, NEURON, V40, P959, DOI 10.1016/S0896-6273(03)00753-0; Wang WH, 1999, AM J PHYSIOL-RENAL, V277, pF826, DOI 10.1152/ajprenal.1999.277.6.F826; Wu J, 2002, J MEMBRANE BIOL, V190, P105, DOI 10.1007/s00232-002-1029-1; Xu HX, 2000, J PHYSIOL-LONDON, V528, P267, DOI 10.1111/j.1469-7793.2000.00267.x; Xu HX, 2001, J BIOL CHEM, V276, P12898, DOI 10.1074/jbc.M009631200; Xu HX, 2000, AM J PHYSIOL-CELL PH, V279, pC1464, DOI 10.1152/ajpcell.2000.279.5.C1464; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7; Yang ZJ, 2000, J GEN PHYSIOL, V116, P33, DOI 10.1085/jgp.116.1.33; Yoo D, 2003, J BIOL CHEM, V278, P23066, DOI 10.1074/jbc.M212301200; Zhu GY, 2000, J CELL PHYSIOL, V183, P53, DOI 10.1002/(SICI)1097-4652(200004)183:1<53::AID-JCP7>3.3.CO;2-I	42	5	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13433	13441		10.1074/jbc.M411895200	http://dx.doi.org/10.1074/jbc.M411895200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15691840	hybrid			2022-12-25	WOS:000228095500031
J	Kang, HJ; Nam, SW; Kim, HK; Rhee, H; Kim, NG; Kim, HY; Hyung, WJ; Noh, SH; Kim, JH; Yun, CO; Liu, ET; Kim, HG				Kang, HJ; Nam, SW; Kim, HK; Rhee, H; Kim, NG; Kim, HY; Hyung, WJ; Noh, SH; Kim, JH; Yun, CO; Liu, ET; Kim, HG			Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors	ONCOGENE			English	Article						gastrointestinal stromal tumors; KIT; PDGFRA; molecular classification; oligonucleotide microarray	OF-FUNCTION MUTATIONS; C-KIT; TYROSINE KINASES; PHOSPHORYLATION; PROTEIN; CELLS; PROLIFERATION; INHIBITION; STATS; OCCUR	Activating mutations of KIT and platelet-derived growth factor receptor alpha (PDGFRA) are known to be alternative and mutually exclusive genetic events in the development of gastrointestinal stromal tumors (GISTs). We examined the effect of the mutations of these two genes on the gene expression pro. le of 22 GISTs using the oligonucleotide microarray. Mutations of KIT and PDGFRA were found in 17 cases and three cases, respectively. The remaining two cases had no detectable mutations in either gene. The mutation status of KIT and PDGFRA was directly related to the expression levels of activated KIT and PDGFRA, and was also related to the different expression levels of activated proteins that play key roles in the downstream of the receptor tyrosine kinase III family. To evaluate the impact of mutation status and the importance of the type of mutation in gene expression and clinical features, microarray-derived data from 22 GISTs were interpreted using a principal component analysis (PCA). Three relevant principal component representing mutation of KIT, PDGFRA and chromosome 14q deletion were identified from the interpretation of the oligonucleotide microarray data with PCA. After supervised analysis, there was at least a two fold difference in expression between GISTs with KIT and PDGFRA mutation in 70 genes. Our findings demonstrate that mutations of KIT and PDGFRA affect differential activation and expression of some genes, and can be used for the molecular classification of GISTs.	Yonsei Univ, Coll Med, Dept Pathol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Projects Med Sci 21, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Seoul 120752, South Korea; Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137710, South Korea; Yonsei Univ, Coll Med, Dept Surg, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul 120752, South Korea; Genome Inst Singapore, Singapore 138672, Singapore	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Catholic University of Korea; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Kim, HG (corresponding author), Yonsei Univ, Coll Med, Dept Pathol, 134 Sichon Dong,CPO Box 8044, Seoul 120752, South Korea.	hkyonsei@yumc.yonsei.ac.kr	Liu, Edison/C-4141-2008; Yun, Chae-Ok/P-3698-2015	Yun, Chae-Ok/0000-0002-9466-4531; Kim, Haeryoung/0000-0002-4205-9081; Noh, Sung Hoon/0000-0003-4386-6886; Hyung, Woo Jin/0000-0002-8593-9214; Kim, Hyunki/0000-0003-2292-5584				Allander SV, 2001, CANCER RES, V61, P8624; Antonescu CR, 2004, CLIN CANCER RES, V10, P3282, DOI 10.1158/1078-0432.CCR-03-0715; Barker SA, 1998, MOL BIOL CELL, V9, P483, DOI 10.1091/mbc.9.2.483; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brizzi MF, 1999, J BIOL CHEM, V274, P16965, DOI 10.1074/jbc.274.24.16965; Burack WR, 1997, BIOCHEMISTRY-US, V36, P5929, DOI 10.1021/bi970535d; Choi YR, 2003, CANCER RES, V63, P2188; El-Rifai W, 1998, ANN CHIR GYNAECOL FE, V87, P287; El-Rifai W, 2000, GENE CHROMOSOME CANC, V27, P387, DOI 10.1002/(SICI)1098-2264(200004)27:4<387::AID-GCC8>3.0.CO;2-C; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Hirota Seiichi, 2000, Journal of Gastroenterology, V35, P75; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JOSEPH LD, 1997, SCIENCE, V278, P680; Kim NG, 2000, INT J CANCER, V85, P633, DOI 10.1002/(SICI)1097-0215(20000301)85:5<633::AID-IJC6>3.3.CO;2-X; Kindblom LG, 1998, AM J PATHOL, V152, P1259; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Lasota J, 1999, AM J PATHOL, V154, P53, DOI 10.1016/S0002-9440(10)65250-9; LEWIN KJ, 1992, GASTROINTESTINAL PAT, P284; Lux ML, 2000, AM J PATHOL, V156, P791, DOI 10.1016/S0002-9440(10)64946-2; Ma YS, 1999, J BIOL CHEM, V274, P13399, DOI 10.1074/jbc.274.19.13399; Maeyama H, 2001, GASTROENTEROLOGY, V120, P210; Miettinen M, 2002, EUR J CANCER, V38, pS39, DOI 10.1016/S0959-8049(02)80602-5; Mui ALF, 1999, CELL MOL LIFE SCI, V55, P1547, DOI 10.1007/s000180050394; Nakahara M, 1998, GASTROENTEROLOGY, V115, P1090, DOI 10.1016/S0016-5085(98)70079-4; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Pawson T, 2002, EUR J CANCER, V38, pS3, DOI 10.1016/S0959-8049(02)80597-4; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Rubin BP, 2001, CANCER RES, V61, P8118; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SUBRAMANIAN S, 2004, ONCOGENE; Taniguchi M, 1999, CANCER RES, V59, P4297; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; West RB, 2004, AM J PATHOL, V165, P107, DOI 10.1016/S0002-9440(10)63279-8; Zhang CY, 1996, MOL PHARMACOL, V50, P864	41	74	82	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1066	1074		10.1038/sj.onc.1208358	http://dx.doi.org/10.1038/sj.onc.1208358			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15690055				2022-12-25	WOS:000226749200012
J	Shammas, C; Menne, TF; Hilcenko, C; Michell, SR; Goyenechea, B; Boocock, GRB; Durie, PR; Rommens, JM; Warren, AJ				Shammas, C; Menne, TF; Hilcenko, C; Michell, SR; Goyenechea, B; Boocock, GRB; Durie, PR; Rommens, JM; Warren, AJ			Structural and mutational analysis of the SBDS protein family - Insight into the leukemia-associated Shwachman-Diamond syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE GENOME; CRYSTAL-STRUCTURE; GLOBAL ANALYSIS; BUDDING YEAST; GENE; REFINEMENT; PREDICTION; DATABASE; BINDING; MODEL	Shwachman-Diamond Syndrome (SDS) is an autosomal recessive disorder characterized by bone marrow failure with significant predisposition to the development of poor prognosis myelodysplasia and leukemia, exocrine pancreatic failure and metaphyseal chondrodysplasia. Although the SBDS gene mutated in this disorder is highly conserved in Archaea and all eukaryotes, the function is unknown. To interpret the molecular consequences of SDS-associated mutations, we have solved the crystal structure of the Archaeoglobus fulgidus SBDS protein orthologue at a resolution of 1.9 angstrom, revealing a three domain architecture. The N-terminal (FYSH) domain is the most frequent target for disease mutations and contains a novel mixed alpha/beta-fold identical to the single domain yeast protein Yhr087wp that is implicated in RNA metabolism. The central domain consists of a three-helical bundle, whereas the C-terminal domain has a ferredoxin-like fold. By genetic complementation analysis of the essential Saccharomyces cerevisiae SBDS orthologue YLR022C, we demonstrate an essential role in vivo for the FYSH domain and the central three-helical bundle. We further show that the common SDS-related K62X truncation is non-functional. Most SDS-related missense mutations that alter surface epitopes do not impair YLR022C function, but mutations affecting residues buried in the hydrophobic core of the FYSH domain severely impair or abrogate complementation. These data are consistent with absence of homozygosity for the common K62X truncation mutation in individuals with SDS, indicating that the SDS disease phenotype is a consequence of expression of hypomorphic SBDS alleles and that complete loss of SBDS function is likely to be lethal.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Cambridge, Dept Hematol, Cambridge CB2 2XY, England; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Pediat, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada	MRC Laboratory Molecular Biology; University of Cambridge; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Warren, AJ (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	ajw@mrc-lmb.cam.ac.uk	Rommens, Johanna/AAT-7465-2021	hilcenko, christine/0000-0002-9596-7833				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BODIAN M, 1964, ACTA PAEDIATR, V53, P282, DOI 10.1111/j.1651-2227.1964.tb07237.x; Boocock GRB, 2003, NAT GENET, V33, P97, DOI 10.1038/ng1062; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Donadieu J, 2005, HAEMATOLOGICA, V90, P45; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; Ginzberg H, 1999, J PEDIATR-US, V135, P81, DOI 10.1016/S0022-3476(99)70332-X; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; Haase SB, 1997, METHOD ENZYMOL, V283, P322; Hazbun TR, 2003, MOL CELL, V12, P1353, DOI 10.1016/S1097-2765(03)00476-3; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jorgensen R, 2003, NAT STRUCT BIOL, V10, P379, DOI 10.1038/nsb923; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Koonin EV, 2001, GENOME RES, V11, P240, DOI 10.1101/gr.162001; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nakashima E, 2004, HUM GENET, V114, P345, DOI 10.1007/s00439-004-1081-2; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Park F, 2004, PROTEINS, V55, P775, DOI 10.1002/prot.20087; Peng WT, 2003, CELL, V113, P919, DOI 10.1016/S0092-8674(03)00466-5; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; Savchenko A, 2005, J BIOL CHEM, V280, P19213, DOI 10.1074/jbc.M414421200; SCHWACHMAN H, 1964, J PEDIATR-US, V65, P645; Smith OP, 1996, BRIT J HAEMATOL, V94, P279, DOI 10.1046/j.1365-2141.1996.d01-1788.x; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Warren AJ, 2000, EMBO J, V19, P3004, DOI 10.1093/emboj/19.12.3004; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Woloszynek JR, 2004, BLOOD, V104, P3588, DOI 10.1182/blood-2004-04-1516; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	45	86	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19221	19229		10.1074/jbc.M414656200	http://dx.doi.org/10.1074/jbc.M414656200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15701631	hybrid			2022-12-25	WOS:000228932300079
J	Zhang, SX; Garcia-Gras, E; Wycuff, DR; Marriot, SJ; Kadeer, N; Yu, W; Olson, EN; Garry, DJ; Parmacek, MS; Schwartz, RJ				Zhang, SX; Garcia-Gras, E; Wycuff, DR; Marriot, SJ; Kadeer, N; Yu, W; Olson, EN; Garry, DJ; Parmacek, MS; Schwartz, RJ			Identification of direct serum-response factor gene targets during Me2SO-induced P19 cardiac cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TINMAN HOMOLOG NKX-2.5; ACTIN GENE; TRANSCRIPTION FACTOR; MICE LACKING; IN-VIVO; PROTEIN; EXPRESSION; SRF; ACTIVATION; KINASE	Serum-response factor (SRF) is an obligatory transcription factor, required for the formation of vertebrate mesoderm leading to the origin of the cardiovascular system. Protein A-TEV-tagged chromatin immunoprecipitation technology was used to collect direct SRF-bound gene targets from pluripotent P19 cells, induced by Me2SO treatment into an enriched cardiac cell population. From 242 sequenced DNA fragments, we identified 188 genomic DNA fragments as potential direct SRF targets that contain CArG boxes and CArG-like boxes. Of the 92 contiguous genes that were identified, a subgroup of 43 SRF targets was then further validated by co-transfection assays with SRF. Expression patterns of representative candidate genes were compared with the LacZ reporter expression activity of the endogenous SRF gene. According to the Unigene data base, 84% of the SRF target candidates were expressed, at least, in the heart. In SRF null embryonic stem cells, 81% of these SRF target candidates were greatly affected by the absence of SRF. Among these SRF-regulated genes, Raf1, Map4k4, and Bicc1 have essential roles in mesoderm formation. The 12 regulated SRF target genes, Mapk10 (JNK3), Txnl2, Azi2, Tera, Sema3a, Lrp4, Actc1, Myl3, Hspg2, Pgm2, Hif3a, and Asb5, have been implicated in cardiovascular formation, and the Ski and Hes6 genes have roles in muscle differentiation. SRF target genes related to cell mitosis and cycle, E2f5, Npm1, Cenpb, Rbbp6, and Scyl1, expressed in the heart tissue were differentially regulated in SRF null ES cells.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Pennsylvania	Schwartz, RJ (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Inst Biosci & Technol, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rschwartz@ibt.tamhsc.edu		Garcia Gras, Eduardo/0000-0002-6930-0111	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL49953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adelman DM, 2000, GENE DEV, V14, P3191, DOI 10.1101/gad.853700; ARENIAN S, 1998, EMBO J, V17, P6289; Aubert J, 2002, NAT BIOTECHNOL, V20, P1240, DOI 10.1038/nbt763; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Boengler K, 2003, BIOCHEM BIOPH RES CO, V302, P17, DOI 10.1016/S0006-291X(03)00095-0; Cahill M.A., 1995, INDUCIBLE GENE EXPRE, V2, P39; CARROLL SL, 1986, J BIOL CHEM, V261, P8965; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; Chai J, 2002, J PHYSIOL PHARMACOL, V53, P147; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Chang J, 2003, CIRCULATION, V108, P407, DOI 10.1161/01.CIR.0000084502.02147.83; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; CHOW KL, 1991, P NATL ACAD SCI USA, V88, P1301, DOI 10.1073/pnas.88.4.1301; Cossins J, 2002, DEVELOPMENT, V129, P2195; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Dalgleish P, 2000, NUCLEIC ACIDS RES, V28, P560, DOI 10.1093/nar/28.2.560; Davis FJ, 2003, J BIOL CHEM, V278, P20047, DOI 10.1074/jbc.M209998200; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; Gallardo TD, 2003, GENESIS, V37, P57, DOI 10.1002/gene.10223; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gray TA, 2001, GENOMICS, V77, P119, DOI 10.1006/geno.2001.6627; Guillemin K, 1996, DEVELOPMENT, V122, P1353; Hara S, 2001, BIOCHEM BIOPH RES CO, V287, P808, DOI 10.1006/bbrc.2001.5659; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JOHANSEN EF, 1995, BIOCHIM BIOPHYS ACTA, V121, P1; Lau D, 2000, J BIOL CHEM, V275, P467, DOI 10.1074/jbc.275.1.467; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Minchiotti G, 2002, GENE, V287, P33, DOI 10.1016/S0378-1119(01)00892-7; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; Nakamura T, 2003, P NATL ACAD SCI USA, V100, P5834, DOI 10.1073/pnas.0935626100; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; REECY JM, 1999, HEART DEV, P273; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; Selvaraj A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-13; Selvaraj A, 2003, J BIOL CHEM, V278, P41977, DOI 10.1074/jbc.M305679200; Sepulveda JL, 2002, J BIOL CHEM, V277, P25775, DOI 10.1074/jbc.M203122200; Shannon MF, 2002, SCIENCE, V296, P666, DOI 10.1126/science.1062936; Shin CH, 2002, CELL, V110, P725, DOI 10.1016/S0092-8674(02)00933-9; Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050-1738(99)00017-1; Solano PJ, 2003, DEVELOPMENT, V130, P1243, DOI 10.1242/dev.00348; Solloway MJ, 2003, CARDIOVASC RES, V58, P264, DOI 10.1016/S0008-6363(03)00286-4; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang H, 2002, PLANT J, V32, P831, DOI 10.1046/j.1365-313X.2002.01455.x; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wessely O, 2000, DEVELOPMENT, V127, P2053; Wessely O, 2001, MECH DEVELOP, V101, P267, DOI 10.1016/S0925-4773(00)00568-2; Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; Xue YZ, 2001, DEVELOPMENT, V128, P1559	76	64	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19115	19126		10.1074/jbc.M413793200	http://dx.doi.org/10.1074/jbc.M413793200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15699019	hybrid			2022-12-25	WOS:000228932300068
J	Jauch, R; Humm, A; Huber, R; Wahl, MC				Jauch, R; Humm, A; Huber, R; Wahl, MC			Structures of Escherichia coli NAD synthetase with substrates and products reveal mechanistic rearrangements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHOPYRIDINE NUCLEOTIDE; BACILLUS-SUBTILIS; GENE; BIOSYNTHESIS; IDENTIFICATION; PROGRAM; CODES	Nicotinamide adenine dinucleotide synthetases ( NADS) catalyze the amidation of nicotinic acid adenine dinucleotide ( NAAD) to yield the enzyme cofactor nicotinamide adenine dinucleotide (NAD). Here we describe the crystal structures of the ammonia-dependent homodimeric NADS from Escherichia coli alone and in complex with natural substrates and with the reaction product NAD. The structures disclosed two NAAD/NAD binding sites at the dimer interface and an adenosine triphosphate (ATP) binding site within each subunit. Comparison with the Bacillus subtilis NADS showed pronounced chemical differences in the NAAD/NAD binding sites and less prominent differences in the ATP binding pockets. In addition, the E. coli NADS structures revealed unexpected dynamical rearrangements in the NAAD/NAD binding pocket upon NAAD-to-NAD conversion, which define a catalysis state and a substrate/ product exchange state. The two states are adopted by concerted movement of the nicotinysyl moieties of NAAD and NAD, Phe-170, and residues 224 - 228, which may be triggered by differential coordination of a magnesium ion to NAAD and NAD. Phylogenetic structure comparisons suggest that the present results are relevant for designing species-specific antibiotics.	Max Planck Inst Biophys Chem, Abt Mol Entwicklungsbiol, D-37077 Gottingen, Germany; Roche Diagnost GmbH, D-82372 Penzberg, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Max Planck Inst Biophys Chem, Abt Zellulare Biochem Rontgenkristallog, D-37077 Gottingen, Germany	Max Planck Society; Roche Holding; Max Planck Society; Max Planck Society	Wahl, MC (corresponding author), Max Planck Inst Biophys Chem, Abt Zellulare Biochem Rontgenkristallog, Fassberg 11, D-37077 Gottingen, Germany.	mwahl@gwdg.de	Wahl, Markus/D-6365-2017	Wahl, Markus/0000-0002-2811-5307				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bieganowski P, 2003, J BIOL CHEM, V278, P33049, DOI 10.1074/jbc.M302257200; Bieganowski P, 2003, J BIOL CHEM, V278, P33056, DOI 10.1074/jbc.M302276200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cantoni R, 1998, J BACTERIOL, V180, P3218, DOI 10.1128/JB.180.12.3218-3221.1998; Devedjiev Y, 2001, ACTA CRYSTALLOGR D, V57, P806, DOI 10.1107/S0907444901003523; Hara N, 2003, J BIOL CHEM, V278, P10914, DOI 10.1074/jbc.M209203200; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NESSI C, 1995, J BIOL CHEM, V270, P6181, DOI 10.1074/jbc.270.11.6181; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PREISS J, 1958, J BIOL CHEM, V233, P488; PREISS J, 1958, J BIOL CHEM, V233, P493; Rizzi M, 2002, CURR OPIN STRUC BIOL, V12, P709, DOI 10.1016/S0959-440X(02)00385-8; Rizzi M, 1996, PROTEINS, V26, P236, DOI 10.1002/(SICI)1097-0134(199610)26:2<236::AID-PROT12>3.0.CO;2-Q; Rizzi M, 1996, EMBO J, V15, P5125, DOI 10.1002/j.1460-2075.1996.tb00896.x; Rizzi M, 1998, STRUCTURE, V6, P1129, DOI 10.1016/S0969-2126(98)00114-2; SCHOEPFER R, 1993, GENE, V124, P83, DOI 10.1016/0378-1119(93)90764-T; SPENCER RL, 1967, J BIOL CHEM, V242, P385; Sutherland S, 2003, DRUG DISCOV TODAY, V8, P335, DOI 10.1016/S1359-6446(03)02665-5; Symersky J, 2002, ACTA CRYSTALLOGR D, V58, P1138, DOI 10.1107/S0907444902006698; Velu SE, 2003, J MED CHEM, V46, P3371, DOI 10.1021/jm030003x; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WILLISON JC, 1992, J BACTERIOL, V174, P5765, DOI 10.1128/JB.174.17.5765-5766.1992; WILLISON JC, 1994, J BACTERIOL, V176, P3400, DOI 10.1128/jb.176.11.3400-3402.1994	27	29	31	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15131	15140		10.1074/jbc.M413195200	http://dx.doi.org/10.1074/jbc.M413195200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15699042	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000228236800096
J	Kim, SW; Ho, SC; Hong, SJ; Kim, KM; So, EC; Christoffolete, M; Harney, JW				Kim, SW; Ho, SC; Hong, SJ; Kim, KM; So, EC; Christoffolete, M; Harney, JW			A novel mechanism of thyroid hormone-dependent negative regulation by thyroid hormone receptor, nuclear receptor corepressor (NCoR), and GAGA-binding factor on the rat CD44 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; INTRAMEMBRANE CLEAVAGE; INTRACELLULAR DOMAIN; STIMULATING HORMONE; MEDIATES REPRESSION; RESPONSE ELEMENT; GENE-EXPRESSION; COMPLEX; TRANSCRIPTION; LOCALIZATION	CD44 is an adhesion molecule in the extracellular matrix that shows various functions, including tumor genesis and metastasis. A recent study showed that CD44 expression level was strongly correlated with the generation of papillary thyroid carcinomas, the most prevalent malignancy of the thyroid gland. We report here that CD44 is negatively regulated by thyroid hormone (T-3) through a novel mechanism. We demonstrate that nuclear receptor corepressor ( NCoR) enhances thyroid hormone receptor (TR)-mediated basal transactivation by a weak TR center dot DNA interaction in the absence of T-3, which is repressed by T-3 through a transient TR center dot DNA interaction. Initially, we identified that CD44 was negatively directly transcriptionally T-3-responsive. Deletion and mutation analysis indicated that both a weak TR and a GAGA-binding factor (GAF) binding sites on the CD44 promoter were required for negative regulation by T-3. The weak TR center dot DNA interaction was further confirmed by electrophoretic gel mobility shift assay, chromatin immunoprecipitation, and transfection assays using a non-DNA-binding TR alpha 1 mutant. More interestingly, NCoR acted as a co-activator to enhance TR-mediated basal transactivation in the absence of T-3. This effect was eliminated by removal of TR or NCoR binding. Most strikingly, T-3 induced a remarkable increase in TR center dot DNA binding at 40 - 60 min after T-3 exposure that rapidly returned to basal levels, suggesting a T-3-induced remodeling of chromatin structure at the early stage of T-3 stimulation resulting in repression. Therefore, we propose a mechanism by which NCoR, GAF, and TR interact with the CD44 negative T-3-responsive element to enhance basal transactivation, whereas T-3 induces the remodeling of chromatin structure for repression.	Brigham & Womens Hosp, Harvard Inst Med, Dept Med, Div Endocrinol Diabet & Hypertens,Thyroid Sect, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kim, SW (corresponding author), Brigham & Womens Hosp, Harvard Inst Med, Dept Med, Div Endocrinol Diabet & Hypertens,Thyroid Sect, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	swkim@rics.bwh.harvard.edu		Christoffolete, Marcelo/0000-0003-0374-0795	NIDDK NIH HHS [DK02867, DK44128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044128, K01DK002867] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apriletti JW, 1998, CLIN EXP PHARMACOL P, V25, pS2, DOI 10.1111/j.1440-1681.1998.tb02293.x; Belandia B, 1998, J BIOL CHEM, V273, P30366, DOI 10.1074/jbc.273.46.30366; Berghagen H, 2002, J BIOL CHEM, V277, P49517, DOI 10.1074/jbc.M209546200; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Castellone MD, 2004, ONCOGENE, V23, P2188, DOI 10.1038/sj.onc.1207322; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DE SB, 1999, NATURE, V398, P518; Drover VAB, 2002, MOL ENDOCRINOL, V16, P14, DOI 10.1210/me.16.1.14; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HOLLENBERG AN, 1995, J BIOL CHEM, V270, P14274, DOI 10.1074/jbc.270.24.14274; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim SW, 1996, MOL CELL BIOL, V16, P4465; KIM SW, 2004, MOL ENDOCRINOL; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Langlois MF, 1997, J BIOL CHEM, V272, P24927, DOI 10.1074/jbc.272.40.24927; Lazar MA, 2003, J CLIN INVEST, V112, P497, DOI 10.1172/JCI200319479; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lehmann M, 2004, TRENDS GENET, V20, P15, DOI 10.1016/j.tig.2003.11.005; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; Lutz M, 2003, EMBO J, V22, P1579, DOI 10.1093/emboj/cdg147; Lutz M, 2000, BIOCHEM SOC T, V28, P386, DOI 10.1042/0300-5127:0280386; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Oberste-Berghaus C, 2000, J BIOL CHEM, V275, P1787, DOI 10.1074/jbc.275.3.1787; Perez-Juste G, 2000, J BIOL CHEM, V275, P1307, DOI 10.1074/jbc.275.2.1307; Pombo PMG, 2000, J BIOL CHEM, V275, P37510, DOI 10.1074/jbc.M006440200; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; Sasaki S, 1999, EMBO J, V18, P5389, DOI 10.1093/emboj/18.19.5389; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Shibusawa N, 2003, J CLIN INVEST, V112, P588, DOI 10.1172/JCI200318377; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; Tagami T, 1999, J BIOL CHEM, V274, P22345, DOI 10.1074/jbc.274.32.22345; TOYODA N, 1995, MOL CELL BIOL, V15, P5100; Villa A, 2004, MOL ENDOCRINOL, V18, P863, DOI 10.1210/me.2003-0260; Waters KM, 1997, BIOCHEM BIOPH RES CO, V233, P838, DOI 10.1006/bbrc.1997.6550; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; XU J, 1993, J BIOL CHEM, V268, P16065; ZHANG WG, 1992, J BIOL CHEM, V267, P15056	50	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14545	14555		10.1074/jbc.M411517200	http://dx.doi.org/10.1074/jbc.M411517200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701601	hybrid			2022-12-25	WOS:000228236800026
J	Vagin, O; Turdikulova, S; Yakubov, I; Sachs, G				Vagin, O; Turdikulova, S; Yakubov, I; Sachs, G			Use of the H,K-ATPase beta subunit to identify multiple sorting pathways for plasma membrane delivery in polarized cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; EPITHELIAL-CELLS; ALPHA-SUBUNIT; GASTRIC H+,K+-ATPASE; TRANSPORTING ATPASE; H+/K+-ATPASE; TRAFFICKING; NA,K-ATPASE; SIGNALS; GLYCOSYLATION	A dynamic equilibrium between multiple sorting pathways maintains polarized distribution of plasma membrane proteins in epithelia. To identify sorting pathways for plasma membrane delivery of the gastric H,K-ATPase beta subunit in polarized cells, the protein was expressed as a yellow fluorescent protein N-terminal construct in Madin-Darby canine kidney (MDCK) and LLC-PK1 cells. Confocal microscopy and surface-selective biotinylation showed that 80% of the surface amount of the beta subunit was present on the apical membrane in LLC-PK1 cells, but only 40% was present in MDCK cells. Nondenaturing gel electrophoresis of the isolated membranes showed that a significant fraction of the H, K-ATPase beta subunits associate with the endogenous Na,K-ATPase alpha(1) subunits in MDCK but not in LLC-PK cells. Hence, co-sorting of the H,K-ATPase beta subunit with the Na,K-ATPase alpha(1) subunit to the basolateral membrane in MDCK cells may determine the differential distribution of the beta subunit in these two cell types. The major fraction of unassociated monomeric H,K-ATPase beta subunits is detected in the apical membrane. Quantitative analysis showed that half of the apical pool of the beta subunit originates directly from the trans-Golgi network and the other half from transcytosis via the basolateral membrane in MDCK cells. A minor fraction of monomeric beta subunits detected in the basolateral membrane represents a transient pool of the protein that undergoes transcytosis to the apical membrane. Hence, the steady state distribution of the H,K-ATPase beta subunit in polarized cells depends on the balance between (a) direct sorting from the trans-Golgi network, (b) secondary associative sorting with a partner protein, and (c) transcytosis.	VAGLAHS, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Vagin, O (corresponding author), VAGLAHS, Bldg 113,Rm 324,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	olgav@ucla.edu	Yakubov, Iskandar/W-6936-2018; Turdikulova, Shahlo/R-7669-2016	Yakubov, Iskandar/0000-0002-7367-428X; Turdikulova, Shahlo/0000-0003-0764-2332	NIDDK NIH HHS [DK46917, DK58333] Funding Source: Medline; PHS HHS [53462, 41301] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046917, R56DK058333, R01DK058333] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beguin P, 2000, MOL BIOL CELL, V11, P1657, DOI 10.1091/mbc.11.5.1657; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Caplan MJ, 1997, AM J PHYSIOL-GASTR L, V272, pG1304, DOI 10.1152/ajpgi.1997.272.6.G1304; Duffield A, 2004, TRAFFIC, V5, P449, DOI 10.1111/j.1398-9219.2004.00192.x; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; Geering K, 2000, BIOCHEMISTRY-US, V39, P12688, DOI 10.1021/bi0009791; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; Hasler U, 1998, J BIOL CHEM, V273, P30826, DOI 10.1074/jbc.273.46.30826; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Keller P, 1997, J CELL SCI, V110, P3001; Koenderink JB, 1999, J BIOL CHEM, V274, P11604, DOI 10.1074/jbc.274.17.11604; Kroepfl JF, 2001, J NEUROCHEM, V77, P1301, DOI 10.1046/j.1471-4159.2001.00343.x; Lambrecht N, 2000, J BIOL CHEM, V275, P4041, DOI 10.1074/jbc.275.6.4041; Li CM, 2003, ANN NY ACAD SCI, V986, P226, DOI 10.1111/j.1749-6632.2003.tb07165.x; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; Muth TR, 1998, AM J PHYSIOL-CELL PH, V274, pC688, DOI 10.1152/ajpcell.1998.274.3.C688; Nelson WJ, 2004, NAT CELL BIOL, V6, P282, DOI 10.1038/ncb0404-282; Nelson WJ, 2001, TRENDS CELL BIOL, V11, P483, DOI 10.1016/S0962-8924(01)02145-6; Nguyen NV, 2004, GASTROENTEROLOGY, V127, P145, DOI 10.1053/j.gastro.2004.04.016; NOGUCHI S, 1992, BIOCHEM BIOPH RES CO, V182, P659, DOI 10.1016/0006-291X(92)91783-M; OJAKIAN GK, 1981, CELL, V23, P95, DOI 10.1016/0092-8674(81)90274-9; Polishchuk R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/ncb1109; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; Rodriguez-Boulan E, 2004, CURR OPIN CELL BIOL, V16, P436, DOI 10.1016/j.ceb.2004.06.013; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SMOLKA A, 1983, AM J PHYSIOL, V245, P589; Sugimoto H, 2002, MOL BIOL CELL, V13, P2374, DOI 10.1091/mbc.E01-10-0096; URUSHIDANI T, 1987, AM J PHYSIOL, V252, pG458, DOI 10.1152/ajpgi.1987.252.4.G458; Vagin O, 2004, J BIOL CHEM, V279, P39026, DOI 10.1074/jbc.M405453200; Vagin O, 2003, AM J PHYSIOL-CELL PH, V285, pC968, DOI 10.1152/ajpcell.00068.2003	38	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14741	14754		10.1074/jbc.M412657200	http://dx.doi.org/10.1074/jbc.M412657200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15695513	hybrid			2022-12-25	WOS:000228236800051
J	Barsotti, C; Pesi, R; Giannecchini, M; Ipata, PL				Barsotti, C; Pesi, R; Giannecchini, M; Ipata, PL			Evidence for the involvement of cytosolic 5 '-nucleotidase (cN-II) in the synthesis of guanine nucleotides from xanthosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE-EXTRACTS; RAT-BRAIN; MYCOPHENOLIC-ACID; XANTHINE; PURINE; SALVAGE; ADENOSINE; INOSINE; CLONING; ENZYME	In this paper, we show that in vitro xanthosine does not enter any of the pathways known to salvage the other three main natural purine nucleosides: guanosine; inosine; and adenosine. In rat brain extracts and in intact LoVo cells, xanthosine is salvaged to XMP via the phosphotransferase activity of cytosolic 5'-nucleotidase. IMP is the preferred phosphate donor (IMP + xanthosine -> XMP + inosine). XMP is not further phosphorylated. However, in the presence of glutamine, it is readily converted to guanyl compounds. Thus, phosphorylation of xanthosine by cytosolic 5'-nucleotidase circumvents the activity of IMP dehydrogenase, a rate-limiting enzyme, catalyzing the NAD(+)-dependent conversion of IMP to XMP at the branch point of de novo nucleotide synthesis, thus leading to the generation of guanine nucleotides. Mycophenolic acid, an inhibitor of IMP dehydrogenase, inhibits the guanyl compound synthesis via the IMP dehydrogenase pathway but has no effect on the cytosolic 5'-nucleotidase pathway of guanine nucleotides synthesis. We propose that the latter pathway might contribute to the reversal of the in vitro antiproliferative effect exerted by IMP dehydrogenase inhibitors routinely seen with repletion of the guanine nucleotide pools.	Univ Pisa, Dept Physiol & Biochem, I-56127 Pisa, Italy	University of Pisa	Ipata, PL (corresponding author), Univ Pisa, Dept Physiol & Biochem, Via San Zeno 51, I-56127 Pisa, Italy.	ipata@dfb.unipi.it	Pesi, Rossana/AAQ-3102-2020	Pesi, Rossana/0000-0003-4785-7282				Allegrini S, 1997, BIOCHEM J, V328, P483, DOI 10.1042/bj3280483; ALLSOP J, 1984, ADV EXP MED BIOL, V165, P21; Barsotti C, 2004, INT J BIOCHEM CELL B, V36, P2214, DOI 10.1016/j.biocel.2004.04.015; Barsotti C, 2003, CELL MOL LIFE SCI, V60, P786, DOI 10.1007/s00018-003-2371-x; Barsotti C, 2002, J BIOL CHEM, V277, P9865, DOI 10.1074/jbc.M111418200; BERGER SJ, 1985, J NEUROCHEM, V44, P1736, DOI 10.1111/j.1471-4159.1985.tb07162.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cappiello M, 1998, BBA-GEN SUBJECTS, V1425, P273, DOI 10.1016/S0304-4165(98)00071-3; CHABNER BA, 1995, CANC CHEMOTHERAPY BI, P235; EUGUI EM, 1991, SCAND J IMMUNOL, V33, P161, DOI 10.1111/j.1365-3083.1991.tb03746.x; EUGUI EM, 1991, TRANSPLANT P, V23, P15; Gille A, 2003, J BIOL CHEM, V278, P7822, DOI 10.1074/jbc.M210162200; Giorgelli F, 1997, BBA-GEN SUBJECTS, V1335, P16, DOI 10.1016/S0304-4165(96)00117-1; Jardim A, 1999, J BIOL CHEM, V274, P34403, DOI 10.1074/jbc.274.48.34403; Latini S, 2001, J NEUROCHEM, V79, P463, DOI 10.1046/j.1471-4159.2001.00607.x; Liu HY, 2002, BIOCHEM PHARMACOL, V64, P583, DOI 10.1016/S0006-2952(02)01251-0; MARKLEY HG, 1973, BIOCHIM BIOPHYS ACTA, V309, P23, DOI 10.1016/0005-2744(73)90313-6; MOMPARLER RL, 1968, J BIOL CHEM, V243, P4298; MURRAY AW, 1971, ANNU REV BIOCHEM, V40, P811, DOI 10.1146/annurev.bi.40.070171.004115; Niwa T, 1998, KIDNEY INT, V53, P1801, DOI 10.1046/j.1523-1755.1998.00944.x; Paletzki RF, 2002, NEUROSCIENCE, V109, P15, DOI 10.1016/S0306-4522(01)00352-9; Pankiewicz KW, 2004, CURR MED CHEM, V11, P887, DOI 10.2174/0929867043455648; PESI R, 1994, ARCH BIOCHEM BIOPHYS, V312, P75, DOI 10.1006/abbi.1994.1282; Pesi R, 1996, BBA-PROTEIN STRUCT M, V1294, P191, DOI 10.1016/0167-4838(96)00021-0; Phillis JW, 1996, J NEUROCHEM, V67, P1525; Seifert R, 1999, MOL PHARMACOL, V56, P348, DOI 10.1124/mol.56.2.348; STONE TW, 1991, PURINES BASIC CLIN A, P8; Stoychev G, 2002, EUR J BIOCHEM, V269, P4048, DOI 10.1046/j.1432-1033.2002.03097.x; Torrecilla A, 2001, J NEUROCHEM, V76, P1291, DOI 10.1046/j.1471-4159.2001.00084.x; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; TURRIANI M, 1994, J BIOCHEM TOXICOL, V9, P51, DOI 10.1002/jbt.2570090108; YAMADA Y, 1980, BIOCHIM BIOPHYS ACTA, V616, P199, DOI 10.1016/0005-2744(80)90138-2; Zimmermann AG, 1998, PROG NUCLEIC ACID RE, V61, P181, DOI 10.1016/S0079-6603(08)60827-2	33	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13465	13469		10.1074/jbc.M413347200	http://dx.doi.org/10.1074/jbc.M413347200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15699053	hybrid			2022-12-25	WOS:000228095500035
J	Zou, Z; Jiang, HB				Zou, Z; Jiang, HB			Manduca sexta serpin-6 regulates immune serine proteinases PAP-3 and HP8 - cDNA cloning, protein expression, inhibition kinetics, and function elucidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-PHENOL-OXIDASE; PROPHENOLOXIDASE-ACTIVATING PROTEINASE-3; GENOME-WIDE ANALYSIS; TOBACCO HORNWORM; BOMBYX-MORI; DROSOPHILA; HEMOLYMPH; INSECT; PURIFICATION; BACTERIA	Analogous to blood coagulation and complement activation in mammals, some insect defense responses (e.g. prophenoloxidase (proPO) activation and Toll pathway initiation) are mediated by serine proteinase cascades and regulated by serpins in hemolymph. We recently isolated Manduca sexta serpin-6 from hemolymph of the bacteria-challenged larvae, which selectively inhibited proPO-activating proteinase-3 (PAP-3) (Wang, Y., and Jiang, H. (2004) Insect Biochem. Mol. Biol. 34, 387-395). To further characterize its structure and function, we cloned serpin-6 from an induced fat body cDNA library using a PCR-derived probe. M. sexta serpin-6 is 55% similar in amino acid sequence to Drosophila melanogaster serpin-5, an immune-responsive protein. We produced serpin-6 in an Escherichia coli expression system and purified the soluble protein by nickel affinity and hydrophobic interaction chromatography. The recombinant protein specifically inhibited PAP-3 and blocked proPO activation in vitro in a concentration-dependent manner. Matrix-assisted laser desorption ionization-time of flight mass spectrometry indicated that the cleavage site of serpin-6 is between Arg(373) and Ser(374). Serpin-6 is constitutively present in hemolymph of naive larvae, and its mRNA and protein levels significantly increase after a bacterial injection. The association rate constant of serpin-6 and PAP-3 is 2.6 x 10(4) M-1 s(-1), indicating that serpin-6 may contribute to the inhibitory regulation of PAP-3 in the hemolymph. We also identified the covalent complex of serpin-6 and PAP-3 in induced hemolymph by immunoaffinity chromatography and mass spectrometry. Furthermore, immulectin-2, serine proteinase homologs, proPO, PO, attacin-2, and a complex of serpin-6 and hemolymph proteinase-8 were also detected in the proteins eluted from the immunoaffinity column using serpin-6 antibody. These results suggest that serpin-6 plays important roles in the regulation of immune proteinases in the hemolymph.	Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Jiang, HB (corresponding author), Oklahoma State Univ, Dept Entomol & Plant Pathol, 127 Noble Res Ctr, Stillwater, OK 74078 USA.	haobo@okstate.edu	zou, zhen/C-6134-2016; Jiang, Haobo/A-6519-2008	zou, zhen/0000-0003-3550-7656; Jiang, Haobo/0000-0003-1357-1315	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058634] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058634, R01 GM058634-07A1, GM58634] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ASHIDA M, 1990, MOLTING METAMORPHOSI, P237; Ashida Masaaki, 1998, P135; Askew DJ, 2004, GENOMICS, V84, P166, DOI 10.1016/j.ygeno.2004.01.014; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Cerenius L, 2004, IMMUNOL REV, V198, P116, DOI 10.1111/j.0105-2896.2004.00116.x; Cherqui A, 2001, INSECT BIOCHEM MOLEC, V31, P761, DOI 10.1016/S0965-1748(00)00172-7; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; De Gregorio E, 2001, P NATL ACAD SCI USA, V98, P12590, DOI 10.1073/pnas.221458698; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; DUNN PE, 1983, J INVERTEBR PATHOL, V41, P77, DOI 10.1016/0022-2011(83)90238-0; Gan H, 2001, INSECT BIOCHEM MOLEC, V31, P887, DOI 10.1016/S0965-1748(01)00034-0; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Irving P, 2001, P NATL ACAD SCI USA, V98, P15119, DOI 10.1073/pnas.261573998; Iwanaga S, 1998, J BIOCHEM, V123, P1; Ji CY, 2004, J BIOL CHEM, V279, P34101, DOI 10.1074/jbc.M404584200; JIANG HB, 1994, J BIOL CHEM, V269, P55; Jiang HB, 2003, INSECT BIOCHEM MOLEC, V33, P1049, DOI 10.1016/S0965-1748(03)00123-1; Jiang HB, 2003, J BIOL CHEM, V278, P3552, DOI 10.1074/jbc.M205743200; Jiang HB, 1996, J BIOL CHEM, V271, P28017, DOI 10.1074/jbc.271.45.28017; Jiang HB, 2000, INSECT BIOCHEM MOLEC, V30, P95, DOI 10.1016/S0965-1748(99)00113-7; Jiang HB, 1997, INSECT BIOCHEM MOLEC, V27, P835, DOI 10.1016/S0965-1748(97)00066-0; Jiang HB, 1997, J BIOL CHEM, V272, P1082, DOI 10.1074/jbc.272.2.1082; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; KANOST MR, 1989, J BIOL CHEM, V264, P965; Kanost MR, 1999, DEV COMP IMMUNOL, V23, P291, DOI 10.1016/S0145-305X(99)00012-9; KANOST MR, 1990, INSECT BIOCHEM, V20, P141, DOI 10.1016/0020-1790(90)90006-G; Kenneth KR, 1998, J BIOL CHEM, V273, P20802, DOI 10.1074/jbc.273.33.20802; Kim YD, 2002, LANGMUIR, V18, P3999, DOI 10.1021/la0117799; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Nappi AJ, 2001, ADV EXP MED BIOL, V484, P329; Park DS, 2000, MOL CELLS, V10, P186, DOI 10.1007/s10059-000-0186-2; SASAKI T, 1991, EUR J BIOCHEM, V202, P255, DOI 10.1111/j.1432-1033.1991.tb16370.x; SASAKI T, 1984, J BIOCHEM-TOKYO, V95, P1009, DOI 10.1093/oxfordjournals.jbchem.a134688; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Wang Y, 2004, INSECT BIOCHEM MOLEC, V34, P731, DOI 10.1016/j.ibmb.2004.03.008; Wang Y, 2004, INSECT BIOCHEM MOLEC, V34, P387, DOI 10.1016/j.ibmb.2003.12.005; Wang Y, 2001, PROTEIN EXPRES PURIF, V23, P328, DOI 10.1006/prep.2001.1517; Yu XQ, 2003, INSECT BIOCHEM MOLEC, V33, P197, DOI 10.1016/S0965-1748(02)00191-1; Yu XQ, 2000, J BIOL CHEM, V275, P37373, DOI 10.1074/jbc.M003021200; Zhu YF, 2003, J BIOL CHEM, V278, P46556, DOI 10.1074/jbc.M309682200	46	88	103	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14341	14348		10.1074/jbc.M500570200	http://dx.doi.org/10.1074/jbc.M500570200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15691825	Green Accepted, hybrid			2022-12-25	WOS:000228095500139
J	O Flowers, L; Subramaniam, PS; Johnson, HM				O Flowers, L; Subramaniam, PS; Johnson, HM			A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; SOCS-1; IL-6; STAT3; complementary peptide	EPIDERMAL-GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; ANDROGEN RECEPTOR; JAK/STAT PATHWAY; GENE-EXPRESSION; CARCINOMA-CELLS; CYCLIN D1; INTERLEUKIN-6; PROGRESSION; LINES	Prostate cancer is the second highest cause of cancer-related deaths of men in the US. Signal transducers and activators of transcription ( STATs) proteins are a small family of latent cytoplasmic transcription factors that act downstream of Janus kinase ( JAK) activation and mediate intracellular signaling from a wide variety of cytokines, growth factors, and hormones. Aberrant activation of STAT3 has been implicated in the progression of many human carcinomas, including prostate cancer. Previously, we have characterized a novel tyrosine kinase inhibitor peptide, Tkip, that is a mimetic of suppressor of cytokine signaling 1 (SOCS-1). Similar to SOCS-1, Tkip binds to the autophosphorylation site of JAK2 and inhibits phosphorylation of STAT1 alpha. In this study, we determined the inhibitory effects of Tkip on the human prostate cancer cell lines DU145 and LNCaP. Tkip inhibited cellular proliferation of both DU145 and LNCaP cells, with a slightly greater antiproliferative effect on DU145 cells. Cell cycle analysis using flow cytometry showed Tkip blockage of progression into the S phase of the cell cycle. Tkip also inhibited constitutive (DU145) and IL-6-induced (LNCaP) activation of STAT3, consistent with the fact that STAT3 activation is mediated by JAK2. Tkip also slightly reduced the levels of cyclin D1, an important regulator of cell cycle progression into S phase, in DU145 and LNCaP cancer cell lines. These data describe a potentially important therapeutic that targets both constitutive and IL-6-induced STAT3 activation in human prostate cancer cell lines.	Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA; Florida Atlantic Univ, Scripps Res Inst, Biomed Sci Ctr, Boca Raton, FL 33431 USA	State University System of Florida; University of Florida; Scripps Research Institute; State University System of Florida; Florida Atlantic University	Johnson, HM (corresponding author), Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA.	johnsonh@ufl.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056152, R56AI056152] Funding Source: NIH RePORTER; NIAID NIH HHS [AI56152] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Barton BE, 2004, MOL CANCER THER, V3, P11; Becker S, 1998, FEBS LETT, V441, P141, DOI 10.1016/S0014-5793(98)01543-9; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Chen TS, 2000, CANCER RES, V60, P2132; Chim CS, 2004, BLOOD, V103, P4630, DOI 10.1182/blood-2003-06-2007; Chung TDK, 1999, PROSTATE, V38, P199; Crawford ED, 2003, UROLOGY, V62, P3, DOI 10.1016/j.urology.2003.10.013; CULIG Z, 1994, CANCER RES, V54, P5474; de la Taille A, 2001, PROSTATE CANCER P D, V4, P204, DOI 10.1038/sj.pcan.4500534; Deutsch E, 2004, LANCET ONCOL, V5, P303, DOI 10.1016/S1470-2045(04)01468-8; Dhir R, 2002, PROSTATE, V51, P241, DOI 10.1002/pros.10079; Flowers LO, 2004, J IMMUNOL, V172, P7510, DOI 10.4049/jimmunol.172.12.7510; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Gregory CW, 2004, J BIOL CHEM, V279, P7119, DOI 10.1074/jbc.M307649200; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hobeika AC, 1998, INT J CANCER, V77, P138, DOI 10.1002/(SICI)1097-0215(19980703)77:1<138::AID-IJC21>3.0.CO;2-9; Hobisch A, 1998, CANCER RES, V58, P4640; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Larsen L, 2002, APMIS, V110, P833, DOI 10.1034/j.1600-0463.2002.1101201.x; Lorenzo Giuseppe Di, 2003, Clin Prostate Cancer, V2, P50; Mora LB, 2002, CANCER RES, V62, P6659; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Okamoto M, 1997, CANCER RES, V57, P141; Petre-Draviam CE, 2003, CANCER RES, V63, P4903; Ritchie CK, 1997, ENDOCRINOLOGY, V138, P1145, DOI 10.1210/en.138.3.1145; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sgambato A, 2004, J CELL PHYSIOL, V201, P97, DOI 10.1002/jcp.20045; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Szente BE, 1996, J INTERF CYTOK RES, V16, P813, DOI 10.1089/jir.1996.16.813; Thiam K, 1999, J MED CHEM, V42, P3732, DOI 10.1021/jm991025f; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Xia L, 2002, J BIOL CHEM, V277, P30716, DOI 10.1074/jbc.M202823200; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675	39	97	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2114	2120		10.1038/sj.onc.1208437	http://dx.doi.org/10.1038/sj.onc.1208437			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688010				2022-12-25	WOS:000227681900017
J	Wang, L; Atkinson, D; Small, DM				Wang, L; Atkinson, D; Small, DM			The interfacial properties of ApoA-I and an amphipathic alpha-helix consensus peptide of exchangeable apolipoproteins at the triolein/water interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; AIR-WATER-INTERFACE; LIPID-PROTEIN INTERACTIONS; A-I; OIL/WATER INTERFACES; SURFACE-ACTIVITIES; STRUCTURAL MODELS; DOMAIN-STRUCTURE; BINDING; PARTICLES	Apolipoprotein A-I (apoA-I) is the major protein in high density lipoprotein (HDL). During lipid metabolism, apoA-I moves among HDL and triacylglycerol-rich lipoproteins. The main structure and the major lipid binding motif of apoA-I is the amphipathic a-helix. To understand how apoA-I behaves at hydrophobic lipoprotein interfaces, the interfacial properties of apoA-I and an amphipathic a-helical consensus sequence peptide (CSP) were studied at the triolein/water (TO/W) interface. CSP ((PLAEELRARLRAQLEELRERLG)(2)-N-H-2) contains two 22-residue tandem repeat sequences that form amphipathic a-helices modeling the central part of apoA-I. ApoA-I or CSP added into the aqueous phase surrounding a triolein drop lowered the interfacial tension (gamma) of TO/W in a concentration- and time-dependent fashion. The gamma(TO/W) was lowered similar to16 millinewtons (mN)/m by apoA-I at 1.4 x 10(-6) m and similar to15 mN/m by CSP at 2.6 x 10(-6) M. At equilibrium gamma, both apoA-I and CSP desorbed from the interface when compressed and readsorbed when expanded. The maximum surface pressure CSP could withstand without being ejected (IIMAX) was 16 mN/m. The IIMAX of apoA-I was only 14.8 mN/m, but re-adsorption kinetics suggested that only part of the apoA-I desorbed at H between 14.8 and 19 mN/m. However, above similar to19 mN/m (IIOFF) the entire apoA-I molecule desorbed into the water. ApoA-I was more flexible at the TO/W interface than CSP and showed more elasticity at oscillation periods 4-128 s even at high compression, whereas CSP was elastic only at faster periods (4 and 8 s) and moderate compression. Flexibility and surface pressure-mediated desorption and re-adsorption of apoA-I probably provides lipoprotein stability during metabolic-remodeling reactions in plasma.	Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA	Boston University	Small, DM (corresponding author), Boston Univ, Sch Med, Dept Physiol & Biophys, 715 Albany St,W-302, Boston, MA 02118 USA.	dmsmall@bu.edu		Small, Donald/0000-0002-3072-243X; Atkinson, David/0000-0002-4796-7396	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL026335] Funding Source: NIH RePORTER; NHLBI NIH HHS [2P0-HL-26335-21] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATKINSON D, 1976, EUR J BIOCHEM, V64, P541, DOI 10.1111/j.1432-1033.1976.tb10334.x; ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P403; BENAMINS J, 1996, COLLOID SURFACE, V114, P245; BENAMINS J, 1998, PROTEINS LIQUID INTE, P341; Bolanos-Garcia VM, 2001, J PHYS CHEM B, V105, P5757, DOI 10.1021/jp010714b; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BROUILLETTE CG, 1984, BIOCHEMISTRY-US, V23, P359, DOI 10.1021/bi00297a027; Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; CHAO Y, 2002, THESIS BOSTON U SCH; Datta G, 2001, J LIPID RES, V42, P1096; FANG Y, 2003, BIOCHEMISTRY-US, V39, P15910; Fang YL, 2003, BIOCHEMISTRY-US, V42, P13260, DOI 10.1021/bi0354031; Gorshkova IN, 2002, BIOCHEMISTRY-US, V41, P10529, DOI 10.1021/bi025807d; Gursky O, 1996, P NATL ACAD SCI USA, V93, P2991, DOI 10.1073/pnas.93.7.2991; IBDAH JA, 1989, BIOCHEMISTRY-US, V28, P1126, DOI 10.1021/bi00429a029; IBDAH JA, 1988, BIOCHEMISTRY-US, V27, P7155, DOI 10.1021/bi00418a073; IBDAH JA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P300, DOI 10.1016/0005-2760(89)90077-5; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1989, J BIOL CHEM, V264, P4818; KREBS KE, 1988, BIOCHIM BIOPHYS ACTA, V959, P229, DOI 10.1016/0005-2760(88)90195-6; KREBS KE, 1983, BIOCHIM BIOPHYS ACTA, V751, P470, DOI 10.1016/0005-2760(83)90308-9; LABOURDENNE S, 1994, CHEM PHYS LIPIDS, V71, P163, DOI 10.1016/0009-3084(94)90068-X; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; PHILLIPS MC, 1986, METHOD ENZYMOL, V128, P387; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; POWNALL HJ, 1979, BIOCHEMISTRY-US, V18, P574, DOI 10.1021/bi00571a004; RITTER MC, 1977, J BIOL CHEM, V252, P1208; Saito H, 2004, PROG LIPID RES, V43, P350, DOI 10.1016/j.plipres.2004.05.002; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; SCANU AM, 1972, BIOCHIM BIOPHYS ACTA, V265, P471, DOI 10.1016/0304-4157(72)90006-8; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SEGREST JP, 1992, J LIPID RES, V33, P141; SHEN BW, 1980, BIOCHEMISTRY-US, V19, P3643, DOI 10.1021/bi00557a001; SMALL DH, 1992, ADV COLLOID INTERFAC, V41, P1, DOI 10.1016/0001-8686(92)80003-G; SMALL DM, 1992, CURRENT ISSUES ENDOC; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; TALL AR, 1977, J BIOL CHEM, V252, P4701; TALL AR, 1977, NATURE, V265, P163, DOI 10.1038/265163a0; TALL AR, 1975, P NATL ACAD SCI USA, V72, P4940, DOI 10.1073/pnas.72.12.4940; Wang LB, 2004, J LIPID RES, V45, P1704, DOI 10.1194/jlr.M400106-JLR200; Wang LB, 2003, J BIOL CHEM, V278, P37480, DOI 10.1074/jbc.M303133200; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; WEINBERG RB, 1992, J BIOL CHEM, V267, P8977; Weinberg RB, 2000, J LIPID RES, V41, P1419; WETTERAU JR, 1982, J BIOL CHEM, V257, P961; Zhu HL, 2004, BIOCHEMISTRY-US, V43, P13156, DOI 10.1021/bi0487894	51	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4154	4165		10.1074/bc.M411618200	http://dx.doi.org/10.1074/bc.M411618200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15695525	Bronze			2022-12-25	WOS:000227096600021
J	Ley, R; Hadfield, K; Howes, E; Cook, SJ				Ley, R; Hadfield, K; Howes, E; Cook, SJ			Identification of a DEF-type docking domain for extracellular signal-regulated kinases 1/2 that directs phosphorylation and turnover of the BH3-only protein Bim(EL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBER; BAX-DEPENDENT APOPTOSIS; PROAPOPTOTIC ACTIVITY; NEURONAL APOPTOSIS; BIM EXPRESSION; MAP KINASES; SITES; PROMOTES; ACTIVATION; PATHWAY	The BH3-only protein, Bim, exists as three splice variants (Bim(S), Bim(L), and Bim(EL)) of differing pro-apoptotic potency. Bim(EL), the least effective killer, is degraded by the proteasome in response to phosphorylation by extracellular signal-regulated kinases 1 and 2 (ERK1/2). ERK1/2-dependent phosphorylation correlates with the presence of a domain unique to the Bim(EL) splice variant that includes the major ERK1/2 phosphorylation site Ser(65). However, efficient phosphorylation by ERK1/2, c-Jun N-terminal kinase, or p38 requires the presence in the substrate of a discrete kinase-docking domain as well as the phosphoacceptor site. Here we show that the region unique to Bim(EL) (amino acids 41-97) harbors two potential DEF-type ERK1/2 kinase-docking domains, DEF1 and DEF2. Peptide competition assays revealed that the DEF2 peptide could act autonomously to bind active ERK1/2, whereas the DEF1 peptide did not. Truncation analysis identified a minimal region, residues 80-97, containing the DEF2 motif as sufficient for ERK1/2 binding. Mutation of key residues in the DEF2 motif abolished the interaction of ERK1/2 and Bim(EL) and also abolished ERK1/2-dependent phosphorylation of Bim(EL) in vivo, thereby stabilizing the protein and enhancing cytotoxicity. Our results identify a new physiologically relevant functional motif in Bim(EL) that may account for the distinct biological properties of this splice variant.	Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Ley, R (corresponding author), Babraham Inst, Mol Signalling Lab, Res Campus, Cambridge CB2 4AT, England.	becky.ley@bbsrc.ac.uk; simon.cook@bbsrc.ac.uk			Biotechnology and Biological Sciences Research Council [BBS/E/B/0000C199, BBS/E/B/0000H151] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Becker EBE, 2004, J NEUROSCI, V24, P8762, DOI 10.1523/JNEUROSCI.2953-04.2004; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; Marani M, 2004, ONCOGENE, V23, P2431, DOI 10.1038/sj.onc.1207364; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Seward RJ, 2003, MOL IMMUNOL, V39, P983, DOI 10.1016/S0161-5890(03)00047-6; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2	32	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17657	17663		10.1074/jbc.M412342200	http://dx.doi.org/10.1074/jbc.M412342200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728578	hybrid			2022-12-25	WOS:000228807200013
J	Schilling, O; Spath, B; Kostelecky, B; Marchfelder, A; Meyer-Klaucke, W; Vogel, A				Schilling, O; Spath, B; Kostelecky, B; Marchfelder, A; Meyer-Klaucke, W; Vogel, A			Exosite modules guide substrate recognition in the ZiPD/ElaC protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER SUSCEPTIBILITY GENE; METALLO-BETA-LACTAMASE; TRANSFER-RNA; CRYSTAL-STRUCTURE; END MATURATION; CCA; MITOCHONDRIAL; REVEALS; ENCODES; NUCLEAR	Escherichia coli ZiPD is the best characterized protein encoded by the elaC gene family and is a model for the 3'-pre-tRNA processing endoribonucleases ( tRNase Z). A metal ligand-based sequence alignment of ZiPD with metallo-beta-lactamase domain proteins of known crystallographic structure identifies a ZiPD-specific sequence insertion of similar to 50 residues, which we will refer to as the ZiPD exosite. Functionally characterized ZiPD homologs from Bacillus subtilis, Methanococcus janaschii, and human share the presence of the ZiPD exosite, which is also present in the amino-terminal, but not in the carboxyl-terminal, domain of ElaC2 proteins. Another class of functionally characterized tRNase Z enzymes from Thermotoga maritima and Arabidopsis thaliana lack characteristic motifs in the exosite but possess a sequence segment with clustered basic amino acid residues. As an experimental attempt to investigate the function of the exosite we constructed a ZiPD variant that lacks this module (ZiPD Delta). ZiPD Delta has almost wild-type-like catalytic properties for hydrolysis of the small, chromogenic substrate bis(p-nitrophenyl) phosphate. Removal of the ZiPD exosite only affects k(cat), which is reduced by less than 40%, whereas both K' and the Hill coefficient ( measures of the substrate affinity and cooperativity, respectively) remain unchanged. Hence, the exosite is not required for the intrinsic phosphodiesterase activity of ZiPD. Removal of the exosite also does not affect the dimerization properties of ZiPD. In contrast to the wild-type enzyme, ZiPD Delta does not process pre-tRNA, and gel shift assays demonstrate that only the wild-type enzyme, but not ZiPD Delta, binds mature tRNA. These findings show that the exosite is essential for pre-tRNA recognition. In conclusion, we identify a ZiPD exosite that guides physiological substrate recognition in the ZiPD/ElaC protein family.	European Mol Biol Lab, Outstn Hamburg, D-22603 Hamburg, Germany; Univ Ulm, D-89069 Ulm, Germany	European Molecular Biology Laboratory (EMBL); Ulm University	Vogel, A (corresponding author), Max Planck Inst Kohlenforsch, Kaiser Wilhelm Pl 1, D-45470 Mulheim An Der Ruhr, Germany.	vogel@mpi-muelheim.mpg.de	Schilling, O/AAC-8302-2019; Meyer-Klaucke, Wolfram/G-1148-2010	Marchfelder, Anita/0000-0002-1382-1794; Schilling, Oliver/0000-0001-7678-7653				Aravind L, 1999, In Silico Biol, V1, P69; Cameron AD, 1999, STRUCTURE, V7, P1067, DOI 10.1016/S0969-2126(99)80174-9; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Dubrovsky EB, 2004, NUCLEIC ACIDS RES, V32, P255, DOI 10.1093/nar/gkh182; Frazao C, 2000, NAT STRUCT BIOL, V7, P1041; Kunzmann A, 1998, P NATL ACAD SCI USA, V95, P108, DOI 10.1073/pnas.95.1.108; Mayer M, 2000, BIOCHEMISTRY-US, V39, P2096, DOI 10.1021/bi992253e; Minagawa A, 2004, J BIOL CHEM, V279, P15688, DOI 10.1074/jbc.M313951200; Mohan A, 1999, RNA, V5, P245, DOI 10.1017/S1355838299981256; Morl M, 2001, EMBO REP, V2, P17, DOI 10.1093/embo-reports/kve006; Overall CM, 2000, METH MOL B, V151, P79, DOI 10.1385/1-59259-046-2:079; Pellegrini O, 2003, EMBO J, V22, P4534, DOI 10.1093/emboj/cdg435; Schierling K, 2002, J MOL BIOL, V316, P895, DOI 10.1006/jmbi.2001.5395; Schiffer S, 2003, BIOL CHEM, V384, P333, DOI 10.1515/BC.2003.039; Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769; Schiffer S, 2005, HANDBOOK OF RNA BIOCHEMISTRY, P667; Schilling O, 2005, BIOCHEM J, V385, P145, DOI 10.1042/BJ20040773; Schilling O, 2004, BIOCHEM BIOPH RES CO, V320, P1365, DOI 10.1016/j.bbrc.2004.05.227; Smith MM, 2004, DEV BIOL, V266, P151, DOI 10.1016/j.ydbio.2003.10.016; Takaku H, 2004, NUCLEIC ACIDS RES, V32, P4429, DOI 10.1093/nar/gkh774; Takaku H, 2003, NUCLEIC ACIDS RES, V31, P2272, DOI 10.1093/nar/gkg337; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Vogel A, 2004, BIOCHEMISTRY-US, V43, P10379, DOI 10.1021/bi049703+; Vogel A, 2002, J BIOL CHEM, V277, P29078, DOI 10.1074/jbc.M112047200	25	43	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17857	17862		10.1074/jbc.M500591200	http://dx.doi.org/10.1074/jbc.M500591200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15699034	hybrid			2022-12-25	WOS:000228807200038
J	Cha, B; Kim, JH; Hut, H; Hogema, BM; Nadarja, J; Zizak, M; Cavet, M; Lee-Kwon, W; Lohmann, SM; Smolenski, A; Tse, CM; Yun, C; de Jonge, HR; Donowitz, M				Cha, B; Kim, JH; Hut, H; Hogema, BM; Nadarja, J; Zizak, M; Cavet, M; Lee-Kwon, W; Lohmann, SM; Smolenski, A; Tse, CM; Yun, C; de Jonge, HR; Donowitz, M			cGMP inhibition of Na+/H+ antiporter 3 (NHE3) requires PDZ domain adapter NHERF2, a broad specificity protein kinase G-anchoring protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-MEDIATED INHIBITION; EXCHANGER REGULATORY FACTOR; BETA(2)-ADRENERGIC RECEPTOR; CA2+-DEPENDENT INHIBITION; MYOSIN PHOSPHATASE; PROXIMAL TUBULE; BINDING; LOCALIZATION; INTERACTS; COMPLEX	Electroneutral NaCl absorption mediated by Na+/H+ exchanger 3 (NHE3) is important in intestinal and renal functions related to water/Na+ homeostasis. cGMP inhibits NHE3 in intact epithelia. However, unexpectedly it failed to inhibit NHE3 stably transfected in PS120 cells, even upon co-expression of cGMP-dependent protein kinase type II (cGKII). Additional co-expression of NHERF2, the tandem PDZ domain adapter protein involved in cAMP inhibition of NHE3, restored cGMP as well as cAMP inhibition, whereas NHERF1 solely restored cAMP inhibition. In vitro conditions were identified in which NHERF2 but not NHERF1 bound cGKII. The NHERF2 PDZ2 C terminus, which binds NHE3, also bound cGKII. A non-myristoylated mutant of cGKII did not support cGMP inhibition of NHE3. Although cGKI also bound NHERF2 in vitro, it did not evoke inhibition of NHE3 unless a myristoylation site was added. These results show that NHERF2, acting as a novel protein kinase G-anchoring protein, is required for cGMP inhibition of NHE3 and that cGKII must be bound both to the plasma membrane by its myristoyl anchor and to NHERF2 to inhibit NHE3.	Johns Hopkins Univ, Sch Med, Dept Physiol, GI Div, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, GI Div, Baltimore, MD 21205 USA; Erasmus Univ, Med Ctr, Dept Biochem, NL-3000 DR Rotterdam, Netherlands; Univ Zagreb, Sch Med, Dept Physiol, Zagreb 41001, Croatia; Univ Med Clin, Dept Clin Biochem, D-97080 Wurzburg, Germany	Johns Hopkins University; Johns Hopkins University; Erasmus University Rotterdam; Erasmus MC; University of Zagreb; University of Wurzburg	Donowitz, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, GI Div, 925 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mdonowit@jhmi.edu		Smolenski, Albert/0000-0001-9210-9406	NCI NIH HHS [R01-CA85428] Funding Source: Medline; NIDDK NIH HHS [P01-DK44484, R01-DK51116, R01-DK61765, R24-DK64388, T32-DK07632, R01-DK26523] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061765, R24DK064388, T32DK007632, R01DK051116, P01DK044484, R01DK026523] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Airhart N, 2003, J BIOL CHEM, V278, P38693, DOI 10.1074/jbc.M304098200; Ammendola A, 2001, J BIOL CHEM, V276, P24153, DOI 10.1074/jbc.M101530200; Bacic D, 2003, KIDNEY INT, V64, P2133, DOI 10.1046/j.1523-1755.2003.00308.x; Casteel DE, 2002, J BIOL CHEM, V277, P32003, DOI 10.1074/jbc.M112332200; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; Hoenderop JGJ, 1999, P NATL ACAD SCI USA, V96, P6084, DOI 10.1073/pnas.96.11.6084; Hu MC, 2001, J BIOL CHEM, V276, P26906, DOI 10.1074/jbc.M011338200; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; Jin XH, 1999, J CLIN INVEST, V103, P167, DOI 10.1172/JCI4327; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kang YJ, 2004, CELL SIGNAL, V16, P791, DOI 10.1016/j.cellsig.2003.12.003; Kim JH, 2002, J BIOL CHEM, V277, P23714, DOI 10.1074/jbc.M200835200; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Lee-Kwon W, 2003, AM J PHYSIOL-CELL PH, V285, pC1527, DOI 10.1152/ajpcell.00017.2003; Lee-Kwon W, 2003, J BIOL CHEM, V278, P16494, DOI 10.1074/jbc.M300580200; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; Li XH, 2004, J PHYSIOL-LONDON, V556, P791, DOI 10.1113/jphysiol.2004.060921; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Oh YS, 2004, MOL CELL BIOL, V24, P5069, DOI 10.1128/MCB.24.11.5069-5079.2004; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Shenolikar S, 2002, P NATL ACAD SCI USA, V99, P11470, DOI 10.1073/pnas.162232699; Suh PG, 2001, BIOCHEM BIOPH RES CO, V288, P1, DOI 10.1006/bbrc.2001.5710; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Vaandrager AB, 2000, GASTROENTEROLOGY, V118, P108, DOI 10.1016/S0016-5085(00)70419-7; Vaandrager AB, 1997, GASTROENTEROLOGY, V112, P437, DOI 10.1053/gast.1997.v112.pm9024297; Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025; Vaandrager AB, 2002, MOL CELL BIOCHEM, V230, P73, DOI 10.1023/A:1014231722696; Vo NK, 1998, BIOCHEM BIOPH RES CO, V246, P831, DOI 10.1006/bbrc.1998.8722; Wade JB, 2003, AM J PHYSIOL-CELL PH, V285, pC1494, DOI 10.1152/ajpcell.00092.2003; Weinman EJ, 2003, FEBS LETT, V536, P141, DOI 10.1016/S0014-5793(03)00043-7; Weinman EJ, 2001, AM J PHYSIOL-RENAL, V281, pF374, DOI 10.1152/ajprenal.2001.281.2.F374; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; Yuasa K, 2000, J BIOL CHEM, V275, P4897, DOI 10.1074/jbc.275.7.4897; Yun CC, 2002, J BIOL CHEM, V277, P7676, DOI 10.1074/jbc.M107768200; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zachos NC, 2005, ANNU REV PHYSIOL, V67, P411, DOI 10.1146/annurev.physiol.67.031103.153004; Zizak M, 1999, J BIOL CHEM, V274, P24753, DOI 10.1074/jbc.274.35.24753	45	75	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16642	16650		10.1074/jbc.M500505200	http://dx.doi.org/10.1074/jbc.M500505200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722341	hybrid			2022-12-25	WOS:000228615500015
J	Korcok, J; Raimundo, LN; Du, XB; Sims, SM; Dixon, SJ				Korcok, J; Raimundo, LN; Du, XB; Sims, SM; Dixon, SJ			P2Y6 nucleotide receptors activate NF-kappa B and increase survival of osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATE; NUCLEAR TRANSLOCATION; INDUCED APOPTOSIS; BONE-RESORPTION; NERVOUS-SYSTEM; MICE LACKING; CELLS; P2Y(6); ATP; EXPRESSION	Nucleotides, released from cells during inflammation and by mechanical stimulation, act through the P2 family of nucleotide receptors. Previous studies have demonstrated the expression of P2Y1 and P2Y2 receptors in osteoclasts. The aim of this study was to determine whether osteoclast P2Y receptors signal through NF-kappa B, a key transcription factor regulating osteoclastogenesis. Immunofluorescence was used to detect the p65 subunit of NF-kappa B, which upon activation translocates from the cytosol to nuclei. Low levels of NF-kappa B activation were observed in untreated rabbit osteoclasts and in those exposed to 2-methylthio ADP ( P2Y1 agonist) or ATP or UTP ( P2Y2 agonists). In contrast, UDP or INS48823 (P2Y6 agonists) induced a significant increase in the number of cells exhibiting NF-kappa B activation, a process sensitive to the proteasome inhibitor lactacystin. In osteoclasts purified by micromanipulation, reverse transcription-PCR revealed the presence of P2Y1, P2Y2, and P2Y6 receptor transcripts, and application of agonists for these receptors induced the transient rise of cytosolic calcium. Treatment of rat osteoclasts with UDP or INS48823, but not 2-methylthio ADP or UTP, increased osteoclast survival. Osteoprotegerin ( a decoy receptor for RANK ligand) did not significantly alter the effects of UDP on NF-kappa B localization or osteoclast survival, consistent with a direct action. Moreover, SN50 (cell-permeable peptide inhibitor of NF-kappa B) suppressed the enhancement of cell survival induced by UDP and INS48823. Our findings demonstrate the presence of functional P2Y6 receptors in osteoclasts. Thus, nucleotides, following their release at sites of inflammation and mechanical stimulation, can act through P2Y6 receptors to initiate NF-kappa B signaling and enhance osteoclast survival.	Univ Western Ontario, Canadian Inst Hlth, Res Grp Skeletal Dev & Remodeling, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; Univ Western Ontario, Div Oral Biol, Fac Med & Dent, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Dixon, SJ (corresponding author), Univ Western Ontario, Canadian Inst Hlth, Res Grp Skeletal Dev & Remodeling, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada.	jeff.dixon@fmd.uwo.ca	Sims, Stephen/G-4510-2013; Dixon, S. Jeffrey/G-3657-2013	Dixon, S. Jeffrey/0000-0001-9162-1686				BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BORN GVR, 1984, J PHYSIOL-LONDON, V354, P419, DOI 10.1113/jphysiol.1984.sp015385; Bowler WB, 2001, BONE, V28, P507, DOI 10.1016/S8756-3282(01)00430-6; Boyce BF, 1999, LAB INVEST, V79, P83; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Buckley KA, 2002, BONE, V31, P582, DOI 10.1016/S8756-3282(02)00877-3; Burnstock G, 2000, BRIT J ANAESTH, V84, P476, DOI 10.1093/oxfordjournals.bja.a013473; Chen BC, 2000, BRIT J PHARMACOL, V130, P777, DOI 10.1038/sj.bjp.0703375; Clohisy JC, 2003, J IMMUNOL, V171, P5547, DOI 10.4049/jimmunol.171.10.5547; Communi D, 1996, BIOCHEM BIOPH RES CO, V222, P303, DOI 10.1006/bbrc.1996.0739; Dixon SJ, 2000, DRUG DEVELOP RES, V49, P187, DOI 10.1002/(SICI)1098-2299(200003)49:3<187::AID-DDR9>3.0.CO;2-F; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; Hoebertz A, 2003, TRENDS PHARMACOL SCI, V24, P290, DOI 10.1016/S0165-6147(03)00123-8; Hoebertz A, 2001, FASEB J, V15, P1139, DOI 10.1096/fj.00-0395com; Hoebertz A, 2000, BONE, V27, P503, DOI 10.1016/S8756-3282(00)00351-3; Hou MY, 2002, AM J PHYSIOL-HEART C, V282, pH784, DOI 10.1152/ajpheart.00997.2000; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Jacobson KA, 2002, J MED CHEM, V45, P4057, DOI 10.1021/jm020046y; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003-0021; Kim SG, 2003, BIOCHEM PHARMACOL, V65, P923, DOI 10.1016/S0006-2952(02)01614-3; Kim SG, 2003, CELL MOL NEUROBIOL, V23, P401, DOI 10.1023/A:1023696806609; Komarova SV, 2003, J BIOL CHEM, V278, P8286, DOI 10.1074/jbc.M206421200; Korcok J, 2004, J BONE MINER RES, V19, P642, DOI 10.1359/JBMR.040108; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lazarowski ER, 1999, BRIT J PHARMACOL, V127, P1272, DOI 10.1038/sj.bjp.0702654; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Maier R, 1997, BIOCHEM BIOPH RES CO, V237, P297, DOI 10.1006/bbrc.1997.7135; Morrison MS, 1998, J PHYSIOL-LONDON, V511, P495, DOI 10.1111/j.1469-7793.1998.495bh.x; Naemsch LN, 1999, J CELL SCI, V112, P4425; Naemsch LN, 2001, J BIOL CHEM, V276, P39107, DOI 10.1074/jbc.M105881200; Parfitt AM, 1996, J BONE MINER RES, V11, P150; Pendergast W, 2001, BIOORG MED CHEM LETT, V11, P157, DOI 10.1016/S0960-894X(00)00612-0; Ralevic V, 1998, PHARMACOL REV, V50, P413; Weidema AF, 2001, AM J PHYSIOL-CELL PH, V280, pC1531, DOI 10.1152/ajpcell.2001.280.6.C1531; Ye RD, 2001, J LEUKOCYTE BIOL, V70, P839; You J, 2002, J BIOL CHEM, V277, P48724, DOI 10.1074/jbc.M209245200; Zimmermann H, 1998, NEUROCHEM INT, V32, P421, DOI 10.1016/S0197-0186(97)00126-5	42	84	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16909	16915		10.1074/jbc.M410764200	http://dx.doi.org/10.1074/jbc.M410764200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722352	hybrid			2022-12-25	WOS:000228615500045
J	Carroll, AM; Haines, LR; Pearson, TW; Fallon, PG; Walsh, CM; Brennan, CM; Breen, EP; Porter, RK				Carroll, AM; Haines, LR; Pearson, TW; Fallon, PG; Walsh, CM; Brennan, CM; Breen, EP; Porter, RK			Identification of a functioning mitochondrial uncoupling protein 1 in thymus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; PROTON CONDUCTANCE; NUCLEOTIDE-BINDING; SKELETAL-MUSCLE; EXPRESSION; ACID; MEMBRANE; GENE; LEAK; UCP1	We present evidence that rat and mouse thymi contain mitochondrial uncoupling protein (UCP 1). Reverse transcriptase-PCR detected RNA transcripts for UCP 1 in whole thymus and in thymocytes. Furthermore, using antibodies to UCP 1 the protein was also detected in mitochondria isolated from whole thymus and thymocytes but not in thymus mitochondria from UCP 1 knock-out mice. Evidence for functional UCP 1 in thymus mitochondria was obtained by a comparative analysis with the kinetics of GDP binding in mitochondria from brown adipose tissue. Both tissues showed equivalent B-max and K-D values. In addition, a large component of the nonphosphorylating oxygen consumption by thymus mitochondria was inhibited by GDP and subsequently stimulated by addition of nanomolar concentrations of palmitate. UCP 1 was purified from thymus mitochondria by hydroxyapatite chromatography. The isolated protein was identified by peptide mass mapping and tandem mass spectrometry by using MALDI-TOF and LC-MS/MS, respectively. We conclude that the thymus contains a functioning UCP 1 that has the capacity to regulate metabolic flux and production of reactive oxygen-containing molecules in the thymus.	Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	Trinity College Dublin; University of Victoria	Porter, RK (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland.	rkporter@tcd.ie	Fallon, Padraic/Y-2711-2019; Haines, Lee/K-9264-2017	Fallon, Padraic/0000-0002-8401-7293; Haines, Lee/0000-0001-8821-6479; Porter, Richard/0000-0001-9854-5161				BHATTACHARYA SK, 1991, ANAL BIOCHEM, V192, P344, DOI 10.1016/0003-2697(91)90546-6; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; BUTTGEREIT F, 1994, EUR J BIOCHEM, V223, P513, DOI 10.1111/j.1432-1033.1994.tb19020.x; Carroll AM, 2004, BBA-PROTEINS PROTEOM, V1700, P145, DOI 10.1016/j.bbapap.2004.05.008; Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; Cunningham O, 2003, BBA-BIOENERGETICS, V1604, P170, DOI 10.1016/S0005-2728(03)00057-4; Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412; Echtay KS, 2001, BIOCHEM SOC T, V29, P763; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Garlid KD, 2000, BBA-BIOENERGETICS, V1459, P383, DOI 10.1016/S0005-2728(00)00175-4; Gonzalez-Barroso MM, 1998, J BIOL CHEM, V273, P15528, DOI 10.1074/jbc.273.25.15528; HUANG SG, 1995, EUR J BIOCHEM, V229, P718, DOI 10.1111/j.1432-1033.1995.tb20519.x; Huang SG, 1996, BIOCHEMISTRY-US, V35, P16806, DOI 10.1021/bi960989v; Jaburek M, 2003, J BIOL CHEM, V278, P25825, DOI 10.1074/jbc.M302126200; Jekabsons MB, 2002, BIOCHEM J, V366, P565, DOI 10.1042/BJ20020469; KENDALL MD, 1991, BRAIN BEHAV IMMUN, V5, P9, DOI 10.1016/0889-1591(91)90004-T; KINTER M, 2000, PROTEIN SEQUENCING I, P147, DOI DOI 10.1002/0471721980; Klingenberg M, 1999, INT J OBESITY, V23, pS24, DOI 10.1038/sj.ijo.0800939; Krauss S, 2002, P NATL ACAD SCI USA, V99, P118, DOI 10.1073/pnas.012410699; LIN CS, 1980, FEBS LETT, V113, P299, DOI 10.1016/0014-5793(80)80613-2; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; NICHOLLS DG, 1976, EUR J BIOCHEM, V62, P223, DOI 10.1111/j.1432-1033.1976.tb10151.x; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NICHOLLS DG, 2004, BIOCHEM SOC T, V29, P751; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Porter RK, 2001, BBA-BIOENERGETICS, V1504, P120, DOI 10.1016/S0005-2728(00)00246-2; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; RICQUIER D, 1986, BROWN ADIPOSE TISSUE, P86; SCARPACE PJ, 1991, CAN J PHYSIOL PHARM, V69, P761, DOI 10.1139/y91-113; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; SUNDIN U, 1980, COMP BIOCHEM PHYS B, V65, P463, DOI 10.1016/0305-0491(80)90298-9; TOKUNAGA K, 1987, CANCER RES, V47, P5616; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199	39	57	59	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15534	15543		10.1074/jbc.M413315200	http://dx.doi.org/10.1074/jbc.M413315200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15695816	hybrid, Green Published			2022-12-25	WOS:000228444800011
J	Dadsetan, S; Shishkin, V; Fomina, AF				Dadsetan, S; Shishkin, V; Fomina, AF			Intracellular Ca2+ release triggers translocation of membrane marker FM1-43 from the extracellular leaflet of plasma membrane into endoplasmic reticulum in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; CELLS; FLUORESCENCE; TRAFFICKING; EXPRESSION; MECHANISM; TRANSPORT; GOLGI	Stimulation of T cell receptor in lymphocytes enhances Ca2+ signaling and accelerates membrane trafficking. The relationships between these processes are not well understood. We employed membrane-impermeable lipid marker FM1 - 43 to explore membrane trafficking upon mobilization of intracellular Ca2+ in Jurkat T cells. We established that liberation of intracellular Ca2+ with T cell receptor agonist phytohemagglutinin P or with Ca2+-mobilizing agents ionomycin or thapsigargin induced accumulation of FM1 - 43 within the lumen of the endoplasmic reticulum ( ER), nuclear envelope ( NE), and Golgi. FM1 - 43 loading into ER-NE and Golgi was not mediated via the cytosol because other organelles such as mitochondria and multivesicular bodies located in close proximity to the FM1-43-containing ER were free of dye. Intralumenal FM1 - 43 accumulation was observed even when Ca2+ signaling in the cytosol was abolished by the removal of extracellular Ca2+. Our findings strongly suggest that release of intracellular Ca2+ may create continuity between the extracellular leaflet of the plasma membrane and the lumenal membrane leaflet of the ER by a mechanism that does not require global cytosolic Ca2+ elevation.	Univ Calif Davis, Dept Physiol & Membrane Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Fomina, AF (corresponding author), Univ Calif Davis, Dept Physiol & Membrane Biol, 1 Shields Ave, Davis, CA 95616 USA.	affomina@ucdavis.edu						Bootman MD, 2002, CELL CALCIUM, V32, P231, DOI 10.1016/S0143416002002002; Chen SC, 2004, BLOOD, V104, P3233, DOI 10.1182/blood-2003-05-1679; Chow C W, 1995, New Horiz, V3, P342; Cochilla AJ, 1999, ANNU REV NEUROSCI, V22, P1, DOI 10.1146/annurev.neuro.22.1.1; Collins TJ, 2003, J EXP BIOL, V206, P1993, DOI 10.1242/jeb.00244; Cornelissen M, 2002, APOPTOSIS, V7, P41; DEERINCK TJ, 1994, J CELL BIOL, V126, P901, DOI 10.1083/jcb.126.4.901; Fomina AF, 2000, J CELL BIOL, V150, P1435, DOI 10.1083/jcb.150.6.1435; Fomina AF, 2003, EXP CELL RES, V291, P150, DOI 10.1016/S0014-4827(03)00372-0; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Geisler C, 2004, CRIT REV IMMUNOL, V24, P67; Gerasimenko OV, 1996, PFLUG ARCH EUR J PHY, V432, P1, DOI 10.1007/s004240050098; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Henkel AW, 1996, P NATL ACAD SCI USA, V93, P1918, DOI 10.1073/pnas.93.5.1918; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Levine T, 2004, TRENDS CELL BIOL, V14, P483, DOI 10.1016/j.tcb.2004.07.017; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Mattaj IW, 2004, NAT REV MOL CELL BIO, V5, P65, DOI 10.1038/nrm1263; Narayanan B, 2003, J BIOL CHEM, V278, P44188, DOI 10.1074/jbc.M306538200; Nishikawa S, 1996, J HISTOCHEM CYTOCHEM, V44, P733, DOI 10.1177/44.7.8675994; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; WELLER M, 1995, EXP CELL RES, V221, P395, DOI 10.1006/excr.1995.1390	23	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16377	16382		10.1074/jbc.M501202200	http://dx.doi.org/10.1074/jbc.M501202200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710604	hybrid			2022-12-25	WOS:000228444800110
J	Dolman, NJ; Gerasimenko, JV; Gerasimenko, OV; Voronina, SG; Petersen, OH; Tepikin, AV				Dolman, NJ; Gerasimenko, JV; Gerasimenko, OV; Voronina, SG; Petersen, OH; Tepikin, AV			Stable Golgi-mitochondria complexes and formation of Golgi Ca2+ gradients in pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; INOSITOL TRISPHOSPHATE; EXOCRINE CELLS; BREFELDIN-A; CALCIUM; TRANSPORT; SIGNALS; OSCILLATIONS; APPARATUS; STORES	We have determined the localization of the Golgi with respect to other organelles in living pancreatic acinar cells and the importance of this localization to the establishment of Ca2+ gradients over the Golgi. Using confocal microscopy and the Golgi- specific fluorescent probe 6-(( N-( 7- nitrobenz- 2- oxa- 1,3- diazol- 4- yl) amino) hexanoyl) sphingosine, we found Golgi structures localizing to the outer edge of the secretory granular region of individual acinar cells. We also assessed Golgi positioning in acinar cells located within intact pancreatic tissue using two- photon microscopy and found a similar localization. The mitochondria segregate the Golgi from lateral regions of the plasma membrane, the nucleus, and the basal part of the cytoplasm. The Golgi is therefore placed between the principal Ca2+ release sites in the apical region of the cell and the important Ca2+ sink formed by the peri- granular mitochondria. During acetylcholine-induced cytosolic Ca2+ signals in the apical region, large Ca2+ gradients form over the Golgi ( decreasing from trans- to cis- Golgi). We further describe a novel, close interaction of the peri- granular mitochondria and the Golgi apparatus. The mitochondria and the Golgi structures form very close contacts, and these contacts remain stable over time. When the cell is forced to swell, the Golgi and mitochondria remain juxtaposed up to the point of cell lysis. The strategic position of the Golgi ( closer to release sites than the bulk of the mitochondrial belt) makes this organelle receptive to local apical Ca2+ transients. In addition the Golgi is ideally placed to be preferentially supplied by ATP from adjacent mitochondria.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Tepikin, AV (corresponding author), Natl Inst Neurol Disorders & Stroke, Synapt Physiol Unit, NIH, Bldg 35,35 Convent Dr, Bethesda, MD 20892 USA.	a.tepikin@liv.ac.uk	Gerasimenko, Oleg/A-6622-2010; Gerasimenko, Julia/A-7688-2010; Petersen, Ole H/E-8708-2010	Gerasimenko, Oleg/0000-0003-2573-8258; Gerasimenko, Julia/0000-0002-2262-2543; Tepikin, Alexei/0000-0002-8172-7513				Ahluwalia JP, 2001, J BIOL CHEM, V276, P34148, DOI 10.1074/jbc.M105398200; Ashby MC, 2003, J BIOL CHEM, V278, P20860, DOI 10.1074/jbc.M302599200; Ashby MC, 2002, PHYSIOL REV, V82, P701, DOI 10.1152/physrev.00006.2002; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BOLENDER RP, 1974, J CELL BIOL, V61, P269, DOI 10.1083/jcb.61.2.269; Bruce JIE, 2004, J BIOL CHEM, V279, P12909, DOI 10.1074/jbc.M309070200; Collins TJ, 2003, J EXP BIOL, V206, P1993, DOI 10.1242/jeb.00244; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Csordas G, 2001, CELL CALCIUM, V29, P249, DOI 10.1054/ceca.2000.0191; Gerasimenko OV, 2002, CELL CALCIUM, V32, P261, DOI 10.1016/S0143416002001938; Gerasimenko OV, 1996, PFLUG ARCH EUR J PHY, V432, P1055, DOI 10.1007/s004240050234; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; IVESSA NE, 1995, J BIOL CHEM, V270, P25960, DOI 10.1074/jbc.270.43.25960; JAMIESON JD, 1971, J CELL BIOL, V50, P135, DOI 10.1083/jcb.50.1.135; Johnson PR, 2003, CELL TISSUE RES, V313, P37, DOI 10.1007/s00441-003-0741-1; Johnson PR, 2002, CELL CALCIUM, V32, P59, DOI 10.1016/S0143-4160(02)00091-X; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; Kiselyov K, 2003, CELL SIGNAL, V15, P243, DOI 10.1016/S0898-6568(02)00074-8; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MELDOLESI J, 1978, J CELL BIOL, V79, P156, DOI 10.1083/jcb.79.1.156; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; Nemoto T, 2001, NAT CELL BIOL, V3, P253, DOI 10.1038/35060042; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; Park MK, 2000, EMBO J, V19, P5729, DOI 10.1093/emboj/19.21.5729; Petersen OH, 1999, BIOESSAYS, V21, P851, DOI 10.1002/(SICI)1521-1878(199910)21:10<851::AID-BIES7>3.3.CO;2-6; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Porat A, 2000, J BIOL CHEM, V275, P29233, DOI 10.1074/jbc.M005316200; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Ribeiro CMP, 2003, J GEN PHYSIOL, V122, P377, DOI 10.1085/jgp.200308893; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; Skulachev VP, 2001, TRENDS BIOCHEM SCI, V26, P23, DOI 10.1016/S0968-0004(00)01735-7; Straub SV, 2000, J GEN PHYSIOL, V116, P547, DOI 10.1085/jgp.116.4.547; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Thomas DDH, 2004, AM J PHYSIOL-GASTR L, V287, pG253, DOI 10.1152/ajpgi.00033.2004; Thorn P, 2004, P NATL ACAD SCI USA, V101, P6774, DOI 10.1073/pnas.0400336101; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; Vanoevelen J, 2004, CELL CALCIUM, V35, P115, DOI 10.1016/j.ceca.2003.08.003; Voronina S, 2002, J PHYSIOL-LONDON, V539, P41, DOI 10.1113/jphysiol.2001.013134; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77	44	76	79	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15794	15799		10.1074/jbc.M412694200	http://dx.doi.org/10.1074/jbc.M412694200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722348	hybrid			2022-12-25	WOS:000228444800042
J	Mishra, R; Seckler, R; Bhat, R				Mishra, R; Seckler, R; Bhat, R			Efficient refolding of aggregation-prone citrate synthase by polyol osmolytes - How well are protein folding and stability aspects coupled?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREFERENTIAL HYDRATION; THERMAL-STABILITY; IN-VITRO; ARTIFICIAL CHAPERONE; DENATURED RHODANESE; ESCHERICHIA-COLI; WATER MIXTURES; CYTOCHROME-C; PIG-HEART; STABILIZATION	Efficient refolding of proteins and prevention of their aggregation during folding are of vital importance in recombinant protein production and in finding cures for several diseases. We have used citrate synthase ( CS) as a model to understand the mechanism of aggregation during refolding and its prevention using several known structure-stabilizing cosolvent additives of the polyol series. Interestingly, no parallel correlation between the folding effect and the general stabilizing effect exerted by polyols was observed. Although increasing concentrations of polyols increased protein stability in general, the refolding yields for CS decreased at higher polyol concentrations, with erythritol reducing the folding yields at all concentrations tested. Among the various polyols used, glycerol was the most effective in enhancing the CS refolding yield, and a complete recovery of enzymatic activity was obtained at 7 M glycerol and 10 mu g/ml protein, a result superior to the action of the molecular chaperones GroEL and GroES in vitro. A good correlation between the refolding yields and the suppression of protein aggregation by glycerol was observed, with no aggregation detected at 7 M. The polyols prevented the aggregation of CS depending on the number of hydroxyl groups in them. Stopped-flow fluorescence kinetics experiments suggested that polyols, including glycerol, act very early in the refolding process, as no fast and slow phases were detectable. The results conclusively demonstrate that both the thermodynamic and kinetic aspects are critical in the folding process and that all structure-stabilizing molecules need not always help in productive folding to the native state. These findings are important for the rational design of small molecules for efficient refolding of various aggregation-prone proteins of commercial and medical relevance.	Jawaharlal Nehru Univ, Ctr Biotechnol, New Delhi 110067, India; Univ Potsdam, D-14476 Golm, Germany	Jawaharlal Nehru University, New Delhi; University of Potsdam	Bhat, R (corresponding author), Jawaharlal Nehru Univ, Ctr Biotechnol, New Delhi 110067, India.	rajivbhat@mail.jnu.ac.in						Arora D, 1996, J BIOTECHNOL, V52, P127, DOI 10.1016/S0168-1656(96)01636-7; BACK JF, 1979, BIOCHEMISTRY-US, V18, P5191, DOI 10.1021/bi00590a025; Baynes BM, 2004, BIOPHYS J, V87, P1631, DOI 10.1529/biophysj.104.042473; Bolen DW, 2001, J MOL BIOL, V310, P955, DOI 10.1006/jmbi.2001.4819; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Buchner J, 1998, METHOD ENZYMOL, V290, P418, DOI 10.1016/S0076-6879(98)90035-0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; CALHOUN DB, 1985, BIOCHEMISTRY-US, V24, P2095, DOI 10.1021/bi00329a043; Cao A, 2002, BIOCHEM BIOPH RES CO, V291, P795, DOI 10.1006/bbrc.2002.6526; Clark ED, 1999, METHOD ENZYMOL, V309, P217; CLELAND JL, 1990, BIO-TECHNOL, V8, P1274, DOI 10.1038/nbt1290-1274; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; COMBES D, 1990, ANN NY ACAD SCI, V613, P559, DOI 10.1111/j.1749-6632.1990.tb18220.x; Daugherty DL, 1998, J BIOL CHEM, V273, P33961, DOI 10.1074/jbc.273.51.33961; Devi YS, 1998, PROGR BIOTECHNOL, V15, P263; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GEKKO K, 1981, J BIOCHEM-TOKYO, V90, P39, DOI 10.1093/oxfordjournals.jbchem.a133468; GEKKO K, 1981, J BIOCHEM-TOKYO, V90, P51, DOI 10.1093/oxfordjournals.jbchem.a133469; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024; GIANFREDA L, 1991, MOL CELL BIOCHEM, V100, P97; Gorovits BM, 1998, BBA-PROTEIN STRUCT M, V1382, P120, DOI 10.1016/S0167-4838(97)00158-1; Grallert H, 1999, J BIOL CHEM, V274, P20171, DOI 10.1074/jbc.274.29.20171; Grallert H, 1998, J BIOL CHEM, V273, P33305, DOI 10.1074/jbc.273.50.33305; Grallert N, 2000, J BIOL CHEM, V275, P20424, DOI 10.1074/jbc.M002243200; GUPTA V, 1995, PERSPECTIVES PROTEIN, P209; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Jaenicke R, 1997, ADV PROTEIN CHEM, V50, P1, DOI 10.1016/S0065-3233(08)60318-6; Jain S, 1997, THERMOCHIM ACTA, V302, P17, DOI 10.1016/S0040-6031(97)00149-4; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Jaspard E, 2000, ARCH BIOCHEM BIOPHYS, V375, P220, DOI 10.1006/abbi.1999.1667; Kamiyama T, 1999, BBA-PROTEIN STRUCT M, V1434, P44, DOI 10.1016/S0167-4838(99)00159-4; Kaushik JK, 1998, J PHYS CHEM B, V102, P7058, DOI 10.1021/jp981119l; Krause M, 2002, FEBS LETT, V532, P253, DOI 10.1016/S0014-5793(02)03689-X; Machida S, 2000, FEBS LETT, V486, P131, DOI 10.1016/S0014-5793(00)02258-4; Majumder A, 2001, J BIOL CHEM, V276, P30948, DOI 10.1074/jbc.M011705200; Mason JM, 2003, CURR OPIN STRUC BIOL, V13, P526, DOI 10.1016/S0959-440X(03)00100-3; MCEVILY AJ, 1986, J BIOL CHEM, V261, P2593; Morar AS, 2001, PROTEIN SCI, V10, P2195, DOI 10.1110/ps.24301; ORSINI G, 1978, J BIOL CHEM, V253, P3453; Panda M, 2000, J BIOL CHEM, V275, P63, DOI 10.1074/jbc.275.1.63; Patra AK, 2000, PROTEIN EXPRES PURIF, V18, P182, DOI 10.1006/prep.1999.1179; Radha C, 1996, J BIOTECHNOL, V50, P235, DOI 10.1016/0168-1656(96)01569-6; Raibekas AA, 1997, J BIOL CHEM, V272, P22248, DOI 10.1074/jbc.272.35.22248; Raibekas AA, 1996, P NATL ACAD SCI USA, V93, P7546, DOI 10.1073/pnas.93.15.7546; ROZEMA D, 1995, J AM CHEM SOC, V117, P2373, DOI 10.1021/ja00113a036; Russo AT, 2003, J MOL BIOL, V330, P851, DOI 10.1016/S0022-2836(03)00626-0; Sasahara K, 2003, J MOL BIOL, V326, P1227, DOI 10.1016/S0022-2836(02)01443-2; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Silow M, 2003, J MOL BIOL, V326, P263, DOI 10.1016/S0022-2836(02)01331-1; SINGH M, 1970, J BIOL CHEM, V245, P4636; SRERE PA, 1963, ACTA CHEM SCAND, V17, P129, DOI 10.3891/acta.chem.scand.17s-0129; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; TANDON S, 1987, J BIOL CHEM, V262, P4486; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; Tieman BC, 2001, J BIOL CHEM, V276, P44541, DOI 10.1074/jbc.M106693200; Timasheff SN, 2002, BIOCHEMISTRY-US, V41, P13473, DOI 10.1021/bi020316e; VALAX P, 1991, ACS SYM SER, V470, P97; VANI GM, 1996, THESIS JAWAHARLAL NE; WANG Z, 1992, PROTEIN SCI, V1, P522; Weber F, 1998, NAT STRUCT BIOL, V5, P977, DOI 10.1038/2952; WEST SM, 1990, BIOCHIM BIOPHYS ACTA, V1037, P332, DOI 10.1016/0167-4838(90)90034-D; WETLAUFER DB, 1995, PROTEIN SCI, V4, P1535, DOI 10.1002/pro.5560040811; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; Xie GF, 1997, PROTEIN SCI, V6, P211; Yu ZH, 2003, PROTEIN PEPTIDE LETT, V10, P199, DOI 10.2174/0929866033479040	72	75	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15553	15560		10.1074/jbc.M410947200	http://dx.doi.org/10.1074/jbc.M410947200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15695514	hybrid			2022-12-25	WOS:000228444800013
J	Takano, J; Tomioka, M; Tsubuki, S; Higuchi, M; Iwata, N; Itohara, S; Maki, M; Saido, TC				Takano, J; Tomioka, M; Tsubuki, S; Higuchi, M; Iwata, N; Itohara, S; Maki, M; Saido, TC			Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains - Evidence from calpastatin mutant mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING FACTOR; CASPASE-ACTIVATED DNASE; FOCAL CEREBRAL-ISCHEMIA; BCL-2 FAMILY-MEMBERS; ALZHEIMERS-DISEASE; MU-CALPAIN; CELL-DEATH; POSTISCHEMIC HIPPOCAMPUS; NEURONAL APOPTOSIS; FODRIN PROTEOLYSIS	Calpain has been implicated in excitotoxic neurodegeneration, but its mechanism of action particularly in adult brains remains unclear. We generated mutant mice lacking or overexpressing calpastatin, the only solely calpain-specific inhibitor ever identified or synthesized. Modulation of calpastatin expression caused no defect in the mice under normal conditions, indicating that calpastatin functions as a negative regulator of calpain only under pathological conditions. Kainate-evoked excitotoxicity in hippocampus resulted in proteolytic activation of a proapoptotic Bcl-2 subfamily member ( Bid), nuclear translocation of mitochondria-derived DNA fragmentation factors (apoptosis-inducing factor and endonuclease G), DNA fragmentation, and nuclear condensation in pyramidal neurons. These apoptotic responses were significantly augmented by calpastatin deficiency. Consistently calpastatin overexpression suppressed them. No evidence of caspase-3 activation was detected. Our results demonstrated that calpain mediates excitotoxic signals through mobilization of proapoptotic factors in a caspase-independent manner. These mutant mice will serve as useful tools for investigating calpain involvement in various diseases.	RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Lab Behav Genet, Wako, Saitama 3510198, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Lab Mol & Cellular Regulat,Chikusa Ku, Nagoya, Aichi 4648601, Japan	RIKEN; RIKEN; Nagoya University	Saido, TC (corresponding author), RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	saido@brain.riken.jp	Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021; Itohara, Shigeyoshi/I-8769-2012; Maki, Masatoshi/AAM-6839-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; Itohara, Shigeyoshi/0000-0002-2410-9989; Maki, Masatoshi/0000-0001-9144-5491				Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Asada K, 1989, J Enzyme Inhib, V3, P49, DOI 10.3109/14756368909030363; Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; Ben-Ari Y, 2000, TRENDS NEUROSCI, V23, P580, DOI 10.1016/S0166-2236(00)01659-3; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Cong M, 1998, J BIOL CHEM, V273, P660, DOI 10.1074/jbc.273.1.660; COOLICAN SA, 1984, J BIOL CHEM, V259, P1627; Cribbs DH, 2004, AM J PATHOL, V165, P353, DOI 10.1016/S0002-9440(10)63302-0; Crocker SJ, 2003, J NEUROSCI, V23, P4081; De Tullio R, 1998, FEBS LETT, V422, P113, DOI 10.1016/S0014-5793(97)01588-3; Donovan M, 2004, BBA-MOL CELL RES, V1644, P133, DOI 10.1016/j.bbamcr.2003.08.011; Eckert A, 2003, BIOCHEM PHARMACOL, V66, P1627, DOI 10.1016/S0006-2952(03)00534-3; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gestwicki JE, 2004, SCIENCE, V306, P865, DOI 10.1126/science.1101262; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hattori A, 2001, J BIOCHEM-TOKYO, V130, P235, DOI 10.1093/oxfordjournals.jbchem.a002977; Higuchi M, 2005, J BIOL CHEM, V280, P15229, DOI 10.1074/jbc.M500939200; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; INOMATA M, 1985, J BIOCHEM-TOKYO, V98, P407, DOI 10.1093/oxfordjournals.jbchem.a135295; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; Iwata N, 2004, J NEUROSCI, V24, P991, DOI 10.1523/JNEUROSCI.4792-03.2004; Iwata N, 2002, J NEUROSCI RES, V70, P493, DOI 10.1002/jnr.10390; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MAKI M, 1988, J BIOL CHEM, V263, P10254; Manya H, 2002, J BIOL CHEM, V277, P35503, DOI 10.1074/jbc.M206033200; Mattson MP, 2003, NEUROMOL MED, V3, P65, DOI 10.1385/NMM:3:2:65; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MURACHI T, 1983, TRENDS BIOCHEM SCI, V8, P167, DOI 10.1016/0968-0004(83)90165-2; NAGAO S, 1994, J BIOCHEM, V115, P1178, DOI 10.1093/oxfordjournals.jbchem.a124476; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; NAKAMURA M, 1989, BIOCHEMISTRY-US, V28, P449, DOI 10.1021/bi00428a007; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; Rao SD, 2004, TRENDS NEUROSCI, V27, P17, DOI 10.1016/j.tins.2003.11.001; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Saido TC, 1997, NEUROSCI LETT, V227, P75, DOI 10.1016/S0304-3940(97)00309-1; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1994, FEBS LETT, V346, P263, DOI 10.1016/0014-5793(94)00487-0; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; Shimohama S, 2001, BIOCHEM BIOPH RES CO, V289, P1063, DOI 10.1006/bbrc.2001.6108; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108; Takano J, 2000, J BIOCHEM, V128, P83, DOI 10.1093/oxfordjournals.jbchem.a022733; Tomioka M, 2002, MOL BRAIN RES, V108, P18, DOI 10.1016/S0169-328X(02)00486-2; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; WANG KKW, 1999, CALPAIN PHARM TOXICO, P77; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Wong PC, 2002, NAT NEUROSCI, V5, P633, DOI 10.1038/nn0702-633; Wu YF, 2004, NEUROSCI LETT, V364, P203, DOI 10.1016/j.neulet.2004.04.093; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; Yang FS, 1998, AM J PATHOL, V152, P379; Yin XM, 2002, J BIOL CHEM, V277, P42074, DOI 10.1074/jbc.M204991200; YOKOTA M, 1995, STROKE, V26, P1901, DOI 10.1161/01.STR.26.10.1901; Young CL, 2004, CURR MOL MED, V4, P77, DOI 10.2174/1566524043479158	80	161	165	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16175	16184		10.1074/jbc.M414552200	http://dx.doi.org/10.1074/jbc.M414552200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15691848	hybrid			2022-12-25	WOS:000228444800087
J	Simon, MF; Daviaud, D; Pradere, JP; Gres, S; Guigne, C; Wabitsch, M; Chun, J; Valet, P; Saulnier-Blache, JS				Simon, MF; Daviaud, D; Pradere, JP; Gres, S; Guigne, C; Wabitsch, M; Chun, J; Valet, P; Saulnier-Blache, JS			Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREADIPOCYTE PROLIFERATION; 3T3F442A PREADIPOCYTES; EXPRESSION; INVOLVEMENT; GENE	Lysophosphatidic acid (LPA) is a bioactive phospholipid acting via specific G protein-coupled receptors that is synthesized at the extracellular face of adipocytes by a secreted lysophospholipase D (autotaxin). Preadipocytes mainly express the LPA(1) receptor subtype, and LPA increases their proliferation. In monocytes and CV1 cells LPA was recently reported to bind and activate peroxisome proliferator-activated receptor gamma (PPAR gamma), a transcription factor also known to play a pivotal role in adipogenesis. Here we show that, unlike the PPAR gamma agonist rosiglitazone, LPA was unable to increase transcription of PPAR gamma-sensitive genes (PEPCK and ALBP) in the mouse preadipose cell line 3T3F442A. In contrast, treatment with LPA decreased PPAR gamma 2 expression, impaired the response of PPAR gamma-sensitive genes to rosiglitazone, reduced triglyceride accumulation, and reduced the expression of adipocyte mRNA markers. The anti-adipogenic activity of LPA was also observed in the human SGBS (Simpson-Golabi-Behmel syndrome) preadipocyte cell line, as well as in primary preadipocytes isolated from wild type mice. Conversely, the anti-adipogenic activity of LPA was not observed in primary preadipocytes from LPA(1) receptor knock-out mice, which, in parallel, exhibited a higher adiposity than wild type mice. In conclusion, LPA does not behave as a potent PPAR gamma agonist in adipocytes but, conversely, inhibits PPAR gamma expression and adipogenesis via LPA(1) receptor activation. The local production of LPA may exert a tonic inhibitory effect on the development of adipose tissue.	Hop Rangueil, INSERM, Inst Louis Bugnard, U586, F-31432 Toulouse, France; Univ Ulm, Dept Pediat, D-89081 Ulm, Germany; Scripps Res Inst, Dept Mol Biol, Helen L Dorris Inst Neurol & Psychiat Disorders, La Jolla, CA 92037 USA	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Ulm University; Scripps Research Institute	Saulnier-Blache, JS (corresponding author), Hop Rangueil, INSERM, Inst Louis Bugnard, U586, BP84225, F-31432 Toulouse, France.	saulnier@toulouse.inserm.fr	Valet, Philippe/N-7472-2017; Chun, Jerold/Y-4670-2019; Saulnier-Blache, Jean Sebastien/X-7729-2018	Valet, Philippe/0000-0001-6520-7393; Pradere, Jean-Philippe/0000-0003-1734-1429; Saulnier-Blache, Jean Sebastien/0000-0002-8971-7723				Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Betuing S, 1997, BIOCHEM BIOPH RES CO, V235, P765, DOI 10.1006/bbrc.1997.6887; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; DESLEX S, 1987, EXP CELL RES, V168, P15, DOI 10.1016/0014-4827(87)90412-5; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Ferry G, 2003, J BIOL CHEM, V278, P18162, DOI 10.1074/jbc.M301158200; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gesta S, 2002, J LIPID RES, V43, P904; Glorian M, 2001, BIOCHIMIE, V83, P933, DOI 10.1016/S0300-9084(01)01343-8; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREGOIRE F, 1991, EXP CELL RES, V196, P270, DOI 10.1016/0014-4827(91)90261-R; Jazet IM, 2003, NETH J MED, V61, P194; Kersten S, 2002, EUR J PHARMACOL, V440, P223, DOI 10.1016/S0014-2999(02)01431-0; Lee CH, 2003, ENDOCRINOLOGY, V144, P2201, DOI 10.1210/en.2003-0288; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Pages C, 2001, J BIOL CHEM, V276, P11599, DOI 10.1074/jbc.M010111200; Pages C, 2000, ANN NY ACAD SCI, V905, P159; Rodway HA, 2004, BIOCHEM J, V382, P83, DOI 10.1042/BJ20040107; Ruiz-Velasco N, 2004, BIOCHEM PHARMACOL, V67, P303, DOI 10.1016/j.bcp.2003.09.006; Saulnier-Blache JS, 2000, J LIPID RES, V41, P1947; Simon MF, 2002, J BIOL CHEM, V277, P23131, DOI 10.1074/jbc.M201530200; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; Wabitsch M, 2001, INT J OBESITY, V25, P8, DOI 10.1038/sj.ijo.0801520; Zhang CX, 2004, J EXP MED, V199, P763, DOI 10.1084/jem.20031619	25	119	145	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14656	14662		10.1074/jbc.M412585200	http://dx.doi.org/10.1074/jbc.M412585200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15710620	hybrid, Green Submitted			2022-12-25	WOS:000228236800040
J	Watanabe, N; Lam, E				Watanabe, N; Lam, E			Two Arabidopsis metacaspases AtMCP1b and AtMCP2b are arginine/lysine-specific cysteine proteases and activate apoptosis-like cell death in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CASPASES; PROTEINS; STRESS; BAX; PURIFICATION; REGULATOR; PROLINE; MARKERS	Metacaspases in plants, fungi, and protozoa constitute new members of a conserved superfamily of caspase-related proteases. A yeast caspase-1 protein (Yca1p), which is the single metacaspase in Saccharomyces cerevisiae, was shown to mediate apoptosis triggered by oxidative stress or aging in yeast. To examine whether plant metacaspase genes are functionally related to YCA1, we carried out analyses of AtMCP1b and AtMCP2b, representing the two subtypes of the Arabidopsis metacaspase family, utilizing yeast strains with wild-type and the disrupted YCA1 gene (yca1 Delta). Inducible expression of AtMCP1b and AtMCP2b significantly promoted yeast apoptosis-like cell death of both the wild-type and yca1 Delta strains, relative to the vector controls, during oxidative stress and early aging process. Mutational analysis of the two AtMCPs revealed that their cell-death-inducing activities depend on their catalytic center cysteine residues as well as caspase-like processing. In addition, the phenotype induced by the expression of two AtMCPs was effectively prevented when the cells were pretreated with a broad-spectrum caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl-ketone. These results suggest that the two subtypes of Arabidopsis metacaspases are functionally related to Yca1p with caspase-like characteristics. However, we found that bacterial and yeast extracts containing AtMCP1b, AtMCP2b, or Yca1p exhibit arginine/lysine-specific endopeptidase activities but cannot cleave caspase-specific substrates. Together, the results strongly implicate that expression of metacaspases could result in the activation of downstream protease(s) with caspase-like activities that are required to mediate cell death activation via oxidative stress in yeast. Metacaspases from higher plants may serve similar functions.	Rutgers State Univ, Biotechnol Ctr Agr & Environm, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Watanabe, N (corresponding author), Rutgers State Univ, Biotechnol Ctr Agr & Environm, 59 Dudley Rd, New Brunswick, NJ 08901 USA.	lam@aesop.rutgers.edu						BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; Coffeen WC, 2004, PLANT CELL, V16, P857, DOI 10.1105/tpc.017947; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fahrenkrog B, 2004, J CELL SCI, V117, P115, DOI 10.1242/jcs.00848; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Hatsugai N, 2004, SCIENCE, V305, P855, DOI 10.1126/science.1099859; Herker E, 2004, J CELL BIOL, V164, P501, DOI 10.1083/jcb.200310014; Hoeberichts FA, 2003, PLANTA, V217, P517, DOI 10.1007/s00425-003-1049-9; Jin C, 2002, NAT REV MOL CELL BIO, V3, P453, DOI 10.1038/nrm832; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Lam E, 2004, NAT REV MOL CELL BIO, V5, P305, DOI 10.1038/nrm1358; Lam E, 2000, PLANT MOL BIOL, V44, P417, DOI 10.1023/A:1026509012695; LAM E, 2005, IN PRESS TRENDS CELL, V15; Laun P, 2001, MOL MICROBIOL, V39, P1166, DOI 10.1046/j.1365-2958.2001.02317.x; Lawen A, 2003, BIOESSAYS, V25, P888, DOI 10.1002/bies.10329; Los M, 2001, TRENDS IMMUNOL, V22, P31, DOI 10.1016/S1471-4906(00)01814-7; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Madeo F, 2002, CURR GENET, V41, P208, DOI 10.1007/s00294-002-0310-2; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Mazzoni C, 2003, MOL BIOL CELL, V14, P721, DOI 10.1091/mbc.E02-05-0258; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; REDDY ASN, 1994, BIOCHEM BIOPH RES CO, V199, P1089, DOI 10.1006/bbrc.1994.1342; Safadi F, 1997, ARCH BIOCHEM BIOPHYS, V348, P143, DOI 10.1006/abbi.1997.0361; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Suarez MF, 2004, CURR BIOL, V14, pR339, DOI 10.1016/j.cub.2004.04.019; Szallies A, 2002, FEBS LETT, V517, P144, DOI 10.1016/S0014-5793(02)02608-X; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Vercammen D, 2004, J BIOL CHEM, V279, P45329, DOI 10.1074/jbc.M406329200; Wadskog I, 2004, MOL BIOL CELL, V15, P1436, DOI 10.1091/mbc.E03-02-0114; Watanabe N, 2004, MOL PLANT PATHOL, V5, P65, DOI 10.1111/j.1364-3703.2004.00206.x; Woltering EJ, 2002, PLANT PHYSIOL, V130, P1764, DOI 10.1104/pp.006338; Woltering EJ, 2004, TRENDS PLANT SCI, V9, P469, DOI 10.1016/j.tplants.2004.08.001; Xiao S, 2000, BLOOD, V96, P699; Xu QL, 1999, METHODS, V17, P292, DOI 10.1006/meth.1999.0743	36	205	219	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14691	14699		10.1074/jbc.M413527200	http://dx.doi.org/10.1074/jbc.M413527200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15691845	hybrid			2022-12-25	WOS:000228236800045
J	Xie, ZC; Romano, DM; Tanzi, RE				Xie, ZC; Romano, DM; Tanzi, RE			RNA interference-mediated silencing of X11 alpha and X11 beta attenuates amyloid beta-protein levels via differential effects on beta-amyloid precursor protein processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE COMPLEX; ALZHEIMERS-DISEASE; A-BETA; PRESENILIN; CLEAVAGE; PEN-2; APP; NICASTRIN; BINDING; APH-1	Processing of the beta-amyloid precursor protein (APP) plays a key role in Alzheimer disease neuropathogenesis. APP is cleaved by beta- and alpha-secretase to produce APP-C99 and APP-C83, which are further cleaved by alpha-secretase to produce amyloid beta-protein (A beta) and p3, respectively. APP adaptor proteins with phosphotyrosine-binding domains, including XII alpha (MINT1, encoded by gene APBA1) and XII beta (MINT2, encoded by gene APBA2), can bind to the conserved YENPTY motif in the APP C terminus. Overexpression of XII alpha and XII beta alters APP processing and A beta production. Here, for the first time, we have described the effects of RNA interference (RNAi) silencing of XII alpha and XII beta expression on APP processing and A beta production. RNAi silencing of APBA1 in H4 human neuroglioma cells stably transfected to express either full-length APP or APP-C99 increased APP C-terminal fragment levels and lowered A beta levels in both cell lines by inhibiting gamma-secretase cleavage of APP. RNAi silencing of APBA2 also lowered A beta levels, but apparently not via attenuation of gamma-secretase cleavage of APP. The notion of attenuating gamma-secretase cleavage of APP via the APP adaptor protein XII alpha is particularly attractive with regard to therapeutic potential given that side effects of gamma-secretase inhibition due to impaired proteolysis of other gamma-secretase substrates, e.g. Notch, might be avoided.	Harvard Univ, Massachusetts Gen Hosp, Sch Med,MassGen Inst Neurodegenerat Dis, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Tanzi, RE (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,MassGen Inst Neurodegenerat Dis, Genet & Aging Res Unit, 114 16th St,C3009, Charlestown, MA 02129 USA.	tanzi@helix.mgh.harvard.edu	Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454	NIA NIH HHS [AG 014713-07, AG 00294-17, P50 AG05134] Funding Source: Medline; NIMH NIH HHS [MH 60009-03] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060009, R37MH060009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005134, R01AG014713] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; Biederer T, 2002, J NEUROSCI, V22, P7340; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1999, J NEUROSCI, V19, P1307; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Ide N, 1998, BIOCHEM BIOPH RES CO, V244, P258, DOI 10.1006/bbrc.1998.8243; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; King GD, 2004, J NEUROCHEM, V88, P971, DOI 10.1046/j.1471-4159.2003.02234.x; King GD, 2003, NEUROSCIENCE, V120, P143, DOI 10.1016/S0306-4522(03)00284-7; Lau KF, 2000, MOL CELL NEUROSCI, V16, P557, DOI 10.1006/mcne.2000.0898; Lee JH, 2003, J BIOL CHEM, V278, P47025, DOI 10.1074/jbc.M300503200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; McLoughlin DM, 1999, EUR J NEUROSCI, V11, P1988, DOI 10.1046/j.1460-9568.1999.00610.x; McLoughlin DM, 2001, J BIOL CHEM, V276, P9303, DOI 10.1074/jbc.M010023200; McLoughlin DM, 1996, FEBS LETT, V397, P197; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087; Wolfe MS, 2003, CURR TOP DEV BIOL, V54, P233, DOI 10.1016/S0070-2153(03)54011-X; Xie ZC, 2004, NEURODEGENER DIS, V1, P29, DOI 10.1159/000076667; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	38	46	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15413	15421		10.1074/jbc.M414353200	http://dx.doi.org/10.1074/jbc.M414353200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15699037	hybrid			2022-12-25	WOS:000228236800128
J	Finlin, BS; Mosley, AL; Crump, SM; Correll, RN; Ozcan, S; Satin, J; Andres, DA				Finlin, BS; Mosley, AL; Crump, SM; Correll, RN; Ozcan, S; Satin, J; Andres, DA			Regulation of L-type Ca2+ channel activity and insulin secretion by the Rem2 GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELL DEATH; PANCREATIC-ISLETS; BINDING PROTEIN; GENE-TRANSCRIPTION; RAS FAMILY; GLUCOSE; CALCIUM; GEM; EXPRESSION; PHOSPHORYLATION	Voltage-dependent calcium (Ca2+) channels are involved in many specialized cellular functions and are controlled by a diversity of intracellular signals. Recently, members of the RGK family of small GTPases (Rem, Rem2, Rad, Gem/Kir) have been identified as novel contributors to the regulation of L-type calcium channel activity. In this study, microarray analysis of the mouse insulinoma MIN6 cell line revealed that the transcription of Rem2 gene is strongly induced by exposure to high glucose, which was confirmed by real-time reverse transcriptase-PCR and RNase protection analysis. Because elevation of intracellular Ca2+ in pancreatic beta-cells is essential for insulin secretion, we tested the hypothesis that Rem2 attenuates Ca2+ currents to regulate insulin secretion. Co-expression of Rem2 with Ca(V)1.2 or Ca(V)1.3 L-type Ca2+ channels in a heterologous expression system completely inhibits de novo Ca2+ current expression. In addition, ectopic overexpression of Rem2 both inhibited L-type Ca2+ channel activity and prevented glucose-stimulated insulin secretion in pancreatic beta-cell lines. Co-immunoprecipitation studies demonstrate that Rem2 associates with a variety of Ca-V beta subunits. Importantly, surface biotinylation studies demonstrate that the membrane distribution of Ca2+ channels was not reduced at a time when channel activity was potently inhibited by Rem2 expression, indicating that Rem2 modulates channel function without interfering with membrane trafficking. Taken together, these data suggest that inhibition of L-type Ca2+ channels by Rem2 signaling may represent a new and potentially important mechanism for regulating Ca2+-triggered exocytosis in hormone-secreting cells, including insulin secretion in pancreatic beta-cells.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Andres, DA (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Rm MS 639 Chandler Med Ctr,800 Rose St, Lexington, KY 40536 USA.	dandres@pop.uky.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [K26RR000171] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL074091, R01HL072936, R01HL074091] Funding Source: NIH RePORTER; NCRR NIH HHS [P20RR0171] Funding Source: Medline; NHLBI NIH HHS [R01 HL072936, R01 HL072936-02, HL-074091, HL-072936] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andres DA, 1997, ARCH BIOCHEM BIOPHYS, V346, P113, DOI 10.1006/abbi.1997.0296; ASHCROFT SJH, 1986, DIABETOLOGIA, V29, P727, DOI 10.1007/BF00870283; Balijepalli RC, 2004, CIRC RES, V95, P337, DOI 10.1161/01.RES.0000141018.33292.21; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Bjorklund A, 2000, DIABETES, V49, P1840, DOI 10.2337/diabetes.49.11.1840; Blalock EM, 2003, J NEUROSCI, V23, P3807; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chandra J, 2001, DIABETES, V50, pS44, DOI 10.2337/diabetes.50.2007.S44; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; Finlin BS, 1999, ARCH BIOCHEM BIOPHYS, V368, P401, DOI 10.1006/abbi.1999.1316; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; Finlin BS, 2003, P NATL ACAD SCI USA, V100, P14469, DOI 10.1073/pnas.2437756100; Foell JD, 2004, PHYSIOL GENOMICS, V17, P183, DOI 10.1152/physiolgenomics.00207.2003; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Ji JZ, 2002, DIABETES, V51, P1425, DOI 10.2337/diabetes.51.5.1425; Juntti-Berggren L, 2004, P NATL ACAD SCI USA, V101, P10090, DOI 10.1073/pnas.0403551101; JUNTTIBERGGREN L, 1993, SCIENCE, V261, P86, DOI 10.1126/science.7686306; Leibiger B, 2000, J BIOL CHEM, V275, P30153, DOI 10.1074/jbc.M005216200; Levy J, 1998, METABOLISM, V47, P185, DOI 10.1016/S0026-0495(98)90218-9; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Mears D, 2004, J MEMBRANE BIOL, V200, P57, DOI 10.1007/s00232-004-0692-9; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Mosley AL, 2003, J BIOL CHEM, V278, P19660, DOI 10.1074/jbc.M212375200; Moyers JS, 1997, J BIOL CHEM, V272, P11832, DOI 10.1074/jbc.272.18.11832; Moyers JS, 1998, BIOCHEM J, V333, P609, DOI 10.1042/bj3330609; Murata M, 2004, CIRC RES, V95, P398, DOI 10.1161/01.RES.0000138449.85324.c5; Ohsugi M, 2004, DIABETES, V53, P1496, DOI 10.2337/diabetes.53.6.1496; OKAMOTO Y, 1992, DIABETES, V41, P1555, DOI 10.2337/diabetes.41.12.1555; Paulik MA, 1997, J CELL BIOCHEM, V65, P527, DOI 10.1002/(SICI)1097-4644(19970615)65:4<527::AID-JCB8>3.3.CO;2-G; Poitout V, 1996, DIABETES METAB, V22, P7; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; ROE MW, 1994, J BIOL CHEM, V269, P18279; SATIN LS, 1995, ENDOCRINOLOGY, V136, P4589, DOI 10.1210/en.136.10.4589; Schulla V, 2003, EMBO J, V22, P3844, DOI 10.1093/emboj/cdg389; Vanhove B, 1997, ENDOTHELIUM-J ENDOTH, V5, P51, DOI 10.3109/10623329709044158; Ward Y, 2004, MOL CELL BIOL, V24, P651, DOI 10.1128/MCB.24.2.651-661.2004; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; Yang SN, 2005, AM J PHYSIOL-ENDOC M, V288, pE16, DOI 10.1152/ajpendo.00042.2004	39	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41864	41871		10.1074/jbc.M414261200	http://dx.doi.org/10.1074/jbc.M414261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	15728182	hybrid			2022-12-25	WOS:000233992700012
J	Smith, DP; Bath, ML; Harris, AW; Cory, S				Smith, DP; Bath, ML; Harris, AW; Cory, S			T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC	ONCOGENE			English	Article						MYC; transgenic; lymphoma; haemopoiesis; progenitor	C-MYC; RAG-1-DEFICIENT MICE; MOUSE; DIFFERENTIATION; MUTATIONS; APOPTOSIS; LEUKEMIA; BCL-2; CHEMORESISTANCE; CLASSIFICATION	Deregulation of MYC expression occurs in many haematological malignancies. Previous studies modelling MYC-induced lymphomagenesis in the mouse used transgenic vectors that directed MYC overexpression in a lineage-specific manner. Here, we describe a transgenic mouse strain in which constitutive MYC expression is driven broadly in haemopoiesis by a vector containing regulatory elements of the Vav gene. Healthy young VavP-MYC17 mice had multiple haemopoietic abnormalities, most notably increased size and numbers of B-lymphoid cells, monocytes and megakaryocytes. The mice rapidly developed tumours and, surprisingly, these were exclusively T-cell lymphomas, mostly of mature CD4(+) CD8(-) T cells, a tumour type that is seldom seen in mouse models. To examine tumour development in the absence of the susceptible T cells, we bred VavP-MYC17 mice lacking the Rag1 recombinase. They survived longer and succumbed to tumours of several different haemopoietic cell types: pre-T cells, pro-B cells, macrophages and unusual progenitor cells. Thus, although T-lineage cells have the shortest latent period to transformation, the VavP-MYC17 transgene drives malignant transformation of multiple cell types and VavP-MYC17 mice provide a new model for tumours of multiple haemopoietic lineages.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Cory, S (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3050, Australia.	cory@wehi.edu.au	Cory, Suzanne/E-1642-2013	Cory, Suzanne/0000-0002-6818-3451				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; Bath ML, 2003, BIOL REPROD, V68, P19, DOI 10.1095/biolreprod.102.007344; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Ceredig R, 2002, NAT REV IMMUNOL, V2, P888, DOI 10.1038/nri937; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Elghetany MT, 1997, LEUKEMIA, V11, P762, DOI 10.1038/sj.leu.2400628; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hann B, 2001, CURR OPIN CELL BIOL, V13, P778, DOI 10.1016/S0955-0674(00)00283-0; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HARRIS NL, 1994, BLOOD, V84, P1361; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; MALJAIE SH, 1995, LEUKEMIA, V9, P1694; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; Michie AM, 2002, SEMIN IMMUNOL, V14, P311, DOI 10.1016/S1044-5323(02)00064-7; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Min BK, 2003, IMMUNITY, V18, P131, DOI 10.1016/S1074-7613(02)00508-3; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Ogilvy S, 1999, BLOOD, V94, P1855; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Pekarsky Y, 2001, JAMA-J AM MED ASSOC, V286, P2308, DOI 10.1001/jama.286.18.2308; Renno T, 1998, EUR J IMMUNOL, V28, P540, DOI 10.1002/(SICI)1521-4141(199802)28:02<540::AID-IMMU540>3.3.CO;2-P; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STEWART M, 1993, INT J CANCER, V53, P1023; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519	42	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3544	3553		10.1038/sj.onc.1208399	http://dx.doi.org/10.1038/sj.onc.1208399			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15688022				2022-12-25	WOS:000229221800002
J	Wolins, NE; Quaynor, BK; Skinner, JR; Schoenfish, MJ; Tzekov, A; Bickel, P				Wolins, NE; Quaynor, BK; Skinner, JR; Schoenfish, MJ; Tzekov, A; Bickel, P			S3-12, adipophilin, and TIP47 package lipid in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-RELATED PROTEIN; DOMINANT-NEGATIVE MUTANT; 3T3-L1 ADIPOCYTES; DROPLETS; PERILIPIN; STORAGE; BODIES; CELL; ASSOCIATION; CAVEOLIN	Animals have evolved mechanisms to maintain circulating nutrient levels when energy demands exceed feeding opportunities. Mammals store most of their energy as triacylglycerol in the perilipin-coated lipid droplets of adipocytes. How newly synthesized triacylglycerol is delivered to perilipin-coated lipid droplets is poorly understood. Perilipin is a member of the evolutionarily related family of PAT proteins (Perilipin, Adipophilin, TIP47), which is defined by sequence similarity and association with lipid droplets. We previously showed that S3-12, which is also a member of this family, associates with a separate pool of lipid droplets that emerge when triacylglycerol storage is driven by adding oleate to the culture medium of adipocytes. Our current data extend these findings to demonstrate that nascent lipid droplets emerge with a coat composed of S3-12, TIP47, and adipophilin. After 100 min of oleate treatment, the nascent lipid droplets are more heterogeneous: S3-12 and TIP47 coat smaller, peripheral droplets and adipophilin coats a more medial population of droplets. Fractionation of untreated and oleate-treated adipocytes shows oleate-dependent redistribution of TIP47 and adipophilin from cytosolic fractions to the lipid droplet fraction. Inhibition of protein synthesis with cycloheximide does not block the oleate-induced formation of the nascent lipid droplets, nor does it prevent TAG accumulation. We suggest that the non-lipid droplet pools of S3-12, adipophilin, and TIP47 constitute a ready reservoir of coat proteins to permit rapid packaging of newly synthesized triacylglycerol and to maximize energy storage during nutrient excess.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Bickel, P (corresponding author), Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave,Campus Box 8127, St Louis, MO 63110 USA.	pbickel@im.wustl.edu	Bickel, Perry/Q-9185-2019		NIDDK NIH HHS [T32 DK07296] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007296] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbero P, 2001, J BIOL CHEM, V276, P24348, DOI 10.1074/jbc.M102468200; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; Bussell R, 2003, J MOL BIOL, V329, P763, DOI 10.1016/S0022-2836(03)00520-5; CUSHMAN SW, 1970, J CELL BIOL, V46, P326, DOI 10.1083/jcb.46.2.326; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; FROST SC, 1985, J BIOL CHEM, V260, P2646; Fujimoto Y, 2004, BBA-MOL CELL RES, V1644, P47, DOI 10.1016/j.bbamcr.2003.10.018; Heid HW, 1996, BIOCHEM J, V320, P1025, DOI 10.1042/bj3201025; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; Hickenbottom SJ, 2004, STRUCTURE, V12, P1199, DOI 10.1016/j.str.2004.04.021; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohashi M, 2003, J BIOL CHEM, V278, P36819, DOI 10.1074/jbc.M301408200; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; Quittnat F, 2004, MOL BIOCHEM PARASIT, V138, P107, DOI 10.1016/j.molbiopara.2004.08.004; Sakashita N, 2000, AM J PATHOL, V156, P227, DOI 10.1016/S0002-9440(10)64723-2; Schaffer JE, 2003, CURR OPIN LIPIDOL, V14, P281, DOI 10.1097/00041433-200306000-00008; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; Sorger D, 2002, J BACTERIOL, V184, P519, DOI 10.1128/JB.184.2.519-524.2002; Spector A A, 1980, Prog Lipid Res, V19, P155; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Than GN, 2001, ANTICANCER RES, V21, P639; Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200; Unger RH, 2003, ENDOCRINOLOGY, V144, P5159, DOI 10.1210/en.2003-0870; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Wolins NE, 2003, J BIOL CHEM, V278, P37713, DOI 10.1074/jbc.M304025200; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	38	272	290	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19146	19155		10.1074/jbc.M500978200	http://dx.doi.org/10.1074/jbc.M500978200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15731108	hybrid			2022-12-25	WOS:000228932300071
J	Konno, T; Morii, T; Shimizu, H; Oiki, S; Ikura, K				Konno, T; Morii, T; Shimizu, H; Oiki, S; Ikura, K			Paradoxical inhibition of protein aggregation and precipitation by transglutaminase-catalyzed intermolecular cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; TISSUE TRANSGLUTAMINASE; NEURODEGENERATIVE DISEASES; MOLECULAR CHAPERONES; ALZHEIMERS-DISEASE; PHASE-TRANSITIONS; ENZYMES	Cross-linking of proteins catalyzed by tissue transglutaminase has been suggested to play key roles in a variety of cellular events, including cell apoptosis and human pathogenesis ( e. g. polyglutamine and Alzheimer diseases). It has often been suggested that tissue transglutaminase enhances aggregation and precipitation of damaged or pathogenic proteins. To ascertain whether this is accurate, we investigated the effects of tissue transglutaminase-catalyzed modulation on the aggregation of structurally damaged and unfolded proteins. Our results indicated that the aggregation and precipitation of some unfolded proteins were inhibited by transglutaminase-catalyzed reaction, although the effect was strongly dependent upon the target protein species. To elucidate the molecular events underlying the inhibitory effect, extensive analysis was performed with regard to reduced beta-lactoglobulin using a number of techniques, including chromatography and spectroscopy. The results indicated that cross-linking yields high molecular weight soluble polymers but inhibits the growth of insoluble aggregates. The cross-linked beta-lactoglobulin retained stable secondary structures with a hydrophobic core. We concluded that the transglutaminase-catalyzed intermolecular cross-linking did not necessarily enhance protein aggregation but could sometimes have a suppressive effect. The results of the present study suggested that tissue transglutaminase modifies aggregation and deposition of damaged or pathogenic proteins in vivo in a wide variety of manners depending on the target protein species and solution conditions.	Univ Fukui, Fac Med Sci, Dept Physiol & Mol Biophys, Fukui 9101193, Japan; Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan; Kyoto Inst Technol, Fac Text Sci, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan	University of Fukui; Kyoto University; Kyoto Institute of Technology	Konno, T (corresponding author), Univ Fukui, Fac Med Sci, Dept Physiol & Mol Biophys, Fukui 9101193, Japan.	konno@fmsrsa.fukui-med.ac.jp	Morii, Takashi/AAL-1392-2020	Morii, Takashi/0000-0003-3663-3267				ABOUMAHMOUD R, 1990, J DAIRY SCI, V73, P256, DOI 10.3168/jds.S0022-0302(90)78668-7; Berke SJS, 2003, CURR OPIN GENET DEV, V13, P253, DOI 10.1016/S0959-437X(03)00053-4; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Citron BA, 2002, NEUROCHEM INT, V40, P69, DOI 10.1016/S0197-0186(01)00062-6; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Ellis RJ, 1999, CURR BIOL, V9, pR137; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; GOLDSTEIN DA, 1979, BIOPHYS J, V26, P235, DOI 10.1016/S0006-3495(79)85247-9; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; IKURA K, 1985, AGR BIOL CHEM TOKYO, V49, P3527, DOI 10.1080/00021369.1985.10867289; Junn E, 2003, P NATL ACAD SCI USA, V100, P2047, DOI 10.1073/pnas.0438021100; Karpuj MV, 1999, P NATL ACAD SCI USA, V96, P7388, DOI 10.1073/pnas.96.13.7388; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kim SY, 2002, NEUROCHEM INT, V40, P85, DOI 10.1016/S0197-0186(01)00064-X; Konno T, 2005, BIOCHEMISTRY-US, V44, P2072, DOI 10.1021/bi047722d; Kulkarni AM, 2003, FARADAY DISCUSS, V123, P37, DOI 10.1039/b204453f; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai TS, 2004, J NEUROCHEM, V88, P1253, DOI 10.1046/j.1471-4159.2003.02249.x; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; Lorand L, 1996, P NATL ACAD SCI USA, V93, P14310, DOI 10.1073/pnas.93.25.14310; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Matsumura Y, 1996, BBA-PROTEIN STRUCT M, V1292, P69, DOI 10.1016/0167-4838(95)00197-2; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; Muschol M, 1997, J CHEM PHYS, V107, P1953, DOI 10.1063/1.474547; PEDERSEN JS, 1994, EUR BIOPHYS J BIOPHY, V22, P379, DOI 10.1007/BF00180159; Piazza R, 2000, CURR OPIN COLLOID IN, V5, P38, DOI 10.1016/S1359-0294(00)00034-0; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Roos-Mattjus P, 2004, ANN MED, V36, P285, DOI 10.1080/07853890310016324; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Selkoe DJ, 2002, NEUROCHEM INT, V40, P13, DOI 10.1016/S0197-0186(01)00057-2; Stradner A, 2004, NATURE, V432, P492, DOI 10.1038/nature03109; Zainelli GM, 2003, J NEUROPATH EXP NEUR, V62, P14, DOI 10.1093/jnen/62.1.14; Zemaitaitis MO, 2000, J NEUROPATH EXP NEUR, V59, P983, DOI 10.1093/jnen/59.11.983	39	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17520	17525		10.1074/jbc.M413988200	http://dx.doi.org/10.1074/jbc.M413988200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731111	hybrid			2022-12-25	WOS:000228615500120
J	Abbott, DW; Chadwick, BP; Thambirajah, AA; Ausio, J				Abbott, DW; Chadwick, BP; Thambirajah, AA; Ausio, J			Beyond the Xi - MacroH2A chromatin distribution and post-translational modification in an avian system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME CORE PARTICLE; HISTONE H2A VARIANTS; CRYSTAL-STRUCTURE; BARR BODY; CHROMOSOME; PROTEIN; STABILITY; RECRUITMENT; REGION; DOMAIN	MacroH2A (mH2A) is a histone variant that is enriched in the inactivated X-chromosomes of mammalian females. To characterize the role of this protein in other nuclear processes we isolated chromatin particles from chicken liver, a vertebrate system that does not undergo X-inactivation. Chromatin digestion and fractionation studies determined that mH2A is evenly distributed at several levels of chromatin structure and stabilizes the nucleosome core particle in solution. However, at the level of the chromatosome, selective salt precipitation showed the existence of a mutually exclusive relationship between mH2A and H1, which may reveal functional redundancy between these proteins. Two-dimensional gel electrophoresis demonstrated the presence of one major population of mH2A containing nucleosomes, which may become ADP-ribosylated. This report provides new clues into how mH2A distribution and a previously unidentified post-translational modification may help regulate the repression of autosomal chromatin.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Inst Genome Sci & Policy, Durham, NC 27710 USA	University of Victoria; Duke University	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada.	jausio@uvic.ca		Chadwick, Brian/0000-0001-5272-8384; Abbott, Wade/0000-0003-4893-5799				Abbott DW, 2004, BIOCHEMISTRY-US, V43, P1352, DOI 10.1021/bi035859i; Abbott DW, 2001, J BIOL CHEM, V276, P41945, DOI 10.1074/jbc.M108217200; Adam M, 2001, MOL CELL BIOL, V21, P6270, DOI 10.1128/MCB.21.18.6270-6279.2001; Allen MD, 2003, J MOL BIOL, V330, P503, DOI 10.1016/S0022-2836(03)00473-X; Angelov D, 2003, MOL CELL, V11, P1033, DOI 10.1016/S1097-2765(03)00100-X; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; Ausio J, 2002, BIOCHEMISTRY-US, V41, P5945, DOI 10.1021/bi020059d; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; Ausio J, 2001, BIOCHEM CELL BIOL, V79, P693, DOI 10.1139/bcb-79-6-693; AUSIO J, 1984, J MOL BIOL, V176, P77, DOI 10.1016/0022-2836(84)90383-8; Ausio J, 2000, BIOPHYS CHEM, V86, P141, DOI 10.1016/S0301-4622(00)00144-7; AUSIO J, 2004, CHROMATIN STRUCTURE, P241; Bao YH, 2004, EMBO J, V23, P3314, DOI 10.1038/sj.emboj.7600316; BLUE ML, 1982, J BIOL CHEM, V257, P1151; CERVANTESLAUREAN D, 1995, J BIOL CHEM, V270, P7929, DOI 10.1074/jbc.270.14.7929; Chadwick BP, 2003, HUM MOL GENET, V12, P2167, DOI 10.1093/hmg/ddg229; Chadwick BP, 2002, J CELL BIOL, V157, P1113, DOI 10.1083/jcb.200112074; Chadwick BP, 2001, NUCLEIC ACIDS RES, V29, P2699, DOI 10.1093/nar/29.13.2699; Chadwick BP, 2001, HUM MOL GENET, V10, P1101, DOI 10.1093/hmg/10.10.1101; Chadwick BP, 2001, J CELL BIOL, V152, P375, DOI 10.1083/jcb.152.2.375; Changolkar LN, 2002, BIOCHEMISTRY-US, V41, P179, DOI 10.1021/bi0157417; Costanzi C, 2000, DEVELOPMENT, V127, P2283; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; EICKBUSH TH, 1988, J BIOL CHEM, V263, P18972; Fan JY, 2002, NAT STRUCT BIOL, V9, P172, DOI 10.1038/nsb767; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; Gautier T, 2004, EMBO REP, V5, P715, DOI 10.1038/sj.embor.7400182; GOLDERER G, 1991, BIOCHEM J, V277, P607, DOI 10.1042/bj2770607; GOMEZCUADRADO A, 1992, EMBO J, V11, P1857, DOI 10.1002/j.1460-2075.1992.tb05237.x; Hoyer-Fender S, 2000, EXP CELL RES, V258, P254, DOI 10.1006/excr.2000.4951; JASON LJ, 2004, J BIOL CHEM; Kuroiwa A, 2002, CYTOGENET GENOME RES, V99, P310, DOI 10.1159/000071609; Ladurner AG, 2003, MOL CELL, V12, P1, DOI 10.1016/S1097-2765(03)00284-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Mermoud JE, 1999, J CELL BIOL, V147, P1399, DOI 10.1083/jcb.147.7.1399; NEELIN JM, 1964, CAN J BIOCHEM PHYS, V42, P1743, DOI 10.1139/o64-185; OLINS AL, 1976, NUCLEIC ACIDS RES, V3, P3271, DOI 10.1093/nar/3.12.3271; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; PEHRSON JR, 1992, SCIENCE, V257, P1398; Pehrson JR, 1998, NUCLEIC ACIDS RES, V26, P2837, DOI 10.1093/nar/26.12.2837; Perche PY, 2000, CURR BIOL, V10, P1531, DOI 10.1016/S0960-9822(00)00832-0; RAJAVASHISTH TB, 1987, J BIOL CHEM, V262, P7058; Rasmussen TP, 1999, NUCLEIC ACIDS RES, V27, P3685, DOI 10.1093/nar/27.18.3685; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Richler C, 2000, CYTOGENET CELL GENET, V89, P118, DOI 10.1159/000015589; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; Siino JS, 2002, FEBS LETT, V527, P105, DOI 10.1016/S0014-5793(02)03176-9; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; Turner JMA, 2001, J CELL SCI, V114, P3367; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Wang XY, 2001, J EXP ZOOL, V290, P431, DOI 10.1002/jez.1085; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; YAGER TD, 1984, J BIOL CHEM, V259, P4212	57	35	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16437	16445		10.1074/jbc.M500170200	http://dx.doi.org/10.1074/jbc.M500170200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15718235	hybrid			2022-12-25	WOS:000228444800117
J	Liu, JY; Lou, Y; Yokota, H; Adams, PD; Kim, R; Kim, SH				Liu, JY; Lou, Y; Yokota, H; Adams, PD; Kim, R; Kim, SH			Crystal structure of a PhoU protein homologue - A new class of metalloprotein containing multinuclear iron clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE-TRANSPORT; ESCHERICHIA-COLI; H-CHAINS; FERRITIN; ALIGNMENT; SOFTWARE; SEQUENCE; SYSTEMS; ROLES	PhoU proteins are known to play a role in the regulation of phosphate uptake. In Thermotoga maritima, two PhoU homologues have been identified bioinformatically. Here we report the crystal structure of one of the PhoU homologues at 2.0 angstrom resolution. The structure of the PhoU protein homologue contains a highly symmetric new structural fold composed of two repeats of a three-helix bundle. The structure unexpectedly revealed a trinuclear and a tetranuclear iron cluster that were found to be bound on the surface. Each of the two multinuclear iron clusters is coordinated by a conserved E(D) XXXD motif pair. Our structure reveals a new class of metalloprotein containing multinuclear iron clusters. The possible functional implication based on the structure are discussed.	Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Struct Genom Ctr, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Kim, SH (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Struct Genom Ctr, Berkeley, CA 94720 USA.	SHKim@cchem.berkeley.edu	Adams, Paul David/A-1977-2013	Adams, Paul David/0000-0001-9333-8219	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062412] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 62412] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Alexeev D, 2003, NAT STRUCT BIOL, V10, P297, DOI 10.1038/nsb903; ASLANIDIS C, 1990, NUCLEIC ACIDS RES, V18, P6069, DOI 10.1093/nar/18.20.6069; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chasteen ND, 1999, J STRUCT BIOL, V126, P182, DOI 10.1006/jsbi.1999.4118; Hogbom M, 2004, FEBS LETT, V567, P179, DOI 10.1016/j.febslet.2004.04.068; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAO NN, 1990, MOL MICROBIOL, V4, P1083, DOI 10.1111/j.1365-2958.1990.tb00682.x; ROSENBERG H, 1977, J BACTERIOL, V131, P505, DOI 10.1128/JB.131.2.505-511.1977; Santambrogio P, 1996, BIOCHEM J, V314, P139, DOI 10.1042/bj3140139; STEED PM, 1993, J BACTERIOL, V175, P6797, DOI 10.1128/jb.175.21.6797-6809.1993; SURIN BP, 1985, J BACTERIOL, V161, P189, DOI 10.1128/JB.161.1.189-198.1985; SURIN BP, 1986, J BACTERIOL, V168, P631, DOI 10.1128/jb.168.2.631-635.1986; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WANNER BL, 1993, J CELL BIOCHEM, V51, P47, DOI 10.1002/jcb.240510110; Wanner BL, 1996, ESCHERICHIA COLI SAL, P1357, DOI DOI 10.1007/978-3-642-75969-7_16; WILLSKY GR, 1980, J BACTERIOL, V144, P356, DOI 10.1128/JB.144.1.356-365.1980; Zeth K, 2004, P NATL ACAD SCI USA, V101, P13780, DOI 10.1073/pnas.0401821101; Zhu HZ, 2003, BIOCHEM J, V376, P35, DOI 10.1042/BJ20031283	27	28	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15960	15966		10.1074/jbc.M414117200	http://dx.doi.org/10.1074/jbc.M414117200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15716271	hybrid			2022-12-25	WOS:000228444800062
J	Hillger, F; Herr, G; Rudolph, R; Schwarz, E				Hillger, F; Herr, G; Rudolph, R; Schwarz, E			Biophysical comparison of BMP-2, ProBMP-2, and the free pro-peptide reveals stabilization of the pro-peptide by the mature growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; FACTOR-BETA; RECEPTOR; COMPLEX; FACTOR-BETA-1; CONVERTASES; PRODOMAIN; DOMAINS	Pro-forms of growth factors have received intensive scientific attention recently because in some cases different biological activities have been ascribed compared with the mature growth factors. Examples are the pro-apoptotic role of the nerve growth factor (NGF) pro-form (proNGF) or the latency of the transforming growth factor (TGF)-beta pro-form (proTGF-beta). To investigate a possible biological function of the pro-form of bone morphogenetic protein (BMP)-2, a member of the TGF-beta family, mature BMP-2, proBMP-2, and the isolated pro-peptide were recombinantly produced in Escherichia coli cells, and a biophysical comparison was performed. Protocols were developed that allowed efficient refolding and subsequent purification of the proteins. ProBMP-2 could be processed to an N-terminally truncated form of BMP-2, digit removed BMP-2 (drBMP-2), that possessed biological activity, i.e. it induced ectopic bone formation. Bone inducing activity was also displayed by proBMP-2. The three proteins were characterized both by fluorescence and CD spectroscopy. From these analyses, predominant beta-sheet secondary structural elements in the pro-peptide were deduced. The thermodynamic stability of the pro-peptide was determined by chemical unfolding assays. As in the case of NGF/proNGF, the mature part of BMP-2 stabilized the structure of the pro-peptide moiety. However, in contrast to NGF/proNGF, the pro-peptide did not stimulate oxidative folding of the mature part in vitro.	Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle Saale, Germany; Adv Tissue Regenerat GmbH, D-35578 Wetzlar, Germany	Martin Luther University Halle Wittenberg	Herr, G (corresponding author), Univ Halle Wittenberg, Inst Biotechnol, Kurt Mothes Str 3, D-06120 Halle Saale, Germany.	Elisabeth.Schwarz@biochemtech.uni-halle.de		Hillger, Frank/0000-0003-4004-6938				Bottinger EP, 1996, P NATL ACAD SCI USA, V93, P5877, DOI 10.1073/pnas.93.12.5877; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; Constam DB, 1999, J CELL BIOL, V144, P139, DOI 10.1083/jcb.144.1.139; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Cui YZ, 2001, GENE DEV, V15, P2797; Degnin C, 2004, MOL BIOL CELL, V15, P5012, DOI 10.1091/mbc.E04-08-0673; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; Greenwald J, 2003, MOL CELL, V11, P605, DOI 10.1016/S1097-2765(03)00094-7; Groppe J, 1998, J BIOL CHEM, V273, P29052, DOI 10.1074/jbc.273.44.29052; Ibanez CF, 2002, TRENDS NEUROSCI, V25, P284, DOI 10.1016/S0166-2236(02)02169-0; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Kliemannel M, 2004, FEBS LETT, V566, P207, DOI 10.1016/j.febslet.2004.04.034; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Lindholm P, 2002, MOL CANCER THER, V1, P365; Lories RJU, 2003, ARTHRITIS RHEUM, V48, P2807, DOI 10.1002/art.11389; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; McMahon GA, 1996, BIOCHEM J, V313, P343, DOI 10.1042/bj3130343; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Pace C N, 1986, Methods Enzymol, V131, P266; PIRCHER R, 1984, CANCER RES, V44, P5538; Rattenholl A, 2001, EUR J BIOCHEM, V268, P3296, DOI 10.1046/j.1432-1327.2001.02232.x; Rattenholl A, 2001, J MOL BIOL, V305, P523, DOI 10.1006/jmbi.2000.4295; REDDY RCK, 2005, IN PRESS PROTEIN SCI; Rudolph R, 1997, PROTEIN FUNCTION PRA, P57; Ruppert R, 1996, EUR J BIOCHEM, V237, P295, DOI 10.1111/j.1432-1033.1996.0295n.x; Sachs L., 1984, ANGEW STAT ANWENDUNG, V6, DOI [10.1007/978-3-662-05748-3, DOI 10.1007/978-3-662-05748-3]; Scheufler C, 1999, J MOL BIOL, V287, P103, DOI 10.1006/jmbi.1999.2590; Schmid F. Z., 1997, PROTEIN STRUCTURE PR, P261; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x; Valentin-Opran A, 2002, CLIN ORTHOP RELAT R, P110; Vallejo LF, 2004, BIOTECHNOL BIOENG, V85, P601, DOI 10.1002/bit.10906; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1	39	56	63	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14974	14980		10.1074/jbc.M414413200	http://dx.doi.org/10.1074/jbc.M414413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15695507	hybrid			2022-12-25	WOS:000228236800078
J	Mariappan, M; Preusser-Kunze, A; Balleininger, M; Eiselt, N; Schmidt, B; Gande, SL; Wenzel, D; Dierks, T; von Figura, K				Mariappan, M; Preusser-Kunze, A; Balleininger, M; Eiselt, N; Schmidt, B; Gande, SL; Wenzel, D; Dierks, T; von Figura, K			Expression, localization, structural, and functional characterization of pFGE, the paralog of the C alpha-formylglycine-generating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SULFATASE DEFICIENCY; PROTEIN MODIFICATION; HUMAN ARYLSULFATASE; CRYSTAL-STRUCTURE; CYSTEINE; GENE; GLYCOSYLATION; CONVERSION; MUTATIONS; MECHANISM	pFGE is the paralog of the formylglycine-generating enzyme (FGE), which catalyzes the oxidation of a specific cysteine to C alpha-formylglycine, the catalytic residue in the active site of sulfatases. The enzymatic activity of sulfatases depends on this posttranslational modification, and the genetic defect of FGE causes multiple sulfatase deficiency. The structural and functional properties of pFGE were analyzed. The comparison with FGE demonstrates that both share a tissue-specific expression pattern and the localization in the lumen of the endoplasmic reticulum. Both are retained in the endoplasmic reticulum by a saturable mechanism. Limited proteolytic cleavage at similar sites indicates that both also share a similar three-dimensional structure. pFGE, however, is lacking the formylglycine-generating activity of FGE. Although overexpression of FGE stimulates the generation of catalytically active sulfatases, overexpression of pFGE has an inhibitory effect. In vitro pFGE interacts with sulfatase-derived peptides but not with FGE. The inhibitory effect of pFGE on the generation of active sulfatases may therefore be caused by a competition of pFGE and FGE for newly synthesized sulfatase polypeptides.	Univ Gottingen, Biochem Abt 2, Inst Biochem & Mol Zellbiol, D-37073 Gottingen, Germany; Max Planck Inst Biophys Chem, Abt Neurobiol, D-37077 Gottingen, Germany	University of Gottingen; Max Planck Society	von Figura, K (corresponding author), Univ Gottingen, Biochem Abt 2, Inst Biochem & Mol Zellbiol, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.	kfigura@gwdg.de	Dierks, Thomas/A-3596-2012; mariappan, malaiyalam/K-9024-2012	Dierks, Thomas/0000-0001-6426-1339; 				Boltes I, 2001, STRUCTURE, V9, P483, DOI 10.1016/S0969-2126(01)00609-8; Cosma MP, 2004, HUM MUTAT, V23, P576, DOI 10.1002/humu.20040; Cosma MP, 2003, CELL, V113, P445, DOI 10.1016/S0092-8674(03)00348-9; Dickmanns A, 2005, J BIOL CHEM, V280, P15180, DOI 10.1074/jbc.M414317200; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 1998, J BIOL CHEM, V273, P25560, DOI 10.1074/jbc.273.40.25560; Dierks T, 1999, EMBO J, V18, P2084, DOI 10.1093/emboj/18.8.2084; Dierks T, 2003, CELL, V113, P435, DOI 10.1016/S0092-8674(03)00347-7; GIESELMANN V, 1992, J BIOL CHEM, V267, P13262; GLOSSL J, 1978, CLIN CHIM ACTA, V88, P111, DOI 10.1016/0009-8981(78)90157-2; Hopwood JJ, 2001, METABOLIC MOL BASES, P3725; Landgrebe J, 2003, GENE, V316, P47, DOI 10.1016/S0378-1119(03)00746-7; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/ng0501-73; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Miech C, 1998, J BIOL CHEM, V273, P4835, DOI 10.1074/jbc.273.9.4835; Preusser-Kunze A, 2005, J BIOL CHEM, V280, P14900, DOI 10.1074/jbc.M413383200; ROMMERSKIRCH W, 1992, P NATL ACAD SCI USA, V89, P2561, DOI 10.1073/pnas.89.7.2561; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Selmer T, 1996, EUR J BIOCHEM, V238, P341, DOI 10.1111/j.1432-1033.1996.0341z.x; STEIN C, 1989, J BIOL CHEM, V264, P13865; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; von Bulow R, 2001, J MOL BIOL, V305, P269, DOI 10.1006/jmbi.2000.4297; von Figura K, 1998, BIOESSAYS, V20, P505, DOI 10.1002/(SICI)1521-1878(199806)20:6<505::AID-BIES9>3.0.CO;2-K; VONFIGURA K, 2004, LYSOSOMAL DISORDERS, P131	24	23	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15173	15179		10.1074/jbc.M413698200	http://dx.doi.org/10.1074/jbc.M413698200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708861	hybrid			2022-12-25	WOS:000228236800101
J	Weihofen, WA; Liu, JG; Reutter, W; Saenger, W; Fan, H				Weihofen, WA; Liu, JG; Reutter, W; Saenger, W; Fan, H			Crystal structures of HIV-1 Tat-derived nonapeptides Tat-(1-9) and Trp(2)-Tat-(1-9) bound to the active site of dipeptidyl-peptidase IV (CD26)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL STRUCTURE; VIRUS TYPE-III; T-CELL GROWTH; ADENOSINE-DEAMINASE; CD26/DIPEPTIDYL-PEPTIDASE IV; IMMUNE-RESPONSE; IV/CD26; PROTEIN; ACTIVATION; CHEMOKINE	CD26 or dipeptidyl-peptidase IV (DPPIV) is engaged in immune functions by co-stimulatory effects on activation and proliferation of T lymphocytes, binding to adenosine deaminase, and regulation of various chemokines and cytokines. DPPIV peptidase activity is inhibited by both Tat protein from human immunodeficiency virus (HIV)-1 and its N-terminal nonapeptide Tat-(1- 9) with amino acid sequence MDPVDPNIE, suggesting that DPPIV mediates immunosuppressive effects of Tat protein. The 2.0- and 3.15-angstrom resolution crystal structures of the binary complex between human DPPIV and nonapeptide Tat-(1-9) and the ternary complex between the variant MWPVDPNIE, called Trp(2)-Tat-(1-9), and DPPIV bound to adenosine deaminase show that Tat-(1-9) and Trp(2)-Tat-(1-9) are located in the active site of DPPIV. The interaction pattern of DPPIV with Trp(2)-Tat-(1-9) is tighter than that with Tat-(1-9), in agreement with inhibition constants (K-i) of 2 x 10(-6) and 250 x 10(-6) M, respectively. Both peptides cannot be cleaved by DPPIV because the binding pockets of the N-terminal 2 residues are interchanged compared with natural substrates: the N-terminal methionine occupies the hydrophobic S1 pocket of DPPIV that normally accounts for substrate specificity by binding the penultimate residue. Because the N-terminal sequence of the thromboxane A2 receptor resembles the Trp(2)-Tat-(1-9) peptide, a possible interaction with DPPIV is postulated.	Free Univ Berlin, Inst Chem Kristallog, D-14195 Berlin, Germany; Charite Univ Med Berlin, Inst Mol Biol & Biochem, D-14195 Berlin, Germany	Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Saenger, W (corresponding author), Free Univ Berlin, Inst Chem Kristallog, Takustr 6, D-14195 Berlin, Germany.	hua.fan@charite.de						Aertgeerts K, 2004, PROTEIN SCI, V13, P412, DOI 10.1110/ps.03460604; Augustyns K, 1999, CURR MED CHEM, V6, P311; BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; Dobers J, 2002, PROTEIN EXPRES PURIF, V25, P527, DOI 10.1016/S1046-5928(02)00043-8; Engel M, 2003, P NATL ACAD SCI USA, V100, P5063, DOI 10.1073/pnas.0230620100; Franco R, 1998, IMMUNOL REV, V161, P27, DOI 10.1111/j.1600-065X.1998.tb01569.x; Gorrell MD, 2001, SCAND J IMMUNOL, V54, P249, DOI 10.1046/j.1365-3083.2001.00984.x; GUTHEIL WG, 1994, P NATL ACAD SCI USA, V91, P6594, DOI 10.1073/pnas.91.14.6594; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBOTA T, 1992, CLIN EXP IMMUNOL, V89, P192; Lorey S, 2003, EUR J BIOCHEM, V270, P2147, DOI 10.1046/j.1432-1033.2003.03568.x; Ludwig K, 2004, BIOCHEM BIOPH RES CO, V313, P223, DOI 10.1016/j.bbrc.2003.11.112; Marguet D, 2000, P NATL ACAD SCI USA, V97, P6874, DOI 10.1073/pnas.120069197; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; Ohtsuki T, 2000, J DERMATOL SCI, V22, P152, DOI 10.1016/S0923-1811(99)00081-X; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Proost P, 2000, BLOOD, V96, P1674, DOI 10.1182/blood.V96.5.1674.h8001674a_1674_1680; Proost P, 1999, J BIOL CHEM, V274, P3988, DOI 10.1074/jbc.274.7.3988; Rasmussen HB, 2003, NAT STRUCT BIOL, V10, P19, DOI 10.1038/nsb882; SCHRADER WP, 1990, J BIOL CHEM, V265, P19312; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; Struyf S, 1999, J IMMUNOL, V162, P4903; Struyf S, 2003, ADV IMMUNOL, V81, P1, DOI 10.1016/S0065-2776(03)81001-5; Thoma R, 2003, STRUCTURE, V11, P947, DOI 10.1016/S0969-2126(03)00160-6; von Bonin A, 1998, IMMUNOL REV, V161, P43; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Weihofen WA, 2004, J BIOL CHEM, V279, P43330, DOI 10.1074/jbc.M405001200; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; Wrenger S, 1996, FEBS LETT, V383, P145, DOI 10.1016/0014-5793(96)00221-9; Wrenger S, 2000, J BIOL CHEM, V275, P22180, DOI 10.1074/jbc.M002338200; Wrenger S, 1997, J BIOL CHEM, V272, P30283, DOI 10.1074/jbc.272.48.30283; Wrenger S, 2000, ADV EXP MED BIOL, V477, P161	39	27	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14911	14917		10.1074/jbc.M413400200	http://dx.doi.org/10.1074/jbc.M413400200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15695814	hybrid			2022-12-25	WOS:000228236800070
J	Winfield, MD; Latifi, T; Groisman, EA				Winfield, MD; Latifi, T; Groisman, EA			Transcriptional regulation of the 4-amino-4-deoxy-L-arabinose biosynthetic genes in Yersinia pestis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMYXIN-RESISTANT MUTANTS; CATIONIC ANTIMICROBIAL PEPTIDES; ENTERICA SEROVAR TYPHIMURIUM; COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI K-12; SYSTEM PHOP-PHOQ; SALMONELLA-TYPHIMURIUM; LIPID-A; 2-COMPONENT SYSTEM; RESPONSE REGULATOR	Inducible membrane remodeling is an adaptive mechanism that enables Gram-negative bacteria to resist killing by cationic antimicrobial peptides and to avoid eliciting an immune response. Addition of 4-amino-4-deoxy-L-arabinose (4-aminoarabinose) moieties to the phosphate residues of the lipid A portion of the lipopolysaccharide decreases the net negative charge of the bacterial membrane resulting in protection from the cationic antimicrobial peptide polymyxin B. In Salmonella enterica serovar Typhimurium, the PmrA/PmrB two-component regulatory system governs resistance to polymyxin B by controlling transcription of the 4-aminoarabinose biosynthetic genes. Transcription of PmrA-activated genes is induced by Fe3+, which is sensed by PmrA cognate sensor PmrB, and by low Mg2+, in a mechanism that requires not only the PmrA and PmrB proteins but also the Mg2+-responding PhoP/PhoQ system and the PhoP-activated PmrD protein, a post-translational activator of the PmrA protein. Surprisingly, Yersinia pestis can promote PhoP-dependent modification of its lipid A with 4-aminoarabinose despite lacking a PmrD protein. Here we report that Yersinia uses different promoters to transcribe the 4-aminoarabinose biosynthetic genes pbgP and ugd depending on the inducing signal. This is accomplished by the presence of distinct binding sites for the PmrA and PhoP proteins in the promoters of the pbgP and ugd genes. Our results demonstrate that closely related bacterial species may use disparate regulatory pathways to control genes encoding conserved proteins.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL)	Groisman, EA (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, 660 S Euclid Ave,Campus Box 8230, St Louis, MO 63110 USA.	groisman@borcim.wustl.edu						Aguirre A, 2000, J BACTERIOL, V182, P3874, DOI 10.1128/JB.182.13.3874-3876.2000; Bengoechea JA, 1998, MICROBIOL-UK, V144, P1509, DOI 10.1099/00221287-144-6-1509; BOLL M, 1994, FEMS IMMUNOL MED MIC, V8, P329; BRADE H, 1999, ENDOTOXIN HLTH DIS, P31; Breazeale SD, 2003, J BIOL CHEM, V278, P24731, DOI 10.1074/jbc.M304043200; Breazeale SD, 2002, J BIOL CHEM, V277, P2886, DOI 10.1074/jbc.M109377200; Brubaker RR, 2004, MICROB ECOL, V47, P293, DOI 10.1007/s00248-003-1022-y; Chamnongpol S, 2000, J MOL BIOL, V300, P291, DOI 10.1006/jmbi.2000.3848; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Deng W, 2002, J BACTERIOL, V184, P4601, DOI 10.1128/JB.184.16.4601-4611.2002; Derzelle S, 2004, J BACTERIOL, V186, P1270, DOI 10.1128/JB.186.5.1270-1279.2004; Ernst RK, 1999, J INFECT DIS, V179, pS326, DOI 10.1086/513850; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; Gibbons HS, 2005, MOL MICROBIOL, V55, P425, DOI 10.1111/j.1365-2958.2004.04409.x; GILLELAND HE, 1982, CAN J MICROBIOL, V28, P830, DOI 10.1139/m82-125; Grabenstein JP, 2004, INFECT IMMUN, V72, P4973, DOI 10.1128/IAI.72.9.4973-4984.2004; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Groisman EA, 1997, J BACTERIOL, V179, P7040, DOI 10.1128/jb.179.22.7040-7045.1997; Gunn JS, 2000, INFECT IMMUN, V68, P6139, DOI 10.1128/IAI.68.11.6139-6146.2000; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Helander IM, 1996, EUR J BIOCHEM, V237, P272, DOI 10.1111/j.1432-1033.1996.0272n.x; Hitchen PG, 2002, MOL MICROBIOL, V44, P1637, DOI 10.1046/j.1365-2958.2002.02990.x; HOLT JG, 1994, BERGEYS MANUAL DETER, P189; Kato A, 2004, GENE DEV, V18, P2302, DOI 10.1101/gad.1230804; Kato A, 1999, J BACTERIOL, V181, P5516, DOI 10.1128/JB.181.17.5516-5520.1999; Kato A, 2003, P NATL ACAD SCI USA, V100, P4706, DOI 10.1073/pnas.0836837100; Kox LFF, 2000, EMBO J, V19, P1861, DOI 10.1093/emboj/19.8.1861; Lejona S, 2003, J BACTERIOL, V185, P6287, DOI 10.1128/JB.185.21.6287-6294.2003; Marchal K, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r9; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; McCue LA, 2002, GENOME RES, V12, P1523, DOI 10.1101/gr.323602; McPhee JB, 2003, MOL MICROBIOL, V50, P205, DOI 10.1046/j.1365-2958.2003.03673.x; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; Moskowitz SM, 2004, J BACTERIOL, V186, P575, DOI 10.1128/JB.186.2.575-579.2004; Mouslim C, 2003, MOL MICROBIOL, V47, P335, DOI 10.1046/j.1365-2958.2003.03318.x; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Oyston PCF, 2000, INFECT IMMUN, V68, P3419, DOI 10.1128/IAI.68.6.3419-3425.2000; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; PERRY RD, 1979, J BACTERIOL, V137, P1290, DOI 10.1128/JB.137.3.1290-1298.1979; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Porwollik S, 2002, P NATL ACAD SCI USA, V99, P8956, DOI 10.1073/pnas.122153699; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rebeil R, 2004, MOL MICROBIOL, V52, P1363, DOI 10.1111/j.1365-2958.2004.04059.x; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shin D, 2005, J BIOL CHEM, V280, P4089, DOI 10.1074/jbc.M412741200; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; Soncini FC, 1996, J BACTERIOL, V178, P6796, DOI 10.1128/jb.178.23.6796-6801.1996; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; STAGGS TM, 1991, J BACTERIOL, V173, P417, DOI 10.1128/jb.173.2.417-425.1991; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; VAARA M, 1979, J BACTERIOL, V139, P664, DOI 10.1128/JB.139.2.664-667.1979; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Wei J, 2003, INFECT IMMUN, V71, P2775, DOI 10.1128/IAI.71.5.2775-2786.2003; Winfield MD, 2004, P NATL ACAD SCI USA, V101, P17162, DOI 10.1073/pnas.0406038101; Wosten MMSM, 2000, CELL, V103, P113, DOI 10.1016/S0092-8674(00)00092-1; Wosten MMSM, 1999, J BIOL CHEM, V274, P27185, DOI 10.1074/jbc.274.38.27185; Yamamoto K, 2002, MOL MICROBIOL, V45, P423, DOI 10.1046/j.1365-2958.2002.03017.x; Zhou DS, 2004, J BACTERIOL, V186, P5138, DOI [10.1128/JB.186.15.5138-5146.2004, 10.1128/jb.186.15.5138-5146.2004]; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	64	80	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14765	14772		10.1074/jbc.M413900200	http://dx.doi.org/10.1074/jbc.M413900200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15710615	hybrid			2022-12-25	WOS:000228236800053
J	Nordlund, HR; Hytonen, VP; Laitinen, OH; Kulomaa, MS				Nordlund, HR; Hytonen, VP; Laitinen, OH; Kulomaa, MS			Novel avidin-like protein from a root nodule symbiotic bacterium, Bradyrhizobium japonicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOTIN-BINDING PROTEINS; CHICKEN AVIDIN; HIGH-AFFINITY; THERMAL-STABILITY; ANTIBODY-RESPONSE; SIGNAL PEPTIDE; IN-VITRO; STREPTAVIDIN; RADIOIMMUNOTHERAPY; PHARMACOKINETICS	Bradyrhizobium japonicum is an important nitrogen-fixing symbiotic bacterium, which can form root nodules on soybeans. These bacteria have a gene encoding a putative avidin- and streptavidin-like protein, which bears an amino acid sequence identity of only about 30% over the core regions with both of them. We produced this protein in Escherichia coli both as the full-length wild type and as a C-terminally truncated core form and showed that it is indeed a high affinity biotin-binding protein that resembles (strept)avidin structurally and functionally. Because of the considerable dissimilarity in the amino acid sequence, however, it is immunologically very different, and polyclonal rabbit and human antibodies toward (strept) avidin did not show significant cross-reactivity with it. Therefore this new avidin, named bradavidin, facilitates medical treatments such as targeted drug delivery, gene therapy, and imaging by offering an alternative tool for use if (strept) avidin cannot be used, because of a deleterious patient immune response for example. In addition to its medical value, bradavidin can be used both in other applications of avidin- biotin technology and as a source of new ideas when creating engineered (strept) avidin forms by changing or combining the desired parts, interface patterns, or specific residues within the avidin protein family. Moreover, the unexpected discovery of bradavidin indicates that the group of new and undiscovered bacterial avidin- like proteins may be both more diverse and more common than hitherto thought.	Univ Jyvaskyla, NanoSci Ctr, Dept Biol & Environm Sci, FIN-40014 Jyvaskyla, Finland; Univ Kuopio, AI Virtanen Inst, Dept Mol Med, FIN-70211 Kuopio, Finland	University of Jyvaskyla; Finland National Institute for Health & Welfare; University of Eastern Finland	Kulomaa, MS (corresponding author), Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland.	markku.kulomaa@uta.fi	Hytonen, Vesa P./E-8855-2013; Kulomaa, Markku S/C-9063-2014; Laitinen, Olli H/A-6618-2016	Hytonen, Vesa P./0000-0002-9357-1480; Laitinen, Olli H/0000-0002-3751-9952				Ahlroth MK, 2000, ANIM GENET, V31, P367, DOI 10.1046/j.1365-2052.2000.00681.x; Akasawa A, 1996, J BIOL CHEM, V271, P25389, DOI 10.1074/jbc.271.41.25389; ALON R, 1993, EUR J CELL BIOL, V60, P1; BAYER EA, 1995, BBA-GENE STRUCT EXPR, V1263, P60, DOI 10.1016/0167-4781(95)00077-T; Bayer EA, 1996, ELECTROPHORESIS, V17, P1319, DOI 10.1002/elps.1150170808; BEAUMIER PL, 1991, CANCER RES, V51, P676; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Boerman OC, 2003, J NUCL MED, V44, P400; BRUCH RC, 1982, BIOCHEMISTRY-US, V21, P5334, DOI 10.1021/bi00264a033; CHAIET L, 1964, ARCH BIOCHEM BIOPHYS, V106, P1, DOI 10.1016/0003-9861(64)90150-X; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; Chinol M, 1998, BRIT J CANCER, V78, P189, DOI 10.1038/bjc.1998.463; FLOWER DR, 1993, FEBS LETT, V333, P99, DOI 10.1016/0014-5793(93)80382-5; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Grana C, 2002, BRIT J CANCER, V86, P207, DOI 10.1038/sj.bjc.6600047; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; Hartley JL, 2000, GENOME RES, V10, P1788, DOI 10.1101/gr.143000; Hertz R, 1942, SCIENCE, V96, P257, DOI 10.1126/science.96.2489.257; Hytonen VP, 2004, J BIOL CHEM, V279, P9337, DOI 10.1074/jbc.M310989200; Hytonen VP, 2003, BIOCHEM J, V372, P219, DOI 10.1042/BJ20021531; Hytonen VR, 2004, BIOCHEM J, V384, P385, DOI 10.1042/BJ20041114; JONES PD, 1962, LIFE SCI, P621, DOI 10.1016/0024-3205(62)90094-2; KANG YS, 1994, J PHARMACOL EXP THER, V269, P344; KLEIN JL, 1989, CANCER RES, V49, P6383; Klumb LA, 1998, BIOCHEMISTRY-US, V37, P7657, DOI 10.1021/bi9803123; KNOX SJ, 1992, RADIOTHER ONCOL, V23, P111, DOI 10.1016/0167-8140(92)90342-R; KORPELA JK, 1981, EXPERIENTIA, V37, P1065, DOI 10.1007/BF02085010; Kramer KJ, 2000, NAT BIOTECHNOL, V18, P670, DOI 10.1038/76531; Laitinen OH, 2003, J BIOL CHEM, V278, P4010, DOI 10.1074/jbc.M205844200; Laitinen OH, 1999, FEBS LETT, V461, P52, DOI 10.1016/S0014-5793(99)01423-4; Laitinen OH, 2002, BIOCHEM J, V363, P609, DOI 10.1042/0264-6021:3630609; Lehtolainen P, 2003, GENE THER, V10, P2090, DOI 10.1038/sj.gt.3302120; Lehtolainen P, 2002, J BIOL CHEM, V277, P8545, DOI 10.1074/jbc.M109431200; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; MAJUMDER K, 1992, GENE, V110, P89, DOI 10.1016/0378-1119(92)90448-X; Marttila AT, 2003, BIOCHEM J, V369, P249, DOI 10.1042/BJ20020886; Meyer DL, 2001, PROTEIN SCI, V10, P491, DOI 10.1110/ps.19901; MORGAN TD, 1993, ENTOMOL EXP APPL, V69, P97, DOI 10.1007/BF02380637; Morpurgo M, 2004, J MOL RECOGNIT, V17, P558, DOI 10.1002/jmr.689; Murray S, 2002, BBA-GEN SUBJECTS, V1570, P81, DOI 10.1016/S0304-4165(02)00157-5; Nordlund HR, 2003, J BIOL CHEM, V278, P2479, DOI 10.1074/jbc.M210721200; Paganelli G, 1999, EUR J NUCL MED, V26, P348, DOI 10.1007/s002590050397; PAGANELLI G, 1991, CANCER RES, V51, P5960; Paganelli G, 1997, EUR J NUCL MED, V24, P350, DOI 10.1007/BF01728778; Pazy Y, 2002, J BIOL CHEM, V277, P30892, DOI 10.1074/jbc.M202874200; Raty JK, 2004, MOL THER, V9, P282, DOI 10.1016/j.ymthe.2003.11.004; Reznik GO, 1996, NAT BIOTECHNOL, V14, P1007, DOI 10.1038/nbt0896-1007; Rosebrough S F, 1996, Q J Nucl Med, V40, P234; Rosebrough SF, 1996, J NUCL MED, V37, P1380; ROSEBROUGH SF, 1993, NUCL MED BIOL, V20, P663, DOI 10.1016/0969-8051(93)90037-U; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SCHECHTER B, 1990, EUR J BIOCHEM, V189, P327, DOI 10.1111/j.1432-1033.1990.tb15493.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Wilchek M, 1999, BIOMOL ENG, V16, P1; WILCHEK M, 1990, METHOD ENZYMOL, V184, P5; Wojda U, 1999, BIOCONJUGATE CHEM, V10, P1044, DOI 10.1021/bc990059z; WOOD HG, 1977, ANNU REV BIOCHEM, V46, P385, DOI 10.1146/annurev.bi.46.070177.002125; Yao ZS, 1998, JNCI-J NATL CANCER I, V90, P25, DOI 10.1093/jnci/90.1.25; Yao ZS, 1999, J NUCL MED, V40, P479	60	52	53	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13250	13255		10.1074/jbc.M414336200	http://dx.doi.org/10.1074/jbc.M414336200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695809	hybrid			2022-12-25	WOS:000228095500008
J	Tao, GZ; Zhou, Q; Strnad, P; Salemi, MR; Lee, YM; Omary, MB				Tao, GZ; Zhou, Q; Strnad, P; Salemi, MR; Lee, YM; Omary, MB			Human ran cysteine 112 oxidation by pervanadate regulates its binding to keratins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; KAPPA-B-ALPHA; ACTIVATION; PHOSPHORYLATION; DJ-1; NEURODEGENERATION; DEGRADATION; INHIBITOR; FILAMENTS; VANADATE	We used a proteomic approach to identify proteins that associate with keratins 8 or 18 (K8/K18) in a pervanadate-dependent manner. Pervanadate triggers Ran-K8/K18 binding and a gel-migration-shift of Ran from 25 to 27 kDa, which does not occur upon exposure to H2O2 or vanadate or if pervanadate is excluded during cell solubilization. Generation of 27-kDa Ran is not related to hyperphosphorylation, is heat-insensitive, but occurs upon conversion of Ran cysteines to cysteic acid. The pervanadate-mediated Ran cysteine -> cysteic acid oxidation and its related gel migration shift affects other proteins including actin. Mutation of the three Ran cysteines (Cys-85, -112, and -120) showed that Ran Cys-112 oxidation generates 27-kDa Ran and accounts for its keratin binding. Proteasome inhibition accentuates Ran-keratin binding after cell exposure to pervanadate. Therefore, cell-free exposure to pervanadate causes cysteine to cysteic acid oxidation of Ran and several other proteins and Ran-K8/K18 association. In cells, stabilization of oxidized Ran by proteasome inhibition promotes Ran-keratin interaction. Keratin sequestration of oxidized Ran may provide a back-up protective mechanism in some cases of oxidative injury.	Palo Alto Vet Affairs Med Ctr, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; Univ Calif Davis, Mol Struct Facil, Davis, CA 95616 USA	Stanford University; University of California System; University of California Davis	Tao, GZ (corresponding author), Palo Alto Vet Affairs Med Ctr, Mail Code 154J,3801 Miranda Ave, Palo Alto, CA 94304 USA.	guozhongtao@stanford.edu	Strnad, Pavel/E-8555-2010	Omary, Bishr/0000-0002-8624-2347	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056339, R01DK052951] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52951, DK56339] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Choi J, 2004, J BIOL CHEM, V279, P13256, DOI 10.1074/jbc.M314124200; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; Coulombe PA, 2004, NAT CELL BIOL, V6, P699, DOI 10.1038/ncb0804-699; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Feng L, 1999, J CELL SCI, V112, P2081; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; Goldman RD, 1999, FASEB J, V13, pS261, DOI 10.1096/fasebj.13.9002.S261; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Hetzer M, 2002, NAT CELL BIOL, V4, pE177, DOI 10.1038/ncb0702-e177; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Kinumi T, 2004, BIOCHEM BIOPH RES CO, V317, P722, DOI 10.1016/j.bbrc.2004.03.110; Ku NO, 2004, J CELL BIOL, V166, P479, DOI 10.1083/jcb.200402051; Ku NO, 2002, P NATL ACAD SCI USA, V99, P4373, DOI 10.1073/pnas.072624299; Kunzler M, 2001, J CELL SCI, V114, P3233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Mukhopadhyay A, 2000, J BIOL CHEM, V275, P8549, DOI 10.1074/jbc.275.12.8549; Omary M B, 1998, Subcell Biochem, V31, P105; Omary MB, 2004, NEW ENGL J MED, V351, P2087, DOI 10.1056/NEJMra040319; Omary MB, 2002, HEPATOLOGY, V35, P251, DOI 10.1053/jhep.2002.31165; Park J, 2000, J CELL PHYSIOL, V185, P348, DOI 10.1002/1097-4652(200012)185:3<348::AID-JCP5>3.0.CO;2-3; Petropoulos I, 2000, J GERONTOL A-BIOL, V55, pB220, DOI 10.1093/gerona/55.5.B220; Quimby BB, 2003, CURR OPIN CELL BIOL, V15, P338, DOI 10.1016/S0955-0674(03)00046-2; Sazer S, 2000, J CELL SCI, V113, P1111; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; Shringarpure R, 2002, FREE RADICAL BIO MED, V32, P1084, DOI 10.1016/S0891-5849(02)00824-9; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; WIELAND T, 1993, J BIOL CHEM, V268, P18111; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	39	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12162	12167		10.1074/jbc.M412505200	http://dx.doi.org/10.1074/jbc.M412505200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15691838	hybrid			2022-12-25	WOS:000227922000014
J	Fazi, F; Travaglini, L; Carotti, D; Palitti, F; Diverio, D; Alcalay, M; McNamara, S; Miller, WH; Lo Coco, F; Pelicci, PG; Nervi, C				Fazi, F; Travaglini, L; Carotti, D; Palitti, F; Diverio, D; Alcalay, M; McNamara, S; Miller, WH; Lo Coco, F; Pelicci, PG; Nervi, C			Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo	ONCOGENE			English	Article						acute promyelocytic leukemia; retinoic acid; DNA methylation; histone deacetylases; differentiation therapy	ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; RECEPTOR-BETA GENE; PML/RAR-ALPHA; BREAST-CANCER; MYELOID-LEUKEMIA; RESIDUAL DISEASE; METHYLATION; TRANSCRIPTION; CELLS	The acute promyelocytic leukemia (PML)-retinoic acid receptor alpha (RAR alpha) fusion product recruits histone deacetylase ( HDAC) and DNA methyltransferase (DNMT) activities on retinoic acid (RA)-target promoters causing their silencing and differentiation block. RA treatment induces epigenetic modi. cations at its target loci and restores myeloid differentiation of APL blasts. Using RA-sensitive and RA-resistant APL cell lines and primary blasts, we addressed the functional relevance of the aberrant methylation status at the RA-target promoter RAR beta 2 and the mechanism by which methylation is reversed by RA. RA decreased DNMT expression and activity, which correlated with demethylation at specific sites on RAR beta 2 promoter/exon-1, and the ability of APL blasts to differentiate in vitro and in vivo. None of these events occurred in an RA-resistant APL cell line containing a PML-RAR alpha defective for ligand binding. The specific contribution of the HDAC and DNMT pathways to the response of APL cells to RA was also tested by inhibiting these enzymatic activities with TSA and/or 5-azacytidine. In RA-responsive and RA-resistant APL blasts, TSA and 5-azacytidine induced specific changes on the chromatin state at RA-target sites, increased the RA effect on promoter activity, endogenous RA-target gene expression and differentiation. These results extend the rationale for chromatin-targeted treatment in APL and RA-resistant leukemias.	Univ Roma La Sapienza, San Raffaele Biomed Sci Pk Rome, I-00128 Rome, Italy; Univ Roma La Sapienza, Dept Histol, I-00128 Rome, Italy; Univ Roma La Sapienza, Dept Med Embryol, I-00128 Rome, Italy; Univ Roma La Sapienza, Dept Biochem Sci, I-00128 Rome, Italy; Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00128 Rome, Italy; European Inst Oncol, Milan, Italy; IFOM, FIRC, Milan, Italy; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol & Med, Montreal, PQ, Canada; Univ Roma Tor Vergata, Dept Biopathol, I-00173 Rome, Italy	Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; Lady Davis Institute; McGill University; McGill University; University of Rome Tor Vergata	Nervi, C (corresponding author), Univ Roma La Sapienza, San Raffaele Biomed Sci Pk Rome, Via Castel Romano 100, I-00128 Rome, Italy.	clara.nervi@uniroma1.it	Alcalay, Myriam/AAB-4300-2019; Alcalay, Myriam/B-3182-2016; Travaglini, Lorena/AAA-6245-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; Fazi, Francesco/K-5304-2018	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Fazi, Francesco/0000-0003-2910-7912; NERVI, Clara/0000-0001-9341-0188; Travaglini, Lorena/0000-0003-0142-6516; CAROTTI, Daniela/0000-0001-6273-9749				APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; Benedetti L, 1996, BLOOD, V87, P1939; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; Cacciamani T, 2002, GENE, V297, P103, DOI 10.1016/S0378-1119(02)00874-0; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CAROTTI D, 1989, NUCLEIC ACIDS RES, V17, P9219, DOI 10.1093/nar/17.22.9219; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; Cote S, 2002, BLOOD, V100, P2586, DOI 10.1182/blood-2002-02-0614; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Fanelli M, 1999, BLOOD, V93, P1477, DOI 10.1182/blood.V93.5.1477.405a33_1477_1481; Ferrara FF, 2001, CANCER RES, V61, P2; Glass CK, 2000, GENE DEV, V14, P121; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hayashi K, 2001, DIFFERENTIATION, V68, P13, DOI 10.1046/j.1432-0436.2001.068001013.x; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; LANOTTE M, 1991, BLOOD, V77, P1080; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lo Coco F, 2002, CANCER RES, V62, P5618; Lo Coco F, 1999, BLOOD, V94, P12, DOI 10.1182/blood.V94.1.12.413a44_12_22; LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P; Mandelli F, 1997, BLOOD, V90, P1014; MARTIN B, 1992, SKIN PHARMACOL, V5, P57; Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MILLER WH, 1993, BLOOD, V82, P1689; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; MUINDI J, 1992, BLOOD, V79, P299; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nervi C, 1998, BLOOD, V92, P2244; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Petti MC, 2002, BLOOD, V100, P1065, DOI 10.1182/blood-2001-12-0368; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sirchia SM, 2002, CANCER RES, V62, P2455; Stirzaker C, 1997, CANCER RES, V57, P2229; Tallman MS, 2002, BLOOD, V99, P759, DOI 10.1182/blood.V99.3.759; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826	58	78	81	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 10	2005	24	11					1820	1830		10.1038/sj.onc.1208286	http://dx.doi.org/10.1038/sj.onc.1208286			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688037				2022-12-25	WOS:000227542000002
J	Lechanteur, C; Jacobs, N; Greimers, R; Benoit, V; Deregowski, V; Chariot, A; Merville, MP; Bours, V				Lechanteur, C; Jacobs, N; Greimers, R; Benoit, V; Deregowski, V; Chariot, A; Merville, MP; Bours, V			Low daunomycin concentrations protect colorectal cancer cells from hypoxia-induced apoptosis	ONCOGENE			English	Article						hypoxia; apoptosis; daunomycin; colorectal cancer; Akt; Bad	LOW-OXYGEN CONDITIONS; SOLID TUMORS; DRUG-RESISTANCE; IN-VITRO; P53; AKT; THERAPY; GROWTH; DOXORUBICIN; INHIBITION	Hypoxia, a common feature of solid tumors, is a direct stress that triggers apoptosis in many cell types. Poor or irregular tumor vascularization also leads to a decreased drug diffusion and cancer cells distant from blood vessels ( hypoxic cells) are exposed to low drug concentrations. In this report, we show that low daunomycin concentrations protect HCT116 colorectal cancer cells from hypoxia-induced apoptosis. While hypoxia induced p53 accumulation without expression of its responsive genes (bax and p21), daunomycin treatment restored p53 transactivation activity and cell cycle progression. We also demonstrated a role for Akt activation in daunomycin-induced protection through phosphorylation and inactivation of the Bcl-2 family proapoptotic factor Bad. Our data therefore suggest that chemotherapy could possibly, because of low concentrations in poorly vascularized tumors, protect cancer cells from hypoxia-induced cytotoxicity.	Univ Liege, Lab Med Chem & Human Genet, CHU B35, Ctr Biomed Integrated Genoprote,Lab Med Chem & Hu, B-4000 Liege, Belgium; Univ Liege, Ctr Biomed Integrated Genoprote, Lab Anatomopathol, Liege, Belgium	University of Liege; University of Liege	Bours, V (corresponding author), Univ Liege, Lab Med Chem & Human Genet, CHU B35, Ctr Biomed Integrated Genoprote,Lab Med Chem & Hu, B-4000 Liege, Belgium.	vbours@ulg.ac.be		Chariot, Alain/0000-0002-1691-4347; BENOIT, Valerie/0000-0002-1098-9452; Jacobs, Nathalie/0000-0002-9895-8465				Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Brown JM, 1998, CANCER RES, V58, P1408; Chao W, 2003, J GENE MED, V5, P277, DOI 10.1002/jgm.347; Clark AS, 2002, MOL CANCER THER, V1, P707; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Hirai K, 2004, MOL BRAIN RES, V124, P51, DOI 10.1016/j.molbrainres.2004.02.009; Kim CY, 1997, CANCER RES, V57, P4200; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Ogiso Y, 2000, CANCER RES, V60, P2429; Plo I, 1999, FEBS LETT, V452, P150, DOI 10.1016/S0014-5793(99)00631-6; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SANNA K, 1994, INT J CANCER, V58, P258, DOI 10.1002/ijc.2910580219; Tanaka M, 2003, GENE THER, V10, P1636, DOI 10.1038/sj.gt.3302056; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Tomida A, 1999, ANTI-CANCER DRUG DES, V14, P169; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yu JL, 2002, DIFFERENTIATION, V70, P599, DOI 10.1046/j.1432-0436.2002.700913.x; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	28	3	3	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1788	1793		10.1038/sj.onc.1208436	http://dx.doi.org/10.1038/sj.onc.1208436			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15688011	Green Published			2022-12-25	WOS:000227345100014
J	Merlino, A; Mazzarella, L; Carannante, A; Di Fiore, A; Di Donato, A; Notomista, E; Sica, F				Merlino, A; Mazzarella, L; Carannante, A; Di Fiore, A; Di Donato, A; Notomista, E; Sica, F			The importance of dynamic effects on the enzyme activity - X-ray structure and molecular dynamics of onconase mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SEMINAL RIBONUCLEASE; NMR RELAXATION MEASUREMENTS; N-15 RESONANCE ASSIGNMENTS; TERMINAL SWAPPED DIMER; PANCREATIC RIBONUCLEASE; CRYSTAL-STRUCTURE; CYTOTOXIC RIBONUCLEASE; ANTITUMOR-ACTIVITY; DOMAIN MOTIONS; N-TERMINUS	Onconase ( ONC), a member of the RNase A superfamily extracted from oocytes of Rana pipiens, is an effective cancer killer. It is currently used in treatment of various forms of cancer. ONC antitumor properties depend on its ribonucleolytic activity that is low in comparison with other members of the superfamily. The most damaging side effect from Onconase treatment is renal toxicity, which seems to be caused by the unusual stability of the enzyme. Therefore, mutants with reduced thermal stability and/or increased catalytic activity may have significant implications for human cancer chemotherapy. In this context, we have determined the crystal structures of two Onconase mutants (M23L-ONC and C87S, des103-104-ONC) and performed molecular dynamic simulations of ONC and C87S, des103-104-ONC with the aim of explaining on structural grounds the modifications of the activity and thermal stability of the mutants. The results also provide the molecular bases to explain the lower catalytic activity of Onconase compared with RNase A and the unusually high thermal stability of the amphibian enzyme.	Univ Naples Federico II, Complesso Univ Monte SantAngelo, Dipartimento Chim, I-80126 Naples, Italy; Complesso Ristrutturato S Andrea delle Dame, Ctr Reg Competenza Bioteknet, I-80138 Naples, Italy; CNR, Ist Biostrutture & Bioimmagini, I-80134 Naples, Italy; Univ Naples Federico II, Dipartimento Biol Strutturale & Funz, I-80126 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR); University of Naples Federico II	Sica, F (corresponding author), Univ Naples Federico II, Complesso Univ Monte SantAngelo, Dipartimento Chim, Via Cynthia, I-80126 Naples, Italy.	filomena.sica@unina.it	Di Fiore, Anna/AAW-3780-2020; Di Donato, Alberto/G-5494-2012; Merlino, Antonello/AAI-2114-2020; Di Fiore, Anna/AAX-5655-2020	Di Fiore, Anna/0000-0003-2924-5194; NOTOMISTA, Eugenio/0000-0003-0097-6487; Merlino, Antonello/0000-0002-1045-7720; DI DONATO, Alberto/0000-0001-9129-9850				ACHARYA KR, 1994, P NATL ACAD SCI USA, V91, P2915, DOI 10.1073/pnas.91.8.2915; AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Berisio R, 1999, J MOL BIOL, V292, P845, DOI 10.1006/jmbi.1999.3093; Berisio R, 2002, ACTA CRYSTALLOGR D, V58, P441, DOI 10.1107/S0907444901021758; Berman HM, 2000, NAT STRUCT BIOL, V7, P957, DOI 10.1038/80734; Blackburn P, 1982, ENZYMES, VXV, P317; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; BORKAKOTI N, 1983, J MOL BIOL, V169, P743, DOI 10.1016/S0022-2836(83)80168-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ceruso MA, 1999, PROTEIN SCI, V8, P147; Chatani E, 2002, PROTEIN SCI, V11, P72, DOI 10.1101/ps.31102; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; Daggett V, 2002, ACCOUNTS CHEM RES, V35, P422, DOI 10.1021/ar0100834; Day R, 2003, ADV PROTEIN CHEM, V66, P373; de Bakker PIW, 1999, J MOL BIOL, V285, P1811, DOI 10.1006/jmbi.1998.2397; de Groot BL, 1998, PROTEINS, V31, P116, DOI 10.1002/(SICI)1097-0134(19980501)31:2<116::AID-PROT2>3.0.CO;2-K; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esposito L, 2000, J MOL BIOL, V297, P713, DOI 10.1006/jmbi.2000.3597; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; FORMANKAY JD, 1992, J BIOMOL NMR, V2, P431, DOI 10.1007/BF02192807; GILLILAND GL, 1997, RIBONUCLEASES STRUCT, P306; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; Gorbatyuk VY, 2004, J BIOL CHEM, V279, P5772, DOI 10.1074/jbc.M311233200; Grottesi A, 2002, PROTEINS, V46, P287, DOI 10.1002/prot.10045; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Irie M, 1998, CELL MOL LIFE SCI, V54, P775, DOI 10.1007/s000180050206; Kelley JJ, 1997, BIOCHEMISTRY-US, V36, P5029, DOI 10.1021/bi962181g; Koshland DE, 1998, NAT MED, V4, P1112, DOI 10.1038/2605; Kowalski JM, 1998, BIOCHEMISTRY-US, V37, P1264, DOI 10.1021/bi9722397; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laity JH, 1997, BIOCHEMISTRY-US, V36, P12683, DOI 10.1021/bi970878b; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JE, 2003, BIOCHEMISTRY-US, V42, P11443, DOI 10.1021/bi035147s; Makarov AA, 2003, FEBS LETT, V540, P15, DOI 10.1016/S0014-5793(03)00225-4; MATOUSEK J, 1995, COMP BIOCHEM PHYS B, V112, P235, DOI 10.1016/0305-0491(95)00075-5; Matousek J, 2001, COMP BIOCHEM PHYS C, V129, P175, DOI 10.1016/S1532-0456(01)90202-9; Matousek J, 2003, COMP BIOCHEM PHYS C, V136, P343, DOI 10.1016/j.cca.2003.10.005; MAZZARELLA L, 1993, ACTA CRYSTALLOGR D, V49, P389, DOI 10.1107/S0907444993003403; Merlino A, 2005, BIOPHYS J, V88, P2003, DOI 10.1529/biophysj.104.048611; Merlino A, 2004, PROTEINS, V57, P692, DOI 10.1002/prot.20270; Merlino A, 2004, BIOPOLYMERS, V73, P689, DOI 10.1002/bip.20016; Merlino A, 2004, BIOPHYS J, V86, P2383, DOI 10.1016/S0006-3495(04)74295-2; Merlino A, 2003, PROTEINS, V53, P101, DOI 10.1002/prot.10466; Merlino A, 2002, BIOPOLYMERS, V65, P274, DOI 10.1002/bip.10225; MOSIMANN SC, 1994, J MOL BIOL, V236, P1141, DOI 10.1016/0022-2836(94)90017-5; Newton DL, 1998, BIOCHEMISTRY-US, V37, P5173, DOI 10.1021/bi972147h; Notomista E, 2001, BIOCHEMISTRY-US, V40, P9097, DOI 10.1021/bi010741s; Notomista E, 2000, BIOCHEMISTRY-US, V39, P8711, DOI 10.1021/bi000415x; Notomista E, 1999, FEBS LETT, V463, P211, DOI 10.1016/S0014-5793(99)01623-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; RASMUSSEN BF, 1992, NATURE, V357, P423, DOI 10.1038/357423a0; Shimotakahara S, 1997, BIOCHEMISTRY-US, V36, P6915, DOI 10.1021/bi963024k; Soucek J, 1996, NEOPLASMA, V43, P335; STONE MJ, 1993, BIOCHEMISTRY-US, V32, P426, DOI 10.1021/bi00053a007; TILTON RF, 1992, BIOCHEMISTRY-US, V31, P2469, DOI 10.1021/bi00124a006; van der Spoel D, 1994, GRONINGEN MACHINE CH; vanAalten DMF, 1997, BIOPHYS J, V73, P2891, DOI 10.1016/S0006-3495(97)78317-6; Vasandani VM, 1999, CANCER CHEMOTH PHARM, V44, P164, DOI 10.1007/s002800050962; Vitagliano L, 1998, PROTEIN SCI, V7, P1691, DOI 10.1002/pro.5560070804; Vitagliano L, 2000, PROTEIN SCI, V9, P1217, DOI 10.1110/ps.9.6.1217; Vitagliano L, 2002, PROTEINS, V46, P97, DOI 10.1002/prot.10033; VOGL T, 1995, J MOL BIOL, V254, P481, DOI 10.1006/jmbi.1995.0632; WU YN, 1993, J BIOL CHEM, V268, P10686; YOULE RJ, 1996, RIBONUCLEASE STRUCTU, P491; ZEGERS I, 1994, PROTEIN SCI, V3, P2322, DOI 10.1002/pro.5560031217	68	35	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17953	17960		10.1074/jbc.M501339200	http://dx.doi.org/10.1074/jbc.M501339200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728177	hybrid			2022-12-25	WOS:000228807200049
J	Ray, N; Nenninger, A; Mullineaux, CW; Robinson, C				Ray, N; Nenninger, A; Mullineaux, CW; Robinson, C			Location and mobility of twin arginine translocase subunits in the Escherichia coli plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT PROTEIN EXPORT; SIGNAL PEPTIDE; THYLAKOID MEMBRANES; TATABC COMPLEX; PATHWAY; SYSTEM; BACTERIAL; TATC; EXPRESSION; COMPONENTS	The twin arginine translocation ( Tat) system transports folded proteins across the bacterial plasma membrane. Two primary Tat complexes have been identified, comprising TatABC or TatA multimers, which may interact at the point of translocation. We have analyzed green/cyan/yellow fluorescent protein (XFP) fusions to each of the Tat subunits. We show that the TatB and TatC fusions are active and incorporated into purified TatABC complexes. Proteolytic clipping of the TatA-XFP fusion precludes a definitive conclusion regarding activity, but we do find that the full fusion protein is preferentially incorporated into the TatABC complex. A previous study has proposed that TatB and possibly TatC are localized at the cell poles, whereas TatA is distributed more uniformly throughout the plasma membrane. Here, we likewise show that TatA-XFP is primarily distributed around the periphery of the cell. However, whereas much of the TatB-XFP is found at the poles, quantitative imaging studies show that approximately half of the protein is uniformly distributed in the plasma membrane. Moreover, we show that the bulk of TatC-XFP is detected as a halo around the cells, in some cases as punctate areas that are much smaller than those occupied by TatB-green fluorescent protein (GFP), indicating a uniform distribution. No evidence for a polar localization of TatC-GFP was obtained. Although TatC-GFP is found correctly complexed with TatB, a high proportion of TatB-GFP is not linked to TatC, and we propose that this "free" TatB forms unphysiological assemblies, possibly because it is synthesized in excess. Since TatC is invariably complexed with TatB in wildtype complexes, the combined data demonstrate that TatABC complexes are uniformly distributed throughout the plasma membrane. The significance of the punctate TatA/B/C-GFP is unclear; fluorescence recovery after photobleaching measurements show that these pools of proteins are immobile, whereas nonaggregated proteins are highly mobile in the plasma membrane.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; UCL, Dept Biol, London WC1E 6BT, England	University of Warwick; University of London; University College London	Robinson, C (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	Crobinson@bio.warwick.ac.uk			Biotechnology and Biological Sciences Research Council [BB/C00437X/1] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Alami M, 2003, MOL CELL, V12, P937, DOI 10.1016/S1097-2765(03)00398-8; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Berthelmann F, 2004, FEBS LETT, V569, P82, DOI 10.1016/j.febslet.2004.05.054; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Bolhuis A, 2000, FEBS LETT, V472, P88, DOI 10.1016/S0014-5793(00)01428-9; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; Clark SA, 1997, MOL BIOL CELL, V8, P923, DOI 10.1091/mbc.8.5.923; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; Elowitz MB, 1999, J BACTERIOL, V181, P197, DOI 10.1128/JB.181.1.197-203.1999; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hynds PJ, 1998, J BIOL CHEM, V273, P34868, DOI 10.1074/jbc.273.52.34868; Jack RL, 2001, J BACTERIOL, V183, P1801, DOI 10.1128/JB.183.5.1801-1804.2001; Jongbloed JDH, 2000, J BIOL CHEM, V275, P41350, DOI 10.1074/jbc.M004887200; Mangels D, 2005, J MOL BIOL, V345, P415, DOI 10.1016/j.jmb.2004.10.043; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Oates J, 2005, J MOL BIOL, V346, P295, DOI 10.1016/j.jmb.2004.11.047; Oates J, 2003, J MOL BIOL, V330, P277, DOI 10.1016/S0022-2836(03)00621-1; Porcelli I, 2002, BIOCHEMISTRY-US, V41, P13690, DOI 10.1021/bi026142i; Robinson C, 2001, NAT REV MOL CELL BIO, V2, P350, DOI 10.1038/35073038; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sarcina M, 2004, J BIOL CHEM, V279, P36514, DOI 10.1074/jbc.M405881200; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; Yen MR, 2002, ARCH MICROBIOL, V177, P441, DOI 10.1007/s00203-002-0408-4	29	24	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17961	17968		10.1074/jbc.M413521200	http://dx.doi.org/10.1074/jbc.M413521200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728576	hybrid			2022-12-25	WOS:000228807200050
J	Becker, M; Bunikis, J; Lade, BD; Dunn, JJ; Barbour, AG; Lawson, CL				Becker, M; Bunikis, J; Lade, BD; Dunn, JJ; Barbour, AG; Lawson, CL			Structural investigation of Borrelia burgdorferi OspB, a bactericidalFab target	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-SURFACE PROTEIN; LYME-DISEASE SPIROCHETE; ANTILYSOZYME ANTIBODY HYHEL-63; LAYER BETA-SHEET; MONOCLONAL-ANTIBODY; MOLECULAR ANALYSIS; PROTECTIVE IMMUNITY; HYDROGEN-EXCHANGE; CRYSTAL-STRUCTURE; IN-VIVO	Certain antibody Fab fragments directed against the C terminus of outer surface protein B (OspB), a major lipoprotein of the Lyme disease spirochete, Borrelia burgdorferi, have the unusual property of being bactericidal even in the absence of complement. We report here x-ray crystal structures of a C-terminal fragment of B. burgdorferi OspB, which spans residues 152-296, alone at 2.0-angstrom resolution, and in a complex with the bactericidal Fab H6831 at 2.6-angstrom resolution. The H6831 epitope is topologically analogous to the LA-2 epitope of OspA and is centered around OspB Lys-253, a residue essential for H6831 recognition. A beta-sheet present in the free OspB fragment is either disordered or removed by proteolysis in the H6831-bound complex. Other conformational changes between free and H6831-bound structures are minor and appear to be related to this loss. In both crystal structures, OspB C-terminal fragments form artificial dimers connected by intermolecular beta-sheets. OspB structure, stability, and possible mechanisms of killing by H6831 and other bactericidal Fabs are discussed in light of the structural data.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Univ Calif Irvine, Coll Med, Dept Microbiol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Mol & Med Genet, Irvine, CA 92697 USA; Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; University of California System; University of California Irvine; University of California System; University of California Irvine; Rutgers State University New Brunswick	Becker, M (corresponding author), Brookhaven Natl Lab, Dept Biol, Bldg 463,POB 5000, Upton, NY 11973 USA.	mbecker@bnl.gov; cathy.lawson@rutgers.edu	Barbour, Alan/B-3160-2009	Barbour, Alan/0000-0002-0719-5248; Lawson, Catherine/0000-0002-3261-7035	NIAID NIH HHS [AI37248, AI24424] Funding Source: Medline; PHS HHS [R01-A137256] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037248, R37AI024424, R01AI024424] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akin E, 1999, INFECT IMMUN, V67, P173, DOI 10.1128/IAI.67.1.173-181.1999; BARBOUR AG, 1984, INFECT IMMUN, V45, P94, DOI 10.1128/IAI.45.1.94-100.1984; BARBOUR AG, 1985, J INFECT DIS, V152, P478, DOI 10.1093/infdis/152.3.478; BARBOUR AG, 1993, SCIENCE, V260, P1610, DOI 10.1126/science.8503006; BENJAMIN DC, 1992, BIOCHEMISTRY-US, V31, P9539, DOI 10.1021/bi00155a005; BERGSTROM S, 1989, MOL MICROBIOL, V3, P479, DOI 10.1111/j.1365-2958.1989.tb00194.x; BRANDT ME, 1990, INFECT IMMUN, V58, P983, DOI 10.1128/IAI.58.4.983-991.1990; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUNDOC VG, 1989, INFECT IMMUN, V57, P2733, DOI 10.1128/IAI.57.9.2733-2741.1989; Bunikis J, 1999, INFECT IMMUN, V67, P2874, DOI 10.1128/IAI.67.6.2874-2883.1999; CHACKO S, 1995, J MOL BIOL, V245, P261, DOI 10.1006/jmbi.1994.0022; COLEMAN JL, 1992, INFECT IMMUN, V60, P3098, DOI 10.1128/IAI.60.8.3098-3104.1992; COLEMAN JL, 1994, INFECT IMMUN, V62, P303, DOI 10.1128/IAI.62.1.303-307.1994; Connolly SE, 2004, J IMMUNOL, V172, P1191, DOI 10.4049/jimmunol.172.2.1191; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; deSilva AM, 1996, J EXP MED, V183, P271, DOI 10.1084/jem.183.1.271; Ding W, 2000, J MOL BIOL, V302, P1153, DOI 10.1006/jmbi.2000.4119; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Dunn J J, 1990, Protein Expr Purif, V1, P159, DOI 10.1016/1046-5928(90)90011-M; Escudero R, 1997, INFECT IMMUN, V65, P1908, DOI 10.1128/IAI.65.5.1908-1915.1997; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fikrig E, 2004, INFECT IMMUN, V72, P1755, DOI 10.1128/IAI.72.3.1755-1759.2004; FIKRIG E, 1995, INFECT IMMUN, V63, P1658, DOI 10.1128/IAI.63.5.1658-1662.1995; FIKRIG E, 1993, P NATL ACAD SCI USA, V90, P4092, DOI 10.1073/pnas.90.9.4092; FIKRIG E, 1992, INFECT IMMUN, V60, P657, DOI 10.1128/IAI.60.2.657-661.1992; FIKRIG E, 1995, J EXP MED, V181, P215, DOI 10.1084/jem.181.1.215; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Golde WT, 1997, INFECT IMMUN, V65, P882, DOI 10.1128/IAI.65.3.882-889.1997; Hertadi R, 2003, J MOL BIOL, V333, P993, DOI 10.1016/j.jmb.2003.09.010; HOWE TR, 1985, SCIENCE, V227, P645, DOI 10.1126/science.3969554; Huang XL, 2001, J MOL BIOL, V308, P367, DOI 10.1006/jmbi.2001.4579; Katona LI, 2000, J IMMUNOL, V164, P1425, DOI 10.4049/jimmunol.164.3.1425; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWSON CL, 1995, ACTA CRYSTALLOGR D, V51, P853, DOI 10.1107/S0907444995002265; Li H, 1995, J STRUCT BIOL, V115, P335, DOI 10.1006/jsbi.1995.1058; Li H, 1997, P NATL ACAD SCI USA, V94, P3584, DOI 10.1073/pnas.94.8.3584; Li YL, 2003, BIOCHEMISTRY-US, V42, P11, DOI 10.1021/bi020589+; Li YL, 2000, BIOCHEMISTRY-US, V39, P6296, DOI 10.1021/bi000054l; Liang FT, 2004, MICROB PATHOGENESIS, V37, P35, DOI 10.1016/j.micpath.2004.02.007; MA JN, 1995, INFECT IMMUN, V63, P2221, DOI 10.1128/IAI.63.6.2221-2227.1995; Marraffini LA, 2004, J BIOL CHEM, V279, P37763, DOI 10.1074/jbc.M405282200; MORONI A, 1992, MICROBIOLOGICA, V15, P99; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nieva J, 2004, TRENDS BIOCHEM SCI, V29, P274, DOI 10.1016/j.tibs.2004.03.009; Ohnishi S, 2001, PROTEIN SCI, V10, P2083, DOI 10.1110/ps.15901; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pal U, 2000, J CLIN INVEST, V106, P561, DOI 10.1172/JCI9427; Pal U, 2001, J IMMUNOL, V166, P7398, DOI 10.4049/jimmunol.166.12.7398; Pham TN, 1998, NAT STRUCT BIOL, V5, P115, DOI 10.1038/nsb0298-115; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; Probert WS, 1997, VACCINE, V15, P15, DOI 10.1016/S0264-410X(96)00123-5; Rathinavelu S, 2003, INFECT IMMUN, V71, P822, DOI 10.1128/IAI.71.2.822-829.2003; READ RJ, 1988, J MOL BIOL, V200, P523, DOI 10.1016/0022-2836(88)90541-4; ROSA PA, 1992, MOL MICROBIOL, V6, P3031, DOI 10.1111/j.1365-2958.1992.tb01761.x; SADZIENE A, 1995, INFECT IMMUN, V63, P1573, DOI 10.1128/IAI.63.4.1573-1580.1995; SADZIENE A, 1994, INFECT IMMUN, V62, P2037, DOI 10.1128/IAI.62.5.2037-2045.1994; SADZIENE A, 1993, INFECT IMMUN, V61, P3590, DOI 10.1128/IAI.61.9.3590-3596.1993; SCHUBACH WH, 1991, INFECT IMMUN, V59, P1911, DOI 10.1128/IAI.59.6.1911-1915.1991; Schwan TG, 2003, BIOCHEM SOC T, V31, P108, DOI 10.1042/BST0310108; SCHWAN TG, 1993, J CLIN MICROBIOL, V31, P3096, DOI 10.1128/JCM.31.12.3096-3108.1993; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; SIMON MM, 1991, J INFECT DIS, V164, P123, DOI 10.1093/infdis/164.1.123; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR PW, 1992, EXP CLIN IMMUNOGENET, V9, P48; Williams DC, 1996, J MOL BIOL, V257, P866, DOI 10.1006/jmbi.1996.0207; WILSKE B, 1988, ANN NY ACAD SCI, V539, P126, DOI 10.1111/j.1749-6632.1988.tb31846.x; Yan S, 2002, J MOL BIOL, V323, P363, DOI 10.1016/S0022-2836(02)00882-3; Yan SD, 2004, J MOL BIOL, V338, P811, DOI 10.1016/j.jmb.2004.02.063; Yang XFF, 2004, J EXP MED, V199, P641, DOI 10.1084/jem.20031960	75	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17363	17370		10.1074/jbc.M412842200	http://dx.doi.org/10.1074/jbc.M412842200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15713683	hybrid			2022-12-25	WOS:000228615500101
J	Ermakova, S; Choi, BY; Choi, HS; Kang, BS; Bode, AM; Dong, ZG				Ermakova, S; Choi, BY; Choi, HS; Kang, BS; Bode, AM; Dong, ZG			The intermediate filament protein vimentin is a new target for epigallocatechin gallate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN TEA CATECHINS; CELL-PROLIFERATION; HUMAN PROSTATE; GROWTH-INHIBITION; MOTILE PROPERTIES; PHOSPHORYLATION; APOPTOSIS; CANCER; INDUCTION; KINASE	Epigallocatechin gallate ( EGCG) is the major active polyphenol in green tea. Protein interaction with EGCG is a critical step in the effects of EGCG on the regulation of various key proteins involved in signal transduction. We have identified a novel molecular target of EGCG using affinity chromatography, two-dimensional electrophoresis, and mass spectrometry for protein identification. Spots of interest were identified as the intermediate filament, vimentin. The identification was confirmed by Western blot analysis using an anti-vimentin antibody. Experiments using a pull-down assay with [H-3] EGCG demonstrate binding of EGCG to vimentin with a K-d of 3.3 nM. EGCG inhibited phosphorylation of vimentin at serines 50 and 55 and phosphorylation of vimentin by cyclin-dependent kinase 2 and cAMP- dependent protein kinase. EGCG specifically inhibits cell proliferation by binding to vimentin. Because vimentin is important for maintaining cellular functions and is essential in maintaining the structure and mechanical integration of the cellular space, the inhibitory effect of EGCG on vimentin may further explain its anti-tumor-promoting effect.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	Ermakova, Svetlana P/G-2766-2013	Ermakova, Svetlana/0000-0002-5905-2046	NCI NIH HHS [CA88961, CA81064] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA081064, R01CA081064, P01CA088961] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad N, 1999, NUTR REV, V57, P78, DOI 10.1111/j.1753-4887.1999.tb06927.x; ANDO S, 1989, BIOCHEMISTRY-US, V28, P2974, DOI 10.1021/bi00433a035; Bousquet O, 1996, CELL MOTIL CYTOSKEL, V33, P115, DOI 10.1002/(SICI)1097-0169(1996)33:2<115::AID-CM4>3.0.CO;2-B; Brusselmans K, 2003, INT J CANCER, V106, P856, DOI 10.1002/ijc.11317; Chen AP, 2003, J BIOL CHEM, V278, P23381, DOI 10.1074/jbc.M212042200; Cheng TJ, 2003, J CELL BIOCHEM, V89, P589, DOI 10.1002/jcb.10511; CHOU YH, 1991, J BIOL CHEM, V266, P7325; Chou YH, 1996, J CELL SCI, V109, P817; Chou YH, 2000, J CELL BIOL, V150, pF101, DOI 10.1083/jcb.150.3.F101; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; Chung LY, 2001, LIFE SCI, V68, P1207, DOI 10.1016/S0024-3205(00)01020-1; Dong ZG, 2000, BIOFACTORS, V12, P17, DOI 10.1002/biof.5520120104; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; Goto H, 2002, GENES CELLS, V7, P91, DOI 10.1046/j.1356-9597.2001.00504.x; Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006/taap.1999.8885; Hayakawa S, 2001, BIOCHEM BIOPH RES CO, V285, P1102, DOI 10.1006/bbrc.2001.5293; He ZW, 2003, CANCER RES, V63, P4396; Helfand BT, 2003, ANNU REV CELL DEV BI, V19, P445, DOI 10.1146/annurev.cellbio.19.111401.092306; HUANG TJ, 1994, J PROTEIN CHEM, V13, P517, DOI 10.1007/BF01901533; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; Islam S, 2000, BIOCHEM BIOPH RES CO, V270, P793, DOI 10.1006/bbrc.2000.2536; Kavanagh KT, 2001, J CELL BIOCHEM, V82, P387, DOI 10.1002/jcb.1164; Kelloff GJ, 2000, J NUTR, V130, p467S, DOI 10.1093/jn/130.2.467S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lalonde R, 2003, REV NEUROSCIENCE, V14, P369; Lambert JD, 2003, J NUTR, V133, p3262S, DOI 10.1093/jn/133.10.3262S; LEA MA, 1993, CANCER LETT, V68, P231, DOI 10.1016/0304-3835(93)90151-X; Liang YC, 1999, CARCINOGENESIS, V20, P733, DOI 10.1093/carcin/20.4.733; LIAO SS, 1995, CANCER LETT, V96, P239, DOI 10.1016/0304-3835(95)03948-V; Matsuzawa K, 1997, BIOCHEM BIOPH RES CO, V234, P621, DOI 10.1006/bbrc.1997.6669; Okayama N, 2000, IN VITRO CELL DEV-AN, V36, P228; Pianetti S, 2002, CANCER RES, V62, P652; SAEZ R, 1991, NEUROCHEM RES, V16, P737, DOI 10.1007/BF00965682; Sazuka M, 1998, BIOSCI BIOTECH BIOCH, V62, P1031, DOI 10.1271/bbb.62.1031; Strelkov SV, 2001, J MOL BIOL, V306, P773, DOI 10.1006/jmbi.2001.4442; Suzuki Y, 2001, CANCER LETT, V173, P15, DOI 10.1016/S0304-3835(01)00685-1; Tachibana H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743; Takai Y, 1996, Tanpakushitsu Kakusan Koso, V41, P1920; TOKUI T, 1990, BIOCHEM BIOPH RES CO, V169, P896, DOI 10.1016/0006-291X(90)91977-Z; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; Uesato S, 2001, CANCER LETT, V170, P41, DOI 10.1016/S0304-3835(01)00571-7; Yang CS, 2002, ANNU REV PHARMACOL, V42, P25, DOI 10.1146/annurev.pharmtox.42.082101.154309; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Yasui Y, 2001, ONCOGENE, V20, P2868, DOI 10.1038/sj.onc.1204407; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147	50	126	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16882	16890		10.1074/jbc.M414185200	http://dx.doi.org/10.1074/jbc.M414185200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15713670	hybrid			2022-12-25	WOS:000228615500042
J	Finigan, JH; Dudek, SM; Singleton, PA; Chiang, ET; Jacobson, JR; Camp, SM; Ye, SQ; Garcia, JGN				Finigan, JH; Dudek, SM; Singleton, PA; Chiang, ET; Jacobson, JR; Camp, SM; Ye, SQ; Garcia, JGN			Activated protein C mediates novel lung endothelial barrier enhancement - Role of sphingosine 1-phosphate receptor transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; THROMBIN-INDUCED INCREASE; FACTOR PATHWAY INHIBITOR; CELL GAP FORMATION; SEVERE SEPSIS; INTRAVASCULAR COAGULATION; BETA RECEPTOR; PERMEABILITY; DEFICIENCY; EXPRESSION	Increased endothelial cell (EC) permeability is central to the pathophysiology of inflammatory syndromes such as sepsis and acute lung injury (ALI). Activated protein C (APC), a serine protease critically involved in the regulation of coagulation and inflammatory processes, improves sepsis survival through an unknown mechanism. We hypothesized a direct effect of APC to both prevent increased EC permeability and to restore vascular integrity after edemagenic agonists. We measured changes in transendothelial electrical resistance (TER) and observed that APC produced concentration-dependent attenuation of TER reductions evoked by thrombin. We next explored known EC barrier-protective signaling pathways and observed dose-dependent APC-mediated increases in cortical myosin light chain (MLC) phosphorylation in concert with cortically distributed actin polymerization, findings highly suggestive of Rac GTPase involvement. We next determined that APC directly increases Rac1 activity, with inhibition of Rac1 activity significantly attenuating APC-mediated barrier protection to thrombin challenge. Finally, as these signaling events were similar to those evoked by the potent EC barrier-enhancing agonist, sphingosine 1-phosphate (S1P), we explored potential cross-talk between endothelial protein C receptor (EPCR) and S1P(1), the receptors for APC and S1P, respectively. EPCR-blocking antibody (RCR-252) significantly attenuated both APC-mediated barrier protection and increased MLC phosphorylation. We next observed rapid, EPCR and PI 3-kinase-dependent, APC-mediated phosphorylation of S1P(1) on threonine residues consistent with S1P(1) receptor activation. Co-immunoprecipitation studies demonstrate an interaction between EPCR and S1P(1) upon APC treatment. Targeted silencing of S1P(1) expression using siRNA significantly reduced APC-mediated barrier protection against thrombin. These data suggest that novel EPCR ligation and S1P(1) transactivation results in EC cytoskeletal rearrangement and barrier protection, components potentially critical to the improved survival of APC-treated patients with severe sepsis.	Johns Hopkins Univ, Div Pulm & Crit Care Med, Ctr Translat Resp Med, Baltimore, MD 21224 USA	Johns Hopkins University	Garcia, JGN (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Med, 5841 S Maryland Ave,W604, Chicago, IL 60637 USA.	jgarcia@medicine.bsd.uchicago.edu	Garcia, Joe GN/E-8862-2010					Abraham E, 2003, JAMA-J AM MED ASSOC, V290, P238, DOI 10.1001/jama.290.2.238; Amerongen GPV, 1998, CIRC RES, V83, P1115, DOI 10.1161/01.RES.83.11.1115; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Birukov KG, 2004, CIRC RES, V95, P892, DOI 10.1161/01.RES.0000147310.18962.06; Birukov KG, 2002, AM J RESP CELL MOL, V26, P453, DOI 10.1165/ajrcmb.26.4.4725; Birukov KG, 2001, J BIOL CHEM, V276, P8567, DOI 10.1074/jbc.M005270200; BONE RC, 1976, AM J MED, V61, P585, DOI 10.1016/0002-9343(76)90135-2; BRANSON HE, 1983, LANCET, V2, P1165; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Feistritzer C, 2003, J ALLERGY CLIN IMMUN, V112, P375, DOI 10.1067/mai.2003.1609; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; Gando S, 1996, THROMB HAEMOSTASIS, V75, P224; Garcia JGN, 1997, AM J PHYSIOL-LUNG C, V273, pL172, DOI 10.1152/ajplung.1997.273.1.L172; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; GARCIA JGN, 1995, J INVEST MED, V43, P117; GARCIA JGN, 1986, J CELL PHYSIOL, V128, P96, DOI 10.1002/jcp.1041280115; GARCIA JGN, 1993, J CELL PHYSIOL, V156, P541, DOI 10.1002/jcp.1041560313; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989; Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; Harada N, 1999, BLOOD, V93, P157, DOI 10.1182/blood.V93.1.157.401k08_157_164; Igarashi J, 2003, P NATL ACAD SCI USA, V100, P10664, DOI 10.1073/pnas.1934494100; Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC; Kalil AC, 2004, SHOCK, V21, P222, DOI 10.1097/01.shk.0000116778.27924.79; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com; LO SK, 1992, J CELL PHYSIOL, V151, P63, DOI 10.1002/jcp.1041510111; LUM H, 1993, J CELL BIOL, V120, P1491, DOI 10.1083/jcb.120.6.1491; McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc; Murakami K, 1997, AM J PHYSIOL-LUNG C, V272, pL197, DOI 10.1152/ajplung.1997.272.2.L197; Oganesyan V, 2002, J BIOL CHEM, V277, P24851, DOI 10.1074/jbc.C200163200; Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC; Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC; Petrache I, 2001, AM J PHYSIOL-LUNG C, V280, pL1168, DOI 10.1152/ajplung.2001.280.6.L1168; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Rosenfeldt HM, 2001, BIOCHEM SOC T, V29, P836, DOI 10.1042/0300-5127:0290836; Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002; Schaphorst KL, 1997, AM J RESP CELL MOL, V17, P443, DOI 10.1165/ajrcmb.17.4.2502; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; Singleton PA, 2002, CELL MOTIL CYTOSKEL, V53, P293, DOI 10.1002/cm.10078; Sturn DH, 2003, BLOOD, V102, P1499, DOI 10.1182/blood-2002-12-3880; Tanimoto T, 2004, CIRC RES, V94, P1050, DOI 10.1161/01.RES.0000126404.41421.BE; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Taylor FB, 2001, BLOOD, V97, P1685, DOI 10.1182/blood.V97.6.1685; Vervloet MG, 1998, SEMIN THROMB HEMOST, V24, P33, DOI 10.1055/s-2007-995821; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; Warren BL, 2001, JAMA-J AM MED ASSOC, V286, P1869, DOI 10.1001/jama.286.15.1869; Waters C, 2003, J BIOL CHEM, V278, P6282, DOI 10.1074/jbc.M208560200; Yuksel M, 2002, THROMB HAEMOSTASIS, V88, P267	56	313	323	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17286	17293		10.1074/jbc.M412427200	http://dx.doi.org/10.1074/jbc.M412427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15710622	hybrid			2022-12-25	WOS:000228615500092
J	Jo, MJ; Thomas, KS; Marozkina, N; Amin, TJ; Silva, CM; Parsons, SJ; Gonias, SL				Jo, MJ; Thomas, KS; Marozkina, N; Amin, TJ; Silva, CM; Parsons, SJ; Gonias, SL			Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PROTEIN-COUPLED RECEPTORS; REGULATED KINASE 1; EGF RECEPTOR; TYROSINE KINASE; BREAST-CANCER; C-SRC; HUMAN CARCINOMA; CELL-MIGRATION; CYCLIN D1	The urokinase-type plasminogen activator (uPA) receptor ( uPAR) functions in concert with co-receptors, including integrins, FPR-like receptor-1/lipoxin A4 receptor, and the epidermal growth factor receptor ( EGFR), to initiate cell signaling. uPAR co-receptors may be dynamically organized into a multiprotein signaling receptor complex. In Chinese hamster ovary-K1 (CHO-K1) cells, uPA-binding to uPAR activates ERK/ MAP kinase, even though these cells do not express the EGFR; however, when CHO-K1 cells are transfected to express the EGFR, ERK activation becomes EGFR-dependent. In this study, we demonstrate that ERK activation in response to uPA follows equivalent biphasic kinetics in EGFR-expressing and -deficient CHO-K1 cells. In both cell types, the response is pertussis toxin-sensitive; however, uPA promotes cell proliferation exclusively in the EGFR-expressing cells. uPA-induced mitogenic activity requires activation of both STAT5b and ERK. STAT5b was tyrosine-phosphorylated, in response to uPA, only in EGFR-expressing cells. uPA-induced cell proliferation was blocked by dominant-negative MEK1, dominant-negative STAT5b, and by expression of an EGFR that is mutated at Tyr-845, which is essential for STAT5b activation. In two cell culture models of uPA-stimulated breast cancer growth, MDA-MB 468 cells treated with uPA and MCF-7 cells treated with uPA-plasminogen activator inhibitor-1 complex, proliferation was completely inhibited when EGFR expression or activity was blocked. We conclude that expression and assembly of uPAR co-receptors in a specific cell type determines the response to uPA. The EGFR selectively cooperates with uPAR to mediate mitogenesis.	Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; Univ Virginia, Sch Med, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Ctr Canc, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA	University of California System; University of California San Diego; University of Virginia; University of Virginia; University of Virginia; University of Virginia	Gonias, SL (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	sgonias@ucsd.edu						Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BOLLA M, 1990, BREAST CANCER RES TR, V16, P97, DOI 10.1007/BF01809293; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CARMICHAEL J, 1987, CANCER RES, V47, P943; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; Duffy MJ, 1999, J SURG ONCOL, V71, P130, DOI 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Guerrero J, 2004, EXP CELL RES, V292, P201, DOI 10.1016/j.yexcr.2003.08.011; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; Jo MJ, 2003, J BIOL CHEM, V278, P46692, DOI 10.1074/jbc.M308808200; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Knoop A, 1998, BRIT J CANCER, V77, P932, DOI 10.1038/bjc.1998.154; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Ma Z, 2002, J CELL BIOL, V159, P1061, DOI 10.1083/jcb.200207070; Ma Z, 2001, J CELL SCI, V114, P3387; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Prenzel N, 2000, BREAST CANCER RES, V2, P184, DOI 10.1186/bcr52; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TOI M, 1991, EUR J CANCER, V27, P977, DOI 10.1016/0277-5379(91)90262-C; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Webb DJ, 2001, J CELL BIOL, V152, P741, DOI 10.1083/jcb.152.4.741; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xu XZ, 2000, ONCOGENE, V19, P3172, DOI 10.1038/sj.onc.1203645; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393	53	85	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17449	17457		10.1074/jbc.M413141200	http://dx.doi.org/10.1074/jbc.M413141200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728176	hybrid			2022-12-25	WOS:000228615500111
J	Perez-Vilar, J; Olsen, JC; Chua, M; Boucher, RC				Perez-Vilar, J; Olsen, JC; Chua, M; Boucher, RC			pH-dependent intraluminal organization of mucin granules in live human mucous/goblet cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SUBMAXILLARY MUCIN; ISOLATED SECRETORY GRANULES; DISULFIDE-BONDED DIMERS; GEL-FORMING MUCINS; AIRWAY GOBLET-CELL; FLUORESCENCE RECOVERY; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; ION-EXCHANGE; C-TERMINUS	To study the mechanism of gel-forming mucin packaging within mucin granules, we generated human mucous/ goblet cells stably expressing a recombinant MUC5AC domain fused to green fluorescent protein (GFP). The fusion protein, named SHGFP-MUC5AC/CK, accumulated in the granules together with native MUC5AC. Inhibition of protein synthesis or disorganization of the Golgi complex did not result in diminished intragranular SHGFP-MUC5AC/CK signals, consistent with long-term storage of the fusion protein. However, SHGFP-MUC5AC/CK was rapidly discharged from the granules upon incubation of the cells with ATP, an established mucin secretagogue. Several criteria indicated that SHGFP-MUC5AC/CK was not covalently linked to endogenous MUC5AC. Analysis of fluorescence recovery after photobleaching suggested that the intragranular SHGFP-MUC5AC/CK mobile fraction and mobility were significantly lower than in the endoplasmic reticulum lumen. Incubation of the cells with bafilomycin A(1), a specific inhibitor of the vacuolar H+-ATPase, did not alter the fusion protein mobility, although it significantly increased ( similar to 20%) the intragranular SHGFP-MUC5AC/CK mobile fraction. In addition, the granules in bafilomycin-incubated cells typically exhibited a heterogeneous intraluminal distribution of the fluorescent fusion protein. These results are consistent with a model of mucin granule intraluminal organization with two phases: a mobile phase in which secretory proteins diffuse as in the endoplasmic reticulum lumen but at a lower rate and an immobile phase or matrix in which proteins are immobilized by noncovalent pH-dependent interactions. An intraluminal acidic pH, maintained by the vacuolar H+-ATPase, is one of the critical factors for secretory protein binding to the immobile phase and also for its organization.	Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Perez-Vilar, J (corresponding author), Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, CB7248, Chapel Hill, NC 27599 USA.	juan_vilar@med.unc.edu	, UNC Flow Cytometry Core/AGU-9839-2022		NIDDK NIH HHS [DK67404] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK067404] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGELIDES KJ, 1988, J CELL BIOL, V106, P1911, DOI 10.1083/jcb.106.6.1911; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BARA J, 1991, INT J CANCER, V47, P304, DOI 10.1002/ijc.2910470222; Barg S, 2001, J CELL SCI, V114, P2145; Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; Bell SL, 2003, BIOCHEM J, V373, P893, DOI 10.1042/BJ20030096; BELL SL, 1998, BIOCHEM J, V357, P203; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595, DOI 10.1165/ajrcmb.20.4.3442; Braeckmans K, 2003, BIOPHYS J, V85, P2240, DOI 10.1016/S0006-3495(03)74649-9; Braga J, 2004, MOL BIOL CELL, V15, P4749, DOI 10.1091/mbc.E04-06-0496; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Chen Y, 2004, AM J RESP CELL MOL, V30, P155, DOI 10.1165/rcmb.2003-0103OC; Chin WC, 2002, NOVART FDN SYMP, V248, P132; Davis CW, 2002, NOVART FDN SYMP, V248, P113; Dayel MJ, 1999, BIOPHYS J, V76, P2843, DOI 10.1016/S0006-3495(99)77438-2; Dekker J, 2002, TRENDS BIOCHEM SCI, V27, P126, DOI 10.1016/S0968-0004(01)02052-7; Demaurex N, 2002, NEWS PHYSIOL SCI, V17, P1; Desseyn JL, 2000, MOL BIOL EVOL, V17, P1175, DOI 10.1093/oxfordjournals.molbev.a026400; Desseyn JL, 1997, J BIOL CHEM, V272, P3168, DOI 10.1074/jbc.272.6.3168; Drose S, 1997, J EXP BIOL, V200, P1; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Escande F, 2001, BIOCHEM J, V358, P763, DOI 10.1042/0264-6021:3580763; Feder TJ, 1996, BIOPHYS J, V70, P2767, DOI 10.1016/S0006-3495(96)79846-6; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Godl K, 2002, J BIOL CHEM, V277, P47248, DOI 10.1074/jbc.M208483200; GUM JR, 1994, J BIOL CHEM, V269, P2440; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; Jackson AD, 2001, TRENDS PHARMACOL SCI, V22, P39, DOI 10.1016/S0165-6147(00)01600-X; Jackson C L, 2000, Subcell Biochem, V34, P233; Johnson LG, 1998, J VIROL, V72, P8861, DOI 10.1128/JVI.72.11.8861-8872.1998; Keeler C, 2004, J MOL NEUROSCI, V22, P43, DOI 10.1385/JMN:22:1-2:43; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Kolset SO, 2004, BIOCHEM J, V379, P217, DOI 10.1042/BJ20031230; Leteurtre E, 2004, BIOL CELL, V96, P145, DOI 10.1016/j.biolcel.2003.12.005; Lidell ME, 2003, BIOCHEM J, V372, P335, DOI 10.1042/BJ20030003; Lidell ME, 2003, J BIOL CHEM, V278, P13944, DOI 10.1074/jbc.M210069200; Marszalek PE, 1997, BIOPHYS J, V73, P1160, DOI 10.1016/S0006-3495(97)78148-7; Marszalek PE, 1997, BIOPHYS J, V73, P1169, DOI 10.1016/S0006-3495(97)78149-9; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; MCCOOL DJ, 1995, BIOCHEM J, V312, P125, DOI 10.1042/bj3120125; Merlin D, 1996, AM J PHYSIOL-CELL PH, V271, pC612, DOI 10.1152/ajpcell.1996.271.2.C612; NEUTRA MR, 1984, CIBA F SYMP, V109, P20, DOI 10.1002/9780470720905.ch3; Nguyen T, 1998, NATURE, V395, P908, DOI 10.1038/27686; Perez-Vilar J, 2004, FREE RADICAL BIO MED, V37, P1564, DOI 10.1016/j.freeradbiomed.2004.07.027; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Perez-Vilar J, 1997, J BIOL CHEM, V272, P33410, DOI 10.1074/jbc.272.52.33410; Perez-Vilar J, 2004, GLYCOBIOLOGY, V14, P325, DOI 10.1093/glycob/cwh041; Perez-Vilar J, 1998, J BIOL CHEM, V273, P14442, DOI 10.1074/jbc.273.23.14442; Perez-Vilar J, 1998, J BIOL CHEM, V273, P6982, DOI 10.1074/jbc.273.12.6982; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; Periasamy N, 1998, BIOPHYS J, V75, P557, DOI 10.1016/S0006-3495(98)77545-9; PHILLIPS TE, 1995, IN VITRO CELL DEV-AN, V31, P421, DOI 10.1007/BF02634251; Quesada I, 2003, BIOPHYS J, V85, P963, DOI 10.1016/S0006-3495(03)74535-4; Reits EAJ, 2001, NAT CELL BIOL, V3, pE145, DOI 10.1038/35078615; Rogers DF, 2003, INT J BIOCHEM CELL B, V35, P1, DOI 10.1016/S1357-2725(02)00083-3; Sheehan JK, 2000, BIOCHEM J, V347, P37, DOI 10.1042/0264-6021:3470037; Siggia ED, 2000, BIOPHYS J, V79, P1761, DOI 10.1016/S0006-3495(00)76428-9; Snapp E.L., 2003, CURRENT PROTOCOLS CE; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; Subramanian K, 1997, CELL, V89, P963, DOI 10.1016/S0092-8674(00)80281-0; Sun-Wada GH, 2004, BBA-BIOENERGETICS, V1658, P106, DOI 10.1016/j.bbabio.2004.04.013; THORNTON DJ, 1995, ANAL BIOCHEM, V227, P162, DOI 10.1006/abio.1995.1266; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; VERDUGO P, 1991, AM REV RESPIR DIS, V144, pS33, DOI 10.1164/ajrccm/144.3_pt_2.S33; VERDUGO P, 1987, BIORHEOLOGY, V24, P625; VERDUGO P, 1990, ANNU REV PHYSIOL, V52, P157, DOI 10.1146/annurev.ph.52.030190.001105; Ward WW, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P45; WEY CL, 1981, BIOPHYS J, V33, P225, DOI 10.1016/S0006-3495(81)84883-7; Wickstrom C, 2001, J BIOL CHEM, V276, P47116, DOI 10.1074/jbc.M106593200	69	25	26	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16868	16881		10.1074/jbc.M413289200	http://dx.doi.org/10.1074/jbc.M413289200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15718243	hybrid, Green Published			2022-12-25	WOS:000228615500041
J	Prunier, C; Howe, PH				Prunier, C; Howe, PH			Disabled-2 (Dab2) is required for transforming growth factor beta-induced epithelial to mesenchymal transition (EMT)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; MOLECULAR MECHANISMS; BINDING PARTNER; ADAPTER PROTEIN; GENE-EXPRESSION; DOMAIN; TRANSDIFFERENTIATION; DOC-2/DAB2; INTEGRINS; OVARIAN	Transforming growth factor beta (TGF beta) induces an epithelial to mesenchymal transition (EMT) during both physiological and pathological processes; however, the mechanism underlying this transition is not fully elucidated. Here, we have demonstrated that TGF beta induces the expression of the adaptor molecule disabled-2 (Dab2) concomitant with the promotion of EMT. We show that TGF beta induces a transient accumulation of Dab2 to the membrane and increases Dab2 binding to beta 1 integrin. Furthermore, small interfering RNA ( siRNA)mediated silencing of Dab2 expression in mouse mammary gland epithelial cells results in inhibition of integrin activation, shown by a decrease of both TGF beta-induced focal adhesion kinase phosphorylation and cellular adherence, leading to apoptosis and inhibition of EMT. Forced re-expression of human Dab2, not targeted by the mouse siRNA sequence, rescues cells from apoptosis and restores TGF beta-mediated integrin activation and EMT. These results are confirmed in the F9 teratocarcinoma cell line, a model for retinoic acid-induced visceral endoderm differentiation in which we demonstrate that ablation of retinoic acid-induced Dab2 expression levels, by stable siRNA silencing of Dab2, blocks visceral endoderm differentiation. Our findings indicate that Dab2 plays an important regulatory role during cellular differentiation and that induction of differentiation in the absence of Dab2 expression commits the cell to apoptosis.	Cleveland Clin Fdn, Cleveland Clin Lerner Coll Med, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Case Western Reserve University; Cleveland Clinic Foundation	Howe, PH (corresponding author), Cleveland Clin Fdn, Cleveland Clin Lerner Coll Med, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	howep@ccf.org	Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273	NATIONAL CANCER INSTITUTE [R01CA055536, R01CA080095, R29CA055536] Funding Source: NIH RePORTER; NCI NIH HHS [CA55536, CA80095] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2002, J CELL SCI, V115, P3193; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Comoglio PM, 2003, CURR OPIN CELL BIOL, V15, P565, DOI 10.1016/S0955-0674(03)00096-6; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Huang CL, 2004, J BIOL CHEM, V279, P42279, DOI 10.1074/jbc.M402540200; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Inoue A, 2002, BIOCHEM BIOPH RES CO, V292, P300, DOI 10.1006/bbrc.2002.6636; Kleeff J, 2002, DIS COLON RECTUM, V45, P1242, DOI 10.1007/s10350-004-6399-2; Kowanetz K, 2003, FEBS LETT, V554, P81, DOI 10.1016/S0014-5793(03)01111-6; Liu SC, 2000, J CELL SCI, V113, P3563; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2002, EMBO J, V21, P1555, DOI 10.1093/emboj/21.7.1555; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Oleinikov AV, 2000, BIOCHEM J, V347, P613, DOI 10.1042/0264-6021:3470613; Piek E, 1999, J CELL SCI, V112, P4557; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Rosenbauer F, 2002, EMBO J, V21, P211, DOI 10.1093/emboj/21.3.211; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Schwahn DJ, 1998, ONCOGENE, V17, P1173, DOI 10.1038/sj.onc.1202038; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Smith ER, 2001, J BIOL CHEM, V276, P47303, DOI 10.1074/jbc.M106158200; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; Tseng CP, 2001, BIOCHEM BIOPH RES CO, V285, P129, DOI 10.1006/bbrc.2001.5133; Valdes F, 2002, MOL CANCER RES, V1, P68; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Yang DH, 2002, DEV BIOL, V251, P27, DOI 10.1006/dbio.2002.0810; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200	52	104	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17540	17548		10.1074/jbc.M500974200	http://dx.doi.org/10.1074/jbc.M500974200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15734730	hybrid			2022-12-25	WOS:000228615500123
J	Trebino, CE; Eskra, JD; Wachtmann, TS; Perez, JR; Carty, TJ; Audoly, LP				Trebino, CE; Eskra, JD; Wachtmann, TS; Perez, JR; Carty, TJ; Audoly, LP			Redirection of eicosanoid metabolism in mPGES-1-deficient macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-E SYNTHASE; VESICULAR GLAND MICROSOMES; E-2 PRODUCTION; MICE LACKING; INFLAMMATORY RESPONSES; PERITONEAL-MACROPHAGES; RHEUMATOID-ARTHRITIS; PAIN PERCEPTION; DEFICIENT MICE; HUMAN PLASMA	Microsomal prostaglandin E synthase (mPGES)-1 is one of several prostaglandin E synthases involved in prostaglandin H-2 (PGH(2)) metabolism. In the present report, we characterize the contribution of mPGES-1 to cellular PGH2 metabolism in murine macrophages by studying the synthesis of eicosanoids and expression of eicosanoid metabolism enzymes in wild type and mPGES-1-deficient macrophages. Thioglycollate-elicited macrophages isolated from mPGES-1-/- animals and genetically matched wild type controls were stimulated with diverse pro-inflammatory stimuli. Prostaglandins were released in the following order of decreasing abundance from wild type macrophages stimulated with lipopolysaccharide: prostaglandin E-2 (PGE(2)) > thromboxane B-2 (TxB(2)) > 6-keto prostaglandin F-1 alpha (PGF1 alpha), prostaglandin F-2 alpha (PGF2 alpha), and prostaglandin D-2 (PGD2). In contrast, we detected in mPGES-1-/- macrophages a > 95% reduction in PGE2 production resulting in the following altered prostaglandin profile: TxB2 > 6-keto PGF1 alpha and PGF2 alpha > PGE2, despite the comparable release of total prostaglandins. No significant change in expression pattern of key prostaglandin-synthesizing enzymes was detected between the genotypes. We then further profiled genotype-related differences in the eicosanoid profile using macrophages pre-stimulated with lipopolysaccharide followed by a 10-min incubation with 10 mu M [H-3] arachidonic acid. Eicosanoid products were subsequently identified by reverse phase high pressure liquid chromatography. The dramatic reduction in [H-3] PGE2 formation from mPGES-1 -/- macrophages compared with controls resulted in TxB2 and 6-keto PGF1 alpha becoming the two most abundant prostaglandins in these samples. Our results also suggest a 5-fold increase in 12-[H-3] hydroxyheptadecatrienoic acid release in mPGES-1-/- samples. Our data support the hypothesis that mPGES-1 induction in response to an inflammatory stimulus is essential for PGE2 synthesis. The redirection of prostaglandin production in mPGES-1 -/- cells provides novel insights into how a cell processes the unstable endoperoxide PGH2 during the inactivation of a major metabolic outlet.	Pfizer Inc, Pfizer Global Res & Dev, Groton Labs, Inflammat, Groton, CT 06340 USA	Pfizer	Audoly, LP (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Pharmacol, 16711 Trans Canada Highway, Kirkland, PQ H9H 3L1, Canada.	laurent_audoly@merck.com						Beuckmann CT, 2000, NEUROCHEM RES, V25, P733, DOI 10.1023/A:1007579507804; Boulet L, 2004, J BIOL CHEM, V279, P23229, DOI 10.1074/jbc.M400443200; Boutaud O, 2003, J BIOL CHEM, V278, P16926, DOI 10.1074/jbc.M300940200; CIPOLLONE F, 2004, ARTERIOSCLER THROMB, V24, P1; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Goulet JL, 2000, J IMMUNOL, V164, P4899, DOI 10.4049/jimmunol.164.9.4899; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; HECKER M, 1989, J BIOL CHEM, V264, P141; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kamei D, 2004, J BIOL CHEM, V279, P33684, DOI 10.1074/jbc.M400199200; Karim S, 1996, J BIOL CHEM, V271, P12042, DOI 10.1074/jbc.271.20.12042; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KUHN DC, 1993, PROSTAG OTH LIPID M, V46, P195, DOI 10.1016/0090-6980(93)90003-P; Kuroda E, 2003, J IMMUNOL, V170, P757, DOI 10.4049/jimmunol.170.2.757; Lazarus M, 2002, ARCH BIOCHEM BIOPHYS, V397, P336, DOI 10.1006/abbi.2001.2614; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528; Meja KK, 1997, BRIT J PHARMACOL, V122, P149, DOI 10.1038/sj.bjp.0701360; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami Y, 2003, ARTHRITIS RHEUM, V48, P2931, DOI 10.1002/art.11271; Naraba H, 1998, J IMMUNOL, V160, P2974; OGINO N, 1977, J BIOL CHEM, V252, P890; OGOROCHI T, 1987, J NEUROCHEM, V48, P900, DOI 10.1111/j.1471-4159.1987.tb05602.x; Penglis PS, 2000, J IMMUNOL, V165, P1605, DOI 10.4049/jimmunol.165.3.1605; Plastaras JP, 2000, J BIOL CHEM, V275, P11784, DOI 10.1074/jbc.275.16.11784; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; Salomon RG, 1997, CHEM RES TOXICOL, V10, P536, DOI 10.1021/tx960157y; Salomon RG, 2000, TRENDS CARDIOVAS MED, V10, P53, DOI 10.1016/S1050-1738(00)00040-2; Schuligoi R, 2003, NEUROSCIENCE, V116, P1043, DOI 10.1016/S0306-4522(02)00783-2; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Stock JL, 2001, J CLIN INVEST, V107, P325, DOI 10.1172/JCI6749; Subbaramaiah K, 2004, J BIOL CHEM, V279, P12647, DOI 10.1074/jbc.M312972200; Sweeney FJ, 2003, MOL CELL ENDOCRINOL, V205, P151, DOI 10.1016/S0303-7207(03)00091-1; TANAKA Y, 1987, J BIOL CHEM, V262, P1374; Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Ueno A, 2001, BIOCHEM PHARMACOL, V62, P157, DOI 10.1016/S0006-2952(01)00654-2; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; Watanabe K, 1999, BBA-MOL CELL BIOL L, V1439, P406, DOI 10.1016/S1388-1981(99)00084-0; Watanabe K, 1997, BIOCHEM BIOPH RES CO, V235, P148, DOI 10.1006/bbrc.1997.6708; Westman M, 2004, ARTHRITIS RHEUM-US, V50, P1774, DOI 10.1002/art.20286; Yokoyama C, 2002, CIRCULATION, V106, P2397, DOI 10.1161/01.CIR.0000034733.93020.BC	46	78	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16579	16585		10.1074/jbc.M412075200	http://dx.doi.org/10.1074/jbc.M412075200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722356	hybrid			2022-12-25	WOS:000228615500007
J	Zhang, YW; Luo, WJ; Wang, H; Lin, P; Vetrivel, KS; Liao, F; Li, F; Wong, PC; Farquhar, MG; Thinakaran, G; Xu, HA				Zhang, YW; Luo, WJ; Wang, H; Lin, P; Vetrivel, KS; Liao, F; Li, F; Wong, PC; Farquhar, MG; Thinakaran, G; Xu, HA			Nicastrin is critical for stability and trafficking but not association of other presenilin/gamma-secretase components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE; CELL-SURFACE; INTRACELLULAR TRAFFICKING; INTRAMEMBRANE PROTEOLYSIS; ENDOPLASMIC-RETICULUM; COMPLEX COMPONENTS; ALZHEIMERS-DISEASE; APH-1 INTERACTS; BETA-APP	gamma-Secretase, which is responsible for the intramembranous cleavage of Alzheimer beta-amyloid precursor protein and the signaling receptor Notch, is a multiprotein complex consisting of at least four components: presenilin ( PS); nicastrin (Nct); APH-1 ( anterior pharynx-defective-1); and presenilin enhancer-2 (PEN-2). Presenilin 1 (PS1) is known to be essential for the stability, interaction, and trafficking of the other PS1/gamma-secretase components. However, the precise functions of the other components remain elusive. Here, we investigated the functions of Nct within the PS1/gamma-secretase complex. We demonstrated that the loss of Nct expression in the embryonic fibroblast cells ( Nct KO cells) results in dramatically decreased levels of APH-1, PEN-2, and PS1 fragments accompanied by a significant accumulation of full-length PS1. In the absence of Nct, PEN-2 and full-length PS1 are subjected to proteasome-mediated degradation, whereas the degradation of APH-1 is mediated by both proteasomal and lysosomal pathways. Unlike the case of wild type cells in which the gamma-secretase complex mainly locates in the trans-Golgi network, the majority of residual PEN-2, APH-1, and the uncleaved full-length PS1 in Nct KO cells reside in the endoplasmic reticulum, which remain associated with each other in the absence of Nct. Interestingly, significant amounts of full-length PS1 and PEN-2, but not APH-1, are detected on the plasma membrane in Nct KO cells, suggesting the Nct-independent cell surface delivery of the PEN-2 center dot PS1. Finally, the diminished PEN-2 protein level in Nct-deficient cells can be partially restored by overexpression of exogenous PS1, APH-1, or PEN-2 individually or collectively, indicating a dispensable role for Nct in controlling PEN-2 level. Taken together, our study demonstrates a critical role of Nct in the stability and proper intracellular trafficking of other components of the PS1/ gamma-secretase complex but not in maintaining the association of PEN-2, APH-1, and full-length PS1.	Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Univ Calif San Diego, Dept Cellular & Mol Med & Pathol, La Jolla, CA 92093 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	Sanford Burnham Prebys Medical Discovery Institute; Rockefeller University; University of California System; University of California San Diego; University of Chicago; Johns Hopkins University	Xu, HA (corresponding author), Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA.	xuh@burnham.org	Xu, Huaxi/AAV-7177-2021; Luo, Wenjie/ABF-8451-2020	Lin, Peter P./0000-0002-6869-9490; Zhang, Yun-wu/0000-0002-7152-7630	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F32AG024895, R01AG021495, R01AG021173, F32AG023432] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG021173, AG021495, F32 AG024895-01A1, R01 AG021495, F32 AG023432, AG021173, F32 AG024895, F32 AG023432-01] Funding Source: Medline; NINDS NIH HHS [NS046673, R01 NS046673] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Bergman A, 2004, J BIOL CHEM, V279, P16744, DOI 10.1074/jbc.M313999200; Cai DM, 2003, J BIOL CHEM, V278, P3446, DOI 10.1074/jbc.M209065200; Chyung JH, 2003, J BIOL CHEM, V278, P51035, DOI 10.1074/jbc.M304989200; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Crystal AS, 2004, BIOCHEMISTRY-US, V43, P3555, DOI 10.1021/bi0361214; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; Greenfield JP, 1999, J BIOL CHEM, V274, P33843, DOI 10.1074/jbc.274.48.33843; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li JH, 2003, J BIOL CHEM, V278, P33445, DOI 10.1074/jbc.M301288200; Li T, 2003, J NEUROSCI, V23, P3272; Lin P, 2000, P NATL ACAD SCI USA, V97, P674, DOI 10.1073/pnas.97.2.674; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Morais VA, 2003, J BIOL CHEM, V278, P43284, DOI 10.1074/jbc.M305685200; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Shirotani K, 2004, J NEUROCHEM, V89, P1520, DOI 10.1111/j.1471-4159.2004.02447.x; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Soriano S, 1999, J BIOL CHEM, V274, P32295, DOI 10.1074/jbc.274.45.32295; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Wang H, 2004, J BIOL CHEM, V279, P40560, DOI 10.1074/jbc.M404345200; Xie ZC, 2004, J BIOL CHEM, V279, P34130, DOI 10.1074/jbc.M401094200; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748	43	95	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17020	17026		10.1074/jbc.M409467200	http://dx.doi.org/10.1074/jbc.M409467200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15711015	Green Accepted, hybrid			2022-12-25	WOS:000228615500059
J	Casoni, F; Basso, M; Massignan, T; Gianazza, E; Cheroni, C; Salmona, M; Bendotti, C; Bonetto, V				Casoni, F; Basso, M; Massignan, T; Gianazza, E; Cheroni, C; Salmona, M; Bendotti, C; Bonetto, V			Protein nitration in a mouse model of familial amyotrophic lateral sclerosis - Possible multifunctional role in the pathogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE BRAIN; SUPEROXIDE-DISMUTASE; TYROSINE NITRATION; PROTEOMIC IDENTIFICATION; OXIDATIVE DAMAGE; NEURODEGENERATIVE SYNUCLEINOPATHIES; MASS-SPECTROMETRY; REDOX PROTEOMICS; TRANSGENIC MICE; MOTOR-NEURONS	Multiple mechanisms have been proposed to contribute to amyotrophic lateral sclerosis (ALS) pathogenesis, including oxidative stress. Early evidence of a role for oxidative damage was based on the finding, in patients and murine models, of high levels of markers, such as free nitrotyrosine (NT). However, no comprehensive study on the protein targets of nitration in ALS has been reported. We found an increased level of NT immunoreactivity in spinal cord protein extracts of a transgenic mouse model of familial ALS (FALS) at a presymptomatic stage of the disease compared with age-matched controls. NT immunoreactivity is increased in the soluble fraction of spinal cord homogenates and is found as a punctate staining in motor neuron perikarya of presymptomatic FALS mice. Using a proteome-based strategy, we identified proteins nitrated in vivo, under physiological or pathological conditions, and compared their level of specific nitration. alpha- and gamma-enolase, ATP synthase beta chain, and heat shock cognate 71-kDa protein and actin were overnitrated in presymptomatic FALS mice. We identified by matrix-assisted laser desorption/ ionization mass spectrometry 16 sites of nitration in proteins oxidized in vivo. In particular, alpha-enolase nitration at Tyr(43), target also of phosphorylation, brings additional evidence on the possible interference of nitration with phosphorylation. In conclusion, we propose that protein nitration may have a role in ALS pathogenesis, acting directly by inhibiting the function of specific proteins and indirectly interfering with protein degradation pathways and phosphorylation cascades.	Dulbecco Telethon Inst, Milan, Italy; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Univ Milan, Proteom & Prot Struct Study Grp, I-20133 Milan, Italy; Univ Milan, CEND, Dept Pharmacol Sci, I-20133 Milan, Italy	Fondazione Telethon; Dulbecco Telethon Institute (DTI); Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan; University of Milan	Bonetto, V (corresponding author), Dulbecco Telethon Inst, Milan, Italy.	bonetto@marionegri.it	Casoni, Filippo/AAN-8298-2020; salmona, mario/AAA-7116-2020; Cheroni, Cristina/AAO-2316-2020; Bonetto, Valentina/ABB-6383-2020; Bonetto, Valentina/I-4694-2018; salmona, mario/ABI-4066-2020; Basso, Manuela/AAA-9147-2020; Casoni, Filippo/E-7531-2010; Bendotti, Caterina/AAB-2273-2020	Casoni, Filippo/0000-0002-1172-8377; salmona, mario/0000-0002-9098-9873; Bonetto, Valentina/0000-0003-0456-2054; Bonetto, Valentina/0000-0003-0456-2054; Basso, Manuela/0000-0002-9278-8960; Bendotti, Caterina/0000-0003-1055-1271; massignan, tania/0000-0002-6176-2696	Telethon [TCP01010] Funding Source: Medline	Telethon(Fondazione Telethon)		Aulak KS, 2004, AM J PHYSIOL-HEART C, V286, pH30, DOI 10.1152/ajpheart.00743.2003; Balabanli B, 1999, P NATL ACAD SCI USA, V96, P13136, DOI 10.1073/pnas.96.23.13136; Beal MF, 1997, ANN NEUROL, V42, P644, DOI 10.1002/ana.410420416; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Bendotti C, 2001, J NEUROCHEM, V79, P737, DOI 10.1046/j.1471-4159.2001.00572.x; Bendotti C, 2004, TRENDS MOL MED, V10, P393, DOI 10.1016/j.molmed.2004.06.009; Bendotti C, 2004, J NEUROPATH EXP NEUR, V63, P113, DOI 10.1093/jnen/63.2.113; Bendotti C, 2001, J NEUROL SCI, V191, P25, DOI 10.1016/S0022-510X(01)00627-X; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; Castegna A, 2003, J NEUROCHEM, V85, P1394, DOI 10.1046/j.1471-4159.2003.01786.x; Castegna A, 2002, J NEUROCHEM, V82, P1524, DOI 10.1046/j.1471-4159.2002.01103.x; CHERONI C, 2004, IN PRESS NEUROBIOL D; Clements MK, 2003, J LEUKOCYTE BIOL, V73, P344, DOI 10.1189/jlb.0802401; Duda JE, 2000, AM J PATHOL, V157, P1439, DOI 10.1016/S0002-9440(10)64781-5; Farah CA, 2003, J NEUROCHEM, V84, P77, DOI 10.1046/j.1471-4159.2003.01505.x; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Ghezzi P, 2003, PROTEOMICS, V3, P1145, DOI 10.1002/pmic.200300435; Gianazza E, 2002, J CHROMATOGR B, V771, P107, DOI 10.1016/S0378-4347(01)00562-X; GIANAZZA E, 1998, 2 D PROTEOME ANAL PR, P172; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; Greenacre SAB, 2001, FREE RADICAL RES, V34, P541, DOI 10.1080/10715760100300471; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; HAYASHI T, 1992, J NEUROSCI RES, V31, P561, DOI 10.1002/jnr.490310321; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Kabashi E, 2004, J NEUROCHEM, V89, P1325, DOI 10.1111/j.1471-4159.2004.02453.x; Kamisaki Y, 1998, P NATL ACAD SCI USA, V95, P11584, DOI 10.1073/pnas.95.20.11584; Kanski J, 2003, FREE RADICAL BIO MED, V35, P1229, DOI 10.1016/S0891-5849(03)00500-8; Kieran D, 2004, NAT MED, V10, P402, DOI 10.1038/nm1021; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Koeck T, 2004, J BIOL CHEM, V279, P27257, DOI 10.1074/jbc.M401586200; Laragione T, 2003, P NATL ACAD SCI USA, V100, P14737, DOI 10.1073/pnas.2434516100; Mattiazzi M, 2002, J BIOL CHEM, V277, P29626, DOI 10.1074/jbc.M203065200; Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200; Monteiro HP, 2002, FREE RADICAL BIO MED, V33, P765, DOI 10.1016/S0891-5849(02)00893-6; Ouyang YB, 2001, NEUROSCI LETT, V298, P159, DOI 10.1016/S0304-3940(00)01721-3; Pancholi V, 2001, CELL MOL LIFE SCI, V58, P902, DOI 10.1007/PL00000910; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Petersson AS, 2001, J MASS SPECTROM, V36, P616, DOI 10.1002/jms.161; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; Sarver A, 2001, J AM SOC MASS SPECTR, V12, P439, DOI 10.1016/S1044-0305(01)00213-6; Schopfer FJ, 2003, TRENDS BIOCHEM SCI, V28, P646, DOI 10.1016/j.tibs.2003.10.006; Simpson EP, 2003, CURR OPIN RHEUMATOL, V15, P730, DOI 10.1097/00002281-200311000-00008; Singh P, 2003, MOL CELL BIOCHEM, V243, P139, DOI 10.1023/A:1021668314070; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Souza JM, 2000, ARCH BIOCHEM BIOPHYS, V380, P360, DOI 10.1006/abbi.2000.1940; Urushitani M, 2004, J NEUROCHEM, V90, P231, DOI 10.1111/j.1471-4159.2004.02486.x; Viera L, 1999, METHOD ENZYMOL, V301, P373; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; Wood JD, 2003, NEUROPATH APPL NEURO, V29, P529, DOI 10.1046/j.0305-1846.2003.00518.x; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085; Yi DH, 2000, J AM SOC MASS SPECTR, V11, P578, DOI 10.1016/S1044-0305(00)00113-6	55	167	169	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16295	16304		10.1074/jbc.M413111200	http://dx.doi.org/10.1074/jbc.M413111200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15699043	Green Published, hybrid			2022-12-25	WOS:000228444800100
J	Chen, J; Zhao, M; Rao, R; Inoue, H; Hao, CM				Chen, J; Zhao, M; Rao, R; Inoue, H; Hao, CM			C/EBP beta and its binding element are required for NF kappa B-induced COX2 expression following hypertonic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED CYCLOOXYGENASE-2 EXPRESSION; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRANSCRIPTIONAL INHIBITORY PROTEIN; MEDULLARY INTERSTITIAL-CELLS; NUCLEAR-FACTOR; GENE-EXPRESSION; SYNTHASE-2 GENE; PHORBOL ESTER; ACTIVATION; LIPOPOLYSACCHARIDE	NF kappa B plays a critical role mediating COX2 expression in renal medullary interstitial cells (RMICs). The trans-activating ability of NF kappa B can be modified by another nuclear factor C/EBP beta that can physically bind to NF kappa B and regulate its activity. Because the COX2 promoter also contains a C/EBP beta site adjacent to the NF kappa B site, the present study examined whether these two transcription factors cooperate to induce COX2 expression following hypertonic stress. Hypertonicity markedly induced COX2 expression in cultured medullary interstitial cells by immunoblot analysis. The tonicity-induced COX2 expression was suppressed by mutant I kappa B (I kappa Bm) that blocks NF kappa B activation, demonstrating that tonicity-induced COX2 expression depends on NF kappa B activation. However, mutation of the NF kappa B site in the COX2 promoter failed to abolish tonicity-induced COX2 reporter activity. I kappa B kinase-1 (IKK1) significantly induced COX2-luciferase activity by 2.3-fold ( n = 10, p < 0.01); mutation of the NF kappa B site also failed to abolish IKK1-stimulated COX2 reporter activity ( 86 +/- 3.1% of wild type, p > 0.05, n = 4). Interestingly, mutation of the C/EBP beta site of the COX2 gene significantly reduced both IKK1 and hypertonicity-induced COX2 reporter activity ( p < 0.01). To further examine the potential role of C/EBP beta in tonicity-induced COX2 expression, a dominant negative C/EBP beta-p20 was transduced into RMICs. C/EBP beta-p20 markedly suppressed hypertonic ( 550 mOsm) induction of COX2 ( immunoblot) to a similar extent as I kappa Bm. No additional suppression was observed when both NF kappa B and C/EBP beta were simultaneously blocked by I kappa Bm and C/EBP beta-p20. Interestingly, IKK-induced COX2 expression was not only blocked by I kappa Bm, but also completely abolished by C/EBP beta-p20. Further studies demonstrated physical association of C/EBP beta to NF kappa B p65 by coimmunoprecipitation. Importantly, this interaction between C/EBP beta and NF kappa B was greatly enhanced following hypertonic stress. These studies indicate C/EBP beta is required for the transcriptional activation of COX2 by NF kappa B, suggesting a dominant role for the C/EBP beta pathway in regulating induction of RMIC COX2 by hypertonicity.	Vanderbilt Univ, Med Ctr, Div Nephrol, Dept Med, Nashville, TN 37232 USA; Natl Cardiovasc Ctr Hosp & Res Inst, Dept Pharmacol, Osaka 5658565, Japan; Fudan Univ, Div Nephrol, Huashan Hosp, Shanghai 200040, Peoples R China	Vanderbilt University; National Cerebral & Cardiovascular Center - Japan; Fudan University	Hao, CM (corresponding author), Vanderbilt Univ, Med Ctr, Div Nephrol, Dept Med, S3223 MCN, Nashville, TN 37232 USA.	chuanming.hao@vanderbilt.edu			NIDDK NIH HHS [DK065024, DK37097] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK065024, R01DK037097] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams DS, 2000, J CELL BIOCHEM, V77, P221, DOI 10.1002/(SICI)1097-4644(20000501)77:2<221::AID-JCB6>3.0.CO;2-V; Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Breyer M D, 2001, Curr Opin Crit Care, V7, P393, DOI 10.1097/00075198-200112000-00005; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DIEHL JA, 1994, MOL CELL BIOL, V14, P6635, DOI 10.1128/MCB.14.10.6635; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; FitzGerald GA, 2001, J CLIN INVEST, V107, P1335, DOI 10.1172/JCI13037; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF18, DOI 10.1152/ajprenal.1997.273.1.F18; Hanlon M, 2001, J BIOL CHEM, V276, P38449, DOI 10.1074/jbc.M102165200; Hao CM, 1999, AM J PHYSIOL-RENAL, V277, pF352, DOI 10.1152/ajprenal.1999.277.3.F352; Hao CM, 2000, J CLIN INVEST, V106, P973, DOI 10.1172/JCI9956; Hao CM, 2002, J BIOL CHEM, V277, P21341, DOI 10.1074/jbc.M200695200; Harrison JR, 2000, J BONE MINER RES, V15, P1138, DOI 10.1359/jbmr.2000.15.6.1138; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; Ikawa H, 2001, EXP CELL RES, V267, P73, DOI 10.1006/excr.2001.5233; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Jover R, 2002, FASEB J, V16, P1799, DOI 10.1096/fj.02-0195fje; Kleemann R, 2003, BLOOD, V101, P545, DOI 10.1182/blood-2002-06-1762; Liao J, 1999, J BIOL CHEM, V274, P31597, DOI 10.1074/jbc.274.44.31597; Lo CJ, 1998, J TRAUMA, V45, P19, DOI 10.1097/00005373-199807000-00004; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Moeckel GW, 2003, J BIOL CHEM, V278, P19352, DOI 10.1074/jbc.M302209200; MUIRHEAD EE, 1973, PROSTAG OTH LIPID M, V3, P581, DOI 10.1016/0090-6980(73)90096-8; Nakao S, 2000, MOL CELL BIOCHEM, V209, P113, DOI 10.1023/A:1007155525020; Okada Y, 2000, J CELL BIOCHEM, V78, P197, DOI 10.1002/(SICI)1097-4644(20000801)78:2<197::AID-JCB3>3.0.CO;2-C; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Paik JH, 2000, J BIOL CHEM, V275, P28173; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; Rao R, 2004, J BIOL CHEM, V279, P3949, DOI 10.1074/jbc.M309325200; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; Ruocco MR, 1996, J BIOL CHEM, V271, P22479, DOI 10.1074/jbc.271.37.22479; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SEGASOTHY M, 1994, AM J KIDNEY DIS, V24, P17, DOI 10.1016/S0272-6386(12)80155-7; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; Thomas B, 2002, BIOCHEM J, V362, P367, DOI 10.1042/0264-6021:3620367; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; Tsai SH, 2002, J CELL BIOCHEM, V84, P750, DOI 10.1002/jcb.10096; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yan XJ, 2002, BIOL REPROD, V66, P1667, DOI 10.1095/biolreprod66.6.1667; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199; Yoshimoto T, 1996, J IMMUNOL, V156, P1082; Zhang MZ, 2002, AM J PHYSIOL-RENAL, V283, pF509, DOI 10.1152/ajprenal.00236.2001; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	53	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16354	16359		10.1074/jbc.M411134200	http://dx.doi.org/10.1074/jbc.M411134200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713664	hybrid			2022-12-25	WOS:000228444800107
J	Gribun, A; Kimber, MS; Ching, R; Sprangers, R; Fiebig, KM; Houry, WA				Gribun, A; Kimber, MS; Ching, R; Sprangers, R; Fiebig, KM; Houry, WA			The ClpP double ring tetradecameric protease exhibits plastic ring-ring interactions, and the N termini of its subunits form flexible loops that are essential for ClpXP and ClpAP complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASES; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; 20S PROTEASOME; DEGRADATION; TRANSLOCATION; PROTEINS; BINDING; PROLINE	ClpP is a conserved serine-protease with two heptameric rings that enclose a large chamber containing the protease active sites. Each ClpP subunit can be divided into a handle region, which mediates ring-ring interactions, and a head domain. ClpP associates with the hexameric ATPases ClpX and ClpA, which can unfold and translocate substrate proteins through the ClpP axial pores into the protease lumen for degradation. We have determined the x-ray structure of Streptococcus pneumoniae ClpP(A153P) at 2.5 angstrom resolution. The structure revealed two novel features of ClpP which are essential for ClpXP and ClpAP functional activities. First, the Ala 3 Pro mutation disrupts the handle region, resulting in an altered ring-ring dimerization interface, which, in conjunction with biochemical data, demonstrates the unusual plasticity of this region. Second, the structure shows the existence of a flexible N-terminal loop in each ClpP subunit. The loops line the axial pores in the ClpP tetradecamer and then protrude from the protease apical surface. The sequence of the N-terminal loop is highly conserved in ClpP across all kingdoms of life. These loops are essential determinants for complex formation between ClpP and ClpX/ClpA. Mutation of several amino acid residues in this loop or the truncation of the loop impairs ClpXP and ClpAP complex formation and prevents the coupling between ClpX/ClpA and ClpP activities.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Affinium Pharmaceut, Toronto, ON M5J 1V6, Canada	University of Toronto	Kimber, MS (corresponding author), Univ Toronto, Dept Biochem, 1 Kings Coll Circle,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	mkimber@afnm.com	Kimber, Matthew/Q-8144-2019	Kimber, Matthew/0000-0001-9454-5586; Fiebig, Klaus/0000-0002-9553-2645				Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burton RE, 2001, EMBO J, V20, P3092, DOI 10.1093/emboj/20.12.3092; Chakrabarti A, 1999, PROTEIN SCI, V8, P2455; Corydon TJ, 1998, BIOCHEM J, V331, P309, DOI 10.1042/bj3310309; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; Feng HP, 1998, CURR BIOL, V8, pR464, DOI 10.1016/S0960-9822(98)70294-5; Frees D, 1999, MOL MICROBIOL, V31, P79, DOI 10.1046/j.1365-2958.1999.01149.x; Frees D, 2003, MOL MICROBIOL, V48, P1565, DOI 10.1046/j.1365-2958.2003.03524.x; FREIFELDER D, 1982, PHYSICAL BIOCH, P537; Glover JR, 2001, BIOCHEM CELL BIOL, V79, P557, DOI 10.1139/bcb-79-5-557; Goodsell DS, 2000, ANNU REV BIOPH BIOM, V29, P105, DOI 10.1146/annurev.biophys.29.1.105; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; Gottesman S, 1998, P NATL ACAD SCI USA, V95, P2731, DOI 10.1073/pnas.95.6.2731; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Gray TM, 1996, PROTEIN SCI, V5, P742; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Gunasekaran K, 1998, J MOL BIOL, V275, P917, DOI 10.1006/jmbi.1997.1505; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; Jones JM, 1998, J BIOL CHEM, V273, P459, DOI 10.1074/jbc.273.1.459; Joshi SA, 2004, NAT STRUCT MOL BIOL, V11, P404, DOI 10.1038/nsmb752; Kang SG, 2004, J STRUCT BIOL, V148, P338, DOI 10.1016/j.jsb.2004.07.004; Kaplan W, 2001, Brief Bioinform, V2, P195, DOI 10.1093/bib/2.2.195; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kim DY, 2003, J BIOL CHEM, V278, P50664, DOI 10.1074/jbc.M305882200; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Kim YI, 2001, NAT STRUCT BIOL, V8, P230, DOI 10.1038/84967; Kohler A, 2001, BIOCHIMIE, V83, P325, DOI 10.1016/S0300-9084(01)01242-1; Lo JH, 2001, PROTEIN SCI, V10, P551, DOI 10.1110/ps.41401; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; Maurizi MR, 2004, STRUCTURE, V12, P175, DOI 10.1016/j.str.2004.01.021; Ortega J, 2004, J STRUCT BIOL, V146, P217, DOI 10.1016/j.jsb.2003.11.023; Ortega J, 2002, EMBO J, V21, P4938, DOI 10.1093/emboj/cdf483; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peltier JB, 2004, J BIOL CHEM, V279, P4768, DOI 10.1074/jbc.M309212200; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SAUER UH, 1992, J BIOL CHEM, V267, P2393; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Seol JH, 1995, FEBS LETT, V377, P41, DOI 10.1016/0014-5793(95)01306-7; Singh SK, 1999, BIOCHEMISTRY-US, V38, P14906, DOI 10.1021/bi991615f; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; Thomsen LE, 2002, MICROBIOL-SGM, V148, P2727, DOI 10.1099/00221287-148-9-2727; Weichart D, 2003, J BACTERIOL, V185, P115, DOI 10.1128/JB.185.1.115-125.2003; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; Wojtyra UA, 2003, J BIOL CHEM, V278, P48981, DOI 10.1074/jbc.M307825200; WOO KM, 1989, J BIOL CHEM, V264, P2088; Zwickl P, 2000, CURR OPIN STRUC BIOL, V10, P242, DOI 10.1016/S0959-440X(00)00075-0	57	84	85	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16185	16196		10.1074/jbc.M414124200	http://dx.doi.org/10.1074/jbc.M414124200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15701650	hybrid			2022-12-25	WOS:000228444800088
J	Guse, AH; Gu, XF; Zhang, LR; Weber, K; Kramer, E; Yang, ZJ; Jin, HW; Li, Q; Carrier, L; Zhang, LH				Guse, AH; Gu, XF; Zhang, LR; Weber, K; Kramer, E; Yang, ZJ; Jin, HW; Li, Q; Carrier, L; Zhang, LH			A minimal structural analogue of cyclic ADP-ribose - Synthesis and calcium release activity in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; ADENOSINE-DIPHOSPHORIBOSE CADPR; RYANODINE RECEPTOR; T-LYMPHOCYTES; CA2+ SIGNALS; STORES; PHARMACOLOGY; PROPAGATION; METABOLITES; MESSENGERS	Cyclic ADP-ribose (cADPR) is an endogenous Ca2+-mobilizing second messenger in many cell types and organisms. Although the biological activity of several modified analogues of cADPR has been analyzed, most of these structures were still very similar to the original molecule. Recently, we have introduced simplified analogues in which the northern ribose (N-1-linked ribose) was replaced by an ether strand (Gu, X., Yang, Z., Zhang, L., Kunerth, S., Fliegert, R., Weber, K., Guse, A. H., and Zhang, L. ( 2004) J. Med. Chem. 47, 5674 - 5682). Here we also demonstrate that the southern ribose ( N-9-linked ribose) can be replaced by an ether strand resulting in N-1-[(phosphoryl-O-ethoxy)methyl]- N-9-[(phosphoryl-O-ethoxy)- methyl]-hypoxanthine-cyclic pyrophosphate (cIDP-DE). This minimal structural analogue of cyclic ADP-ribose released Ca2+ from intracellular stores of permeabilized Jurkat T lymphocytes. In intact T lymphocytes initial subcellular Ca2+ release events, global Ca2+ release, and subsequent global Ca2+ entry were observed. Cardiac myocytes freshly prepared from mice responded to cIDP-DE by increased recruitment of localized Ca2+ signals and by global Ca2+ waves.	Univ Hamburg, Hosp Eppendorf, Ctr Med Expt, Inst Biochem & Mol Biol 1, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Ctr Med Expt, Inst Cellular Signal Transduct, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Ctr Med Expt, Dept Pharmacol, D-20246 Hamburg, Germany; INSERM, U582, F-75013 Paris, France; Peking Univ, Sch Pharmaceut Sci, Natl Lab Nat & Biomimet Drugs, Beijing 100083, Peoples R China	University of Hamburg; University of Hamburg; University of Hamburg; Institut National de la Sante et de la Recherche Medicale (Inserm); Peking University	Guse, AH (corresponding author), Univ Hamburg, Hosp Eppendorf, Ctr Med Expt, Inst Biochem & Mol Biol 1, Martinistr 52, D-20246 Hamburg, Germany.	guse@uke.uni-hamburg.de; zdszlh@bjmu.edu.cn						Ashamu GA, 1997, BIOCHEMISTRY-US, V36, P9509, DOI 10.1021/bi9705671; Bailey VC, 1996, FEBS LETT, V379, P227, DOI 10.1016/0014-5793(95)01515-9; Bruzzone S, 2003, J CELL BIOL, V163, P837, DOI 10.1083/jcb.200307016; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Cui Y, 1999, BIOCHEM J, V342, P269, DOI 10.1042/0264-6021:3420269; Galione A, 2002, CELL CALCIUM, V32, P343, DOI 10.1016/S0143416002001902; Gu XF, 2004, J MED CHEM, V47, P5674, DOI 10.1021/jm040092t; Guo XQ, 1996, CIRC RES, V79, P147, DOI 10.1161/01.RES.79.1.147; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; Guse AH, 2004, CURR MED CHEM, V11, P847, DOI 10.2174/0929867043455602; Guse AH, 2004, CURR MOL MED, V4, P239, DOI 10.2174/1566524043360771; Guse AH, 2002, BIOCHEMISTRY-US, V41, P6744, DOI 10.1021/bi020171b; Higashida H, 1999, J BIOL CHEM, V274, P33348, DOI 10.1074/jbc.274.47.33348; Higashida H, 2000, BIOCHEM J, V352, P197, DOI 10.1042/0264-6021:3520197; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang LJ, 2002, J MED CHEM, V45, P5340, DOI 10.1021/jm010530l; Kunerth S, 2004, J CELL SCI, V117, P2141, DOI 10.1242/jcs.01063; Kunerth S, 2003, CELL SIGNAL, V15, P783, DOI 10.1016/S0898-6568(03)00015-9; Lee HC, 2004, CURR MOL MED, V4, P227, DOI 10.2174/1566524043360753; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; Mendez F, 1998, J PHYSIOL-LONDON, V507, P365, DOI 10.1111/j.1469-7793.1998.365bt.x; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; Potter BVL, 2004, CURR MOL MED, V4, P303, DOI 10.2174/1566524043360744; Prakash YS, 2000, AM J PHYSIOL-HEART C, V279, pH1482, DOI 10.1152/ajpheart.2000.279.4.H1482; Rakovic S, 1996, CURR BIOL, V6, P989, DOI 10.1016/S0960-9822(02)00643-7; ROBBINS M J, 1991, Canadian Journal of Chemistry, V69, P1468; Robins MJ, 1996, J ORG CHEM, V61, P9207, DOI 10.1021/jo9617023; Schuber F, 2004, CURR MOL MED, V4, P249, DOI 10.2174/1566524043360708; Shuto S, 2004, CURR MED CHEM, V11, P827, DOI 10.2174/0929867043455639; WADA T, 1995, NUCLEOS NUCLEOT, V14, P1301, DOI 10.1080/15257779508010692; Wagner GK, 2003, CHEM COMMUN, P1944, DOI 10.1039/b305660k	31	47	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15952	15959		10.1074/jbc.M414032200	http://dx.doi.org/10.1074/jbc.M414032200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713671	hybrid			2022-12-25	WOS:000228444800061
J	ZhuO, J; Qiu, ZH; Wiese, C; Ishii, Y; Friedrichsen, J; Rajashekara, G; Splitter, GA				ZhuO, J; Qiu, ZH; Wiese, C; Ishii, Y; Friedrichsen, J; Rajashekara, G; Splitter, GA			Nuclear and mitochondrial localization signals overlap within bovine herpesvirus 1 tegument protein VP22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; PARVOVIRUS MINUTE VIRUS; SELF-ASSOCIATION; UL49 HOMOLOG; HISTONES; CELLS; INFECTION; INTERACTS; SEQUENCE; VIRIONS	VP22, a tegument protein of bovine herpesvirus 1, accumulates in the nucleus of infected and transiently transfected cells. Previous studies indicated a possible regulatory function of VP22 within nuclei, but how VP22 enters nuclei is unknown. Despite the abundance of basic residues within this protein, no classic nuclear localization signal (NLS) motif has been identified. To identify the signal directing nuclear accumulation, a series of truncations, internal deletions, and point mutations were constructed. Fluorescence microscopy of cells transfected with VP22 constructs indicated that a sequence of 103 residues is necessary and sufficient for nuclear localization. This NLS sequence is conformation-sensitive in contrast to a classical sequential NLS. Energy depletion assays and co-immunoprecipitation suggested that this NLS sequence also binds histone H4, resulting in nuclear retention of VP22. In addition, a mitochondrial targeting sequence was identified at the C-terminal 49 amino acids, which overlapped the sequence required for nuclear targeting. Our findings demonstrate the diversity of VP22 protein to localize within the cell and provide the opportunity for VP22 to direct cargo specifically to different subcellular compartments.	Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Splitter, GA (corresponding author), Univ Wisconsin, Dept Anim Hlth & Biomed Sci, 1656 Linden Dr, Madison, WI 53706 USA.	Splitter@svm.vetmed.wisc.edu	Rajashekara, Gireesh/E-3913-2011		NIGMS NIH HHS [R01-GM60986] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060986] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baake M, 2001, J CELL BIOCHEM, V81, P333, DOI 10.1002/1097-4644(20010501)81:2<333::AID-JCB1048>3.3.CO;2-4; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; ELLIOTT G, 1995, J VIROL, V69, P7932, DOI 10.1128/JVI.69.12.7932-7941.1995; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; Fischer D, 1999, PROTEINS, P209; Freeman L, 1996, P NATL ACAD SCI USA, V93, P12780, DOI 10.1073/pnas.93.23.12780; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; Harms JS, 2000, J VIROL, V74, P3301, DOI 10.1128/JVI.74.7.3301-3312.2000; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kretsovali A, 2001, J BIOL CHEM, V276, P32191, DOI 10.1074/jbc.M103164200; LIANG XP, 1995, J VIROL, V69, P3863, DOI 10.1128/JVI.69.6.3863-3867.1995; Liang XP, 1997, VACCINE, V15, P1057, DOI 10.1016/S0264-410X(97)00008-X; Lischka P, 2003, J VIROL, V77, P3734, DOI 10.1128/JVI.77.6.3734-3748.2003; Lombardo E, 2000, J VIROL, V74, P3804, DOI 10.1128/JVI.74.8.3804-3814.2000; Lombardo E, 2002, J VIROL, V76, P7049, DOI 10.1128/JVI.76.14.7049-7059.2002; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; Pomeranz LE, 2000, J VIROL, V74, P10041, DOI 10.1128/JVI.74.21.10041-10054.2000; Qiu ZH, 2005, HUM GENE THER, V16, P101, DOI 10.1089/hum.2005.16.101; Ren XD, 2001, J VIROL, V75, P8251, DOI 10.1128/JVI.75.17.8251-8258.2001; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SAHR KE, 1993, J BIOL CHEM, V268, P22656; Sciortino MT, 2002, P NATL ACAD SCI USA, V99, P8318, DOI 10.1073/pnas.122231699; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Sorg G, 1999, BIOTECHNIQUES, V26, P858, DOI 10.2144/99265bm12; Stochaj U, 2000, FASEB J, V14, P2130, DOI 10.1096/fj.99-0751fje; VAN LH, 2003, J GEN VIROL, V84, P2501; Wang P, 1997, J VIROL, V71, P1850, DOI 10.1128/JVI.71.3.1850-1856.1997	31	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16038	16044		10.1074/jbc.M500054200	http://dx.doi.org/10.1074/jbc.M500054200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705574	hybrid			2022-12-25	WOS:000228444800071
J	Cheng, JK; Perkins, ND; Yeh, ETH				Cheng, JK; Perkins, ND; Yeh, ETH			Differential regulation of c-Jun-dependent transcription by SUMO-specific proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL PHOSPHORYLATION; ACTIVATED PROTEIN-KINASES; CELL-CYCLE PROGRESSION; HISTONE DEACETYLASE-1; ANDROGEN RECEPTOR; MOUSE DEVELOPMENT; ONCOPROTEIN E1A; P300; AP-1; APOPTOSIS	c-Jun is a transcription factor that plays an important role in regulating cell growth, apoptosis, differentiation, and transformation. The transcriptional activity of c-Jun can be regulated by both phosphorylation and sumoylation. It has also been shown that c-Jun transcription can be regulated by SuPr-1, an alternatively spliced form of SUMO-specific protease 2 (SENP2). However, the ability of SuPr-1 to enhance c-Jun transcription is dependent on promyelocytic leukemia but is independent of the desumoylation activity of SuPr-1. Here, we show that SUMO-specific protease 1 (SENP1) also markedly enhances the transcription activity of c-Jun. The action of SENP1 on c-Jun transcription is independent of the sumoylation and phosphorylation status of c-Jun but is critically dependent on the desumoylation activity of SENP1. We further show that p300 is essential for SENP1 to enhance c-Jun-dependent transcription because SENP1 can desumoylate the CRD1 domain of p300, thereby releasing the cis-repression of CRD1 on p300. Thus, two SUMO-specific proteases regulate c-Jun-dependent transcription through entirely different mechanisms.	Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA; Univ Texas, Houston Hlth Sci Ctr, Ctr Cardiovasc Dis, Brown Fdn Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Dundee	Yeh, ETH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, 1515 Holcombe Blvd,Unit 449, Houston, TX 77030 USA.	etyeh@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA080089] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA80089] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; Bannister AJ, 1995, ONCOGENE, V11, P2509; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3; ECKNER R, 1994, COLD SPRING HARB SYM, V59, P85, DOI 10.1101/SQB.1994.059.01.012; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Goodman RH, 2000, GENE DEV, V14, P1553; Gregory DJ, 2002, CELL CYCLE, V1, P343, DOI 10.4161/cc.1.5.153; Grimm C, 2001, CELL DEATH DIFFER, V8, P859, DOI 10.1038/sj.cdd.4400871; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Holmstrom S, 2003, P NATL ACAD SCI USA, V100, P15758, DOI 10.1073/pnas.2136933100; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kadoya T, 2002, MOL CELL BIOL, V22, P3803, DOI 10.1128/MCB.22.11.3803-3819.2002; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Perkins ND, 2002, CELL CYCLE, V1, P39, DOI 10.4161/cc.1.1.98; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Thompson PR, 2004, NAT STRUCT MOL BIOL, V11, P308, DOI 10.1038/nsmb740; Vries RGJ, 2001, EMBO J, V20, P6095, DOI 10.1093/emboj/20.21.6095; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	70	49	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14492	14498		10.1074/jbc.M412185200	http://dx.doi.org/10.1074/jbc.M412185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701643	hybrid			2022-12-25	WOS:000228236800019
J	Komura, J; Ono, T				Komura, J; Ono, T			Disappearance of nucleosome positioning in mitotic chromatin in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-RESPONSE FACTOR; TRANSCRIPTION FACTORS; DEPENDENT TRANSCRIPTION; PROMOTER; CHROMOSOMES; PROTEIN; GENES; BINDING; MITOSIS; ASSOCIATION	During mitosis, transcription is silenced and most transcription factors are displaced from their recognition sequences. By in vivo footprinting analysis, we have confirmed and extended previous studies showing loss of transcription factors from an RNA polymerase II promoter (c-FOS) and, for the first time, an RNA polymerase III promoter (U6) in HeLa cells. Because little was known about nucleosomal organization in mitotic chromosomes, we performed footprinting analysis for nucleosomes on these promoters in interphase and mitotic cells. During interphase, each of the promoters had a positioned nucleosome in the region intervening between proximal promoter elements and distal enhancer elements, but the strong nucleosome positioning disappeared during mitosis. Thus, the nucleosomal organization that appears to facilitate transcription in interphase cells may be lost in mitotic cells, and nucleosome positioning during mitosis does not seem to be a major component of the epigenetic mechanisms to mark genes for rapid reactivation after this phase.	Tohoku Univ, Grad Sch Med, Dept Cell Biol, Sendai, Miyagi 9808575, Japan	Tohoku University	Komura, J (corresponding author), Tohoku Univ, Grad Sch Med, Dept Cell Biol, Sendai, Miyagi 9808575, Japan.	junkom@mail.tains.tohoku.ac.jp						Becker PB, 2002, EMBO J, V21, P4749, DOI 10.1093/emboj/cdf486; Boyd DC, 2003, GENE, V315, P103, DOI 10.1016/S0378-1119(03)00717-0; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Chen DY, 2002, MOL BIOL CELL, V13, P276, DOI 10.1091/mbc.01-10-0523; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; Christova R, 2002, NAT CELL BIOL, V4, P79, DOI 10.1038/ncb733; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Hernandez N, 2001, J BIOL CHEM, V276, P26733, DOI 10.1074/jbc.R100032200; Herrera RE, 1997, CHROMOSOMA, V106, P284, DOI 10.1007/s004120050249; HERSHKOVITZ M, 1995, P NATL ACAD SCI USA, V92, P2379, DOI 10.1073/pnas.92.6.2379; Jeppesen P, 1997, BIOESSAYS, V19, P67, DOI 10.1002/bies.950190111; Komura J, 2003, BIOCHEMISTRY-US, V42, P15084, DOI 10.1021/bi034802t; Komura J, 1997, J BIOL CHEM, V272, P10975; Komura J, 2001, BIOCHEMISTRY-US, V40, P4096, DOI 10.1021/bi002539f; KUO MT, 1982, NUCLEIC ACIDS RES, V10, P4565, DOI 10.1093/nar/10.15.4565; Lucchini R, 2001, EMBO J, V20, P7294, DOI 10.1093/emboj/20.24.7294; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Michelotti EF, 1997, NATURE, V388, P895, DOI 10.1038/42282; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Nissen LJ, 2001, J BIOL CHEM, V276, P5213, DOI 10.1074/jbc.M007824200; Pfeifer GP, 1999, METHOD ENZYMOL, V304, P548; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; Spencer JA, 1999, J BIOL CHEM, V274, P15686, DOI 10.1074/jbc.274.22.15686; THOMA F, 1992, BIOCHIM BIOPHYS ACTA, V1130, P1, DOI 10.1016/0167-4781(92)90455-9; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; Zhao XY, 2001, MOL CELL, V7, P539, DOI 10.1016/S1097-2765(01)00201-5	35	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14530	14535		10.1074/jbc.M500637200	http://dx.doi.org/10.1074/jbc.M500637200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705567	hybrid			2022-12-25	WOS:000228236800024
J	Tong, YR; Jiang, HB; Kanost, MR				Tong, YR; Jiang, HB; Kanost, MR			Identification of plasma proteases inhibited by Manduca sexta serpin-4 and serpin-5 and their association with components of the prophenol oxidase activation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLOTRICHIA-DIOMPHALIA LARVAE; PRO-PHENOL-OXIDASE; PEPTIDOGLYCAN RECOGNITION PROTEINS; IMMUNE-RESPONSES; TOBACCO HORNWORM; SERINE-PROTEASE; BOMBYX-MORI; DROSOPHILA-MELANOGASTER; COLEOPTERAN INSECT; MOLECULAR-CLONING	One innate immune response pathway of insects is a serine protease cascade that activates prophenol oxidase (pro-PO) in plasma. However, details of this pathway are not well understood, including the number and order of proteases involved. Protease inhibitors from the serpin superfamily appear to regulate the proteases in the pathway. Manduca sexta serpin-4 and serpin-5 suppress pro-PO activation in plasma, apparently by inhibiting proteases upstream of the direct activator of pro-PO. To identify plasma proteases inhibited by these serpins, we used immunoaffinity chromatography with serpin antibodies to isolate serpin-protease complexes that formed after activation of the cascade by exposure of plasma to bacteria or lipopolysaccharide. Covalent complexes of serpin-4 with hemolymph proteases HP-1 and HP-6 appeared in plasma activated by Gram-positive or Gram-negative bacteria, whereas serpin-4 complexes with HP-21 and two unidentified proteases were unique to plasma treated with Gram-positive bacteria. HP-1 and HP-6 were also identified as target proteases of serpin-5, forming covalent complexes after bacterial activation of the cascade. These results suggest that HP-1 and HP-6 may be components of the pro-PO activation pathway, which are activated in response to infection and regulated by serpin-4 and serpin-5. HP-21 and two unidentified proteases may participate in a Gram-positive bacteria-specific branch of the pathway. Several plasma proteins that co-purified with serpin-protease complexes, most notably immulectins and serine protease homologs, are known to be components of the pro-PO activation pathway. Our results suggest that after activation by exposure to bacteria, components of the pro-PO pathway associate to form a large noncovalent complex, which localizes the melanization reaction to the surface of invading microorganisms.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA	Kansas State University; Oklahoma State University System; Oklahoma State University - Stillwater	Kanost, MR (corresponding author), Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA.	kanost@ksu.edu	Jiang, Haobo/A-6519-2008	Jiang, Haobo/0000-0003-1357-1315; Kanost, Michael/0000-0002-6827-0061	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041247, R37GM041247, R29GM041247, R01GM058634] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41247, R01 GM058634, GM58634, R01 GM058634-07A1, R37 GM041247, R01 GM041247] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arlaud GJ, 2001, IMMUNOL REV, V180, P136, DOI 10.1034/j.1600-065X.2001.1800112.x; Ashida M., 1997, MOL MECH IMMUNE RESP, P135; DUNN PE, 1983, J INVERTEBR PATHOL, V41, P77, DOI 10.1016/0022-2011(83)90238-0; Elliott PR, 2000, PROTEIN SCI, V9, P1274, DOI 10.1110/ps.9.7.1274; Gan H, 2001, INSECT BIOCHEM MOLEC, V31, P887, DOI 10.1016/S0965-1748(01)00034-0; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Harlow E., 1988, ANTIBODIES LAB MANUA; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Ji CY, 2004, J BIOL CHEM, V279, P34101, DOI 10.1074/jbc.M404584200; Jiang H, 1999, INSECT MOL BIOL, V8, P39, DOI 10.1046/j.1365-2583.1999.810039.x; JIANG HB, 1994, J BIOL CHEM, V269, P55; Jiang HB, 2004, INSECT BIOCHEM MOLEC, V34, P89, DOI 10.1016/j.ibmb.2003.09.006; Jiang HB, 2003, INSECT BIOCHEM MOLEC, V33, P1049, DOI 10.1016/S0965-1748(03)00123-1; Jiang HB, 2003, J BIOL CHEM, V278, P3552, DOI 10.1074/jbc.M205743200; Jiang HB, 1996, J BIOL CHEM, V271, P28017, DOI 10.1074/jbc.271.45.28017; Jiang HB, 2000, INSECT BIOCHEM MOLEC, V30, P95, DOI 10.1016/S0965-1748(99)00113-7; Jiang HB, 1997, INSECT BIOCHEM MOLEC, V27, P835, DOI 10.1016/S0965-1748(97)00066-0; Jiang HB, 2001, ADV EXP MED BIOL, V484, P313; Jiang HB, 1997, J BIOL CHEM, V272, P1082, DOI 10.1074/jbc.272.2.1082; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Kanost Michael R, 2004, Immunol Rev, V198, P97, DOI 10.1111/j.0105-2896.2004.0121.x; KANOST MR, 1989, J BIOL CHEM, V264, P965; Kanost MR, 2001, ADV EXP MED BIOL, V484, P319; Kawabata Shun-ichiro, 1996, P255; Kim MS, 2002, J BIOL CHEM, V277, P39999, DOI 10.1074/jbc.M205508200; Kurata S, 2004, DEV COMP IMMUNOL, V28, P89, DOI 10.1016/S0145-305X(03)00121-6; Kwon TH, 2000, EUR J BIOCHEM, V267, P6188, DOI 10.1046/j.1432-1327.2000.01695.x; Lee KY, 2002, EUR J BIOCHEM, V269, P4375, DOI 10.1046/j.1432-1033.2002.03155.x; Lee MH, 2004, J BIOL CHEM, V279, P3218, DOI 10.1074/jbc.M309821200; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; Li JP, 1999, STRUCTURE, V7, P103, DOI 10.1016/S0969-2126(99)80013-6; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; Matsushita M, 2001, IMMUNOL REV, V180, P78, DOI 10.1034/j.1600-065X.2001.1800107.x; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Nappi AJ, 2001, ADV EXP MED BIOL, V484, P329; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Ross J, 2003, GENE, V304, P117, DOI 10.1016/S0378-1119(02)01187-3; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Thiel S, 2000, J IMMUNOL, V165, P878, DOI 10.4049/jimmunol.165.2.878; Tong YR, 2005, J BIOL CHEM, V280, P14923, DOI 10.1074/jbc.M500531200; Wang RG, 2001, EUR J BIOCHEM, V268, P895, DOI 10.1046/j.1432-1327.2001.01945.x; Wang Y, 2004, INSECT BIOCHEM MOLEC, V34, P731, DOI 10.1016/j.ibmb.2004.03.008; Wang Y, 2004, INSECT BIOCHEM MOLEC, V34, P387, DOI 10.1016/j.ibmb.2003.12.005; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Yu XQ, 2003, DEV COMP IMMUNOL, V27, P189, DOI 10.1016/S0145-305X(02)00099-X; Yu XQ, 2003, INSECT BIOCHEM MOLEC, V33, P197, DOI 10.1016/S0965-1748(02)00191-1; Yu XQ, 1999, INSECT BIOCHEM MOLEC, V29, P585, DOI 10.1016/S0965-1748(99)00036-3; Yu XQ, 2002, INSECT BIOCHEM MOLEC, V32, P1287, DOI 10.1016/S0965-1748(02)00091-7; Yu XQ, 2000, J BIOL CHEM, V275, P37373, DOI 10.1074/jbc.M003021200; Zhu YF, 2003, J BIOL CHEM, V278, P46556, DOI 10.1074/jbc.M309682200	56	106	111	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14932	14942		10.1074/jbc.M500532200	http://dx.doi.org/10.1074/jbc.M500532200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15695806	Green Accepted, hybrid			2022-12-25	WOS:000228236800073
J	Bastie, CC; Nahle, Z; McLoughlin, T; Esser, K; Zhang, WW; Unterman, T; Abumrad, NA				Bastie, CC; Nahle, Z; McLoughlin, T; Esser, K; Zhang, WW; Unterman, T; Abumrad, NA			FoxO1 stimulates fatty acid uptake and oxidation in muscle cells through CD36-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-RECEPTOR-DELTA; FORKHEAD TRANSCRIPTION FACTORS; INSULIN-RESPONSE SEQUENCE; ACETYL-COA CARBOXYLASE; SKELETAL-MUSCLE; PROTEIN-KINASE; MALONYL-COA; GENE-EXPRESSION; CD36 DEFICIENCY; RAT	Emerging evidence documents a key function for the forkhead transcription factor FoxO1 in cellular metabolism. Here, we investigate the role of FoxO1 in the regulation of fatty acid ( FA) metabolism in muscle cells. C2C12 cells expressing an inducible construct with either wild type FoxO1 or a mutant form ( FoxO1/ TSS) refractory to the protein kinase B inhibitory effects were generated. FoxO1 activation after myotube formation altered the expression of several genes of FA metabolism. Acyl- CoA oxidase and peroxisome proliferatoractivated receptor delta mRNA levels increased 2.2- fold and 1.4- fold, respectively, whereas mRNA for acetyl- CoA carboxylase decreased by 50%. Membrane uptake of oleate increased 3- fold, and oleate oxidation increased 2- fold. Cellular triglyceride content was also increased. The enhanced FA utilization induced by FoxO1 was mediated by a severalfold increase in plasma membrane level of the fatty acid translocase FAT/ CD36 and eliminated by cell treatment with the CD36 inhibitor sulfo- N-succinimidyl-oleate. We conclude that FoxO1 activation induces coordinate increases in FA uptake and oxidation and that these effects are mediated, at least in part, by membrane enrichment in CD36. The data suggest that FoxO1 contributes to preparing the muscle cell for the increased reliance on FA metabolism that is characteristic of fasting. Dysregulation of FoxO1 in muscle could contribute to intramuscular lipid accumulation and insulin resistance by maintaining activation of FA uptake.	Washington Univ, Dept Med, Div Nutr Sci, St Louis, MO 63110 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA; Univ Toledo, Dept Kinesiol, Toledo, OH 43606 USA; Univ Illinois, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA; Jesse Brown VA Med Ctr, Chicago, IL 60612 USA	Washington University (WUSTL); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Kentucky; University System of Ohio; University of Toledo; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Abumrad, NA (corresponding author), Washington Univ, Dept Med, Div Nutr Sci, Campus Box 8031, St Louis, MO 63110 USA.	nabumrad@wustl.edu		Bastie, Claire/0000-0001-8178-4748	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033301, R01DK041430, R29DK041430] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR445617] Funding Source: Medline; NIDDK NIH HHS [DK600022, DK41430, DK33301] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; Agellon LB, 2002, J BIOL CHEM, V277, P20131, DOI 10.1074/jbc.C200105200; Altomonte J, 2003, AM J PHYSIOL-ENDOC M, V285, pE718, DOI 10.1152/ajpendo.00156.2003; Arden KC, 2002, ARCH BIOCHEM BIOPHYS, V403, P292, DOI 10.1016/S0003-9861(02)00207-2; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Bastie CC, 2004, DIABETES, V53, P2209, DOI 10.2337/diabetes.53.9.2209; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Bonen A, 2004, FASEB J, V18, P1144, DOI 10.1096/fj.03-1065fje; Bonen A, 2003, ACTA PHYSIOL SCAND, V178, P347, DOI 10.1046/j.1365-201X.2003.01157.x; Bonen A, 1999, AM J PHYSIOL-ENDOC M, V276, pE642, DOI 10.1152/ajpendo.1999.276.4.E642; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Farmer SR, 2003, MOL CELL, V11, P6, DOI 10.1016/S1097-2765(03)00003-0; Furuhashi M, 2003, DIABETES CARE, V26, P471, DOI 10.2337/diacare.26.2.471; Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022; Furuyama T, 2002, MICROSC RES TECHNIQ, V59, P331, DOI 10.1002/jemt.10213; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hajri T, 2002, ANNU REV NUTR, V22, P383, DOI 10.1146/annurev.nutr.22.020402.130846; Hajri T, 2001, J BIOL CHEM, V276, P23661, DOI 10.1074/jbc.M100942200; HARMON CM, 1993, J MEMBRANE BIOL, V133, P43; Heron-Milhavet L, 2004, ENDOCRINOLOGY, V145, P4667, DOI 10.1210/en.2003-1543; Hirano K, 2003, TRENDS CARDIOVAS MED, V13, P136, DOI 10.1016/S1050-1738(03)00026-4; Holness MJ, 2003, BIOCHEM SOC T, V31, P1143; Holst D, 2003, EXP CELL RES, V288, P168, DOI 10.1016/S0014-4827(03)00179-4; Holst D, 2003, BBA-MOL CELL BIOL L, V1633, P43, DOI 10.1016/S1388-1981(03)00071-4; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; Ibrahimi A, 1999, J BIOL CHEM, V274, P26761, DOI 10.1074/jbc.274.38.26761; Kaestner KH, 2000, GENE DEV, V14, P142; Kwon HS, 2004, DIABETES, V53, P899, DOI 10.2337/diabetes.53.4.899; Liang CP, 2004, J CLIN INVEST, V113, P764, DOI [10.1172/JCI200419528, 10.1172/JCI19528]; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Luiken JJFP, 2004, MOL PHARMACOL, V65, P639, DOI 10.1124/mol.65.3.639; Luiken JJFP, 2001, AM J PHYSIOL-ENDOC M, V281, pE704, DOI 10.1152/ajpendo.2001.281.4.E704; Luiken JJFP, 1999, J LIPID RES, V40, P1007; Luquet S, 2003, FASEB J, V17, P2299, DOI 10.1096/fj.03-0269fje; Muoio DM, 1999, BIOCHEM J, V338, P783, DOI 10.1042/0264-6021:3380783; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Rosa G, 2003, OBES RES, V11, P1306, DOI 10.1038/oby.2003.177; Saha AK, 1999, AM J PHYSIOL-ENDOC M, V276, pE1030, DOI 10.1152/ajpendo.1999.276.6.E1030; SAHA AK, 1995, AM J PHYSIOL-ENDOC M, V269, pE283, DOI 10.1152/ajpendo.1995.269.2.E283; Saha AK, 2003, MOL CELL BIOCHEM, V253, P65, DOI 10.1023/A:1026053302036; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sinha R, 2002, DIABETES, V51, P1022, DOI 10.2337/diabetes.51.4.1022; TURCOTTE LP, 1994, J APPL PHYSIOL, V77, P517, DOI 10.1152/jappl.1994.77.2.517; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; WINDER WW, 1990, AM J PHYSIOL, V259, pE266, DOI 10.1152/ajpendo.1990.259.2.E266; WINDER WW, 1995, J APPL PHYSIOL, V78, P578, DOI 10.1152/jappl.1995.78.2.578; Wu PF, 1998, BIOCHEM J, V329, P197, DOI 10.1042/bj3290197; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200; Zhao XS, 2004, BIOCHEM J, V378, P839, DOI 10.1042/BJ20031450	52	108	112	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14222	14229		10.1074/jbc.M413625200	http://dx.doi.org/10.1074/jbc.M413625200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15691844	hybrid			2022-12-25	WOS:000228095500125
J	Papadopoulos, MC; Verkman, AS				Papadopoulos, MC; Verkman, AS			Aquaporin-4 gene disruption in mice reduces brain swelling and mortality in pneumococcal meningitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE BACTERIAL-MENINGITIS; WATER CHANNELS; RAT-BRAIN; STREPTOCOCCUS-PNEUMONIAE; BARRIER PERMEABILITY; OXIDATIVE STRESS; TRANSGENIC MICE; EDEMA; ASTROCYTES; EXPRESSION	The astroglial water channel aquaporin-4 (AQP4) facilitates water movement into and out of brain parenchyma. To investigate the role of AQP4 in meningitis-induced brain edema, Streptococcus pneumoniae was injected into cerebrospinal fluid (CSF) in wild type and AQP4 null mice. AQP4-deficient mice had remarkably lower intracranial pressure (9 +/- 1 versus 25 +/- 5 cm H2O) and brain water accumulation (2 +/- 1 versus 9 +/- 1 mu l) at 30 h, and improved survival (80 versus 0% survival) at 60 h, through comparable CSF bacterial and white cell counts. Meningitis produced marked astrocyte foot process swelling in wild type but not AQP4 null mice, and slowed diffusion of an inert macromolecule in brain extracellular space. AQP4 protein was strongly up-regulated in meningitis, resulting in a similar to 5-fold higher water permeability (P-f) across the blood-brain barrier compared with non-infected wild type mice. Mathematical modeling using measured P-f and CSF dynamics accurately simulated the elevated lower intracranial pressure and brain water produced by meningitis and predicted a beneficial effect of prevention of AQP4 up-regulation. Our findings provide a novel molecular mechanism for the pathogenesis of brain edema in acute bacterial meningitis, and suggest that inhibition of AQP4 function or up-regulation may dramatically improve clinical outcome.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu		Papadopoulos, Marios/0000-0001-9174-4176	NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER; NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Aoki K, 2003, ACTA NEUROPATHOL, V106, P121, DOI 10.1007/s00401-003-0709-y; Arima H, 2003, J BIOL CHEM, V278, P44525, DOI 10.1074/jbc.M304368200; Aronin Steven I, 2002, Expert Opin Pharmacother, V3, P121, DOI 10.1517/14656566.3.2.121; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Betz A L, 1990, Adv Neurol, V52, P73; BETZ AL, 1994, J CEREBR BLOOD F MET, V14, P29, DOI 10.1038/jcbfm.1994.5; Binder DK, 2004, J NEUROSCI, V24, P8049, DOI 10.1523/JNEUROSCI.2294-04.2004; BOHR V, 1984, ARCH NEUROL-CHICAGO, V41, P1045, DOI 10.1001/archneur.1984.04050210043012; Braun JS, 2002, J CLIN INVEST, V109, P19; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; FAUSTUMANN PM, 1995, ACTA NEUROPATHOL, V89, P239; GORDON CR, 1990, ACT NEUR S, V51, P268; GOTOH O, 1985, STROKE, V16, P101, DOI 10.1161/01.STR.16.1.101; HATASHITA S, 1988, J CEREBR BLOOD F MET, V8, P552, DOI 10.1038/jcbfm.1988.96; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; HU SX, 1994, GLIA, V10, P227, DOI 10.1002/glia.440100309; Jain M, 2000, Indian Pediatr, V37, P608; Kastenbauer S, 2002, NEUROLOGY, V58, P186, DOI 10.1212/WNL.58.2.186; KIM YS, 1995, J INFECT DIS, V171, P1363, DOI 10.1093/infdis/171.5.1363; KIOUMEHR F, 1995, J COMPUT ASSIST TOMO, V19, P713, DOI 10.1097/00004728-199509000-00005; KLATZO I, 1994, ACTA NEUROCHIR, P3; Koedel U, 1999, BRAIN PATHOL, V9, P57; KOLLER H, 1994, J NEUROL SCI, V124, P156, DOI 10.1016/0022-510X(94)90321-2; Li J, 2002, INVEST OPHTH VIS SCI, V43, P573; Li J, 2001, J BIOL CHEM, V276, P31233, DOI 10.1074/jbc.M104368200; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Matkowskyj KA, 1999, AM J PHYSIOL-GASTR L, V277, pG455, DOI 10.1152/ajpgi.1999.277.2.G455; MAXWELL WL, 1994, ACTA NEUROCHIR, P45; MCCRACKEN GH, 1995, PEDIATR INFECT DIS J, V14, P424, DOI 10.1097/00006454-199505001-00004; MENZIES SA, 1993, J NEUROSURG, V78, P257, DOI 10.3171/jns.1993.78.2.0257; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; Nielsen S, 1997, J NEUROSCI, V17, P171; Oshio K, 2004, FASEB J, V18, P76, DOI 10.1096/fj.04-1711fje; Papadopoulos M, 2004, NEUROSCIENCE, V129, P1009; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2004, FASEB J, V18, P425, DOI 10.1096/fj.04-2834fje; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; PFISTER HW, 1993, ARCH NEUROL-CHICAGO, V50, P575, DOI 10.1001/archneur.1993.00540060015010; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; Roos KL, 2000, SEMIN NEUROL, V20, P293, DOI 10.1055/s-2000-9393; RUNGE VM, 1995, INVEST RADIOL, V30, P484, DOI 10.1097/00004424-199508000-00006; Saadoun S, 2003, J CLIN PATHOL, V56, P972, DOI 10.1136/jcp.56.12.972; Saadoun S, 2002, J NEUROL NEUROSUR PS, V72, P262, DOI 10.1136/jnnp.72.2.262; Saez-Llorens X, 2003, LANCET, V361, P2139, DOI 10.1016/S0140-6736(03)13693-8; SCHREIBER JR, 1995, PEDIATR CLIN N AM, V42, P519; SCHUIER FJ, 1980, STROKE, V11, P593, DOI 10.1161/01.STR.11.6.593; Spach DH, 1999, NEUROL CLIN, V17, P711, DOI 10.1016/S0733-8619(05)70163-8; Tang RB, 2001, CHILD NERV SYST, V17, P453, DOI 10.1007/s003810000422; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Vajda Z, 2000, BIOCHEM BIOPH RES CO, V270, P495, DOI 10.1006/bbrc.2000.2472; Vajda Z, 2002, P NATL ACAD SCI USA, V99, P13131, DOI 10.1073/pnas.192457099; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wiesmann M, 2002, NEUROL RES, V24, P307, DOI 10.1179/016164102101199792	55	259	298	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13906	13912		10.1074/jbc.M413627200	http://dx.doi.org/10.1074/jbc.M413627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15695511	hybrid			2022-12-25	WOS:000228095500091
J	Kuiperij, HB; van der Horst, A; Raaijmakers, J; Weijzen, S; Medema, RH; Bos, JL; Burgering, BMT; Zwartkruis, FJT				Kuiperij, HB; van der Horst, A; Raaijmakers, J; Weijzen, S; Medema, RH; Bos, JL; Burgering, BMT; Zwartkruis, FJT			Activation of FoxO transcription factors contributes to the antiproliferative effect of cAMP	ONCOGENE			English	Article						cAMP; protein kinase B; FoxO; p27(Kip1); cyclin D1; growth arrest	KINASE INHIBITOR P27(KIP1); CELL-CYCLE PROGRESSION; SIGNAL-REGULATED KINASE-2; BREAST-CANCER CELLS; G1 PHASE ARREST; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; D1 EXPRESSION; DEPENDENT DEGRADATION; ERK INHIBITION	cAMP is a potent inhibitor of cell proliferation in a variety of cell lines. Downregulation of cyclin D1 and upregulation of the cell cycle inhibitor p27(Kip1) are two mechanisms by which cAMP may induce a G1-arrest. Here we show that cAMP inhibits proliferation of cells that constitutively express cyclin D1 or are deficient for Rb, demonstrating that changes in these cell cycle regulators do not account for the cAMP-induced growth effects in mouse embryo fibroblasts (MEFs). Interestingly, the antiproliferative effect of cAMP mimics the effect previously observed for FoxO transcription factors. These transcription factors are under negative control of protein kinase B (PKB). We show that in MEFs cAMP strongly induces transcriptional activation of FoxO4 through the inhibition of PKB. Accordingly, not only p27(Kip1) but also the FoxO target MnSOD is upregulated by cAMP. Importantly, introduction of dominant-negative FoxO partially rescues cAMP-induced inhibition of proliferation. From these results we conclude that inhibition of PKB and subsequent activation of FoxO transcription factors mediates an antiproliferative effect of cAMP.	Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Utrecht University; Utrecht University; Netherlands Cancer Institute	Zwartkruis, FJT (corresponding author), Univ Utrecht, Med Ctr, Dept Physiol Chem, Universiteitsweg 100, NL-3584 CG Utrecht, Netherlands.	G.J.T.Zwartkruis@med.uu.nl	Medema, Rene H/G-5415-2011; Kuiperij, Bea/A-4737-2013; Medema, Rene H/E-2981-2013	Kuiperij, Bea/0000-0002-0635-7428; Medema, Rene/0000-0002-6754-0381				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Balmanno K, 2003, MOL CELL BIOL, V23, P9303, DOI 10.1128/MCB.23.24.9303-9317.2003; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Boucher MJ, 2001, BIOCHEM BIOPH RES CO, V285, P207, DOI 10.1006/bbrc.2001.5147; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; Kim TY, 2001, INVEST OPHTH VIS SCI, V42, P3142; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee HT, 2003, INVEST OPHTH VIS SCI, V44, P3816, DOI 10.1167/iovs.03-0147; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lee TH, 2000, ONCOGENE, V19, P3766, DOI 10.1038/sj.onc.1203715; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rao S, 1999, EXP CELL RES, V252, P211, DOI 10.1006/excr.1999.4620; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; SEWING A, 1993, J CELL SCI, V104, P545; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Vadiveloo PK, 1997, ATHEROSCLEROSIS, V133, P61, DOI 10.1016/S0021-9150(97)00116-0; van Oirschot BA, 2001, J BIOL CHEM, V276, P33854, DOI 10.1074/jbc.M104395200; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Williamson EA, 1997, LEUKEMIA, V11, P73, DOI 10.1038/sj.leu.2400551; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	57	19	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2087	2095		10.1038/sj.onc.1208450	http://dx.doi.org/10.1038/sj.onc.1208450			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688004				2022-12-25	WOS:000227681900013
J	Reed, CC; Waterhouse, A; Kirby, S; Kay, P; Owens, RT; McQuillan, DJ; Iozzo, RV				Reed, CC; Waterhouse, A; Kirby, S; Kay, P; Owens, RT; McQuillan, DJ; Iozzo, RV			Decorin prevents metastatic spreading of breast cancer	ONCOGENE			English	Article						decorin proteoglycan; adenovirus gene therapy; breast carcinoma; doxycycline inducible promoter	LEUCINE-RICH PROTEOGLYCANS; GENE-EXPRESSION; EGF RECEPTOR; GROWTH SUPPRESSION; DOWN-REGULATION; CELLS; INHIBITION; CARCINOMA; MIGRATION	Metastases in breast cancer are a vital concern in treatment, with epidermal growth factor receptor and ErbB2 strongly implicated in mediating tumor invasion and spreading. In this study, we investigated the role of decorin in suppressing both primary breast carcinomas and pulmonary metastases. We show that decorin causes marked growth suppression both in vitro and in vivo using a metastatic breast cancer cell line and an orthotopic mammary carcinoma model. Treatment with decorin protein core reduced primary tumor growth by 70% and eliminated observed metastases. An adenoviral vector containing the decorin transgene caused primary tumor retardation of 70%, in addition to greatly reducing observed metastases. Moreover, we demonstrate that ErbB2 phosphorylation and total receptor protein levels are reduced in this model system upon de novo expression of decorin under the control of a doxycycline-inducible promoter. Primary tumor growth in vivo was reduced by up to 67% upon decorin induction, and pulmonary metastases were markedly hampered as well. These effects are likely occurring through decorin's long-term downregulation of the ErbB2 tyrosine kinase cascade. These results demonstrate a novel role for decorin in reduction or prevention of tumor metastases in this breast cancer model and could eventually lead to improved therapeutics for metastatic breast cancer.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, JAH, Philadelphia, PA 19107 USA; LifeCell Corp, Branchburg, NJ 08876 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cellular Biol & Signaling Program, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, JAH, Room 249,1020 Locust St, Philadelphia, PA 19107 USA.	iozzo@mail.jci.tju.edu	Waterhouse, Anna/E-2464-2011; Waterhouse, Anna/M-1681-2018; Iozzo, Renato/AAS-1980-2020	Waterhouse, Anna/0000-0003-1498-9393; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADANY R, 1990, J BIOL CHEM, V265, P11389; Ahmed F, 2002, CANCER RES, V62, P7166; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Davies CD, 2001, MICROVASC RES, V62, P26, DOI 10.1006/mvre.2001.2311; Goldoni S, 2004, J BIOL CHEM, V279, P6606, DOI 10.1074/jbc.M310342200; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grant DS, 2002, ONCOGENE, V21, P4765, DOI 10.1038/sj.onc.1205595; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Koninger J, 2004, CLIN CANCER RES, V10, P4776, DOI 10.1158/1078-0432.CCR-1190-03; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Nash MA, 2002, CLIN CANCER RES, V8, P1754; Nash MA, 1999, CANCER RES, V59, P6192; NERI A, 1982, J NATL CANCER I, V68, P507; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Reed CC, 2002, GLYCOCONJUGATE J, V19, P249, DOI 10.1023/A:1025383913444; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Tralhao JG, 2003, FASEB J, V17, P464, DOI 10.1096/fj.02-0534fje; Troup S, 2003, CLIN CANCER RES, V9, P207; Verbeek BS, 1998, FEBS LETT, V425, P145, DOI 10.1016/S0014-5793(98)00224-5; Wang WG, 2002, CANCER RES, V62, P6278; Wyckoff JB, 2000, CANCER RES, V60, P2504; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	33	173	184	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1104	1110		10.1038/sj.onc.1208329	http://dx.doi.org/10.1038/sj.onc.1208329			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15690056				2022-12-25	WOS:000226749200017
